<SEC-DOCUMENT>0001564590-21-016297.txt : 20210330
<SEC-HEADER>0001564590-21-016297.hdr.sgml : 20210330
<ACCEPTANCE-DATETIME>20210330061503
ACCESSION NUMBER:		0001564590-21-016297
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		25
CONFORMED PERIOD OF REPORT:	20201231
FILED AS OF DATE:		20210330
DATE AS OF CHANGE:		20210330

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Sensei Biotherapeutics, Inc.
		CENTRAL INDEX KEY:			0001829802
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-39980
		FILM NUMBER:		21783537

	BUSINESS ADDRESS:	
		STREET 1:		620 PROFESSIONAL DRIVE
		CITY:			GAITHERSBURG
		STATE:			MD
		ZIP:			20879
		BUSINESS PHONE:		(240) 243-8000

	MAIL ADDRESS:	
		STREET 1:		620 PROFESSIONAL DRIVE
		CITY:			GAITHERSBURG
		STATE:			MD
		ZIP:			20879
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>snse-10k_20201231.htm
<DESCRIPTION>10-K
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
snse-10k_20201231.htm
</title>
</head>
<!-- NG Converter v5.0.2.50 -->
<body>

<p style="border-top:Double 2.25pt;padding-top:1pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:3pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:16pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">UNITED STATES </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:16pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">SECURITIES AND EXCHANGE COMMISSION </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Washington, D.C. 20549 </p>
<p style="text-align:center;border-bottom:Solid 0.75pt;padding-bottom:1pt;margin-bottom:0pt;margin-top:0pt;margin-left:40%;margin-right:40%;text-indent:0%;font-size:3pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:center;margin-top:3pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:18pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">FORM 10-K<font style="font-weight:normal;"> </font></p>
<p style="text-align:center;border-bottom:Solid 0.75pt;padding-bottom:1pt;margin-bottom:0pt;margin-top:0pt;margin-left:40%;margin-right:40%;text-indent:0%;font-size:3pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-top:3pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Mark&#160;One) </p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  style="width:4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Segoe UI Symbol;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#9746;</p></td>
<td valign="top"  style="width:96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">ANNUAL REPORT PURSUANT TO SECTION&#160;13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF&#160;1934 </p></td>
</tr>
</table></div>
<p style="text-align:center;margin-top:3pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">For the fiscal year ended December 31, 2020</p>
<p style="text-align:center;margin-top:3pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">OR </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:3pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  style="width:4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Segoe UI Symbol;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#9744;</p></td>
<td valign="top"  style="width:96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">TRANSITION REPORT PURSUANT TO SECTION&#160;13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF&#160;1934 FOR THE TRANSITION PERIOD FROM&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; TO &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</p></td>
</tr>
</table></div>
<p style="text-align:center;margin-top:3pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Commission File Number:&#160;001-39980</p>
<p style="text-align:center;border-bottom:Solid 0.75pt;padding-bottom:1pt;margin-bottom:0pt;margin-top:0pt;margin-left:40%;margin-right:40%;text-indent:0%;font-size:3pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:center;margin-top:3pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:24pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">Sensei Biotherapeutics, Inc.</font></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(Exact name of Registrant as specified in its Charter) </p>
<p style="text-align:center;border-bottom:Solid 0.75pt;padding-bottom:1pt;margin-bottom:0pt;margin-top:0pt;margin-left:40%;margin-right:40%;text-indent:0%;font-size:3pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:3pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  style="width:50%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">Delaware</font></p></td>
<td valign="bottom"  style="width:50%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">83-1863385</font></p></td>
</tr>
<tr>
<td valign="bottom"  style="width:50%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(State or other jurisdiction of</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">incorporation or organization)</p></td>
<td valign="bottom"  style="width:50%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(I.R.S. Employer</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Identification No.)</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:50%;">
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1405 Research Blvd, Suite 125</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Rockville, MD</p></td>
<td valign="bottom"  style="width:50%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">20850</font></p></td>
</tr>
<tr>
<td valign="bottom"  style="width:50%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Address of principal executive offices)</p></td>
<td valign="bottom"  style="width:50%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Zip Code)</p></td>
</tr>
</table></div>
<p style="text-align:center;margin-top:3pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Registrant&#8217;s telephone number, including area code: <font style="Background-color:#FFFFFF;color:#000000;">(240)&#160;243-8000</font></p>
<p style="text-align:center;border-bottom:Solid 0.75pt;padding-bottom:1pt;margin-bottom:0pt;margin-top:0pt;margin-left:40%;margin-right:40%;text-indent:0%;font-size:3pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-top:3pt;margin-bottom:0pt;text-indent:0%;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Securities registered pursuant to Section&#160;12(b) of the Act: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:3pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  style="width:40%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Title of each class</p></td>
<td valign="bottom"  style="width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:18%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Trading Symbol(s)</p></td>
<td valign="bottom"  style="width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:40%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Name of each exchange on which registered</p></td>
</tr>
<tr>
<td valign="top"  style="width:40%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">Common Stock, $0.0001 par value per share</font></p></td>
<td valign="bottom"  style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:18%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">SNSE</font></p></td>
<td valign="bottom"  style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:40%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">The Nasdaq Stock Market LLC</font></p></td>
</tr>
</table></div>
<p style="margin-top:3pt;margin-bottom:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Securities registered pursuant to Section&#160;12(g) of the Act: <font style="font-weight:bold;">None </font></p>
<p style="margin-top:3pt;margin-bottom:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Indicate by check mark if the Registrant is a well-known seasoned issuer, as defined in Rule&#160;405 of the Securities Act.&#160;YES&#160;<font style="font-family:Segoe UI Symbol;">&#9744; </font>NO&#160;<font style="font-family:Segoe UI Symbol;">&#9746;</font></p>
<p style="margin-top:3pt;margin-bottom:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Indicate by check mark if the Registrant is not required to file reports pursuant to Section&#160;13 or 15(d) of the Act. &#160;YES&#160;<font style="font-size:8.5pt;font-family:Segoe UI Symbol;">&#9744;</font> NO&#160;<font style="font-family:Segoe UI Symbol;">&#9746;</font></p>
<p style="margin-top:3pt;margin-bottom:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Indicate by check mark whether the Registrant: (1)&#160;has filed all reports required to be filed by Section&#160;13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12&#160;months (or for such shorter period that the Registrant was required to file such reports), and (2)&#160;has been subject to such filing requirements for the past 90&#160;days. &#160;YES&#160;<font style="font-size:8.5pt;font-family:Segoe UI Symbol;">&#9744;</font> NO&#160;<font style="font-family:Segoe UI Symbol;">&#9746;</font></p>
<p style="margin-top:3pt;margin-bottom:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Indicate by check mark whether the Registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule&#160;405 of Regulation&#160;S-T (&#167;232.405 of this chapter) during the preceding 12&#160;months (or for such shorter period that the Registrant was required to submit such files). &#160;YES&#160;<font style="font-family:Segoe UI Symbol;">&#9746;</font> NO&#160;<font style="font-family:Segoe UI Symbol;">&#9744;</font></p>
<p style="margin-top:3pt;margin-bottom:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:3pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr style="height:10.8pt;">
<td valign="top"  style="width:16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Large&#160;accelerated&#160;filer</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:61%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8.5pt;font-family:Segoe UI Symbol;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#9744;</p></td>
<td valign="top"  style="width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top"  style="width:18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accelerated&#160;filer</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8.5pt;font-family:Segoe UI Symbol;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#9744;</p></td>
</tr>
<tr style="height:1.9pt;">
<td valign="top"  style="width:16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:3pt;">&nbsp;</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:3pt;">&nbsp;</p></td>
<td valign="top"  style="width:61%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:3pt;">&nbsp;</p></td>
<td valign="top"  style="width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:3pt;">&nbsp;</p></td>
<td valign="top"  style="width:18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:3pt;">&nbsp;</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:3pt;">&nbsp;</p></td>
<td valign="top"  style="width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:3pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Non-accelerated filer</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:61%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Segoe UI Symbol;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#9746;</p></td>
<td valign="top"  style="width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top"  style="width:18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Smaller&#160;reporting&#160;company</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Segoe UI Symbol;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#9746;</p></td>
</tr>
<tr style="height:1.9pt;">
<td valign="top"  style="width:16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:3pt;">&nbsp;</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:3pt;">&nbsp;</p></td>
<td valign="top"  style="width:61%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:3pt;">&nbsp;</p></td>
<td valign="top"  style="width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:3pt;">&nbsp;</p></td>
<td valign="top"  style="width:18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:3pt;">&nbsp;</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:3pt;">&nbsp;</p></td>
<td valign="top"  style="width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:3pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:61%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Emerging growth company</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Segoe UI Symbol;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#9746;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:3pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. &#160;<font style="font-family:Segoe UI Symbol;">&#9744;</font></p>
<p style="margin-top:3pt;margin-bottom:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Indicate by check mark whether the registrant has filed a report on and attestation to its management&#8217;s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report.&#160;&#160;<font style="font-family:Segoe UI Symbol;">&#9744;</font></p>
<p style="margin-top:3pt;margin-bottom:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Indicate by check mark whether the Registrant is a shell company (as defined in Rule&#160;12b-2 of the Exchange Act). &#160;YES&#160;<font style="font-family:Segoe UI Symbol;">&#9744;</font> NO&#160;<font style="font-family:Segoe UI Symbol;">&#9746;</font></p>
<p style="margin-top:3pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">There was no aggregate market value of shares of common stock held by non-affiliates of the registrant as of June&#160;30, 2020, the last business day of the registrant&#8217;s most recently completed second fiscal quarter, because the registrant&#8217;s common stock was not trading on any exchange on that date.<font style="color:#000000;"> </font></p>
<p style="margin-top:3pt;margin-bottom:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The number of shares of Registrant&#8217;s Common Stock outstanding as of March 25, 2021 was 30,588,495. </p>
<p style="border-bottom:Double 2.25pt;padding-bottom:1pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:3pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Table of Contents</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:82.82%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.08%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Page</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">PART I</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:82.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.08%; border-top:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;1.</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:82.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_1_BUSINESS"><font style="text-decoration:underline;">Business</font></a></p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;1A.</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:82.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_1A_RISK_FACTORS"><font style="text-decoration:underline;">Risk Factors</font></a></p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">32</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;1B.</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:82.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_1B_UNRESOLVED_STAFF_COMMENTS"><font style="text-decoration:underline;">Unresolved Staff Comments</font></a></p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">73</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;2.</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:82.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_2_PROPERTIES"><font style="text-decoration:underline;">Properties</font></a></p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">73</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;3.</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:82.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_3_LEGAL_PROCEEDINGS"><font style="text-decoration:underline;">Legal Proceedings</font></a></p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">73</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;4.</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:82.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_4_MINE_SAFETY_DISCLOSURES"><font style="text-decoration:underline;">Mine Safety Disclosures</font></a></p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">73</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:82.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">PART&#160;II</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:82.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;5.</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:82.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_5_MARKET_FOR_REGISTRANTS_COMMON_EQU"><font style="text-decoration:underline;">Market for Registrant&#8217;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities</font></a></p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">74</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;6.</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:82.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_6_SELECTED_FINANCIAL_DATA"><font style="text-decoration:underline;">Selected Financial Data</font></a></p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">75</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;7.</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:82.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_7_MANAGEMENTS_DISCUSSION_ANALYSIS_F"><font style="text-decoration:underline;">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</font></a></p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">76</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;7A.</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:82.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_7A_QUANTITATIVE_QUALITATIVE_DISCLOS"><font style="text-decoration:underline;">Quantitative and Qualitative Disclosures About Market Risk</font></a></p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">85</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;8.</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:82.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_8_FINANCIAL_STATEMENTS_SUPPLEMENTAR"><font style="text-decoration:underline;">Financial Statements and Supplementary Data</font></a></p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">85</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;9.</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:82.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_9_CHANGES_IN_DISAGREEMENTS_WITH_ACC"><font style="text-decoration:underline;">Changes in and Disagreements With Accountants on Accounting and Financial Disclosure</font></a></p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">85</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;9A.</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:82.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_9A_CONTROLS_PROCEDURES"><font style="text-decoration:underline;">Controls and Procedures</font></a></p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">86</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;9B.</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:82.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_9B_OR_INFORMATION"><font style="text-decoration:underline;">Other Information</font></a></p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">86</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:82.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">PART&#160;III</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:82.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;10.</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:82.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_10_DIRECTORS_EXECUTIVE_FICERS_CORPO"><font style="text-decoration:underline;">Directors, Executive Officers and Corporate Governance</font></a></p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">87</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;11.</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:82.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_11_EXECUTIVE_COMPENSATION"><font style="text-decoration:underline;">Executive Compensation</font></a></p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">90</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;12.</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:82.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_12_SECURITY_OWNERSHIP_CERTAIN_BENEF"><font style="text-decoration:underline;">Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</font></a></p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">100</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;13.</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:82.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_13_CERTAIN_RELATIONSHIPS_RELATED_TR"><font style="text-decoration:underline;">Certain Relationships and Related Transactions, and Director Independence</font></a></p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">101</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;14.</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:82.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_14_PRINCIPAL_ACCOUNTING_FEES_SERVIC"><font style="text-decoration:underline;">Principal Accounting Fees and Services</font></a></p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">104</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:82.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">PART&#160;IV</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:82.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;15.</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:82.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_15_EXHIBITS_FINANCIAL_STATEMENT_SCH"><font style="text-decoration:underline;">Exhibits, Financial Statement Schedules</font></a></p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">105</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;16</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:82.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_16_FORM_10K_SUMMARY"><font style="text-decoration:underline;">Form 10-K Summary</font></a></p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">106</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">i</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p><a name="_AEIOULastRenderedPageBreakAEIOU1"></a>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">PART I</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="ITEM_1_BUSINESS"></a><a name="ITEM_1_BUSINESS"></a>Item 1. Business. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Overview </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Hlk66109163"></a><a name="_Hlk66109163"></a>We are a clinical-stage immunotherapy company engaged in the discovery and development of next-generation therapies with an initial focus on treatments for cancer. Our proprietary ImmunoPhage platform is a powerful, self-adjuvanted and highly differentiated immunotherapy approach that is designed to utilize bacteriophage to induce a robust, focused and coordinated innate and adaptive immune response. We are engineering our ImmunoPhage product candidates to directly target antigen presenting cells, or APCs, and modulate the tumor microenvironment, or TME, through the targeted use of nanobodies which further enhances therapeutic activity. We believe our ImmunoPhage platform has the potential to deliver personalized, off-the-shelf product candidates tailored to a patient&#8217;s specific tumor. The versatility of our ImmunoPhage platform allows us to design product candidates in a modular fashion, based on a cocktail of common and patient-specific antigens built from our proprietary library of ImmunoPhages, which we refer to as Phortress. We are currently conducting an ongoing 30-patient Phase 1/2 clinical trial of our lead product candidate, SNS-301, in combination with the PD-1 inhibitor pembrolizumab, as a potential treatment for squamous cell carcinoma of the head and neck, or SCCHN. <font style="color:#auto;">As of March 9, 2021</font>,<font style="color:#auto;"> we have enrolled 17 patients in the trial. As of December 10, 2020, we have evaluated ten patients for efficacy and ten for safety.</font><font style="color:#000000;font-size:9.5pt;font-family:Segoe UI;"> </font>We have observed disease control in seven of the patients evaluable for efficacy, including one patient with a partial response, or PR, and two patients who have achieved longstanding stable disease, or SD, for greater than 36 weeks following treatment. Treatment with SNS-301 has generally been well tolerated. We anticipate reporting a large additional subset of data from this trial by the end of 2021. If the results of this trial are positive, subject to feedback from the U.S. Food and Drug Administration, or FDA, we intend to initiate a randomized, registration-enabling trial for SNS-301. We are leveraging the insights from our experience with SNS-301 to expand our development pipeline to include SNS-401 for the treatment of Merkel cell carcinoma, or MCC, as well as a human monoclonal antibody, or mAb, program targeting the novel immune checkpoint VISTA, or V-set immunoglobulin domain suppressor of T cell activation. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Monoclonal antibodies targeting the programmed cell death protein 1, or PD-1, and its related ligand, or PD-L1, have emerged as one of the most promising classes of therapeutics for the treatment of cancer. However, in a majority of patients they generally fail to produce meaningful results. Drugs utilizing PD-1 blockade have been approved by the FDA to treat at least 20 different types of cancer and, in 2019, generated sales of approximately $19.4&#160;billion worldwide. By 2024, the total global market for drugs utilizing PD-1 blockade is estimated to exceed $36 billion. Two of the most common reasons for non-response to PD-1 blockade treatment include a lack of tumor infiltrating lymphocytes, or TILs, or the presence of alternate immunosuppressive mechanisms such as VISTA. To address these mechanisms of non-response to PD-1 blockade, there has been considerable focus on the development of therapies that induce the body&#8217;s immune system to mount a response towards tumor antigen targets. Our ImmunoPhage platform is designed to address the challenges of converting PD-1 blockade non-responsive tumors into responsive ones by triggering the generation of tumor antigen-specific T cells and circumventing immunosuppressive pathways. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pioneering work with bacteriophage led to our discovery of their utility as a powerful, self-adjuvanted immunotherapy platform. The foundation of ImmunoPhage is the bacteriophage lambda, or lambda phage, which we selected for its native immunostimulatory capabilities, large and tractable genome, and tolerability profile. The highly immunogenic nature of bacteriophage promotes a balanced, coordinated and robust response by both the innate and the cellular and humoral components of the adaptive immune system. We believe that the unique features of bacteriophage, including the ability to generate both T cell responses and B cell mediated antibody responses, give it the potential to be used in the development of differentiated treatments for cancer. The modularity of the ImmunoPhage platform allows for personalized, dynamic substitution of particular phage components to optimize patient therapy. Our creation of a phage cocktail expressing multivalent antigens along with the integration of nanobody technology is designed to enhance the utility, precision and therapeutic activity of our product candidates. This allows for an adaptive clinical trial design, which we have discussed with the FDA. To date, we have constructed over 25 unique ImmunoPhage configurations in-house in accordance with current good manufacturing practices, or cGMP, and we are continuing to expand our Phortress library of ImmunoPhages. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">SNS-301 is an ImmunoPhage product candidate that we are developing as a treatment for locally advanced unresectable or metastatic SCCHN.&#160;Head and neck cancer is the sixth most common malignancy worldwide, accounting for approximately 6% of all cancer cases, and is responsible for an estimated 1% to 2% of all cancer deaths.&#160;An estimated 650,000 cases of head and neck cancer are diagnosed annually worldwide, including approximately 50,000 cases in the United States. Human papilloma virus, or HPV, infection accounts for an estimated 70% of SCCHN cases in the United States. The current standard of care in our target patient population is PD-1 inhibition as a single agent or in combination with chemotherapy.&#160;Despite improvements in diagnoses and disease management, long-term survival rates for patients with SCCHN have not increased significantly over the past 30 years and are among the lowest for major cancers. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We selected SCCHN as our first indication based on a high unmet patient need, robust scientific rationale, a clearly defined regulatory path and accessibility of these tumors for biopsy. SNS-301 has been engineered to produce a targeted immune response against the tumor associated antigen, or TAA, aspartate </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#946;-hydroxylase</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> or ASPH. ASPH is found to be overexpressed in 70% to 90% of human malignancies, including SCCHN. Expression of ASPH is related to cancer cell growth, invasiveness, and disease progression through the Notch signaling pathway. As SCCHN tumors are often lacking intratumoral CD8 T cells, we believe that the addition of SNS-301 has the potential to generate and expand ASPH specific anti-tumor T cells and thereby enhance PD-1 blockade activity. </font></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are currently evaluating SNS-301 in combination with the PD-1 inhibitor pembrolizumab in a 30-patient Phase 1/2 clinical trial. <font style="color:#auto;">As of March 9, 2021</font>,<font style="color:#auto;"> we have enrolled 17 patients in the trial. As of December 10, 2020, we have evaluated ten patients for efficacy and ten for safety</font><font style="color:#000000;font-size:9.5pt;font-family:Segoe UI;">.</font> The trial includes patients with locally advanced unresectable or metastatic SCCHN who have been treated with PD-1 blockade for at least 12 weeks with the best overall response being SD or unconfirmed progressive disease, or PD. Patients who achieved a PR, complete response, or CR, or confirmed progression on PD-1 blockade, are not eligible. Based on an initial assessment of the ten evaluable patients, SNS-301 in combination with pembrolizumab has been well tolerated and has shown promising anti-tumor activity, including a PR in one patient with a PD-L1 negative tumor who achieved SD as best overall response on PD-1 inhibition alone as well as SD in six patients. Of the six SD patients, one patient previously had PD on PD-L1 inhibition and two patients have achieved longstanding SD for greater than 36 weeks following treatment. We anticipate reporting a large additional subset of data from this trial by the end of 2021. If the results of this trial are positive, subject to feedback from the FDA, we intend to initiate a randomized, registration-enabling trial for SNS-301. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Based on the results we have observed to date, we have commenced enrollment of patients in an additional treatment arm of our ongoing Phase 1/2 trial to evaluate the addition of SNS-301 to pembrolizumab in PD-1 blockade na&#239;ve SCCHN patients. We intend to use an ImmunoPhage cocktail targeting the E6/E7 antigens of HPV, in combination with SNS-301, in HPV positive patients in our ongoing trial of SNS-301, which we expect to incorporate in 2021. In addition, we are currently planning a Phase 2 trial to evaluate the safety and efficacy of SNS-301 in combination with durvalumab for patients with locally advanced resectable SCCHN in the neoadjuvant setting. We intend to initiate the first trial in patients with locally advanced resectable SCCHN in the neoadjuvant setting in 2021. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition to SNS-301, we are currently developing our next ImmunoPhage candidate, SNS-401, for the treatment of MCC. We plan on submitting an IND for SNS-401 in 2022. We are also developing a mAb therapy targeting VISTA. Through the use of proprietary functional and in vivo assays, we intend to select a product candidate and initiate IND-enabling studies for our lead mAb by the end of 2021. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Our Pipeline </font></p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are utilizing our pioneering ImmunoPhage platform, which harnesses the intrinsic immunostimulatory characteristics and capabilities of bacteriophage, to develop a pipeline of product candidates with an initial focus on treatments for cancer. We have worldwide commercial rights for each of our product candidates. Our current portfolio of therapeutic initiatives is presented in the diagram below: <br /></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="g0fyk5pshdve000001.jpg" title="" alt="" style="width:678px;height:349px;"></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Our Approach to Immunotherapy </p>
<p style="margin-bottom:0pt;margin-top:6pt;margin-left:2.26%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Our ImmunoPhage Platform </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We believe that the unique features of bacteriophage give it the potential to be used in the development of differentiated treatments for cancer. The pioneering work with bacteriophage documented in scientific literature describes its potential utility as a powerful, self-adjuvanted immunotherapy platform. However, we have not directly evaluated our ImmunoPhase platform in clinical trials beyond those described below. We selected bacteriophage because of its native immunostimulatory capabilities, large and tractable genome, and tolerability profile. The highly immunogenic nature of bacteriophage promotes a balanced, coordinated and robust response by both the innate and the cellular and humoral components of the adaptive immune system. Bacteriophage has the ability to generate both T cell responses and B cell mediated antibody responses. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The bacteriophage lambda, or lambda phage, is the foundation of our ImmunoPhage platform. Lambda phage is composed of an icosahedral head, or capsid, consisting of major capsid proteins gpD and gpE that surround a single copy of a 48.5 kb double-stranded DNA genome and a flexible tail structure. The gpD protein forms specialized structures on the capsid that results in over 400 copies of the protein being displayed on the capsid surface, which can be modified with antigens to increase the antigen presentation capacity of the phage. The lambda phage DNA genome contains abundant CpG sequence motifs, which are known to function as potent APC activators, through TLR9-mediated signaling. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As bacteriophages are ubiquitous, patients either have pre-existing anti-phage antibody titers or quickly develop anti-phage antibodies upon repeat dosing. However, rather than contributing to neutralization, as is experienced with many viral and protein-based therapies, the presence of phage antibodies may augment ImmunoPhage activity through a process known as antibody-dependent enhancement, or ADE. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition to its natural characteristics, lambda phage can be manufactured without significant difficulty and is amenable to further optimization through our proprietary engineering capabilities, such as the addition of antigens and integration of our proprietary nanobodies, which can be used to direct the phage to specific cells and as payloads that can be incorporated into our product candidates. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:15pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Structure of Lambda Phage </font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="g0fyk5pshdve000002.jpg" title="" alt="" style="width:220px;height:205px;"></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our ImmunoPhage platform capitalizes on the following key immunostimulatory features: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:1.13%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-weight:bold;font-size:10pt;color:#000000;">Self-adjuvanted:</font><font style="font-size:10pt;color:#000000;">&#160;&#160;&#160;&#160;ImmunoPhage elicits an enhanced immune response and displays a high-density of the protein sequence of the targeted antigen and contains multiple CpG motifs in its DNA genome, eliminating the need to include an exogenous adjuvant common to competing viral and mRNA nanoparticle immunotherapies. </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:1.13%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-weight:bold;font-size:10pt;color:#000000;">Intrinsic APC targeting:</font><font style="font-size:10pt;color:#000000;">&#160;&#160;&#160;&#160;ImmunoPhage demonstrates a natural tropism for APCs. We have identified and are advancing additional mechanisms, such as engineering moieties on ImmunoPhage targeted to proteins found on APCs, to further optimize APC targeting and costimulatory signaling. </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:1.13%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-weight:bold;font-size:10pt;color:#000000;">Modular antigen design:</font><font style="font-size:10pt;color:#000000;">&#160;&#160;&#160;&#160;We intend to use off-the-shelf common antigens together with viral and patient-specific antigens as an array of customized, multi-antigen phage configurations, which we refer to as phage cocktails. We believe that the ability to dose cocktails of ImmunoPhage displaying different antigens have the potential to create a personalized, patient-specific immunotherapy. </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:1.13%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-weight:bold;font-size:10pt;color:#000000;">Targeted use of nanobodies:</font><font style="font-size:10pt;color:#000000;">&#160;&#160;&#160;&#160;We are developing nanobodies targeted to immune checkpoints and other immune stimulatory molecules that can be packaged into the phage as immunomodulatory payloads to enhance immunogenicity. </font></p></td></tr></table></div>
<p style="text-align:center;margin-bottom:0pt;margin-top:15pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Structure of Our ImmunoPhage </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="g0fyk5pshdve000003.jpg" title="" alt="" style="width:452px;height:233px;"></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our proprietary nanobodies, derived from alpacas, are antibody-like structures that consist of a single monomeric variable domain located on the heavy chain. Nanobodies are small (approximately 1/10 the size of mAb), robust protein-binding molecules that we believe represent the optimal class of molecules for use as immunomodulatory proteins, where payload space in a delivery vector or vehicle is limited. Like conventional antibodies, nanobodies can bind selectively to a specific antigen, but they possess additional advantages to conventional antibodies, including: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:1.13%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-weight:bold;font-size:10pt;color:#000000;">Small size:&#160;&#160;&#160;&#160;</font><font style="font-size:10pt;color:#000000;">Provides better access to binding grooves and contours on proteins on target cells. </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:1.13%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-weight:bold;font-size:10pt;color:#000000;">Stability:&#160;&#160;&#160;&#160;</font><font style="font-size:10pt;color:#000000;">Stable at a wide range of temperatures and able to refold properly at varying temperatures. </font></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4</a></p>
<hr style="page-break-after:always;width:100%;">
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:1.13%;white-space:nowrap"></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:1.13%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-weight:bold;font-size:10pt;color:#000000;">High Solubility:&#160;&#160;&#160;&#160;</font><font style="font-size:10pt;color:#000000;">Hydrophilic, single-chain structure allows nanobodies to avoid aggregation issues common to mAbs. </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:1.13%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-weight:bold;font-size:10pt;color:#000000;">Ease of manufacturing:&#160;&#160;&#160;&#160;</font><font style="font-size:10pt;color:#000000;">Easier and less expensive to produce due to benefits from improved screening and isolation techniques and bacterial cell production. </font></p></td></tr></table></div>
<p style="text-align:center;margin-top:15pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Size of Conventional Human Antibody versus Camelid Nanobody</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="g0fyk5pshdve000004.jpg" title="" alt="" style="width:268px;height:144px;"></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We maintain the ability to produce our customized nanobodies in-house that are compatible with our ImmunoPhage engineering processes. Our product candidates are able to be manufactured through the well-established principles of bacterial fermentation, which provides cost and scalability advantages. We can achieve GMP manufacture of an ImmunoPhage dose configuration in-house in as little as four weeks. We believe that these advantages, along with the long-term stability of ImmunoPhage, make personalized ImmunoPhage cocktails a commercially viable solution to the current challenges facing fully personalized patient-specific immunotherapy. </p>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:2.26%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">ImmunoPhage Mechanism of Action </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our mechanism of action focuses on what we believe to be the critical step leading to the generation of effective anti-tumor T cells, the immune priming step where APCs acquire and process tumors antigens, and interact with CD4 and CD8 T cells in the immune synapse. ImmunoPhage mimics a pathogenic virus and naturally targets APCs that capitalize on phage-intrinsic danger signals which activate these critical cells. The aggregation of antigen and danger signals enable self-adjuvant capabilities in a single entity which help to enhance the immunogenicity and augment downstream immune responses, including antigen-specific B and T cell responses. In order to drive optimal generation of antigen-specific T cells, the APC must deliver three discrete critical signals to the T cell, as shown below. </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:15pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">ImmunoPhage Activates Three Discrete Critical Signals Required to Drive Activation of T Cells </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="g0fyk5pshdve000005.jpg" title="" alt="" style="width:322px;height:198px;"></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="g0fyk5pshdve000006.jpg" title="" alt="" style="width:28px;height:28px;">&#160;&#160;&#160;&#160;</p></td>
<td valign="bottom"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Signal one<font style="font-weight:normal;"> involves antigenic peptides, derived from APC protein processing pathways, presented in the context of the appropriate major histocompatibility complex, or MHC, molecules, Class&#160;II for CD4 T cells and Class&#160;I for CD8 T cells. An alternate MHC Class&#160;I presentation pathway results in the activation of CD8 T cells through a process called cross presentation.</font></p></td>
</tr>
<tr style="height:6pt;">
<td valign="middle"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="middle"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="g0fyk5pshdve000007.jpg" title="" alt="" style="width:28px;height:28px;">&#160;&#160;&#160;&#160;</p></td>
<td valign="bottom"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Signal two<font style="font-weight:normal;"> involves the APC expressing positive costimulatory molecules CD80 (or CD86) interacting with CD28 on the T cells. In the presence of significant negative costimulatory signals through molecules like PD-L1 or VISTA, or the lack of sufficient positive co-stimulation, the interaction between APC and T cell can lead to dysfunction of the T cell rather than T cell activation.</font></p></td>
</tr>
<tr style="height:6pt;">
<td valign="middle"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="middle"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5</a></p>
<hr style="page-break-after:always;width:100%;">
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="g0fyk5pshdve000008.jpg" title="" alt="" style="width:28px;height:28px;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;&#160;&#160;</font></p></td>
<td valign="bottom"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Signal three<font style="font-weight:normal;"> collectively refers to the cytokine microenvironment of the immune synapse wherein the priming interaction between APC and T cell is occurring. This cytokine milieu determines the differentiation and fitness of the downstream T cell response. For instance, a rich IL-12 environment leads to a Th1 biased immune response and enhanced generation of CTLs.</font></p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We believe that ImmunoPhage can efficiently deliver antigen to and activate DCs, driving these three critical signals in the priming phase of the immune response. We have observed that increasing doses of ImmunoPhage on human skin-derived DC cultures increase the critical components of signals two and three in a dose-dependent fashion. Importantly, in the context of anti-tumor immune responses, which require the generation of tumor antigen-specific CD8 T cells, phages can drive cross-presentation of displayed antigens, even breaking tolerance to &#8220;self&#8221; TAAs. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Since the development of pembrolizumab and other inhibitors of the PD-1 signaling pathway, it has become clear that a prerequisite for response to PD-1 blockade is the presence of a sufficient number of tumor-specific T cells, particularly, CD8 T cells in the TME. Patients with poorly immunogenic tumors lacking CD8 T cells represent a major unmet medical need. We believe that there is a significant opportunity for our ImmunoPhage platform to drive the generation of tumor antigen-specific T-cells and potentially convert PD-1 blockade non-responders into responders. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">To optimize immunotherapy in cancer, a two-fold approach may be required: the first is the systemic generation of antigen-specific T cells through vaccination or adoptive transfer and the second refers to inhibition of immunosuppressive mechanisms limiting the entry of T cells into the TME. In situ vaccination has been shown to &#8220;soften&#8221; the TME and increase T cell infiltration. We believe that ImmunoPhage delivered to the tumor, either by direct intralesional injection or by the development of tumor-targeted phages, can deliver both a potent generation of tumor-specific T cells and enhancement of T cell infiltration into tumors. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition to our ImmunoPhage-based approach, we are developing a human mAb targeting the immunosuppressive VISTA checkpoint protein as well as nanobody programs targeting other key molecules preventing T cell entry into the TME and cytotoxic activity, including TGF<font style="font-family:'Times New Roman';"><font style="font-size:10pt;font-family:'Times New Roman'">b</font></font>, IL-10 and PD-1. The goal of these programs is to limit the immunosuppressive mechanisms that prevent T cell entry into the TME. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ImmunoPhage leverages anti-drug antibodies that limit the use of other viral and protein-based therapies to enhance immunogenicity. ADE occurs when anti-phage antibodies which coat the capsid surface result in enhanced uptake by, and activation of, DCs through the binding and activation of Fc receptors, or FcRs. The high-density of phage-bound antibody is thought to lead to massive cross-linking of certain FcRs, leading to a strong immunogenic response to FcR-mediated endocytosis of the phage antigen/antibody complex. This mode of DC activation can lead to enhanced T cell responses, including CD8 priming by enabling cross-presentation. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="g0fyk5pshdve000009.jpg" title="" alt="" style="width:336px;height:192px;"></p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:2.26%;text-indent:0%;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:8pt;margin-left:2.26%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Our Adaptive Approach to ImmunoPhage Cocktail Therapy </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our ImmunoPhage platform enables a cocktail therapy approach that has the potential to provide patients with the benefits of both an off-the-shelf treatment and a personalized approach to their individual cancer. Each ImmunoPhage product candidate we produce has a unique therapeutic armament, such as various multivalent antigens, including those targeting CD4, CD8 and B cell epitopes designed to deliver broad epitope coverage, and nanobody payloads added to boost antigenicity or provide direct cancer cell killing capabilities. Based on the profile of a patient&#8217;s tumor, multiple distinct ImmunoPhage product candidates, each having a distinct profile, can be combined for treatment. We believe that broad epitope coverage along with nanobody payloads, combined with the intrinsic immunostimulatory activity of our ImmunoPhage product candidates, can provide patients a therapy with meaningful clinical benefits. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The modular nature of the Phortress library allows for personalized dynamic substitution of </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">particular ImmunoPhage</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> components to optimize patient therapy. Moreover, the ease of manufacturing allows us to perform immune monitoring in patients to assess the immunogenicity of each phage component of a cocktail and adjust the cocktail </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">during the course of</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> treatment. To date, we have constructed over 25 unique ImmunoPhage configurations and anticipate expanding our Phortress library as we advance our clinical stage programs. </font></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We also intend to utilize the potential of an adaptive cocktail therapy approach in our ongoing and future clinical trials, including in our SNS-301 and SNS-401 programs. We have discussed the proposed clinical trial design, including the adaptive cocktail therapy approach, with the FDA. We believe this strategy will allow us to use insights derived from initial study cohorts, such as antibody titers raised against a target antigen, to dictate phage substitutions to the phage cocktail which are subsequently tested in additional cohorts. The best performing cocktail can then be advanced into dose expansion and later-stage clinical trials. </p>
<p style="text-align:center;margin-top:15pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">ImmunoPhage Adaptive Cocktail Therapy Approach</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="g0fyk5pshdve000010.jpg" title="" alt="" style="width:582px;height:308px;"></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:2pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We believe that the speed of manufacturing and antigenic capacity of ImmunoPhage cocktails will allow us to address the limitations of neoantigen-only vaccine approaches.&#160;With the Phortress library, we have the ability to quickly initiate an off-the-shelf immunotherapy with a patient-specific ImmunoPhage cocktail from our shared antigen library within 1 to 2 weeks of diagnosis as display in steps 1 through 3 in the figure below, and then to augment the cocktail with a newly designed neoantigen phage within 4 to 6 weeks, as displayed in steps 4 through 6 below.&#160;We believe that this approach has the potential to address the urgency of treatment and provide the patient with an enhanced anti-tumor immune response. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:center;margin-top:15pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Our Personalized Immunotherapy Process</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="g0fyk5pshdve000011.jpg" title="" alt="" style="width:617px;height:370px;"></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">SNS-301: Our Lead ImmunoPhage Candidate Targeting ASPH for Treatment of SCCHN<font style="font-style:italic;"> </font></p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our lead product candidate, SNS-301, is an ImmunoPhage construct engineered to generate a strong, specific immune response against the TAA ASPH. We believe the immune stimulatory effects generated by our ImmunoPhage platform, combined with the inhibition of the PD-1 immune system checkpoint, act in a complementary manner to produce an enhanced immune response in SCCHN patients. SNS-301 is being studied in an ongoing Phase 1/2 trial in combination with pembrolizumab. As of December&#160;10, 2020, ten patients were evaluable for efficacy. Of these patients, we have observed that SNS-301 in combination with pembrolizumab has been well tolerated and has shown promising anti-tumor activity, including a PR in one patient with a PD-L1 negative tumor and disease control in seven of ten evaluable patients. </p>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:2.26%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Head and Neck Cancer </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Head and neck cancer is the sixth most common malignancy worldwide, accounting for approximately 6% of all cancer cases, and is responsible for an estimated 1% to 2% of all cancer deaths. Head and neck cancers encompass an array of cancers originating in the squamous cells that line the moist, mucosal surfaces inside the head and neck. More than 90% of head and neck cancers are classified as squamous cell carcinomas that raise from the mucosal surfaces of the oral cavity, oropharynx and larynx. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">An estimated 650,000 cases of head and neck cancer are diagnosed annually worldwide, including approximately 50,000 cases in the United States, with more than 350,000 deaths annually worldwide. HPV infection accounts for an estimated 70% of SCCHN cases in the United States. The primary causes of SCCHN are smoking, heavy alcohol use and certain types of HPV. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Early-stage head and neck cancer is typically either treated with surgery or radiation alone; however, approximately 66% of patients present with advanced disease and fewer than 30% of these are cured. The management of advanced disease consists of multiple-modality therapy with surgery, radiation, chemotherapy and immunotherapy. Despite improvements in diagnoses and local management, long-term survival rates for patients with SCCHN have not increased significantly over the past 30 years and are among the lowest when compared against other major cancers. </p>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:2.26%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Targeting ASPH </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ASPH is a TAA, strongly expressed in 70% to 90% of human malignancies, including carcinomas, such as SCCHN, and sarcomas and hematologic malignancies. Expression of ASPH is related to cancer cell growth, invasiveness, and disease progression </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">through the Notch signaling pathway. SNS-301 is designed to overcome self-tolerance and induce robust and durable humoral and cellular immune responses that target tumors expressing ASPH. </font></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the course of conducting our ongoing Phase 1/2 trial for SNS-301, we collected ASPH-positive tumor samples from 30 patients who had been screened for inclusion in our trial, although some patients who had samples collected did not satisfy other criteria for ultimate inclusion in our trial. The samples were stained to show intratumoral ASPH expression. Depicted below is a staining of a representative patient&#8217;s tumor biopsy using an immunohistochemistry assay. The first figure shows the magnification at low power, while the second figure shows the same sample at a higher power of magnification. In each figure, the ASPH is shown in the darker color. </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:15pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Representative Patient ASPH-Positive Tumor Sample </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="g0fyk5pshdve000012.jpg" title="" alt="" style="width:226px;height:268px;"></p>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:2.26%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">SNS-301&#8212;A Potential Solution for SCCHN </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We believe that SNS-301, in combination with pembrolizumab, has the potential to produce enhanced activity in patients with SCCHN compared to currently available therapies. We are developing SNS-301 for the treatment of SCCHN due to the cancer&#8217;s lack of intratumoral T cells and the consequent modest objective response rate to PD-1 blockade. We selected SCCHN as our first indication based on a high unmet need, a clearly defined regulatory path and easily accessible tumor for obtaining biopsies for early translational data to evaluate immune activation. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Although drugs utilizing PD-1 blockade have been approved for several years in the treatment of advanced SCCHN after platinum containing chemotherapy, the objective response rate, or ORR, has been reported to be as modest as 13% to 18% in relapsed or refractory SCCHN patients with progression free survival, or PFS, of two months and overall survival, or OS, of eight months. Objective responses predominantly occur in patients with PD-L1 positive tumors, with demonstrated ORR of 21% for PD-L1 positive patients, while patients with PD-L1 negative tumors are reported to have a response rate of only 6%. Pembrolizumab has been approved for use as a first-line therapy in combination with chemotherapy for all patients and as a single agent for patients with PD-L1 positive of T cells infiltrating the tumor. As SCCHN tumors are often lacking intratumoral CD8 T cells, we believe that the addition of SNS-301 has the potential to generate and expand ASPH specific anti-tumor T cells and thereby enhance PD-1 blockade activity. </p>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:2.26%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">SNS-301: Ongoing Phase 1/2 Trial Status and Design </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are currently conducting an open-label, multi-center Phase 1/2 clinical trial of SNS-301 in combination with pembrolizumab. The primary objectives of this trial are to assess the safety and tolerability of SNS-301 in combination with pembrolizumab and the anti-tumor activity of the combination treatment as measured by ORR, PFS per iRECIST and OS. The secondary objective is to assess the preliminary immune response, which is measured by evaluating antigen-specific antibody and T cells and other lymphocytes. Examination of paired pre- and post-treatment biopsy samples are being utilized to evaluate whether the addition of SNS-301 to PD-1 blockade results in increased inflammation, determined by the presence of TILs, PD-L1, inflammatory gene signatures. <font style="color:#auto;">As of March 9, 2021 we have enrolled 17 patients in the trial.&nbsp;&nbsp;As of December 10, 2020, we have evaluated ten patients for efficacy and ten for safety.</font> Our Phase 1/2 trial includes patients with locally advanced unresectable or metastatic SCCHN who have been treated with PD-1 blockade for at least 12 weeks with the best overall response being SD or unconfirmed PD based on </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">RECIST1.1 and iRECIST, industry accepted standard guidelines for tumor evaluation. RECIST 1.1 defines a CR, PR, </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">SD</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> and PD as follows: </font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle"  style="width:29%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Category</p>
<p style="text-align:center;border-top:Solid 1pt;padding-top:1pt;margin-top:1pt;line-height:1pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle"  style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&nbsp;</p></td>
<td valign="middle"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:70%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Description</p>
<p style="margin-top:0pt;text-align:center;border-top:Solid 1pt;padding-top:1pt;line-height:1pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="middle"  style="width:29%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Complete Response (CR)</p></td>
<td valign="middle"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="middle"  style="padding-left:0pt;width:70%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Disappearance of all Tumor Lesions</p></td>
</tr>
<tr>
<td valign="middle"  style="width:29%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Partial Response (PR)</p></td>
<td valign="middle"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="middle"  style="padding-left:0pt;width:70%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Reduction of <font style="font-family:'Times New Roman';"><font style="font-size:10pt;font-family:'Times New Roman'">&#8805;</font></font>30% of the Sum of Target Diameters</p></td>
</tr>
<tr>
<td valign="middle"  style="width:29%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stable Disease (SD)</p></td>
<td valign="middle"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="middle"  style="padding-left:0pt;width:70%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Reduction of &lt;30% or increase of &lt;20% of the Sum of Target Diameters</p></td>
</tr>
<tr>
<td valign="middle"  style="width:29%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Progressive&#160;Disease&#160;(PD)</p></td>
<td valign="middle"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="middle"  style="padding-left:0pt;width:70%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Increase of <font style="font-family:'Times New Roman';"><font style="font-size:10pt;font-family:'Times New Roman'">&#8805;</font></font>20% of the Sum of Target Diameters</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Patients who achieved a PR, CR or confirmed progression on PD-1 blockade are not eligible for participation in this clinical trial. The rationale for this restrictive inclusion criteria is based on reported data demonstrating that the median time to a PR or CR with PD-1 blockade is two months. Therefore, by excluding patients that achieved PRs or CRs while on PD-1 blockade alone for at least 12 weeks, we believe that any PRs or CRs observed in our Phase 1/2 trial are likely attributable to the addition of SNS-301. Similarly, we believe that a patient with PD on single-agent PD-1 blockade achieving stabilization after the addition of SNS-301 is an indication of clinical benefit from the treatment combination. </p>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:2.26%;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Phase 1/2 trial design </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The treatment regimen consists of repeat doses of SNS-301 administered intradermally on Day 0, Week 3, Week 6, Week 9, then every 6 weeks for 6 additional doses, and thereafter every 12 weeks until confirmed disease progression, unacceptable toxicity, patient intolerability as determined by the investigator or up to 24 months in patients without disease progression. Pembrolizumab is administered intravenously as per standard of care at either 200 mg every 3 weeks or 400 mg every 6 weeks. </p>
<p style="text-align:center;margin-top:15pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Design of the Phase 1/2 Clinical Trial of SNS-301 in SCCHN</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="g0fyk5pshdve000013.jpg" title="" alt="" style="width:582px;height:137px;"></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Phase 1/2 trial consists of a safety run-in followed by a Simon two-stage design in the absence of any dose-limiting toxicities, or DLTs, during the safety run-in, with a total initial enrollment of 15 patients, which we refer to as Stage 1. The trial design allows additional expansion up to a total of 30 patients if one CR or PR is observed in Stage 1. We did not observe any DLTs during the safety run-in and are continuing to enroll patients through Stage 1. Since one patient in our clinical trial has already achieved a confirmed PR, as described below, the pre-defined efficacy criteria of Stage 1 has been met, allowing us to continue into Stage 2 and dose up to a total of 30 patients in the trial. </p>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:2.26%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Ongoing Phase 1/2 Trial Results </p>
<p style="margin-bottom:0pt;margin-top:6pt;margin-left:2.26%;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Preliminary evidence of clinical benefit of SNS-301 in combination with pembrolizumab </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of the December 10, 2020 data cutoff for the first 11 patients in Stage 1 of our ongoing Phase 1/2 trial, we observed the following results in the first ten patients evaluable for efficacy: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:1.13%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">PR in one patient with a PD-L1 negative tumor who previously achieved SD on PD-1 inhibition alone; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:1.13%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">SD in six patients, including: </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:1.13%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Courier New;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Courier New;text-transform:none;font-variant: normal;letter-spacing:0pt;">o</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">one patient that has achieved SD for more than 4 months following PD at enrollment after 10 months of PD-L1 blockade treatment; and </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:1.13%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Courier New;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Courier New;text-transform:none;font-variant: normal;letter-spacing:0pt;">o</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">two patients with longstanding SD for 9 and 9.5 months, respectively, of which one SD occurred in a patient with a PD-L1 negative tumor; and </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:1.13%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">PD in three patients, including two patients who had PD at enrollment while on PD-1 blockade. </font></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10</a></p>
<hr style="page-break-after:always;width:100%;">
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:1.13%;white-space:nowrap"></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">One patient withdrew consent prior to the first efficacy evaluation and was therefore not evaluable for efficacy. As shown in the figure below, disease control, as evidenced by PR or SD, was achieved in seven of the ten patients regardless of HPV status. Tumor regression was observed regardless of PD-L1 or HPV status. </p>
<p style="text-align:center;margin-top:15pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Duration of Response in Ongoing Phase 1/2 Trial of SNS-301 in Combination with Pembrolizumab</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="g0fyk5pshdve000014.jpg" title="" alt="" style="width:596px;height:288px;"></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Patient G referred to in the chart above achieved a PR at 12 weeks. This patient was diagnosed in May 2018 with HPV negative and PD-L1 negative SCCHN. At diagnosis, the cancer was classified as Stage II and graded T2N0M0, an enlarged tumor (&lt;4 cm) that had not spread to lymph nodes or other organs. This patient received radiation therapy followed by two cycles of platinum-based chemotherapy, achieving a PR. At the time of enrollment into this trial, the patient had received pembrolizumab for more than 12 weeks with SD. After six weeks on SNS-301 in combination with pembrolizumab, the combined lesion measurement had decreased by 29%. After 12 weeks, the combined lesion measurement had decreased by 43% from baseline, achieving a PR that was confirmed at the 18-week scans. Furthermore, the 30 week scan showed an additional decrease to 52%, maintaining a PR. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Patient C is another patient of notable clinical interest who had been treated with the PD-L1 inhibitor atezolizumab for 10 months when scans showed PD per RECIST 1.1. After receiving combination therapy with SNS-301 and pembrolizumab, two consecutive scans six weeks apart showed SD. Given that SCCHN is an aggressive disease, we believe stabilization of an ongoing progression suggests that SNS-301 likely added to the improvement of the patient&#8217;s disease status. Safety concerns related to COVID-19 prevented the acquisition of paired biopsies to evaluate the TME in this patient. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, of the two Patients (A and B) with longstanding SD of 9 and 9.5 months, respectively, Patient&#160;A&#8217;s tumor was assessed as PD-L1 negative in the clinical setting. </p>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:2.26%;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Translational Data Demonstrated T Cell Integration into the Tumor Supporting Antitumor Activity of SNS-301 </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A comparison of pre-treatment and on-treatment biopsies showed a definitive increase in PD-L1 expression, which likely represents an influx of T cells into the TME and aligns with the achieved clinical benefit. As illustrated below, a predominance of tumor cells was observed pre-treatment, with a pronounced influx of immune cells noted upon treatment. Multiplex IHC demonstrates that the PD-L1 staining in the post-treatment biopsy is found in close proximity to PD-1 positive CD4 and CD8 TILs. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:center;margin-top:15pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">SNS-301 Catalyzes Conversion of PD-L1</font><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><sup style="font-size:85%;line-height:120%;vertical-align:top">NEG</sup></font><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> Immune Desert Tumor into Inflamed Phenotype in Patient with PR</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="g0fyk5pshdve000015.jpg" title="" alt="" style="width:384px;height:212px;"></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Given that the patient initially had a PD-L1 negative tumor with no objective response to PD-1 blockade alone and that after combination treatment the patient achieved a PR with transformation of the tumor into a PD-L1 positive inflamed phenotype, we believe the additional treatment benefit is likely attributable to the addition of SNS-301. Serology data indicated the presence of anti-phage antibodies prior to treatment, suggesting increased immunogenic activity related to ADE. </p>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:2.26%;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"><a name="_Hlk67674517"></a>SNS-301 in Combination with Pembrolizumab has been well tolerated </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Hlk67674504"></a>As of December 10, 2020, based on the 11 patients enrolled in our ongoing Phase 1/2 trial, the combination of SNS-301 and pembrolizumab has been generally well tolerated. No DLTs have been observed in the safety run-in and observed adverse events, or AEs, have primarily been either Grade 1 or 2 or unrelated to treatment. Three Grade 3 related AEs, dehydration, electrocardiogram QT prolongation and rash, have been reported. Four serious adverse events, or SAEs, have been reported. The Grade 3 dehydration was also an SAE as a result of hospitalization; however, it was attributed to an underlying cancer and concomitant medication by the sponsor, and therefore not a reportable event. One patient experienced an SAE for Grade 2 hemoptysis and two weeks later a second SAE of Grade 2 dehydration. Neither of these events were considered related to study drug, but were instead attributed to disease progression<a name="_Hlk67674504"></a>. There was one SAE of Grade 2 systemic inflammatory response syndrome that occurred during the follow-up visit but was assessed as not being a treatment-related adverse event. </p>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:2.26%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">SNS-301: Future Clinical Plans </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We expect to report a large subset of data from the Phase 1/2 trial by the end of 2021. If the results from our Phase 1/2 trial are positive, subject to feedback from the FDA, we intend to initiate a randomized, registration-enabling trial of SNS-301 against standard of care, single-agent pembrolizumab. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Based on the results we have observed to date, we have commenced enrollment of patients in an additional treatment arm of our ongoing Phase 1/2 trial to evaluate the addition of SNS-301 to pembrolizumab in PD-1 blockade na&#239;ve&#160;SCCHN patients.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We also intend to use an ImmunoPhage cocktail targeting the E6/E7 antigens of HPV, in combination with SNS-301, in HPV positive patients in our ongoing trial of SNS-301, which we expect to incorporate in 2021. As a significant percentage of SCCHN patients are HPV positive, we believe the opportunity to incorporate our HPV-specific E6/E7 ImmunoPhage into a combination with SNS-301 has the potential to increase the evidence of clinical benefit seen to date. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We entered into a clinical trial collaboration with AstraZeneca in May 2019 to evaluate the safety, tolerability and preliminary efficacy of AstraZeneca&#8217;s PD-1 inhibitor, durvalumab, in combination with SNS-301. Under the agreement, AstraZeneca will be supplying us with durvalumab for the trial with no upfront, milestone or royalty payments required by us. We intend to initiate a first trial under this collaboration in patients with locally advanced resectable SCCHN in the neoadjuvant setting in 2021. </p>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:2.26%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Prior Clinical Results </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In 2018, we completed a Phase 1 trial evaluating the safety, immunogenicity and efficacy of SNS-301 in patients with biochemical relapse of localized prostate cancer after surgery or radiotherapy. SNS-301 was dosed intradermally in three cohorts of patients, using a fixed dose escalation scheme every 21 days to establish the maximum tolerated dose, or MTD. Patients who tested positive for ASPH in either tumor tissue or serum were eligible to continue in the study. The treatment regimen consisted of three repeat doses of SNS-301 at each dose level (2.0 x 10<sup style="font-size:85%;line-height:120%;vertical-align:top">10</sup>, 1.0 x 10<sup style="font-size:85%;line-height:120%;vertical-align:top">11</sup> and 3.0 x 10<sup style="font-size:85%;line-height:120%;vertical-align:top">11</sup> particles) administered intradermally every 21 days </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">for nine cycles plus six months of follow up. Three patients were enrolled in the low and mid dose cohorts and six patients were enrolled in the high dose cohort. </font></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">SNS-301 was well tolerated in the trial, with few and mostly mild AEs, no observed DLTs and no patients experiencing study drug related SAEs or Grade 4 or Grade 5 AEs. Importantly, there were no indications of an off-target autoimmune response. Furthermore, the MTD of SNS-301 was not reached. Three major protocol deviations occurred during the study: two patients went from middle to high dose prematurely of which one stayed at the higher dose level and one patient varied between middle and high dose levels in subsequent cycles, and one patient (assigned to the lowest dose level) was started on the excluded anti-androgen drug bicalutamide after one year on study treatment. Of the 12 treated subjects, nine discontinued the study before completing all protocol required assessments: six because of sponsor decision, one due to investigator decision, and one with prostate-specific antigen doubling time &lt;90 days and one from an AE (severe arthralgia not related to study drug). </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">All patients had antigen-specific immune responses, with SNS-301 inducing a multi-variate immune response including T cells and B cells in the majority of patients. In addition, seven of the 12 participants in this Phase 1 safety trial, or 58%, demonstrated a reduction in the doubling time of biomarker prostate specific antigen, or PSA, levels through cycle 2. The second dosage level of 1.0 x 10<sup style="font-size:85%;line-height:120%;vertical-align:top">11</sup> was chosen as the recommended Phase 2 dose based on safety, immunogenicity data and the observation of an improvement in PSA doubling time for the mid-dose patients (two of three patients) compared to the high dose (three of six patients).</p>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:2.26%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Preclinical Study Results </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">SNS-301 was evaluated in rodents for immunogenicity and efficacy. Immunogenicity was observed in mice and rats, with both humoral and cellular immune response specific to ASPH to the amount of and number of doses. Efficacy data was obtained in three rodent tumor models, BNLT3, 4T1 and MLLB-2, showing inhibition of tumor and or metastasis growth. A repeat dose toxicology study in rats has been conducted with no adverse safety findings for SNS-301. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As illustrated in the graph below, in a murine model of hepatocellular carcinoma, co-administration of SNS-301 and a PD-1 inhibitor resulted in a significant decrease in tumor growth, as did administration of SNS-301 or an anti-PD-1 antibody individually. We believe the results of this study provide encouraging evidence that checkpoint inhibition removes immunological encumbrances while at the same time SNS-301 works to drive antigen-specific immune activation. </p>
<p style="text-align:center;margin-top:15pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">SNS-301 and PD-1 Blockade Slowed Tumor Growth in a Liver Cancer (Hepa 1-6) Treatment Model</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="g0fyk5pshdve000016.jpg" title="" alt="" style="width:452px;height:172px;"></p>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:2.26%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">SNS-401: Our ImmunoPhage Candidate Targeting Merkel Cell Carcinoma </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are currently developing our next ImmunoPhage candidate, SNS-401, for the treatment of MCC. MCC is a rare but highly aggressive neuroendocrine carcinoma of the skin in which MCPyV infection and chronic exposure to ultraviolet radiation are key risk factors. Approximately 2,500 cases are diagnosed each year with the disease-specific mortality approaching 50%. Integration of MCPyV is evidenced by the presence of virus-specific epitopes in 80% of cases diagnosed in the U.S. In these cases, expression of a virus-related T cell oncogenic antigen appears intimately linked to tumor growth. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Checkpoint inhibitors have proven to be a major advancement in the treatment of advanced MCC and have revolutionized the treatment of locally advanced, inoperable and metastatic MCC. Systemic PD-1/PD-L1 inhibition therapy is associated with a high ORR, prolonged durable responses, and good tolerability in advanced-stage MCC. However, even with the advances made by checkpoint inhibitors, refractory PD-1/PD-L1 inhibitor disease remains a significant unmet medical need with an aggressive clinical course. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In March 2020, we established an exclusive exploratory collaboration with The University of Washington, one of the world&#8217;s leading research centers for the study of MCC. This collaboration provides for the joint construction, to the preclinical development stage, of the first custom MCC vaccine consisting of MCPyV epitopes together with other patient specific antigens. There are no upfront, milestone or royalty payments payable to either party as part of this collaboration. The University of Washington will design MCPyV T cell constructs and determine the immunogenicity and mechanism of candidate ImmunoPhages developed by us. We will develop ImmunoPhages specifically targeting MCPyV T cell constructs and other TAAs using our cocktail approach. We believe that the MCPyV epitope space can be completely addressed with an ImmunoPhage cocktail of two bacteriophage carriers. We have an option to license on an exclusive, worldwide basis the intellectual property developed as part of this collaboration. Currently, </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">we plan on s</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ubmitting an IND for SNS-401 in </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2022. </font></p>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:2.26%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">SNS-VISTA: Monoclonal Antibody targeting VISTA </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are developing a mAb therapy targeting VISTA. VISTA is an immunoregulatory receptor and is highly expressed on various immune system cells including neutrophils, monocytes, macrophages, basophils and DCs. While highly expressed on CD4 T helper cells and certain T regulatory cells, it exhibits much lower expression on CD8 CTLs. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">VISTA is an important checkpoint regulator. Effective PD-1 blockade is often confounded by alternative immune checkpoints, such as VISTA, and we have chosen to develop a mAb targeting VISTA in the expectation that our development of this checkpoint inhibitor will closely complement our ImmunoPhage development activities. Unlike other checkpoint regulators, which are induced after activation, VISTA expression is maintained at a steady state. This broad pattern of expression suggests that VISTA has an important role in regulating immune system activity and preserving homeostasis. VISTA&#8217;s presence in tumors is often indicative of a poor prognosis. Analysis of the TME often reveals an absence of TILs as well as a reduction in cytokines and other co-stimulatory molecules. VISTA blockade appears to dramatically modulate the TME towards a state that favors an immune system response, resulting in improved T-cell effector function and anti-tumor activity. Accordingly, VISTA has been identified as a promising therapeutic target. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Hlk66112532"></a>In January 2020, we entered into a collaborative agreement with AdiMab to expedite antibody development through the production of human IgGs that we may evaluate as potential therapeutic product candidates. Under this agreement, we provide key proprietary reagents and information to AdiMab to enable the initiation of antibody discovery and development. In March 2020, AdiMab initiated our VISTA antibody campaign. In June 2020, we received a first shipment of 84 IgGs for further screening. Among these, several have passed through our proprietary screening criteria and we believe multiple antibodies possess the desired biophysical properties and mechanism of action for a potential clinical candidate. Through the use of proprietary functional and in vivo assays, we intend to select a product candidate and initiate IND-enabling studies for our lead mAb by the end of 2021. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Manufacturing </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have manufactured SNS-301 bulk drug substance for clinical trials, as well as our current Phortess library, at our own manufacturing facility. We are in the process of establishing a new manufacturing facility, which will further enable production of drug substance under cGMP conditions. We believe that having control over the manufacturing process allows us to reduce cycle times, increase the robustness and consistency of the process and potentially reduce cost of goods for commercial production, which are critical to the construction of our Phortress library consisting of multiple novel ImmunoPhage. We expect that having a dedicated manufacturing facility will allow us to optimize commercial-scale processes and to develop a suitable workforce capable of supporting market launch. As we advance into later-stage clinical trials and additional indications, we intend to expand our current manufacturing capabilities to support larger scale clinical trials and the potential commercialization of our product candidates. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We may also rely on contract manufacturing organizations, or CMOs, to produce our product candidates for clinical use. We require that our CMOs produce bulk drug substances and finished drug products in accordance with cGMP, and all other applicable laws and regulations. Although we have established our own manufacturing facility, we may rely on CMOs for parts of the process, like filling and labelling of our products for commercial sale. Any agreements with potential and existing manufacturers will include confidentiality and intellectual property provisions to protect our proprietary rights related to our product candidates. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Intellectual Property </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Intellectual property is of vital importance in our field and in biotechnology generally. We seek to protect and enhance proprietary technology, inventions, and improvements that are commercially important to the development of our business by seeking, maintaining, and defending patent rights, whether developed internally or licensed from third parties. We will also seek to rely on regulatory protection afforded through inclusion in expedited development and review, data exclusivity, market exclusivity and patent term extensions where available. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have sought patent protection in the United States and internationally for our clinical product SNS-301. The claims of U.S. Patent Nos. 9,744,223 and 10,702,591 encompass the clinical product.&#160;We continue to pursue claims directed to the clinical product in related applications.&#160;Such applications may not result in issued patents and, even if patents do issue, such patents may not be in a form that will provide us with meaningful protection for our product. We also rely on trade secrets that may be important to the development of our business. Trade secrets are difficult to protect and provide us with only limited protection. </font></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We expect to file additional patent applications in support of current and new clinical candidates as well as new platform and core technologies. Our commercial success will depend in part on obtaining and maintaining patent protection and trade secret protection of our current and future product candidates and the methods used to develop and manufacture them, as well as successfully defending these patents against third-party challenges and operating without infringing on the proprietary rights of others. Our ability to stop third parties from making, using, selling, offering to sell or importing our products depends on the extent to which we have rights under valid and enforceable patents or trade secrets that cover these activities. We cannot be sure that patents will be granted with respect to any of our pending patent applications or with respect to any patent applications filed by us in the future, nor can we be sure that any patents that may be granted to us in the future will be commercially useful in protecting our product candidates, discovery programs and processes. For this and more comprehensive risks related to our intellectual property, please see &#8220;Risk Factors&#8212;Risks Related to Our Intellectual Property.&#8221; </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The term of individual patents depends upon the legal term of the patents in the countries in which they are obtained. In most countries in which we file, including the United States, the patent term is 20 years from the earliest date of filing a non-provisional patent application. In the United States, a patent&#8217;s term may be lengthened by patent term adjustment, which compensates a patentee for administrative delays by the U.S. Patent and Trademark Office, or USPTO, in examining and granting a patent, or may be shortened if a patent is terminally disclaimed over an earlier filed patent. In the United States, the patent term of a patent that covers an FDA-approved drug may also be eligible for patent term extension, which permits patent term restoration as compensation for the patent term lost during the FDA regulatory review process. The Hatch-Waxman Act permits a patent term extension of up to five years beyond the expiration of the patent. The length of the patent term extension is related to the length of time the drug is under regulatory review. Patent term extension cannot extend the remaining term of a patent beyond a total of 14 years from the date of product approval, only one patent applicable to an approved drug may be extended and only those claims covering the approved drug, a method for using it, or a method for manufacturing it may be extended. Similar provisions are available in Europe and other foreign jurisdictions to extend the term of a patent that covers an approved drug. In the future, if and when our products receive FDA approval, we expect to apply for patent term extensions on patents covering those products. We plan to seek patent term extensions to any issued patents we may obtain in any jurisdiction where such patent term extensions are available, however there is no guarantee that the applicable authorities, including the FDA in the United States, will agree with our assessment of whether such extensions should be granted, and if granted, the length of such extensions. For more information regarding the risks related to our intellectual property, see &#8220;Risk Factors&#8212;Risks Related to Our Intellectual Property.&#8221; </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In some instances, we submit patent applications directly with the USPTO as provisional patent applications. Corresponding&#160;non-provisional&#160;patent applications must be filed not later than 12 months after the provisional application filing date. While we intend to timely file&#160;non-provisional&#160;patent applications relating to our provisional patent applications, we cannot predict whether any such patent applications will result in the issuance of patents that provide us with any competitive advantage. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We file U.S. non-provisional applications and Patent Cooperation Treaty, or PCT, applications that claim the benefit of the priority date of earlier filed provisional applications, when applicable. The PCT system allows a single application to be filed within 12 months of the original priority date of the patent application, and to designate all of the PCT member states in which national patent applications can later be pursued based on the international patent application filed under the PCT. The PCT searching authority performs a patentability search and issues a non-binding patentability opinion which can be used to evaluate the chances of success for the national applications in foreign countries prior to having to incur the filing fees. Although a PCT application does not issue as a patent, it allows the applicant to seek protection in any of the member states through national-phase applications. At the end of the period of two and a half years from the first priority date of the patent application, separate patent applications can be pursued in any of the PCT member states either by direct national filing or, in some cases by filing through a regional patent organization, such as the European Patent Office. The PCT system delays expenses, allows a limited evaluation of the chances of success for national/regional patent applications and enables substantial savings where applications are abandoned within the first two and a half years of filing. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For all patent applications, we determine claiming strategy on a&#160;case-by-case&#160;basis. Advice of counsel and our business model and needs are always considered. We seek to file patents containing claims for protection of all useful applications of our proprietary technologies and any products, as well as all new applications and/or uses we discover for existing technologies and products, assuming these are strategically valuable. We continuously reassess the number and type of patent applications, as well as the pending and issued patent claims to pursue maximum coverage and value for our processes, and compositions, given existing patent office rules and regulations. Further, claims may be modified during patent prosecution to meet our intellectual property and business needs. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We recognize that the ability to obtain patent protection and the degree of such protection depends on </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">a number of</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> factors, including the extent of the prior art, the novelty and&#160;non-obviousness&#160;of the invention, and the ability to satisfy the enablement requirement of the patent laws. In addition, the coverage claimed in a patent application can be significantly reduced before the patent is issued, and its scope can be reinterpreted or further altered even after patent issuance. Consequently, we may not obtain or maintain adequate patent protection for any of our future product candidates or for our technology platform. We cannot predict whether the patent applications we are currently pursuing will issue as patents in any particular jurisdiction or whether the claims of any issued patents will provide sufficient proprietary protection from competitors. Any patents that we hold may be challenged, </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">circumvented</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> or invalidated by third parties. </font></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition to patent protection, we also rely on trademark registration, trade secrets, know how, other proprietary information and continuing technological innovation to develop and maintain our competitive position. We seek to protect and maintain the confidentiality of proprietary information to protect aspects of our business that are not amenable to, or that we do not consider appropriate for, patent protection. Although we take steps to protect our proprietary information and trade secrets, including through contractual means with our employees and consultants, third parties may independently develop substantially equivalent proprietary information and techniques or otherwise gain access to our trade secrets or disclose our technology. Thus, we may not be able to meaningfully protect our trade secrets. It is our policy to require our employees, consultants, outside scientific collaborators, sponsored researchers and other advisors to execute confidentiality agreements upon the commencement of employment or consulting relationships with us. These agreements provide that all confidential information concerning our business or financial affairs developed or made known to the individual during the course of the individual&#8217;s relationship with us is to be kept confidential and not disclosed to third parties except in specific circumstances. Our agreements with employees also provide that all inventions conceived by the employee in the course of employment with us or from the employee&#8217;s use of our confidential information are our exclusive property. However, such confidentiality agreements and invention assignment agreements can be breached and we may not have adequate remedies for any such breach. In addition, our trade secrets may otherwise become known or be independently discovered by competitors. To the extent that our consultants, contractors or collaborators use intellectual property owned by others in their work for us, disputes may arise as to the rights in related or resulting trade secrets,&#160;know-how&#160;and inventions. For more information regarding the risks related to our intellectual property, see &#8220;Risk Factors&#8212;Risks Related to Intellectual Property.&#8221; </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The patent positions of biotechnology companies like ours are generally uncertain and involve complex legal, scientific and factual questions. Our commercial success will also depend in part on not infringing upon the proprietary rights of third parties. Third-party patents could require us to alter our development or commercial strategies, or our products or processes, obtain licenses or cease certain activities. Our breach of any license agreements or our failure to obtain a license to proprietary rights required to develop or commercialize our future products may have a material adverse impact on us. If third parties prepare and file patent applications in the United States that also claim technology to which we have rights, we may have to participate in interference or derivation proceedings in the USPTO to determine priority of invention. For more information, see &#8220;Risk Factors&#8212;Risks Related to Intellectual Property.&#8221; </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">When available to expand market exclusivity, our strategy is to obtain, or license additional intellectual property related to current or contemplated development platforms, core elements of technology and/or clinical candidates. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Hlk66112657"></a>As of March 9, 2021, our solely owned patent estate included four issued U.S. patents, two issued foreign patents, eight pending U.S. patent applications, two pending international (PCT) patent applications, and over eight foreign patent applications (pending in Canada, Europe, Hong Kong and Japan).&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">With regard to SNS-301, we own one pending U.S. patent application and two issued U.S. patents with composition of matter claims covering SNS-301. The issued U.S. patents and U.S. patent application, if issued, are expected to expire in 2033, subject to payment of required maintenance fees, annuities and other charges. We also own one issued European EP patent (in force in France, Germany and the United Kingdom) and five pending foreign patent applications (pending in Canada, Europe, Hong Kong and Japan), where the EP European patent and the pending foreign patent applications, if issued, are expected to expire in 2034.&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We own one pending U.S. patent application and one pending, published PCT application with claims directed to methods for using and making the SNS-301 product candidate. The U.S. patent application and patent applications claiming the benefit of the PCT application, if issued, are expected to expire in 2039, subject to payment of required maintenance fees, annuities and other charges.&#160;&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We own one pending U.S. patent application and one pending, published PCT application relating to methods for using the SNS-301 product candidate in combination with immune checkpoint protein inhibitors. The U.S. patent application and patent applications claiming the benefit of the PCT application, if issued, are expected to expire in 2040, subject to payment of required maintenance fees, annuities and other charges.&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We own one provisional U.S. patent application relating to phage-based vaccines targeting SARS-CoV-2 proteins. Subject to payment of required maintenance fees, annuities and other charges, and assuming either U.S. non-provisional or foreign patent applications are filed at the appropriate time, if issued, are projected to expire in 2041.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We own one provisional U.S. patent application relating to phage-based vaccines targeting human papilloma virus proteins. Subject to payment of required maintenance fees, </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">annuities</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> and other charges, and assuming either U.S. non-provisional or foreign patent applications are filed at the appropriate time, if issued, are projected to expire in 2042.</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We own one provisional U.S. patent application relating to decorated phage-based vaccines and cocktails of such vaccines. Subject to payment of required maintenance fees, annuities and other charges, and assuming either U.S. non-provisional or foreign patent applications are filed at the appropriate time, if issued, are projected to expire in 2042.</p>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:2.26%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">License Agreement with Fred Hutch </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In connection with our acquisition of Alvaxa Biosciences, Inc., or Alvaxa, in May 2020, we acquired a non-exclusive license agreement, or the Fred Hutch Agreement, with Fred Hutchinson Cancer Research Center, or Fred Hutch, which was originally entered into in January 2020 and amended in March 2020. Pursuant to the Fred Hutch Agreement, we obtained a non-exclusive, non-sublicensable, worldwide license to possess, maintain, and use certain biological materials, including llama-derived antibodies, for any and all uses. Under the Fred Hutch Agreement, we are obligated to use commercially reasonable efforts to develop and commercialize at least one product containing or derived from an antibody in any form, or a developed product. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As partial consideration for the licensed rights granted under the Fred Hutch Agreement, Alvaxa issued Fred Hutch 1,429,412 shares of its common stock, which were subsequently exchanged for 45,656 shares of our common stock in connection with our acquisition of Alvaxa. Under the Fred Hutch Agreement, we are obligated to pay an annual license maintenance fee ranging from the mid-single digit thousands to approximately $0.1&#160;million, depending on net sales of developed products in a given calendar year. We are also obligated to pay up to $300,000 in development milestone payments for each therapeutic developed product and up to $165,000 for each diagnostic developed product, in each case including each unique target covered by such developed product. We have no obligation to pay royalties under the Fred Hutch Agreement. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Fred Hutch Agreement expires 20 years after the effective date. We may terminate the agreement for convenience, and Fred Hutch may terminate the agreement for our insolvency. Either party may terminate the agreement for breach of material obligations by such other party. </p>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:2.26%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Trademarks, Trade Secrets and Know-How </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our trademark portfolio currently consists of two registered trademarks and one trademark application. In addition to patent and trademark protection, we rely upon unpatented trade secrets and know-how and continuing technological innovation to develop and maintain our competitive position. We seek to protect our proprietary information, in part, using confidentiality agreements with our commercial partners, collaborators, employees, and consultants, and employees. These and other agreements, such as invention assignment agreements, grant us ownership of technologies that are developed through a relationship with a third party. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Competition </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The biotechnology and pharmaceutical industries have made substantial investments in recent years into the rapid development of novel immunotherapies for the treatment of a range of pathologies, including cancers and infectious diseases, making this a highly competitive market. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We face substantial competition from multiple sources, including large and specialty pharmaceutical, biopharmaceutical and biotechnology companies, academic research institutions and governmental agencies and public and private research institutions. Our competitors compete with us on the level of the technologies employed, or on the level of development of product candidates. In addition, many small biotechnology companies have formed collaborations with large, established companies to (i)&#160;obtain support for their research, development and commercialization of products or (ii)&#160;combine several treatment approaches to develop longer lasting or more efficacious treatments that may potentially directly compete with our current or future product candidates. We anticipate that we will continue to face increasing competition as new therapies and combinations thereof, technologies, and data emerge within the field of immunotherapy and, furthermore, within the treatment of cancers and infectious diseases. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition to the current standard of care treatments for patients with cancers and infectious diseases, numerous commercial and academic preclinical studies and clinical trials are being undertaken by a large number of parties to assess novel technologies and product candidates in the field of immunotherapy. Results from these studies and trials have fueled increasing levels of interest in the field of immunotherapy. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Large pharmaceutical companies that have commercialized or are developing immunotherapies to treat cancer include AstraZeneca, Bristol Myers Squibb, Gilead Sciences, Merck, Novartis, Pfizer, and Roche/Genentech. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On the technology level, other companies which can potentially develop competing product candidates which act to stimulate the body&#8217;s immune response as a treatment for SCCHN and other solid tumors include companies developing cell-based therapeutics such as CAR-T/TCR/NK therapies as well as companies developing therapeutic vaccines including BioNTech, Moderna, Gritstone Oncology and Oncorus, among others. In addition, </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">a number of</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> companies are developing oncolytic virus approaches, including Boehringer Ingelheim, Johnson and Johnson, Regeneron, Vyriad, Replimune and Turnstone. Amgen has received FDA approval for its oncolytic virus-based product, T-VEC. Ablynx, a subsidiary of Sanofi, and Oncorus are actively pursuing the development of nanobodies as therapeutics. </font></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Many of our competitors, either alone or in combination with their respective strategic partners, have significantly greater financial resources and expertise in research and development, manufacturing, the regulatory approval process, and marketing than we do. Mergers and acquisition activity in the pharmaceutical, biopharmaceutical and biotechnology sector is likely to result in greater resource concentration among a smaller number of our competitors. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Smaller or early-stage companies may also prove to be significant competitors, particularly through sizeable collaborative arrangements with established companies. These competitors also compete with us in recruiting and retain qualified scientific and management personnel and establishing clinical trial sites and patient registration for clinical trials, as well as in acquiring technologies complementary to, or necessary for, our programs. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our commercial opportunity could be reduced or eliminated if one or more of our competitors develop and commercialize products that are safer, more effective, better tolerated, or of greater convenience or economic benefit than our proposed product offering. Our competitors also may be in a position to obtain FDA or other regulatory approval for their products more rapidly, resulting in a stronger or dominant market position before we are able to enter the market. The key competitive factors affecting the success of all of our programs are likely to be product safety, efficacy, convenience and treatment cost. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Government Regulation </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Government authorities in the United States at the federal, state and local level and in other countries regulate, among other things, the research, development, testing, manufacture, quality control, approval, labeling, packaging, storage, record-keeping, promotion, advertising, distribution, post-approval monitoring and reporting, marketing and export and import of biological products. Generally, before a new drug or biologic can be marketed, considerable data demonstrating its quality, safety and efficacy must be obtained, organized into a format specific for each regulatory authority, submitted for review and approved by the regulatory authority. </p>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:2.26%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">U.S. Biological Product Development </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the United States, the FDA regulates biologics under the Federal Food, Drug and Cosmetic Act, or FDCA, the Public Health Service Act, or the PHSA, and their implementing regulations. Biologics also are subject to other federal, state and local statutes and regulations. The process of obtaining regulatory approvals and the subsequent compliance with appropriate federal, state and local statutes and regulations requires the expenditure of substantial time and financial resources. Failure to comply with the applicable U.S. requirements at any time during the product development process, approval process or post-market may subject an applicant to administrative or judicial sanctions. These sanctions could include, among other actions, the FDA&#8217;s refusal to approve pending applications, suspension or revocation of a license, a clinical hold, untitled or warning letters, product recalls or market withdrawals, product seizures, total or partial suspension of production or distribution, injunctions, fines, refusals of government contracts, restitution, disgorgement and civil or criminal penalties. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our product candidates and any future biological product candidates we develop must be approved by the FDA through a biologics license application, or BLA, before they may be legally marketed in the United States. The BLA is a request for approval to market the biologic for one or more specified indications and must contain proof of safety, purity and potency. The FDA review and approval process generally involves the following: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:1.13%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">completion of extensive preclinical studies conducted in accordance with applicable regulations, including studies conducted in accordance with good laboratory practices, or GLP, requirements; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:1.13%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">submission to the FDA of an IND, which must become effective before human clinical trials may begin; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:1.13%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">approval by an Institutional Review Board, or IRB, or independent ethics committee at each clinical trial site before each trial may be initiated; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:1.13%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">performance of adequate and well-controlled human clinical trials in accordance with applicable IND regulations, good clinical practice, or GCP, requirements and other clinical trial-related regulations to establish the safety and efficacy of the investigational product for each proposed indication; </font></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">18</a></p>
<hr style="page-break-after:always;width:100%;">
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:1.13%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="text-decoration:none;Background-color:#auto;font-size:10pt;font-family:'Times New Roman';"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">submission to the FDA of a BLA; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:1.13%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">a determination by the FDA within 60&#160;days of its receipt of a BLA to accept the filing for review; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:1.13%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">satisfactory completion of an FDA pre-approval inspection of the manufacturing facility or facilities where the biologic will be produced to assess compliance with cGMP requirements to assure that the facilities, methods and controls are adequate to preserve the biologic&#8217;s identity, strength, quality and purity; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:1.13%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">potential FDA audit of the preclinical study and clinical trial sites that generated the data in support of the BLA; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:1.13%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">payment of user fees for FDA review of the BLA (unless a fee waiver applies); and </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:1.13%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">FDA review and approval of the BLA, including consideration of the views of any FDA advisory committee, prior to any commercial marketing or sale of the biologic in the United States. </font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:2.26%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Preclinical Studies and IND </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Before testing any biological product candidate in humans, the product candidate enters the preclinical testing stage. Preclinical studies include laboratory evaluation of product biological characteristics, chemistry and formulation, as well as in vitro and animal studies to assess the potential for adverse events and in some cases to establish a rationale for therapeutic use. The conduct of preclinical studies is subject to federal regulations and requirements, including GLP regulations for safety/toxicology studies. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">An IND sponsor must submit the results of the preclinical studies, together with manufacturing information, analytical data, any available clinical data or literature and plans for clinical trials, among other things, to the FDA as part of an IND. An IND is a request for authorization from the FDA to administer an investigational product to humans, and must become effective before human clinical trials may begin. Some long-term preclinical testing may continue after the IND is submitted. An IND automatically becomes effective 30&#160;days after receipt by the FDA, unless before that time, the FDA raises concerns or questions related to one or more proposed clinical trials and places the trial on clinical hold. In such a case, the IND sponsor and the FDA must resolve any outstanding concerns before the clinical trial can begin. As a result, submission of an IND may not result in the FDA allowing clinical trials to commence. </p>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:2.26%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Clinical Trials </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The clinical stage of development involves the administration of the investigational product to healthy volunteers or patients under the supervision of qualified investigators, generally physicians not employed by or under the trial sponsor&#8217;s control, in accordance with GCP requirements, which include the requirement that all research subjects provide their informed consent for their participation in any clinical trial. Clinical trials are conducted under protocols detailing, among other things, the objectives of the clinical trial, dosing procedures, subject selection and exclusion criteria and the parameters to be used to monitor subject safety and assess efficacy, including stopping rules that assure a clinical trial will be stopped if certain adverse events should occur. Each protocol, and any subsequent amendments to the protocol, must be submitted to the FDA as part of the IND. Further, each clinical trial must be reviewed and approved by an IRB for each institution at which the clinical trial will be conducted to ensure that the risks to individuals participating in the clinical trials are minimized and are reasonable in relation to anticipated benefits. The IRB also approves the informed consent form that must be provided to each clinical trial subject or his or her legal representative, and must monitor the clinical trial until completed. There also are requirements governing the reporting of ongoing clinical trials and completed clinical trial results to public registries. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A sponsor who wishes to conduct a clinical trial outside of the United States may, but need not, obtain FDA authorization to conduct the clinical trial under an IND. If a foreign clinical trial is not conducted under an IND, the sponsor may submit data from the clinical trial to the FDA in support of a BLA. The FDA will accept a well-designed and well-conducted foreign clinical trial not conducted under an IND if the study was conducted in accordance with GCP requirements, and the FDA is able to validate the data through an onsite inspection if deemed necessary. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Clinical trials generally are conducted in three sequential phases, known as Phase&#160;1, Phase&#160;2 and Phase&#160;3, and may overlap or be combined, such that the objectives of multiple phases are addressed within the design of a single trial. </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:1.13%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">Phase&#160;1 clinical trials generally involve a small number of healthy volunteers or disease-affected patients who are initially exposed to a single dose and then multiple doses of the product candidate. The primary purpose of these clinical trials is to assess the metabolism, pharmacologic action, side effect tolerability and safety of the product candidate. When conducted in disease-affected patients and including an endpoint of early activity or efficacy, such a trial may be a Phase 1/2 trial, comprising a Phase 1 portion and a Phase 2 portion. </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:1.13%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">Phase&#160;2 clinical trials involve studies in disease-affected patients to determine the dose required to produce the desired benefits. At the same time, safety and further pharmacokinetic and pharmacodynamic information is collected, possible </font></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">19</a></p>
<hr style="page-break-after:always;width:100%;">
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:1.13%;white-space:nowrap"></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="font-size:10pt;color:#000000;">adverse effects and safety risks are identified and a preliminary evaluation of efficacy is conducted. Multiple Phase 2 clinical trials may be conducted to obtain information prior to beginning larger and more expensive Phase 3 clinical trials. Phase 2/3 trials may also be designed to sequentially address both dose finding and effectiveness in a single trial. </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:1.13%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">Phase&#160;3 clinical trials generally involve a large number of patients at multiple sites and are designed to provide the data necessary to demonstrate the effectiveness of the product for its intended use, its safety in use and to establish the overall benefit/risk relationship of the product candidate and provide an adequate basis for product labeling. </font></p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In August 2018, the FDA released a draft guidance entitled &#8220;Expansion Cohorts: Use in First-In-Human Clinical Trials to Expedite Development of Oncology Drugs and Biologics,&#8221; which outlines how developers can utilize an adaptive trial design commonly referred to as a seamless trial design in early stages of oncology biological product development (i.e., the Phase 1 first-in-human clinical trial) to compress the traditional three phases of trials into one continuous trial called an expansion cohort trial. Information to support the design of individual expansion cohorts are included in IND applications and assessed by FDA. Expansion cohort trials can potentially bring efficiency to biological product development and reduce developmental costs and time. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Post-approval trials, sometimes referred to as Phase&#160;4 clinical trials, may be conducted after initial marketing approval. These trials are used to gain additional experience from the treatment of patients in the intended therapeutic indication. In certain instances, the FDA may mandate the performance of Phase&#160;4 clinical trials as a condition of approval of a BLA. Failure to exhibit due diligence with regard to conducting required Phase 4 clinical trials could result in withdrawal of licensure for biological products. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During all phases of clinical development, regulatory agencies require extensive monitoring and auditing of all clinical activities, clinical data, and clinical trial investigators. Progress reports detailing the results of the clinical trials, among other information, must be submitted at least annually to the FDA and written IND safety reports must be submitted to the FDA and the investigators for serious and unexpected suspected adverse events, findings from other studies or animal or in vitro testing that suggest a significant risk for human subjects, and any clinically important increase in the rate of a serious suspected adverse reaction over that listed in the protocol or investigator brochure. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Phase&#160;1, Phase&#160;2 and Phase&#160;3 clinical trials may not be completed successfully within any specified period, if at all. The FDA or the sponsor may suspend or terminate a clinical trial at any time on various grounds, including a finding that the research subjects or patients are being exposed to an unacceptable health risk. Similarly, an IRB can suspend or terminate approval of a clinical trial at its institution if the clinical trial is not being conducted in accordance with the IRB&#8217;s requirements or if the biological product candidate has been associated with unexpected serious harm to patients. Additionally, some clinical trials are overseen by an independent group of qualified experts organized by the clinical trial sponsor, known as a data safety monitoring board or committee. This group provides authorization for whether a trial may move forward at designated check points based on access to certain data from the trial. There are also requirements governing the reporting of ongoing clinical studies and clinical study results to public registries. Concurrent with clinical trials, companies usually complete additional animal studies and also must develop additional information about the chemistry and physical characteristics of the biological product candidate as well as finalize a process for manufacturing the product candidate in commercial quantities in accordance with cGMP requirements. The manufacturing process must be capable of consistently producing quality batches of the product and, among other things, companies must develop methods for testing the identity, strength, quality, purity and potency of the final product. Additionally, appropriate packaging must be selected and tested and stability studies must be conducted to demonstrate that the product candidate does not undergo unacceptable deterioration over their shelf life. </p>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:2.26%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">FDA Review Process </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Following completion of the clinical trials, data are analyzed to assess whether the investigational product is safe and effective for the proposed indicated use or uses. The results of preclinical studies and clinical trials are then submitted to the FDA as part of a BLA, along with proposed labeling, chemistry and manufacturing information to ensure product quality and other relevant data. The BLA may include both negative and ambiguous results of preclinical studies and clinical trials, as well as positive findings. Data may come from company-sponsored clinical trials intended to test the safety and efficacy of a product candidate&#8217;s use or from a number of alternative sources, including studies initiated by investigators. To support marketing approval, the data submitted must be sufficient in quality and quantity to establish the safety, purity and potency of the investigational product to the satisfaction of FDA. FDA approval of a BLA must be obtained before a biologic may be marketed in the United States. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the Prescription Drug User Fee Act, or PDUFA, as amended, each BLA must be accompanied by a user fee. The FDA adjusts the PDUFA user fees on an annual basis. The sponsor of an approved BLA is also subject to an annual prescription drug program fee. Fee waivers or reductions are available in certain circumstances, including a waiver of the application fee for the first application filed by a small business. Additionally, no user fees are assessed on BLAs for products designated as orphan drugs, unless the product also includes a non-orphan indication. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The FDA reviews all submitted BLAs before it accepts them for filing, and may request additional information rather than accepting the BLA for filing. The FDA decides whether to accept a BLA for filing within 60&#160;days of receipt, and such decision could include a refusal to file by the FDA. Once the submission is accepted for filing, the FDA begins an in-depth review of the BLA. Under the goals and policies agreed to by the FDA under PDUFA, the FDA has ten months from the filing date in which to complete its initial review of an original BLA and respond to the applicant, and six months from the filing date of an original BLA designated for priority review. The FDA does not always meet its PDUFA goal dates for standard and priority BLAs, and the review process is often extended by FDA requests for additional information or clarification. </font></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Before approving a BLA, the FDA will conduct a pre-approval inspection of the manufacturing facilities for the new product to determine whether they comply with cGMP requirements. The FDA will not approve the product unless it determines that the manufacturing processes and facilities are in compliance with cGMP requirements and adequate to assure consistent production of the product within required specifications. The FDA also may audit data from clinical trials to ensure compliance with GCP requirements. Additionally, the FDA may refer applications for novel products or products which present difficult questions of safety or efficacy to an advisory committee, typically a panel that includes clinicians and other experts, for review, evaluation and a recommendation as to whether the application should be approved and under what conditions, if any. The FDA is not bound by recommendations of an advisory committee, but it considers such recommendations when making decisions on approval. The FDA likely will reanalyze the clinical trial data, which could result in extensive discussions between the FDA and the applicant during the review process. After the FDA evaluates a BLA, it will issue an approval letter or a complete response letter. An approval letter authorizes commercial marketing of the biologic with specific prescribing information for specific indications. A complete response letter indicates that the review cycle of the application is complete and the application will not be approved in its present form. A complete response letter usually describes all of the specific deficiencies in the BLA identified by the FDA. The complete response letter may require additional clinical data, pivotal Phase 3 clinical trial(s) as well as other significant and time-consuming requirements related to clinical trials, preclinical studies or manufacturing. If a complete response letter is issued, the applicant may either resubmit the BLA, addressing all of the deficiencies identified in the letter, or withdraw the application. Even if such data and information are submitted, the FDA may decide that the BLA does not satisfy the criteria for approval. </p>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:2.26%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Orphan Drug Designation </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the Orphan Drug Act, the FDA may grant orphan designation to a biological product intended to treat a rare disease or condition, which is generally a disease or condition that affects fewer than 200,000 individuals in the United States, or more than 200,000 individuals in the United States and for which there is no reasonable expectation that the cost of developing and making the product available in the United States for this type of disease or condition will be recovered from sales of the product. Orphan drug designation for a biologic must be requested before submitting a BLA. After the FDA grants orphan drug designation, the identity of the therapeutic agent and its potential orphan use are disclosed publicly by the FDA. Orphan drug designation does not convey any advantage in or shorten the duration of the regulatory review and approval process. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Orphan drug designation entitles a party to financial incentives such as opportunities for grant funding towards clinical trial costs, tax advantages and user fee waivers. If a product that has orphan drug designation subsequently receives the first FDA approval for the disease or condition for which it has such designation, the product is entitled to orphan drug exclusivity, which means that the FDA may not approve any other applications to market the same biological product for the same indication for seven years from the date of such approval, except in limited circumstances, such as a showing of clinical superiority to the product with orphan exclusivity by means of greater effectiveness, greater safety or providing a major contribution to patient care or in instances of drug supply issues. Competitors, however, may receive approval of either a different product for the same indication or the same product for a different indication but that could be used off-label in the orphan indication. Orphan drug exclusivity also could block the approval of one of our products for seven years if a competitor obtains approval before we do for the same product, as defined by the FDA, for the same indication we are seeking approval, or if our product is determined to be contained within the scope of the competitor&#8217;s product for the same indication or disease. If a biological product designated as an orphan drug receives marketing approval for an indication broader than that which is designated, it may not be entitled to orphan drug exclusivity. Orphan drug status in the European Union has similar, but not identical, requirements and benefits. </p>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:2.26%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Expedited Development and Review Programs </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The FDA has a fast track program that is intended to expedite or facilitate the process for reviewing new biologics that meet certain criteria. Specifically, new biological product candidates are eligible for fast track designation if they are intended to treat a serious or life-threatening condition and preclinical or clinical data demonstrate the potential to address unmet medical needs for the condition. Fast track designation applies to both the product and the specific indication for which it is being studied. The sponsor of a biological product candidate can request the FDA to designate the product for fast track status any time before receiving BLA approval, but ideally no later than the pre-BLA meeting. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Any product submitted to the FDA for marketing, including under a fast track program, may be eligible for other types of FDA programs intended to expedite development and review, such as priority review and accelerated approval. Any product candidate is eligible for priority review if it treats a serious or life-threatening condition and, if approved, would provide a significant improvement in safety and effectiveness compared to available therapies. The FDA will attempt to direct additional resources to the evaluation of an application for a new biologic designated for priority review </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">in an effort to</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> facilitate the review. </font></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A product candidate may also be eligible for accelerated approval, if it treats a serious or life-threatening condition and generally provides a meaningful advantage over available therapies. In addition, it must demonstrate an effect on a surrogate endpoint that is reasonably likely to predict clinical benefit or on a clinical endpoint that can be measured earlier than irreversible morbidity or mortality, or IMM, that is reasonably likely to predict an effect on IMM or other clinical benefit. As a condition of approval, the FDA may require that a sponsor of a biological product candidate receiving accelerated approval perform adequate and well-controlled post-marketing clinical trials. If the FDA concludes that a biological product candidate shown to be effective can be safely used only if distribution or use is restricted, it will require such post-marketing restrictions, as it deems necessary to assure safe use of the product. If the FDA determines that the conditions of approval are not being met, the FDA can withdraw its accelerated approval for such biologic. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Additionally, a biological product candidate may be eligible for designation as a breakthrough therapy if the product candidate is intended, alone or in combination with one or more other drugs or biologics, to treat a serious or life-threatening condition and preliminary clinical evidence indicates that the product candidate may demonstrate substantial improvement over currently approved therapies on one or more clinically significant endpoints. The benefits of breakthrough therapy designation include the same benefits as fast track designation, plus intensive guidance from the FDA to ensure an efficient drug development program. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Fast track designation, priority review, accelerated approval and breakthrough therapy designation do not change the standards for approval, but may expedite the development or approval process. </p>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:2.26%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Pediatric Information </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the Pediatric Research Equity Act, or PREA, a BLA or supplement to a BLA must contain data to assess the safety and efficacy of the biological product candidate for the claimed indications in all relevant pediatric subpopulations and to support dosing and administration for each pediatric subpopulation for which the product is safe and effective. The FDA may grant deferrals for submission of pediatric data or full or partial waivers. Unless otherwise required by regulation, PREA does not apply to any biological product candidate for an indication for which orphan designation has been granted. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Food and Drug Administration Safety and Innovation Act, or FDASIA, amended the FDCA to require that a sponsor who is planning to submit a marketing application for a drug that includes a new active ingredient, new indication, new dosage form, new dosing regimen or new route of administration submit an initial Pediatric Study Plan, or PSP, within 60&#160;days of an end-of-Phase&#160;2 meeting or, if there is no such meeting, as early as practicable before the initiation of the registration-enabling trial. The initial PSP must include an outline of the pediatric study or studies that the sponsor plans to conduct, including study objectives and design, age groups, relevant endpoints and statistical approach, or a justification for not including such detailed information, and any request for a deferral of pediatric assessments or a full or partial waiver of the requirement to provide data from pediatric studies along with supporting information. The FDA and the sponsor must reach an agreement on the PSP. A sponsor can submit amendments to an agreed-upon initial PSP at any time if changes to the pediatric plan need to be considered based on data collected from preclinical studies, early phase clinical trials as well as other clinical development programs. </p>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:2.26%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Post-Marketing Requirements </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Following approval of a new product, the manufacturer and the approved product are subject to continuing regulation by the FDA, including, among other things, monitoring and record-keeping activities, reporting of adverse experiences, complying with promotion and advertising requirements, which include restrictions on promoting products for unapproved uses or patient populations (known as &#8220;off-label use&#8221;) and limitations on industry-sponsored scientific and educational activities. Although physicians may prescribe legally available products for off-label uses, manufacturers may not market or promote such uses. Prescription drug and biologic promotional materials must be submitted to the FDA in conjunction with their first use. Further, if there are any modifications to the biologic, including changes in indications, labeling or manufacturing processes or facilities, the applicant may be required to submit and obtain FDA approval of a new BLA or BLA supplement, which may require the development of additional data or preclinical studies and clinical trials. The FDA may also place other conditions on approvals including the requirement for a Risk Evaluation and Mitigation Strategy, or REMS, to assure the safe use of the product. If the FDA concludes a REMS is needed, the sponsor of the BLA must submit a proposed REMS. The FDA will not approve the BLA without an approved REMS, if required. A REMS could include medication guides, physician communication plans or elements to assure safe use, such as restricted distribution methods, patient registries and other risk minimization tools. Any of these limitations on approval or marketing could restrict the </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">22</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">commercial promotion, distribution, prescription or dispensing of products. Product approvals may be withdrawn for non-compliance with regulatory standards or if problems occur following initial marketing. </font></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">FDA regulations require that products be manufactured in specific facilities and in accordance with cGMP regulations. We rely, and expect to continue to rely, on third parties for the production of clinical and commercial quantities of our products in accordance with cGMP regulations. These manufacturers must comply with cGMP regulations that require, among other things, quality control and quality assurance, the maintenance of records and documentation and the obligation to investigate and correct any deviations from cGMP. Manufacturers and other entities involved in the manufacture and distribution of approved biologics are required to register their establishments with the FDA and certain state agencies, and are subject to periodic unannounced inspections by the FDA and certain state agencies for compliance with cGMP requirements and other laws. Accordingly, manufacturers must continue to expend time, money and effort in the area of production and quality control to maintain cGMP compliance. The discovery of violations, including failure to conform to cGMP regulations, could result in enforcement actions, and the discovery of post-approval problems with a product may result in restrictions on a product, manufacturer or holder of an approved BLA, including recall. </p>
<p style="margin-top:18pt;margin-bottom:0pt;margin-left:2.26%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">U.S. Healthcare Reform and Other U.S. Healthcare Laws </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Manufacturing, sales, promotion and other activities following product approval are also subject to regulation by numerous regulatory authorities in the United States in addition to the FDA, including the Centers for Medicare&#160;&amp; Medicaid Services, or CMS, other divisions of the Department of Health and Human Services, the Department of Justice, the Drug Enforcement Administration, the Consumer Product Safety Commission, the Federal Trade Commission, the Occupational Safety&#160;&amp; Health Administration, the Environmental Protection Agency and state and local governments. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Healthcare providers, physicians and third-party payors in the United States and elsewhere play a primary role in the recommendation and prescription of pharmaceutical products. Arrangements with third-party payors and customers can expose pharmaceutical manufactures to broadly applicable fraud and abuse and other healthcare laws and regulations, including, without limitation, the federal Anti-Kickback Statute and the federal False Claims Act, or FCA, which may constrain the business or financial arrangements and relationships through which companies sell, market and distribute pharmaceutical products. In addition, transparency laws and patient privacy regulations by federal and state governments and by governments in foreign jurisdictions can apply to the manufacturing, sales, promotion and other activities of pharmaceutical manufactures. The applicable federal, state and foreign healthcare laws and regulations that can affect a pharmaceutical company&#8217;s operations include: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:1.13%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">The federal Anti-Kickback Statute, which prohibits, among other things, knowingly and willfully soliciting, receiving, offering or paying any remuneration (including any kickback, bribe, or rebate), directly or indirectly, overtly or covertly, in cash or in kind, to induce, or in return for, either the referral of an individual, or the purchase, lease, order or recommendation of any good, facility, item or service for which payment may be made, in whole or in part, under the Medicare and Medicaid programs, or other federal healthcare programs. A person or entity can be found guilty of violating the statute without actual knowledge of the statute or specific intent to violate it. In addition, the government may assert that a claim including items or services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the FCA. The Anti-Kickback Statute has been interpreted to apply to arrangements between pharmaceutical manufacturers on the one hand and prescribers, purchasers, and formulary managers on the other. There are a number of statutory exceptions and regulatory safe harbors protecting some common activities from prosecution; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:1.13%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">The federal civil and criminal false claims laws and civil monetary penalty laws, including the FCA, which prohibit any person or entity from, among other things, knowingly presenting, or causing to be presented, a false, fictitious or fraudulent claim for payment to, or approval by, the federal government or knowingly making, using or causing to be made or used a false record or statement, including providing inaccurate billing or coding information to customers or promoting a product off-label, material to a false or fraudulent claim to the federal government. As a result of a modification made by the Fraud Enforcement and Recovery Act of 2009, a claim includes &#8220;any request or demand&#8221; for money or property presented to the federal government. In addition, manufacturers can be held liable under the FCA even when they do not submit claims directly to government payors if they are deemed to &#8220;cause&#8221; the submission of false or fraudulent claims. The FCA also permits a private individual acting as a &#8220;whistleblower&#8221; to bring actions on behalf of the federal government alleging violations of the FCA and to share in any monetary recovery; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:1.13%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">The anti-inducement law, which prohibits, among other things, the offering or giving of remuneration, which includes, without limitation, any transfer of items or services for free or for less than fair market value (with limited exceptions), to a Medicare or Medicaid beneficiary that the person knows or should know is likely to influence the beneficiary&#8217;s selection of a particular provider, practitioner or supplier of items or services reimbursable, whole or in part, by a federal or state governmental program; </font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:6pt;margin-left:5.67%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The federal Health Insurance Portability and Accountability Act of 1996, or HIPAA, which created federal criminal statutes that prohibit knowingly and willfully executing, or attempting to execute, a scheme to defraud any healthcare benefit program or obtain, by means of false or fraudulent pretenses, representations, or promises, any of the money or property owned by, or </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">23</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:6pt;margin-left:5.67%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">under the custody or control of, any healthcare benefit program, regardless of the payor (e.g.,&#160;public or private) and knowingly and willfully falsifying, concealing or covering up by any trick or device a material fact or making any materially false statements in connection with the delivery of, or payment for, healthcare benefits, items or services relating to healthcare matters. </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Similar to</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> the federal Anti-Kickback Statute, a person or entity can be found guilty of violating HIPAA without actual knowledge of the statute or specific intent to violate it; </font></p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:1.13%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act of 2009, or HITECH, and their respective implementing regulations, which impose, among other things, specified requirements relating to the privacy, security and transmission of individually identifiable health information held by covered entities, including certain healthcare providers, health plans, and healthcare clearinghouses, as well as their respective business associates that create, receive, maintain or transmit individually identifiable health information for or on behalf of a covered entity, and their subcontractors that use, disclose or otherwise process individually identifiable health information. HITECH also created new tiers of civil monetary penalties, amended HIPAA to make civil and criminal penalties directly applicable to business associates, and gave state attorneys general new authority to file civil actions for damages or injunctions in federal courts to enforce the federal HIPAA laws and seek attorneys&#8217; fees and costs associated with pursuing federal civil actions; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:1.13%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">The federal legislation commonly referred to as the Physician Payments Sunshine Act, created under the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act of 2010, or collectively the ACA, and its implementing regulations, which requires manufacturers of drugs, devices, biologics and medical supplies for which payment is available under Medicare, Medicaid or the Children&#8217;s Health Insurance Program (with certain exceptions) to report annually to CMS, information related to payments or other transfers of value made to physicians (defined to include doctors, dentists, optometrists, podiatrists and chiropractors) and teaching hospitals, as well as ownership and investment interests held by physicians and their immediate family members. Effective January&#160;1, 2022, covered manufacturers will be required to&nbsp;&nbsp;report information regarding payments and other transfers of value made to physician assistants, nurse practitioners, clinical nurse specialists, anesthesiologist assistants, certified registered nurse anesthetists and certified nurse midwives during the previous year; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:1.13%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">Federal government price reporting laws, which require us to calculate and report complex pricing metrics in an accurate and timely manner to government programs; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:1.13%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">Federal consumer protection and unfair competition laws, which broadly regulate marketplace activities and activities that potentially harm consumers; and </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:1.13%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">Analogous state laws and regulations, including: state anti-kickback and false claims laws, which may apply to our business practices, including, but not limited to, research, distribution, sales and marketing arrangements and claims involving healthcare items or services reimbursed by any third-party payor, including private insurers; state laws that require pharmaceutical companies to comply with the pharmaceutical industry&#8217;s voluntary compliance guidelines and the relevant compliance guidance promulgated by the U.S. federal government, or otherwise restrict payments that may be made to healthcare providers and other potential referral sources; state laws that require drug manufacturers to file reports with states regarding pricing and marketing information, such as the tracking and reporting of gifts, compensations and other remuneration and items of value provided to healthcare professionals and entities; state and local laws requiring the registration of pharmaceutical sales representatives; and state and foreign laws governing the privacy and security of health information in certain circumstances, many of which differ from each other in significant ways and may not have the same effect, thus complicating compliance efforts. </font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pricing and rebate programs must comply with the Medicaid rebate requirements of the U.S. Omnibus Budget Reconciliation Act of 1990 and more recent requirements in the ACA. If products are made available to authorized users of the Federal Supply Schedule of the General Services Administration, additional laws and requirements apply. Products must meet applicable child-resistant packaging requirements under the U.S. Poison Prevention Packaging Act. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The distribution of pharmaceutical products is subject to additional requirements and regulations, including extensive record-keeping, licensing, storage and security requirements intended to prevent the unauthorized sale of pharmaceutical products. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The scope and enforcement of each of these laws is uncertain and subject to rapid change in the current environment of healthcare reform, especially in light of the lack of applicable precedent and regulations with respect to certain laws. Federal and state enforcement bodies have recently increased their scrutiny of interactions between healthcare companies and healthcare providers, which has led to a number of investigations, prosecutions, convictions and settlements in the healthcare industry. Prohibitions or restrictions on sales or withdrawal of future marketed products could materially affect our business in an adverse way. Changes in regulations, statutes or the interpretation of existing regulations could impact our business in the future by requiring, for example: (i)&#160;changes to our manufacturing arrangements; (ii)&#160;additions or modifications to product labeling; (iii)&#160;the recall or discontinuation of our products; or (iv)&#160;additional record-keeping requirements. If any such changes were to be imposed, they could adversely affect the operation of our business. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">24</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Ensuring our business arrangements comply with applicable healthcare laws, as well as responding to possible investigations by government authorities, can be time- and resource-consuming and can divert a company&#8217;s attention from the business. </font></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">It is possible that governmental and enforcement authorities will conclude that a pharmaceutical manufacturer&#8217;s business practices do not comply with current or future statutes, regulations or case law interpreting applicable fraud and abuse or other healthcare laws and regulations. The failure to comply with any of these laws or regulatory requirements subjects companies to possible legal or regulatory action. Depending on the circumstances, failure to meet applicable regulatory requirements can result in civil, criminal and administrative penalties, damages, fines, disgorgement, individual imprisonment, possible exclusion from participation in federal and state funded healthcare programs, contractual damages and the curtailment or restricting of our operations, as well as additional reporting obligations and oversight if we become subject to a corporate integrity agreement or other agreement to resolve allegations of non-compliance with these laws. Additionally, private individuals have the ability to bring actions on behalf of the U.S. government under the federal FCA as well as under the false claims laws of several states against a pharmaceutical manufacturer. The approval and commercialization of a pharmaceutical manufacturer&#8217;s product candidates outside the United States will also likely subject it to foreign equivalents of the healthcare laws mentioned above, among other foreign laws. Lastly, if any of the physicians or other healthcare providers or entities with whom we expect to do business are found to be not in compliance with applicable laws, they may be subject to criminal, civil or administrative sanctions, including exclusions from government funded healthcare programs, which may also adversely affect our business. Any action for violation of these laws, even if successfully defended, could cause a pharmaceutical company to incur significant legal expenses and divert management&#8217;s attention from the operation of the business. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the United States, there have been and continue to be a number of legislative initiatives to contain healthcare costs. For example, in March 2010, the ACA was passed, which substantially changes the way healthcare is financed by both governmental and private insurers, and significantly impacts the U.S. pharmaceutical industry. The ACA, among other things, subjects biological products to potential competition by lower-cost biosimilars, addresses a new methodology by which rebates owed by manufacturers under the Medicaid Drug Rebate Program are calculated for drugs that are inhaled, infused, instilled, implanted or injected, increases the minimum Medicaid rebates owed by manufacturers under the Medicaid Drug Rebate Program and extends the rebate program to individuals enrolled in Medicaid managed care organizations, establishes annual fees and taxes on manufacturers of certain branded prescription drugs, and creates a new Medicare Part&#160;D coverage gap discount program, in which manufacturers must now, as amended by the Bipartisan Budget Act of 2018, effective January&#160;1, 2019, agree to offer 70% point-of-sale discounts off negotiated prices of applicable brand drugs to eligible beneficiaries during their coverage gap period, as a condition to coverage under Medicare Part&#160;D for the manufacturer&#8217;s outpatient drugs. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">There have been executive, judicial and congressional challenges. While Congress has not passed comprehensive repeal legislation, there have been a number of significant changes to the ACA and its implementation. For example, the Tax Cuts and Jobs Act of 2017, or Tax Act, included a provision repealing, effective January&#160;1, 2019, the tax-based shared responsibility payment imposed by the ACA on certain individuals who fail to maintain qualifying health coverage for all or part of a year that is commonly referred to as the &#8220;individual mandate.&#8221; On December&#160;14, 2018, a federal district court in Texas ruled the individual mandate is a critical and inseverable feature of the ACA, and therefore, because it was repealed as part of the Tax Act, the remaining provisions of the ACA are invalid as well. Additionally, on December&#160;18, 2019, the U.S. Court of Appeals for the Fifth Circuit upheld the District Court ruling that the individual mandate was unconstitutional and remanded the case back to the District Court to determine whether the remaining provisions of the ACA are invalid as well. The United States Supreme Court is currently reviewing this case, although it is uncertain when a decision will be reached or how the Supreme Court will rule. Although the U.S. Supreme Court has not yet ruled on the constitutionality of the ACA, on January 28, 2021, President Biden issued an executive order to initiate a special enrollment period from February 15, 2021 through May 15, 2021 for purposes of obtaining health insurance coverage through the ACA marketplace. The executive order also instructs certain governmental agencies to review and reconsider their existing policies and rules that limit access to healthcare, including among others, reexamining Medicaid demonstration projects and waiver programs that include work requirements, and policies that create unnecessary barriers to obtaining access to health insurance coverage through Medicaid or the ACA. It is unclear how the Supreme Court ruling, other such litigation, and the healthcare reform measures of the Biden administration will impact the ACA and our business. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other legislative changes have been proposed and adopted in the United States since the ACA was enacted. On August&#160;2, 2011, the Budget Control Act of 2011, among other things, created measures for spending reductions by Congress. A Joint Select Committee on Deficit Reduction, tasked with recommending a targeted deficit reduction of at least $1.2 trillion for the years 2013 through 2021, was unable to reach required goals, thereby triggering the legislation&#8217;s automatic reduction to several government programs. This includes aggregate reductions of Medicare payments to providers of 2% per fiscal year. These reductions went into effect on April&#160;1, 2013 and, due to subsequent legislative amendments to the statute, will remain in effect through 2030 unless additional congressional action is taken. The Coronavirus Aid, Relief and Economic Security Act, or CARES Act, which was signed into law in March 2020, along with other COVID-19 relief legislation suspended the 2% Medicare sequester from May 1, 2020 through March 31, 2021. On January&#160;2, 2013, the American Taxpayer Relief Act of 2012 was signed into law, which, among other things, further reduced Medicare payments to several types of providers. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">25</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Moreover, payment methodologies may be subject to changes in healthcare legislation and regulatory initiatives which could limit the amounts that federal and state governments will pay for healthcare products and services and result in reduced demand for certain pharmaceutical products or additional pricing pressures. </font></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Additionally, there has been increasing legislative and enforcement interest in the United States with respect to specialty drug pricing practices. Specifically, there have been several recent U.S. congressional inquiries and proposed and enacted federal and state legislation designed to, among other things, bring more transparency to drug pricing, reduce the cost of prescription drugs under Medicare, review the relationship between pricing and manufacturer patient programs, and reform government program reimbursement methodologies for drugs.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">At the federal level, the Trump administration used several means to propose or implement drug pricing reform, including through federal budget proposals, executive orders and policy initiatives. For example, on July 24, 2020 and September 13, 2020, the Trump administration announced several executive orders related to prescription drug pricing that sought to implement several of the administration&#8217;s proposals. As a result, the FDA also released a final rule on September 24, 2020 providing guidance for states to build and submit importation plans for drugs from Canada. Further, on November 20, 2020, HHS finalized a regulation removing safe harbor protection for price reductions from pharmaceutical manufacturers to plan sponsors under Part D, either directly or through pharmacy benefit managers, unless the price reduction is required by law. The implementation of the rule has been delayed by the Biden administration from January 1, 2022 to January 1, 2023 in response to ongoing litigation. The rule also creates a new safe harbor for price reductions reflected at the point-of-sale, as well as a safe harbor for certain fixed fee arrangements between pharmacy benefit managers and manufacturers, the implementation of which have also been delayed pending review by the Biden administration until March 22, 2021. Further, in November 2020, CMS issued an interim final rule implementing the Most Favored Nation, or MFN, Model under which Medicare Part B reimbursement rates will be calculated for certain drugs and biologicals based on the lowest price drug manufacturers receive in Organization for Economic Cooperation and Development countries with a similar gross domestic product per capita. The MFN Model regulations mandate participation by identified Part B providers and will apply in all U.S. states and territories for a seven-year period beginning January 1, 2021, and ending December 31, 2027. On December 28, 2020, the United States District Court in Northern California issued a nationwide preliminary injunction against implementation of the interim final rule. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">At the state level, individual states are increasingly aggressive in passing legislation and implementing regulations designed to control pharmaceutical and biological product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing. In addition, regional health care authorities and individual hospitals are increasingly using bidding procedures to determine what pharmaceutical products and which suppliers will be included in their prescription drug and other health care programs. These measures could reduce the ultimate demand for our products, once approved, or put pressure on our product pricing.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We expect that additional foreign, federal and state healthcare reform measures will be adopted in the future, any of which could limit the amounts that federal and state governments will pay for healthcare products and services, and result in reduced demand for our current product candidates and any future product candidates or additional pricing pressures. It is possible that additional governmental action is taken in response to the COVID-19 pandemic. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Legislative and regulatory proposals, and enactment of laws, at the foreign, federal and state levels, directed at containing or lowering the cost of healthcare, will continue into the future. Further, we cannot predict the likelihood, nature, or extent of healthcare reform initiatives that may arise from future legislation or administrative action, particularly as a result of the recent presidential election. </p>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:2.26%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">U.S. Patent-Term Restoration and Marketing Exclusivity </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Depending upon the timing, duration and specifics of FDA approval of our product candidates and any future product candidates we develop, some of our U.S. patents may be eligible for limited patent term extension under the Drug Price Competition and Patent Term Restoration Act of 1984, commonly referred to as the Hatch-Waxman Amendments. The Hatch-Waxman Amendments permit restoration of the patent term of up to five years as compensation for patent term lost during product development and FDA regulatory review process. Patent-term restoration, however, cannot extend the remaining term of a patent beyond a total of 14&#160;years from the product&#8217;s approval date. The patent-term restoration period is generally one-half the time between the effective date of an IND and the submission date of a BLA plus the time between the submission date of a BLA and the approval of that application, except that the review period is reduced by any time during which the applicant failed to exercise due diligence. Only one patent applicable to an approved biologic is eligible for the extension and the application for the extension must be submitted prior to the expiration of the patent. The USPTO in consultation with the FDA, reviews and approves the application for any patent term extension or restoration. In the future, we may apply for restoration of patent term for our currently owned or licensed patents to add patent life </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">26</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">beyond its current expiration date, depending on the expected length of the clinical trials and other factors involved in the filing of the relevant BLA. </font></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">An abbreviated approval pathway for biological products shown to be similar to, or interchangeable with, an FDA-licensed reference biological product was created by the Biologics Price Competition and Innovation Act of 2009 as part of the ACA. This amendment to the PHSA, in part, attempts to minimize duplicative testing. Biosimilarity, which requires that the biological product be highly similar to the reference product notwithstanding minor differences in clinically inactive components and that there be no clinically meaningful differences between the product and the reference product in terms of safety, purity and potency, can be shown through analytical studies, animal studies and a clinical trial or trials. Interchangeability requires that a biological product be biosimilar to the reference product and that the product can be expected to produce the same clinical results as the reference product in any given patient and, for products administered multiple times to an individual, that the product and the reference product may be alternated or switched after one has been previously administered without increasing safety risks or risks of diminished efficacy relative to exclusive use of the reference biological product without such alternation or switch. A reference biological product is granted 12&#160;years of data exclusivity from the time of first licensure of the product, and the FDA will not accept an application for a biosimilar or interchangeable product based on the reference biological product until four years after the date of first licensure of the reference product. &#8220;First licensure&#8221; typically means the initial date the particular product at issue was licensed in the United States. Date of first licensure does not include the date of licensure of (and a new period of exclusivity is not available for) a biological product if the licensure is for a supplement for the biological product or for a subsequent application by the same sponsor or manufacturer of the biological product (or licensor, predecessor in interest, or other related entity) for a change (not including a modification to the structure of the biological product) that results in a new indication, route of administration, dosing schedule, dosage form, delivery system, delivery device or strength, or for a modification to the structure of the biological product that does not result in a change in safety, purity, or potency. Therefore, one must determine whether a new product includes a modification to the structure of a previously licensed product that results in a change in safety, purity, or potency to assess whether the licensure of the new product is a first licensure that triggers its own period of exclusivity. Whether a subsequent application, if approved, warrants exclusivity as the &#8220;first licensure&#8221; of a biological product is determined on a case-by-case basis with data submitted by the sponsor. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pediatric exclusivity is another type of regulatory market exclusivity in the United States. Pediatric exclusivity, if granted, adds six months to existing regulatory exclusivity periods. This six-month exclusivity, which runs from the end of other exclusivity protection or patent term, may be granted based on the voluntary completion of a pediatric trial in accordance with an FDA-issued &#8220;Written Request&#8221; for such a trial. </p>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:2.26%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">U.S. regulation of companion diagnostics </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our product candidates may require use of an&#160;<font style="font-style:italic;">in vitro</font>&#160;diagnostic to identify appropriate patient populations. These diagnostics, often referred to as companion diagnostics, are regulated as medical devices. In the United States, the FDCA and its implementing regulations, and other federal and state statutes and regulations govern, among other things, medical device design and development, preclinical and clinical testing, premarket clearance or approval, registration and listing, manufacturing, labeling, storage, advertising and promotion, sales and distribution, export and import and post-market surveillance. Unless an exemption applies, companion diagnostic tests require marketing clearance or approval from the FDA prior to commercial distribution. The two primary types of FDA marketing authorization applicable to a medical device are premarket notification, also called 510(k) clearance, and premarket approval, or PMA approval. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If use of companion diagnostic is essential to safe and effective use of a drug or biologic product, then the FDA generally will require approval or clearance of the diagnostic contemporaneously with the approval of the therapeutic product. On August&#160;6, 2014, the FDA issued a final guidance document addressing the development and approval process for &#8220;<font style="font-style:italic;">In Vitro</font>&#160;Companion Diagnostic Devices.&#8221; According to the guidance, for novel candidates such as our product candidates, a companion diagnostic device and its corresponding drug or biologic candidate should be approved or cleared contemporaneously by FDA for the use indicated in the therapeutic product labeling. The guidance also explains that a companion diagnostic device used to make treatment decisions in clinical trials of a biologic product candidate generally will be considered an investigational device, unless it is employed for an intended use for which the device is already approved or cleared. If used to make critical treatment decisions, such as patient selection, the diagnostic device generally will be considered a significant risk device under the FDA&#8217;s Investigational Device Exemption, or IDE, regulations. Thus, the sponsor of the diagnostic device will be required to comply with the IDE regulations. According to the guidance, if a diagnostic device and a drug are to be studied together to support their respective approvals, both products can be studied in the same investigational study, if the study meets both the requirements of the IDE regulations and the IND regulations. The guidance provides that depending on the details of the study plan and subjects, a sponsor may seek to submit an IND alone, or both an IND and an IDE. In July 2016, the FDA issued a draft guidance document intended to further assist sponsors of therapeutic products and sponsors of&#160;<font style="font-style:italic;">in vitro</font>&#160;companion diagnostic devices on issues related to&#160;co-development&#160;of these products. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The FDA generally requires companion diagnostics intended to select the patients who will respond to cancer treatment to obtain approval of a PMA for that diagnostic contemporaneously with approval of the therapeutic. The review of these&#160;<font style="font-style:italic;">in </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">27</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:12pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-style:italic;">vitro</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;companion diagnostics in conjunction with the review of therapeutic candidates involves coordination of review by the FDA&#8217;s Center for Biologics Evaluation and Research and by the FDA&#8217;s Center for Devices and Radiological Health. The PMA process, including the gathering of clinical and&#160;preclinical&#160;data and the submission to and review by the FDA, can take several years or longer. It involves a rigorous premarket review during which the applicant must prepare and provide the FDA with reasonable assurance of the device&#8217;s safety and effectiveness and information about the device and its components regarding, among other things, device design, </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">manufacturing</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> and labeling. PMA applications are also subject to an application fee. </font></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">PMAs for certain devices must generally include the results from extensive&#160;preclinical&#160;and adequate and well-controlled clinical trials to establish the safety and effectiveness of the device for each indication for which FDA approval is sought. In particular, for a diagnostic, the applicant must demonstrate that the diagnostic produces reproducible results when the same sample is tested multiple times by multiple users at multiple laboratories. In addition, as part of the PMA review, the FDA will typically inspect the manufacturer&#8217;s facilities for compliance with the Quality System Regulation, or QSR, which imposes elaborate testing, control, documentation and other quality assurance requirements. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If the FDA evaluations of both the PMA application and the manufacturing facilities are favorable, the FDA will either issue an approval letter or a not-approvable letter, which usually contains a number of conditions that must be met in order to secure the final approval of the PMA, such as changes in labeling, or specific additional information, such as submission of final labeling, in order to secure final approval of the PMA. If the FDA concludes that the applicable criteria have been met, the FDA will issue a PMA for the approved indications, which can be more limited than those originally sought by the applicant. The PMA can include post-approval conditions that the FDA believes necessary to ensure the safety and effectiveness of the device, including, among other things, restrictions on labeling, promotion, sale and distribution. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If the FDA&#8217;s evaluation of the PMA or manufacturing facilities is not favorable, the FDA will issue an order denying approval of the PMA or issue a not approvable order. A not approvable letter will outline the deficiencies in the application and, where practical, will identify what is necessary to make the PMA approvable. The FDA may also determine that additional clinical trials are necessary, in which case the PMA approval may be delayed for several months or years while the trials are conducted and then the data submitted in an amendment to the PMA. Once granted, PMA approval may be withdrawn by the FDA if compliance with post approval requirements, conditions of approval or other regulatory standards is not maintained or problems are identified following initial marketing. PMA approval is not guaranteed, and the FDA may ultimately respond to a PMA submission with a not approvable determination based on deficiencies in the application and require additional clinical trial or other data that may be expensive and time-consuming to generate and that can substantially delay approval. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">After a device is placed on the market, it remains subject to significant regulatory requirements. Medical devices may be marketed only for the uses and indications for which they are cleared or approved. Device manufacturers must also establish registration and device listings with the FDA. A medical device manufacturer&#8217;s manufacturing processes and those of its suppliers are required to comply with the applicable portions of the QSR, which cover the methods and documentation of the design, testing, production, processes, controls, quality assurance, labeling, packaging and shipping of medical devices. Domestic facility records and manufacturing processes are subject to periodic unscheduled inspections by the FDA. The FDA also may inspect foreign facilities that export products to the United States. </p>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:2.26%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">European Union Drug Development </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the European Union, or EU, our future products also may be subject to extensive regulatory requirements. As in the United States, medicinal products can be marketed only if a marketing authorization from the competent regulatory agencies has been obtained. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Similar to the United States, the various phases of preclinical and clinical research in the European Union are subject to significant regulatory controls. Although the EU Clinical Trials Directive 2001/20/EC has sought to harmonize the EU clinical trials regulatory framework, setting out common rules for the control and authorization of clinical trials in the EU, the EU member states have transposed and applied the provisions of the Directive differently. This has led to significant variations in the member state regimes. Under the current regime, before a clinical trial can be initiated it must be approved in each of the EU countries where the trial is to be conducted by two distinct bodies: the National Competent Authority, or NCA, and one or more Ethics Committees, or ECs. Under the current regime all suspected unexpected serious adverse reactions to the investigated drug that occur during the clinical trial have to be reported to the NCA and ECs of the member state where they occurred. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The EU clinical trials legislation currently is undergoing a transition process mainly aimed at harmonizing and streamlining clinical-trial authorization, simplifying adverse-event reporting procedures, improving the supervision of clinical trials and increasing their transparency. Recently enacted Clinical Trials Regulation&#160;EU No 536/2014 ensures that the rules for conducting clinical trials in the EU will be identical. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">28</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-top:18pt;margin-bottom:0pt;margin-left:2.26%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">European Union Drug Review and Approval </font></p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the European Economic Area, or EEA, which is comprised of the 28 member states of the EU and Iceland, Liechtenstein, Norway, medicinal products can only be commercialized after obtaining a Marketing Authorization, or MA. There are two types of marketing authorizations. </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:1.13%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">The Community MA is issued by the European Commission through the Centralized Procedure, based on the opinion of the Committee for Medicinal Products for Human Use, or CHMP, of the EMA and is valid throughout the entire territory of the EEA. The Centralized Procedure is mandatory for certain types of products, such as biotechnology medicinal products, orphan medicinal products, advanced-therapy medicines such as gene-therapy, somatic cell-therapy or tissue-engineered medicines and medicinal products containing a new active substance indicated for the treatment of HIV, AIDS, cancer, neurodegenerative disorders, diabetes, auto-immune and other immune dysfunctions and viral diseases. The Centralized Procedure is optional for products containing a new active substance not yet authorized in the EEA, or for products that constitute a significant therapeutic, scientific or technical innovation or which are in the interest of public health in the EU. </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:1.13%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">National MAs, which are issued by the competent authorities of the Member States of the EEA and only cover their respective territory, are available for products not falling within the mandatory scope of the Centralized Procedure. Where a product has already been authorized for marketing in a member state of the EEA, this National MA can be recognized in other member states through the Mutual Recognition Procedure. If the product has not received a National MA in any member state at the time of application, it can be approved simultaneously in various member state through the Decentralized Procedure. Under the Decentralized Procedure an identical dossier is submitted to the competent authorities of each of the member state in which the MA is sought, one of which is selected by the applicant as the Reference Member State, or RMS. The competent authority of the RMS prepares a draft assessment report, a draft summary of the product characteristics, or SPC, and a draft of the labeling and package leaflet, which are sent to the other member state, referred to as the Member States Concerned, for their approval. If the Member States Concerned raise no objections, based on a potential serious risk to public health, to the assessment, SPC, labeling, or packaging proposed by the RMS, the product is subsequently granted a national MA in all the member states (i.e.,&#160;in the RMS and the Member States Concerned). Under the above described procedures, before granting the MA, the EMA or the competent authorities of the member states of the EEA make an assessment of the risk-benefit balance of the product on the basis of scientific criteria concerning its quality, safety and efficacy. </font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:2.26%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">European Union Orphan Designation and Exclusivity </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the European Union, the EMA&#8217;s Committee for Orphan Medicinal Products grants orphan drug designation to promote the development of products that are intended for the diagnosis, prevention or treatment of life-threatening or chronically debilitating conditions affecting not more than five in 10,000 persons in the European Union community (or where it is unlikely that the development of the medicine would generate sufficient return to justify the investment) and for which no satisfactory method of diagnosis, prevention or treatment has been authorized (or, if a method exists, the product would be a significant benefit to those affected). </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the European Union, orphan drug designation entitles a party to financial incentives such as reduction of fees or fee waivers and ten years of market exclusivity is granted following medicinal product approval. This period may be reduced to six years if the orphan drug designation criteria are no longer met, including where it is shown that the product is sufficiently profitable not to justify maintenance of market exclusivity. Orphan drug designation must be requested before submitting an application for MA. Orphan drug designation does not convey any advantage in, or shorten the duration of, the regulatory review and approval process. </p>
<p style="margin-top:18pt;margin-bottom:0pt;margin-left:2.26%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">European Union Drug Marketing </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Much like the Anti-Kickback Statute prohibition in the United States, the provision of benefits or advantages to physicians to induce or encourage the prescription, recommendation, endorsement, purchase, supply, order or use of medicinal products is also prohibited in the EU. The provision of benefits or advantages to physicians is governed by the national anti-bribery laws of European Union member states, such as the U.K. Bribery Act 2010. Infringement of these laws could result in substantial fines and imprisonment. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Payments made to physicians in certain EU member states must be publicly disclosed. Moreover, agreements with physicians often must be the subject of prior notification and approval by the physician&#8217;s employer, his or her competent professional organization as well as the regulatory authorities of the individual EU member states. These requirements are provided in the national laws, industry codes or professional codes of conduct, applicable in the EU member states. Failure to comply with these requirements could result in reputational risk, public reprimands, administrative penalties, fines or imprisonment. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">29</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:2.26%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">European Data Collection </font></p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The collection and use of personal health data in the EU is governed by the provisions of the Data Protection Directive, and as of May 2018 the General Data Protection Regulation, or GDPR. This directive imposes several requirements relating to the consent of the individuals to whom the personal data relates, the information provided to the individuals, notification of data processing obligations to the competent national data protection authorities and the security and confidentiality of the personal data. The Data Protection Directive and GDPR also impose strict rules on the transfer of personal data out of the EU to the United States. Failure to comply with the requirements of the Data Protection Directive, the GDPR, and the related national data protection laws of the EU member states may result in fines and other administrative penalties. The GDPR introduces new data protection requirements in the EU and substantial fines for breaches of the data protection rules. The GDPR regulations may impose additional responsibility and liability in relation to personal data that we process and we may be required to put in place additional mechanisms ensuring compliance with the new data protection rules. This may be onerous and adversely affect our business, financial condition, results of operations and prospects. </p>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:2.26%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Rest of the World Regulation </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For other countries outside of the EU and the United States, such as countries in Eastern Europe, Latin America or Asia, the requirements governing the conduct of clinical trials, product licensing, pricing and reimbursement vary from country to country. Additionally, the clinical trials must be conducted in accordance with GCP requirements and the applicable regulatory requirements and the ethical principles that have their origin in the Declaration of Helsinki. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If we fail to comply with applicable foreign regulatory requirements, we may be subject to, among other things, fines, suspension or withdrawal of regulatory approvals, product recalls, seizure of products, operating restrictions and criminal prosecution. </p>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:2.26%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Reimbursement </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Sales of our products, when and if approved, will depend, in part, on the extent to which our products will be covered by third-party payors, such as government health programs, commercial insurance and managed healthcare organizations. In the United States, no uniform policy of coverage and reimbursement for drug or biological products exists. Accordingly, decisions regarding the extent of coverage and amount of reimbursement to be provided for any of our products will be made on a payor-by-payor basis. As a result, coverage determination is often a time-consuming and costly process that will require us to provide scientific and clinical support for the use of our products to each payor separately, with no assurance that coverage and adequate reimbursement will be obtained. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The U.S. government, state legislatures and foreign governments have shown significant interest in implementing cost containment programs to limit the growth of government-paid health care costs, including price-controls, restrictions on reimbursement and requirements for substitution of biosimilars for branded prescription drugs. For example, the ACA contains provisions that may reduce the profitability of drug products through increased rebates for drugs reimbursed by Medicaid programs, extension of Medicaid rebates to Medicaid managed care plans, mandatory discounts for certain Medicare Part&#160;D beneficiaries and annual fees based on pharmaceutical companies&#8217; share of sales to federal healthcare programs. Adoption of general controls and measures, coupled with the tightening of restrictive policies in jurisdictions with existing controls and measures, could limit payments for pharmaceutical drugs. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Medicaid Drug Rebate Program requires pharmaceutical manufacturers to enter into and have in effect a national rebate agreement with the Secretary of the Department of Health and Human Services as a condition for states to receive federal matching funds for the manufacturer&#8217;s outpatient drugs furnished to Medicaid patients. The ACA made several changes to the Medicaid Drug Rebate Program, including increasing pharmaceutical manufacturers&#8217; rebate liability by raising the minimum basic Medicaid rebate on most branded prescription drugs from 15.1% of average manufacturer price, or AMP, to 23.1% of AMP and adding a new rebate calculation for &#8220;line extensions&#8221; (i.e.,&#160;new formulations, such as extended release formulations) of solid oral dosage forms of branded products, as well as potentially impacting their rebate liability by modifying the statutory definition of AMP. The ACA also expanded the universe of Medicaid utilization subject to drug rebates by requiring pharmaceutical manufacturers to pay rebates on Medicaid managed care utilization and by enlarging the population potentially eligible for Medicaid drug benefits. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Medicare Prescription Drug, Improvement, and Modernization Act of 2003, or the MMA, established the Medicare Part&#160;D program to provide a voluntary prescription drug benefit to Medicare beneficiaries. Under Part&#160;D, Medicare beneficiaries may enroll in prescription drug plans offered by private entities that provide coverage of outpatient prescription drugs. Unlike Medicare Part&#160;A and B, Part&#160;D coverage is not standardized. While all Medicare drug plans must give at least a standard level of coverage set by Medicare, Part&#160;D prescription drug plan sponsors are not required to pay for all covered Part&#160;D drugs, and each drug plan can develop its own drug formulary that identifies which drugs it will cover and at what tier or level. However, Part&#160;D prescription drug formularies must include drugs within each therapeutic category and class of covered Part&#160;D drugs, though not necessarily all the drugs in each category or class. Any formulary used by a Part&#160;D prescription drug plan must be developed and reviewed by a </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">30</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:12pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">pharmacy and therapeutic committee. Government payment for some of the costs of prescription drugs may increase demand for products for which we receive marketing approval. However, any negotiated prices for our products covered by a Part&#160;D prescription drug plan likely will be lower than the prices we might otherwise obtain. Moreover, while the MMA applies only to drug benefits for Medicare beneficiaries, private payors often follow Medicare coverage policy and payment limitations in setting their own payment rates. Any reduction in payment that results from the MMA may result in a similar reduction in payments from non-governmental payors. </font></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For a drug product to receive federal reimbursement under the Medicaid or Medicare Part&#160;B programs or to be sold directly to U.S. government agencies, the manufacturer must extend discounts to entities eligible to participate in the 340B drug pricing program. The required 340B discount on a given product is calculated based on the AMP and Medicaid rebate amounts reported by the manufacturer. As of 2010, the ACA expanded the types of entities eligible to receive discounted 340B pricing, although, under the current state of the law, with the exception of children&#8217;s hospitals, these newly eligible entities will not be eligible to receive discounted 340B pricing on orphan drugs. In addition, as 340B drug pricing is determined based on AMP and Medicaid rebate data, the revisions to the Medicaid rebate formula and AMP definition described above could cause the required 340B discount to increase. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As noted above, the marketability of any products for which we receive regulatory approval for commercial sale may suffer if the government and third-party payors fail to provide coverage and reimbursement. Obtaining coverage and reimbursement for newly approved drugs and biologics is a time-consuming and costly process, and coverage may be more limited than the purposes for which a drug is approved by the FDA or comparable foreign regulatory authorities. Assuming coverage is obtained for a given product by a third-party payor, the resulting reimbursement payment rates may not be adequate or may require co-payments that patients find unacceptably high. Additionally, coverage policies and third-party reimbursement rates may change at any time. Patients who are prescribed medications for the treatment of their conditions, and their prescribing physicians, generally rely on third-party payors to reimburse all or part of the costs associated with their prescription drugs. Patients are unlikely to use products unless coverage is provided and reimbursement is adequate to cover all or a significant portion of the cost of prescribed products. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, in most foreign countries, the proposed pricing for a drug must be approved before it may be lawfully marketed. The requirements governing drug pricing and reimbursement vary widely from country to country. For example, the EU provides options for its member states to restrict the range of medicinal products for which their national health insurance systems provide reimbursement and to control the prices of medicinal products for human use. A member state may approve a specific price for the medicinal product or it may instead adopt a system of direct or indirect controls on the profitability of the company placing the medicinal product on the market. There can be no assurance that any country that has price controls or reimbursement limitations for pharmaceutical products will allow favorable reimbursement and pricing arrangements for any of our products. Historically, products launched in the European Union do not follow price structures of the United States and generally prices tend to be significantly lower. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Employees and Human Capital Resources </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of March 15, 2021, we had 30 full-time employees and 2 part-time employees. We consider our relationship with our employees to be good. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our human capital resources objectives include, as applicable, identifying, recruiting, retaining, incentivizing and integrating our existing and new employees, advisors and consultants. The principal purposes of our equity incentive plans are to attract, retain and reward personnel through the granting of stock-based compensation awards in order to increase stockholder value and the success of our company by motivating such individuals to perform to the best of their abilities and achieve our objectives.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Corporate Information</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our common stock is listed on The Nasdaq Global Market under the symbol "SNSE".</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">Our principal executive offices are located at 1405 Research Blvd, Suite 125, Rockville, MD 20850. Our telephone number is (240)&#160;243-8000</font><font style="color:#000000;">.</font></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">The Sensei design logo, &#8220;Sensei&#8221;, &#8220;ImmunoPhage&#8221;, &#8220;Phortress&#8221; and our other registered or common law trademarks, service marks, or trade names appearing in this Annual Report on Form 10-K are the property of Sensei Biotherapeutics, Inc. Other trade names, trademarks and service marks used in this Annual Report on Form 10-K are the property of their respective owners</font><font style="color:#000000;">. Solely for convenience, trademarks and trade names referred to in this Annual Report on Form 10-K exclude the &#174; or TM symbols.</font></p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Available Information</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our website address is www.senseibio.com. Our Annual Report on&#160;Form&#160;10-K,&#160;Quarterly Reports on&#160;Form&#160;10-Q,&#160;Current Reports on&#160;Form&#160;8-K,&#160;and amendments to reports filed pursuant to Sections&#160;13(a) and 15(d) of the Exchange Act are made available </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">31</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">free of charge on or through our website as soon as reasonably practicable after such reports are filed with, or furnished to, the United States Securities and Exchange Commission, or SEC. The information contained on, or that can be accessed through, our website is not incorporated by reference into this Annual Report on Form 10-K or in any other report or document we file with the SEC, and any references to our website are intended to be inactive textual references only.</font></p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="ITEM_1A_RISK_FACTORS"></a><a name="ITEM_1A_RISK_FACTORS"></a>Item 1A. Risk Factors. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">You should carefully consider the risks described below, as well as general economic and business risks and the other information in this Report on Form 10-K. The occurrence of Any of the events or circumstances described below or other adverse events could have a material adverse effect on our business, results of operations and financial condition and could cause the trading price of our common stock to decline. Additional risks or uncertainties not presently known to us or that we currently deem immaterial may also harm our business.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">SUMMARY OF RISK FACTORS</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The risk factors summarized below could materially harm our business, operating results, and/or financial condition, impair our future prospects, and/or cause the price of our common stock to decline. These risks are discussed more fully below. Material risks that may affect our business, financial condition, results of operations, and trading price of our common stock include the following:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:1.13%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><font style="font-weight:bold;font-style:italic;">Risks Related to our Financial Position</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:1.13%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">We have incurred significant losses in every year since our inception. We expect to continue to incur losses over the next several years and may never achieve or maintain profitability.</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:1.13%;white-space:nowrap">
<p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">We will need additional funding to complete the development of our product candidates. A failure to obtain this necessary capital when needed could force us to delay, limit, reduce or terminate our product development or commercialization efforts.</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:1.13%;white-space:nowrap">
<p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Our business, operations and clinical development plans and timelines could be adversely affected by the effects of health epidemics, including the recent&#160;COVID-19&#160;pandemic, on the manufacturing, clinical trial and other business activities performed by us or by third parties with whom we conduct business.</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:1.13%;white-space:nowrap">
<p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><font style="font-weight:bold;font-style:italic;">Risks Related to the Development of our Product Candidates</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:1.13%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Our development efforts are in the early stages. All of our product candidates are in clinical development or in preclinical development. If we are unable to advance our product candidates through clinical development, obtain regulatory approval and ultimately commercialize our product candidates, or experience significant delays in doing so, our business will be materially harmed.</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:1.13%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">The development of product candidates with our ImmunoPhage platform represents an emerging approach to the treatment of cancer and infectious diseases and faces significant challenges and hurdles. We may not be successful in applying our ImmunoPhage platform to the discovery and development of commercially viable products.</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:1.13%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Our business is highly dependent on the success of our lead product candidate,&#160;SNS-301&#160;and any other product candidates that we advance into the clinic. All of our product candidates may require significant additional preclinical and clinical development before we may be able to seek regulatory approval for and launch a product commercially. If the clinical trials of any of our product candidates fail to demonstrate safety and efficacy to the satisfaction of the FDA or other comparable regulatory authorities, or do not otherwise produce favorable results, we may incur additional costs or experience delays in completing, or ultimately be unable to complete, the development and commercialization of our product candidates.</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:1.13%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Interim data from our clinical trials that we announce or publish from time to time, such as the data from our Phase 1/2 clinical trial of SNS-301 for the treatment of SCCHN, may change as more patients are enrolled and additional data become available.</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:1.13%;white-space:nowrap">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">We depend on timely enrollment of patients in our clinical trials for our product candidates. If we encounter difficulties enrolling patients in our clinical trials, our clinical development activities could be delayed or otherwise adversely affected.</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:1.13%;white-space:nowrap">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Clinical trials are difficult to design and implement, can be lengthy and expensive, involve uncertain outcomes and may not ultimately be successful.</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:1.13%;white-space:nowrap">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><font style="font-weight:bold;font-style:italic;font-size:10pt;">Risks Related to our Dependence on Third Parties</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:1.13%;white-space:nowrap">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">We collaborate with third parties in connection with the development of our product candidates, and may depend upon future collaboration partners to commit to the research, development, manufacturing and marketing of our product candidates.</p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">32</a></p>
<hr style="page-break-after:always;width:100%;">
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:1.13%;white-space:nowrap">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We rely, and expect to continue to rely, on third parties to conduct the preclinical and clinical trials for our product candidates, and those third parties may not perform satisfactorily, including failing to meet deadlines for the completion of such trials or failing to comply with applicable regulatory requirements.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:1.13%;white-space:nowrap">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><font style="font-weight:bold;font-style:italic;font-size:10pt;">Risks Related to Regulatory Approval of our Product Candidates and Other Legal Compliance Matters</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:1.13%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Healthcare legislative reform measures may have a material adverse effect on our business and results of operations.</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:1.13%;white-space:nowrap">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><font style="font-weight:bold;font-style:italic;font-size:10pt;">Risks Related to the Commercialization of our Product Candidates</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:1.13%;white-space:nowrap">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">If we are unable to establish sales, marketing and distribution capabilities for our product candidates, or enter into sales, marketing and distribution agreements with third parties, we may not be successful in commercializing our product candidates, if approved.</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:1.13%;white-space:nowrap">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">We operate in a rapidly changing industry and face significant competition, which may result in others discovering, developing or commercializing products before or more successfully than we do.</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:1.13%;white-space:nowrap">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Even if any of our product candidates receives marketing approval, it may fail to achieve the degree of market acceptance by physicians, patients, third-party payors and others in the medical community necessary for commercial success.</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:1.13%;white-space:nowrap">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><font style="font-weight:bold;font-style:italic;font-size:10pt;">Risks Related to our Intellectual Property</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:1.13%;white-space:nowrap">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">If we are unable to obtain and maintain patent protection for our ImmunoPhage platform and phase-based cocktail technology and product candidates, or if the scope of the patent protection obtained is not sufficiently broad, our competitors could develop and commercialize technology and biologics similar or identical to ours, and our ability to successfully commercialize our technology and product candidates may be impaired.</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:1.13%;white-space:nowrap">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Third parties may initiate legal proceedings alleging that we are infringing their intellectual property rights, the outcome of which would be uncertain and could significantly harm our business.</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:1.13%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><font style="font-weight:bold;font-style:italic;font-size:10pt;">Risks Related to our Business Operations</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:1.13%;white-space:nowrap">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">We will need to grow the size of our organization, and we may experience difficulties in managing this growth.</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:1.13%;white-space:nowrap">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Our future success depends on our ability to retain key members of senior management and to attract, retain and motivate qualified personnel.</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:1.13%;white-space:nowrap">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><font style="font-weight:bold;font-style:italic;font-size:10pt;">Risks Related to our Securities and our Status as a Public Company</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:1.13%;white-space:nowrap">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">The trading price of our common stock may be volatile, and you could lose all or part of your investment.</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:1.13%;white-space:nowrap">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">If we fail to implement and maintain an effective system of internal control over financial reporting to remediate our material weaknesses, we may be unable to accurately report our results of operations, meet our reporting obligations or prevent fraud, and investor confidence in our company and the market price of our common stock may be materially and adversely affected.</p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Risks Related to Our Financial Position </p>
<p style="margin-bottom:0pt;margin-top:6pt;margin-left:2.26%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">We have incurred significant losses in every year since our inception. We expect to continue to incur losses over the next several years and may never achieve or maintain profitability. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are a clinical-stage immunotherapy company and we have incurred significant net losses since our inception. Our net loss was $20.1 million and $16.7&#160;million for the years ended December&#160;31, 2020 and 2019, respectively. As of December 31, 2020, we had an accumulated deficit of $112.4 million. We have funded our operations to date primarily with proceeds from the sale of our equity securities and borrowings of convertible debt. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have no products approved for commercial sale, have not generated any revenue from commercial sales of our product candidates, and are devoting substantially all of our financial resources and efforts to research and development of our ImmunoPhage platform and SNS-301, and to our other product candidates. Investment in therapeutic product development is highly speculative because it entails substantial upfront capital expenditures and significant risk that any potential product candidate will fail to demonstrate adequate effect or an acceptable safety profile, gain regulatory approval and become commercially viable. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We expect that it will take at least several years until any of our product candidates receive marketing approval and are commercialized, and we may never be successful in obtaining marketing approval and commercializing product candidates. We expect to continue to incur significant expenses and increasing operating losses for the foreseeable future. These net losses will </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">33</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:12pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">adversely impact our stockholders&#8217; equity and net assets and may fluctuate significantly from quarter to quarter and year to year. We anticipate that our expenses will increase substantially as we: </font></p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:1.13%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">complete our Phase 1/2 clinical trial of SNS-301 and continue clinical development of SNS-301; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:1.13%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">prepare to file INDs and then initiate clinical development of additional product candidates, including SNS-401 and SNS-VISTA; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:1.13%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">continue the research and development of our other product candidates; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:1.13%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">invest in our ImmunoPhage platform; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:1.13%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">seek to discover and develop additional product candidates or acquire or&#160;in-license&#160;drugs, product candidates or technologies; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:1.13%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">seek regulatory approvals for any product candidates that successfully complete clinical trials; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:1.13%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">ultimately establish a sales, marketing and distribution infrastructure and scale up manufacturing capabilities to commercialize any product candidates for which we may obtain regulatory approval; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:1.13%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">manufacture our product candidates or otherwise secure the clinical and commercial supply of our product candidates; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:1.13%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">hire additional research and development and selling, general and administrative personnel; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:1.13%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">maintain, expand and protect our intellectual property portfolio; and </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:1.13%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">incur additional costs associated with operating as a newly public company. </p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">To become and remain profitable, we must succeed in developing and eventually commercializing products that generate significant revenue. Achievement will require us to be successful in a range of challenging activities, including completing preclinical studies and clinical trials of our product candidates, obtaining regulatory approval, manufacturing, marketing and selling any products for which we may obtain regulatory approval, as well as discovering and developing additional product candidates. We may never succeed in these activities and, even if we do, may never generate revenues that are significant enough to achieve profitability. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Because of the numerous risks and uncertainties associated with the development and commercialization of therapeutic product candidates, we are unable to accurately predict the timing or amount of expenses or when, or if, we will be able to achieve and maintain profitability. If we are required by regulatory authorities to perform studies in addition to those currently expected, or if there are any delays in the initiation and completion of our clinical trials or the development of any of our product candidates, our expenses could increase and profitability could be further delayed. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Even if we achieve profitability, we may not be able to sustain or increase profitability on a quarterly or annual basis. Our failure to become and remain profitable would depress the value of our common stock and could impair our ability to raise capital, expand our business, maintain our research and development efforts or continue our operations. A decline in the value of our common stock could also cause you to lose all or part of your investment. </p>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:2.26%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Our operating history may make it difficult for you to evaluate the success of our business to date and to assess our future viability. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As an organization, we have not demonstrated an ability to successfully complete late-stage clinical trials, obtain regulatory approvals, manufacture our product candidates at commercial scale or arrange for a third party to do so on our behalf, conduct sales and marketing activities necessary for successful commercialization, or obtain reimbursement in the countries of sale. We may encounter unforeseen expenses, difficulties, complications, and delays in achieving our business objectives. Our operating history makes any assessment of our future success or viability subject to significant uncertainty. If we do not address these risks successfully or are unable to transition at some point from a company with a research and development focus to a company capable of supporting commercial activities, then our business will suffer. In addition, we will need to transition at some point from a company with a research and development focus to a company capable of supporting commercial activities. We may not be successful in such a transition. </p>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:2.26%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">We will need additional funding to complete the development of our product candidates. A failure to obtain this necessary capital when needed could force us to delay, limit, reduce or terminate our product development or commercialization efforts. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We will require substantial additional funding to meet our financial needs and to pursue our business objectives. If we are unable to raise capital when needed, we could be forced to delay, reduce or altogether cease our product development programs or commercialization efforts. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">34</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our future capital requirements will depend on many factors, including: </font></p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:1.13%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">the scope, progress, results and costs of discovery, laboratory testing, manufacturing, preclinical and clinical development for our current and future product candidates; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:1.13%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">the development requirements of other product candidates that we may pursue; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:1.13%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">the timing and amounts of any milestone or royalty payments we may be required to make or may be entitled to receive under license agreements; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:1.13%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">the costs of building out our infrastructure including hiring additional clinical, quality control and manufacturing personnel; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:1.13%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">the costs, timing and outcome of regulatory review of our product candidates; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:1.13%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">the costs and timing of future commercialization activities, including product manufacturing, marketing, sales and distribution, for any of our product candidates for which we receive marketing approval; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:1.13%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">the revenue, if any, received from commercial sales of our product candidates for which we receive marketing approval; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:1.13%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">the costs and timing of preparing, filing and prosecuting patent applications, maintaining and enforcing our intellectual property rights and defending any intellectual property-related claims; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:1.13%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">the costs of operating as a public company; and </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:1.13%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">the extent to which we acquire or in-license other product candidates and technologies. </p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We cannot be certain that additional funding will be available on acceptable terms, or at all. If we are unable to raise additional capital in sufficient amounts or on terms acceptable to us, we may have to significantly delay, scale back or discontinue the development or commercialization of our product candidates or other research and development initiatives. Any of our current or future license agreements may also be terminated if we are unable to meet the payment or other obligations under the agreements. </p>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:2.26%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Raising additional capital may cause dilution to our stockholders, restrict our operations or require us to relinquish rights to our technologies or product candidates. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We expect that significant additional capital may be needed in the future to continue our planned operations, including conducting clinical trials, commercialization efforts, expanded research and development activities and costs associated with operating a public company. Until such time, if ever, as we can generate substantial product revenues, we expect to finance our cash needs through any or a combination of securities offerings, debt financings, license and collaboration agreements and research grants. If we raise capital through securities offerings, such sales may also result in material dilution to our existing stockholders, and new investors could gain rights, preferences and privileges senior to the holders of our common stock. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">To the extent that we raise additional capital through the sale of equity or convertible debt securities, your ownership interest will be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect your rights as a stockholder. Debt financing and preferred equity financing, if available, could result in fixed payment obligations, and we may be required to accept terms that restrict our ability to incur additional indebtedness, force us to maintain specified liquidity or other ratios or restrict our ability to pay dividends or make acquisitions. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If we raise additional funds through collaborations, strategic alliances or marketing, distribution or licensing arrangements with third parties, we may be required to relinquish valuable rights to our technologies, future revenue streams, research programs or product candidates or to grant licenses on terms that may not be favorable to us. In addition, we could also be required to seek funds through arrangements with collaborators or others at an earlier stage than otherwise would be desirable. If we raise funds through research grants, we may be subject to certain requirements, which may limit our ability to use the funds or require us to share information from our research and development. If we are unable to raise additional funds through equity or debt financings when needed, we may be required to delay, limit, reduce or terminate our product development or future commercialization efforts or grant rights to a third party to develop and market product candidates that we would otherwise prefer to develop and market ourselves. Raising additional capital through any of these or other means could adversely affect our business and the holdings or rights of our stockholders, and may cause the market price of our common stock to decline. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, we may seek additional capital due to favorable market conditions or strategic considerations even if we believe that we have sufficient funds for our current or future operating plans. If we raise additional funds through collaboration and licensing arrangements with third parties, we may have to relinquish some rights to our technologies or our product candidates on terms that are not favorable to us. Any additional capital raising efforts may divert our management from their day-to-day activities, which may adversely affect our ability to develop and commercialize our current and future product candidates, if approved. If we are unable to raise capital when needed or on attractive terms, we could be forced to delay, reduce or altogether cease our research and development programs or future commercialization efforts. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">35</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Risks Related to the Development of our Product Candidates </font></p>
<p style="margin-bottom:0pt;margin-top:6pt;margin-left:2.26%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Our development efforts are in the early stages. All of our product candidates are in clinical development or in preclinical development. If we are unable to advance our product candidates through clinical development, obtain regulatory approval and ultimately commercialize our product candidates, or experience significant delays in doing so, our business will be materially harmed. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our lead product candidate, SNS-301, is our only product candidate in clinical development. There is no assurance that this, or any other future clinical trials of our product candidates, will be successful or will generate positive clinical data and we may not receive marketing approval from the FDA or other regulatory agencies for any of our product candidates. With the exception of SNS-301, we have not submitted an IND to the FDA. Our other product candidates are in preclinical development. There can be no assurance that the FDA will permit the INDs for our other product candidates to go into effect in a timely manner or at all. Without the IND, we will not be permitted to conduct clinical trials in the United States. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Biopharmaceutical development is a long, expensive and uncertain process, and delay or failure can occur at any stage of any of our clinical trials. Failure to obtain regulatory approval for our product candidates will prevent us from commercializing and marketing our product candidates. The success in the development of our product candidates will depend on many factors, including: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:1.13%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">completing preclinical studies; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:1.13%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">submission of INDs for and receipt of allowance to proceed with our planned clinical trials or other future clinical trials; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:1.13%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">initiating, enrolling, and completing clinical trials; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:1.13%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">obtaining positive results from our preclinical studies and clinical trials that support a demonstration of efficacy, safety, and durability of effect for our product candidates; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:1.13%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">receiving approvals for commercialization of our product candidates from applicable regulatory authorities; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:1.13%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">establishing sales, marketing and distribution capabilities and successfully launching commercial sales of our products, if and when approved, whether alone or in collaboration with others; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:1.13%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">acceptance of our products, if and when approved, by patients, the medical community and third-party payors; manufacturing our product candidates at an acceptable cost; and </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:1.13%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">maintaining and growing an organization of scientists, medical professionals and business people who can develop and commercialize our products and technology. </p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Many of these factors are beyond our control, including the time needed to adequately complete clinical testing and the regulatory submission process. It is possible that none of our product candidates will ever obtain regulatory approval, even if we expend substantial time and resources seeking such approval. If we do not achieve one or more of these factors in a timely manner or at all, or any other factors impacting the successful development of biopharmaceutical products, we could experience significant delays or an inability to successfully develop our product candidates, which would materially harm our business. </p>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:2.26%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">The development of product candidates with our ImmunoPhage platform represents an emerging approach to cancer treatment and faces significant challenges and hurdles. We may not be successful in applying our ImmunoPhage platform to the discovery and development of commercially viable products. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have concentrated our primary research and development efforts on our ImmunoPhage platform which utilizes the power of bacteriophage to facilitate the creation of vaccines for enhanced immune system activation. Our future success is highly dependent on the successful development and manufacture of our product candidates. We do not currently have any approved or commercialized products. Because bacteriophage-based therapies represent a relatively new field of cellular immunotherapy and cancer treatment generally, developing and commercializing our product candidates subjects us to a number of risks and challenges, including: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:1.13%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">obtaining regulatory approval for our product candidates, as the FDA and other regulatory authorities have limited experience with phage-based therapies for cancer; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:1.13%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">patients receiving chemotherapy in conjunction with the delivery of our product candidates, which may increase the risk of adverse side effects of our product candidates; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:1.13%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">sourcing clinical and, if approved, commercial supplies of the materials used to manufacture our product candidates; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:1.13%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">developing product candidates with desired properties, while avoiding adverse reactions; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:1.13%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">establishing manufacturing capacity suitable for the manufacture of our product candidates in line with expanding enrollment in our clinical studies and our projected commercial requirements; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:1.13%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">achieving cost efficiencies in the scale-up of our manufacturing capacity; </p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">36</a></p>
<hr style="page-break-after:always;width:100%;">
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:1.13%;white-space:nowrap"></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:1.13%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">developing protocols for the safe administration of our product candidates; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:1.13%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">educating medical personnel regarding our phage-based technologies and the potential side effect profile of each of our product candidates; and </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:1.13%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">the availability of coverage and adequate reimbursement from third-party payors for our novel and personalized therapies in connection with commercialization of any approved product candidates. </p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We may not be able to successfully develop our phage-based product candidates or any other product candidates in a manner that will yield products that are safe and effective, scalable or profitable. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Moreover, physicians, hospitals and third-party payors often are slow to adopt new products, technologies and treatment practices that require additional upfront costs and training. Treatment centers may not be willing or able to devote the personnel and establish other infrastructure required for the administration of our therapies. Based on these and other factors, health systems, hospitals and payors may decide that the benefits of this new therapy do not or will not outweigh its costs. </p>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:2.26%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">The regulatory approval processes of the FDA and comparable foreign authorities are lengthy, time-consuming and inherently unpredictable, and if we are ultimately unable to obtain regulatory approval for our product candidates, our business will be substantially harmed. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We do not have any products that have gained regulatory approval. Our business is substantially dependent on our ability to obtain regulatory approval for, and, if approved, to successfully commercialize our SNS-301 product candidate and our preclinical programs. We cannot commercialize product candidates in the United States without first obtaining regulatory approval for the product from the FDA. Before obtaining regulatory approvals for the commercial sale of any product candidate for a particular indication, we must demonstrate with substantial evidence gathered in preclinical and clinical studies, that the product candidate is safe and effective for that indication and that the manufacturing facilities, processes and controls are adequate with respect to such product candidate. Prior to seeking approval for any of our product candidates, we will need to confer with the FDA and other regulatory authorities regarding the design of our clinical trials and the type and amount of clinical data necessary to seek and gain approval for our product candidates. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The time required to obtain approval by the FDA and other regulatory authorities is unpredictable and typically takes many years following the commencement of preclinical studies and clinical trials and depends upon numerous factors, including the substantial discretion of the regulatory authorities. In addition, approval policies, regulations, or the type and amount of clinical data necessary to gain approval may change during the course of a product candidate&#8217;s clinical development and may vary among jurisdictions. It is possible that none of our existing product candidates or any future product candidates will ever obtain regulatory approval. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our product candidates could fail to receive regulatory approval from the FDA or other comparable regulatory authorities for many reasons, including: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:1.13%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">disagreement with the design, protocol or conduct of our clinical trials, including with respect to our ImmunoPhage cocktail approach; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:1.13%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">failure to demonstrate that a product candidate is safe and effective for its proposed indication; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:1.13%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">failure of clinical trials to meet the level of statistical significance required for approval; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:1.13%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">failure to demonstrate that a product candidate&#8217;s clinical and other benefits outweigh its safety risks; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:1.13%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">disagreement with our interpretation of data from preclinical studies or clinical trials; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:1.13%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">insufficiency of data collected from clinical trials of our product candidates to support the submission and filing of a Biologics License Application, or BLA, or other submission or to obtain regulatory approval; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:1.13%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">failure to obtain approval of the manufacturing processes or our facilities; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:1.13%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">changes in the approval policies or regulations that render our preclinical and clinical data insufficient for approval; or </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:1.13%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">lack of adequate funding to complete a clinical trial in a manner that is satisfactory to the applicable regulatory authority. </p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Many of these risks are beyond our control, including the risks related to clinical development. If we are unable to develop, receive regulatory approval for, or successfully commercialize SNS-301 or our other product candidates, or if we experience delays as a result of any of these risks or otherwise, our business could be materially harmed. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">37</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The FDA or a comparable regulatory authority may require more information, including additional preclinical or clinical data to support approval, including data that would require us to perform additional clinical trials or modify our manufacturing processes, which may delay or prevent approval and our commercialization plans, or we may decide to abandon the development program. If we change our manufacturing processes, we may be required to conduct additional clinical trials or other studies, which also could delay or prevent approval of our product candidates. If we were to obtain approval, regulatory authorities may approve any of our product candidates for fewer indications than we request (including failing to approve the most commercially promising indications), may limit indications, may grant approval contingent on the performance of costly post-marketing clinical trials or other post-marketing commitments, or may approve a product candidate with a label that does not include the labeling claims necessary or desirable for the successful commercialization of that product candidate. </font></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Even if a product candidate were to successfully obtain approval from the FDA or other comparable regulatory authorities in other jurisdictions, any approval might contain significant limitations related to use restrictions for specified age groups, warnings, precautions or contraindications, or may be subject to burdensome post-approval study or risk management requirements. If we are unable to obtain regulatory approval for one of our product candidates in one or more jurisdictions, or any approval contains significant limitations, we may not be able to obtain sufficient funding to continue the development of that product or generate revenues attributable to that product candidate. Also, any regulatory approval of our current or future product candidates, once obtained, may be withdrawn. </p>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:2.26%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Our business is highly dependent on the success of our lead product candidate, SNS-301 and any other product candidates that we advance into the clinic. All of our product candidates may require significant additional preclinical and clinical development before we may be able to seek regulatory approval for and launch a product commercially and we may not be successful in our efforts to build a pipeline of product candidates. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A key element of our strategy is utilizing our ImmunoPhage platform to develop what we believe are safer and more effective and personalized phage-based vaccines. We currently have no products that are approved for commercial sale and may never be able to develop marketable products. We are very early in our development efforts, and our product candidates, including SNS-301, are in early clinical development. Because SNS-301 is our lead product candidate, if SNS-301 encounters safety or efficacy problems, development delays, regulatory issues or other problems, our development plans and business would be significantly harmed.&#160;By leveraging insights gained from our experience with SNS-301, we have adapted our platform to generate personalized, off-the-shelf product candidates based on a cocktail of common and patient-specific antigens, dosed together as an array of customized, multi-antigen phage configurations in a modular approach. However, we may not be able to develop product candidates that are safe and effective, or which compare favorably with other commercially available alternatives. Even if we are successful in continuing to build our pipeline and develop personalized, off-the-shelf product candidates, the potential product candidates that we identify may not be suitable for clinical development, including as a result of lack of safety, lack of tolerability, or other characteristics that indicate that they are unlikely to be products that will receive marketing approval, achieve market acceptance or obtain reimbursements from third-party payors. We cannot provide you with any assurance that we will be able to successfully advance any of these additional product candidates through the development process. Our research programs may initially show promise in identifying potential product candidates, yet fail to yield product candidates for clinical development or commercialization for many reasons, including the following: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:1.13%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">our ImmunoPhage platform may not be successful in identifying additional product candidates; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:1.13%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">we may not be able or willing to assemble sufficient resources to acquire or discover additional product candidates; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:1.13%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">our product candidates may not succeed in preclinical or clinical testing; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:1.13%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">a product candidate may on further study be shown to have harmful side effects or other characteristics that indicate it is unlikely to be effective or otherwise does not meet applicable regulatory criteria; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:1.13%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">competitors may develop alternatives that render our product candidates obsolete or less attractive; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:1.13%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">product candidates we develop may nevertheless be covered by third parties&#8217; patents or other exclusive rights; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:1.13%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">the market for a product candidate may change during our development program so that the continued development of that product candidate is no longer reasonable; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:1.13%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">a product candidate may not be capable of being produced in commercial quantities at an acceptable cost, or at all; and </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:1.13%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">a product candidate may not be accepted as safe and effective by patients, the medical community or third-party payors, if applicable. </p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If any of these events occur, we may be forced to abandon our development efforts for a program or programs, or we may not be able to identify, discover, develop, or commercialize additional product candidates, which would have a material adverse effect on our business and could potentially cause us to cease operations. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">38</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If we do not successfully develop and commercialize product candidates or collaborate with others to do so, we will not be able to obtain product revenue in future periods, which could significantly harm our financial position and adversely affect the trading price of our common stock. </font></p>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:2.26%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">We are developing product candidates designed to produce responses against novel targets through a cocktail therapy approach for which there is little clinical experience, and the FDA or other regulatory authorities may not consider the endpoints of our clinical trials to predict or provide clinically meaningful results. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">SNS-301 has been engineered to produce a targeted immune response against ASPH.&#160;We are also developing a human mAb program targeting the novel immune checkpoint VISTA. There are currently no approved therapies that target ASPH or VISTA in the field of oncology. To evaluate these product candidates, we are also pioneering an adaptive clinical trial design that enables substitution of ImmunoPhage cocktail components throughout clinical development. As a result of the novelty of our targets as well as the novelty of our anticipated clinical trial design, the design and conduct of clinical trials of our product candidates or any future product candidate may take longer, be more costly or be less effective. There may also be inconsistent or contradictory efficacy or safety results amongst different cocktail product candidates for different patients in the same clinical trial. In some cases, we may use endpoints or methodologies that regulatory authorities may not consider to be clinically meaningful and that we may not continue to use in clinical trials or that we may determine after the initiation of the trial to no longer be an appropriate endpoint or methodology. Any such regulatory authority may require evaluation of additional or different clinical endpoints in our clinical trials or ultimately determine that these clinical endpoints do not support marketing approval. In addition, if we are required to use additional or different clinical endpoints by regulatory authorities, our product candidates may not achieve or meet such clinical endpoints in our clinical trials. Even if a regulatory authority finds our clinical trial success criteria to be sufficiently validated and clinically meaningful, we may not achieve the pre-specified endpoint to a degree of statistical significance in any pivotal or other clinical trials we may conduct for our product candidate. Further, even if we do achieve the pre-specified&#160;criteria, our trials may produce results that are unpredictable or inconsistent with the results of other efficacy endpoints in the trial. Regulatory authorities also weigh the benefits of a product against its risks and may not view the efficacy and safety results we product with our adaptive clinical trial design as supportive of approval. </p>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:2.26%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">We may expend our limited resources to pursue a particular product candidate or indication and fail to capitalize on product candidates or indications that may be more profitable or have a greater likelihood of success. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Because we have limited financial and management resources, we focus on research programs and product candidates that we identify for specific indications. As a result, we may forego or delay pursuit of opportunities with other product candidates or for other indications that later prove to have greater commercial potential. Our resource allocation decisions may cause us to fail to capitalize on viable commercial products or profitable market opportunities. Our spending on current and future research and development programs and product candidates for specific indications may not yield any commercially viable products. If we do not accurately evaluate the commercial potential or target market for a particular product candidate, we may relinquish valuable rights to that product candidate through collaboration, licensing or other royalty arrangements in cases in which it would have been more advantageous for us to retain sole development and commercialization rights to such product candidate. </p>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:2.26%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">If the clinical trials of any of our product candidates fail to demonstrate safety and efficacy to the satisfaction of the FDA or other comparable regulatory authorities, or do not otherwise produce favorable results, we may incur additional costs or experience delays in completing, or ultimately be unable to complete, the development and commercialization of our product candidates. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Most of our product candidates are still in the preclinical development stage, and the risk of failure of preclinical programs is high. Before we can commence clinical trials for a product candidate, we must complete extensive preclinical testing and studies to obtain regulatory clearance to initiate human clinical trials. We cannot be certain of the timely completion or outcome of our preclinical testing and studies and cannot predict if the FDA or other regulatory authorities will accept our proposed clinical programs or if the outcome of our preclinical testing and studies will ultimately support the further development of our programs. As a result, we cannot be sure that we will be able to submit INDs or similar applications for our preclinical programs on the timelines we expect, if at all, and we cannot be sure that submission of INDs or similar applications will result in the FDA or other regulatory authorities allowing clinical trials to begin. It is impossible to predict accurately when or if any of our product candidates will prove effective or safe in humans and will receive regulatory approval. Before obtaining marketing approval from regulatory authorities for the commercial sale of any of our product candidates, we must demonstrate through lengthy, complex and expensive preclinical testing and clinical trials that our product candidates are both safe and effective for use in each target indication. Clinical testing is expensive, difficult to design and implement, can take many years to complete and is uncertain as to outcome. A failure of one or more clinical trials can occur at any stage of testing. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">39</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We may experience numerous unforeseen events prior to, during, or </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">as a result of</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, clinical trials that could delay or prevent our ability to receive marketing approval or commercialize any of our product candidates, including: </font></p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:1.13%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">the FDA or other comparable regulatory authority may disagree as to the number, design or implementation of our clinical trials, or may not interpret the results from clinical trials as we do; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:1.13%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">regulators or institutional review boards may not authorize us or our investigators to commence a clinical trial or conduct a clinical trial at a prospective trial site; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:1.13%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">we may not reach agreement on acceptable terms with prospective clinical trial sites, the terms of which can be subject to extensive negotiation and may vary significantly among different clinical trial sites; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:1.13%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">clinical trials of our product candidates may produce negative or inconclusive results; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:1.13%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">we may decide, or regulators may require us, to conduct additional preclinical studies or clinical trials or abandon our product development programs; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:1.13%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">the number of patients required for clinical trials of our product candidates may be larger than we anticipate, enrollment in these clinical trials may be slower than we anticipate, participants may drop out of these clinical trials at a higher rate than we anticipate or we may fail to recruit suitable patients to participate in a trial; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:1.13%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">our third-party contractors may fail to comply with regulatory requirements or meet their contractual obligations to us in a timely manner, or at all; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:1.13%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">regulators may issue a clinical hold, or regulators or institutional review boards may require that we or our investigators suspend or terminate clinical research for various reasons, including noncompliance with regulatory requirements or a finding that the participants are being exposed to unacceptable health risks; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:1.13%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">the cost of clinical trials of our product candidates may be greater than we anticipate; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:1.13%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">the FDA or other comparable regulatory authorities may fail to approve our manufacturing processes or facilities; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:1.13%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">the supply or quality of our product candidates or other materials necessary to conduct clinical trials of our product candidates may be insufficient or inadequate; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:1.13%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">our product candidates may have undesirable side effects or other unexpected characteristics, particularly given their novel, first-in-human application, causing us or our investigators, regulators or institutional review boards to suspend or terminate the clinical trials; and </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:1.13%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">the approval policies or regulations of the FDA or other comparable regulatory authorities may significantly change in a manner rendering our clinical data insufficient for approval. </p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">To the extent that the results of the trials are not satisfactory for the FDA or regulatory authorities in other countries or jurisdiction to approve our BLA or other comparable application, the commercialization of our product candidates may be significantly delayed, or we may be required to expend significant additional resources, which may not be available to us, to conduct additional trials in support of potential approval of our product candidates. </p>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:2.26%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Clinical trials are difficult to design and implement, can be lengthy and expensive, involve uncertain outcomes and may not ultimately be successful. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">It is impossible to predict when or if any of our current or future product candidates will prove effective and safe in humans or will receive regulatory approval. Before obtaining marketing approval from regulatory authorities for the sale of any product candidate, we must complete preclinical studies and then conduct extensive clinical trials to demonstrate the safety and efficacy of our product candidates in humans. Human clinical trials are expensive, can take many years to complete, and are difficult to design and implement, in part because they are subject to rigorous regulatory requirements. The design of a clinical trial can determine whether its results will support approval of a product and flaws in the design of a clinical trial may not become apparent until the clinical trial is well advanced. As an organization, we have limited experience designing clinical trials and may be unable to design and execute a clinical trial to support regulatory approval. There is a high failure rate for oncology product candidates proceeding through clinical trials, which may be higher for our product candidates because they are based on a new approach. Many companies in the pharmaceutical and biotechnology industries have suffered significant setbacks in late-stage clinical trials even after achieving promising results in preclinical testing and earlier-stage clinical trials. Data obtained from preclinical and clinical activities are subject to varying interpretations, which may delay, limit or prevent regulatory approval. In addition, we may experience regulatory delays or rejections as a result of many factors, including changes in regulatory policy during the period of our product candidate development. Any such delays could negatively impact our business, financial condition, results of operations and prospects. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">40</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:2.26%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Success in preclinical studies or clinical trials may not be predictive of results in future clinical trials. </font></p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Results from preclinical studies and early clinical trials may not be predictive of the success of later clinical trials, and interim results of clinical trials are not necessarily predictive of final results. While we have received initial data in our Phase 1/2 clinical trial of SNS-301 for the treatment of locally advanced unresectable or metastatic SCCHN, we still need to conduct additional clinical trials prior to seeking regulatory approval. We have also not yet begun clinical trials for our other product candidates. For that reason, we do not know whether these candidates will be effective for the intended indications or safe in humans. Our product candidates may fail to show the desired safety and efficacy in clinical development despite positive results observed in preclinical studies or having successfully advanced through initial clinical trials. This failure to establish sufficient efficacy and safety could cause us to abandon clinical development of our product candidates. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Additionally, some of our past, planned and ongoing clinical trials utilize an open-label study design. An &#8220;open-label&#8221; clinical trial is one where both the patient and investigator know whether the patient is receiving the investigational product candidate or either an existing approved therapy or placebo. Most typically, open-label clinical trials test only the investigational product candidate and sometimes may do so at different dose levels. Open-label clinical trials are subject to various limitations that may exaggerate any therapeutic effect, as patients in open-label clinical trials are aware when they are receiving treatment. Open-label clinical trials may be subject to a &#8220;patient bias&#8221; where patients perceive their symptoms to have improved merely due to their awareness of receiving an experimental treatment. Moreover, patients selected for early clinical studies often include the most severe sufferers and their symptoms may have been bound to improve notwithstanding the new treatment. In addition, open-label clinical trials may be subject to an &#8220;investigator bias&#8221; where those assessing and reviewing the physiological outcomes of the clinical trials are aware of which patients have received treatment and may interpret the information of the treated group more favorably given this knowledge. Given that our Phase 1/2 clinical trial of SNS-301 includes an open-label dosing design, the results from this clinical trial may not be predictive of future clinical trial results with this or other product candidates for which we conduct an open-label clinical trial when studied in a controlled environment with a placebo or active control. </p>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:2.26%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Interim topline and preliminary data from our clinical trials that we announce or publish from time to time may change as more patients are enrolled and additional data become available, and are subject to audit and verification procedures that could result in material changes in the final data. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">From time to time, we may publish interim topline or preliminary data from our clinical trials. Interim data from clinical trials that we may complete are subject to the risk that one or more of the clinical outcomes may materially change as patient enrollment continues and more patient data become available. We also make assumptions, estimations, calculations and conclusions as part of our analyses of data, and we may not have received or had the opportunity to fully and carefully evaluate all data. As a result, the topline or preliminary results that we report may differ from future results of the same studies, or different conclusions or considerations may qualify such results, once additional data have been received and fully evaluated. Preliminary or topline data also remain subject to audit and verification procedures that may result in the final data being materially different from the preliminary data we previously published. As a result, interim and preliminary data should be viewed with caution until the final data are available. From time to time, we may also disclose interim data from our clinical trials. Interim data from clinical trials are subject to the risk that one or more of the clinical outcomes may materially change as patient enrollment continues and more patient data become available or as patients from our clinical trials continue other treatments for their disease. For instance, we have reported interim data from our ongoing Phase 1/2 clinical trial of SNS-301 for the treatment of SCCHN based on our first 11 enrolled patients, of which ten patients were evaluable for efficacy as of December 10, 2020, and the overall results from the Phase 1/2 trial may materially change as we complete enrollment and report results for the full 30 patients that we anticipate enrolling in the trial. Adverse differences between preliminary or interim data and final data could significantly harm our reputation and business prospects. Further, disclosure of interim data by us or by our competitors could result in volatility in the price of our common stock. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Further, others, including regulatory agencies, may not accept or agree with our assumptions, estimates, calculations, conclusions or analyses or may interpret or weigh the importance of data differently, which could impact the potential of the particular program, the likelihood of marketing approval or commercialization of the particular product candidate, any approved product, and our company in general. In addition, the information we choose to publicly disclose regarding a particular study or clinical trial is derived from information that is typically extensive, and you or others may not agree with what we determine is material or otherwise appropriate information to include in our disclosure. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If the interim, topline, or preliminary data that we report differ from actual results, or if others, including regulatory authorities, disagree with the conclusions reached, our ability to obtain approval for, and commercialize, our product candidates may be harmed, which could harm our business, operating results, prospects or financial condition. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">41</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:2.26%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">We depend on timely enrollment of patients in our clinical trials for our product candidates. If we encounter difficulties enrolling patients in our clinical trials, our clinical development activities could be delayed or otherwise adversely affected. </font></p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Identifying and qualifying patients to participate in clinical trials of our product candidates is critical to our success. We may experience difficulties in patient enrollment in our clinical trials for a variety of reasons. The timely completion of clinical trials in accordance with their protocols depends, among other things, on our ability to enroll a sufficient number of patients who remain in the study until its conclusion. The enrollment of patients depends on many factors, including: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:1.13%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">the patient eligibility criteria defined in the protocol; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:1.13%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">the number of patients with the disease or condition being studied; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:1.13%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">the perceived risks and benefits of the product candidate in the trial; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:1.13%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">clinicians&#8217; and patients&#8217; perceptions as to the potential advantages of the product candidate being studied in relation to other available therapies, including any new drugs that may be approved for the indications we are investigating or drugs that may be used off-label for these indications; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:1.13%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">the size and nature of the patient population required for analysis of the trial&#8217;s primary endpoints; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:1.13%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">the proximity of patients to study sites; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:1.13%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">the design of the clinical trial; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:1.13%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">our ability to recruit clinical trial investigators with the appropriate competencies and experience; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:1.13%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">competing clinical trials for similar therapies or other new therapeutics; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:1.13%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">our ability to obtain and maintain patient consents; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:1.13%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">the risk that patients enrolled in clinical trials will drop out of the clinical trials before completion of their treatment; and </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:1.13%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">factors we may not be able to control, such as current or potential pandemics, including the COVID-19 pandemic, that may limit patients, principal investigators or staff or clinical site available. </p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In particular, some of our clinical trials will look to enroll patients with specific limited characteristics. For instance, in our ongoing Phase 1/2 of SNS-301 in SCCHN, we restricted enrollment to SCCHN patients who were treated with PD1 blockade for at least 12 weeks and did not achieve an objective response or confirmed progression, which limits the pool of patients from which we have to recruit trial participants. In addition, because the number of qualified clinical investigators is limited, we expect to conduct some of our clinical trials at the same clinical trial sites that some of our competitors use, which could further reduce the number of patients who are available for our clinical trials in these clinical trial sites. Moreover, because our product candidates represent a departure from more commonly used methods for cancer treatment, potential patients and their doctors may be inclined to use conventional therapies, such as chemotherapy and antibody therapy, rather than enroll patients in our clinical trials. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Delays in patient enrollment may result in increased costs or may affect the timing or outcome of the planned clinical trials, which could prevent completion of these clinical trials and adversely affect our ability to advance the development of our product candidates. In addition, many of the factors that may lead to a delay in the commencement or completion of clinical trials may also ultimately lead to the denial of regulatory approval of our product candidates. </p>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:2.26%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">We may seek Fast Track designation for some or all of our current or future product candidates, but we may be unable to obtain such designations or, where obtained, we may be unable to maintain such designations or obtain or maintain the benefits associated with such designations. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We may seek Fast Track designation for some or all of our other current and future product candidates, but we may be unable to obtain such designation or, where obtained, we may be unable to maintain such designation or obtain or maintain the benefits associated with such designation. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If a biologic is intended for the treatment of a serious or life-threatening condition and the product demonstrates the potential to address unmet medical needs for this condition, the product sponsor may apply for FDA Fast Track designation for a particular indication. We may seek Fast Track designation for SNS-301 and some or all of our other current and future product candidates, but there is no assurance that the FDA will grant this status to any of our proposed product candidates. Marketing applications filed by sponsors of products in Fast Track development may qualify for priority review under the policies and procedures offered by the FDA, but the Fast Track designation does not assure any such qualification or ultimate marketing approval by the FDA. The FDA has broad discretion whether or not to grant Fast Track designation, so even if we believe a particular product candidate is eligible for this designation, there can be no assurance that the FDA would decide to grant it. Even if we do receive Fast Track designation, we may not experience a faster development process, review or approval compared to conventional FDA procedures, and receiving a Fast </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">42</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:12pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Track designation does not provide assurance of ultimate FDA approval. In addition, the FDA may withdraw Fast Track designation if it believes that the designation is no longer supported by data from our clinical development program. In addition, the FDA may withdraw any Fast Track designation at any time. </font></p>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:2.26%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">The market opportunities for certain of our product candidates may be limited to those patients who are ineligible for or have failed prior treatments and, therefore, may be small, and our projections regarding the size of the addressable market may be incorrect. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our immunotherapy approach is based on novel ideas and technologies that are unproven and may not result in marketable products, which makes it difficult for us to predict the time and cost of product development and potential for regulatory approval. Cancer therapies are sometimes characterized as first line, second line or third line, and the FDA often approves new therapies initially only for third line use. When cancers are detected they are treated with first line of therapy with the intention of curing the cancer. This treatment generally consists of chemotherapy, radiation, antibody drugs, tumor targeted small molecules, or a combination of these. If the patient&#8217;s cancer relapses, then the patient is given a second line or third line therapy, which can consist of more chemotherapy, radiation, antibody drugs, tumor targeted small molecules, or a combination of these. Generally, the higher the line of therapy, the lower the chance of a cure. With third or higher line, the goal of the therapy is to control the growth of the tumor and extend the life of the patient, as a cure is unlikely to happen. Patients are generally referred to clinical trials in these situations. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">While we are initially developing SNS-301 as a first line therapy and later lines of therapy for patients with SCCHN, there is no guarantee that it, or any of our product candidates, even if approved, would be approved for an early line of therapy. In addition, we may have to conduct additional large randomized clinical trials prior to gaining approval for the earlier line of therapy. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our projections of both the number of people who have the cancers we are targeting, as well as the size of the patient population subset of people with these cancers in a position to receive first, second, third and fourth line therapy and who have the potential to benefit from treatment with our product candidates, are based on our beliefs and estimates. These estimates have been derived from a variety of sources, including scientific literature, surveys of clinics, patient foundations, or market research and may prove to be incorrect. Further, new studies may change the estimated incidence or prevalence of these cancers. The number of patients may turn out to be fewer than expected. Additionally, the potentially addressable patient population for our product candidates may be limited or may not be amenable to treatment with our product candidates. Even if we obtain significant market share for our product candidates, because the potential target populations are small, we may never achieve significant revenues without obtaining regulatory approval for additional indications or as part of earlier lines of therapy. </p>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:2.26%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">We are developing SNS-301, and potentially future product candidates, in combination with other therapies, which exposes us to additional risks. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are developing SNS-301, and may develop future product candidates, for use in combination with one or more currently approved cancer therapies. In particular, we are developing SNS-301 in combination pembrolizumab, an approved anti-PD-1 cancer treatment. Even if any product candidate we develop was to receive marketing approval or be commercialized for use in combination with other existing therapies, we would continue to be subject to the risks that the FDA or similar foreign regulatory authorities could revoke approval of the therapy used in combination with our product candidate or that safety, efficacy, manufacturing or supply issues could arise with these existing therapies. Combination therapies are commonly used for the treatment of cancer, and we would be subject to similar risks if we develop any of our product candidates for use in combination with other drugs or for indications other than cancer. This could result in our own products being removed from the market or being less successful commercially. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If the FDA or similar foreign regulatory authorities do not approve these other drugs or revoke their approval of, or if safety, efficacy, manufacturing, or supply issues arise with, the drugs we choose to evaluate in combination with SNS-301 or any product candidate we develop, we may be unable to obtain approval of or market SNS-301 or any product candidate we develop. </p>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:2.26%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Adverse side effects or other safety risks associated with our product candidates could delay or preclude approval, cause us to suspend or discontinue clinical trials, cause us to abandon product candidates, could limit the commercial profile of an approved label, or could result in significant negative consequences following any potential marketing approval. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our clinical trials include cancer patients who are very sick and whose health is deteriorating, and we expect that additional clinical trials of our other product candidates will include similar patients with deteriorating health. It is possible that some of these patients may experience similar side effects and that additional patients may die during our clinical trials for various reasons. The causes of death could include receiving our product candidates because the patient&#8217;s disease is too advanced or because the patient experiences medical problems that may not be related to our product candidate. Even if the patient deaths are not related to our product candidate, the deaths could affect perceptions regarding the safety of our product candidate. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">43</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Patient deaths and severe side effects caused by our product candidates, or by products or product candidates of other companies that are thought to have similarities with our therapeutic candidates, could result in the delay, suspension, clinical hold or termination of our clinical trials, the </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">FDA</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> or other regulatory authorities for a number of reasons. If we elect or are required to delay, </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">suspend</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> or terminate any clinical trial of any product candidates that we develop, the commercial prospects of such product candidates will be harmed and our ability to generate product revenues from any of these product candidates would be delayed or eliminated. Serious adverse events observed in clinical trials could hinder or prevent market acceptance of the product candidate at issue. Any of these occurrences may harm our business, prospects, financial </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">condition</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> and results of operations significantly. </font></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Additionally, if one or more of our product candidates receives marketing approval, and we or others later identify undesirable side effects caused by such products, including during any long-term follow-up observation period recommended or required for patients who receive treatment using our products, a number of potentially significant negative consequences could result, including: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:1.13%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">regulatory authorities may withdraw or limit their approval of such products; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:1.13%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">regulatory authorities may require the addition of labeling statements, such as a &#8220;boxed&#8221; warning or a contraindication; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:1.13%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">we may be required to create a Risk Evaluation and Mitigation Strategy, or REMS, plan, which could include a medication guide outlining the risks of such side effects for distribution to patients, a communication plan for healthcare providers, and/or other elements to assure safe use, such as restricted distribution methods, patient registries and other risk minimization tools; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:1.13%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">we may decide to remove such products from the marketplace; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:1.13%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">we could be sued and held liable for harm caused to patients; and </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:1.13%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">our reputation may suffer. </p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Any of the foregoing could prevent us from achieving or maintaining market acceptance of the particular product candidate, if approved, and could significantly harm our business, results of operations, and prospects. </p>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:2.26%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">We may not be successful in achieving cost of goods at commercial scale that provide for an attractive margin. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have limited commercial manufacturing experience and may underestimate the cost and time required to establish manufacturing capacity at commercial scale, or overestimate cost reductions from economies of scale that can be realized with manufacturing processes. While we are planning to internally develop this capability, including plans for the potential construction of our own manufacturing facility, we have also held discussions with multiple contract manufacturing organizations regarding commercial-stage manufacturing. We may ultimately be unable to manage the cost of goods for our product candidates to levels that will allow for a margin in line with our expectations and return on investment if those product candidates are commercialized. </p>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:2.26%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">We may not be successful in manufacturing our product candidates on our own for use in clinical trials and, if approved, for commercial sale. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As we advance into later-stage clinical trials and additional indications, we intend to expand our current manufacturing capabilities to support larger scale clinical trials and the potential commercialization of our product candidates. However, we have not yet constructed or acquired manufacturing facilities or capabilities that would allow us to meet commercial-scale quantities. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The implementation of this plan is subject to many risks. For example, the expansion of a manufacturing facility is a complex endeavor requiring knowledgeable individuals. Expanding our internal manufacturing infrastructure will rely upon finding personnel with an appropriate background and training to staff and operate the facility. Should we be unable to find these individuals, we may need to rely on external contractors or train additional personnel to fill the needed roles. There are a small number of individuals with relevant experience and the competition for these individuals is high. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We may never be successful in expanding our own manufacturing capability to support large scale clinical trials and commercialization of product candidates, if approved. We may establish additional manufacturing sites as we expand our commercial footprint to multiple geographies, which may lead to regulatory delays or prove costly. Even if we are successful, our manufacturing operations could be affected by cost-overruns, unexpected delays, equipment failures, labor shortages, natural disasters, power failures and numerous other factors, or we may not be successful in establishing sufficient capacity to produce our product candidates in sufficient quantities to meet the requirements for the potential launch or to meet potential future demand, all of which could prevent us from realizing the intended benefits of our manufacturing strategy and have a material adverse effect on our business. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">44</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:2.26%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">The manufacture of our product candidates is complex and we may encounter difficulties in production, particularly with respect to process development or scaling-out of our manufacturing capabilities. If we encounter such difficulties, our ability to provide supply of our product candidates for clinical trials or our products for patients, if approved, could be </font><font style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">delayed</font><font style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"> or stopped. </font></p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have developed a process for manufacturing and stock storing bacteriophage viruses and we believe that our current processes are readily scalable and suitable for commercialization. Each manufacturing process must be validated through the performance of process validation runs to guarantee that the facility, personnel, equipment, and process work as designed. We have not yet manufactured or processed our product candidates on a commercial scale and may not be able to do so for any of our product candidates. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We may encounter difficulties in production, particularly in scaling up or out, validating the production process, and assuring high reliability of the manufacturing process. These problems include delays or break-downs in logistics and shipping, difficulties with production costs and yields, quality control, and product testing, operator error, lack of availability of qualified personnel, as well as failure to comply with strictly enforced federal, state and foreign regulations. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Furthermore, if microbial, viral or other contaminations are discovered in our supply of product candidates or in the manufacturing facilities, such manufacturing facilities may need to be closed for an extended period of time to investigate and remedy the contamination. We cannot assure you that any of these or other issues relating to the manufacture of our product candidates will not occur in the future. Any delay or interruption in the supply of clinical trial supplies could delay the completion of clinical trials, increase the costs associated with maintaining clinical trial programs and, depending upon the period of delay, require us to begin new clinical trials at additional expense or terminate clinical trials completely. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Manufacturing facilities also require commissioning and validation activities to demonstrate that they operate as designed, and are subject to government inspections by the FDA and other comparable regulatory authorities. If we are unable to reliably produce products to specifications acceptable to the regulatory authorities, we may not obtain or maintain the approvals we need to manufacture our products. Further, manufacturing facilities may fail to pass government inspections prior to or after the commercial launch of our product candidates, which would cause significant delays and additional costs required to remediate any deficiencies identified by the regulatory authorities. Any of these challenges could delay completion of clinical trials, require bridging clinical trials or the repetition of one or more clinical trials, increase clinical trial costs, delay approval of our product candidate, impair commercialization efforts, increase our cost of goods, and have an adverse effect on our business, financial condition, results of operations and growth prospects. </p>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:2.26%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Prior treatments can alter the cancer and negatively impact chances for achieving clinical activity with our ImmunoPhage product candidates. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Patients with head and neck and other cancers typically receive highly toxic lympho-depleting chemotherapy as their initial treatments that can impact the patient&#8217;s responses to new therapies. Patients could also have received prior therapies that target the same target antigen on the cancer cells as our intended ImmunoPhage and thereby lead to a selection of cancer cells with low or no expression of the target. As a result, our product candidates may not recognize the cancer cell and may fail to achieve clinical activity. If any of our product candidates do not achieve a sufficient level of clinical activity, we may discontinue the development of that product candidate, which could have an adverse effect on the value of our common stock. </p>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:2.26%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Even if we complete the necessary preclinical studies and clinical trials, the marketing approval process is expensive, time-consuming and uncertain and may prevent us or any future collaboration partners from obtaining approvals for the commercialization of SNS-301 as well as for any other product candidate we develop. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Any product candidate we may develop and the activities associated with their development and commercialization, including their design, testing, manufacture, safety, efficacy, recordkeeping, labeling, storage, approval, advertising, promotion, sale, and distribution, are subject to comprehensive regulation by the FDA and other regulatory authorities in the United States and by comparable authorities in other countries. Failure to obtain marketing approval for a product candidate will prevent us from commercializing the product candidate in a given jurisdiction. We have not received approval to market any product candidates from regulatory authorities in any jurisdiction and it is possible that none of the product candidates we may seek to develop in the future will ever obtain regulatory approval. We have no experience in filing and supporting the applications necessary to gain marketing approvals and expect to rely on third-party contract research organizations, or CROs, or regulatory consultants to assist us in this process. Securing regulatory approval requires the submission of extensive preclinical and clinical data and supporting information to the various regulatory authorities for each therapeutic indication to establish the biologic product candidate&#8217;s safety, purity, efficacy and potency. Securing regulatory approval also requires the submission of information about the product manufacturing process to, and inspection of manufacturing facilities by, the relevant regulatory authority. Any product candidates we develop may not be </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">45</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">effective, may be only moderately effective, or may prove to have undesirable or unintended side effects, toxicities or other characteristics that may preclude our obtaining marketing approval or prevent or limit commercial use. </font></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The process of obtaining marketing approvals, both in the United States and abroad, is expensive, may take many years if additional clinical trials are required, if approval is obtained at all, and can vary substantially based upon a variety of factors, including the type, complexity, and novelty of the product candidates involved. Changes in marketing approval policies during the development period, changes in or the enactment of additional statutes or regulations, or changes in regulatory review for each submitted product application, may cause delays in the approval or rejection of an application. The FDA and comparable authorities in other countries have substantial discretion in the approval process and may refuse to accept any application or may decide that our data are insufficient for approval and require additional preclinical, clinical or other studies. In addition, varying interpretations of the data obtained from preclinical and clinical testing could delay, limit, or prevent marketing approval of a product candidate. Any marketing approval we ultimately obtain may be limited or subject to restrictions or post-approval commitments that render the approved product not commercially viable. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If we experience delays in obtaining approval or if we fail to obtain approval of any product candidates we may develop, the commercial prospects for those product candidates may be harmed, and our ability to generate revenues will be materially impaired. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Risks Related to our Dependence on Third Parties </p>
<p style="margin-bottom:0pt;margin-top:6pt;margin-left:2.26%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">We collaborate with third parties in connection with the development of our product candidates, and may depend upon future collaboration partners to commit to the research, development, manufacturing and marketing of our product candidates. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We collaborate with third parties for the development of our product candidates, including, for instance, our clinical trial collaboration with AstraZeneca for future Phase 2 clinical trials of SNS-301 in combination with durvalumab in the neoadjuvant setting and our collaboration with the University of Washington pursuant to which we are conducting preclinical studies for our SNS-401 program. We may enter into additional collaborations for our other current or future product candidates or technologies. We cannot control the timing or quantity of resources that our existing or future collaborators will dedicate to research, preclinical and clinical development, manufacturing or marketing of our products. Our collaborators may not perform their obligations according to our expectations or standards of quality. Our collaborators could terminate our existing agreements for a number of reasons. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In order to optimize the launch and market penetration of certain of our future product candidates, we may enter into distribution and marketing agreements with pharmaceutical industry leaders. For these product candidates, we would not market our products alone once they have obtained marketing authorization. The risks inherent in entry into these contracts are as follows: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:1.13%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">the negotiation and execution of these agreements is a long process that may not result in an agreement being signed or that can delay the development or commercialization of the product candidate concerned; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:1.13%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">these agreements are subject to cancellation or&#160;non-renewal&#160;by our collaborators, or may not be fully complied with by our collaborators; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:1.13%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">in the case of a license granted by us, we lose control of the development of the product candidate licensed; in such cases, we would only have limited control over the means and resources allocated by our partner for the commercialization of our product; and </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:1.13%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">collaborators may not properly obtain, maintain, enforce, or defend our intellectual property or proprietary rights or may use our proprietary information in such a way as to invite litigation that could jeopardize or invalidate our proprietary information or expose us to potential litigation. </p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Should any of these risks materialize, or should we fail to find suitable collaborators, this could have a material adverse effect on our business, prospects, financial condition and results of operations. </p>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:2.26%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">We have entered, and may in the future enter into, partnership agreements with third parties for the development and commercialization of our product candidates. Our prospects with respect to those product candidates will depend in significant part on the success of those collaborations. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The advancement of our product candidates and development programs and the potential commercialization of our current and future product candidates will require substantial additional cash to fund expenses. For some of our programs, we may decide to collaborate with additional pharmaceutical and biotechnology companies with respect to development and potential </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">46</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">commercialization. As such, we have </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">entered into</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> and may seek to enter into additional collaborations or partnerships with third parties for the development and potential commercialization of our product candidates. </font></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We face significant competition in seeking appropriate collaborators. Should we seek to collaborate with a third party with respect to a prospective development program, we may not be able to locate a suitable partner or to enter into an agreement on commercially reasonable terms or at all. Even if we succeed in securing partners for the development and commercialization of our product candidates, we have limited control over the time and resources that our partners may dedicate to the development and commercialization of our product candidates. These partnerships pose a number of risks, including the following: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:1.13%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">partners may not have sufficient resources or decide not to devote the necessary resources due to internal constraints such as budget limitations, lack of human resources or a change in strategic focus; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:1.13%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">partners may believe our intellectual property is not valid or is unenforceable or the product candidate infringes on the intellectual property rights of others; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:1.13%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">partners may dispute their responsibility to conduct development and commercialization activities pursuant to the applicable collaboration, including the payment of related costs or the division of any revenues; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:1.13%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">partners may decide to pursue a competitive product developed outside of the collaboration arrangement; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:1.13%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">partners may not be able to obtain, or believe they cannot obtain, the necessary regulatory approvals; or </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:1.13%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">partners may delay the development or commercialization of our product candidates in favor of developing or commercializing another party&#8217;s product candidate. </p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Thus, partnership agreements may not lead to development, regulatory approval or successful commercialization of product candidates in the most efficient manner or at all. Some partnership agreements are terminable without cause on short notice. Once a partnership agreement is signed, it may not lead to regulatory approval and commercialization of a product candidate. We also face competition in seeking out partners. If we are unable to secure new collaborations that achieve the collaborator&#8217;s objectives and meet our expectations, we may be unable to advance our product candidates and may not generate meaningful revenues. </p>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:2.26%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">We rely, and expect to continue to rely, on third parties to conduct the preclinical and clinical trials for our product candidates, and those third parties may not perform satisfactorily, including failing to meet deadlines for the completion of such trials or failing to comply with applicable regulatory requirements. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We depend and will continue to depend upon independent investigators and collaborators, such as universities, medical institutions, and strategic partners to conduct our preclinical studies and clinical trials. Agreements with such third parties might terminate for a variety of reasons, including a failure to perform by the third parties. If we need to enter into alternative arrangements, our product development activities would be delayed. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our reliance on these third parties for research and development activities will reduce our control over these activities but will not relieve us of our responsibilities. For example, we will remain responsible for ensuring that each of our clinical trials is conducted in accordance with the general investigational plan and protocols for the trial. Moreover, the FDA requires us to comply with regulatory standards, commonly referred to as good laboratory practices, or GLP, and good clinical practices, or GCP, for conducting, recording and reporting the results of preclinical and clinical trials to assure that data and reported results are credible and accurate and that the rights, integrity and confidentiality of trial participants are protected. We are also required to register certain ongoing clinical trials and post the results of certain completed clinical trials on a government-sponsored database within specified timeframes. Failure to do so by us or third parties can result in FDA refusal to approve applications based on the clinical data, enforcement actions, adverse publicity and civil and criminal sanctions. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Furthermore, these third parties may also have relationships with other entities, some of which may be our competitors. If these third parties do not successfully carry out their contractual duties, meet expected deadlines or conduct our clinical trials in accordance with regulatory requirements or our stated protocols, we will not be able to obtain, or may be delayed in obtaining, marketing approvals for our product candidates and will not be able to, or may be delayed in our efforts to, successfully commercialize our product candidates. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, principal investigators for our clinical trials may serve as scientific advisors or consultants to us from time to time and may receive cash or equity compensation in connection with such services. If these relationships and any related compensation result in perceived or actual conflicts of interest, or the FDA concludes that the financial relationship may have affected the interpretation of the trial, the integrity of the data generated at the applicable clinical trial site may be questioned and the utility of the </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">47</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:12pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">clinical trial itself may be jeopardized, which could result in the delay or rejection by the FDA. Any such delay or rejection could prevent us from commercializing our clinical-stage product candidates or any future product candidates. </font></p>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:2.26%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">To develop immunotherapeutic candidates, we rely on the availability of reagents, specialized equipment, and other specialty materials, which may not be available to us on acceptable terms or at all. For some of these reagents, equipment, and materials, we may rely on sole source vendors or a limited number of vendors, which could impair our ability to manufacture and supply our products. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Manufacturing our product candidates will require many reagents, which are substances used in our manufacturing processes to bring about chemical or biological reactions, and other specialty materials and equipment, some of which are manufactured or supplied by small companies with limited resources and experience to support commercial biologics production. We currently depend on a limited number of vendors for access to facilities and supply of certain materials and equipment used in the manufacture of our product candidates. For example, we purchase equipment and reagents critical for the manufacture of our product candidates from third parties on a purchase order basis. Some of our suppliers may not have the capacity to support commercial products manufactured under cGMP by biopharmaceutical firms or may otherwise be ill-equipped to support our needs. We also do not have supply contracts with many of these suppliers, and may not be able to obtain supply contracts with them on acceptable terms or at all. Accordingly, we may not be able to obtain key materials and equipment to support clinical or commercial manufacturing. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For some of these reagents, equipment, and materials, we may in the future rely on sole source vendors or a limited number of vendors. An inability to source product from any of these suppliers, which could be due to regulatory actions or requirements affecting the supplier, adverse financial or other strategic developments experienced by a supplier, labor disputes or shortages, widespread business interruption, unexpected demands, or quality issues, could adversely affect our ability to satisfy demand for our product candidates, which could adversely and materially affect our product sales and operating results or our ability to conduct clinical trials, either of which could significantly harm our business. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As we continue to develop and scale our manufacturing process, we may need to obtain rights to and supplies of certain materials and equipment to be used as part of that process. We may not be able to obtain rights to such materials on commercially reasonable terms, or at all, and if we are unable to alter our process in a commercially viable manner to avoid the use of such materials or find a suitable substitute, it would have a material adverse effect on our business. </p>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:2.26%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Our employees, principal investigators, CROs and consultants may engage in misconduct or other improper activities, including non-compliance with regulatory standards and requirements. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are exposed to the risk that our employees, principal investigators, CROs and consultants may engage in fraudulent conduct or other illegal activity. Misconduct by these parties could include intentional, reckless and/or negligent conduct or disclosure of unauthorized activities to us that violate the regulations of the FDA and other regulatory authorities, including those laws requiring the reporting of true, complete and accurate information to such authorities; healthcare fraud and abuse laws and regulations in the United States and abroad; or laws that require the reporting of financial information or data accurately. In particular, sales, marketing and business arrangements in the healthcare industry are subject to extensive laws and regulations intended to prevent fraud, misconduct, kickbacks, self-dealing and other abusive practices. These laws and regulations may restrict or prohibit a wide range of pricing, discounting, marketing and promotion, sales commission, customer incentive programs and other business arrangements. Activities subject to these laws also involve the improper use of information obtained in the course of clinical trials or creating fraudulent data in our preclinical studies or clinical trials, which could result in regulatory sanctions and cause serious harm to our reputation. We have a code of conduct applicable to all of our employees, but it is not always possible to identify and deter misconduct by employees and other third parties, and the precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to comply with these laws or regulations. Additionally, we are subject to the risk that a person could allege such fraud or other misconduct, even if none occurred. If any such actions are instituted against us, and we are not successful in defending ourselves or asserting our rights, those actions could have a significant impact on our business, including the imposition of civil, criminal and administrative penalties, damages, monetary fines, possible exclusion from participation in Medicare, Medicaid and other federal healthcare programs, contractual damages, reputational harm, diminished profits and future earnings, and curtailment of our operations, any of which could adversely affect our ability to operate our business and our results of operations. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">48</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Risks Related to Regulatory Approval of our Product Candidates and Other Legal Compliance Matters </font></p>
<p style="margin-bottom:0pt;margin-top:6pt;margin-left:2.26%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">If we are not able to obtain, or if there are delays in obtaining, required regulatory approvals for our product candidates, we will not be able to commercialize, or will be delayed in commercializing, our product candidates, and our ability to generate revenue will be materially impaired. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our product candidates and the activities associated with their development and commercialization, including their design, testing, manufacture, safety, efficacy, recordkeeping, labeling, storage, approval, advertising, promotion, sale, distribution, import and export are subject to comprehensive regulation by the FDA and other regulatory agencies in the United States and by comparable authorities in other countries. Before we can commercialize any of our product candidates, we must obtain marketing approval. Currently, all of our product candidates are in development, and we have not received approval to market any of our product candidates from regulatory authorities in any jurisdiction. It is possible that our product candidates, including any product candidates we may seek to develop in the future, will never obtain regulatory approval. Whether the results from our current ongoing clinical trials and other trials will suffice to obtain approval will be a review issue and the FDA may not grant approval and may require that we conduct one or more controlled clinical trials to obtain approval. Additionally, even if FDA does grant approval for one or more of our product candidates, it may be for a more narrow indication than we seek. Regulatory authorities, including the FDA, also may impose significant limitations in the form of narrow indications, warnings or a REMS. These regulatory authorities may require labeling that includes precautions or contra-indications with respect to conditions of use, or they may grant approval subject to the performance of costly post-marketing clinical trials. In addition, regulatory authorities may not approve the labeling claims that are necessary or desirable for the successful commercialization of any product candidates we may develop. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have only limited experience in filing and supporting the applications necessary to gain regulatory approvals and expect to rely on third-party CROs and/or regulatory consultants to assist us in this process. Securing regulatory approval requires the submission of extensive preclinical and clinical data and supporting information to the various regulatory authorities for each therapeutic indication to establish the product candidate&#8217;s safety and efficacy. Securing regulatory approval also requires the submission of information about the product manufacturing process to, and inspection of manufacturing facilities by, the relevant regulatory authority. Our product candidates may not be effective, may be only moderately effective or may prove to have undesirable or unintended side effects, toxicities or other characteristics that may preclude our obtaining marketing approval or prevent or limit commercial use. In addition, regulatory authorities may find fault with our manufacturing process or facilities or that of third-party contract manufacturers. We may also face greater than expected difficulty in manufacturing our product candidates. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The process of obtaining regulatory approvals, both in the United States and abroad, is expensive and often takes many years. If the FDA or a comparable foreign regulatory authority requires that we perform additional preclinical studies or clinical trials, approval, if obtained at all, may be delayed. The length of such a delay varies substantially based upon a variety of factors, including the type, complexity and novelty of the product candidates involved. Changes in marketing approval policies during the development period, changes in or the enactment of additional statutes or regulations, or changes in regulatory review for each submitted BLA, premarket approval application, or equivalent application types, may cause delays in the approval or rejection of an application. The FDA and comparable authorities in other countries have substantial discretion in the approval process and may refuse to accept any application or may decide that our data are insufficient for approval and require additional preclinical, clinical or other studies. Our product candidates could be delayed in receiving, or fail to receive, regulatory approval for many reasons, including the following: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:1.13%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">the FDA or comparable foreign regulatory authorities may disagree with the design or implementation of our preclinical studies or clinical trials; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:1.13%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">we may not be able to enroll a sufficient number of patients in our clinical studies; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:1.13%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">we may be unable to demonstrate to the satisfaction of the FDA or comparable foreign regulatory authorities that a product candidate is safe and effective for its proposed indication or a related companion diagnostic is suitable to identify appropriate patient populations; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:1.13%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">the results of clinical trials may not meet the level of statistical significance required by the FDA or comparable foreign regulatory authorities for approval; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:1.13%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">we may be unable to demonstrate that a product candidate&#8217;s clinical and other benefits outweigh its safety risks; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:1.13%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">the FDA or comparable foreign regulatory authorities may disagree with our interpretation of data from preclinical studies or clinical trials; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:1.13%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">the data collected from clinical trials of our product candidates may not be sufficient to support the submission of an NDA or other submission or to obtain regulatory approval in the United States or elsewhere; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:1.13%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">the FDA or comparable foreign regulatory authorities may find deficiencies with or fail to approve the manufacturing processes or facilities of third-party manufacturers with which we contract for clinical and commercial supplies; and </p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">49</a></p>
<hr style="page-break-after:always;width:100%;">
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:1.13%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the approval policies or regulations of the FDA or comparable foreign regulatory authorities may significantly change such that our clinical data are insufficient for approval. </font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Even if we were to obtain approval, regulatory authorities may approve any of our product candidates for fewer or more limited indications than we request, thereby narrowing the commercial potential of the product candidate. In addition, regulatory authorities may grant approval contingent on the performance of costly post-marketing clinical trials, or may approve a product candidate with a label that does not include the labeling claims necessary or desirable for the successful commercialization of that product candidate. Any of the foregoing scenarios could materially harm the commercial prospects for our product candidates. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If we experience delays in obtaining approval or if we fail to obtain approval of our product candidates, the commercial prospects for our product candidates may be harmed and our ability to generate revenues will be materially impaired. </p>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:2.26%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Obtaining and maintaining regulatory approval of our product candidates in one jurisdiction does not mean that we will be successful in obtaining regulatory approval of our product candidates in other jurisdictions. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We may also submit marketing applications in other countries. Regulatory authorities in jurisdictions outside of the United States have requirements for approval of product candidates with which we must comply prior to marketing in those jurisdictions. Obtaining foreign regulatory approvals and compliance with foreign regulatory requirements could result in significant delays, difficulties and costs for us and could delay or prevent the introduction of our products in certain countries. If we fail to comply with the regulatory requirements in international markets and/or receive applicable marketing approvals, our target market will be reduced and our ability to realize the full market potential of our product candidates will be harmed. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Obtaining and maintaining regulatory approval of our product candidates in one jurisdiction does not guarantee that we will be able to obtain or maintain regulatory approval in any other jurisdiction, while a failure or delay in obtaining regulatory approval in one jurisdiction may have a negative effect on the regulatory approval process in others. For example, even if the FDA grants marketing approval of a product candidate, comparable regulatory authorities in foreign jurisdictions must also approve the manufacturing, marketing and promotion of the product candidate in those countries. Approval procedures vary among jurisdictions and can involve requirements and administrative review periods different from, and greater than, those in the United States, including additional nonclinical studies or clinical trials as clinical trials conducted in one jurisdiction may not be accepted by regulatory authorities in other jurisdictions. In short, the foreign regulatory approval process involves all of the risks associated with FDA approval. In many jurisdictions outside the United States, a product candidate must be approved for reimbursement before it can be approved for sale in that jurisdiction. In some cases, the price that we may intend to charge for our products will also be subject to approval. </p>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:2.26%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Even if we receive regulatory approval for any of our product candidates, we will be subject to ongoing regulatory obligations and continued regulatory review, which may result in significant additional expense. Additionally, our product candidates, if approved, could be subject to post-market study requirements, marketing and labeling restrictions, and even recall or market withdrawal if unanticipated safety issues are discovered following approval. In addition, we may be subject to penalties or other enforcement action if we fail to comply with regulatory requirements. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If the FDA or a comparable foreign regulatory authority approves any of our product candidates, the manufacturing processes, labeling, packaging, distribution, storage, advertising, promotion, import, export, recordkeeping, monitoring, and reporting for our product will be subject to extensive and ongoing regulatory requirements. These requirements include submissions of safety and other post-marketing information and reports, establishment registration and listing, as well as continued compliance with cGMPs and GCPs for any clinical trials that we conduct post-approval. Any regulatory approvals that we receive for our product candidates may also be subject to limitations on the approved indicated uses for which the product may be marketed or to the conditions of approval, or contain requirements for potentially costly post-marketing studies, including Phase 4 clinical trials, and surveillance to monitor the safety and efficacy of the product. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The FDA may require a REMS in order to approve our product candidates, which could entail requirements for a medication guide, physician communication plans or additional elements to ensure safe use, such as restricted distribution methods, patient registries and other risk minimization tools. Later discovery of previously unknown problems with a product, including adverse events of unanticipated severity or frequency, or with our third-party manufacturers or manufacturing processes, or failure to comply with regulatory requirements, may result in, among other things: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:1.13%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">restrictions on the marketing or manufacturing of the product, withdrawal of the product from the market, or voluntary or mandatory product recalls; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:1.13%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">revision to the labeling, including limitations on approved uses or the addition of additional warnings, contraindications or other safety information, including boxed warnings; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:1.13%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">imposition of a REMS, which may include distribution or use restrictions; </p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">50</a></p>
<hr style="page-break-after:always;width:100%;">
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:1.13%;white-space:nowrap"></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:1.13%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">requirements to conduct additional post-market clinical trials to assess the safety of the product; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:1.13%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">fines, warning letters or other regulatory enforcement action; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:1.13%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">refusal by the FDA to approve pending applications or supplements to approved applications filed by us; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:1.13%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">product seizure or detention, or refusal to permit the import or export of products; and </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:1.13%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">injunctions or the imposition of civil or criminal penalties. </p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The FDA&#8217;s and other regulatory authorities&#8217; policies may change and additional government regulations may be enacted that could prevent, limit or delay regulatory approval of our product candidates. If we are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we are not able to maintain regulatory compliance, we may lose any marketing approval that we may have obtained, which would adversely affect our business, prospects and ability to achieve or sustain profitability. </p>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:2.26%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">If we are unable to successfully validate, develop and obtain regulatory approval for any required companion diagnostic tests for our product candidates or experience significant delays in doing so, we may fail to obtain approval or may not realize the full commercial potential of these product candidates. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In connection with the clinical development of our product candidates for certain indications, we may develop or engage third parties to develop or obtain access to <font style="font-style:italic;">in vitro</font> companion diagnostic tests to identify patient subsets within a disease category who may derive benefit from our product candidates, as we are targeting certain genetically defined populations for our treatments. Such companion diagnostics may be used during our clinical trials and may be required in connection with the FDA approval of our product candidates. To be successful, we or our collaborators will need to address a number of scientific, technical, regulatory and logistical challenges. Companion diagnostics are subject to regulation by the FDA, EMA and other regulatory authorities as medical devices and require separate regulatory approval prior to commercialization. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We may rely on third parties for the design, development and manufacture of companion diagnostic tests for our therapeutic product candidates that may require such tests. If we enter into such collaborative agreements, we will be dependent on the sustained cooperation and effort of our future collaborators in developing and obtaining approval for these companion diagnostics. We and our future collaborators may encounter difficulties in developing and obtaining approval for the companion diagnostics, including issues relating to selectivity/specificity, analytical validation, reproducibility, or clinical validation of companion diagnostics. We and our future collaborators also may encounter difficulties in developing, obtaining regulatory approval for, manufacturing and commercializing companion diagnostics similar to those we face with respect to our therapeutic product candidates themselves, including issues with achieving regulatory clearance or approval, production of sufficient quantities at commercial scale and with appropriate quality standards, and in gaining market acceptance. If we are unable to successfully develop companion diagnostics for these therapeutic product candidates, or experience delays in doing so, the development of these therapeutic product candidates may be adversely affected, these therapeutic product candidates may not obtain marketing approval or such approval may be delayed, and we may not realize the full commercial potential of any of these therapeutics that obtain marketing approval. As a result, our business, results of operations and financial condition could be materially harmed. In addition, a diagnostic company with whom we contract may decide to discontinue developing, selling or manufacturing the companion diagnostic test that we anticipate using in connection with development and commercialization of our product candidates or our relationship with such diagnostic company may otherwise terminate. We may not be able to enter into arrangements with another diagnostic company to obtain supplies of an alternative diagnostic test for use in connection with the development and commercialization of our product candidates or do so on commercially reasonable terms, which could adversely affect and/or delay the development or commercialization of our therapeutic product candidates. </p>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:2.26%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Our relationships with customers, healthcare professionals, and third-party payors will be subject to applicable anti-kickback, fraud and abuse and other healthcare laws and regulations, which could expose us to significant penalties, including criminal sanctions, administrative civil penalties, exclusion from government healthcare programs, contractual damages, reputational harm and diminished profits and future earnings. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our current and future business operations and activities may subject us to additional healthcare statutory and regulatory requirements and enforcement by the federal government and the states and foreign governments in which we conduct our business. Healthcare providers and third-party payors play a primary role in the recommendation and prescription of any product candidates for which we obtain marketing approval. Our current and future arrangements with healthcare professionals, third-party payors and customers may expose us to broadly applicable fraud and abuse and other healthcare laws and regulations that may constrain the business or financial arrangements and relationships through which we research as well as market, sell and distribute our product candidates for which we obtain marketing approval. These laws and regulations may restrict or prohibit a wide range of ownership, pricing, discounting, marketing and promotion, structuring and commission(s), certain customer incentive programs and other </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">51</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">business arrangements generally. Restrictions under applicable federal and state healthcare laws and regulations, include the following: </font></p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:1.13%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">the federal Anti-Kickback Statute prohibits, among other things, persons and entities from knowingly and willfully soliciting, offering, receiving or providing remuneration, directly or indirectly, in cash or in kind, to induce or reward either the referral of an individual for, or the purchase, order or recommendation of, any good or service, for which payment may be made under federal and state healthcare programs such as Medicare and Medicaid. The Anti-Kickback Statute has been interpreted to apply to arrangements between pharmaceutical manufacturers, on the one hand, and prescribers, purchasers and formulary managers, on the other. A person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:1.13%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">the federal civil and criminal false claims, including the federal False Claims Act, or FCA, which can be enforced through civil whistleblower or qui tam actions, and civil monetary penalties laws, which impose criminal and civil penalties against individuals or entities for knowingly presenting, or causing to be presented, to the federal government, claims for payment that are false or fraudulent or making a false statement to avoid, decrease or conceal an obligation to pay money to the federal government. In addition, the government may assert that a claim including items and services resulting from a violation of the federal Anti-Kickback Statute constitutes a false of fraudulent claim for purposes of the FCA; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:1.13%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">the federal Health Insurance Portability and Accountability Act of 1996, or HIPAA, imposes criminal and civil liability for executing a scheme to defraud any healthcare benefit program, or knowingly and willfully falsifying, concealing or covering up a material fact or making any materially false statement in connection with the delivery of or payment for healthcare benefits, items or services; similar to the federal Anti-Kickback Statute, a person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:1.13%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">the federal physician payment transparency requirements, sometimes referred to as the &#8220;Sunshine Act&#8221; under the Affordable Care Act, require certain manufacturers of drugs, devices, biologics and medical supplies that are reimbursable under Medicare, Medicaid, or the Children&#8217;s Health Insurance Program to report to the Centers for Medicare&#160;&amp; Medicaid Services, or CMS, information related to transfers of value made to physicians (currently defined to include doctors, dentists, optometrists, podiatrists and chiropractors) and teaching hospitals, as well as ownership and investment interests of such physicians and their immediate family members. Effective January&#160;1, 2022, applicable manufacturers will be required to report information regarding payments and other transfers of value made to certain non-physician providers such as physician assistants, nurse practitioners, clinical nurse specialists, anesthesiologist assistants, certified registered nurse anesthetists and certified nurse midwives during the previous year; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:1.13%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act of 2009 and its implementing regulations, impose obligations on certain covered entity healthcare providers, health plans, and healthcare clearinghouses and their business associates that perform certain services involving the use or disclosure of individually identifiable health information as well as their covered subcontractors, including mandatory contractual terms, with respect to safeguarding the privacy, security and transmission of individually identifiable health information; and </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:1.13%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">analogous state laws and regulations, such as state anti-kickback and false claims laws may apply to sales or marketing arrangements and claims involving healthcare items or services reimbursed by non-governmental third-party payors, including private insurers. Some state laws require pharmaceutical companies to comply with the pharmaceutical industry&#8217;s voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal government in addition to requiring drug manufacturers to report information related to payments to physicians and other health care providers or marketing expenditures. Some state and local laws require the registration of pharmaceutical sales representatives. Further, many state laws governing the privacy and security of health information in certain circumstances, differ from each other in significant ways and often are not preempted by HIPAA, thus complicating compliance efforts. </p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Because of the breadth of these laws and the narrowness of the statutory exceptions and regulatory safe harbors available, it is possible that some of our business activities, including compensation of physicians with stock or stock options, could, despite efforts to comply, be subject to challenge under current or future statutes, regulations or case law interpreting applicable fraud and abuse or other healthcare laws and regulations. Ensuring that our business arrangements with third parties comply with applicable healthcare laws and regulations could involve substantial costs. It is possible that governmental authorities will conclude that our business practices do not comply with current or future statutes, regulations or case law involving applicable fraud and abuse or other healthcare laws and regulations. If our operations, including anticipated activities to be conducted by our sales team, were to be found to be in violation of any of these laws or any other governmental regulations that may apply to us, we may be subject to significant civil, criminal and administrative penalties, damages, fines, disgorgement, imprisonment, exclusion from government funded healthcare programs, such as Medicare and Medicaid, contractual damages, integrity oversight and reporting obligations, reputational harm, diminished profits and future earnings, and the curtailment or restructuring of our operations, any of which could adversely affect our ability to operate our business and our results of operations. If any of the physicians or other providers or entities with whom we expect to do business is found not to be in compliance with applicable laws, they may be subject to significant criminal, civil or administrative sanctions, including exclusions from government funded healthcare programs. In addition, the approval and </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">52</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:12pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">commercialization of any of our product candidates outside the United States will also likely subject us to foreign equivalents of the healthcare laws mentioned above, among other foreign laws. </font></p>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:2.26%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Healthcare legislative reform measures may have a material adverse effect on our business and results of operations. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The U.S. and many foreign jurisdictions have enacted or proposed legislative and regulatory changes affecting the healthcare system that could prevent or delay marketing approval of our current or future product candidates or any future product candidates, restrict or regulate post-approval activities and affect our ability to profitably sell a product for which we obtain marketing approval. Changes in regulations, statutes or the interpretation of existing regulations could impact our business in the future by requiring, for example: (i)&#160;changes to our manufacturing arrangements, (ii)&#160;additions or modifications to product labeling, (iii)&#160;the recall or discontinuation of our products or (iv)&#160;additional record-keeping requirements. If any such changes were to be imposed, they could adversely affect the operation of our business. In the U.S., there have been and continue to be a number of legislative initiatives to contain healthcare costs. For example, in March 2010, the Patient Protection and Affordable Care Act, as amended by the Health Care Education and Reconciliation Act, or collectively the ACA, was passed, which substantially changed the way healthcare is financed by both governmental and private insurers, and significantly impacted the U.S. pharmaceutical industry. The ACA, among other things, subjected biological products to potential competition by lower-cost biosimilars, addressed a new methodology by which rebates owed by manufacturers under the Medicaid Drug Rebate Program are calculated for drugs that are inhaled, infused, instilled, implanted or injected, increases the minimum Medicaid rebates owed by manufacturers under the Medicaid Drug Rebate Program and extended the rebate program to individuals enrolled in Medicaid managed care organizations, established annual fees and taxes on manufacturers of certain branded prescription drugs, and created a new Medicare Part D coverage gap discount program, in which manufacturers must agree to offer 70% (increased pursuant to the Bipartisan Budget Act of 2018, effective as of 2019) point-of-sale discounts off negotiated prices of applicable brand drugs to eligible beneficiaries during their coverage gap period, as a condition for the manufacturer&#8217;s outpatient drugs to be covered under Medicare Part&#160;D. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">There have been executive, judicial and Congressional challenges to certain aspects of the ACA. For example, President Trump signed several Executive Orders and other directives designed to eliminate the implementation of certain provisions of the ACA or otherwise circumvent some of the requirements for health insurance mandated by the ACA. Concurrently, Congress considered legislation to repeal or repeal and replace all or part of the ACA. While Congress has not passed comprehensive repeal legislation to date, the Tax Act, repealed, effective January&#160;1, 2019, the tax-based shared responsibility payment imposed by the ACA on certain individuals who fail to maintain qualifying health coverage for all or part of a year that is commonly referred to as the &#8220;individual mandate.&#8221; On December&#160;14, 2018, a federal district court in Texas ruled the individual mandate is a critical and inseverable feature of the ACA, and therefore, because it was repealed as part of the Tax Act, the remaining provisions of the ACA are invalid as well. On December&#160;18, 2019, the Fifth Circuit U.S. Court of Appeals held that the individual mandate is unconstitutional, and remanded the case to the lower court to determine whether the remaining provisions of the ACA are invalid as well. The U.S. Supreme Court is currently reviewing this case, although it is unclear how the Supreme Court will rule. Although the U.S. Supreme Court has not yet ruled on the constitutionality of the ACA, on January 28, 2021, President Biden issued an executive order to initiate a special enrollment period from February 15, 2021 through May 15, 2021 for purposes of obtaining health insurance coverage through the ACA marketplace. The executive order also instructs certain governmental agencies to review and reconsider their existing policies and rules that limit access to healthcare, including among others, reexamining Medicaid demonstration projects and waiver programs that include work requirements, and policies that create unnecessary barriers to obtaining access to health insurance coverage through Medicaid or the ACA. It is unclear how the Supreme Court ruling, other such litigation and the healthcare reform measures of the Biden administration will impact the ACA and our business. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, other legislative changes have been proposed and adopted since the ACA was enacted. In August 2011, the Budget Control Act of 2011, among other things, created measures for spending reductions by Congress. A Joint Select Committee on Deficit Reduction, tasked with recommending a targeted deficit reduction of at least $1.2 trillion for the years 2013 through 2021, was unable to reach required goals, thereby triggering the legislation&#8217;s automatic reduction to several government programs. This includes aggregate reductions of Medicare payments to providers up to 2% per fiscal year, and, due to subsequent legislative amendments, will remain in effect through 2030 unless additional Congressional action is taken. However, the Medicare sequester reductions under the Budget Control Act of 2011 have been suspended from May&#160;1, 2020 through March 31, 2021 due to the COVID-19 pandemic. The American Taxpayer Relief Act of 2012 among other things, reduced Medicare payments to several providers, including hospitals, imaging centers and cancer treatment centers, and increased the statute of limitations period for the government to recover overpayments to providers from three to five years. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">There has been increasing legislative and enforcement interest in the U.S. with respect to specialty drug pricing practices. Specifically, there have been several recent U.S. Congressional inquiries and proposed federal and state legislation designed to, among other things, bring more transparency to drug pricing, reduce the cost of prescription drugs under Medicare, review the relationship between pricing and manufacturer patient programs, and reform government program reimbursement methodologies for drugs. At the federal level, the Trump administration used several means to propose or implement drug pricing reform including through federal budget proposals, executive orders and policy initiatives.&nbsp;&nbsp;For example, on July 24, 2020 and September 13, 2020, the Trump </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">53</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:12pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">administration announced several executive orders related to prescription drug pricing that </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">sought</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> to implement several of the administration&#8217;s prop</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">osals. As a result, the FDA also released a final rule on September 24, 2020 providing guidance for states to build and submit importation plans for drugs from Canada. Further, on November 20, 2020, HHS finalized a regulation removing safe harbor protection for price reductions from pharmaceutical manufacturers to plan sponsors under Part D, either directly or through pharmacy benefit managers, unless the price reduction is required by law. </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The implementation of the rule has been delayed by the Biden administration from January 1, 2022 to January 1, 2023 in response to ongoing litigation</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">. </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The rule also creates a new safe harbor for price reductions reflected at the point-of-sale, as well as a safe harbor for certain fixed fee arrangements between pharmacy benefit managers and manufacturers, </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the implementation of which have also been delayed pending review by the Biden administration until March 22, 2021</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">. Further, in November 2020, CMS issued an interim final rule implementing the Most Favored Nation, or MFN, </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Model under which Medicare Part B reimbursement rates will be calcul</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ated for certain drugs and biologicals based on the lowest price drug manufacturers receive in Organization for Economic Cooperation and Development countries with a similar gross domestic product per capita. The MFN Model regulations mandate participation by identified Part B providers and will apply in all U.S. states and territories for a seven-year period beginning January 1, 2021, and ending December 31, 2027. On December 28, 2020, the United States District Court in Northern California issued a nationwide preliminary injunction against implementation of the interim final rule.</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">At the state level, individual states are increasingly aggressive in passing legislation and implementing regulations designed to control pharmaceutical and biological product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing. In addition, regional health care authorities and individual hospitals are increasingly using bidding procedures to determine what pharmaceutical products and which suppliers will be included in their prescription drug and other health care programs. These measures could reduce the ultimate demand for our products, once approved, or put pressure on our product pricing. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We expect that additional state and federal healthcare reform measures will be adopted in the future, particularly in light of the new U.S. presidential administration, any of which could limit the amounts that federal and state governments will pay for healthcare products and services, which could result in reduced demand for our current or future product candidates or additional pricing pressures. In particular any policy changes through CMS as well as local state Medicaid programs could have a significant impact on our business in light of the higher proportion of SCD patients that utilize Medicare and Medicaid programs to pay for treatments. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our revenue prospects could be affected by changes in healthcare spending and policy in the U.S. and abroad. We operate in a highly regulated industry and new laws, regulations or judicial decisions, or new interpretations of existing laws, regulations or decisions, related to healthcare availability, the method of delivery or payment for healthcare products and services could negatively impact our business, operations and financial condition. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">There have been, and likely will continue to be, legislative and regulatory proposals at the foreign, federal and state levels directed at broadening the availability of healthcare and containing or lowering the cost of healthcare. We cannot predict the initiatives that may be adopted in the future, including repeal, replacement or significant revisions to the ACA. The continuing efforts of the government, insurance companies, managed care organizations and other payors of healthcare services to contain or reduce costs of healthcare and/or impose price controls may adversely affect: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:1.13%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">the demand for our current or future product candidates, if we obtain regulatory approval; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:1.13%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">our ability to set a price that we believe is fair for our products; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:1.13%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">our ability to obtain coverage and reimbursement approval for a product; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:1.13%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">our ability to generate revenue and achieve or maintain profitability; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:1.13%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">the level of taxes that we are required to pay; and </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:1.13%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">the availability of capital. </p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Any reduction in reimbursement from Medicare or other government programs may result in a similar reduction in payments from private payors, which may adversely affect our future profitability. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Further, it is possible that additional governmental action is taken in response to the COVID-19 pandemic. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">54</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:2.26%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">We are subject to the U.K. Bribery Act 2010, or the Bribery Act, the U.S. Foreign Corrupt Practices Act of 1977, as amended, or the FCPA, and other anti-corruption laws, as well as export control laws, import and customs laws, trade and economic sanctions laws and other laws governing our operations.</font></p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our operations are subject to anti-corruption laws, including the Bribery Act, the FCPA, the U.S. domestic bribery statute contained in 18 U.S.C. &#167;201, the U.S. Travel Act, and other anti-corruption laws that apply in countries where we do business. The Bribery Act, the FCPA and these other laws generally prohibit us and our employees and intermediaries from authorizing, promising, offering, or providing, directly or indirectly, improper or prohibited payments, or anything else of value, to government officials or other persons to obtain or retain business or gain some other business advantage. Under the Bribery Act, we may also be liable for failing to prevent a person associated with us from committing a bribery offense. We and our commercial partners operate in a number of jurisdictions that pose a high risk of potential Bribery Act, or FCPA, violations, and we participate in collaborations and relationships with third parties whose corrupt or illegal activities could potentially subject us to liability under the Bribery Act, FCPA or local anti-corruption laws, even if we do not explicitly authorize or have actual knowledge of such activities. In addition, we cannot predict the nature, scope or effect of future regulatory requirements to which our international operations might be subject or the manner in which existing laws might be administered or interpreted.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are also subject to other laws and regulations governing our international operations, including regulations administered by the governments of the United Kingdom and the United States, and authorities in the European Union, including applicable export control regulations, economic sanctions and embargoes on certain countries and persons, anti-money laundering laws, import and customs requirements and currency exchange regulations, collectively referred to as the Trade Control laws.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">There is no assurance that we will be completely effective in ensuring our compliance with all applicable anti-corruption laws, including the Bribery Act, the FCPA or other legal requirements, including Trade Control laws. If we are not in compliance with the Bribery Act, the FCPA and other anti-corruption laws or Trade Control laws, we may be subject to criminal and civil penalties, disgorgement and other sanctions and remedial measures, and legal expenses, which could have&#160;an adverse impact on our business, financial condition, results of operations and liquidity. Likewise, any investigation of any potential violations of the Bribery Act, the FCPA, other anti-corruption laws or Trade Control laws by United Kingdom, United States or other authorities could also have an adverse impact on our reputation, our business, results of operations and financial condition.</p>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:2.26%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">If we fail to comply with environmental, health and safety laws and regulations, we could become subject to fines or penalties or incur costs that could have a material adverse effect on the success of our business.</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are subject to numerous environmental, health and safety laws and regulations, including those governing laboratory procedures and the handling, use, storage, treatment and disposal of hazardous materials and wastes. Our operations involve the use of hazardous and flammable materials, including chemicals and biological materials. Our operations also produce hazardous waste products. We generally contract with third parties for the disposal of these materials and wastes. We cannot eliminate the risk of contamination or injury from these materials. In the event of contamination or injury resulting from our use of hazardous materials, we could be held liable for any resulting damages, and any liability could exceed our resources. We also could incur significant costs associated with civil or criminal fines and penalties. Furthermore, environmental laws and regulations are complex, change frequently and have tended to become more stringent. We cannot predict the impact of such changes and cannot be certain of our future compliance. In addition, we may incur substantial costs in order to comply with current or future environmental, health and safety laws and regulations. These current or future laws and regulations may impair our research, development or production efforts. Failure to comply with these laws and regulations also may result in substantial fines, penalties or other sanctions.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Although we maintain workers&#8217; compensation insurance to cover us for costs and expenses we may incur due to injuries to our employees resulting from the use of hazardous materials or other work-related injuries, this insurance may not provide adequate coverage against potential liabilities. In addition, we may incur substantial costs in order to comply with current or future environmental, health and safety laws and regulations. These current or future laws and regulations may impair our research, development or production efforts. Failure to comply with these laws and regulations also may result in substantial fines, penalties or other sanctions or liabilities, which could materially adversely affect our business, financial condition, results of operations and prospects.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Risks Related to the Commercialization of our Product Candidates </p>
<p style="margin-bottom:0pt;margin-top:6pt;margin-left:2.26%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">If we are unable to establish sales, marketing and distribution capabilities for our product candidates, or enter into sales, marketing and distribution agreements with third parties, we may not be successful in commercializing our product candidates, if approved. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We currently plan to work to build our global commercialization capabilities internally over time such that we are able to commercialize any product candidate for which we may obtain regulatory approval. However, we currently have no sales, marketing or distribution capabilities and have no experience in marketing or distributing pharmaceutical products. To achieve commercial </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">55</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">success for any product candidate for which we may obtain marketing approval, we will need to expand our sales and marketing organization and establish logistics and distribution processes to commercialize and deliver our product candidates to patients and healthcare providers. The development of sales, marketing and distribution capabilities will require substantial resources, will be time-consuming and could delay any product launch. </font></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If we are unable or decide not to establish internal sales, marketing and distribution capabilities, we would have to pursue collaborative arrangements regarding the sales and marketing of our products. However, we may not be successful in entering into arrangements with third parties to sell, market and distribute our product candidates or may be unable to do so on terms that are favorable to us, or if we are able to do so, that they would be effective and successful in commercializing our products. Our product revenues and our profitability, if any, would likely to be lower than if we were to sell, market and distribute any product candidates that we develop ourselves. In addition, we would have limited control over such third parties, and any of them may fail to devote the necessary resources and attention to sell and market our product candidates effectively. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If we do not establish sales, marketing and distribution capabilities successfully, either on our own or in collaboration with third parties, we will not be successful in commercializing our product candidates in the United States or overseas. </p>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:2.26%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">We operate in a rapidly changing industry and face significant competition, which may result in others discovering, developing or commercializing products before or more successfully than we do. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The development and commercialization of new biopharmaceutical products is highly competitive and subject to rapid and significant technological advancements. We face competition from major multi-national pharmaceutical companies, biotechnology companies and specialty pharmaceutical companies with respect to our current and future product candidates that we may develop and commercialize in the future. There are a number of large pharmaceutical and biotechnology companies that currently market and sell products or are pursuing the development of product candidates for the treatment of cancer. Smaller or early-stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large, established companies. Potential competitors also include academic institutions, government agencies and other public and private research organizations. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition to the current standard of care treatments for patients with infectious diseases or cancers, numerous commercial and academic preclinical studies and clinical trials are being undertaken by a large number of parties to assess novel technologies and product candidates in the field of immunotherapy. Results from these studies and trials have fueled increasing levels of interest in the field of immunotherapy. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Large pharmaceutical companies that have commercialized or are developing immunotherapies to treat cancer include AstraZeneca, Bristol Myers Squibb, Gilead Sciences, Merck, Novartis, Pfizer, and Roche/Genentech. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On the technology level, other companies which can potentially develop competing product candidates which act to stimulate the body&#8217;s immune response as a treatment for SCCHN and other solid tumors include companies developing cell-based therapeutics such as CAR-T/TCR/NK therapies as well as companies developing therapeutic vaccines including BioNTech, Moderna, Gritstone Oncology and Oncorus, among others. In addition, a number of companies are developing oncolytic virus approaches, including Boehringer Ingelheim, Johnson and Johnson, Regeneron, Vyriad, Replimune and Turnstone. Amgen has received FDA approval for its oncolytic virus-based product, T-VEC. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Ablynx, a subsidiary of Sanofi, and Oncorus are actively pursuing the development of nanobodies as therapeutics. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our competitors with development-stage programs may obtain marketing approval from the FDA or other comparable regulatory authorities for their product candidates more rapidly than we do, and they could establish a strong market position before we are able to enter the market. In addition, our competitors may succeed in developing, acquiring or licensing technologies and products that are more effective, more effectively marketed and sold or less costly than any product candidates that we may develop, which could render our product candidates non-competitive and obsolete. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Many of our competitors, either alone or with their strategic collaborators, have substantially greater financial, technical and human resources than we do. Accordingly, our competitors may be more successful than we are in obtaining approval for treatments and achieving widespread market acceptance, which may render our treatments obsolete or non-competitive. Mergers and acquisitions in the biotechnology and pharmaceutical industries may result in even more resources being concentrated among a smaller number of our competitors. These competitors also compete with us in recruiting and retaining qualified scientific and management personnel and establishing clinical trial sites and patient registration for clinical studies, as well as in acquiring technologies complementary to, or necessary for, our programs. Smaller or early-stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">56</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our commercial opportunity could be reduced or eliminated if our competitors develop and commercialize products that are safer, more effective, have fewer or less severe side effects, are more convenient or are less expensive or better reimbursed than any products that we may commercialize. Our competitors also may obtain FDA or other regulatory approval for their products more rapidly than we may obtain approval for ours, which could result in our competitors establishing a strong market position for either the product or a specific indication before we are able to enter the market. </font></p>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:2.26%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Even if any of our product candidates receives marketing approval, it may fail to achieve the degree of market acceptance by physicians, patients, third-party payors and others in the medical community necessary for commercial success. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Even if we obtain approvals from the FDA or other comparable regulatory agencies and are able to initiate commercialization of our clinical-stage product candidates or any other product candidates we develop, the product candidate may not achieve market acceptance among physicians, patients, hospitals, including pharmacy directors, and third-party payors and, ultimately, may not be commercially successful. The degree of market acceptance of our product candidates, if approved for commercial sale, will depend on a number of factors, including: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:1.13%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">the clinical indications for which our product candidates are approved; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:1.13%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">physicians, hospitals, cancer treatment centers, and patients considering our product candidates as a safe and effective treatment; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:1.13%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">the potential and perceived advantages of our product candidates over alternative treatments; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:1.13%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">the prevalence and severity of any side effects; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:1.13%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">product labeling or product insert requirements of the FDA or other regulatory authorities; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:1.13%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">limitations or warnings contained in the labeling approved by the FDA; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:1.13%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">the timing of market introduction of our product candidates as well as competitive products; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:1.13%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">the cost of treatment in relation to alternative treatments; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:1.13%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">the amount of upfront costs or training required for physicians to administer our product candidates; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:1.13%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">the availability of coverage, adequate reimbursement from, and our ability to negotiate pricing with, third-party payors and government authorities; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:1.13%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">the willingness of patients to pay out-of-pocket in the absence of comprehensive coverage and reimbursement by third-party payors and government authorities; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:1.13%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">relative convenience and ease of administration, including as compared to alternative treatments and competitive therapies; and </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:1.13%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">the effectiveness of our sales and marketing efforts and distribution support. </p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our efforts to educate physicians, patients, third-party payors and others in the medical community on the benefits of our product candidates, if approved, may require significant resources and may never be successful. Such efforts may require more resources than are typically required due to the complexity and uniqueness of our product candidates. Because we expect sales of our product candidates, if approved, to generate substantially all of our product revenue for the foreseeable future, the failure of our product candidates to find market acceptance would harm our business and could require us to seek additional financing. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, although we are not utilizing embryonic stem cells or replication competent vectors, adverse publicity due to the ethical and social controversies surrounding the therapeutic use of such technologies, and reported side effects from any clinical trials using these technologies or the failure of such trials to demonstrate that these therapies are safe and effective, may limit market acceptance our product candidates. If our product candidates are approved but fail to achieve market acceptance among physicians, patients, hospitals, cancer treatment centers or others in the medical community, we will not be able to generate significant revenue. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Even if our product candidates, if approved, achieve market acceptance, we may not be able to maintain that market acceptance over time if new products or technologies are introduced that are more favorably received than our products, are more cost effective or render our products obsolete. </p>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:2.26%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Coverage and adequate reimbursement may not be available for our current or any future product candidates, which could make it difficult for us to sell profitably, if approved. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Market acceptance and sales of any product candidates, if approved, that we commercialize will depend in part on the extent to which reimbursement for these products and related treatments will be available from third-party payors, including government health </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">57</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">administration authorities, managed care organizations and private health insurers. Third-party payors decide which therapies they will pay for and establish reimbursement levels. In the United States, the principal decisions about reimbursement for new medicines are typically made by CMS, an agency within HHS. CMS decides whether and to what extent a new medicine will be covered and reimbursed under Medicare and private payors tend to follow CMS to a substantial degree. However, decisions regarding the extent of coverage and amount of reimbursement to be provided for any product candidates that we develop will be made on a payor-by-payor basis. Further, no uniform policy for coverage and reimbursement exists in the United States, and coverage and reimbursement can differ significantly from payor to payor. As a result, one payor&#8217;s determination to provide coverage for a drug does not assure that other payors will also provide coverage and adequate reimbursement for the drug. Additionally, a third-party payor&#8217;s decision to provide coverage for a therapy does not imply that an adequate reimbursement rate to allow us to establish or maintain pricing sufficient to realize a sufficient return on our investment will be approved. Third-party payors are increasingly challenging the price, examining the medical </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">necessity</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> and reviewing the cost-effectiveness of medical products, therapies and services, in addition to questioning their safety and efficacy. We may incur significant costs to conduct expensive pharmaco-economic studies </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">in order to</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> demonstrate the medical necessity and cost-effectiveness of our product candidates, in addition to the costs required to obtain FDA approvals. Our product candidates may not be considered medically necessary or cost-effective. </font></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Each payor determines whether or not it will provide coverage for a therapy, what amount it will pay the manufacturer for the therapy, and on what tier of its list of covered drugs, or formulary, it will be placed. The position on a payor&#8217;s formulary, generally determines the co-payment that a patient will need to make to obtain the therapy and can strongly influence the adoption of such therapy by patients and physicians. Patients who are prescribed treatments for their conditions and providers prescribing such services generally rely on third-party payors to reimburse all or part of the associated healthcare costs. Patients are unlikely to use our products, and providers are unlikely to prescribe our products, unless coverage is provided and reimbursement is adequate to cover a significant portion of the cost of our products and their administration. Therefore, coverage and adequate reimbursement is critical to new medical product acceptance. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, companion diagnostic tests require coverage and reimbursement separate and apart from the coverage and reimbursement for their companion pharmaceutical or biological products. Similar challenges to obtaining coverage and reimbursement, applicable to pharmaceutical or biological products, will apply to companion diagnostics. Additionally, if any companion diagnostic provider is unable to obtain reimbursement or is inadequately reimbursed, that may limit the availability of such companion diagnostic, which would negatively impact prescriptions for our product candidates, if approved. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A primary trend in the U.S. healthcare industry and elsewhere is cost containment. Third-party payors have attempted to control costs by limiting coverage and the amount of reimbursement for particular medications. We cannot be sure that coverage and reimbursement will be available for any drug that we commercialize and, if reimbursement is available, what the level of reimbursement will be. Even if favorable coverage and reimbursement status is attained for one or more product candidates for which we receive regulatory approval, less favorable coverage policies and reimbursement rates may be implemented in the future. Inadequate coverage and reimbursement may impact the demand for, or the price of, any drug for which we obtain marketing approval. If coverage and adequate reimbursement are not available, or are available only to limited levels, we may not be able to successfully commercialize our current and any future product candidates that we develop. In many countries, the prices of medical products are subject to varying price control mechanisms as part of national health systems. In general, the prices of medicines under such systems are substantially lower than in the United States. Other countries allow companies to fix their own prices for medicines, but monitor and control company profits. Additional foreign price controls or other changes in pricing regulation could restrict the amount that we are able to charge for our product candidates. Accordingly, in markets outside the United States, the reimbursement for products may be reduced compared with the United States and may be insufficient to generate commercially reasonable revenues and profits. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We cannot be sure that coverage and reimbursement in the United States or elsewhere will be available for any product that we may develop, and any reimbursement that may become available may be decreased or eliminated in the future. </p>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:2.26%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Product liability lawsuits against us could cause us to incur substantial liabilities and to limit commercialization of any products that we may develop. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We face an inherent risk of product liability exposure related to the testing of our product candidates in human clinical trials and will face an even greater risk if we commercially sell any products that we may develop. If we cannot successfully defend ourselves against claims that our product candidates or products caused injuries, we will incur substantial liabilities. Regardless of merit or eventual outcome, liability claims may result in: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:1.13%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">reduced resources of our management to pursue our business strategy; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:1.13%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">decreased demand for any product candidates or products that we may develop; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:1.13%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">injury to our reputation and significant negative media attention; </p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">58</a></p>
<hr style="page-break-after:always;width:100%;">
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:1.13%;white-space:nowrap"></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:1.13%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">withdrawal of clinical trial participants; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:1.13%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">initiation of investigations by regulators; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:1.13%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">product recalls, withdrawals or labeling, marketing or promotional restrictions; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:1.13%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">significant costs to defend the resulting litigation; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:1.13%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">substantial monetary awards paid to clinical trial participants or patients; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:1.13%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">loss of revenue; and </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:1.13%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">the inability to commercialize any products that we may develop. </p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We currently do not have product liability in place as the cost of coverage exceeds the covered amount during clinical trials.&#160;Once we are ready for a product launch, we intend to bind a policy with product liability insurance coverage in the aggregate and a per incident limit at an amount adequate to cover estimated liabilities that we may incur. We may need to increase our insurance coverage as we expand our clinical trials or if we commence commercialization of our product candidates. Insurance coverage is increasingly expensive. We may not be able to maintain insurance coverage at a reasonable cost or in an amount adequate to satisfy any liability that may arise. </p>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:2.26%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Inadequate funding for the FDA, the SEC and other government agencies could hinder their ability to hire and retain key leadership and other personnel, prevent new products and services from being developed or commercialized in a timely manner or otherwise prevent those agencies from performing normal business functions on which the operation of our business may rely, which could negatively impact our business. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The ability of the FDA to review and approve new products can be affected by a variety of factors, including government budget and funding levels, ability to hire and retain key personnel and accept the payment of user fees, and statutory, regulatory, and policy changes. Average review times at the agency have fluctuated in recent years as a result. In addition, government funding of the SEC and other government agencies on which our operations may rely, including those that fund research and development activities, is subject to the political process, which is inherently fluid and unpredictable. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Disruptions at the FDA and other agencies may also slow the time necessary for product candidates to be reviewed and/or approved by necessary government agencies, which would adversely affect our business. For example, over the last several years, the U.S. government has shut down several times, and certain regulatory agencies, such as the FDA and the SEC, have had to furlough critical employees and stop critical activities. Separately, in response to the&#160;COVID-19&#160;pandemic, on March&#160;10, 2020, the FDA announced its intention to temporarily postpone most inspections of foreign manufacturing facilities and products. On March&#160;18, 2020, the FDA announced its intention to temporarily postpone routine surveillance inspections of domestic manufacturing facilities and provided guidance regarding the conduct of clinical trials, which has since been further updated. As of June&#160;23, 2020, the FDA noted it was continuing to ensure timely reviews of applications for medical products during the&#160;COVID-19&#160;pandemic in line with its user fee performance goals and conducting mission critical domestic and foreign inspections to ensure compliance of manufacturing facilities with FDA quality standards. On July&#160;16, 2020, FDA noted that it is continuing to expedite oncology product development with its staff teleworking full-time. However, FDA may not be able to continue its current pace and review timelines could be extended. As of July 2020, utilizing a rating system to assist in determining when and where it is safest to conduct such inspections based on data about the virus&#8217; trajectory in a given state and locality and the rules and guidelines that are put in place by state and local governments, the FDA is either continuing to, on a case-by-case basis, conduct only mission critical inspections, or, where possible to do so safely, resuming prioritized domestic inspections, which generally include pre-approval inspections. Foreign pre-approval inspections that are not deemed mission-critical remain postponed, while those deemed mission-critical will be considered for inspection on a case-by-case basis. The FDA will use similar data to inform resumption of prioritized operations abroad as it becomes feasible and advisable to do so. The FDA may not be able to maintain this pace, and delays or setbacks are possible in the future. Should the FDA determine that an inspection is necessary for approval and an inspection cannot be completed during the review cycle due to restrictions on travel, the FDA has stated that it generally intends to issue a complete response letter. Further, if there is inadequate information to make a determination on the acceptability of a facility, the FDA may defer action on the application until an inspection can be completed. Additionally, regulatory authorities outside the United States may adopt similar restrictions or other policy measures in response to the&#160;COVID-19&#160;pandemic. If a prolonged government shutdown occurs, or if global health concerns continue to prevent the FDA or other regulatory authorities from conducting their regular inspections, reviews, or other regulatory activities, it could significantly impact the ability of the FDA to timely review and process our regulatory submissions, which could have a material adverse effect on our business. Further, future government shutdowns could impact our ability to access the public markets and obtain necessary capital in order to properly capitalize and continue our operations. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">59</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Risks Related to Our Intellectual Property </font></p>
<p style="margin-bottom:0pt;margin-top:6pt;margin-left:2.26%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">If we are unable to obtain and maintain patent protection for our phage-based vaccine and ASPH-targeting technologies and product candidates, or if the scope of the patent protection obtained is not sufficiently broad, our competitors could develop and commercialize technology and biologics similar or identical to ours, and our ability to successfully commercialize our technology and product candidates may be impaired. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our success depends, in large part, on our ability to obtain and maintain patent protection in the United States, Canada, China, the European Union and other countries with respect to our product candidates. We seek to protect our proprietary position by filing patent applications related to our technology and product candidates in the major pharmaceutical markets, including the United States, Canada, China, major countries in Europe and Japan. If we do not adequately protect our intellectual property, competitors may be able to use our technologies and erode or negate any competitive advantage that we may have, which could harm our business and ability to achieve profitability. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">To protect our proprietary positions, we file patent applications in the United States and other countries related to our novel technologies and product candidates that are important to our business. The patent application and prosecution process is expensive and time-consuming. We may not be able to file and prosecute all necessary or desirable patent applications at a reasonable cost or in a timely manner. We may also fail to identify patentable aspects of our research and development before it is too late to obtain patent protection. It is possible that defects of form in the preparation or filing of our patents or patent applications may exist, or may arise in the future, such as with respect to proper priority claims, inventorship, claim scope or patent term adjustments. If any current or future licensors or licensees are not fully cooperative or disagree with us as to the prosecution, maintenance or enforcement of any patent rights, such patent rights could be compromised and we might not be able to prevent third parties from making, using and selling competing products. If there are material defects in the form or preparation of our patents or patent applications, such patents or applications may be invalid and unenforceable. Moreover, our competitors may independently develop equivalent knowledge, methods and know-how. Any of these outcomes could impair our ability to prevent competition from third parties. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">It is also possible that we will fail to identify patentable aspects of our research and development output before it is too late to obtain patent protection. The patent applications that we own may fail to result in issued patents with claims that cover our current and future product candidates in the United States or in other foreign countries. Our patent applications cannot be enforced against third parties practicing the technology claimed in such applications unless, and until, a patent issues from such applications, and then only to the extent the issued claims cover the technology. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If the patent applications we hold with respect to our development programs and product candidates fail to issue, if their breadth or strength of protection is threatened, or if they fail to provide meaningful exclusivity for our current and future product candidates, it could threaten our ability to commercialize our product candidates. Any such outcome could have a negative effect on our business. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The patent position of biotechnology and pharmaceutical companies generally is highly uncertain. Changes in either the patent laws or interpretation of the patent laws in the United States and other countries may diminish the value of our patents or narrow the scope of our patent protection. In addition, the protections offered by laws of different countries vary. No consistent policy regarding the breadth of claims allowed in biotechnology and pharmaceutical patents has emerged to date in the United States or in many foreign jurisdictions. In addition, the determination of patent rights with respect to pharmaceutical compounds and technologies commonly involves complex legal and factual questions, which has in recent years been the subject of much litigation. As a result, the issuance, scope, validity, enforceability and commercial value of our patent rights are highly uncertain. Furthermore, recent changes in patent laws in the United States, may affect the scope, strength and enforceability of our patent rights or the nature of proceedings that may be brought by or against us related to our patent rights. Additionally, the U.S. Supreme Court has ruled on several patent cases in recent years either narrowing the scope of patent protection available in certain circumstances or weakening the rights of patent owners in certain situations. In addition to increasing uncertainty with regard to our ability to obtain patents in the future, this combination of events has created uncertainty with respect to the value of patents, once obtained. Depending on decisions by the U.S. Congress, the U.S. federal courts, and the U.S. Patent and Trademark Office, or USPTO, the laws and regulations governing patents could change in unpredictable ways that could weaken our ability to obtain patents or to enforce any patents that we might obtain in the future. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We may not be aware of all third-party intellectual property rights potentially relating to our current and future our product candidates. Publications of discoveries in the scientific literature often lag behind the actual discoveries, and patent applications in the United States and other jurisdictions are typically not published until 18 months after filing, or in some cases not at all. Therefore, we cannot be certain that we were the first to make the inventions claimed in our patents or pending patent applications, or that we were the first to file for patent protection of such inventions. Similarly, should we own any patents or patent applications in the future, we may not be certain that we were the first to file for patent protection for the inventions claimed in such patents or patent applications. As a result, the issuance, scope, validity and commercial value of our patent rights cannot be predicted with any certainty. Moreover, we may be subject to a third-party pre-issuance submission of prior art to the USPTO or become involved in opposition, derivation, reexamination, <font style="font-style:italic;">inter partes</font> review or interference proceedings, in the United States or elsewhere, challenging our patent rights or the </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">60</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:12pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">patent rights of others. An adverse determination in any such submission, proceeding or litigation could reduce the scope of, or invalidate, our patent rights, allow third parties to commercialize our technology or product candidates and compete directly with us, without payment to us, or result in our inability to manufacture or commercialize products without infringing third-party patent rights, which could significantly harm our business and results of operations. </font></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our pending and future patent applications may not result in patents being issued that protect our technology or product candidates, in whole or in part, or which effectively prevent others from commercializing competitive technologies and products. Even if our patent applications issue as patents, they may not issue in a form that will provide us with any meaningful protection against competing products or processes sufficient to achieve our business objectives, prevent competitors from competing with us or otherwise provide us with any competitive advantage. Our competitors may be able to circumvent our owned or licensed patents, should they issue, by developing similar or alternative technologies or products in a non-infringing manner. Our competitors may seek approval to market their own products similar to or otherwise competitive with our products. In these circumstances, we may need to defend and/or assert our patents, including by filing lawsuits alleging patent infringement. In any of these types of proceedings, a court or other agency with jurisdiction may find our patents invalid and/or unenforceable. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The issuance of a patent is not conclusive as to its inventorship, scope, validity or enforceability, and our owned and licensed patents may be challenged in the courts or patent offices in the United States and abroad. Such challenges may result in loss of exclusivity or freedom to operate or in patent claims being narrowed, invalidated or held unenforceable, in whole or in part, which could limit our ability to stop others from using or commercializing similar or identical technology and products, or limit the duration of the patent protection of our technology and products. In addition, given the amount of time required for the development, testing and regulatory review of new product candidates, patents protecting such candidates might expire before or shortly after such candidates are commercialized. </p>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:2.26%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Third parties may initiate legal proceedings alleging that we are infringing their intellectual property rights, the outcome of which would be uncertain and could significantly harm our business. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our commercial success depends, in part, on our ability to develop, manufacture, market and sell our product candidates and use our proprietary phage-based vaccine technology without infringing the intellectual property and other proprietary rights of third parties. Numerous third-party U.S. and non-U.S. issued patents exist in the area of biotechnology, including in the area of vaccine therapies and including patents held by our competitors. If any third-party patents cover our product candidates or technologies, we may not be free to manufacture or commercialize our product candidates as planned. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">There is a substantial amount of intellectual property litigation in the biotechnology and pharmaceutical industries, and we may become party to, or threatened with, litigation or other adversarial proceedings regarding intellectual property rights with respect to our technology or product candidates, including interference proceedings before the USPTO. Intellectual property disputes arise in a number of areas including with respect to patents, use of other proprietary rights and the contractual terms of license arrangements. Third parties may assert claims against us based on existing or future intellectual property rights and claims may also come from competitors against whom our own patent portfolio may have no deterrent effect. The outcome of intellectual property litigation is subject to uncertainties that cannot be adequately quantified in advance. Other parties may allege that our product candidates or the use of our technologies infringes patent claims or other intellectual property rights held by them or that we are employing their proprietary technology without authorization. As we continue to develop and, if approved, commercialize our current and future product candidates, competitors may claim that our technology infringes their intellectual property rights as part of business strategies designed to impede our successful commercialization. There are and may in the future be additional third-party patents or patent applications with claims to, for example, materials, compositions, formulations, methods of manufacture or methods for treatment related to the use or manufacture of any one or more of our product candidates. Moreover, we may fail to identify relevant third party patents or patent applications, or we may incorrectly conclude that the claims of an issued patent are invalid or are not infringed by our activities. Because patent applications can take many years to issue, third parties may have currently pending patent applications which may later result in issued patents that any of our product candidates may infringe, or which such third parties claim are infringed by our technologies. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If we are found to infringe a third party&#8217;s intellectual property rights, we could be forced, including by court order, to cease developing, manufacturing or commercializing the infringing product candidate or product. Alternatively, we may be required or may choose to obtain a license from such third party in order to use the infringing technology and continue developing, manufacturing or marketing the infringing product candidate. However, we may not be able to obtain any required license on commercially reasonable terms or at all. Even if we were able to obtain a license, it could be non-exclusive, thereby giving our competitors access to the same technologies licensed to us. In addition, we could be found liable for monetary damages, including treble damages and attorneys&#8217; fees if we are found to have willfully infringed a patent. A finding of infringement could prevent us from commercializing our product candidates or force us to cease some of our business operations. Claims that we have misappropriated the confidential information or trade secrets of third parties could have a similar negative effect on our business. Even if successful, the defense of any claim of </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">61</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:12pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">infringement or misappropriation is time-consuming, expensive and diverts the attention of our management from our ongoing business operations. </font></p>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:2.26%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">We may need to license intellectual property from third parties, and such licenses may not be available or may not be available on commercially reasonable terms. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A third party may hold intellectual property rights, including patent rights, that are important or necessary to the development or manufacture of our product candidates. It may be necessary for us to use the patented or proprietary technology of third parties to commercialize our product candidates, in which case we would be required to obtain a license from these third parties. Such a license may not be available on commercially reasonable terms, or at all, and we could be forced to accept unfavorable contractual terms. If we are unable to obtain such licenses on commercially reasonable terms, our business could be harmed. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The licensing and acquisition of third-party intellectual property rights is a competitive practice, and companies that may be more established, or have greater resources than we do, may also be pursuing strategies to license or acquire third-party intellectual property rights that we may consider necessary or attractive in order to commercialize our product candidates. More established companies may have a competitive advantage over us due to their larger size and cash resources or greater clinical development and commercialization capabilities. We may not be able to successfully complete such negotiations and ultimately acquire the rights to the intellectual property surrounding the additional product candidates that we may seek to acquire. </p>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:2.26%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">We may become involved in lawsuits to protect or enforce our intellectual property, which could be expensive, time-consuming and unsuccessful. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Competitors may infringe our patents, if issued, trademarks, copyrights or other intellectual property. To counter infringement or unauthorized use, we may be required to file infringement claims, which can be expensive and time-consuming and divert the time and attention of our management and scientific personnel. Any claims we assert against perceived infringers could provoke these parties to assert counterclaims against us alleging that we infringe their patents, trademarks, copyrights or other intellectual property. In addition, in a patent infringement proceeding, there is a risk that a court will decide that a patent of ours is invalid or unenforceable, in whole or in part, and that we do not have the right to stop the other party from using the invention at issue. There is also a risk that, even if the validity of such patents is upheld, the court will construe the patent&#8217;s claims narrowly or decide that we do not have the right to stop the other party from using the invention at issue on the grounds that our patents do not cover the invention. An adverse outcome in a litigation or proceeding involving our patents could limit our ability to assert our patents against those parties or other competitors, and may curtail or preclude our ability to exclude third parties from making and selling similar or competitive products. Similarly, if we assert trademark infringement claims, a court may determine that the marks we have asserted are invalid or unenforceable, or that the party against whom we have asserted trademark infringement has superior rights to the marks in question. In this case, we could ultimately be forced to cease use of such trademarks. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In any infringement litigation, any award of monetary damages we receive may not be commercially valuable. Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information could be compromised by disclosure during litigation. In addition, there could be public announcements of the results of hearings, motions or other interim proceedings or developments and if securities analysts or investors perceive these results to be negative, it could have a substantial adverse effect on the price of our common stock. Moreover, there can be no assurance that we will have sufficient financial or other resources to file and pursue such infringement claims, which typically last for years before they are concluded. Some of our competitors may be able to sustain the costs of such litigation or proceedings more effectively than we can because of their greater financial resources and more mature and developed intellectual property portfolios. Even if we ultimately prevail in such claims, the monetary cost of such litigation and the diversion of the attention of our management and scientific personnel could outweigh any benefit we receive as a result of the proceedings. Accordingly, despite our efforts, we may not be able to prevent third parties from infringing, misappropriating or successfully challenging our intellectual property rights. Uncertainties resulting from the initiation and continuation of patent litigation or other proceedings could have a negative impact on our ability to compete in the marketplace. </p>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:2.26%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">We may be subject to claims by third parties asserting that we or our employees have misappropriated their intellectual property, or claiming ownership of what we regard as our own intellectual property. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Many of our employees were previously employed at universities or other biotechnology or pharmaceutical companies. Although we try to ensure that our employees do not use the proprietary information or know-how of third parties in their work for us, we may be subject to claims that these employees or we have inadvertently or otherwise used intellectual property, including trade secrets or other proprietary information, of any such employee&#8217;s former employer. We may also in the future be subject to claims that we have caused an employee to breach the terms of his or her non-competition or non-solicitation agreement. Litigation may be necessary to defend against these potential claims. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">62</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, while it is our policy to require our employees and contractors who may be involved in the development of intellectual property to execute agreements assigning such intellectual property to us, such employees and contractors may breach the agreement and claim the developed intellectual property as their own. </font></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If we fail in prosecuting or defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights or personnel. A court could prohibit us from using technologies or features that are essential to our products if such technologies or features are found to incorporate or be derived from the trade secrets or other proprietary information of the former employers. Even if we are successful in prosecuting or defending against such claims, litigation could result in substantial costs and could be a distraction to management. In addition, any litigation or threat thereof may adversely affect our ability to hire employees or contract with independent service providers. Moreover, a loss of key personnel or their work product could hamper or prevent our ability to commercialize our products. </p>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:2.26%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">We may be subject to claims challenging the inventorship or ownership of our owned patent rights and other intellectual property. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We generally enter into confidentiality and intellectual property assignment agreements with our employees, consultants, outside scientific collaborators, sponsored researchers and other advisors. However, these agreements may not be honored and may not effectively assign intellectual property rights to us. For example, disputes may arise from conflicting obligations of consultants or others who are involved in developing our technology and product candidates. Litigation may be necessary to defend against these and other claims challenging inventorship or ownership. If we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights, such as exclusive ownership of, or right to use, valuable intellectual property. Such an outcome could have a material adverse effect on our business. Even if we are successful in defending against such claims, litigation could result in substantial costs and be a distraction to management and other employees. </p>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:2.26%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Any trademarks we may obtain may be infringed or successfully challenged, resulting in harm to our business. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We expect to rely on trademarks as one means to distinguish any of our product candidates that are approved for marketing from the products of our competitors. We have not yet selected trademarks for our product candidates and have not yet begun the process of applying to register trademarks for our product candidates. Once we select trademarks and apply to register them, our trademark applications may not be approved. Third parties may oppose our trademark applications, or otherwise challenge our use of the trademarks. In the event that our trademarks are successfully challenged, we could be forced to rebrand our products, which could result in loss of brand recognition and could require us to devote resources to advertising and marketing new brands. Our competitors may infringe our trademarks and we may not have adequate resources to enforce our trademarks. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, any proprietary name we propose to use with our clinical-stage product candidates or any other product candidate in the United States must be approved by the FDA, regardless of whether we have registered it, or applied to register it, as a trademark. The FDA typically conducts a review of proposed product names, including an evaluation of the potential for confusion with other product names. If the FDA objects to any of our proposed proprietary product names, we may be required to expend significant additional resources in an effort to identify a suitable proprietary product name that would qualify under applicable trademark laws, not infringe the existing rights of third parties and be acceptable to the FDA. </p>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:2.26%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">If we are unable to protect the confidentiality of our trade secrets, our business and competitive position would be harmed. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition to seeking patent and trademark protection for our product candidates, we also rely on trade secrets, including unpatented know-how, technology and other proprietary information, to maintain our competitive position. We seek to protect our trade secrets, in part, by entering into non-disclosure and confidentiality agreements with parties who have access to them, such as our employees, consultants, advisors and other third parties. We also enter into confidentiality and invention or patent assignment agreements with our employees and consultants. Despite these efforts, any of these parties may breach the agreements and disclose our proprietary information, including our trade secrets. Monitoring unauthorized uses and disclosures of our intellectual property is difficult, and we do not know whether the steps we have taken to protect our intellectual property will be effective. In addition, we may not be able to obtain adequate remedies for any such breaches. Enforcing a claim that a party illegally disclosed or misappropriated a trade secret is difficult, expensive and time-consuming, and the outcome is unpredictable. Furthermore, some courts inside and outside the United States are less willing or unwilling to protect trade secrets. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Moreover, our competitors may independently develop knowledge, methods and know-how equivalent to our trade secrets. Competitors could purchase our products and replicate some or all of the competitive advantages we derive from our development efforts for technologies on which we do not have patent protection. If any of our trade secrets were to be lawfully obtained or independently developed by a competitor, we would have no right to prevent them, or those to whom they communicate it, from using that technology or information to compete with us. If any of our trade secrets were to be disclosed to or independently developed by a competitor, our competitive position would be harmed. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">63</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:2.26%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">We may not be able to protect our intellectual property rights throughout the world. </font></p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Filing, prosecuting and defending patents on product candidates in all countries throughout the world would be prohibitively expensive, and our intellectual property rights in some countries outside the United States could be less extensive than those in the United States. In some cases, we may not be able to obtain patent protection for certain technology outside the United States. In addition, the laws of some foreign countries do not protect intellectual property rights to the same extent as federal and state laws in the United States, even in jurisdictions where we do pursue patent protection. Consequently, we may not be able to prevent third parties from practicing our inventions in all countries outside the United States, even in jurisdictions where we do pursue patent protection or from selling or importing products made using our inventions in and into the United States or other jurisdictions. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Competitors may use our technologies in jurisdictions where we have not pursued and obtained patent protection to develop their own products and, further, may export otherwise infringing products to territories where we have patent protection, but enforcement is not as strong as that in the United States. These products may compete with our product candidates and preclinical programs and our patents or other intellectual property rights may not be effective or sufficient to prevent them from competing. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Many companies have encountered significant problems in protecting and defending intellectual property rights in foreign jurisdictions. The legal systems of certain countries, particularly certain developing countries, do not favor the enforcement of patents, trade secrets and other intellectual property protection, particularly those relating to biotechnology products, which could make it difficult for us to stop the infringement of our patents, if pursued and obtained, or marketing of competing products in violation of our proprietary rights generally. Proceedings to enforce our patent rights in foreign jurisdictions could result in substantial costs and divert our efforts and attention from other aspects of our business, could put our patents at risk of being invalidated or interpreted narrowly and our patent applications at risk of not issuing and could provoke third parties to assert claims against us. We may not prevail in any lawsuits that we initiate and the damages or other remedies awarded, if any, may not be commercially meaningful. Accordingly, our efforts to enforce our intellectual property rights around the world may be inadequate to obtain a significant commercial advantage from the intellectual property that we develop or license. </p>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:2.26%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Obtaining and maintaining our patent protection depends on compliance with various procedural, document submission, fee payment and other requirements imposed by governmental patent agencies, and our patent protection could be reduced or eliminated for non-compliance with these requirements. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Periodic maintenance and annuity fees on any issued patent are due to be paid to the USPTO and patent agencies outside the United States in several stages over the lifetime of the patent. The USPTO and various foreign governmental patent agencies require compliance with a number of procedural, documentary, fee payment and other similar provisions during the patent application process. While an inadvertent lapse can in many cases be cured by payment of a late fee or by other means in accordance with the applicable rules, there are situations in which noncompliance can result in abandonment or lapse of the patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction. Non-compliance events that could result in abandonment or lapse of a patent or patent application include failure to respond to official actions within prescribed time limits, non-payment of fees and failure to properly legalize and submit formal documents. If we fail to maintain the patents and patent applications covering our products or product candidates, our competitors might be able to enter the market, which would harm our business. In addition, to the extent that we have responsibility for taking any action related to the prosecution or maintenance of patents or patent application in-licensed from a third party, any failure on our part to maintain the in-licensed rights could jeopardize our rights under the relevant license and may expose us to liability. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Risks Related to our Business Operations </p>
<p style="margin-bottom:0pt;margin-top:6pt;margin-left:2.26%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">We will need to grow the size of our organization, and we may experience difficulties in managing this growth. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of March 15, 2021, we had 32 employees, 30 of whom are employed full-time. As our development and commercialization plans and strategies develop, and as we transition into operating as a public company, we expect to need additional managerial, operational, financial and other personnel, including personnel to support our product development and planned future commercialization efforts. Future growth will impose significant added responsibilities on members of management, including: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:1.13%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">identifying, recruiting, integrating, maintaining and motivating additional employees; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:1.13%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">managing our internal development efforts effectively, including the preclinical, clinical and FDA review processes for our product candidates; and </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:1.13%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">improving our operational, financial and management controls, reporting systems and procedures. </p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">There are a small number of individuals with experience in immunotherapy and the competition for these individuals is high. Our future financial performance and our ability to commercialize our product candidates will depend, in part, on our ability to </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">64</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:12pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">effectively manage any future growth, and our management may also have to divert a disproportionate amount of its attention away from day-to-day activities </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">in order to</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> devote a substantial amount of time to managing these growth activities. </font></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If we are not able to effectively expand our organization by hiring new employees, we may not be able to successfully implement the tasks necessary to further develop and commercialize our product candidates and, accordingly, may not achieve our research, development and commercialization goals. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition to expanding our organization, we anticipate increasing the size of our facilities and building out our development and manufacturing capabilities, which would require significant capital expenditures. If these capital expenditures are higher than expected, it may adversely affect our financial condition and capital resources. In addition, if the increase in the size of our facilities is delayed, it may limit our ability to rapidly expand the size of our organization in order to meet our corporate goals. </p>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:2.26%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Our future success depends on our ability to retain key members of senior management and to attract, retain and motivate qualified personnel. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our ability to compete in the highly competitive biopharmaceutical industry depends upon our ability to attract and retain highly qualified management, research and development, clinical, financial and business development personnel. We are highly dependent on our management, scientific and medical personnel, including John Celebi, our Chief Executive Officer, Dr.&#160;Marie-Louise Fjaellskog, our Chief Medical Officer, Dr.&#160;Robert Pierce, our Chief Scientific Officer, and Anupama Hoey, our Chief Business Officer. Our senior management may terminate their employment with us at any time. We do not maintain &#8220;key person&#8221; insurance for any of our employees. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Recruiting and retaining qualified scientific and clinical personnel and, if we progress the development of any of our product candidates, commercialization, manufacturing and sales and marketing personnel, will be critical to our success. The loss of the services of members of our senior management or other key employees could impede the achievement of our research, development and commercialization objectives and seriously harm our ability to successfully implement our business strategy. Furthermore, replacing members of our senior management and key employees may be difficult and may take an extended period of time because of the limited number of individuals in our industry with the breadth of skills and experience required to successfully develop, gain regulatory approval of and commercialize our product candidates. Our success also depends on our ability to continue to attract, retain and motivate highly skilled junior, mid-level and senior managers, as well as junior, mid-level and senior scientific and medical personnel. Competition to hire from this limited candidate pool is intense, and we may be unable to hire, train, retain or motivate these key personnel on acceptable terms given the competition among numerous pharmaceutical and biotechnology companies for similar personnel. We also experience competition for the hiring of scientific and clinical personnel from universities and research institutions. In addition, we rely on consultants and advisors, including scientific and clinical advisors, to assist us in formulating our research and development and commercialization strategy. Our consultants and advisors may have commitments under consulting or advisory contracts with other entities that may limit their availability to us. If we are unable to continue to attract and retain high-quality personnel, our ability to pursue our growth strategy will be limited. </p>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:2.26%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">If we engage in future acquisitions or strategic collaborations, this may increase our capital requirements, dilute our stockholders, cause us to incur debt or assume contingent liabilities and subject us to other risks. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">From time to time, we may evaluate various acquisitions and strategic collaborations, including licensing or acquiring complementary products, intellectual property rights, technologies or businesses, as we may deem appropriate to carry out our business plan. For instance, in May 2020, we acquired Alvaxa Biosciences LLC to enhance the depth of our nanobody assets and know-how. Any potential acquisition or strategic collaboration may entail numerous risks, including: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:1.13%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">increased operating expenses and cash requirements; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:1.13%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">the assumption of additional indebtedness or contingent liabilities; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:1.13%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">assimilation of operations, intellectual property and products of an acquired company, including difficulties associated with integrating new personnel; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:1.13%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">the diversion of our management&#8217;s attention from our existing programs and initiatives in pursuing such a strategic partnership, merger or acquisition; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:1.13%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">retention of key employees, the loss of key personnel and uncertainties in our ability to maintain key business relationships; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:1.13%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">risks and uncertainties associated with the other party to such a transaction, including the prospects of that party and their existing products or product candidates and regulatory approvals; and </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:1.13%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">our inability to generate revenue from acquired technology sufficient to meet our objectives in undertaking the acquisition or even to offset the associated acquisition and maintenance costs. </p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">65</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Additionally, if we undertake future acquisitions, we may issue dilutive securities, </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">assume</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> or incur debt obligations, incur large one-time expenses and acquire intangible assets that could result in significant future amortization expenses. Moreover, we may not be able to locate suitable acquisition opportunities and this inability could impair our ability to grow or obtain access to technology or products that may be important to the development of our business. </font></p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Risks Related to our Securities and our Status as a Public Company </p>
<p style="margin-bottom:0pt;margin-top:6pt;margin-left:2.26%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">An active trading market for our common stock may not continue to develop or be sustained. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prior to our initial public offering, there was no public market for our common stock, and we cannot assure you that an active trading market for our shares will continue to develop or be sustained. As a result, it may be difficult for you to sell shares at an attractive price or at all. </p>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:2.26%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">The trading price of our common stock may be volatile, and you could lose all or part of your investment. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The trading price of our common stock is likely to be highly volatile and could be subject to wide fluctuations in response to various factors, some of which are beyond our control, including limited trading volume. The stock market in general and the market for biopharmaceutical companies in particular have experienced extreme volatility that has often been unrelated to the operating performance of particular companies. As a result of this volatility, investors may not be able to sell their common stock at or above the price paid for the common stock. In addition to the factors discussed elsewhere in this &#8220;Risk Factors&#8221; section, these factors include: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:1.13%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">the commencement, enrollment or results of our planned and future clinical trials; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:1.13%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">positive or negative results from, or delays in, testing and clinical trials by us, collaborators or competitors; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:1.13%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">the loss of any of our key scientific or management personnel; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:1.13%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">regulatory or legal developments in the United States and other countries; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:1.13%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">the success of competitive products or technologies; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:1.13%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">adverse actions taken by regulatory agencies with respect to our clinical trials or manufacturers; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:1.13%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">changes or developments in laws or regulations applicable to our product candidates and preclinical program; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:1.13%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">changes in the structure and scope of health care payment systems; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:1.13%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">changes to our relationships with collaborators, manufacturers or suppliers; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:1.13%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">concerns regarding the safety of our product candidates or ImmunoPhage platform in general; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:1.13%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">announcements concerning our competitors or the pharmaceutical industry in general; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:1.13%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">actual or anticipated fluctuations in our operating results; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:1.13%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">changes in financial estimates or recommendations by securities analysts; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:1.13%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">potential acquisitions, financing, collaborations or other corporate transactions; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:1.13%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">the results of our efforts to discover, develop, acquire or in-license additional product candidates; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:1.13%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">the trading volume of our common stock on Nasdaq; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:1.13%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">sales of our common stock by us, members of our senior management and directors or our stockholders or the anticipation that such sales may occur in the future; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:1.13%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">general economic, political, and market conditions and overall fluctuations in the financial markets in the United States; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:1.13%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">stock market price and volume fluctuations of comparable companies and, in particular, those that operate in the biopharmaceutical industry; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:1.13%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">investors&#8217; general perception of us and our business; and </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:1.13%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">other events and factors, many of which are beyond our control. </p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:9pt;text-indent:0%;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">These and other market and industry factors may cause the market price and demand for our common stock to fluctuate substantially, regardless of our actual operating performance, which may limit or prevent investors from selling their common stock at or above the price paid for the common stock and may otherwise negatively affect the liquidity of our common stock. In addition, the stock market in general, and biopharmaceutical companies in particular, have experienced extreme price and volume fluctuations that have often been unrelated or disproportionate to the operating performance of these companies. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">66</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Some companies that have experienced volatility in the trading price of their shares have been the subject of securities class action litigation. From time to time, we have been, and may continue to be, subject to legal proceedings and claims in the ordinary course of business.&#160;For instance, during 2017, we became actively involved, along with other defendants, in a breach of contract claim in the Ontario (Canada)&#160;Superior Court of Justice seeking declaratory and other relief, including monetary damages. While we believe there is no merit to the allegations of that claim, any lawsuit to which we are a party, with or without merit, may result in an unfavorable judgment. We also may decide to settle lawsuits on unfavorable terms. </font></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Any such negative outcome could result in payments of substantial damages or fines, damage to our reputation or adverse changes to our business practices. Defending against litigation is costly and time-consuming, and could divert our management&#8217;s attention and our resources. Furthermore, during the course of litigation, there could be negative public announcements of the results of hearings, motions or other interim proceedings or developments, which could have a negative effect on the market price of our common stock. </p>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:2.26%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">A significant portion of our total outstanding shares are restricted from immediate resale, but may be sold into the market in the near future. This could cause the market price of our common stock to drop significantly, even if our business is doing well. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Sales of a substantial number of our common stock in the public market could occur at any time. If our stockholders sell, or the market perceives that our stockholders intend to sell, substantial amounts of our shares of common stock in the public market, the market price of our common stock could decline significantly. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The shares sold in our initial public offering are freely tradable, and the remaining 22,558,200 shares of common stock will be available for sale in the public market beginning 180 days after the date of pricing our initial public offering, or with respect to shares purchased in our Series BB financing, 120 days after the date of pricing our initial public offering, following the expiration of lock-up agreements entered into by our stockholders in connection with the offering and subject to the restrictions of Rule 144 of the Securities Act. The representatives of the underwriters may agree to release these stockholders from their lock-up agreements at any time and without notice, which would allow for earlier sales of shares in the public market. Sales of a substantial number of such shares upon expiration of the lock-up agreements, the perception that such sales may occur, or early release of restrictions in the lock-up agreements, could cause the market price of our common stock to fall or make it more difficult for you to sell your common stock at a time and price that you deem appropriate. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, we have filed a registration statement registering the issuance of approximately 7.3&#160;million shares of common stock subject to options or other equity awards issued or reserved for future issuance under our equity incentive plans. Shares registered under these registration statements will be available for sale in the public market subject to vesting arrangements and exercise of options, the lock-up agreements described above and, in the case of our affiliates, the restrictions of Rule 144 under the Securities Act. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Additionally, the holders of an aggregate of approximately 19.0&#160;million of our shares of common stock, or their transferees, have rights, subject to some conditions, to require us to file one or more registration statements covering their shares or to include their shares in registration statements that we may file for ourselves or other stockholders. If we were to register the resale of these shares, they could be freely sold in the public market. If these additional shares are sold, or if it is perceived that they will be sold, in the public market, the trading price of our common stock could decline. </p>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:2.26%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">If we fail to implement and maintain an effective system of internal control over financial reporting to remediate our material weaknesses, we may be unable to accurately report our results of operations, meet our reporting obligations or prevent fraud, and investor confidence in our company and the market price of our common stock may be materially and adversely affected. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prior to our initial public offering, we only had limited accounting personnel and other resources with which to address internal control over financial reporting. In connection with the audits of our consolidated financial statements as of and for the years ended December&#160;31, 2019 and 2020, we and our independent registered public accounting firm identified material weaknesses in our internal control over financial reporting. As defined in the standards established by the U.S. Public Company Accounting Oversight Board, or PCAOB, a &#8220;material weakness&#8221; is a deficiency, or combination of deficiencies in internal control over financial reporting, such that there is a reasonable possibility that a material misstatement of the annual or interim financial statements will not be prevented or detected on a timely basis. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are in the process of implementing a number of measures to address the material weaknesses and deficiencies that have been identified including: (i)&#160;hiring additional accounting and financial reporting personnel with generally accepted accounting principles in the United States, or US GAAP, and SEC reporting experience, (ii)&#160;developing, communicating and implementing an accounting policy manual for our accounting and financial reporting personnel for recurring transactions and period-end closing processes, and (iii)&#160;establishing effective monitoring and oversight controls for non-recurring and complex transactions to ensure the accuracy and completeness of our company&#8217;s consolidated financial statements and related disclosures. See &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8212;Internal Control Over Financial Reporting.&#8221; However, we cannot assure </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">67</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:12pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">you that these measures may fully address the material weaknesses and deficiencies in our internal control over financial reporting or that we may conclude that they have been fully remediated. </font></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">Pursuant to Section 404 of the Sarbanes-Oxley Act of 2002, or Section 404, we are required to furnish a report by our management on our internal control over financial reporting </font><font style="color:#000000;">beginning with our second annual report on Form 10-K after becoming a public company</font><font style="Background-color:#FFFFFF;">. However, while we remain an emerging growth company, we will not be required to include an attestation report on internal control over financial reporting issued by our independent registered public accounting firm. </font><font style="color:#000000;">In addition, our reporting obligations may place a significant strain on our management, operational and financial resources and systems for the foreseeable future. We may be unable to timely complete our evaluation testing and any required remediation. </font></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During the course of documenting and testing our internal control procedures, in order to satisfy the requirements of Section&#160;404, we may identify other weaknesses and deficiencies in our internal control over financial reporting. If we fail to maintain the adequacy of our internal control over financial reporting, as these standards are modified, supplemented or amended from time to time, we may not be able to conclude on an ongoing basis that we have effective internal control over financial reporting in accordance with Section&#160;404. Generally speaking, if we fail to achieve and maintain an effective internal control over financial reporting, it could result in material misstatements in our financial statements and could also impair our ability to comply with applicable financial reporting requirements and related regulatory filings on a timely basis. As a result, our businesses, financial condition, results of operations and prospects, as well as the trading price of our common stock, may be materially and adversely affected. Additionally, ineffective internal control over financial reporting could expose us to increased risk of fraud or misuse of corporate assets and subject us to potential delisting from the stock exchange on which we list, regulatory investigations and civil or criminal sanctions. We may also be required to restate our financial statements from prior periods. </p>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:2.26%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">We do not anticipate paying any cash dividends on our common stock in the foreseeable future. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We do not intend to pay any cash dividends on our common stock in the foreseeable future and we currently intend to retain our future earnings, if any, to fund the development and growth of our business. Therefore, you should not rely on an investment in our common stock to provide dividend income. Our board of directors has complete discretion as to whether to distribute dividends. Even if our board of directors decides to declare and pay dividends, the timing, amount and form of future dividends, if any, will depend on, among other things, our future results of operations and cash flow, our capital requirements and surplus, the amount of distributions, if any, received by us from our subsidiaries, our financial condition, contractual restrictions and other factors deemed relevant by our board of directors. As a result, capital appreciation, if any, on our common stock will be your sole source of gains for the foreseeable future. </p>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:2.26%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Our ability to use our net operating losses to offset future taxable income may be subject to certain limitations. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our net operating loss, or NOL, carryforwards could expire unused and be unavailable to offset future income tax liabilities because of their limited duration or because of restrictions under U.S. tax law. NOLs generated in taxable years beginning before January&#160;1, 2018 are permitted to be carried forward for only 20 taxable years under applicable U.S. federal income tax law.&#160;Under the Tax Cuts and Jobs Act, or the Tax Act, as modified by the Coronavirus Aid, Relief, and Economic Security Act, or the CARES Act, NOLs arising in taxable years beginning after December&#160;31, 2017, and before January&#160;1, 2021 may be carried back to each of the five tax years preceding the tax year of such loss, and NOLs arising in tax years beginning after December&#160;31, 2020 may not be carried back. Moreover, under the Tax Act as modified by the CARES Act, NOLs generated in taxable years beginning after December&#160;31, 2017 may be carried forward indefinitely, but the deductibility of such NOLs generally will be limited in taxable years beginning after December&#160;31, 2020 to 80% of current year taxable income. The extent to which state income tax law will conform to the Tax Act and CARES Act is uncertain. As of December&#160;31, 2020, we had NOL carryforwards for federal and state income tax purposes of approximately $81.3&#160;million and $80.0 million, respectively.&#160;NOL carryforwards generated in 2020 and 2019 for federal tax reporting purposes of $16.6&#160;million and $10.7&#160;million, respectfully, have an indefinite life. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In general, under Section&#160;382 of the Internal Revenue Code of 1986, as amended, or the Code, a corporation that undergoes an &#8220;ownership change&#8221; (as defined under Section&#160;382 of the Code and applicable Treasury Regulations) is subject to limitations on its ability to utilize its pre-change NOLs to offset future taxable income. We have not determined whether our NOLs are limited under Section&#160;382 of the Code.&#160;We may have experienced an ownership change in the past, and may experience ownership changes in the future as a result of subsequent shifts in our stock ownership, some of which are outside our control. Furthermore, our ability to utilize NOLs of companies that we have acquired or may acquire in the future may be subject to limitations. There is also a risk that due to regulatory changes, such as suspensions on the use of NOLs or other unforeseen reasons, our existing NOLs could expire or otherwise be unavailable to reduce future income tax liabilities, including for state tax purposes.&#160;For these reasons, we may not be able to utilize a material portion of the NOLs reflected on our balance sheet, even if we attain profitability, which could potentially result in increased future tax liability to us and could adversely affect our operating results and financial condition. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">68</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:2.26%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">We </font><font style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">have begun to incur </font><font style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">significantly increased costs </font><font style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">as a result of</font><font style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"> operating as a company whose common stock is publicly traded, and our management will be required to devote substantial time to new compliance initiatives. </font></p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As a newly public company, we have begun to incur significant legal, accounting and other expenses that we did not incur previously. These expenses will likely be even more significant after we no longer qualify as an emerging growth company. The Sarbanes-Oxley Act, the Dodd-Frank Wall Street Reform and Consumer Protection Act, the listing requirements of Nasdaq and other applicable securities rules and regulations impose various requirements on public companies in the United States, including the establishment and maintenance of effective disclosure and financial controls and corporate governance practices. Our senior management and other personnel will need to devote a substantial amount of time to these compliance initiatives. Moreover, these rules and regulations will increase our legal and financial compliance costs and will make some activities more time-consuming and costly. For example, we expect that these rules and regulations may make it more difficult and more expensive for us to obtain director and officer liability insurance, which in turn could make it more difficult for us to attract and retain qualified senior management personnel or members for our board of directors. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">However, these rules and regulations are often subject to varying interpretations, in many cases due to their lack of specificity, and, as a result, their application in practice may evolve over time as new guidance is provided by regulatory and governing bodies. This could result in continuing uncertainty regarding compliance matters and higher costs necessitated by ongoing revisions to disclosure and governance practices. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pursuant to Section&#160;404, we will be required to furnish a report by our senior management on our internal control over financial reporting beginning with our second annual report on Form 10-K after becoming a public company. However, while we remain an emerging growth company or a smaller reporting company, we will not be required to include an attestation report on internal control over financial reporting issued by our independent registered public accounting firm. To prepare for eventual compliance with Section&#160;404, we will be engaged in a process to document and evaluate our internal control over financial reporting, which is both costly and challenging. In this regard, we will need to continue to dedicate internal resources, potentially engage outside consultants and adopt a detailed work plan to assess and document the adequacy of internal control over financial reporting, continue steps to improve control processes as appropriate, validate through testing that controls are functioning as documented and implement a continuous reporting and improvement process for internal control over financial reporting. Despite our efforts, there is a risk that we will not be able to conclude, within the prescribed timeframe or at all, that our internal control over financial reporting is effective as required by Section&#160;404. </p>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:2.26%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">We are an &#8220;emerging growth company&#8221; and as a result of the reduced disclosure and governance requirements applicable to emerging growth companies, our common stock may be less attractive to investors. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are an &#8220;emerging growth company&#8221; as defined in the JOBS Act. For as long as we continue to be an emerging growth company, we may take advantage of exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies, including not being required to comply with the auditor attestation requirements of Section&#160;404, exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and stockholder approval of any golden parachute payments not previously approved. As an emerging growth company, we are able to report only two years of financial results and selected financial data compared to three and five years, respectively, for comparable data reported by other public companies. We may take advantage of these exemptions until we are no longer an emerging growth company. We could be an emerging growth company for up to five years, although circumstances could cause us to lose that status earlier, including if the aggregate market value of our shares of common stock, held by non-affiliates exceeds $700&#160;million as of the end of our second fiscal quarter before that time, in which case we would no longer be an emerging growth company as of the following December 31st (the last day of our fiscal year). We cannot predict if investors will find our common stock less attractive because we may rely on these exemptions. If some investors find our common stockless attractive as a result, there may be a less active trading market for our common stock and the price of our common stock may be more volatile. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, the JOBS Act provides that an emerging growth company can take advantage of an extended transition period for complying with new or revised accounting standards. This allows an emerging growth company to delay the adoption of certain accounting standards until those standards would otherwise apply to private companies. We have elected not to &#8220;opt out&#8221; of such extended transition period, which means that when a standard is issued or revised and it has different application dates for public or private companies, we will adopt the new or revised standard at the time private companies adopt the new or revised standard and will do so until such time that we either (i) irrevocably elect to &#8220;opt out&#8221; of such extended transition period or (ii) no longer qualify as an emerging growth company. Therefore, the reported results of operations contained in our consolidated financial statements may not be directly comparable to those of other public companies. </p>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:2.26%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Our amended and restated certificate of incorporation provides that the Court of Chancery of the State of Delaware and, to the extent enforceable, the federal district courts of the United States of America, will be the&#160;exclusive&#160;forum&#160;for substantially all </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">69</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:2.26%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">disputes between us and our stockholders, which could limit our stockholders&#8217; ability to obtain a favorable judicial forum for disputes with us or our directors, officers, or employees. </font></p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our amended and restated certificate of incorporation provides that the Court of Chancery of the State of Delaware and, to the extent enforceable, the federal district courts of the United States of America, will be the&#160;exclusive&#160;forum&#160;for the following types of actions or proceedings under Delaware statutory or common law: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:1.13%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">any derivative claim or cause of action brought on our behalf; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:1.13%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">any claim or cause of action for breach of a fiduciary duty owed by any of our current or former directors, officers or other employees to us or our stockholders; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:1.13%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">any claim or cause of action against us or any of our current or former directors, officers or other employees, arising out of or pursuant to any provision of the DGCL, our certificate of incorporation or our bylaws; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:1.13%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">any claim or cause of action seeking to interpret, apply, enforce or determine the validity of our certificate of incorporation or our bylaws; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:1.13%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">any action or proceeding as to which the DGCL confers jurisdiction to the Court of Chancery of the State of Delaware; and </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:1.13%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">any claim or cause of action against us or any of our current or former directors, officers or other employees that is governed by the internal-affairs doctrine, in all cases to the fullest extent permitted by law and subject to the court having personal jurisdiction over the indispensable parties named as defendants. </p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">This provision would not apply to suits brought to enforce a duty or liability created by the&#160;Securities Act&#160;or the&#160;Securities Exchange Act of 1934, or the Exchange Act,&#160;or any claim for which the U.S. federal courts have exclusive jurisdiction. Our amended and restated certificate of incorporation will provide that the federal district courts of the United States of America will be the&#160;exclusive&#160;forum&#160;for resolving any complaint asserting a cause of action arising under the&#160;Securities Act. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">These&#160;exclusive-forum&#160;provisions may limit a stockholder&#8217;s ability to bring a claim in a judicial forum that it finds favorable for disputes with us or our directors, officers, or other employees, which may discourage lawsuits against us and our directors, officers, and other employees. If any other court of competent jurisdiction were to find either&#160;exclusive-forum&#160;provision in our amended and restated certificate of incorporation to be inapplicable or unenforceable, we may incur additional costs associated with resolving the dispute in other jurisdictions, which could seriously harm our business. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">General Risk Factors </p>
<p style="margin-bottom:0pt;margin-top:6pt;margin-left:2.26%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Our business, operations and clinical development plans and timelines could be adversely affected by the effects of health epidemics, including the recent&#160;COVID-19&#160;pandemic, on the manufacturing, clinical trial and other business activities performed by us or by third parties with whom we conduct business, including our contract manufacturers, CROs, shippers and others. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our business could be adversely affected by health epidemics wherever we have clinical trial sites or other business operations. In addition, health epidemics could cause significant disruption in the operations of third-party manufacturers, CROs and other third parties upon whom we rely. For example, in December 2019, a novel strain of coronavirus,&#160;SARS-CoV-2,&#160;causing a disease referred to as&#160;COVID-19,&#160;was reported to have surfaced in Wuhan, China. Since then,&#160;COVID-19&#160;has spread to multiple countries worldwide, including the United States. In March 2020, the World Health Organization declared the&#160;COVID-19&#160;outbreak a pandemic, and the U.S. government ordered the closure of all&#160;non-essential&#160;businesses, imposed social distancing measures, &#8220;shelter-in-place&#8221;&#160;orders and restrictions on travel between the United States, Europe and certain other countries. The global pandemic and government measures taken in response have also had a significant impact on businesses and commerce worldwide, as worker shortages have occurred; supply chains have been disrupted; facilities and production have been suspended across a variety of industries; and demand for certain goods and services, such as medical services and supplies, has spiked, while demand for other goods and services, such as travel, has fallen. On March&#160;18, 2020, the FDA issued updated industry guidance for conducting clinical trials during the&#160;COVID-19&#160;pandemic, which requires clinical trial sponsors to consider the need to delay or cease patient recruitment, change protocol regarding patient monitoring and assessment that minimizes&#160;in-person&#160;visits, alternative administration of certain investigational products due to compromised clinical sites and to put in place new processes or modify existing processes in consultation with the FDA that would ensure the safety of clinical trial participants. In connection with&#160;COVID-19,&#160;we implemented optional work-from-home policies for most employees. The effects of government orders and our work-from-home policies may negatively impact productivity, disrupt our business and delay our clinical programs and timelines, the magnitude of which will depend, in part, on the length and severity of the restrictions and other limitations on our ability to conduct our business in the ordinary course. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If our relationships with our suppliers or other vendors are terminated or scaled back as a result of the&#160;COVID-19&#160;pandemic or other health epidemics, we may not be able to enter into arrangements with alternative suppliers or vendors or do so on commercially reasonable terms or in a timely manner. Switching or adding additional suppliers or vendors involves substantial cost and requires </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">70</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:12pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">management time and focus. In addition, there is a natural transition period when a new supplier or vendor commences work. As a result, delays may occur, which could adversely impact our ability to meet our desired clinical development and any future commercialization timelines. Although we carefully manage our relationships with our suppliers and vendors, there can be no assurance that we will not encounter challenges or delays in the future or that these delays or challenges will not harm our business. </font></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, our preclinical studies and clinical trials may be affected by the&#160;COVID-19&#160;pandemic. Clinical site initiation, patient enrollment and activities that require visits to clinical sites, including data monitoring, may be delayed due to prioritization of hospital resources toward the&#160;COVID-19&#160;pandemic or concerns among patients about participating in clinical trials during a pandemic. Some patients may have difficulty following certain aspects of clinical trial protocols if quarantines impede patient movement or interrupt healthcare services. These challenges may also increase the costs of completing our clinical trials. Similarly, if we are unable to successfully recruit and retain patients and principal investigators and site staff who, as healthcare providers, may have heightened exposure to&#160;COVID-19&#160;or experience additional restrictions by their institutions, city or state, our clinical trial operations could be adversely impacted. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The spread of&#160;COVID-19,&#160;which has caused a broad impact globally, may materially affect us economically. While the potential economic impact brought by, and the duration of,&#160;COVID-19&#160;may be difficult to assess or predict, a widespread pandemic has resulted in significant disruption of global financial markets, resulting in an economic downturn that could continue to significantly impact our business and operations and may reduce our ability to access capital, which could in the future negatively affect our liquidity. In addition, a recession or market correction resulting from the spread of&#160;COVID-19&#160;could materially affect our business and the value of our common stock. In addition, a recurrence or &#8220;second wave&#8221; of COVID-19 cases could cause other widespread or more severe impacts depending on where infection rates are highest. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Further, we may experience additional disruptions that could severely impact our business and clinical trials, including: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:1.13%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">diversion of healthcare resources away from the conduct of clinical trials, including the diversion of hospitals serving as our clinical trial sites and hospital staff supporting the conduct of our clinical trials; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:1.13%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">interruption or delays in the operations of the FDA or other regulatory authorities, which may impact review and approval timelines; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:1.13%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">limitations on employee resources that would otherwise be focused on the conduct of our preclinical studies and clinical trials, including because of sickness of employees or their families or the desire of employees to avoid contact with large groups of people; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:1.13%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">risk that participants enrolled in our clinical trials will acquire&#160;COVID-19&#160;while the clinical trial is ongoing, which could impact the results of the clinical trial, including by increasing the number of observed adverse events; and </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:1.13%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">refusal of the FDA to accept data from clinical trials in these affected geographies. </p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">These and similar, and perhaps more severe, disruptions in our operations could have a material adverse effect on our business, results of operations, cash flows, financial condition and/or prospects. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The global pandemic of&#160;COVID-19&#160;continues to evolve rapidly. The ultimate impact of the COVID-19 pandemic or a similar health epidemic is highly uncertain and subject to change. We do not yet know the full extent of potential delays or impacts on our business, our clinical trials, healthcare systems or the global economy as a whole. However, these effects could have a material impact on our operations, and we continue to monitor the&#160;COVID-19&#160;situation closely. To the extent the&#160;COVID-19&#160;pandemic adversely affects our business, results of operations, cash flows, financial condition and/or prospects, it may also have the effect of heightening many of the other risks described in this &#8220;Risk Factors&#8221; section. </p>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:2.26%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Our internal computer systems, or those of our collaborators or other contractors or consultants, may fail or suffer security breaches, which could result in a significant disruption of our product development programs and our ability to operate our business effectively. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our internal computer systems and those of our current and any future collaborators and other contractors or consultants may be vulnerable to a variety of disruptive elements, including computer viruses, unauthorized access, natural disasters, terrorism, war and telecommunication and electrical failures. While we have not experienced any significant system failure, accident or security breach to date, if such an event were to occur and cause interruptions in our operations, it could result in a disruption of our development programs and our business operations, whether due to a loss of our trade secrets or other proprietary information, significant delays or setbacks in our research, or other similar disruptions. For example, the loss of clinical trial data from completed or future clinical trials could result in delays in our regulatory approval efforts and significantly increase our costs to recover or reproduce the data. To the extent that any disruption or security breach were to result in a loss of, or damage to, our data or applications, or inappropriate </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">71</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">disclosure of confidential or proprietary information, we could incur liability, our competitive position could be harmed, our reputation could be damaged, and the further development and commercialization of our product candidates could be delayed. </font></p>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:2.26%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">We are or may become subject to a variety of privacy and data security laws, and our failure to comply with them could harm our business. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We maintain sensitive information, including confidential business and personal information in connection with our preclinical studies and our employees, and are subject to laws and regulations governing the privacy and security of such information. In the United States, there are numerous federal and state privacy and data security laws and regulations governing the collection, use, disclosure and protection of personal information, including federal and state health information privacy laws, federal and state security breach notification laws, and federal and state consumer protection laws. Each of these constantly evolving laws can be subject to varying interpretations. In May 2018, a new privacy regime, the General Data Protection Regulation, the GDPR, took effect in the European Economic Area, the EEA, into which we may expand our business. The GDPR governs the collection, use, disclosure, transfer or other processing of personal data of European persons. Among other things, the GDPR imposes requirements regarding the security of personal data and notification of data processing obligations to the competent national data processing authorities, changes the lawful bases on which personal data can be processed, expands the definition of personal data and requires changes to informed consent practices, as well as more detailed notices for clinical trial subjects and investigators. In addition, the GDPR increases the scrutiny of transfers of personal data from clinical trial sites located in the EEA to the United States and other jurisdictions that the European Commission does not recognize as having &#8220;adequate&#8221; data protection laws, and imposes substantial fines for breaches and violations (up to the greater of&#160;&#8364;20&#160;million or 4% of our consolidated annual worldwide gross revenue). The GDPR also confers a private right of action on data subjects and consumer associations to lodge complaints with supervisory authorities, seek judicial remedies and obtain compensation for damages resulting from violations of the GDPR. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Compliance with these and any other applicable privacy and data security laws and regulations is a rigorous and time-intensive process, and we may be required to put in place additional mechanisms ensuring compliance with the new data protection rules. If we fail to comply with any such laws or regulations, we may face significant fines and penalties that could adversely affect our business, financial condition and results of operations. Furthermore, the laws are not consistent, and compliance in the event of a widespread data breach is costly. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, states are constantly adopting new laws or amending existing laws, requiring attention to frequently changing regulatory requirements. For example, California enacted the California Consumer Privacy Act, or the CCPA, on June&#160;28, 2018, which took effect on January&#160;1, 2020 and has been dubbed the first &#8220;GDPR-like&#8221; law in the United States. The CCPA gives California residents expanded rights to access and delete their personal information, opt out of certain personal information sharing and receive detailed information about how their personal information is used by requiring covered companies to provide new disclosures to California consumers (as that term is broadly defined and can include any of our current or future employees who may be California residents) and provide such residents new ways to opt-out of certain sales of personal information. The CCPA provides for civil penalties for violations, as well as a private right of action for data breaches that is expected to increase data breach litigation. As we expand our operations and trials (both preclinical or clinical), the CCPA may increase our compliance costs and potential liability. Some observers have noted that the CCPA could mark the beginning of a trend toward more stringent privacy legislation in the United States. Other states are beginning to pass similar laws. </p>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:2.26%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Business disruptions could seriously harm our future revenue and financial condition and increase our costs and expenses. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our operations, and those of our vendors and suppliers, could be subject to power shortages, telecommunications failures, water shortages, civil unrest, labor disputes, violence, earthquakes, floods, hurricanes, typhoons, fires, extreme weather conditions, infectious disease, medical epidemics and other natural or man-made disasters or business interruptions, for which we are predominantly self-insured. The occurrence of any of these business disruptions could seriously harm our operations and financial condition and increase our costs and expenses. We currently rely on third-party suppliers to produce and process our product candidates on a patient-by-patient basis. Our ability to obtain clinical supplies of our product candidates could be disrupted if the operations of these suppliers are affected by a man-made or natural disaster or other business interruption. </p>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:2.26%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">If equity research analysts do not publish research or reports, or publish unfavorable research or reports, about us, our business or our market, the price and trading volume of our common stock could decline. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The trading market for our common stock will be influenced by the research and reports that equity research analysts publish about us and our business. As a newly public company, we have only limited research coverage by equity research analysts. Equity research analysts may elect not to initiate or continue to provide research coverage of our common stock, and such lack of research coverage may adversely affect the market price of our common stock. Even if we continue to have equity research analyst coverage, we will not have any control over the analysts or the content and opinions included in their reports. The price of our common stock could decline if one or more equity research analysts downgrade our common stock or issue other unfavorable commentary or </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">72</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">research about us. If one or more equity research analysts ceases coverage of us or fails to publish reports on us regularly, demand for our common stock could decrease, which in turn could cause the trading price or trading volume of our common stock to decline. </font></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="ITEM_1B_UNRESOLVED_STAFF_COMMENTS"></a><a name="ITEM_1B_UNRESOLVED_STAFF_COMMENTS"></a>Item 1B. Unresolved Staff Comments. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Not applicable. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="ITEM_2_PROPERTIES"></a><a name="ITEM_2_PROPERTIES"></a>Item 2. Properties. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our principal executive offices are located in Rockville, Maryland, pursuant to a lease that expires in February 2027. We also lease office and laboratory space in Boston, Massachusetts, pursuant to a lease that expires in May 2026. We believe that our current facilities are adequate to meet our ongoing needs, and that, if we require additional space, we will be able to obtain additional facilities on commercially reasonable terms. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="ITEM_3_LEGAL_PROCEEDINGS"></a><a name="ITEM_3_LEGAL_PROCEEDINGS"></a>Item 3. Legal Proceedings. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are not currently a party to any material legal proceedings. From time to time, we may become involved in other litigation or legal proceedings relating to claims arising from the ordinary course of business. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="ITEM_4_MINE_SAFETY_DISCLOSURES"></a><a name="ITEM_4_MINE_SAFETY_DISCLOSURES"></a>Item 4. Mine Safety Disclosures.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Not applicable.</p><a name="_AEIOULastRenderedPageBreakAEIOU2"></a>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">73</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">PART II</font></p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="ITEM_5_MARKET_FOR_REGISTRANTS_COMMON_EQU"></a><a name="ITEM_5_MARKET_FOR_REGISTRANTS_COMMON_EQU"></a>Item 5. Market for Registrant&#8217;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Dividend Policy</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">We have never declared or paid cash dividends on our capital stock. We currently intend to retain all available funds and future earnings, if any, to fund the development and expansion of our business, and we do not anticipate paying any cash dividends in the foreseeable future. Any future determination regarding the declaration and payment of dividends, if any, will be at the discretion of our board of directors and will depend on then-existing conditions, including our financial condition, operating results, contractual restrictions, capital requirements, business prospects and other factors our board of directors may deem relevant. Our future ability to pay cash dividends on our capital stock may also be limited by the terms of any future debt or preferred securities or future credit facility</font>.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Stockholders</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Hlk67846526"></a>Our common stock is listed on the Nasdaq Global Market under the symbol &#8220;SNSE<a name="_Hlk67846526"></a>&#8221;.&#160;As of&#160;<font style="color:#231F20;">March 25, 2021</font>, we&#160;<font style="color:#231F20;">had 30,588,495</font>&#160;shares of common stock outstanding held by&#160;327&#160;holders of record. The actual number of stockholders is greater than this number of record holders and includes stockholders who are beneficial owners but whose shares are held in street name by brokers and other nominees. This number of holders of record also does not include stockholders whose shares may be held in trust by other entities.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Use of Proceeds from Initial Public Offering of Common Stock</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On February 3, 2021, our Registration Statement on Form S-1, as amended (File No. 333-252704) was declared effective in connection with our initial public offering, or IPO, pursuant to which we sold <font style="Background-color:#FFFFFF;">8,030,295 </font>shares of our common stock, including the partial exercise of the underwriters&#8217; option to purchase additional shares, at a price to the public of $19.00 per share. The initial closing of our initial public offering occurred on February 8, 2021.&#160;We received net proceeds from the initial public offering of $138.5 million (after deducting underwriters&#8217; discounts and commissions and additional offering related costs of $14.1 million). <font style="Background-color:#FFFFFF;">Citigroup, Piper Sandler&#160;&amp; Co. and Berenberg acted as joint book-running managers for the IPO. Oppenheimer&#160;&amp; Co. acted as the lead manager for the IPO</font>.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">No expenses incurred by us in connection with our initial public offering were paid directly or indirectly to (i) any of our officers or directors or their associates, (ii) any persons owning 10% or more of any class of our equity securities, or (iii) any of our affiliates, other than payments in the ordinary course of business to officers for salaries and to non-employee directors as compensation for board or board committee service.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">There has been no material change in the planned use of proceeds from our initial public offering from those disclosed in the final prospectus for our initial public offering dated as of February 3, 2021 and filed with the SEC on February 4, 2021 pursuant to Rule 424(b)(4).</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Recent Sales of Unregistered Securities</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;margin-left:2.57%;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><br />Preferred Stock</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">From December 2020 through the date hereof, we sold an aggregate of 165,956,208 shares of Series BB convertible preferred stock to a total of 43 accredited investors at a purchase price per share of $0.207383 per share for an aggregate gross proceeds of $34.4 million.</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-size:10pt;">&nbsp;</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">From January 2020 through the date hereof, we issued an aggregate of 747,683,172 shares of our Series&#160;AA convertible preferred stock to a total of 128 accredited investors at a price per share of $0.082135 per share. We received aggregate gross proceeds of $26.1 million for the sale of 317,608,273 shares of Series&#160;AA convertible preferred stock. The redemption of convertible notes resulted in the issuance of 219,764,874 shares of Series&#160;AA convertible preferred stock. In exchange for our convertible preferred stock series&#160;A through&#160;F, including cumulative and unpaid dividends, we issued 210,310,025 shares of Series&#160;AA convertible preferred stock as part of the Recapitalization.</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On February 8, 2021, upon the closing of our initial public offering, all shares of our then-outstanding convertible preferred stock were automatically converted into <font style="Background-color:#FFFFFF;">19,034,069&#160;</font>shares of common stock. The issuance of such shares of common stock was exempt from the registration under Section&#160;3(a)(9)&#160;of the Securities Act.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">74</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Warrants to Purchase Common Stock</font></p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">From January&#160;1, 2020 through February 2, 2021, we issued warrants to purchase 2,748,243 shares of common stock to accredited investors, at exercise prices ranging from $0.01 to $3.95 per share. Of these, warrants to purchase an aggregate of 4,094 shares have been cancelled without being exercised and 2,358,918 shares have been issued upon the exercise of warrants, at a weighted average exercise price of $0.01 per share.</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Option and Common Stock Issuances</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">From January&#160;1, 2020 through February 2, 2021, we granted to certain employees, consultants and directors options to purchase an aggregate of 1,972,423 shares of common stock under our 2018 Plan, at exercise prices ranging from $1.23 to $9.22 per share. Of these, options to purchase an aggregate of 13,322 shares have been cancelled without being exercised and 16,666 shares have been issued upon the exercise of stock options, at a weighted average exercise price of $1.23 per share, for aggregate proceeds of approximately $20,400.</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">None of the foregoing transactions involved any underwriters, underwriting discounts or commissions, or any public offering. Unless otherwise specified above, we believe these transactions were exempt from registration under the Securities Act in reliance on Section&#160;4(a)(2) of the Securities Act (and Regulation D or Regulation&#160;S promulgated thereunder) or Rule 701 promulgated under Section&#160;3(b) of the Securities Act as transactions by an issuer not involving any public offering or under benefit plans and contracts relating to compensation as provided under Rule 701. The recipients of the securities in each of these transactions represented their intentions to acquire the securities for investment only and not with a view to or for sale in connection with any distribution thereof, and appropriate legends were placed on the share certificates issued in these transactions. All recipients had adequate access, through their relationships with us, to information about us. The sales of these securities were made without any general solicitation or advertising.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Purchases of Equity Securities by the Issuer and Affiliated Parties</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">None.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="ITEM_6_SELECTED_FINANCIAL_DATA"></a><a name="ITEM_6_SELECTED_FINANCIAL_DATA"></a>Item 6. Selected Financial Data. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Not applicable.&nbsp;&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">75</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="ITEM_7_MANAGEMENTS_DISCUSSION_ANALYSIS_F"></a><a name="ITEM_7_MANAGEMENTS_DISCUSSION_ANALYSIS_F"></a>Item 7. Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">You should read the following discussion and analysis of our financial condition and results of operations together with our consolidated financial statements and the related notes and other financial information included elsewhere in this Form 10-K. Some of the information contained in this discussion and analysis or set forth elsewhere in this Form 10-K, including information with respect to our plans and strategy for our business, includes forward-looking statements that involve risks and uncertainties. You should review the &#8220;Risk Factors&#8221; section of this Form 10-K for a discussion of important factors that could cause actual results to differ materially from the results described in or implied by the forward-looking statements contained in the following discussion and analysis. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Overview </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are a clinical-stage immunotherapy company engaged in the discovery and development of next-generation therapies with an initial focus on treatments for cancer. Our ImmunoPhage platform is a powerful, self-adjuvanted and highly differentiated immunotherapy approach that is designed to utilize bacteriophage to induce a robust, focused and coordinated innate and adaptive immune response. We are engineering our ImmunoPhage product candidates to directly target APCs and modulate the TME through the targeted use of nanobodies to further enhance therapeutic activity. We believe our ImmunoPhage platform has the potential to deliver on the promise of personalized, off-the-shelf product candidates tailored to a patient&#8217;s specific tumor. The versatility of our ImmunoPhage platform allows us to design product candidates in a modular fashion, based on a cocktail of common and patient-specific antigens built from our proprietary library of ImmunoPhages, which we refer to as Phortress. We are currently conducting an ongoing 30-patient Phase 1/2 clinical trial of our lead product candidate, SNS-301, in combination with the PD-1 inhibitor pembrolizumab, as a potential treatment for SCCHN. As of March 9, 2021, we have enrolled 17 patients in the trial. As of December 10, 2020, we have evaluated ten patients for efficacy and ten for safety.<font style="color:#000000;font-size:9.5pt;font-family:Segoe UI;"> </font>We have observed disease control in seven of the patients evaluable for efficacy, including one patient with a PR, and two patients who have achieved longstanding SD for greater than 36 weeks following treatment. Treatment with SNS-301 has generally been well tolerated. We anticipate reporting a large additional subset of data from this trial by the end of 2021. If the results of this trial are positive, subject to feedback from the FDA, we intend to initiate a randomized, registration-enabling trial for SNS-301. We are leveraging the insights from our experience with SNS-301 to expand our development pipeline to include SNS-401 for the treatment of MCC and a human mAb program targeting the novel immune checkpoint VISTA. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Since our inception, we have devoted the majority of our efforts and financial resources to research and development activities related to our ImmunoPhage platform and our lead product candidate SNS-301, including raising capital, protecting our intellectual property portfolio and conducting preclinical studies and clinical trials. We do not have any product candidates approved for sale, have not generated any revenue from product sales, and do not expect to generate any revenue from product sales for at least the next several years. We have largely funded our operations with proceeds from the sale of convertible preferred stock, common stock and convertible debt. Through the date of this report, we have raised an aggregate of $123.4&#160;million of gross proceeds from private placements of our equity and convertible debt securities and net proceeds of $138.5 million from our initial public offering, or IPO, in February 2021. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have incurred significant operating losses over the last several years. Our net loss was $20.1&#160;million and $16.7&#160;million for the years ended December&#160;31, 2020 and 2019, respectively. As of December&#160;31, 2020, we had an accumulated deficit of $112.4&#160;million. We expect to continue to incur significant expenses and operating losses for the foreseeable future. We anticipate that our expenses will increase significantly in connection with our ongoing activities, as we: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:1.13%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">complete our Phase 1/2 clinical trial of SNS-301 and continue clinical development of SNS-301; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:1.13%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">prepare to file INDs and then initiate clinical development of additional product candidates, including SNS-401 and SNS-VISTA; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:1.13%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">continue the research and development of our other product candidates; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:1.13%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">invest in our ImmunoPhage platform; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:1.13%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">seek to discover and develop additional product candidates or acquire or&#160;in-license&#160;drugs, product candidates or technologies; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:1.13%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">seek regulatory approvals for any product candidates that successfully complete clinical trials; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:1.13%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">ultimately establish a sales, marketing and distribution infrastructure and scale up manufacturing capabilities to commercialize any product candidates for which we may obtain regulatory approval; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:1.13%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">manufacture our product candidates or otherwise secure the clinical and commercial supply of our product candidates; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:1.13%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">hire additional research and development and selling, general and administrative personnel; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:1.13%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">maintain, expand and protect our intellectual property portfolio; and </p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">76</a></p>
<hr style="page-break-after:always;width:100%;">
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:1.13%;white-space:nowrap"></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:1.13%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">incur additional costs associated with operating as a public company. </p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash used to fund operating expenses is impacted by the timing of when we pay these expenses, as reflected in the change in our accounts payable and accrued expenses. We expect to continue to incur net losses and negative cash flows for the foreseeable future, and we expect our research and development expenses, general and administrative expenses, and capital expenditures will continue to increase. In particular, we expect our expenses to increase as we continue our development of, and seek regulatory approvals for, our product candidates, as well as hire additional personnel, pay fees to outside consultants, lawyers and accountants, and incur other increased costs associated with being a public company. In addition, if we seek and obtain regulatory approval to commercialize any product candidate, we will also incur increased expenses in connection with commercialization and marketing of any such product. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Recapitalization and Recent Security Issuances </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In January 2020, we entered into an agreement with a third party, who is the holder of the 2019 Bridge Note with a principal balance of $1.0&#160;million, and the holders of a majority of our Series A through F convertible preferred stock, or the Majority Legacy Preferred Stockholders, that provided a new source of capital and restructured our existing capital structure, or the Recapitalization. The third party invested $4 million in exchange for 48,700,311 shares of Series AA convertible preferred stock, or our Series AA Preferred Stock, and a warrant to purchase 634,118 shares of our common stock at an exercise price of $0.01 per share. The warrant was subsequently exercised in January 2020. Additionally, the agreement with the Majority Legacy Preferred Stockholders caused all other holders of our Series A through F convertible preferred stock, or the Minority Legacy Preferred Stockholders, and the Majority Legacy Preferred Stockholders to receive an aggregate of 627,871 shares of our common stock, or the Newly Issued Common Stock, in exchange for their holdings of our Series A through F convertible preferred stock, including cumulative and unpaid dividends, as part of the Recapitalization. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Majority Legacy Preferred Stockholders agreed to invest additional capital in exchange for Series AA Preferred Stock. The Minority Legacy Preferred Stockholders were provided the opportunity to invest additional capital in exchange for Series AA Preferred Stock. All Majority and Minority Legacy Preferred Stockholders who invested additional capital during January 2020 were allowed to convert their Newly Issued Common Stock into Series AA Preferred Stock at a conversion rate based upon their incremental and historical investment. The Majority and Minority Legacy Preferred Stockholders invested $6.6 million in exchange for 79,954,952 shares of Series AA Preferred Stock. The Majority and Minority Legacy Preferred Stockholders also exchanged 148,732 shares of Newly Issued Common Stock for 210,310,025 shares of Series AA Preferred Stock under the Recapitalization agreement. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our issuance of Series AA Preferred Stock triggered the redemption of certain convertible promissory notes, as well as accrued and unpaid interest and repayment premium, as applicable for certain notes, into shares of Series AA Preferred Stock. These debt instruments were redeemed for 188,173,050 shares of the Series AA Preferred Stock, which resulted in a gain on debt extinguishment of $45 thousand. Our remaining convertible promissory note was redeemed in November 2020. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Hlk67846810"></a><a name="_Hlk67846810"></a>On May 7, 2020, we issued warrants to a third party to purchase 389,325 shares of our common stock with an exercise price of $3.95 per common share. As of December 31, 2020, these warrants have not been exercised and have a five-year maturity date. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">From October to November 2020, we issued and sold 85,499,239 shares of Series AA convertible preferred stock at $0.082135 per share in exchange for $7.0 million in gross proceeds. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">From December 2020 through January 2021, we issued and sold 165,956,208 shares of our Series BB convertible preferred stock at a purchase price of $0.207383 per share for aggregate gross proceeds of $34.4&#160;million. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In February 2021, we issued and sold an aggregate of 8,030,295 shares of our common stock at a price to the public of $19.00 per share for aggregate gross proceeds of $152.6 million in our initial public offering.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Impact of COVID-19 </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In March 2020, COVID-19 was declared a global pandemic by the World Health Organization and to date, the COVID-19 pandemic continues to present a substantial public health and economic challenge around the world. The length of time and full extent to which the COVID-19 pandemic will directly or indirectly impact our business, results of operations and financial condition will depend on future developments that are highly uncertain, subject to change and are difficult to predict. While we continue to conduct our research and development activities, the COVID-19 pandemic may cause disruptions that impact the timing of our ongoing and planned clinical trials of SNS-301 and affect our ability to complete preclinical studies, future clinical trials or to procure items that are essential for our research and development activities. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">77</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, a recurrence or &#8220;second wave&#8221; of COVID-19 cases could cause other widespread or more severe impacts depending on where infection rates are highest. We plan to continue to closely monitor the ongoing impact of the COVID-19 pandemic on our employees and our business operations, as we deal with the disruptions and uncertainties relating to the COVID-19 pandemic. </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In an effort to</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> provide a safe work environment for our employees, we have, among other things, implemented various social distancing measures in our office and labs including replacing in-person meetings with virtual interactions, and are working remotely when possible. We expect to continue to take actions as may be required or recommended by government authorities or as we determine are in the best interests of our employees and other business partners </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">in light of</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> the pandemic. To date, there has not been a significant impact on the development of&#160;SNS-301 or the rest of our pipeline; however we cannot at this time predict the specific extent, duration, or full impact that the COVID-19 pandemic could potentially have on our ongoing business plan, financial condition and operations. </font></p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Components of Our Results of Operations </p>
<p style="margin-bottom:0pt;margin-top:6pt;margin-left:2.26%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Operating Expenses </p>
<p style="margin-bottom:0pt;margin-top:6pt;margin-left:2.26%;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Research and Development Expense </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our research and development expense consists of expenses incurred in connection with the discovery and development of our product candidates. These expenses include: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:1.13%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">expenses incurred under agreements with CROs, as well as investigative sites and consultants that conduct our clinical trials and preclinical studies;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:1.13%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">the cost of manufacturing our product candidates including the potential cost of CMOs that manufacture product for use in our preclinical studies and clinical trials and perform analytical testing, scale-up and other services in connection with our development activities; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:1.13%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">the cost of outsourced professional scientific development services;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:1.13%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">employee-related expenses, including salaries, benefits and stock-based compensation for employees engaged in the research and development function; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:1.13%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">expenses relating to regulatory activities, including filing fees paid to regulatory agencies;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:1.13%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">fees for maintaining licenses and other amounts due under our third party licensing agreements; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:1.13%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">laboratory materials and supplies used to support our research activities; and </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:1.13%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">allocated expenses for utilities and other facility-related costs. </p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We expense all research and development costs in the periods in which they are incurred. Costs for certain research and development activities are recognized based on an evaluation of the progress to completion of specific tasks using information and data provided to us by our vendors and third-party service providers. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We do not track our research and development expenses by program. Our direct external research and development expenses consist primarily of external costs, such as fees paid to CROs, CMOs, research/testing laboratories and outside consultants in connection with our preclinical development, process development, manufacturing and clinical development activities. We do not allocate these costs to specific product candidates because many of them are deployed across several of our development programs and, as such, are not separately classified. We use internal resources primarily to conduct research and manage our preclinical development, outsourced clinical trials, process development, manufacturing and clinical development activities. These employees work across multiple development programs and, therefore, we do not track their costs by program and, as such, are not separately classified. Research and development activities are central to our business model. Product candidates in later stages of clinical development generally have higher development costs than those in earlier stages of clinical development, primarily due to the increased size and duration of later-stage clinical trials. We expect our research and development expenses to increase significantly over the next several years as we increase personnel costs, including stock-based compensation, conduct our registration-enabling clinical trial of SNS-301 in patients with SCCHN, conduct other clinical trials and prepare regulatory filings for our product candidates. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The successful development of our product candidates is highly uncertain. At this time, we cannot reasonably estimate or know the nature, timing and costs of the efforts that will be necessary to complete the remainder of the development of, or when, if ever, material net cash inflows may commence from any of our other product candidates. This uncertainty is due to the numerous risks and uncertainties associated with the duration and cost of clinical trials, which vary significantly over the life of a project as a result of many factors, including: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:1.13%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">the scope, progress, outcome and costs of our preclinical studies and clinical trials of SNS-301, our other product candidates and any other product candidates we may acquire or develop; </p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">78</a></p>
<hr style="page-break-after:always;width:100%;">
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:1.13%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">manufacturing of our product candidates or </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">making arrangements</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> with potential third-party manufacturers for both clinical and commercial supplies of these product candidates; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:1.13%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">successful patient enrollment in, and the initiation, duration and completion of clinical trials; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:1.13%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">the cost of gaining regulatory approvals for our product candidates, subject to the successful outcome of ongoing and future clinical trials; and </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:1.13%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">the extent of any required post-marketing approval commitments to applicable regulatory authorities. </p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our expenditures are subject to additional uncertainties, including the terms and timing of regulatory approvals, and the expense of filing, prosecuting, defending and enforcing any patent claims or other intellectual property rights. We may never succeed in achieving regulatory approval for any of our product candidates. We may obtain unexpected results from our clinical trials. We may elect to discontinue, delay or modify clinical trials of some product candidates or focus on others. A change in the outcome of any of these variables with respect to the development of a product candidate could mean a significant change in the costs and timing associated with the development of that product candidate. For example, if the FDA or other regulatory authorities were to require us to conduct clinical trials beyond those that we currently anticipate, or if we experience significant delays in enrollment in any of our clinical trials, we could be required to expend significant additional financial resources and time on the completion of clinical development. Product commercialization will take several years and significant additional development costs. </p>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:2.26%;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">General and Administrative Expense </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">General and administrative expenses consist principally of salaries and related costs for personnel in executive, administrative, finance and legal functions, including stock-based compensation, travel expenses and recruiting expenses. Other general and administrative expenses include facility related costs, patent filing and prosecution costs and professional fees for legal, auditing and tax services, and insurance costs. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We anticipate that our general and administrative expenses will increase as a result of increased payroll, expanded infrastructure and higher consulting, legal and tax-related services associated with maintaining compliance with Nasdaq listing and SEC requirements, accounting and investor relations costs, and director and officer insurance premiums associated with being a public company. </p>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:2.26%;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Alvaxa IPR&amp;D </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On May 18, 2020, we acquired Alvaxa Biosciences, or Alvaxa, in a cash and stock purchase pursuant to a Stock Purchase Agreement. Under the terms of the Stock Purchase Agreement, we acquired Alvaxa&#8217;s existing camelid nanobodies and other biomaterials, or the Biomaterials, expertise in nanobody discovery, as well as a license agreement with a research organization. The former majority shareholder of Alvaxa is our current Chief Scientific Officer. Under the Stock Purchase Agreement, we paid $197 thousand to settle liabilities assumed from Alvaxa and issued 304,376 shares of our common stock to the shareholders of Alvaxa. We have evaluated the acquisition under ASC 805, <font style="font-style:italic;">Business Combinations </font>and determined this to be an asset acquisition. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The 304,376 shares of common stock was valued at $1.78 per share, or $541 thousand in total, based on a valuation determined with the assistance of a third party. We determined that substantially all the value acquired in the transaction related to the Biomaterials and represents in-process research and development, or IPR&amp;D. The liabilities of $197 thousand assumed were related to previously incurred employee costs as well as contractually required vendor payments. The consideration transferred in this transaction was recorded as an expense in the IPR&amp;D line item within our Statement of Operations during the year ended December 31, 2020. </p>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:2.26%;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Other Expense </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our other expense consists of changes in the fair value of our derivative liability related to an embedded derivative on certain 2019 promissory notes, gain/loss on debt extinguishments and interest expense on our outstanding convertible debt. </p>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:2.26%;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Income Taxes </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Since our inception, we have not recorded any income tax benefits for the net losses we have incurred or for the research and development tax credits earned in each year, as we believe, based upon the weight of available evidence, that it is more likely than not that all of our net operating loss carryforwards and tax credit carryforwards will not be realized. </p>
<p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">79</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Results of Operations </p>
<p style="margin-bottom:0pt;margin-top:6pt;margin-left:2.26%;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Comparison of Years Ended December&#160;31, 2020 and 2019 </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following sets forth our results of operations for the years ended December&#160;31, 2020 and 2019: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.68%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Hlk67671466"></a>&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.32%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:25.86%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December 31,</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.76%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.68%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Hlk67417315"></a>(in thousands)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.32%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.32%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Change</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.68%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating expenses:</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11,185</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,350</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,835</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">General and administrative</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,528</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,085</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,443</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Alvaxa IPR&amp;D</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">738</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">738</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total operating expenses</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">19,451</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12,435</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,016</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Loss from operations</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(19,451</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(12,435</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(7,016</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.68%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total other expense</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.32%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(649</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.32%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(4,305</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.32%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,656</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.68%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.32%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(20,100</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.32%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(16,740</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.32%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(3,360</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:6pt;margin-left:2.26%;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Research and Development Expenses </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development expenses were $11.2&#160;million for the year ended December&#160;31, 2020, compared to $8.4&#160;million for the year ended December&#160;31, 2019. The increase of $2.8 million was primarily attributable to <font style="Background-color:#FFFFFF;color:#000000;">investments being made in early research and development activities and the clinical and preclinical development of&#160;SNS-301, SNS-401 and SNS-VISTA.</font> </p>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:2.26%;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">General and Administrative Expenses </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">General and administrative expenses were $7.5&#160;million for the year ended December&#160;31, 2020, compared to $4.1&#160;million for the year ended December&#160;31, 2019. The increase of $3.4&#160;million was primarily attributable to consulting fees for strategic and development-related advice, stock-based compensation expense resulting from new stock award grants during 2020, and additional recruiting fees incurred for the hiring of additional team resources. </p>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:2.26%;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"><a name="_Hlk67846999"></a>Other Expense </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other expense was $0.6&#160;million for the year ended December&#160;31, 2020, compared to $4.3&#160;million for the year ended December&#160;31, 2019. The decrease of $3.7&#160;million was  primarily attributable to fair value adjustments of embedded derivative liabilities associated with certain 2019 promissory notes, as well as lower interest expense on debt due to the redemption of notes in 2020. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:6pt;margin-left:2.26%;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Comparison of Years Ended December&#160;31, 2019 and 2018 </p>
<p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following sets forth our results of operations for the years ended December&#160;31, 2019 and 2018:</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="width:71%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:auto; border-bottom:solid 1pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:auto; border-bottom:solid 1pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td colspan="6" valign="bottom"  BGCOLOR="#FFFFFF" style="width:auto; border-bottom:solid 1pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year&#160;Ended&#160;December&#160;31,</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:auto; border-bottom:solid 1pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:auto; border-bottom:solid 1pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="width:auto; border-bottom:solid 1pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:auto; border-bottom:solid 1pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:auto; border-bottom:solid 1pt transparent;white-space:nowrap;">
<p style="border-bottom:Solid 1pt #000000;padding-bottom:0pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:auto; border-bottom:solid 1pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="width:auto; border-bottom:solid 1pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2019&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:auto; border-bottom:solid 1pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:auto; border-bottom:solid 1pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="width:auto; border-bottom:solid 1pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2018&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:auto; border-bottom:solid 1pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:auto; border-bottom:solid 1pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="width:auto; border-bottom:solid 1pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Change</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:auto; border-bottom:solid 1pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CCEEFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating expenses:</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:36pt;;text-indent:-12pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,350</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:auto;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,227</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:auto;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">123</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:auto;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CCEEFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:36pt;;text-indent:-12pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">General and administrative</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:auto;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,085</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:auto;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:auto;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,513</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:auto;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:auto;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(428</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:auto;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)&#160;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total operating expenses</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12,435</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:auto;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12,740</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:auto;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(305</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:auto;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)&#160;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CCEEFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Loss from operations</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:auto;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(12,435</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:auto;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)&#160;</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:auto;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(12,740</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:auto;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)&#160;</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:auto;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">305</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:auto;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total other expense</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(4,305</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:auto;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)&#160;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(299</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:auto;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)&#160;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(4,006</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:auto;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)&#160;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="border-top:Solid 0.75pt #000000;padding-top:0pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="border-top:Solid 0.75pt #000000;padding-top:0pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="border-top:Solid 0.75pt #000000;padding-top:0pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="border-top:Solid 0.75pt #000000;padding-top:0pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="border-top:Solid 0.75pt #000000;padding-top:0pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="border-top:Solid 0.75pt #000000;padding-top:0pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CCEEFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:auto;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(16,740</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:auto;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)&#160;</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:auto;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(13,039</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:auto;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)&#160;</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:auto;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(3,701</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:auto;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)&#160;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="border-top:Double 2.25pt #000000;padding-top:0pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="border-top:Double 2.25pt #000000;padding-top:0pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="border-top:Double 2.25pt #000000;padding-top:0pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="border-top:Double 2.25pt #000000;padding-top:0pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="border-top:Double 2.25pt #000000;padding-top:0pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="border-top:Double 2.25pt #000000;padding-top:0pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="Background-color:#FFFFFF;margin-top:18pt;margin-bottom:0pt;margin-left:2.57%;text-indent:0%;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Research and Development Expenses</p>
<p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development expenses were $8.4&#160;million for the year ended December&#160;31, 2019, compared to $8.2&#160;million for the year ended December&#160;31, 2018. Costs remained relatively flat between the two years, with investments being made in early research and development activities and the clinical and preclinical development of&#160;SNS-301,&#160;SNS-401&#160;and&#160;SNS-VISTA.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">80</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="Background-color:#FFFFFF;margin-top:18pt;margin-bottom:0pt;margin-left:2.54%;text-indent:0%;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"><font style="font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">General and Administrative Expenses</font></p>
<p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">General and administrative expenses were $4.1&#160;million for the year ended December&#160;31, 2019, compared to $4.5&#160;million for the year ended December&#160;31, 2018. The decrease of $0.4&#160;million was primarily attributable to decreased spend associated with external corporate legal costs, partially offset by an increase headcount-related costs in the same period.</p>
<p style="Background-color:#FFFFFF;margin-top:18pt;margin-bottom:0pt;margin-left:2.57%;text-indent:0%;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Other Expense</p>
<p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other expense was $4.3&#160;million for the year ended December&#160;31, 2019, compared to $0.3&#160;million for the year ended December&#160;31, 2018. The increase of $4.0&#160;million was primarily attributable to a $2.0 fair value adjustments of embedded debt derivative liability associated with certain 2019 promissory notes, and an increase of $2.0&#160;million in interest expense on outstanding convertible promissory notes.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Liquidity and Capital Resources </p>
<p style="margin-bottom:0pt;margin-top:6pt;margin-left:2.26%;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Sources of Liquidity </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have not generated any product revenue and have incurred net losses and negative cash flows from our operations. We have financed our operations through sales of our common stock, convertible preferred stock and convertible debt. Through the date of this report, we have raised an aggregate of $123.4&#160;million of gross proceeds from private placements of our equity and convertible debt securities and net proceeds of $138.5 million from our initial public offering, or IPO, in February 2021. Our net loss was $20.1&#160;million and $16.7&#160;million for the years ended December&#160;31, 2020 and 2019, respectively. As of December&#160;31, 2020, we had an accumulated deficit of $112.4&#160;million. Our primary use of cash is to fund operating expenses, which consist primarily of research and development expenditures, and to a lesser extent, general and administrative expenditures. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December&#160;31, 2020, we had cash and cash equivalents of $16.6&#160;million. From December&#160;2020 to January&#160;2021, we issued and sold 165,956,208 shares of Series&#160;BB convertible preferred stock to a group of investors, in exchange for $34.4&#160;million of new gross proceeds, of which approximately $10.9 million was received in December 2020. <font style="color:#000000;">In February 2021, we issued an aggregate of </font>8,030,295 <font style="color:#000000;">shares of common stock in our initial public offering at a price to the public of $19.00 per share, for aggregate gross proceeds of $152.6 million.&#160; We paid underwriting discounts and commissions of $10.7 million, and we also incurred expenses of $3.4 million in connection with the offering.&#160; As a result, the net offering proceeds to us, after deducting underwriting discounts and commissions and offering expenses, were $138.5 million.&#160;</font></p>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:2.26%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Cash Flows </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table summarizes our sources and uses of cash for each of the periods below: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Hlk67417316"></a>&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December 31,</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net cash used in operating activities</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(17,705</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(8,571</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net cash used in investing activities</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,403</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(53</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net cash provided by financing activities</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">35,453</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,222</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net increase (decrease) in cash and cash equivalents</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16,345</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(402</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:6pt;margin-left:2.26%;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"><a name="_Hlk67677132"></a>Operating Activities </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During the year ended December 31, 2020, our operating activities used $ 17.7 million of cash, primarily resulting from our net loss. During the year ended December 31, 2019, operating activities used $8.6 million of cash, primarily resulting from our net loss. The increase in net cash used in operating activities for the year ended December 31, 2020 as compared to the year ended December 31, 2019 is attributed to the increase in net loss.  </p>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:2.26%;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Investing Activities </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During the year ended December 31, 2020, net cash used in investing activities was $1.4 million from the purchase of Alvaxa and purchases of property and equipment. During the year ended December 31, 2019, net cash used in investing activities was related to purchases of property and equipment.<font style="font-style:italic;"> </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">81</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:2.26%;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"><font style="font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Financing Activities </font></p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During the year ended December 31, 2020, net cash provided by financing activities was $35.5&#160;million, primarily from the issuance of our Series AA and Series BB convertible preferred stock, as well as $0.6 million received in unsecured loan funding from the Paycheck Protection Program, offset by approximately $2.1 million of IPO costs. During the year ended December 31, 2019, net cash provided by financing activities was $8.2 million from the issuance of convertible promissory notes, as well as cash proceeds from the exercise of common stock warrants. </p>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:2.26%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Funding Requirements </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We expect our expenses to increase in connection with our ongoing activities, particularly as we continue the research and development of, continue or initiate clinical trials of, and potentially seek marketing approval for, our product candidates. In addition, we expect to incur significant costs associated with operating as a newly public company, including significant legal, accounting, investor relations and other expenses that we did not incur as a private company. The timing and amount of our operating expenditures will depend largely on: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:1.13%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">the initiation, progress, timing, costs and results of current and future preclinical studies and clinical trials for SNS-301, SNS-401 and SNS-VISTA and our other product candidates; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:1.13%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">the cost and timing of the manufacture of additional clinical trial material as well as any costs related to the scale-up of manufacturing activities; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:1.13%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">the costs to seek regulatory approvals for any product candidates that successfully complete clinical trials; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:1.13%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">the extent to which we or any third-party service providers on whom we rely experience delays or interruptions to preclinical studies and clinical trials, or to our supply chain due to the COVID-19 pandemic; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:1.13%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">the need to hire additional clinical, quality assurance, quality control and other scientific personnel; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:1.13%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">the number and characteristics of product candidates that we develop or may in-license; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:1.13%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">the outcome, timing and cost of meeting and maintaining compliance with regulatory requirements; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:1.13%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">the cost of filing, prosecuting, defending and enforcing our patent claims and other intellectual property rights; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:1.13%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">the terms of any collaboration agreements we may choose to enter into, including the achievement of milestones or occurrence of other developments that trigger payments under any license or collaboration agreements we might have at such time; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:1.13%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">the cost associated with the expansion of our operational, financial and management systems and increased personnel, including personnel to support our operations as a public company; and </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:1.13%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">the cost of establishing sales, marketing and distribution capabilities for any product candidates for which we may receive regulatory approval in regions where we choose to commercialize our products, if approved, on our own. </p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We expect our existing cash and cash equivalents will enable us to fund our operating expenses and capital expenditure requirements at least into the second half of 2023. We have based this estimate on assumptions that may prove to be wrong, and we may use our available capital resources sooner than we currently expect. Our future capital requirements will depend on many factors, including: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:1.13%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">the scope, progress, results and costs of product discovery, preclinical studies and clinical trials; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:1.13%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">the scope, prioritization and number of our research and development programs; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:1.13%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">the costs, timing and outcome of regulatory review of our product candidates; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:1.13%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">our ability to establish and maintain collaborations on favorable terms, if at all; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:1.13%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">the extent to which we are obligated to reimburse, or entitled to reimbursement of, clinical trial costs under collaboration agreements, if any; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:1.13%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">the costs of preparing, filing and prosecuting patent applications, maintaining and enforcing our intellectual property rights and defending intellectual property-related claims; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:1.13%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">the extent to which we acquire or in-license other product candidates and technologies; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:1.13%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">the costs of securing manufacturing arrangements for commercial production; </p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">82</a></p>
<hr style="page-break-after:always;width:100%;">
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:1.13%;white-space:nowrap"></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:1.13%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">the costs of establishing or contracting for sales and marketing capabilities if we obtain regulatory approvals to market our product candidates; and </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:1.13%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">the impact of the COVID-19 pandemic and the corresponding responses of businesses and governments. </p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Until such time, if ever, as we can generate substantial product revenue, we expect to finance our operations through a combination of equity offerings, debt financings, collaborations, strategic alliances and marketing, distribution or licensing arrangements. We do not currently have any committed external source of funds. To the extent that we raise additional capital through the sale of equity or convertible debt securities, your ownership interest may be materially diluted, and the terms of such securities could include liquidation or other preferences that adversely affect your rights as a common stockholder. Debt financing and preferred equity financing, if available, may involve agreements that include restrictive covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends. In addition, debt financing would result in fixed payment obligations. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If we raise additional funds through collaborations, strategic alliances or marketing, distribution or licensing arrangements with third parties, we may have to relinquish valuable rights to our future revenue streams, research programs or product candidates or grant licenses on terms that may not be favorable to us. If we are unable to raise additional funds through equity or debt financings or other arrangements when needed, we may be required to delay, limit, reduce or terminate our research, product development or future commercialization efforts or grant rights to develop and market product candidates that we would otherwise prefer to develop and market ourselves. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Internal Control Over Financial Reporting </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During the audit of our financial statements for the year ended December&#160;31, 2020, material weaknesses were identified in our internal control over financial reporting. Under standards established by the PCAOB, a &#8220;material weakness&#8221; is a deficiency, or combination of deficiencies in internal control over financial reporting, such that there is a reasonable possibility that a material misstatement of the annual or interim financial statements will not be prevented or detected on a timely basis. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are in the process of implementing a number of measures to address the material weaknesses and deficiencies that have been identified including: (i)&#160;hiring additional accounting and financial reporting personnel with generally accepted accounting principles in the United States, or US GAAP, and SEC reporting experience, (ii)&#160;developing, communicating and implementing an accounting policy manual for our accounting and financial reporting personnel for recurring transactions and period-end closing processes, and (iii)&#160;establishing effective monitoring and oversight controls for non-recurring and complex transactions to ensure the accuracy and completeness of our company&#8217;s consolidated financial statements and related disclosures. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">These additional resources and procedures are designed to enable us to broaden the scope and quality of our internal review of underlying information related to financial reporting and to formalize and enhance our internal control procedures. With the oversight of senior management and our audit committee, we have begun taking steps and plan to take additional measures to remediate the underlying causes of the material weaknesses. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We intend to complete the implementation of our remediation plan during fiscal year 2021. Although we believe that our remediation plan will improve our internal control over financial reporting, additional time may be required to fully implement it and to make conclusions regarding the effectiveness of our internal control over financial reporting. Our management will closely monitor and modify, as appropriate, the remediation plan to eliminate the identified material weakness. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If our remediation of the material weaknesses is not effective, or if we experience additional material weaknesses or otherwise fail to maintain an effective system of internal control over financial reporting in the future, we may not be able to accurately or timely report our financial condition or results of operations. Accordingly, there could continue to be a reasonable possibility that a material misstatement of our financial statements would not be prevented or detected on a timely basis. We cannot assure you that the measures we have taken to date, or any measures we may take in the future, will be sufficient to remediate the material weaknesses we have identified or avoid potential future material weaknesses. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We, and our independent registered public accounting firm, were not required to report on our evaluation of the Company&#8217;s internal control over financial reporting as of December&#160;31, 2020 in accordance with the provisions of the Sarbanes-Oxley Act. Accordingly, we cannot assure you that we have identified all, or that we will not in the future have additional, material weaknesses. Material weaknesses may still exist when we report on the effectiveness of our internal control over financial reporting as required by reporting requirements under Section&#160;404 of the Sarbanes-Oxley Act. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">83</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Off-Balance Sheet Arrangements </font></p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We did not have during the periods presented, and we do not currently have, any off-balance sheet arrangements, as defined in the rules and regulations of the U.S. Securities and Exchange Commission. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Critical Accounting Policies and Significant Judgements and Estimates </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">This Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations is based on our financial statements, which are prepared in accordance with US GAAP. The preparation of our financial statements requires us to make estimates, assumptions and judgments that affect the reported amounts of assets, liabilities, costs and expenses. We base our estimates and assumptions on historical experience and other factors that we believe to be reasonable under the circumstances. We evaluate our estimates and assumptions on an ongoing basis. Our actual results may differ from these estimates. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We define our critical accounting policies as those accounting principles that require us to make subjective estimates and judgments about matters that are uncertain and are likely to have a material impact on our financial condition and results of operations, as well as the specific manner in which we apply those principles. While our significant accounting policies are more fully described in note 2 to our annual financial statements beginning on page&#160;F-1 of this Form 10-K, we believe the following are the critical accounting policies used in the preparation of our financial statements that require significant estimates and judgments. </p>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:2.26%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Accrued Research and Development Expenses </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We incur substantial expenses associated with clinical trials. Accounting for clinical trials relating to activities performed by CROs and other external vendors requires management to exercise significant estimates in regard to the timing and accounting for these expenses. We estimate costs of research and development activities conducted by service providers, which include, the conduct of sponsored research, preclinical studies and contract manufacturing activities. The diverse nature of services being provided under CRO and other arrangements, the different compensation arrangements that exist for each type of service and the lack of timely information related to certain clinical activities complicates the estimation of accruals for services rendered by CROs and other vendors in connection with clinical trials. We record the estimated costs of research and development activities based upon the estimated amount of services provided but not yet invoiced and include these costs in the accrued and other current liabilities or prepaid expenses on the balance sheets and within research and development expense on the consolidated statements of operations. We determine the estimated costs through discussions with the internal personnel and external service providers as to the progress, or stage of completion of the services and the agreed-upon fees to be paid for such services. This process involves a thorough review of open contracts and evaluation by internal personnel to identify services received that have been performed for us and estimating the associated cost incurred for these services for which we have not yet been invoiced or otherwise notified of the actual cost. In estimating the duration of a clinical study, we evaluate the start-up, treatment and wrap-up periods, compensation arrangements and services rendered attributable to each clinical trial and fluctuations are regularly tested against payment plans and trial completion assumptions. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our expenses related to clinical trials are based on estimates of patient enrollment and related expenses at clinical investigator sites as well as estimates for the services received and efforts expended pursuant to contracts with multiple research institutions and CROs that may be used to conduct and manage clinical trials on our behalf. We determine the estimated costs through discussions with internal personnel and external service providers as to the progress, or stage of completion of the services and the agreed-upon fees to be paid for such services. We generally accrue expenses related to clinical trials based on contracted amounts applied to the level of patient enrollment and activity. If timelines or contracts are modified based upon changes in the clinical trial protocol or scope of work to be performed, we modify our estimates of accrued expenses accordingly on a prospective basis. </p>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:2.26%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Stock-Based Compensation </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We measure all stock-based awards granted based on their estimated fair value on the date of the grant and recognize the corresponding compensation expense for those awarded to employees and directors over the requisite service period, which is generally the vesting period of the respective award, and for those awarded to nonemployees over the period during which services are rendered by nonemployees until completed. We have typically issued stock options and warrants with service-based vesting conditions and we record the expense for these awards using the straight-line method. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We estimate the fair value of each stock option grant using the Black-Scholes option-pricing model, which uses as inputs the fair value of our common stock and assumptions we make for the volatility of our common stock, the expected term of our stock options and warrants, the risk-free interest rate for a period that approximates the expected term of our stock options and warrants and our expected dividend yield. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">84</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Recent Accounting Pronouncements </font></p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">See note 2 in our annual financial statements included elsewhere in this Form 10-K for a description of recent accounting pronouncements applicable to our financial statements. Other than as disclosed in our financial statements, we do not expect that any recently issued accounting standards will have a material impact on our financial statements or will otherwise apply to our operations. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Emerging Growth Company and Smaller Reporting Company Status </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We qualify as an EGC, as defined in the JOBS Act. As an EGC, we may take advantage of specified reduced disclosure and other requirements that are otherwise applicable generally to public companies, including reduced disclosure about our executive compensation arrangements, exemption from the requirements to hold non-binding advisory votes on executive compensation and golden parachute payments and exemption from the auditor attestation requirement in the assessment of our internal control over financial reporting. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We may take advantage of these exemptions until the last day of the fiscal year following the fifth anniversary of our initial public offering or such earlier time that we are no longer an emerging growth company. We would cease to be an EGC earlier if we have more than $1.07&#160;billion in annual revenue, we have more than $700.0&#160;million in market value of our stock held by non-affiliates (and we have been a public company for at least 12 months and have filed one annual report on Form 10-K) or we issue more than $1.0&#160;billion of non-convertible debt securities over a three-year period. For so long as we remain an EGC, we are permitted, and intend, to rely on exemptions from certain disclosure requirements that are applicable to other public companies that are not EGCs. We may choose to take advantage of some, but not all, of the available exemptions. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, the JOBS Act provides that an EGC can take advantage of an extended transition period for complying with new or revised accounting standards. This allows an EGC to delay the adoption of certain accounting standards until those standards would otherwise apply to private companies. We have elected not to &#8220;opt out&#8221; of such extended transition period, which means that when a standard is issued or revised and it has different application dates for public or private companies, we will adopt the new or revised standard at the time private companies adopt the new or revised standard and will do so until such time that we either (i)&#160;irrevocably elect to &#8220;opt out&#8221; of such extended transition period or (ii)&#160;no longer qualify as an EGC. Therefore, the reported results of operations contained in our consolidated financial statements may not be directly comparable to those of other public companies. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are also a &#8220;smaller reporting company,&#8221; meaning that the market value of our stock held by non-affiliates is less than $700&#160;million and our annual revenue was less than $100&#160;million during the most recently completed fiscal year. We may continue to be a smaller reporting company if either (i)&#160;the market value of our stock held by non-affiliates is less than $250&#160;million or (ii)&#160;our annual revenue is less than $100&#160;million during the most recently completed fiscal year and the market value of our stock held by non-affiliates is less than $700&#160;million. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If we are a smaller reporting company at the time we cease to be an EGC, we may continue to rely on exemptions from certain disclosure requirements that are available to smaller reporting companies. Specifically, as a smaller reporting company we may choose to present only the two most recent fiscal years of audited financial statements in our Annual Report on Form 10-K and, similar to EGCs, smaller reporting companies have reduced disclosure obligations regarding executive compensation. <font style="font-size:1pt;">&#160;</font></p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="ITEM_7A_QUANTITATIVE_QUALITATIVE_DISCLOS"></a><a name="ITEM_7A_QUANTITATIVE_QUALITATIVE_DISCLOS"></a>Item 7A. Quantitative and Qualitative Disclosures About Market Risk. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are a smaller reporting company as defined by Item 10 of Regulation S-K and are not required to provide the information otherwise required under this item. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="ITEM_8_FINANCIAL_STATEMENTS_SUPPLEMENTAR"></a><a name="ITEM_8_FINANCIAL_STATEMENTS_SUPPLEMENTAR"></a>Item 8. Financial Statements and Supplementary Data. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The financial statements required to be filed pursuant to this Item&#160;8 are appended to this Annual Report on Form 10-K. An index of those financial statements is found in Item&#160;15,&#160;Exhibits and Financial Statement Schedules, of this Annual Report on Form 10-K.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="ITEM_9_CHANGES_IN_DISAGREEMENTS_WITH_ACC"></a><a name="ITEM_9_CHANGES_IN_DISAGREEMENTS_WITH_ACC"></a>Item 9. Changes in and Disagreements With Accountants on Accounting and Financial Disclosure.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">None. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">85</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="ITEM_9A_CONTROLS_PROCEDURES"></a><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="ITEM_9A_CONTROLS_PROCEDURES"></a>Item 9A. Controls</font><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> and Procedures.</font></p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU103"></a>Disclosure Controls and Procedures</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The term &#8220;disclosure controls and procedures,&#8221; as defined in Rules&#160;13a-15(e)&#160;and 15d-15(e)&#160;under the Securities Exchange Act of 1934, as amended, or the Exchange Act, refers to controls and procedures that are designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the SEC&#8217;s rules&#160;and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that such information is accumulated and communicated to a company&#8217;s management, including its principal executive and principal financial officers, as appropriate to allow timely decisions regarding required disclosure.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In designing and evaluating our disclosure controls and procedures, management recognizes that disclosure controls and procedures, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the disclosure controls and procedures are met. Additionally, in designing disclosure controls and procedures, our management necessarily was required to apply its judgment in evaluating the cost-benefit relationship of possible disclosure controls and procedures. The design of any system of controls also is based in part upon certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions; over time, controls may become inadequate because of changes in conditions, or the degree of compliance with policies or procedures may deteriorate. Because of the inherent limitations in a control system, misstatements due to error or fraud may occur and not be detected.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our management, with the participation of our Chief Executive Officer and Senior Vice President of Finance and Administration, has evaluated the effectiveness of our disclosure controls and procedures as of December&#160;31, 2020. <font style="Background-color:#FFFFFF;">Based on this evaluation, and due to the material weaknesses described elsewhere in Item 7. Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations, the Chief Executive Officer and </font>Senior Vice President of Finance<font style="Background-color:#FFFFFF;"> and Administration concluded that, as of December&#160;31, 2020, our disclosure controls and procedures were not effective.</font></p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Changes in Internal Control over Financial Reporting:</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">There were no&#160;changes&#160;in our internal control over financial reporting (as defined in Rules&#160;13a-15(f)&#160;and 15d-15(f)&#160;under the Exchange Act) that occurred during the quarter ended December&#160;31, 2020 which have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Management&#8217;s Report on Internal Control over Financial Reporting and Attestation Report of the Registered Public Accounting Firm</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">This Annual Report does not include a report of management&#8217;s assessment regarding internal control over financial reporting or an attestation report of our independent registered public accounting firm due to a transition period established by the rules&#160;of the SEC for newly public companies.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="ITEM_9B_OR_INFORMATION"></a><a name="ITEM_9B_OR_INFORMATION"></a>Item 9B. Other Information. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Not applicable. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">86</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">PART III </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="ITEM_10_DIRECTORS_EXECUTIVE_FICERS_CORPO"></a><a name="ITEM_10_DIRECTORS_EXECUTIVE_FICERS_CORPO"></a>Item 10. Directors, Executive Officers and Corporate Governance. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Executive Officers and Directors </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table sets forth information for our executive officers and directors as of December&#160;31, 2020: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45.72%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Name</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.52%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Age</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45.72%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Position</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45.72%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Executive Officers</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.52%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45.72%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">John Celebi</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.52%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">49</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">President, Chief Executive Officer and Director</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Anupama Hoey</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.52%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">50</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Chief Business Officer</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Marie-Louise Fjaellskog, M.D., Ph.D.</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.52%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">56</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Chief Medical Officer</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Robert Pierce, M.D.</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.52%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">56</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Chief Scientific Officer</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Erin Colgan</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.52%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">40</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Senior Vice President of Finance and Administration</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Non-Employee Directors</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Bob Holmen(1)(2)</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.52%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">57</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Director</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">James Peyer, Ph.D.(1)(3)</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.52%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">34</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Director</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Samuel Broder, M.D.(3)</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.52%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">75</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Director</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Thomas Ricks(1)(2)</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.52%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">67</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Director</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deneen Vojta, M.D.(3)</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.52%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">56</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Director</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;border-bottom:Solid 0.75pt;padding-bottom:1pt;margin-top:0pt;margin-right:66.67%;text-indent:0%;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:2pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1)</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:2pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Member of the Audit Committee </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2)</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Member of the Compensation Committee </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(3)</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Member of the Nominating and Governance Committee </p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Executive Officers </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">John Celebi<font style="font-style:italic;font-weight:normal;"> </font><font style="font-weight:normal;">has served as our President and Chief Executive Officer and a member of our board of directors since February 2018. Prior to joining us, from June 2016 until February 2018, Mr.&#160;Celebi served as Chief Operating Officer of X4 Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company. Prior to X4 Pharmaceuticals, from 2011 until June 2016, he served as Chief Business Officer at Igenica Biotherapeutics, Inc., an immunotherapy company. Prior to joining Igencia Biotherapeutics, Mr.&#160;Celebi served in various roles at ArQule, Inc., a biotechnology and pharmaceutical company from 2003 until 2011, including as Vice President of Business Development and New Product Planning and Alliance Management. Mr.&#160;Celebi received a B.S. in Biophysics from the University of California, San Diego and an M.B.A. from Carnegie Mellon University. We believe that Mr.&#160;Celebi&#8217;s perspective and deep experience in the biotechnology industry, as well as his experience leading our company as the President and Chief Executive Officer, qualifies him to serve on our board of directors. </font></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Anupama Hoey <font style="font-weight:normal;">has served as our Chief Business Officer since October 2020. Prior to joining us, Ms.&#160;Hoey served as Chief Business Officer of Second Genome Inc., a biotechnology company, from July 2018 until June 2020. Prior to that, Ms.&#160;Hoey served as Chief Business Officer of Invenra Inc., a biotechnology company, from March 2017 until July 2018. Prior to Invenra, Ms.&#160;Hoey served as Vice President of Business Development of Arcus Biosciences, Inc. from November 2015 until December 2016. Ms.&#160;Hoey received a B.S. in Molecular Genetics from the Ohio State University, an M.S. from Case Western Reserve University and an M.B.A. from the University of San Francisco. </font></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Marie-Louise Fjaellskog, M.D., Ph.D.<font style="font-weight:normal;"> has served as our Chief Medical Officer since June 2020. Prior to joining us, Dr.&#160;Fjaellskog served as Vice President, Clinical Development at Merus N.V., an immuno-oncology company from May 2019 until June 2020. Prior to joining Merus, Dr.&#160;Fjaellskog served as Vice President, Clinical Development at Infinity Pharmaceuticals, a biopharmaceutical company, from February 2018 until April 2019. From 2012 to February 2018, Dr.&#160;Fjaellskog held positions of increasing responsibility at Novartis, most recently as Global Clinical Program Leader. Dr.&#160;Fjaellskog has also served as an Associate Professor of Oncology at Uppsala University in Sweden since 2008, where she also received an M.D. and a Ph.D. </font></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Robert Pierce,<font style="font-style:italic;"> </font>M.D.<font style="font-style:italic;"> </font><font style="font-weight:normal;">has served as our Chief Scientific Officer since March 2020. Prior to joining us, Dr.&#160;Pierce served as Scientific Director of the Immunopathology Lab in the Clinical Research Division of the Fred Hutchinson Cancer Research Center from November 2016 until March 2020. Prior to that, Dr.&#160;Pierce served as Chief Scientific Officer of OncoSec Medical Incorporated, a biotechnology company, from 2014 until June 2016. Dr.&#160;Pierce received a B.A. in Philosophy from Yale College and an M.D. from Brown University. </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">87</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Erin Colgan</font><font style="font-weight:normal;"> has served as our Senior Vice President of Finance </font><font style="font-weight:normal;">and Administration</font><font style="font-weight:normal;"> </font><font style="font-weight:normal;">since January 2021 and previously served as our Vice President of Finance from July 2020 to January 2021. Prior to joining us, Ms. Colgan served as the Vice President of FP+A and Commercial Planning at Intarcia Therapeutics from August 2019 to June 2020. Prior to Intarcia, from August 2010 to August 2019, Ms. Colgan held various roles of increasing responsibility at Vertex Pharmaceuticals, most recently as Senior Director, FP+A and Global Revenue. Ms.&#160;Colgan began her career in public accounting at PricewaterhouseCoopers where she worked in both audit and business development. Ms. Colgan holds a B.A. in Accounting from the University of Massachusetts, Amherst. </font></p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Non-Employee Directors </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Bob Holmen<font style="font-weight:normal;"> has served as a member of our board of directors since January 2017. Mr.&#160;Holmen provides legal services focused on venture capital and private equity markets to investors through his boutique law firm Investor Counsel, where he has served as a Principal since 2016. Mr.&#160;Holmen has also served as a Managing Director since 2001 and Chief Financial Officer since 2002 at Miramar Venture Partners, a venture capital firm, and as a Principal of Holmen Ventures, a strategic financial consulting firm, since 2013. Prior to Miramar, Mr.&#160;Holmen served as an Executive Officer for CoCensys, Inc., a biopharmaceutical company, and First Consulting Group, Inc., a healthcare consulting firm. Mr.&#160;Holmen received a B.S. in Electrical Engineering from Stanford University and a J.D. from University of California, Berkeley School of Law. We believe that Mr.&#160;Holmen&#8217;s education and professional background in advising companies in the biotechnology industry qualifies him to serve on our board of directors. </font></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">James Peyer, Ph.D.<font style="font-weight:normal;"> has served as a member of our board of directors since January 2020. In September&#160;2019, Dr.&#160;Peyer founded Cambrian Biopharma, where he serves as the Chief Executive Officer. In 2018, Dr.&#160;Peyer founded Cleara Biotech, a biopharmaceutical company, where he served as Executive Director from February 2018 to June 2019. Dr.&#160;Peyer also founded and served as Managing Partner at Apollo Health Ventures GmbH from June 2016 until March 2019. Prior to his service at Apollo Ventures, Dr.&#160;Peyer served as a consultant at McKinsey&#160;&amp; Company from August 2015 until June 2016. Dr.&#160;Peyer received a B.A. in Biology from the University of Chicago and a Ph.D. in Stem Cell Biology at The University of Texas Southwestern Medical Center at Dallas. We believe that Dr.&#160;Peyer&#8217;s experience in the biopharmaceutical industry, his years of business and leadership experience and expertise qualifies him to serve on our board of directors. </font></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Samuel Broder<font style="font-style:italic;">,</font><font style="font-style:italic;font-weight:normal;"> </font>M.D.<font style="font-weight:normal;"> has served as a member of our board of directors since April 2019. Prior to his retirement, Dr.&#160;Broder was Senior Vice President from 2012 to June 2016 and Head of the Health Sector from 2015 to June 2016 for Intrexon Corporation, a synthetic biology company. Prior to Intrexon, he served as the Executive Vice President for Medical Affairs and Chief Medical Officer at Celera Corporation from 1998 to 2010. Prior to Celera, Dr.&#160;Broder served as Senior Vice President, Research and Development and Chief Scientific Officer at IVAX Corporation from 1995 to 1998. Dr.&#160;Broder served as the director of the National Cancer Institute from 1989 to 1995 appointed by President Ronald Reagan, where he oversaw the development of numerous anti-cancer therapeutic agents. Dr.&#160;Broder received a B.S. from University of Michigan and an M.D. from the University of Michigan Medical School, with post-graduate training at Stanford University in Palo Alto. We believe that Dr.&#160;Broder&#8217;s significant scientific experience with therapeutic agents qualifies him to serve on our board of directors. </font></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Thomas Ricks<font style="font-weight:normal;"> has served as a member of our board of directors since 2015. Mr.&#160;Ricks served as former Chief Investment Officer of H&amp;S Ventures, LLC, a Forbes 150 family office, from 2001 until his retirement in 2018. Prior to his service, Mr.&#160;Ricks served as Chief Executive Officer of The University of Texas Investment Management Company from 1996 to 2001. Mr.&#160;Ricks has been a director of Ovintiv, Inc. since 2019 and currently serves as Chair of the Human Resources and Compensation Committee, and on the Corporate Responsibility and Governance Committee. He was a director of Newfield Exploration Company from 1992 to 2019 and most recently served as Chair of its Audit Committee. Mr.&#160;Ricks also served on the boards of several privately-held companies; BDM International (acquired by TRW), LifeCell Corporation, and Argus Pharmaceuticals. Mr.&#160;Ricks is a former director of the Ocean Institute, and a former member of the Investment Committees for St. David&#8217;s Foundation and the University of California &#8211; Irvine Foundation. Mr.&#160;Ricks received a B.A. in Economics from Trinity College and an M.B.A. from the University of Chicago. We believe Mr. Ricks&#8217; extensive experience as a director of public company and private companies in the healthcare industry qualifies him to serve on our board of directors. </font></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Deneen Vojta<font style="font-style:italic;">, </font>M.D. <font style="font-weight:normal;">has served as a member of our board of directors since January 2021. Dr.&#160;Vojta has served in various roles at UnitedHealth Group since 2006, including most recently as the Executive Vice President for Global Research &amp; Development since 2016. Prior to UnitedHealth, she founded Mynetico, a company focused on the childhood obesity epidemic, and served as its Chief Executive Officer from 2003 to 2006. Prior to that, she served as the Chief Medical Officer of Health Partners from 1997 to 2000 and Frankford Health System from 2000 to 2003. Dr.&#160;Vojta received a B.S. from the University of Pittsburgh and an M.D. from Temple University School of Medicine. We believe that Dr. Vojta&#8217;s significant scientific experience and experience as an executive of life sciences companies qualifies her to serve on our board of directors. </font></p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Family Relationships </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">There are no family relationships among any of our directors or executive officers. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">88</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Composition of Our Board of Directors </font></p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our business and affairs are managed under the direction of our board of directors. We have six directors serving as members of our board of directors. Our current directors will continue to serve as directors until their resignation, removal or successor is duly elected. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our amended and restated certificate of incorporation and amended and restated bylaws permit our board of directors to establish the authorized number of directors from time to time by resolution. Each director serves until the expiration of the term for which such director was elected or appointed, or until such director&#8217;s earlier death, resignation or removal. In accordance with our amended and restated certificate of incorporation, our board of directors will be divided into three classes with staggered three-year terms. At each annual general meeting of stockholders, the successors to directors whose terms then expire will be elected to serve from the time of election and qualification until the third annual meeting following election. Our directors will be divided among the three classes as follows: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:1.13%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">the Class&#160;I directors will be John Celebi and Samuel Broder, M.D., and their terms will expire at our first annual meeting of stockholders; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:1.13%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">the Class&#160;II directors will be Bob Holmen and Deneen Vojta, M.D., and their terms will expire at our second annual meeting of stockholders; and </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:1.13%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">the Class&#160;III directors will be James Peyer, Ph.D. and Thomas Ricks, and their terms will expire at our third annual meeting of stockholders. </p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We expect that any additional directorships resulting from an increase in the number of directors will be distributed among the three classes so that, as nearly as possible, each class will consist of one third of the directors. The division of our board of directors into three classes with staggered three-year terms may delay or prevent a change of our management or a change in control. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our board of directors meets on a regular basis and additionally as required. The members of our current board of directors were elected in compliance with the provisions of our amended and restated certificate of incorporation. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Director Independence </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our board of directors has undertaken a review of the independence of each director. Based on information provided by each director concerning her or his background, employment and affiliations, our board of directors has determined that all of our directors except for Mr.&#160;Celebi do not have relationships that would interfere with the exercise of independent judgment in carrying out the responsibilities of a director and that each of these directors is &#8220;independent&#8221; as that term is defined under the listing standards of the Nasdaq Stock Market. In making these determinations, our board of directors considered the current and prior relationships that each non-employee director has with our company and all other facts and circumstances our board of directors deemed relevant in determining their independence, including the beneficial ownership of our shares by each non-employee director and the transactions described in the section titled &#8220;Certain Relationships and Related Party Transactions.&#8221; </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Code of Business Conduct and Ethics </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have adopted a written code of business conduct and ethics that applies to our directors, officers and employees, including our principal executive officer, principal financial officer, principal accounting officer or controller, or persons performing similar functions. Our code of business conduct and ethics is available under the Corporate Governance section of our website at www.senseibio.com. In addition, we intend to post on our website all disclosures that are required by law or the listing standards of the Nasdaq Stock Market concerning any amendments to, or waivers from, any provision of the code. The reference to our website address does not constitute incorporation by reference of the information contained at or available through our website, and you should not consider it to be a part of this Form 10-K. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Audit Committee and Audit Committee Financial Expert</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our audit committee consists of Mr.&#160;Ricks, Mr.&#160;Holmen and Dr.&#160;Peyer. Our board of directors has determined that each of Mr.&#160;Ricks and Mr.&#160;Holmen satisfy the independence requirements under the listing standards of the Nasdaq Stock Market and Rule&#160;10A-3(b)(1) of the Securities and Exchange Act of 1934, or the Exchange Act. Under Rule&#160;10A-3 under the Exchange Act, we are permitted to phase in our compliance with the independent audit committee requirements set forth in Nasdaq Rule&#160;5605(c) and Rule&#160;10A-3 under the Exchange Act as follows: (1)&#160;one independent member at the time of listing, (2)&#160;a majority of independent members within 90&#160;days of listing and (3)&#160;all independent members within one year of listing. Within one year of our listing on the Nasdaq Global Market, we expect that each director serving on the audit committee will satisfy the independence requirements under the applicable Nasdaq listing requirements and under Rule&#160;10A-3 of the Exchange Act. The chair of our audit committee is Mr.&#160;Ricks, who our board of directors has determined is an &#8220;audit committee financial expert&#8221; within the meaning of SEC regulations. Each </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">89</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">member of our audit committee can read and understand fundamental financial statements in accordance with applicable requirements. In arriving at these determinations, our board of directors has examined each audit committee member&#8217;s scope of experience and the nature of their employment in the corporate finance sector. </font></p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Compensation Committee Interlocks and Insider Participation </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">None of the members of the compensation committee is currently or has been at any time one of our officers or employees. None of our executive officers currently serves, or has served during the last year, as a member of the board of directors or compensation committee of any entity that has one or more executive officers serving as a member of our board of directors or compensation committee.  </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="ITEM_11_EXECUTIVE_COMPENSATION"></a><a name="ITEM_11_EXECUTIVE_COMPENSATION"></a>Item 11. Executive Compensation. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our named executive officers, consisting of our principal executive officer and the next two most highly compensated executive officers, as of December&#160;31, 2020, were: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:1.13%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">John Celebi, our President and Chief Executive Officer; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:1.13%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Robert Pierce, our Chief Scientific Officer; and </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:1.13%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Anupama Hoey, our Chief Business Officer. </p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Summary Compensation Table </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table sets forth information concerning the compensation of our named executive officers during the fiscal year ended December&#160;31, 2020: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.36%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Name and Principal Position</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.08%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.08%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Salary</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">($)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.08%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Bonus</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">($)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.08%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Option</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Awards</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">($)(1)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.08%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Non-Equity</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Incentive Plan</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Compensation</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">($)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.08%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">All Other</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Compensation</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">($)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.08%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total ($)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.36%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">John Celebi</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.08%; border-top:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.08%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">394,625</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.08%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.08%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,775,500</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.08%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">118,965</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.08%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">19,040</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(5)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.08%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,308,130</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">President and Chief Executive Officer</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.08%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.08%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.08%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.08%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.08%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.08%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Robert Pierce(2)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.08%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">266,806</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.08%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.08%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">670,000</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.08%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">102,000</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.08%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">32,780</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(6)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.08%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,071,586</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Chief Scientific Officer</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.08%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.08%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.08%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.08%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.08%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.08%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Anupama Hoey(3)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.08%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">74,529</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.08%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">25,000</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(4)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.08%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,250,000</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.08%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">22,118</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.08%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.08%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,371,647</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Chief Business Officer</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.08%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.08%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.08%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.08%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.08%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.08%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;border-bottom:Solid 0.75pt;padding-bottom:1pt;margin-top:0pt;margin-right:66.67%;text-indent:0%;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:2pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1)</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:2pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">The amounts disclosed represent the aggregate grant date fair value of the awards granted to our named executive officers during 2020 under our 2018 Plan, computed in accordance with ASC Topic 718. The assumptions used in calculating the grant date fair value of the awards are set forth in Note 10 to our audited consolidated financial statements included elsewhere in this Form 10-K. This amount does not reflect the actual economic value that may be realized by the named executive officer. </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2)</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Dr.&#160;Pierce joined as our Chief Scientific Officer in March 2020. </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(3)</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Ms. Hoey joined as our Chief Business Officer in October 2020. </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(4)</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Pursuant to her employment agreement, Ms. Hoey received a $25,000 signing and retention bonus upon joining our company, as further described below in &#8220;&#8212;Employment Agreements with our Named Executive Officers.&#8221; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(5)</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Includes 401(k) plan matching contributions, a housing allowance and a vehicle allowance. </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(6)</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Includes 401(k) plan matching contributions, a housing allowance, and a payment in connection with our acquisition of Alvaxa as further described in &#8220;Certain Relationships and Related Party Transactions&#8212;Business Combination.&#8221; </p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Narrative to the Summary Compensation Table </p>
<p style="margin-bottom:0pt;margin-top:6pt;margin-left:2.26%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Annual Base Salary </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our named executive officers receive a base salary to compensate them for services rendered to us. The base salary payable to each named executive officer is intended to provide a fixed component of compensation reflecting the executive&#8217;s skill set, experience, role and responsibilities. Mr.&#160;Celebi&#8217;s annual base salary was $385,000 from January&#160;1, 2020 to March&#160;31, 2020 and was $396,550 from April&#160;1, 2020 to December&#160;31, 2020. The base salaries for Dr.&#160;Pierce and Ms.&#160;Hoey during 2020 were $340,000 and $345,000, respectively. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">90</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Bonus </font></p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our named executive officers are eligible to receive annual bonuses of up to a percentage of the applicable executive&#8217;s gross base salary based on performance metrics, as determined by our board of directors. For 2020, the target bonus for each of Mr. Celebi, Dr. Pierce and Ms. Hoey was 30% of their respective base salaries. For 2020, our board of directors determined that the corporate performance goals had been achieved at a 100% level in the aggregate. </p>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:2.26%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Employment Agreements with our Named Executive Officers </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Below are descriptions of our employment agreements with our named executive officers. The agreements generally provide for&#160;at-will employment and set forth the named executive officer&#8217;s initial base salary, eligibility for employee benefits and severance benefits upon a qualifying termination of employment. Furthermore, each of our named executive officers has executed a form of our standard proprietary information and inventions assignment agreement. The key terms of the employment agreements with our named executive officers, including potential payments upon termination or change of control, are described below. We have also entered into new employment agreements with our named executive officers, <font style="font-size:12pt;"> </font>which were effective upon the closing of our initial public offering, as described further below under &#8220;&#8212;Post IPO Employment Agreements.&#8221; </p>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:2.26%;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">John Celebi </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On January 1, 2021, we entered into an amended and restated executive employment agreement with John Celebi, or the Celebi Employment Agreement, which provides for his continued at will employment as our President and Chief Executive Officer, with no specific term. The Celebi Employment Agreement provides for an annual base salary of $395,000, which amount is subject to review and adjustment from time to time, an annual discretionary bonus of up to 30% of this base salary, the amount of which will be decided in the sole discretion of our board of directors based upon our and Mr. Celebi&#8217;s achievement of objectives and milestones determined on an annual basis by our board of directors, and reimbursement for reasonable travel expenses for so long as Mr. Celebi&#8217;s primary residence is in Connecticut, not to exceed $4,000 per month. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the event of his termination without cause (as such term is defined in the Celebi Employment Agreement) or resignation for good reason (as such term is defined in the Celebi Employment Agreement), Mr. Celebi shall be entitled to (i) salary continuation for the nine month period following such termination, or the Severance Period, provided that such salary continuation will be reduced by 50% of any amounts Mr. Celebi receives as salary from any other entity within the life sciences industry during the Severance Period, (ii) any annual bonus declared but not yet paid, (iii) accelerated vesting of the portion of her time-based equity awards that would have otherwise vested during the nine-month period following the termination and (iv) continuation of medical insurance through the Severance Period at no cost to Mr. Celebi, unless he begins subsequent employment prior to the end of such nine-month period. The foregoing severance benefits are conditioned upon Mr. Celebi&#8217;s execution of a separation agreement, including a release of claims and compliance with certain restrictive covenants. </p>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:2.26%;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Robert Pierce </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On February&#160;9, 2020, we entered into an executive employment agreement with Robert Pierce, or the Pierce Employment Agreement, which provides for his at will employment as our Chief Scientific Officer, with no specific term. The Pierce Employment Agreement provides for an annual base salary of $340,000, which amount is subject to review and adjustment from time to time, an annual discretionary bonus of up to 30% of this base salary, the amount of which will be decided in the sole discretion of our board of directors based upon our and Dr.&#160;Pierce&#8217;s achievement of objectives and milestones determined on an annual basis by our board of directors, and a one-time bonus in the event that Dr.&#160;Pierce is required to repay to Fred Hutchinson Cancer Research Center, or FHCRC, a portion of the home loan forgiveness provided by FHCRC. The Pierce Employment Agreement also provides for relocation expense reimbursement of up to $25,000, a housing stipend and repayment of certain other business-related expenses. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the event of his termination without cause (as such term is defined in the Pierce Employment Agreement), Dr.&#160;Pierce shall be entitled to (i)&#160;salary continuation for the Severance Period, (ii)&#160;any annual bonus declared but not yet paid, (iii)&#160;accelerated vesting of the portion of his time-based equity awards that would have otherwise vested during the six-month period following the termination, (iv)&#160;any accrued but unpaid expenses and (v)&#160;continuation of medical insurance through the Severance Period at no cost to Dr.&#160;Pierce, unless he begins subsequent employment prior to the end of the Severance Period. The foregoing severance benefits are conditioned upon Dr.&#160;Pierce&#8217;s execution of a separation agreement, including a release of claims and compliance with certain restrictive covenants. </p>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:2.26%;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Anupama Hoey </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On October 13, 2020, we entered into an employment agreement with Anupama Hoey, or the Hoey Employment Agreement, which provides for her at-will employment as our Chief Business Officer, with no specific term. The Hoey Employment Agreement provides for an annual base salary of $345,000, which amount is subject to review and adjustment from time to time, and an annual </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">91</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">discretionary bonus of up to 30% of this base salary, the amount of which will be decided in the sole discretion of our board of directors based upon our and Ms. Hoey&#8217;s achievement of objectives and milestones determined on an annual basis by our board of directors. The Hoey Employment Agreement also provides for a signing and retention payment of $25,000, which we paid to Ms. Hoey in October 2020, and which is subject to repayment if Ms. Hoey&#8217;s employment terminates prior to October 14, 2021 other than in the event of her termination without cause or if Ms. Hoey terminates her employment for good reason (as such terms are defined in the Hoey Employment Agreement). </font></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the event of her termination without cause or if Ms. Hoey terminates her employment for good reason, Ms. Hoey shall be entitled to (i) an amount equal to Ms. Hoey&#8217;s then current salary for six months, (ii) accelerated vesting of the portion of her time-based equity awards that would have otherwise vested during the six-month period following the termination, (iii) any accrued and unpaid business expenses, and (iv) continuation of medical insurance for six months at no cost to Ms. Hoey, unless she begins subsequent employment prior to the end of such Severance Period. The foregoing severance benefits are conditioned upon Ms. Hoey&#8217;s execution of a separation agreement, including a release of claims and compliance with certain restrictive covenants. </p>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:2.26%;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Post-IPO Employment Agreements </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In January 2021, we entered into new employment agreements with our named executive officers, which became effective upon the closing of our initial public offering. The agreements generally provide for at-will employment and set forth the named executive officer&#8217;s base salary, target bonus and eligibility for employee benefits and severance benefits upon a qualifying termination of employment. Under the new agreements, Mr.&#160;Celebi&#8217;s, Dr.&#160;Pierce&#8217;s and Ms.&#160;Hoey&#8217;s annual base salaries are $500,000, $420,000 and $365,000, respectively, subject to review and revision by our board of directors. In addition, the target bonus for each of Mr.&#160;Celebi, Dr.&#160;Pierce and Ms.&#160;Hoey will be up to 55%, 40% and 40%, respectively, of their respective base salaries, subject to review and revision by our board of directors. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The new employment agreements provide that, subject to certain conditions and limitations, upon the termination of the employment of an eligible executive officer without Cause or resignation for Good Reason (each, as defined in the employment agreements) not in connection with a Change in Control (as defined in the 2018 Plan): </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:1.13%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Dr.&#160;Pierce and Ms.&#160;Hoey will be eligible to receive a cash severance benefit equal to nine&#160;months&#8217; base salary; Mr.&#160;Celebi will be eligible to receive a cash severance benefit equal to 12&#160;months&#8217; base salary; and </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:1.13%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">such executive officer shall be eligible to receive COBRA premiums for the applicable length of the severance period as described above. </p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, the new employment agreements provide that, subject to certain conditions and limitations, upon the termination of the employment of an eligible executive officers without Cause or resignation for Good Reason (each, as defined in the employment agreements) within 12&#160;months following a Change in Control: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:1.13%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Dr.&#160;Pierce and Ms.&#160;Hoey will be eligible to receive a cash severance benefit equal to 12&#160;months&#8217; base salary and 100% of the officer&#8217;s target bonus; Mr.&#160;Celebi will be eligible to receive a cash severance benefit equal to 18&#160;months&#8217; base salary and 150% of his target bonus; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:1.13%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">all unvested equity awards held by such executive officer will become immediately vested and fully exercisable; and </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:1.13%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">such executive officer shall be eligible to receive COBRA premiums for the applicable length of the severance period as described above. </p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The severance benefits described above are conditioned upon the executive officer&#8217;s execution and non-revocation of a separation agreement, including a release of claims, and compliance with certain restrictive other obligations. </p>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:2.26%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Equity-Based Incentive Awards </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We believe that equity awards provide our executives with a strong link to our long-term performance, create an ownership culture and help to align the interests of our executives and our stockholders. To date, we have only used stock option grants for this purpose because we believe they are an effective means by which to align the long-term interests of our executive officers with those of our stockholders. The use of stock options also can provide tax and other advantages to our executive officers relative to other forms of equity compensation. We believe that our equity awards are an important retention tool for our executive officers, as well as for our other employees. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We award stock options broadly to our employees, including to&#160;our&#160;non-executive&#160;employees.&#160;Grants to our executives and other employees are made at the discretion of our board of directors and are not made at any specific time period during a year. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">92</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prior to </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">our initial </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">public </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">offering, </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">all of</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> the stock options we have granted were made pursuant to our 2018 Plan. </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the future</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> we will grant equity incentive awards under the terms of our 2021 Equity Incentive Plan, or 2021 Plan. The terms of our equity plans are described under the section titled &#8220;&#8212;Equity Incentive Plans&#8221; below. </font></p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Hlk67844832"></a>Outstanding Equity Awards as of December&#160;31, 2020 </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table presents estimated information regarding outstanding equity awards held by our named executive officers as of December&#160;31, 2020. All awards were granted pursuant to the 2018 Plan. See the section titled &#8220;&#8212;Equity Incentive Plans&#8212;2018 Stock Incentive Plan&#8221; below for additional information. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.04%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Hlk67417318"></a>&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="14" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:48.72%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Option Awards</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.04%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Name</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Number of</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Securities</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Underlying</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unexercised</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Options</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exercisable</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Number of</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Securities</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Underlying</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unexercised</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Options</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unexercisable</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Option</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exercise</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Price</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Option</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Expiration</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Date</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.04%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">John Celebi</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.12%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.12%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">559,375</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.12%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.22</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.12%; border-top:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">08/04/2030</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">President and Chief Executive Officer</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">18,333</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,333</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">122.88</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.12%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">04/01/2028</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Robert Pierce</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">208,333</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(3)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.22</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.12%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">08/04/2030</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Chief Scientific Officer</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">499</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(4)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">122.88</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.12%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">01/21/2029</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Anupama Hoey</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">208,333</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(5)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.00</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.12%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12/28/2030</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Chief Business Officer</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.12%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;border-bottom:Solid 0.75pt;padding-bottom:1pt;line-height:6pt;margin-top:0pt;margin-right:66.67%;text-indent:0%;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:2pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1)</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:2pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">The unvested shares underlying this option vest as to 25% of the shares on February 15, 2021, with the remainder vesting in 36 equal monthly installments thereafter, subject to the officer&#8217;s continued service through each applicable vesting date. </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2)</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">The unvested shares underlying this option vest in 15 equal monthly installments until March 1, 2022, subject to the officer&#8217;s continued service through each applicable vesting date. </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(3)</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">The unvested shares underlying this option vest as to 25% of the shares on March 18, 2021, with the remainder vesting in 36 equal monthly installments thereafter, subject to the officer&#8217;s continued service through each applicable vesting date. </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(4)</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">The unvested shares underlying this option vest on January 22, 2021, subject to the officer&#8217;s continued service through each applicable vesting date. </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(5)</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">The unvested shares underlying this option vest as to 25% of the shares on October 14, 2021, with the remainder vesting in 36 equal monthly installments thereafter, subject to the officer&#8217;s continued service through each applicable vesting date. </p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Employee Benefit Plans </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We believe that our ability to grant equity-based awards is a valuable and necessary compensation tool that aligns the long-term financial interests of our employees, consultants and directors with the financial interests of our stockholders. In addition, we believe that our ability to grant options and other equity-based awards helps us to attract, retain and motivate employees, consultants and directors, and encourages them to devote their best efforts to our business and financial success. The principal features of our equity incentive plans and our 401(k) plan are summarized below. These summaries are qualified in their entirety by reference to the actual text of the plans, which, other than the 401(k) plan, are filed as exhibits to the registration statement of which this Form 10-K is a part. </p>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:2.26%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><a name="_Hlk67845430"></a>2021 Equity Incentive Plan </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our board of directors adopted our 2021 Plan on January&#160;27, 2021 and our stockholders approved our 2021 Plan on January&#160;28, 2021. Our 2021 Plan provides for the grant of incentive stock options, or ISOs, to employees, including employees of any of our parent or subsidiary corporations, and for the grant of nonstatutory stock options, or NSOs, stock appreciation rights, restricted stock awards, restricted stock unit awards, performance awards and other forms of stock awards to employees, directors, and consultants, including employees and consultants of our affiliates. Our 2021 Plan is a successor to the 2018 Plan, and became effective on the execution of the underwriting agreement related to our initial public offering. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Authorized Shares<font style="font-style:normal;">.&#160;&#160;&#160;&#160;Initially the maximum number of shares of our common stock that may be issued under our 2021 Plan was the sum of (i)&#160;2,469,935 new shares; plus (ii)&#160;the number of shares that remain available for issuance under our 2018 Plan at the time our 2021 Plan becomes effective; and (iii)&#160;any shares subject to outstanding stock options or other stock awards that were granted under our 2018 Plan that are forfeited, terminate, expire or are otherwise not issued. In addition, the number of shares of our common stock reserved for issuance under our 2021 Plan will automatically increase on January&#160;1 of each calendar year, starting on January&#160;1, 2022 through January&#160;1, 2031, in an amount equal to 4.0% of the total number of shares of our capital stock outstanding on the last day of the calendar month before the date of each automatic increase, or a lesser number of shares determined by our board of </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">93</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:12pt;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"><font style="font-style:normal;">directors. The maximum number of shares of our common stock that may be issued on the exercise of ISOs under our 2021 Plan is 10,000,000&#160;shares. </font></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Shares subject to stock awards granted under our 2021 Plan that expire or terminate without being exercised in full, or that are paid out in cash rather than in shares, do not reduce the number of shares available for issuance under our 2021 Plan. Additionally, shares become available for future grant under our 2021 Plan if they were issued pursuant to stock awards granted under our 2021 Plan and we repurchase such shares or they are forfeited. This includes shares used to pay the exercise price of a stock award or to satisfy the tax withholding obligations related to a stock award. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Plan Administration<font style="font-style:normal;">.&#160;&#160;&#160;&#160;Our board of directors, or a duly authorized committee of our board of directors, administers our 2021 Plan. The plan administrator may also delegate to one or more of our officers the authority to (i)&#160;designate employees (other than officers) to receive specified stock awards and (ii)&#160;determine the number of shares subject to such stock awards. Under our 2021 Plan, the plan administrator has the authority to determine and amend the terms of awards and underlying agreements, including: </font></p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:1.13%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">the recipients; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:1.13%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">the exercise, purchase or strike price of stock awards, if any; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:1.13%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">the number of shares subject to stock awards; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:1.13%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">the vesting schedule applicable to stock awards, together with any vesting acceleration; and </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:1.13%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">the form of consideration, if any, payable on exercise or settlement of stock awards. </p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the 2021 Plan, the plan administrator also generally has the authority to effect, with the consent of any adversely affected participant: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:1.13%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">the reduction of the exercise, purchase, or strike price of any outstanding stock award; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:1.13%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">the cancellation of any outstanding stock award and the grant in substitution therefore of other stock awards, cash, or other consideration; or </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:1.13%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">any other action that is treated as a repricing under generally accepted accounting principles. </p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Stock Options.<font style="font-style:normal;">&#160;&#160;&#160;&#160;ISOs and NSOs are granted under stock option agreements adopted by the plan administrator. The plan administrator determines the exercise price for stock options, within the terms and conditions of the 2021 Plan; provided, that the exercise price of a stock option generally cannot be less than 100% of the fair market value of our common stock on the date of grant. Options granted under the 2021 Plan vest at the rate specified in the stock option agreement as determined by the plan administrator. </font></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Tax Limitations on ISOs<font style="font-style:normal;">.&#160;&#160;&#160;&#160;The aggregate fair market value, determined at the time of grant, of our common stock with respect to ISOs that are exercisable for the first time by an optionholder during any calendar year under all of our equity incentive plans may not exceed $100,000. Options or portions thereof that exceed such limit will generally be treated as NSOs. No ISO may be granted to any person who, at the time of the grant, owns or is deemed to own stock possessing more than 10% of our total combined voting power or that of any of our affiliates unless (i)&#160;the option exercise price is at least 110% of the fair market value of the stock subject to the option on the date of grant; and (ii)&#160;the option is not exercisable after the expiration of five years from the date of grant. </font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Restricted Stock Unit Awards.&#160;&#160;&#160;&#160;<font style="font-style:normal;">Restricted stock units are granted under restricted stock unit award agreements adopted by the plan administrator. Restricted stock units may be granted in consideration for any form of legal consideration that may be acceptable to our board of directors and permissible under applicable law. A restricted stock unit may be settled by cash, delivery of stock, a combination of cash and stock as deemed appropriate by the plan administrator, or in any other form of consideration set forth in the restricted stock unit agreement. Additionally, dividend equivalents may be credited in respect of shares covered by a restricted stock unit. Except as otherwise provided in the applicable award agreement, restricted stock units that have not vested will be forfeited once the participant&#8217;s continuous service ends for any reason. </font></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Restricted Stock Awards.<font style="font-style:normal;">&#160;&#160;&#160;&#160;Restricted stock awards are granted under restricted stock award agreements adopted by the plan administrator. A restricted stock award may be awarded in consideration for cash, check, bank draft or money order, past services to us, or any other form of legal consideration that may be acceptable to our board of directors and permissible under applicable law. The plan administrator determines the terms and conditions of restricted stock awards, including vesting and forfeiture terms. If a participant&#8217;s service relationship with us ends for any reason, we may receive any or all of the shares of common stock held by the participant that have not vested as of the date the participant terminates service with us through a forfeiture condition or a repurchase right. </font></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Stock Appreciation Rights.<font style="font-style:normal;">&#160;&#160;&#160;&#160;Stock appreciation rights are granted under stock appreciation grant agreements adopted by the plan administrator. The plan administrator determines the purchase price or strike price for a stock appreciation right, which generally </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">94</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:12pt;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"><font style="font-style:normal;">cannot be less than 100% of the fair market value of our common stock on the date of grant. A stock appreciation right granted under the 2021 Plan vests at the rate specified in the stock appreciation right agreement as determined by the plan administrator. </font></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Performance Awards.&#160;&#160;&#160;&#160;<font style="font-style:normal;">The 2021 Plan permits the grant of performance-based stock and cash awards. The plan administrator may structure awards so that the shares of our stock, cash, or other property will be issued or paid only following the achievement of certain pre-established performance goals during a designated performance period. The performance criteria that will be used to establish such performance goals may be based on any measure of performance selected by the plan administrator. The performance goals may be based on a company-wide basis, with respect to one or more business units, divisions, affiliates, or business segments, and in either absolute terms or relative to the performance of one or more comparable companies or the performance of one or more relevant indices. Unless specified otherwise (i)&#160;in the award agreement at the time the award is granted or (ii)&#160;in such other document setting forth the performance goals at the time the goals are established, we will appropriately make adjustments in the method of calculating the attainment of performance goals as follows: (1)&#160;to exclude restructuring and/or other nonrecurring charges; (2)&#160;to exclude exchange rate effects; (3)&#160;to exclude the effects of changes to generally accepted accounting principles; (4)&#160;to exclude the effects of any statutory adjustments to corporate tax rates; (5)&#160;to exclude the effects of items that are &#8220;unusual&#8221; in nature or occur &#8220;infrequently&#8221; as determined under generally accepted accounting principles; (6)&#160;to exclude the dilutive effects of acquisitions or joint ventures; (7)&#160;to assume that any business divested by us achieved performance objectives at targeted levels during the balance of a performance period following such divestiture; (8)&#160;to exclude the effect of any change in the outstanding shares of our common stock by reason of any stock dividend or split, stock repurchase, reorganization, recapitalization, merger, consolidation, spin-off, combination or exchange of shares or other similar corporate change, or any distributions to common stockholders other than regular cash dividends; (9)&#160;to exclude the effects of stock based compensation and the award of bonuses under our bonus plans; (10)&#160;to exclude costs incurred in connection with potential acquisitions or divestitures that are required to be expensed under generally accepted accounting principles; (11)&#160;to exclude the goodwill and intangible asset impairment charges that are required to be recorded under generally accepted accounting principles; and (12)&#160;to exclude the effects of the timing of acceptance for review and/or approval of submissions to the FDA or any other regulatory body. In addition, we retain the discretion to reduce or eliminate the compensation or economic benefit due upon attainment of the goals. The performance goals may differ from participant to participant and from award to award. </font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Other Stock Awards.&#160;&#160;&#160;&#160;<font style="font-style:normal;">The plan administrator may grant other awards based in whole or in part by reference to our common stock. The plan administrator will set the number of shares under the stock award and all other terms and conditions of such awards. </font></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Non-Employee Director Compensation Limit<font style="font-style:normal;">.&#160;&#160;&#160;&#160;The aggregate value of all compensation granted or paid to any non-employee director with respect to any calendar year, including stock awards granted and cash fees paid by us to such non-employee director, will not exceed $750,000 in total value, or in the event such non-employee director is first appointed or elected to the board during such annual period, $1,000,000 in total value (in each case, calculating the value of any such stock awards based on the grant date fair value of such stock awards for financial reporting purposes); provided, that the foregoing limitations will not apply during the year in which the 2021 Plan is first adopted. </font></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Changes to Capital Structure.<font style="font-style:normal;">&#160;&#160;&#160;&#160;In the event there is a specified type of change in our capital structure, such as a stock split, reverse stock split, or recapitalization, appropriate adjustments will be made to (1)&#160;the class and maximum number of shares reserved for issuance under the 2021 Plan, (2)&#160;the class and maximum number of shares by which the share reserve may increase automatically each year, (3)&#160;the class and maximum number of shares that may be issued on the exercise of incentive stock options, and (4)&#160;the class and number of shares and exercise price, strike price, or purchase price, if applicable, of all outstanding stock awards. </font></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Corporate Transactions.&#160;&#160;&#160;&#160;<font style="font-style:normal;">The following applies to stock awards under the 2021 Plan in the event of a corporate transaction, unless otherwise provided in a participant&#8217;s stock award agreement or other written agreement with us or one of our affiliates or unless otherwise expressly provided by the plan administrator at the time of grant. In the event of a corporate transaction, any stock awards outstanding under the 2021 Plan may be assumed, continued or substituted for by any surviving or acquiring corporation (or its parent company), and any reacquisition or repurchase rights held by us with respect to the stock award may be assigned to the successor (or its parent company). If the surviving or acquiring corporation (or its parent company) does not assume, continue or substitute for such stock awards, then with respect to any such stock awards that are held by participants whose continuous service has not terminated prior to the effective time of the transaction, or current participants, the vesting (and exercisability, if applicable) of such stock awards will be accelerated in full to a date prior to the effective time of the transaction (contingent upon the effectiveness of the transaction), and such stock awards will terminate if not exercised (if applicable) at or prior to the effective time of the transaction, and any reacquisition or repurchase rights held by us with respect to such stock awards will lapse (contingent upon the effectiveness of the transaction). With respect to performance awards with multiple vesting levels depending on performance level, unless otherwise provided by an award agreement or by the administrator, the award will accelerate at 100% of target. If the surviving or acquiring corporation (or its parent company) does not assume, continue or substitute for such stock awards, then&#160;with respect to&#160;any such stock awards that are held by persons other than current participants, such awards will terminate if not exercised (if applicable) prior to the effective time of the transaction, except that any reacquisition or repurchase rights held by us with respect to such stock awards will not terminate and may continue to be exercised notwithstanding the transaction. The plan administrator is not obligated to treat all </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">95</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:12pt;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"><font style="font-style:normal;">stock awards or portions of stock awards in the same manner and is not obligated to take the same actions with respect to all participants. In the event a stock award will terminate if not exercised prior to the effective time of a transaction, the plan administrator may provide, in its sole discretion, that the holder of such stock award may not exercise such stock award but instead will receive a payment equal in value to the excess (if any) of (i)&#160;the value of the property the participant would have received upon the exercise of the stock award over (ii)&#160;any exercise price payable by such holder in connection with such exercise. </font></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under our 2021 Plan, a corporate transaction is defined to include: (i)&#160;a sale of all or substantially all of our assets, (ii)&#160;the sale or disposition of more than 50% of our outstanding securities, (iii)&#160;the consummation of a merger or consolidation where we do not survive the transaction, and (iv)&#160;the consummation of a merger or consolidation where we do survive the transaction but the shares of our common stock outstanding before such transaction are converted or exchanged into other property by virtue of the transaction, unless otherwise provided in an award agreement or other written agreement between us and the award holder. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Change in Control.&#160;&#160;&#160;&#160;<font style="font-style:normal;">In the event of a change in control, as defined under our 2021 Plan, awards granted under our 2021 Plan will not receive automatic acceleration of vesting and exercisability, although this treatment may be provided for in an award agreement. </font></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the 2021 Plan, a change in control is defined to include (i)&#160;the acquisition by any person or company of more than 50% of the combined voting power of our then outstanding stock; (ii)&#160;a merger, consolidation or similar transaction in which our stockholders immediately before the transaction do not own, directly or indirectly, more than 50% of the combined voting power of the surviving entity (or the parent of the surviving entity); (iii) the approval by our stockholders or our board of directors of a plan of complete dissolution or liquidation of the company, or the occurrence of a complete dissolution or liquidation of the company, except for a liquidation into a parent corporation; (iv)&#160;a sale, lease, exclusive license or other disposition of all or substantially all of our assets other than to an entity more than 50% of the combined voting power of which is owned by our stockholders; and (v)&#160;an unapproved change in the majority of our board of directors. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Transferability.&#160;&#160;&#160;&#160;<font style="font-style:normal;">A participant may not transfer stock awards under our 2021 Plan other than by will, the laws of descent and distribution, or as otherwise provided under our 2021 Plan. </font></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Plan Amendment or Termination.<font style="font-style:normal;">&#160;&#160;&#160;&#160;Our board of directors has the authority to amend, suspend, or terminate our 2021 Plan; provided, that such action does not materially impair the existing rights of any participant without such participant&#8217;s written consent. Certain material amendments also require the approval of our stockholders. No ISOs may be granted after the tenth anniversary of the date our board of directors adopted our 2021 Plan. No stock awards may be granted under our 2021 Plan while it is suspended or after it is terminated. </font></p>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:2.26%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">2021 Employee Stock Purchase Plan </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our board of directors adopted, and our stockholders approved, our 2021 Employee Stock Purchase Plan, or the ESPP, in January 2021. The ESPP became effective on the execution of the underwriting agreement related to our initial public offering. The purpose of the ESPP is to secure the services of new employees, to retain the services of existing employees, and to provide incentives for such individuals to exert maximum efforts toward our success and that of our affiliates. The ESPP is intended to qualify as an &#8220;employee stock purchase plan&#8221; within the meaning of Section&#160;423 of the Code for U.S. employees. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Share Reserve.<font style="font-style:normal;">&#160;&#160;&#160;&#160;Following our initial public offering, the ESPP authorizes the issuance of 333,333&#160;shares of our common stock under purchase rights granted to our employees or to employees of any of our designated affiliates. The number of shares of our common stock reserved for issuance will automatically increase on January 1 of each calendar year, beginning on January&#160;1, 2022 through January&#160;1, 2031, by 1.0% of the total shares of our common stock outstanding on December&#160;31st of the preceding calendar year, or the Evergreen Measurement Date; provided, that (i)&#160;the number of shares added to the share reserve will be reduced automatically to the extent necessary to avoid causing the share reserve to exceed a number of shares equal to 1.0% of the shares of our common stock outstanding on the applicable Evergreen Measurement Date and (ii)&#160;our board of directors may act prior to the first day of any calendar year to provide that there will be no January 1st increase in the share reserve for such calendar year or that the increase in the share reserve for such calendar year will be a lesser number of shares of our common stock than would otherwise occur. </font></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Administration.<font style="font-style:normal;">&#160;&#160;&#160;&#160;Our board of directors has delegated its authority to administer the ESPP to our compensation committee. The ESPP is implemented through a series of offerings under which eligible employees are granted purchase rights to purchase shares of our common stock on specified dates during such offerings. Under the ESPP, we may specify offerings with durations of not more than 27 months, and may specify shorter purchase periods within each offering. Each offering will have one or more purchase dates on which shares of our common stock will be purchased for employees participating in the offering. </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">96</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"><font style="font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Payroll Deductions.&#160;&#160;&#160;&#160;</font><font style="font-style:normal;">Generally, all regular employees, including executive officers, employed by us or by any of our designated affiliates, may participate in the ESPP and may contribute, normally through payroll deductions, up </font><font style="font-style:normal;">to&#160;</font><font style="font-style:normal;">1</font><font style="font-style:normal;">5</font><font style="font-style:normal;">% </font><font style="font-style:normal;">of their earnings (as defined in the ESPP) for the purchase of our common stock under the ESPP. Unless otherwise determined by our board of directors, common stock will be purchased for the accounts of employees participating in the ESPP at a price per share that is at least the lesser of (i) 85% of the fair market value of a share of our common stock on the first date of an offering; or (ii) 85% of the fair market value of a share of our common stock on the date of purchase. For the initial </font><font style="font-style:normal;">public </font><font style="font-style:normal;">offering, which we expect will commence on the execution and delivery of the underwriting agreement relating to </font><font style="font-style:normal;">our initial public </font><font style="font-style:normal;">offering, the fair market value on the first day of the offering period will be the price at which shares of common stock are first sold to the public. </font></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Limitations<font style="font-style:normal;">.&#160;&#160;&#160;&#160;Employees may have to satisfy one or more of the following service requirements before participating in the ESPP, as determined by our board of directors, including: (i)&#160;being customarily employed for more than 20 hours per week; (ii)&#160;being customarily employed for more than five months per calendar year; or (iii)&#160;continuous employment with us or one of our affiliates for a period of time (not to exceed two years). No employee may purchase shares under the ESPP at a rate in excess of $25,000 worth of our common stock based on the fair market value per share of our common stock at the beginning of an offering for each year such a purchase right is outstanding. Finally, no employee will be eligible for the grant of any purchase rights under the ESPP if immediately after such rights are granted, such employee has voting power over 5% or more of our outstanding capital stock measured by vote or value under Section&#160;424(d) of the Code. </font></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Changes to Capital Structure.<font style="font-style:normal;">&#160;&#160;&#160;&#160;In the event that there occurs a change in our capital structure through such actions as a stock split, merger, consolidation, reorganization, recapitalization, reincorporation, stock dividend, dividend in property other than cash, large nonrecurring cash dividend, liquidating dividend, combination of shares, exchange of shares, change in corporate structure, or similar transaction, the board of directors will make appropriate adjustments to: (i)&#160;the number of shares reserved under the ESPP; (ii)&#160;the maximum number of shares by which the share reserve may increase automatically each year; (iii)&#160;the number of shares and purchase price of all outstanding purchase rights; and (iv)&#160;the number of shares that are subject to purchase limits under ongoing offerings. </font></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Corporate Transactions.<font style="font-style:normal;">&#160;&#160;&#160;&#160;In the event of certain significant corporate transactions, including: (i)&#160;a sale of all or substantially all of our assets; (ii)&#160;the sale or disposition of 90% of our outstanding securities; (iii)&#160;the consummation of a merger or consolidation where we do not survive the transaction; and (iv)&#160;the consummation of a merger or consolidation where we do survive the transaction but the shares of our common stock outstanding immediately before such transaction are converted or exchanged into other property by virtue of the transaction, any then-outstanding rights to purchase our stock under the ESPP may be assumed, continued or substituted for by any surviving or acquiring entity (or its parent company). If the surviving or acquiring entity (or its parent company) elects not to assume, continue, or substitute for such purchase rights, then the participants&#8217; accumulated payroll contributions will be used to purchase shares of our common stock within ten business days before such corporate transaction, and such purchase rights will terminate immediately. </font></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Amendment or Termination<font style="font-style:normal;">.&#160;&#160;&#160;&#160;Our board of directors has the authority to amend or terminate our ESPP, provided that except in certain circumstances such amendment or termination may not materially impair any outstanding purchase rights without the holder&#8217;s consent. We will obtain stockholder approval of any amendment to our ESPP as required by applicable law or listing requirements. </font></p>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:2.26%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">2018 Stock Incentive Plan </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our board of directors and our stockholders approved the 2018 Plan, which became effective in March&#160;26, 2018. The 2018 Plan provides for the grant of ISOs to our employees and our parent and subsidiary corporations&#8217; employees, and for the grant of NSOs, restricted stock awards and other forms of stock compensation to our employees, including officers, consultants and directors. Following the effectiveness of the 2021 Plan, no additional awards will be granted under the 2018 Plan. Any outstanding awards granted under our 2018 Plan will remain subject to the terms of our 2018 Plan and applicable award agreements. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Authorized Shares.&#160;&#160;&#160;&#160;<font style="font-style:normal;">As of December 31, 2020, a total of 2,552,083&#160;shares of our common stock were reserved for issuance under the 2018 Plan. As of December 31, 2020, 1,947,123&#160;shares of our common stock were subject to outstanding option awards. </font></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Administration<font style="font-style:normal;">.&#160;&#160;&#160;&#160;Our board of directors or a duly authorized committee of our board of directors administers the 2018 Plan and the stock awards granted under it. Under the 2018 Plan, the administrator has the authority to: (i)&#160;construe and interpret the 2018 Plan and any agreement thereunder; (ii)&#160;to determine the fair market value of our common stock; (iii)&#160;to select award recipients; (iv)&#160;to determine whether an option will be an ISO or an NSO; (v)&#160;to determine the number of shares subject to awards; (vi)&#160;to establish the terms and conditions of the awards; (vii)&#160;to amend, cancel, accept the surrender of, or modify any award; (viii)&#160;to accelerate the vesting of or terminate the restrictions of an award; (ix)&#160;to amend the terms of an award agreement, as required by the Internal Revenue Code of 1986, as amended, or the Code, or with the consent as the participant, as applicable; and (x)&#160;to establish policies and procedures for the exercise of awards. </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">97</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"><font style="font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Stock Options.&#160;&#160;&#160;&#160;</font><font style="font-style:normal;">ISOs and NSOs </font><font style="font-style:normal;">were </font><font style="font-style:normal;">granted pursuant to award agreements adopted by the plan administrator. </font><font style="font-style:normal;">The</font><font style="font-style:normal;"> plan administrator </font><font style="font-style:normal;">determined </font><font style="font-style:normal;">the exercise price for a stock option, within the terms and conditions of the 2018 Plan; provided, that the exercise price of an ISO generally cannot be less than 100% (or 110% in the case of ISOs granted to certain stockholders) of the fair market value of our common stock on the date of grant. Options granted under the 2018 Plan vest at the rate specified by the plan administrator. Payment for the purchase of common stock issued upon the exercise of an option may be made (i)&#160;in cash; (ii)&#160;by good check payable to the Company or electronic funds transfer of immediately available funds to the Company; or (iii)&#160;in accordance with the terms of the applicable award agreement. The plan administrator determines the term of stock options granted under the 2018 Plan, up to a maximum of 10 years in the case of ISOs (or five years in the case of ISOs granted to certain stockholders). </font></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Changes in Capital Structure.&#160;&#160;&#160;&#160;<font style="font-style:normal;">In the event there is a specified type of change in our capital structure, such as a stock dividend, division, combination, reclassification or similar change in the capital structure of the Company, appropriate adjustments will be made to (i)&#160;the number of shares authorized or reserved for issuance under the 2018 Plan; and (ii)&#160;the exercise prices of and number of shares subject to outstanding awards under the 2018 Plan. </font></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Transferability.&#160;&#160;&#160;&#160;<font style="font-style:normal;">A participant may not transfer stock awards under our 2018 Plan other than by will, the laws of descent and distribution, or as otherwise provided under our 2018 Plan or an award granted thereunder. </font></p>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:2.26%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Nonqualified Deferred Compensation </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our named executive officers did not participate in, or earn any benefits under, a nonqualified deferred compensation plan sponsored by us during fiscal 2020. </p>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:2.26%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Termination or Change in Control Benefits </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our named executive officers may become entitled to certain benefits in connection with a qualifying termination. Each of our named executive officers&#8217; employment agreements entitles them to certain benefits, upon a qualifying termination. For additional discussion, please see &#8220;Employment Agreements with our Named Executive Officers.&#8221; </p>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:2.26%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Health and Welfare; Perquisites </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">All of our current named executive officers are eligible to participate in our employee benefit plans, including our medical, dental, vision, disability and life insurance plans, in each case on the same basis as all of our other employees. We generally do not provide perquisites or personal benefits to our named executive officers, except in limited circumstances (including Mr. Celebi&#8217;s housing and vehicle allowances and Dr.&#160;Pierce&#8217;s housing allowance). </p>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:2.26%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">401(k) Plan </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We maintain a safe harbor 401(k) plan that provides eligible U.S. employees with an opportunity to save for retirement on a tax advantaged basis. Eligible employees are able to defer eligible compensation up to certain limits of the Code, which are updated annually. We have the ability to make matching and discretionary contributions to the 401(k) plan. Currently, make matching contributions or discretionary contributions to the 401(k) plan up to a maximum of 4% of such employee&#8217;s annual compensation. The 401(k) plan is intended to be qualified under Section&#160;401(a) of the Code, with the related trust intended to be tax exempt under Section&#160;501(a) of the Code. As a tax-qualified retirement plan, contributions to the 401(k) plan are deductible by us when made, and contributions and earnings on those amounts are not generally taxable to the employees until withdrawn or distributed from the 401(k) plan. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Non-Employee Director Compensation </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">With the exception of the payments provided pursuant to the consulting arrangement described below, prior to our initial public offering, we had not historically paid cash retainers or other cash compensation with respect to service on our board of directors, except for reimbursement of direct expenses incurred in connection with attending meetings of the board or committees. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table sets forth information regarding the compensation earned or paid to our non-employee directors during the year ended December&#160;31, 2020. John Celebi, our President and Chief Executive Officer, is also a member of our board of directors, </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">98</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:12pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">but did not receive any additional compensation for service as a director. The compensation of Mr.&#160;Celebi as a named executive officer is set forth below under &#8220;Executive Compensation&#8212;Summary Compensation Table.&#8221; </font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.08%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Name</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.68%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Option</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Awards</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">($)(1)(2)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.68%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">All Other</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Compensation</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">($)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.68%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">($)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.08%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Bob Holmen</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.68%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">188,337</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.68%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.68%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">188,337</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">James Peyer, Ph.D.</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.68%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">62,779</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.68%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.68%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">62,779</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Samuel Broder, M.D.</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.68%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">62,779</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.68%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">84,000</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(3)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.68%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">146,779</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Thomas Ricks</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.68%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">62,779</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.68%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.68%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">62,779</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;border-bottom:Solid 0.75pt;padding-bottom:1pt;margin-top:0pt;margin-right:66.67%;text-indent:0%;font-size:6pt;font-family:Times New Roman;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:2pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1)</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:2pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Amounts reported represent the aggregate grant date fair value of option awards granted to our directors during 2020 under our 2018 Stock Incentive Plan, as amended, or 2018 Plan, computed in accordance with Financial Accounting Standard Board Accounting Standards Codification, Topic&#160;718, or ASC Topic&#160;718. The assumptions used in calculating the grant date fair value of the awards reported in this column are set forth in the notes to our audited consolidated financial statements included elsewhere in this Form 10-K. This amount does not reflect the actual economic value that may be realized by the non-employee director. </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2)</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">As of December&#160;31, 2020, Mr.&#160;Holmen, Dr.&#160;Peyer, Dr.&#160;Broder and Mr.&#160;Ricks held options to purchase 43,145, 19,520, 20,145 and 20,770&#160;shares of our common stock, respectively. </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(3)</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Consists of payments pursuant to the consulting arrangement described below. </p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:2.26%;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Non-Employee Director Compensation Policy </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our board of directors adopted a&#160;non-employee&#160;director compensation policy in January 2021 that is applicable to all of our non-employee directors. This compensation policy provides that each such non-employee director will receive the compensation described below for service on our board of directors: </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Cash compensation<font style="font-style:normal;">. Under this policy, we will pay each of our non-employee directors cash retainers for service on our board of directors and committees of our board of directors as follows: </font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Hlk67417320"></a>&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.82%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Annual Cash</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Retainer ($)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Annual retainer</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">35,000</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Additional retainer for independent chair</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">30,000</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Additional retainer for audit committee chair</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15,000</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Additional retainer for audit committee non-chair member</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,500</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Additional retainer for compensation committee chair</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,000</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Additional retainer for compensation committee non-chair member</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,000</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Additional retainer for nominating and corporate governance committee chair</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,000</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Additional retainer for nominating and corporate governance committee non-chair member</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,000</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Equity compensation.<font style="font-style:normal;"> In addition to cash compensation, each non-employee director will be eligible to receive options under our 2021 Plan. Any options granted under this policy will have a term of ten years from the date of grant, subject to earlier termination in connection with a termination of service. Vesting schedules for equity awards will be subject to the non-employee director&#8217;s continuous service on each applicable vesting date, provided that each option will vest in full upon a change in control of the company, as defined in the 2021 Plan. </font></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Initial award.<font style="font-style:normal;"> Each new non-employee director elected or appointed to our board of directors after the effective date of the policy will be granted an initial, one-time option to purchase 16,666&#160;shares of our common stock, which will vest in equal monthly installments such that the option is fully vested on the third anniversary of the grant date. On the date of the pricing of our initial public offering, each non-employee director received an option to purchase 16,666 shares of our common stock with an exercise price of $19.00 per share, which will vest in equal monthly installments such that the option is fully vested on the third anniversary of the grant date. </font></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Annual awards.<font style="font-style:normal;"> On the date of each annual meeting of stockholders of our company after the effective date of the policy, each non-employee director that continues to serve on our board of directors will be granted an option to purchase 8,333 shares of our common stock, which will vest in equal monthly installments such that the option is fully vested on the first anniversary of the grant date, provided that such option will in any case become fully vested on the date of our next annual stockholder meeting. </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">99</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:2.26%;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"><font style="font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Consulting Arrangements </font><font style="font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"><br /></font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In May 2018, we entered into an Independent Contractor and Strategic Advisory Services Agreement with Samuel Broder, M.D., pursuant to which Mr.&#160;Broder received $7,000 per month. We entered into an amended agreement as of April&#160;5, 2020, pursuant to which Mr.&#160;Broder receives $7,000 per month. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Hlk67906372"></a><a name="ITEM_12_SECURITY_OWNERSHIP_CERTAIN_BENEF"></a><a name="ITEM_12_SECURITY_OWNERSHIP_CERTAIN_BENEF"></a>Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table sets forth certain information regarding the ownership of our common stock as of March 1, 2021 by: (i)&#160;each director; (ii)&#160;each of the executive officers listed in the Summary Compensation Table; (iii)&#160;all currently serving executive officers and directors as a group; and (iv)&#160;all those known by us to be beneficial owners of more than five percent of our common stock. Except as otherwise noted below, the address for persons listed in the table is c/o<font style="Background-color:#FFFFFF;"> Sensei Biotherapeutics, Inc., 1405 Research Blvd, Suite 125, Rockville, Maryland 20850</font>.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_DV_M635"></a>&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:81.53%;">
<tr>
<td style="width:59.67%;"></td>
<td style="width:1.53%;"></td>
<td style="width:8.36%;"></td>
<td style="width:1.53%;"></td>
<td style="width:7.94%;"></td>
<td style="width:2.5%;"></td>
</tr>
<tr style="height:1pt;">
<td valign="bottom" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom"  style=" border-bottom:solid 1pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Beneficial&#160;Owner&#160;(1)</p></td>
<td valign="bottom"  style=" border-bottom:solid 1pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;&#160;&#160;</p></td>
<td valign="bottom"  style=" border-bottom:solid 1pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Number&#160;of<font style="font-weight:normal;"><br /></font>Shares<font style="font-weight:normal;"><br /></font>Beneficially<font style="font-weight:normal;"><br /></font>Owned</p></td>
<td valign="bottom"  style=" border-bottom:solid 1pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;&#160;&#160;</p></td>
<td valign="bottom"  style=" border-bottom:solid 1pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Percent&#160;of<font style="font-weight:normal;"><br /></font>Shares<font style="font-weight:normal;"><br /></font>Beneficially<font style="font-weight:normal;"><br /></font>Owned</p></td>
<td valign="bottom"  style=" border-bottom:solid 1pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style=" border-top:solid 1pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:7.2pt;;text-indent:-7.2pt;;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Greater than 5% Stockholders:</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style=" border-top:solid 1pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style=" border-top:solid 1pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:7.2pt;;text-indent:-7.2pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cambrian BioPharma Inc. (2)</p></td>
<td valign="bottom" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,780,292&#160;</p></td>
<td valign="bottom" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15.6&#160;</p></td>
<td valign="bottom" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%&#160;&#160;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:7.2pt;;text-indent:-7.2pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Future Ventures, L.P. (3)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,601,247&#160;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.2&#160;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:7.2pt;;text-indent:-7.2pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">H&amp;S Investments I, L.P. (4)</p></td>
<td valign="bottom" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,441,622&#160;</p></td>
<td valign="bottom" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14.5&#160;</p></td>
<td valign="bottom" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:7.2pt;;text-indent:-7.2pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:7.2pt;;text-indent:-7.2pt;;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Named Executive Officers and Directors:</p></td>
<td valign="bottom" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" >
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" >
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:7.2pt;;text-indent:-7.2pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">John Celebi (5)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">183,706&#160;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">*&#160;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:7.2pt;;text-indent:-7.2pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Robert Pierce, M.D. (6)</p></td>
<td valign="bottom" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">130,406</p></td>
<td valign="bottom" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">*&#160;</p></td>
<td valign="bottom" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:7.2pt;;text-indent:-7.2pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Anupama Hoey</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;&#160;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:7.2pt;;text-indent:-7.2pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Bob Holmen (7)</p></td>
<td valign="bottom" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">33,895</p></td>
<td valign="bottom" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">*&#160;</p></td>
<td valign="bottom" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:7.2pt;;text-indent:-7.2pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">James Peyer, Ph.D. (2)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,780,292&#160;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15.6&#160;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:7.2pt;;text-indent:-7.2pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Samuel Broder, M.D. (5)</p></td>
<td valign="bottom" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12,123</p></td>
<td valign="bottom" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" >
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">*</p></td>
<td valign="bottom" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:7.2pt;;text-indent:-7.2pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Thomas Ricks (8)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">315,974</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.0&#160;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:7.2pt;;text-indent:-7.2pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deneen Vojta, M.D. (5)</p></td>
<td valign="bottom" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">925</p></td>
<td valign="bottom" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" >
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">*</p></td>
<td valign="bottom" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:7.2pt;;text-indent:-7.2pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">All current directors and executive officers as a group (10 persons)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,457,321</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17.7&#160;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:13.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="g0fyk5pshdve000017.jpg" title="" alt="" style="width:122px;height:0px;"></p>
<p style="text-align:justify;margin-bottom:6pt;margin-top:0pt;margin-left:3.33%;text-indent:-3.33%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_DV_M636"></a>*Less than one percent.</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  style="width:3.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_DV_M637"></a><a name="_DV_M640"></a>(1)</p></td>
<td valign="middle"  style="width:0.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:96.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">This table is based upon information supplied by officers, directors and principal stockholders and Schedules 13D and 13G if any filed with the SEC.&#160;&#160;&#160;Unless otherwise indicated in the footnotes to this table and subject to community property laws where applicable, we believe that each of the stockholders named in this table has sole voting and investment power with respect to the shares indicated as beneficially owned.&#160;&#160;Applicable percentages are based on 30,588,495 shares outstanding on March 1, 2021, adjusted as required by rules promulgated by the SEC.</p></td>
</tr>
<tr>
<td valign="top"  style="width:3.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2)</p></td>
<td valign="middle"  style="width:0.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:96.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">Consists of 4,768,794 shares of common stock and 11,498</font> <font style="Background-color:#FFFFFF;">shares issuable pursuant to stock options exercisable within 60&#160;days following March 1, 2021 held by Cambrian Biopharma Inc, or Cambrian. Cambrian is a Delaware corporation and Mr. Peyer serves as Cambrian&#8217;s Chief Executive Officer.&#160;In such capacity Mr. Peyer may direct the voting and disposition of the shares held by Cambrian, subject in certain instances to the approval of Cambrian&#8217;s Board of Directors.&#160;Cambrian&#8217;s business address is 19 Morris Avenue, Brooklyn Navy Yard, Building 128, Brooklyn, New York 11025.</font></p></td>
</tr>
<tr>
<td valign="top"  style="width:3.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(3)</p></td>
<td valign="middle"  style="width:0.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:96.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">Consists of 1,505,746 shares of common stock held by Future Ventures, L.P. and 95,501 shares of common stock held by Future Ventures Side Fund, L.P. The shares directly held by Future Ventures L.P. and Future Ventures Side Fund, L.P. are indirectly held by Future Ventures GP, LLC, the general partner of Future Ventures, L.P. and Future Ventures Side Fund, L.P.&#160;The managing members of Future Ventures GP, LLC are Maryanna Saenko and Steve Jurvetson.&#160;Future Ventures GP, LLC, Maryanna Saenko and Steve Jurvetson&#160;may be deemed to have voting and dispositive power with respect to the shares held by Future Ventures, L.P. and Future Ventures Side Fund, L.P. The principal business address of Future Ventures, L.P. and Future Ventures Side Fund, L.P. is 465 1st Street, Los Altos, California 94022.</font></p></td>
</tr>
<tr>
<td valign="top"  style="width:3.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(4)</p></td>
<td valign="middle"  style="width:0.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:96.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">Consists of 4,425,998 shares of common stock and warrants exercisable for 15,624 shares of common stock held by H&amp;S Investments I, L.P. H&amp;S Ventures, LLC, its general partner, and Michael Schulman, manager of H&amp;S Ventures, may be deemed to have voting and dispositive power with respect to the shares held. The principal business address of H&amp;S Investments I, L.P. is 2101 E Coast Highway 3rd Floor Corona Del Mar, CA 92625.</font></p></td>
</tr>
<tr>
<td valign="top"  style="width:3.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(5)</p></td>
<td valign="middle"  style="width:0.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:96.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">Consists of shares issuable pursuant to stock options exercisable within 60&#160;days following March 1, 2021.</font></p></td>
</tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">100</p>
<hr style="page-break-after:always;width:100%;">
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  style="width:3.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</font></p></td>
<td valign="middle"  style="width:0.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:96.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">Consists of 73,463 shares of common stock and 56,943 shares issuable pursuant to stock options exercisable within 60&#160;days following March 1, 2021.</font></p></td>
</tr>
<tr>
<td valign="top"  style="width:3.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(7)</p></td>
<td valign="middle"  style="width:0.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:96.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">Consists of 16,666 shares of common stock and 17,229 shares issuable pursuant to stock options exercisable within 60&#160;days following March 1, 2021.</font></p></td>
</tr>
<tr>
<td valign="top"  style="width:3.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(8)</p></td>
<td valign="middle"  style="width:0.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:96.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">Consists of 301,769 shares of our common stock and a warrant to purchase 1,457 shares of our common stock held by Ricks Family Trust, and 12,748 shares issuable pursuant to stock options exercisable within 60&#160;days following March 1, 2021 held by Thomas Ricks. Thomas Ricks is a trustee of the Ricks Family Trust and accordingly may be deemed to have voting and dispositive power with respect to the shares held by Ricks Family Trust.</font></p></td>
</tr>
</table></div>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Equity Compensation Plan Information</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table provides certain information regarding our equity compensation plans in effect as of December&#160;31, 2020:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr style="height:1pt;">
<td valign="top"  style="width:45.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="width:2.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="width:16.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="width:2.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="width:13.76%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="width:2.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="width:16.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="width:0.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:45.32%; border-bottom:solid 1pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman Bold;font-style:normal;text-transform:none;font-variant: normal;">Plan&#160;Category</p></td>
<td valign="bottom"  style="width:2.18%; border-bottom:solid 1pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman Bold;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;&#160;&#160;</p></td>
<td valign="bottom"  style="width:16.62%; border-bottom:solid 1pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman Bold;font-style:normal;text-transform:none;font-variant: normal;">Number&#160;of&#160;securities&#160;to<font style="font-family:Times New Roman;font-weight:normal;"><br /></font>be&#160;issued&#160;upon&#160;exercise<font style="font-family:Times New Roman;font-weight:normal;"><br /></font>of&#160;outstanding&#160;options,<font style="font-family:Times New Roman;font-weight:normal;"><br /></font>warrants&#160;and&#160;rights<font style="font-family:Times New Roman;font-weight:normal;"><br /></font>(1)</p></td>
<td valign="bottom"  style="width:2.04%; border-bottom:solid 1pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman Bold;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;&#160;&#160;</p></td>
<td colspan="2" valign="bottom"  style="width:14.76%; border-bottom:solid 1pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman Bold;font-style:normal;text-transform:none;font-variant: normal;">Weighted-average<font style="font-family:Times New Roman;font-weight:normal;"><br /></font>exercise<font style="font-family:Times New Roman;font-weight:normal;"><br /></font>price&#160;of&#160;outstanding<font style="font-family:Times New Roman;font-weight:normal;"><br /></font>options,<font style="font-family:Times New Roman;font-weight:normal;"><br /></font>warrants&#160;and&#160;rights</p></td>
<td valign="bottom"  style="width:2.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman Bold;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;&#160;&#160;</p></td>
<td valign="bottom"  style="width:16.5%; border-bottom:solid 1pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman Bold;font-style:normal;text-transform:none;font-variant: normal;">Number&#160;of&#160;securities<font style="font-family:Times New Roman;font-weight:normal;"><br /></font>remaining&#160;available&#160;for<font style="font-family:Times New Roman;font-weight:normal;"><br /></font>future&#160;issuance&#160;under<font style="font-family:Times New Roman;font-weight:normal;"><br /></font>equity&#160;compensation<font style="font-family:Times New Roman;font-weight:normal;"><br /></font>plans<font style="font-family:Times New Roman;font-weight:normal;"><br /></font>(excluding&#160;securities<font style="font-family:Times New Roman;font-weight:normal;"><br /></font>reflected&#160;in&#160;column&#160;(1))</p></td>
<td valign="bottom"  style="width:0.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman Bold;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CCEEFF" style="width:45.32%; border-top:solid 1pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:7.2pt;;text-indent:-7.2pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Equity compensation plans approved by security holders:</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:2.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:16.62%; border-top:solid 1pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:2.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:1%; border-top:solid 1pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:13.76%; border-top:solid 1pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:2.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:16.5%; border-top:solid 1pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:0.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top"  style="width:45.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:21.6pt;;text-indent:-7.2pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2018 Plan</p></td>
<td valign="bottom"  style="width:2.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="width:16.62%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,951,525&#160;</p></td>
<td valign="bottom"  style="width:2.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  style="width:13.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.70&#160;</p></td>
<td valign="bottom"  style="width:2.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="width:16.5%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">600,558</p></td>
<td valign="bottom"  style="width:0.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top"  style="width:45.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:7.2pt;;text-indent:-7.2pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Equity compensation plans not approved by security holders</p></td>
<td valign="bottom"  style="width:2.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="width:16.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">465,072</p></td>
<td valign="bottom"  style="width:2.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  style="width:13.76%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9.58</p></td>
<td valign="bottom"  style="width:2.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="width:16.5%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  style="width:0.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr style="height:5.3pt;">
<td valign="top"  BGCOLOR="#CCEEFF" style="width:45.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:7.2pt;;text-indent:-7.2pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:2.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:16.62%; border-top:solid 1pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,416,597</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:2.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:13.76%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:2.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:16.5%; border-top:solid 1pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">600,558&#160;</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:0.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:13.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="g0fyk5pshdve000018.jpg" title="" alt="" style="width:122px;height:0px;"></p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:101.94%;">
<tr>
<td style="width:0.06%;"></td>
<td style="width:3.33%;"></td>
<td style="width:0.06%;"></td>
<td style="width:98.5%;"></td>
</tr>
<tr>
<td valign="middle" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:13.5pt;">&nbsp;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1)</p></td>
<td valign="middle" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Effective upon our initial public offering, no additional further options or awards may be granted under the 2018 Plan; all outstanding stock awards will continue to be governed by their existing terms.&nbsp;&nbsp;For a description of the terms of our 2018 Plan, see the section above titled <font style="color:#000000;">&#8220;Executive Compensation&#8212;Equity Incentive Plans&#8212;2018 Stock Incentive Plan.&#8221;</font></p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:13.5pt;">&nbsp;</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="ITEM_13_CERTAIN_RELATIONSHIPS_RELATED_TR"></a><a name="ITEM_13_CERTAIN_RELATIONSHIPS_RELATED_TR"></a>Item 13. Certain Relationships and Related Transactions, and Director Independence. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other than compensation arrangements for our directors and executive officers, which are described elsewhere in this Form 10-K, below we describe transactions since January&#160;1, 2019 to which we were a party or will be a party, in which: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:1.13%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">the amounts involved exceeded or will exceed $120,000; and </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:1.13%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">any of our directors, executive officers or holders of more than 5% of our voting securities, or any member of the immediate family of, or person sharing the household with, the foregoing persons, had or will have a direct or indirect material interest. </p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Series BB Convertible Preferred Stock Financing </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">From December 2020 through January 2021, we issued an aggregate of 165,956,208 shares of our Series BB convertible preferred stock at a purchase price of $0.207383 per share for an aggregate gross proceeds of $34.4 million in cash. The following table summarizes purchases of convertible preferred stock by holders of more than five percent of our voting securities and their affiliated entities, our directors and our executive officers. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Hlk67417321"></a>Name</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.82%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Series BB</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Preferred</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Stock(1)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cambrian BioPharma, Inc.</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,821,996</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Entities affiliated with Future Ventures</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,679,592</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Entities affiliated with Presight Capital</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">28,931,976</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Ricks Family Trust</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,037,849</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;border-bottom:Solid 0.75pt;padding-bottom:1pt;margin-top:0pt;margin-right:66.67%;text-indent:0%;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:2pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1)</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:2pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Upon the closing of our initial public offering, each share of our Series BB preferred stock converted into one share of common stock. </p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">101</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Series AA Convertible Preferred Stock and Warrant Financing </font></p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">From January 2020 through the date of this Form 10-K, we issued an aggregate of 747,683,172 shares of our Series AA convertible preferred stock to a total of 128 accredited investors at a price per share of $0.082135 per share. We received aggregate gross proceeds of $26.1 million for the sale of 317,608,273 shares of Series&#160;AA convertible preferred stock. The redemption of convertible notes resulted in the issuance of 219,764,874 shares of Series AA convertible preferred stock. In exchange for our convertible preferred stock series A through F, including cumulative and unpaid dividends, we issued 210,310,025 shares of Series AA convertible preferred stock as part of the Recapitalization. In connection with the issuance or our Series AA convertible preferred stock, (1)&#160;the principal and accrued interest under the Secured Note, the Existing Stockholder Notes and the Existing Bridge Note described below under the heading &#8220;&#8212;Convertible Note and Warrant Financings&#8221; converted into an aggregate of 219,764,874 shares of our Series AA convertible preferred stock, (2)&#160;we issued warrants to purchase an aggregate of 1,530,737 shares of our common stock, (3)&#160;accrued and unpaid dividends payable to holders of our convertible preferred stock, and (4)&#160;immediately prior to the issuance of our Series AA convertible preferred stock, all shares of convertible preferred stock then outstanding were converted into 210,310,025 shares of our common stock. In connection with the issuance of our Series AA convertible preferred stock, certain purchasers of Series AA convertible preferred stock were entitled to convert certain shares of common stock held by such purchaser into shares of Series AA convertible preferred stock. The following table summarizes purchases of convertible preferred stock by holders of more than five percent of our voting securities and their affiliated entities, our directors and our executive officers, as well as the number of shares of common stock such persons received upon conversion of shares of our then-outstanding convertible preferred stock. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.44%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Hlk67417322"></a>Name</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.76%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Series AA</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Convertible</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Preferred</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Stock(1)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.76%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Shares of</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Common</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Stock</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.44%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cambrian BioPharma, Inc.</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">110,729,827</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Entities affiliated with Future Ventures</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">66,962,926</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">H&amp;S Investments I, L.P.</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">209,368,245</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">34,998</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Entities affiliated with Presight Capital</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">48,974,005</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;border-bottom:Solid 0.75pt;padding-bottom:1pt;margin-top:0pt;margin-right:66.67%;text-indent:0%;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:2pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1)</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:2pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Immediately prior to the closing of our initial public offering, each share of our Series AA convertible preferred stock converted into one share of common stock. For a description of the material rights and privileges of the convertible preferred stock, see Note 8 to our audited consolidated financial statements included elsewhere in this Form 10-K. </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2)</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Includes shares acquired upon exercise of warrants in January 2021 issued in connection with the financing. </p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Convertible Note and Warrant Financings </p>
<p style="margin-bottom:0pt;margin-top:6pt;margin-left:2.26%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Transferred Note </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In March 2020, Cambrian BioPharma, Inc., or Cambrian, purchased an outstanding convertible promissory note issued by us to a prior investor and, as a result, we issued a replacement convertible promissory note, or the Transferred Note, to Cambrian in the principal amount of $1.0&#160;million. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In November 2020, Cambrian converted the Transferred Note into 31,591,824 shares of our Series AA convertible preferred stock. </p>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:2.26%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Existing Bridge Note </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In November 2019, we issued an unsecured convertible promissory note, or the Existing Bridge Note, to Cambrian, in a principal amount of $1.0&#160;million. The Existing Bridge Note converted into shares of our Series AA convertible preferred stock in the Series AA convertible preferred stock and warrant financing described above. </p>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:2.26%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Secured Note </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In September 2019, we issued a secured convertible promissory note, or the Secured Note, to H&amp;S Investments I, L.P., or H&amp;S, in a principal amount of up to a maximum of $3.0&#160;million to be paid in installments. Pursuant to the terms of the Secured Note, H&amp;S paid two installments, equal to an aggregate principal amount of $1.5&#160;million. Prior to the payment of all required installments, the Secured Note converted into shares of our Series AA convertible preferred stock in the Series AA convertible preferred stock and warrant financing described above. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In connection with the issuance of the Secured Note, we entered into a Security Agreement with H&amp;S, providing for a security interest in all of our (1)&#160;goods and equipment, (2)&#160;inventory, (3) contract rights and general intangibles, (4)&#160;accounts, accounts </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">102</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:12pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">receivable, royalties, license rights and all other forms of obligation arising out of the sale or leads or good, the licensing of technology or the rendering of services, (4)&#160;commercial tort claims, (5)&#160;documents, cash, deposit accounts, securities, investment property, letters of credit, certificates of deposit, instruments, chattel paper and supporting obligation, (6)&#160;all patents and patent application, and (7)&#160;any claims, rights and interests in any of the aforementioned property. </font></p>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:2.26%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Existing Stockholder Notes and Warrants </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">From December 2018 to November 2019, we issued unsecured convertible promissory notes, or collectively, the Existing Stockholder Notes, to certain of our existing stockholders in an aggregate principal amount of $11.4&#160;million. In connection with the issuance of the Existing Stockholder Notes, we issued warrants to purchase an aggregate of 26,823 shares of our common stock to the holders of the Existing Stockholder Notes. The following table summarizes purchases of our Existing Stockholder Notes and the issuance of the related warrants to purchase common stock by our directors, executive officers and holders of more than 5% of any class of our capital stock: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Hlk67417323"></a>Name</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Principal</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Amount of</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Existing Stockholder</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Notes</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Warrants to</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Purchase</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Common</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Stock</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">H&amp;S Investments I, L.P.</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,000,000</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15,624</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Ricks Family Trust</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">375,000</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,457</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Existing Stockholder Notes converted into shares of our Series AA convertible preferred stock in the Series AA convertible preferred stock and warrant financing described above. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Investors&#8217; Rights Agreement </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are party to an investors&#8217; rights agreement, or IRA with certain holders of our convertible preferred stock, including our 5% stockholders and their affiliates. The IRA provides these stockholders with certain registration rights, including the right to demand that we file a registration statement or request that their shares be covered by a registration statement that we are otherwise filing, and also the right to obligate us to an agreement to provide for additional rights to demand that we file a registration statement or request that their shares be covered by a registration statement that we have filed and maintain as effective. The IRA provided these stockholders with information rights, which terminated immediately before consummation of our initial public offering. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Consulting Agreement</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In December 2020, we entered into a consulting agreement with Apeiron Advisory Ltd., or Apeiron Advisory, an affiliate of Presight Sensei Co-Invest Fund, L.P., one of the holders of more than 5% of our voting securities. Pursuant to the consulting agreement, Apeiron Advisory provided us with strategic and development-related advice in exchange for a one-time retaining fee of $1.5 million, which we paid to Apeiron Advisory in January 2021.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Business Combination </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In May 2020, we entered into a Stock Purchase Agreement to purchase 100% of the shares of Alvaxa. Dr.&#160;Pierce, the Company&#8217;s Chief Scientific Officer, and his spouse together held a majority of the shares of Alvaxa. Under the Stock Purchase Agreement, we paid an aggregate of $0.2&#160;million and issued 304,376 shares of our common stock to the shareholders of Alvaxa. Dr.&#160;Pierce and his spouse collectively received $70,336 and 169,286 shares of our common stock in connection with the acquisition. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Indemnification Agreements </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our amended and restated certificate of incorporation contains provisions limiting the liability of directors, and our amended and restated bylaws provides that we will indemnify each of our directors and officers to the fullest extent permitted under Delaware law. Our amended and restated certificate of incorporation and amended and restated bylaws also provide our board of directors with discretion to indemnify our employees and other agents when determined appropriate by the board. In addition, we have entered into an indemnification agreement with each of our directors and executive officers, which requires us to indemnify them. For more information regarding these agreements, see the section titled &#8220;Executive Compensation&#8212;Limitations of Liability and Indemnification Matters.&#8221; </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">103</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Policies and Procedures for Related Person Transactions </font></p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our board of directors has adopted a written related person transaction policy setting forth the policies and procedures for the review and approval or ratification of related-person transactions. This policy covers, with certain exceptions set forth in Item 404 of Regulation S-K under the Securities Act, any transaction, arrangement or relationship, or any series of similar transactions, arrangements or relationships in which we were or are to be a participant, where the amount involved exceeds $120,000 and a related person had or will have a direct or indirect material interest, including, without limitation, purchases of goods or services by or from the related person or entities in which the related person has a material interest, indebtedness, guarantees of indebtedness and employment by us of a related person. In reviewing and approving any such transactions, our audit committee is tasked to consider all relevant facts and circumstances, including whether the transaction is on terms comparable to those that could be obtained in an arm&#8217;s length transaction and the extent of the related person&#8217;s interest in the transaction. All of the transactions described in this section occurred prior to the adoption of this policy. <font style="font-size:1pt;">&#160;</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman Bold;font-style:normal;text-transform:none;font-variant: normal;">Director Independence</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_DV_C132"></a><a name="_DV_M340"></a><a name="_DV_M342"></a><a name="_DV_C140"></a><a name="_DV_M343"></a><a name="_DV_C132"></a><a name="_DV_M340"></a>As required under&#160;the&#160;Nasdaq&#160;listing standards, a majority of<a name="_DV_M342"></a> the members of a listed company&#8217;s board of directors must qualify as &#8220;independent,&#8221; as affirmatively determined by the Board.<a name="_DV_C140"></a><a name="_DV_M343"></a>&#160;The Board consults with our counsel to ensure that the Board&#8217;s determinations are consistent with relevant securities and other laws and regulations regarding the definition of &#8220;independent,&#8221; including those set forth in pertinent listing standards of&#160;Nasdaq, as in effect from time to time.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_DV_M344"></a><a name="_DV_C142"></a>Consistent with these considerations, after review of all relevant identified transactions or relationships between each director, or any of his or her family members, and our company, senior management and independent auditors, the Board has affirmatively determined that all of<a name="_DV_C142"></a> our directors are independent directors within the meaning of the applicable&#160;Nasdaq&#160;listing standards with the exception of Mr. Celebi.&#160;&#160;In making these determinations, the Board found that none of these directors or nominees for director had a material or other disqualifying relationship with our company.&#160;</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="ITEM_14_PRINCIPAL_ACCOUNTING_FEES_SERVIC"></a><a name="ITEM_14_PRINCIPAL_ACCOUNTING_FEES_SERVIC"></a>Item 14. Principal Accounting Fees and Services. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table represents aggregate fees billed to us for the fiscal years ended December&#160;31, 2020 and 2019 by our principal accountants. All such fees described below were approved by the audit committee. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.14%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"><a name="_Hlk67671468"></a>(in thousands)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.14%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fiscal year</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">ended</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fiscal year</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">ended</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Audit fees(1)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">412</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">230</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Audit-related fees(2)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,304</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.14%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Tax fees(3)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">30</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">26</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.14%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,746</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">256</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="border-bottom:Solid 0.75pt;padding-bottom:1pt;margin-bottom:0pt;margin-top:0pt;margin-right:66.67%;text-indent:0%;font-size:6pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:2pt;margin-left:4.54%;text-indent:-4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1)<font style="font-size:3pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font>Audit fees consists of fees billed or incurred for professional services rendered in connection with the audit of our consolidated financial statements and review of the interim condensed consolidated financial statements included in our quarterly reports.</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:-4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2)<font style="font-size:3pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font>Audit-related fees includes fees billed or incurred for professional services rendered in connection with our initial public offering.</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:-4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(3)<font style="font-size:3pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font>Tax fees includes services related to the preparation or review of the U.S. federal, state and local tax returns, and other advisory and professional services.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">All fees described above were pre-approved by our audit committee following our initial public offering or by our Board of Directors.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our audit committee has adopted a policy and procedures for the pre-approval of audit and, if applicable, non-audit services rendered by our independent registered public accounting firm. The policy generally pre-approves specified services in the defined categories of audit services, audit-related services, and tax services up to specified amounts. Pre-approval may also be given as part of the audit committee&#8217;s approval of the scope of the engagement of the independent registered public accounting firm or on an individual explicit case-by-case basis before the independent registered public accounting firm is engaged to provide each service. On a periodic basis, the independent registered public accounting firm reports to the audit committee on the status of actual costs for approved services against the approved amounts.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">104</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">PART IV </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="ITEM_15_EXHIBITS_FINANCIAL_STATEMENT_SCH"></a><a name="ITEM_15_EXHIBITS_FINANCIAL_STATEMENT_SCH"></a>Item 15. Exhibits, Financial Statement Schedules. </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(3)</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Exhibits</p></td></tr></table></div>
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:4.54%;text-indent:-4.54%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="border-bottom:Solid 0.75pt;padding-bottom:1pt;margin-bottom:0pt;margin-top:0pt;margin-right:86.67%;text-indent:0%;font-size:6pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Number</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:89%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Description</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:89%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">2.1+&#94;</font></p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:89%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/0001829802/000119312521010054/d43789dex21.htm"><font style="Background-color:#FFFFFF;text-decoration:underline;">Stock Purchase Agreement, by and among Sensei Biotherapeutics, Inc. and the stockholders of Alvaxa Biosciences, Inc., dated as of May&#160;18, 2020 </font><font style="text-decoration:underline;">(incorporated by reference to </font><font style="Background-color:#FFFFFF;text-decoration:underline;">Exhibit 2.1 to the Registrant&#8217;s Registration Statement on Form&#160;S-1&#160;(File&#160;No.&#160;333-252138)).</font></a></p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">3.1</font></p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:89%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1557746/000110465915070341/a15-21034_1ex3d1.htm"><font style="text-decoration:underline;">Amended and Restated Certificate of Incorporation </font><font style="Background-color:#FFFFFF;text-decoration:underline;">(incorporated by reference to Exhibit&#160;3.1 to the Registrant&#8217;s Current Report on Form&#160;8-K (File No.&#160;001-3</font><font style="text-decoration:underline;">9980</font><font style="Background-color:#FFFFFF;text-decoration:underline;">), filed with the SEC on F</font><font style="text-decoration:underline;">ebruary 11, 2021</font><font style="Background-color:#FFFFFF;text-decoration:underline;">).</font></a></p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">3.2</font></p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:89%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1557746/000110465915070341/a15-21034_1ex3d1.htm"><font style="text-decoration:underline;">Amended and Restated Bylaws </font><font style="Background-color:#FFFFFF;text-decoration:underline;">(incorporated by reference to Exhibit&#160;3.2 to the Registrant&#8217;s Current Report on Form&#160;8-K (File No.&#160;001-3</font><font style="text-decoration:underline;">9980</font><font style="Background-color:#FFFFFF;text-decoration:underline;">), filed with the SEC on F</font><font style="text-decoration:underline;">ebruary 11, 2021</font><font style="Background-color:#FFFFFF;text-decoration:underline;">).</font></a></p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">4.1</font></p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:89%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1829802/000119312521023615/d43789dex41.htm"><font style="Background-color:#FFFFFF;text-decoration:underline;">Investors&#8217; Rights Agreement, dated as of December 29, 2020, by and among the Registrant and certain of its stockholders </font><font style="text-decoration:underline;">(incorporated by reference to Exhibit 4.1 to the Registrant&#8217;s Registration Statement on Form&#160;S-1&#160;(File&#160;No.&#160;333-252138)).</font></a></p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">4.2</font></p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:89%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Forms of Warrant to Purchase Common Stock (incorporated by reference to Exhibits <a href="http://www.sec.gov/Archives/edgar/data/1829802/000119312521023615/d43789dex42.htm"><font style="text-decoration:underline;">4.2</font></a><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, </font><a href="http://www.sec.gov/Archives/edgar/data/1829802/000119312521023615/d43789dex42.htm"><a href="http://www.sec.gov/Archives/edgar/data/1829802/000119312521023615/d43789dex43.htm"><font style="text-decoration:underline;">4.3</font></a><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> and </font><a href="http://www.sec.gov/Archives/edgar/data/1829802/000119312521023615/d43789dex42.htm"><a href="http://www.sec.gov/Archives/edgar/data/1829802/000119312521023615/d43789dex43.htm"><a href="http://www.sec.gov/Archives/edgar/data/1829802/000119312521023615/d43789dex44.htm"><font style="text-decoration:underline;">4.4</font></a><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> to the Registrant&#8217;s Registration Statement on Form&#160;S-1&#160;(File&#160;No.&#160;333-252138)).</font></p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">4.3*</font></p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:89%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="snse-ex43_634.htm"><font style="text-decoration:underline;">Description of Securities.</font></a></p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">10.1#</font></p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:89%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/0001829802/000119312521010054/d43789dex101.htm"><font style="Background-color:#FFFFFF;text-decoration:underline;">Sensei Biotherapeutics, Inc. 2018 Equity Incentive Plan, as amended, and forms of agreements thereunder </font><font style="text-decoration:underline;">(incorporated by reference to Exhibit 10.1 to the Registrant&#8217;s Registration Statement on Form&#160;S-1&#160;(File&#160;No.&#160;333-252138)).</font></a></p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">10.2#</font></p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:89%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/0001829802/000119312521023615/d43789dex102.htm"><font style="Background-color:#FFFFFF;text-decoration:underline;">Sensei Biotherapeutics, Inc. 2021 Equity Incentive Plan and forms of agreements thereunder </font><font style="text-decoration:underline;">(incorporated by reference to Exhibit 10.2 to the Registrant&#8217;s Registration Statement on Form&#160;S-1&#160;(File&#160;No.&#160;333-252138)).</font></a></p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">10.3+</font></p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:89%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/0001829802/000119312521010054/d43789dex103.htm"><font style="Background-color:#FFFFFF;text-decoration:underline;">Non-exclusive&#160;License Agreement, by and between Alvaxa Biosciences, Incorporated and Fred Hutch Cancer Research Center, dated as of January&#160;3, 2020 </font><font style="text-decoration:underline;">(incorporated by reference to Exhibit 10.3 to the Registrant&#8217;s Registration Statement on Form&#160;S-1&#160;(File&#160;No.&#160;333-252138))</font><font style="Background-color:#FFFFFF;text-decoration:underline;">.</font></a></p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">10.4#</font></p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:89%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/0001829802/000119312521010054/d43789dex104.htm"><font style="Background-color:#FFFFFF;text-decoration:underline;">Form of Indemnification Agreement entered into by and between Sensei Biotherapeutics, Inc. and each director and executive officer (incorporated by reference to Exhibit 10.4 to the Registrant&#8217;s Registration Statement on Form&#160;S-1&#160;(File&#160;No.&#160;333-252138)).</font></a></p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">10.5</font></p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:89%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/0001829802/000119312521010054/d43789dex108.htm"><font style="text-decoration:underline;">Independent Contractor and Strategic Advisory Services Agreement entered into by and between Sensei Biotherapeutics, Inc. and Samuel Broder M.D., dated as of May&#160;8, 2018, as amended on April&#160;5, 2020 (incorporated by reference to Exhibit 10.8 to the Registrant&#8217;s Registration Statement on Form&#160;S-1&#160;(File&#160;No.&#160;333-252138)).</font></a></p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">10.6</font></p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:89%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/0001829802/000119312521010054/d43789dex109.htm"><font style="Background-color:#FFFFFF;text-decoration:underline;">Lease Agreement, by and between Sensei Biotherapeutics, Inc. and Are-Maryland No. 8 Corp., dated as of October 22, 2020 (incorporated by reference to Exhibit 10.9 to the Registrant&#8217;s Registration Statement on Form&#160;S-1&#160;(File&#160;No.&#160;333-252138)).</font></a></p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">10.7#</font></p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:89%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/0001829802/000119312521023615/d43789dex1010.htm"><font style="Background-color:#FFFFFF;text-decoration:underline;">Sensei Biotherapeutics, Inc. 2021 Employee Stock Purchase Plan</font><font style="text-decoration:underline;"> (incorporated by reference to Exhibit 10.10 to the Registrant&#8217;s Registration Statement on Form&#160;S-1&#160;(File&#160;No.&#160;333-252138)).</font></a></p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">10.8#</font></p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:89%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/0001829802/000119312521023615/d43789dex1012.htm"><font style="Background-color:#FFFFFF;text-decoration:underline;">Amended and Restated Employment Agreement, by and between Sensei Biotherapeutics, Inc. and John Celebi, dated as of January&#160;28, 2021 (incorporated by reference to Exhibit 10.12 to the Registrant&#8217;s Registration Statement on Form&#160;S-1&#160;(File&#160;No.&#160;333-252138)).</font></a></p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">10.9#</font></p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:89%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/0001829802/000119312521023615/d43789dex1013.htm"><font style="Background-color:#FFFFFF;text-decoration:underline;">Amended and Restated Employment Agreement, by and between Sensei Biotherapeutics, Inc. and Marie-Louise Fjaellskog, dated as of January&#160;28, 2021 (incorporated by reference to Exhibit 10.13 to the Registrant&#8217;s Registration Statement on Form&#160;S-1&#160;(File&#160;No.&#160;333-252138)).</font></a></p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">10.10#</font></p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:89%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/0001829802/000119312521023615/d43789dex1014.htm"><font style="Background-color:#FFFFFF;text-decoration:underline;">Amended and Restated Employment Agreement, by and between Sensei Biotherapeutics, Inc. and Robert&#160;H. Pierce, dated as of January&#160;28, 2021 (incorporated by reference to Exhibit 10.14 to the Registrant&#8217;s Registration Statement on Form&#160;S-1&#160;(File&#160;No.&#160;333-252138)).</font></a></p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">10.11#</font></p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:89%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/0001829802/000119312521023615/d43789dex1015.htm"><font style="Background-color:#FFFFFF;text-decoration:underline;">Amended and Restated Employment Agreement, by and between Sensei Biotherapeutics, Inc. and Anupama Hoey, dated as of January&#160;28, 2021 (incorporated by reference to Exhibit 10.15 to the Registrant&#8217;s Registration Statement on Form&#160;S-1&#160;(File&#160;No.&#160;333-252138)).</font></a></p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">10.12*#</font></p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:89%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="snse-ex1012_633.htm"><font style="text-decoration:underline;">Non-Employee Director Compensation Policy.</font></a></p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">21.1</font></p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:89%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1829802/000119312521010054/d43789dex211.htm"><font style="text-decoration:underline;">Subsidiaries of the Registrant (incorporated by reference to Exhibit 21.1 to the Registrant&#8217;s Registration Statement on Form S-1 (File No. 333-252138)).</font></a></p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">23.1*</font></p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:89%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="snse-ex231_632.htm"><font style="Background-color:#FFFFFF;text-decoration:underline;">Consent of Deloitte&#160;&amp; Touche LLP, independent registered public accounting firm.</font></a></p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">31.1*</font></p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:89%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="snse-ex311_9.htm"><font style="text-decoration:underline;">Certification of Principal Executive Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</font></a></p></td>
</tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">105</p>
<hr style="page-break-after:always;width:100%;">
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:89%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">31.2*</font></p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:89%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="snse-ex312_8.htm"><font style="text-decoration:underline;">Certification of Principal Financial Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</font></a></p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:89%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">32.1**</font></p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:89%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="snse-ex321_7.htm"><font style="text-decoration:underline;">Certification of Principal Executive Officer and Principal Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</font></a></p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:89%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
</table></div>
<p style="border-bottom:Solid 0.75pt;padding-bottom:1pt;margin-bottom:0pt;margin-top:0pt;margin-right:86.67%;text-indent:0%;font-size:6pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">*</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Filed herewith.</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">**</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#FFFFFF;color:#000000;">This certification is being furnished solely to accompany this Annual Report pursuant to 18 U.S.C. Section 1350, and are not being filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and is not to be incorporated by reference into any filing of the Registrant, whether made before or after the date hereof, regardless of any general incorporation language in such filing.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">+</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Portions of this exhibit (indicated by asterisks) have been omitted as the Registrant has determined that (i)&#160;the omitted information is not material and (ii)&#160;the omitted information would likely cause competitive harm if publicly disclosed.</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#94;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pursuant to Item 601(b)(2) of Regulation&#160;S-K,&#160;the schedules and exhibits to this agreement are omitted, but will be furnished to the Securities and Exchange Commission upon request.</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">#</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Indicates management contract or compensatory plan.</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="ITEM_16_FORM_10K_SUMMARY"></a><a name="ITEM_16_FORM_10K_SUMMARY"></a>Item 16. Form 10-K Summary</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">None.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">106</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">SIGNATURES</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pursuant to the requirements of Section&#160;13 or 15(d) of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this Report to be signed on its behalf by the undersigned, thereunto duly authorized<font style="font-weight:bold;">.</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:12pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.76%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:39.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:55.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Sensei Biotherapeutics, Inc.</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.76%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:39.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:4.76%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Date:</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:39.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> March 30, 2021</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.5%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By:</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.4%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/&#160;John Celebi</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.76%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:39.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.4%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">John Celebi</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.76%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:39.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.4%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">President and Chief Executive Officer</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, this Report has been signed below by the following persons on behalf of the Registrant in the capacities and on the dates indicated.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:32%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Name</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:32%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Title</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:32%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Date</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:32%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:4pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:4pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:32%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:4pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:4pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:32%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:4pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:32%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/&#160;John Celebi</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:32%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">President, Chief Executive Officer and Director (<font style="font-style:italic;">Principal Executive Officer</font>)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:32%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">March 30, 2021</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:32%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">John Celebi</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:32%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:4pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:4pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:32%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:4pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:4pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:32%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/&#160;Erin Colgan</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:32%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Senior Vice President of Finance and Administration (<font style="font-style:italic;">Principal Financial and Accounting Officer)</font></p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:32%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">March 30, 2021</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:32%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Erin Colgan</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:32%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:4pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:4pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:4pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:4pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:4pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:32%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/&#160;Bob Holmen</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:32%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Director</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:32%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">March 30, 2021</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:32%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Bob Holmen</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:32%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:4pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:4pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:4pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:4pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:4pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:32%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/&#160;James Peyer, Ph.D.</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:32%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Director</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:32%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">March 30, 2021</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:32%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">James Peyer, Ph.D.</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:32%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:4pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:4pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:4pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:4pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:4pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:32%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/&#160;Samuel Broder, M.D.</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:32%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Director</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:32%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">March 30, 2021</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:32%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Samuel Broder, M.D.</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:32%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:4pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:4pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:4pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:4pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:4pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:32%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/&#160;Thomas Ricks</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:32%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Director</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:32%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">March 30, 2021</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:32%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Thomas Ricks</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:32%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:4pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:4pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:4pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:4pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:4pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:32%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/&#160;Deneen Vojta</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:32%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Director</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:32%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">March 30, 2021</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:32%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Deneen Vojta</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:32%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:4pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:4pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:4pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:4pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:4pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">107</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">SENSEI BIOTHERAPEUTICS, INC. </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">INDEX TO FINANCIAL STATEMENTS </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:90.88%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-weight:normal;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:9.12%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Page</p></td>
</tr>
<tr>
<td valign="top"  style="width:90.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#REPORT_INDEPENDENT_REGISTERED_PUBLIC_ACC"><font style="text-decoration:underline;">Report of Independent Registered Public Accounting Firm</font></a></p></td>
<td valign="bottom"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:9.12%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-2</p></td>
</tr>
<tr>
<td valign="top"  style="width:90.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#CONSOLIDATED_BALANCE_SHEETS"><font style="text-decoration:underline;">Consolidated Balance Sheets as of December 31, 2020 and 2019</font></a></p></td>
<td valign="bottom"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:9.12%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-3</p></td>
</tr>
<tr>
<td valign="top"  style="width:90.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#CONSOLIDATED_STATEMENTS_OPERATIONS"><font style="text-decoration:underline;">Consolidated Statements of Operations for the Years Ended December 31, 2020 and 2019</font></a></p></td>
<td valign="bottom"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:9.12%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-4</p></td>
</tr>
<tr>
<td valign="top"  style="width:90.88%;">
<p style="margin-bottom:1pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#CONSOLIDATED_STATEMENTS_CONVERTIBLE_PREF"><font style="text-decoration:underline;">Consolidated Statements of Convertible Preferred Stock, Common Stock and Stockholders&#8217; Deficit for the Years Ended December 31, 2020 and 2019</font></a></p></td>
<td valign="bottom"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:9.12%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-5</p></td>
</tr>
<tr>
<td valign="top"  style="width:90.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#CONSOLIDATED_STATEMENTS_CASH_FLOWS"><font style="text-decoration:underline;">Consolidated Statements of Cash Flows for the Years Ended December 31, 2020 and 2019</font></a></p></td>
<td valign="bottom"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:9.12%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-6</p></td>
</tr>
<tr>
<td valign="top"  style="width:90.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#NOTES_TO_CONSOLIDATED_FINANCIAL_STATEMEN"><font style="text-decoration:underline;">Notes to Consolidated Financial Statements</font></a></p></td>
<td valign="bottom"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:9.12%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-7</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-1</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="REPORT_INDEPENDENT_REGISTERED_PUBLIC_ACC"></a><a name="REPORT_INDEPENDENT_REGISTERED_PUBLIC_ACC"></a>REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">To the shareholders&#160;and the Board of Directors of Sensei Biotherapeutics, Inc.</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Opinion on the Financial Statements </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">We have audited the accompanying consolidated balance sheets&#160;of Sensei Biotherapeutics, Inc. and subsidiary (the "Company") as of December 31, 2020 and 2019, the related consolidated statements of operations, convertible preferred stock, common stock and stockholders&#8217; deficit, and cash flows, for each of the years then ended, and the related notes (collectively referred to as the "financial statements"). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2020 and 2019, and the results of its operations and its cash flows for the years then ended, in conformity with accounting principles generally accepted in the United States of America.</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Basis for Opinion </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">These financial statements are the responsibility of the Company's management. Our responsibility is to express an opinion on the Company's financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits, we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company&#8217;s internal control over financial reporting. Accordingly, we express no such opinion.</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ Deloitte &amp; Touche LLP </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Baltimore, Maryland </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">March 30, 2021</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have served as the Company&#8217;s auditor since 2016.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-2</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">SENSEI BIOTHERAPEUTICS, INC. </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="CONSOLIDATED_BALANCE_SHEETS"></a><a name="CONSOLIDATED_BALANCE_SHEETS"></a>CONSOLIDATED BALANCE SHEETS </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(In thousands, except share and per share data) </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.14%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.86%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.86%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Hlk67671469"></a>Assets</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Current assets:</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash and cash equivalents</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16,596</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">251</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred offering costs</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,105</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.14%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prepaid expenses</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,375</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">251</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total current assets</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20,076</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">502</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property and equipment, net</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,266</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">268</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.14%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deposits</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">86</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">447</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.14%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total assets</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21,428</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,217</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Liabilities, convertible preferred stock and stockholders&#8217; deficit</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Current liabilities:</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accounts payable and accrued liabilities</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,882</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,547</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Current portion of long-term debt, $6,187 with related parties as</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; December 31, 2019</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16,055</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued interest, including $323 with related parties as of December 31, 2019</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,398</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.14%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other liabilities</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">948</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">714</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total current liabilities</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,830</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21,714</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Debt</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">567</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.14%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other non-current liabilities</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">138</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">620</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total liabilities</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,535</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">22,334</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Commitments and contingencies (Note 7)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Convertible preferred stock (Series A-F), $0.0001 par value; no shares</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; authorized, issued or outstanding at December 31, 2020; 20,000,000 shares</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; authorized, 15,257,663 issued and outstanding at December 31, 2019</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">47,545</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Convertible preferred stock (Series AA), $0.0001 par value; 870,211,737 shares</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; authorized, 747,683,172 issued and outstanding at December 31, 2020;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; liquidation value of $61,411 thousand at December 31, 2020; no shares</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; authorized, issued or outstanding at December 31, 2019</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">61,411</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Convertible preferred stock (Series BB), $0.0001 par value; 870,211,737 shares</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; authorized, 52,680,306 issued and outstanding at December 31, 2020;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; liquidation value of $10,925 thousand at December 31, 2020; no shares</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; authorized, issued or outstanding at December 31, 2019</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,925</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stockholders&#8217; deficit:</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Common stock, $0.0001 par value; 1,230,000,000 shares authorized as of</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; December 31, 2020, 1,875,422 shares and 369,491 shares issued and</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; outstanding at December 31, 2020 and December 31, 2019, respectively</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Additional paid-in capital</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">55,969</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">23,650</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.14%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accumulated deficit</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(112,412</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(92,312</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.14%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total stockholders&#8217; deficit</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(56,443</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(68,662</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.14%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total liabilities, convertible preferred stock and stockholders&#8217; deficit</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21,428</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,217</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:2pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">The accompanying notes are an integral part of these consolidated financial statements. </p><a name="_AEIOULastRenderedPageBreakAEIOU9"></a>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-3</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">SENSEI BIOTHERAPEUTICS, INC. </font></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="CONSOLIDATED_STATEMENTS_OPERATIONS"></a><a name="CONSOLIDATED_STATEMENTS_OPERATIONS"></a>CONSOLIDATED STATEMENTS OF OPERATIONS </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(In thousands, except share and per share data) </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December 31,</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Hlk67671470"></a>&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating expenses:</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11,185</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,350</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">General and administrative</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,528</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,085</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Alvaxa IPR&amp;D</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">738</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total operating expenses</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">19,451</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12,435</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Loss from operations</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(19,451</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(12,435</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other expense:</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Interest expense, including $645 and $320 with related parties in</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; 2020 and 2019, respectively</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,689</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2,256</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Fair value adjustments on embedded debt derivatives, including</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; $575 and $1,070 with related parties in 2020 and 2019,</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; respectively</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">995</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,973</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Gain (loss) on debt extinguishment</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">45</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(75</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other (expense) income, net</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(20,100</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(16,740</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cumulative dividends on convertible preferred stock</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(104</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(3,804</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss attributable to common stockholders</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(20,204</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(20,544</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss per common share, basic and diluted</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(12.53</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(55.92</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Weighted-average number of shares used in computing net loss per</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; common share, basic and diluted</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,612,140</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">367,359</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">The accompanying notes are an integral part of these consolidated financial statements. </p><a name="_AEIOULastRenderedPageBreakAEIOU10"></a>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-4</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">SENSEI BIOTHERAPEUTICS, INC. </font></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="CONSOLIDATED_STATEMENTS_CONVERTIBLE_PREF"></a><a name="CONSOLIDATED_STATEMENTS_CONVERTIBLE_PREF"></a>CONSOLIDATED STATEMENTS OF CONVERTIBLE PREFERRED STOCK, COMMON STOCK AND STOCKHOLDERS&#8217; DEFICIT </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(In thousands, except share data) </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.58%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Convertible</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Preferred Stock</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Series A-F)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.58%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Convertible</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Preferred Stock</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Series AA)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.58%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Convertible</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Preferred Stock</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Series BB)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.66%; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.66%; border-left:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.58%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Common Stock</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.44%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Additional</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Paid-In</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.44%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Accumulated</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.44%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Stockholders&#8217;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:20.9%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.66%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Shares</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Amount</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Shares</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Amount</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.66%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Shares</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Amount</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.66%; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.66%; border-left:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Shares</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Amount</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.66%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.44%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Capital</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.44%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Deficit</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.44%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Deficit</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:20.9%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Balance at January 1, 2019</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.66%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15,257,663</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.66%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">47,545</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.66%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.66%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.66%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.66%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.66%; border-right:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.66%; border-left:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">367,213</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.66%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.66%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">22,092</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.66%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(75,572</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.66%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(53,480</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock-based compensation</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; expense</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.44%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.44%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.44%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.44%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.44%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.44%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.66%; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.66%; border-left:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.44%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.44%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.44%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,176</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.44%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.44%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,176</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exercise of common stock</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; warrants</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.44%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.44%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.44%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.44%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.44%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.44%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.66%; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.66%; border-left:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.44%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,278</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.44%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.44%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">154</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.44%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.44%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">154</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Issuance of common stock</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; warrants</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.44%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.44%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.44%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.44%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.44%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.44%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.66%; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.66%; border-left:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.44%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.44%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.44%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">228</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.44%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.44%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">228</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:20.9%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.66%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.44%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.66%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.44%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.66%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.44%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.66%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.44%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.66%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.44%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.66%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.44%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.66%; border-right:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.66%; border-left:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.44%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.66%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.44%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.66%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.44%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.66%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.44%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(16,740</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.66%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.44%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(16,740</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:20.9%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Balance at December 31,</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; 2019</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.66%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.44%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15,257,663</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.66%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.44%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">47,545</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.66%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.44%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.66%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.44%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.66%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.44%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.66%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.44%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.66%; border-right:solid 0.75pt #000000; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.66%; border-left:solid 0.75pt #000000; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.44%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">369,491</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.66%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.44%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.66%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.44%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">23,650</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.66%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.44%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(92,312</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.66%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.44%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(68,662</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock-based compensation</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; expense</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.44%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.44%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.44%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.44%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.44%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.44%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.66%; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.66%; border-left:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.44%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.44%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.44%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,492</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.44%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.44%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,492</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Conversion of series</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; A,B,C,D,E,F preferred</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; stock into common stock</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.44%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(15,257,663</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.44%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(47,545</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.44%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.44%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.44%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.44%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.66%; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.66%; border-left:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.44%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">627,871</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.44%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.44%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">47,545</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.44%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.44%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">47,545</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Conversion of common</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; stock into series AA</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; preferred stock</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.44%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.44%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.44%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">210,310,025</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.44%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17,274</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.44%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.44%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.66%; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.66%; border-left:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.44%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(148,732</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.44%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.44%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(17,274</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.44%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.44%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(17,274</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Preferred stock issued in</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; exchange for note</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; redemption</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.44%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.44%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.44%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">219,764,872</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.44%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">18,050</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.44%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.44%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.66%; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.66%; border-left:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.44%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.44%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.44%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.44%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.44%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Issuance of series AA</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; preferred stock</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.44%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.44%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.44%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">317,608,275</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.44%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">26,087</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.44%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.44%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.66%; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.66%; border-left:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.44%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.44%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.44%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.44%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.44%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Issuance of series BB</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; preferred stock</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.44%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.44%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.44%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.44%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.44%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">52,680,306</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.44%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,925</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.66%; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.66%; border-left:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.44%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.44%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.44%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.44%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.44%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Issuance of common stock</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.44%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.44%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.44%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.44%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.44%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.44%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.66%; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.66%; border-left:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.44%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">705,750</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.44%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.44%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.44%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.44%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exercise of options into</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; common stock</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.44%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.44%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.44%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.44%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.44%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.44%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.66%; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.66%; border-left:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.44%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16,666</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.44%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.44%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.44%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.44%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Issuance of common stock</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; related to Alvaxa</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; IPR&amp;D acquisition</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.44%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.44%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.44%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.44%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.44%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.44%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.66%; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.66%; border-left:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.44%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">304,376</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.44%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.44%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">541</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.44%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.44%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">541</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:20.9%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.66%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.44%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.66%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.44%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.66%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.44%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.66%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.44%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.66%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.44%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.66%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.44%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.66%; border-right:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.66%; border-left:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.44%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.66%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.44%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.66%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.44%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.66%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.44%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(20,100</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.66%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.44%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(20,100</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:20.9%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Balance at December 31,</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; 2020</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.66%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.44%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.66%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.44%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.66%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.44%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">747,683,172</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.66%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.44%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">61,411</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.66%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.44%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">52,680,306</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.66%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.44%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,925</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.66%; border-right:solid 0.75pt #000000; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.66%; border-left:solid 0.75pt #000000; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.44%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,875,422</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.66%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.44%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.66%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.44%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">55,969</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.66%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.44%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(112,412</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.66%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.44%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(56,443</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">The accompanying notes are an integral part of these consolidated financial statements. </p><a name="_AEIOULastRenderedPageBreakAEIOU11"></a>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-5</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">SENSEI BIOTHERAPEUTICS, </font><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">INC</font><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">. </font></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="CONSOLIDATED_STATEMENTS_CASH_FLOWS"></a><a name="CONSOLIDATED_STATEMENTS_CASH_FLOWS"></a>CONSOLIDATED STATEMENTS OF CASH FLOWS </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(In thousands) </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.14%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.28%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December 31,</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.14%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Operating activities</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(20,100</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(16,740</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Adjustments to reconcile net loss to net cash used in operating activities:</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock-based compensation expense</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,492</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,176</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Depreciation and amortization</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">209</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">73</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accretion on debt</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,578</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,394</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Fair value adjustments on embedded debt derivatives</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(995</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,973</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Interest on capital lease</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Issuance of common stock for Alvaxa acquisition</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">541</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(Gain) loss on debt extinguishment</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(45</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">75</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Changes in operating assets and liabilities:</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prepaid expenses and other current assets</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,124</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">377</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deposits</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">361</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accounts payable and accrued liabilities</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">335</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,659</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued interest</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">53</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">894</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.14%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other liabilities</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(22</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">539</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net cash used in operating activities</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(17,705</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(8,571</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Investing activities</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Purchases of property and equipment</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,206</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(53</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.14%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Alvaxa IPR&amp;D acquisition</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(197</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.14%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net cash used in investing activities</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,403</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(53</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Financing activities</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Proceeds from the PPP loan</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">567</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Proceeds from the exercise of common stock warrants and options</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">154</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred offering costs</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2,105</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Capital lease payments</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(41</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(27</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Proceeds on the issuance of series AA convertible preferred stock</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">26,087</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Proceeds on the issuance of series BB convertible preferred stock</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,925</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.14%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Proceeds on the issuance of debt, including $3,750 with</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; related parties in 2019</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,095</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.14%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net cash provided by financing activities</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">35,453</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,222</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net increase (decrease) in cash and cash equivalents</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16,345</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(402</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash and cash equivalents at beginning of period</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">251</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">653</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.14%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash and cash equivalents at end of period</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16,596</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">251</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Supplemental disclosure of noncash financing information:</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Capital equipment</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">166</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property and equipment additions included in accounts payable and accrued liabilities</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">204</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred offering costs included in accounts payable and accrued liabilities</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,207</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Interest on financing</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Conversion of series A,B,C,D,E,F convertible preferred stock into common stock</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">47,545</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Conversion of common stock into series AA convertible preferred stock</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17,274</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Convertible preferred stock issued in exchange for note redemption</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">18,050</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">The accompanying notes are an integral part of these consolidated financial statements. </p><a name="_AEIOULastRenderedPageBreakAEIOU12"></a>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-6</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">SENSEI BIOTHERAPEUTICS,</font><font style="text-transform:uppercase;">&#160;INC.</font><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </font></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-size:10pt;text-transform:uppercase;font-family:Times New Roman;font-style:normal;font-variant: normal;"><a name="NOTES_TO_CONSOLIDATED_FINANCIAL_STATEMEN"></a><a name="NOTES_TO_CONSOLIDATED_FINANCIAL_STATEMEN"></a>NOTES TO consolidated FINANCIAL STATEMENTS<font style="text-transform:none;"> </font></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">AS OF AND FOR THE YEARS ENDED DECEMBER&#160;31, 2020 AND 2019 </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1. ORGANIZATION AND OPERATIONS </p>
<p style="margin-bottom:0pt;margin-top:6pt;margin-left:2.26%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Business </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Sensei Biotherapeutics,&#160;Inc. (the &#8220;Company&#8221; or &#8220;Sensei&#8221;) is a clinical-stage immunotherapy company that was incorporated in 1999 as a Maryland corporation until incorporated in Delaware on December&#160;1, 2017. The Company is engaged in the discovery and development of next generation therapies with an initial focus on treatments for cancer. </p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On May&#160;18, 2020, the Company acquired Alvaxa Biosciences, Inc. (&#8220;Alvaxa&#8221;) in a cash and stock purchase (&#8220;Stock Purchase Agreement&#8221;).&#160;Under the terms of the Stock Purchase Agreement, the Company acquired Alvaxa&#8217;s existing camelid nanobodies and other biomaterials (&#8220;Biomaterials&#8221;), expertise in nanobody discovery, as well as a license agreement with a research organization.&#160;The former majority shareholder of Alvaxa is the Company&#8217;s current Chief Scientific Officer. Under the Stock Purchase Agreement, the Company paid $197&#160;thousand to settle liabilities assumed from Alvaxa and issued 304,376 shares of the Company&#8217;s common stock to the shareholders of Alvaxa. The Company has evaluated the acquisition under ASC 805<font style="font-style:italic;">, Business Combinations</font>&#160;and determined this transaction to be an asset acquisition.</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The 304,376 shares of common stock was valued at $541&#160;thousand in total, based on a valuation determined with the assistance of a third party.&#160;The Company determined that substantially all the value acquired in the transaction related to the Biomaterials and represents&#160;in-process&#160;research and development (&#8220;IPR&amp;D&#8221;).&#160;The liabilities of $197&#160;thousand assumed were related to previously incurred employee costs as well as contractually required vendor payments. The consideration transferred in this transaction was recorded as an expense in the Alvaxa IPR&amp;D line item within the Statement of Operations during the year ended December&#160;31, 2020.</p>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:2.27%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Liquidity and capital resources</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;color:#auto;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Since its inception, the Company has devoted substantially all of <font style="color:#000000;">its</font> resources to advancing development of <font style="color:#000000;">its</font> portfolio of programs, establishing and protecting <font style="color:#000000;">its</font> intellectual property, conducting research and development activities, organizing and staffing <font style="color:#000000;">the</font> <font style="color:#000000;">C</font>ompany, business planning, raising capital and providing general and administrative support for these operations. The Company is subject to risks and uncertainties common to early-stage companies in the biotechnology industry including, but not limited to, technical risks associated with the successful research, development and manufacturing of product candidates, development by competitors of new technological innovations, dependence on key personnel, protection of proprietary technology, compliance with government regulations and the ability to secure additional capital to fund operations. Current and future programs will require significant research and development efforts, including extensive preclinical and clinical testing and regulatory approval prior to commercialization. These efforts require significant amounts of additional capital, adequate personnel and infrastructure. Even if the Company&#8217;s drug development efforts are successful, it is uncertain when, if ever, the Company will realize significant revenue from product sales.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;color:#auto;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Since its inception, the Company has incurred substantial losses and had a net loss of $<font style="color:#000000;">20.1</font> million for the year ended December&#160;31, 20<font style="color:#000000;">20</font>. As of December&#160;31, 20<font style="color:#000000;">20</font>, the Company had an accumulated deficit of $<font style="color:#000000;">112.4</font>&#160;million. The Company expects to generate operating losses and negative operating cash flows for the foreseeable future.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;color:#auto;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On February <font style="color:#000000;">3</font>, 202<font style="color:#000000;">1</font>, the Company completed its initial public offering, or IPO, in which the Company issued and sold <font style="color:#000000;">8,030,295</font> shares of its common stock, including <font style="color:#000000;">1,030,243</font> shares pursuant to the full exercise of the underwriters&#8217; option to purchase additional shares, at a public offering price of $<font style="color:#000000;">19.00</font> per share, for aggregate gross proceeds of $<font style="color:#000000;">152.6</font> million. The Company received $<font style="color:#000000;">138.5</font> million in net proceeds after deducting underwriting discounts and estimated offering expenses payable by the Company.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;color:#auto;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company expects that its cash<font style="color:#000000;"> and</font> cash equivalents as of December&#160;31, 20<font style="color:#000000;">20</font> of $<font style="color:#000000;">16.6</font> million, along with $<font style="color:#000000;">138.5</font>&#160;million in net proceeds<font style="color:#000000;"> from its initial public offering</font>, will be sufficient to fund its operations for at least the next twelve months from the date of issuance of these financial statements. The Company will need additional financing to support its continuing operations and pursue its growth strategy. Until such time as the Company can generate significant revenue from product sales, if ever, it expects to finance its operations through a combination of equity offerings, debt financings, collaborations, strategic alliances and licensing arrangements. The Company may be unable to raise additional funds or enter into such other agreements when needed on favorable terms or at all. The inability to raise capital as and when needed would have a negative impact on the Company&#8217;s financial condition and its ability to pursue its business strategy. The Company will need to generate significant revenue to achieve profitability, and it may never do so.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-7</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES </font></p>
<p style="margin-bottom:0pt;margin-top:6pt;margin-left:2.26%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Basis of Presentation and Principles of Consolidation </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company has prepared the accompanying consolidated financial statements in conformity with generally accepted accounting principles in the United States (&#8220;US GAAP&#8221;). The consolidated financial statements include those accounts of the Company and its subsidiaries after elimination of all intercompany accounts and transactions. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:8pt;margin-left:2.26%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Use of Estimates </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of consolidated financial statements in conformity with US&#160;GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the consolidated financial statements, and the reported amounts of expenses during the reporting periods presented. Estimates are used for, but are not limited to, depreciation of equipment, the Company&#8217;s enterprise value, fair value of financial instruments, the Company&#8217;s ability to continue as a going concern and contingencies. Actual results may differ from those estimates. </p>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:2.26%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Cash and Cash Equivalents </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash equivalents are highly liquid investments with an original maturity of 90&#160;days or less at the date of purchase and consist of time deposits and investments in money market funds with commercial banks and financial institutions. </p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:18pt;margin-left:3.46%;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Deferred Offering Costs</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company capitalizes as prepaid expenses certain legal, professional accounting and other third-party fees that are directly associated with preferred stock or common stock financings as deferred offering costs until such financings are consummated. After consummation of the equity financing, these costs are recorded as a reduction of additional&#160;paid-in&#160;capital generated as a result of the offering. </p>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:2.26%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Concentrations of Credit Risk and Off-Balance Sheet Risk </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company maintains its cash in bank deposit and checking accounts that at times exceed insured limits. The Company has not experienced any losses in such accounts and believes it is not exposed to any significant credit risk. </p>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:2.26%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Property and Equipment </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property and equipment are recorded at cost and depreciated or amortized over the estimated useful lives of the assets. Repairs or maintenance costs are expensed as incurred. Depreciation is computed using the straight-line method over the following estimated useful lives: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  style="width:50%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Office equipment and furniture</p></td>
<td valign="bottom"  style="width:50%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3&#8212;7&#160;years</p></td>
</tr>
<tr>
<td valign="top"  style="width:50%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research equipment</p></td>
<td valign="bottom"  style="width:50%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1&#8212;7 years</p></td>
</tr>
<tr>
<td valign="top"  style="width:50%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Capital lease</p></td>
<td valign="bottom"  style="width:50%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Lesser of the asset life or lease term</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:2.26%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Fair Value of Financial Instruments </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">US&#160;GAAP requires disclosure of fair value information about financial instruments, whether or not recognized in the balance sheet, for which it is practicable to estimate that value. The framework provides a fair value hierarchy that prioritizes the inputs for the valuation techniques. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level&#160;1 measurements)&#160;and the lowest priority to unobservable inputs (Level&#160;3 measurements)&#160;and minimizes the use of unobservable inputs. The most observable inputs are used, when available. The three levels of the fair value hierarchy are described as follows: </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Level&#160;1<font style="font-weight:normal;font-style:normal;">&#8212;Inputs to the valuation methodology are unadjusted quoted prices for identical assets or liabilities in active markets that the Company has the ability to access. </font></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Level&#160;2<font style="font-weight:normal;font-style:normal;">&#8212;Inputs to the valuation methodology include quoted prices for similar assets and liabilities in active markets; quoted prices for identical or similar assets and liabilities in markets that are not active; inputs other than quoted prices that are observable for the asset or liability; and inputs that are derived from, or corroborated by, observable market data by correlation or other means. </font></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Level&#160;3<font style="font-weight:normal;font-style:normal;">&#8212;Inputs to the valuation methodology are unobservable and significant to the fair value measurement. </font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-8</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:8pt;margin-left:2.26%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Classification of Convertible Preferred Stock </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company classifies convertible preferred stock outside of stockholders&#8217; deficit on its balance sheets as the requirements of triggering a deemed liquidation event are not within the Company&#8217;s control. In the event of a deemed liquidation event, the proceeds from the event are distributed in accordance with liquidation preferences (Note 8). The Company adjusts the carrying value of the convertible preferred stock to their redemption values when it becomes probable a redemption event will occur. </p>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:2.26%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Research and Development </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development costs are expensed in the period incurred. Research and development costs include payroll and personnel expense; consulting costs; external contract research and development costs; raw materials and allocated overhead such as depreciation and amortization, rent and utilities. Advance payments for goods and services to be used in future research and development activities are recorded as prepaid expenses and are expensed over the service period as the services are provided or when the goods are consumed. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Clinical trial costs are a component of research and development expenses. The Company estimates expenses incurred for clinical trials that are in process based on services performed under contractual agreements with clinical research organizations&#160;and actual clinical investigators. Included in the estimates are (1)&#160;the fee per patient enrolled as specified in the clinical trial contract with each institution participating in the clinical trial and (2)&#160;progressive data on patient enrollments obtained from participating clinical trial sites and the actual services performed. Changes in clinical trial assumptions, such as the length of time estimated to enroll all patients, rate of screening failures, patient&#160;drop-out&#160;rates, number and nature of adverse event reports, and the total number of patients enrolled can impact the average and expected cost per patient and the overall cost of the clinical trial. The Company monitors the progress of the trials and their related activities and adjusts, when applicable, the accruals accordingly. Adjustments to accruals are charged to expense in the period in which the facts that give rise to the adjustment become known. In the event of early termination of a clinical trial or site, the Company would accrue an amount based on estimates of the remaining noncancellable obligations associated with winding down the clinical trial or cancelation of a participating site. </p>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:2.26%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Stock-Based Compensation </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company accounts for all stock-based compensation, including stock options and warrants, at fair value and recognizes stock-based compensation expense for those equity awards, net of actual forfeitures, over the requisite service period, which is generally the vesting period of the respective award. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The fair value of the Company&#8217;s stock options and warrants on the date of grant was determined by the Company with the assistance of a third-party valuation specialist in accordance with the guidance in the American Institute of Certified Public Accountants Valuation Guide, <font style="font-style:italic;">Valuation of Privately-Held-Company Equity Securities Issued as Compensation</font>, as the Company&#8217;s common stock was not actively traded prior to February 3, 2021. </p>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:2.26%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Income Taxes </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Income taxes are accounted for using the asset and liability method of accounting for taxes. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the consolidated financial statement carrying amounts of existing assets and liabilities and their respective tax bases, including operating loss carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the year in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A valuation allowance is established when necessary to reduce net deferred tax assets to the amount expected to be realized through future operations. Income tax expense consists of taxes payable for the current period and the net change during the period in deferred tax assets and liabilities.</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company evaluates its uncertain tax positions based on a determination of whether and how much of a tax benefit taken by the Company in its tax filings or positions is more likely than not to be realized. Potential interest and penalties associated with any uncertain tax positions are recorded as a component of income tax expense. Management has evaluated the Company&#8217;s tax position and concluded that the Company has taken no uncertain tax positions that would require adjustment or disclosure in the consolidated financial statements. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-9</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:2.26%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Net Loss Per Share </font></p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company follows the two-class method when computing net loss per share as the Company has issued shares that meet the definition of participating securities. The two-class method determines net loss per share for each class of common and participating securities according to dividends declared or accumulated, and participation rights in undistributed earnings. The two-class method requires income available to common stockholders for the period to be allocated between common and participating securities based upon their respective rights to receive dividends as if all income for the period had been distributed. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Basic net loss per share attributable to common stockholders is computed by dividing the net loss attributable to common stockholders by the weighted average number of common shares outstanding for the period. Diluted net loss attributable to common stockholders is computed by adjusting net loss attributable to common stockholders to reallocate undistributed earnings based on the potential impact of dilutive securities. Diluted loss per share attributable to common stockholders is computed by dividing the diluted net loss attributable to common stockholders by the weighted average number of common shares outstanding for the period, including potential dilutive common stock. For purpose of this calculation, outstanding stock options, stock warrants and convertible preferred stock are considered potential dilutive common stock and are excluded from the computation of net loss per share as their effect is anti-dilutive. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company&#8217;s convertible preferred stock contractually entitles the holders of such shares to participate in dividends but does not contractually require the holders of such shares to participate in losses of the Company. Accordingly, in periods in which the Company reports a net loss, such losses are not allocated to such participating securities. In periods in which the Company reports a net loss attributable to common stockholders, diluted net loss per share attributable to common stockholders is the same as basic net loss per share attributable to common stockholders, since dilutive common shares are not assumed to be outstanding if their effect is anti-dilutive. The Company reported a net loss attributable to common stockholders for the years ended December&#160;31, 2020 and 2019. </p>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:2.26%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Comprehensive Loss </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">There were no differences between net loss and comprehensive loss presented in the consolidated statements of operations for 2020 and 2019. </p>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:2.26%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Segments </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating segments are defined as components of an entity for which separate financial information is available and that is regularly reviewed by the chief operating decision maker (&#8220;CODM&#8221;), in deciding how to allocate resources to an individual segment and in assessing performance. The Company&#8217;s CODM is its chief executive officer. The Company has determined it operates in one segment.</p>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:2.26%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Reclassifications</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Certain reclassifications have been made to the presentation of amounts in the consolidated balance sheet and consolidated statement of cash flows as of and for the year ended December 31, 2019 to conform to the current year presentation related to accounts payable and accrued liabilities and other current liabilities. </p>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:2.26%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Emerging Growth Company Status </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company is an &#8220;emerging growth company,&#8221; (&#8220;EGC&#8221;) as defined in the Jumpstart Our Business Startups Act, (the &#8220;JOBS Act&#8221;), and may take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not EGCs. The Company may take advantage of these exemptions until it is no longer an EGC under Section&#160;107 of the JOBS Act and has elected to use the extended transition period for complying with new or revised accounting standards. As a result of this election, the Company&#8217;s financial statements may not be comparable to companies that comply with public company Financial Accounting Standards Board (&#8220;FASB&#8221;) standards&#8217; effective dates. The Company may take advantage of these exemptions up until the earliest of (i)&#160;December 31, 2026, (ii) the last day of the fiscal year in which it has total annual gross revenues of $1.07&#160;billion or more, (iii)&#160;the date on which it has issued more than $1.0&#160;billion in nonconvertible debt during the previous three years or (iv)&#160;the date on which it is deemed to be a large accelerated filer under the rules of the Securities and Exchange Commission (&#8220;SEC&#8221;), which generally is when it has more than $700&#160;million in market value of its stock held by non-affiliates as of the prior June 30th. </p>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:2.26%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Recently Issued Accounting Standards </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In February 2016, the FASB issued Accounting Standards Updates (&#8220;ASU&#8221;)&#160;No. 2016-02,<font style="font-style:italic;">&#160;Leases&#160;(Topic 842)</font>, as amended, with guidance regarding the accounting for and disclosure of leases. The update requires lessees to recognize the liabilities related to all </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-10</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">leases, including operating leases on the balance sheet. This update also requires lessees and lessors to disclose key information about their leasing transactions. This update is effective for entities other than public business entities, including emerging growth companies that elected to defer compliance with new or revised financial accounting standards until a company that is not an issuer is required to comply with such standards, for annual reporting periods beginning after December&#160;15, 2021, and interim periods within annual periods beginning after December&#160;15, 2022. Early adoption is permitted. The Company is currently assessing the impact of adopting ASU No.&#160;2016-02&#160;on the consolidated financial statements and related disclosures. </font></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In June 2016, the FASB issued ASU No.&#160;2016-13,<font style="font-style:italic;"> Financial Instruments-Credit Losses: Measurement of Credit Losses on Financial Instruments (Topic 326)</font>. ASU No.&#160;2016-13 requires measurement and recognition of expected credit losses for financial assets. In April 2019, the FASB issued clarification to ASU No.&#160;2016-13 within ASU No.&#160;2019-04,<font style="font-style:italic;"> Codification Improvements to Topic 326, Financial Instruments-Credit Losses, Topic 815, Derivatives and Hedging, and Topic 825, Financial Instruments</font>. This update is effective for entities other than public business entities, including emerging growth companies that elected to defer compliance with new or revised financial accounting standards until a company that is not an issuer is required to comply with such standards, for annual reporting periods beginning after December&#160;15, 2022.The Company is currently evaluating the impact that ASU No.&#160;2016-13 will have on the consolidated financial statements and related disclosures. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In August 2018, the FASB issued ASU No.&#160;2018-13, <font style="font-style:italic;">Fair Value Measurement</font> (<font style="font-style:italic;">Topic 820</font>), Disclosure Framework&#8212;Changes to the Disclosure Requirements for Fair Value Measurement. This update removed the following disclosure requirements: (1)&#160;the amount of and reasons for transfers between Level&#160;1 and Level&#160;2 of the fair value hierarchy; (2)&#160;the policy for timing of transfers between levels; and (3)&#160;the valuation processes for Level&#160;3 fair value measurements. Additionally, this update added the following disclosure requirements: (1)&#160;the changes in unrealized gains and losses for the period included in other comprehensive income and loss for recurring Level&#160;3 fair value measurements held at the end of the reporting period; (2)&#160;the range and weighted average of significant unobservable inputs used to develop Level&#160;3 fair value measurements. For certain unobservable inputs, an entity may disclose other quantitative information (such as the median or arithmetic average) in lieu of the weighted average if the entity determines that other quantitative information would be a more reasonable and rational method to reflect the distribution of unobservable inputs used to develop Level&#160;3 fair value measurements. The Company adopted ASU&#160;No.&#160;2018-13 on January 1, 2020 and it did not have a material effect on the consolidated financial statements and related disclosures. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In December 2019, the FASB issued ASU No.&#160;2019-12,<font style="font-style:italic;"> Simplifying the Accounting for Income Taxes</font>. ASU No.&#160;2019-12 eliminates certain exceptions related to the approach for intra-period tax allocation, the methodology for calculating income taxes in an interim period and the recognition of deferred tax liabilities for outside basis differences. It also clarifies and simplifies other aspects of the accounting for income taxes. This update is effective for entities other than public business entities, including emerging growth companies that elected to defer compliance with new or revised financial accounting standards until a company that is not an issuer is required to comply with such standards, for annual reporting periods beginning after December&#160;15, 2021, and interim periods within annual periods beginning after December&#160;15, 2022. The Company is currently evaluating the impact that ASU No.&#160;2019-12&#160;will have on the consolidated financial statements and related disclosures. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In August 2020, the FASB issued ASU No.&#160;2020-06, <font style="font-style:italic;">Debt &#8211; Debt with Conversion and Other (Subtopic 470-20) and Derivatives and Hedging &#8211; Contracts in Entity&#8217;s Own Equity (Subtopic 815-40)</font>. This update simplifies the accounting for convertible debt instruments by removing certain accounting separation models as well as the accounting for debt instruments with embedded&#160;conversion&#160;features that are not required to be accounted for as derivative instruments. The update also updates and improves the consistency of earnings per share calculations for convertible instruments. The amendments in this ASU are effective for fiscal years beginning after December&#160;15, 2021, including interim periods within those fiscal years. The Company is currently evaluating the impact that the implementation of this update will have on the Company&#8217;s consolidated financial statements and related disclosures. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">3. PROPERTY AND EQUIPMENT, NET </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property and equipment, net consist of the following (in thousands): </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Hlk67417329"></a>&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Office equipment and furniture</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">94</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research equipment</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,767</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">641</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total property and equipment</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,861</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">655</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Less accumulated depreciation and amortization</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(595</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(387</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property and equipment, net</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,266</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">268</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-11</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Depreciation and amortization expense for the years ended December&#160;31, 2020 and 2019 was $209&#160;thousand and $73&#160;thousand, respectively. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;text-transform:uppercase;font-family:Times New Roman;font-style:normal;font-variant: normal;">4. Other current liabilities<font style="text-transform:none;"> </font></p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other current liabilities consist of the following (in thousands): </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.14%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Hlk67417330"></a>&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.86%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.86%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Compensation and benefits</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">916</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">685</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.14%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">32</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">29</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.14%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total other current liabilities</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">948</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">714</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-size:10pt;text-transform:uppercase;font-family:Times New Roman;font-style:normal;font-variant: normal;">5. Debt<font style="text-transform:none;"> </font></p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Debt consists of the following (in thousands): </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Hlk67417331"></a>&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">PPP Loan</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">567</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2019 Notes</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,345</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2019 Secured Notes (related party)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,854</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2019 Bridge Note</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,000</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2019 Special Note (related party in 2020)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,570</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2018 Bridge Notes (related party)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,000</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2017 Notes</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,050</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Discounts</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(764</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total debt</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">567</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16,055</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Less current portion</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(16,055</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Noncurrent debt</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">567</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Hlk67669403"></a>As of December&#160;31, 2020, the remaining debt is presented as a non-current liability in the Company&#8217;s consolidated balance sheet. </p>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:2.26%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">PPP loan</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In May 2020, the Company received $567 thousand in loan funding from the Paycheck Protection Program (&#8220;PPP&#8221;) pursuant to the Coronavirus Aid, Relief, and Economic Security Act, as amended by the Flexibility Act, and administered by the Small Business Administration. The unsecured loan (the &#8220;PPP Loan&#8221;) is with Silicon Valley Bank. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the terms of the PPP Loan, interest accrues on the outstanding principal at a rate of 1.0% per annum. The term of the PPP Loan is two years, though it may be payable sooner in connection with an event of default under the PPP Loan. To the extent the PPP Loan amount is not forgiven under the PPP, the Company is obligated to make equal monthly payments of principal and interest, beginning after determination of forgiveness by the lender. If the Company applies for forgiveness before August 2021 and forgiveness is not granted, principal and interest payments will be required beginning in May 2022. If the Company does not apply for loan forgiveness by August 2021, principal and interest will be required beginning in August 2021.</p>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:2.26%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">2019 Notes </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During the period from April 2019 through September 2019, the Company issued $2,345&#160;thousand of convertible promissory notes (&#8220;2019 Notes&#8221;). Interest on the principal amount outstanding is fixed at 10% with a one-year maturity date, if not previously converted to shares of the Company&#8217;s equity securities. The 2019 Notes were redeemed in January 2020 as part of the Company&#8217;s recapitalization disclosed in Note 8.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The 2019 Notes include detachable warrants to purchase 7,313 of the Company&#8217;s common stock at exercise prices between $64.80 and $122.88 per share. The detachable warrants have an expiration date of ten years from the issuance date, or fiscal year 2029.&#160;The estimated fair value of the detachable warrants was determined using the Black-Scholes option-pricing model (Level&#160;3 </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-12</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:12pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">hierarchy) and totaled $51&#160;thousand upon issuance. The fair value of the detachable warrants was treated as a discount on the 2019 Notes and amortized as incremental interest expense using the effective interest method over the life of the 2019 Notes. </font></p>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:2.26%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">2019 Secured Notes (Related Party) </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In September and October 2019, the Company issued an aggregate of $1,500&#160;thousand in secured convertible promissory notes (&#8220;2019 Secured Notes&#8221;) with a repayment premium of 150% of the principal amount. Interest on the principal amount outstanding is fixed at 10% with a maturity date of December&#160;31, 2020. The repayment premium of $2,250&#160;thousand was being amortized as incremental interest expense using the effective interest method over the life of the 2019 Secured Notes. The 2019 Secured Notes were redeemed in January 2020 as part of the Company&#8217;s recapitalization disclosed in Note 8.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;<font style="font-size:10pt;">The automatic conversion features of the 2019 Secured Notes were determined by management to be embedded derivative instruments. The embedded derivative instruments are initially measured at fair value and classified as a liability on the balance sheet, within the same line item as the 2019 Secured Notes. Subsequent changes in fair value are in net loss on the consolidated statement of operations as fair value adjustments on embedded debt derivatives expense. To determine the fair value of the aggregated automatic conversion features, management utilized a &#8220;with-and-without&#8221; in a modified convertible bond model, incorporating the automatic conversion features. Key assumptions utilized in determining the initial fair value were: (a) 5% to 10% probability of settlement at the contractual maturity date; (b) 25% probability of settlement on a change of control or upon a qualified initial public offering in 9 to 10 months of issuance; and (c) 65% probability of settlement on a qualified financing in 6 months of issuance. Based upon the modified convertible bond model utilized by management, the fair value of the automatic conversion features was determined to be $940&#160;thousand upon issuance of the 2019 Secured Notes and is being amortized as incremental interest expense using the effective interest method over the life of the 2019 Secured Notes. </font></p>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:2.26%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">2019 Bridge Note </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In November 2019, the Company issued a $1,000&#160;thousand bridge convertible promissory note (&#8220;2019 Bridge Note&#8221;). Interest on the principal amount is fixed at 7% and commences 60 days after the issuance date with a maturity date of December&#160;31, 2020. The 2019 Bridge Note was redeemed in January 2020 as part of the Company&#8217;s recapitalization disclosed in Note 8.</p>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:2.26%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">2019 Special Note </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In April 2019, the Company issued a $1,000&#160;thousand convertible promissory note (&#8220;2019 Special Note&#8221;). Interest on the principal amount outstanding is fixed at 10% with a one-year maturity date, if not previously converted to shares of the Company&#8217;s equity securities.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The 2019 Special Note contains a feature requiring amendment of the original instrument if the Company issues additional instruments with preferable terms relative to those contained in the 2019 Special Note. In September 2019, the original agreement was amended requiring a 150% repayment premium in addition to the original 10% interest rate based upon the Company&#8217;s issuance of the 2019 Secured Notes. The contractual amendment was treated as a debt extinguishment and a loss of $75&#160;thousand was recorded in net loss on the consolidated statement of operations as a loss on extinguishment expense. The repayment premium of $1,500&#160;thousand is being amortized as incremental interest expense using the effective interest method over the life of the 2019 Special Note. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The automatic conversion features of the 2019 Special Note were determined by management to be embedded derivative instruments. The embedded derivative instruments are initially measured at fair value and classified as a liability on the balance sheet, within the same line item as the 2019 Special Note. Subsequent changes in fair value are in net loss as fair value adjustments on embedded debt derivatives expense. To determine the fair value of the aggregated automatic conversion features, management utilized a &#8220;with-and-without&#8221; in a modified convertible bond model, incorporating the automatic conversion features. Key assumptions utilized in determining the initial fair value were: (a) 10% probability of settlement at the contractual maturity date; (b) 25% probability of settlement on a change of control or upon a qualified initial public offering in 10 months of issuance; and (c) 65% probability of settlement on a qualified financing in 6 months of issuance. Based upon the modified convertible bond model utilized by management, the fair value of the automatic conversion features was determined to be $663&#160;thousand upon issuance of the 2019 Special Note and is being amortized as incremental interest expense using the effective interest method over the life of the 2019 Special Note. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The 2019 Special Note includes a detachable warrant allowing the purchase of 3,886 of the Company&#8217;s common stock at an exercise price of $64.32 per share. The detachable warrant has an expiration date of ten years from the issuance date, or fiscal year 2029.&#160;The fair value of the detachable warrant was treated as a discount on the 2019 Special Note and amortized as incremental interest expense using the effective interest method over the life of the 2019 Special Note. The estimated fair value of the detachable warrant was determined using the Black-Scholes option-pricing model (Level&#160;3 hierarchy) and totaled $74&#160;thousand upon issuance. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-13</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On March&#160;27, 2020, the Company consented to the exchange of the 2019 Special Note where the original holder of the 2019 Special Note sold it to a current equity owner of the Company. The detachable warrant issued in conjunction with the 2019 Special Note for 3,886 common stock </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">was </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">not included in the exchange and </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">was </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">subsequently canceled. </font></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">The 2019 Special Note matured in April 2020 and stopped accruing interest at that time. Management determined the fair value of the conversion features within the 2019 Special Note was zero as of September&#160;30, 2020 since the 2019 Special Note had matured, and the conversion features provided no incremental value to the holder beyond the contractually obligated amount. In November 2020, the 2019 Special Note, repayment premium and accrued interest was redeemed into 31,591,824 shares of Series AA convertible preferred stock. The delay from maturity in April 2020 to redemption in November 2020 was administrative in nature, as the holder is a principle owner related party.</font></p>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:2.26%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">2018 Bridge Notes (Related Party) </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company issued $2,250 thousand and $750&#160;thousand 2018 convertible promissory notes (&#8220;2018 Bridge Notes&#8221;) in 2019 and 2018, respectively, to fund the Company&#8217;s operations. Interest on the principal amount outstanding is fixed at 10%. The 2018 Bridge Notes were redeemed in January 2020 as part of the Company&#8217;s recapitalization disclosed in Note 8. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The 2018 Bridge Notes include detachable warrants to purchase 11,718 and 3,906&#160;shares issued in 2019 and 2018, respectively, of the Company&#8217;s common stock at an exercise price of $122.88 per share. The detachable warrants expire on December&#160;19, 2028.&#160;The estimated fair value of the detachable warrants was determined using the Black-Scholes option-pricing model (Level&#160;3 hierarchy), treated as a discount on the 2018 Bridge Notes and amortized as incremental interest expense using the effective interest method over the life of the 2018 Bridge Notes. </p>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:2.26%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">2017 Notes </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company issued $4,050&#160;thousand convertible promissory notes in 2017 (&#8220;2017 Notes&#8221;) in exchange for cash of the same amount. Interest on the principal amount outstanding is fixed at 8%. The 2017 Notes were redeemed in January 2020 as part of the Company&#8217;s recapitalization disclosed in Note 8. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">6. FAIR VALUE MEASUREMENTS </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company did not have any financial liabilities measured at fair value on a recurring basis as of December 31, 2020. The following table presents information about the Company&#8217;s financial liabilities measured at fair value on a recurring basis as of December 31, 2019 and indicate the level of the fair value hierarchy utilized to determine such fair values (in thousands): </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Hlk67417332"></a>&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="14" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.42%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair Value Measurements as of December 31, 2019</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 1</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 2</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 3</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Current liabilities</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Embedded debt derivatives</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,920</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,920</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total liabilities measured at fair value</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,920</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,920</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company&#8217;s embedded debt derivatives are measured at fair value using a probability-weighted discounted cash flow valuation methodology. The determination of the fair value of embedded debt derivatives includes inputs not observable in the market and as such, represents a Level&#160;3 measurement. The methodology utilized requires inputs based on certain subjective assumptions, including probabilities of debt settlement scenarios and a discount rate. This approach results in the classification of these embedded debt derivatives as Level&#160;3 of the fair value hierarchy. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The assumptions utilized to value the embedded debt derivatives during the year ended December&#160;31, 2020 prior to the settlement of such instruments included the actual outcome of the underling debt host contract, whether it was settled on a qualified financing prior to the contractual maturity date or settlement at the contractual maturity date. For the year ended December&#160;31, 2020, the Company recognized $1.0&#160;million of income in the statement of operations as other income&#8212;fair value adjustments on embedded debt derivatives.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The assumptions utilized to value the embedded debt derivatives at December&#160;31, 2019 were the probability of (a) 3% probability of settlement at the contractual maturity date; (b) 5% probability of settlement on a change of control or upon a qualified initial public offering prior to the contractual maturity date; and (c) 92% probability of settlement on a qualified financing prior to the contractual maturity date. For the year ended December&#160;31, 2019, the Company recognized a $2.0&#160;million expense in the statement of operations as other expense&#8212;fair value adjustments on embedded debt derivatives. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-14</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table provides a reconciliation of embedded debt derivatives measured at fair value on a recurring basis using significant unobservable inputs (Level 3) (in thousands): </font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Hlk67417333"></a>&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.86%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.78%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Amount</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance at January 1, 2019</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.78%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Additions</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,947</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Change in fair value</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.86%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,973</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance at December 31, 2019</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.78%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,920</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Change in fair value</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(995</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Settlement</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.86%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2,925</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.34%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance at December 31, 2020</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.86%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">There were no transfers among Level&#160;1, Level&#160;2 or Level&#160;3 categories in the years ended December&#160;31, 2020 and 2019. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;text-transform:uppercase;font-family:Times New Roman;font-style:normal;font-variant: normal;">7. COMMITMENTS AND CONTINGENCIES<font style="text-transform:none;"> </font></p>
<p style="margin-bottom:0pt;margin-top:6pt;margin-left:2.26%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Operating Lease </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Hlk67117458"></a>As of December&#160;31, 2020, the Company leases an office facility and other equipment under operating leases, which expire at various dates through 2027<a name="_Hlk67117458"></a>. Lease expense for the years ended December&#160;31, 2020 and 2019 was $1,439 thousand and $1,107 thousand, respectively. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;<font style="font-size:10pt;">The following table presents the future annual minimum payments required under noncancellable operating leases at December&#160;31, (in thousands): </font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">427</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2022</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">314</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2023</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">323</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2024</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">328</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2025</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">337</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2026</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">347</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2027</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.86%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">59</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.34%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total operating lease obligations</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.86%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.78%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,135</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:6pt;margin-left:2.26%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Capital Lease </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company leases research equipment under a capital finance lease. The capital lease asset is classified within property and equipment, net within the Company&#8217;s consolidated balance sheets. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table presents the future annual minimum payments under the capitalized lease, together with the present value of net minimum lease payments at December&#160;31, (in thousands): </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Hlk67417335"></a>2021</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">41</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2022</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">41</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2023</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">41</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2024</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total capital lease obligations</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">137</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Less amount representing interest</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.86%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(19</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.34%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Present value of minimum capital lease obligations</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.86%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.78%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">118</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:6pt;margin-left:2.26%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">License Agreements </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the normal course of business, the Company enters into licensing agreements with various parties to obtain the right to make, use, and sell licensed products currently in development. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-15</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:2.26%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Litigation </font></p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company records estimated losses from loss contingencies, such as a loss arising from a litigation, when it determines that it is probable a liability has been incurred and the amount of loss can be reasonably estimated. Litigation is subject to many factors that are difficult to predict so that there can be no assurance, in the event of a material unfavorable result in one or more claims, the Company will not incur material costs. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During 2017, the Company became actively involved in a matter pending in the Ontario (Canada)&#160;Superior Court of Justice which names, among multiple other defendants, the Company and two former officers of the Company. The claims pending in this matter allege breach of contract by the Company and seek declaratory and other relief, including monetary damages from the Company, and the individual defendants, including the Company&#8217;s former officers. The claims by such plaintiffs were originally made in a lawsuit filed in Ontario during October&#160;2011, but was not pursued by such plaintiffs in any material manner until 2017.&#160;The Company believes that there is no merit to the claims alleged against the Company and its former officers, including no alleged breach of contract by the Company, and intends to vigorously defend against the claims pertaining to the Company and its former officers. At the present stage of the suit, management believes the outcome in this matter is not likely to have any material impact on the Company&#8217;s results, cash flows, or financial position. </p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:18pt;margin-left:3.46%;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Coronavirus pandemic</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On January 30, 2020, the World Health Organization (&#8220;WHO&#8221;) announced a global health emergency because of a new strain of coronavirus originating in Wuhan, China (the &#8220;COVID-19 outbreak&#8221;) and the risks to the international community as the virus spreads globally beyond its point of origin. In March 2020, the WHO classified the COVID- 19 outbreak as a pandemic, based on the rapid increase in exposure globally. The full impact of the COVID-19 outbreak continues to evolve as of the date of these financial statements. As such, it is uncertain as to the full magnitude that the pandemic will have on the Company&#8217;s financial condition, liquidity, and future results of operations. Management is actively monitoring the global situation on its financial condition, liquidity, operations, suppliers, industry, and workforce. Given the daily evolution of the COVID-19 outbreak and the global responses to curb its spread, the Company is not able to estimate the effects of the COVID-19 outbreak on its results of operations, financial condition, or liquidity. Although the Company cannot estimate the length or gravity of the impact of the COVID-19 outbreak at this time, if the pandemic continues, it may have a material adverse effect on the Company&#8217;s results of future operations, financial position, and liquidity in 2021.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;text-transform:uppercase;font-family:Times New Roman;font-style:normal;font-variant: normal;">8. Equity</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;margin-left:3.46%;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">January Recapitalization</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In January 2020, the Company entered into an agreement with a third party, who is the holder of the 2019 Bridge Note, and the majority of the Company&#8217;s convertible preferred stock series A through F holders (&#8220;Majority Legacy Preferred Stockholders&#8221;) that provided a new source of capital and restructured the Company&#8217;s existing capital structure (the &#8220;Recapitalization&#8221;). The third party invested $4&#160;million in exchange for 48,700,311 shares of Series AA convertible preferred stock and a warrant to purchase 634,118 shares of the Company&#8217;s common stock at an exercise price of $0.01 per share. The warrant was subsequently exercised in January 2020. Additionally, the agreement with the Majority Legacy Preferred Stockholders caused all other holders of convertible preferred stock series A through F holders (&#8220;Minority Legacy Preferred Stockholders&#8221;) and the Majority Legacy Preferred Stockholders to receive 30,140,432 shares of the Company&#8217;s common stock (&#8220;Newly Issued Common Stock&#8221;) in exchange for their holdings of the Company&#8217;s convertible preferred stock series A through F, including cumulative and unpaid dividends, as part of the Recapitalization.</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Majority Legacy Preferred Stockholders agreed to invest additional capital into the Company in exchange for Series AA convertible preferred stock. Minority Legacy Preferred Stockholders were provided the opportunity to invest additional capital into the Company in exchange for Series AA convertible preferred stock. All Majority and Minority Legacy Preferred Stockholders who invested additional capital into the Company during January 2020 were allowed to convert their Newly Issued Common Stock into Series AA convertible preferred stock at a conversion rate based upon their incremental and historical investment into the Company. The Majority and Minority Legacy Preferred Stockholders invested $6.6&#160;million in exchange for 79,954,952 shares of Series AA convertible preferred stock. The Majority and Minority Legacy Preferred Stockholders also exchanged 148,732 shares of Newly Issued Common Stock for 210,310,025 shares of Series AA convertible preferred stock under the Recapitalization agreement.</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company&#8217;s issuance of Series AA convertible preferred stock triggered the redemption of the 2019 Notes, 2019 Secured Notes, 2019 Bridge Note, 2018 Bridge Notes, and 2017 Notes, as well as accrued and unpaid interest and repayment premium on the 2019 Secured Notes, into shares of Series AA convertible preferred stock. These debt instruments were redeemed for 188,173,050 shares of the Series AA convertible preferred stock, which resulted in a gain on debt extinguishment of $45&#160;thousand.</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company amended and restated its certificate of incorporation as part of the Recapitalization authorizing a total number of common stock and preferred stock of 1,230,000,000 and 870,211,737 respectively, with a par value of $0.0001 for each share.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-16</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:2.26%;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Secondary Series AA Convertible Preferred Stock Issuance</font></p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">From July to September 2020, the Company issued and sold 103,453,773 shares of Series AA convertible preferred stock at $0.082135 per share in exchange for $8.5 million in gross proceeds. </p>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:2.26%;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Series BB Convertible Preferred Stock Issuance</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In December 2020, the Company issued and sold 52,680,306 shares of Series BB convertible preferred stock at $0.207383 per share in exchange for $10.9 million in gross proceeds. </p>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:2.26%;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Convertible Preferred Stockholder Rights</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As described in Note 14 below, in connection with the Company&#8217;s initial public offering, all outstanding shares of convertible preferred stock converted into shares of the Company&#8217;s common stock. A summary of the more significant rights and preferences of the Series AA convertible preferred stock and Series BB convertible preferred stock as of December 31, 2020 are as follows:</p>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:2.27%;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Dividend Rights</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company shall not declare, pay, or set aside any dividends on shares of any other class or series of capital stock unless the holders of the convertible preferred stock then outstanding shall first receive a dividend at the rate of 8% of the original issue price, subject to adjustment for stock dividend, stock split, combination or other similar recapitalization. The Company has not declared or paid any dividends.</p>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:2.27%;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Liquidation Rights</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the event of any voluntary or involuntary liquidation, the holders of Series BB convertible preferred stock shall be entitled to be paid out of the Company&#8217;s assets available for distribution to its stockholders before any payment shall be made to holders of Series AA convertible preferred stock or common stock. The entitled amount for Series BB convertible preferred stockholders is the original issue price, subject to adjustment for stock dividend, stock split, combination or other similar recapitalization, plus declared and unpaid dividends.<font style="font-size:12pt;"> </font></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">After payment in full of all Series BB convertible preferred stock in a liquidation event, the holders of Series AA convertible preferred stock shall be entitled to be paid out of the Company&#8217;s assets available for distribution to its stockholders before any payment shall be made to holders of common stock. The entitled amount for Series AA convertible preferred stockholders is the original issue price, subject to adjustment for stock dividend, stock split, combination or other similar recapitalization, plus declared and unpaid dividends.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_DV_M104"></a>After the payment in full of the Series BB convertible preferred stock and Series AA convertible preferred stock,<a name="_DV_M104"></a> the remaining Company assets, shall be distributed among the holders of the shares of Series BB convertible preferred stock, Series AA convertible preferred stock and common stock, pro rata based on the number of shares held by each holder, as if the convertible preferred stock had been converted to common stock prior to liquidation.</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A merger or consolidation of substantially all or a significant portion of the Company&#8217;s assets shall be considered a deemed liquidation event unless the holders of at least two-thirds of the outstanding shares of Series AA convertible preferred stock and Series BB convertible preferred stock, voting together as a single class on an as-converted to common stock basis, elect otherwise by written notice sent to the Company.</p>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:2.27%;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Voting Rights</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Holders of outstanding shares of Series AA convertible preferred stock and Series BB convertible preferred stock shall be entitled to cast the number of votes equal to the number of shares of common an as-converted to basis and vote together with the holders of common stock as a single class. </p>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:2.27%;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Conversion Rights</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Each share of Series AA convertible preferred stock and Series BB convertible preferred stock shall be convertible, at the option of the holder, into shares of common stock. The conversion ratio for Series AA convertible preferred stock and Series BB convertible preferred stock is one share of common stock for every 48 shares of convertible preferred stock as a result of the reverse stock split disclosed in Note 14. The conversion ratio is subject to adjustment should specified dilutive events occur. All shares of the Series AA </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-17</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">convertible preferred stock </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Series </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">BB</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> convertible preferred stock convert</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ed</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> into shares of the Company&#8217;s common stock </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">closing of the IPO disclosed in Note 14</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.</font><font style="font-weight:bold;"> </font></p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Hlk67849969"></a>Series A, B, C, D, E and F Convertible Preferred Stock</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">All Series&#160;A, B, C, D,&#160;E, and F convertible preferred stock were converted into common stock as part of the January Recapitalization discussed above.&nbsp;&nbsp;There were no other transactions involving Series&#160;A, B, C, D,&#160;E, and F convertible preferred stock during the years ended December 31, 2020 and 2019. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following is a summary of the Company&#8217;s Series&#160;A, B, C, D, E, and F&#160;convertible preferred stock as of December&#160;31, 2019 (in thousands, except for share and par value data): </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Hlk67417336"></a>&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Par Value</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Outstanding</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Value</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Series A convertible preferred stock</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.0001</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,035,428</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,425</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Series B convertible preferred stock</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.0001</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,809,996</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,715</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Series C convertible preferred stock</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.0001</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,156,667</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,470</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Series D convertible preferred stock</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.0001</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,969,693</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,800</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Series E convertible preferred stock</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.0001</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,285,879</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17,135</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Series F convertible preferred stock</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.76%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.0001</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,000,000</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,000</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.76%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15,257,663</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">47,545</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Dividends are cumulative and accrue annually on all outstanding Series A, B, C, D, E and F of preferred stock at 8% per annum. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cumulative and unpaid dividends were converted into shares of common stock at the same rates as the underlying convertible preferred stock as part of the January Recapitalization disclosed above. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following is a summary of cumulative and unpaid dividends on the Company&#8217;s convertible preferred stock as of December 31, 2019 (in thousands): </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Series A convertible preferred stock</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,173</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Hlk67417337"></a>Series B convertible preferred stock</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,872</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Series C convertible preferred stock</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,071</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Series D convertible preferred stock</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,965</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Series E convertible preferred stock</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,751</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:78.88%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Series F convertible preferred stock</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.82%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.82%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.46%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,311</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:78.88%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.82%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.82%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.46%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">38,143</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:6pt;margin-left:2.27%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Common Stock Warrants</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During 2020, the Company granted warrants to purchase approximately 1,099,536 shares of the Company&#8217;s common stock in connection with equity fundraising events. The Company used the Black-Scholes option-pricing model to estimate the grant date fair value of the common stock warrants between $0.60 and $7.49 per share and $1.44 per share on a weighted average basis.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following is a summary of the common stock warrant activity related to common stock warrants issued in conjunction with equity and debt fundraising events during the years ended December 31, 2020 and 2019:</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-18</a></p>
<hr style="page-break-after:always;width:100%;">
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.54%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Number</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">of Common</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Stock</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Warrants</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted-</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Average</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exercise</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Price</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted-</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Average</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Remaining</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Contractual</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Term</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in years)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Aggregate</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Intrinsic</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Value (in</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">thousands)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Hlk67671473"></a>Outstanding at December 31, 2018</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,906</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">122.88</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9.98</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">22,917</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">99.30</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exercised</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.54%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expired</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.54%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outstanding at December 31, 2019</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">26,823</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">102.74</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9.17</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,099,536</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.40</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exercised</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(710,211</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.01</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.54%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expired</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(3,886</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">64.32</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.54%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outstanding at December 31, 2020</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">412,262</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9.60</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.71</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,380</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-weight:bold;font-size:10pt;text-transform:uppercase;font-family:Times New Roman;font-style:normal;font-variant: normal;">9. STOCK-BASED COMPENSATION<font style="text-transform:none;"> </font></p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In 2018, the board of directors approved the Company&#8217;s 2018 Stock Incentive Plan (the &#8220;2018 Plan&#8221;)&#8212;which supersedes and replaces previous incentive stock plans&#8212;and reserved 104,167 common shares for issuance under the 2018 Plan. All previously issued and outstanding stock-based awards issued under predecessor incentive plans were adopted into the 2018 Plan. The 2018 Plan provides the issuance of stock awards to attract and retain employees, directors, consultants and advisors and to provide incentive for individuals to contribute to the growth of the Company. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During the year ended December 31, 2020, the Company&#8217;s 2018 Plan was amended to increase the number of shares of common stock reserved for issuance under the Plan from to 2,552,083 shares in the aggregate. As of December 31, 2020, 600,588 common shares remain available for future awards under the 2018 Plan.</p>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:2.26%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Stock Options </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During 2020, the Company granted options to purchase 1,899,507 shares of common stock to employees, consultants, and nonexecutive directors pursuant to the 2018 Plan. The stock options granted during 2020 vest over a period of 6 to 48 months with an exercise price of $1.23 to $6.00 per share. The Company uses the Black-Scholes option-pricing model to estimate the fair value of the stock options on the grant dates between $2.29 and $6.06 per share.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During 2019, the Company granted options to purchase 6,246 shares of common stock to employees, consultants, and nonexecutive directors pursuant to the 2018 Plan. The stock options granted during 2019 vest over a period of 6 to 48&#160;months with an exercise price between $16.32 and $122.88 per share. The Company uses the Black-Scholes option-pricing model to estimate the fair value of the stock options on the grant dates between $0.48 and $2.88 per share. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-19</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following is a summary of the stock option award activity under the 2018 Plan during the years ended December&#160;31, </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2020 </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2019</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">: </font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Number</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">of Stock</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Options</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted-</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Average</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exercise</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Price</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted-</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Average</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Remaining</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Contractual</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Term</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in years)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Aggregate</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Intrinsic</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Value</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Hlk67671474"></a>Outstanding at December 31, 2018</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">80,794</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">120.73</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9.20</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,246</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">42.96</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exercised</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Forfeited</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(8,160</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(122.47</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expired</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,276</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(116.53</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outstanding at December 31, 2019</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">77,604</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">114.11</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8.12</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,899,507</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.02</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exercised</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(16,666</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1.23</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Forfeited</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(13,322</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(119.38</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expired</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outstanding at December 31, 2020</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,947,123</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.70</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9.56</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,284</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exercisable at December 31, 2020</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">123,108</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">49.25</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8.52</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">441</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Options expected to vest at December 31, 2020</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,824,015</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.75</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9.65</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,843</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The aggregate intrinsic value of stock options exercised in the year ended December 31, 2020 was $0.1 million.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The total fair value of options vested during the years ended December 31, 2020 and 2019 was $1.1 million and $1.8 million, respectively.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">At December 31, 2020, there was approximately $5.9 million of unrecognized stock-based compensation expense associated with the stock options, which is expected to be recognized over a weighted-average period of 2.99 years. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">At December 31, 2019, there was approximately $1.2 million of unrecognized stock-based compensation expense associated with the stock options, which is expected to be recognized over a weighted-average period of 2.26 years.</p>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:2.26%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Common Stock Warrants </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During 2019, the Company granted warrants to purchase 208 shares of the Company&#8217;s common stock to a vendor. The common stock warrants granted during 2019 vested immediately with an exercise price of $122.88 per share. The Company uses the Black-Scholes option-pricing model to estimate the fair value of the awards on the grant date of $10.08 per share. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following is a summary of the common stock warrant activity during the years ended December&#160;31, 2020 and 2019: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.54%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Number</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">of Common</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Stock</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Warrants</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted-</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Average</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exercise</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Price</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted-</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Average</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Remaining</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Contractual</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Term</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in years)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Aggregate</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Intrinsic</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Value (in</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">thousands)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Hlk67671475"></a>Outstanding at December 31, 2018</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">75,120</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">24.19</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.34</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">596</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">208</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">122.88</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exercised</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2,278</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(67.51</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.54%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expired</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(15,630</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(78.72</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.54%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outstanding at December 31, 2019</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">57,420</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7.95</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.83</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exercised</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.54%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expired</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(208</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(96.00</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.54%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outstanding and exercisable at December 31, 2020</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">57,212</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7.62</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.64</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">98</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-20</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December&#160;31, 2020, there was no unrecognized stock-based compensation expense associated with the common stock warrants. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During 2020 and 2019, the Company utilized the Black-Scholes option-pricing model for estimating the fair value of the stock options and common stock warrants granted. The following table presents the assumptions and the Company&#8217;s methodology for developing each of the assumptions used: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.56%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Hlk67671476"></a>&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="4" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.82%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Years Ended December 31,</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.56%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Volatility</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.4%; border-top:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">90%-100%</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.78%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">90.0</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected life (years)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.4%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.5&#8211;6.1</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.78%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.5&#8211;10.0</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Risk-free interest rate</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.4%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.1%&#8211;0.7%</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.78%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.4%-2.5%</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Dividend rate</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.4%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;%</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.78%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;%</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">Volatility&#8212;The Company estimates the expected volatility of its common stock at the date of grant based on the historical volatility of comparable public companies over the expected term. </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">Expected life&#8212;The expected life is estimated as the contractual term. </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">Risk-free interest rate&#8212;The risk-free rate for periods within the estimated life of the stock award is based on the U.S. Treasury yield curve in effect at the time of grant. </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">Dividend rate&#8212;The assumed dividend yield is based upon the Company&#8217;s expectation of not paying dividends in the foreseeable future. </font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock-based compensation expense was recorded in the following line items in the consolidated statements of operations for the years ended December&#160;31, 2020 and 2019 (in thousands): </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Years Ended December 31,</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Hlk67671477"></a>&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">555</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">588</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">General and administrative</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">937</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">588</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total stock-based compensation expense</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,492</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,176</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">10. EMPLOYEE RETIREMENT PLAN </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company maintains a defined contribution&#160;401(k)&#160;profit-sharing plan (the &#8220;Plan&#8221;) for all employees. Under the Plan, participants may make voluntary contributions up to the maximum amount allowable by law. The Plan is based on employees&#8217; salary deferral, and the Company matches employees&#8217; contributions up to 4% of the employees&#8217; base salary. Employees are 100% vested in the Company&#8217;s match contributions. During the years ended December&#160;31, 2020 and 2019, the Company&#8217;s matching contributions were $116&#160;thousand and $102&#160;thousand, respectively. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">11. RELATED-PARTY TRANSACTIONS </p>
<p style="margin-bottom:0pt;margin-top:6pt;margin-left:2.26%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Debt </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During 2019, the Company entered into debt arrangements with a principal owner of the Company. These arrangements relate to the 2019 Secured Notes and 2018 Bridge Notes disclosed in Note 5. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During March 2020, a principal owner of the Company purchased the 2019 Special Note directly from the original holder.</p>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:2.26%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Consulting Agreement </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During 2020, the Company entered into an agreement with a principal owner of the Company to provide consulting services to the Company in exchange for $1,500 thousand. Under the terms of the agreement, the Company recorded expense of $1,125 thousand in 2020, with payment made in January 2021. The contract was completed and the remaining balance of $375 thousand under the agreement was recorded as an expense in January 2021. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-21</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">12. <font style="text-transform:uppercase;">INCOME TAXES</font> </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Income tax expense consists of the following (in thousands): </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Hlk67671478"></a>&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year&#160;Ended&#160;December&#160;31,</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Current:</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Federal</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">State</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Current tax provision</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred:</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Federal</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2,097</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2,551</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">State</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(430</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(776</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred tax benefit</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2,527</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(3,327</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Less change in valuation allowance</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,527</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,327</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total income tax provision</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The effective income tax rate for the years ended December&#160;31, 2020 and 2019 is different from the federal statutory income tax rate primarily due to the change in valuation allowance against deferred tax assets and permanent differences primarily related to non-deductible interest and embedded debt derivatives income and expense. The reconciliation of the federal statutory income tax rate to the Company&#8217;s effective income tax rate is as follows: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.14%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Hlk67671479"></a>&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.28%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December 31,</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.14%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Federal statutory income tax rate</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21.0</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21.0</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">State income taxes, net of federal benefit</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.6</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.6</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Non-deductible interest and embedded debt derivative income and expense</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1.7</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(5.4</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Non-deductible transactions costs</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1.2</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(0.4</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(0.4</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Equity-based compensation deferred tax asset adjustment</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(8.7</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.14%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Change in valuation allowance</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(12.6</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(19.8</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.14%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Effective income tax rate</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.86%; border-bottom:double 2.5pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;&nbsp;&nbsp;%</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.86%; border-bottom:double 2.5pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;&nbsp;&nbsp;%</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company&#8217;s deferred tax assets consist primarily of its net operating loss and research and development tax credit carryforwards, along with other minor temporary differences. No amounts are being considered as an uncertain tax position or disclosed as an unrecognized tax benefit. The Company has provided a valuation allowance against its total net deferred tax assets because the Company&#8217;s ability to generate sufficient future taxable income is uncertain. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Significant components of the Company&#8217;s deferred tax assets and liabilities consist of the following (in thousands): </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Hlk67671480"></a>&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net operating loss carryforwards</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">22,271</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">18,338</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Equity-based compensation</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">706</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,384</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development tax credit carryforwards</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,364</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,364</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other accruals</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">414</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">142</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total deferred tax assets</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">24,755</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">22,228</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Valuation allowance</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(24,755</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(22,228</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net deferred tax assets</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company has incurred annual net operating losses in each year since inception. The Company believes it could be subject to certain limitations on the utilization of these net operating losses pursuant to Internal Revenue Code Section&#160;382. Therefore, the Company has not reflected the benefit of any such net operating loss carryforwards in the financial statements. Due to the Company&#8217;s history of losses, and lack of other positive evidence, the Company has determined that it is more likely than not that its net deferred tax assets will not be realized, and therefore, the net deferred tax assets are fully offset by a valuation allowance at December&#160;31, 2020 and 2019. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-22</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Future realization of the tax benefits of existing temporary differences and net operating loss carryforwards ultimately depends on the existence of sufficient taxable income within the carryforward period. As of December 31, 2020 and 2019, the Company performed an evaluation to determine whether a valuation allowance was needed. The Company considered all available evidence, both positive and negative, which included the results of operations for the current and preceding years. The Company determined that it was not possible to reasonably quantify future taxable income and determined that it is more likely than not that all of the deferred tax assets will not be realized. Accordingly, the Company maintained a full valuation allowance as of December 31, 2020 and 2019.&nbsp;&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The utilization of NOLs and tax credit carryforwards to offset future taxable income may be subject to an annual limitation as a result of ownership changes that have occurred previously or may occur in the future. Under Sections 382 and 383 of the Internal Revenue Code of 1986, as amended, (&#8220;IRC&#8221;), a corporation that undergoes an ownership change may be subject to limitations on its ability to utilize its pre-change NOLs and other tax attributes otherwise available to offset future taxable income and/or tax liability. An ownership change is defined as a cumulative change of 50% or more in the ownership positions of certain stockholders during a rolling three-year period. The Company has not completed a formal study to determine if any ownership changes within the meaning of IRC Section 382 and 383 have occurred as of December 31, 2020. An ownership change would restrict its ability to use its NOLs or tax credit carryforwards and could require the Company to pay federal or state income taxes earlier than would be required if such limitations were not in effect. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company&#8217;s valuation allowance increased during the year by $2,527 thousand for the year ended December 31, 2020 due primarily to the generation of net operating losses.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December 31, 2020, the Company has net operating loss carryforwards for federal and state tax reporting purposes of $81,325 thousand and $79,974 thousand, respectively, a portion of which expire beginning in 2021. Net operating loss carryforwards generated in 2020 and 2019 for federal tax reporting purposes of $16,604 thousand and $10,702 thousand, respectively, have an indefinite life. The remaining federal net operating losses are subject to a 20-year carryforward period. As of December 31, 2020, the Company has research and development tax credit carryforwards of approximately $1,364 thousand, which expire beginning in 2034.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company evaluates its uncertain tax positions under ASC 740-10, which requires that realization of an uncertain income tax position be recognized in the financial statements. The benefit to be recorded in the financial statements is the amount most likely to be realized assuming a review by tax authorities having all relevant information and applying current conventions. The Company concluded that there are no uncertain tax positions in any of the periods presented.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company files tax returns as prescribed by the tax laws of the jurisdictions in which it operates. In the normal course of business, the Company is subject to examination by federal and state jurisdictions, where applicable. The earliest tax years that remain subject to examination by jurisdiction is 2017 for both federal and state. However, to the extent the Company utilizes net operating losses from years prior to 2017, the statute remains open to the extent of the net operating losses or other credits are utilized.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">13. NET LOSS PER SHARE </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Basic and diluted net loss per share attributable to common stockholders is calculated as follows (in thousands except share and per share amounts): <font style="font-size:12pt;">&#160;</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Hlk67671481"></a>&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Years Ended December 31,</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Hlk67417346"></a>&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(20,100</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(16,740</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cumulative dividends on convertible preferred stock</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(104</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(3,804</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss attributable to common stockholders</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(20,204</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(20,544</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss per share&#8212;basic and diluted</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(12.53</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(55.92</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Weighted-average number of shares used in computing net loss per</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; share&#8212;basic and diluted</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,612,140</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">367,359</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-23</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following outstanding potentially dilutive securities have been excluded from the calculation of diluted net loss per share, as their effect is anti-dilutive: <font style="font-size:12pt;">&#160;</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Hlk67417347"></a>&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Years Ended December 31,</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Convertible preferred stock</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">747,683,172</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15,257,663</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock options to purchase common stock</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,947,123</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">77,604</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Warrants issued to employees and contractor to purchase common stock</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">57,212</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">57,420</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Warrants issued related to convertible notes and other equity agreements</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">412,262</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">26,823</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="N15_SUBSEQUENT_EVENTS"></a>14<a name="N15_SUBSEQUENT_EVENTS"></a>. SUBSEQUENT EVENTS </p>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:2.26%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Reverse stock split </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On January&#160;29, 2021, the Company effected a reverse stock split of the Company&#8217;s common stock on a 48-for-1 basis (the &#8220;Reverse Stock Split&#8221;). In connection with the Reverse Stock Split, the conversion ratio for the Company&#8217;s Series&#160;AA and Series&#160;BB convertible preferred stock was proportionately adjusted such that the common stock issuable upon conversion of such preferred stock was decreased in proportion to the Reverse Stock Split. Accordingly, all common stock share and per share amounts, as well as all preferred stock conversion ratios, for all periods presented in these financial statements have been retroactively adjusted, to reflect this reverse stock split and adjustment of the Series&#160;AA and BB convertible preferred stock conversion ratios.  </p>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:2.26%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Massachusetts operating lease </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In January 2021, the Company entered into a new operating lease for general office purposes including laboratory use in Boston, Massachusetts, with a term commencing in May 2021 and continuing through May 2026. The amount of square feet of office space is 10,082 square feet and the Company&#8217;s minimum commitment under the new lease is approximately $880 thousand dollars annually. </p>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:2.26%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Common stock warrants </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In January 2021, the Company issued warrants as a result of the Series&#160;AA and Series&#160;BB convertible preferred stock raises to an existing principal owner to purchase 1,648,707 shares of common stock with an exercise price of $0.01 per common share. The warrants had a maturity date of 30&#160;days and was exercised in January 2021. </p>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:2.26%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Stock-based compensation </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:2.26%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Hlk67833037"></a>In January 2021, the board of directors approved and granted options to purchase 72,916 shares of the common stock under the 2018 Plan. The awards vest over four years with an exercise price of $9.22 per share. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:2.26%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Hlk67671110"></a>In February 2021, the board of directors approved and granted options to purchase 1,028,117 shares of the common stock under the 2021 Plan. The awards vest over four years with an exercise price of $19.00 per share.</p>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:2.26%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Series BB convertible preferred stock </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> In January 2021, the Company issued and sold 113,275,902 shares of Series&#160;BB convertible preferred stock at $0.207383 per share in exchange for $23.5&#160;million in gross proceeds. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Initial Public Offering</p>
<p style="text-align:left;Background-color:#auto;margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;color:#auto;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In February 202<font style="color:#000000;">1</font>, the Company completed its <font style="color:#000000;">IPO </font>in which the Company issued and sold <font style="color:#000000;">8,030,295</font> shares of its common stock, including <font style="color:#000000;">1,030,243</font> shares pursuant to the <font style="color:#000000;">partial</font> exercise of the underwriters&#8217; option to purchase additional shares, at a public offering price of $<font style="color:#000000;">19.00 </font>per share, for aggregate gross proceeds of $<font style="color:#000000;">152.6</font> million. The Company received approximately $<font style="color:#000000;">138.5</font> million in net proceeds after deducting underwriting discounts and estimated offering expenses payable by the Company. In connection with <font style="color:#000000;">the IPO</font>, all outstanding shares of <font style="color:#000000;">convertible p</font>referred <font style="color:#000000;">s</font>tock converted into <font style="color:#000000;">19,034,069</font> shares of the Company&#8217;s common stock.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-24</a></p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.3
<SEQUENCE>2
<FILENAME>snse-ex43_634.htm
<DESCRIPTION>EX-4.3
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
snse-ex43_634.htm
</title>
</head>
<!-- NG Converter v5.0.2.50 -->
<body>

<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 4.3</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">DESCRIPTION OF SENSEI BIOTHERAPEUTICS, INC. CAPITAL STOCK</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;">&nbsp;</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">The following description of the common stock of Sensei Biotherapeutics, Inc., or the Company, is a summary and does not purport to be complete. This summary is qualified in its entirety by reference to the provisions of the Delaware General Corporation Law, or the DGCL, and the complete text of the Company&#8217;s amended and restated certificate of incorporation, or the certificate of incorporation, and amended and restated bylaws or the bylaws, which are incorporated by reference as Exhibits 3.1 and 3.2, respectively of the Company&#8217;s Annual Report on Form 10-K to which this description is also an exhibit. The Company encourages you to read that law and those documents carefully.</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">General</p>
<p style="Background-color:#FFFFFF;margin-top:18pt;margin-bottom:0pt;text-indent:7.69%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the certificate of incorporation, our authorized capital stock consists of 250,000,000 shares of common stock, $0.0001 par value per share, and 10,000,000 shares of preferred stock, $0.0001 par value per share, all of which shares of preferred stock are undesignated. Our board of directors may establish the rights and preferences of the preferred stock from time to time. </p>
<p style="Background-color:#FFFFFF;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Common Stock</p>
<p style="Background-color:#FFFFFF;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Voting Rights</p>
<p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Holders of our common stock are entitled to one vote per share of common stock. Our common stock does not have cumulative voting rights. Accordingly, the holders of a majority of the outstanding shares of common stock entitled to vote in any election of directors can elect all of the directors standing for election, if they so choose, other than any directors that holders of any preferred stock we may issue may be entitled to elect. </p>
<p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Dividends</p>
<p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Subject to preferences that may be applicable to any then outstanding preferred stock, holders of our common stock are entitled to receive ratably those dividends, if any, as may be declared by the board of directors out of legally available funds. </p>
<p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Liquidation</p>
<p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the event of our liquidation, dissolution or winding up, the holders of our common stock will be entitled to share ratably in the assets legally available for distribution to stockholders after the payment of or provision for all of our debts and other liabilities, subject to the prior rights of any preferred stock then outstanding.</p>
<p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Rights and Preferences</p>
<p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> Holders of our common stock have no preemptive rights or other subscription rights and there are no redemption or sinking funds provisions applicable to our common stock. All outstanding shares of our common stock are duly authorized, validly issued, fully paid and nonassessable. The rights, preferences and privileges of holders of our common stock are subject to and may be adversely affected by the rights of the holders of shares of any series of preferred stock that we may designate and issue in the future.</p>
<p style="Background-color:#FFFFFF;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Preferred Stock</p>
<p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the terms of the certificate of incorporation, our board of directors has the authority, without further action by our stockholders, to issue up to 10,000,000&#160;shares of preferred stock in one or more series, to establish from time to time the number of shares to be included in each such series, to fix the dividend, voting and other rights, preferences and privileges of the shares of each wholly unissued series and any qualifications, limitations or restrictions thereon, and to increase or decrease the number of shares of any such series, but not below the number of shares of such series then outstanding.</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our board of directors may authorize the issuance of preferred stock with voting or conversion rights that could adversely affect the voting power or other rights of the holders of the common stock. The issuance of preferred stock, while providing flexibility in connection with possible acquisitions and other corporate purposes, </p>
<hr style="page-break-after:always;width:100%;">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">could, among other things, have the effect of delaying, deferring or preventing a change in our control and may adversely affect the market price of the common stock and the voting and other rights of the holders of common stock. We have no current plans to issue any shares of preferred stock.</font></p>
<p style="Background-color:#FFFFFF;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Anti-Takeover Effects of Delaware Law and Our Certificate of Incorporation and Bylaws</p>
<p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Some provisions of Delaware law, our certificate of incorporation and our bylaws contain provisions that could make the following transactions more difficult: an acquisition of us by means of a tender offer; an acquisition of us by means of a proxy contest or otherwise; or the removal of our incumbent officers and directors. It is possible that these provisions could make it more difficult to accomplish or could deter transactions that stockholders may otherwise consider to be in their best interest or in our best interests, including transactions which provide for payment of a premium over the market price for our shares.</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">These provisions, summarized below, are intended to discourage coercive takeover practices and inadequate takeover bids. These provisions are also designed to encourage persons seeking to acquire control of us to first negotiate with our board of directors. We believe that the benefits of the increased protection of our potential ability to negotiate with the proponent of an unfriendly or unsolicited proposal to acquire or restructure us outweigh the disadvantages of discouraging these proposals because negotiation of these proposals could result in an improvement of their terms.</p>
<p style="Background-color:#FFFFFF;margin-top:18pt;margin-bottom:0pt;margin-left:4.82%;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Stockholder Meetings</p>
<p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our bylaws provide that a special meeting of stockholders may be called only by our chairman of the board, chief executive officer or president, or by a resolution adopted by a majority of our board of directors.</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;margin-left:4.82%;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;margin-left:4.82%;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Requirements for Advance Notification of Stockholder Nominations and Proposals</p>
<p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our bylaws establish advance notice procedures with respect to stockholder proposals to be brought before a stockholder meeting and the nomination of candidates for election as directors, other than nominations made by or at the direction of the board of directors or a committee of the board of directors.</p>
<p style="Background-color:#FFFFFF;margin-top:18pt;margin-bottom:0pt;margin-left:4.82%;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Elimination of Stockholder Action by Written Consent</p>
<p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our certificate of incorporation and bylaws eliminate the right of stockholders to act by written consent without a meeting.</p>
<p style="Background-color:#FFFFFF;margin-top:18pt;margin-bottom:0pt;margin-left:4.82%;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Staggered Board</p>
<p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our board of directors is divided into three classes. The directors in each class serve for a three-year term, one class being elected each year by our stockholders. For more information on the classified board, see &#8220;Management&#8212;Board Composition and Election of Directors.&#8221; This system of electing and removing directors may tend to discourage a third-party from making a tender offer or otherwise attempting to obtain control of us, because it generally makes it more difficult for stockholders to replace a majority of the directors.</p>
<p style="Background-color:#FFFFFF;margin-top:18pt;margin-bottom:0pt;margin-left:4.82%;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Removal of Directors</p>
<p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our certificate of incorporation provides that no member of our board of directors may be removed from office by our stockholders except for cause and, in addition to any other vote required by law, upon the approval of not less than two thirds of the total voting power of all of our outstanding voting stock then entitled to vote in the election of directors.</p>
<p style="Background-color:#FFFFFF;margin-top:18pt;margin-bottom:0pt;margin-left:4.82%;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Stockholders Not Entitled to Cumulative Voting</p>
<p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our certificate of incorporation does not permit stockholders to cumulate their votes in the election of directors. Accordingly, the holders of a majority of the outstanding shares of our common stock entitled to vote in </p>
<hr style="page-break-after:always;width:100%;">
<p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">any election of directors can elect all of the directors standing for election, if they choose, other than any directors that holders of our convertible preferred stock may be entitled to elect.</font></p>
<p style="Background-color:#FFFFFF;margin-top:18pt;margin-bottom:0pt;margin-left:4.82%;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Delaware Anti-Takeover Statute</p>
<p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are subject to Section&#160;203 of the Delaware General Corporation Law, which prohibits persons deemed to be &#8220;interested stockholders&#8221; from engaging in a &#8220;business combination&#8221; with a publicly held Delaware corporation for three years following the date these persons become interested stockholders unless the business combination is, or the transaction in which the person became an interested stockholder was, approved in a prescribed manner or another prescribed exception applies. Generally, an &#8220;interested stockholder&#8221; is a person who, together with affiliates and associates, owns, or within three years prior to the determination of interested stockholder status did own, 15% or more of a corporation&#8217;s voting stock. Generally, a &#8220;business combination&#8221; includes a merger, asset or stock sale, or other transaction resulting in a financial benefit to the interested stockholder. The existence of this provision may have an anti-takeover effect with respect to transactions not approved in advance by the board of directors.</p>
<p style="Background-color:#FFFFFF;margin-top:18pt;margin-bottom:0pt;margin-left:4.82%;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Choice of Forum</p>
<p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our certificate of incorporation provides that the Court of Chancery of the State of Delaware (or, if and only if the Court of Chancery of the State of Delaware lacks subject matter jurisdiction, any state court located within the State of Delaware or, if and only if all such state courts lack subject matter jurisdiction, the federal district court for the District of Delaware) and any appellate court therefrom is the sole and exclusive forum for the following claims or causes of action under the Delaware statutory or common law: (i)&#160;any derivative claim or cause of action brought on our behalf; (ii)&#160;any claim or cause of action for a breach of fiduciary duty owed by any of our current or former directors, officers, or other employees to us or our stockholders; (iii)&#160;any claim or cause of action against us or any of our current or former directors, officers or other employees arising out of or pursuant to any provision of the DGCL, our certificate of incorporation, or our bylaws (as each may be amended from time to time); (iv) any claim or cause of action seeking to interpret, apply, enforce or determine the validity of our certificate of incorporation or our bylaws (as each may be amended from time to time, including any right, obligation, or remedy thereunder); (v) any claim or cause of action as to which the DGCL confers jurisdiction to the Court of Chancery of the State of Delaware; and (vi)&#160;any claim or cause of action against us or any of our current or former directors, officers, or other employees governed by the internal-affairs doctrine, in all cases to the fullest extent permitted by law and subject to the court&#8217;s having personal jurisdiction over the indispensable parties named as defendants. This choice of forum provision would not apply to claims or causes of action brought to enforce a duty or liability created by the Securities Act, the Exchange Act or any other claim for which the federal courts have exclusive jurisdiction, or the Securities Act. Our certificate of incorporation provides that the federal district courts of the United States of America will be the exclusive forum for resolving any complaint asserting a cause of action arising under the Securities Act. Additionally, our certificate of incorporation provides that any person or entity holding, owning or otherwise acquiring any interest in any of our securities shall be deemed to have notice of and consented to these provisions.</p>
<p style="Background-color:#FFFFFF;margin-top:18pt;margin-bottom:0pt;margin-left:4.82%;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Amendment of Charter Provisions</p>
<p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The amendment of any of the above provisions, except for the provision making it possible for our board of directors to issue convertible preferred stock, would require approval by holders of at least two thirds of the total voting power of all of our outstanding voting stock.</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The provisions of Delaware law, our certificate of incorporation and our bylaws could have the effect of discouraging others from attempting hostile takeovers and, as a consequence, they may also inhibit temporary fluctuations in the market price of our common stock that often result from actual or rumored hostile takeover attempts. These provisions may also have the effect of preventing changes in the composition of our board and management. It is possible that these provisions could make it more difficult to accomplish transactions that stockholders may otherwise deem to be in their best interests.</p>
<p style="Background-color:#FFFFFF;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Transfer Agent and Registrar</p>
<hr style="page-break-after:always;width:100%;">
<p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The transfer agent and registrar for our common stock </font><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">is</font><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> American Stock Transfer &amp; Trust Company, LLC. The transfer agent&#8217;s address is 6201 15th Avenue, Brooklyn, New York 11219.</font></p>
<p style="Background-color:#FFFFFF;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Exchange Listing</p>
<p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our common stock is listed on the Nasdaq Global Market under the symbol &#8220;SNSE&#8221;.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.12
<SEQUENCE>3
<FILENAME>snse-ex1012_633.htm
<DESCRIPTION>EX-10.12
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
snse-ex1012_633.htm
</title>
</head>
<!-- NG Converter v5.0.2.50 -->
<body>

<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 10.12</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-variant: small-caps;font-size:12pt;font-style:normal;text-transform:none;">Sensei Biotherapeutics, Inc.</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman Bold;font-variant: small-caps;font-size:12pt;font-style:normal;text-transform:none;">Non-Employee Director Compensation Policy</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Each member of the Board of Directors (the &#8220;<font style="font-weight:bold;font-style:italic;">Board</font>&#8221;) who is not also serving as an employee of or consultant to Sensei Biotherapeutics, Inc. (the &#8220;<font style="font-weight:bold;font-style:italic;">Company</font>&#8221;) or any of its subsidiaries (each such member, an &#8220;<font style="font-weight:bold;font-style:italic;">Eligible Director</font>&#8221;) will receive the compensation described in this Non-Employee Director Compensation Policy for his or her Board service upon and following the date of the underwriting agreement between the Company and the underwriters managing the initial public offering of the Company&#8217;s common stock (the &#8220;<font style="font-weight:bold;font-style:italic;">Common Stock</font>&#8221;), pursuant to which the Common Stock is priced in such initial public offering (the &#8220;<font style="font-weight:bold;font-style:italic;">Effective Date</font>&#8221;). An Eligible Director may decline all or any portion of his or her compensation by giving notice to the Company prior to the date cash may be paid or equity awards are to be granted, as the case may be. This policy is effective as of the Effective Date and may be amended at any time in the sole discretion of the Board or the Compensation Committee of the Board.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Annual Cash Compensation</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The annual cash compensation amount set forth below is payable to Eligible Directors in equal quarterly installments, payable in arrears on the last day of each fiscal quarter in which the service occurred. If an Eligible Director joins the Board or a committee of the Board at a time other than effective as of the first day of a fiscal quarter, each annual retainer set forth below will be pro-rated based on days served in the applicable fiscal quarter, with the pro-rated amount paid on the last day of the first fiscal quarter in which the Eligible Director provides the service and regular full quarterly payments thereafter. All annual cash fees are vested upon payment. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><font style="text-decoration:underline;">Annual Board Service Retainer</font>: </p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:7.69%;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">a.<font style="margin-left:36pt;">All Eligible Directors: $35,000</font></p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">b.</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">Independent Chair of the Board Service Retainer (in addition to Eligible Director Service Retainer): $30,000</p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:7.69%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><font style="text-decoration:underline;">Annual Committee Chair Service Retainer</font>:</p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:7.69%;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">a.<font style="margin-left:36pt;">Chair of the Audit Committee: $15,000</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:7.69%;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">b.<font style="margin-left:36pt;">Chair of the Compensation Committee: $10,000</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:7.69%;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">c.<font style="margin-left:36pt;">Chair of the Nominating and Corporate Governance Committee: $8,000</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:7.69%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><font style="text-decoration:underline;">Annual Committee Member Service Retainer (not applicable to Committee Chairs)</font>:</p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:7.69%;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">a.<font style="margin-left:36pt;">Member of the Audit Committee: $7,500</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:7.69%;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">b.<font style="margin-left:36pt;">Member of the Compensation Committee: $5,000</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:7.69%;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">c.<font style="margin-left:36pt;">Member of the Nominating and Corporate Governance Committee: $4,000</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Equity Compensation</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The equity compensation set forth below will be granted under the Company&#8217;s 2021 Equity Incentive Plan (the &#8220;<font style="font-weight:bold;font-style:italic;">Plan</font>&#8221;), subject to the approval of the Plan by the Company&#8217;s stockholders. All stock options granted under this policy will be nonstatutory stock options, with an exercise </p>
<p style="margin-top:12pt;margin-bottom:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:7.69%;">1</a>.</p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#auto;font-size:8pt;font-family:Times New Roman;letter-spacing:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:none;"><strike Style="text-decoration:none;">241965695 v3</strike></font><font style="font-size:12pt;color:#000000;"> </font></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">price per share equal to 100% of the Fair Market Value (as defined in the Plan) of the underlying Common Stock on the date of grant, and a term of te</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">n years from the date of grant (</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">subject to earlier termination in connection with a termination of </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">service as provided in the Plan</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Initial Grants</font>: For each Eligible Director who is first elected or appointed to the Board following the Effective Date, on the date of such Eligible Director&#8217;s initial election or appointment to the Board (or, if such date is not a market trading day, the first market trading day thereafter), the Eligible Director will be automatically, and without further action by the Board or the Compensation Committee of the Board, granted a stock option to purchase 16,667 shares of Common Stock (the &#8220;<font style="font-weight:bold;font-style:italic;">Initial Grant</font>&#8221;). The shares subject to each Initial Grant will vest in equal monthly installments over a three year period such that the option is fully vested on the third anniversary of the date of grant, subject to the Eligible Director&#8217;s Continuous Service through each such vesting date and will vest in full upon a Change in Control, subject to the Eligible Director&#8217;s Continuous Service through such date.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Annual Grants</font>: On the date of each annual stockholder meeting of the Company held after the Effective Date, each Eligible Director who has served as a non-employee member of the Board for at least six months prior to such stockholder meeting and who continues to serve as a non-employee member of the Board following such stockholder meeting will be automatically, and without further action by the Board or the Compensation Committee of the Board, granted a stock option to purchase 8,333 shares of Common Stock (the &#8220;<font style="font-weight:bold;font-style:italic;">Annual Grant</font>&#8221;). The shares subject to the Annual Grant will vest in equal monthly installments over a one year period such that the option is fully vested on the first anniversary of the date of grant, subject to the Eligible Director&#8217;s Continuous Service through each such vesting date; provided, that the Annual Grant will in any case be fully vested on the date of Company&#8217;s next annual stockholder meeting, subject to the Eligible Director&#8217;s Continuous Service through such vesting date; provided, further, that the Annual Grant will vest in full upon a Change in Control, subject to the Eligible Director&#8217;s Continuous Service through such date.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Non-Employee Director Compensation Limit</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Hlk55205503"></a><a name="_Hlk55205503"></a>Notwithstanding the foregoing, the aggregate value of all compensation granted or paid, as applicable, to any individual for service as a Non-Employee Director (as defined in the Plan) shall in no event exceed the limits set forth in Section 3(d) of the Plan.</p>
<p style="margin-top:12pt;margin-bottom:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:7.69%;">2</a>.</p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#auto;font-size:8pt;font-family:Times New Roman;letter-spacing:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:none;"><strike Style="text-decoration:none;">241965695 v3</strike></font><font style="font-size:12pt;color:#000000;"> </font></p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>4
<FILENAME>snse-ex231_632.htm
<DESCRIPTION>EX-23.1
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
snse-ex231_632.htm
</title>
</head>
<!-- NG Converter v5.0.2.50 -->
<body>

<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 23.1</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Consent of Independent Registered Accounting Firm</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We consent to the incorporation by reference in Registration Statement No. 333-252954 on Form S-8 of our report dated March 30, 2021, relating to the financial statements of Sensei Biotherapeutics, Inc. appearing in this Annual Report on Form 10-K for the year ended December 31, 2020. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">/</font><font style="font-size:12pt;font-family:Times New Roman;color:#000000;">s/ Deloitte &amp; Touche LLP</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Baltimore, Maryland</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-right:1.92%;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">March 30, 2021</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>5
<FILENAME>snse-ex311_9.htm
<DESCRIPTION>EX-31.1
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
snse-ex311_9.htm
</title>
</head>
<!-- NG Converter v5.0.2.50 -->
<body>

<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:right;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 31.1</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">PURSUANT TO SECTION&#160;302 OF THE SARBANES-OXLEY ACT OF 2002<br /></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">I, <font style="color:#000000;">John Celebi</font>, certify that:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">1.</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">I have reviewed this </font><font style="color:#000000;">Annual Report on Form&#160;10-K for the year ended December 31, 2020 of Sensei Biotherapeutics, Inc. (the &#8220;registrant&#8221;)</font><font style="color:#000000;">;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">2.</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="color:#000000;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">3.</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="color:#000000;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">4.</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="color:#000000;">The registrant&#8217;s other certifying officer(s)&#160;and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules&#160;13a-15(e)&#160;and 15d-15(e)) for the registrant and have:</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a)</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><font style="color:#000000;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b)</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><font style="color:#000000;">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(c)</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><font style="color:#000000;font-size:5pt;">&#160;</font><font style="color:#000000;">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting; and</font> </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">5.</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="color:#000000;">The registrant&#8217;s other certifying officer(s)&#160;and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions):</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a)</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><font style="color:#000000;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information; and</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b)</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><font style="color:#000000;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:5.24%;text-indent:-5.24%;font-size:12pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:45.46%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Date: March 30, 2021</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.04%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.04%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By:</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.46%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ John Celebi</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.46%; border-top:solid 0.75pt #000000;">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">John Celebi</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">President and Chief Executive Officer<font style="font-weight:bold;color:#000000;"> </font></p>
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(Principal Executive Officer)<font style="font-weight:bold;color:#000000;"> </font></p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>6
<FILENAME>snse-ex312_8.htm
<DESCRIPTION>EX-31.2
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
snse-ex312_8.htm
</title>
</head>
<!-- NG Converter v5.0.2.50 -->
<body>

<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:right;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 31.2</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><br /><font style="font-family:Times New Roman Bold;font-size:12pt;">CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER</font></p>
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman Bold;font-style:normal;text-transform:none;font-variant: normal;">PURSUANT TO SECTION&#160;302 OF THE SARBANES-OXLEY ACT OF 2002</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">I, <font style="color:#000000;">Erin Colgan</font>, certify that:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">1.</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">I have reviewed this </font><font style="color:#000000;">Annual Report on Form&#160;10-K for the year ended December 31, 2020 of Sensei Biotherapeutics, Inc. (the &#8220;registrant&#8221;)</font><font style="color:#000000;">;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">2.</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="color:#000000;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">3.</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="color:#000000;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">4.</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="color:#000000;">The registrant&#8217;s other certifying officer(s)&#160;and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules&#160;13a-15(e)&#160;and 15d-15(e)) for the registrant and have:</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a)</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><font style="color:#000000;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b)</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><font style="color:#000000;font-size:5pt;">&#160;</font><font style="color:#000000;">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</font> </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(c)</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><font style="color:#000000;font-size:5pt;">&#160;</font><font style="color:#000000;">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting; and</font> </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">5.</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="color:#000000;">The registrant&#8217;s other certifying officer(s)&#160;and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions):</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a)</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><font style="color:#000000;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information; and</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b)</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><font style="color:#000000;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:5.24%;text-indent:-5.24%;font-size:12pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:45.46%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Hlk66358877"></a>Date: March 30, 2021</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.04%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.04%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By:</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.46%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ Erin Colgan</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.46%; border-top:solid 0.75pt #000000;">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Erin Colgan</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Senior Vice President of Finance and Administration</p>
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(Principal Financial Officer)<font style="font-weight:bold;color:#000000;"> </font></p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>7
<FILENAME>snse-ex321_7.htm
<DESCRIPTION>EX-32.1
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
snse-ex321_7.htm
</title>
</head>
<!-- NG Converter v5.0.2.50 -->
<body>

<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:right;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 32.1</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;"><br />CERTIFICATIONS OF</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">PRINCIPAL EXECUTIVE OFFICER AND PRINCIPAL FINANCIAL OFFICER</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">PURSUANT TO 18 U.S.C. SECTION&#160;1350,</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">AS ADOPTED PURSUANT TO</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">SECTION&#160;906 OF THE SARBANES-OXLEY ACT OF 2002</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pursuant to the requirement set forth in Rule&#160;13a-14(b)&#160;of the Securities Exchange Act of 1934, as amended, (the &#8220;Exchange Act&#8221;) and Section&#160;1350 of Chapter 63 of Title 18 of the United States Code (18 U.S.C. &#167;1350), John Celebi, President and Chief Executive Officer of Sensei Biotherapeutics, Inc. (the &#8220;Company&#8221;), and Erin Colgan, Senior Vice President of Finance and Administration of the Company, each hereby certifies that, to the best of his or her knowledge:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:12pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1)</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><font style="color:#000000;">The Company&#8217;s Annual Report on Form&#160;10-K for the year ended December 31, 2020, to which this Certification is attached as Exhibit&#160;32.1 (the &#8220;Annual Report&#8221;), fully complies with the requirements of Section&#160;13(a)&#160;or Section&#160;15(d)&#160;of the Exchange Act; and</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:12pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2)</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><font style="color:#000000;">The information contained in the Annual Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></p></td></tr></table></div>
<p style="text-align:center;margin-bottom:0pt;margin-top:12pt;margin-left:10.47%;text-indent:-5.24%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">IN WITNESS WHEREOF<font style="font-weight:normal;">, the undersigned have set their hands hereto as of the 30th&#160;day of March, 2021.</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:5.24%;text-indent:-5.24%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  style="width:44.62%; border-bottom:solid 1pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ John Celebi</p></td>
<td valign="top"  style="width:10.84%; border-bottom:solid 1pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:44.54%; border-bottom:solid 1pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ Erin Colgan</p></td>
</tr>
<tr>
<td valign="top"  style="width:44.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">John Celebi</p></td>
<td valign="top"  style="width:10.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:44.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Erin Colgan</p></td>
</tr>
<tr>
<td valign="top"  style="width:44.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">President and Chief Executive Officer<br />(Principal Executive Officer)</p></td>
<td valign="top"  style="width:10.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:44.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Senior Vice President of Finance and Administration<br />(Principal Financial Officer)</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:8pt;margin-top:0pt;margin-left:5.07%;text-indent:-3.39%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">*&#160;&#160;&#160;&#160;This certification accompanies the Form&#160;10-K to which it relates, is not deemed filed with the Securities and Exchange Commission and is not to be incorporated by reference into any filing of the Company under the Securities Act of 1933, as amended, or the Exchange Act (whether made before or after the date of the Form&#160;10-K), irrespective of any general incorporation language contained in such filing.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>g0fyk5pshdve000016.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g0fyk5pshdve000016.jpg
M_]C_X  02D9)1@ ! 0$!+ $L  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" (:!80# 2(  A$! Q$!_\0
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M@_*C ]!^5+10 F!Z#\J,#T'Y4M% "8'H/RHP/0?E2T4 )@>@_*C ]!^5+10
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M\UXA^SI_R1WP3_V!K/\ ])XJ]OH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MH%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** $(!QGMTI:** "BBB@#XC^/G_ "5GP3_UTM?_
M &6OM:W_ ./>#_KC%_Z M?%/Q\_Y*SX)_P"NEK_[+7VM;_\ 'O!_UQB_] 6N
M#"?Q\=_U_7_I)YF#_P!\S'_K[3_]-HFHHS17>>F%%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 U?XO\
M>-%"_P 7^\:* %'0?0?RI:0=!]!_*EH **** "BBB@ HHHH **** "B@]#7B
MGQ0_:"^$?P86'_A9/B_3?#33*&A6^D16=6^[M#.IZ8H ]KHKY \,_MV_LM^,
M-4AT;P]\3M'U'4;B588;>$J6>1SA5'[P]37JOQ&_:#^$'PFTJWUKQ[XQTS0=
M/ND$D$MU*@,B, 054L#R",?_ *J /:J*^<?A5^UA\ OC5?G2_AQX^TGQ%?!B
MAMK>1!)N'50-Y.?2NJ^*?Q[^%'P4M4NOB1XMT_PY%(H=3=2('8$9&%+J>1T_
M/O0![)17SA\+/VLO@'\:+U].^'/C_2O$%\K%#;P2HLN[IC!<GKQ^5?1J@C.>
M_P#G^M &1XB_Y &M?]@J_P#_ $EEK_./_;6_Y2D^'/\ L:[7_P!+A7^CCXB!
M.@:T!_T"K_\ ])9:_P X_P#;6!'_  5*\.\=/%=K_P"EPH _T&?V=/\ DCO@
MG_L#6?\ Z3Q5[?7B'[.9_P"+.^"?^P-9?^D\5>WT %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M (D]D._:VBKW(M@@<\UX?^SBH7X.^"@!Q_8]G_Z30U[CCV_2@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MK=VT4Q [;6="RXZC!QGJ#6S10!R?A_P-X2\+ _V#H&F:<Y)8RVUI!'*2>?\
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MP.,="&SUZ?6C4O$ND:2 );^W#DC]UYB%P,=<9SCIU]?:OCS1O!>J_"KX/_\
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M+I0C']S(K;3CC."2,'UKX7^'OQG\8ZW^T=J_@.^E9M$M)95CC)( 4$XP#_\
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MGBKV^@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M+K[)=2PQN-XC))C=5.>O>@#^QOPC\6_ASXZ?RO#'B[1=5N02IM;6^MY9P?\
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MK[5_'W\5_COX9_:%_P""C_A7Q;X5N5N;&X\26<Z2+T*F\4_RYH _TC/V=/\
MDCO@G_L#6?\ Z3Q5[?7A_P"SD0?@[X)(.1_8UG_Z3Q5[A0 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M<4#..>O^?2EINWYMV?PQ[8I@.HII&<'TY^M-DD$2-(Y"JH)8DX  ]Z/OU?\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M9+K<^1/CM_R4?PGQ_P M;?\ ]"6OL"TW?8[3''^C09_[])7YS?&GXW_#V_\
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MI7NGWZM[]=.A^+.E_LO?&/X0>,M?O/"I==&U>\FE18P0-DCDC@#N/SZU]=?
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M5YO?6WN^:>[5U=_C^1FE?L[?&[XK?$W0_%WQ+N)9]*TN2 E92S_NXL #G_9
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MB)>1W">(U,]E''C$0DE$H&!TP./T^OXDZ)XS\#ZSJ\.E>&Y(GUH3B"%!@$7
M.% ]]PZ?_6K^H#_@FYH/Q'TCP#/)XV65;2>%&TW><CRVVE-O_ /PH _3<L%&
M3P/7L/<D] .]>7^.?C+\-_AU87-]XG\7:)8- C/]EFU&V6X<J.56/?N4_4?0
M5Z1>Q-/9W4*'#RVT\:-_==XF56]L$@YK^9;]O/\ 9I\#3^/KKQ-\6?VBI_!-
ME)=-)'HS:NT".C/D)Y/G*""./NT ?H7XY_X*^?LZ^";^:PD%UJ3PR-'OM+A'
M5MIQD;4;@XXJMX0_X+"?L[>++F.W2WO[#S&"[[J9%49.,Y:)1Q_GMG\M=/\
M@=_P3^\+_#7_ (3'4_BEI?B2X2W#(T]Y#+)-(%)SAI"Q+'Z]?4UY)\-M%_8E
M^,'BEO!=OXOTWPU>WDOD:;+YT=LTC2,5C(8LN>2,?3\* /ZJ?AO^T)\*/BAI
M\%YX;\8:'+-,%/V%]2M1<@L!@!2ZY.3C&,U[(LBR$,C!T.TJZD%6!Y!4C((]
MZ_GX^%G_  2)\6?#KQMI/Q$\#_&O4-1\.RSQ:A%ID6H3O!);,PD4* _EN-O&
M%+8.00#T_>WPQ8SZ5X=TC3;F0S7-G9PV\TI.6DDC'+GN230!T5%("2.1S2T
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MYK8G$XR\,'-+E3;5?F]Y2DKV5UKKV.[GEMK&%[B9XK:WA0M)(V$1% ZL>!@
M9Y_&ORY_;1_;%^$GAK3[+PJ^K65[?1:B&D,=Q&^PJ54C@_+C!Z]2/PKZ2_:@
M^*.G1_!CQS:>%M4+>)9-+GCL8H,^:LNR3E2I)SD8&/7L:_@[^+NN?%N;QOKY
M\=7NIFX.IW;6BSBXX3S&V%2W8#ZYK^_?"O@"CQ+B*^/QV)EA89?4A[+#6Y*M
M:4HW4U>SY(WUMU/M.(<Y>!IPHT::J>V7O5+IQA%-:6_F?F?WO?LW_'OX=?$?
MX=Z#)H^O::DUK81QR6[7,2OP"Q.-V<\X/KC YKN?$/QM\/Z#<M;FWFN\' >
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MPQ[8H =1111W *3 SGO2TC#<,=.: %.<''7M35W9^;I^']*<. !Z44 %%%%
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M1@<\_I7@G[-GB;Q!XM^%6@:MXET7_A']3>TBCETWRQ'Y $2\;0%QCITQ7OU
M"-NQ\O7/^>M-0DYSST_K3ZX#QO\ %#P-\.;877C'7[/1H2 0;B15)SC&%+ ]
MQVH [^BO+O GQF^&_P 2BZ^#/$^GZRZ9RD$J%\@9.%WDGZ#KVK=\8_$+PAX
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** $+8ZYI:,9ZC/X44 %%%% !1110 4449[=_2@ KG-;\+Z
M;KT30WRLR-V7_/K71T4FE)--73W0FE).,E>,E9I[-=C\Y_BW\+?#5OX_T&!"
MP1KJ/."0<;Q_G_&OM[PUX)T?0K:RDL0X=+:'!)X/[I><9[G].*^9/C"<_$70
M./\ EYC'X>8O-?95E_QY69/&+:W_ /1*BN>C2I1G4<(13YK)KM9/Y?F>/EU*
MG#%YAR4XQ:JP2LM=8)_GV)T#C);'\_\ />I*:1NP<]#^?^<4[-=-_P!/Z^9[
M(A .,]NE+4>\DX4 \G//^?UKE==\8Z/H2NMS<*+K:=D.<EG' 7&>IP.WM6=2
MK3HQYZLXTXKK)\J]-;:OHMV3.<81<IR48K2[:6N]O5]#I;BYAMHVDFE2) #D
MN< CIP3^8Q7COB3XCQR32:1HL;27C9C69 2FXYZ$<<_0UR4FI^*?B%>/:B&7
M3].#D1S*K('7/#9X[=\XZ5ZOX8\ Z;H<*M.B7=WP3<, 6!'N><]^_P!:\>6*
MQ>8ODP,94,,[J>+J1LY).SC2@]4^JEKIJNAP^WKXJRP\>2BW[U::LVM%+DCO
M?L]5Z'GGA_X>ZMKUQ_:'BV61XR=\*;B> <\@GOT].N<U[!=:38Z=H%]:06T+
M0QV-Q\KHIW8B;&[(.<#I]/RZ)5V@ = , >E9NM\Z1J0Z?Z%<?^BVKOP>!HX.
M-H)U)RUJ5JKYZDWI\4FM5?9'13P\*$9."YIN+O.6LI.U]6_/[NY\>_LU+ OC
M#QJB6T"8N)L%8U!7$Q/RXZ9Z'K]:^TE4ABQ]3@?Y]O?\*^*_V:2?^$S\:Y_Y
M^)_Q_>G!_P _6OM4L0<8],=NOX>M;89-4O>LK.3T222OY674XLF3C@8IZ?O:
MVB5O^7C_ .''T57N;F*TA>XG8)%&-SL3C ]LXSWXXKS?5?BSX2LHYX[;4$N+
MY P2W4<F0=CR>_'IWY%=E&C5KNU&G.I9J[C%M*^UW:R7F]#TY2C%7DTEY_UK
M\CTR1P@W,P1!]YCC%8&K^*=&T>U>YN+ZW8)D^6LJ%SCJ !D_F":^8KCXK?$#
MQ)?/I-EH4D-A*^Q;Q864;2<;BP X_''I6Q9_ _5]6GBU+5=<G\N5EE:U:23;
MR0S+MYQW'H:]-993P[3S#%4Z"E:484VJTY1T;3Y7[C?=IM7=]K&'UCGTI4Y3
M=[-R]U1\]?B^3/F_X[?&6SUCX@>';+2;.?[3%-$D<F&P2'"Y!X'7T]NU>WQZ
M#\8/$TEA))<RIHLT$19-Q'[ME7MG^[_]?C%<E\5?!/AW0/'WA"*.PB>8RV^Z
M;:-S%BI)SC.2<\G'N!UK[KL45+*S2,!$6V@"KC@#REQTQ7#A<PPN%Q>/C@,(
MDW4@G5Q/[U[)J5/K';IMYGFX2E.KC,Q]M4>E6G:--\NG(FN9]5TM^)XA9? 3
MPG-#'+J\<MU<R)_I"/AHRQ'S JV0>_;'X<5\&?M@_L+? ;5=*L?$[Z';VNI2
M:@L4A6&(>8&*DME0#_%@Y'&.#S@?K;7R?^UI_P B9IG_ &$D_P#0DKW^'LZS
M6CG&#E1Q^)I.=7EDJ=1PC*+3O%I-+E_R^9U8["X>>%J\]&$^6-US*^JMK^ S
M]E[]G'X8?!_P3H5SX/TBVBN;S3XIIKGR8PWF-G.#MW9XZG'Y<GZP .[)Q[?Y
M_$]:\^^%/_)/?#([?V;$,_AUKT-> !G/O7BYIB<1B\?BZV*K5*]:5>IS5*LG
M*;M-V3;[*R['7AZ<*5&G"G",(J$?=BK)/E5Q:***X#8**** "BBB@ HHHH 0
M\@CU%,\I#C>BL0<_, W\Q4E)CYBWKV_+_"@#X)_:(6%/C%X$ MX3F6SS\B\_
M,AYP/_UU]V6D<7V:V*Q1K^XAQM11C,:\# R,=!7PE^T;G_A<7@/'>6SS],Q\
MU]WV@S9VJ_\ 3O!S](TKZ'-E_P )F0WV>%JV\DJB[6^6O8X\._\ :,6K?\O(
M^OP(LT4G3 SZ4M?/?([ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** &K_%_O&BA?XO\ >-% 'R_^T_X^
M^"'@3P4+OXV+H\VCM#,8XM46!B55%W[!*"<,0.!W'UK^7W]JW]I7_@EEJD.I
MVMOX$N=1U:3S4@?0[<E&D.0A3R!@C=S_ )Q7] _[>W[";?MHZ'HNAR^+)O#U
MKIT(BF1))464%]S$B/&2P./PKYO^!'_!&?\ 9=^%J:=;^-M.T7QAJ=H$W_;S
M#)+.Z\Y*S OECSD@GZT ?QA3_#WXU?$3QY'J/[(.A>,O#^D2WI:TWK>Q!59\
MQGMT!%?VF_\ !'GP!^U-X$^%%S;?M+W]]>ZK+;QC3_MSR/(N#&V/WAR/DS_G
M%?I;X+_9Q^!WP]@@M/"'PW\-:,L"J(FMK!5?"@ '>,*3P.0!7M$<$5ND<-O$
MD428"I&@55 P!@ =@/Y4 3D ]:\7_:$NO#UE\'_&MQXH@:XT2+2+@W<2 EF7
MRWP .M>TUY/\<-%D\0_"[Q=I$5F+^2[TR=$M6&X2MY;X!!^M '\&WA;Q]\8[
M']KCQ->?LZ6%M'X<_M>[ M[JW1WR)F!X92<_7UK]._#7Q?\ VXY_%5C'J6D:
M<+=KB 3%;&,'!8%L'RQV/_ZZ_-_XB?\ "W_V8_VDO$'B32?"CQ6,VJ74JVD<
M1*E3*Q!VA<=0>E>[>#/^"@GQGU3QEIEM-X)F2&:ZMT=C;'@-(H)^Z.W/Z4W]
M^G](#^Q7]F^^\2:C\+]%N?%<:1:Q)#$;E$78H)B7/R@ #G/2O>Z^;?V4_%.H
M>,O@[X>US4K<VMW=V\9DB(P5)B4\CVSC\*^DAT%+^K ,E#&*0)PY1PA_VBIV
M_KBOYY/^"C?[-'[4_CWQHWCZRU;46^%F@!KK4]/L9I-SVT8+']W&=V,)@Y&.
M?7K_ $+W+NEO.\8RZ0R.@]71"RC\2 *_ C]KK_@HK\;?A'\6U^%FK?#F6\^'
M6M-)8W^K?V9N1K64^6V^<19V8.2"V"1G'0T ?A]^P9^T7\7V_;8UGP5X.U;4
M=$\'Z#=LEW%JEQ+$DK6\A67:)& .=AZ>OY^[_MX_M3?&CX]_M@?#_P#9T\(:
MU=1Z5?75O8ZH]E<,$FPRHS#8<'./US7S+K/@+XE_$/\ :[BUS]G[PU=:3I>L
MZA')J5WIUK)&I\]]TN]XE']\YR>]>C?M%? _XV?LR_M9?!KXSMX=O=0M+1K.
MYUS4/L\LAC<['=G;! .<]2..XH V1\3/CE_P3K_:CTG0]7UK49O#.HM:3O%=
M7$A3][Y;-P[8QR:V_P!KW]L7XR_M6_M,_"/X0^"]7O+7PUXK%FFH1VMPZ[@_
MEJW",,]3]?7O7,_%BQ^*O_!0_P#:KT26R\.7AT&P%G$]V;:4(&C\M6R^T 8(
M/?\ .LWX_P#[.GQ>_9$_:[^"_P 0]-\-W=WX8T V+7][';RND0386+.%('3G
M)_QH TM7^)'QV_X)R?M6:)HM]K6HS>#M0DM)KB*YN)-ACE$9?AFQT)_SFOZ
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MYZGW[T ?Z47[.+!O@YX)(_Z ]F/_ "6B^E>XUX;^SBFSX.>"@#G_ (D]F?\
MR6B_PKW+- !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1128^8-Z=
MOS_QH "V.N:6C&>HS^%% "%L=<TM&,]1G\** "BFLVW''6G4 %%%% !1110
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MAPN<CL<\5[^6P0.>:6C'M^E &/XA)&@ZT02"-*O\$9!'^BR]#7^<=^VP6/\
MP5)\.DDD_P#"5VO4YY^W#UK_ $</$7_( UK_ +!5_P#^DLM?YQ_[:W_*4GPY
M_P!C7:_^EPH _P!!G]G+=_PIWP3NZ_V/9_\ I-%Z5[?@$YQR*\1_9TY^#O@H
M>NC6?_I-%7MXX 'I0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M=\O6]4T8VK.$=9GBVDYYZL!^8]:_,N&OI+<6^(V98SAS/>%,MPV#Q4G/"8G
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MZ4M?.W\FO)G:%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M,+(N#DU<B_84^!'@'4[;Q&?B0=0^PR).8H]9,A;RV#XP)CGD =/SK[^\<_\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M.M-4DYR,>G6@!U%%% !1110 4444 %%(PW#'3FE'  ]* "BC..M-5<=\YQ0
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M$X&>3[?Y/\ZTIU(U8\T;VO;5-/[F:TJL:L>:'-;^]%Q>U^I)11FBM#0****
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M!XH _0."\M+HN+:ZM[@QG$@@FCE*'IAPC,5.?7%<]K_B_1_#C1+J4RQ-,P5
MSJI)/3&<_P"?J*_F2_X)T_MW?M'^.?C;\3O"VHZ)?ZWIEIJ]U"PFBEECM$6X
M8<!@P78!GVQGM7ZF_M:_%.30]+\(ZEKUR='O+V\ME: L8OG9U!4C(QC.,?\
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M*"3D8YYZBOY:?VW-9^(_C7]OOX;^#[3Q7?:3I>JZM91W>GQSRI$?,N$!5D#
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M+2<+,D9?!V/R",XZ9Z'VZU_)7J/[86K67B/7+?[)*^^^F(S&XV_.3C!'7_\
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M 9QT'^<FON*U\'^&[1(PFDVPEC S+Y:[RPQSGCJ0#TKIXD2)5BB39&HPH P
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MX*U/Q1-)JES:M8VMWF-6*$;4;Y>#G/;'MQUK[.^-TVKK:ZF+6_D@C,<@*H[
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M>/8R+8?\?./DXSS@@?K_ #K5(*G(YSGL>*QO$.K0Z!I5UJMPZK#:1F1VD8
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M&KZ-7OT+A4J4I*=.<J<XN\9Q=I)]T^C/QA\?:%XVB\4:5'(UPKM<1@*"P_C
MP<#Z?ATK[X^#.C>)K":R?5!)Y)AB;#@\?*,9S]3TXKF_BQ:62>/]""P+M-S&
M",+W<=1C_/;BOL"P@MXK.T,<2H/L\&,+R,Q*1T[_ -:XZ$(^TJNRYE)>=DK6
MUOWUVZGW'$^,QM3)N&HU<76FI8/$>TA*5XSO.*][ONR\20W/0\ >_%.IA;TY
MZ?\ ZOK3\]N_I78?"!11FB@! <Y'I2T=/;UHSGI0 5EZV?\ B4:E_P!><_\
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M\?>(?!NC126(\/7LUN&"M"&\IRF<_+DDCZYY[\_:GPRO/&]KJ']EZ[:R-9@
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M/,\/.I5HSO2JT8>TJJ:LHTUJY*6S[6^]'V^:>&V?8'!Y3F6#]AFF79SBXX#
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M=\%?"/PV\&:1X3L],M)H]-MXXC*T8W.RHJDDCKR#7<R>"_#4IYTBU'OL /\
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M\_-6;6]FU==;=1:*!T%% @HHHH **** "BBB@ HHHH :O\7^\:*%_B_WC10
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M1COS^9_ETKX%F^/WQL#83P3+^%HWOG^#Z8IJ_'GXWRC_ )$V=..UJWK[(?\
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M>\'Z19WME=75_!;VXF=T=F9UC 8G//WLY_QJ?4?BW\9+%LV_ANYF"]!Y+G)
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MW_\ K#^*KQ-_P7N^-?C7QA+\21<WZVUA=FX@MOW@!5)B5 7@<J,?Y%?U3?\
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MO\7^\:* %'0?0?RI:0=!]!_*EH **** "BBB@ HHHH **** &LVU68]%!)_
M9K\*O^"JG[?/CGX%>%M0\*?#?1=3?6[F.2*/4+:*7RXFVD!F=1@<DG)/;VK]
MUB 00>A!!^A&#^E?$7[;GPJ^'/B#X$>/]9UGPCIFI:O;:3-+9W[6RR7D4XCE
M(*N=W'WLA1G(7GB@#^??_@B'^US\=_C9\=/%EA\6=3N[JWLFNYUBGF=]D?S$
M+ACP1_G%:G_!3;]NSXX^,/VLM!_9A^ FJ7%DU_=P:?<?9IF5M^523.PCDMGK
MWKQS_@B3I=[#^UE\3K%[.:UMYKK4H+<-"\:A T@ &0!@#IC\J\N_;&\,^(OV
M;O\ @J7X8^+OBZPN+7P2=;CO)=7\F0Q1PO*)%;S""H&TYZX':@#TCX0_M6_M
M3?L1?M(6/@SX^ZU=WGAS4)+>14NIW9-DQ4GAC@#!Z>E>@?MW?\%$OC1\;/CI
M\./@Q^S_ *G/96_C'[,DIM9G3/GA!_ 1W.1]*^8OVMO%P_;Z_:PT&#X.+/X@
ML+-+*&6YAA=U#1B-6&Y!CU_R:X3X@?#OQ?\ LC?MH? OQI\0-+N=.\+:,VGM
MJ.IO ^R!5,9;<[+M7 '?TH ^C?AI^UG^U1^PY^TSI7@7X[:U>W7AC5Y;=Q]J
MGD,:I<%3SN.!C)Y[U_35:_M^?L]Q>&M#UO5O&^B64NK6D$WD2:C;QLKR(K,-
MK'/<\>M?R9_MH>,#^W]^UIX;TOX*Q3^(-,06%K<:E#"[BW9=BN?,1<+MP><]
M:^[?%G_!OOXZ^)WA?PQ>2_&;4M!ODLK>2XTU;VYB%N6C4A<!PH(],Y]A0!^Y
M^K?\% _V:9M"UAH_B#H!<:?>(J'5+4[VDMY$ QN!.2:_@U_:>^(7AWXC_P#!
M3?PQK'A>_MM0LG\36DB2VKI(A0WJD$%20<X]?I7[;WO_  ;:>.K72=2G_P"%
M_:HTD%I-,D']I71$WE1L[ G?M&0#C)'H.U?SEZI^S;J'[,/_  4'\(^"M3UZ
M77YK7Q!9VQNII&E9BMVHW98L3G'\\4 ?Z8W[.9S\'?!)_P"H-9?^DT->WDX&
M:\-_9P4I\'/!0Z_\2BS/YVT->YT (#D9I:** "BBB@ HHHH **** "BBB@ H
MHHH ***,T %%%% !1110 4444 %%%)D#J10 M%&:* "B@G')X Y)/:N%UCXC
M^#M#G-MJ>KPV\V=NPX)SZ?>%:4Z56M+EI4YU);\L(N3^Y)BE*,5>4E%=V[?F
M=U56>ZM(.+BY@@[_ +R5(_\ T(BOG+Q+\9-<65QX0TQM6MS_ *N18M_'X G\
MC_C7)66@^/?BD3/JTUSH>U@Q7YHQ@=1VZG\/TKTJ>535.-?%U:>%HM:\TE*K
M%O9>R3YK]T<\L3':G&5271+1/;:3_P MSP__ (*2?'7Q%\,/A%=CP/))=:A=
MVLPE^P2%W4,K!1F,GM@]>]?Q4>+?B7\3_$7BW4-=U.ZUN/4GO3,J-+/O#^86
M &2".1C^5?V5_M@IX ^%'@1H/&VIPZS=W$++'#<R+(V<,H^5R6&<#^$']<_S
M'>/AI^L?$,:QHGA^/^Q&NEF.R$>68@Y8DX!!X)R??\!]YPAXU>'7AM1KY7GL
MJ?UNK/G^NJ"YZ\6URPY&^:,8^=_/L?08?P=XAXSPE#.7F6'R' 55*GAY9N_J
MF%Q%:%N6.%Q%7EIXB<G_ "-\O6W3]2/^"3/CSXR?%R]?PIXNDU0:!:+M0W<D
MI!C7CC<>NT9_QK^BK2_@QX3TJ=;I$D>Y!W%G.4+#V)Z5^-O_  3;^,'PKTJ]
M72"MIH^J%5B; CB9GP V>C'G/0\]NU?M/JGQ7\!Z2BRWVLPQAP"AX.0?0[A_
M]>OB^)O$+*.*\RQ&;9)4H9?E6(:5*G3JPIJJM.:I**MK+MI:YR9AP7F'!=>A
ME.;>VJXMPC4HUZU&=.GB(S2<7AI325>FDO=G"Z:]3O[:SMK:)(H8(D5!@;8U
M'3C.0.O'6K+,BCYF51[L%_7(KYKUW]H'3$AD?PT!J) /EX3?EN<#H3UZ>HKQ
MRX^+'Q7\6W#06NB3VL&XA&6)D!7U' ]>I[9Z]:^*JYUAE4]E157$UGK'V<)2
MA+:_[VSCI^9-# X[%3=.CA9QJ=/K"^K4Y;;5*B4>I]T7>J6-G"\LUS#M4$D"
M123CJ.I_6O*=2^,_ANRN'LRP,FXKG=P#[^_?Z5\P"U^+%U=+'<0W7V=C\^=X
M !Z_3@^W-=I8?#/3]1VS:Y<BUN2 6#'!W8'';//I@5SU\9F$HQ;]CED'9^TQ
M3BXS6FB;M9[^BWU/6CPKF:BI9AB\'EL+<UZ%2&8SDGM[E%WB]-%Z[H]/N_%&
MKZW&9M$U&*)2"=GFJ#SC&.GY>H/K7A'QC\8^)_#?@K5;Z9IKRZCM;@+Y!+-G
MRVP1CGCCIT]:])@^&EEI[;M/\1/[1K*>W;&[^6:U&\)RW=G=:??V?]K6\UO+
M'^\3S 2R8!YZ]<\\=/P\S%5L'&G)U\?6KU)1:7U1O$4E)K?V=.]O2^C>IZ.5
M\.\/X/,L%C,?C\3G%'#XFC7KX*4)8&G7A3E&4Z3E4LK23:=]]MS^1;Q;\7M>
MUCXJ>)+C7'EABCN+DI'<,01B1L8#'T]/ZU8U'QO'J/A:\O[6ZC6:W9F50PW%
MEY&.<YR.O3H>:]C_ ."E'P)C^"?B35?'E]''HFFZDTLL2!A$")"6P!P!P<=/
MRZ5^5?P>\>Z1\3/$EKX(TK6U>]O;N%!;><!YBO)@YYZ<]AS]:_E#/\FQE?,\
M15P>"J.%+&N=:I7R^I*M7I.:<E"+7-K]B73<_N;-O"WZ*7B+Q;P'XDSJX#)<
M'E^68>7$&4T%"&#6+RRG'DH8JDI<M6=62M*3?[QZ]F?T4_\ !++XP?%'QK?W
MWATW,T=A;%DA:1SL*C@8R<=.,]/Z?M7=V?Q16601ZD"FYB ).Q.>F?Q%?&/[
M&/P%\$_ ;X<Z5XBUO48=+U&^MXII9%=-S&1 W)'7)_G[U]B:C\1_![6\CZ%X
MD-_>G<4A5\EF[#"D]3Q].1TK^H.%EG>#R+ 8>675)J-*$Z525=1:I3473C*F
M]8N,=.7HU;38_G/QEXVX%SOQ"S;'<#8#*<%PU1IT<!@L,\N2C_LJY'4@EM&=
MDX]%N4+O3_B9( UQ<RN@.&P6[<C/!_QK,.^-C'K6HK"6!1Q)+M^]CN2/;H?3
MGICSW6?BW\7;:0PZ3X<N+VUD) E$#M\I/!S@]O3O]:LZ/\+_ !Q\4\7NO2W&
MB,PWLAWQ8S@XQQ@C/0?3US[TJ6?56N2='"76U2/M;;:-K333K^1^8KBFC3BX
MK#81*UHO"T51:V^]WU[+N?DM_P %4OAQH^F^'K;QCH$OV^XME^T2M&WF"/ +
MDM@D#N>N*_F1\4?$GQEK^L)?:7XHM].@TPK')$+L1X$9^9&7>,$ 8QCOZ5_>
M?\1OV-?!WBCP3K'AKQOKRW%MJUK+;1SSO_J=\97(\SGY<GD<=*_ER^.7_!$K
MPQ9?$^[TKPO\3I8]+UG4S.XBNCMBCEE+%!M<8X.,>V>:^3S#A7&4\7/-(YOA
MJ./Q#5#$)4^6G*#25^7R[_B?TWX=>/TLSX8I\!<8\%8_BKA_)XU<PRK%82;I
M8FA4I6DZ$ZZ7O1<K)+ML>(_L;7^J_&7XD>'[9(I-5N]&O87N+JW!F!$4B9)=
M0W''KSBO[%O"6N>-+?POX?T;1XT@:TL((&\U ""D:K@YYR#U_+TKXV_X)M?\
M$X_@U^RCI4=W'K%IXGU^YB!DDF9)G61E!Y)RV<Y[YX[5^MUU\/[*1C)8,+4,
M2R!/EVJ>>WY>HKU<ER7%<.QK3P#H9I]::EB)*2A*516>DG96\OD?E'C1XP9C
MXMYAE.&S7+JW#.4<.X=X3)<KE&2G0P]E%>V:M[235GS>K1\ZSV/QONBKV=_
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M[X;'XBP:IXB\//=:+8:C&\,+6V]56*0,O!4] !V]N^*_M:^)Q\$:/X6UB_\
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MA+$5'AJ,Z%'F?)1J2YITTG;EE+JUL]C/;1]-;K9P=^D:\9_"HSH6E'@V</\
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MK$A_I5T$>PSSVIU:'G-MMMZM[LIC3[ 9Q9VO/_3",_S6G"QLATL[7_P'B_\
MB*M44"(/LUMQ_H\''3]U'Q]/EIWD0#I#%_W[3_XFI:* (?L]O_SPA_[])_\
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MX?M)=1G>:6YB7>2<@F0#()[_ -,Y]OO_ ,'Z#K.GV^FS:A>RW2FTA;#$G&Y
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MB@! <CV-<SXH\,Z7XRT*^\.:U$)]-U"(Q7$1 (=6!4C!X/#'K73<#T _*EH
M^5?A/^QY\&/@IXHO/&7@704T[6[UY))YUCB7>\I);)0 \D]S2_M#_L?_  7_
M &G;%+7XFZ!#?2(BQI=11Q?:4"+M7$C#=D #&",#CGK7U3357;[GUQ0!\*?L
MZ?\ !/']G+]F'5Y->^'?AWR]49S+]JO4AED5NHP<,>".*](_:%_9!^#'[3>F
MK8_$KP_#>%4")<PQ0BX0*,#$A4'(&.X[5]28!Z@?E2T ?"/[.?\ P3N_9R_9
MCU5];^'OAP#4W<R&ZOHX99 QSR#ACQGCFONZBB@#'\0L5T'6B.HTK4,?^ LM
M?YQ_[;#%O^"I7ATDY/\ PE=KZ_\ /\*_T;_$7_( UK_L%7__ *2RU_G'_MK?
M\I2?#G_8UVO_ *7"@#_0:_9T_P"2.^"?^P-9_P#I/%7M]>(?LZ?\D=\$_P#8
M&L__ $GBKV^@ HHHH **** "BBB@ HHHH **** "BBB@ II&>1UXP?QIU(V<
M'&<^WUH 13V/49SZ=:4M@@<\TBCCD<\YXYZUG:IJ5II=N]W?/Y5M%DO(>@
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M** &K_%_O&BA?XO]XT4 *.@^@_E2T@Z#Z#^5+0 4444 %%%% !1110 4444
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M,_ __@J9^SC^TE\:?@+K%AI6J- ECIT[S(CE7DS&[,@Q@L3V&.O6O\XCXD_
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M@W9.3QV_SBL[5([B2UD%J2)RIVD9ZXR/Y?XU>(+'!X SC@\T_('4BDU=-7:O
MVW7IV'%\K3LG9WL]GZGS#XF\#>/O$%PQ>>3R,GRQEL =L=O;_/&GX6\(^/M#
MD2!YY#;;E#9)P5';//;MCBOHRC/;OZ5Y2R;#*M[?VN)]I??VKV['H?VE6]DJ
M3I4.16LO9+3:]M=&[;E&T\U+:-9L^<% 8^XZ_P!?>KU(?7'(_.A22.1CGT->
MJE:*6KLK7>[LEOUOZGGMW;??L+1113$%%%% !1110 4444 %)@9SCG_(I:*
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M<C'/H:]M7LKZNRN^[ZL\M^6PM%%%,!" >2.F:10I' []QG_&G4QQQP._8>U
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M7\\FNKSGW]:3@<#'KBJ_LK+O^@+#_P#@N/E_DB?K^-_Z"JW?XW_73^KLY?\
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M]IKZOB<8L7%5H<V&K5XU(JI3CIS49S24HIZ7BWZB06\5M$L,*!(U^ZH  'Y
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M401[C_K 0.B@8X(/K6?\;O\ @H7\'?!7A6ZO/!'B:P\1ZV(V,$%N\<GS;3M
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M^C_^.4?\-I_LV?\ 13-%_P"_T?\ \<H ^J**^5_^&T_V;/\ HIFB_P#?Z/\
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M -_H_P#XY0!]445\K_\ #:?[-G_13-%_[_1__'*/^&T_V;/^BF:+_P!_H_\
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M5\K_ /#:?[-G_13-%_[_ $?_ ,<H_P"&T_V;/^BF:+_W^C_^.4 ?5%%?*_\
MPVG^S9_T4S1?^_T?_P <H_X;3_9L_P"BF:+_ -_H_P#XY0!]445\K_\ #:?[
M-G_13-%_[_1__'*/^&T_V;/^BF:+_P!_H_\ XY0!]445\K_\-I_LV?\ 13-%
M_P"_T?\ \<H_X;3_ &;/^BF:+_W^C_\ CE 'U. !G'?K2U\LK^VC^S:V<?$O
M1/<F>(?SEIK_ +:/[-:#)^)>A_A-$?\ VI0!]3D ]12U\KC]M3]FS _XN7HO
M_?Z/_P".4?\ #:?[-G_13-%_[_1__'* /JBBOE?_ (;3_9L_Z*9HO_?Z/_XY
M1_PVG^S9_P!%,T7_ +_1_P#QR@#ZHHKY7_X;3_9L_P"BF:+_ -_H_P#XY1_P
MVG^S9_T4S1?^_P!'_P#'* /JBJ5UI]M>+LGC##W /\_ZU\R?\-I_LV?]%,T7
M_O\ 1_\ QRC_ (;3_9L_Z*9HO_?Z/_XY2:35FDT^C5T--IW6C/HM?#FDJ"/L
MD9]RBDCKZC_"K=KI5G9MN@B"GZ#_ #Q7S3_PVG^S9_T4S1?^_P!'_P#'*/\
MAM/]FS_HIFB_]_H__CE2J=-6:A%-;6BM/ZL/GG:W-*VUF[JQ]445\K_\-I_L
MV?\ 13-%_P"_T?\ \<H_X;3_ &;/^BF:+_W^C_\ CE62?5%%?*__  VG^S9_
MT4S1?^_T?_QRC_AM/]FS_HIFB_\ ?Z/_ ..4 ?4X &<=^M+7RP/VTOV;#_S4
MS1/QGB'\Y:#^VE^S8/\ FIFB'Z3Q'^4M 'U*RAU*MT-<+J?P[\/:M<&YNXI&
MD8G.#P<_Y_+->)_\-I_LV?\ 13-%_P"_T?\ \<H_X;3_ &;/^BF:+_W^C_\
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M&MW?SZ[-<S2"XGPID)R<DX')QZ#MSZ9K[2^*'AVVTWX8:SIVB620O]E*A8D
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MYI4W84X. >W!'6OTRC5458T0)'&JHB@8"JHP%4=    !V% '\5Y_X(>?MGO
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MOVA_#^G?#;3[FPTG5-=CAN(+&"01;)+@*V?*&.YY[5_39_P2\^$/A>T_9_\
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ML'\5_P#PX\_;._Z'/6/_  /F_P#CE/3_ ((=_MFMNSXUU=<*2,ZA*,D8P/\
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MM0HHY?.7WO\ K_A_2P?Q7_\ #CS]L[_H<]8_\#YO_CE'_#CS]L[_ *'/6/\
MP/F_^.5_:A11R^<OO?\ 7_#^E@_BO_X<>?MG?]#GK'_@?-_\<IZ?\$.OVS6)
MSXUU=<#/.H2C)]!F2O[3:*+>;^]_U_PX'^9]_P %&OV:_P!J+]AG^QO^$B\6
MZVW]J2QQ+_ITX^^RJ/XQZ]OY5]7_ +%'_!-S]K?]J[X7V?Q#TGQEK45G=6\,
MJE[^4 ^<@( )?KR3C/KQQ7VO_P '.MKKVLGP1'96]Q=+%=VRA8H7EVJCHH V
M*?NCI_7K7["?\$*4U.U_9#T*SU!)HMEGISB*5&3#+"5!PP!X!88I@?C,_P#P
M0]_;-P!_PFFM$Y/W;^;C_P ?[TYO^"'O[9N>/&FLGZW\W_QRO[3J*5M.N^]W
MY:?U_P $#^*__AQY^V=_T.>L?^!\W_QRC_AQY^V=_P!#GK'_ ('S?_'*_M0H
MHY?.7WO^O^']+!_%?_PX\_;._P"ASUC_ ,#YO_CE'_#CS]L[_H<]8_\  ^;_
M ..5_:A11R^<OO?]?\/Z6#^*_P#X<>?MG?\ 0YZQ_P"!\W_QRC_AQY^V=_T.
M>L?^!\W_ ,<K^U"BCE\Y?>_Z_P"']+!_%?\ \.//VSO^ASUC_P #YO\ XY1_
MPX\_;._Z'/6/_ ^;_P".5_:A11R^<OO?]?\ #^E@_BO_ .''G[9W_0YZQ_X'
MS?\ QRC_ (<>?MG?]#GK'_@?-_\ '*_M0HHY?.7WO^O^']+!_%?_ ,.//VSO
M^ASUC_P/F_\ CE/3_@AW^V:Q.?&NKK]=0E'_ +/7]IM%'+YR^]_U_P /Z6#_
M #2O^"D_[+_[4G[!MGI%UXD\7:W(NJNBQ$7\^TARNT@AP"#G^O-?2_[#'_!.
M?]K7]KOX3VWQ)T?QEK,5E<10E2U_, 3.NY1EI.3M!]^#]:_0#_@Z2LM<U3P_
MX%@TZVGNHXFM0$BA:0+A@3]T$C).3[FOU'_X("1:G:?L::19Z@DL11-.?RI8
MRA5E@=0<$ @X8_X4WJK?EN!^0P_X(>?MG]_&>L$_]?\ +_\ '*/^''G[9W_0
MYZQ_X'S?_'*_M0HI6\W][_K_ (?TL'\5_P#PX\_;._Z'/6/_  /F_P#CE'_#
MCS]L[_H<]8_\#YO_ (Y7]J%%'+YR^]_U_P /Z6#^*_\ X<>?MG?]#GK'_@?-
M_P#'*/\ AQY^V=_T.>L?^!\W_P <K^U"BCE\Y?>_Z_X?TL'\5_\ PX\_;._Z
M'/6/_ ^;_P".4?\ #CS]L[_H<]8_\#YO_CE?VH44<OG+[W_7_#^E@_BO_P"'
M'G[9W_0YZQ_X'S?_ !RC_AQY^V=_T.>L?^!\W_QRO[4**.7SE][_ *_X?TL'
M\5__  X\_;._Z'/6/_ ^;_XY1_PX\_;._P"ASUC_ ,#YO_CE?VH49HY?.7WO
M^O\ A_2P?Q7_ /#CS]L[_H<]8_\  ^;_ ..4W_AQ[^V?N4?\)GK !(!/VZ7
MR>23YE?VI4TELC XXS0E;J_F[]OZ^;^0?YO'_!2O]C_]J?\ 8,\':7XJ\0^,
M-:DM]13=&5OYMIPY1L$/CJI!]/I7I?\ P3Y_8#_:P_;3^$O_  LG1/&.LQ6;
M>6%+7\P7=*,@ E\9QGCV-?KO_P '2UEK.J? KP9:Z;!/<+'&Y,<,+28)NI6.
M0H/)SU/; KZF_P"#<*#5;']C**QU&*: ++8R"*:-H\.(W4'# '(#,/QZ4P/S
M0;_@AW^V=_T.FL\?W=0F_P#CE'_#CS]L[_H<]8_\#YO_ (Y7]IY)'0$_Y^E+
M2MZ_>P/XK_\ AQY^V=_T.>L?^!\W_P <H_X<>?MG?]#GK'_@?-_\<K^U"BCE
M\Y?>_P"O^']+!_%?_P .//VSO^ASUC_P/F_^.4?\.//VSO\ H<]8_P# ^;_X
MY7]J%%'+YR^]_P!?\/Z6#^*__AQY^V=_T.>L?^!\W_QRC_AQY^V=_P!#GK'_
M ('S?_'*_M0HHY?.7WO^O^']+!_%?_PX\_;._P"ASUC_ ,#YO_CE'_#CS]L[
M_H<]8_\  ^;_ ..5_:A11R^<OO?]?\/Z6#^*_P#X<>?MG?\ 0YZQ_P"!\W_Q
MRC_AQY^V=_T.>L?^!\W_ ,<K^U"BCE\Y?>_Z_P"']+!_%?\ \.//VSO^ASUC
M_P #YO\ XY2K_P $._VS2P!\::N 2,DW\P _\B5_:?11;S?WO^O^']+!_F^?
M\%)_V/OVI_V$/!]CXKU_QAK4EM>1;T87\Y! <J?FWXZ@@X]".M=S_P $]/V"
MOVL/VV_A.WQ+T+QEK,5B#&@W7\P!9P"H!+@9QGCV-?L;_P '1-KK.I_ ?PY9
MZ;!/<A+9@(XH6EQNN78YV GDL>M?17_!MC;ZMI_[%_V'4HIH"+JUE$4L;1G<
MJLH.& .=K$?C3UU\_EI_770#\X3_ ,$._P!L\8"^--7X[_;Y3Z?[=+_PX\_;
M._Z'/6/_  /F_P#CE?VH44K>OWL#^*__ (<>?MG?]#GK'_@?-_\ '*/^''G[
M9W_0YZQ_X'S?_'*_M0HHY?.7WO\ K_A_2P?Q7_\ #CS]L[_H<]8_\#YO_CE'
M_#CS]L[_ *'/6/\ P/F_^.5_:A11R^<OO?\ 7_#^E@_BO_X<>?MG?]#GK'_@
M?-_\<H_X<>?MG?\ 0YZQ_P"!\W_QRO[4**.7SE][_K_A_2P?Q7_\.//VSO\
MH<]8_P# ^;_XY1_PX\_;._Z'/6/_  /F_P#CE?VH44<OG+[W_7_#^E@_BO\
M^''G[9W_ $.>L?\ @?-_\<H_X<>?MG?]#GK'_@?-_P#'*_M0HHY?.7WO^O\
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M ('S?_'*_M0HSCK0E;6[^]_U_P /Z6#^*_\ X<>?MG?]#GK'_@?-_P#'*/\
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M(.@^@_E2T %%%% !1110 4444 %%%% !1110 4444 %,VG(QP.XR?Q_2GT4
M)M'O^9_QI:** "BBB@ JG>WEKIMM/>WD\=M:6\;RS2RL%1512Q)9NG ]:N5\
M9?M_>+=6\#?LJ_$WQ'HDTD&HV.ED02Q;A(I>&X!V[?FYP.E 'Y7?ME?M9_L
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M'>OR6_X)J?#&Q_;!^._QIO\ XLM'KS:-JFM&S35) 3%Y4D^S8)B>F!T[]/<
M_KB_9<_;@^$O[5%H7\%7T<.H(FZ3399T:Y3C.&CX8'GH1V-?:-?PY?\ !/+Q
M'XA^$/\ P5.^(/PUT"_F'A6WU2X@@TR%W:UCC69D "J2@P#C  ]!7]P]O(98
M(96&#)%&Y'H74-C]: )J*** "BBB@ HHHH **** "BBB@"-I%4$LP15R69L!
M0!G.2>!^-?)'[3?[:/P7_9<\*OXE\=>)M*+)((Q81W\'V@GIRH8D,3QC&1W%
M?4'B&UGO-#U2UMF,=S<6D\4+KPRNV<$$<Y]*_CX_X+8?L _$1/@_K7QNU;X@
MZ@UC::J9UT5[N81;5E$@3R]^ -K8''3M0!^]FB:;^S%_P4[\!V'B[6=&AUC2
MK0(;9)%BE;8IX;?(""!QT'W>?X37BOQ%_;Q_9)_X)S7EO\#])L%9X75%LM-:
M-'\R)"BH0BG=LY48 !.2.*^>/^"&=_<VW[%=[=V1WZC:Z;,+8 DEI(X& QSU
M+ 5^(/[2G[-?[57QE_:YUWXD#P%/XET;1M3O+E(9HWEC:""5WSM((P0/IR:
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MC(Z5_<WHLSW.CZ5<2??GTVQF?(Q\TEM$Y_5J -.BBB@ HHHH **** "BBB@
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M!],?2O[JM(D:?2=*F<Y>73[*5CZM):QLWZL30!HT444 %%%% !1110 4444
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M9?\ C1XI\6? &ZO+;0?%FHW<TZVF]5,5V[L?]7@$8<^V*_LM6)$QY:JF.RJ
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M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4@W=SG_/TI:*
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M%% !1110 4444 %%%% !1110 4444 %%%% !1110 44@)R<CH>.#2T %%%%
M!1110 4444 %%%% !1110 A.,#UI:0DC'&<_I2T % &.!110 @W=SG_/TI:*
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@!J_Q?[QHH7^+_ 'C1
M0 HZ#Z#^5+2#H/H/Y4M !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MV:>UT>SBL;=YX@':*%=J9&TC@#U;Z]*Z>CWQS0!6^SVF<^1!GU\E,_GMJ8;
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MY?7^?^%.HH ;N7U_G_A1N7U_G_A3J* &[E]?Y_X4;E]?Y_X4ZB@!NY?7^?\
MA1N7U_G_ (4ZB@!NY?7^?^%&Y?7^?^%.HH ;N7U_G_A1N7U_G_A3J* &[E]?
MY_X4;E]?Y_X4ZB@!NY?7^?\ A1N7U_G_ (4ZB@!NY?7^?^%&Y?7^?^%.HH ;
MN7U_G_A1N7U_G_A3J* &[E]?Y_X4;E]?Y_X4ZB@!NY?7^?\ A1N7U_G_ (4Z
MB@!NY?7^?^%&Y?7^?^%.HH ;N7U_G_A1N7U_G_A3J* &[E]?Y_X4;E]?Y_X4
MZB@!NY?7^?\ A1N7U_G_ (4ZB@!NY?7^?^%&Y?7^?^%.HH ;N7U_G_A1N7U_
MG_A3J* &[E]?Y_X4;E]?Y_X4ZB@!NY?7^?\ A1N7U_G_ (4ZB@!NY?7^?^%&
MY?7^?^%.HH ;N7U_G_A1N7U_G_A3J* &[E]?Y_X4;E]?Y_X4ZB@!NY?7^?\
MA1N7U_G_ (4ZB@!NY?7^?^%&Y?7^?^%.HH ;N7U_G_A1N7U_G_A3J* &[E]?
MY_X4;E]?Y_X4ZB@!NY?7^?\ A1N7U_G_ (4ZB@!NY?7^?^%&Y?7^?^%.HH ;
MN7U_G_A1N7U_G_A3J* &[E]?Y_X4;E]?Y_X4ZB@!NY?7^?\ A1N7U_G_ (4Z
MB@!NY?7^?^%&Y?7^?^%.HH ;N7U_G_A1N7U_G_A3J* &[E]?Y_X4;E]?Y_X4
DZB@!NY?7^?\ A1N7U_G_ (4ZB@!H/7 )&?;T'KBBG44 ?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>g0fyk5pshdve000007.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g0fyk5pshdve000007.jpg
M_]C_X  02D9)1@ ! 0$!+ $L  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" !8 %@# 2(  A$! Q$!_\0
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MPDM/B3=FO5K:U^W]Y_[(7_!1?X'_ +6VEPR>'=2LM%ULQ*SZ==WL0$LIQN2
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M[/XC^';T*8I8QNZ?,/\ ''K6D_C+1D7>9X\'W7/\Z].-6%KQG&SLKWTN[?\
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EVVWZL^NC&,(J,(J,4K*,4DDET26@A))7 /WAG([<T445!1__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>g0fyk5pshdve000005.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g0fyk5pshdve000005.jpg
M_]C_X  02D9)1@ ! 0$!+ $L  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" )M _ # 2(  A$! Q$!_\0
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ME1@>@_*EHH 3 ]!^5&!Z#\J6B@!,#T'Y48'H/RI:* $P/0?E1@>@_*EHH 3
M]!^5&!Z#\J6B@!,#T'Y48'H/RI:* $P/0?E1@>@_*EHH 3 ]!^5&!Z#\J6B@
M!,#T'Y48'H/RI:* $P/0?E1@>@_*EHH 3 ]!^5&!Z#\J6B@!,#T'Y4GRY(P,
MCV%!)R !QQG@^M.]\<T )@>@_*C ]!^5(%P",]<]O48I0,#%-^6OF FU3U5?
MR%+M']T?D*15VYYSGVI<?,6]>WY?X4@,#Q#XDT?PS8RZAJUS#;PQ*6(9D5F
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M]:V,JX"I<0,C''/0]?\ 'TKKK#]I7Q_IX066A:?+MZ[822!]>?U'KSTKU/\
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ME1@>@_*EHH 3 ]!^5&!Z#\J6B@!,#T'Y48'H/RI:* $P/0?E1@>@_*EHH 3
M]!^5&!Z#\J6B@!,#T'Y48'H/RI:* $P/0?E1@>@_*EHH 3 ]!^5(0!C@<D#I
M3J:W\/\ O"@!1T'T'\J6D'0?0?RI: "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ I,\@=S2T4 %<'\2?'>E?#CPAK'BO6)5AM--M)YBSD!=Z1,Z
MD\?> KO*_)[_ (+#?$V3X??LF>*#I]TT&J7B3K$$;#E/(VCH02"7/Y?6O3R7
M /,\UR_+]?\ :\52HRMT4Y)2=^B]=CCQ^)^IX+$XIV_<49U-?[JO8_CJ_P""
MA'[0OBK]IG]I/Q'IEUJ%Q=^&+74KA+&))F:%42<A<*"1P.<?D.M<SX3\.VOA
MW2;>WCB4.8EYVC.1CJ< Y[G\.M>"_!V.?Q9J=YXBU7,MY-=7#M))DOS*W))Z
MY&>]?3[287RP.5X'7IG/Z"O[[R++:.69?A<+0IQIT\-2A1A&,4HMPC%2GIUD
M]7WW/YAS'%5,7B*M>HY2E6J2J-N6J4M4N^FEM?+74M:98S:UJ]GHUL";F_D6
M.,#.<L<#&/3MWS^O[&_L\?\ !+J'Q)H%KXS\>>,M/TBQN8HYUM+V>.-BK ,<
M+(V>A]\=>F*_'K0-5D\/:YI_B"%!)/ITB2HAQR5(;H:]T^(7[5WQ=\;Z?;Z;
MIWB?5O#]E96_E)!:3RPQ[43"_*C =OTQC/7EXBP?$>8+#X7(LPHY72J7^N8N
MI356:L_@IP>SDFO>3W1U917RG"NI6S/"SQE2+2P]",W",M%[TY;:/H]'^#_7
MKXM?\$D],UKPA?>(OA5XGL=8?2[5[B:'3Y(Y&;RE&5/EDY.<<<U^$OC;P=K/
MP]\0WWAK7K:6VO;*YDMB)05+F-BI(! SZ<>WX?M1_P $=/C=\1[KQ1J/ACQ)
MXAU/Q'I=ZTD5PE[-)-$$<E2K;RPQC@Y[8KY7_P""M&CZ-HW[1:+HT$-O%=2O
M-,L 4#S&8DY"^^1_ATKY#A7->(<OXOQW!V=XV&;4H87ZWA,>J?LYQBDG*$X[
MWU5K[:VU/=SK!Y5B\CP^?Y;AY8*4ZRH5\,Y\T6W9*49=+?/:W4_-@QI,C0RJ
M&CD!# C/8U\Q?$7PY=^&=<T[Q3HCR6AL+Z.\,D#&-OW+^9R5(.,KWZ5].DA3
MU[G'X?2N0\>Z:NI^'KF';D^1)VY^Z>^/\YK],Q%)5:4HM:V?2]TU9I]TTV?'
MTIN$MVM4U;NFK>G37_AG_6[_ ,$7OVQ&_: ^$T'@W4KWSK_PGIZ6\8DDW2,(
M0JD98EB>#7[DDXY-?P??\$3_ (N77PI^,Z^&4NFBBUB^$+Q;MH</+C&W/.<^
ME?W=6DWVBUMI_P#GO;PS?]_(U?\ ]FK^(/$S(Z>2\3XN.'@H8;%6Q%)+9.5O
M:+_P-G]$\'9E+,<FH.K+FK4/W4]=;)+DUUZ=_P!"P#GFBBBOST^J"BBB@ HH
MHH ***3;SNYS_P#6Q0 M%%% !12$9P?2@G'6@!:*:H Z9YQ3J "BBB@ HHHH
M **** "BBB@ HHHH **** &L>PZG&/3K2C..>M-D=(T9Y65(U!9F8X4 <DD^
MV*^2/C=^U/X4^'-G<6>DWL-YK2)(/*5D.QAE1@ D$@Y.?7Z''S_$O%.1<(Y9
M6S;/\PH8#!T8RES59152JTOX=&FVI59OI&/S,ZE6%*+G4DHQ7?KZ=SZ#\:^/
M_#G@72[C4M9O[>+R$+" RJ)7*C)&,Y''KZ_7'YX>(/V]M,'BZVTVP399RW8M
MUP>-N\(/7J,DG/(]2:^ /BM\=/%GQ.U":YO=0N;>U:0@0*[!&#'@%00/3I7J
M/[/G[+FM_$W5=/\ $&I0!=*AN(YDFQDMM<,2>^?\GV_A[B+Z0G'WB/Q1A.&_
M"? SPV&CBZ7-B)T^>MB:,*T.>O7:_P!WH<G-H[I]6SQ*V.Q&)J1IX2+2YM=[
MR6FKMLEV/W%\#^*H?&'A^PUJ%"JW4$<A]"S+DX_0_C77<Y/IV%<UX1\-VOA/
M0K#1+3'E6<$<60.I1<?XXKIJ_O/+%C8Y=@EF+A+'K"T%C)0^%XA0C[5Q\N>Y
M[L.;ECS?%RKF];:_B5[FUM[R%H+F))HG&&1U##\B"*H)H^GVEE<VMG9P0I/%
M*C*L: ,71A\V%Y&3D ]ZU6944L[*JCDLQ"J/J3@"O+/%7QG^'_@YWCUK6X(7
M3.55D;D>^\?RK',\=E&64GC,UQ6!P--1E#ZUC*E&BHQDK2BJE1IV:W28I2A%
M<TW&*VO*R\MWZH_$W]L?PG_PC/CIG\D0B[O5F&%V YDSP!['CMTQBOT._8D\
M:IJ'A*+07G'^C1!@C.,#:AQU/'Y?7UKX:_;)^(WA3XI>);2^\.SI-%:[%WHP
M.[8>I([G&2.QQ]*\1^'7QM\1_"QY&T;S)/-4*50DX&/8^_;_  K_ #3ROCW(
M?#/QVXCS_"XJ.,X9Q->I2E7P+52-6A.\Y<BC\:55]O,^<CB(8?'5)I_NG)IN
M*^S9/1>M_P#AC^CJ?5]*@W"XU"TBV_>#SHN/S.:H-XK\,QCYM<TQ /[UW$/Y
MMFOY[/$7[3/C_7I'=KK48/.))$?F@#/3I^>>W\O-[GXB?$'5'.S6M97.3@&?
M&/3.??TY^M?LF9?3.R2E4E#*N%L7F$;V@YXA47)='9P=KK6W0ZY9S#7DI2DK
M]7;MY=;_ "ZZ'])DGC_P;&<-XBTS/M<*?\_UIC^/?!SVT\B>(M,PD4A/^D+N
M^Z<8'<YZ8K^;)-4^)$XW+K6LGWS/_CU]<T-JGQ(@!+ZUK6TCD$SX(],9&<_C
M_CY;^F7CG?\ XU[74'%V?UUW5UHW[FR]-K^0O[8G;_=G?UNMTM=//N>]?MD:
MY:Z_XZ2:RN4NH4O%P\;[U W]>"1Z5^BG[%=KI]GX0AN6NX5FD@ \MG"DDK@]
M2..>X^O)K\3KZZU*X??J:WEU+G?YDD<A.X<]6!.>.GJ<XKUCP5\=_%W@:*.#
M3'ODAC"@)AU''3CMQ7X9P!XNY;P_XI9OQ]GF J^SS5SE]6IN3J8:<V_M6]ZR
M=OD]T<.'Q<(8AXBI#XNBO[M[:^;\NZ/Z20P==R,&!Z,""#^(R*%W9YZ?A7XB
M>&/V^O'6EM'!=6C31 J#YJ[@1QG(;C./QXKZS^'_ .W)X;U?RE\2O#9EB-_W
M4(SUZ#J.OITK^Y^&_I)^%G$=2G0IYS/+Z\[*4<PHO#TH2=M/:RERM:[I'MT\
MRPM33G<7UYDTM;=?FM3]"0<^O7'->,_&3X.Z)\6M"?3=3B5IT1A;N^,*2#CK
MZ'GK6GX4^,W@#QCY:Z+K4$TD@7",Z+@MCC.[KSZ?EV]#U/4(]/TR\U%G0Q6M
MM+<%\C85C4M][)'/3/0G\J_6<4^&^+LDQ="K6P&<Y+BJ$UBE3JTL10G24>>3
MDXN25E[R;M9KR.J7LJU.2;C.FU[UG=6M?='\^GQZ_9\O/@_JS0W%XOD3-NMT
M1@"$?E<8[8(P>>.E>,>&/'7B?P7=)>Z#?W$;QMN&97P.<]SC_P#57N_[6?Q6
ME^(WCEQ!.SP6-X;81H25 5]B@ ?+@  #'M]:]\_9X_9'L/B+X9DUO7B8(IX0
M;<LI&YF' []_;&.]?Y9U>"*O%?BGG>2>$<*V'H9=7JSP6)6*E#V=.E\53ZQ=
M>SCSJ48KII;HCYCV3J8F4,%%VC+W9-V:6S=^V_:WIOL_ W]N*ZM[BVTCQK-]
MI>0Q0!W<D G"@Y)ZYQTQ7ZM>&M?M/$VC6>M6)!MKV,21D'/! /7Z$5^14W[#
M&M6?C2,6L3_V5%>+(+@(3A%<,,GN.!7ZO^ O#?\ PB/A/2M!!+FQ@6/)SDG:
MH.?RK^VO "OXMT8YOD_B+0F\%E=J.78[$7>)KU8S49)U)>]6I\B;53;MN>U@
M'BESTZZ;C!>[.6[>FE^JM=I[>AV=%%-;'&21UQ_G%?TKJ>D.HHI N"3SS0 M
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4UOX?]X4ZFM_#_ +PH
M 4=!]!_*EI!T'T'\J6@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M ***"<=: #O^?]*_GG_X+O:G=)\'+BT!?R# _ SMYC)SCISC_P"OS7]"_H?;
M^>/\*_$+_@N'X"DUC]F+6/$=M"TCV44R2;5W'<L988X/\./U'>OK>!:E.EQ5
MDSJ:1EC*<+OHY25M_P"NQX/$T9SR/,%"]U0E*RZI;_U]Y_&1\!XU73"R@#+R
MYP/]LBO?V0<OWR?7UQZ^GM7S5^SYJ!>TEM)LI)'+.NU^""'88Y[>GUY/2OI9
MF/(XQG^1K^]J/\-6VN]/2ROZ/H?S//1Z7>BWNNGG^'XD8SSGIGBH9"[R0VL*
M[YKN06\:#))>3Y5 Q[GMSVZTZ:7RHV?!8C&%498Y..!U/X5^GW[ '[%M[\7/
M$*?$3QY:M9^ ](*ZBTMY&8XR(3YAPS@+R%KBS?.,%D67U\RQ]10HT(MP@OCK
M5=.2E3CO*<FU9(ZLMP&*S/%TL'AX\TZC7-.WNTHO><VDTHQW;9][?\$R_@HO
M[/?PD\6?&3X@_P#$O6>PFO-*-WA#(6B9T">9@^@&.GI7XM_M;_& _'+XO:WX
M@5BT-EJEQ%;MG<#&DI"$?ASQ_6OT5_X**?MI:=]@A^ OPF+VNA^'D2QFDT]L
M1S)"HA;=Y9 .<?J/Q_%B NS//(K":<F24N""TC<L6SR22>M?%<$93CL3CLPX
MUSFFZ6/SAI8+#/26&P,4E336_-4BU*7FSZ+B+&X6AA\-P]E[4\-@-<166JKX
MG1S:?50EHNEOE>R$#'G^$]/\_2J>K*'L+E3C'DR=LCIC%6B<\UA^)[Q;#1[F
M=F"CR).O^Z3_ (_I7Z-*W*[[6/DENO5?F:?[!&HW6G_M;^#H+8LL<FMVRMMR
M!C[0H.<<>AYK_1MT,DZ+HY/).EZ>3]3:0DU_GT?\$L_ -S\0/VDM#UNU@:=+
M#5(I'=$WA=LX/. =O.37^@YIB>3IFG1'CRK&SC/MLMXU_I7\B>-M6E//,!"'
MQT\-/VFV[FN6]NMK[[[G[EX<PG'+<3.7PSK1Y/11U_%E^BBBOQ,_10K/U35+
M'1[*>_U"XCMK:WC>2221@HPBEB,GO@5H5\3?MU>+K[PM\)2=.GDM[F^N9("\
M9*GRW5$[<]V]J[,OPKQV-PV$3Y?;U8TW*U^5/=_)'@<4YY3X:X>S?/:D/:PR
MS!U<5[.]O:.%E&'SDU\C@O'G[?NA>&M=NM%T'PS-XA^R2M'+/:^=(ORL5)_=
MG'&.W?UP:];\,_M7:+K?@]_%%[I$FG/'"939R>8K\#)7#G=D?6O%?V,/@AX9
MO/!2^*_$5A;:O>ZQ%YKO=QK*P:3YLY<$\;CSZ]Z]-_:)^&7AWPYX"OM1T:W2
MSV^8OD0HL:%=F<87@C]>^2>*^GQ='A]8R&5T,+656G7A2GBG5E:I+137)]G6
MZ6B^9^.Y+F/BA6R"MQIC\ZP$L#B\OK8[#9)'!4HRP=)^_AY_6-ZLE"SE%[_,
M\LF_X*'Z,=0N+*Q\&7=[';.4DGC^T,H"D@DE3CC%?4/P>_:.\'?%F-HK6:+3
M]21=S6,C_O%]058ELC^?&,U\C?L:_#_PMXITWQ%_;&CV=RY5_P!Y)"CN-TBI
MD9&<@$]>M>$>._"\GP/_ &DEE\-74T.E7]\$-K$2D:H[]-@^4$!NF.!^==5?
M*LFQ.(QN6X6C5PF-PM'VM.I*K*I"JXQC*46GI%N^]SP,NXW\1<ERS(.+L]S'
M YSD&=9E' XK!4L'2PM?+X5JDZ=*I"I!7J\KC:5WTU6I]W?'+]KC3OA!=O9Q
M>'YM:=#M9X1*P4\]D(';KTQS]*/P'_;/\+?&?66T'[!_8^H)]Y)BZD?4.3T^
MG^->DS_#/P-K7A,^*_$UK;7)N=+-]<2WB(40E&ZN^2,\ <#D^E?EE\(/#4.J
M?M.ZJG@N)H-'%Q+"'M5Q ,,1U0;>F/\ ZQS7/@,!DV.RW'KZO5I8K T'.6,=
M27LW432MR;7WLCUN)^)_$'AOBSAJM_:V QN3<2YG2PU#A^GA*7UJGA:L>95/
M;I>T>CCS2M[KT\C](_CC^U;H?PDNTTRRTT^(=1DVA(;8N[;FP2 L9R<9QR/S
MKD/@]^VEI'Q&\1KX9UC09?#U_(RJBW(DC;YCZ.0.X[=N:^1/CS!<?!KXL:3X
MI\5Q1ZMHSSQRO!.!*-C$8&ULC'_U^W7/^'5]I_QT^/\ 8ZYX3M(-&TJW,.](
MD$&2H4G[NWTQ792R++'E:K.A.I%X.==YBJK4(U8M)4726EV_F_1'SV,\3>,5
MQH\NIYEA\-7CQ#A<KCP?/ TY5ZN!K*\L8L9K/E6^_D^A^V4<B2HLD;!T895E
MY!'M3ZI:=:?8;&VM-Q?R(ECWDY+$#KFKM?G[W=M5?1]UT/ZI@Y.$7)<LG&+E
M%:\LFE=7\GH%%%%(H**** "BBB@ HHHH **** "BBB@#P']H[6=?T;X<:O<>
M'4D.H"&0(8MV[E#Q\O-?@19>'_B'\1O$LD>HZ??W%]=7[PESYK;%:0CD$'@?
MEZ>M?TRZII=EK%G+8W\*3V\R[71U##\B".]>?>'?A#X*\-:E+JECI5K]ID8N
M"T$9"L?X@"#R.WOUSW_FKQD\#,R\5.),CQTN(JN!R3!4O8XW+E>5-^_&4JU.
MGM*K**<5+I?6VYYN,P$L74C+VKC!63CVLUJO-VL?@3\3_@9XE^&5K83ZC;3-
M#=I'(6*L-G ;!R.V?3(_2OL/]B?X_#3M0'@W5YXHK)B((-^ 2Q("X)[AB.GI
MSQQ7Z'?';X4Z?\1O!NI6:6D+:C%;.;5O+ (VJW3 ZCY> !P*_ ?6='UGX4^.
MA:L[VUWI^H--\A*G"2 X/3/3I[5_-'&?"F:?1N\0\DXGX>=>MPSBI4:4G*]I
MPO"G7P=:6SE/WJJB^EDG8\VO2GEM>G4IW=-V2OY<J<6_G?[O4_IF:[MX[87<
MDT<=N8UE\UV"H$90P.X\<@YKYV^*7[3'@7X;V\C->VVHW"*V8X90<.,@#Y3D
MX(YR!7Y>^+/VT_&^I^&+;PS:%XTCMU@DGC;$C;4V#)4AC@$]>@]J^5[+3O&O
MQ'U9DAEU"\FN)2V)!)(GSM[Y!'ITK]0XX^EG1J4Z&5^'665\QS7%TH1EBL11
M;6&Q,XQ;IT:&JKN,I-<ST;6B1T5\VNXT\/!N<DM;;3=G9+6Z74^L_BO^VWXG
M\4S7$?A>ZDTV%F*J%<H,9P!QCH#Q^=?)^I:U\1O'TH>Z2_U1IG)W1O*_WO8'
MCC_$U]D_"O\ 8QO]46&?Q?%]GC?:^=FW/?G@=<?3TZ\_>O@CX#>"/ D42VMG
M;7A0+DR1JQW 9ZD=:_,L%X6^,7BQB'FG&V=XS*LOQ#4I4*]6<&E)J2Y<O;<$
MFK6L81PF+Q?OUZDH0EWUM>WV-?EZKR/R1\$?LS>-/%GE[[6\LO, .9A(#R,\
MENG4]>!BOJ3PM^PKJ%H(KC5+SS5.TLC'/&/?/?Z?RK]*8[73K=56UT^WMMN
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M\CP Y**,DCK@YY]Z_G OM(\3_#G6$>ZMKNVOK>0%94C=2&4YSNP...QK[E^
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MO2J4:BO3JPE":[QDK,_S#OB?X8U'X$?'[Q)X&N+5[*SL-3N8P65XUV^<PX)
M'^>U>Z65U%?6D%Q XD5HPS,"#R0#V^N?QK]V/^"UG_!-^]UVUNOC1\*=*9K\
M"2]U=;2W)FRNZ27_ %:DY."<^F/I7\ROP]\?76A7EQX:\10SV5SI\OV.9+P&
M.0R1DHWROAL[AT K^Y^!N*<+Q#DV&Q5*:E4C2A2Q5)O]Y3K145)S5[^\[N+[
M'\W<1Y/B,IS"M0J4W[.4W/#SM:$J3=THO9V5D[];V/L?X86>FZA\4/"EEKS*
MFA37UNNH/)CRUB\U-^[.!C;ZFO["=$O_ -FY/V?M,^'/@SXB:%X;GOM'ACNV
MBN[>&7S)(=LXD^92IR0!AF)Y)QP*_C%M[RWNXDN;&Y5&8 QR1-\Z9&05(YSG
MGCG^EA=2\6H<IXMUQ% PJK>3J%Z8 P^ /RJ^,.#/];YY=/\ MBMEBRZ?M(0I
MTE6I5JJ:<9U(2]V\?-#R#B#^P%BXO 4\8\6N24IS=.=.&B<8R5]U_P  _HY_
MX8#_ &7-6U:35=6^+6BW&I7<DDEQ<27\#EF<ECDM+W)!]*_+W]LWX$_#7X1:
MYY'@'Q-9:]:Y/SVDL<JX!_V6/7I[>U?!(UGQMG_D<O$&.H/VZX_^.9_04IN]
M6N%)U36;W4&QRU[.\AZCNY/'^?449/PKG.68ZGBL5Q9BLRH4X\OU*IAHTJ;T
M5K..R71;:;CQV>Y?C<-*C2R+#X2K)J7MXU9SGLF]&E?7^KE>%C+@D%1G&?3_
M #Z_X5XA\7O%4%K8+HJRXGN\V\>#R7D^4*,<DDD?XUVWC+QMI_AJSE!FC,Y4
M[%#@')&.!GOS^GK6K^QS^RYXY_;%^-.C::-,OSHUOJMO.UPT,C6YC$RL<M@I
MC;QUQ[],_0YOFF$RW"5\3B:L:=&C3E4JS<K*,4MDWO+I;JSQ\#A*V*Q%*A2A
M*I4JS5.$4KM-N*N]W97UO]]C]Z_^#?G]E[4_#]EK/Q%\5Z6WDW4;W.G33QG:
MQD.8RI<'U[&OZL@H50H'RJ  /8# KPG]G/X,:-\#/A;X9\#Z79PVTNFZ?!#>
M/$@4R3(@4[B .>.?4U[O7\)<79]/B+/L;F4M(5*CA1CVI0]V+MT;5FS^D\BR
MR.4Y9AL&M90AS5';5SEJTWUY=E<****^:/8"OB+]N[PAJ/BGX2$Z9 ]Q<V%R
M\Y1 2=BJK9P,^_;BOMVLW5M*LM;L+C3M0A2>UN8VBD1U###C!(!XSBNW+\6\
M#C<-BU'F]A5C4<?YDMU\T?/\59%#B;AW-\AJ3]E',\%5PWM$OX<I).$OE)+Y
M'YM?L7_M!^"]-\%?\(EXMUJTT/4-'C$)CO'$8W1G!!SAAP#_  GGV.:]:_:'
M^*OA3Q3X!NK3P]J,&I0D2L]Q"P9/N8&"I.!QG_.*YCQM^P%\/_$6L7&KZ7?7
M6EO>3&2>.W)A W-DX"-@]3_A7K7AG]E+P7X>\*OX;^TW%VDD6QI9LMR5P>IS
MUYX__7]+BL5P]+&QS3#U<4JM2LJT\*Z:Y:4G9SM/>5G>U]_R_'<DR?Q5H\/U
MN"LRR[)?[.PN7U<#A\ZAC9.OBJ2TPT'0^&#Y$HSENMO7Y>_8\^*WPY\(:=X@
MCU_Q)9Z==*KXCGD52=L@=@!GECM(&>,]Q7B_B3Q!<_'S]I#S/#D#W7A^ROS)
M]MC5VB,22==P!&,#J3Q^-?4EW_P3S^'=YJ,U[_:EY:K.VYXX&=0<L21@%>OY
M?U^E_A1^SWX%^$EK+%H-MY]Q-$8WNKB-?-^88)#98Y]\BNFMF^2X>MB\PPE3
M$XC&XJBZ485:?)3H\T8IR4OM-:VN>-EW 7B)F^7Y#PIQ!A<HROAS),Q6-KXK
M!XIU\9F*I5)5*5)TF[03<M6OO=KGPS^U9^T78^%=*TKX0:9J2V<UU%#I]W<H
MY7R4.%8,PY&.2.OJ<5ZO^RMIWP=^'_A=[V/Q1I>H^+KN)KN65Y0UPKM$TFR(
MC<Q<M@?.RC@8SGCJ_B9^Q'X!^)>O7&OZK<.+N>3S,X)9"23\IP<8)&,&LGP7
M^PMX/\':LFIVNN7\NPJ?):60IA?X<'/!''TK&6.R.640P5/%XO#U9/VV)C"C
M=8BO>Z4I/:"UT;:.JAPUXF4./L1Q%C,BR/.,#22P.1SQ&/<)9-@(KEYZ-!7C
M*O))2Y]))W2MI;Y!\8ZUIOQ>^-9TKXC:E':>&K2\:.W^TD*DD22$+MWX!!&,
M?SK*U&VT/X8?&S2X?A%JD5S932P+-;VC[ASC/"9YZ_RS7W[\2?V//!7C8V]W
M;2RV-_;;2)8OW;.1W+*<DYR3D\_J(?AA^QSX,\#:W'XENYYM1U1"&3SR90I7
MIDO_ $SGKZ5V1S[*X85<E:O&$<++#/+O9KV,YNR51^;:3<MUML>%5\+^-:^<
MU56R_+:F(Q&?4,W_ -;OKLUF-##TVF\-".]HKW8P3M);Z;_5WA6ZN;WP[I%U
M=@K<SV43S!NN\CG/O705'%$D,:11*$CC4*BCH%'05)7P$G>4FE9.3:79-WM\
MC^JJ,)4J-*G*3J2ITZ<)3>\Y0BHN;\Y-7?J%%%%2:"9'J*6F%0/FY]?ZTX'(
MS0 M)@Y)SQZ4M% !FC/;O2%<D'GBC')/<_Y_I1_7Y;  !'4DTV21(8WED8)'
M&K.['@*JC))^@%/KXZ_:J^.UK\.O"MYINF72_P!K74<L+JC@.JLNWC!)]>W_
M -;YSBOB?*^#\AS#/\WK1HX3 8>I5:;2E6J1B^2C33MS3J2LDEK:[Z&=6K&C
M3E4GI&*N^_HCU6\^/O@*T\1+X=_M6V>[,@B?$JY1]P7!^;^E>SVEW;WT$=S:
MRK-#*H9'0Y!! (_0U_-3X!3Q3XZ^)]K=6=SJ$USJ%Y'*2ID9$W2[N>HP/T],
MFOZ(?AIH^I:'X2TS3]49VNXH(_,9_O'*+UK\8\#/&#//%2MQ!5QN21P.6X'$
MRC@,73<G"=-RM3ISDTDYRIVF[;/[CCP.,J8ISYJ?*H[-;/;3\3O2"2#DC';U
MI2<<G@#DD]J"<#)X ZD\"OC?]I']I72OAKI5WI6D74<FMO')&=DBDIN4J-N#
MQW//7^?[/Q5Q5DO!N38O/<]Q=/"8+"P<O>DE4K32]VC1B]9U)/1)>IV5:L*,
M'.H[17XOLN[.S^-W[1/ACX6:7<*+JWN]2,3JL(<.4=E.!C)R1GG(Z\#UK\+O
MB7XVD^)OBRZU^"$_:+J:0)$J\DL25&!^'\LYK/\ $/B7Q7\5?$LCSRW=U/>7
M ,<89W0;WZ8!('7\_P *^_/V?/V3X]MKK_BZ$!5*3QQR)@<X8=?<'O\ S%?Y
MV\5<5\;_ $DN(X9)DF#^J<*X'%^THNI!^RHI/E6*KUG_ ,O7!<RAMTN?.U)U
M\SJ\L(M4H2NK[+S;76R>A\[?!G]F'Q+X]N8+_4[>:RLRRN/,#*KKG=GD '/7
M^7>OU0^'_P $O!O@.QMXTT^!]1B5";@1*26  )SR>2">OZUZG8:?I^CVL5AI
MMK#!#;J(T:)0I*@8'0?AU/Y5;'/S.<@\<DD_YZU_3?AYX-\)^'^&ISIX:GFF
M=N,?;YEBJ<9VG&SE[&$DU3M+:4=3U</@Z.'2:2G4MK*2VV>BZ-.ZTZ;]A%E<
MIY> (U "@+CC_P#5Z4VE )Z GZ FJFH:AIVE6[75[>VT2HI8H\BJW';!.?TK
M]=E-*$JE:480C&[J5)J$8127632LEMKM\SK>MW?W4MW96LM?+[O(M@$G &34
MXMIBNX+\O7)('^??T[U\P>./VJ/ 'A99[-)XWO4W*"C*1D;L=".X]3^-?&7C
M7]M;Q0TDD?AYAY3$A<.,D9(^O;KS_2OR;B?QK\/.%'.&+SBGF%>FVIT,M:KU
M*<U:\9K:Z=UH_OZ<=3&X:C;][SM;0CJT[]5TUWUM8_5BYU;1[#/VZ]C@QG.Y
MU'3J>N:R)O'G@.W_ -?X@M8R.#F:/K^?M7X>:Y^T1\1O$18S_;?GZ^3O/7TQ
MZ\UYU<^)?&^LR<G6@6.?E$V.2>G'^1[5^-9E]+++H2:R7ABOC5JH/$JK3<MK
M-J$6E]_YG)/-HKX*3E;^9-+[/9;]_B^6Y^^DGQ2^&\;;?^$EL_QFC_\ BJ6+
MXI?#>1@/^$DL^?\ IO&/UW5^ O\ 8OC>X.\2ZV,Y)R9L\^W I'T?QQ;C<9=<
M(&#@>=V_'_.>]>'_ ,36<36YO]0:*I6OI6Q-K73Z0Z+]?0A9K4W^KQ:ZO6WV
M=?S[?CK_ $'P>/? EP,0:_:2D],2H3Z=C6Q;:II%]C[%>1SEL8VNIS],>O7\
M/>OYW[/Q7XWT>0!3K)*D8W";MZ\>XYX]/6O2-%_:,^(_A\H83>9C/'FE@..G
MT_SVKW,L^EEEM2:6=\-8C!15E)X6-6K)?#>RG%;;K_+:HYM"37/2:3M?ENTK
M6=UI_74_>DVTP&=G!Z<CGZ>OX5"01P:_*/P3^VKXB\R)/$C#R@5#;FYVC&>I
M''IG^M?9G@G]J3X?>*D@M/M$4=X^T,7D7&XD#J2,<_3Z]J_:.&/&CP]XL]G#
M YU3R^O4Y;8;,FJ%:HVO@A%[N_=]?N[J6,PU5KEJ<C;LE/1MZ62\]?\ (^C2
MV"!CK4_FL4,;!6C;A@RYR.]4[*]L-3MTNK*\MYDD4,J1R*Q&1G'!)]>U3U^J
M0DGRSIU(RA./NSA-.$H/7>+:LSIU3M^*?IIVL>2_$'X*>#?'MC<1R:? FHRJ
M^+@QJ"&/?./Z_J:_*SXT?LP>(O =S/?Z;;S7MH&9LQ!SL7).?ESVQZ]/2OVN
M!(Y!(/MQ52_TW3M8M9;'4K6&>&X4H[2J&*@@C(ST_.OR7Q#\&>$_$'"U)U,+
M2RW.8Q?L,QPL(P?/9-.M"*M4YI)7E+97.3$8*CB-TXU&])KOWMU\[_YI_A%\
M*/CEXP^$>M09O+A;"*5$FL2\A PPW J>^.#Z5^V?P4_:$\+_ !5TNW9;N"WU
M/RT#PLX#.^.1C^\?U)YZY'PE^T+^RA$1=:_X1@#*V^:2.-,X(&[  [\?2O@K
MPIXH\6?";Q/$T,MW;36L_P"\C8LD9"MR,$@= /Z]:_FWAKC7Q!^CMQ%3R+B6
MGB,SX1Q%=0BY2G5H0I.2BJV$K.ZBU%W=)6BNBL>9"M7RVLJ51\U-O7JFM%[K
MZ6[6[G]-V>_;KFOSK_;6\2?#Z#0?L+K9W6NX8,(]C.A/][JVX9YZ ?A7+Q_M
MRZ<?AM(I<?\ "4K9F%/F^;?Y6P'J3GI@U^9>O:_XM^*WBII9FO+N\U&Y*QQK
MN=4\R3@X^8 <^@],8K]7\;_'_AC,>%*'#O"D*/$&8<38>FFG256.7PJN*4)0
MLU]<YG91^SOU1UX['TY4O94;3=1*[WY;V=MM9:G%6NIW&DZM_:6ESO;7,<ZR
MQLC,IVJV[ V_YYS7Z_\ [)G[4]IXBL[7PGXINQ%>0JL,$TS %RH"K@L1UX/_
M .NO+O"'[$$^H?#9]3U%"OB*:U,\",A#<(6'!&?3TR*^(E\!^-_ WQ,T_2X[
M/4(I[>_4"2".14;;( -Q &1ZU^ <+4/%+P&S7A_B.IEF)64\2RPZQ& C&I.A
M6AB9P_=8B$;JCBHQGSIVOLNQP47BL#*G5Y'&%5I2B]I7:5GVDK^M[']*$4L<
M\:31.)(Y%#(Z\AE/0@U)7F?PE?67\%:0=:#?:?LL.-X^;&P=??\ R>U>F5_J
M+EN,>89?@L<Z4Z#Q>&HXAT:B:G3=6"GR23UNK_<?41?-%2M:Z3MVN@HHHKN&
M%%%% !1110 4444 %%%% !1110 4444 %-;^'_>%.IK?P_[PH 4=!]!_*EI!
MT'T'\J6@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *0G Z9]J6B
M@!IYQSM_S^'2C&3N!Z>E*0#U%  '2@#%\1>'='\5:1>Z'KME#?Z;?PR07%O.
MBNK)(I4X# @'!_QK^6+_ (*6?\$6UU:]U3XL_!.SVW;237;Z38I@M+@R8:.-
M0>3[8/;/-?U<4R1(Y$*2HDD9X9'4.I!XY5@0>O<5]%PYQ/FG#&,6+RZLXIV5
M:A)OV5:'6,ET;VYDKGE9MDV"SG#O#XNG>VL*B2YX/35/Y;;'^8-K_@KXX? [
M4)[3Q[X<U'3K>SD=,RVTX&R-F4?>7G(4#/?UXS45C^T!IDZ^7*KK)'\K[HG&
M#W'('0]O\G_1)^-W[$_P&^/:S_\ ";>%+)Y+A6$DEK:6R%BPY; 1>>_7'I@
M8_,[XA?\$)_V=-0EEN?"5BEMYK,WEO!&CJ3VP R_B">G;I7]"9+XX93.E369
MX?$X7$V2DJ*4Z%]$_>E[WWV/RS'^'6/A.3P=6C7I<VBJ-QJ6OIM96ZO\3^/J
M;X[:1#'O!)QGCRV(Z'VKFW^*NM>-9?[,\*6=Q<WLI\N)([>0[G.< ;5Z_P O
M2OZV= _X(+_"Q+U3J\<;6N[)!1#\N??/0?Y[5]O?"?\ X(__ +*7PPGL]2M_
M#B7NJVS)(96MX/+WJ0?X@6(SGL.V*]''^-G#M&G+V"Q>)J\ON1A3BHMZ-*3?
MPK_ACDPGAYG%2:]K*A1@I+FE*5Y+ORI;_/S/Y'OV3/\ @F9^T!^T_P"+--?Q
MKH&HZ1X>GN(C]KGAGBC,1D4YW,H'*\_3K[_VM_L:_L1?#C]DOP58Z-H>F65S
MX@CBB%SK B4S!U0!@DFT$G=D;@2.,C/!KZ[\+^#O#?@W2[72/#ND6.FV=I&L
M<:VUM%$Y"@#+.B!B>/7 ^I)/35^#\7^(6;\5MT9OZIEZ=XX2E)VE9Z.H]Y:;
MQNU>Y^EY#PK@<D7M4OK&+DK.O.*O%65U!;+UM<#2 $=3FEHKX ^H"BBB@ I,
M'.<G'I^'^32T4 %%%% "$D8XSG]*6BB@ HSCK12$ ]: #DXP?TZU'-/#;KOG
MECA0G :1U0$GH 6(R?84]F5%+,RHBC)9B%50.Y)X ]R:_C^_X*__ /!5SXL?
M"O\ :%\._!+X+WL]Q+/KL-C*;"5R,-.$P0C'U.>/YY'U?!_".9<9YK_966\D
M:D:%3$5:M5VI4J5)7E*4NAG5JQHPYYWM=+3S/[ E8, RD,K#(92""#T((X(/
MJ*6OD;]B3Q'\0/%G[._@#Q/\2/-37-6T2VNY?M!(DVL@)=MYSMSN&X\<'GCC
MZ-USQWX-\-VLUYKGB?0]-@MU9I3<ZE:(ZA021Y?F^9GCIMZ]<5X&+P57"XW$
MX)6KU,-7J8=RHISC.=.3@W"R;:;6G<M.Z3[I/[SK**_+CXX?\%;_ -E/X&O=
MQ:]XFMK^2UWAOL=_;D,R9Z?*QP<?_7K\B/CA_P '%G@S4H[J#X,Z7=73Q+(D
M#6S-*SN,A267.6)Q^/  7BOJ\H\.N,<ZY)X3),6J$[6Q%:#I45?9N4K6W[&<
MJ]*&\UZ+5_*V^Y_5X[*BL[LJ(H)9G(55 ZEB<  =R>*\S\0_&3X9>%-XU[QA
MHVG>7G>);I!MQG.<'''>OX,/'/\ P6@_X*&?%+59=)\#^%O%,>F7+LD4D4-U
MM".VT$D#MG(Y_*L>Q\ ?\%+/VF@'NY_%6G?;\9S+=1[3)UZGMV^@X K] H>!
M^,P<8UN(^(<GRJC)*34<3"K4BG:_,NC5]FM[=],/KB?\.$Y/TMV_S_S\O[>/
M$G[>'[*OA6.1]6^+OAN-HPQ,*74;2DCL SHN2?\ :KY'\>_\%C?V5O"QF&F^
M+]-U'RBP#+/&V[&<8VR8YX^E?R\:#_P0+_;J^)EU'K'BCQMXB@M)'#O')J%P
MB\G<0 T@&><8Z]>>M?9/P^_X-T/'MN(!XO\ $^I76-OG>9=N^> 6/S,>?Z_7
MCK?!'A+E=I8WCF68SC\='#0C:ZM=)Q_5]K![7$R^&C;9W?R_/7N_N/O3QG_P
M<)?!+PY)*MC!:WHC+!2JLV[&>F'_ "[^W(JS^RU_P7P\"?M(_%2'X<:;X?BM
MGFO$M4N%@E!)=P@Y+$=P<CUKD_!W_!O5\((HX1XFN);AL#>9"&[\YXX^G_ZZ
M^XOV>?\ @C+^R_\ L^^)[;QCX=L';7;>5)UE2",+YJ,&R6.&Z@9Z].*X<QK>
M"V&P&+HX/#YMB\>Z4HX:MJH1JV7+*72U_P +^HXK%77,X<NE^_3^OO[GZ7^-
M?B3IOA'P'+XMNY8XFDL!<6\3$ M(\98  D=/3J#CKW_GW^-/Q/U+XF>+;_5K
MFYD-H9YDCA+-MQD@<9(Z#]!7VO\ M[>+/$^@R:;X6TB"[DT>$) H@#;2@ 3!
MQUP/Z#IBO'/V9_V;+_XFR75]K=K-%8RQ%X?-0CYR-V?F';IG^0K_ "!\?>).
M)_%+Q$_XA5PQA,4L'E.(?M:;A4A2KXB7O0KUZB48^SC']W9NU_/0\K'5*F*Q
M7U6',E"RM;24G]KT5[7[V[7,7]ECXF^&/A_XFM!KEE"ZR2IMO947]UEA@@MP
M#[<>_:OW6\+^,-!\8V$5_H6H0W<4D:2$1NK,FX9P0#R!G&?H:_"?X[?LQ^*_
MAI>W%W:P7$VFLWF0-;H3MC^\OS*.,#KV_+-<Y\(?VAO&OPM^T6L5Q=+#@HL<
M[L-I&> &/;\L$UYOA9XM9SX'YA6X"X\R.KA<KA6G..(IT''$49I-*::2CB*<
M]+2E*^J(PN+J8*3H5X>[>^B:DM/Q['Z^?M)?'C3?A=X>N[.&Y0:O<0E(@K R
M(Q'3:#G(XSCG(]*_##7=?\3?%;Q29G,][<7ETR@?.^U6;&>"1QUK9^)/Q$\2
M_%S7_M&H2W$\\DP\J)6+_>;& O\ P+^?X?H%^RO^SM#86UOXKU^V 9PDJ1S1
MC(. <@,,]^.U>/Q/G_$OTDN/Z>3Y3[?!\(9?43C=RC"&%4DYXG$K2#K2LU%.
M[2=ET)G4KYEB.2":H)W](JVKU6IM_LW_ +-%AX=LK77_ !!:I)=2)'*BRKDJ
MV%;^(=CQ]:^ZU"00I;6ZB."-514  'RC'8?YQ2%8XU6"%1'#%A45!@848_*F
MC=N]NWUX_&O[-X0X/R7@C)\/DN28>%*E2IQC6K**]KB:MH\]2<TDW>2;2NU9
MZ'MT:<*$%3I*R2M>VK??S_KR'$8Z'-)(\=O";BY<16Z?,[LP  QG/)XK.UO7
M=*\+Z=-JVK7,4,,*2,8Y"%)VKGN?\^U?F#\??VM;O49+K1O"$YCB8O"S(^,@
M<'!&.3^G->5Q[XC<.>'F6O&YQB(2Q<X-X/+:<HRQ.(E;3W-6HN2L[_H9UZ]/
M#1YJC]YZQAU=N_K^I]7_ !:_:?\ "W@&&XM]*N8K^[C#*R(RN0WI@9/!Z?KW
MK\R?B)^T=XR\>WLOV*_N;.*:1E2!"Z@@DC P?0X'7)]Z\YT#PGXN^)FL!(8[
M^>YNY=SR,6:/+D<]Q]#7Z,_!_P#8WT^QAMK_ ,:H@8!),R(,#.""<CZ_YS7\
MAUL_\7O'C'SP^20KY)PTY\KE"57#X.G&ZLZF)3C-S<-7&_+=/H>2ZF,S"7+%
M<E-O;:*737[OUW/SUT;X9_$'QS>12MIEU>1S%2;@K(>&[YQZ'^O-?6_@+]B"
M\UA8KG5)WM?NLT;DC.>2,-Q_GGW_ $ETS3OA_P" ;1;:SN-)"1KM ;R0XP!W
MZ]L?_6-6[;Q_X4NI1#%J5A"2<?)*BCJ/0]AQ@<#CUK]4X7^C=P'DTZ53BW-Z
M>>9E/EE5P]7%4H0532_+4C/FGKUDSJHY90A)^VFIREI9->6S7I??\&?.WAG]
MDKPIH(07L4-WMV[MP5MV.2>0>IX]/J!7M.G?!WX;6"*A\/6C.H +>3'R>_\
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M]W!O7'7*^9D$>AY]J\UU']HWX.:4S"]\9Z7$RYW?Z1;GIU_Y;"O\XA_VQ_\
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MY4HREP0W0YZ]A_7\O_VT_BA]I63PG;SE9+?*D(QR=N<\#O7VA\+O%[1?LP>
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M8JE5PE98NGK%OFE;X4]+Q:6MNGZ']$^AZ_I?B&P@U+2[N*YMIU#*R.I(W $
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MX2^*Z72OY0M[]8LDXP%D _EU]SZ\5_11X2U7^VO#VF:ENW_:;='+#H25&?\
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MY]NM>#>._P!HKX=_#S48],UZ_$=S(^W:KH-K$XYX)S7NTKHD;EF50$8DD@<
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MB]?+J?2^.&5X;+N-JV*P\7&&9T:>(=.[:AHE9*]E>]W;U*PYX]:0A@Q!Z?\
MUOSIW.<=\X_&@ALX )8G'/\ /WKXU]_O25K?\.?CPT@'G'3IUJ14=_NJS?09
MJKJ6HZ9H%L;[6[J*TM47<[O*B@#&?XB.W///I7PQ\<_V]OAU\+;:Y70-0AU2
M[B5P8XG69MRYX 0GN .GZ\UVX'+L;F=6-+ X:I7E)I)PBW!/2_-/X5_6Q[&3
M</YQQ!B(8;)\!7QE2<E'FA"7LHMNWO5+<L?FT?>3M8VZ%[W4+>S"@EO/=4X&
M?[Q'I_/TKP[Q[^TI\+_ALLK:OK.G3^2"6"3H>!G=T;Z^GX<U^%OBW]L#X]_M
M+7T^C_"G3=6%Q,YCC6VMK@9W,5&"B\CD>OY<5[K\!?\ @E3^V7^T+?6__"S;
M+6K'3=1D4F:YCND'E2$<[FP!\IKZZ7"67Y12^L\3YY@\MA!<T\)[6'UAI6?N
MIM2>E_)]+W/W_AKZ.N88J-.OQ%CUAT^64L%ATW42TNO:Q7+=]5_GK[S\0_\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MY=2\5Z,D]VA#>=&(T8D=R=O<U[Y134FG=-W[]3&?#F0U,MCD]3*,OGE4&G'
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M *^Y^&_VK/\ @HMH^@6MSX:^&\KZC+<AX!-: S.I<E!CR\GO]>OI7SS^R?\
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M>^CZ/S/C7]E/X!:K\(M"$6OG??A0 3_GG&/U)S7V510>01ZUT<*<+95P;D.
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ME&.FF_;4_P W\\SO'\19KB\WS&K*IB,74E.S;M3IMWC22>RBM/D&#R?3_/\
M2DHJ2--YY("K@L3QA<\\_P#ZJ\L\C:[>WY D8;+.=D0!WR' 50!DY)(_/M7Q
M/^U#^U3HOPPT>ZT71;V%M7>&2)71QNW[3@<9/TYK6_:G_:3TCX5^';O3=.ND
M;4;B-T'E.-ZLXVC&#GJWX^W?\Y/V5/V7OBW^WI\:;.QBM-0N=(DU9'GGEAE>
M$6[R M\Y!& K'OC@DYK]Q\,_#C#XZA/B_BW_ &/A[ WK4H5_<^MNG9W:E;FA
MS)*W6Z1_07A!X35.)*U+/\^HSAD]*4983"SCRO&U$TU*5]Z:;6EFFOQR/@#^
MSQ\<?V\?BI8V5G8:M-IE_>H&OHUF:WC1I<DLV-H&W')X_ 5_6=IW_!O_ /#8
M_L^1^%[B&U7XDR::N=3<1"1+EX,D&0XVNKM@@G(88/0U^L7[#/[!_P -/V0_
MA[I.E:1HUA+XEDL+8W]\UM$TD,Y0,ZQN5SNZ G^'D=>GZ 5EQIXQYEC,=A\)
MPG)Y/DF55$L)3H+D>(]DURSJ)6_=RMK!Z-:V1_;^"R_#X/#4\-2I4Z=&E!0I
M4J<5&%.*2244M+JV_<_SS/C!_P $0/VGO@)KE_?>&[_6-2M#*[VZ6LLSIM+$
MIL"$C&",8R#V/0UY=H?_  37_;)^)$R:'>1^(K2*5_L^]VN5 !^7/.!CG/L?
MI7^CM>Z9IVHJ%O[&UO%' 6Y@CF 'L)%;UJA;^&/#MHXDMM#TN!P<AHK&W1@?
M4$1Y!K:CX_<2JA!8G!8#$8N"2CBG2C%Z*R?+:U^I%3*,#5JJM4P]&=1.ZJ3I
MQE-6M:TGKT/Y#/V(/^#>'5?#7B+2_&'QSU!M6L'DANI;&^D69RH8.1Y<K%CG
M&.G..#7]-SZ'\-/V//A#=R>"?"D%KI&A6#,+2SAC2:Y-I;<;VAC5RK%0=@).
M3U. 1VOQW^.7A'X ^!-4\<>+9'CT_3;=I=L:YSM'3 Z  ?R[5Y)\!/V@/AC^
MVG\.[W4M$B-UI)FDMYX;B(%67E6^1Q@\ #O_ "KXGB#B?BSC%0SOB!XG$Y+0
MQ5.A5CATZ.#A)^\J:C!V51Q5E*UU]YW4X4Z?N1LG9::7LM%\ET70\U_8L_;H
MB_:VUCQCIB>$KGP_'X;GFC22XBE03"&4I@>8,,",$=3[^OZ(@!>%  ]AC^5>
M1_#/X(_#[X3/?2>#-"LM)EU%F:[DM;>. REFW,6V#DD^M>NU\?G%?+<1CZU7
M*<+/!X%J"I4*DW4G%J"4VYO5\TKORN7'FLN:U_(****\LH**** "BBB@ HHH
MH ^%OVU= ;4/"4E\$R((#D[2?NK_ (?Y[U^9O[*&JC2OB!(Y?9F[V9R!SO('
M)Y[_ .>:_:']I#15U?X6>(<(&F@M9&CXY^9&S^H'>OP)^'6IS^%?', F)B>3
M5RHZJ<>=Z>W3\N:_ST^D92_U9\:.#.(FN6EB52Q,JFR4X5H4+-]_^"?/YA^Z
MQU"JD]5=OI>\5;[C^A>UE$]C;S_>\U%(;KU4'.:FA.)8S_MC^=87A2Z%WX/T
M2Z4AC-:QN3G/6,8R/T_6MA"P8$@#'?\ R37]D8>JJM#!XA6:K8?#5KIZ/VE*
M%2Z?71]/4]G3W7?=*3^>NGYH_.C]N?PZVI26VH",D6X!+!>!C/)ZCKCKCH.O
M6O%/V(?$(L?'-Q;W#XC,FQ0Q[C('7CC ^O?TK[X_:;\*IK/P^U/40F^6"*1@
M=N3D*3P/P&/U-?D+\%_$\G@_QQ;L[&)IM3\H]N#+CCGG_.*_AWQ3A_J7X]</
M\2U+TJ&88JAC9R^&$HWA0]Y[73>UWZ'BXFV'S"E5N[2M-_\ DJN_\C^@F5Q*
MYF7[DARN/H*BK.T"Y6^\-Z1>A@QN((W.#G[R9Y_3]:T:_N6-55Z=&O'58BC2
MKIIW356$9JWWGMR=[/357T\]=?,****"2S9*V^3)S^YD]3T4G^E?B%^U?JLL
MWQ)U&S9SLC=_EW9Z$D\>_P#]>OV^L@$DD(Z^3)U_W37X6?M502#XJZK(00I:
M7M_M'&#T/_UZ_FGZ5-:I2X RI4^9JKG<:=3E;^'V:WZ6T6]MCSLU?^S4_P#K
MZCK_ -CO08[OXDZ7?NH8Q2Q'GL 01V[9[&OWRK\+/V+[N./QS8PDC>\D6 3S
MU X'XFOW3KZ[Z)%"A2\.<5*BDIU<UG.M;^?V:6OGRV_IFN4V^KRM:_/K_P"
MK?\ K\@HHHK^J#U HHHH **** "OB3]MW18]7^'\7F+N\D2L.,GJ3Z'O7VW7
MR'^V#<)#X 8.0-R2XR<>M?G/BU1I8CPZXKI5TG2EE=7F4MM'%J]_.QS8M7PU
M5/\ E_5=S\'M.F;3-7A*,5\J[B0'..C\?B*_?;X%W#7?POT>X8[BT,7.<GA!
MW_$5^ $\9FUCY<\W\9XY_P"6G'YY_*OWT_9_0Q?"715?@F&'_P!!'\Z_A[Z)
ME6JN*>*,-9^PCECG'^7F^L<J:\[/[CQ<IO[:JMOW7JM^WX'7^-/!ND^-]%GT
M?4X$D6='7<R*3D@XY(X^HK\U?'7[#WB.'5)[SP[?3P6<TC,D4,K*!N8D#"D
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M **** "BBB@ IK?P_P"\*=36_A_WA0 HZ#Z#^5+2#H/H/Y4M !1110 4444
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MA2@DHTZ<8I15EIS62N]V]3\4?&G_  4/^+O@?]IC3?A&?AEJVI>']8U5+/\
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M\.<S]A%U:^4_\*%.DDW.4HI1DHI;M*[VV./'P]KAIW5W3M)+;JE?^O,_/O\
M9<\0MI'Q:T0N^RV::$-D_*<NOT&/H>M?T1VUQ'=V\-Q"P>.:-)%(.>'4-CZC
M-?RY:!JMSX3URUOH<I=64\0<CAAL< ].1S[\?A7]!W[.7Q%L?''@'23]I674
M8(%$Z;PS\(N,C)/&#[8_,_FOT.N+Z$,/GO!F*J*&+]NLSPT9R2<EI1G1@GO*
M-F^5:V6QRY/67[RCK=_O%?Y)KU6]NGW6^AJ*0YQQU_SZT#..>O\ GTK^[#W1
M:*** "BBD) Z\47_ *_'0!:_.O\ ;]\4)I_@ZST^"0><V[>H(_B)/UZ?X\U^
MA5Y>6]A;37=U(L4$"%W=C@ *">IX[5^"?[7'Q0E\8>.]1TB.?S=/M99 FUMR
M#:P4 =?7T_\ K?SM])GB_#<.>&V8Y>ZJCCN(?^$["P4E[2*;C.=3EWY;+EYM
MKL\[,ZRIX:4+VE5]U=]U?1GS;X(L&U[Q#86H0L\L\1(QDGYA^/!XK]]_A3I[
M:5X TRPD3:4@BX/'\(_'/_ZNU?CY^RYX'N=?\?:??-"7T^&2,NVPE %8'DXQ
MC_#'-?M\+:&RABL[?B%(8AQZA<'CZ_XU^'_11X<K8?*,ZXDK0E3^MU?J5*4D
MTZM)6DYQ?5.76]M7KL<>4TI1A5JR35UR1;W:TU]'KW^\8,CJ<^]+35QCCD9I
MU?UPE:UGUUOUV6[VV/55^H4RX@2\L[BRE&Z&="CJ>A# CWJ3!QGM2JV/H<9I
MM73C))J47&2W4HR5I+JFFFT&SM;6V]NCZ?\  /D75?V4=!U+Q6/$"0IY)G$\
MD95?F8-O/'?G/^/&:^J-%TV#0M+@TFS01VUNBHB@8QM _#H.WX5J[V'W&;:.
M,;CC/TS]*C)R<U\]D?"?#O#>(QN*R3+:6"Q&8U'5QE6"2E5E+5K1*T6[OEO:
MY,*=.FVX12<OB??R3Z+?[_(3 )'KTS_GZU\_?M)>+D\)^#;R%I1&+RW=!DXW
M!D([^N<C\:^A$4MN/]Q2_P#WSS7Y>_MQ>/TU&--%M9P'M!AT1L'*\'(!&,CC
MG'OFOE/&'B6/"WA[GV/554\56P\L-A%>TJDJB<)J.ST@V]/\S/&5%2PU22=G
M))17G?57]+O[C\^&O_LFLW>IQ2!7>[\Y6/KD,#G)_"OM/X8?MIZOX+M;.PU"
M9KJUM J+'EB-JXXP?88K%_9B_9\LOB](L^KAA9!1ND*DKDCKGZG\QS7O/Q'_
M &#);=I3X/A$XP3%B/.3CH.*_C+P\X'\9\NR6/'G :E3PF,G.7LJ,Y3Q&)7-
M[5R>%T52'-M=[^IX>'H8R$/K%#;HEN]NG775]?N.O\5_MO\ A_Q=X%O[.QMA
M:7]S!Y;$,V2=A!QD_+ECV _I7YF>'K>?Q7\6-(NE625[S4$+,"Q(#3 GGOCC
MK_*M'XA?"/Q;\*]0DT_Q&IMW^8I'C9D<XXZU[G^QMX,'C#QI%<^2)/[/N X8
MJ"!L<'C\ASS^77CS?/\ CWQ7X[X5X9XSISI9Q@,PPU&>$^K+#S3HUX5:LYT(
MZ0FXIWO;1KT)E4Q&+K4XUD^=.*Y7&S5FKW2]+_F?MO\ #[1?[!\*:18G.196
M[D'G!:)6Q^M=ADL<#C'U]J2WC$%O!%T$,,47_?"*G]*E!!SC\>*_U;P.&IX+
M!X7"4H\E/#4*5&$?Y8TX**7X'U<4HQ44K)))+L+11174,**** "BBB@ HHHH
M **** "FM_#_ +PIU-;^'_>% "CH/H/Y4M(.@^@_E2T %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%-^;=_L_AZ?GUH =7\G'_!
MQ!^U!%I&BV/P)COQ&^M70MWM1)R[3[4/R @\C';MS7]5/BC6H?#GAW6-=G8+
M#I=A/>2,>@$2YR?Q(K_/?_X*$ZY>?MM_\%"=&T33;B6^ATKQ3"CP0N9$ CN@
M,%03QQR,>W2OV/P4R>CCN*GFF-C; 9)A:^.JU7\,*U./-2OI;=.SZ'-BI-4U
M%;S:CY[K;S/Z$O\ @@#^RX?@Q\%1XUDL#;MXKLWE25D(:3S]DC$,1GD/SVP:
M_HLKYO\ V2? $7PS^ 'PZ\(I;K;OINAVR3*$V,9#&@);@'.%'MQ7TA7P7&&<
MU<_XDS?,ZTN=U\964)7;O2ISE"E_Y(EIT-J<>2$8J^B5[[WMJ?-O[67Q5L?A
M%\"?B%XLGOHK.]L_#]ZUAND".T_EL5*Y]E(XYR17^:AXI\6:S^UU^TYKNM:\
M\ES]A\33F.:1RP\M+DD$%CTP!ST[\5_5W_P<2?M07'PY^'FC>!O#NI%;C4X'
MMM2BMY>3YKN"KJK8P%./4X]*_BP\%>/-<\$ZK/KOA^"2;4=0D\]_*7+F23+9
M..^3G@=O6OZ8\%.%<9A.#\USK">SIYKG5.I1RVM5]SZO&'N2DY.UHRO?T=_)
M^!Q#]>KX#&X7+)TZ>-J8:=/#SJ2Y84ZLTDIR>RM=ZMKY,_I4\&W_ ()\&>$M
M*T&75+6VN+*&&.13)$IW*H!SR#^>?H*[2QUS0-6(33+^&Y8C "2H>3]#[C^G
M:OYTI/'/QJ\82OJ @UF+S/FPHF"\>@ '_P"KGU%7=+^/'QJ^'-Y%(+?5BJ2
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M[P)K-SIFIVMPGERN%FV,% !.,''IW':O\[_$7@WB3P6XZH<6<-.O3RQXMXW
M8NDI2I4I3FIU,'B4O=Y9IR34O=2?D?/8FA5P6(5:DY*#?-!VO%;/D>WHS^DC
MP=XWT#QOI5MJFBWT%RL\*2O%&X9XRP!(('8$_4=_4]< 02<DY[>E?SE?";]H
M'QO\+[J&/3+RXFL=R[U>1BJIN&X=< 8]L]!7Z:_#S]N;P5J%I!;>*)3%?D(&
M=64'<0-V2<@X/7^E?UWX;_28X*XMP=##Y_BZ7#N=0IQCB8XN7L\#5JI)-T*[
M>O.[M1M9;7/6PV9T:J2JM4YK>_PWT6C\WT9^@!Y'!_$4TML '7GJ>_\ ]>O%
M-)^/_P /-8B66VU2-58<!Y8P>V!^HSTQFM>X^,W@6",R/JMN5 !_UL?IGU^O
M\^E?NM+BWABO1]O1S[*ZE%KF52.+I<MK)WUDNC7]7.]5:35U.+6^_33_ #/5
MQ4,\L,$33W$BQ0Q L\CG"JO'+$]J^6O%'[7?PN\-Q2^;>^;.H.Q%E4J6YQG:
M,D?E7P+\8OVU_$/B*.[T[PK,T6GS;X]R.5(5N.N<=,_@*_.>,_'GP[X.P=:K
M5SK#YKCH1DJ>7Y9..(KRJ6]Q3Y7:$92:N[NRUL<U?'X>C&3YU.2^S!W=^BT_
MJQ](_M:?M.Z7X?TF\\'^&;R.YOKE6BFN8'!V-@K@$$X"G(SQUY[X_'<+J/B;
M5E25GN+W4;@J7^9VS(X[\G/S<4M[>ZKXCU![J=[B_O+J7+#+2MN<D\#D@ G^
ME?H/^R]^S;/=3VWBOQ3;%;<,LUNDT?('#+PP[=/_ *]?P/FN;<8_2,X]HJG0
MJ4\!3G&G2H0<_J>58!34I2J3V=2<;WEJ^9V9X,I5LQKQ]W1[+[,(W5[^?SWL
M?2/[+'PG7P1X3CN-2@ N[J)9(W8#(W $8) /I_D5]5;RS$'MWSZ<4L<<5M;P
MV=NBI!;((XPO VJ-HP!CL/U_,K_0/ACAS!<*9%EF09=#EPV7X:%%.VM6HHIU
M*DG97;E?5ZVW/?I05*G"FMH*UWUT5V"+_#GJ>N/;_P"M2F-V;:F2?;C).,4#
MGC')^O\ G]*XWX@^/=(^'GA^]U#49XEN!$S0*6 8,5(7J>N1Z''I7J8S&X7+
ML)BL=CJU/#X3"TI5JU:I)1C"$%S-W;^)V:BNKLMC5M0]Z3BDES.[_#U+.O\
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M *:W\/\ O"G4UOX?]X4 *.@^@_E2T@Z#Z#^5+0 4444 %%%% !1110 4444
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M% !36_A_WA3J:W\/^\* %'0?0?RI:0=!]!_*EH **** "BBB@ HHHH ****
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M=B.3^-*02?;N.?\ /I0 03SQV&3^%?1F@K*&&&4,#U# $?D>*0<?*%P ,#C
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MFU"SM&47C[O."O.3C%?*7[&OPCU7]LK7IM8L+27PWIVDW/EW\?,"S+&V)"^
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M=O3O7Q9_P2Z^*O@;P!X9\9W.KR6FGYO[G:B-''*P\PDE5_B!QZ'(/XUG:O\
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M!& ?$TN,]_\ 2&Y[<\@_C7^F3\3K;[;\/_%MKC)FT:Z0#Z@?X5_FK_M[V/\
MPBO[7=TCC9YWB-FYXZW!]?7C//:OZ*\ W[2IQ+A;N]; 3?*MW:GT_KL>)Q!!
MU,KQE-+66&K+_P EOY]NQ^OGP^?=X#T9O6WB/'^ZA_I73UQGPJD%Q\-= GX(
M>UA/'?\ =CU!X([5V=?A&8)QS+,HO>./Q,7\JC1_EMF,7',<Q35K8_%1_P#
M:K6W0*R_$L33>'-65.2+"7_T%C_A^&:U*?-$)M)UA&YS83@=^L;# KGIS]G4
MI5+7Y*M*7W5(G-3J>RJT:G\E:B__ "I$_GV^"C&U_P""A_@MVP!'XFMLGC'%
MZM?ZB_P^N%N_ WA"X0Y63PYI&".<[;&%#^JFO\N;PNC:#^WCH&HR K'%XB@8
M-P !]L4\'CTZ?S[_ .FM^SCKR>(?@[X)O5?>1HEC&S9SR(%_S^E?T-X]0=3
M<"8I:Q_L.C!M;)NE3=K[75D?ZF\,34\DRN47=2R[ RO;_J'A?7KK_6Q[B-V3
MGIGBEHS17\W'T!F:Q=M8Z;>72?>AA=Q]0,U_.O\ M5ZO/K_Q4N)IY&)>Z>,
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MWLD>W3I4Z,>6G%17DM_5_(*"<<T45]":" YY%+1TZ"B@ HHHH **** "BBD
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M$WLB:-&G0AR4XJ,?+^OSU%#9Z9I:,8Z#'X4@(/0@X].:^F-1:0G')I:.O44
M%%%&<=: *6H7T6FVDUY."8H5+OCK@ D_RK\[?B)^V[IGA?Q3=Z' RA86=-N_
M!&TD'OU^OI]:_1#4["/4[&XL9>$N(VC8^@8%3^A-?EI\7/V&FU_Q5>>(+%S)
M]I=WVC)^^Q/K^0'XU^&>-^*\4\+E.75/#/#TZU=8J^8W_BJC;3E6K:WO:VO<
MX<:\4HQ^K)/7WN^C5M?S_,^(_C[\48?BWKL6J0N/E8M][.>3[\?E_.O0_P!D
MOXR^&O@OX@O=0\0X,-TDD9(8!@)%VDJ3GIDD>_.,5UUY^Q'XIM26M;>1L \
M,<\_X''Y^M<;JG['OC]0VS2IINN/D<Y(SWQW]?\ )_A"'#_C/DG&=/CY\,XJ
MMQ'1Q+QGMIX6I7HRKN/*W*G&-[<K]?2VGA>SQ<*T<0Z<G44N:]F_>T6WW'ZB
M^!_VPOAAX[UR#0M+FD6[N'"IYDT>/FX!Q@=_Z<]:^KXY%E1)$(9'4,K Y!#
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M:VFNJT/CGP7^V9\3O#]S:6=U=R/IT&Q"K2$GRUX/&>.!^/M7ZH? K]ICPO\
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MT'T'\J6D'0?0?RI: "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M5M+?397_ ",O>F]^MWVMY+N+^R7^R5'816GC#QE:[IW59K:&9,D9.Y1A@/\
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M%.HH 0*HY"@'U  HP,Y[TM% !7X-?MI:S/-X\U2SED;RXGEV@MD#YCC@]/\
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MND:5JBC"ZEIMC?J/1;RUBN /RDK2H("BBB@ HHHH *:W\/\ O"G4UOX?]X4
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M^RS\/_ MC:O=:9!>:K$ 7GVI@. !G=AB>1GM_2O0OC3\,-,^)?PM\1>!9K6
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M #[]*@M,^4F?[G]:MYK];E;9+R=^OJCX2]^_1^7I?K_D?+7BBQU[X6>+]/\
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ML^E_/I_PY^$>(:FLXUNE*E[NG9+\/\V?13G+D^IJ(Y8%>G3GOR/\]ZF=3N;
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MVC&W7[Q#T/T/\J^X/V /!D/Q$^-EGX=G3S% $JID#+(,@#/<XQ_]<YKX>.%
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M['%7=WT_,OA0N H 51@*!@ #ICZ#BG445SFH4=.@HHH ****  T@!'4YI:*
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MPI:+8:1J=[#;HH55CGD4!<8X&1QT[>U;*_M5?&!'WC6=2R#D?Z1*/IT;M_\
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M#@G%:0SW_2OY[/A7^UWX_P# <46F7UY(+&'">7+(VX!<=0QS_GZ5](WG[?\
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M_ABT-GX<TBTF7)BL+=)%8 \[!D$8P<9QC%<9X@^#O@?Q+=->ZCI<3S.2255
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M0E.6\Y-KTZ?\ *0G'^>M+2$ ]17XF=@*21R,<^AI:** "BBB@ HHHH ****
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MFMKSXO:W<VDJSVY;Y'C.Z,^XQQ_^OFO&I4WS6AYPEU"QQV =?Z9KVL!AJ?\
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M,C)KY,_0R2BBB@ HI&.!G'>E!R ?6@ HHHH **3!W$YX].?:FA^>GZ__ %J
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MK9MJWN/>SZ/6Q_;7A#X+4>#?9Y[GZAB\^JP3I4;*5+ <R5XI.]ZJ[KK8Z_\
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MW'NE;5>>Q#Q.'C&4I5Z*C%\LI.K!1C*]N63<K)WTL];GH603CO2UXYX>^/\
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MI::IR.!CFG5B>60W%Q#:P37-Q(D,$$;RS2R,%2..-2[NS'  5022?2OX6_\
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M14<Y);1V2BO1)"UY7\9OBEX?^#_P^\1>-O$.H6UA;Z3IMW<PFXD6,2311,R
M;B,X./QP/6O2KV^M-.M9KV]GCMK6W1I)IY6"HB*,EBQXZ#^O2OXNO^"Y'_!2
M+4_B7XA'[,'P@U.2.\FGDTV5].D9C=/).8SN,!)).=O.< >E?7\#<(8SC'/<
M-EU"+CA825;'XEK]WA\-!\U24I;7<4U;MKHM3RZU54H-_:^RN[;L?F[^U+\7
M?B+_ ,%4_P!M&+P#X<?4[K1M+\2Q6R_9F>6R:VCN]G.S*[=H[\5_<W^PK^RY
MH7[+WP/\*>#[;3+6UUV/38#JL\42QR/(8DX<J 2?O$YSU'>OQN_X(8_\$W[?
MX1^!K3XS_$?0U3QKJT=M>V\]W#^_D\_=+YF95+>IR3_2OZ9Z^W\6>+,)B*F#
MX-X?DJ>0</P5!^S=HXG%02C4J-QTE"ZND[Z_CEAZ;2=6>M2IJ_).SL%-;=QM
M_'I_6E!SU&#Z'K2U^*G4%%%% !110: "BD!)ZC%+0 4444 %%%% !1110 44
M44 %%%% !1110 4444 %-;^'_>%.IK?P_P"\* /,M+^$/@;2/$\7C"QT>W@U
MV.$0B\2-%DV =V"AOKSS7IS ,"I&0P((]01@_I0.@^@_E2U<ZE2HU*I.4VE%
M)R;;2CLDWT\C.E1I48N-&G"G&4G-J$5%.3WD[;M]7NSR73/@MX T7QC/X[L-
M&MX/$=PQ:6]6*,2,QY^^%#9./6GZ[\&? 7B7Q3:>,]5T>WN->LG62"\:.-G1
MU((PQ4L.>>O6O5Z:200 .#U.*OZQ7YN;VM3FY/9\W,[^S_DO_+Y=C+ZGA>1P
M^KT>1U/;./LXV=5:^T:MK.^O,];GB/Q0_9Z^&7Q;:TD\7:#;75Q9[/*N%AC\
M[$>-H+E<\8]?PK-T/]F;X3^';W3]2TOP[:0:AID7E6ET((A*F$V@[E0-QP>#
MZ\\U]!452Q>*5-4EB*JIJ]H<\N57WLKVU(EEV!G5=>6$P[K2<7*HZ4.=N/PM
MRM>ZMH]S^3;]I/\ 9#_:!\ _MG:Y\?;6RN-5\,7DTK6L'E-,BIORH VL!\HP
M.,#%8'P^_85^//[1/[5O@GXY7\=]HGAWPU?VMU<VR*\$3QPRAW5E 48VC&.0
M:_K4U31=)UJ(0:MI]K?PC.$N8A(.>O7G]:-*T32=$A-OI&GVNGP$Y,=M$(U)
M]\5];#C7&T\-"$</06)AA/J,:_+I]7<>2W+_ #M/?N? 3\,\MJ8RI4EB\2\%
M5S'^U)X5S?,\7S*:?M%9^S4E\/8\J^('P&^'GQ1\.6&@>,=#M+Y+.RM[5;CR
M(OM&(H4C.9"NXDE2=Q.>3DGC'+_#']E;X2_":Z6\\*Z*D%PA!21TCW*0=V00
M,CFOI!AN&.G-(I/0C&,8X-?)+%XE4Y457JJE)MNFIM0=WVO;?HOU/OWE^!E7
MCB982A+$02C&LZ<7425K>]:^ED#*K*490RLI5E(R"I&""#U!'!KYZ\5?LO\
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MO_"#P#K[>)M"\,6$>K,B+YYM;?"E% #( F0<C(YX]Z^@ONE57"J  %    X
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M;EEKJXIO5+?H?FG#F99AD^90S' 8.>-=.$J=>DJ3JQ=*3BY)V3Y6TM&?V?\
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M"D/@_P %:)I*1JDT-E"+@@8)<+CG\LUZ)2<+@=!T I:Y&[MONS4***0D#K2
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MI<BZ7;^?74Y*7'V(Q?$T,KP^"JSRW$Y=3Q='$*F^>*K4U*-23WY4O>:/T?\
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MU/07:6P0LR0PG=@9) PH.#^HZ\U\/ZQX2\8^#=4*3:=JELUM)Q-^]1-R'KN
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M:*4ZSW]M[1W;CK?8_-7_ (*H>!-#^&?P"_9O\)>%$271+;5]'\MHQNB<>;$
M<*""#C//4>]?8?[?[*/^"5'@399VZL= TL$I JMQ"A)R%R&YY(Y.!GI7Z;?%
MS]A'X7?&7P;X,\&^+));FR\%R6LFGS/$))&:UVE"=S9!)4$G)/\ .O0OB?\
MLJ> /BI\%=-^!^O*?^$8TNUAM8 (PQ\N%0B_*2!T7'6O/CQ'@O9Y%&7M9SR_
M-,1C,3-Q=YTZDTXR6NLFEJMUW/9EP?F7M.*94HX:G3S?(\)EV"I1G[M*K1I*
M$H2[4UJHM;]&?SGSVVJW'_!+OX?7ME9&YBL%66X*QE_+C4;F+$#@>N?QXQ7W
M1_P30_:,\#ZS^SGXF\$PW^G#7+?1KV)[1-@G$OV:6+:PQO/WB<'^( XR!7Z;
M>'_V/?ACH'P,?X#16JS^%6MY+=6DA7?&KH8\JI)Y YZCGO7SO\#?^"7?P?\
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MDL%Y DP",&*!NS8K;W?-MQ_G&:^=/V:_#7B#PWX%L;;7VD,S6L6Q9,Y4#;P
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MR?4]BAGV;X;"RP=''5X8>2<>13?NQ=KJ+WBO)=RO965MI]M':6D2PP1*%1%
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MGO7]"G_!%_\ X)M:A<:C;?&/XI:.VU6&H:4]W">6!#IMWC^\5 [9[XS75?\
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M^9?3_P#@CY\>OAEXB?2?AO\ &36=+\'3ZG+>PV5G>3QP1)-*6"[4< ;58C!
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M7(ZCKS@>^*^]=.TZSTJTAL;"".WMH$5(XXU"@!1@9P!DXJ*E5-.,=N]M]O\
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M3:=!'%=Z;"9I]B ,VW+9XY(X_#I7XM^%=?U?P#XRM)].EE@N(=32%\,5X60
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MFV]DE=@345Q^H?$'P-I2/)J/B[P[9)&&+FXU:RCVA>3D&;=QCH!FOC3XU?\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M_>%.IK?P_P"\* %'0?0?RI:0=!]!_*EH **** "BBB@ HHHH **** "BBB@
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M@WL\DFD7DD<3B8G;&K-LZ-P,#';BOW5\/:_I_B72[75=-F6>WN(HW#*00&=
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M_>_04 .HIN&_O?H*,-_>_04 .HIN&_O?H*,-_>_04 .HIN&_O?H*,-_>_04
M.HIN&_O?H*,-_>_04 .HIN&_O?H*,-_>_04 .HIN&_O?H*,-_>_04 .HIN&_
MO?H*,-_>_04 .HIN&_O?H*,-_>_04 .HIN&_O?H*,-_>_04 .HIN&_O?H*,-
M_>_04 .HIN&_O?H*,-_>_04 .HIN&_O?H*,-_>_04 .HIN&_O?H*,-_>_04
M.HIN&_O?H*,-_>_04 .HIN&_O?H*,-_>_04 .HIN&_O?H*,-_>_04 .HIN&_
MO?H*,-_>_04 .HIN&_O?H*,-_>_04 .HIN&_O?H*,-_>_04 .HIN&_O?H*,-
M_>_04 .HIN&_O?H*,-_>_04 .HIN&_O?H*,-_>_04 .HIN&_O?H*,-_>_04
M.HIN&_O?H*,-_>_04 .HIN&_O?H*,-_>_04 .HIN&_O?H*,-_>_04 .HIN&_
>O?H*,-_>_04 .IK=O]X48;^]^@HP>[9_ =J /__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>g0fyk5pshdve000001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g0fyk5pshdve000001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" ,C!A4# 2(  A$! Q$!_\0
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M(!=-ITCR+;2F*1BA4;O;/6N#^)R3>'=5T_Q3IR@2F.2SF'0$,IVG]3^0KJ_
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MRGSH>?08IQII),F563;7];GO%%%%<YV!52#_ )"5W_NQ_P C5NJD'_(2N_\
M=C_D:8%NBBBD 4444 >73W_BK6/B#K6CZ;XA73[>S59$#P(XP0O'(SU-0Z7X
MSUZ3P]XJMKN[AFOM)C)BOH%7#')'3&#TXXJ-?"5EXE^*OB%-6MIS;(B/&RDH
M"V$'7OWKI=<\,:;X?^'NMVFCV?E^;;L6QEG<]LGJ:Z&XZ+T.1*;O*_?J0>&_
MB1I$]AI-GJ-](VHW$:K)*T)"&4]1N QG)^E:FL?$'0-$U"2QN)II)X1F800E
MQ'_O'M7#Z_I\B_"OPE'#:OYJ74+,JQG<N5<L3Z<U6\2W^I3>(O$%E=+J%JK*
M4MH-/M!_I0YP7?&2._XGI1[.+=P]K.*MZ'I-]XVT*PTNSU![II(;W_CV6*,L
M\GKA>O'O3](\8Z+K-E=W5M=%$LQFY6=2C1#GD@_0UY9+;1GP!X:>ZL]4B>WD
ME O;,?/;$MW7J<X!'(Z=:GTF#Q'KOASQ/8QF>\M&B4V]S/!Y4L[@@E?4Y /4
MGMZTO91L-5I7VZ?H>A:7\0O#NKZDEA;74@FE)$)EB9%E_P!TGK6UK&I#2-)N
M+]H);CR5R(H1EG). !^)KQ?1+=M3OO#M@[:Y-<6<BDPM;JD=K@C/)&=O%>[5
M-2*B]#2E.4T[GGO@;Q-KFM^+M:M]61K9(8D>.S*C]SG&.>I.,9SZUZ%7 >&H
M)4^*WBJ5HG6-XXMKE2 W"]#7?U-2U]!T;\NO=A1114&H56N/^/FT_P"NA_\
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MY\MSUW5_&.B:)9VMS=7>];M=UNL*EVE''( [<BK>A^(--\1V)N],N/-C5MK
MJ593Z$'I7E/B&UUR#6/#?B'4EN[4"Q6&>:RA#/;R?-_!T&0P_7TKJ/A?9A$U
MC4$34 EY.&#WB*ID(+$L .F=W-1*$5&YI&K)SY2[XRN?$\=TITV^M])TF& R
M3W\P1\OGA,')].W>KGP_US4/$/A2&^U) +C>R;PNT2@?Q8_P]*SO&GB!=/OE
MTW6= EO=#N(MQFA!<[P<A2.,8(]?2F_"FUU&V\,S?;8YH;>2X9K2&;.Y(\#U
M[9_Q[T-?N]03_>V3.[HHHK$Z HHHH J67^LN_P#KN?\ T%:MU4LO]9=_]=S_
M .@K5NA@%%%% !1110 5GZ[JL6B:'>:E,?DMXBX']X]A^)P*T*\[^*!O-6.E
M>&+"-S)?3!YI-IVH@.!D_7)_X#505Y6(J2Y8MHJ?#GQAK-_K4VF>(96:6YMU
MNK,LBKE>N!@<Y'/X&NHU/Q_X?TC4;FPNKB875N!NC2%F)R,\8Z\5Y]KOAWQ-
MX7O-(\0W%Y'J7V&1( EM"598^>.!R,9'XUT/AZ(7/Q:UN]\AS!+:(8I&0@$$
M)ZUM*,7[W0YX3FER=;]2YXB^(UG:^#1K.BR+/)-)Y,0DC;"MWW#M@5%#XL.J
M:GX8>VUEX([L%9K9K7_CX<<-SCY><UQEII]XWP@UN%;6;S!J&_9L.=HV\X]*
MU_MAUGQ-X&N[>UN4BA4Q2>9$1M*@ _A3Y(K\1>TDW=^7YG8ZG\1O#>DZC)8W
M%U(TL3;93%$S+&?]HBH[W7-_C/0H;76@MG=VYE%JL.X7 PQ#;\<?_6KB-.U,
M^#F\2:3JFA7-_<WERTD.(=R7"GH"?3OWZFM6X@N'^(/@^8Z7]A463E[>(92#
M(?Y<@ =ZGD2*]I)_?^IO/\4O"T><W4YVR%'Q;L=F.YXZ5J:MXST31K&TN[BZ
M+I>#-NL*%VE''( ^HKR+0M=@L?"GB/2WTRZN)[Z>1(9(H=RLQ&,$^HZ_C6K?
M_P!L^'M&\*6-Q'-:0")FGNX+82S0L23L&1\IP1^9]*;I1O82KR:N=;JWQ+TU
M/"=WJNDN9;B*181%-&P*N<XW#TP#^56=.^(&D?\ ")6NKZA=,K,1"X$1#/*
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MU%>6?\+PTS_H#W?_ '\6C_A>&F?] >[_ ._BT>QGV#ZQ2[GJE! (P1FO*_\
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M\-,_Z ]W_P!_%I>QGV#ZQ2[GJE%>5_\ "\-,_P"@/=_]_%H_X7AIG_0'N_\
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M8I=SUFBO*_\ A>&F?] >[_[^+1_PO#3/^@/=_P#?Q:7L9]@^L4NYZI17E?\
MPO#3/^@/=_\ ?Q:/^%X:9_T![O\ [^+1[&?8/K%+N>J48&<XKRO_ (7AIG_0
M'N_^_BT?\+PTS_H#W?\ W\6CV,^P?6*7<]4(!ZBBO*_^%X:9_P! >[_[^+1_
MPO#3/^@/=_\ ?Q:/8S[!]8I=SU2BO*_^%X:9_P! >[_[^+1_PO#3/^@/=_\
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M5_\ "\-,_P"@/=_]_%H_X7AIG_0'N_\ OXM'L9]@^L4NYZI17E?_  O#3/\
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M_P!_%H_X7AIG_0'N_P#OXM+V,^P_K%+N>J  # %%>5_\+PTS_H#W?_?Q:/\
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M^_*_X4?V5IW_ #X6O_?E?\*MT478614_LK3O^?"U_P"_*_X4?V5IW_/A:_\
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M%%V%D5/[*T[_ )\+7_ORO^%']E:=_P ^%K_WY7_"K=%%V%D5/[*T[_GPM?\
MORO^%']E:=_SX6O_ 'Y7_"K=%%V%D5/[*T[_ )\+7_ORO^%']E:=_P ^%K_W
MY7_"K=%%V%D5/[*T[_GPM?\ ORO^%)_9>G?\^%K_ -^5_P *N4E%V%D5/[*T
M[_GPM?\ ORO^%']E:=_T#[7_ +\K_A5RBB["R*G]E:=_SX6O_?E?\*/[*T[_
M )\+7_ORO^%6Z*+L+(J?V5IW_/A:_P#?E?\ "C^RM._Y\+7_ +\K_A5NBB["
MR*G]E:=_SX6O_?E?\*/[*T[_ )\+7_ORO^%6Z*+L+(J?V5IW_/A:_P#?E?\
M"C^RM._Y\+7_ +\K_A5NBB["R*G]E:=_SX6O_?E?\*3^RM._Y\+7_ORO^%7*
M*+L+(J?V5IW_ #X6O_?E?\*/[*T[_GPM?^_*_P"%6Z*+L+(J?V5IW_/A:_\
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M8A:*04M !1110,**** "BBB@!#0*.II: "BBBD 4444 %%%% !1110 4444
M%%%% "&EHI!P:8"T444 %%%% !1110 444AH .II:** "BBBD 4444 %%%%
M!1110 4444 %(:6BF @I:;T-.H **** "BBB@ HHHH *3J:6@4 %%%%( HHH
MH **** "BBB@ HHHH **** "DI:*8!1110 4444 %%%% !1112 ****8!111
M2 **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "E7[Z_6DI5^^OUH N4445F:%>?[X^E15DZ_J^K6%[
M''8>'I]1C:/<TL=PD84Y(QAN>P/XUD_\)+XC_P"A*N__  -A_P :UC%V,932
M9UE%<G_PDOB/_H2KO_P-A_QH_P"$E\1_]"5=_P#@;#_C3Y6+G7])G645R?\
MPDOB/_H2KO\ \#8?\:/^$E\1_P#0E7?_ (&P_P"-'*PYU_29UE%<G_PDOB/_
M *$J[_\  V'_ !H_X27Q'_T)5W_X&P_XT<K#G7])G645R?\ PDOB/_H2KO\
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M"5=_^!L/^-'_  DOB/\ Z$J[_P# V'_&CE8<Z_I,ZRBN3_X27Q'_ -"5=_\
M@;#_ (T?\)+XC_Z$J[_\#8?\:.5ASK^DSK**Y/\ X27Q'_T)5W_X&P_XT?\
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MU8ZTM<F?$OB/_H2KO_P-A_QH_P"$F\1_]"5=_P#@;#_C1RL.=?TF=917)_\
M"2^(_P#H2KO_ ,#8?\:/^$E\1_\ 0E7?_@;#_C2Y6'.OZ3.LHKD_^$E\1_\
M0E7?_@;#_C1_PDOB/_H2KO\ \#8?\:.5ASK^DSK**Y/_ (27Q'_T)5W_ .!L
M/^-'_"2^(_\ H2KO_P #8?\ &CE8<Z_I,ZRBN3_X27Q'_P!"5=_^!L/^-'_"
M2^(_^A*N_P#P-A_QHY6'.OZ3.LHKD_\ A)?$?_0E7?\ X&P_XT?\)+XC_P"A
M*N__  -A_P :.5ASK^DSK**Y/_A)?$?_ $)5W_X&P_XT?\)+XC_Z$J[_ / V
M'_&CE8<Z_I,ZRF]37*GQ-XC_ .A*N_\ P-A_QH'B7Q'_ -"5=_\ @;#_ (T^
M5ASK^DSJ\48KE/\ A)?$?_0E7?\ X&P_XT?\)+XC_P"A*N__  -A_P :.5AS
MK^DSJ\48KE/^$F\1_P#0E7?_ (&P_P"-'_"2^(_^A*N__ V'_&CE8<Z_I,ZO
M%&*Y3_A)?$?_ $)5W_X&P_XT?\)+XC_Z$J[_ / V'_&CE8<Z_I,ZO%)TKE?^
M$E\1_P#0E7?_ (&P_P"-'_"2^(_^A*N__ V'_&CE8<Z_I,ZRBN3'B7Q'_P!"
M5=_^!L/^-'_"2^(_^A*N_P#P-A_QI<K#G7])G645R?\ PDOB/_H2KO\ \#8?
M\:/^$E\1_P#0E7?_ (&P_P"-'*PYU_29UE%<G_PDOB/_ *$J[_\  V'_ !H_
MX27Q'_T)5W_X&P_XT<K#G7])G645R?\ PDOB/_H2KO\ \#8?\:/^$E\1_P#0
ME7?_ (&P_P"-'*PYU_29UE%<G_PDOB/_ *$J[_\  V'_ !H_X27Q'_T)5W_X
M&P_XT<K#G7])G645R?\ PDOB/_H2KO\ \#8?\:/^$E\1_P#0E7?_ (&P_P"-
M'*PYU_29UE%<G_PDOB/_ *$J[_\  V'_ !H_X2;Q'_T)5W_X&P_XT<K#G7])
MG5FC%<I_PDOB/_H2KO\ \#8?\:/^$E\1_P#0E7?_ (&P_P"-/E8<Z_I,ZO%&
M*Y3_ (27Q'_T)5W_ .!L/^-'_"2^(_\ H2KO_P #8?\ &CE8<Z_I,ZO%&*Y3
M_A)?$?\ T)5W_P"!L/\ C1_PDOB/_H2KO_P-A_QHY6'.OZ3.LQ1BN3_X27Q'
M_P!"5=_^!L/^-'_"2^(_^A*N_P#P-A_QHY6'.OZ3.KI:Y/\ X27Q'_T)5W_X
M&P_XT?\ "2^(_P#H2KO_ ,#8?\:.5ASK^DSK**Y/_A)?$?\ T)5W_P"!L/\
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M HHHI@%%)2T %%%%( HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** $'?ZTM(.
M_P!:6F 4444@"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *5?OK]:2E7[Z_6@"Y
M11169H5I_P#6#Z5'4EQ_K!]*CK1;&;W"BBB@ HHHH **** "BBD-, ZFEI!2
MT""BBBD,**** "BBB@ HHHH 8GWG^M/IB?>?ZT^F(*3H:6D- Q:*04M !111
M2 **** "BBB@ I#2T@ZTP 4M%% !1112 **** &Q_<%.IL?W!3J8@HHHI#"B
MBB@!#UI:*04P%HHHI %%%% !1110 4444 !I!1U-+3 ****0!1110 A[?6EI
M#V^M+3 ****0!1110 4&BBF 44E+0 4444@"BBB@ HHHH ***2F 4M%% !11
M12 **** "BBB@ HHHH **** "BBBF 4444@"BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH 0=_K2T@[_6EI@%%%%( HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
ME7[Z_6DI5^^OUH N4445F:%>X^^/I4/2I;C[X^E1"M%L9O<,T9I<48IB$S1F
MEQ1B@!,T9I<48H&)FCJ:7%)T- "T444@"BBB@ HHHH **** "BBB@!B?>?ZT
M^F)]Y_K3Z8@HHHI#$Z&C-'4TN*8"9HS2XHQ0 F:,TN*,4 )FC-+BC% #2:=2
M$4"@!:***0!1110 4444 -C^X*=38_N"G4Q!1112&%%%% !2&EI.II@&:,TN
M*,4 )FC-+BC% "9HS2XHQ0 F:,TN*,4 (*6D%+0 4444@"BBB@!#V^M+2'M]
M:6F 4444@"BBB@ HHHH *2EHI@%%%% !1110 4444 %)2T4 %%%%( HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M_?7ZTE*OWU^M %RBBBLS0KS_ 'Q]*BJ6?[X^E15HMC-[A1110 4444 %%%%
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M?^?N?_P';_"CDEV#VD.Z.XHKA_\ A;?A'_G[G_\  =O\*/\ A;?A'_G[G_\
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M  ';_"CDEV#VD.Z.XHKA_P#A;?A'_G[G_P# =O\ "C_A;?A'_G[G_P# =O\
M"CDEV#VD.Z.XHKA_^%M^$?\ G[G_ / =O\*/^%M^$?\ G[G_ / =O\*.278/
M:0[H[BBN'_X6WX1_Y^Y__ =O\*/^%M^$?^?N?_P';_"CDEV#VD.Z.XHKA_\
MA;?A'_G[G_\  =O\*/\ A;?A'_G[G_\  =O\*.278/:0[H[BBN'_ .%M^$?^
M?N?_ ,!V_P */^%M^$?^?N?_ ,!V_P *.278/:0[H[BBN'_X6WX1_P"?N?\
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M_AK27O+&[%KY<UB@2W,4C(%4<[2 0"/8U?.K6,_9N]S'\:?\A3PK_P!A9/\
MT$U?\:R-'X*UAXW*NMJY#*<$<5=UC0=-U^&*'4K<S)"_F1[970JV,9RI!JC!
MX)\/V\=Q''9RE+B(PRJ]W,X9#C(Y<XZ#D<U*:T*<97=NIS,6E1Z_XJL[2^GN
M3:KH-O*T,<[('<LPR<'FL>2YU :98:"DEU=6YUB[M&7[3Y3RQQ'Y(S(>F?UQ
MBO4+?2+&UO5O(8-LZVZVH?>Q_=*20N"<=2>>M59_"VC7-E-9RV0:&:X:Z8;V
MR)6.2P;.5.?0BJ4T0Z;.4\-PZO9:SJ>F6:1Z?&]H)H+6YO!<F&3<!NQG=M(/
MYBHO#]MXF_X3;7_]/T_S%DM_M1\AL2#9QLYXX_6NTTCP]IFAF9K&!EDF(,LL
MDC2.^.F68D_A6G@ D@#)ZFDY[E*GM<6BBBLS4**** "BBB@!#V^M?*GB7_D:
M-5_Z^Y?_ $(U]5GM]:^5/$O_ "-&J_\ 7W+_ .A&MZ&[.7%?"C+HHHKI.$**
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@#T_X3^,O[.O!H5[)_HT[9@9C]Q_3
MZ&O<:^0%9D8,I*LIR".H-?1'PW\8+XDT86UP_P#Q,+50LF?XU[-7-6A;WD=N
M'JW7*SMZ***P.L**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** $'?ZU#?3R6UA<SPPF:6*)G2)>KD D*/KTJ8=_
MK2TQ'+>!O$>I>)=*GNM2T[[')',47"L XQZ'TZ5U-%%#=V**:5F4]5U&'2=)
MN]0G.(K>)I#[X'3ZGI7D_A/7-/TWQ%I%Q#?K-<ZL'CU--K#;*[;D/(P<$[:]
M.\0:&GB'3DL9IWB@\Y))0HSYBJ<[?8&EU_0X-?T6739)&A#%621!S&RG((^F
M*N+25F1.,F[KH<GJM[KVN:/XCN;2[M[>RM&FMDMFAW&8(OSDMGY3R<8%2:-?
MZSJ8M=)TN[ALHK#2[6265X?-:1W3Y5QD8&%.:O7?@B>9;V&VUZZM;74/FNX4
MB0AW( 9E)Y7=CD"II/!\D,EM/IFKW%A<QVB6<TB1JXF1!@$JW 8>M.\;$\LK
MW.6\/75U!I/ANW*V_GW&I7:/(T0?RVW/RF>G-)HEQ>:?8Z.9YH+J.?6YH\26
MRYCP\FYE/."3S[=*ZK3_  5#I]OI$0OII/[-N9;A6=1F0OG(/YU';^"/(NX7
M.JS26MO?F]@MVB7",Q8LN[J02W?TIN2$H25OZ[&2/$'B.X\,7'BR&ZM4M(V=
MTT]H<[HE8@Y?.=W![5,NL>(M8U+7!IU_;VEK8QQ2PJ]N'9RT0?:3D8')Y]ZN
M/X#S#+IT>L74>B32F5[!47N=Q0/C<%)[5L6?AZ&RN]6GCE;&HA 4V\1A8P@Q
MZ\"E>(U&7470=8?4_"EGJ]P@5Y;?S9%3ID#G'Y5RG_"0^)$\+#Q<US:FT+"0
MZ<(?^6)?;_K,YW=^E=EHVDQZ/H5KI2R&:."/R]S#&X>XKGU\!#[.-,;6+IM#
M$OFC3RB_WMVS?C=MSVI)QN5)2LBMH=K<3_$C6;N2[21$B@8*UN,E60E0#GY<
M9[=:?XDN;^T\?Z/)IVGK?3_89QY+3B+C<F3N(-=)9Z-'9ZY?ZFDI+7B1H8]N
M @08&*6?1TF\16FL&9@]M!)"(\<,'(.<_A1S*X<CY;>?ZG')>ZI>?$K26U/2
MET]EL;@(JW(FWCCG( Q63H)2[\ PV,?@ZXO;B6&1%N3#$$8EFPV\MGCZ9XKT
M.YT..Y\1V>LF=E>V@DA$87A@_?-2:#I":%HEKID<K2K;J0'88)R2?ZT<RL+V
M;OK_ %L<=I^FS>$=6\-W%W)EKNV&FWC Y D',7/?GY?RI]EK^E6^MZIXHU2?
MRH)9O[/L7*%LI']\C _B;G\!76>(=$A\0Z-+I\TCQ;RKI*GWHV4@AA^53:1I
M<&C:1:Z=;C,=O&%#$<L>['W)R?QHYDUJ/D:=EL<AXB\5W45U9SVNH&QT>XM1
M+'??8C,KR$GY6_NC&#^-+!K>OZMJ>D6-KJ-A$MS8-<7%Q!'YJDAL?)G'7C@]
M.:W=7\/7E[J(OM/UF?3Y&A\F5!&LJ.N20=K< \]:YE?!]UIWB72K32+ZZM(K
M33G7[9Y:N&8R9(8$8YR3BFN6Q+4TQMYXWU*RMO[-N9(4U)=1>S>[2 NHC50V
M\1CDG!7BEA\;ZC;VFK(7%\T"Q&SN9+9H [2.$VLI]"0>.HK<_P"$'MUTR.*/
M4+E-1CNC>#4, R&8]21TP1QCI3E\'&YL]1CU;5KJ_FOE56D($8B"G*[%' ((
M!S[47@'+4*FJ_P#"2Z5I6JRWUW9:C9C3I9,M;A-DH4_+LR0R'WKG-12[_M_4
M=0::VD\CP\9UADM%9-N#\F#VSW].*ZH^#+B[6Z.JZ[<WTLMF]G$S1J@B5Q@M
MM7@M[FK-QX1AN'NV-VX^TZ9_9QPH^5?[WU]J%)('"3,JPU35]:GM],TRZM]/
M6VTZ&>:3[.'R[C(55R % _PKJM';47TJ ZLD*WP&)?).4)]16)+X0EB>VGTO
M6)["ZCM$M)9$B5Q,B]"5;H1ZULZ+I,.B:3#80R22K&#F25LLY)R2?QJ9-="X
MJ2>IYUX2>[&F7(A\(P:FGVV?_27FC4GYSQAE)XK0U@7UWXNT:SM]$M6EBT][
MB.TN) (+=R^TL=H^; X  ZMFM.S\%:IIJ2Q:?XKN[:W>5Y?*6UB8 L<GD@FK
MMSX7NKA;"Y76[A-6LU=!?"),R(QR59,;2.GY53DKW,U"7+;_ ".9$X/AC4-%
M@LEL=0O-4%G<01/NC4R;2[)Z*4R<=N:2R6>#Q5XDCM?#,.JQK<QKODD1?+Q$
MO'S UU&G>$H[&[M+E[V6YFBFEN9GD49FE=0NXXX&%!  ]:@F\(Z@NKW]_IWB
M.YL1>R"22)+>-QD*%ZM]*.9#Y):,MK%8CPZ]WJ^@VEFD >5[9D20)@=00,9(
M JAX!TA(=-DUR:TB@O=4/G%(T"B.+^! !T&,'WSS5Z7PW>7GAN^TC4=;GNVN
MN/M#0HC(O&5 7 ['\ZWXT6.-8U&%4!0!Z"I;TL6HZIL=1114&@4444 %*OWU
M^M)2K]]?K0!<HHHK,T*\_P!\?2HJEG^^/I45:+8S>X4444 %%%% !1110 44
M44 %)U-!I13 ****0!1110 4444 %%%% #$^\_UI],3[S_6GTQ"4M%)0,6BB
MBD 4444 %%%% !15*YU6VMI C%G;OL7.WZU9BFCG0/&X93Z4 24444P$I:**
M "BBBD 4444 -C^X*=38_N"G4Q!1112&(QPC$=A7/>#M=FUOPY%?7TD*SM+(
MI"_*,*Y XSZ"N@D_U;?0UYIX&\&:!J_A>*]O[ RW#S3!G\Z1<XD8#@,!5I*V
MIG)OF5CIM \3K/H%YJ>KW$$$4%Y-#YF-HVJV%^I_G6EIOB31]7AFELKZ-U@&
M90P*,@]2& ('OC%>7"QEB\(6<MOYD=E8:],\S1Q^:8D!(#[3G<![U>^U175Y
MK&K6-Q<^()(-,:)V-HJ6[@G.PXP6(&3C'2K<$9JH]+G=V'C'P_J=^MC9ZDDE
MPX)12C*'Q_=) #?@:I^(O&VE:3;W]O%J$/\ :4$3%8RK,H?&0I(& ?8G-<5'
MJ:7VK^%W35_[06.]C#K!9"&&V+*0$W8SD] ,]CQ4MQJFFZ3X4\1:#J<3+JTD
MUPXB,1+3[R61P<<C&.>VVCD5P]JVCTW2;F2]T:QNI<>9/;QR/M&!EE!/\ZX5
M/&FL2>)_LX>S6(:I]@.FF,^?Y?>;.>G?IBNMTLSKX*LC:@&X&G)Y0/\ >\L8
M_6O)1+';V]I?:%<7\GC0AX[V"2)G=R1\^0>!M(X^@I02=QU)-)'N=<1X2\:S
MZMK=_I.IQ+%,L\OV.15PLJ(Q4C_>&*Z+PU??VEX<L+LRR2N\0WO*FQBPX;([
M<@UQ6FZ#)K/A2[DLY/)U.RU6YGLY?1Q(?E/L>AI)+5,J3=TXG2:)XD:>/7I]
M4F@AM]/OY8%D/R@(IXS[UHZ5XET?6WD33[U)7C&YT*LC >N& ./?I7EEK]NU
M3P9JUXT$L3KKPNKN*./S&1 <O\I^]@\X/I6DNWQ#JS2:9K5WJMS#I\Z"6.T2
M*)-Z$!&(P22<$#GI5."(51Z'>6OB[0;W4?[/MM2BDN22%4 [7(ZA6QM8^P-9
M^@>+8IO#\-]K%Q%%--=2V\:HARY5RH 49).!VK#T;7=$FTKP]HL6F&ZU2V,2
M26K1%&M'08>1B1Q@Y/O7/^&X9-!>R\473?:=-:YN+6577/V,&4XD7ZG.3[TN
M1![1W7]=CV:BD!#*&4@@C(([TM9'0%%%% "'M]:^5/$O_(T:K_U]R_\ H1KZ
MK/;ZU\J>)?\ D:-5_P"ON7_T(UO0W9RXKX49=%%%=)PA1110 4444 %%%% !
M1110 5W<?A&RN?A=9:S;PR/JUS?"V7]YA3EBH&#P.W-<)7L.AL/^%2^'^1QK
MD6>?^FIJ*C:M8VI13;OV.-D^&'C&*">9]&<+ "6 FC)( R< -\WX5R2H[R"-
M59G8[0H')/I7O]K>SO\ '34K=[AS NGX6,L=HX4]/J3^=>/^&[VUTWQ[8WEZ
M0MM#>AG8CA1NZ_AU_"IA.3W'4IQ35N]B>]^'7BO3]);4[G272V1=[XD0LB^I
M4'(_+CO3=*^'WBC6M,&HV&EM);,,HS2(A?Z!B":],\0:#K"7_B+7G\5K8:-=
M0AHGC82B9=O"8)&/08/.:MW-I>^*I_"NL^&]6B@TJQ1/M$0EV>3M(+94=> 5
MP?3T-3[5V-/81OU/(=+\$^(]:6Y-AI<DIMI1#,I=49']"&(/^%:0^%OC(W36
M_P#8S;E3?N\Z/81[-NP3[=:])U76[6^\/>/K[2)QLW11B:(XWD(JL0?3J,]Z
MJWE_<K'\-5%S(%D9#)AS\QPHY]>"?SH]I/\ KT#V,%_7G8X_PGX$&L:-XFCN
MK*<ZQ8;8[>$/M(D.[@CH>0/:LV+P-JND^)]*L=>TN;R;R8*%AE0^8.X# X!^
MI%>K643W&L?$:V@NDMIYO*CBE9]H5VB8+SVY(JK"DF@:/X.\/ZQ=QS:O_:BR
MA!)O,<>7[^GS ?RZ5/M)7?\ 70KV,;+^NIYO?^ ]6OO$&K0:!I$YMK*=8VBD
MFC+QY' /S<_AFL_4? OB72]2M-/N=+E^T7AQ L;*X<CJ,J2..^>G7I7JEQ<2
M6]I\3)89#'(LB[64X(^3'%2:+%'JGA;P*MYJ=Q:L7E EBG,<CD!@$W=>0,?A
MBG[627]=B?8Q;M_6]CR_4?AQXJTM('NM+(6>585*3(P#L<*#@\9/&3Q[UU%_
M\+UT76_#T,UO<WUI=_N[O9*B,9L,VU<D8  ZYQQUKK_$EG+9_#CQ# ME'9ND
MOFJB7;3R,NX'S&8\@G&?PI=2M;BY\7>!]9CF5]/,:PDB3.9#&[ X^@/-+VLG
M^)7L8I_=^9Y._@O5-6\5:KIVA:9,8[2=T*RR+^Z . &;.,_0FJDO@KQ%!KT6
MB2Z:Z:A,"8HRZ@. ,Y#9VG\Z]8DW:[I7BWP[H]]';:T=5EE,9D\LRIO'0_08
M_#GK5M+B.T\1>"=#O+N.ZUBRCD^TR*VXIF/&"??W],]Z?M9$^QB_Z\]CR34/
MA[XITO2Y-2O-)>.VBSYA$B,5&<9*@DX]ZRM&T#4_$,\T.EVWVB2&,RNOF*I"
MCJ?F(S]!7JVDWD]S_P +)2>=Y%"R;5=L@8WCC\ *X+X<:RNB^.-/ED;$$[?9
MY?3#\ GZ'!JU.33[HSE3@I+LS+/A?61H$6N?87.G2R>4DP93ELE<;<[NH(Z5
MUD/P\O+3PUJ@U+1KC^V(Y(Q;O'=1&- [* & ?J>?S%>P0MI#:M_PAPC7R[.W
MBO47/<29_GM/XUPMUK7]M>"/'VH1R95KU!$P/\*F-5(_ 5'M92-71A'K<H/\
M)HM-\5Z#9W0FN=,ND*7,WF*A,VUVVJ <@84>OUKF/$GPZUW27U&_ATR1=)@F
M?RW,BEA&&(#%<[L8[X]Z]7U"SN;KXA>$]<AG232VM_*!$N<N8Y&SCZ$<US^D
MWL]U<?$Y;B=Y%5) BNQ( 'F@8_  ?A2C4EO_ %N.5*&UOZL>1Z1I%]KNIQ:=
MIL'GW4H)2/>JYP"3RQ Z UKZEX \4:1I3:E?:5)%:I]]MZL4'J0"2![UI?"3
M_DI.F_[LW_HIJ]&-I=^&X?&NK:[J44^F:@)!:Q^=O\PG> H'8X(7 ]/05I.H
MXRLC*G24HW9Y19?#[Q3J&D#5+;2)7M2N]3N4,Z^H4G<?RY[5%I'@?Q'KUG]K
MTW36F@\XPEO,1=K@9(()!'UZ5[M#.FHC1-9TFWM)[6"U(-U)J#Q);_+RK(,@
M^G/3%<5J&J/)\)_$5W9S)%Y^LM\UM(=I!9"=IP#@_05*JR9;H06MSC5^%WC)
MI9XQHSYA^\3+& W^Z=V&_"M31OA\=;^'LU[9V4TFNK?& (9-H51C.0< 8YZU
MZ!?7]P?BAX1@^TOY+:>SL@?Y6)5LD^O0?E55-.N]8\!^(].TZYC@NY]:F$>Z
M39OPZDKGW -3[232N4J,$W;7<\H/@3Q*NO#1#IC"_:,RK&9$ 9!U(8G:?SIU
MSX \3VFHV>GRZ6WVJ\4M#&LB,2!C).#A<9'7%>U6-Q';^+O#&C7%W'<ZI9:;
M*+IE;<5)5!@GU.">>>_>N+^'WB W/BKQ#;7^I-'J%[')'93SOD1MN8X7/3D@
MX']VJ5235R71@FEW.)U'P1KF@7MDNLZ>\-O<3+&)%=74Y/3*DX/UKL[_ ,":
M):^+M:TZ'3;RXM[73EN(Q'.H,;D'EBS#(]AFM.2WN?"?P_?2/$E_'/J%Y?QM
M:P^:9&4!T);)Z#@GTY]36_.1_P +"\5\C_D"I_(U+J2?]>A4:45_7J>26_PN
M\8W5M%<PZ0&BE02(WVF$94C(/+^E9.I>%-:TC3HM0OK/RK669H$?S4;+J6!&
M 2>JMSTXKV_0O"^L>'? NS1[B*XUN\1=TUQ*=D"D<! <]/U//;%8-SX=O?$'
MPUT_2([RU:^TK4I/M[2S8"8>3<Q)]F!JE5=_(ET%;2]['G9^'WBC^UI-+_LL
MF]C@%PT0GC/[LD@'.[!Y!XZU9;X7^,5G@A.C/NF!((E0JN.NXYPOX]>U>R3R
M[?B=J4D;C(T!65@?^FC5P#ZE>#X$Q3+=S"9M1*EQ(=V-Q/7KUH523!T8*^_7
M\#B%\&>(6\0MH0TR4ZBJ[C%D8"_WMV=NWWSCM6M!\/M6TSQ+HUIK]@T5G?72
M0EXY58$$C(RI.#BO6=1L;?4OB:HEOKB*4:(C)!!<F$W)\R3*E@<D?_K[4V_M
MI(-'\+1-9P6AM]9A#V\,YF$.6. 6/)/(S]:7MFQK#Q5SS/Q9\,]9TZ_U*ZTO
M2Y6T>W;,;>8K/L &3MSN(SGM7 U]')9W>D^/];\4W^JPC0/LWED>=G# *-NW
MH""K>_/N:^=9F5YY'1=JLQ*CT&:NE-R6IE6@HNZ(Z***U, HHHH **** "BB
MB@ HHHH *U/#^N7/A[68-1M6(:-OF7LR]Q673XHGFE2*)2\CD*J@<DFAI-:C
M3:=T?5VC:M:ZYI4&H6CAHI5S[J>X/O5^N5\ >&G\,^&X[>=V:YF/F2J6R%)[
M"NJK@=KZ'JQO;4****104444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 @[_6EI!W^M+3 ****0&7XDU.71?#E_J4*(\E
MM$9%5\X)'KBF2>)-+L[2"34=0M;622%)2CR '##L.OK^55/'G_(BZS_U[-63
MIMI#/X\M7FA20QZ#'MWKG!+@'\<?SJTE:YE*34K(Z-/$VAR74-LFK6;33@&)
M%F4EL],?6B?Q-H5M<_9I]7LXYMYC,;3*"&'8^E>>1V5O!\--.:*W1)!JRD,%
MYSYY'7Z<58OK*W?PKX\F>!&E:^E^<KSQMQS[57(B?:2L=];^(-'NYYX+?4[6
M66!2\JI("54=3]!4QU6P%K;W)O(1!<LJ0R;QMD9N@![DUQ&I62KKWAV"UA5&
MDTJYC 08S^Z&!^=8HURSNO#?A/1XC(;ZTU"V%S$8V!A*DC#9'!R:7)?8;J-;
MGHW_  E.@?:$M_[8LO-=MBKYPSG.,?7-2W_B#2-+G6"_U*VMY6&0DD@!QZGT
M'N:\W:S@'PBUJ;R4\TWLC[]O.1. #GZ5I6FH:7H6L>(%\1I^\O662 R1%_M$
M.P *O'..F*?(A>T?4Z+7M;U2WU;2=/T6.RE>_25]]P6V@( >"I[YK-NO%^LZ
M/+>V6K6%F+N/3Y;VVDMW8QOL!RK \CIZU@V6B7DO_"$Z=>SWMC.+:Z):"0I+
M&,*0N>W&!BM[6/"ECI'AK7[\3WEY?/ILT?VB\G,KA=A.!GH*+16@KR=VOZT-
MW1O%&EZLEO#'J%HU\\2N\$<@)!(R0![5*WB?0DU 6+:M:"Z+;/+\T9W?W?K[
M5R=W:06D'@-H+=$99T'R* <&(DC\:X^_U);OPM)$)H;:9;D2/I4%D=]OB4$M
M)(V2/KQUQ0H)C=1Q6I[#>:_I&GW2VMYJ5K!.W(CDE /M]*BO_$VC:;907=S?
M1B&X&8#&#(91URH4$D>^*XF:^L-*_P"$HM-:MI);J_=Y+<" N;B(IA I [=/
M:L^%GTP^&]3N[^YTZQ;1DMUNXH%D$<F<D-N5MN1CGVHY$#J,]0TS5;'6;,7>
MGW"SPDE=P!!!'4$'D'V-1:AKVDZ3*D>H:C;6TC\JLL@!QZX]/>L3P2-.D_M2
M[T_4KG4!<3JTL\L(C5G"X^4!0.F,\5F76IZ3H7B?Q$?$,8 O5B-L7B+":(1A
M2B\==V>/>IY=;%<[Y4SK;[Q#H^F^5]LU.U@\U=R;Y!\R^OT]^E.N]>TFQBBE
MNM2M88Y4+QL\H =1CD>O4=/6N T:^TKP_K&H3:W9-I\%[;0&QCN$+XB" &('
MGD'M2>&=-9-4\*I>6C1J(;^:"&9>8T+)L!!Z$*:KD0O:-G<?\)7X?/D8UFR/
MVC_58F7YN<?SXK.3QG9V_B+6--U2ZM+2.SDB6!G?:S[D#$G)[$]:XVXLK9/
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MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@!!W^M+2#O]:6F
M4444@(IX%N(]C,ZC.<HQ4_F*K?V3;]I+@?2=N/3OV[5+?ZA:Z78RWM[,(;:(
M9>0@D#G';W-95GXU\.7]U';6^JPF:0X17#)N/H-P&31R7UL4J\H>ZI6-#^R;
M?^_<$>GGMT[CKWZFC^R8/^>MSGU\]LY]>O7M4MIJ%K?/<);3"1K:4PS  _(X
M ./R(JS2Y(]B_K%7^9E'^R;?M)<#_MNW'IW[=J3^R+;/W[CGK^_;GU[]^]7Z
M*.2/8/;U?YF4?[)@_P">MSGU\]LY]>O7'%(=(ML_?N..G[YN/3OV[5?J"\O+
M;3[.6[NYEAMXEW.['@"CDCV#ZQ5_F9!_9-O_ '[@CT\]OQ'7OWH_LF#_ )ZW
M.?7SVSGUZ]<<?2I)M2M+?2VU*68+9K%YIDP3\N,YQU_#K5"X\5Z#:WPLI]4M
MX[@D JQX4GH&/13[$BCV:[">)J+>7XEO^R;?L]P/^V[<>G?MVI!I%L"3NGYZ
M_OFY]>_?O5\'(R*K7%_:VEQ;6\\P26Z<I"I!^=@"2/R!HY(]A_6*O\S.?O?!
MLEU>22P^(-4MX)>9(%D# G&#@L"1D5T%G80V-OY$7F,@  $CE\ =!S5FHH[F
M"6:6&.:-Y8L>8BL"4SR,CM3LB'4FU9LE  & , =A2$ XR <<BEHH)$(!Z@'%
M+110 4A /4 XI:K1W]K+?S6*3!KF!5>2/!RH;H?QQ3$6:***0Q, $D 9/4TN
M!G..:BANH+EI5@FCD,+^7($8'8V <'T."./>J5WK^EV6JV^EW%VJWMQCRX55
MF)R< G .![G%.S%=(T2 >H!I:**0PHHHH **K6FH6M^UPMK,)#;2F&4 'Y7
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MI!]7IG@'_"G/%']ZP_[_ )_^)H_X4YXH_O6'_?\ /_Q->_T4>VD'U>F> ?\
M"G/%']ZP_P"_Y_\ B:/^%.>*/[UA_P!_S_\ $U[_ $4>VD'U>F> ?\*<\4?W
MK#_O^?\ XFC_ (4YXH_O6'_?\_\ Q->_T4>VD'U>F> ?\*<\4?WK#_O^?_B:
M/^%.>*/[UA_W_/\ \37O]%'MI!]7IG@'_"G/%']ZP_[_ )_^)H_X4YXH_O6'
M_?\ /_Q->_T4>VD'U>F> ?\ "G/%']ZP_P"_Y_\ B:/^%.>*/[UA_P!_S_\
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MI!]7IG@'_"G/%']ZP_[_ )_^)H_X4YXH_O6'_?\ /_Q->_T4>VD'U>F> ?\
M"G/%']ZP_P"_Y_\ B:/^%.>*/[UA_P!_S_\ $U[_ $4>VD'U>F> ?\*<\4?W
MK#_O^?\ XFC_ (4YXH_O6'_?\_\ Q->_T4>VD'U>F<[X,\+0^%="CM%PUP_S
MSR#^)O\  5T5%%9MWU-TDE9!1112&%%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% "#O]:@OI)XM/N9+6,2W"1,
MT49/#. <#\34X[_6EIB.8\$:EXAU/3)Y?$5C]DG67;&/+*%EQZ'WKIZ**&[L
M4596.7^(W_(@:MQGY$_]#6L._M/$/BC2;;2W\.V^G0,T3->M=J[(%(.54*#G
MCUKM=:TF#7=(N--NGD2&< ,T1 88(/&01V]*NQ1B*)(UR510HS[52E9$RAS2
M\CS2WM]5W^,+^QUB6R6TOI)$BCC1@[B-2=VX'(Q@8^M6KS7KW49K%%U6\A,V
MG17#6NEVOFRAW .YV((5>>!D5UD7AVTAMM6@62<KJDKRS$L,J64*=O' P.^:
MS6\#6:S0RVFI:G9LEM':R_9YE7SD087=\O7'<8JN9=2.22V.>AUSQ+J7A'2K
MN-KQU^T317TMG"AN"JL0I53QGCG%1R>+;\:;9V5GJES=3W%^T#S"R NH8U7=
MM,9&"_OBNC7P!ID.G6]I;7=_;O:SO-;7$<H\R(O]Y0<<J??)]ZD_X072SI[0
M/->/<M.+DWYE_?\ FC@-NQCIQC&*.:(N69#X5O\ 5WU:\LKR/49;!8EDM[F^
MMQ%(&SAD.!@^H/UI/B%HEKJ7AR\O+EIF-I;2/'$)"$+8X8@=2.U:NB^&[;1K
MBXN_M-U>WMP LES=.&<J.BC   _"KVIZ?%JNF7-A.SK%<1F-RA 8 ^F0:F_O
M71IRMPLSEM2#7N@^&=&3_E^: R_]<HU$C?\ H('XU5UZ"R\B]\):!:K/J&H.
MTMT[DLMN'.6D=CT/H*ZN'1((;VQN1)*QLK4VT2L1C!VY8\=?E%8,7P\M[>XN
M9K?Q!KT#W,IEE\NX0;F/<_)331,HLU=;O)/#7@VYN8/WLEE:@(7&<D  $US-
M[8:G8^(O"LU_K3WPDN'9UDC155_);E=H&%Z\5W$EA!/IAT^YW7$#1>5)YIR7
M&,<GUKG[7P)907MG<RZEJ=U]B)%O%/.&1%*E2N-O3!]<\#FE%I#E%MZ'(WOB
M?5H+,:M;ZQ?7;)<A6\JS"V)3?C:&8 GCN"3FM"T>YTK6/'%\NK>486C >X0&
M,,44AB ,DCH .OO6J_PWTZ2P;3WU35C8AMT-MYZ[(3NSE?EY[]<]:O7O@G3K
M^\U*>:YO NHQ*ES"L@",RXVOC'##:/;VJ^:)')/<P=&UC4H_%FE6IO\ 5;JU
MOTE\PZA:+"I94W!H^ 1].G-;'BVXU/\ M;0M.T[4'LA>RRI-(B*QVA<\9'6I
MK3P;;V^J6>ISZKJ=Y>6A;RI+B96&UE*E<;<8Y^N>]:M[I%O?ZEI]]*\HEL6=
MX@I&TEA@[N/Y8J6U>Y:C+ELSA)-8UJYU;4K!+[5\:85@BDL[-)/-DVY+R<=S
MV&!BIYM>U:ZM])M[Z[N]/O);5I+BSL+0R7+-NP&P00B<>W-=%J?@^UU"_GO(
M+^_T^6Y4)<_8Y0HF X&X$'G'&1BH9? NG+):2:==7NF26T'V8/:2@%X\YPVX
M'/))SUYI\T2>69S>E>)=;U&TL]*:]EBN9]3GM&O'A02K%&,X*XVAST_.FRW6
MH^&M5\67!O/MMU#:VH@FE4 X9BHW #'!/X@5TT7@32H-.DLX9[U US]KCF$H
M\R&3&,JV/YYZU)9^"=-MQJ/VB>[OFU&)8[IKJ0,7QG!X P>>WH*.:(<DS*U*
M?6?"]U8&76IM0CO3)#*LT2+LD\LLKIM' R.G-3G6K\>$O"EY]I/VB]N+-)WV
MC]X''S#IW]JOV'@ZTM+J.XN;[4-1:%&C@%Y,'$2L,': !SCC)JK;?#_3[:6T
M/]HZI+#93K/:V\DX,<)4Y  V].W/:E>(^616^']M-#/XC9[R691JLJ%7"X)"
MH=W ZG./3BL^[BNK;Q[XDO8K^826^D^<@VH1T?"].@(!'ZYKK],\/6^DZIJ%
M[;7-SB^D\V2W=P8U<XRRC&03CUHG\.6=QJ&HWKR3B2_M!:2@,,!.>5XZ\GKF
MCF5[AR/E2.2AN_$$=GH,$FNRO<ZZ5=YC!&!;*$W,$&.IR!DYZ$TW6]7USPZF
MLZ:NIM=21645W:7$L:^8FZ785; P>G7'>NLO/#-C>Z-9Z<\EPGV()]FN(W"R
MQE1@,#C&<>V/:JB^"=/:POH+BZO;F>^"B>[FD!E(4@@ XP!D=,4^9=1.$NAC
MO%XAB\5V^BMXDG>"[LVN))?(C#HRG!"<8 .1Z_UK:\%:C>ZCHDWV^?SY[:[E
MMC,5 +A&P"0.,XK3?1[>37+?5R\OVB"!H%4$;2K$$DC&<\>M)H^C6^B6\\-L
M\KK-</<,9""0SG) P!Q4MIHM1:9PD>I2Z=;:_P"1J"V3S>(&CWB$RR,"B96-
M<'+?456D\2ZU8P^(K:.]OV%M9)<VTE_;JDR,7"GC'(Y[BNONO ^G7*3XN;R&
M>2^-^D\<@#Q2D ?+QC&!T.:A/P_TZ1KUYM0U*::]MQ;W$LDRLS@,&!^[P> .
M.,=JOFB9N$^AG!M=35-*T-M?G+W\3W<]SY,8=  /D3C &3]165=^)M>T=]7L
M'OY+R9=0M[.WF$"EHU=68D*  S8'0]ZZ+QAITS+IDEOIMY<K;%A]HL)@EU!P
M "N>&![BJ/ASP8+C3M7_ +7M[B%=0N$FB26;=<1E!PY<='R2>/\ ZU":M=@U
M*]D6O#E_K0\0FSF75+C3'@+^?J%L(WCD!Z9 &017:5@Z1X6M]+U%]1EO;W4+
MUH_*6>\D#%$_NK@ "MZLY--Z&L$TM0I5^^OUI*5?OK]:DLN4445F:%>?_6#Z
M5%4L_P!\?2HJT6QF]PHK+E\2Z'#>_8Y=7L4N0VTQF=<@^AYX/M5JZU*QL988
MKN\@@DG.V)9) I<^@SUZBG9BNBU15:XU"SM)[>"YNH89;AML*2. 9#QPH/7J
M/SJ'4-;TO22HU#4+:U9^56:4*3] :+,+HOT5#:W5O>VZ7%K/'/"_*R1L&4_0
MBBZO+:QMVN+NXBMX5ZR2N%4?B: N345#:WEM?6ZW%I<17$+?=DB<,I_$5#::
MOIM_/)!9ZA:W$T7WXXIE9E^H!HL%T6Z6JUY?V=@D;7ES%;K(XC0RN%W,>@&>
M]6: "BBBD,**** "BBB@ HHHH 8GWG^M/IB?>?ZTYG5$9W8*JC)). !3$+15
M7^T[#_G^MO\ OZO^-6$=9$#HP96&0RG(- 7'4444AA1110 R5%D3# D @X'M
MS5)E9+#:PVRW#X(]V//Y#^57O,C$HC+KYA&0N>2/7%*55B"5!*G(R.E "@8&
M*JS9CO+>0=&S&WX\C^7ZU:I"JMC< <'(S0!5A@*W+[E.U6WQL/\ :ZC\^:MT
MQI8T=$:15=_NJ6P6^E*\B1(7D=41>2S' % #J*B@N8+J/S+>:.9/[T;AA^8J
M,:C9,VU;RW+$XP)5S_.F*Y9HIK21HZHSJK/]T$\M]*'ECC*AW52YPH)QD^@H
M =1112&-C^X*=38_N"G4Q!1112&%%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 (>WUI:0]OK2TP"BBBD 4444 %%%% !1110 4444 %%%%
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M5Z_7,>,_#5SXDBTQ+::&(VEXMP_F9Y4=A@=:Z>LI.Z1M"-I,****@U"BBB@
MHHHH **** &)]Y_K27$$5U;R6\\:R0RJ4=&&0RD8(-*GWG^M/IB/.#X5T'_A
M9R6/]E6OV4Z4TIBV?+O\Q1G'KBMC5]6O=$N5T_3QI&FV$$*F.6_DPK_[**K
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MLCJ!:Y^W+;!?./V?R2Q)CP,;L_Q9STXJW65HMQJ-Q)J7V]0J1WCQVQ$97=$
M,'GKSD9[XK5K-FRV&Q_<%.IL?W!3J "BBBD,**** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH 0]OK2TA[?6EI@%%%%( HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** $'?ZTM(._UI:8!1112 ****
M "BBB@ HHHH **** "FNH=&1NC#!IU% %33-/@TG3+?3[;=Y%N@C3<<G ]35
MNBBF+8****0PHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 (._UI:0=_K2T
MP"BBBD 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !2K]]?K24J_?7ZT 7****S-
M"O/]\?2HJEG^^/I45:+8S>X4444 %%%% !1110 4444 %%%% !1110 4444
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MHHH **** "BBB@ HHHH **** "BBB@!#V^M+2'M]:6F 4444@"BBB@ HHHH
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M.?:EHH 3GVHY]J6B@!.?:CGVI:* $Y]J.?:EHH 3GVHY]J6B@!.?:CGVI:*
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MN_X7?I/_ $";W_OI/\:/^%WZ3_T";W_OI/\ &O$:*/8P#ZQ4/;O^%WZ3_P!
MF]_[Z3_&C_A=^D_] F]_[Z3_ !KQ&BCV, ^L5#V[_A=^D_\ 0)O?^^D_QH_X
M7?I/_0)O?^^D_P :\1HH]C /K%0]N_X7?I/_ $";W_OI/\:/^%WZ3_T";W_O
MI/\ &O$:*/8P#ZQ4/;O^%WZ3_P! F]_[Z3_&C_A=^D_] F]_[Z3_ !KQ&BCV
M, ^L5#V[_A=^D_\ 0)O?^^D_QH_X7?I/_0)O?^^D_P :\1HH]C /K%0]N_X7
M?I/_ $";W_OI/\:/^%WZ3_T";W_OI/\ &O$:*/8P#ZQ4/;O^%WZ3_P! F]_[
MZ3_&C_A=^D_] F]_[Z3_ !KQ&BCV, ^L5#V[_A=^D_\ 0)O?^^D_QH_X7?I/
M_0)O?^^D_P :\1HH]C /K%0]N_X7?I/_ $";W_OI/\:/^%WZ3_T";W_OI/\
M&O$:*/8P#ZQ4/;O^%WZ3_P! F]_[Z3_&C_A=^D_] F]_[Z3_ !KQ&BCV, ^L
M5#V[_A=^D_\ 0)O?^^D_QH_X7?I/_0)O?^^D_P :\1HH]C /K%0^A_#/Q0TK
MQ)JZZ:MM/:S2*3&9F7#D?PC'>NYKY"AFDMYHYHG*21L&1E."".AKZ4\">+(_
M%>@+,^%O8,1W* _Q=F'L<9_,=JQJT^75'10K.>DMSJ:***Q.D**** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH 0=_K2T@[_6EI@%%%%( HHHH **** "BBB@
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M=.:G&X4445!H%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MJ_?7ZTE*OWU^M %RBBBLS0KS_?'TJ*I9_OCZ5%6BV,WN%%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 ,3[S_6GTQ/O/]:?3$%%%%(84444
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MVUF"KP./4''KVKG].FM%^&G]E7T<S2-JT<LMN$;<T.\%B#TZ9[\=\5YA]IN
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MVL8C@A0(BCL!5BN*<N9W/3IP4(V"BBBH- HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** $'?ZTM(._P!:6F!YA>Z79'XZV1^SI\]K]H88X,@# -]>!^54_BBVF+XV
MT$ZP)#IX@?SO+SNQDXQCGKBO6Z*M3U3,72NFN[N>;^!+SP.-=>'PX+L7DL)#
M>=O(V @G[Q]A5WXE^-)?"^FPVMC@7]X#MD/2)!U;Z\\?C7=T4N9<UV5R/EY4
M['B$5MI.K?#K5M/T!KJ]U.-H[N[EEC(:8AN<=2<#)Q_4UK:1JL/BGX@:7J]G
M'*MGI>FXNI'4J$?#97/X_H:]9I  .@ SSQ5>T(5*UM3PJ7QMI7B/Q4+_ ,13
M3IIED^ZSLH8]P<Y^\_Z?R^O:?%G8WA"TE10/,OX6SCD_*W6O0J*3FKII;#5)
MV:;W,#7M4T?34TH:M:B<W%PD5MF%9-DAZ'GI]14_BO\ Y%'5_P#KSE_]!-;%
M%3<TMN>>^'? >F:CX9TR:]O-4GCEMHW:W>\;RN0#C:.WM5ZWM+<?%:91"FV'
M1U6-=O"C>!Q^'%=I13YV2J:5K'CJ7_\ 9MFJ^7;00?V]<@W\\'FK:<+C"]B<
MFGV,UO?ZOXI-Q+=ZK;W&F(WF0VZQ/.H."T:\ @'OWQWKUX@,,, 0>QI:?/Y$
M^R\SRG2-1FOM7@L=*U*'6D:QF1;F2S$<]C\N%!D [G _"LNVD@F\-V6@3:Q>
M?;5D2,Z7#I\?G1R*V<[B!T(SNSR*]I"JN=H R<G HVC=NP-W3.*.?R#V7F9O
MB#6[?P[H=UJEUDQPKPHZLQX _$D5PWA/7M&U?7X-3U358KG7+@&.VMHU;R[9
M3SM7(Y;'4UZ914II*Q<HMN]SEOB%A?"4LS*2D-Q;R.0,X42J2?RK.\.266J?
M$'7[^#RYXGM;5H9-O\)4GC/T%=U1T&!34K*P.%Y7/&-,U3^S](T .UM8Q-/>
M'^U)[;S?)/F'Y5[ GW_I3?/$VD^.'^T27'F_99%FDA$1E7*C<%   /;CFO:"
MH888 CW%+5>T\C/V3[_U:QG:_P#\BYJG_7I+_P"@&N*\*PQR>+M)=T5BGAF
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M&"&ZC)Y'2ASAK9H2P]?1N+^[U.QHHHJ"@HHHH 0]OK7R9JO_ "&+[_KXD_\
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MI#2?^@M>_P#?*?X4?\*0TG_H+7O_ 'RG^%'MH!]7J'B-%>W?\*0TG_H+7O\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 (._UI:0=_K2TP"BBBD 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH 0=_K2T@[_6EI@%%%%( HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "E7[Z_6DI5^^OUH N4445F:%>?[X^E15+/]
M\?2HJT6QF]PHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@!B
M?>?ZT^F)]Y_K3Z8@HHHI#"BBB@ HHHH *HZFQ\N)/-:-78AF7K@ G^E7JHZG
M:RW4,?DE=T;[L-T;VI2O;0$8MLC/<$22M%\V!E1]S!_7_&G6)>*;.^16\T*
M" "N<<C'6B8DSA;AH49)?,(;<N1CD?3BIK6VN;RZ%QM1$\W>6P>1G.!ZUG%/
MJ;*6CN=!1116IB%%%% !1110 4444 -C^X*=38_N"G4Q!1112&%%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 (>WUI:0]OK2TP"BBBD 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% "#O\ 6EI!
MW^M+3 ****0!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %*OWU^M)2K]]?K0!<H
MHHK,T*\_WQ]*BJ6?[X^E15HMC-[A1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% #$^\_UI],3[S_ %I],04444AA1110 4444 %5VO(DE9#N
M^7[S!20#Z5+-*L,+2-T49K/B4MYGF,P6-=TFQB,N>2./08H JZV8I_LK(P8;
MCRH!]*U3=P)\H;>P_A09/Z52ATBWF0S7$67D&=N3\O\ ]?WI8;+R?-MXW9'5
M=T;*Q /U'2@9HQ2K-$LBYP?6GU1LI3YA4C"R#S%'H>C#\_YU>H$%%%% !111
M0 4444 -C^X*=38_N"G4Q!1112&%%%!Z4 %%<EX%\8R>++:\-S:I;7%O(,(A
M)#(1PW/N#2Z!XQ;7/%>KZ4MO&EK8C]W.&.9,-M)],9!JG%JY"G%I/N=915&U
MUK2[VY:VM-1M)YU^]'',K,/P!K-UOQ78:=I-[/:WEG<7=O"\JVXF!+;<YX!S
MP0?RI68W))7.@HJG#J-LYMHI)XDNIXA(L.\;B,9.!UQ38]:TJ:]-E%J5H]T#
M@PK,I?\ +.:+,=T7J*Q=!UJ35[G5XI(4C%C>M;*5)^8  Y/OS535O$EXNNKH
M6B6<=UJ B\Z9YW*Q0)VSCDD^E/E=["YE:YTM%<[I&MZH^LR:/K6GI!<B+SHK
MBV):&1<X(R>5/L:U(M:TJ>]-E%J5H]T#@PK,I<?AG-)IH%),O45Q]QXQN(8;
MAQ:Q'RM:73 "QY4D#=]>:["AIH%)/8****104444 (>WUKYFU+QCXDCU2\1-
M=U!46=PJBX;  8^]?3)[?6ODS5?^0Q??]?$G_H1KHH).YR8IM)6-'_A-/$__
M $']1_\  AO\:/\ A-/$_P#T']1_\"&_QK"HK?E1R<TNYN_\)IXG_P"@_J/_
M ($-_C1_PFGB?_H/ZC_X$-_C6%11RH.:7<W?^$T\3_\ 0?U'_P "&_QH_P"$
MT\3_ /0?U'_P(;_&L*BCE0<TNYN_\)IXG_Z#^H_^!#?XT?\ ":>)_P#H/ZC_
M .!#?XUA44<J#FEW-W_A-/$__0?U'_P(;_&C_A-/$_\ T']1_P# AO\ &L*B
MCE0<TNYN_P#":>)_^@_J/_@0W^-'_":>)_\ H/ZC_P"!#?XUA44<J#FEW-W_
M (33Q/\ ]!_4?_ AO\:/^$T\3_\ 0?U'_P "&_QK"HHY4'-+N;O_  FGB?\
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M>_\ 'I>_]C<G\TKU6H3:6Q!!MX3E_,.4'+_WOK[U-4RE<N,>4****DL****
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 (._UI:0=_K2TP,=O#=FWBM/$1DG^V);_ &<)N'E[>><8SGGUINF^&;+2
M]>U+6();AKC4"#*KL"BX_N@ '\R:VJ*+LGE1C:3X:LM&U?5-3MY9VFU*023+
M(P*J02?EP 1]X]2:S/$/@#3O$NKQZG=7^I0SQH$C%M*JA ,\C*DYY]:ZRBGS
M.]Q.$6K6.53P%IA\/7.C75WJ%[;SRB7S+F8/)&P  *G Q^7<T:9X#T_3(-0
MO;^>ZOX3!+>32AI@F,84XP/R/05U5%',PY(]CA=/^%>E:9+&]KJ^MQJD@D\M
M;E0C$>H"<]*)OA9I<NI7-^-7UJ*XN7+R-%<(N23G'"=*[JBGSR[B]E#L8/\
MPBMM]HT>8WU^S:4A6/,H/F\ 9DX^8\=L5I:MID.LZ3<Z=<-(L-PA1VC(# 'T
MR"/TJY14W97*C)M_#]I;:M;ZDDDQF@LA9*I8;2@.<GC.[\<>U0GPIII\5?\
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M=:V,+,T5M$L*%SEB%  SCOQ5BBE=C22,_1M'M]#LGM;9Y7C>9YB92"<NV3T
MXYJAJ_A2#5]8BU0:EJ-E=10^0&M)%7*Y)YRI[FM^BB[O<7*K6.;MO!=A;B\D
M:\U">\NH#;M>SS!YD0]0AQA?RK8TW3+;2])@TVW4FW@C$:A^21[_ %JY10VV
M"BEL9F@Z';>'M-^P6<L[VZNSH)F!*9.=HP!Q6G110W<:5E9!1112&%%%% !1
M110 4J_?7ZTE*OWU^M %RBBBLS0KS_?'TJ*I9_OCZ5%6BV,WN%%%% !1110
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M!W0.1GUHHHK,U"BBB@ HHHH ;']P4ZFQ_<%.IB"BBBD,**** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH 0]OK7R9JO_(8OO\ KXD_]"-?69[?
M6LI_"WAZ1V=]!TMF8Y+&SC))_*M:<^0PK4G4M8^5:*^J/^$3\.?]"_I7_@''
M_A1_PB?AS_H7]*_\ X_\*T]NNQC]5?<^5Z*^J/\ A$_#G_0OZ5_X!Q_X4?\
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MYN3N=-.FH1L%%%%0:!1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@!!W^M+2#O\ 6EI@%%%%( HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH 0=_K2T@[_6EI@%%%%( HHHH
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M,@]#ZX.>^*-Q[#-%TY;6S@D>2664Q* THPP&.X]3WSS6I113)"BBB@ HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M_<%.H&%%%%(84444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 (._UI:0=_K2TP"BBBD 4444 %%%% !1110 4444 %%%% !1110
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M0 4444 %%%% !1110 4444 %%%% !117+_$/4;O2O!-]>6,[P7"&/;(G49<
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M E*"+,VT\Y<#H?:KI^(.AGPR^O1M,]M'*(I$"?O$8]B#4\C+]I'N=517#?\
M"U-"%L+F2"^CMVF$2R-#P<C.>N<8I%^*NAEY8FM=26Y3!2W-L=\@ZY ^G/-/
MDEV%[6'<[JBLGP[XBL/$^F?;K OY8<HRR+AE8=C6M4M6+335T%%%%(84444
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M^M0HCI>;$QF-MP![HW7\C0(T****8!1110 V/[@IU-C^X*=0(****0PHHHH
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M_P!IH!;61C/F-@YR5'.?\37KU%+V@_9+N>3ZWHVH/X \(VT.FW33V\\32Q)
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M7*['E; P6'8';^O>O6**/:,/8KY'A^J2:Q?_  YM/#<?A;5%N[&1?.?[,2N
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M:02-:K<#RR1]1G'7O71KHUBB*BQ,%48 \QL8].O3O]>:;J2Z(2H4WO)_<O\
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M4KM+8R#U&>U6Y_OCZ5%6BV(ZG+VOAI;3PY)H$6G0'3Y P*/<,Q^8YSG&>/\
M]6*HR>!K*708=';2T^R02F:(?:VWH3UPV.N>?3'%=M11[W=E<T/Y%^/^9Q6F
M^![32;QKJTT]1.\+0R.;QSO!^\3D=^WI[U./"4(\+MX=&GQC3F;<5-RV<[MP
M.<9X(Y'>NNHH][NPYH+["_'_ #.1UCPC;:[9VMO>Z5"5M4"0NER1(J@8V[L<
M],__ %^:CMO!=I9Z#=:-#I4"VMUM\\BY;?(5.?O8S]/3WKLJ*/>[L.:%[\B_
M'_,X.S^'6EV6H0WL.D1"2$AHU>Z=D5NS;<=N_J>15K7O!EIXCNUN[_2HA< 8
M,D-R49EZ8) Y/OZ<5V5%'O7O=AS4[6Y%^/\ F<H/"ELOATZ$-'M/L!Y*"=LE
MAU;.,Y/;T]ZH:=\/M/TN]MKRUTQ1<VS[XY'NW;GMD8Y Z8_*NZHH][NPYH?R
M+\?\SDAX2M=FJH^D0R1ZI+YUTCW+'+9)&..""2<BH-$\$6F@7WVVTTR-[@+L
M5YKIGVCOMR. 1P/3WKM**/>[L.:'\B_'_,\_;X:Z2URTO]DHJ,^\PB\<19['
M;CH.A'Y>E=U:^8(%$D*0XX6-&R% Z=A4U%&O5B;C;W8I>@4444$A1110 Q/O
M/]:?3$^\_P!:?3$%%%%(84444 1FWA,K2F&,R,NTMM&2/3-+%#%!&(X8TC0=
M%08 I]% !1110 4444 0RVZO!Y2G8N03@=LY(_&IJ** (YHO-CV[MI#!@<>A
MS3MJEP^!N QGVI30*8"T444@"BBB@!L?W!3J;']P4ZF(****0PHHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M^?1?^^F_QHY_(/9^;,+[;XR_Z%NR_P#!@/\ XFD^W>,O^A;LO_!@/_B:WO\
MA']*_P"?1?\ OIO\:/\ A']*_P"?1?\ OIO\:.?R#V?F8/VWQE_T+=G_ .#
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M_H6[+_P8#_XFNPHHY_(/9^;./^V^,O\ H6[+_P & _\ B:/MOC+_ *%NR_\
M!@/_ (FNPHHY_(/9^;./^V^,O^A;LO\ P8#_ .)H^V^,O^A;LO\ P8#_ .)K
ML**.?R#V?FSC_MOC+_H6[+_P8#_XFC[;XR_Z%NR_\& _^)KL**.?R#V?FSC_
M +;XR_Z%NR_\& _^)H^V^,O^A;LO_!@/_B:["BCG\@]GYLX_[;XR_P"A;LO_
M  8#_P")H^V^,O\ H6[+_P & _\ B:["BCG\@]GYLX_[;XR_Z%NR_P#!@/\
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M *%NR_\ !@/_ (FNPHHY_(/9^;./^V^,O^A;LO\ P8#_ .)H^V^,O^A;LO\
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MA;LO_!@/_B:/MOC+_H6[+_P8#_XFNPHHY_(/9^;./^V^,O\ H6[+_P & _\
MB:/MOC+_ *%NR_\ !@/_ (FNPHHY_(/9^;./^V^,O^A;LO\ P8#_ .)H^V^,
MO^A;LO\ P8#_ .)KL**.?R#V?FSC_MOC+_H6[+_P8#_XFC[;XR_Z%NR_\& _
M^)KL**.?R#V?FSC_ +;XR_Z%NR_\& _^)H^V^,O^A;LO_!@/_B:["BCG\@]G
MYLX_[;XR_P"A;LO_  8#_P")H^V^,O\ H6[+_P & _\ B:["BCG\@]GYLX_[
M;XR_Z%NR_P#!@/\ XFC[;XR_Z%NR_P#!@/\ XFNPHHY_(/9^;./^V^,O^A;L
MO_!@/_B:/MOC+_H6[+_P8#_XFNPHHY_(/9^;./\ MOC+_H6[+_P8#_XFC[;X
MR_Z%NR_\& _^)KL**.?R#V?FSC_MOC+_ *%NR_\ !@/_ (FC[;XR_P"A;LO_
M  8#_P")KL**.?R#V?FSC_MOC+_H6[+_ ,& _P#B:/MOC+_H6[+_ ,& _P#B
M:["BCG\@]GYLX_[;XR_Z%NR_\& _^)H^V^,O^A;LO_!@/_B:["BCG\@]GYLX
M_P"V^,O^A;LO_!@/_B:/MOC+_H6[+_P8#_XFNPHHY_(/9^;./^V^,O\ H6[+
M_P & _\ B:/MOC+_ *%NR_\ !@/_ (FNPHHY_(/9^;./^V^,O^A;LO\ P8#_
M .)H^V^,O^A;LO\ P8#_ .)KL**.?R#V?FSC_MOC+_H6[+_P8#_XFC[;XR_Z
M%NR_\& _^)KL**.?R#V?FSC_ +;XR_Z%NR_\& _^)H^V^,O^A;LO_!@/_B:[
M"BCG\@]GYLX_[;XR_P"A;LO_  8#_P")H^V^,O\ H6[+_P & _\ B:["BCG\
M@]GYLX_[;XR_Z%NR_P#!@/\ XFC[;XR_Z%NR_P#!@/\ XFNPHHY_(/9^;./^
MV^,O^A;LO_!@/_B:/MOC+_H6[+_P8#_XFNPHHY_(/9^;./\ MOC+_H6[+_P8
M#_XFC[;XR_Z%NR_\& _^)KL**.?R#V?FSC_MOC+_ *%NR_\ !@/_ (FC[;XR
M_P"A;LO_  8#_P")KL**.?R#V?FSC_MOC+_H6[+_ ,& _P#B:/MOC+_H6[+_
M ,& _P#B:["BCG\@]GYLX_[;XR_Z%NR_\& _^)H^V^,O^A;LO_!@/_B:["BC
MG\@]GYLX_P"V^,O^A;LO_!@/_B:/MOC+_H6[+_P8#_XFNPHHY_(/9^;./^V^
M,O\ H6[+_P & _\ B:/MOC+_ *%NR_\ !@/_ (FNPHHY_(/9^;./^V^,O^A;
MLO\ P8#_ .)H^V^,O^A;LO\ P8#_ .)KL**.?R#V?FSC_MOC+_H6[+_P8#_X
MFC[;XR_Z%NR_\& _^)KL**.?R#V?FSC_ +;XR_Z%NR_\& _^)H^V^,O^A;LO
M_!@/_B:["BCG\@]GYLX_[;XR_P"A;LO_  8#_P")H^V^,O\ H6[+_P & _\
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M_P & _\ B:["BCG\@]GYLX_[;XR_Z%NR_P#!@/\ XFC[;XR_Z%NR_P#!@/\
MXFNPHHY_(/9^;./^V^,O^A;LO_!@/_B:/MOC+_H6[+_P8#_XFNPHHY_(/9^;
M./\ MOC+_H6[+_P8#_XFC[;XR_Z%NR_\& _^)KL**.?R#V?FSC_MOC+_ *%N
MR_\ !@/_ (FC[;XR_P"A;LO_  8#_P")KL**.?R#V?FSC_MOC+_H6[+_ ,&
M_P#B:/MOC+_H6[+_ ,& _P#B:["BCG\@]GYLX_[;XR_Z%NR_\& _^)H%]XR!
M!_X1NRX_ZB _^)KL**.?R#V?FR*W:5[:-IXQ',5!=%;<%/<9[T5+14&AG:5_
MK=1_Z^V_]!6M&L[2O];J/_7VW_H*UHT 9FM,1;Q*"1N?'!QG@US8B/E$;F,B
M89CG@C_Z]=C<V\-U'Y<H!YR/4&N?ATWS-6EM';]S& V0.3Z"E;6XT[,V-'<R
M:;&VXGE@"3VR:O5'!%%!$(H@%1>PJ2F(**** &AT,AC#J7 R5SR!3JXK6+^X
MTS6?$-[:;?/BL+8IN&1G>XHEN_$Z:K>:8=3M-T-H+P3"U]2PV 9Z97KUH [6
MBN+76=<U6ZM8K&YM[02Z3'?.S0[\.?X1ST.?TING:]K1GT:>\GMWAU:"5UAC
MBV^25CW@YSDY[T =M17)VFOWTVD>&[AWC\S4'Q/\O7Y&/'IR!572]9UZ2WTC
M4KNZMGMKZY^SM;K#@J/F ;=GK\O3IS0!VU5VOK1)#&]U L@."ID /Y5RG]M:
MU_9O_"0?:+;[#]H\O[%Y//E^9Y>=^<[N^.E4!;+<:MKZ_P#"+C57-ZRB<M&H
M7]VGRY8@^_'K0!Z!YB>8(]Z[R-P7/)'KBG5YU9Z5K-EKFBZ>E]'#>QZ7*))F
M3S0B^:"% )&<?*N3V%:$OB/4)-%TUC>P6MU.\L<K1VS32.8V9?DC'J1R3TH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110!'/;PW,?ESQ+(GHPS5+^P=+_Y\HORHHH /[!TO_GRB_*C^P=+_ .?*
M+\J** #^P=+_ .?*+\J/[!TO_GRB_*BB@ _L'2_^?*+\J/[!TO\ Y\HORHHH
M /[!TO\ Y\HORH_L'2_^?*+\J** #^P=+_Y\HORH_L'2_P#GRB_*BB@ _L'2
M_P#GRB_*C^P=+_Y\HORHHH /[!TO_GRB_*C^P=+_ .?*+\J** #^P=+_ .?*
M+\J/[!TO_GRB_*BB@ _L'2_^?*+\J/[!TO\ Y\HORHHH /[!TO\ Y\HORH_L
M'2_^?*+\J** #^P=+_Y\HORI!H6E_P#/E%^5%% A?[!TO_GRB_*C^P=+_P"?
M*+\J**!A_8.E_P#/E%^5']@Z7_SY1?E110 ?V#I?_/E%^5']@Z7_ ,^47Y44
M4 ']@Z7_ ,^47Y4?V#I?_/E%^5%% !_8.E_\^47Y4AT+2\?\>47Y444 P&A:
M7_SY1?E2_P!@Z7_SY1?E110"#^P=+_Y\HORH_L'2_P#GRB_*BB@ _L'2_P#G
MRB_*C^P=+_Y\HORHHH NPV\-M'Y<$21IZ*,5)110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
:1110 4444 %%%% !1110 4444 %%%% '_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>g0fyk5pshdve000017.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g0fyk5pshdve000017.jpg
M_]C_X  02D9)1@ ! 0$!+ $L  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1"  " 7\# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#^2;]L']L'
M]K;P]^UK^U'H&@?M1_M%Z'H6A_M%_&W1]%T71_C;\2],TG1])TSXE^)K+3=+
MTO3;+Q-!9Z?IVGV<$-I965I##;6EM#%!!%'%&B#YT_X;9_;,_P"CM_VG/_#]
M?%3_ .:NBB@ _P"&V?VS/^CM_P!IS_P_7Q4_^:NC_AMG]LS_ *.W_:<_\/U\
M5/\ YJZ** #_ (;9_;,_Z.W_ &G/_#]?%3_YJZ/^&V?VS/\ H[?]IS_P_7Q4
M_P#FKHHH /\ AMG]LS_H[?\ :<_\/U\5/_FKH_X;9_;,_P"CM_VG/_#]?%3_
M .:NBB@ _P"&V?VS/^CM_P!IS_P_7Q4_^:NC_AMG]LS_ *.W_:<_\/U\5/\
MYJZ** #_ (;9_;,_Z.W_ &G/_#]?%3_YJZ/^&V?VS/\ H[?]IS_P_7Q4_P#F
MKHHH /\ AMG]LS_H[?\ :<_\/U\5/_FKH_X;9_;,_P"CM_VG/_#]?%3_ .:N
MBB@ _P"&V?VS/^CM_P!IS_P_7Q4_^:NC_AMG]LS_ *.W_:<_\/U\5/\ YJZ*
M* #_ (;9_;,_Z.W_ &G/_#]?%3_YJZ/^&V?VS/\ H[?]IS_P_7Q4_P#FKHHH
M /\ AMG]LS_H[?\ :<_\/U\5/_FKH_X;9_;,_P"CM_VG/_#]?%3_ .:NBB@
M_P"&V?VS/^CM_P!IS_P_7Q4_^:NC_AMG]LS_ *.W_:<_\/U\5/\ YJZ** #_
M (;9_;,_Z.W_ &G/_#]?%3_YJZ/^&V?VS/\ H[?]IS_P_7Q4_P#FKHHH /\
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M &G/_#]?%3_YJZ/^&V?VS/\ H[?]IS_P_7Q4_P#FKHHH /\ AMG]LS_H[?\
M:<_\/U\5/_FKH_X;9_;,_P"CM_VG/_#]?%3_ .:NBB@ _P"&V?VS/^CM_P!I
MS_P_7Q4_^:NC_AMG]LS_ *.W_:<_\/U\5/\ YJZ** #_ (;9_;,_Z.W_ &G/
A_#]?%3_YJZ/^&V?VS/\ H[?]IS_P_7Q4_P#FKHHH __9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>g0fyk5pshdve000002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g0fyk5pshdve000002.jpg
M_]C_X  02D9)1@ ! 0$!+ $L  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" *" K # 2(  A$! Q$!_\0
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MH/RHP/0?E2T4 )@>@_*C ]!^5+10 F!Z#\J,#T'Y4M% "8'H/RHP/0?E2T4
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MFG[R_C_*@!1T'T'\J6D'0?0?RI: "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH ***#T- !12 DCD<TM !128^8MZ]OR_P *Y_Q!XIT/PQ;FZUF^
MBM(PK-\[*&(49Z$CKVIQC*348IR;V23;^X&[*[T2W;T1T!(4$L0 .22< ?4G
M@5YEX]^*WA;P#8O=:G>PR2!21!%*A;@9&0"3SZ<?4'I\??%[]KJ*S-UI/A<"
M:-]\?VF(Y(X(!W#GJ,CWK\_O$?C#Q'XLO)KK4]1GEBF8L(7=MH!)XP21T./\
MXKW,'DM6K:>(_=4]';[4EIIIJG:_W::GFXC,(4[QI>_+77[*?3U/I_XL_M5Z
M]XFFN+/PS-)!I[ET(5RORDXX (&<?EU[8KY%O+R]U.>2[OKB:6:4DN'D9ADG
M)X)/?-5D2-,A% /?'X?AZ4\G )/05]-1H4</%0HP4+=4O>?J^OKUT/%JUJE:
M7-.3DUM=:):7MTV# &2!CU_S^%1!I&.V)3,Y( 1.3SV QUY_*M;0=*O/$NHP
MZ9IL,LLLKB-L1DCYN.P.,=_;/M7Z)?"3]E32+1+/6?$TBBY?RY%MI,?,>#@J
MW7G^=1B<50PD8RJS]Z7PTUK*7RO?;^NI=##U:[:A&R3LY/;[^_D?''P^^"OB
M[XASQQV=I/:HQ WNC!3DYSTQ77_$/]FGQCX$LTO'CDO%V[F$(+].O0=O;_\
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M>>6*1#O7RW*?,![8KZ6^%_[2OBKP;/;VNIW,LVEQE%*N[-\@QG@G'X^G%?-
M.1D4L@60 ,H(';MV_P *Z:M"E5CR58JI'2W-'7I=Q;V?GU,:=2I3:E3E)-/I
M?RW[W/V_^''QV\(^/X8Q!=16MR4&Y)9%4,^!G&3W/X5[<CQRH&C=9$;HR,&4
M_1E)'ZU_/#I>M:SH5Q'<:5?36OE,'VQNRYV\]B.W'ZU]L?"+]K?4-,^RZ-XA
M!EM\I&US+R1T4G<_?CZX]:^<QF1R@O:85N:W<&]8I6Z[_AZ'K8?,E)QA65I/
M126S[:?F?J2!C@45POA#XB>&/&=M%+H^HPS2N@9H0ZEE..0,'G)SC\J[JOGY
M1E"3C.+C)/5233/5C)25XM27=.Z_ ***0$'IS4C%HI@SO)QQC_"GDXZT %%(
M"#T/\Z6@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *:?O+^/\J=
M33]Y?Q_E0 HZ#Z#^5+2#H/H/Y4M !1110 4444 %%%% !1110 4444 %%%%
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M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ II^\OX_RIU-/WE_'^5
M"CH/H/Y4M(.@^@_E2T %%%% !1110 4444 %%%% !1110 4U01G)S^9IU-5=
MN><Y]J '44F1G'>EH :7 ..:<:HZCJ5GI5K)>7\Z6]O$"6=R!P.N,D9QW_\
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MG_P#J***0[LC X[_ .<URFXM%%% !1110 4444 %%%% !1110 4444 %%%%
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MW:/O_3/TAHHHKYL]8**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M_BC^:/V5'0?04M(.@^@_E2U^?GU 4444 %%%% !1110 4444 %%%% !1110
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MW_D=_$'_ %_3?^AM7Z\ZO^T[\%#I&I-_PFFD2#[%<J4-W;#<7A90/]<>I/&
M3Z5^&OCGX\?"R7QGKTT>OZ88WO9F5A=PX(+L1SNKZ/('&^(4G:ZA;6U]?O\
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MC:N[J<UHPS17$4<T$BRPRJ'CD0[D=3T92."#V-?@C_P7/^.?C;X*^"O@K?\
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MOPFUOQ-X*MY]4UR"SGFM[.U5GD9EB+* J9;DX& #]*]>\<>#KWPCK,T+Q2"
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MFTK2[J87,^GV4UP.5N)+:%IA_P!M2GF<?[U7U544*H"JHP .@'H* ;,O7/\
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MTL4J,&5U<H3D$ ]:-7^"7PSUV]T?4-5\+V-W=:"D4>ER2(I^RI#@1J@*G 7
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M _'/P\U3PE?21O"[VNXD, 2, YXZ_P"1P:_3IY$C&7=$'J[!1^I%>8^-=/\
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MT/\ DGB?[TE?DA:?\>\?TK[+)/\ </\ N-,^?S+_ 'C_ +=C^2+$?_'Y:?\
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M??V[G]&/Q9_X.DO'_P 0&N#X;TF?1D?<D0B1XE5><8"X  [# Z=:_-3XH_\
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MRT_ZZK_6OV6_9B_Y$Y/^N2?^R5^-,?\ Q^6G_75?ZU^RW[,7_(G)_P!<D_\
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MN+:W@0O(XVR,^% )./*&?\F@:W7JCXH_X(G?LI_#+XA_ /3/VD_B%X:L]?\
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MVGL9H9V5IVAE'S(6((W^W0\YH&E>Z>B<4_NM^=O\S]Y_^"P_[=?B/]C3X2>
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M>>7QZ=J_>_XK?M3Z=^R)^Q!\//&0CCO=>M_ OAVRTW33AI'F;35W,$P22K8
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M:6CO?KVO_7_!/Z8!T'T'\J6D'0?0?RI:" HHHH **** "BBB@ HHHH ****
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M?0?RI:!!1110 4444 %%%% !1110 4444 %&/;]*** /C7]M#CX=+Z;W_/\
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M,KQ( ">Y&,\>F1C'\_I\'G-*MR0Q"4*FRFE:+V6KWN^WZGC8G+I0O.D^:/\
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MS%*@=?+D5B,C)! .>*^4Q&%K867+5@UVE]E^C/<I5Z=:*E"5[J]NJ]4:F:*
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M)E;:RE2OS#DCM_GWJ0 8.>,#BOU%^,G[)^GZ['/J'A*(6UQAIFC55!+ ,2,
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M]3&A/^GMGJ:UN$W,S +U)/ '7J2< "L2\N8M)%UJ5XP2WAC9]Q. < G@GO\
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M984444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M (]O\]E^UO\ W4_*OL>:7<^;4%K=O?2W1?\ #'\YW_#J*_\ [K?E1_PZBO\
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MFG4W' #<_G3J "BBFD$D$'CC(Y]: '4444 %%-#9)&.F?YTZ@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ II^\OX_P J=33]Y?Q_E0 H
MZ#Z#^5+2#H/H/Y4M !1110 4444 %%%% !1110 444$X!/I0 44U<D[NQ[9/
M^>U.H **** "BBB@ HHHH **** "BBB@ I#G''6EHH :3M4L_  );T &2?TK
M\S/VR_%>E7-Y;6%HD;S1A4D<!=VX *<X]".G?WK]+[@%H)U7JT,BCZE& _6O
MQI_:@T74[#Q9<37<4GE2S,R,V[!7<2,>O&?2O8R2$)XM.4FI1C>*CM)NR?\
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MY?A_79?<'MGV_K3_ (/];?Y+?_#M7_@I%_T,7CW_ +ZU'_&C_AVK_P %(O\
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M)_X2*U[D_P#+RG3@X_\ KU_1E\*1%-\%O!*W<_DP/X-TT3SNVT)$+0;F+$C
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MF,N,>QIEQHFCW=PEW=:3IMS=18\JYGL;:6>/'3RY9(FD3';:PQ6G10%QI48
MQ@#& .,8X 'M3J** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M;@2#R,Y'&?T%>QA\]JPY57@JB76.DKZ:ON<%3*Z;NZ<G%MZ)MN*76WZ:>1^
M.9%_UL,D/./W@VG/7OBE,H8@9!],>_X^U?K!XZ_9!\/^)&DDTVXBL2<LJ ,G
M/.!D+M_'^E?%_P 0OV<-7\#M*+7-WY.>0V[(4G/3./3WP<=:]O#YIA<0THRM
M.2NXS7PZ:>\_/]-CSJF"KTKMPO%?:6J/F\J#U /X4W:R_P"JD>'WC^7T],>E
M6;BUN;.1H;J,Q2JQ!4\=/ZU#7<G_ )HY.O;O_P $Z#0?%WB'PW.EQ9:A=,R'
M(4RN5X]L_G_^NOI/P9^UKXWTEXK74G9[92H+,Q)*YQU)]LX_R/DS/;O3'&[
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MZ&[)\S24=?QUOZ?>19[6UZ+>]S-#  ;F /U%*'FZ1VTLP8X^12W4<= :^LO
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M4$$$'HV.U>)7H5<-4=*K'EDOG=='Z/S1Z5*K"M!3@[I_@^J^6Q\Q_M/^ _\
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MO!'B^QN(7,8NKI$<@D##2+^'?U&.V2*_<;P]J<>KZ+IVH1L'^T6D,C8.?F*
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MCS<5@%5]^E:$]VNDO\FS\(%8,,@@_P!*01EU.X 8Y!XR"![5]%_%O]GCQ'X
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ME]WT6KTM9:)_YGS:3T2W;TO=J[\C[=_8\^'3S:RWB2[@+6S .C,N5R1G )!
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M@_ADM.FU]#&M0IUX\LUVM):27S/YWM5TG4]"O)+'4K2:!HY&3?*A7.WCN/\
M]?X'%('(R.17[,_&3]GSPUX\TV\N[>VALKZ&"6=3&FW>Z(6/(]AG!/TK\?\
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M%]FM)U967=Q5N9-?C_5RLNHJI6<G9QIJ]NMW:W3^O(]IHHIJKMSSG/M7QI]
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MG[/#P2^U[^UOBL)GDCN*  .@I::I)SD8_ UYIUCJ*** "BBB@ HHHH ****
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MU?DJ^S>U39MV2:V5O,_0"D#9Z9I:*^1/?"BBB@ HHHH **** "BBB@ HHHH
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M4#Q'XF2V63=]BD\O )P A*\C/T[<>G:OUE\2ZA%IFAZG=RN$"6=QM)./F,3
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M)2]E0A'JUS2_Q-*_Y!1117"=(4444 %?+W[3WBT:+X-O--$@1KV%@1G!(9"
M/S.>?3Z5]09&,]O6OS&_;;\3DZC8:?9R!E4(D@![X ;@9]"*[\LI>VQE&-M%
M+F?ERZKRW.7&U/9X>;UUM'3=WT^7J? <0(DN2<Y>>1N3GJQ/K_A1</LCS_M*
M#^)J5>GUY/U-2VUD^I745D@RTLD8  .?O"OO%:W,]%'=OY6]++^NWS*6R7DE
M^1^E7['/@\6ML?$'E8\U/OX[L"?\\\5^@5>$_L[Z$-"^'&EPM'ME=59R0-V
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MQ7G_ ,(_V<?#'P]6'498(Y]1PKL'0$(V.<D@<YZ=\5]-*%50J@*H "@#  [
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MAU&QN.A@G23/^ZP/7VQ7[5?LZ^*U\2^#+8+)O%E#''USC@#!_*OQ.F.(V;N
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MC^)3_C_D5[V)I+$8>I1DKIQ;2[RTM^/Z[;GET:CI583O:THW]+JZ^X_H,!!
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M<'+X/'O7G#R_+F/]X?[J8)..V.M>\? +X8:[XS\86-\+2>/3H98S(SQL%PK
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MYT;AZC\Z %HI-P]1^=&X>H_.@!:*3</4?G1N'J/SH AN4,EO.B_>>*11]2A
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G* # ]!^5&!Z#\J** # ]!^5&!Z#\J** # ]!^5& .@'Y444 ?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>g0fyk5pshdve000003.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g0fyk5pshdve000003.jpg
M_]C_X  02D9)1@ ! 0$!+ $L  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" +9!80# 2(  A$! Q$!_\0
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MZ#^5+0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MDE>21 &120!D<D@8_P ]*^G]*^#'P\U2Z6WCU^+YFVC,J<CMWX_SBOK;X=?
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 U?XO]XT4+_%_O&B@!1T'T'\J6D'0?
M0?RI: "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M;O+CW45YSA)2Y'%J5[6>]V>$Z52-3V4X2A4YE'EDG%IMV2:>VIPOQ"^*&A>
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MZ#Z#^5+2#H/H/Y4M !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MP0#R/:OYF_"7C;]L3_@K=^T-I/AZW\::YIVA:WK%K+>V)O+B.V$4UPID1@9
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M),/&Q5AQTY!KZ'K^:?\ X(C7VK7/C7XY3ZA?S7:6FLZO.BR,QVI%-(W )/3
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M5^$7QH\*_"XV\+GQ#>PVH=D1F'F.J<$@_P![M0"3;L?H]17Y/?M6?\%&]/\
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M HZ#Z#^5+2#H/H/Y4!=O3/- "T4F3N(QQZX/M28)!##'3I_DT .HI ,#%+0
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M#*KA9<'&0#_">N?R(K\Z_CA^W#KWB,WFA^&2T.GN9(X[B' .,E=P9<<X[_\
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MVBVFOZ9<Z9>QB2&=&7!&>2I Z_6OS&^+GP)UWPQJMUJ.F6\EQ8RM))''$K$
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M_P#@O)_P41F<L?$FJ#)SA;JX50?8=J@'_!>'_@HD.#XGU8D],W=Q7]FVB?\
M!OY^Q;XPTFP\1^'+JSOM&U6WCNK*YLXX[F"2*10PVRQEE)&<,.H(YK4_XAU_
MV2?[J?7[)0<KG'I!;]>VGKY]O\OXM_\ A_#_ ,%$O^AFU;_P+N*/^'\/_!1+
M_H9M6_\  NXK^TC_ (AU_P!DGT7_ ,!/_K4?\0Z_[)/HO_@)_P#6H'SQ_D7]
M?/U_IZ?Q;_\ #^'_ (*)?]#-JW_@7<4?\/X?^"B7_0S:M_X%W%?VD?\ $.O^
MR3Z+_P" G_UJ/^(=?]DGT7_P$_\ K4!SQ_D7]?/U_IZ?Q;_\/X?^"B7_ $,V
MK?\ @7<4?\/X?^"B7_0S:M_X%W%?VD?\0Z_[)/HO_@)_]:C_ (AU_P!DGT7_
M ,!/_K4!SQ_D7]?/U_IZ?Q;_ /#^'_@HE_T,VK?^!=Q1_P /X?\ @HE_T,VK
M?^!=Q7]I'_$.O^R3Z+_X"?\ UJ/^(=?]DGT7_P !/_K4!SQ_D7]?/U_IZ?Q;
M_P##^'_@HE_T,VK?^!=Q1_P_A_X*)?\ 0S:M_P"!=Q7]I'_$.O\ LD^B_P#@
M)_\ 6H_XAU_V2?1?_ 3_ .M0'/'^1?U\_7^GI_%O_P /X?\ @HE_T,VK?^!=
MQ1_P_A_X*)?]#-JW_@7<5_:1_P 0Z_[)/HO_ ("?_6H_XAU_V2?1?_ 3_P"M
M0'/'^1?U\_7^GI_(#\!/^"X__!0/Q7\;?"'AK6/$NJ/I6H7]I#=1M=W!5D>9
M5;()Q]TG_P#5T_T??V2/&VO_ ! ^"7A+Q-XDD:75K_3[66Y=R2QD>W1VR3SU
M-?DYX0_X-]?V4_!WBO3/%FG!!?:9-%-#_HF/FB8,#TZY&?\ /'[@?#GP'I?P
MU\*:;X4TC L--AC@API7Y8XUC7CMPHH(DXO5*STTZ?([RDSR1W%&>,CTXH!)
M'(YH)%HHHH ^7_VH_ GQ9\>^ [[2/A)KAT+Q!/;RQP78G\C:[K@'?D8_SS7\
M<_[0W[)?[=VA?%V#2O$OCZZN]<N-686=RUY(Q5GE!C^;)]5Y_P :_NXKY7^)
M'[+/A7XD^,+7QCJU[*M_:7*7,8 ) 9&5@!V'W<>U T[7VU\CX\_X)^? 7]J[
MX8>'-$;XU^-)==LY+&TFMX);MI6BAD1712C'(RA!&1T(/3K^BGQU('P<^)9/
M '@W7"3Z8LI#7I.F60TW3K'3U=I%LK6"U1V^\R01K&F?HJ@#V%<W\0]!;Q3X
M&\6>'$^]K>A:AIJ_6Z@>(?\ H5 7U3]/P]$?SH?\$19HG\4?M B-U;%]KX.#
MG&&G/]*\J_X)W?#GP7JO_!5WX[:Q?6T=YJ5HWB&ZACF E19H8[J5#M<$#:Z@
M]/;K7ZK?\$_OV*K_ /9EU?XE7UXK*/%MSJ4L>X$?\?9?IZ_?/3UK-_9;_8@U
M'X-_M@?$CXY3JWV7Q6FK!"1@$WL<Z#G_ +:?YXH*YM7:ZT27X?\ !/QR_;V^
M&_@CQ'_P6N^!VEZI;QQ6<T_AZ>6S@"QPR2RQ6CN6B0!#EV)Y'7M7U7_P7A\,
M>';,_LQVMO:P:>ECXBLHK4VR) ^RWU!8XE9XPI;:J@<]Q^7UW\??V!]1^)G[
M?OP]_::B1OLOA=M++$ X_P!"2!3D]/\ EF:]4_X*,_L=WW[54_PLDLU9O^$.
MU:.\?:"<!;SS^<?Y_H#3NXZ[+KT_K^NI^?O_  43TK3?&'[*?P:T;Q!(TFGQ
MZ-HBH-Y!($$>,GOGC_.:^CM3^&'@.'_@E5>Z4NF6GV*+PE*R7'DQ^>'\G Q)
MMW9QSG.:]X_:(_8ZO/BI\)? _@J)6\SP[8V%NP ).;:-4[?0?Y->RWO[/-Q<
M?LB77P.P?M$NBO8@8.=QC"]/_K4$+=>J/S#_ ."%/PO\"V'[-_Q4:WL8+UKG
M7+BTE>ZC6X*030ZD9 ID#$<HN!Z5\;?\$S&*?M>?MJ:-93/);0GQ$D%FCGRT
MQ). $B'RKQQ@ 5^YW_!/G]EJ[_9@^%7B[P==A@^MZH]XNX$'!CNT_P#:X]*\
M"_8P_8)N_@1^TK\:_BEJ,;-8?$6;4Y0'4[6%W(Y R>.C=LT%-IN72Z5ON3_R
M/E;_ ()V:WX>TO\ :)\<Z?J^KP6-_P#VYJ!^S3RJL@43N<[6(/;TXKSW]O+Q
M)X0UO]N?X56FA^(;/4[VWUVS$UM;3J[QL)XR595/&#QC_)]2_:+_ ."?OQ3\
M!_M!3_%WX(S7SV^M732W=M:"0HGVDY<D)P"NXYXX([XK-\#_ /!*GQFWQM\(
M_M!^*M9OM0UO[?!?W]A<O(XMF\U'90K$XQS^E [I<KWTL_)JS/,_VVO!GAKQ
M_P#M@_"71?%2^=916NCR)#DX+A(R,KWYZCOBOM[_ (*)> ?!EA^S5X7M+?3[
M6WCT72[06$L4,<<J&."/:?,50V>_!SW[9KT_XR_L67WC_P"/?A#XEQJWE:'!
M9(V%) ,&W(R.WR_E[U] ?M1?L]7'QB^%UGX.A4^9;VL,. #_  QA3V)'0?YQ
M03=V6NVOI_G_ ,&Q_/A^V9KNNV__  2V\(G3Y[J1!K]G#/+%*X9+;S0K;F4Y
MVA<YSQ[8K]N_V!K3X26_["/PPADO=">PU+P$+CQ/-<&V>5+R5)DE%P7!8O&B
MQLF>['GKBGI_[!?A[QQ^R[-\!O&Z*+<&5[9W3.R?RV,3<Y(PY'/;K]/S+A_8
M_P#VJ/A-:ZK\$?!$^KS^ +UGL;:\C\\QVEFY*;8V' 4(<C!% W9]=$UIMIHK
MKO\ HCS+]EJV;1_V\_C;9_#VXDN_AX^BZZ\D]H[-8JWDSYP$_=CDG&/I6[_P
M18^'G@OQ!^UY^UOXLU"VBU#6M(U[4'L6F"S+&S:M#$QVN&4821N,<^V:_6;]
MC#]@S1OV=O /B:?5)/[4\:^+](OX;R^G&^YC>[MI5 +ME@=[X"YSW/;/%_\
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M9JO/@#''!J45_IEQ;S:G-'NE2ZGA*JRR,-WRR$Y.2#G.3@&OR)\'_L ?M ?
M;QGXN\$>!=1U27P3XVNKHSWD33%+2.X+X*.#@! ^1CT[B@=]&KZ:=-]ONM8^
M</V$M+\$:1_P5G_:+T[X=W=K>Z*5UDQ/9,K1%B\G V?+^1Z5],?!+5M%T?\
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MYVD_NUSTH'RZVNOO/Z"6!.,''YBG5^-?_!/G_@H;XI_:17QWX)\>V<-G\1/
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MQ1TG4M,U.WEL[NSNX;26":&X1HI$;=='9E7(#K\R]0<U_!S_ ,%J_ _['_\
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M@1F\N255D8@$[0I/4X[_ /UJ^/\ XU?MD^$O!5I<6GAF\BOM4C#@[2K$.!T
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MQT!_SZ]*])WW=^]WV]3W/6R25VWI9=WV2_K8^F?V5;BZ_P"$UN;;<_DM&R@
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M_!/PA\5^*]0M<6DHM/-4N6C/W,KG/'MS7ZA?#GP)8^!=$@L[9 LTD*>?P/\
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M3!ML=-A6"W7& J*   !TZ4%<SLOGOVTT-Q"MI9H9W"I;6Z^;(QX58HQO8GT
M4DFOY%?^"OOQ+\9_%?\ :[^&O@WX274VJV.FW.G6FJ16$CR1K) \4<GFI'N7
M[R$G/O7]<.L61U+2=2T\,4-[8W5J'&<J9X7C!&.X+<5^=GPI_P"">?@;P?\
M%35/BEXB:/7=4NK][RW6[7SFB8RF0;2X;: 3VP/K0).SN_EZGX%?MP?!/]H3
MXF_!_P (Z;JEEJ#Z+\/[.UU@QI'*JQ"RB69V; X"!#D_CD=:^X/V7/VFM/\
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ML_\ H#^,/^_E_7^L7_PA7A#_ *%C0O\ P5V?_P :H_X0KPA_T+&A?^"NS_\
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MIEBUFX\.1Z]<:H92K/+<VAN=@G+?,3NY&?Y''S#_ ,$XOAMXC7]G+]I'X.>
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MAOQ+:PW&G:G:R/*H/D^:OF GMC-=?FOP"\*?$?Q1X+NH[NSU&ZF6-E(C+MM
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M=N@"#=SGT&?>O3/HE?\ &_I_7<]\_9KU*ZM?'\42.QC+J/+!..W;I],]*_6
M-E 2/O 9'INQ_+-?G5^R_P##N_;68_$]Q Z6NY6!="/3'4<=?TK]%O4=L8_G
M_P#6KX_.JE.>,_=M24814FNLNJ].SZW/S#BVO2K9FE3<6Z=&,)N/\RW3\UK]
MX# Z=/SI:0#' I:\<^6&X.[.>/3GT]/K3J** "@]#110 @R!SR:6BB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M_P""FVC_  2\8R^#O!W@BX^(M[;[Q.VEBXGV%!\PQ;N._J!7VW^U/K=YX<^
M'Q0UJP:1+S3_  S>SV[19\P2*!M*XP<_2OY$/V-?$/[4OC7XA>-?&GA;PW:>
M+S_:]];Q0:S"MS*J&5D^5)<M@ ^GO0.*3U>K[=.GXZ[']+'[('_!0+PW^TU=
M7VC:SH!\!>(;56,6E:BTL,TS(P!0)<.S9(SMP.3@9K\8/#NF1+_P7HU#4=\V
MS[<\N_S7\KRO.SOVY*[2#G_ZW-7_ (/_ +,?[;6H_M:^&/B9XBT./PIX5CU!
M;C5K#3HOLT+1&16962/"XP>G^0:9*L'_  66\1G.;[3/#4XF(/S_ &J&([B
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M!=VVJAFCN+9UEB()!5A@CGZC/XY%>\:AX^\8ZS8Q:;J>I32VL$8BC0ROPB@
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M "BBB@ HHHH **** "BBB@ HHHH **** "C-%(%P2>>: %HHHH **0$'I2T
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M(_8;^ 6I_"K]CW3_ (->(T+7<ECX@LKA95))75+-+8 AAR/EXXZ^]?@5H/\
MP2 ^+/@+]NQ?'.A7UW'\+M;UY-1U?35>7[+*KW32R;HO]6<CU'2OZ\45$4+&
MJHO944*OY  ?I2&&%G$C11F0=',:EQ]&(W#\Z!-MW\S\]_VV?V0F^.OP2MO
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MP7!(;RF$F[?VVX.3UK]S[33K"P!6RLK2T4]1;6\4 /X1HM6/)BW^;Y4?F?\
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M%U)MW8VI*C'H#VSUX]??]E5BB0DI%&A/4JBJ3]2 *#%$QRT4;$="44G\R,T
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M'P2)WB>WB2&5U8IN"C&,CK_,]CZ-!(Y'M^61FO+?B/X*_P"$DLMULH-PHX(
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M !KXQ_2<S3Q7R/#\.1X>H9%E\:BK8E4Z[KSKR2C[MV[P5];I+7?R@N$$-S-
M#N6-F4-_> .,@_YQ_*.G,6)RW+'J3R3R>IIAW=AG_/UK]):>CNM5JEWTU\O3
MS/Y>Z>73^ON#CKQ]?_KU&85=U;+!@1@JQ'?/;WJ0C(Q2]!]*5VM@OW.Y\-_$
MKQIX191I>J316Z$'8)7QM!Z8!QT[9[5]Y? K]J5-6N+;0/$<FZYF81B:1N=Q
M.W=N)!QG/^<FOS3!!Z<BKFD7$VGZQ97ULYBDAD4C9\I/S#'3FN3$X&ABH24J
M:4FM)Q5GS:6N]^G?7:QU4,35HS34GRNR:>JMY)_G_P $_H?MYXKF%)X7$D<J
MAU8'(PP!%35XO\"-;NM=\"6-W=NSR*L<>6))X0Y_^M[5[17PU6FZ52=.6K@[
M,^DA+GA&2VE%/[U<****S*"BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ Z=!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MG%2ISE63VE3]Z+VZK;O_ )GR>(R/-,)5>'QN$JX/$0?OT,1&5*K!NV\6KO\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% #5_B_WC10O\7^\:* %'0?0?RI:0=!]!_*EH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MU%?E9I&I2Z'JUMK-N[*]G(CC!(^ZP(_' K]K/@'\1$\=^#;*>>=7O8$2-D+
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MZM&-2V1B1U7/3+'A>??/Z Y]?2M2_P"">GBK7-,BU7P@!-;7*!XB@+$9 ;G
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M5BD_9U7"/+4Y;7O):F?\!OV^O%^@^*;-?&%]+?6%U<11N)G9E42,%YW$^I_
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MFTUO=)_=J?M3^S9_R3JS_P!Z/_T77T%7S[^S9_R3JS_WH_\ T77T%7Y[B_\
M>:__ %\E^9]7A_X%'_KW#\D%%%%<YL%%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% #5_B_WC10O\7^\:* %'0?0?RI:0=!]!_*EH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "@G )]**0D#&>_2@ !R,TA;!
M QUQ_.G44 %%%% !1110 5Y1\:_^2=:[_P!<A_Z!)7J]>4?&O_DG6N_]<A_Z
M!)6V'_CT?^OD/S1E7_@U/\$OR/PNU#_D(7/_ %VE_P#0FJNPRA.>1GC\/_KU
M8U#_ )"%S_UVE_\ 0FJN>>/6OT*.O)\OT/E#[Q_8>U*V77-3MWD5',<RJN0
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M+C7L1RQ0S1*<'KDA@, $=<=<<=:]!_;F18O#>APQ(L<2C C10J@+*P "C@8
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MT^-T7PW.M:!>6Y>74U>(!D)V[]RYY! //X]/6N>N)?M=W<WXR%O)GG ] Y)
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MC,H*G+&T<=)?Q)5%'GA*%37EOK%>I^BMC<07]K'<VTBR*RACM(P. <=!CO\
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M(BVF&-E8%64$8]/6I[7B[@Q_?3_T,5F:7'-#I]HLIR_DJ"?; _7UK2M2/MD
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MRTBU#3XY 0RP3?<!!Y! 'U]>] 'KQ!/0XI1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44A;! YYI: "BBB@
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M?#3*H8/%XS%0@HU,RE%*4\)"MI)1D]);6?S-_;8N$(QA/V=&[Z*\]M$^W?\
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M91_Q%"_&?_GZ/_@5_P#;* ]E+R^_T_S1_H1T5_GN?\10OQG_ .?H_P#@5_\
M;*/^(H7XS_\ /T?_  *_^V4![*7E]_I_FC_0CHK_ #W/^(H7XS_\_1_\"O\
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M)P/]6XSS7[Z?!OXM>'/C3X)TWQEX;F$MG=V]L\NUE8)/+"'=>!P VX 'L.M
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MD#;'1,@9#$;3SCGH>?WIU?X)^!-<UO0]=U'2H)[SP^D2:<7B1A"L6 @4GE<
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MC_B$7^'?_11K;_ONZ_\ B*_M7HH#FEW?]?U_6I_%1_Q"+_#O_HHUM_WW=?\
MQ%'_ !"+_#O_ **-;?\ ?=U_\17]J]% <TN[_K^OZU/XJ/\ B$7^'?\ T4:V
M_P"^[K_XBC_B$7^'?_11K;_ONZ_^(K^U>B@.:7=_U_7]:G\5'_$(O\._^BC6
MW_?=U_\ $4?\0B_P[_Z*-;?]]W7_ ,17]J]% <TN[_K^OZU/XJ/^(1?X=_\
M11K;_ONZ_P#B*4?\&C'PZYS\1K;V^>Y_JG\J_M6HH#FEW/XJ/^(1?X=_]%&M
MO^^[K_XBG_\ $(O\.21_Q<>V [DM=?\ LL9/Z5_:IFOS-_X*/?MX:3^R#\*=
M;ETBWN=3\?:GISQ^';>P/FR17,R,(W"1@L) VS:<\ GC., *4MDWK8_@L_X*
ML_\ !*+X(_\ !.G0_)T/X@V6N>,40--I,=TDDZ<$D-%N,BGIE656'1@#D5^!
M'A2Q\0^/[B#3?!VF7.JZO<NJ1VL-O+(2[, %^53]/IS7]''AK_@FM^W5_P %
M6_CA>_&KQ]+XEM_"U_K,TQL-4:Y\@6$DNX )+\H C.>F*_J[_8E_X(&_LQ?L
M\Z3H?B#Q3X?@U3QK;)!+.)+:*2-9H]K-YA?G[X.  3W..,AOS\D;7NUK\G\_
MO^9_%I^Q)_P0Z_:0_:JUC3%\;>%]2\+:'>21D7D]O/ C12%3NW.H .TY'\Z_
MM&_8#_X(%_L]_LCW&FZ_XET_3O%OB.S2*59Y%$K1W"!3CS&4@@,.2I(P.#7[
MU^&_"7AOPCIEGI/AW1=.TJRL88X(([.T@@(6-0H+,B!F8@9))/H,  5T=!C*
M<I;O3L9VE:3IVAV,&F:5:Q6=C:H(X+>$;8XT4!0JCT  %><_&O\ Y)UKO_7(
M?^@25ZO7E'QK_P"2=:[_ -<A_P"@25MA_P"/1_Z^0_-'/7_@U/\ !+\C\+=1
M)&H7& 3^^E_]";VJ#!..,@>V?\]<U8U#_D(7/_7:7_T)JA#$<#%?H*U47V2_
M)?Y'RAZ5X-^).I^#+2]M=/D:'[7&T<FW/.X$8X'^?IQ7G-Y/)>7UW?3,6DNI
M6E8GDY9B2<GOS41.[J!^5)3BDE)[2D[RLW9[6OZ="N:32C>Z3T7:]MNVPA)X
M[CO[=.WTS71?#[6M'T_QG8-K6TV:S1%A(,*,,#GGM_+H:A\+Z/=>(->T_3;:
M)Y5N)DC?:N[:&;;DX^H_Q]?</BO^Q]XSAL;/6M!$P1HDED$08,"0K]AGIC].
M]?DGC;Q;Q-P=P-C,TX.RNIFV>^UITZ>%I)SG##2:]KB++7W%K_PY:I591]I2
M@ZCIR3DK7OM=6\OE\S],]%^+_P ,M&\*6$J:]8V\$%FA6W\Q Y8*,@ $#D\]
MB!VSU^6OB5^WKX?\)RSV^CVL5\59E255\WL<'&2I_$=>*_/NR_9Z^,GB,II4
M5QJ\:HQC4!I0..!^'U/L>E?4'PS_ &#M=:2&7QNTDT;;2PGR3CWW<]!_+N,U
M_%\O%GQ_X\A0RWA7@RKP]4Y(4\1GN(I2J4G6Y8J<YJLK4TY7:Y>KTV.WZUF&
M(484*'L5%).;5]4DK.]K+TL_D<!K?[>.M>*HKK2S!*D6IJT##RRJJCY&.P
MQ@8_#FO"I)/M,\M[WO':9N.A?YCG\?Y]:_4/Q5^QM\+-$\(ZGJ%E9!=1TZR>
MX67RU"ET7&%.21R1S@9QVK\NIT^SZCJ%HO\ J[:ZDAC_ -U6;'\O\]:_J'Z/
M?#WB=D&$XF_XB9G6&SK%8S$86KEM3"S<XT8<B]M"=](OF>RZ;'-7IXN$H_6I
M1J2E\+B^FB:?;UZ_(:Z;QC_/8_T]*^BOV:/B/I_@OQU"-8E6WLRZ*97("CDC
MG) SP>^,9)Q7SR&V\^E3IX \1>,VV>'C*+@$$-#D/VQTY^G-?I?BCFV;9%P/
MG&<9'A)X[,LOI2Q%'!4TY/%.'+>DTKNTDWLF81G4ISC.FG*<)+W$M7M_GMW/
MW)U3XZ?#73;!KYO$EC)F,O'$LJAV.W(!&[CWP2?YU^??[1/[6_A;Q+I,_ABT
MM$FW2.L=PJ[\9X!#?,>H/?'?![_*-C^S!\9O$<J68NM6^0X 9I=O8'^6,8[]
M^E?5'PU_8/U0&&3QNSRGY2QE&3@D$YSSGV["OX<POBU](;C7$X"'"W \N&(T
MJM&5?'XJ$IT9N\'5C.=2SIQ<;I<O<]"6)S'%7A3P_LHM6;DKK6U[WZH^*K&Z
MAO(OM$)R'YV],9Y]L=NWZ8J^""/NX/K^O]<5]8_M#_ &T^&-M93>'(7-LR@R
M,BG:!CG.!@8Q_/WS\F1LIX;J  W7AL#(_G7^AV28C&8K*,MK9@J<<Q>$P_U]
M47S4_K2IP]LXM]'/FMVT.&I3J49<DU:5M;;?UY!@'!(SCD4M*>IQTSQ25ZE[
MMOKU^[_(S>^FB[?=J&2.AQZ_YS1_G':BB@?X?>(JD9[CUQ_GVKO_ (7>"KSQ
MWXMT^RM$+K;W,9E"@GY0^3GC\,].]< [,%54!9WD50H!)Y]./;_/-?J'^R-\
M*UT?3X_%UQ!B2[7<GF+R&92<C//&1Q^>:Y,;BEA,-.K>\FG&"[RDNM[:?J;X
M6BZU:,;>ZFG+T_7T_%'V-X.T"U\.>']-TVV@6$PVL2R[0 6?;SG'I6YJ/_'C
M=_\ 7O+_ .@&KE4]0_X\;O\ Z]Y?_0#7PKDY3YGO*5WZMW/ITE%)+9*R^1^)
M7[0W_(Y7GM<'_P!"(_K7B"_+CO@_US7M_P"T+_R.5Y_UW/\ Z%7B%?H&'_W>
MB^O)'\(Q/EL1_&J?XOT.;\3^$YO%^G3Z?9QF2Z*.54?,<8].OUZ^I%?#?B#1
M)_#NKW.AWJLEQ"S!T<$'J0>#ST/TX^E?K#\![:WOOB/:6=VJO#.!&4<97+\9
MP>.]>._MV_L[:KX$\32^-["PFET_4%$@^SQL517[D@<8Z_U.:_&?%?*95)X7
M-*-.\J=)4Z_*M>31J32ZWZL_O'Z%_B+2R_$9IP#F6*5*ECZOUW*I5IJ*GB[)
M/#4Y2LE[JORJVK/)OV.?C,_PO^)VG#4+LV^C//&)-S%8^6&>^.GX]17])^E>
M)?"/Q.\/,NG7]I>V^I6A'EJZLZ>8G) R<XS]>.E?QY1REA&RR&"=,/\ *VV1
M&'9CU!'?I7T'X"_:B^*OPRBMX= U&YEB@VE \K'[HX')]/Y>Y)^ X:XH_LBF
M\/B(SJ8;GYHN&LZ<M/A79=O)6M?3]Y\<OH^?\1,QE'/LBQ=# 9[3H?5J]+$+
MDPN+A'55)U%KS[J^KMY'Z4?M$_"#4?A[XEFN+2WW:9>2-,)XR3'M<[AV&,#M
MP>Q&:^<P0>1SCO6+J/[;.O\ C_0?L7C<+)>8VB1_O@XQG/)_E[51\,^*],\1
M0C['(N\')&>>1TQ_3M7[YPUQ;E.>4X8>CB%'&QLE1JOEJU>\HQ?;?>Y_GGXC
M^!O'_AO[3%YSE3K97%_O,RP"E6P=)MJRG42TW3VL=2LDT,]O<0.4DAF23<"0
M<*P/..<<<_CWKVOQY\5;GQIX4TKP_=$L=.C1 S'D[ !USW _PS7BIX_Q]:2O
MJI0A4E"<E>5-MQ?5-[W\S\>C4DHRBG[L[<R_F5T[?UYC5&U0OH,5+;+F\A.>
MKIV_V@*94MM_Q]P?[Z?^ABM.C77H^WRZDIVO;[S]J?V;/^2=6?\ O1_^BZ^@
MJ^??V;/^2=6?^]'_ .BZ^@J_/\7_ +S7_P"ODOS/J</_  */_7N'Y(^5_P!I
MG]D'X-_M2^#]4\+_ !(\,6&IO>V\L<-[/$'DB>1< G(/ /((P0?KQ_'+^WC_
M ,&PW_".VVN?$/X)W@O03<7$&BV/F$QM\TJQ^2H!''RC"X..,X-?WA4R2..5
M"DL:2H>J2*KJ?JK J?QKG.A2E'9V/\8SXW_LC?M#?L]:Q?V7Q"\"ZGI&F64\
MD2W<UE<*K1QDC?N:,=0"<^U<-^SSH?A+XI?%SP]X"\5ZDFD:'JMW;V][J,Y\
ME+<32*C;F? 7&?7K]>/]>G]I;]A?]G[]J?2)=*^)7@_393+"\3W=I86R3L75
ME#OA4#, W)R"V,DY)-?R)?\ !0O_ (-G-?MYM5\3?LL">QCM2;V-[!&2=%C?
MS0%,?S*1@# Z=,=:#:-527++39)K4Z+X:_\ !J[\%OBWX$\.^/O"_P 4K*\T
MO7[""\CFAN99T,CQJ[H'@$B!DW@%68, 0<8()[H?\&B_PZ''_"QK;_ONZ_\
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M:UU73X;":[=I(<QRHJ*&?*]N *_2'_@H7HOP(L?^"8=_<:Y9:3':?\(+H_\
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MV>?VE/#/P\^'5FU]X7U/5(+/49-)CWVWV>258G+F(%=NTDG/'7VK]$/VMO\
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M4D?7_5O,I7&2.,?AW[T5]J?L[^$8O"GP;\"Z)/;*EW:Z0GVP,F&^U-(_FDC
M(/RC.><T4$W/<1T'T'\J6D'0?0?RI:!!1110 4444 -"X).>N>WJ<TI&1BEK
M\\OV_/VH=0^!OPXO--\#707XB7\MLNEP(^)MLG]Q00>=P_(=.X!^A@&!BEKY
M7_8V\9^/?'OP#\*>*?B4)%\4Z@LTEZ9R=^P)"Z,Q;MAV.2?6OIJ+4]-FD,,.
MHV4TP.#%'=V[R@],&-'+ ^Q&: +U%-9U12[LJ*HRS,0JJ/4DX 'N356WU'3[
MIBEK?6=RZ_>2WN89F7'7*QNQ'XB@"Y2 GN/\_I7Y>_\ !17]K'Q5^S-)\.%\
M-R-'_P )1>QP7(5BNY6NWAP,$9X7Z].U=S^T-^U]:? C]C[3_CKK5Y#'J6HZ
M':S0*TJB0WEW#*5P,YX=4/(YW9H _0D\]@?K_P#J-+7X4_L"_%/]L[X^WEI\
M7O%&M&[^%/B2>6;2;83[_+M1(I12F2!\C@<^AK]THM_E1;_O^6F__>VC=^N:
M )*,]N_I5>XO+2T7?=W5O:K_ 'KB>*%?SD91^M$%Q:W2^;:SP7*?\]()4F3_
M +ZC9EZ>] %BCKU%,DDCB0R2ND:*,L\C!$4>I9B !]37YI?\%.OVL=:_95^!
M.E_$/PA>PR7MYXDBTLM;SHX,3^1GYHV(&/,/>@#],**^ -!_:6UVZ_9-^'WQ
MEECFN-6\2Z7:W<_E[F;?+$KMR 3U8\\_K7T1^S_\2KKXF>!8O$FI*UO*\XCQ
M.=AP5)'WR/:@#W>F[?FW9_#'MB@.I7<&4K_>!&W\^E,,\"\M-$![R(/YF@"6
MBD#!AE2&!Z$'(/XCBF>=%O\ +\R/S/[F]=__ 'SG=^E $E%4I]2T^U8)=7]E
M;.> D]U!"Q^BR.I/Y5:22.1!)&Z21D9#HRLA'J&4E2/<&@!]%1-/"B&5Y8DC
M7[TC2(J+]7)"C\33(+NUN@6MKFWN%'4P31S ?4QLP'XT 6**^>_B1^TQ\+_A
M;XLTSP=XJUFWM-8U4Q+!$]Q''@S$! RL,YR>>16I\6_&E_;?"7Q+XS\"WL5W
M<Z7H-[J\#VTJN2MM;&?'R$X) QR/<4 >X45^5G_!-/\ ;#\2?M0Z;\0X?&$I
MCU7PIJSV44,SXD98[AH6*ACD\8Z#/M7ZI%L=<T +1110 4444 %%%% !1110
M 4444 %%%% !1110!'*ADBDC!P7C= ?0LI /X9S7Q=XU_8N\!?%/QI;^)OB;
M!!XHM+299;?3[Q?-10C95,2*R@=!T('H>_VK10!Q_@WP%X.^'NF)HW@WP_IW
MA[34"*+;3X!#&0@PN3W/?&<9YQ784A /6EH **** "O*/C7_ ,DZUW_KD/\
MT"2O5Z\H^-?_ "3K7?\ KD/_ $"2ML/_ !Z/_7R'YHRK_P &I_@E^1^%VH?\
MA"Y_Z[2_^A-5?-6-0_Y"%S_UVE_]":JY&>#7Z%%>ZG=;+3KT/E S37("DGT/
M\J7A1["N[\&_#C5OB!,]II<@C;86R>.0,^N.A_SBN;&XJ.!P6+QLZ<ZT<)AZ
MM?V5-7J573BY*G376<NBZC2?-%)-R;5DMWM_FCZ1_8KTKPYK?B2[>_,4UU;>
M8\".5W;T!*@9Y.6'&!FOU(UK6-"T>U/]M75K;6VS!6X*[=B\#Y3V ]J_GGN-
M2^(7P"\8WD.C1WCW44A)>(/M?GVZ@GM_6M?4_C9\;OBBRZ9=6FKA9?D#Q";'
MS\=OS_PQFO\ /O%?2]PZGFV7YMPOFU7B.AF.+PF!P4,+5^K3P\:G+AXUY*#<
M9N/QI:7.S#9G3PU-T'1G[92>BBW=NUE)[WM_6Y^O?BK]H?X2>"][Z;=V%Q>+
MN+>1Y8&1UQ\Q/X\8].]<MX6_;%\$ZYJB6-W+!:1R.$60MCEB .2V/?O]*_-_
MP?\ L9?%GQE-%JMW=:C';RD2.MPTGW6.[JQ SG^?UJI\9_V6O&/PMTZ#Q T]
MV+6V(E=XV/5/FZKD=1S],5\KB_&?QXI8.IQ53X IY1PU@VJU7#2HVA4PR:YJ
MSFTIJ+CK.22M9;%RQN8).M]7Y*4?>:2TY;1NWI]^NGX'[:^+M3LM:^'FNZCI
MTR7-I<:3,\<L9# @A3C()&1D<>XK\%]47.MZR.G^GSYX_P"FC5]K?LI?&JZ\
M3_#+Q+X<U>Y++8V-Q##YSDL<(P[GG[@QS_A7Q=JV/[>UHJ/E:_N"OH09&Z5_
M<'@SQM@/$/@W"<49?:G#&QA&O0;UH8F"BJL'UY.;X&TKH6+Q$<32PU:+^*,K
MK56::_#S*+<(1UP!_2OL']E;6?#FBZ\;CQ+<0V]J%R&N"-F0#C<&ZC('3T_"
MOD/&-I/0_P N*B_LCQ+XB8:7H!NEED/E[K8L#D].5_+/M]*^@\2,_P 1PSP7
MGF=X3+_[5Q6"PE2=# 6;^M5+)0IVBF]6]++>WD<E*K*A*-6,>>2EL^NWEOYG
M[#>+?VG/A=X.E>/2[JRNIEX=X/+"DGJ."3CMD')^F!4WP_\ VI_!'C/4%T][
MJWM9)#MC)<#+'H,%OI_C7YH>#/V(_BEX@":CJ-Y>^3)ARLTCGJ<X^;OT]Z\@
M^)_PT\5? SQII\9N;N,Q7,;.X=E7"N"<D8X./UK_ #[QGCKXV9%0PG%N>\"Q
MRCA6>)P]&I@YTN1>RKM*,E->\KQO+FTU6KZ'9+,,?!JK4P_)1;2:MHKVM9[[
M;ZZ?,_>#XJ^&=.\:>"-14QQW)^R/-:R@!L@J<$'TY[>]?AUXBT=_#VMWVGR#
M!%U(%!SP S ?Y]OR_8?]G/Q[#\0_AY8V]Q*)Y;>Q2"?YM[%?E!R23GEC[Y/-
M?$_[5/P9U+0_$4WBNPA8Z5*[R'8AVC)).<#KS]/Y5_=?!7%M+.,%DN8X5>VR
MW.\-1JQ=-\SHXBK&+Y9:V]G"5XM]UKY;XZ'MJ5/$TUS:+FMK:]KM^G9=K]SX
MZHI%8,JG&&YRISGVI:_4&FFTU;7I\OZ7D>0%!.!D\"BF[7FEBM8U+/<-Y:X_
MO'@4 >I_!OP3<^-O&FFVP@,MCYT?G':648;G)Q^//IZ5^X'AC0;;PUHUGI%H
MH6*UC50 ,#(4 ]/<?3TKY*_9-^%G_"->'O[8U.W NKE5>!G3Y@#M.02/3/\
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M(****YS8*0@,"K $$$$$9!!X((/!!'!!ZTM-.[(QTXST]?SH ^3OB_\ L9_
M[XM,-4U'P5HUIXFAN/M5OK<%JB7'G9W%G8 MG< P*E<'.0<@CV#X4_#R7X<:
M!!H)OVO;>UA2WMMS,1'$A&U1GIC!Z>M>IT4 %%(3CDTH.>: "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HQWQSZXHI"<<F@!:* <\T4 %%%'X?Y_&@
MHIJ[OXO;'^13J "BFLZHI9V5%')9B%4?4G 'XT)(DBAXW613T9&#*?H5)!_.
M@!U(21T&:6C/3W__ %T &:*Y'4/'?A+2]8M] OM<T^WU>Z91#827$:W#ECP%
MC)W$Y]!_];KJ "C..O%%(0#U% "T4@.>12#=DYZ<X_.@!U%%% "9ST(_G2T@
M '2@MCKF@!:*** "BBB@ HHHH 0X[X_&EIK8QR.,THZ#'3% !DYQ@X]?P^E+
M2;N<<Y_^MFEH ***0M@@<\T +112'...O^?6@ YSGVQC'^?2EIN2 "W7_P#7
M3J "BBB@ HHHH J7]C::G976G7\"7-G>PR6]S!(,I+#*I5T8=P0:_+KXS?\
M!-C0O%GB*;7OA?KR_#][R9I[V*S\R'SF<LS9,*C/)/;G/Y?JA10--K8_/K]G
MC]@[PA\)KMM:\8S6_C77T.ZWOKQ#*T4A(._=(-V1C(P1SCK7Z QQI!%'%$@6
M.)$CC11@*B *J@>BJ !["GEL=<TM AI)&/E)S^GZ4ZBB@ SCKQ12$9^O.*%W
M8^;KG_/2@!LD:3(T4J!XW!5T895E/4$>E?+%A^RMX,TGXUM\9-,A@M=4>3S7
MBC3:2YY/10.O3D_T/U23C ]:6@ HH)QS2 YY% "YHIH(;L>/\_TIU !1110
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MI_E3[7_C[@_WT_\ 0Q5)7ZI>H?B?M5^S:V[X=69P>L8YZ_ZLU] U\^_LV?\
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M:^5([G<Q6*& +D]3U-!/1;_=I\G]Q[/\2?BMX)^$^ASZ_P"--5BTNP@0L7?
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MS":TC"!V#_ZN4XQC-=Q^RA^QSXZU_P" _P =OB9X6U#4SK/QAL-3NM/)FE+
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M #&>HS^%%%% !1110 4444 'X4444 %'3H*** #&.@Q^%%%% !1110 4444
M-7^+_>-%"_Q?[QHH 4=!]!_*EI!T'T'\J6@ HHHH **** "OP?\ ^"IGP U%
M?&?AO]I/1+%[G4?"$VG_ +R*,NZ>0P(^[D]%X_#%?O!7)>-O!.@?$#P]=^&?
M$EFE[I5YM\V%U5N4S@C<#SR?KWH"[6Q^;D_PP\2?MU?LK^!YSXGN_!>L&W6
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M_3_/-6+.W^W7<%BC;'F(7>> "2!R3QCGUKZ,T?\ 93\;Z_81ZC87(F@D3?\
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M^@_E2T %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %1RQ1SQM%,BR1N-K(XRK ]B#4E% '
MA?Q'^!'A+QY:/&+*VL;IE8>=%&%+'G!R 3DYY/X]>GYP_$[]F+Q/X-N)I-$M
M9;VT4LQ=59@%'/\ #D=#T.,XZU^R55[FUM[R%X+F))HI%*LKJ&&&&#C(.#7H
MX3,L1A?=4G.G=^Y)NVMKV^[[SDKX*C7UY>2?\T=/O6WX'\[-W;W6FSM::A$\
M-PAVE2C#D?6F@Y /KS7[%_$W]F;PIXLM[BZTNU2VU-]Q!"J 20>A &.<?3CM
M7YQ_$;]G_P 7_#R:666WGN[?)*>6K,-H/&,9XQQGT]J^HPF98;%+E35.J[)1
MD[7>E^7IWW?X'B5\'5H:M<T?YHJZ^9X<R*_W@#CU_P ^U;>C>)O$'AVXCGTG
M49[58V#%(Y&4'!SC@\\"L)_/B^6XB:VD!(*2 @C''?U^G\JDSGD<BNZUU[R3
M6NC]Z+_1]-?N.9-IIIM-=M.W^1]X_"K]K_4+,VFC>(@9H%V(US,,D<X)#$9
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MOM>?F?.3J2J2E.;YI2W;^7Y+0;)(L:Y;/)P, G)/3BO??A?\!->^)N@:[>-
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ,9ZC/X4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% #5_B_P!XT4+_ !?[QHH 4=!]!_*EI!T'T'\J
M6@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M?3K"XNED8*DT:,RL#T.0",&OK[X5_LF:_K;V^J:YNBL7='>*7@[3R1@_3O\
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M^+_>-%"_Q?[QHH 4=!]!_*EI!T'T'\J6@ HHHH **** "BBB@ HHHH ****
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 -7^+_ 'C10O\
M%_O&B@!1T'T'\J6D'0?0?RI: "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M;N_77\F?746G2IN.W+'\D%%%%8FH4444 %%%% !1110 4444 %%%% !1110
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 -7^+_ 'C10O\ %_O&B@!1T'T'\J6D'0?0?RI: "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MFU]-._?7TT.^GFC_ .7E._\ AW_R\]C]Z5 '3O3LU^5G@K]L34=%$2Z[ON^
M'W'=GD9ZG/.?7Z=J^I_!_P"U7X/\3M$DJI9%]H+,Y&"P[AF^M>36RO&4;MTG
M**^U'5?Y[:G=2QN'JV2GRRZQENK_ -?YGU917,:?XS\,:G%'+9ZU8R"0 A1,
MN_D X*_C721RQRH)(G61&Z,IR#^(KSW&4?BBUZIK\SJ4D]FGZ._Y#Z\P^+GA
M5O%_@^_TQ,;A%+(,].$R?T4UZ?7CWQO\377A7P/?ZC:,5F*21@CT9,']#_\
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MRO;FHR>[O!?F?2M%%%?-'L!1110 4444 %%%% !1110 4444 %%%% !1110
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MH4K.--.2^T]6_P!.AE6>@Z/81K%:Z=:1*@ &V"//'?.W.:U555 55"J.@4
M?0# I:*XFV]VWZZG2%%%%(#YX_:+^'R>-?!5V((%:\MU=]X4;M@7/7KD8/\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* &K_%_O&BA?XO\ >-% "CH/H/Y4M(.@^@_E2T %%%% !1110 4444 %%%%
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M,I0_PECCGV_IQVKS77/BOK'B")XKVV7,G5L<]/4]^?\ .<UYF>I^M-8X&?\
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MUPHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH :O\7^\:*%_B_WC10 HZ#Z#^5+2#H/H/Y4M !1110
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M'*BR*PY!##-35\^_L\^/HO&7@BQ$UPLE_!$JNI8%MNW'3.[C'Y5]!#@ >E?
M5J4J-6=.2LX2:^5]'\T?4TY^TIPFOM13^;6H4445D6%%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 -7^+_>
M-%"_Q?[QHH 4=!]!_*EI!T'T'\J6@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% #5_B_WC10O\7^\:*
M%'0?0?RI:0=!]!_*EH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M\[GN%M..*@M)6C42V3T2>W7J>MEM?1T'96O*/GW7RTMU/;J***^</7"BBB@
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M\6",\L*VJ*:;BTUHTTT_- ]='L]#\)?C;X.?P1XUN].$3+'+</)G;@<LQX/
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M9)(81]Z9Q& ,G[QQ_7N"*_5O]DGX9?\ "-Z$=:OK<>;>Q[X&=>S>F0#T(_\
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M(=+T_:7%U<1H5 [%E']>_%?N5\'/"J^%/!FGVBH$,T,4Q  '53Z >N:_)/\
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M^X^'0 !CL:]5^"WBZY\*^.M**RF*S:>/SL,0I!;HWKQ]/K7E*DD<C!'!'O\
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M;GL=(5R0>>*6BOG3U@HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH :O\7^\:*%_B_WC10 HZ#Z#^5+2#H/H/Y4M !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %!S@XZ]J** $7=CYNN?\]*6BB@ KS3XJ^+[
M3PEX2U6ZGF6*>2TE6V!8*3)M.,9(R<C^==/K?B_P[X=!.L:I;66T%B))%!&.
M2,9Z^WX=:_-;]KKXO:;XHBM-,\,ZB)X("5E,3\,,_,2%/(/IUKKP=%5L13C-
M\M/F3E)[67J8XB;A2FXZRM[JZMMV_7<^-_%&NW?B;7=1O[Z1I&^U2>6S')V[
MN,?K^O)K$JLDOR@Y&3C=G.2>M$DA9"$^\2 /4DG'3_Z^,CK7W$*E%\L(5(<J
M245>UK):[VZ7V\NA\U*E5UE*,G?=V=];?/K]YZ[\%? \OC_QG:::8F,<,\;E
M]I*X5@>?_K?_ %Z_;_PUI$>@Z'I^E1(J+9VZQ$*,#([\=>W-?&O[(/P\L+30
M4\5.J"^<Q^A;E2>>XZ'V'UK[FSR>.F.?6OE<YQ?MZ_LH/]W2TTZRMJ[]GT/9
MR[#NE2YY7YI_^DZ-?/\ K43YMW^S^'I^?6G44UF5%+.0JJ,DGH![UXQZ1X/^
MT'XZ'@GP/=W,<H2:X22, , VTKCIGODBOQ0U&[;5M5O-6D)9[J5Y"2222S%O
M7WK[)_:Z^(TNI^(Y?#$$WF6D;,,*V5ZGCCC.?3K7Q7$GEQJ@'0?_ %Z^TR?#
M?5\-&<DN:J^:]K^[TOYH^<Q]55:[2;Y865KZ<RM?3NO(<S;59O0$U]4?LL?#
MQ_%'BJUUYHBT5E*I8D97"G/T_/\ F*^68D-Q=VMHH+-<RB(  GER% XZG)Z5
M^R/[,7P__P"$-\(QSRP[9M0B24,0,X.T\=\GFKS3$K#X6:3:G4;A#SCU?ET[
M]NC%@J#JUHM_#!J3[Z6M^>A].HBQHD:#"HJHH'0*H  _(4H7;TSS2T5\0?2!
M1110 4444 (=V1CIGFOF/]J'Q5%H_@&_T])0ES=1O@9P<;.,<@_Q'C^=?3I.
M 2> .2?05^5_[:'C&1O$EMH]K*6@X20 _+G&#GMU_IWZ>AE='V^,I1Z1]_;^
M5I_UW.;&5/9X>;[Z+OJTCX9BDDF,LLO+O*YR>O4_SS4KL H'=N.W4]/<^_)
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M=,31])LM.086VA2, =.% /\ *M>BBO@&VW=ZMW;?F?4+31;+0**** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** &AP3CFOCS]KWPB?$/A
M."XCB+/:J[.RKGA2QYX].Y]/:OL3 ]!^5<9\0='@UKPGK-K*@=OL4[1Y&?G"
M-C'XFNG"5G0Q%*JOLS7W-V?]=S*O#VE*<.ZZKMJ?@#M\J22W[P,8R/3:2/\
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M\7^\:*%_B_WC10 HZ#Z#^5+2#H/H/Y4M !1110 4444 %%%% !1110 4444
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M?^,G,B=HW:/'<%3_ )_2DGC,D94$@@ALCC[IS79>//#4O@WQ3>Z1.I5C<RL
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M\-]?TUM#UB[TPC:T$L@(],,>W_ZZ_H:NH([FWF@E4.DD;H0>GS(5_K7X@_M
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MWTZ?.W0_6/X7Z-_8/@G1M-"!&AMUW<8.2JXSP.?\^M>A4R.-(HTCC4*B*%4
M8P ,#I3Z_/IS<YRF]Y2;?S/K(I1BHK:*27R5@HHI 0>E0,6BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *_.3]M?PBL-G9ZQ
M:0_/,2SLJ\_>P22!V([U^C0(/2O"?C_X03Q1X*OG,?F-86TLH&,X R<_GCWK
MNRZLJ.,H3EI'G2EK;1[?C;<YL7#VF'J1M=V7+Y.Z_0_$*+(0*>J@ _6GK.UG
M*EY&2'A(8$=<@Y'\ATI]TAAU/4(""/(N)(@,$8"L144L>^,J1PW]:^[ZJ^UU
M=^NOWV/F#]DOV5O% U_P!"LLH>>$QC!;)VA2.,G/<5]0U^6O['?C8V^N1^&_
M,PCD?(3P<]L9P!_G%?J57PV:471QE72RF^=>C/I<%5]IAX/=Q]Q][I+_ #"B
MBBO/.L*0@'&>W2EH/0T %-# Y[8ZD]J0,?XA@?0]:XGXC:^WACP;K.LQ?ZRU
MMF9,<'.UB#^E.*<FHKJTOO=A-V3;Z')_$OXR^$OA]97"ZI<Q33-!*ODB1>2R
M%<,!U!)Y [&OQH^)/B32/$WB2^U?1XA''<SO(0HP/F8D>@_D:RO'OCG6?'GB
M"]OKZ\ED@6YE00LS%0 QXP2?3_/2N.5%0850![5Z^'<L+=TIRC*2M)KKY??K
MT."LHU[*<=(NZMNGZ[DQE?U(_$U=TO4[C2K^#4+9F6:%U=2IP>#G@]?U_P *
MSJ*W6)KJ_P"]F[IIIMVL]]/E_5S-4J?_ #[BK/3OZWW/TO\ @_\ M;Z+;6-E
MH7B)B9?DC65FY4X5<Y]P.]?>GA_Q%I?B6PAU#2[F.XAE0-A'#%<@'!Q]:_G6
M,07+PXCE&2KC@AL<'-?;7[)WQ:UG3_$%KX3O;J6ZBNF5$W,S! QVC&>.E>?5
MPZ:<XWONU9OU\DD=E.K\,7;32_Y?UY?=^ME%%%<!T!1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 -7^+_>-%"_Q?
M[QHH 4=!]!_*EI!T'T'\J6@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MKGJ8A)<M-WNK.3OV5U_F_GN:4Z762ZZ(U:*0# Q2UQ'0%%%% !1110 4444
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M=S%L9R>Y]_YUSZH2<'IT'X]Q3(&S&HP05 !!&"#4U>DK*VFBT^78XKMBL-I
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M[E]?Y_X4;E]?Y_X4ZB@!NY?7^?\ A1N7U_G_ (4ZB@!H/7 )&>O'MZXHIU%
#'__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>g0fyk5pshdve000004.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g0fyk5pshdve000004.jpg
M_]C_X  02D9)1@ ! 0$!+ $L  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" '" T8# 2(  A$! Q$!_\0
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M!^5&!Z#\J6OFC]J/]J'X=?LK_#C5?'WQ!OWL[>WLKF2PB1-YN+A(W\M<]OG
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M<]*^2=!_X*/_ +)'B3Q:W@G2OB5;RZ\EU]C,#PQ1Q?:-VS9YQNB/O<=/PZ9
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M@CA>T:TC11A50IL  %?B/\'/^"7$7PW_ &]KW]J]#\]S?270&./FE+=?Q_\
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MT?#WQH\/^"_"_AZWCM--\,M8*/)C"%X[-H@&<*.I5.??O05?6-Y775I^EO\
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M%G?A#\/_ (JWGPC\'6-[XBU_0KHQ:T;!6N6B*$+("(E(55PWOW)/&,SX4?\
M!;?X-_$OXJS?"#^SKC2O%*V+2QV]VCQ3&<1D@;'"G.['&* Y9/H]KG[>WNLZ
M5ILL$%_?VUI-<L%MXII51Y23@!%/)YXKE_$/Q-\!>%;N"Q\0^*-*TF[N2H@@
MN[@1R2;ON[1@YSVK^+O]K+_@K;\7H?V[O"GP\L$U6'PSI^OPQ-'$TJQ30BX
M VJ0""OH#UQZUV__  4N_:RUY?%/PV\;P7>L:?:&UTR:XM(9)HVED*Q%@4!&
M<G/;\QF@=GIUO>UOZ^_YG]GMC?6NI6L%]8SQW5I<H)(+B)MR2(20&4]P<?\
MUJMU_,W\'?\ @MAX#^%W@;X7^'/'>D:E$FL165G#>WD<@5Q+L7<9&&>2<YSG
MTK^AKX4?%+PW\7_!NE>-?"TXGTO5+6WN8CN#%?/C$@7(QTR10)IK='HY?!(Q
MT/K_ /6I^:87 XYIQ&1B@0N<].:*0+MZ9YI: &C[S?A_*B@?>;\/Y44 *.@^
M@_E2T@Z#Z#^5+0 W<0V"./7\/7I3J0@'K7X<_P#!17_@L]\-_P#@G[\1?#O@
MWQIHLETNJ7$$$BE6#/YT@0E6'(P,X((P._>@:3;LMS]Q_7Z_T%?S6_\ !9+_
M (+$?%+_ ()U?$#PCH7A;P?/KEGK<UNJA;5IXI8Y74$M\C*<J>_%?K]^R7^W
M5\$?VN/!NG>)?!/B/3+34;V&"9M NK^%;Y?.C#?)&Y5FPQ(Q][IC/./SS_X+
M??L5V?[0'P2U/XIVFF1:AX@^'>F&\M8Q DL[K K,,#!; *@9[9'/8GX>94.5
M32J)J-TI::I75W;T/DCP[_P<,_#CQ3\$-2NOB!!#X/\ &^N^'I[6RLUA,+I>
M7EF8PRJ ,'<_0  9X&,5^7G[ W[,^@_M1?&+XE?&/XYV \<^&M>U"\O]!35E
M::)(9I7EB\M9MR_=(P0.!V&*Y+]AC]EK]F+]JKP--H_Q0M&M/B5X>U)K9-.S
MY<V;9]H_<@@D?+Z>PK]^OA;\'?"/P/\ #MGX1\'6B6=I8QI""J;6954 ;SU)
MX%>WE^!]Z&(<H5*;@G%[N[M>Z[^3^?0_4.&>%X4<13S.=:CBL+.GS48VYFI2
M4;QFGI=7_4^9O&W_  3M_9RUQ)8/"W@C2_#Q(:(M;Q)'N7)'.T#VS_3D5Z)^
MSE^RIX'_ &9GN[CPQ96\=S>[O,EB5-QW]<D#)_7GOGI]._-N(SR3D\GKUH?<
M<;CGT_3_ .M7L*A1C)3C3BI+9I;;=O0^\A@\'3JQKT\-3IU5M.,8QDMNR6NG
M^9\'?ML?L1^#_P!I/PE=Z[H%E#HWC[1X9-1M-:@58KJ2YB4O& \>UR2X &"3
MU^E>1_\ !*/_ (*-^.?V>_B.?V4_VEKVZMX(KH:/X8U'5#(JSHLXB@,<DQYS
MC@@XPW4U^J$4IC.#RC8#J>C+W!'<$<'.>*_(S_@IO^RK;^(- '[1G@F Z?XH
M\ >7J,#Z>OD222VI\X%C& 6SM[_CSBN#,,$JT75II*I'5JUE**6M[=596^9\
MQQ9P]1S+#SQN'@H8N@G*7*K>U@DK\R756WU?WG]E-G>V^H65IJ%E(D]K>P0W
M-O*A#I)#/&)(W!4D'*L.A.#Q5P=!7XH_\$5?VR=1_:3_ &=;+2?&^H!_&GAB
M6/3/L\\NZX>VM8S$00QW'E%(]?Y?M=7S9^,---I[IM/U3LPI"3D8'4\\&EHH
M$%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 55O;VVT^TN+Z\F2W
MM+2)Y[B>0[4BBC!9V8]  !5K/]/UXK\MO^"K/[5^G_LU_L\^(+**_2R\3>-=
M)O-/T0F0)(9)M\*^5R#N,HX(Z$"@:3;22NV[)+JWLC\;_P#@L!_P4C\7_$?Q
MNO['O[.-]/+>:O>#3]6U[22[$>:1#*&F@R0H^;@M\N<<5+^PM^PUX<_9]\+6
M7C+QE9PZK\2]2 O+_4[H"6Z,MP/,8LSY;.YN<YY[5\P?\$N?V;;W6;GQ3\=_
MBW!+J7BW5-1GU/1KG4E\\B*:5I8S&TF3C!&"#CTK]L[N[:XD$CJ$^4*$0850
MHP !Q7T>78-4HJM-7G+6/]U:-->?_!/V+A#AZG@,-',,3&,L77BI4TU?V,'9
MK=:3[_H>:_%'X4>"/C#I4FC^,=&MM2@?*J)XD8(A[#(P!CW_ *Y\@\'_ +#G
M[*?A-4>3X5Z'=7*L7,IM8222<D_=_$G_ "?J'-!/4FO3=.#ES.$7+:[BF^FW
MW'V+H4*E559T*,ZFD>>=.,G;3JU?\;'XQ_\ !3S]D'X;>"OA"OQC^#'A"U\.
M>+]&NXKM+C38O+N%2W<.<>2 V,#V[_6M_P""?_!=[Q)\(?V._#7AK1="F\7_
M !&\+Z7/8Z@TUL\UQ RQA%<[E9LQLK%3C*DYSG!K]7/%?A+0_B'H<WA;Q1;)
M=Z-<J8YH)%#KL<;6.T@CIST^M?C5^W-\&OV8_P!DOP;?V7@RPM7\9_$"![73
M[8QHQ6[O/E CCP>=\F!@>V><5Y./P2J2]NI1IPC'WTEOJE=+OZ;_ "/B^)N&
M:&+K/,75I86A0H_O[)0YI*SNDM&WM_E<]Z_X)8_\%:?VC/VQ/VCU\.^*?#VH
M6/AR:_"SL\$PAA#/AE+%=HP.V?;M7]@E?SD?\$%?V.;OX7_";5OB9X_T1(O$
M7B.[AO\ 1II;98Y8[:Y8SQNK% 2IC&!CCG/KG]7/VN_V[O@K^R+X-O\ Q%XQ
M\1:7=ZM;PS/!H,%]$UXSQJQ DBC8N"S*5" AN#G'%?/][7WZGY'54/:25*[@
MG:#:U:V3^>_S/MNC-?RZ?L<?\%YH/VO?VK[3X+Z!X?O=/TZ[U".WA9XG5)(W
MDVKMRH&""#QQS^?]16 #G')HZ)W33^\AIQ=FFGV:L]1<YZ44@ '2EH$%%%%
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M-*\G[&UQ(DC1_9\>7@M&QXP.A%,B^B\K_F?S\?\ !43X+?"'P_\ LJ? 36=
M\$VECK*66D2"[M[7$HD\N%MQ**&!W<\]^/6OVT_X)+W=U<_LOZ&+EI&$,5C'
M$) P*H('^4!N1CI_G%?6/Q+_ &3O@U\6/"^B^$/&7AY-0T30$B33;<[,0K"
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MQ7KU[WMT/QX\:?LH?M"_L677A;X\?LZZYK%[!:V%EJ.H>%[*2=K5((XD>13
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MMWH;MY>;V&NK;LDKMO9(R_''C;PY\+_"&J>,O%=Y!9:9;6-P\;2RK$3,J,R
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M?7D8-9GA/X=^"O ZNGA;P_I^C^9G>;6%5<YZ_-]X9'7':@TY[QLTG+H[=/\
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MVSR]VP@HQ&,=J^5_A?\ LG?$7XI_$/P7H&CPZUJT6ARZ:EZVIQ32)&]NT7F
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M?)XBTE;>U>W:V?S"850'Y-N>,'G'I7]5MUX6\/WVD?V#=:59SZ1L\L6+Q*8
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M$DV > ._H>N#7[5V\UCJ5K'J&DWD&HV,RAX[BU821,K*""&4D=Z;_P %)O\
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MH5$4#@*J@  = *DKPVVVV]6]V?EDYRG*4YR<I2=Y2>K;>[;[A1112)"BBB@
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MW6=*TCP[J&J1V=I]MN1& LTJQA5#GJVU<X]"<#)KJ_V0M-^*_@/_ (* >/\
M]EZ]^)&JZGX9M[;5+=EDO)WC94\Z,D@O@[E!_P"^C0#A9VOTN].FG_!^X_=_
MX;_\%A?A7\2OVG;_ . 6FW]G;WVE:E+87 >9 9&CF,65!89RPZ8_3%;'Q$_:
M(^/EE^V)8^#= \2V:_#>XL_M1T\7*^:R[=PPF[/(Z<?2OYGOV1_V-8_&'_!7
M;QLUGXC.G?\ "/\ B6>20-<^3]I,=R['.YEW[L'ZYYKZP^/_ (F\?^#O^"R'
MA?P-;^*;UM M;"&WDL5G<P2!453E<[3G&.E ^6SMO[M_*[Z?GZ?(_1/XM?\
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M5_UO^O4<?Q=/ZU_6;^Q_8W6F_L]_#RSO XGBTB(,'R6&8XR,YYK^.S5WU/\
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M'O[+MS\%FU^!]8O9))Y[H7$94S2DECOR1]XD\GO7]*]% .3?_ Z^I^+O[/\
M_P $YO&GPJ_96^)?P-U#68Y]4\9Z==VEM<K.C+&UQ%(@);=M&"PZ^G/K7/\
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M 50,  #   X  X ' %+2+NQ\W7/^>E+02%%%% !1110 4444 %%%% !1110
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M-G)&T'"]#^=?TC7CV]R_VNR82V<RHT4J8*.K $%2.#^9[5@TT[/\#>]]>_\
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M    >E.HHJS(**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M ,)V?_Y&H_X:2^"/_2/+5O\ PG9__D:E=?U\O\U]X>S\G]_I_FOO^[^DT?\
M!PE^P02!_;GB09(&?L'3W^Y7Y>?\%._^"P?['7[1'@&P\,^!+O5[_6(4V07%
MU:-#\TDA91P, *S8R22>IP,8_/8?M)?!$$'_ (=Y:MU_Z%V?_P"1J^<?VG/C
MM\,M<\#:C_PCO[$.I^!KB.WP-<ET&:!;0X&)3(8%V[3R3GM33OL$8).]ME^=
MOZTUU9_9!_P10\0-XC_97AOTD+VLEW:-;@G.U#%-MSWSCCFOV/K\"_\ @WJU
MT:_^QR]XK87^T[4+;YYMAY=P/*([%<8QV_.OWTH,9;OU_P"&"FMGH!USFG44
M"/RL_P""PUU=VO['7BN2S\P2FZ4'R\YV^2V>G('_ .JOQL_X)1PV3^!Q=(4-
M_+),TV/];DL2=PZ]:_I1_:P^"4'Q]^#/B?P%-C==6-W<6ZG^.>*VD,:#/\3,
M HQR2<#FOXR_V5OV@=:_8<_:B\:_"CXV:;/X8\"PZG>0:9K-_&\5L\1N&5&2
M20*F-N#D''YU$U=7ML:0O;2V]W?MIMYG]*TV?-DSUWG/US2)%)(0JJ1G/S$'
M X/4X]J^<KO]MW]CXZ8-:'QBT+$\1N/+^V0#:Q&X)C?^'?!XQ7YZ?M!?\%;]
M/\.17?AOX#^'7^)-_>AX+2XTJ!KHJ[916!B5\<G/7]*RBF]%KUUZ?\ M_B?I
MG\<OV@OAI^SIX/O_ !9X\UFR"06TK06T5S$;EKA4+1J(MVXDL   ,\]*_ .P
MT[]H[_@KM\;['2?#UKK.D_ _2M2/FW!BGBM[JP@F^;?@;'5HAZG^=>P?LV_\
M$X/VJ/\ @H9XYM?BM\?-5U7PS\./MT.HOX1U&:YMXG@9UD\H02E5)*<!<'.3
M@<5_7;^SG^S)\*_V9?!6G>#OAMX=LM(AMK2*"[NH88TFNI%5?,8NJAMK,N>2
M2W4]<#502M?5_P!:?U_P")3TTW>^^ASW[)?[*?P\_90^&.D> _!.EV=O+#9V
M@U.]BMXXY;B[C@59B75=Q!D+DG/S9].OU31GMWIK G&#C\Q5F8ZBBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH ***1C@9QWH 6B@'(!]:KW=PEI:W-U)PEM;S7#YZ;88VD;]%- 'YA?\
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M3CP9_P"$]IO_ ,CUZ7G/2B@+OS_K_AE]QYI_PIKX3#G_ (5SX,'_ '+VF?\
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M**"1,<@]Q_G^M+110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MN_X*>^)]6\2ZSK&KZ5\%=;N)OL>GRSSQQ-922$HI0G:08V Q6U^TYXS\6?\
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M>G6TL.E:+:V9BEB4@%5.>HX//X5Y5\0?V7O!WC-IIX8X["9@Q1(TVKN/0<8
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M "BBB@ HHHH **** "BBB@ HHHH ***0G )]J *U]/\ 9K*\N3P+>UN)\_\
M7*)Y/_9:_AT_X* ^*;K]LS]N;POX8\][^Q^'FOPQ-;HY=$6SO N'09& $Z$=
M,^]?VQ?$/5XM"\">+]6G8(EEX;UB;<3@"0:?<"/G_KH5K^&W_@F_I]Q\5_\
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MMNKZB<8R:;BFULVM5Z?U^HZBBBI&%%%% !1110 4444 %%%% !1110 4444
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MW4UL]%=??KT]>A^(\89I#,<S<:+YJ.&3I0EO=WUMTLG=?UIVII <CICVI1G
MSU[T5PGR8@)/4$?Y^E+110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 T?>;\/Y44#[S?A_*B@!1T'T'\J6D'0?0?
MRI: "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#D/'^EPZWX'\6Z7,H>.
M]\.ZQ!@C(W-I]QL/U#8K^&?_ ()X7EU\'/\ @H'\?M+U8FWM=5U_5DM%ERBL
M)+R8+LW8'.1TX]*_N^N[=;FTNK4CY;FWG@.?2:)HS^C5_$!_P4K\(W?[&G[;
MW@SQ5:V[P:?\0->MY+BZ13'$5NKP9+,HP1ANY[4FKV?8N,FDXV;ONOZ_I']"
M\Q\S;<#E;@&4'U#'</Y_CBH#R"/6L_PSK-CXC\%>$=8TZ=+J.]T.RN)'C8.%
M>2!&()!/.2:T#GM6!J$:X*CKEAV]2!7YH?\ !4GQC'H_P7UGP<TP27Q#9F!(
M=V#(94*8"]_O=,<U^FMM&Q8R,-R0XED([(IR<]/0U_.W_P %9/B9<_$3]HSX
M+_"KP8[7R7VL:=::M%:DL(PUS%&_FJI([G@TTKR3MJM0_K]3]QO^"!WP\F^'
MO[(UW9SP-"VHZY#>C<NW>'BN#D9 )^\.>]?,/_!PG\-KCQ/IGPM\61VS2Q^&
M98KEY0FX1B*[:3)..!QGK7[J_LD_".S^#?P1\%^&+:)8I9-"TB]NPJA?W\]C
M%*<@=QYI!SS7S]_P5 ^"T7Q:_93^)<MM;"?6_#_AV]O]/(0-)F-#@)P2#O<=
M,_E6VZU6CZ&,7[WKIIYGYR_L'^-HO'7P3TF2*83?V5IMO:,0P;:8H54@C/&-
MOM^N:^O*_#;_ ((M?%][#PAX[^%OC"8P^)+77+JTM+2X;$^Q)F50J/@X(XX%
M?NA/$8',;*5<8)!ST(]ZPY>72UNIN]'_ %U5R#-:6F3QV=U%>W!V00EFD=N
M %)R3_GBLVO._CGXLM? ?P0\=^+KFZ2V?1]+NKA-Y"D[(7(P3CN*.U]%>U_N
M_P Q6;T6_P#5_P #^?[Q#/<_%?\ X+*>%/#M@&NM)BU:V,CH"\8VS \L,KV[
M]Z_NIT32X=$TJPTJW $-C;16Z8&!B-0N<>^*_C/_ .".?PSN_P!HW]JC6?VD
MGM9)K?0]>DC2]92Z?NYVP!(00,X]?QK^T2MTK*QG4=WYK?[E8****9F%%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !7YS?\%!_P#@GM\//VXOAI=>
M&]6@M=*\3VZ7$^FZVD86X-P4+1*TH4L&\S^(L%YYQCG]&:*+A<_@@UGX*_\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M 4444 %%%% !1110 4444 %%%% !1110 4444 (6P0.>:6BB@#\[?V^?V_?
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MO=W6_P"1HE9)+7S]=2K5F*_BT>)]8N&"0V0:5V.  JJQ)YX[<U6KP?\ :O\
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M7]$M9\FK:7%-]GEU+3XKC./(DO+=)L^GE-('S_P&@.:2OKOI_7]6/Y+/C_\
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M4[_@G?8^,_"&L?'+0_$5_?S:C;W^J0SSB>0V]PVZ92T)SM*DCC;Z\=J^V/\
M@F%^SQX/^(7[3WQ5U'Q?'>W.;34F1+IFDB&X2-E5?*]N,?KTH'**3UNKK9>B
MZ^?_  Y_1O\ LC_\%'_A9^TOJVH^&!>VFD^)K!G0V+NL;%H\[E*%MP/![=<
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MY<:IN//)V@9ZGKZFI><]>/3%+10 4444 %%%% !1110 4444 %%%% !1110
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ME\+26&HBQ^QRK(I?/FX?$A)Y$>>.*^K[CQ!HEI>IIUSJ=G#?2$!+:295E))
M QV))'!_&@1L44UW2-=SLJ+_ 'F(4?F>*H76K:99*KW=_:P(WW6DF0 _3DT
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MTO9>;_X9Z?<<#^TE^WY^U7^TM^VA-^R;^S??SV^BV=W)9IY$F&(&V$-@'IA
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MDT+2?#EY:07.M3Z,T0$4#QIYAD:$?PKNR#Z\ T#BKKF5M/BOVTV_KKJ>\_\
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M.(]K,H!R6'0T"37O[:K3^O7\S^HBBBB@S"BBB@ HHHH **** "BBB@ HHHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M2ES(&:%VB0C>#DY!KZ-^)O["GP4TS_@DOX2_:"-K<#Q_:^%[35(=7$[[Q</
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MU'YT;AZC\Z %HI-P]1^=&X>H_.@!:*3</4?G1N'J/SH 6BDW#U'YT;AZC\Z
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@ &!Z#\J,#T'Y444 &!Z#\J,#T'Y444 +TZ"BBB@#_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>g0fyk5pshdve000011.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g0fyk5pshdve000011.jpg
M_]C_X  02D9)1@ ! 0$!+ $L  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" 2&!XD# 2(  A$! Q$!_\0
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M>TJ_\_:G_@<O+S_NHQ#X2T4@#,O'_3>X_H_]:0^#]$)R&FX[?:+G'X_/6]2
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MD_[_ -S_ /'*WR<DGU-)4JC07_+BEO\ \^Z?ZP]?ZW?M*O\ S]J?^!R\O/\
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M_1A2?\(CHGK)_P!_[G_XY6^3DD^II*'1H-?P:3;W_=0TVZ\H>TJ+_E[5_P#
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M[5T_Z>27;LUV_K0Q/^$1T3UE^OGW&/PQ)^/?^E'_  B.B?WI/^_]S_\ '*W
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M,'_A$=$_O2?]_P"Y_P#CE'_"(Z)_>D_[_P!S_P#'*WJ*/8T/^?-+_P %4_\
MY#U_I:GM*O\ S]J_^!RZ6\_[J,'_ (1'1/[TG_?^Y_\ CE'_  B.B?WI/^_]
MS_\ '*WJ*/8T/^?-+_P53_\ D/7^EJ>TJ_\ /VK_ .!RZ6\_[J,'_A$=$_O2
M?]_[G_XY1_PB.B?WI/\ O_<__'*WJ*/8T/\ GS2_\%4__D/7^EJ>TJ_\_:O_
M ('+I;S_ +J,'_A$=$_O2?\ ?^Y_^.4?\(CHG]Z3_O\ W/\ \<K>HH]C0_Y\
MTO\ P53_ /D/7^EJ>TJ_\_:O_@<NEO/^ZC!_X1'1/[TG_?\ N?\ XY1_PB.B
M?WI/^_\ <_\ QRMZBCV-#_GS2_\ !5/_ .0]?Z6I[2K_ ,_:O_@<NEO/^ZC!
M_P"$1T3^])_W_N?_ (Y1_P (CHG]Z3_O_<__ !RMZBCV-#_GS2_\%4__ )#U
M_I:GM*O_ #]J_P#@<NEO/^ZC!_X1'1/[TG_?^Y_^.4?\(CHG]Z3_ +_W/_QR
MMZBCV-#_ )\TO_!5/_Y#U_I:GM*O_/VK_P"!RZ6\_P"ZC!_X1'1/[TG_ '_N
M?_CE'_"(Z)_>D_[_ -S_ /'*WJ*/8T/^?-+_ ,%4_P#Y#U_I:GM*O_/VK_X'
M+I;S_NHP?^$1T3^])_W_ +G_ ..4?\(CHG]Z3_O_ '/_ ,<K>HH]C0_Y\TO_
M  53_P#D/7^EJ>TJ_P#/VK_X'+I;S_NHP?\ A$=$_O2?]_[G_P".4?\ "(Z)
M_>D_[_W/_P <K>HH]C0_Y\TO_!5/_P"0]?Z6I[2K_P _:O\ X'+I;S_NHP?^
M$1T3^])_W_N?_CE'_"(Z)_>D_P"_]S_\<K>HH]C0_P"?-+_P53_^0]?Z6I[2
MK_S]J_\ @<NEO/\ NHP?^$1T3^])_P!_[G_XY1_PB.B?WI/^_P#<_P#QRMZB
MCV-#_GS2_P#!5/\ ^0]?Z6I[2K_S]J_^!RZ6\_[J,'_A$=$_O2?]_P"Y_P#C
ME'_"(Z)_>D_[_P!S_P#'*WJ*/8T/^?-+_P %4_\ Y#U_I:GM*O\ S]J_^!RZ
M6\_[J,'_ (1'1/[TG_?^Y_\ CE'_  B.B?WI/^_]S_\ '*WJ*/8T/^?-+_P5
M3_\ D/7^EJ>TJ_\ /VK_ .!RZ6\_[J,'_A$=$_O2?]_[G_XY1_PB.B?WI/\
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MZ2\3PS1I-"T<L<BATDCVLKHPR&5AD$$>AIR[3G"CWX%?A5_P3'_X*::!\:=
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M&</58XOV."=Z/U>CB:CJNSP_MEI2J-Z*:V>B^1^6X=2<9 ;NI/S#\*:)03M
MRW]T')_+%?H5\?\ ]C9/AQ:^%_&.ESB?1?$UY!!&Z."N)W55Z<=#UKZ!U+]A
M?X4^"_!/A_QGXJ\3VUC=:QIT=VEM+<(I9Y8E=1@L.I/;J.@.:[JG&620H8.O
M&I5K+'5*M&A"E2E.HZM!VJP<8NZY6];HYX</YC*IB*;A3A]6C"I4E.HHQY*E
MG"2;T:E?2Q^.V[M@[O[O?^5.R1]Y2GH&X)K]//A?^QSX<\?^(M5U2#4(F\.V
M DD$X==A1<D8YQT Z=>?K7SA\;_A?X2L/%;>&_!-^E_J%O=K:R0189OOA"=J
M^G/3K^8KJPW$N68K&2P5&55U:=*-2NW3DHT$[-*H[))][O0PJY1BZ-!8BHH*
M$YN%-<ZO5:ZP5KOY7/E#?N)$8\PCJ%YQ]<9H#@G!PK#^$GD?Y_I7ZK>%/V0/
MACX.\#:+XK\<^(K>SU'61%]HM)Y41H%EY.58Y!!]>U>5_M#_ +)>B^%O#5KX
M_P#ASJ"ZUH,TD9N;BW<2QQ"1ER"4RHP#6.&XNR;%8N&$A.M#VM:>'HUZE&4*
M-2M!I2BJCM&[>D;/WNES6KD6.I4)5FH2<*<:M2E&<74A3FDU+DW=M;]C\_#*
M VWC/89&3]!_*EWC.&^0GH&.":_7CPA^PO\ #-/@QX=^+GC?Q+;Z3%J2PR%)
MIDC'(!/WB,XS_P#KZUYM\;OV/_"UG\.9/BE\/M5CU71[%<S2P2*Z!%ZL2AQT
M/YUA1XUR2OBXX2$JZ;Q4\#[>5&:H_6H2Y?9JH_=;<M%;_@EU.'LPI4?;25/^
M#'$*DIIU/8R2ES\OQ62;>RTOZGYH[B3B-3(PZA>2/KC-1-.J36L+_(]S<Q6Z
MJW7=(P4?S]*^Y?@7\(OA-K^G6>HZQXB@%_=R&.:U>09C(8JPYSC!R,'ICTKK
MOVC?V0-%\):#I'Q"\*7RWFF1ZC:S.8F!0#S4;G&1_3\,UW/B;+*>84\OK*O2
MJU*DJ5.=2C.,*E572BG+W=7L^J.=9/C)X6>*I^SG"$5.2C.,I1@[>\TM=GJG
M^NOE/Q"_9@UWPEX*\%^))'$4?C 6XM97P%3SU&UB>@P6!//'&*\N^(WP+USX
M66MC<ZKJ5O?"_MTN(Q"X?:LBA@" >N/\>>M?I_\ M*"Z\0_L]? C2()S!-=C
M3H(;@?*8FVQ*&!7!^]GUKY4^,OP?U+PMJ'AJS\7^)I;^PO+*U=9+B8MY:,J<
M#<>P(^G3KG/SV2<18W$0PSQ>*I*53%YI3GAU2<JE:EA:SA#V=3[+C&W,EO\
M@>MF64X>E*I["C-J-#!255U(QC3G7IQE+GCUNWOT1\ ^;TRI&3CG _GUIY=0
M,D@#Z_I7[%?"C]B+X5?%+X>ZYXJT_P 1VQDT6T>YE'FHN#'&6(!/TXXKY3^%
M_P"RM:_$;XC:KH@N]GAG2;R>*340V(_W)(P7^Z>F,$XYKV*'&&2UGF$74K4G
ME:7UOVM*4'%RUC&*?Q2EM%+5[ZGG3R',*:PSM3J+%O\ <N$T[I64I-K1)/O]
M_4^("Q7!=2BGHS< _3BAI$49+#U'(YXS7[!WO[#W@3Q+H_B6VT?6(#=^&8)&
M@VRJ&N'B0D 8Y.3V'KS7RS\#?V1KKQMXZU72?&TC:1X>TV>54OI3Y:/'$2-V
M]OE.0,GDT4.,,EKX?&8CVU2"P,82K4ITY1JN-2,7#V<7K-R3O:*;6U@J9#F%
M.KAZ2A&?UFZISC).*:LI.32M%)O=Z:'S]\)OAA?_ !/NGMK,&/!(!;@-P<8/
M7G].36+\3O ]Q\.?$']A79S+@G]3T_+VK]M_@G\ /@]X<U37+3PYXKM9;O1O
M,$:Q3QEI6C!XP#DY(Z^_>OR<_;$:1?BI=;CN6WDE5#_?5"<'L.<9Z=ZX\EXE
M_MG/JV%H>UC@X8;VBIUJ4J<U*2BX-7U:=W?M^>^895' 9;3K5?9RQ#J\CG2G
M&<;)I-:=;_TUM\U,X4@'O_G\:&8*,Y!S_GO7W!^S!^S?H/QO^''C/Q/?W\=K
MJ?A^VN9;6V9U5IGB5F50O5B2 !COT[5QW[,G[/,WQ=^)/BOPEXEW:;8Z&;S[
M/<2@Q+(MN6VD%L;LA<]^.M>U4X@RRE_:G/4E%Y-R?78N+4OWG+R^S7V]UL<%
M/*\746!Y(J2S'F^KRT2?+OS/[-OQ^9\GEU&,D;CC"YY.>U!?;_K%,8]7XK]#
MOAC^Q?;^/?'7C6WDN_+T;P9<SIYVX;)$MW89W< \+GBO6=9_8H\(^.-%U!/!
MFIPW6K:5#,;F"-UW*8@V[.T\8V\C'>N&MQCDE"M&C4JU-J4JU10?)05=1E2]
MH[6C=2UOM?[NBGD.858<\81U<U3CS*]7V;Y9<J:U2=UI<_+O2/"6M^(+.;4=
M,LY[BUM03+)$I90%Y))&16"Z/$[1R*5=&*,#UW#J#[CFOWE_8?\ @K\-K7X=
M_$3PWXKDM9+_ $V*\BN)9MA:!T5U/S-RN"I/;WYK\HOVB?!O@_PGXIU9/"VI
M17L*W=R<1.K!2'; ^7IT].#WJ,KXJHYGG.893"C52P<J2HUO9RY*D*L%-2<M
ME?S[Z&F,R6>$R_"8Z56G+V\9.=/F2E&46ERVW^:V^5SP+3=,OM:U"#2M.MY+
MB[N76...)2[$N=O0<]?T^M?;?A#_ ()W?%'QAH\&M#6[;2!<HDB6=W((IL.
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M.+%X2M@:L:-=)3E2A623O[E1)QOYV>Q)1117><H4444 %%%% !1110 4444
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** $/0_0_RI:0]#]#_*EH _S:O"/_ " S_P!=;C_TH>MVL+PC
M_P @,_\ 76X_]*'K=K_26E_ H?\ 7JG_ .FJ9_)$OXE7_K[/_P!*-7PDH?XA
M^!@W"G7K(,>F!Y\9SGVY-?NQ^V]^TCXA^!W@3X3Q^%H[2]FETBSSYBK)LW0Q
M]<YY!_Q]*_!FQG-CJFG:HG^NTZY2YB/HT9# C\:]=^+OQHUCXQ6.B66LN\B:
M%#%!!O)( B0*,9)';M['Z?-9[D"SK-\AQ->G3K8'+UBEBJ-3:;K14866^C6Z
M/9RW-/J&!S*C"<J6)Q7L51J1W7)).7]6WL;NJ?M"^.OC%\4? UUXRG>.PCUN
MS8VX)%LB^>G\'W0 .3D>W:OV;_;.UGPW=^ /A7+IQ:]2STNQ,JZ82^UHX8S\
MXCZ'(Q@\_P Z_GBC+02PW$!\N>W97AD7@HZX*D$?2OKWX7_M;WO@_3!I7C>P
M;Q1!%'Y=JMT//\I0N% #[L8XZ#M7G\0<,RJXC)L;E-",8Y-]8@LOHM4_:JND
MFX2;:3CU;3O^!TY5G/LZ688?'UGSX]TG]9JKVG(Z33?,EK+F_K8]Q^*WQTU[
MQC8_#+P/-#+;Z)9:Q8HGVC*NH66(9.X9_7'%=1_P4;O;F'PI\+[.RU:=(1I-
M@"EM.RK_ *I>&56^GZU\4?$WXXV?C_6+#5-(TI-)CTZX2XAAC0)M9&##:!CT
M]N.>^*Y[XH?&#6?BM9:1::K([#1X8XHMY)XC "XR?11G''\J6$X<K4L;D.+A
MAXX.& GC:V*H2M-JIBDO>OLY-WNUN/$9K3J8;,J#K.O+$QPT*-17BN2EY;I6
MVOV/HC]F;XK^// TMAIEXMY?>&-7F2"[,>]W$$F%;<><<$]^/P)K[+\9?"CX
M4:3XOT;XGZ)<) +ORKC4;:\<9\^0AB-KG.=QX[\8K\Y?@_\ M":=\,(UBUC1
M(]9B3'E+)&L@0C.,9YX..G?WK$^,/[0>O_%"]CET6231=.CD5UM(BR)M7!QM
M&!TYZ5EC,@S'%YU.OAZ3R[#U(5*>*Q5*:5+%TYI)1G26KG%/23MJK[%T,UPE
M#+X4JK^MU82A.C2G%N="<;-N,]N6^\?TW^T?VT/AUXN\6^%M'USPM?7<^F:B
ML45M!ITCLL60N#MC)VXZC@5Z5X7B'PM_8DOO"WC6]6Y\0:DT+6T=])ONEW[<
M "0EQZ#'/YXKX[^&?[9FI>"="@\/>)K(Z];6J@6R3+YHC8  $%\X/?Z?7->-
M?&7XZ>(_BYJ$4D5Q+8Z/#*DB6 8I&JHV0NP8'  [?XUC2X>SC$1P&3XJG1I9
M=EV80QT,=324ZZI23I4N6*<HO6TV[I_GM/-<NISQ.88>52>*Q>%>&EAI7<:;
MFHJ<]VFD]O(_0+]L&XN%_8-\!1VNIS6\ODQ-LMIF1P"HZA6!].H_3FK_ , [
MQD_X)Y:Y#=WINIYU$/\ I,A>8"0*N<L2>_MS^5?G9XZ^-^M>//A[IOPYO7=M
M-TR-(XT8G: @ '!^F0>V*3P_\;];\._#*X^%]O)(NF3C#*"VS/&#@<<8K5<,
MX[^Q:& :IK$4^)WF\FDM<,ZWM+76O-:VE^]U<QEG-!YC4Q7O^S>3++UJ_P"+
M[-0=U?5)IKK>Y^B'AC]G[X8_#CX'>%OB#?W$^H:MX@DW^3:R,[0/*^?F53\N
M"QSG^F:]M^,L&FVO[*=N;.X#)-<V[QQRMF55++@8))! XQ^N.*_,CX:_M7:C
MX,\-_P#"*^*+5O$&FP BPAN 95MCR%V AL$$@Y'\^N5X\_:?USQMX?D\,1B2
MUTQI_-BM@2$C52"% Z< >GOFN"?#.?XG,J-7%U9UJ>&S7ZZL3.HG3GA^9NG2
MIT]'!TH^Z[Z/?UZH9QEM'!3AAX1I.I@EAW146IQK6BI3E*]GSVTZ^I^AOQID
MM_\ A2O[/6VXC+BYT[<%8$K\T><\^_6O+_VO_"U[X^U'P%H&C7>VXDM-/65H
MWPPC94##(.1P3^/Z_$&M_'O7M?T'PSH%S+*T'A9HFME).!Y9!!'7&,#@>U6K
MG]H?7[S7=,UV=Y&?2TBCC!)/^JQCKGT'>NO \,YI@9X2M!TYU<+6S2M%/6-\
M95<Z*>EFE%ZF>)SC XN%:E/G4*T,#"4ET6&A&-37?7_AMC]"/BQI&K?L[?L^
M6&C_  [EOY];UVP2/7&A:0_ZV/\ >9P3@<G.>M;'[$FI:5<?#S6M&U2XC@\2
M7R3W,S2L%NC(X9F )._).>!SCZ5\I7O[<R:UH3:)K>A+?D1>6DDL0?;A=HZC
MC]?;' KYNT/XUZYX:\:'Q7HTLEI9M,9&LHRRH4)SLV @8QQTKFI<-9MB\IQV
M!QM"-#&U<4\:\=S1E+$U%*].G)K50BGRQ3T2^XN6;X&ACL-BL-5<\-3H_5_J
MRBU&E&2BI35W\4GK)WU=[:GZ">)/BK>>!-5\5Z5HUIJ/VE6F66X*R>5)][G=
MT8'\1^=>F?"KQ)_PM7X:Z[I%G<06?BEH+AMT#!+DL5<XR"&))[=\>IKXP\4?
MMD>'O$V@W&FGPC FK7<1274/(7S&<H5+%L9R3UYS[YQ7SQ\,?C-XC^&?BZ;Q
M+974OV2>8S-:*S;?++9*[<X.0<8Z?GFKCPQCL5@*G/@U@\PH2HU:,YU%4^M5
M**5D[77))_9E?3[Q?VS0I8B%J[KX6:G3G&G%P=*-2VJOO*/=/7SW/OG]E/X*
M^/(_B#XMN-4U:^M8M.GN'E-Y-(B3@%B=N\X8$ D=N@[5\>_M@LA^*,T"NLGE
M221NRG()#;<YR>N#7IWBO]N'6]8^?PS:MHMQ,N+Z6!?+:XR,,6*A<[N<Y/X<
MXKY#\:>*KOQOJ[:SJ#M)<.Q9W;[Q;.2>??G^IYKV,ERW.(YO/-LSIT:"EA8X
M>&'IJ/-"48I2<G&UU*S<>RZ'GYAB\O>!C@<'.=5JLZLJLKVFFTTN5O1I:/O\
MCZ#_ &1?B3>^&/B'I7@E9VATOQ#<1P7:>85C*3,%;>.A&"?7KWK]?OVI/AWH
M'[./P^B^*/A22WBNM9TWS[AK7:C%IHBS[F3!)R3GFOP=^!T-O+\8_"2W<_V.
MW^UPE[LMM$6'!SN. ,?7H!^/Z)?MW?'%;S0-)^%UCK)UG3UT^%"XD\U5S']W
MJ<;<]\UXW$N55\3Q;DBP=X4<32=;-J*A>&)H4VDW4DM'):)1?^9Z&3XRE0R3
M,95U>I2FJ> J.2YJ4Y)?#%OF2>]UI?J?0G[!_C/2?&?PI^)GB.>[ACO;Z"]E
MEB=P+B5BCYVY.XDG'//;FOG'0OC/>_#G4/&4OANRU".[NVOX)'N%E\HJWF+E
M<_*1@Y'3\<$'X!^#_P 7?$GP>GC72KJ5-(<G[98(S!)U+9=64'!W#J",<U]!
M^._VM?#7B_1CING^$H-.O9(3'/=1PJC.Y&&=B%&XDY/O[]*JOPKB:.;YG.&$
M^O9?FM6A**52,(86E144H58/6IM=<KTLMA4L[HU<!A82K?5L5@J<XZQ;E6G4
M=^>FU\+[WZ]MCZO_ &0=1N?%O@?XQWESJ#1:UJ_]HR" 2$2,[B0XC&?4]AU_
M3\K_ (B>%]:T'Q#K$>K&[+2W]RRFY+Y*EV(QN[9Z?TKM/A3\;==^%7B)]7LI
M9&TZX=GNK-6.R4,<D%>AR..1Q^8J?XR?&.V^+.JC4+?3%T\8PP5 FYAP2<#D
MGK^78U[V799C\NSS'8BG3ISP&81HSE43BI8>5"DJ:I);O1)W6AYF+QF&QF68
M:E*<HXO"2J)1=VJJJ2YN?2Z33>S6I]1_L$^---CU27X=75Q%;3Z\)(DFF8*@
M,@91DGIDD#^=<%^UM^S=XPT3XKR:?ID,NI6VK,3%=6J&6)?M!)7+("  &]>G
M/T^/-"UK5O"^J6VM:%=O9:E:.KQ7,;,CKM.>JD'MVK[H\+_MVSZ=I,=MXOT@
M:_J\,2I%J%Q$)75E4 ,'8$Y! ]/QZUCCLNS;+\[GG62TZ>,ABZ+IXO!SM&;K
M7M&M&;T48K>-^ER\/BL%B<MAE^.FZ,Z%13HUHIN+A;WJ;BM7)O9^9]?_  6\
M/P?LY?LA>-M'\97T$>L^(K.5K.W=PDH,L9V@H2"#D@'CZ5Y3\/9Y9_V=]>G;
M4I8GD2]D1%E*G#[B"!N].E?!GQD^//B[XO7@)OI[72 V4L S(BH#PH0$+T_#
MZDU4TOXTZUI7A9_"D,D@M'C,3*"=IRN#[9/'_P!>O.I<*YA.G7Q6)JTWF.99
MK1S+%Q2_=T53BDJ<%;I'1M=>YVRSK#*=*C24EA,)@I86B_M3<FFY/736_P!^
MI^C/[*#2?\,__%<2ZK.)"NH!/,G;?T;A,MGOVS[<=?@_X6>._#W@OQCJMUXG
M_P!,A-]<D&X._CS6_O$_7]![<]X/^.6N>#/#6L>&+*61+;6?,$X!.#YOWLXP
M._\ ]:O%+O%Y/+/,-S2N[G/7+L6_KS7LX+(IQQ>>2Q<K4,SK4JE/V5HRY(4X
MP:NM8W:T]-;'GXC,DZ&6>P7[[!PE"2G=IRE+F5U=W5K'W)I_Q&\)^,?C/HMU
MH!CL(%GB^>/$:C+CN,>O&>*]<_:S\):[>7/AC5;6ZO+BQ+6S%XY':+;\G!8$
MC!'OVR:_,+3YY](NXK_3I#;W,+HZR(2&^0@X!'3IVKZ_N/VNKG4O!-EX1U73
MS>75E$D:7CIN;Y% !W'GL._^-<V-R3%X;'Y;BLKA]8I8>G+#U85I7G&$EK/F
M>K?>WZFF&S*C6P^,H8V?LIU9*K"<(^ZY1Y?<45M\]-SZC^)MQ-%^SS:6\&HR
M0.MI$K)#,4;=Y?<*P[XY/_UZ7X'7IC^#;/J5\UU!!%*SQW4AD&%4D\.2.QZ<
M>E?G[K?QLUK7M%ET.1Y!:.<)'EMJC Q@'CITXZ?2H](^,NM:-X<F\-P/(+>9
M&C(!(^\"IZ<?E@5RRX;QKRZ>%?(JE3,GBV[)-4Y6YO>M>^K6C^_2^ZSC"_6H
MUK3Y8X18=*[:<U:S:>FMKM=]S]KO &I:#JO[/_BK4]/GB$-IYXDLK9P)7V Y
MQ&ISZ]NN?7%?%#_';5O#WA36M+T2SO8+>\2XAE%XKA<'<IVAOJ<<]Z^3?A/^
MT9XB^&-Q<PW4DE_H%XY>XTUBS12!S\P*'(.?<>W-==\5OVE] ^(>FBQT/PS%
MHS%<.T42Q[F*\DX"\[N<_P!:X,-PKC,+C\12JX7Z[@\5BJ>)AB>>*A045#]W
M4@_>G)2BW=/0ZJN=T*V&I2A76&KT:$J+I*+<IM[2A+:*:=K6\CY7N5;4O$&H
MSL0)]0O'=B>@DE?MT[G/X5]7_">T^.?P2U31/%'A)[_4+349HFC@'F26Z;G4
MCY1N7&/4#]*^0\N+D7*L5<2B4$'G(.>/3\Z^W/AM^V5#X&T"WT/5]$353:HB
MV\DD0<H5&!@D'&".#QZ>Y^OSVECZF%ITL'@:&8TYQY,1A:]K2AR<L;-[6=WI
MK;[SP,NEA8UG/$8BIA:BESTJ].]U+F3E=*W_  Q^AOQF31_'_P *=(\:?$5;
M"U\>(UM)!$%CCGWY5AD<-G/XD_K\T_MEW=W+\"/AU]GU6XB9%MOEMYF0J!L
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M#S4-=\4303W>D6SS6?VHK(Z"%"R;-^<=!CIS7XS?'/\ :)\2_&2TDLFEDM]
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MX7"TU3HTU:,5U?63[R?5BT445P'2%%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M^8O[/QSM_L=?_P %RZ\OEY_U<<(P"2$P3P<+_GTIVTCHN/H#4?\ PKW]H?\
MZ$"__P# .;_XW1_PKW]H?_H0+_\ \ YO_C=']L93_P!#+!?^#X?Y@L!CO^@/
M$=/^7<O[OEY_@NZ'E,]4S]5S_,4NW P$P/8&H_\ A7O[0_\ T(%__P" <W_Q
MNC_A7O[0_P#T(%__ . <W_QNC^V,I_Z&6"_\'P_S#^S\=_T!U];7_=R\O+7?
M^KH<4!ZH#]5S_2G@%1@+@>@7'\A47_"O?VA_^A O_P#P#F_^-T?\*]_:'_Z$
M"_\ _ .;_P"-T?VQE/\ T,L%_P"#X?Y@LOQW_0'7Z?\ +N7]WR\_P7=#]F.0
MN#Z[?_K4;><[>?7;S3/^%>_M#_\ 0@7_ /X!S?\ QNC_ (5[^T/_ -"!?_\
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M?\*]_:'_ .A O_\ P#F_^-TO[8RK_H9X+_PHA_F)8#'?] =?I_R[E_=\O/\
M!=T.V =$'_?/_P!:G;3_ '3^51_\*]_:'_Z$"_\ _ .;_P"-T?\ "O?VA_\
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M /\  .;_ .-T?\*]_:'_ .A O_\ P#F_^-TUG&5+;,\&O3$0_P Q_4,=_P!
M>(_\%R\O+S_JZ'A,# 4C\/\ ZU&W_9_\=IG_  KW]H?_ *$"_P#_  #F_P#C
M='_"O?VA_P#H0+__ , YO_C=+^V,JW_M/!7_ .PB'^8?4,=_T!XC_P %R\O+
MS_JZ'[2>J_I2X/H?RJ/_ (5[^T/_ -"!?_\ @'-_\;H_X5[^T/\ ]"!?_P#@
M'-_\;H_M?*?^AE@O_!\/\P6 QW_0'B.G_+N7]WR\_P %W1)@^A_*DV=]G/KM
M_P#K4S_A7O[0_P#T(%__ . <W_QNC_A7O[0__0@7_P#X!S?_ !NC^V,I_P"A
ME@O_  ?#_,/J&._Z \1_X+EY>7G_ %=#]O\ L_\ CM&T]=O/TIG_  KW]H?_
M *$"_P#_  #F_P#C='_"O?VA_P#H0+__ , YO_C=']L93_T,L%_X/A_F)8#'
M?] =?7_IW+KR^7G_ %<>5SU7/U7/]*%3;]U OT0#^E,_X5[^T/\ ]"!?_P#@
M'-_\;H_X5[^T/_T(%_\ ^ <W_P ;H_MC*O\ H9X+_P *(?YA_9^.O?ZG7O\
M]>Y?W?+7?\/,DP?0_E2;,\E.?7;_ /6IG_"O?VA_^A O_P#P#F_^-T?\*]_:
M'_Z$"_\ _ .;_P"-T?VQE7_0SP7_ (40_P Q_4,=_P! >(_\%R\O+S_JZ),'
M^[CZ+C_/6DVD=%_2F?\ "O?VA_\ H0+_ /\  .;_ .-T?\*]_:'_ .A O_\
MP#F_^-T?VQE/_0RP7_@^'^8?4,=_T!XC_P %R\O+S_JZ'[3UV\_2@IGJF?JN
M?YBF?\*]_:'_ .A O_\ P#F_^-T?\*]_:'_Z$"__ / .;_XW1_;&4_\ 0RP7
M_@^'^8OJ&.?_ #!U^G_+N7EY>?Y=T/"8Z)CZ+C^0I/+S_!^0(_E]*;_PKW]H
M?_H0+_\ \ YO_C='_"O?VA_^A O_ /P#F_\ C=']KY3_ -#+!?\ @^'^8?4,
M=_T!U^G_ "[EY>7G_5T2@$# 7'_ >?ITI,'T/Y5'_P *]_:'_P"A O\ _P
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M_P# .;_XW1_PKW]H?_H0+_\ \ YO_C=']KY3_P!#+!?^#X?YA]0QW_0'B/\
MP7+R\O/^KH?MYSMY]=O-+M)ZJ3^%1_\ "O?VA_\ H0+_ /\  .;_ .-T?\*]
M_:'_ .A O_\ P#F_^-T?VOE/_0RP7_@^'^8?4,=_T!XC_P %R\O+S_JZ)-IZ
M;3CTQ1M/]WCTQ4?_  KW]H?_ *$"_P#_  #F_P#C='_"O?VA_P#H0+__ , Y
MO_C=']KY3_T,L%_X/A_F'U#'_P#0'B.G_+N7EY>?]70[RQ_SS'_?-.VGIM./
M3%1_\*]_:'_Z$"__ / .;_XW1_PKW]H?_H0+_P#\ YO_ (W1_;&5?]#/!?\
MA1#_ ##ZAC_^@/$?^"Y=>7R\_P %W1)M(Z*?RI"F>J9^J_\ UJ9_PKW]H?\
MZ$"__P# .;_XW1_PKW]H?_H0+_\ \ YO_C=']L95_P!#/!?^%$/\Q?4,=_T!
MU^G_ "[EY>7G^"[HEBWP2QSQ I+$=T;*,$,.A!QQS_\ 7K2U+6M4UM8QJ<\U
MR(0%C$S%RH'89Z#I[\5D?\*]_:'_ .A O_\ P#F_^-T?\*]_:'_Z$"__ / .
M;_XW2>;90Y*3S' N<?ADZ\'*-[;.]UMT[E+ YA:RPF)2=KI0G9[;JVN_]70[
MR@%*A,*>H K<@\1ZU:Z<^CV]U<16$O#PH[",@]05!Q[8QW]*P?\ A7O[0_\
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M8+_P?#_,/J&._P"@/$?^"Y>7EY_U=$F#Z'\J,'T/Y5'_ ,*]_:'_ .A O_\
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M>7G_ %=$F#Z'\J,'T/Y5'_PKW]H?_H0+_P#\ YO_ (W1_P *]_:'_P"A O\
M_P  YO\ XW1_:^4_]#+!?^#X?YA]0QW_ $!XC_P7+R\O/^KHDP?0_E1@^A_*
MH_\ A7O[0_\ T(%__P" <W_QNC_A7O[0_P#T(%__ . <W_QNC^U\I_Z&6"_\
M'P_S#ZACO^@/$?\ @N7EY>?]71)@^A_*C!]#^51_\*]_:'_Z$"__ / .;_XW
M1_PKW]H?_H0+_P#\ YO_ (W1_:^4_P#0RP7_ (/A_F'U#'?] >(_\%R\O+S_
M *NB3!]#^5&#Z'\JC_X5[^T/_P!"!?\ _@'-_P#&Z/\ A7O[0_\ T(%__P"
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M##T\-AJ:ITJ:222U;2UE)]9/=L****\\Z@HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M_P#X-G_F'U>A_P ^:7_@N/EY>2/&O^%!?"O_ *%/2O\ P$@_^-T?\*"^%?\
MT*>E?^ D'_QNO9:*/KF+_P"@FO\ ^#9_YA]7H?\ /FE_X+CY>7DCQK_A07PK
M_P"A3TK_ ,!(/_C='_"@OA7_ -"GI7_@)!_\;KV6BCZYB_\ H)K_ /@V?^8?
M5Z'_ #YI?^"X^7EY(\:_X4%\*_\ H4]*_P# 2#_XW1_PH+X5_P#0IZ5_X"0?
M_&Z]EHH^N8O_ *":_P#X-G_F'U>A_P ^:7_@N/EY>2/&O^%!?"O_ *%/2O\
MP$@_^-T?\*"^%?\ T*>E?^ D'_QNO9:*/KF+_P"@FO\ ^#9_YA]7H?\ /FE_
MX+CY>7DCQK_A07PK_P"A3TK_ ,!(/_C='_"@OA7_ -"GI7_@)!_\;KV6BCZY
MB_\ H)K_ /@V?^8?5Z'_ #YI?^"X^7EY(\:_X4%\*_\ H4]*_P# 2#_XW1_P
MH+X5_P#0IZ5_X"0?_&Z]EHH^N8O_ *":_P#X-G_F'U>A_P ^:7_@N/EY>2/&
MO^%!?"O_ *%/2O\ P$@_^-T?\*"^%?\ T*>E?^ D'_QNO9:*/KF+_P"@FO\
M^#9_YA]7H?\ /FE_X+CY>7DCQK_A07PK_P"A3TK_ ,!(/_C='_"@OA7_ -"G
MI7_@)!_\;KV6BCZYB_\ H)K_ /@V?^8?5Z'_ #YI?^"X^7EY(\:_X4%\*_\
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M2O\ P$@_^-T?\*"^%?\ T*>E?^ D'_QNO9:*/KF+_P"@FO\ ^#9_YA]7H?\
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M;KV6BCZYB_\ H)K_ /@V?^8?5Z'_ #YI?^"X^7EY(\:_X4%\*_\ H4]*_P#
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M>7DCQK_A07PK_P"A3TK_ ,!(/_C='_"@OA7_ -"GI7_@)!_\;KV6BCZYB_\
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M_P#X-G_F'U>A_P ^:7_@N/EY>2/&O^%!?"O_ *%/2O\ P$@_^-T?\*"^%?\
MT*>E?^ D'_QNO9:*/KF+_P"@FO\ ^#9_YA]7H?\ /FE_X+CY>7DCQK_A07PK
M_P"A3TK_ ,!(/_C='_"@OA7_ -"GI7_@)!_\;KV6BCZYB_\ H)K_ /@V?^8?
M5Z'_ #YI?^"X^7EY(\:_X4%\*_\ H4]*_P# 2#_XW1_PH+X5_P#0IZ5_X"0?
M_&Z]EHH^N8O_ *":_P#X-G_F'U>A_P ^:7_@N/EY>2/&O^%!?"O_ *%/2O\
MP$@_^-T?\*"^%?\ T*>E?^ D'_QNO9:*/KF+_P"@FO\ ^#9_YA]7H?\ /FE_
MX+CY>7DCQK_A07PK_P"A3TK_ ,!(/_C='_"@OA7_ -"GI7_@)!_\;KV6BCZY
MB_\ H)K_ /@V?^8?5Z'_ #YI?^"X^7EY(\:_X4%\*_\ H4]*_P# 2#_XW1_P
MH+X5_P#0IZ5_X"0?_&Z]EHH^N8O_ *":_P#X-G_F'U>A_P ^:7_@N/EY>2/&
MO^%!?"O_ *%/2O\ P$@_^-T?\*"^%?\ T*>E?^ D'_QNO9:*/KF+_P"@FO\
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M_M-_]#_J_P#X%S?_ !RC_B!'$/\ T'87_P  GY?WO/\ %?,_XB3E?_0-7_\
M H^7^;^X_P! '^W-%_Z"^E_^#"T_^/4?VYHO_07TO_P86G_QZO\ /^_X;!_:
M;_Z'_5__  +F_P#CE'_#8/[3?_0_ZO\ ^!<W_P <H_X@1Q#_ -!V%_\  )^7
M][S_ !7S/^(DY7_T#5__  */E_F_N/\ 0!_MS1?^@OI?_@PM/_CU']N:+_T%
M]+_\&%I_\>K_ #_O^&P?VF_^A_U?_P "YO\ XY1_PV#^TW_T/^K_ /@7-_\
M'*/^($<0_P#0=A?_  "?E_>\_P 5\S_B).5_] U?_P "CY?YO[C_ $ ?[<T7
M_H+Z7_X,+3_X]1_;FB_]!?2__!A:?_'J_P _[_AL']IO_H?]7_\  N;_ ..4
M?\-@_M-_]#_J_P#X%S?_ !RC_B!'$/\ T'87_P  GY?WO/\ %?,_XB3E?_0-
M7_\  H^7^;^X_P! '^W-%_Z"^E_^#"T_^/4?VYHO_07TO_P86G_QZO\ /^_X
M;!_:;_Z'_5__  +F_P#CE'_#8/[3?_0_ZO\ ^!<W_P <H_X@1Q#_ -!V%_\
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M?_0-7_\  H^7^;^X_P! '^W-%_Z"^E_^#"T_^/4?VYHO_07TO_P86G_QZO\
M/^_X;!_:;_Z'_5__  +F_P#CE'_#8/[3?_0_ZO\ ^!<W_P <H_X@1Q#_ -!V
M%_\  )^7][S_ !7S/^(DY7_T#5__  */E_F_N/\ 0!_MS1?^@OI?_@PM/_CU
M']N:+_T%]+_\&%I_\>K_ #_O^&P?VF_^A_U?_P "YO\ XY1_PV#^TW_T/^K_
M /@7-_\ '*/^($<0_P#0=A?_  "?E_>\_P 5\S_B).5_] U?_P "CY?YO[C_
M $ ?[<T7_H+Z7_X,+3_X]1_;FB_]!?2__!A:?_'J_P _[_AL']IO_H?]7_\
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M7_\  N;_ ..4?\-@_M-_]#_J_P#X%S?_ !RC_B!'$/\ T'87_P  GY?WO/\
M%?,_XB3E?_0-7_\  H^7^;^X_P! '^W-%_Z"^E_^#"T_^/4?VYHO_07TO_P8
M6G_QZO\ /^_X;!_:;_Z'_5__  +F_P#CE'_#8/[3?_0_ZO\ ^!<W_P <H_X@
M1Q#_ -!V%_\  )^7][S_ !7S/^(DY7_T#5__  */E_F_N/\ 0!_MS1?^@OI?
M_@PM/_CU']N:+_T%]+_\&%I_\>K_ #_O^&P?VF_^A_U?_P "YO\ XY1_PV#^
MTW_T/^K_ /@7-_\ '*/^($<0_P#0=A?_  "?E_>\_P 5\S_B).5_] U?_P "
MCY?YO[C_ $ ?[<T7_H+Z7_X,+3_X]1_;FB_]!?2__!A:?_'J_P _[_AL']IO
M_H?]7_\  N;_ ..4?\-@_M-_]#_J_P#X%S?_ !RC_B!'$/\ T'87_P  GY?W
MO/\ %?,_XB3E?_0-7_\  H^7^;^X_P! '^W-%_Z"^E_^#"T_^/4?VYHO_07T
MO_P86G_QZO\ /^_X;!_:;_Z'_5__  +F_P#CE'_#8/[3?_0_ZO\ ^!<W_P <
MH_X@1Q#_ -!V%_\  )^7][S_ !7S/^(DY7_T#5__  */E_F_N/\ 0!_MS1?^
M@OI?_@PM/_CU']N:+_T%]+_\&%I_\>K_ #_O^&P?VF_^A_U?_P "YO\ XY1_
MPV#^TW_T/^K_ /@7-_\ '*/^($<0_P#0=A?_  "?E_>\_P 5\S_B).5_] U?
M_P "CY?YO[C_ $ ?[<T7_H+Z7_X,+3_X]1_;FB_]!?2__!A:?_'J_P _[_AL
M']IO_H?]7_\  N;_ ..4?\-@_M-_]#_J_P#X%S?_ !RC_B!'$/\ T'87_P
MGY?WO/\ %?,_XB3E?_0-7_\  H^7^;^X_P! '^W-%_Z"^E_^#"T_^/4?VYHO
M_07TO_P86G_QZO\ /^_X;!_:;_Z'_5__  +F_P#CE'_#8/[3?_0_ZO\ ^!<W
M_P <H_X@1Q#_ -!V%_\  )^7][S_ !7S/^(DY7_T#5__  */E_F_N/\ 0!_M
MS1?^@OI?_@PM/_CU']N:+_T%]+_\&%I_\>K_ #_O^&P?VF_^A_U?_P "YO\
MXY1_PV#^TW_T/^K_ /@7-_\ '*/^($<0_P#0=A?_  "?E_>\_P 5\S_B).5_
M] U?_P "CY?YO[C_ $ ?[<T7_H+Z7_X,+3_X]1_;FB_]!?2__!A:?_'J_P _
M[_AL']IO_H?]7_\  N;_ ..4?\-@_M-_]#_J_P#X%S?_ !RC_B!'$/\ T'87
M_P  GY?WO/\ %?,_XB3E?_0-7_\  H^7^;^X_P! '^W-%_Z"^E_^#"T_^/4?
MVYHO_07TO_P86G_QZO\ /^_X;!_:;_Z'_5__  +F_P#CE'_#8/[3?_0_ZO\
M^!<W_P <H_X@1Q#_ -!V%_\  )^7][S_ !7S/^(DY7_T#5__  */E_F_N/\
M0!_MS1?^@OI?_@PM/_CU']N:+_T%]+_\&%I_\>K_ #_O^&P?VF_^A_U?_P "
MYO\ XY1_PV#^TW_T/^K_ /@7-_\ '*/^($<0_P#0=A?_  "?E_>\_P 5\S_B
M).5_] U?_P "CY?YO[C_ $ ?[<T7_H+Z7_X,+3_X]1_;FB_]!?2__!A:?_'J
M_P _[_AL']IO_H?]7_\  N;_ ..4?\-@_M-_]#_J_P#X%S?_ !RC_B!'$/\
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M%S?_ !RC_B!'$/\ T'87_P  GY?WO/\ %?,_XB3E?_0-7_\  H^7^;^X_P!
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M_M-_]#_J_P#X%S?_ !RC_B!'$/\ T'87_P  GY?WO/\ %?,_XB3E?_0-7_\
M H^7^;^X_P! '^W-%_Z"^E_^#"T_^/4?VYHO_07TO_P86G_QZO\ /^_X;!_:
M;_Z'_5__  +F_P#CE'_#8/[3?_0_ZO\ ^!<W_P <H_X@1Q#_ -!V%_\  )^7
M][S_ !7S/^(DY7_T#5__  */E_F_N/\ 0!_MS1?^@OI?_@PM/_CU']N:+_T%
M]+_\&%I_\>K_ #_O^&P?VF_^A_U?_P "YO\ XY1_PV#^TW_T/^K_ /@7-_\
M'*/^($<0_P#0=A?_  "?E_>\_P 5\S_B).5_] U?_P "CY?YO[C_ $ ?[<T7
M_H+Z7_X,+3_X]1_;FB_]!?2__!A:?_'J_P _[_AL']IO_H?]7_\  N;_ ..4
M?\-@_M-_]#_J_P#X%S?_ !RC_B!'$/\ T'87_P  GY?WO/\ %?,_XB3E?_0-
M7_\  H^7^;^X_P! '^W-%_Z"^E_^#"T_^/4?VYHO_07TO_P86G_QZO\ /^_X
M;!_:;_Z'_5__  +F_P#CE'_#8/[3?_0_ZO\ ^!<W_P <H_X@1Q#_ -!V%_\
M )^7][S_ !7S/^(DY7_T#5__  */E_F_N/\ 0!_MS1?^@OI?_@PM/_CU']N:
M+_T%]+_\&%I_\>K_ #_O^&P?VF_^A_U?_P "YO\ XY1_PV#^TW_T/^K_ /@7
M-_\ '*/^($<0_P#0=A?_  "?E_>\_P 5\S_B).5_] U?_P "CY?YO[C_ $ ?
M[<T7_H+Z7_X,+3_X]1_;FB_]!?2__!A:?_'J_P _[_AL']IO_H?]7_\  N;_
M ..4?\-@_M-_]#_J_P#X%S?_ !RC_B!'$/\ T'87_P  GY?WO/\ %?,_XB3E
M?_0-7_\  H^7^;^X_P! '^W-%_Z"^E_^#"T_^/4?VYHO_07TO_P86G_QZO\
M/^_X;!_:;_Z'_5__  +F_P#CE'_#8/[3?_0_ZO\ ^!<W_P <H_X@1Q#_ -!V
M%_\  )^7][S_ !7S/^(DY7_T#5__  */E_F_N/\ 0!_MS1?^@OI?_@PM/_CU
M']N:+_T%]+_\&%I_\>K_ #_O^&P?VF_^A_U?_P "YO\ XY1_PV#^TW_T/^K_
M /@7-_\ '*/^($<0_P#0=A?_  "?E_>\_P 5\S_B).5_] U?_P "CY?YO[C_
M $ ?[<T7_H+Z7_X,+3_X]1_;FB_]!?2__!A:?_'J_P _[_AL']IO_H?]7_\
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M7_\  N;_ ..4?\-@_M-_]#_J_P#X%S?_ !RC_B!'$/\ T'87_P  GY?WO/\
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M']IO_H?]7_\  N;_ ..4?\-@_M-_]#_J_P#X%S?_ !RC_B!'$/\ T'87_P
MGY?WO/\ %?,_XB3E?_0-7_\  H^7^;^X_P! '^W-%_Z"^E_^#"T_^/4?VYHO
M_07TO_P86G_QZO\ /^_X;!_:;_Z'_5__  +F_P#CE'_#8/[3?_0_ZO\ ^!<W
M_P <H_X@1Q#_ -!V%_\  )^7][S_ !7S/^(DY7_T#5__  */E_F_N/\ 0!_M
MS1?^@OI?_@PM/_CU']N:+_T%]+_\&%I_\>K_ #_O^&P?VF_^A_U?_P "YO\
MXY1_PV#^TW_T/^K_ /@7-_\ '*/^($<0_P#0=A?_  "?E_>\_P 5\S_B).5_
M] U?_P "CY?YO[C_ $ ?[<T7_H+Z7_X,+3_X]1_;FB_]!?2__!A:?_'J_P _
M[_AL']IO_H?]7_\  N;_ ..4?\-@_M-_]#_J_P#X%S?_ !RC_B!'$/\ T'87
M_P  GY?WO/\ %?,_XB3E?_0-7_\  H^7^;^X_P! '^W-%_Z"^E_^#"T_^/4?
MVYHO_07TO_P86G_QZO\ /^_X;!_:;_Z'_5__  +F_P#CE'_#8/[3?_0_ZO\
M^!<W_P <H_X@1Q#_ -!V%_\  )^7][S_ !7S/^(DY7_T#5__  */E_F_N/\
M0!_MS1?^@OI?_@PM/_CU']N:+_T%]+_\&%I_\>K_ #_O^&P?VF_^A_U?_P "
MYO\ XY1_PV#^TW_T/^K_ /@7-_\ '*/^($<0_P#0=A?_  "?E_>\_P 5\S_B
M).5_] U?_P "CY?YO[C_ $ ?[<T7_H+Z7_X,+3_X]1_;FB_]!?2__!A:?_'J
M_P _[_AL']IO_H?]7_\  N;_ ..4?\-@_M-_]#_J_P#X%S?_ !RC_B!'$/\
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M%S?_ !RC_B!'$/\ T'87_P  GY?WO/\ %?,_XB3E?_0-7_\  H^7^;^X_P!
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M_M-_]#_J_P#X%S?_ !RC_B!'$/\ T'87_P  GY?WO/\ %?,_XB3E?_0-7_\
M H^7^;^X_P! '^W-%_Z"^E_^#"T_^/4?VYHO_07TO_P86G_QZO\ /^_X;!_:
M;_Z'_5__  +F_P#CE'_#8/[3?_0_ZO\ ^!<W_P <H_X@1Q#_ -!V%_\  )^7
M][S_ !7S/^(DY7_T#5__  */E_F_N/\ 0!_MS1?^@OI?_@PM/_CU']N:+_T%
M]+_\&%I_\>K_ #_O^&P?VF_^A_U?_P "YO\ XY1_PV#^TW_T/^K_ /@7-_\
M'*/^($<0_P#0=A?_  "?E_>\_P 5\S_B).5_] U?_P "CY?YO[C_ $ ?[<T7
M_H+Z7_X,+3_X]1_;FB_]!?2__!A:?_'J_P _[_AL']IO_H?]7_\  N;_ ..4
M?\-@_M-_]#_J_P#X%S?_ !RC_B!'$/\ T'87_P  GY?WO/\ %?,_XB3E?_0-
M7_\  H^7^;^X_P! '^W-%_Z"^E_^#"T_^/4?VYHO_07TO_P86G_QZO\ /^_X
M;!_:;_Z'_5__  +F_P#CE'_#8/[3?_0_ZO\ ^!<W_P <H_X@1Q#_ -!V%_\
M )^7][S_ !7S/^(DY7_T#5__  */E_F_N/\ 0!_MS1?^@OI?_@PM/_CU']N:
M+_T%]+_\&%I_\>K_ #_O^&P?VF_^A_U?_P "YO\ XY1_PV#^TW_T/^K_ /@7
M-_\ '*/^($<0_P#0=A?_  "?E_>\_P 5\S_B).5_] U?_P "CY?YO[C_ $ ?
M[<T7_H+Z7_X,+3_X]1_;FB_]!?2__!A:?_'J_P _[_AL']IO_H?]7_\  N;_
M ..4?\-@_M-_]#_J_P#X%S?_ !RC_B!'$/\ T'87_P  GY?WO/\ %?,_XB3E
M?_0-7_\  H^7^;^X_P! '^W-%_Z"^E_^#"T_^/4?VYHO_07TO_P86G_QZO\
M/^_X;!_:;_Z'_5__  +F_P#CE'_#8/[3?_0_ZO\ ^!<W_P <H_X@1Q#_ -!V
M%_\  )^7][S_ !7S/^(DY7_T#5__  */E_F_N/\ 0!_MS1?^@OI?_@PM/_CU
M']N:+_T%]+_\&%I_\>K_ #_O^&P?VF_^A_U?_P "YO\ XY1_PV#^TW_T/^K_
M /@7-_\ '*/^($<0_P#0=A?_  "?E_>\_P 5\S_B).5_] U?_P "CY?YO[C_
M $ ?[<T7_H+Z7_X,+3_X]1_;FB_]!?2__!A:?_'J_P _[_AL']IO_H?]7_\
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M7_\  N;_ ..4?\-@_M-_]#_J_P#X%S?_ !RC_B!'$/\ T'87_P  GY?WO/\
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M']IO_H?]7_\  N;_ ..4?\-@_M-_]#_J_P#X%S?_ !RC_B!'$/\ T'87_P
MGY?WO/\ %?,_XB3E?_0-7_\  H^7^;^X_P! '^W-%_Z"^E_^#"T_^/4?VYHO
M_07TO_P86G_QZO\ /^_X;!_:;_Z'_5__  +F_P#CE'_#8/[3?_0_ZO\ ^!<W
M_P <H_X@1Q#_ -!V%_\  )^7][S_ !7S/^(DY7_T#5__  */E_F_N/\ 0!_M
MS1?^@OI?_@PM/_CU!UO13Q_:^E\_]1"T_P#CM?Y_W_#8/[3?_0_ZO_X%S?\
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MW5IUZ-2BKWJTYQE35M6W->ZDNNHW3G&2A.$X3;2C":DI2;M:R>O;U^95PO\
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M"_W5_7_&C"_W5_7_ !HHH"WK][_KI_5V&%_NK^O^-&%_NK^O^-%% 6]?O?\
M73^KL,+_ '5_7_&C"_W5_7_&BB@+>OWO^NG]7887^ZOZ_P"-&%_NK^O^-%%
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MNO6_[=P;QA',80R[,:BCC812I59.RKI)*S;^VO.U_.Y^YS'Y3]/Y\4W>/?\
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M4(T)<KG-2LYWM=63Z=;6_#?Q'H=_X1UJY\/:M%)%J%F[)*D@*G*DCH1GM_\
M6%>X_LE>"O#_ ,1_C%9>'?%,D4.F;U=6G8!"X92HY(!.1TX)S7T-KW@_X;?'
MGX^^)M2O=:M=%T=YI?(F:2.)& )^89('/'3 KRGXH?#K3/A!XAAOOAAXC74-
M0MIA+YMI,&8I&<X)C8GG'')!ZU]5+.8X_"?V:E7P6:8W+HS]I[*2IX>K6@I-
M^T^"+BWW6_8\2&!EA:ZQ:]GB<%0Q37*YQYZU.$DK<M^977^=[GVU^T;\7/%_
M[.]V/!GACPLNI^#61(Q?6UGYD8B*[0QD52H^7!SG ]\UXK^PQXATSQK^U5_:
M"6$,AO[<^;:RQJR)-+NR"I&!@G'->M_ +]L?P'\5AI'P-^)GA2+4_$NL&/2U
MU*ZM@\D;M^Y#^9(I(.X]S_\ 6[7X9? 6S_9Q_;;L[#3BKVNO63:C;1H<K"LJ
MM(@ ' P<8_SGX1RAE>59YDV8Y?/ YS5RC%UJ.)51RAFM*GR<^(^+W&KW>UVS
MZ:,)8W&Y=C\'BEB<OCCJ%.K1<.66!J3MRTK_ &K[=?-GC_[37[ WQ3\;_'/Q
MGXNT*]LK;3I6EEAL(V17()+!4C!SG' Z_A7YS^(_A=XK\*^*1X*U"SN&UAKC
M[,J"-BQ;<%W!<9V\]?SK]!/B3^T)\68OV^[3P;:^)+F/PU/K$<$^GB5O*DB,
MP4J5SM(*G'(_I7UQKW@OPSK_ .V]X5T_4K&$VMSI%O<3!E0*9S"',IR ,[B.
M?7GBO3P'$&=9'A<!2S9X7%X:IPS_ &IA(X:#A4IT\)3@E3JM_'.6CNOOZ+BQ
M.4Y?F-;%5,"J]"K#.%@ZSK2YHU)5IMN4$OABK;/UVW_-33/V _B[JFB0:ZFH
M6T2W4:R1632*+D!EW@>7D,".0>/Y5T?[)W@#6/A?\?+SP]XNLO,N5A<!+E,J
MVT$94,"/IUST'O\ H#\2](3P1^T(]S-\5DT[PQI5X)!H'VH+$(U.=GEA@N ,
MKT_(UY=)XT\*^/\ ]JB&\\+R17$-M8^5-<18VR,$P6RO7.,]>_?FN7_6;-LR
MP&,H8E4\3@L;D];&>VHX6IA_JC?+*E0E.22J2L[7B[;&KRC X7$T*E+FHXG#
M8Z%!PJ5H5?;I:3G%1;Y5>S2:NCD=(^"]Y\4?VL;'5-+6TM[/2M4CDGMF"JCJ
MDHR-A !SM]/I7??\%.?^%D>'CI&D);Z=;^$;?3HH6CMEC21MD>TDA>3D#T(]
MJ\LB\3^)O#?[6NF6F@W\EE;W6JQK<1HQ <-+SG!'&3SZ?S\Y_P""E_CKQI>?
M%/1M$O=6FETF6QB+VK.Q0DKR=I)!]:QRW"XW&<4\-JI4PM3"T,EE5HTJM.3J
M4XQY5*SO;VK;O&70UQ-?#TLCS:48UXUYYC&G*4)1492EJD[ZJG9ZKKHS\W_.
MS 988WD]$526))[ #GKTKZ2\&_ K6_%'@^3Q.FGW8CCB,N#$P+ #<,?+^?Y5
MY)X"N-)T[Q!92ZM$DFGI-&94<#:5W#(.>.?6OZ"?A)XK^&LOPG2:TL+06BV2
M^: D6#A!DD8/I]>]?7<79_BLFIX987"5:KJUX)U4_=Y?=]Q^;Z:Z'A9'E=#'
MSJ.O7C%0I2:IVUNK>]Z+6ZM^!_.GJEE=:;J=WI]S:SVY@D=,RHRYP2.-PKZ.
M_8ZT73M=^*EG!J\:2V$%U%),KC*^6KY;@^W^>M;_ .UCXA\%:UXDF3PG:06T
MD<K><8509^<YSLZ9Z\\<#/I53]BB)I?B1>( 22FWZ$C'\SS]37H8W&U<7PQC
M,7*G/"3G@V^23]^%TDY)Z-73O%_<['+0HJAG&'HJ:KQCB%[R5XNST5O)JW]6
M/U&_;F_9V\"_$OX5IXN^&MO;0S>%[:-]16U10[&% 6R%&225[\^M?*/@7P5H
M4O[-5YJEU9QIJ-G')$6DC E9HUVG!(SU%>Y1?&1_#WQ D^#>IS;-(\6W2VUR
MSGY L[[#G=QCDCGI7N/[1'P6'PN^%UI;:'")/#NJ6ZW<ES& 8_WZAF^91M_B
M!ZY]:_*L)F&,RO#Y7DF+Q%62KX^GC<LKSD^:KA79UJ<IO=\]^5=MD?;5\/1Q
M=7&9EAZ,4Z>%>&QE.$?=C6^Q-1>RY4KRVUN?B=\.OV=_&_QJU;5)/"X-M:6L
MLBM)+\L8 9OXC@8P,]?;Z]?\2OV,?BC\*] /BG5)TU*P";V2T82NH .<A,D=
M/\<"OU4_9X^'>E1_!SQ-?Z-K$6AS26\SS7ZNBF-@#DELCD'//;]*\PTCQKX7
M\,Z/J>D>,/B!#XTM[F6>!+.:=9_))+IC#LV,>WIBOIY<8YI4S'$PP7LYX; U
MZ6'E@_JE2=>K%Q3FU72]G"5]KM:?<>.L@P,,-1E7YU6Q-*=15_;05.$N96]Q
M^])>BW]4?F)\(OV;_B!\<%GE\,QR6D=J<3/.I14P<'<6X'/8_P#Z_2_'W["O
MQ;^'&B2>(KZZBU2TAB,TD5D1,Z*HW'<$R1@>M??5I>7'P^^#GC3Q'\.8OL<=
M['<SQWENH'V<,&<<IR,<]/\ "O-_^":WQ2\=_&#5OBEI/Q1U:;Q'HEE9:F;:
M&[)D2((DF-HE+ 8[8[^V*Z<1Q+GLL/FN<X:6!IY5E->A"K@JM/FQ=:-1P3BJ
MFJA.+EHWV^9C0RC+/:X3+Z\<1/&8ZG4E3Q-.?+1BX:Q?+NXM)/39>9^>_P -
M/@)XK^+,T]OHMY!8S6K[)DN'$;*PX.0Q!'(]*]-^(/[$7Q4^&?AT^*M2NX=1
ML$C,SK:LLI5 ,Y8(3V_+\S7L_@+X&^./&'Q&^*.N>$]?E\+^$](UJ\$MU%(T
M4,"1S,3E@0HP.!T]Z^\_ /@N0?#3Q@NK^/1XZM+?2;I4B>;[0(G6-AQEFY!!
MQQUQQ3SCBS&8'$T9X7&X2I0Y\)]8P/U6I.M#ZQ&G+V<L0DX4YKGTYK7ML+ 9
M)A\32J1K8;$0J6JNEBO;1C3E[)M<RI.SE%\NMM+_ "/QY^$G[*GQ)^..GW>K
M^%%:&ST]BMS(X(5"I(.XX&,>_OGN:[_QE^P1\8/!OAV?Q++=1ZC;P1&6:*U8
M2N@122&"9Q@5^@_[,.MWG@W]FOXY:EH1^R7=K/J?V:1  T.WS2F#C(QCKQVK
MRG_@G%\7/'OQ:_X6_IOQ"U>;7=,L[755M;:X8RK$%$P3 D)48VC& /PK+&<3
M\1QGGN/PSP$,LR+&8.C4P]2BYXBM3Q,:3M&>R:<[W\MC2CD^4O\ LS"UHXEX
MW,Z%:I"K"=J5-TF]7"U[/E6G<\Y_8]_8S'QLT;5KS59X(KC3ED22.8J'$JYR
M"#TY&,?RK2G_ &%/BMX(\?W][X2O;"?3K21Y$A+H3A23C;] /?ISWKJOV9?&
M'BW0/&_Q0L-!U*6RL8M3U!4@C8A0%DDP %Z<?EP/IY]X9^.'Q8N_V@[[1IO%
M%T^G&\*/;&23;LWGC!..!W/OUKEJXGB6IFF<SHX[!/!QP%+$+"XBE.<(TZD(
M3<59Z3][?\C6%+)X8++XU<-B?;O$RI^VI5%%RG&7+&3ONE97^>AX#\4?AK\1
M_'OQ)LO ]Y:>1K@D6%)(X]L9.<9R!@COG]:[^S_X)L?'#4X[J6SU"WE:PB$]
MQ&CJ75,;SD#I@9Z]_P Z^];'3?[:^.^@)/"+>:XB3?JQ4 )(P^_N[$$@YSUY
M]:]>-QJ7P-U[XG:SK_Q)\^RO=*N&T^TDN P#-$=B*I;'' &![<=*Y,1QCF^%
MI8/"99+!T*RP5*M#"RPTZ[Q%2=94Y*FXW]FEJ[/9&]+(,#6G7KXM5ZE/ZQ*$
MJJK1I^RA&GS*34K7[.VGWGX0I\ ?'%QX[/PW@5GUI9_L[SJ,QHX8@Y/(&#Z\
M_3I7N&I_\$_OC!I6F7VIOJ%O.NFP&XN((Y%:0HJ[R, D]..>H]:^S_V1K+3_
M (HZ[XW\6WMZ@U=+^[DLM1<KN">8Y1U)P>!@C';UZ5W,^M6G@+Q1XEE\1_%*
M.]BF297TA[D.-I!'E["S#VZ?E7HX_B[.HXV6!PKH4ZV#HT9XFC+"5*SQ%>IR
M.?LY03]G&S:7,[)I:G)ALBRZ6'AB:OM94:U2HJ4U6A#V<(W47).SE*\4]-U]
MY^0'@;X$^./B-K]QX6T6"6/4;69K=]R$993MR ?\.AX]*^D9_P#@F_\ &V#2
M;[5C?V[KID+3W%L'7SBJKN/R\DGJ/_K]?J[X'>+-%F^*FI:YX9AC2-4N',D:
MKB1^3OXX)Z8.?Q].*\,?'WXJ7W[2'B+PY<^(+B3P[>7,D+:>78Q^66(V[,[>
M@QTKHQ7$7$M;$XB&7K X6E@\#2QE>&)I.=23<E[2G&WPO1M-[-HSH93DU&C1
MEBEB:\L1B)8>G.C/EC!M>Y)I[ZVO;[S\J]>T2_\ #>I76C:G%)%=V4[02;U*
M[F0E20,=#CC_  KV[X&?'35O@]>L+"S@NENFVMYR*X ) [@_Y^IKN/VVM(LM
M*^(ELUC"MNUX?.GVC&]VPS$\<Y)-?)5GAK^V4_,-Z_CR/ZC\Z^SH?5\^RBA4
MQ-&,J>+H*<Z3O9M6[6T<O/;Y'@3]KEV/J0HSM.C4Y8SZ\KLUY7:T?S]#^@#5
MOC'%;?LW7OQ,71M/_MIK61P?(C!SLW#!QZ^N3[U\T_L=_$N^^-R^)H=1TVT^
MUWAN8X=T2$*6R!C(XQGUZ5M^(8=O[%-R<<?8G.?^ 'W^E>#_ /!.&>33]-\2
MZC;G;-;?:G1AU#+NP?7@@?CWYK\NI9?A:/#W$V)I4TL1ALY]AAYN4KTX*:Y(
M:MOE3_X.Y]C+%XB69Y12J3;I5<#[6K'E2YY.*<I/17=F_P"M]SXH_P#!/SXN
M>,/$FJ:QHMY;"%&GN_LL3*'\H$OC:/8<#&>M?!;_  S\4+X]/PR6TG.N1W#6
MDDNQMJR!]F2<8&&[G _I^FWPH^/OQ0O_ -I36=*EUZX?0Q]I@-B9&,>P;QMV
MDX^N!7O'PS^'GA;Q5\6O&&N:A##!JWGS2P7;! T<A+'<"<8Y':O7I\2YUDE.
MO1S9X7%4Z668?$X-X:DXNG4JVC&-:]W-1T;WNKG%4RG+LPG2G@57HSJ8RI1Q
M"K34E-4[-NG;2-]4KJ^I^>9_X)Z_&/[&;E=0MG<6OVTP"16D$>W?C;DG...G
M7I7SEI?P>\8:OXRF^']M;S#6H9S;,2C?-(&V<#'KZ=/I7[07UXG@+X@7^I:]
M\5E^R*DL<>E/<@J8@"!%Y9?'3CI@\_6OG[P;XL\-:Q\?[;7- CAG*W_F23QJ
MI\XARQ;/?)YYZ9]\G3 <59Y4IXNK75#$TXX'ZSAJU+"U,/2IUK<WLYN:M./3
M1BQ>299&>'A2]I0G+$^QJ0E6C4E*G>*<ERZQ=]=?/:UCY7\:?L&_%OX=Z%;>
M(_$-]!%;7BJ\=O(ZK+\PR/E.#W_.H?"7[#_Q+\<P6\VF:Q8Q_:E+1(\T:GH#
MC!;KQ[^M>G_M[_&_XF:Q\7M!\*V.N7$&B7#0VD.G+(P0.VQ%&P-M/48X[5[;
MX#^!/Q&\*Z7X5\1>)?B?/X7CU:.":PM9;IHO,60!E"AG'WLX]_KFMGGN>X?)
M<OQN.S++</C<SC5K8>G'!U*J<(J\:2IQNY2C9.4K=]C'^S\KJ9CB</A<'C*U
M#!\D*LG7A!<[Y4Y<SV3>D5OL?G1\4/@'XV^#>MVOA_Q,K3W%[,MO!/&-T3.Y
M"KAQP<D\"O<O#W_!/GXS>(-(TSQ!]JBT_3]9C2:T:Y81AD<!EP6 QP<#MZ5]
MM_M>^&;?3O!?@*ZOKR/7=2.JZ?\ \38XD>53-'SO&2<_4\>U9W_!0_XL_$GX
M>? /X-?\()J5QHP?3],$DUONC)!2,')C(SGU/3V-88?BK/<RAP_ALOE@Z6-S
M;%8O"5\1B*3]C?"Q4E4A2WCS/[+^[4UGD^7826:5L5'$2P^"H8>M3HTIKGM7
MDER2EM)Q6SZZ['Y]?$#]D#XG?#:ZMK?629XKV18H+J/YH6=S@!7&1UQW[UYK
M\2_@UXO^$%GI=YXHAEV:T(S8[D(+B4+M*\<]?\*_73Q!XHUKQ%^Q3X$\:^)Y
M6N=8M;FQN;G591^\8(%9\NWS] >XZ^O2YK7@.V_;(L?A;#HT"7=GX?L[4:C+
M&JE<VZ)N+%0<_=YSS3PO&684?9SS6.'^JX7&YA@<RQ-&')!2PD4Z<H7TC[66
MBBM?+05?A_!5'.&#=55J^&PN)P=*4KR<:[7/&:6_)'?1H_)G6/V>O'/AWX=V
MOQ2U+*:!>()(XW!#;6&X=?8CZ]*\2BE6:-94^ZXR*_2?]MOQ]/X-BM_@1:R
M:;IUND/DK@*&C&UAM''!7T'/?-?FK#'Y$*QJ,A!@#\?\FOLN'\;C,RRY8W&1
MIP>(JSJ8-4URJ6#=O8N2>\VM_P#*QX&9X;#X/%?5L.YOV-.,*[F^;_:$E[1)
MW?NI[6)FW8^7KG_/6E&>](#D=,>U+7L'!I9]]+?J%%%% @HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MDTE*,XW]YONETNT<D<SQ=.-=4YJ'M\5'&U)1^)5HN]XZ:+_,_734OB1^R_\
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MJ*2VT7<5+/<;1I4Z=J,W2C*%.K-/VD83OS1371MM][]3]$/AS^TQH'A?X/\
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M"GA</0PM%<M'#TH4J:[1BDDCPJM6=>K4K5-9U9RG+U84445J9A1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M>!#O898;2&52>OOTK^V?X+_!GP7\#_!6D^#?!VE6FG6]C96]O<RP1JCW<L2
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ME']?EK^OT?\ !'+X1C)$=EGW0<_^.G_/-/7_ ((Y?"/.6%@.3P48]O:(T_\
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MTI\8VYY.GW0S_P!,S_\ $FOZ^_\ ASG\)/\ GG9_]\#_  H_X<Y?",=([/\
M[X'^%'_$<N&O^?%?_P !EY?=_P %]@7ASFB27M(?-I]O^#_3/Y _^$PM_P#H
M'W7_ '[/_P 32#QC;$D?V?=\?],S_P#$U_7[_P .<OA&>L=G_P!\#_"C_ASE
M\(QTCLQ_P ?X4+QRX;7_ "XKV_PO?3NF_P ?R8_^(<YK_P _(?U_3_IZ?R!#
MQA:CY/[-NCGGF)S[?W?_ *U(?%EH#G^S+D$<\1-G\BM?U_?\.<OA'_SSL_\
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M37]?G_#G/X2?\\[/_O@?X4?\.<_A)_SSL_\ O@?X4?\ $<N&_P#GQ7Z?8?\
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M%O\ ] ^Z_P"_9_\ B:_K\_X<Y_"3_GG9_P#? _PH_P"'.?PD_P">=G_WP/\
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ML/\ N_U\WV8?\0YS7_GY#^OZ?]/3^0/_ (3"W_Z!]U_W[/\ \31_PF%O_P!
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M#_N_U\WV8?\ $.<U_P"?D/Z_I_T]/Y _^$PM_P#H'W7_ '[/_P 31_PF%O\
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MG_WP/\*/^(Y<-_\ /BOT^P_[O]?-]F'_ !#G-?\ GY#^OZ?]/3^0/_A,+?\
MZ!]U_P!^S_\ $T?\)A;_ /0/NO\ OV?_ (FOZ_/^'.?PD_YYV?\ WP/\*/\
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M_P!/3^0/_A,+?_H'W7_?L_\ Q-'_  F%O_T#[K_OV?\ XFOZ_/\ ASG\)/\
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M/^(Y<-_\^*_3[+_N_GZ:7?G<_P"(<YK_ ,_(?U_3_IZ?R"?\)A;_ /0/NO\
MOV?_ (FC_A,+?_H'W7_?L_\ Q-?U^?\ #G/X2?\ /.S_ .^!_A1_PYS^$G_/
M.S_[X'^%'_$<N&M/W%?I]A_W?\OQ?F'_ !#G-?\ GY#^OZ?]/3^0/_A,+?\
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M?9A_Q#G-?^?D/Z_I_P!/3^0/_A,+?_H'W7_?L_\ Q-'_  F%O_T#[K_OV?\
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M (CEPW_SXK]/L/\ N_U\WV8?\0YS7_GY#^OZ?]/3^0/_ (3"W_Z!]U_W[/\
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M.?PD_P">=G_WP/\ "C_B.7#?_/BOT^P_[O\ 7S?9A_Q#G-?^?D/Z_I_T]/Y
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M=G_WP/\ "C_ASG\)/^>=G_WP/\*/^(Y<-_\ /BOT^P_[O]?-]F'_ !#G-?\
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M_P#0/NO^_9_^)H_X3"W_ .@?=?\ ?L__ !-?U^?\.<_A)_SSL_\ O@?X4?\
M#G/X2?\ /.S_ .^!_A1_Q'+AO_GQ7Z?8?]W^OF^S#_B'.:_\_(?U_3_IZ?R!
M_P#"86__ $#[K_OV?_B:/^$PM_\ H'W7_?L__$U_7Y_PYS^$G_/.S_[X'^%'
M_#G/X2?\\[/_ +X'^%'_ !'+AO\ Y\5^GV'_ '?Z^;[,/^(<YK_S\A_7]/\
MIZ?R!_\ "86__0/NO^_9_P#B:/\ A,+?_H'W7_?L_P#Q-?U^?\.<_A)_SSL_
M^^!_A1_PYS^$G_/.S_[X'^%'_$<N&_\ GQ7Z?8?]W^OF^S#_ (ASFO\ S\A_
M7]/^GI_('_PF%O\ ] ^Z_P"_9_\ B:/^$PM_^@?=?]^S_P#$U_7Y_P .<_A)
M_P \[/\ [X'^%'_#G/X2?\\[/_O@?X4?\1RX;_Y\5^GV'_=_KYOLP_XASFO_
M #\A_7]/^GI_('_PF%O_ - ^Z_[]G_XFC_A,+?\ Z!]U_P!^S_\ $U_7Y_PY
MS^$G_/.S_P"^!_A1_P .<_A)_P \[/\ [X'^%'_$<N&_^?%?I]A_W?Z^;[,/
M^(<YK_S\A_7]/^GI_('_ ,)A;_\ 0/NO^_9_^)H_X3"W_P"@?=?]^S_\37]?
MG_#G/X2?\\[/_O@?X4?\.<_A)_SSL_\ O@?X4?\ $<N&_P#GQ7Z?8?\ =_KY
MOLP_XASFO_/R']?T_P"GI_('_P )A;_] ^Z_[]G_ .)H_P"$PM_^@?=?]^S_
M /$U_7Y_PYS^$G_/.S_[X'^%'_#G/X2?\\[/_O@?X4?\1RX;_P"?%?I]A_W?
MZ^;[,/\ B'.:_P#/R']?T_Z>G\@?_"86_P#T#[K_ +]G_P")H_X3"W_Z!]U_
MW[/_ ,37]?G_  YS^$G_ #SL_P#O@?X4?\.<_A)_SSL_^^!_A1_Q'+AO_GQ7
MZ?8?]W^OF^S#_B'.:_\ /R']?T_Z>G\@?_"86_\ T#[K_OV?_B:/^$PM_P#H
M'W7_ '[/_P 37]?G_#G/X2?\\[/_ +X'^%'_  YS^$G_ #SL_P#O@?X4?\1R
MX;_Y\5^GV'_=_KYOLP_XASFO_/R']?T_Z>G\@?\ PF%O_P! ^Z_[]G_XFC_A
M,+?_ *!]U_W[/_Q-?U^?\.<_A)_SSL_^^!_A1_PYS^$G_/.S_P"^!_A1_P 1
MRX;_ .?%?I]A_P!W^OF^S#_B'.:_\_(?U_3_ *>G\@?_  F%O_T#[K_OV?\
MXFC_ (3"W_Z!]U_W[/\ \37]?G_#G/X2?\\[/_O@?X4?\.<_A)_SSL_^^!_A
M1_Q'+AO_ )\5^GV'_=_KYOLP_P"(<YK_ ,_(?U_3_IZ?R!_\)A;_ /0/NO\
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M[/\ [X'^%'_#G+X1_P#/.S_[X'^%"\<N&_\ GQ7Z:\OI^=NW7U#_ (ASFO\
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M?8?]WR\OQ?F'_$.<U_Y^4S^0'_A,+?\ Z!]U_P!^S_\ $T?\)A;_ /0/NO\
MOV?_ (FOZ_/^'.?PD_N6?_? _P */^'.?PD_YYV?_?(_^)H7CEPU?6C7_P#
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M,5:,8K1));)"'H?H?Y4M(>A^A_E2UF4(.@^@_E2T@Z#Z#^5+0 4444 %%%%
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M)O"4/XM*Z5XSGM=?/R/S7,?$["TIRIY;A)5N5V5>K_#GJK-0W7H_\CZOU?\
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M^6A_69X9_P"#C#]B'5;B.QU2]U&RNY'5!Y4J"/)P.1)&Q_\ 'Q^M?H'\$?\
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M4914KQ?O*_\ -#>.O<_22BBBO,.D**** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHI#R,=* %KC_ !EX
M\\*> =&OM=\4ZYIVDV-C"\TIN[NW@=@BEBL:2.KL2!G@' Y]*^$OV[/^"C7P
M@_8O\$ZCJ>L:UINH^+(H)6M-"$ZO-YB A5:,-N9RXQC!7W/./XEOVD_^"@?[
M5/[>7C/4K[PUXAU;P5X.:\D"V*3W%M%/:L6'"*RJ05]?Z9KU\ER+-N(<9'!9
M1@ZF+K2:4G%-4Z:;5W.=N563O9N_Y'%C\QP65X=XG'XB&'I+9S>LGO:,5K+Y
M']5O[0W_  7I_9-^$$^H>'=+U*75_$D)FACV2QR0+*A*@JL:\G<."6(P>G>O
MQ[^)O_!?_P"/.M7-Q)\*;6?[([NUK\I'[LGY/T_+\.?QMT/]GOPH_EWOCVW.
MO:V3OFO9I&E=Y#R22V2>>>?7/O7JNF^"_"FBJL>EZ<D"(,(-H^4=AT_SQUK]
MYR3P"J3I1JY[F:C*=FZ&&3C.ELW&4MFUIKM;H?FV8>)]*$Y1RS!<_*[>UK>]
M"=K:J.Z3WMK9GT[=?\%T?^"D9O"UK:7)M221P<8SP.OI7K_@/_@O7^U_IMQ
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MO]&?X?>,M,\?>#?#GBS2;B.YM=<T?3]1#1L&"M=6T<KJ=N0"&8\>F*_A//\
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MO*SPQ3*?59$5Q^C5_F/>#/$-[\._VY?@B^FRM;VM[KNF?:MA**P:YBW;@O!
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MXW&GV\Q/XE\UO5_)"=]3]N"BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M=NA**HXZ$]Z_L8!R 1T(!'T-?YS?_!/OQ[/\)?VV? _AJUG-JGB'5K17B#;
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M^ES^TRBBF@$#^\?RK^;C]7'44#/<8_6B@ HHHH **** "BBB@ HHHH ****
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MI7&44 =G_P )3+[?I1_PE,OM^E<910!V?_"4R^WZ4?\ "4R^WZ5QE% '9_\
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MSQ\@J_0 UVVJS>@S7&W?B.2WF,8Z X'3MWKL)?\ 5O\ [IKR/5?^/MO]YO\
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M@LG:5?+/ON.,?K_]:@#^+;_@OEK=WK?Q@\,QWQ9HH]13RP_W0/.3&,\#&/\
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M1M?_ "5NY5UC#Z)J8?&#;N#Z?=X_6OI'_@CKK%YI/[5=A#:EQ;/?1[@OW?\
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M1;_>5'XH^J^3OH?YW?[,2*/%'Q7E &^7Q!?L_P!?/DSGWQS7U4VW'R]<^_\
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MIO"_9I]W#8.,!?;'U&*_OI/[K2M$L.^G:;;VA'H88U0CV^[7X0_\$,_V,O\
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M'PNCT'X;:=I=MK"QE2UJD2R;L$<;!GOD>_TK\&HDVG#=.1G\>/>J\&FV]O\
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M/,HJ9=E53&5H\M7,&K0DO>5*%N27>TD>U2,68YYQD#Z G%,HHK\5/OPHHHH
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M@T =;1110!CZ[_R#9OP_DU>2K_%_O&O6M=_Y!LWX?R:O)5_B_P!XT .HHHH
M**** "BBB@ HHHH **** &@DGC[OK^'^>U7+9XMWE74:SVKAUE@D&Y'#*5(9
M3P<Y[^M5>G04@.21CH: /Y0O^"V'_!-/6H-9E_:=^#>FL-<MFEO[ZSTZ G,:
M$R/E8AU(SVK\2/@U\5[;QC8#PYKH;3_%>E!H=3AO?W,IFC.U@%?:QY4].W:O
M]&O7-$T+QAHE_P"&O%-G%J&EZA;O:M#-$L@VRJR-PPQT)K^2C_@J!_P1C\1^
M'M:UCXZ_LZP36:PR3:A>:/IP9&NMK-,Z>5".=V2,8^O/7],\.O$/%\%XSV&(
M4\3DN*FEB,/=WH2;5Z]*[>JWEILK(^4XJX6P_$>&4X\M#,:,7[&MTGHK4ZEM
M]K)KUT/S;9"IX.Y>S#[I^AZ?K3*^9O"WQG\3>%[R3PO\7/#]SX2N;"4V37&H
M0R0>88B4,F9%7.2"<Y[^E?0.E>*?"VOQQOHFKV]^) "ODR*V<C/^>/QXK^Q,
MGX@R?B#"T\7E6.H8BG.*?(IQ55.UVI4[\U]U>UG8_ \QRK,,JK2P^-PU2G*#
M^/EDX-.WO<R5DFE>V^_8V**M?8[C /EG!Z&FBUF/1#7M<LOY9?\ @+/,YH]U
M_7]?UJ5LC..]. ).*G:TF0%WC*J.2QXX^OX5R6L^.?!GAU'?6-=MK)T!RDLB
MJ=PS@8///;@<=<U$YPHQ<ZU2%""5W.K)4XI==9-+\2HJ51J-.,YR;BK0BY/5
MJVB5]=CJ5C')D98T7[S.< #@]<@8QWSQ7S;\8?B=?RW4'PS^'L,^I^--7FBM
M;7^SP9\&=_+^;R]V,%CD$]NO-9VI^/\ XF?&/6H/ ?PA\*W^MQZM.+%=7L+>
M:1(3*0@D\R-2!C(.2?Q Y/\ 2C_P2S_X(R6_PP;2OC-\?+?^W/$M['%J%G#?
MKY\EG(=LRKMF!*[2<=!@]Z_"_$3Q<P.5X:OE'#E6&+S*JITJN+A).CA4U:33
M5^:=G[CC>S^]_IG"? N(Q=6EC\XI2H8.$HU*="7\2O)6<=-+1_F3_(]$_P""
M*W_!-=?@9X:@^//Q,TY)/'VNQQ7LD%[#B1//429PXSD9K^AJZF$\TDBKLC9B
MR1CA4!QP!VJ***TT^TM]-TR%+:PM88[>*&-%C4)$ JX48QP/3ZTROY/J3J5:
ME2M5J2JU:U256K.3;E*<G>4FWU;^78_:THQC&$(J%.$5&$(Z*,8JR226BT"B
MBBH&%%%% !1110 4444 %%%% !2K]^/_ 'Q_6DI5^_'_ +X_K0![!IG_ !XV
M_P#N5?JAIG_'C;_[E7Z (Y?]6_\ NFO(]4_X^V_WF_\ 9J]<E_U;_P"Z:\CU
M3_C[;_>;_P!FH SZ*** "BBB@ HHHH **** "BBB@ JQ;S>5-$[ ,B.I9".&
M4'D'/M5501G)S^9IU'K^';_,5]?.WX'\]W_!<#_@GN?C?X1G^/O@73@OB[PQ
M&UU!%90[II#;C?T1<G.T^O-?S#?!#XE76HPS^!?&BR:?XQTNXDM)XKW]S(1;
ML8N%?!ZKVX/4]\_Z15S9Z7K6GW6B:_;1WND7D$L$UO+&LBD2J5.588_B/\Z_
MDF_X*Q_\$A/$7ASQ!J7[0OP#LYDDWSZC=:9IJLOF;BTS+Y4(QVQT[]<BOT3P
M\XYQ/!69\T^>KE.,:CC,->ZC=Q7MJ:V4XK=V6B>USYKBGARAQ%@N5*-/'8>+
M>&K6LV_^?<WU3?X]#\U'41R%&.0"1N'*GTP1]?\ )XIK#'(Z'I^/ZU\V_#_X
MVW%O</X0^*ED_A/7=*;[(RZ@CP27$J?NRW[T*22RYQ_7!KZ0MIK;4HDN-,F6
M[MV4,LD;!@0>A'..A]>G2O[2R?.,MS_!T<=E6*IXK#UH1FN22=2%[74X+WHN
M+=KM):,_GG'Y?C,KQ$\+CJ%2C4INS<HODEV:E:S3WTVNKA3EV\[OPZ_TI6C=
M,[E(QU_R*97I:]CC7PIMJ_5+[[_U\@I,<D]S_G^E+R>*G6WF<$JAP.M-*3V3
M?HKBT7E?4@JMJ6HV.A:=<:SJ<T<-M8JTLBR,$9D4;C@-CT/K_C@>)_'GA/P=
M:23ZOJUO;7**_EV\CKN=U!(4+G))( P!FO+/A5\(_CA^WC\1]-\$^#?#^IZ=
MX->]CM[O5HH9X[:YMS* S>8JA2"F>_<^]?'\7<:Y1PC@)XG&UX3QCC;"X*G*
M+JU:MO=3BG>$>KYDM/6Z]_(>'L?GV)A3P].4,.I1=;$SBU"$.MKKWGTT>YN_
MLV_ WQO^WI^T5HWA?2["^?X9Z?JUN]Y=-"[6Q$4H+?/C9@X/)R.:_P!!GX%?
M"30O@'\(O#7PLT*T@@AT2RM8_.B4*S%8P#NP!SD'_P#5U^7/V _V"_A_^Q7\
M+]*TF+3;:;Q7=V$3W5\8D>7[08QN+2$%MVX]SVK[TDEDF<R2'+'C/L.!]/I7
M\1<09]C>)LVQ.:YA-NK7D_90;;A0I<UX4X+HDDO0_HW+,LPN4X*C@,(E&G3C
M'FEUJU+>]4E:]W>^[\NA'3@2O;K_ )_K3:<K#^+GT[X_.O%7NM:O;5K?;;71
MG;:UM.ET-HHHJ0"BBB@ HHHH **** "FO]T_A_,4ZFO]T_A_,4 >A>%_]6/]
MW_&NPKC_  O_ *L?[O\ C784 %13_P"J?Z?U%2U%/_JG^G]10!Y#JG_'\_U-
M4JNZI_Q_/]35*@ HHHH **** "BBB@ HHHH ***4'!Y'% $UM<&VF28#<4.=
MOK7X;?\ !8K_ ()QV?[27PWOOBE\.]/B_P"%F:3;S7RFVA!N2+=6D/*_-DX]
M_6OW#'+>V?ZU-N3;-;S(DEM=0O!/$ZAU:*1=K+M((Y''TJH3G3G&I3G*G4IR
M4X3CI*$HNZDGT:!I23C.*E"2:E%[23Z-'^:I\*/B)JWA'6KKX0?$JWNM.\3:
M!<36LTE^C0!VBD,8VF3&<D8KZ@DVE5EC998W&5:/YAM/3D$CG/K7[Z?\%2_^
M"-F@_'JTU+XN? ^U30/&-DKWM[]B402WLR+YCC$0!8LX..YSZ5_+8_B/XM_L
M_P#B.Z^'?Q8\):C8V>G7'V(:Y>V\RQ,L3!#)YKJ!R%)SGH,FOZH\-_%O"8S#
MX;)>):RH8VDH4</C9O\ =XA12C&,WTE;=NZZ/N?B_%G F(H5JF8Y/3E6P]1R
MJ5L-'6=*3UDXKMULD?30 &2._/\ G\Z6N4T3X@>!_$<49TG7;6ZG<#=#'(A9
M6.,C /8\'./SKLDBEE0&.,LAY#=L$Y!S^/O7[Y2J0KP4Z%6%>G)*2E1FJD6N
ME^5M:]MS\QJ0G2ERU82IR3LU.+CJM'NEUT(**L&UF'5#_G^5.%G<'/[L\<UI
MRS_EE_X"_P#(SYH]U_5OZ_IE6G*A8@#@>IS@<XSGVK*U/Q%X;T%'DUS58+!$
M!+&5U7&/K_\ 7_K7@'B_XX:OJ4\?A[X3Z+/XQOK]_L:/IT+W!B:3Y0Q\I6Q@
MD'/7ZUY&;Y[E&0X6IB\UQU##4Z:NXRJ1]H]G94T^?6]KVW/1R_+,=F=:%#!8
M:K6G-I)J+4%>VKDU:UG?Y'<_%OXK:=\/-(EM;-A>^([K$=C;VC"24O(=J HI
M+=2.V?;I7ZF_\$7?^"<'B?XD>/8_VF?B[I4K:9)<QWME:ZI;G:JEED0JL@QT
MQT'XU0_X)J_\$:?'7Q?\3:/\;/V@(;E=+$D&H+H>H;\1KN\X1^5,,=".,8K^
MPWPIX2\+?#?PQI_@SP-IUOI>AZ?:Q6IMX(4B#-$JKN^51UQD_A7\>^)/B+7X
MSQ4<)A%/#Y+A:G-0IJ34L1*-E&K5LU?:\=U8_?.%.%*/#M#VM9QJYE7BO:U;
M+]RM'[.._31V>Z-T0VNF6L6CZ8BQ:;9*L5M"G$:(B[0%48   XJN2!UI$;..
M.F/QI[8)Z<>F*_+CZT2B@<8]*4G)X'% "4444 %%%% !1110 4444 %>B>&?
M]7_P'_XFO.Z]$\,_ZO\ X#_\30!UE%%% &-KO_(.F^A_E7DXZ?B?YFO6-=_Y
M!TWT/\J\G'3\3_,T +1110 4444 %%%% !1110 4444 %6[2:)'*W,2W%N\<
MD;PR &-A(I'(/'<U4HIIVZ)^HTF]O/3[O\S^4/\ X+7?\$T-:M]:G_:;^"NG
M-_;R--J&JVNG0%F$0;S),K$/3../7'>OQ'^#OQ8M/&-C_P ([K>[3_%.D P:
MG!??N9#<191@!)@G+ ^_TK_1IUO1-$\7:)?^'/$MG#?Z;J-N]M)%-$DJ[)%*
M-PP(Z'VK^2C_ (*@?\$8?$>@:WJOQW_9T@FLTBFDU&^T;3PRFZ*LTSKY40&=
MYSQCG/7T_2_#KQ#Q7!6-]C7Y\3DV)E'ZQ03;=!MK]Y2OL_Y^Z2ZZ'RG%/"V'
MXBP_/%JCF-%/V%6VE1:6ISVWVCK;T1^;C(5/]X=0R\J?H:97S/X7^,_B;PM>
MOX5^+F@7'A*YL9?L;76HPO;^88LHSAI%&<D9ZX/O7O\ IGBCPOK\:/HFKV]]
MY@4KY4@.<\C'U_R?7^Q<ES_*.(<+3QF58VA7IU$GR>T2JQ;2?*X-\][OL?@.
M991F&65Y4,=A:M&<)?%:\&NZDERV>ZZ_KM $]*2K*VER #L;D=>>0>12"UF)
MQL/^?R'ZU[/)/^67S3_KJ>=S+OO_ ,#^OO\ ,A+J@! YZ'KZ?XBHP2,EOP_S
M_C5M[29%+2(0B]2<<?S_ ,_E7':SX[\%^'HI&UG7+6S=,C9+(H)8$8&,C\,>
MQK.<Z=).=:=.C!*\IU91IJR_O3:6VPXJ4Y1A3A.I.324:<7)ZM+9)]_S.JC"
MMR[")%/S/)\JCZG_ .O7S7\7OB7J>H7UM\,/AQ!<:GXRU:XBLXOL"F<*L[B,
MY,>['7G\\]*HWGC;XH?&G6[?P#\'_"E_K$6KS_85UFPMII(X3(0GF^9&I"@9
MSGVXP!Q_3+_P2S_X(SV7PE&E_&'X[6XUSQ7?)%J%LE\OGO:2'$JIMF!(*DX/
M3^=?A?B+XMX'+,/7R?ARM'%9C5C*E6Q<&G2PJ>DN62OS3M\+B[?K^G<)\"8C
M$UJ>89Q3='"4VITL/+XZ\M&KZ:1ZOR/1O^"+7_!-J#]GSPK;_''XB:='+X[\
M111W=S#>P_O86N LF0'&X$%NPZC/%?T"7$OFRNRC:A=BB#[J@] !V H L[.U
M@T[3(([:PMHHX8HHD6-0L2A1\J@#@ 5!7\H5*E2M4J5:LY5*M6<IU*DG>4YR
M?O2D^[9^TQ2C&$(1480BHPA%6C&*5DDNP4445 PHHHH **** "BBB@ HHHH
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MN[%@%4'  .1CGI[BOR7\7_L'_P#!2/X=ZC+"GAG49M$@;;'(+:1LQ*<9!QW
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M%M;+Q';Q_+'&O9548  '  'M5>BOF5HK:OS;;;]6]6SUM?\ @;+[E:P4444
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M2#_<_J:MU4L?^/2#_<_J:MT %>>^*/\ 7G_/<5Z%7GOBC_7G_/<4 <C1110
M4444 %%%% !1110 4444 %%%% !3E9E8,K%2#PPZCWIM+@^A_*@#'\5^%?"?
MCS29]#\6Z!I^MV]U"UNTE_#'.45UVDCS%." 3^5?@_\ M??\$%/@E\4KF_\
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M** "BBB@!#T_$?S%>B>&O]6/H?\ T&O.ST_$?S%>B>&O]6/H?_0: .MHHHH
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ME*23@>E)10 N#C/:DI<G&.U !)  R3T% 6LO+;[A**>T<B<NI7ZU$S;<<=:
M'4444 _2X4444 %%%)@DK@XYYZ^HH 6BG,-IQUIM !37^Z?P_F*=37^Z?P_F
M* /0O"_^K'^[_C785Q_A?_5C_=_QKL* "HI_]4_T_J*EJ*?_ %3_ $_J* /(
M=4_X_G^IJE5W5/\ C^?ZFJ5 !1110 4444 %%%% !1110 4444 %%%% #ACN
M2/3_ #BF;>=W.?\ ZV*6B@! .3CN?\_SH*8;)SG_ "*6E))ZU3:M97MUO\O\
M@$I ,=R?K2T5(!SW]>/I_C29&<=_2EI,#.<<_P"10 M*"1R*2B@ )SS1110
M4444 %%%% !1110 4444 %%%% !7HGAG_5_\!_\ B:\[KT3PS_J_^ __ !-
M'64444 8VN_\@Z;Z'^5>3CI^)_F:]8UW_D'3?0_RKR<=/Q/\S0 M%%% !111
M0 4444 %%%% !1110 4444 %%%% "D$<&DI22>M)0-/R3];B'/84[)/7)I**
M-6UY*WY?E^HA0">E-(R,4X$CI24 (!@8I2<=:*",\&@ !STHH QP** "BBB@
M HHHH **** "BBB@ HHHH *<G^LB_P"NBTVG)_K(O^NBT >QV/\ QZ0?[G]3
M5NJEC_QZ0?[G]35N@ KSWQ1_KS_GN*]"KSWQ1_KS_GN* .1HHHH **** "BB
MB@ HHHH **** "BBB@ H9F(  '_ZJ** "G#'<D>G^<4VBGWT 4 G@4!2<\=*
M 2.E )&>>M(!* <<T44+3SUOK^7H /\ /U_3_)]:!QQZ444V[]/N ****0!1
M110 4444 %%%% !1110 4444 %%%% '<>%_^0;>?]?T'_H<-=A7'^%_^0;>?
M]?T'_H<-=A0!P?BKII/_ %ZM_P"@QUR==9XJZ:3_ ->K?^@QUR= !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 (>GXC^8KT3PU_JQ]#_P"@UYV>GXC^8KT3PU_J
MQ]#_ .@T =;1110!CZ[_ ,@V;\/Y-7DJ_P 7^\:]:UW_ )!LWX?R:O)5_B_W
MC0 ZBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH *5?OQ_[X_K24J_?C_WQ_6@#V#3
M/^/&W_W*OU0TS_CQM_\ <J_0!'+_ *M_]TUY'JG_ !]M_O-_[-7KDO\ JW_W
M37D>J?\ 'VW^\W_LU &?1110 5R7COX@>&?A9H4_BCQC.EMH]M$TTLCL%&Q%
MW-@G'8=__P!76U^>/_!5B>XA_9CU<P.\9;2KH,48JV/);N.?UZ?H <EJ7_!:
MS]AC2=<F\.3:T9;^";[/.T4@>-) QC^9@" ,^^*^ZOA-\<_AO\>O#\/BKX<Z
MK:7NFSHKJD4Z22@. 5!"DG/.#G\*_BC_ &&?V>/V1/'_ ,%/CIXN^,'B6PT_
MQUI\>IS:0;^]C687"B9XMGF-N^^ ,#VQ7T!_P1N^._C7X7_%#X@6^J:S/>?"
M+PU<ZE<:;<RSR26<MK:-(T*J7)C.44<#^M!;2UMS76NNG]/^D?V<+;#:?,EC
MB8'A9&"D].@."35=D*'&<_[7;KZXQUK^7/XL?\%M]3\9>./'<_@+29TT7P#J
M,L$S0!]EU';2,CL-F=P(3Z?6OT._9-_X*D^$?VB/@_X@U[9';>(/#>FSW%S9
MDA9=UK&S/D'YNJF@5K:[I-7?X_J?L*T.0#YD:C_>_P XQG]:8L&XX,B(O]]C
MA?SZ?K7\H?A3_@NIXZ^)/QR\2_![P'X"U+7ET'4IK&XO;.WFE6(13-&Q+1A@
M.A)R1BO:?CI_P6A;P=:6GPZETU]+\:LJAH) T=P9"%^3D!B<G\?2@.65[-6?
M^??L?TI21",@"1)1SS$P;_/-.6 ,3F6.(#_GH=OIZX]:_)G]C;]LCQ7XE^&>
MH_$/XE:1<V.BVEE-=)J%VK+"RQQ%P0[@#G'')K\X?C)_P69\=>./B;XB\(?!
MWP=J&K:7X7-RTVI6$,LD,HMRV1OB4@Y"\#/^% E&3TMKU[?U<_J"=6CR 0ZG
M^)>1SQU''3G\Z!#D ^8G/OT^M?B!_P $\/\ @K1IW[1^KZI\-/'.DMX>\6:3
M%<PB&]4Q32RP*W0. Q.1^9]J^0OCU_P7*UCX3_M,>,/@#X<\'W?B;5+ W,-N
MEI#),R.C$(0$!//6@:C)Z)?TO^'/Z?9(#& PD20'^X=V/R_KS35BW#)=(_>0
M[1^I'^>:_FF_8Q_X+3ZQ\0OV@;?X$?%#PU=>'=7\0W&-.34(GA<!WPBJ)=I[
MC@<\^M?77[;_ .WA\3_A?XCNO!OA7P+JGV6VMTGCUF&WF\J567>")%7!R.>I
M_.@&I*R:M?5+U/VICL6D6X9)$E$$$D[&-MP"QJ6.2,CMZXK\PY_^"BW@&T^-
M^H_!V>[0:EIUT]O+'Y@W91BI&W.<X'3W%? O[#?_  68_P"$X^-Q_9T\>::\
M'B+6+2X@@DN0PD#2(P4@OSP>?<9SD5^=/BW1(++_ (*>>))9&E:*75WN'4.V
MTI++O'R@XZ&@%'>^FEUV_P ^J_K0_HRF_P""DOP5'QQT+X"H]P?%>NO%'!\C
M>7NEP!DXQC/7K7Z.3Z<T'E[IH@9(HY0I89"RJ'''T(Z@5_+S/\9_V:[7]O\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH *<G^LB_ZZ+3:<G^LB_P"NBT >QV/_ !Z0?[G]35NJEC_QZ0?[
MG]35N@ KSWQ1_KS_ )[BO0J\]\4?Z\_Y[B@#D:*** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH [CPO_R#;S_K^@_]#AKL*X_PO_R#;S_K^@_]#AKL* .#\5=-
M)_Z]6_\ 08ZY.NL\5=-)_P"O5O\ T&.N3H **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HH)P"?2H\GENP[9/\ A[T /.[L,_Y^M+32V #CK_GT
MIU !1110 4444 %%%% !1110 4444 %%%% !1110 AZ?B/YBO1/#7^K'T/\
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M.>"0/3(/!%>L?\%3/V3?V?==\;^(OB7X2>TMOB/X=@O-1.DQ!%5I;?=(J+&
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M[ 7@K4OC-<_&"6SB.I7+AVDV+NRN._+?YY[T"<DTEV5O3;_@G\TM_P#9X_\
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MTY+C.>WO^=3Z=^WY^SIJOCL> 8/'NA/<RS>1:.MY;YGE+;55?FP22P Q[>U
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M!/X4G0C(/4?EG\*^6_C-^V=\$?@A>?V1K7C#2?[:5RDFGR7,)G0J2&RF[/\
M"<\>O-=7\#_VJ/@S\>8&'A;Q;I5[J<:L9+"WN(6E1@K9!16R#D=,=^E [:[:
M?W>O]:7_ ,SZ-@L+6:/?)JVFVA_N75U%$X^JNRG_ #^:2:?"/]1JFFWC?W;6
MZBE/_CCGGVK^+K_@H+^TG^U]\0_^"@T7[-/P+\;:AX?M)[N2-([6ZEB!4R%5
M 5& ]/Z5?\!_MB?M8?\ !/O]I_X>?"?]I+Q)J/B&U\9:I:6D37T\LJE;J2-
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MHHH **** "BBB@ HHKG_ !MX@_X0KP=JOC#R3=?V3#)-]F4;FD\I2V-HZYH
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MGO82+B-F3RKDLA&'&.C^E?EM_P %%_\ @B;XRU7]K*S^+?PHAN8+/7-9AO\
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M"OR#_8?_ &?_ (C:K\"/VE?BI/H.H6-AXKT769]-LI(I4207$4\B+'&5QSN
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MVH_B!X>_:8_9Q^*/A+X,:P+GQ%-H-_;VZV,PDE\_[-(HVB,Y)R/0U\3?L_\
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MMM\O3ST/DG]@+]H?]NSX/_"'XF1_L\^%;V[\"6VN7\]_>6EO*4$,<SLY+H,
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MB_92^&7Q(^#/C?X@_MF^'KK4&TG1/&\K3BW$NP1I?L'+%>, =<^G2O\ 1/\
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M"GP9X7^,D/PKN/'FJ6&H2VT]D+?3?W9FMV4QX!4\@J<#IGBN-_X*0?!7Q/\
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M#&L0%N1M:$8V%?0CH1VK./ASP69C=?\ "+::+TG<;K[/%YI<]6W;<Y)YS_\
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MO?#7]DCX9_"_P7??#ZWTRQO] OHI85M9(HVAA64$?*I7;P&_SW^1M0_X(\?
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MBBB@ I5^_'_OC^M)2K]^/_?']: /8-,_X\;?_<J_5#3/^/&W_P!RK] $<O\
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M+6V/AJ.W6U6)D3RMBJ$& 1MQ@?YYKJO@?\$O#'[//A!/!'@V*&WTR.0RJMN
MB[C[+QGUKUE6)SQ@BG9H&]EK?JUV_P""7UU*]4,HN)2'5D*EB1AA@C'O7PQ\
M>?\ @GW\(_VA==LO%6N65E9:U97*W/VT1QK-(ZMO^9\!LG&1S7VT2.,#&/84
M;F]?\_A0&JL]5<^-KO\ 84^&.IZ-I>B:E%:WD6D1Q10/*J,?W(4*>1_LCVKT
M7Q5^S#X%\8^ ]/\ AUJ5O;/HVF*JPQLB&,!!@!001V_6OH+)Z]Z*!'A?AO\
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MX5_X)-:!\9K/2I(_&R^';.\BU+S")!,MLDH829W??YX/_P!?H?@YKVH>(_\
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MP[NM0TC4=;$VIZ;O6>.WD61E:(E6#!<E?F'?W^E?SQ?\$X_$FO\ A;PG\;_
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MJR2[VQC* D]<=NU?RXVOPI\&?LM?\%A)?!WPE\[2M'2QN7^QK,R1F2/?L_=
M@9R/3\:S[#3/"/[6/_!17Q+X7_:1U-CX<TK6Q%8V][<,L;Q)<X0*DC!3QZ4#
M<5I:^L;VZ]/\S]\OB9_P4-^$O[2G[/GB33O!6H7=KXBET>\>W.&C;#0.4(.
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M?DL>1WZUM_M^_P#!2?QEXM_92^&D7P$UWR?B',-)M-8FL9\3F=Q$LV\Q-O\
MO$Y!Z=Z!<NWG^&W^9_4*VP']W+',O:2)PZ'Z,I(--KY _P""?_\ PL'5/V4?
MAIXI^)U[-?>*-5TNVEU"29F:3S7C5B26.>K9Y/\ *OK^@35NJ>MM HHHH$%%
M%% !1110 4444 %%%% "'I^(_F*]$\-?ZL?0_P#H->=GI^(_F*]$\-?ZL?0_
M^@T =;1110!CZ[_R#9OP_DU>2K_%_O&O6M=_Y!LWX?R:O)5_B_WC0 ZBBB@
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M&S2WO:S]?2Y_4]ITVDZP)#I^KZ7.8SM9(KV%W)# <*KD\Y].E?DW_P %2?\
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ME&!^0H(YI-.[OK_7Z:$=%%% @HHHH *<G^LB_P"NBTVG)_K(O^NBT >QV/\
MQZ0?[G]35NJEC_QZ0?[G]35N@ KSWQ1_KS_GN*]"KSWQ1_KS_GN* .1J:WD\
MJ>*0]$D5OR.:AHH _(+_ (*9?L5:U^U9XFT'5=+B>1-/GMG;:N[ B=2?IT]/
M3ZUX?^US_P $[?$?QD_98^&'PAL897O/"E[IT\RJA) MMF>/P/7UK]](KAH
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MQST.=W7_  K]UFNRT(B\N(8P=PC7=U_O=<8[5'+<O(BQ[(E5<<J@#'\0/\*
MYY=^EO/I_P ,_D?@)\9O^"=OB/Q+^U5XQ_:'BAD_L^UTNZN?,"D_ZM"^5;UX
M_P#K5_/+XO7P)X[_ &HM>\/>/+>:]AT?5)TVWT#-$IAE<<>8NW&4K_06DN#/
MI]WI,T<366H0O;W:F-=S1.-K+GKR#7Y??&/_ ():? CQMXEN/&GAC1(;+7K^
M9I[ZX2)%9Y';<_S 9ZL>_- *:CK)NWX(_GM_8A_;:\3^"/VPX/@=\+?#UPOA
MA+F*V>2WM76V";U4L&10N-HZGVK^TC3)YM0T#3=3O1LOKJ".2X0\,':,$@CZ
M_P#UO6O@C]G_ /X)R? 3X(ZZOCVVT"V;QN6#O?- ADWXS]\@GJ,]?QK[^ RH
M1/EC3A% X  &..V!C% FUNE9?U^I%1110([CPO\ \@V\_P"OZ#_T.&NPKC_"
M_P#R#;S_ *_H/_0X:["@#@_%732?^O5O_08ZY.NL\5=-)_Z]6_\ 08ZY.@ H
MHHH **** "BBB@ HHHH **** +^F,%OK<L< 2#FOY6?^"\/A+Q'J7C/1M;T_
M2I]3TVTO;>:=$MVF1HXY [@@ @C ((_R?ZF%8J0PX(Z&O,/'_P #?AC\6XC!
MX^TF#48R-O[Z%)..G5@?\\4#6Z]4?QP_%;X\>'_BC^R'X=^"/PT^$UE;_$2?
M3XK ZK;Z2J7L=R5$9D\Q(@X8-SUS^E>AZK^S1\;OA1_P23UWPY\0HM2OO$.M
M7\5W86D\<LDL,,C!E5$;+*%& ,?X8_J&\,_L*_LQ^"]4BUK0?"UHE];R>=#O
MMHV17!+<*5XY_P \U[KXS^&_@GXC>'8?!OBO2[6X\-VZJL5F+>/R@$P%^3;M
MR![?XT%\[V6BO?N^W7R]3^/CQ!^R?\4?BE_P3P^%>KZ%I-S+J7@RSAN9[8P2
M>9F!$DP4VYYV8(P/QKH/A]_P4:\2>#_V1=6_9_NM(U*/QNEO+X>BTX6T@#LT
M?V?/E[>>3U[]*_KE\/\ PU\$>$_"S^ ]$TNTB\+R1&%K0P(4\LC:0%V[?N]L
M>U?.EQ_P3R_9+N_$3>+I_"5J=::Y%XS"VC$9G#"0':!C[PY%!+DW]]_ZZ?@?
MS:_LM?LM^/\ X:?LE?M!_%_QWITFF+XUT+5;I%FC:(@7,4D@Y8 YP_OR/:OC
MG_@EG_P41\6?LP?"CXV^$=,T2>^TO6M2UVPAN(;<RX>YDFC0@JIPQ#D9'."1
MTS7]B?[9?PB/C']DWX@?"3P':16?V[1)[+38K6(1MDP%$ " <\#IFOR7_P""
M1_\ P2Q\$_#[X6>-=(^/NA"_U+4-;N;ZV:[A#/AYW<',@)( / '!( R,F@I2
MBT[]9+UMI_EJ? 7_  2(^!?C_4_BI^T#^TO\1- G@\+^)I-7U&WM[NV94N8I
MGEFVE74!MR_6OG#_ (*'>'/ _C1H_$_[/6M:KX/^+%EXKQ)I&A++;><R77\2
MV^TG<P)Y)_#M_;9X;^#WPY\$>%Y? WA?2;6R\-SP_9Y88;=(R\14HV=H&?E/
MXUX/!_P3X_94M_$K>,1X8ADUQ[DWK/+ CH;@G=OVD8)W=Z YUSN5K.WN^5DE
MK^'XGY5V'P!^(7QC_P""7[:I\889[SQSX?\ "S265[J09KHRPV.Y&+R OG<%
M.<C\Z_E[_P""5.@?%+XP_MDZM\"_'\-U>^'M(\72):)<*[VZP0W15-I;*CY5
MX[?C7^@Y^TIX>EE_9A\=> ?!=JD-S/H]Q:Z7!;1A-N^%T0!%P,_=Z#/'M7X=
M_P#!)W_@G=XG^#OQ.\2?&?QW:%-<NM:N+N%YHMKF-IV<8)4=OPH!-6?-K=_/
MU^[3RZ']$GA3PM;_  ^\':-X&LU$=KHUM;Q1Q)PJ[8P,  <8[5J5>U*Z-[=R
MS]"^!^0Q5!00.3GGWH,Q:*** "BBB@ HHHH **** "BBB@!#T_$?S%>B>&O]
M6/H?_0:\[/3\1_,5Z)X:_P!6/H?_ $&@#K:*** ,?7?^0;-^'\FKR5?XO]XU
MZUKO_(-F_#^35Y*O\7^\: '4444 %%%% !0#CFBB@!Q<D8XKG/'&IZCX>\$:
MYXAT5#+J^G6TLMG$N2S/&A<  <\D"NAIDT4=S!):S@/!*"LB,,AE88((/&"*
M /YW?C7_ ,%*?!5]I?C3X?\ QU^&]MJNNRV>HZ9IDM]IRS,9722*)E+QL<D[
M2,<^E?C9^PI^QU\:_BIJO[1&M>'-)O="\(>+AJ\F@V,-O+;V[0SB9HD1 %4C
M:P& /PXK^PWQS^P5^R_\3M:'B/QCX9@N-5\P3>8L"8,F=V6X]3Z>M>[_  \^
M%O@'X/Z;'HW@#2+*QL(T,85+:--R8Q\V%&<C_P#70/F>JMVU]+:+7]$?P/?
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M3/\ CQM_]RK]4-,_X\;?_<J_0!'+_JW_ -TUY'JG_'VW^\W_ +-7KDO^K?\
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MY%O^"<?P9\=:C\7_ -HBUFTJZA?4M;UZ2W>2W=!+ODG92K%1NR,<C.<UXO\
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MM[_*W^8@SWZ]_K1110(**** "BBB@ HHHH **** "BBB@!#T_$?S%>B>&O\
M5CZ'_P!!KSL]/Q'\Q7HGAK_5CZ'_ -!H ZVBBB@#'UW_ )!LWX?R:O)5_B_W
MC7K6N_\ (-F_#^35Y*O\7^\: '4444 %%%% !0>>/6BB@ 'RC:.G_P!?--8D
M8P,_@:=10 4444 .4 GDX_S[TAZGZTE% !['D'J.Q'H:8+330?,6RB$Q_P"6
MNU=V?7(P<T^B@ I1U'UI** %/!XY%-) QGOTI:0@'&>W2@!:4@CJ*2E))Z\T
M -) ZTN,=\YYZY__ %4A /6EH#MOI_6H4N"1G' I*7) QVH#^OR $@@@D$'(
M(Z@TVYL='U1/^)QIT.HE?N^>J/C&,'YAG/\ GFEHH =;16.G1^5I=HEC%C'E
MQ *OY+_G^B$DDD\D]3W-)10 4444 %%%% !1110 4J_?C_WQ_6DI5^_'_OC^
MM 'L&F?\>-O_ +E7ZH:9_P >-O\ [E7Z (Y?]6_^Z:\CU3_C[;_>;_V:O7)?
M]6_^Z:\CU3_C[;_>;_V:@#/HHHH **** "BBB@ HHHH ***=(-EE>7'>",L/
M7(&?\: +*V+&$R&>$=?E:10Y]@"<_3_.:8X&!GCUK^<_XY?\%(?&G@S]OSP-
M^S]87,@TG7-6M+6:(.P4QRW C;*C Z9_^M7]$NL^-/ACH$%@/$'C72-&NGTV
MVNIX+J[@1U#PH[.P9E*\EN#SQDGF@-?O+E7[.T^T;F^T6T.T=)YDC)^FXBO.
MM$^-/P%\1W[Z3X=^*7AS6-77<@T^TO[:68R= NQ9"P)/ XK\JO\ @I9J_P ;
M=%USP$WPP\?IX1M+C5;47:/>?9A=P-*I* ;UW;E..^<T#2NTK[^NGWVW/V.=
M"C,N0VTD%E(*G'HPX/X4RO,?A;K^FZ!\&O!.K?$;Q-9V5P^B6TFHZQ=SQK#-
M,(%\R4RNP# G))SZ]\UIZ-\:?@3XEO&T[PY\4/#FKWP8HEM:W]M)*TG38%1R
M2<^WMB@7]=?O.[HJIJ>M^&?#MF^J>)];M-%TA07_ +0O)4B@V#G<7<A<8YR#
MBN(T_P".GP!UM+UM!^*GAK56T]6:Y6VO[60Q[ 2P8*YP1T.>XYH ]$V-MW8X
MJ[:6GVA9#]HMH2HR!/,D1.,_=#$9^@R?:OQHUC_@LS^S[H_[5VG?LTSZ_I(B
MO;Q+.;Q 9X1:V[-)L)>3=M&WN216)_P4?^+>MZGXL^&MM^SC\=-"075[9MJ]
MCI>M02--&TRAD_<2+OWH,XVY&[!Y% [/JK?(_:1E*,RDJV#C<AW*?<$9!II(
M'7BO,OA5JUOH7PJ\*ZK\2/$%M92'1K:2_P!7O)56&240@O(9)&P<D$DY[@YI
M^G_'_P#9UUC4#I&F_%SPM=ZB6*16L6HVC2R2?="JHDR6R,>M 6;V3^X]+I1U
M'UJE=^(/"6CP+J6N^(++2]'<;TU&YFC2W=".&#L0N.00<UQ=Y\=?V>+*XAMI
M?B[X666Y.R%#J5KF1B<;5S(,GH!WYH$>@G Z<BI R+&8Y!OAD!\R,XVL".00
M1T_^OZU3M-1T;5X([WP_J,&K:?*H>.ZMG22)D(!#!D+ [LY'KGBISSU],?A0
M"Z7^=OTN5X='\-6DYN[+1+:VO"<FXCCC60M_>) SG_/:KDDCR'+,3Z9]/\]J
MCHH"W04$CD4A.>:** 'J<C:>!_\ 7S3#QGT&?RHHH 0$'I2T@ '2EH *:_W3
M^'\Q3J:_W3^'\Q0!Z%X7_P!6/]W_ !KL*X_PO_JQ_N_XUV% !44_^J?Z?U%2
MU%/_ *I_I_44 >0ZI_Q_/]35*KNJ?\?S_4U2H **** "BBB@ HHHH *3'(/<
M?Y_K2T4 *KXR!U_'M_\ KH!P<TW !SCDTM  3GFD)(' YI:*  =!2X.,XX_R
M*2ER<8[>E ^FPI  &#UZ^U( 3TI*4$CI0+]1**** [A1110 A8K@?WN/\_G4
MGS;>G'K^/U]:C(!QGMTIV3C';TH 2D(!X/UI:* [^OZ(!1110 4444 %%%%
M!1110 4444 %>B>&?]7_ ,!_^)KSNO1/#/\ J_\ @/\ \30!UE%%% &-KO\
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M_71:;3D_UD7_ %T6@#V.Q_X](/\ <_J:MU4L?^/2#_<_J:MT %>>^*/]>?\
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M1^$7["&FZ5XE_P""5_Q6/B#34UEK*XU*.W^T1"1H8HWD"J@8-@ 8Z?X5V/\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M% !37^Z?P_F*=37^Z?P_F* /0O"_^K'^[_C785Q_A?\ U8_W?\:["@ J*?\
MU3_3^HJ6HI_]4_T_J* /(=4_X_G^IJE5W5/^/Y_J:I4 %%%% !1110 4444
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ME.2..#0!>CU&]BC,4=S*L9&"@;"_E4<5W<P,7BFDC9NI4X)^M5E4GCO10'_
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MH%#''IV_K5&D(!QGMTH GED>;]Y*Y>3U8Y/7\^E18)&<<"DI<D#':@!****
M"BBB@ HHHH [CPO_ ,@V\_Z_H/\ T.&NPKC_  O_ ,@V\_Z_H/\ T.&NPH X
M/Q5TTG_KU;_T&.N3KK/%732?^O5O_08ZY.@ I4&\X7FE4%F"CJ3BOFO]IO\
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M_#I^/X8H629D]L-+[UY?YA_:."TM7C=]-?+]6T?T";&]/Y4WOCOUQ7X$:?\
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MK^>K_B(+^#7_ $"$_P"_?_UJ/^(@OX-?] A/^_?_ -:C^Q,R_P"@>7W][?\
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MV_WF_P#9J]<E_P!6_P#NFO(]4_X^V_WF_P#9J ,^BE )R?2E0;F5?4@4??\
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M1J5ZL:5*-ZDU[L5O*UKO\?Z9,YQIP=2;Y81WD^GZGWB(7(!P.1ZT>4_I_/\
MPK^<V+_@X(^$\N6&EK\CLAX]#@XY_G5X?\' OPB[Z4N?I_\ 6KT?[$S+_H&E
M^'E_FCC68X'KB(ZV[^6VG9_?ZZ_T2>4_I^A_PH\I_3]#_A7\[?\ Q$#?"+_H
M$K_G\*/^(@;X1?\ 0)7_ #^%+^Q<R_Z!I?>O+_-#_M+ ?]!$>G?^[Y>;_#OK
M_1)Y3^GZ'_"CRG]/T/\ A7\[?_$0-\(O^@2O^?PH_P"(@;X1?] E?\_A1_8N
M9?\ 0-+[UY?YH/[2P'_01'IW_N^7F_P[Z_T2>4_I^A_PH\I_3]#_ (5_.W_Q
M$#?"+_H$K_G\*/\ B(&^$7_0)7_/X4?V+F7_ $#2^]>7^:#^TL!_T$1Z=_[O
MEYO\.^O]$GE/Z?H?\*/*?T_0_P"%?SM_\1 WPB_Z!*_Y_"C_ (B!OA%_T"5_
MS^%']BYE_P! TOO7E_F@_M+ ?]!$>G?^[Y>;_#OK_1)Y3^GZ'_"CRG]/T/\
MA7\[?_$0-\(O^@2O^?PH_P"(@;X1?] E?\_A1_8N9?\ 0-+[UY?YH/[2P'_0
M1'IW_N^7F_P[Z_T2>4_I^A_PH\I_3]#_ (5_.W_Q$#?"+_H$K_G\*?'_ ,'
M_P ( V6TE<?3_P"M1_8N9?\ 0-+[UY?YH/[2P/3$1O\ /^[Y>;_#Y_T0^4_I
M^A_PH\I_3]#_ (5_/0O_  <%_!OG.D+^*@_^RT[_ (B"_@U_T"$_[]__ %J?
M]B9E_P! \OO[V_\ DD+^T<%_S_C^/^1_0KY3^GZ'_"CRG]/T/^%?SU?\1!?P
M:_Z!"?\ ?O\ ^M1_Q$%_!K_H$)_W[_\ K4?V)F7_ $#R^_O;_P"20_[1P7_/
M^/W/_+^K>E_Z%?*?T_0_X4>4_I^A_P *_GJ_XB"_@U_T"$_[]_\ UJ/^(@OX
M-?\ 0(3_ +]__6H_L3,O^@>7W][?_)(/[1P7_/\ C]S_ ,OZMZ7_ *%?*?T_
M0_X4>4_I^A_PK^>K_B(+^#7_ $"$_P"_?_UJ/^(@OX-?] A/^_?_ -:C^Q,R
M_P"@>7W][?\ R2#^T<%_S_C]S_R_JWI?^A7RG]/T/^%'E/Z?H?\ "OYZO^(@
MOX-?] A/^_?_ -:C_B(+^#7_ $"$_P"_?_UJ/[$S+_H'E]_>W_R2#^T<%_S_
M (_<_P#+^K>E_P"A7RG]/T/^%'E/Z?H?\*_GJ_XB"_@U_P! A/\ OW_]:C_B
M(+^#7_0(3_OW_P#6H_L3,O\ H'E]_>W_ ,D@_M'!?\_X_<_\OZMZ7_H5\MAU
M_K_A3=C>G\J_GO3_ (.#/@P&!;1T(]-G_P!:KW_$0C\$ /\ D"I[G:/\!_A2
M_L7,O^@:3]/1/]4"S+ ]:\7]_EZ>:^X_H$"':20>/3I4=?A9\/?^"\GP8^(G
MB^P\'V.CI'=7\T<*-M .9&"#H.Q/K]??]L?!?B6W\;^&K+Q/9ILM[V".=5'I
M(H8?H?TS[5R8C!8G"\OMZ4J?-\-^NB?ZFU'$T,0W[&HI\NKL=%1117*;A7HG
MAG_5_P# ?_B:\[KT3PS_ *O_ (#_ /$T =91110!C:[_ ,@Z;Z'^5>3CI^)_
MF:]8UW_D'3?0_P J\G'3\3_,T +36+#&!FG5#?3K8Z==:@X^2WC=SQGA5W=/
MP_6@"T(F8 C'(]?\]L4HA?OC\Z_$#]H[_@LY\.?V?/'LW@?5;!9KF&=X2V!R
M5<KZ_P">3]?$HO\ @X$^$P)W:6N,^GTSU_S[]J].&3YA4C&<,/)QFE*+TU3M
MK^)QRQ^#@W&5>*:E9IWT>GE_3/Z*GMF)R"/\_E2B)QQCIQW_ ,*_G;_XB!OA
M%_T"5_S^%'_$0-\(O^@2O^?PJO[%S+_H&E]Z\O\ -"698#_H(CT[_P!WR\W^
M'<_HFV/MVX_'GUSZ4Q8'0YZ\C]/IFOYW/^(@;X1?] E?\_A1_P 1 WPB_P"@
M2O\ G\*/[%S+_H&E]Z\O\T']I8'_ *"(_<_[OEYOUT[G]$[*[#&W'/O_ (4S
MRG]/T/\ A7\[?_$0-\(O^@2O^?PH_P"(@;X1?] E?\_A1_8N9?\ 0-+[UY?Y
MH%F6 _Z"(_C_ '?+S?X=S^B3RG]/T/\ A1Y3^GZ'_"OYV_\ B(&^$7_0)7_/
MX4?\1 WPB_Z!*_Y_"C^Q,R_Z!I?>O+_- LRP'_01'\?[M^GF_P .^O\ 1)Y3
M^GZ'_"E$;@@XZ'W_ ,*_G:_XB!OA%_T"5_S^%'_$0-\(O^@2O^?PH_L3,O\
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M_P ]Q0!R-%%% !4@B8],?G7->-=?B\'>%-0\47 W0:?%)*Z]<B-2_P#(8_\
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MIW_N^7F_P[Z_T1B!UXZ]^_\ 3-/5'7/&<_7_  K^=G_B(&^$7_0)7_/X4?\
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M?U8/["PO6K/[K=O\GKYG\%O_  Z#_:!_Z$^7_P !I/\ "C_AT'^T#_T)\O\
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M/_B:/^'0/Q__ .A-D_\  63_ .)K^]3^TQ_SX:?_ . T?^%']IC_ )\-/_\
M :/_  H_UHQVG[FETZO^[_D_N] _L+"?\_9].G^'R\G]_FS^"O\ X= _'_\
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MP1^^/4?^K\(RG_MU?^@/%5_^'0?[0/\ T)\O_@-)_A7]Z8U(#_EPL/QMH_\
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M$Z_\(;)G_KTD_P#B:#_P2&_:$/7P=+_X"2?_ !-?WO\ ]II_T#[#_P !X_\
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M_3K?J?G%_P %(_@3XC^._P /;K1/#5DU]<RV[H$5"YRT94=.Y)^O(K^61?\
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M<48[_GS1Z=_[O_!_JP+(L+I^]G]W^'U[/[_,_@J_X=!?'[./^$.DS_UZR?\
MQ-+_ ,.@?C__ -";)_X"R?\ Q-?WI_VBN0?L&GY'_3M'_A2_VF/^?#3_ /P&
MC_PI_P"M&.T_<TNG5_W?\G]WH']A83_G[/IT_P /EY/[_-G\%?\ PZ!^/_\
MT)LG_@+)_P#$T?\ #H'X_P#_ $)LG_@+)_\ $U_>I_:8_P"?#3__  &C_P *
M/[3'_/AI_P#X#1_X4?ZT8[3]S2Z=7_=_R?W>@?V%A/\ G[/IT_P^7D_O\V?P
M5_\ #H'X_P#_ $)LG_@+)_\ $T?\.@?C_P#]";)_X"R?_$U_>I_:8_Y\-/\
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M^A/E_P# :3_"C_AT%^T!_P!"=+_X#2?X5_>G_:8_Y\-/_P# :/\ PH_M,?\
M/AI__@-'_A0N*,=I^YH]._\ =_\ MOZL']A83_G[/IT_P^7D_O\ -G\%?_#H
M'X__ /0FR?\ @+)_\31_PZ!^/_\ T)LG_@+)_P#$U_>I_:8_Y\-/_P# :/\
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M^O\ 5@_L+"?\_9].G^'R\G]_FS^"O_AT#\?_ /H39/\ P%D_^)H_X= _'_\
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M;)NG+VZ$\#'7%>EE^9U\N<W1C&7/:ZE\M5_6IQXO!4L:HQJ2<%'9Q7I_P?\
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M+"Z?O9].B_N^7KW/X+?^'0?Q_P '_BCY<]A]FD_^)_K2?\.@_P!H'_H3Y?\
MP&D_PK^]/^TQ_P ^&G_^ T?^%']IC_GPT_\ \!H_\*/]9\;_ ,^:/2^_]V_Z
M[!_86$_Y^SZ=/\/^3^_S/X+/^'0?[0/_ $)\O_@-)_A2?\.@OV@/^A.D_P#
M63_"O[U/[3'_ #X:?_X#1_X4?VF/^?#3_P#P&C_PH7%&._Y\T>G?^[_P?ZL'
M]A83_G[/IT_P^7D_O\V?P5_\.@?C_P#]";)_X"R?_$T?\.@?C_\ ]";)_P"
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MBI:BG_U3_3^HH \AU3_C^?ZFJ57=4_X_G^IJE0 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !7HGAG_ %?_  '_ .)KSNO1/#/^K_X#_P#$T =91110!C:[_P @
MZ;Z'^5>3CI^)_F:]8UW_ )!TWT/\J\G'3\3_ #- "T444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !3D_UD7_71:;3D_UD7_71: /8['_CT@_W/ZFK=5+'_CT@_P!S
M^IJW0 5Y[XH_UY_SW%>A5Y[XH_UY_P ]Q0!R-%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 =QX7_P"0;>?]?T'_ *'#785Q_A?_ )!MY_U_0?\ H<-=A0!P
M?BKII/\ UZM_Z#'7)UUGBKII/_7JW_H,=<G0 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% "'I^(_F*]$\-?ZL?0_P#H->=GI^(_F*]$\-?ZL?0_^@T =;1110!C
MZ[_R#9OP_DU>2K_%_O&O6M=_Y!LWX?R:O)5_B_WC0 ZBBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH *5?OQ_[X_K24J_?C_WQ_6@#V#3/^/&W_P!RK]4-,_X\;?\
MW*OT 1R_ZM_]TUY'JG_'VW^\W_LU>N2_ZM_]TUY'JG_'VW^\W_LU &?1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %-?[I_#^8IU-?[I_#^8H ]"\+_ZL?[O^-=A
M7'^%_P#5C_=_QKL* "HI_P#5/]/ZBI:BG_U3_3^HH \AU3_C^?ZFJ57=4_X_
MG^IJE0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MZM_]TUY'JG_'VW^\W_LU &?1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %-?[I_#
M^8IU-?[I_#^8H ]"\+_ZL?[O^-=A7'^%_P#5C_=_QKL* "HI_P#5/]/ZBI:B
MG_U3_3^HH \AU3_C^?ZFJ57=4_X_G^IJE0 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MZ"GK:SX^6&3'7[IH;7^=[>7^?Y"L^S^[^MR D#KQ020.!S5HV-R0/W$A_P"
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M+?\ NF@!E%/\M_[IH\M_[IH 92$XQG\?IC_]52>6_P#=-(R-_$IQ_A]* O\
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M'49[N5=AF,EP7W'(W<DG)QU_E7VAX5_X)'? 2SMX_P"W;!;F48W8178GC/4
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MC_T-=E_X$1?XU_ SY%V!DZIJ7;'^E2>_^U2)%=]6U/4OI]JD/I_M4UPU@_\
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ML_4****0PHHHH **** "O1/#/^K_ . __$UYW7HGAG_5_P# ?_B: .LHHHH
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M-"-.A1ITH12BE"$8Z+35I7?S"C.>E%( !TKD-Q:0Y_O8'T']:"V.N:4C/!H
M3G']<4#=W(/^?\]J6B@#D->\ ^#/$ZR)K_AO2M4$@*O]KMED)!&#SP<\U^;7
M[2O_  2S^#OQOCN;G2K*Q\/WA622&."$1YF()4!D4+U[DKQ]:_52BO9RKB#.
M<EKPQ&69CB<+4A\/)5DX673V;;A;IL>?CLKP&94G2QF%I5H2WYH+F_\  DN;
M\3^+WXR_L>_M+?LC>(CJO@"YU>7PSI,QD9K47+(T43[C]SC&T?K7VM^Q_P#\
M%4I7U&S^'7Q5$M@T)BLI+R\5HB9%*HV6E([@YR3T^M?TC^*?"/A_QEI-UHOB
M'3;;4+&\C:.5)H8W8!@02K,I(."?;\0"/P<_;C_X)0:7XAM;_P 9_!J"33-0
MM?,U%XK-1%*)%RY4>7@GYAU&,G!P"<5^R9?QOPWQSAX9-QQ@J.%QTXJEAL[H
MPC#EJ.R4ZSMS<SEKJ[;GP>*X>S?ANK+,.',14JX:/O5LNJ-R3@M7&FFVK)?Y
M:'Z^^$_%?ASQ[I,&L^%K^"^M9HUDW1S(_##=R%)Y_P#K<UM]"1Z$C\0<&OY.
M?V;?VP?B_P#LG>/8?A]\31J$6B:=<K:2R7[R!72.7R^#)U&T>_7\_P"G_P"$
MGQ?\'?&SPC8^*/"VH6LIEMHGEM(G5I-[@%CM!SG)]/7/K7Y[QIP)F/"%:-:Z
MQ^48E<V#S&C[].496Y54E&ZC)II^5SZGA[B3"Y]3E"WU;'T5:OA*GNSYHVYG
M!.VE[_UJ_1Z*4@J2"""."",$4E?">A]&%%%% !1110 4444 (>GXC^8KT3PU
M_JQ]#_Z#7G9Z?B/YBO1/#7^K'T/_ *#0!UM%%% &/KO_ "#9OP_DU>2K_%_O
M&O6M=_Y!LWX?R:O)5_B_WC0 ZBBB@ W%>0,D=OTIX7>0!]YB>.PZ^U,K#\:W
MTNB^!/$6N6QQ=:?:32Q'IADC+ Y[?Y]\EG>,5JY-)/HFW97^;0=&^RN;5Q>Z
M=8-Y5[=V\3GG:\Z*>WJ0?457_MC0QR=0M2#V^TQ\?^/9K^*3]J__ (*#_M12
M?&W5?"G@O4[XQ6^IS6T4-O-)G:KLJX53D\#T^O2N$B_:=_X*!3QK*D?B QL%
M*G-R001QC''^>N:^EAPW7E3A4=>E'G2E%-ZZI/7\?P/'EG-&,Y15.I+EDXNT
M;[-;6O\ ?Z]M?[EO[9T+_G_M?_ E/_BJ/[9T+_G_ +7_ ,"4_P#BJ_AM_P"&
ME_\ @H)_SS\0?E<T?\-+_P#!03_GGX@_*YI_ZM5O^@FC]_\ P1?VS2_Y\UO_
M  "7EY>?]:7_ +DO[9T+_G_M?_ E/_BJ/[9T+_G_ +7_ ,"4_P#BJ_AM_P"&
ME_\ @H)_SS\0?E<T?\-+_P#!03_GGX@_*YH_U:K?]!-'[_\ @A_;-+_GS6_\
M EY>7G_6E_[DO[9T+_G_ +7_ ,"4_P#BJF.M:%]FE_T^USY<O_+RG]QO]JOX
M9_\ AI?_ (*"?\\_$'Y7-'_#2_\ P4%PPV>(-NUL\W(X(YZX'ZT?ZMUEJ\31
MTM]KS]0_MJE_SYJ]_A?EW7G_ %UU_P#@H=/;S_M\:1+:RK(H\0QD.C!QS<+W
M&0.W?_&OZK?@/<W<OP8\$0K,_.FVY !_NPH>_ Z5_#U%XC\>>+/CSX?U7XG_
M &C_ (25M9MS)]JW&7<9TW?>R<YY_P#K5_<-^SU_R2+P-_V#(O\ TG%>QCJ7
MLL/@Z-^9TZ?*VM4[1Z=-?Q/+PT_:UZ\[-*<FTFM5=K1_U_DOBS]JG_@H%8?L
MVW\FDM,LE[$6'E%ESD9Z ]3T]Z^$Q_P7)M1@/;3;LX.(F('X@=*^*_\ @KC"
MUQ^T/HNG--*(-1UB*VD0-\I260(05Z=Z_9K]E;_@CO\ L^?$GX(^#/&6NV2O
MJ.LZ;#<S.T2DEWB1F/()ZMS_ %J:GU#!86A5Q$)2]KLXK;17O\RXQQ6(KU*5
M%J/LK<U]5K;5;=]?EL?'?_#\FS_Y]YO^_3_X4U?^"YEIM;-O-QD@^2W<?[OM
M7ZEG_@AW^S-_SX)_WZ7'Y8%)_P .._V9_P#GPC_[]+7+_:62_P#/NK_7I_7R
M-_J&9?\ /V'W+^[Y^O;_ "_+9?\ @N5:$ FWF_[]/Z_2E_X?DV?_ #[S?]^G
M_P *_4C_ (<=_LS_ //A'_WZ6C_AQW^S/_SX1_\ ?I:/[2R7_GW5^[_@?U?T
M#ZAF7_/V'W>GGZ_\#I^6_P#P_)L_^?>;_OT_^%'_  _)L_\ GWF_[]/_ (5^
MI'_#CO\ 9G_Y\(_^_2T?\.._V9_^?"/_ +]+1_:62_\ /NK]R_R_J_I8^H9E
M_P _8?=Z>?K_ ,#I^6__  _)L_\ GWF_[]/_ (4?\/R;/_GWF_[]/_A7ZD?\
M.._V9_\ GPC_ ._2T?\ #CO]F?\ Y\(_^_2T?VEDO_/NK]R_R_J_I8^H9E_S
M]A]WIY^O_ Z?EL?^"Y5F/^7:<_2%S_2E_P"'Y%GU^S3<=_)?^>*_3'7O^"+_
M .R9X2T;4-?UW[)86.F6\EU(]PL<:.(ADKEV&2>F!D\CC&37Y@6?P^_X)X:U
M\7?^%26.FVGVV.]%B;P)'Y;N9/+W*PR#D]^1GBN_ PP^9NHLNR_&8QTHNI65
M*%XPA%7<V[=-_5[;G-B8UL&H?6L90H<\E&'.[<\G;1+N]O\ )Z%X_P#!<JS'
M/V>;C_ID_P#A1'_P7$MYY(A'!(-\B1G>A7 8GU_/\N>:_3S1?^"*O[+&N6%E
MJ]C9PRV=]#'/&R1H5*.H;C [!NU?EO\ \%/?^":?P>_9P^'$WB7P9;""Y0^:
MC(@7H-PZ#W^M<]+%935K+#JE4C5<N1J2M:2=FG\].GEK8UGA<?3INJZL'%)2
M3CU3LU;UOO\ ET_6K]FK]IRS_:$\.V^LV5R/M,L89XU9>"PW=!G^M>9?\%.K
MNZ/[)?B:.25F5;:Z!4\_\LG/]<=.*^%?^"-TDDGA=B\LCD,Z .20 NX?AT[>
MG:ON7_@I]_R:EXK_ .N-W_Z):L_91HX^G"-_<K0LG\5N9?G_ %8%)U,-.36]
M&5_/1?UN?F#_ ,&Z'S>.O%O_ %]WQX&>?,?(_P ]Z_K2U#_C]NO^NS_SK^2K
M_@W+?/CSQ8.?^/N^/X>;)_45_6KJ'_'[=?\ 79_YUXG$/_(UK+^['\E\SU<G
M_P"1=AU;;F7_ *24Z***\4](*5?OQ_[X_K24J_?C_P!\?UH ]@TS_CQM_P#<
MJ_5#3/\ CQM_]RK] $<O^K?_ '37D>J?\?;?[S?^S5ZY+_JW_P!TUY'JG_'V
MW^\W_LU &?1110 4444 %%%% !1UZBBBG=VMT#_+]5^ES@_B]JD^B?#76]1M
M&:*XBMIPDBD@J?*.",=/:OY8_B#^RI/\:/&GBOXF>/\ QQ/]@TAKN_L].N;I
MA&7CWR*BH[8ZJ!C'Z\C^I'XW0^?\*=?7H!;3L?PCS7\GGC[Q[XJ^*OC77?A1
M\/S=)>V%S<+J1MBPS"KL'W;>V <Y/Z8KZ#)%.U:5-\C37-5LKPAI?SU5T>3F
MCAS4E+WDXNT$VN:>C7S3U_JQ\1^!-=A\=_&2X\%VLYBE\.7;V>FD$KYJQ.R(
M5SU!"C\Q]:^C?'_@36M,O]4N/$\S :?9M<6?F-_%&FY-H/?L<<\?05F1?LS:
MU\/X]1^+^@VMQ)K'AHO+JJHC,SS0?O'WX&<[@<Y__5Q?A/XA^/OVM)O$FEZ3
MI]TE[H%M<17RQQ-O$=LC*VX 9_A).<=Z^H=IM5*;2IPC&$V]XMN-WY<WD];]
M.GAIRBN6I2:K3;=-:\LDK6^:6_WEW]E[X<:!^UMXMU'X=^(=8_L[6K:65-+N
MGD\MT$7^JV-D$8V\8].*_9__ ()I^&/&?P4_:)U_X(ZQXGNM>T?2]XMEFG>:
M-45OEQN8CA<"OS%_9%^ NO>!]&\:?'G3$N1?^!I+M;V*+<K>9!NW;@N.<CGB
MOOW_ ()3?$^Z^-'[2?B?QMJ"/'>&>XMF23.[]W(4).1G/ Y/)KS<REST<<H2
M52A2I).+6M.MH[JVNJ\^M^YVX&$85,/SQM6G4<E.[]ZGU3Z.STZZ?(_H_OR$
MN[E%7 $C >WX8JFH!/)Q_GWJ[J8Q?7(_Z:-5"OAULO1?D?2A1113 **** %&
M"I.><],CVK$\77,ECX.UV\A.R:"UD=''53M;D$=^GY<\5L@ =*Q/&2>9X)\0
M+V-G*.?]QJPQ?-]2Q[BVI+!8IQ:W4E2E9KSN=&"47C\O4U>+QV$4D^L7B*?,
MOFC\=M:^$MQ\0GUWQYXFU^4V-C//(EK+,VW,;,0 I;'8=L?3I7S'I5_!K.M:
MAH:S%K*Q9TL^>I1MJ@9X[9_/WKZ0TOQ%J?BW7M?^%E@LP\^XN"7C)  RW4].
MA/)X[&O&[/X2:SIGB#Q!!IT<TLV@F2:Z9 Q.%R6)(Z_F>I^M?Y]9]A(8RMEV
M+R3+ZU>G6Q>+HYYC'.I5K8['TG*=6C>=_=HP3FHQT5KVL?Z.\.XJ>$H9G@L[
MS+#T:E'!8*OD6#Y*=&E@<NJJG"C7]Q)<U:H_9N6[O;H=%JGAC4K;P7/?7TS)
M9P@O&2>H7YEQG\.G?(YZ5S/P=\-:5\;)+O0-5OA9-9%TLIF;8=ZDX*'UXXIO
MAOQAX@^*%Q=?#F&WE$5J\D$[*K?PDJV3CIQSWQ^&>\\._"?6/"%Y/J?AX31_
MV"3+J(CR"RH=SAMO)X!_ D5QX;#T<US#+,QP&7U\SX=H4YX3-*5;GC+%U*6M
M>G'JEAHISO':V]CHQ6)K91E^:9;F&88?*^(ZU2&,RFM1Y90P<*S2H59WTYL4
MVH>]OS:'UQ^SAH.N?#;QPG@Z;69M0L&<+$'D9U"9 7J2.5]/Y8K]+[I0DI"C
M PI_2ORZ_9N\:IX[^(T=XJ[9;%U@E!)R70[6Z^_K[]^GZCWG^N/^ZM?V3X13
MP=3A6L\ME.>71S"K# <]2=5TZ"2_=QG-\UH2O&S[;;'\5^,M/&T^+:+S*%.&
M:3RVE+,)4Z<*2J8AM7JN$$HWG&TKVZ[E6BF9^?';M]<9I]?I]_)+^NO2_H?D
MME>]M7OZ:!1110,**** "FO]T_A_,4ZFO]T_A_,4 >A>%_\ 5C_=_P :["N/
M\+_ZL?[O^-=A0 5%/_JG^G]14M13_P"J?Z?U% 'D.J?\?S_4U2J[JG_'\_U-
M4J "BBB@ HHHH **** +FG ?;(#@9WCM7\P__!=#_C^_X"?_ $&OZ>=._P"/
MR#_?%?S#?\%T/^/[_@)_]!KULD_Y&-#_ +>_(X<S_P!RG_B7YQ/Y=_"EJ-4U
M_3=(?B.]O!$Q/0!Y0I/ZU_5%^R3_ ,$5_AE\:_A1I7CC6M<CMI]0B@8*5=_F
MDBWMQ&CE<9&-V.I]./Y9O 7_ ".N@?\ 81B_]'BO]$C_ ()FL3^SGH(RVT6]
MD<$D@'R#ZDCI^E?5<08FOAJ%.="HZ<G.S:[77]>AX&44*5>I.-6'.E%6O?32
M+_KS/SP_XA^?@Q_T,T?_ 'YN/_C-'_$/S\&/^AFC_P"_-Q_\9K^A$:OI1F^S
MC4[ W .# +NW,H.<8\OS-_7CI5N:XB@3S)&"J< '/!STYZ8KY-YMFBM?$5==
M4FEKMMIKL>]]0P.K]E#3=IO2WS/YWYO^#?SX,QQ22#Q)&QCC=\>7,,[5)ZM$
M%7IU)Q[U^0?Q)_8V^%G@'X_6WP:%XLEI/?I9&YVY4;I F=V,>O)K^YF1(KZV
MDC))BG0HQ'!*L,'!]QQ7Y\>+?V*?@+XK^,D'B[56A_MY)UNQ$60S&96WA<DC
MG=QDX -?5<*Y]EE&MCGQ)#%XRD\)46%C1CS.GB=%"<K+:+_6YXV=95BJE+#K
M*?8T9^WA[9U)-*5+K%=VUMZ+H?FAX8_X((_!OQ!H&E:T_B..,ZG9Q787RY6P
M)5R#E(V7GKP>*W6_X-^O@R$./$D98 X_=3@D]0,F' STY./7BOZ [2RL?"GA
M^&RLP4L=*M1' K')$<8X&?S-&@ZQ%KME+/$V5#&(E3R,AAU'?'2OF:F;8]U*
MLZ6)J1HNH^5-+2#E[J=E:_+:^NMCV(9?A%&$9TH\_(N:S>LDES-:]]O0_B,_
M:'_8G^%_P3^,&D_#"TO%N8[^]CM)90N0@>41GD ]._\ 7K7Z?> /^"$7P<\:
M>$]'\2R>(8X3JMG#=!=LC_ZQ QYC1@,$].#7Z@?'']C;X)>-OB/H?B[7C%'K
M374<Q69E+E_-W KGGYB,]CV^OW/X>T+2O!'AFVTK3-RZ?I]JB09.1A(@%(]-
MP4'CVKZK/<^RBIE.30R:&+PV90I/^TZU6-H5ZEU[T7L[=&KZ>IXN695C(8S'
MRS!T*F%=3_9(0D^:E#1I2MY)/6UOD?@6?^#?GX,=O$T?_?JX/_M$5^4O[8G[
M"WPH_9>\?:9X(MKY;MM0O8[7<%S\LCA=QR 1E3GD @<'J<?V?>$?$<FMW5_&
MSET@9@@+%L -CU_^O^=?'O[3_P"Q]\%/BYK=AXO\:&--;@O$FC>9E)9PP8$'
MJ#DGKCKD5APKGF!PV;+_ %G6)QF7^QG'V-!<T_;2BG2>BO97UW-,XRVO6P$O
M[(='#8I3@^>J_=Y$US16ZNU9).W;>Q^1OP<_X(<?!WXH?#SP[XXFU^."77;.
M.Z:/9(^-Z*Q'[M& Y8\$@XQQ@BO3_P#B'Y^#'_0S1_\ ?FX_^,U^[_PM\(:-
MX'\$Z)H&@G.FVEG$L!#$KM P-HR0!@ ?A7H=>!C<YQ,L7B982O5AAG7J.A"2
M2<*7.^2+6NJC9?\ #V/2P^6X=4*/MJ476]E3]K)-V=117,U9[.2NK'\[A_X-
M^?@SQ_Q4L?U\J?\ ^-4-_P &_7P:"/M\2QEMIV_NIP=P!P 3$ ,GCD@>IK^B
M.H;@D03D<$0R$$=OD:N99QF+:7UJ>Z[>7^6IM_9V#_Y\1_'_ #/\[#_@I)^R
M=H?[(?CR+PUH5TMW#).8LJ01C<P!RO';_P#7S7Q%\(3GXK^ 3ZZY8G\YXS7[
M$?\ !==F/QBMLDG_ $UNI)_Y:-7X[?!__DJW@#_L-V/_ */CK[W!U)5<OIU)
MR<IRHR<I/J^7_@?D?+8N$:>*G""Y8QG"RZ)<R7Z'^D3\$_\ D@_PU_[ =E_Z
M315W5<+\$_\ D@_PU_[ =E_Z315W5?F,_P")5_Z^2/M8?!3_ .O=/_TB(444
M5)04444 %%%% !7HGAG_ %?_  '_ .)KSNO1/#/^K_X#_P#$T =91110!C:[
M_P @Z;Z'^5>3CI^)_F:]8UW_ )!TWT/\J\G'3\3_ #- "T444 %%%% !1110
M 4444 %%%% !1110 4'D$>M%% #D551I)&VQ1 M(W3"C)/?C%?GW^U=^WGX9
M^ -M/::/(M]JH)A,$>)&#-\N<#)R#[=N:^_-4;9X>UMA]X64Q4]P?+(&#ZY(
MK\-=:^&7PV\8?$#Q'X@^)S^?IUC<7#;+A@T8\MF/1OEX(_KBOHN',%@L3B*M
M7,*=6K0PRB_84E^\JRE:T4OF[^1[>18;!XBO4JXZ%6I0PZC)T:2O.HY:*/XV
MT^\^+OCS\;-6^..B6'BI?&%WILFK7*QW.EK<.FV*4C(,6X$#!].AKYO\1_!'
MP-9C2)K75Q-JVHQQRW%UO)D61OF))SG()S^E1?%V7PS9_'JQT[PM;S'P)+J2
M00^5N%L@$H&["_(./;IZ=_L'Q3\./ &E>(O!FI&\1]+N;**6Y4N"L9:-3@\X
M&"2.U?LL'#+*."I4/;8>G7I5*].G"G!/E44U1J-*[E#;WO\ ,_5X2C@*.$A1
M=:C2KTIUH4XTXWBDE*-*=E=RCLD]W\SCOA!\0;[X#R#4+/QQ=ZB;%1.-,-R[
M#Y.0OE[CZ<#'8''(K];?V6?^"C'AOXUZC%X/\0.+#6(F%O DO[MI3]P'YL$Y
M/ Q_^O\  ;4!H2_M+Z;86T%S>^#[W4((;GRRSVZPM*JL6QN4#&??ZXK]+]9^
M$GPE\)?'3X8:O\,I5CFO%L)=1BM6 "RDH7$BH?7()([\UX>?Y9EF*BEC*-:6
M+Q6$JXK#XN$(Q5&5**DZ=;EM9RVU_+;QLZR[+L1&/UFG6EBL1A)XBAB8PC'V
M<H13<*JCI=[:Z_<T?T#$*5CD0Y21%=3U&& (Y]\_X<4RJNE,SZ/IY8Y(M+<9
M]M@_P%6J_%7HVNS/R=Z-KLPHHHI""BBB@ HHHH **** "BBB@ HHHH *<G^L
MB_ZZ+3:<G^LB_P"NBT >QV/_ !Z0?[G]35NJEC_QZ0?[G]35N@ KSWQ1_KS_
M )[BO0J\]\4?Z\_Y[B@#D:*** "BBB@ HHHH **** "BBB@ HHHH **** "C
M/^>:*LA8((6O+N58+:%2TLLAPB* "6).,#CO1<:UZ7?3^O0C.R&VEN;IXXK:
MWC:621V" (H))R3@?G_];X/^*/\ P40_9]^&'B0^&+_Q58C4;>3R[N/[5"?+
M*MA\_-V(/T_E\%_\%0O^"GFA_"/1=1^&GPYU*&?Q/<Q36AN+.8$HSAD()1L@
M_C]?2OX]_&'B;Q1\1?$5]XL\3:UJ4FJZA/-+-_I4I $DA;CYN.IKZ7*LAEBZ
M3KXGFITY+W%:TGJK2MY]-3Q<=FRH3]C0Y:DXOWWO&&UU?O\ -^G4_P!$'P9^
MW3^S!XTMH39>-M/:\E5?W7VR '>P/&-_KV_R?H7P]XZ\&>,%1O#FKV=V),%,
M7,?.><<-Z?YQ7^:!X;\7>+/"$\=UH>NZLLD; J#>38R.1QOP>O<?XU]6>"/^
M"A/[3'P^> :#K]]LAV##W,AX'_ O8?\ ZQFNNOPMJWA\0_*-3;IO;T,*6?6Y
M57HJW7D6K]/,_P!#3Q)J&C^!=%N_$OBN^M;+2[2W>Y$K7$0#>6I;'+8.<8_'
M'K7\E'_!4O\ X*DZWX^UN^^#WP@OKAO,D:PB.GEG\_+&$9,.<D[AP>Q_/X&^
M)/\ P59_:*^*/@1/ .OZW=;]0'V(,ERX<F5=@SAADY/OS7W9_P $O/\ @F'J
M7Q+US3_C1\65FU&VGF2_M3?#SE;+"<<N#GJ/KZ]<&&RNCE,98S,)0FX?PZ:V
ME)6M;S\NPJV/J9@XX?!QE!27[R;T<8OJ_7IKVMH];'_!+G_@E_K?Q UVU^-?
MQEL7GDFN(]3BAOXF))9EE#8F!YSS_G%?UH:-HNG>%M#L_#>D0I;Z?I\<44$4
M:A458T"C: ,=NU0^'?#VB>#-$LO#WAZSM[.RLK=+95@C6,%8U"@_*!SQ_2M,
M@@;C]??IFOG<?CZV/KRJ5)/D6E.'2$>WX(]?"82GA*2A"[F[.I-[R>CUWZ[H
M2BD!SR*6N$Z@HHHH **** "BBB@ HHHH **** .X\+_\@V\_Z_H/_0X:["N/
M\+_\@V\_Z_H/_0X:["@#@_%732?^O5O_ $&.N3KK/%732?\ KU;_ -!CKDZ
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M1\KATFZUTG^]>Z79,R_^%:?"W_H4--_\!HO_ (W1_P *T^%O_0H:;_X#1?\
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ML_\ .OY)/^#<?_D?O%W_ %]WW_HZ6OZV]0_X_;K_ *[/_.OG>(/^1MB/2/\
MZ3$];)_^1=1]9?E$IT445XQZ84J_?C_WQ_6DI5^_'_OC^M 'L&F?\>-O_N5?
MJAIG_'C;_P"Y5^@".7_5O_NFO(]4_P"/MO\ >;_V:O7)?]6_^Z:\CU3_ (^V
M_P!YO_9J ,^BBB@ HHHH **** "G9^4#'0_X_P"--HH!WZ*_X'+_ !#TN3Q#
MX%UC1+<9GNK2X2->Y8QL%^N21QBOXX/B7?\ Q=_8B_:.\8^.;SP3=7NA>(9[
MU(;TV<CJ%F9@#N*$ 8;^5?VEA@K JN?4-T->._&']GOX8?'K1)M(\;:)ITLB
MQ,+>4VT9DWD$ EMN<G%>IEN/CA)U(UH>TH5THU4M&E?XEYHXL7@WB5"4*GLJ
MU)\T'T;ZIW\NN_8_CO\ #7[>?BR_A\2>$(_"S7K^-WN'2UD@X7[5D8(9>/O>
MWX<5ROP,^+OC?]E7Q1XW\03^ XP/&=I=IY(@!\K[8K+G!7 (W^@K[%_;S_X)
MU^/O@!J%S\:/AS&D/AWP^SSQQB,"/RH29 ,8Q]T#G@X/<]/RE\ ?$?XN_M4^
M-;'PGIPB6[2]&GR;$'_+.01MD 8[?YZU]C0CA<31E4H*#P\DG7;E+F3CRM)K
MRT[_ 'GS=65>C6A2J.H\1%_N+136MKROM9W>G_#'U#\-OV]/'/@30?B%\.].
M\+7&HS?$B^N7%@EJ\JJ;YV & I ^_P 5^O\ _P $>O@9\1?"GBG4OB3XM\/3
M:!8ZS))>1PO \*@7#>8H *@#AA_GI]"_L<?\$N_!'A/0]%\:?%K3K:]\1F"&
MY@,L"N#*%#C.Y?4@X']:_8#3--TO0-+@T71M/M+.QM8TBC%O"D>5C "YV@<X
M_K7SN99IAW&OA\'3259VKU-?><4DN5?+??\ 7V<%@J]Z5;$5+NE=PA_*I:V>
MSZZ_+1&G?2"6[GD4Y#2-@^HS52E(*\'GBDKYQ62ZWZ=K62]3V.KTM?73;L%%
M(#GD4M !1110-;[7"L[Q#:O?^&=7L(N9KFWD2->Y8HP''7O_ "]:TN,'CGM3
MDSG(QP>]$E&=.K2E?DK4IT9_X:D7&37R;'";IU:5:/QT:M.K#LY4YQFD_)N*
MN?A1XJO/&?P ^)NI^*9/#\LMK<33 7/D,V%<L,YV\<']?2N4\*_M&:O8:IXL
MU(Z0;MO%B3Q9>/[GG CH1P1NZ>_M7[E^-OAKX2^(FGRV'B"PMG#HP5O)0OO(
MX.=N<Y[GI[]:_)']I7]F#7OAXTNN^%$":1;%IE55X"CYO3'Y$YX-?QOQ_P"'
M7&O!4:V;\.YMB<;P[A\7B<RCA*-&G/%8*MBXNGBJC@])4_8N2O*[/[5\._$O
M@?CKV.3<2Y3A\OXEQ.#PF6SQ5>O5AA,?1P<X5,)2C._-"HJRC+E6C^3/ / O
MB?Q#\,+_ %3QDWAY=FI32S>=L&5\TE@,XXQGG^?-=%9_M,^(;6/7;>WT:2YF
M\3H\,:+"7YE!7C Z\^E>.>%_$WC?XJZE#\.;$(KI.('PHW9!VXZ>H_IZU^N_
MP+_9!T+0],TZ]\;VT,]];".2(R1*WS8WC.1ZD>W/.*^"\/LHXOXSG3P7!F98
MO!Y-@Y57B,=C,/1IT*6-Q%X8V$7'XI<DI*/,G:7E='Z'XCYSP;P32GC^.<MP
M>+SS&*BL-EV"Q%2I7KX'#*,\!4:DWRQ4XP<K=#R3]BCX;>*M/U*X\4ZWILEA
M'J$YN55D9.)&W#@CT/O^'.?U-N7#2DY'0#\JJ6=G8Z7;16.G6T,%O"@C3RXU
M3Y5&!T [ ?C[T\@'J*_MG@GA/#\%\/X7(\/B:F+5)^TKXBHDI5*T]:DE%627
M.W9*RM;4_A;COB_$<<<18K/L1A:>#]JE1HX>G)RC3H025.+<M>91BD_U8OOC
MCU_^O12DDC!Z>E)7UA\<%%%% !1110 4U_NG\/YBG4U_NG\/YB@#T+PO_JQ_
MN_XUV%<?X7_U8_W?\:["@ J*?_5/]/ZBI:BG_P!4_P!/ZB@#R'5/^/Y_J:I5
M=U3_ (_G^IJE0 4444 %%%% !1110!=T[_C\@_WQ7\P__!= _P"G8]C^JC_"
MOZ>-._X_(/\ ?%?S#?\ !=#_ (_O^ G_ -!KULD_Y&-#_M[\C@S-)X*=_P"9
M?G$_E_\  7_(Z:!_V$(__1PK_0\_X)PO)'^R[8O;+NN4TJ-X5'5IET^8Q@>I
M+A?QXK_/#\!?\CIH'_80C_\ 1PK_ $1O^"9I"_LX:&[D*BV]F6+<*!]G)))/
M&  <D\"OI.)=*%"5K\M5.W1ZK1^IXV1J]2KT]S1]O=BK_B?D:GCC]K>S_;3^
MQ21:Q_P@\^NE &%P+<0&YP.^S&S^O&*_H9\>>)YM,\.>'HMY%[<6MH\ZY((D
M-O#OR/\ >W$]Z\%^(?QB^"MMXZM-,L[CP_\ \));706? MQ<M('^;IALYZXY
MYR>^/37@?Q[J=A<Q_-8I;I(F.4( !&.V-OICT]:UXIS:><_V-4K9+2R>.#P,
M:5Z5-TUBU%14:LKI<SE;=7O?4K)\#' O,(0Q\L>\1B.>TY\_L&VVX*S;25WI
MM?Y'KVGZW)%X%?5H_P!Y<6VGRR[>I,@!*CZX.1],U_.E\1_VI/CQ8_M600Z3
MI^H/I(UA+8QK%.8O*\T#/]W&,?G^7[H+XE?3[NZ\+D%87W1 L<*,KC..G],U
MYCXE\ _ _2;J'5[^^T%/%\MP)E64VXGWD@]\MG)X_3)K'A7,\#DN(QT\;E*S
M58O"U*5"/)*3HN:_B/EB[1CU=M/+4O.L'B,=2PT</C7@W0K0G4:DH\_*U[MV
MU=M;+K?JCWU?$M]J?PGTW5-10P:IJ6G0&:$Y#"21"6!'7/8@\^M5OA%J3KIN
MIVDI/G1*\Z*<Y)4-P/T[5A:GJ4.KV?AO3K!TEM?W*.8<>65  ' XQC_Z_>G7
M+?\ "'>)$9?W=I/; /V7)3!+9./U^M?,U(PE&JE#DE5JSJQA]F*4TU"[N[):
M*Z/7BVI4Y2O+DA"#EI[S:C>7;=W=O7;?\2OVP?VEOC9I7[1FC:-H=A?C2+'4
MHHP8XYC&Z+. <E>,;1@BOVW\%^-]4\0_!G3-<UF)K;49]*@#H059G,(R2#SD
M]/RY%>,:[X1^">O:Q?:_XLU#0QK8<R62SFW\X2 Y7EOF'S<CW]37HNCZE::K
MH5OX>T^6*6WC=8X/(QL,8(VX XP5_P ]J^KSW-,OS'*\EPN'R98"ME]/EKXK
MDE'ZP]')IM+FYGKO+==#QLLP>)PN,S"K6Q_UF&*ES4Z+DG[+2R32V7+M:VQT
M?P<GFBOKO[22!>"1D)XS@[N_TK\;?^"DO[1WQG\&_&+1_"?@S3[Z31O[3C#S
MV\<K(4\P \IQT_QSUK]D-<27P<^C-"I7[F_:,=N<_P!<YKS3Q1X6^"_C;7UU
M;QWJ&A1WL<>^%+XP>;YP *_ZSYMV[\?SKFX8S/!Y5F\<QQF6?VMAY4:E-89P
M<[3:48S2BF[Q-,XP=?&X#ZK0QGU.JJL)>U345**:;BVVM^_>QWW[*GC;6?%O
MP=\,:CXCB:"]CTV#[0905;<44G=NYZD]?6OI:"XBN$\R%PZ9QD<\U\O^$M7T
MK1M#U/1="F@:QVLFG&W*^68Q]W9MXY&.GY\BNI^%_BB[-U+I&HEE)D8H\IP#
MDG;@GU]<XKY_,(1KXG&8JE2]A"=>=2%!)^Y"<N;ELU=<M[6MI;H>KA9<E##T
MI3=24:<82J/7FE%)7NK[O;O\CWVH;G_CWG_ZXR_^@-7XS?\ !3S]M7XA?LRW
M_A^S\"VEY>"_^RB<6@=L&4J'SLSG&ZON+]C+XMZ]\:?@3I'C3Q);SVVIWT+>
M?'.K"3YX-W(;GU]:]'%\*YE@N'L#Q+6]C_9^85G1HI37M>9;\T-TGT?S.2AG
M.$KYIB<HAS_6L-352I>+4'%V^&77?\/N_D1_X+L-GXPVY':\/Z.WI_G%?CM\
M'LGXJ^ "1@_VY88'MYT?^?TK]B/^"Z_'QAM_:\;]':OQX^#_ /R5;P!Z_P!M
MV'_HY/\ ZU?4Y>V\KHW_ .?,K;W^'7R/!Q[_ -LJIN[]I%_+F2[6Z+UU/](G
MX)_\D'^&O_8#LO\ TFBKNJX7X)_\D'^&O_8#LO\ TFBKNJ_,I_Q*O_7R1]G#
MX*?_ %[I_P#I$0HHHJ2@HHHH **** "O1/#/^K_X#_\ $UYW7HGAG_5_\!_^
M)H ZRBBB@#&UW_D'3?0_RKR<=/Q/\S7K&N_\@Z;Z'^5>3CI^)_F: %HHHH *
M*** "BBB@ HHHH **** "BBB@ HHI1U&>F>:$!#J*>9H.M*>ALI?U1O\*_FS
M^-7BG6]5^.%Y\(]*+1Q:]?O&TP)4*))6!^88SZ]>_K7]*DH6:SO+0?\ +S$T
M8Z_Q+@]0?4]?RK^>W]N+]F#XO>#OB"WQI^'\4]P;&=KD1VZ,SD*=Y^Z,]^O]
M:^TX)JX=8[%4:]6E2J5Z36%E6=H>W2C[.[>CM+77T\SZOA*K0AC<13KU*<)U
MJ=L/*J[0]LDN3RTEW^3L<VG[+>E07-]X9NHH)]:L+4WMO<NR&0S; XPQ.>O?
M-?"\EC\2=:^+I^$=\9E<W#6^G,6;"Q!]J[3P,8 'IWK1OOCM\=+;6;/7M6FG
MTS4M0E6Q9+IC&1SLY#D'J*W]6\/?$[2O'7A[XBRZS9/KMU$ES;3+(N$+ .-S
M ]>.OX\"OU##4L9AG/ZUB<+6=7#R6';E*2AB8I<S@]4HMV;6UN^Q^B8>CB<.
MI_6,1AJTJM&7L&VY*GB8J[E%JZY+I<R5EV/L#]GS]G&PLO&WB'PMXJMH+C7K
M>U:6SFG9-Z3%"5(+<@Y(/'KQ7CWA6X\3_#[]KW3O"?B.62>VEU:)-.#MN6.(
MSA5"\D8  R!CL?2O$;CXU?''1OB/?:W97;ZEKLR%!]B<N<@  80G_/4U]5_L
ML_LX_';XZ?&C2/C/X]@N;6STNZ@N"LZ,I98Y _.X#/ R>^/PKAQ%.IA*>.QN
M98["/#5LL=-0<_>6)<4H^QB]5&4E]QQUH3PL,7B\PQF&=&KE_LTN;WO;\EDJ
M,7TD[:):WU/Z1M*&-&T\_P!ZTMFQCIF,'^M6:6-%@M+2V7_EA;01'W,:*IS[
M\8X[TE?A3W?JS\=;NV^[84444A!1110 4444 %%%% !1110 4444 %.3_61?
M]=%IM.3_ %D7_71: /8['_CT@_W/ZFK=5+'_ (](/]S^IJW0 5Y[XH_UY_SW
M%>A5Y[XH_P!>?\]Q0!R-%%% !1110 4444 %%%% !1110 4444 %%%2_N88G
MN[N18+6'YI99/E15 R222!@=^WO0MD]'Y+K_ , !ZI'%#+=7+K%! C2NTCA
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MH X/Q5TTG_KU;_T&.N3KK/%732?^O5O_ $&.N3H **** "BBB@!V?E QT/\
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M+.^MO"WB:ZTNY2T9Y;>WFD3Y-I)!"L.".>,?0U^)VI6X^(OQ<AT;Q9J<D_\
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ME%]7:[7X]3^FRUNK?4K*UU6QD$^GWT:S6DRMN#Q.-RG(R.01Q4AYX]:^#O\
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M,J1^*-.C+$ ;[R#G/XC_ #^@!]$4S!WYP<>N/:N0TGXA>"-;C233/%6A7.\
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MOOK4445^?GU 4444 (>GXC^8KT3PU_JQ]#_Z#7G9Z?B/YBO1/#7^K'T/_H-
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MPS3:O\)[E;"WMX@6F(LGV+M49//ECZ5^]7[(GQ)U'XN? G1/&.L6\UM?R1I
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MD\5Z#H?V)6>[\"B-YTA^:0FW8$A@,G^'G_)KY#B#+Y<.\01KY1"2HTHX;/\
M)8J4I1GB\5R?VG2I]X4L/SRC3CHK*Q]KPWF<>).&YX?.W%UZT\3PYGLN10<,
M+A.9Y36G9^[.KB>6,IR=Y7Z:L_5T'S;:UNL@BZA2<8YR)!D=/\.]-KRSX+^,
MYO'/@Z&[N(9(9-.C2U*R A_W0VYYY[<9SD=<5ZF#GFOZ)R_&T,RP&#S##-RH
M8NA3K4VTTW>*4KIZKWU(_FG,<!7RO'XS+L4E'$8/$5*-6*=XJSO"S6_N-!11
M176<84444 %-?[I_#^8IU-?[I_#^8H ]"\+_ .K'^[_C785Q_A?_ %8_W?\
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M@:V\1:!KOCN[B#3K*95E91DLTF%Y()ZL#QQ^AI__  6;\2/J7@#2/#P<X?\
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M\N52ZM)N?&,,,]^?4UXS\,_@1\3?VG_$-[J.A:;J=T\TVZY=(9)(P Y)((!
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M*U_P-1]<HU*-.E7PZJ*FDH_^2J_S7;R\AJG5A4E.E5<.:VJ:U7N^?7_+>Y^
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MGR7' #9.?0#Z=<UDJOML=3J*+7-6A96[-?IK^/4TY5"A.*=^6E+UMHS\O/\
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M3;E.?9RD[N3M9-MW$HHHJR HHHH *:_W3^'\Q3J:_P!T_A_,4 >A>%_]6/\
M=_QKL*X_PO\ ZL?[O^-=A0 5%/\ ZI_I_45+44_^J?Z?U% 'D.J?\?S_ %-4
MJNZI_P ?S_4U2H **** "BBG;3D#C)_S_2@!M%/  )#>WK4?S;AZ=_U_'TH
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MU;?X5S?VEL_JM);/X?\ !MIY?BC98.GI^_J].O\ A_X']/7^+[[3_P %%?\
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M+IT_P>7E^*[A]3I_\_ZO3K_A_P"!]WGK_%]]I_X**_\ /KXC_P"^;RFQW?\
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MW*GC';VIHN?^"BO_ #[>)/Q2\']!7]J^I1?#\PZ8 GA;/]G6I.(K;.?*3/\
M#ZGK_C65Y/@#^[X6'UCMN?IQ7*LSOJ\)2U::T>BO%VV^_P W\SI^IT]/WU7I
MUVVV_#R\MC^+[[1_P44Z_9_$GT*W>/P_S]:/M/\ P45_Y]?$?_?-Y7]H/D^
M?[GA?_OU;?X4>3X!_N>%_P#OU;?X4EF6W^RTNG3_  >7E^*[B6#I=*]7[_\
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M_P#?']: /8-,_P"/&W_W*OU0TS_CQM_]RK] $<O^K?\ W37D>J?\?;?[S?\
MLU>N2_ZM_P#=->1ZI_Q]M_O-_P"S4 9]%%% !1110 4444 %%%% #!MD!5A\
MO<=<]^_TQ3@(T 2--H]0H_4CT_K2T[:0,_YYIZVZVN#M?3^M-1M'OCFB@G'6
MEKOVT 4$@Y'%-*0[MXC DYRP51DG]?ZTM%->=[=;#T:U6M]^R\O,*.>N.**"
MV ,],]/SI"[^OZ(****;\KV\QMM[A112%L=<TA"_YQ3B0R[2..,^XQBFT4/I
M;:VM^_EY#L[K5:ZWOL_TV%&U1MC&T<Y&!S2444?U9;+R7D+[WYO<***4=1GI
MGF@!"$SE5P?7 _\ U_K0>01ZTYL9^7I^/]::/?I335T[7Z]O3H/5B*IZ#GO2
MT\D Y7T]_P"M,I6TO?KMUV_+]1?U;^M0HHHH **** "FO]T_A_,4ZFO]T_A_
M,4 >A>%_]6/]W_&NPKC_  O_ *L?[O\ C784 %13_P"J?Z?U%2U%/_JG^G]1
M0!Y#JG_'\_U-4JNZI_Q_/]35*@ HHHH *7)ZY.:2BBU[+S7Y@'F;OE]/Z<>M
M*"2-H'4__6Q2!>?E!)/IDD]^E<A\1?B9X0^#OA+4?&?C'4;2TM+*TGE6WN9%
MCD9T0LH 8@G/I_\ KIQC*4E&"<I.2245=MZ6MWZ"<E%.3:2CNWHE]Y8\?_$;
MPM\'?"]_XQ\8ZC!I\6GP-<VZR3(GF%$+  ,PZX'Y_C7\3/\ P5#_ &X[7]I7
MXBWUAH:J^F:?=26ZRI@JZJQ0-D<'@>O/KVKJO^"DW_!2OQ3\?/$^I^#/!FHW
M%OX6@EFMH_LD[JC(KE1]Q@",#GTS]!7XS1I(3)/-(\TTQW2O*=SEB022><G/
MO7W.29,\-RXO$_QY+W(=8)V?O;ZOI\SYG,\R]NY4:.E*Z4I?SM-;>K\@CC\M
M"@)P2Q_.HS;0MRRY-6**^GZ:7U>OZ'C%;[);_P#/,4?9+?\ YYBK-%(+>7X?
MUV7W%;[);_\ /,4?9+?_ )YBK-% 6\OP_KLON*WV2W_YYBC[);_\\Q4Y+?=C
M4R2GA(EY=SV  !)I1IWBUN4\):RZ'E76TF*L#T((0C%%[;Z"T[?AZ?\  ^[R
M*_V2W_YYBC[);_\ /,59_LSQA_T*&M?^ DW_ ,11_9GC#_H3];/L+28G_P!%
MTN9=U]X:=OP?EY>G](K?9+?_ )YBC[);_P#/,5.8-7MCC5='OM*)^[]LA>'=
MZ8W@4ZG<%;M^%NW^2^XK?9+?_GF*/LEO_P \Q5FB@=O+\/Z[+[BM]DM_^>8H
M^R6_]P5;7;SN_#K_ $I#C/'2@%]PV...,?* N#G'KCG_ #_C6EX?U=_#OBG0
MO$D8RVBWT-[M'?RI ^,8YSBLULY&WIGGZ9]_:E"J<[AU&.Y].U#5U:VEM=]4
M]/UZ!V\K?AL?W+?\$V/^"AW@3]H'X=^'_ &OZA;Z7X@T.R@LK.UEE2-YS'&L
M:@ L">0 /_U5^M4MNT17)&UU#HP(8%6^Z01ZCD5_F@?"KXL^,?@KXPT[QAX0
MU&\MKBQN89?*AF:.-@D@8Y4$ \ ]NAK^T[_@G-_P4A\'?M(>$]-\(>+-4M;3
MQM;006TCW4RAI'1%4@;VY.?SS],?"9SDLL-*>(PRYJ$Y7G#=TV^O5\MV_P"M
M#Z?+,Q]M&-"NU&K%)0D[6DDK*/KV2=K=#]:<YZ<T5+)"J?/$PEA?E)4Y1AC(
M*D<'KVXJ*OFWIYGLA1112 **** "O1/#/^K_ . __$UYW7HGAG_5_P# ?_B:
M .LHHHH QM=_Y!TWT/\ *O)QT_$_S->L:[_R#IOH?Y5Y..GXG^9H 6BBB@ H
MHHH **** "BBB@ HHHH *0G Z9]J"<<FE!SS0'R_/]!I8X! Y)Z<^]8GBKP]
M;>,/#]UX<OT#VEXI61&Q@Y'O^7T[UNTX@KC^E.,I0E&4=)1:DGU36J:_I%*3
MBXN.CC)23ZJ2ZK^D<7X*\$:/\-_"]YI6AVD<+QH\D?EJH)DQQT&<Y/4'FOSO
MU3X3>+_B%^T#IGC;6].E%MH]\CP3R(V-L<H(()'IT]:_4//KS]?Y5.BVP4F2
MW@MU RURR*H '!)<@8QZY_E7HX3,ZV$EB:UO:5L33E3E5G+WHQFK3L_-=#MP
MN85L-/$5(I5*N(A*G*M.5Y04TE+_ ,"6COL+/)YB6B=3%:PP_BB!<?F#3Q8W
M!C\T!=F,_?&?RKYG^//[6/PL_9[T&]U#Q#JECJ$Z0NT4,$Z-(' ^[M#$YS_G
MU_"[5_\ @M4T7Q/1[:WG3P8EVJ2 E@GE-)@D]L[<<>G!%>]D' ?$_$E"KB<L
MR^I+#TH.:K54X1K/1N-).S<G?16M^OS^*S3 X)QA6K+GNDXQU<5I9O>WSU7R
MU_IB$:S![.;_ %4^8Y,],$$?3O\ XU^67Q/^%_C?0?VJ?"^J^%M-FD\,2W<$
MFH742,8D!E#.691MX'/.?>OIG]G;]M'X4_M%Z5:SZ)J%II<TD48+7,J1[I&4
M9QN(R23VS7UYMM/*+0Q6FH \I>JBR$#U63#=CV/\S7DK^T.'<9B<-CL%4H5Y
M4JF'JT*\6OC22G>W*W'=:W>A[>79BJ"G6P[IXFG7HSI-7TM427-;O'I_PQR?
MC[P3H?C^VL+76+6*\2VM8-@D56V2*B9QD?WOY4>&O#MIX6LUT^Q18[=%"*B\
M *, # X[?YXQT 8@Y!.?Y#TI,UY'M)^S5+GDZ<7=0;]U/NELFWVZF"JS]DJ3
M<G36JIO9-VN[=W;4*,YZ44@ '2H(6R%HHHH **** "BBB@ HHHH **** "G)
M_K(O^NBTVG)_K(O^NBT >QV/_'I!_N?U-6ZJ6/\ QZ0?[G]35N@ KSWQ1_KS
M_GN*]"KSWQ1_KS_GN* .1HHHH **** "G*I=E11EF( 'N>!3:?'(8I$D7JC!
MA^!H ^/?VQ?VN?!W[*/@&^U_5;Z,>((T+6M@Q&Z3CC Z]>^*\'_8@_X*4^ _
MVKH6T[4;VVTW6A.T*6KR1QNV&(4X)SSP!_\ JKJ?^"A/[%.G_M7_  ^U*>SF
MF3Q3;6TS6449.QFC3<HQSGD?_6K^+"[TOXU?L"_&LQM_;%DVFZM)+/,3+#;O
M"DQ(YRJX*@8_,>I^ERS+L#C\%4IJIRXU-R3EI:UK**_E?=]=.IXV.QN+PF(I
MS<$\+HK)7OM=N^S_ ,[ZG^C+- 8\.F&AD.8G4[@RGD$$9S_G%<%\3_B5X1^#
M'A+4O&7C+4K>PALK:2XMDFF1/.9$W*NUF&<X]Z_*_P#8V_X*K_#/QI\&4UOX
M@:C:)J6D:6PE6>9/,>>* ?WFR267/OW-?@5_P4E_X*.^+OVA?%VH^$/"FI7,
M'@Z"::&#[+.RHT88H,[6 QC'M7)A<DQ-;%NA5BZ=.G*U2HUHU=:0>S;5SHKY
MG1I4(UJ<XRG-)PA>[UM\2[+MOUT/2/VMO^"O?Q!UCXZ)K7P^U&YM= T/5$A:
M"V=Q%<6\<X5LA#M8%!Z=*_4[P1XJ^!__  5"^ SZ'K!TZW^)EKIBQYD,"74M
MRL XYPY9GYQW//;%?QRQ1EMTDI,TL@)=Y/F8GG))/4^N>>*]K_9\_:%\;_LS
M^/\ 2O&'A+4[M+:&\BGO;-)W2*2-9%9EV*P!R 1@#BOK<3E%+ZO36$M1Q&'B
MG2J1T<FK/EF]+WMYV?S/GZ68555E+$-U:%7^)3:3LM%>/I]VGS.V_:U_9*\<
M_LR^/-5T;6]*N(]'6^D6QNC%(8S&LAV.KXVXVD'(/&,]Z^F?^">'_!0[QI^S
M%XUTG2-9U6YOO"%]=1PO#+*[0VL1D12<,2%"C/IQR#7]!GA'3_AS_P %5?V;
MY-2N-!AM?'&G:.Y:Z:W EDN$A)#;RN22W.<\_D*_E+_:K_99\=?LV>/-6T'6
M]-O8]-BNIUMKSR75 GF$HRO@#[O0@^U3A<52S"E4P..IJ.*I^[4@^MEI.&M[
MN]^_XWJMAI864,7AI.5&;YH373:\9>3\^Y_H._!GXW> ?CCX'L?&WAO5[2YM
MY-/6^OBL\?[EM@D=3AN,9^@QWK\;/^"EO_!2F'P;!<_!OX-W1U3Q=K"OI[)8
M$S2PSR?N>/))8$%C]:_F@^#'[>GQK^ ?@Y_!G@[5[Y]/U7%DVZXD)B2X'ED?
M>X"[O8CGD5^\?_!+O]AS2?C7X@A_:(^+NJPZ]J=[*NH6UC=2+=-%)*PFP4<M
MC!XP0,8KQWE.&RR=3%XN7M*--WH4EK*I+HI;_/RN>DLQKXZ%/"X:/)6FE[>?
M2G&T4Y1=U=O\V=/_ ,$V?^";>L^*M8C_ &AOV@X)-2U>^F35K.SU,,[)O(F4
M*D^>A/8<#-?T=10V6FV<.E:1 EGI=M%'%!;1J%1%C4*  H '2ECM[32[.VTC
M3;6&RL=/C%O!%;QB)/*0;5^4 #I["@  9;H<8Z^]?/8[&UL=5=2J[15E3IKX
M:<5M%+;UZ_,]7#8>GA::ITU=M>_4?Q2;LW?375?<1T445QG0%%%%--K8#\^/
M^"I5[=V7[.EH;29H6FN4BD*DC<C'Y@<8R",Y]:M_\$Z_V??@_K/P-T7Q%K'@
M;1]2UF\A1KJ[NX$E:0N-Q)(P^[/3+8QG/-4_^"J:;?V9FG.,VQ,Z_6/)_IG(
M]*_$C]FO_@IQXO\ A%X.M?"EE,X@LU,2@.1@(<>H].WX5]OPOPSF_%."GA,G
M476H5?:54YN'NN*2U6^ZTUZGS><9O@,GQ<:V.;5*I34:=H\UI*U]'^+[[G]?
M/AOX<>!O"#^9X:\,:5H\G]^R@\MN/?)K9\3>(M-\)Z!JOB/6)TMM,T>TDO;R
M:1@BQPQ@9)9N!R0*_E]/_!8WQXI(%RWXNV?_ $/N?_U5Y/\ '3_@JYXR^(/P
MI\5^"Y[V6%M?L)K)W25E94=2!M^;(YZU]!4\'N,8)UJ]&C[."YYR=5M\D=9;
M];7LKK7SV\Z/'>0RM"E4FYOX(J%DV]MMNG2]C]35_P""R_P1;XQCX="^L/[-
M.I#31J/FI@S>;Y>W?NQG)'<_A7ZL-X<^&OQBT#2/$>I:#I'B73=3LXKNQGNX
MEN 89!\N&5O;I^-?Y<Z:1J,?C--4.L7WVE?$']J><9VWD^>9?O;LX_\ K?C_
M $W? G_@JWXT^'GPO\,>#8;Z68:)8Q6JNTQ9B$B1<D[N?N]>N<]:Y<+X=YGG
M$Y1R2/[W#^[7C4GR*^UXM:N7,M>FOW7/BO"8-<V9-*G5:=)PCS)72=GY6UU7
M<_6G_@J!\ _A%I'P(L]4TGP/H^G:A;:T/(N+.W6)DPL1&223P3Q@COFNW_X)
M[WES-\(=%LYY6>VM[)8X8R3B,!  !V&% ';VS7X,_M7_ /!2_P 5_&?PGHGA
M"]G9H+C48RX+D_,[(I[\YVCMV]\5^[/_  3F;[1\&M!N6ZS6,;GD]XP?\\^E
M>3Q/PSFW"^%HX3.%%5ZD_:4U&3E[K2ZM?C;7Y'=DV;8+.,34Q&!DW2C3C&6G
M*[Q?:UO)?>??1ZGZG^=)2GJ?J?YTE?$=$^_3L?27Z=0HHHI %%%% '<>%_\
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MU/6?V8_V5?@'\0?A9''XIT?3+B_OK-4^W3^5O+M&>=S\YR?7]*^,/&-EKW[
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M\5]3?%W_ ()IZG%H0\6^$+TQ:SI@^T0RP.5<F'[BY4@Y^45Z9\(OVF++P?\
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MC_L8&_\ 1QK^L6[&?A-=#UTQ/_2;_P"M7\G7A?\ Y/WN/^Q@;_T<:_K&N_\
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M^ </_P 31_:-/3_9J?W?X;]/7^K!]5_Z?3_#R_X'],_D?_X7?^W)_P ^&O\
MY77^-'_"[_VY/^?#7_RNO\:_K@_X5=X!_P"A?TK_ , X?_B:/^%7> ?^A?TK
M_P  X?\ XFC^T*?_ $#4^G3_  WZ?XOZL'U7_I]/\/+_ ('W^9_(_P#\+O\
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MLZO=(USH-S.Y>!)R"RF)VR-H..G^-8GBWX3^ )5\/Z1:V,"SZM!#-/M491F
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M+S6VOTLE;O;<]VA_8._9]^,/A*R\4^%[;3=+BEMXY);R%HHSGR]Q)*[>_O\
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M7+I99D6"HU(VK5*?M:SZN4[25_.VOST$HHHKX@^A"BBB@!#T_$?S%>B>&O\
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M)'@#0^P^RVW.<?\ +)/Y]:_DK\0_\GNQ_P#8?_\ ;FOZU?AYS\/]#'K:VO\
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MB@ KE_B7_P DL\8?]@^Z_P#1!KJ*Y?XE_P#)+/&'_8/NO_1!JH?'3_Z^4_\
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M^+'Q&T]CJERPO8+FZ0EI68B52/,&3G.?4GZU^_3>6D<,$*A(K>-844  ;4
MZ?3_ /75#2-'TKPQH]GX>T2VAMK#3XTBA\A0@944)SMQGIU[U;K\LXKXGQW%
MF<5\TQDG&$FX83#I_N\/07PP@NETKM=-3[+),FPV1X"E@<.KRBDZU6WO5:C2
MYFWN]>^H4445\T>JDEL%%%% PHHHH 0]/Q'\Q7HGAK_5CZ'_ -!KSL]/Q'\Q
M7HGAK_5CZ'_T&@#K:*** ,?7?^0;-^'\FKR5?XO]XUZUKO\ R#9OP_DU>2K_
M !?[QH =1110 5R_Q+_Y)9XP_P"P?=?^B#745R_Q+_Y)9XP_[!]U_P"B#50^
M.G_U\I_^EQ!_#/\ PO\ -'\1OA?_ )/WN/\ L8&_]'&OZQKO_DD]S_V"U_\
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MW??^CI:_K;U#_C]NO^NS_P Z_DD_X-Q_^1^\7?\ 7W??^CI:_K;U#_C]NO\
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M((*2 .",<8P>.?SK^;'5=$N/$WPI\,^!-.++K_P_OA>ZD8^9UCM9-[^9M^;
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MA+,KB/801]X@#]0:^>7$T,,Z?]HT52]HE*'U=NIRQFER^UT]UZV?9^A^WU?
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M?ZFJ5 !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M;D^2JKDC )V]!Z=*YKXR>&?"_C/QO#\*_#V@0Q[[@12:E%$HV_-@DNH]N_\
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M]\4?Z\_Y[BO0J\]\4?Z\_P">XH Y&BBB@ HHHH **** "BBB@ HHHH ****
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MI\W+4G*UVY)OU.^/'(7/T&/Z4IRVTY(QSCGVXK@/^$QU;_H4M<_\ IO\*/\
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M(6!7 .#MR.A_F?;]@O%'[*GPB\:22R:AH>FQ-)DL%MXQ]XG/\'^?QKPW6?\
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M %%%% !1110 4444 (>GXC^8KT3PU_JQ]#_Z#7G9Z?B/YBO1/#7^K'T/_H-
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MJFT]/032>\4_)I/\SP7_ (8__96_Z)KI?_@%#_\ &Z/^&/\ ]E;_ *)KI?\
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M-=A0!P?BKII/_7JW_H,=<G76>*NFD_\ 7JW_ *#'7)T %%%% !1110 4444
M%%%% !1110 44447 ****;?;16M:_P#6X"Y(Z9%)D].U%%( HHHH **** "F
MG('';MC_  ^N:=10"TMY>K&J^XCY<8 /_P"O_']*>3GH,4E%%QMW=PHHHH$%
M%%% !1110 4444 %%%% "'I^(_F*]$\-?ZL?0_\ H->=GI^(_F*]$\-?ZL?0
M_P#H- '6T444 8^N_P#(-F_#^35Y*O\ %_O&O6M=_P"0;-^'\FKR5?XO]XT
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M?_08U/\ \"I/_BZN.!QD4E]8:226_9KS7GM_P7F\11;;=):N^NO;S_JS^?\
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M_"$_MZ?WO$/_ )-T<D]/]OAT^VO[M_M>;_I!>/\ T#/_ ,!]//R7W??^K/\
MP[4_9M_Z"NF_]_X/\:/^':G[-O\ T%=-_P"_\'^-?E-_PA/[>G][Q#_Y-T?\
M(3^WI_>\0_\ DW1R3T_V^'3[:_NW^UYO^D%X_P#0,_\ P'T\_)?=]_ZL_P##
MM3]FW_H*Z;_W_@_QH_X=J?LV_P#05TW_ +_P?XU^4W_"$_MZ?WO$/_DW1_PA
M/[>G][Q#_P"3=')/3_;X=/MK^[?[7F_Z07C_ - S_P# ?3S\E]WW_JO_ ,.U
M?V;=Q']JZ;G'_/:#V[[OZ4\?\$T_V;""?[6TS/3'GP<X_P"!>]?E+_PA/[>?
MKXASZYNO\_K1_P (3^WI_>\1?^35')4>^80UM?WUTY;)Z^OZO1A>/_0,U;^[
MVMY];?UU_5D?\$T_V;5(8:IIF1R/W\';\:MO_P $XOV=73RVU;2]GIYMN.OO
MG_/UK\F_^$)_;T_O>(?_ ";H_P"$)_;T_O>(?_)NCDJ:?[?3Z?:C_<O]KU_$
M.:/_ $#/_P !?EY^7X/OK^JX_P"":O[-V<?VIIN,G_EM#_/=^O>G?\.U/V;O
M^@KIO_?^#_&ORG_X0K]O/U\19^MU_A_6D_X0G]O3^]XA_P#)NA0J*W_"A3^4
MTOY?[RZ7_'J).*_YAG\X^G9^5_DS]6#_ ,$U?V;1UU73?^_\'^-+_P .U/V;
M?^@KIO\ W_@_QK\IU\#_ +>CL%!\0DD\#_2OZFO)OB1\0/VN?@^ _C&YUVWC
MP<O*\Z+P,GEB/_K4XTJTVHPQL)2TT4]7\-[6;VU5O^ #E3BKO#VMNW%V7PV^
M>B^X_;'_ (=J?LV_]!73?^_\'^-'_#M3]FW_ *"NF_\ ?^#_ !K^=_\ X;7^
M-#_=UK43@X.+B4<@D'D,>XZ4G_#:OQK_ .@QJ9_[>I?ZL*V^I8S_ *"7T_\
M;;_:_P 7]6(]O0_Y]+[GY>?DO6Q_1!_P[5_9L)Q_:NFY'_3>'_&OFO\ ;'_8
M2^!?PM^!FL>+_"^H6$VL6UO,\4<4L+2$K&Q& ISUSC_./QQ;]M;XTQAI&UK4
M0H&3_I$G'U.[^?UKN=)\7?M+_M-Z)+X;TF;6-2TVX!C=0998OGXZ<CO^55'#
MXFC*-2IB+4XM<_,]''3?UL^F_P @]K1:<8TKRE%\MEL_=U^2Z'ZP?\&ZDID\
M=^*MPV[;B[7\$=E'Z"OZRM0_X_;K_KL_\Z_G,_X(B_LD_%']GCQ#K.N>/K2:
MVMK_ ,UXO-B9.9LGG('KT_\ K5_1C>N)+JX=>5:5F'T)KXW/:D:F8U94Y1E#
MEBDXNZVZ>A]'E<9PP-*,TU*\FT]]5&S^95HHHKR#T I5^_'_ +X_K24J_?C_
M -\?UH ]@TS_ (\;?_<J_5#3/^/&W_W*OT 1R_ZM_P#=->1ZI_Q]M_O-_P"S
M5ZY+_JW_ -TUY'JG_'VW^\W_ +-0!GT444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M )ZTHS@9Z]Z\;GFOM2^]^7]?\.ST.6/\L?N7]=$<W_P@'@+_ * EK_X#1?\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M5/\ C[;_ 'F_]FH SZ*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH *:_W3^'\Q3J:_W3^'\Q0!Z%X7_U8_W?\:["N/\
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M%2U%/_JG^G]10!Y#JG_'\_U-4JNZI_Q_/]35*@ HHHH **** "BBB@ HHHH
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M/'4'\C1SUP<?2@%TNO5!10.3@9)] ":4@CJ"/J"*!OR5OQ$H'./?^M-968<
MGFGXPJ\'T.0?P_3TH$*PVG'6FU)&D;'$L\5NO_/29@B?F2!QWYJX8M&'#>)-
M#4]PU_ "/8C?UH S\XZT<GD#CUJ:>&$#-O=V]Y'G_66LBRIWQEE+"K$,5D83
MYNKZ=;RX.VWFN8UF;@#"H7#$_P# >M %&D)((&"??_(J4(F_;)-'"N>))&"H
M1Z@DC(../6G2"-!B*XAN0>I@<28R/]DF@"&BKD,%FZEKC5+"S.,A+FXCB9CZ
M*'89/MUJLR89MC+(@)Q*A!C<>JL."#U&.U #*<R[<<YS[4VB@ HHHH ****
M"BBB@ HHHH **** "BBB@ I5^_'_ +X_K24J_?C_ -\?UH ]@TS_ (\;?_<J
M_5#3/^/&W_W*OT 1R_ZM_P#=->1ZI_Q]M_O-_P"S5ZY+_JW_ -TUY'JG_'VW
M^\W_ +-0!GDX!/I0#D ^M%*H+$  ^Y[*/4GH* WZVZ_\#U8E."Y..GX5;,-D
M(]T>KZ=+,.3;QW$;2@]<% VX'M]>,54W'<3QGI[=NE "'@D>AI*<0W4J<>N#
MBD )Z GZ#- "49[=Z7&",@CGG((^M)M!=BH8\=@<8X]OZT &:*0KR"<@C_\
M73L-Z'\C0 E%+@^A_*DD/DQ23R?+'"I>0G@ +R<T (3CZ^G>E7)&<'/ICZ_X
M5R-CX_\ #&J7[:;8WEO+>Q/L:))%+A@<8(!SWY';I78XD7#LN,CN.QZ>GMTH
M 0+D$YZ9[>@S3:X^Z^(OA6PUF'PW<7UNNK7#!8[=I5$A)Z83.23QV-=FT;K@
M%3E@&&!G@C(Z>U #**4@CJ"/J,4E ^GG?\!"<#- .1FG ,>@)^@)I*!!1110
M 4444 %%%% !1110 4444 %%%% !1110 4U_NG\/YBG4U_NG\/YB@#T+PO\
MZL?[O^-=A7'^%_\ 5C_=_P :["@ J*?_ %3_ $_J*EJ*?_5/]/ZB@#R'5/\
MC^?ZFJ57=4_X_G^IJBQ.. 2?89^I_*@!:*LF&W\E734+.6?^*VCF1IU^L8.X
M?EZ5 J.^=JL< D\'( !)S] .: &T5RG_  GOAC^TVT3[;;_VBAVM#YJ^9NSM
M(VDYSG]<5UJ /&'7)#?=(&<\9Z"@ 4;L\]/QIM)LVDD@@GU&/?TIV">@/Y4
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M6.3T&: )6&TXZTVEP3@@$@C*D#@@]"/4$<@T8(Z@_E0 F<=:*0C=QS^%.VD
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M3:F\H;-WFQ[O^>6?WG3/W>OM5=[FPMSY=Y?6EG,_^KAN9DBEDXX\M7(+$Y[
M]J '4YEVXYSGVI "0"H)5OND#(8=B/4'/%*58=5([]/\XH%?U^YC&.!G'>C/
M3WQQ]:#N/W1D^E!0Y!8$$8XZ>] Q:*7!]#^5&".H/Y4 )35;=GCI2D@=:6@
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M;SHH%<R@L V=QY;UH&DVNV[U](G[T_"+]KOX>_%O4)[ :C:V:PNRB0L@R%)
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M>%I(V1BK!D#%L@^H..]>I_![]H?X<_&?2[B\T?7+-M0M59I;*.:/S%1026*
MY ^H'Y5_/#^P3^QYX6^.?[77QVD\:^,+RXMH+G5)8M.^T^<RGS'*B*!Y OR'
MYF&1A%8]@#>\#:9J'[/_ /P5 UWX!>#M=N[WPIJ5K=V=NB3,ULLL@>./(#%
M02N1GKQSW Y>VNG,[=/QZ'[G^-OVP?A[X4\3#PKHVH6FL7\4OE:C'#)'(]H=
M^UO,"EBNWG.<8YKLH?VD_  CM9K_ %:UM(;L(JL\B*!(^!LR3C.>,?\ UB?Y
MT)?@_P#$?]EG]J[XF_$3X[:A=W'PRU[49;BTDF=V@M;:>1W!4L2$PC ]OK7U
M!^VOI/A3Q_\ LL>%_BI^S3K-W?);:K9S:D]A(TC1HKQM*',9)4+\V<X]>G-
M<NC=]+I??;[K7/W8U[XB^%O#OAC_ (2Z^U."/2GB$T$[R)Y<B$9!4EL'(P?U
MH^'OCK2?B7HS:YH,\=U:!]@DB(92<X_AX[>M?S=_'+]J&]\3_#O]G7X(Z-J\
MTVMZ]!I5EXC^S3%YXW?RHY!.%8D$$L#NK^AK]F[X61_!GX7:'H\<SW3WNF6=
M_(\N2V^2..0CGG.2>/\ ]5 -:+SW\NWZV[G1?$7XK^ ?A3I,NH>,==M-(O0K
M-:V=Q+'&]P1T"H[ MGIQ_P#J^:_A]^W9\+?&'B8:%KFJV6BVLER(+6ZGDCB2
M<E@J[68J#GVZ]J_)'_@IOJVL_$[]K+X4^!+C7+K1-$N-3LH+J%)V@AF4W" A
MEW*&!SCG/'M76?\ !43]D7PC\$O@?\,_&O@;Q%/IVL+J&F":2";R9KIDALI3
M*A23,D4C2L$?(W?-D4"2;:5M]OG_ ,.>[_\ !6#]J*;X:^"XO#WA?5O+L?$<
M<26U]#+A)4G 565U.#PWK_A5S_@E#HMM>>"?^$JO[XW^KWLOGM*TAD;]X QY
M))ZGUKX8_:8\"VGQA_9T^$-UXINI6O+;2]._TF9B9)F5(R"7/))QGJ?SK]=/
M^"<?P>T3P-\%;/4-.N6FD\M."2>-H _E_GF@J222U5[V=OZZ61^@]PQ:5V;N
M>_Y?SJ'MGMZ]J=(QD)+=3U_/-(#A=O;]>W^%! E%%% !1110 AZ?B/YBO1/#
M7^K'T/\ Z#7G9Z?B/YBO1/#7^K'T/_H- '6T444 8^N_\@V;\/Y-7DJD\CMN
M->M:[_R#9OP_DU>2K_%_O&@-SS+XW^#?$WQ&^'MYX3\%:D^B^(+I&2&_C8QN
MC."H.Y<$8)'?MZU_*/\ \%$_A+^W#^R;XH^'%E9_&K4KFW\>:M%:1F+4YF5!
M/<B+ (E(^0DJ<$X*[3TK^PV*1UFC=258.F"O!^\*_GV_X+S7#_\ "=?LXJTS
M877]-*@MP"UU$Q(!Z%B6)QWH*AK+\?\ ASWC]E#]D_\ :8^$R>#_ (N?%/XL
M7.O^'=0TBRU6\T^;4))A&L]NEP!)&\AV[D.1N R,D<9K]1O#OQD\'>/K^]@T
M"_M[@Z<A6Y2)T.QHE <L%)P?E.*\]^(-S=#]D/P6\4THD?P-8;F1CN.W2XPI
M)'91P/05^6W_  3LN;J?QA\5Q>ZX)=O]H;8[FXYA^:7&0S_+CB@3[I:7T/U^
MTWXR>#]7\0W'A:TU*WDU*UWF:%9$+J(P2Q(SQC!/M]:\=\6?MN?!?PEJ^K>'
M9O%.G-KNC;A<V!GA,JLG#!D#9Z\8K\Q/@?>7Q_:_\;1C6GO+<0:KMBCN/-B3
MY)<' 8@8QQWKXT_8U_99T?\ :8_X*"?M!V_C?Q1J/V#3KW5GAL1.[(!%)(P2
M.,L%S@<#@9XX'0#KK?3?N?T#:!^V]\#->\+W6N/XOTN'4[;?C33<0B1@O/";
M]W8UT7P7_:M^&GQMU2YT71=;LFU"W=HUMTECWL4)  7=G)QV]O6OYK'_ &3=
M(T[_ (*.2?!F#Q?J2^$FNY83:K<R" KYI3!0-MZ>WX5]"?$3X81?L8?M.Z*O
M@'7+NZM[R_MS+;B5BK>8X+C;GG^1H&HZVONKI_/K>W]6/WQ^+W[1?PS^#ENT
M.K:_9#Q$03'I+S1&=P!VCW;CG'8'Z5Q/P<_;$^%WQ5U#^QK_ %JRTG5IV*6=
MG+)'').^?E"*Q4DG(Z#C\J_$!_"4G[3?[?GA2S\7>)+BQTJ>*S\S39KEDA;S
M<;LQ,V#U/:K'_!1+X(:=^S%^U#\ [_X;Z_=VT>K:EIS7FGP2F)VW7"HPFA20
MCY]NX9SE"K=\4 EJNS5_Z_SVZG[P^/\ ]ISX6?"[66T3QAXCL-*N&0R6XN)H
M4:5<94C<PSGCIU]Q5GX-_'WPY\<+O4(O#$T5U9V+,([F(JRR!20"&4D'@9].
M?QK^=/\ :@\ 7G[1O[7/P]\)ZWK]_I%D^F:8TR0S/&)"T<6[< PR3DYSTK^A
M/]FK]FOPQ^SCX3M++P[>/?23P1^;-(=SL3&"26[]??.<4 U:WI?\M/U^?D>8
M_P#!17QWXC^''P.DU+PE>/8:O>1R017,3,C*[*55@5(/!(YK\4_@3^R-^W-^
MT1H-[XTTSXT:G9P70DN;:V_M*X4*,ET0#S.IRJ!<<DX':OU]_P""I39^!%BQ
MP,S;N>F<@U<_X)=W./AQ9;]0B$*V3DPM.HS\B@<%L<'#'_=S05?W6TK6LEUL
ME;J?!G[%G[8?Q$^&7QSU?]D7XSW%QJ>LZ:)8%U^[9WWM$>HEEY/0]#^/:O@K
M_@IA^U3^T9\'OVH=!\4>!_$]_'\-]%U6U_M2U@N)1;3P+,ID#*C;,%0>O:OH
M;XXSZ1K'_!1_6=)\*I#+XACN)FFO+#;(3AFW$R1Y[>_XU@?&;X667QC^*EI\
M)_$D,<TVK3K'/-. TBM[[N0<GB@EZ26FC24K^5GM^?\ 5_TSU[]JR[^+_P"Q
MSX?^+'@R_P#L.L+H]LEVT3[7:Y6#]XQP0V2_4XSWKT3_ ()L_$3Q5\2M&U:Y
M\:ZB]\8(IF5YG8A>V<L3C .>N.*_G_\ '?Q'US]E#Q\_[+^J-/;> 6A)MKBX
MS%:G<N5"LVU3QVY]N:_5S]E_XB6_PM_9>^)'Q/TNZB$&GV-U-;O'*,N@B=LH
M0>3@9XST^E!7+HFM[Z):VU]/SZH_-S_@IO\ M?\ [0P_:LTGX5?!G6K^PTG1
M];1M4DLY9E0VD5R-X<Q'&-@(YXQWZU_2!^R1\6;;XI_!3P?:S7BWWBC2=+MX
M]=E#!I3=)"@D\SDMG?GKS7\VOP/_ &EOV9/';_%/XM?$O39[WQ<]OK$.G3/;
M&5A=JLHC9'*M_'C&#7U-_P $0OVF-/\ %GCKXO:/K%S+:V%UJU^/#MMJ#&(^
M2TCB$11R8R-I &![4!)::IIQ26UEK;^EV/Z,<$,<].F.>H]J6I9496R1P^73
MW4G(/XBHJ#/^OZ>P4444 %%%% !1110 4444 %%%% !1110 4J_?C_WQ_6DI
M5^_'_OC^M 'L&F?\>-O_ +E7ZH:9_P >-O\ [E7Z (Y?]6_^Z:\CU3_C[;_>
M;_V:O7)?]6_^Z:\CU3_C[;_>;_V:@#/KE/B)XTTOX?\ @?Q'J^JSQVSRZ3=)
M82NP4"Y:)A&5+$<AL=/:NM56<A5&2:_'?_@M/\>X/A?\"- AT.[<ZM_:,(OK
M:S?-P8/-'F!D0EL;<YR.>1VH&E?R7?;2Z3/Q?\ _MK_M,^"?V]1X:\4ZWJ-W
M\./%'B#R]-\R6=K5;::]VQ[=Q,>/+.!_]:O[#]:\7>$?#?A'1O%&N:O;V-A<
M:);7IN)9$19)I( Y7<2 3DX//:OY'_BC^T)^RYJ'[.'@#XGV6CW$?Q0T"PM+
MB[N?LI6X^U1(CLS/MR#Y@SUK]*?!&L>.OV\/V!+;4/ NL2VFO:3 (H0)REPT
M<,?R)@,&Y50,?TH'+II9ZI^=K:]ON/T2\._MD^$/%'C-?!]BT,BS3>5:W"%2
M)ANVAE8'GC'0^G:O3_BU^T)X!^$MC \^L6MSK,L(F;3O-C,J@KNP4W%N,^@^
MGI^!?[(OB?P7\!?BEH/@G]I'4)+;QBDRVVE-<.5:XG+;(S\Y!;+;3GOU]QVO
M[<_P#^,EW\5[7XT^&]4NKKX<&W2[N;6.5I(DTW_6%M@)7B+OC^I(#C9QUO?^
MOQ[G[B?!KXY^'/C'IT^J0SQ6MO:HTEP^Y0(]@).3D 8QGKGZUYG\1?VR/A[X
M#U\:#8:A:ZG(DICNGC>-_)12 [,58XV\]?2OS5\,?M$_"30_V*_B3K?PIU1I
M?'F@Z?=)JT44H\Z&Y6)Q(  =PPX/'%?FA^RIX?\ B!\</AAXX^)E[J-U=Z[J
M3ZG;6D,\C22Q.QD1&4,200<<CT]: Y?-;V?3M>WSO]Q_6!X6^,W@'QQX4?Q7
MX<URTU&*TA\S4DAFC?[(0N760*QVE><Y]*\0\7_MP?!OPRGE6'B73M0U.*0I
M>6<<T+O!M.'+ ,=NWD<CM7XS?L*_#'X\?!CX0_&JZ\>ZA?W6GZRVH-IYN'D;
M[/%+YA7R]Q^7"D8QCH*P?V1?V0O#OQ-U7XJ^-?$7B>^N;E;75IXK6:X=XX9"
MLK#8I8A<<<C&*!\OGHGJ_N_S9^W\7[<'P+OO#$NM:;XQTRZUF!-TFE)<P-*K
MXR5*!RP(/M74> OVEOAW\:? _BZ#PUK=I-XGMM.NA_9D,L?GHRQM@A =^>/[
MN/Y5_.E^P!^Q;H7CK]HKXDVFM^,-2N--L=1U'R+&6YD>W C>0JJQEMN.,"N]
M_95\,W/PD_X*&?&'PII&MW=WH5M97XCT]YG:W&U9!\L9;;S@=1_]<!*.NKTL
M]O/7Y?U9GH_P\_:0;X;?'WQ!'XL\2K%+;:M,(=*FG.]PLQ^41LP[#ICM7[5?
M"?\ :T^%OQFN)=#TO7;)=>MX$#V"RQ"4,HP<INW=<=O?I7X%^#/V8?"?QZ_;
M(U[7/$>OIIK0:O<$6+7 C5SYC8_=EAGH,<&MSXV_!VU_8_\ VDM'\2_#SQ-/
M?OK5[;PW.GVMR9%19'4-F-6..#Z?CZ@..JLUJE9Z]EIZ_P#!1ZY\8/&_C2W_
M ."A/@[0;/4I_P"QGU* 26ZROL:,3+D[0VW&,YZ]Z_9SXW?M+?#OX41V=O'K
M%E?ZZMC UQID<T;S1D1KG>F[<K>HP<'/)K\(O'&MR3?MA_"WQ-.NZ]OM-AN9
M5(RXD>-7)(SG()/6OCVXU_Q]\4_^"@GCG0;K5KV?1X Z1V$TSM#&@XPD;$@8
M[8 H!J]ME:*=_N6OZ;G]2OPA_:-^'WQ<M66'6;2UUG'R:=YL8E9B,@*F[<?3
MI7NLA6WB>XN6$-O$OF2R-PJQ\G<3Z8YK^7?X/? W]H;PW^VQX8UK0KR_7X;1
M7T#:C K2"W*;_FRN0F,<\CIFOZB?'5QIL'A?4[W4)/L^B6ND(VIS@[?*1(!Y
MKEN,8&<\]A0)I);[I:?=OVWT/DKXH_MC>"/AQJJZ=;7%OJ"K*(IY$96$1R V
MXC(&/7\?2O:OAE\7_ _Q:TF*_P##6LVMY?NJM/90RHSQ$XR"JMD$'/\ 6OQ!
M^)U]\$OB3K'BG3OAKK9U2\MC>&\E\T2B&X0/N&X%L%7[9']1Y9_P1L\2>)5_
M:H^)'@W5=7NK[3=/NKM(+>29Y(8U623&U2Q P.P ^G% <NE^RUNFM^WY>J['
M]+A!!((P1P1Z&DJYJ "WMTH& )G _.J=!(4444 %%%% !12@$\"DH **3(SC
MOZ4M !1110 4444 %-?[I_#^8IU-?[I_#^8H ]"\+_ZL?[O^-=A7'^%_]6/]
MW_&NPH *BG_U3_3^HJ6HI_\ 5/\ 3^HH \AU3_C^?ZFKFC0QS2W8D4,$L;J1
M0>S+$Q!_ U3U3_C^?ZFM#0?]=>YZ?V==_P#HIJ /YY_V2_C[\5_%?_!3WXE?
M#3Q#K]Q<>!-+O;Q+;3GF<PPHDI ^0DJH4=P.@[<5^O'QB_:X^%/P<\27N@7F
MMV,NI.D\8M/.C9D<H1@ '/#;ATSZ]Z_ K]G34'T;_@HW^TUK=H1]LTJPUJZM
MRO\ K/,B29AM YSD5U_[$_P5TW]N+XU_%WQ;\3_$MQ:W'AG6-4BL[*YGP2J3
M.B%8Y''RKG<Y[1JQYQB@UDHWLM-%W?\ *O/SV-'X;_M&S_%']KZ^AT'Q(+BV
MDU*3_B61SD[$:7@;-Q P,=NGO7[B?$C]HCP!\(-!TNWU?6+4^)9;>,II+RQ^
M?(Q12?W9;>>OIZXYK^='P5^S]X:_9[_;+\;^(?#&MKJ<UA-<RPVJ3B3#1DD;
M4!/ICIUKROXK>)_'GQP_:=L-9NM5O+:/2[@V\6ER3,L4@5BHQ$2-PZ8PM!%K
MR:V22_)>GS[:G].WPC_:7\ ?%TRVEMJMI;ZU"2)-/\V,2J?= =WK6?\ $?\
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M_:'\5_#O1?@'X@EE\0VL^D3ZFEO-NW3+Y1E#;#W8'KZU[1^WMI7B7X=?&_\
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M7D$K1.#-*L9.]"IXSZ_2OV"( QZD9/\ G\Z_$C_@OF4'P5^%)=@N/$.GD$D
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ME<8'\J^AOV//AW^T3\!8/VD/BEX@OM1GT:+3-6NM(MG>0I"#%(T?E(3@<'C
M_P : Y?><>J^_=+;Y_>?N[\7?VQ_AG\*=4_L*#6;/4=320I/:I+&\D>#\V0K
M9&WGTZ5Z'\(?VB/AG\:+,'P]X@LI]4@&Z_L8I8S);$ [@ZAL@C!ZBOPW_P""
M8'P#T']M#2/BA\8OBAX@NI-<LM8U*RMK&XEWF#+S 321R.#'!'M^>09V[E&W
M)->?>$?#Y_9)_:CUY/#7B2YU3P_K6HRQZA;Q7#2PV<+3D/\ *&*IA2<B@?(]
M5LUT:U\O+77J?N=\5OVL?!WPNU,:7'/!?W"R;9E4JS1@'YB>21@ D^W-=_\
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MJWEZ+N_U11!;/,?+5IY5(PO3@D?UZ5^MG[+7[#_Q U[XO:G^T_\ $"YF'BN
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ML($LHUX"0 (H4=L+CMQ4,UCHMZ=^IZ1::A+U\RXB21L]SE@3V_K0.^R>U_\
MA_Z\_0_.CX3^#_&GC/X(>+M*\06LEI=:U!.;2W>(HT8=&VC! (ZXZ=?UYO\
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M8_$?5_V@?'<[7&L^+WEFOXI\M(RW1)97W<GAB"".WM7Q+_P4G_X)N_$/X_\
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MPF,]   ,=L>E/V1+S!"L*]"% &3_ /7H$(>IQTR:*** "BBB@ HHHH ****
M"G)_K(O^NBTVG)_K(O\ KHM 'L=C_P >D'^Y_4U;JI8_\>D'^Y_4U;H *\]\
M4?Z\_P">XKT*O/?%'^O/^>XH X\AB0<\#''/:OS _P""O7[.?B7]I[X+^&="
M\)>:=1\/W<-V!"&W$PNLF!MR<\'_ #BOU!I?*@E&+JW2YBZ&.0 KCIT/Y=*!
M\S5M=O+;[OQ/YR_#W@G]K+Q5\%O#?P#T*_U70;C3+"#3%U //#M1%$>=V5XQ
MGC/''O7Z&_LA_L"VWP4^&_B>#Q_,NM_$CQ9IMQ;RZW-B6?S+R)E.96RW5NN3
M^5?I$MEHL$OFV>CVEO+NR)HHD1QSUR.?0_SJW),\FTL[%EQC))Q@=B?2@=];
M[Z*_KH^GI]_W'\V^B?LE?$C]BGXH>-_$^E6-SXAT_P ;:K<7@CAC>41K<3.W
M(4$ 8;W_ *U^E_P(TGQQXM\!^/CK%E)IT/B'0;VSM[1X3$PDGMV08^4'(+8]
MNU?HC/:Z3?@?VKIEMJ17[INHUEVGID;@:$@TVV41V=A!9P=/*A144^V!@8ZT
M"OUZWW_X&WS/Q!_96_8T\7?#+X??'C0=1$PF\;:GJ-Q8[]VXI<22,NW/^\,8
M_6OJ/]CK]GC6OACX0\6>&=<#M%XABO+=Q(.L=P'4_>]0>.E?H[LM1Q';1Q@_
M?"C&_P!SZFD98E_U$*Q_3C_"@+MNY_+O>?\ !+GXG^%?VVHO&OAN]NH/AKK.
MNIJ&KZ=&[BUF5[IIGW1C]V003U%?KE^W]^PS8?M,_"GPGX8\,[+$>![*SGBB
MC 3=<6L49.%7@G='Z=>E?HNRV[X9[6-Y1C]\0-PY[$\]/\\4Z-V0%=S%&R&7
M/#*>QH"[^ZWX6_R/Y^_AM%\6O!=EI7PDG\.7DIT+R-/M]2:WD9!'"RQAMQ7'
M0#I^'%?6/[6O[.OBWXT_"OX<Z5&9#J6CRV<UR4!!PA1B"!CTQS7ZE-I/AQG,
M_P#PC]A]I/S&Y\B/S"W]XMMS_G\*E"6P(62!'C!^5"HPO/0?A^% 7UNM/F[_
M /#GC/[//@^[\!_#C0?#U]GS['3X(&W=<I& >ISV[\UUWQGT.7Q;\$OB-X-M
M"?MFOZ'>6<&!SOF@=!C'NU=VP0'$:A5[*.@I!@\,NY3]Y3T(]#0(_,/_ ()3
M?LV>(/V9O!7Q7T?Q)YBS>)K^_O+7S=P.'DF=<9_WQW_"O#?V8OV*/$WAG]I+
MX]>(==\T:'\2_P"TX(FD#;-EX9MIYP.CCT'OVK]K2D"8^SPI;@_>" #=]?KS
M3V^RQA6A@2&?C=,@PQ('/(&>OO0-.U_0_G2_X93^(/[&7Q'\27?A33[G6/#O
MB75;F\DMK:-I$_?RE\D*I'!/H,5^A7[.WA'Q=\3_  ;XX\-^+;%]-TSQE8W%
MFEO-#Y>P3Q%1G<!@#/IV^E?H_/:Z5?X.JZ9;:BPZ-<HLF/?Y@:2*UL;7 TVQ
MAL$'(6!%C ],8 ]?TH$KZ]7W>_3\>GH?SI:?^S[\=OV&O&OBC3?ARU_>^%?%
M5[=NUM:><8D-V[X8B/Y<KOZU[#^R_P#L(?$+Q=KGC7XB_%6_GG?Q@MS)I5M=
M,S-9/<;F3:),E-I8= ,8]:_<V:STB_(.J:7:ZC(/NO=(LA!'.<L"<_Y]ZE7R
MK=1%9PK:PQG"11?*B8_N@8 ]L8H&GUW=]W\O\OQ/YJ_$'[(/CGX)_%/7Y(-,
MO=;.L+=P6EX!+,L*7 =$P?F VAAT_P 37I?_  3Y_85^('P?UCXU^-?$TL^/
MB&NH-:6\NX&/[4)&  /3!;I_D?T!R6>D73"2_P!*M;V<=)IHU=P?]YAG]>IJ
M0QVL:A+>TC@B[(@"KT'8<=/I_@!=NWE_P/\ (_+K]DS]FKQ%\+?%?C#5=2,@
MCU>6^:+>#C%PTA&,^S =JPOAK^R[XE\.?M,ZK\2+GS3I]S?RSJ"#MVNY/?\
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M(X_Y9DY/M7Z_M';$;EMT6?C]\!\W'OU_6CR[=@3-;I-*!\LK@%@<8!R?\^]
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MS(ZJ?<=NE 6=[6=_0^]/B?\ $SP[\']#A\1>+;V'3M/N)%ACFG=40NQ  RQ
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M>+_CEX,\"^-].^'>MZI;6NOZLZ1VUG+(BS.\IV@*K'<<G &*_GX^(?@+6?\
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M ,>D'^Y_4U;JI8_\>D'^Y_4U;H *\]\4?Z\_Y[BO0J\[\3L3<,/?'Z__ %J
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MX444 .V_+NS^&/?%-HHH"^_G_P ..5BO(IN6/WB/;%%% !3MN5)SCK_*FT4
M(,@<\FA3OR.GO^!^E+10 8*\$Y([_K1110 4444 =QX7_P"0;>?]?T'_ *'#
M785Q_A?_ )!MY_U_0?\ H<-=A0!PGBL\:3@?\NS_ );8\5RB[\_)G=@]/3O^
ME=5XI^[I&>OV4_\ H*9KFK>012;B,_*R\_[7% 'R+^TY^SE\#?VFM F\(>)K
MFP7Q;Y9CTYF,2SV]T<['#$[E(<@__7S7X%Z3??'/_@G5^U]X2^%VJ_$2?7/
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MXA^UOKFF> _VJ-&\>:]>1'PEJNM1BRU*8@VK;[A=I1F^3)W#IUK^B7P'\0/
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M$N!\B\$[@.WMBN8^$W[%/Q%_:$^)WAWXI?M(-<6NH^$+F.XTV&Y# %K9@8P
MX/<#\?KF@?,G)-ZZ)/39[]M_\[GQ+\;_ (>^'/C+^VA\/-"^($#W=I_9FF9@
M=FPP,4()*GKD]?<U_1_\'?@I\-_@QX6L+/X>:4FF"2"(3;$"ELQC.<#GKCG/
MTKXA\8_L=3:O^TOHGQ4M8]ECHL<%O$53 ,=NH53G&.0N?R[5^EUHIM[*W@/_
M "R1%/!_A4?UH);O;R7X_P!)'Y_?\%374?L]*CG;+<J\<3D<I*PX;\#S_P#7
MK^<2']D+]JJ[^".M?&'3/']_-\,])A>[U+PU'=3&*YM8P9'C,*MM.Y!MY4_E
M7]5O[7'PDG^.WPZMO"EN,O"^[@9.0<#I^%<?\'_V=D\.?!+4_A+K>9+#5;.2
MVGAESY9$B%#E3Q^8- XR27S7Z?EN?+/_  3.\;_#_P 5?L2>/F\/VEMI&MV.
M@ZK::A9@+',]Q#9W.^0K@,29$ )(Z-ZU^4_[%_P/T[XXVG[6=II]HD_CF"^U
MIM*NDC#7$$D<T^PHX&]?FQC!]/P_8+X"_LBZS\$?$'C;0]%,D'A+Q#;7\2V\
M8*P;KI7_ (1A>=Q]>M=9^P=^R;)^S7\2OBCXHO8MUIXTN[R8(Z#81<3&3HV5
M/8=.E V[7_[=:O\ )ZO^MO,_F>^*?QXO/!G@CPA^RU\0KTR^-;3QK%!&MT[/
M<+&M[L0?O/F''TK]@_VZ?VC;7X5?L3?"_P"#T(^VZMXJ\/Z?!!I29:>Y#0*4
M54&6))F;VR36C^U[_P $C] ^-G[16F?'O27\B]L]935#9Q+^[WK-YW 4=<U[
M5\6OV$[SXM_$#X+^(]<C^T:;\.%T]'L)5+6\RVGE9#H05.=GI^5 O=;6MMW^
M6W3Y_?T/PN\>?M >/M9_9-\+_!Y_@CJULOAV^CU:743I<RLD*.)?/,GE [<#
M.<_XU_0=_P $H?VC[3X\_!33/"L5RK7?@JQ2RN;+=F2U>"((4=3R""I!Z<U^
MA_B?X9_"S6_ .K^&$\!>'4DOO#<FD*ZZ79!T=K3R599!%Y@9'^<,3N8\,>M?
MG3^P;^QYJ7[)'CCXAZG8F3^R_%^H7=U'!M(B@2>5FVH.@"[L #%!-]/1_??_
M (;_ ('4_44 !V!Q@$CGV..]-88/UY_.E)5B6)/S9)^I.?3W-,H$%%%% !11
M10 4444 %%%% !1110 4444 %*OWX_\ ?']:2E7[\?\ OC^M 'L&F?\ 'C;_
M .Y5^J&F?\>-O_N5?H CE_U;_P"Z:\CU3_C[;_>;_P!FKUR7_5O_ +IKR/5/
M^/MO]YO_ &:@".Q(^T+D=<XX]C7\^?\ P5HT3POKVN>'++QE<"WTN36+=27D
M\M64RKD<X&3Z?A7]!5G_ ,?"?C_(U_/#_P %A?!S>/9=(TN-KN&X@U"-[>2V
M#Y,RN"HRH[D#^G>@:W6MO,[[X]_LW?LM>'_V%-$\;>'[>Q@\;6.AVT^CW:2Q
M_:9KD0;QM &\;65&#;B7WD8&W+?E5\1?B1X[U[]B71-.\:W%Y%IT.M);6,LL
MDJA[=90L2J['D;<=.*^XOA)^RA^T+\7?!GPY\.>+I=2C^'EG!:)^]$HCFMU$
M>/,!X(*CGC\*_3SXZ_\ !/7X=_$'X!:5\)]-B@M3HMM'=1/"BAI+V*-6 .T<
MDNH_K06FHV>_O76M^F__  ]M3\7]'_9SMOBI^SGX/30]&N;?6YM/M38ZTF]=
MC;5*N)!@]0#G=Z5T_P#P4&^$^N^!/V ?A=X \<ZI/J$]QK5C!-,\SLYMWEC!
MC+;B>F1C/?ZU]8?#7X9_M0_#^ZT?X70>&6/@?0GCL[;4!;,"UO&VP-OV_P!Q
M>N?;K7UM^V%^RKJ?[17P8\$^"Y@QO=%N[2\G7!8J\;([#&#T((Z<>E N9W6_
MQ7O?9=C%^ /[$WP6U']@SP/I/AC28='UKQ#X/M#+K6X)(+N2*4N=^,X*E3OW
M9)X]Z_)"Y\-^'?\ @GI\1-&U#XH:#-XV\/ZOXCC6SOY5:YBA\VX&TAB'&!G/
MX5_1]X=\"W_A7]F7P[\+]+DDBU;0]%AL8FCRKJ\,)"XQ\P))QQSV-?CG\4OV
M;/C_ /'77]+\#^-_#QNO"6E:LMQ;ZK=6Y>18TD)#"1UXXY'J:!1NWJ_5OU7Z
MV_(\1_;P^-5K\6?BK\"M'TV1K#X2^+$TE[^P1V2VA@G,6Y'48085B#N],=Z^
M\/VG/V6?V1] _9KTJ]TR'3[<V^BP7VG72/&"^H?9DD!##'S^;V!)_BSSM'HW
MQ7_X)V>"_%/P;T*SL)57Q?X<L(4TYU&)8I((@$V8^8$., #TKX,L?V4?VG_B
M2-*^%GCR;4X? VC7R"*[?SE$MK$X"J7. 5*#'7']0I.ZWY;=._G_ )[]V?.^
MEZCXA\6_LB?$/PWXIDN&\-6!FMM%:1WV-:+A4V$]BB\8_+I7U+^SS^Q]^SY?
M_P#!/_4?%=WX=2;Q#86MU=VU\5W.DZH7#!R,_>7(-??_ ,1/V+M"'P!@^&'A
MJ&-;AK6.*YEC0;Y75-I9R!DDG/7J>:[?X6?L_P _@W]F._\ @[*I\^YM9H<$
M'/SH1T/^]Z4"NDFEW3NOE?U6]M_,_+[]BWXV>%?A7^S=\6]:^)2C6?!7AZ:]
MMX=+G8RJ(HV=50*^1TP  *^*?V@_B#\(?C9\-M+\?>%?!3:#X=^VN=/N%B,4
M7FAV*L&"KWP0<U^N/AK_ ()]Q_\ "D/B+\.-19D/BB2ZGC1@<,SEW4;>^2?_
M -?6OD#PU^PG\6]0\*P_ [5M 6R\$Z-=2/9:BEML,BJ[%#O"CJN#WH'S)WOU
MZ?)>6^GX&)J^MW&H?\$XM=2ZN6FM+5(DM=SLX2-=NW:3[#BO!OCTL-Q^Q'^S
M0YD8$>(M.\LH[)D^?" /EQG_ #ZU^OD_[%-P/V8M4^#$8)>Z"JI*GD* ,XQG
MZ^W%<9XW_8,O?$OP+^$_PV"$R>"=4M;R4;3TAE5CD$< [?Y4"NE9:_%=>:6E
MSKOV@_&/P=^'7[$/@7Q)XP@M=4\3R>%+&TLM.9E>ZD>:T"8"$;L %,$9))/3
M S\;_L)?L@^$_!_P9^,G[6^BVSZ;J_B/1=8OK"Q9B'@D:,M'M4\K]_(P/0U[
MK^V%^QA\0?B7HW@2R\,27%S9^&--M()-,PS6[O:QH.8_NY)7N/?TKM/V5_AE
M\>M T.\^%WC?39['P3?PO8R0>6Z6X@=2A^0@+R.3P??UH%I9V>V_>W3_ #?R
M^?XI?L6A/C!XX^+>K^/;&XUCQ#;:SJUOI2REY)$5II%C**V2 .V/_KU]>_LY
M?LN^-_@X_P"T%\6=&N;NPGNM(U2ZM;1I9 8R8I74*F>,=./KZFOI3XE_L3^.
M?@#XYF\6_ #21?\ ]KSO=7UO#"60R2LSN6"KC.3_ )YK["_9:\ ?$W7+'Q%9
M?&'3#I]MXEMI+2Z@>-DC"2HR-P0!@@_S]Z!N6EU:UK./7Y?+U_ _-/\ X)-_
M"SX.?'^T^,/BSX]06VJ>,=/U+4DM_P"T+@"2*$S2K+-'YH9G:-.5C&T,>XVD
M'@/V4?!WPI\%_MX>.K'X<36P\O5;A7MX&4E,7!&"%]L>WYU]'_$C]B7XL?!/
MXGZMJ'P#:[3P[XCN9VU"*R$@BVW)8N6$7!^\3^'UQVO['O\ P3NUGX2_%C4O
MC;XDO+B?Q!KTYN;R"8N=C2-O;A@>YYXS1<5]VG;;1>B_K\[:'[?F62/PIK<J
M+F5/#E_(O'1UMW([=CG]:_EH_P""?7@_X>_&_P#;V^/NE_&LPZO::??ZN-*L
MK^?$2R)-)Y2?O 0@.%&0,>N.H_J4BN-MA<6;J"MW92V4H]$F4HWT #'KZ?E^
M$?QN_8&\;_"+XIZY\8_V?WN)-?\ %EQ)<:E%:A\@W#EW#!.1@G^?X@15]]+[
M/ST_$]I_X*1^%/AE\!OV<KF[^"<-MI>NR7C6SQ:?/OD-JP ?<T:(P RR@ '@
M?GP'["W[/'[,WCW]FR[\:>,HK.\\7ZU832^))I9(WEC9HF,ID+DL#DG[WIWK
MWGX3_LM>)?B_\/KW3_CS/.=0EM'*6UX7*F=HR,A9.,ACZ>G>OA_6?V2_VC?@
M[X@\0^#OA4^H3^!_$3RVS&(2F*WMYFVDQXX7"-U'8?6@=E9>][R;N]=MM'U\
MD?&=WK>N_!CXW>(_"7P#GG;P%<SWD5^+*21H$B=I!)GRR4& ><D]/:ONC_@G
MC\#?V=/B-XO^(6L^.TL=4U>\:X?6([F53LD)8N)&8.4^;<?NG&.:^V/V5OV#
M_"W@#P3K,_C9$U'Q/KMI.\TUXH>:*>Z5M^TR L"I<_B!BOA#Q'^Q-\</@=\3
M/%.J_!J:^N-'\:7,K7OD"0I;1W$C%MFWA0H8XQVQ0)Z]7H]'M=W5[_UZZL])
M_P""RG@SX;?#K]AFXT?X1)9VFEQW4ALTLI1+']H!!A^953#F0$8VC''K7Y,?
M\$G]8'B*;P/9_M:/(+2VDC7P.VJNX0@2#[*(//..FT +V_*OW+^*7[(/BGXN
M?LNZ/\,O$L\]YK*WUOJ%T)]SMN$@D="&R0.,8],YK(^)G_!.+1O%7PP^%(\/
M!= \4_#:"R*_8%\F2[EM53_6>6 6+%/XO6@I2LN2_7==/1^NYX+_ ,%EOA3\
M*8_AKX UX6,"Q7-W8I!=878UJS($ ;H<IC'.,8/>OL_X42?!/]GC_@GYHGCQ
M-.MIM%/AR*XU>W&PB[WV[^8I0#GY5!!).2^,<5S7[2_[*WBC]I#]FS1_ VO>
M:OB3PQ!"E@Q#&5WM(U$9[G)*CZBN.^"7[,GQ-\2_LU:_\!?BF+B'3K.PFL=(
M697"RHL92/AOO<4$MV23[OYK1^5^MO(_)'X]?%#X-_'KX3MXO\(>!FT'P[;:
MM(%NDB,4;7"REO,#A5'+>AYR*^H/!FK/JG[!/BZR>Z>32[;2G2T'FL=J!?E
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M-,B,">5VDY!_6OWW_9E_X)_^%/AO\-/%MAKFTZ_\3+.>/Q$S@>8'NXF\[?D
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M[XF_L;S>*?VC/"_Q0LHREGH-U;RHJC"HL3@\8&!C;V__ %!2:3[VCOU;T?\
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MR]FU #WVC=QQUZ^GY4P@@X-5+W5--TF$3ZE<PVT;$!6FD5%))P "Q S^.?Z
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M-C/?^[WQZXZ_I4>&SC!SZ8.?RH E\]_+\K";?7:-WYTBS.BE %P>N5!--,;
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M"J3@X10N/R JU'J$T2; D)&,9:-2<?4C-4@K-]U2<>@S3O*;&?TP<],^GX4
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M1T5-Y3C)4;@H+$@$@ #G-?,?Q@_;.^!7P!D\KXB:BD,W(V(XWY'!^7J3[8H
M^EJDQN4;5Y'4\=AS7R_\(/VU_@)\>[]=*\":F@OI #&EQ(J,V2 N%)![]O\
M&K'Q7_:>\"?"/Q5I'A'7[N-=1UF>."V"R+\S2NJ+CUZ]CUH':SM9WZ]=;?Y'
MTF3@$XZ4H.0#ZT6G^EZ5IVK1\P:C;17,)]4E0.N..>"*0AVX49SG)P<#\?QH
M$+G/2D ()R>IXZ\5((2GNIY)'/;Z>HQ0JEC@ XSC.#P/<XH 913VC8$8^9<9
M)&3C'OTI K'H#]<' ^I[4 "D \C/X?XTW()./7\J>R,ON/4 X_.HP,9/K0 N
M>W?TIJ@C.3G\S2[>=W.?_K8I: "BBB@ HHHH **** "BBB@#N/"__(-O/^OZ
M#_T.&NPKC_"__(-O/^OZ#_T.&NPH X7Q2/ETD_\ 3L>/^ Q_XUR21ECM0<XS
MW[?G75^*NFD_]>K?^@QUBZ64%R2^,"*7KT^Z<?CG% 'P]^V'^VMX<_9)\-VU
M^MHOB+6=180)ID $LZ2.=F-BY(P>F17P)X8_X*Z:_8^)=#C\7?#G4-*\.>)#
M$XU:YM98[>VCF88+.\81<9R<D5XA^USJ*Z;^UQI?_"RXI+SP9/K,:6<-XA>R
M!:;Y?]8-@'3_  K[&_X*,?\ "D;3]B"*W\,:)X>A\7:CIEF?#TVF06QU"%FC
M)W*T0\T[RR8'&TJ>.<T%I1:27Q?/YGR-_P %>?V\O%6C_##X>^*/A!!<&REN
MK.>>]LMPCGW$,8MT>02=V,?@/?VKP3^UEXF_:)_8*@M_%'A>^TF]A\/H9[^>
M*6/[2R6^2V]@,Y.XYSD]SC&/SW^+6AW5C_P3R^#/_"9:0]YJK^(K!I9[J M/
M]G,PP)-ZEMNW'7CGU.*_9[Q G@B#_@G'X;?PYIFDV5RWA6S69;!(5G\[[,QE
M,GEC=E@R ANA7(')H#3W?\7Y63\]=&?C7^RM^WIKWP(CUW2-$\":EK<&B3W=
MU<7<4$TJLD+ECEMK=A^E?N1^Q#^WWX8_;%\/^(M9U"S3PK-X96X^U170\EF>
MW5BRD/@Y.,8]>U?%?_!/?P+X&U#X1?$W4M8\)Z;J-W)IVI_OKNUB>7_5R\@N
MA/TQZ=:^1O@_8WFA6GQHL? 4$ND7$FIZJ5@T^,Q#;N?@+&%[9XQS0)VOIU>_
MZ>=O+N?>_P 7O^"KD6A_$#7OA_X3\*7&KQ^%_.::_M86=)Q;DYPZ*<Y /&3]
M:]\_9<_X*'^%/VA_#>M7E_9)X?U;P]%/OT^X7RIIGMU;.%;#9)7W//X5^%7[
M+D7CCQ;\3?%OAFV\.VE_K\KW*7D^IPH)&!+!B7EY/![]J_0OX5?LH:OX(O?$
M'B[4_)TJ9TNI)['3R%@=BKD[EC^7U_/% Y)*WI^/?YD_BW_@LV[?&I_@OX2\
M 7FM7EI?-:W$]K:O)M5)?++,44X]<GC^5?LW\'O%UU\2/"<&OZA82:5<R6'V
MI[69#&ZN(R^S:0#G)QBOPG_X)U> / U[^V1X^U75_#6GZI=&XO/+DO+2*4QN
M)#AU\Q3D@X.,X-?T/R6]E9W=U!IMK%86^YD6"!%CC"=-@5<*!CTXH)=M+:::
M^I_*]_P56_X* _%GX9?&KPGX4\(Z)J5M8Z;JT"RRPI*J7J1S@%1M #;P#QW'
M-?K/H/[?K^&OV1/#?QO\8>&9].FM--LX9X+F)D:XE,<>7PXR<[B<]:^%/^"O
M-AX.TWXI_!^XU'P]9%KC7=/$]RUO'^]#7*;O-<KR#R>3BOI;_@I_;>'--_X)
MQ^"KW0M+LX-,;3]'=XM-BC*%6M;7<6\D?-\_F;B>A)'88"]'R+[[=[+\3[J\
M$_M*:7XR_9@N/VEXK4)IL&FRZB;7&,B%0Q&..N?3\:^:_"W_  4@\->)O@'X
MN^.Z::$L?"5W<6TEMM'[QK=F&!ZD[3V_QKPKX3?%?P%X3_X),/!J][!')?\
MAJ\A@LA(GG>9+''L#1;MRXVD8QSDYQBOS@^%A@F_X)P?$^[@MR+6_P#$-Q(B
M"/[\;S,>1@YR#WZ^] E&_P I6^7^?X'VW_P^>U7Q/H<7BS1?AEJ#>';)V>]U
M&.SD,"PQ%MSLX39C:,\G@#-*?^"VLGC;2/M'@#X:7VMQ:>PCU&ZL[225("@
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MV7;I>U]UZ^7XL_=WX _$;4/BUX4TK7-7TF71;F]MUEDMKB,QO&73?@A@I!Y
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MX-$-[H+ZM!$CF"2%WMVD$X7Y=I4G.X="?6@$KO\ &U^E]ON/M:Z_X+$>*M$
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M)S!!-;0F4OEL @HK9'^1ZUX5H'_!;\6_BZ7X?ZY\.+VUU:5<0++:2*[%L;0
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M%4O"(\2Z+#H5[<68>6WL8E2W\QHR<$IA1SV_K0-1W]+I^O\ PS^\_9;XY?\
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M7%G*L;W,B0J)2[I@_>5O?.<<US__  5@MO"MC\3OV=+G4]!M&DO-3T7[5<O
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M2/RY/,=0"S >O?Z"@?+97>OEL^G^?WZ'[,?&?_@HGX3^$7PN\&>-I+%+N_\
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MG_!2I_AA)JW@72_A=H^F:=XS;^SY&GT.*+SRA"'YFMQNSC^5?+GQ2\%V.O\
MQ+_9S'C;3EU.]MI]*^UQ7T(D\PB2$D2+*#ZGK_.@$M=5WTVV7R[H_7;X??\
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MO^OZ'VA^S1_P4-\._M&_"3Q%\28-,&FS>$5E6^L64)()(!\RE3@YR#U%>K_
M[]K[2/C7:>(;FRLOLZZ EP\G&-PM]^?SVG_ZU?B7^POIOE_#S]HVPTBT:WMS
MJ^L;;2&,J@19I1A4 '& 1P.GUKZ0_8-\<>%M,LOBKIM]/;V5Y86>HO<Q7#K"
MY"K*6PKD$G .,#UH$U9V]/R1]^?#_P#;?T+Q[XWUKP7!8>7-H\MPCOMZFW+!
ML\?[/XY&17PY\4/^"SL7A;XK^)?@_P"%/ -WXAU;PX)O-:SMFF8F$D<[$8]C
M_A7AO[(OC3PWXW^/'Q$D\/(9!:7>J),^W@E7DSM8=03DYSZ"I_V!O _@W5_^
M"AGQ7D\0^&K#6/.FOE_T^UCF12QDP?WB_-@GD$]J MO?HD_OM_F??7['G_!1
M_3/VC=:O/"7B70G\*>((1(4LKR,P3-Y>> D@#<_3I6)^T=_P4XT_X8>-+OX9
M>!_#<GBWQ#8G9<P6$1GFB*_*Q98@S#'7^=?#WQ8TNS\*?\%)[;3O ^FQZ%9S
M-<[[+3HA#;L"KG[L8"]^1@UF?L"S>$KS_@IG\8+#X@6=KJ,LB:A%9IKT4;6L
M4[Q.(F3[4/+;;(0V.AQS05RK_P EO;]?\^U^I]N_LZ?\%4K3Q]\2(_@]XV\)
MS^&=<U6W80O>PM"RM(, ?O%4Y&X9Z'I7Q+^U%X:\ >./VI]*T3XIZ@K>%YM2
MC+F6?;"89)@?XF"X"^OK6A^VLW@J+_@H1X8TCP!IME9:V7A&[1(8U@9AL5V)
MM@$4%@6 '"YP.E?/_P"U3\.-?^(7QH\/Z#<W=W8ZH;BV1YX]ZR#+*/O#!SCU
M/'XT#25XZ7TN^G;7SZG;_'[PS\./@9^T#X!?]F/Q' ZW$6G_ &K2["Y#.Y8K
MOS'&QSVR<=JY7_@HE\6-7\&:M\'?&FN:;=ZAXA^U:;,]FGF&5W#QM@J/F.X_
MX5^GW[/'_!*CPCX7\2>&?C5XJ\2W.LZS;:?;7,6G7LC2H&6-7 VR$C@U\D?\
M%&M%T75/VB_A/:7>F13V$&L:?$MH8@T!6.=  5(VCH.WX4!?WE;7NWYO_@GJ
M7PC_ ."P-[?^(? /PU\7?#Z^\/:;+8:?9)JUY:R0Q$-'&BOYDBJI_/\ ^M^A
MO[1O[5^I_!OPGHGB'P?X2N_&=MXDBA>.?3X&N%@\Z/>#E%8#:#7P!_P4E\#^
M!]"^$WPOUKPWX4TW1=52RTAFOK"TCBN"0D(R7C7=G.3G/4UQ?Q8_;7UOX'?
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M5)_9%MYD]@;6\E\A-TCF+869L9)W9.:_->U_X)Y_M-^ ?$"67PH\:/HWP_\
M[1-U)ID<IC1H6D+E2H('W<#_  K]NLG=NR=W'S=^/>K(OKL+M%Q*%Z8#$#\J
M!)M;:'Q-K_[/OQ%O_AFN@Z=K+P>-EMO*_M%)&4^=LQNW ^O/_P!>OE'X-?\
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MQ=+H.G60BBN(5G95>$ +(-H."-H-?3_[&7[&>D? EI_&GB)$O?B1J<;#5-3
M&Z5Y4(E8MU.2QX_^O7U,MU<1C$<\B9(SM;&<G%>@>'9))$!=V<X/+')Y H$=
M51110!CZ[_R#9OP_DU>2K_%_O&O6M=_Y!LWX?R:O)5_B_P!XT .E EL[RT.<
M7=M-;GZ2H4Q^OTKX?_9Z_8]L?@;\=/%7QB@V^9XEGN)9%  .VX+%^?<.1_\
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MW'C2^N+R1Y8][*9I&DX<Y8<MV_QK[,-Q,< R,0.@)) ^E,::1QAW+@# W$G
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M9:5X<NM7TCPS=:=%/<PPO)# D;Q E]JD *!DYXQUKS_]I7QI\4?"7PQ^'(^
M]O-_PDP&DQWB:=$PGC3$8D5_*7=P,Y[_ (U_3_X]^&7@WXG6,EEXIT:RU"<H
M5ANKF)))83T#*[ D%>O'2O(/!'[)/PZ\$ZP=7N+2UUF,2>9%:72)+'%C[H57
M! VX' Y]J!N3=M-OS[GRS#^RK+^U=^RG\-/$?Q M/*^,6G:=:317ETG^E6]X
MD"LK,[@.") #ST.*X+X/_L<_M;^$?%=I<^-?'<NH^$].N(A9V33LZQVD)'EH
M%+<84 =NWMG]>X5@LE6#3(5L+., 0VL "1Q = H7 &!TXJPU[=N-K7$K+Z%B
M10)R>OF]?OW/@K]HS]C.T^/_ (T^'/C&_*/<^!)[*8,P!):U9')'XIGKQ7IG
M[67[.=G^TQ\,/"GPYN@OE>&S8$[N06LX8(LC/'"PJ/P[U]1I+*@*H[*&Z@'&
M:%>2(DJQ0GJ0>3]: N]/+8_/[XJ_LM_$O4/A-X.\ _"?7)-"U+PC9Q6T$L4K
M1 &) O12!V_^MS7EG[-'[ 'BKP#\1/\ A:OQDU%=?\5!PR7;$._# YW<G/'U
M[>E?JI'<7",761D8]U;D_J?:GR7-Q,,2S.X]&;- A)-A)6 ;85 V+[ 8'\JA
MI02,CUI* "BBB@ HHHH **** "BBB@ HHHH **** "O1/#/^K_X#_P#$UYW7
MHGAG_5_\!_\ B: .LHHHH QM=_Y!TWT/\J\G'3\3_,UZQKO_ "#IOH?Y5Y..
MGXG^9H <I*D,.Q!_(YKY?_:D_9>\(?M+Z)$VM64,OB?28\Z'>/&K-;SJ!Y3*
MY!(*L%.1CI^%?3].5V0[D8J1W!P: N?C7\//V)OVN_#'B*(:UX]EN?!]E<(+
M"P,[D16<3?NX]N<#:H  KZ6^)?[&L_Q9\3^!?$7B^X:]?P=-;3(C-NC)MV1O
MF0G:<E<'(_\ K_H,U]=LNUKB4KC&"YQCTJ'S9<'#MSVSP3[T#N_^&5G]Y^?_
M ,0?V$O#&L>/K?XM^$K>+2_$^C:4L(GMT6'?]GB  ^3&<A3]:_%GXW_L^^.O
MBE\>8K.TMKR'Q5:7ZK9ZRHD79(D@4/Y@QWP<YS7]4J33+')'O(652CJ"<%2.
M<\UYJOPE\*+K@\1K8VPU+S/-$X1?-W9W;LXSGH?P H!.VOI\]4?F5^SK_P $
MX/&/A3QKIGC_ ..&LOXGD6W@>U2YD-P(5"JR+M<L%( %?3?Q-_8UT;QQ\1_#
MGC2QCC@M?#MS!-;1!0H40LI  '3 7C'U^OW2]U<S1QQ2322)$@1%8D@*HP!C
MT']:C$DJC:&90>,9P#[4#<F[=TW^AY7\8_A!X/\ CCX%A\$^,[&._M;*P2VL
MDE19!'<1PK%&X!'!&Q3G/;/I7Y/Q_L!?M4>%O$<EGX$\</IOP]2?_1-+29DC
MCM@YP@0$ #9P !7[9?,I!Y!ZY[_6K7V^\VA!<2A1P &.*";GQ#XY^ 'Q-U_X
M'VG@'1=;>U\8V\"_\3%)"C&X4?>+#GD\_P"-?)WP?_X)T?$*3XA:)X^_:%UD
M>*;SPVZMI$DK><T7E,&B.XG(Q@<__JK]B%EF#^8KL).NX'!_.GR75S*-LLTC
MCT9LT!=ZVZJQ^5_[1O[(O[1?Q&\:?VG\,/&$VC^&KBV^P7EEYS+&]EM"%-F=
MN"@QC'K74_#+_@G_ *'X$^"?BWX=7,<;^(?&R2G6[P*/W\\RGS&8]\LQS^/T
MK])X[NYB&(YY$'HK$4PS2L^\R,7SG=GG- [NWDK7MM>UK_/^NI\ >'?V)K#0
M?@E;_"!-GD07+7'0$9+[OISZ_P!:]<\-_LZ6N@?">^^&2[1%>PF$]AAAM/M[
M?X5]1&60MN+MN]<\T-*[$,6.1T.30*Y^(/[8'[/%Y\"?A&G_  CVCS:U+>&1
MY8K2-G*"3<3N" G_ .M7YQ:1=:UX3^#&MZ]H&G&U\9.&:WLA#MNA(<D#&W?G
M)QTSFOZR]6TG2/$=C/IWB'3[?5K:=#&L=W&LJIN!' <''7J*^79OV+_AK+X@
M.O?9[86S2B5M,V+Y!.[=MV8VD=AV_J%7>FJ]W9=]OZ5O^"?('_!+;Q-\;/%/
M@L:A\45OH8?-(BANO,&(\G:0'']TCIQS[XK](/CQ\)O#?QS^'VL?#KQ';1W-
MAJ$4J(K*&^=DPI!/^USV%=QHOA[0?"VFQ:5X?TNVTZWA54"VT21@[5 S\H'7
M&?2M7G<&!(([B@GTT/PY\/?\$O/BII UCP7/XEG;X57?GK8Z*+A_)CCD+[5\
MK=MX!Z8_QKZN^&/[!&C_  X^!WB7X/6:QK#X@E>64@ 9+DYSCC)SW/.>:_2$
MWET5"F>0J.@W<4SS)7<,SN2/XL\CCUH'=VMT/@6+]D?7O#'PA@\ >!K]M-U>
MS#-:7$3&/9+@X;*GUKYJ^%W_  3V^,#?$V#QI\;O$7_"1:;9W*26L4KF5DB1
M\@ MGL!GFOV1WS[]RN^>S9Y''MTI\MQ=N-LDTCCI@L2*!7=OZ\O\C\X_VS/V
M$]/^/VD^'K?X=$:-J&@"W:"9,QLLL.T@A@0<[ESG/X50TC]C#QEK7P?M/AM\
M2=6;6+O3U@2UEFD,FQ8=H !8DC[H_P :_26.:6$YC=HSWVG'6G&>5LLTKE_7
M//Y__7H _.7XL?L'Z?\ $_PE\,_#4VS;\.[JTN(<C/-NZ,,>_P G\N37T!^T
M=^S_ &GQZ^ V@_!B8+Y6C6]C"2>A^PP1PI^2Q@<>F:^F%FE4DK(P)ZD'K]::
MKNC%T8JQZL."?QH&VV[^=SXRG_8V\$ZQ^SMIGP9UVQAN=2T"S\G1KEHU9K>5
M(P(V1CRA5L'((^M?$'PA_P"">/[0?@/QN9M;\:7=W\/8[Y9;?2FNY6C2U23<
ML83<0/D &/3Z5^U;2MNWEVWG^+O4QN[HKL:XE9?1F)'3&*!7/S5_;*_8/C_:
M-T#PU;^%)1IVO^%T@-E=K\KI- 5(8.,$'<N<]>/S^G?V5_AOX\^$'PXM_"'Q
M(U:36M2LH$M[6>61I2D<:A5 9B2!@>O3]?HJ.:6%MT4C1L>ZG!J.6269LRL7
M_P!ICD_YS[4 (_S8V\?IZ^E% XX]** "G)_K(O\ KHM-IR?ZR+_KHM 'L=C_
M ,>D'^Y_4U;JI8_\>D'^Y_4U;H *\]\4?Z\_Y[BO0J\]\4?Z\_Y[B@#DAR0/
M4U\H?MD_LSVG[5GACPUX<N]I7P]?07J[L'#0R"3/UX_G7U=2B62'YHV*D\$C
MC(QW]:!IM;'PYXY_8\L_&/A[X?:$^TIX&M;2W3('2V5%&,_[N?K70?'3]EBT
M^,GPX\.> 9MOE:"UNRY (_<!>@]L?F<U]BB63KO8%N3@]<CO0LDB$LKLI/4@
M]:!7>Y\N>)?V<[3Q!^S?_P *#8+]G-DMIT&T[(_+Q^0]\?R\U\*?L;V7AKX&
M6WP939Y%M(TG0;?FZ_SS^'>ONW=)GS%8[Q_%GFCS92=[.V_N<\_G0--K9GR-
MH7[,5MHWPCU7X8 +Y.IQO&V!Q\PQD_ASQ_\ 6J;X,?LS6GPF\">)/!D.W9X@
MM;JW?'3%PKK_ ";\LU];&5F.YG.\9P<G^?UIK-(<,S$D=,DDB@1\5?LW_L@:
M'\$)_&JW\,<]EXOFNYI(BJD;KDL3D?\  O:OB+XI?\$Q_B/J'Q/U?Q;\*=?D
MT+0-?EE&IV<,SPK+!,Q+J50@$%21VSW[5^V+R2/@.[-CIDYQ4B75S&-J3RJI
MXVAL"@=];^=S\X?V;OV"=$^ DUQJ=L =7U*.3^U)SR9KB53YC%CDDEB<FO1/
M@K^R-9_";XW>(?B]#M\S7))';&,GS&8\G.>_\J^UVEE?[SLV?4TIDE==I=F4
M=B>!0%W]Y\1>)_V1+/Q!^T):_'+Y/.MY=S@@$E"?F'?L<?\ ZZ\'_:?_ .">
MNH^-?%UQ\3/@!>_\(GX\OU!O]2MR;>260 ;B7C()RV3WS7ZJ"64 Q!G"]UY
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M10LZQ[B%W953@#-?2?A>6Z\5>&M+\116DB#4X$G-OM^:+<H;:0,8(_6OR_\
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M/X*\?:MKWA?2]3U*/PWJ3QW=S;122HZVLI#!F4D$-S0/333U\_\ (_+'1_\
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M_!-3X@-X[N+V^!U6[GT(ZF)"X@$C&!8_-.<;=N,5F_L__M8_MK?"WX*2ZO\
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MS?\ UQ0(_3,:3J('-K+GO\I^O\JJFWF63RC&P?.-N.<\?XU_,EX=_P""B?\
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MU_JQ]#_Z#0!UM%%% &/KO_(-F_#^35Y*O\7^\:]:UW_D&S?A_)J\E7^+_>-
M#J*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M7\=/V1_ G[0/@.P\#ZN(=/N=+MH[2SUA JW$21(%4I*!N&,9&/Q KY"\&?\
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MR\D4*@\1JA8@*!QCCI0$FG]_YK7\D?I=:2?:+9+@)L$@W!3U .,?I]*L4\L
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M?LR?$3XH_M9S^-]%2]DTOP=JSZU>0P&4*]O!,)F5U7@@JI'/&/SK^H_X"_\
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M** "BBB@ HHHH *5?OQ_[X_K24J_?C_WQ_6@#V#3/^/&W_W*OU0TS_CQM_\
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M5?B!;+8ZG:W$D5NIP R!B V>F"/<=Z^E5TH%=W]H:<#_ '6NX@WT*[\Y]L4
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %>B>&?\ 5_\  ?\
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ME4(5894ALX.1SU_.@#,YSD,0/3/7\,^_I3R#@$DG/]1FKDNG^6OF?;;-\?\
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MKDZ "G%2O7O3:* "G#)X!ZY_E3:* %(P<4E%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 (>GXC^8
MKT3PU_JQ]#_Z#7G9Z?B/YBO1/#7^K'T/_H- '6T444 8^N_\@V;\/Y-7DJ_Q
M?[QKUK7?^0;-^'\FKR5?XO\ >- #J*** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ I
M5^_'_OC^M)2K]^/_ 'Q_6@#V#3/^/&W_ -RK]4-,_P"/&W_W*OT 1R_ZM_\
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M_P ??AAXO\5?L-_"3Q;ID$]VGAG0M/N+FT*,S!8H$9E:,=" ASD#I4G[./\
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MH **** "O1/#/^K_ . __$UYW7HGAG_5_P# ?_B: .LHHHH QM=_Y!TWT/\
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M7D_,V<$=Z\+\-_!;]B_XH:#\/?#^N_&75=<GTZ+21/I-]>/+#%?0B',7ENQ
MPXQC' '2LC_@K?9^%/A'J'[,J:(J3^!?#5QHK6[A05,$4D)! Z<JO^/2@:UD
MKK7JK:;:?UZ%CXN:Q^W%^S_X5\&?M%^)/%>HW/@G6Y=.GDTEKB8XAN/+9ALW
M=-KCMT/O7V#\7_VKV\3?"_X2^,H&47NO063WL9Y<.ZKOW ]R>N?_ *]>)?MU
M_MV?!7XR_LH?#KX8?#V:;5/&3P:';OHZP;D@DCM;6V<!5!+ M&9,X&W=C'>O
M)OB5X#UOPI\$/@I=:G:3QW%U;6#M:+"_[C>$P-N/EZ],<4":?*M-;O2VKO\
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M\0-9;+AWR7\R.,!B21GD@]:=\5H8K?\ X)O6UK;63QQ/I$!EM8XSEV,*_>C
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M!MY_U_0?^APUV% '!^*NFD_]>K?^@QUR==9XJZ:3_P!>K?\ H,=<G0 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% "'I^(_F*]$\-?ZL?0_^@UYV>GXC^8KT3PU_
MJQ]#_P"@T =;1110!CZ[_P @V;\/Y-7DJ_Q?[QKUK7?^0;-^'\FKR5?XO]XT
M .HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "E7[\?\ OC^M)2K]^/\ WQ_6@#V#
M3/\ CQM_]RK]4-,_X\;?_<J_0!'+_JW_ -TUY'JG_'VW^\W_ +-7KDO^K?\
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M!Y#JG_'\_P!35*KNJ?\ '\_U-4J "BBB@ HHHH **** "BBB@ HHHH ****
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MH&I-?=;7]#XF\$_\$V_V3="TWP=XBB\,C^WK/2=/F=I@)%:[2WC+EHV7"%9
M5ZL6VY! PM?2_B/X*?#?QC8Z9I6OZ7!-8:*L::='Y2XC6( ( ",# QT KTD
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M_9]("#G';K0$79]?O:_KT/+OA;\!_AC\"-%N?#/PTTR+3]'OH7ANHEC"AXY
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M !1110 4444 %%%% !1110 4444 %%%% !28 .<<FEHH **** %R<8[4E%%
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M !2DD]>:2B@!02.E)110 4H)'2DHH 4DGK2444 %%%% !1110 4444 %%%%
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M 9,=E<12L!ZD([' %1ZGXW^&_A]_(\1^--(T:Y&-T%Y=0Q.I/&,,X[U_-_\
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M=LO^?FRE26/\&1F'/7K[5=))Z\U_/]^PI\2/&GP/_:4O?V5-;UJ\\06=M>-
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M@#R'5/\ C^?ZFJ57=4_X_G^IJE0 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7
MHGAG_5_\!_\ B:\[KT3PS_J_^ __ !- '64444 8VN_\@Z;Z'^5>3CI^)_F:
M]8UW_D'3?0_RKR<=/Q/\S0 M%%% !1110 4444 %%%% !1110 4444 %%%%
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MI3"_ZU]VT '@GD5^P?\ P25\+ZQX,_8O\/Z-XBLYM.U1G2=[6Y0I*F\[L%6
M(P#Z#WK[*C^#'P(MG:2W^%_A^)G.YREA;99O7[GX_P#ZJ[&QT[3-)@6QT*QB
MTS3D \NS@41QJ!TPJX QQV_2@;:M9*VM][GYV?\ !4;0]8\0?LX:M9Z'I\VI
MW9G0K;P1M([8;^ZH)^GL:X[]FS0M=L?^";FM:#>:7/;:P^C7*+I[Q,LQ8P,
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M10 4444 %%%% !1110 4444 %%%% !1110 4J_?C_P!\?UI*5?OQ_P"^/ZT
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "G)_K(O^NBTVG)_K(O^NBT >QV/_'I!_N?U-6ZJ6/\ QZ0?[G]35N@
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M* "BBB@ HHHH *5?OQ_[X_K24J_?C_WQ_6@#V#3/^/&W_P!RK]4-,_X\;?\
MW*OT 1R_ZM_]TUY'JG_'VW^\W_LU>N2_ZM_]TUY'JG_'VW^\W_LU &?1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %-?[I_#^8IU-?[I_#^8H ]"\+_ZL?[O^-=A
M7'^%_P#5C_=_QKL* "HI_P#5/]/ZBI:BG_U3_3^HH \AU3_C^?ZFJ57=4_X_
MG^IJE0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M^.??%+#/#$KH]G:3QN,>7-"DB*#C[JLI QCC&*@;YS@\#U^G-(5V#'./7]:
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M5TTG_KU;_P!!CKDZ "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MR/5/^/MO]YO_ &:O7)?]6_\ NFO(]4_X^V_WF_\ 9J ,^BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH *:_W3^'\Q3J:_W3^'\Q0!Z%X7_P!6/]W_ !KL*X_PO_JQ
M_N_XUV% !44_^J?Z?U%2U%/_ *I_I_44 >0ZI_Q_/]35*KNJ?\?S_4U2H **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ KT3PS_J_P#@/_Q->=UZ)X9_U?\ P'_X
MF@#K**** ,;7?^0=-]#_ "KR<=/Q/\S7K&N_\@Z;Z'^5>3CI^)_F: %HHHH
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MH-BFIY^]]J6!1+NSSG?G.>>E7J"+A1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 =QX7_ .0;>?\ 7]!_Z'#785Q_A?\ Y!MY_P!?T'_H<-=A0!P?
MBKII/_7JW_H,=<G76>*NFD_]>K?^@QUR= !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 (>GXC^8KT3PU_JQ]#_Z#7G9Z?B/YBO1/#7^K'T/_H- '6T444 8^N_\
M@V;\/Y-7DJ_Q?[QKUK7?^0;-^'\FKR5?XO\ >- #J*** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ I5^_'_OC^M)2K]^/_ 'Q_6@#V#3/^/&W_ -RK]4-,_P"/&W_W
M*OT 1R_ZM_\ =->1ZI_Q]M_O-_[-7KDO^K?_ '37D>J?\?;?[S?^S4 9]%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M7!]#^5&#Z'\J $HI<'T/Y48/H?RH 2BEP?0_E1@^A_*@!**7!]#^5&#Z'\J
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M )12X/H?RHP?0_E0 E%+@^A_*C!]#^5 "44N#Z'\J,'T/Y4 )7HGAG_5_P#
M?_B:\\P?0_E7HGAH'RCP?N^G^[0!U=%%% &-KO\ R#IOH?Y5Y..GXG^9KUG7
M03ITV 3P>WM7DX!QT/4]O<T %%+@^A_*C!]#^5 "44N#Z'\J,'T/Y4 )12X/
MH?RHP?0_E0 E%+@^A_*C!]#^5 "44N#Z'\J,'T/Y4 )12X/H?RHP?0_E0 E%
M+@^A_*C!]#^5 "44N#Z'\J,'T/Y4 )12X/H?RHP?0_E0 E%+@^A_*C!]#^5
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M / 27_X]1]JO?^?;1_\ P$E_^/444 'VJ]_Y]M'_ / 27_X]1]JO?^?;1_\
MP$E_^/444 'VJ]_Y]M'_ / 27_X]1]JO?^?;1_\ P$E_^/444 'VJ]_Y]M'_
M / 27_X]1]JO?^?;1_\ P$E_^/444 'VJ]_Y]M'_ / 27_X]1]JO?^?;1_\
MP$E_^/444 'VJ]_Y]M'_ / 27_X]1]JO?^?;1_\ P$E_^/444 'VJ]_Y]M'_
M / 27_X]1]JO?^?;1_\ P$E_^/444 'VJ]_Y]M'_ / 27_X]1]JO?^?;1_\
MP$E_^/444 'VJ]_Y]M'_ / 27_X]1]JO?^?;1_\ P$E_^/444 'VJ]_Y]M'_
M / 27_X]1]JO?^?;1_\ P$E_^/444 'VJ]_Y]M'_ / 27_X]1]JO?^?;1_\
MP$E_^/444 'VJ]_Y]M'_ / 27_X]1]JO?^?;1_\ P$E_^/444 'VJ]_Y]M'_
M / 27_X]1]JO?^?;1_\ P$E_^/444 'VJ]_Y]M'_ / 27_X]1]JO?^?;1_\
MP$E_^/444 'VJ]_Y]M'_ / 27_X]1]JO?^?;1_\ P$E_^/444 'VJ]_Y]M'_
M / 27_X]1]JO?^?;1_\ P$E_^/444 'VJ]_Y]M'_ / 27_X]1]JO?^?;1_\
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M /M5[_S[:/\ ^ DO_P >H^U7O_/MH_\ X"2__'J** #[5>_\^VC_ /@)+_\
M'J/M5[_S[:/_ . DO_QZBB@ ^U7O_/MH_P#X"2__ !ZC[5>_\^VC_P#@)+_\
M>HHH /M5[_S[:/\ ^ DO_P >H^U7O_/MH_\ X"2__'J** #[5>_\^VC_ /@)
M+_\ 'J/M5[_S[:/_ . DO_QZBB@ ^U7O_/MH_P#X"2__ !ZC[5>_\^VC_P#@
M)+_\>HHH /M5[_S[:/\ ^ DO_P >H^U7O_/MH_\ X"2__'J** #[5>_\^VC_
M /@)+_\ 'J/M5[_S[:/_ . DO_QZBB@ ^U7O_/MH_P#X"2__ !ZC[5>_\^VC
M_P#@)+_\>HHH /M5[_S[:/\ ^ DO_P >H^U7O_/MH_\ X"2__'J** #[5>_\
M^VC_ /@)+_\ 'J/M5[_S[:/_ . DO_QZBB@ ^U7O_/MH_P#X"2__ !ZC[5>_
M\^VC_P#@)+_\>HHH /M5[_S[:/\ ^ DO_P >H^U7O_/MH_\ X"2__'J** #[
M5>_\^VC_ /@)+_\ 'J47-[N7_1]'ZC_ETES^!\[@T44 =/ \KQ(S^7N(YV!@
MOX ECCZFIOG_ -G]:** &N756(VY XSG&>V:YJYNKTRG]SI;X_BEMY7?OW\T
M444 0?:KW_GVT?\ \!)?_CU'VJ]_Y]M'_P# 27_X]110 ?:KW_GVT?\ \!)?
M_CU'VJ]_Y]M'_P# 27_X]110 ?:KW_GVT?\ \!)?_CU'VJ]_Y]M'_P# 27_X
M]110 ?:KW_GVT?\ \!)?_CU'VJ]_Y]M'_P# 27_X]110 ?:KW_GVT?\ \!)?
M_CU'VJ]_Y]M'_P# 27_X]110 ?:KW_GVT?\ \!)?_CU'VJ]_Y]M'_P# 27_X
M]110 ?:KW_GVT?\ \!)?_CU'VJ]_Y]M'_P# 27_X]110 ?:KW_GVT?\ \!)?
M_CU'VJ]_Y]M'_P# 27_X]110 ?:KW_GVT?\ \!)?_CU'VJ]_Y]M'_P# 27_X
M]110 ?:KW_GVT?\ \!)?_CU'VJ]_Y]M'_P# 27_X]110 ?:KW_GVT?\ \!)?
M_CU'VJ]_Y]M'_P# 27_X]110 ?:KW_GVT?\ \!)?_CU'VJ]_Y]M'_P# 27_X
M]110 ?:KW_GVT?\ \!)?_CU'VJ]_Y]M'_P# 27_X]110 ?:KW_GVT?\ \!)?
M_CU'VJ]_Y]M'_P# 27_X]110 ?:KW_GVT?\ \!)?_CU'VJ]_Y]M'_P# 27_X
M]110 ?:KW_GVT?\ \!)?_CU'VJ]_Y]M'_P# 27_X]110 ?:KW_GVT?\ \!)?
M_CU'VJ]_Y]M'_P# 27_X]110 ?:KW_GVT?\ \!)?_CU(;F^Q_P >VC?C:38_
M]'444 ;FGS7,B@2+:H .%@CD11] SL!^5:?S_P"S^M%% !\_^S^M-<R*K$;,
M@<9W8_&BB@#F;FYOO./[C2G_ -J6VF>3V^;SA4/VJ]_Y]M'_ / 27_X]110
M?:KW_GVT?_P$E_\ CU'VJ]_Y]M'_ / 27_X]110 ?:KW_GVT?_P$E_\ CU'V
MJ]_Y]M'_ / 27_X]110 ?:KW_GVT?_P$E_\ CU'VJ]_Y]M'_ / 27_X]110
M?:KW_GVT?_P$E_\ CU'VJ]_Y]M'_ / 27_X]110 ?:KW_GVT?_P$E_\ CU'V
MJ]_Y]M'_ / 27_X]110 ?:KW_GVT?_P$E_\ CU'VJ]_Y]M'_ / 27_X]110
M?:KW_GVT?_P$E_\ CU'VJ]_Y]M'_ / 27_X]110 ?:KW_GVT?_P$E_\ CU'V
MJ]_Y]M'_ / 27_X]110 ?:KW_GVT?_P$E_\ CU'VJ]_Y]M'_ / 27_X]110
M?:KW_GVT?_P$E_\ CU'VJ]_Y]M'_ / 27_X]110 ?:KW_GVT?_P$E_\ CU'V
MJ]_Y]M'_ / 27_X]110 ?:KW_GVT?_P$E_\ CU'VJ]_Y]M'_ / 27_X]110
M?:KW_GVT?_P$E_\ CU'VJ]_Y]M'_ / 27_X]110 ?:KW_GVT?_P$E_\ CU'V
MJ]_Y]M'_ / 27_X]110 ?:KW_GVT?_P$E_\ CU'VJ]_Y]M'_ / 27_X]110
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M_GVT?_P$E_\ CU%% !]JO?\ GVT?_P !)?\ X]1]JO?^?;1__ 27_P"/444
M'VJ]_P"?;1__  $E_P#CU'VJ]_Y]M'_\!)?_ (]110 ?:KW_ )]M'_\  27_
M ./4?:KW_GVT?_P$E_\ CU%% !]JO?\ GVT?_P !)?\ X]1]JO?^?;1__ 27
M_P"/444 'VJ]_P"?;1__  $E_P#CU'VJ]_Y]M'_\!)?_ (]110 ?:KW_ )]M
M'_\  27_ ./4?:KW_GVT?_P$E_\ CU%% !]JO?\ GVT?_P !)?\ X]1]JO?^
M?;1__ 27_P"/444 'VJ]_P"?;1__  $E_P#CU'VJ]_Y]M'_\!)?_ (]110 ?
M:KW_ )]M'_\  27_ ./4?:KW_GVT?_P$E_\ CU%% !]JO?\ GVT?_P !)?\
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9QI]Z,[F5G?+].1CH/05J?+_M?I110!__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>g0fyk5pshdve000012.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g0fyk5pshdve000012.jpg
M_]C_X  02D9)1@ ! 0$!+ $L  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" -& L0# 2(  A$! Q$!_\0
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M]^W>O=/#?[16G&X>?5-,L)+2<Y48.%# _7'&/ZU^8'BW5+/4?+GMX!;R1JN
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MNE&3NDTNJOHT[?/Y77M.D^/+:RAGNIBX$@<*#G 8\C'^'L:X'4IK?5X]2O\
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M>5.@^[M/'?T-<II?PN\+^!-4N/$D,4;SWI+8"C!9N3@8]^*\L^)OC_Q!X/\
M#^HZM86TA6*Y8?*I^8;C[<__ %Z]%^%OB/5_B)X)T[6]2M741;&*LI&=HSW]
MO7\??K?L$[.#T?;9Z:JR?Z[GG0]LZ$K2^TK7?1M:+^OD=A%>?OWNXI$MY&5M
ML;$)G(XP..#_ )Q7SMK/B2[\%>+;C798$NU=R[>6H=L9/IGM_GG->Y^(?!6J
M>)[B+5=/N&T^"SPK0JQ4/@=<#'7'Z]/7E+OP+;>&DDUOQ0POK)D#.LOS*J@$
ML><CI_A1K>Z3T>FFFR:^Y6Z_\'?#)JT7N^G?1::^C^^_0Y"__:$TKQE:IHJZ
M9.&) D#QG;V!X(]C7L?@GQ!I][86VEZ+;BUNTV^857:#^@_KUIOP^\*?#'QM
M;S77A_3[7SH0QD=50%64$'/3O^=4Y'TK1/$<6D:.B)>+-L<IUSNQC(QU^O:M
M%[;2\HV=K67:W]+;O?5DMTHRLXM6O>WRVU_3O\^7_:"^)^L^&/#W]AVA=KZY
MQ&#'G/SC';GGZ>_3BN<^$NCZ;8>#)O$OCB^MA<74;R11W;J&!<;EVASGC)P>
M^??-5_CW)I^D7EG?^(-OW Z[\'+@ CU.>O\ ^JOA7QA-\2?BAK.G:%H5U=Z=
MX<>=(HYHR\<91F"CE< ^Q]/SKS\1C*F'KJ-9\ZMRJWO-WM:UM-/Z\O0PV!CB
ML,W2_=V=VY:*RL[]%T^^ZZ,^[8M1U+Q%IVHZ+X;OXVLYI6"I%("/+)P<!2>,
M$?YS7L_PRT_0? 6E"34K."XU+&^9Y8U8Y.23R/7O^''%?*=M\(?''P3\-Z=X
MDL;^;5Y6BB,D(=I"V0"<C)YX[_IW^J? %G?>-/")UW6[8V=Q+%AHV&"IVXZ<
M'CK_ /6Q7713>J33DKQBUWVTZ=F<E6,:=DY1E:RO?1NZ32>RO_P#:DCT'Q?K
M)U2&2*U2,,ICB(1>F.0,9/7\>O:O#M2^!DNE>)]5\86#/)%<)(Y7DK@Y/;U_
M'Z#FN\3PI_95I>WUEJ/,<C'R0Y!P">,9S73:;\15GTF/2BHFE&$F&!G:!@Y/
M\\__ %Z<7R?[Q>4;ZI==;)*VV]CE;YI?N%RZ[O=I6UOUV^:\SB/ NH:S#IM]
M9:<C0OYC!L KGDAA[CG/],5Z_!>Z0NE6]KK"VT.H.<&5PJR.QZX) ).3_3N*
MY.RUGP[;WJ6T,\=O=3D%X@5!RW7(_'OS[>OB'[2,^IK<^%T\+7;M<?:X/M*0
ML3QN7.=I[\]?QK6Z;M'RLK=+_G;3N:VEU6MM=/O?_!.R^+6@>*K6T6Z\+22,
MC$.-A.&'/3'J,<CWI/A-XNU6&.WM?%TJ)<QRKY0N& )8#C&\]1@8Z\X]\>KV
M1UJ70/#Z3VQE<:<CW&X9)98@22#WZYXKY&MX-1^*GQ>'@[2[AM.EL[T*XC.W
MD, =V",]*4FM;-*5FEKKS.WSO>WI<(+_ &6[B[<Z3=NB:O\ (^S_  7KFHW>
MGZE,)E*'Q!K C*,"IC%S\N#SV/K16AX ^%VJ>%]%NM'N;IIIK?6M69I"S$MO
MN3@YR<],Y[T5%*GB_9PYGK97T_P]]>GX>EIG/#.<G%>ZY76RTO'I\MO+S1]B
MCH/H/Y4M(.@^@_E2UZIP!1110 4444 ?GC^T3:>*=)\90:QX= CWSC[3(W"^
M66^;))P1_P#6-<I>>._#GVO0+-;.RNO$<ZQBYFB5'=92!DLPR0<^_'2O)_VY
M?VB=5T_Q5-\-O"MJ[ZPY:'S(D)?)R,_+R>O^17D/[.&G>(-%O$UWQW%+<:A*
M&>V2<,2CG)7 ?GN,\?TKSHU7&M-)72>MU=)]+?CV_,]/V'/0ISNO@3LKIIZ.
MUO+_ "U.2_:Y\=^(?"WB"PENYHC9AXY'M]_S+#E21MR#T''' 'TKSG5_'5C\
M6O".GV_@^=XY[:*,:A$K$;F4?/\ *,9YS_\ JK/^._PU\4_%3XR2WNH:G+#H
M@8XLBY55BZ#Y<XZ$]?R[U+X#^&MGX$\9Z=8:3<!K":55O@K90#=\VX#CD9Z_
MIFN&7UBO)QC904G:2:Y5:V]MOT1Z-)4,/2@Y7;Y(\U]V[1ULWK^G3H>U_#-#
MX+\,I)J$ <3%499%R<G()PW/XU[+K&AZ#;?#[5O'-E9+)J<,$DT$8B#.6568
M;1@GW[<U2U#0DU7Q#9:9:0>9I*+&TC*/DSP3D@;>/_K?7TWQ1XF\)?#_ ,+S
M-K*P_P!D6L$GVJ)]NQE6+D')]CVY]*]6A1Y</+F:35KMO3=:J_ITOZ]3S*W,
M\5#ENU*S2WLKKIWTOY'Y7_%+XWZ!H_PNUGQ/XKF-IJ82>"WM96,;AE5E0>6>
M?3M] >E?S[^+OB7XE\6Z[J]W:SRC3+V:9K<*S?<9F*]\<#'ITKZ6_;Q^/>F?
M%+XCWWASP, GAN&YD5[> XBW L#D1DCK_+-?%>BS#3%C2<;(8/O9' _ ]:^"
MS3&_6:[3:_<2<8OI[MO\NWWGW>1X#V-.55WBYI/WOD]+K73L_37>]#>ZF+>6
MTOG=XFR<2$D?@#QG&.W;%<A<)+%.WDO*D.3N49"D9]!U_P ]:[V]TO6]<7[?
MHMG)<6B9,C1J2 O<G&1S_3O38!97$+6<B 7J#$J;<LK#DCIG.?;_  KQI2<F
MI?9>K>G96U?Z+J?2Q>D>5I-)*RT;VZ?<<E#$UPI54S"!SQZY]A_7^M9L<,=C
M<MY,6[<<L2G3DXX_'Z5Z?I5D+;= \&5;."1T/3(XS61J5I:V8FFF4*#DKD>W
M'^/;-2Y72GH^5=-M=_SN=7V8O16Z?=]S[K]3C;R[CA F5FC>/YP$]0,CIWS7
MTE^SMXNU#Q7J2Z;?'%C"VPLQXVCC)[<#GU_"OE/5)U:)WA0R<,..>O\ ];^7
M->V_L_3K8QWNQ_)NYO\ 5+G#9[?KC..?6NG*J_L*U"5^:4L0G9;VTOI>_I;T
M/)S?#O$82H[M<L=TKKF5M^W4_0?7/AMX;L)UURVN'8I&)9-K93(&3G''?'(_
MK4?A^V\(^+HKI5(%Y9!MN<8.SIP??U^OM4OA_5KK4?",NDWL+-<NC#SV!R5(
M/0G)'\A@U'X.\'2Z=8:MJ-G&0\2R.[#^+KG\_P N,\U^CYEAI\U',L&W"AB.
M6EB87;;;44W;2R[/3]3X7"8U<E3#8M*6(@^7#R6RC%]6NNVG;\?*-5GT_1M:
MF4PQM-&SA2J@G )Z?YQZU#::A=:_]H2WC9-J]2",;2>G (/^%4[R+S=9DU.[
M3>!<%&0@YQNQT/Y<UWEQ=:+H&G)?V6SSY$#-"-N<E02,?7_/2O;P4%'#^RC\
M$5[J>GNI)[WM>^[N>;C'*5>FY:NZOUUO'Y=/+8\DT>UU?3_$V;AI3#YAX8\=
MN #QZ#TYK[I^$PM-<5]$U&.%([T>6KR!1]X;1R>_^?K\N^';J'Q)?+-=QBU5
M7ZL NX9]>,XX/^'?V&>[M])DLSI6H+%-'C#(X!R.^0<\8XZXYZUY.:X!2AA7
M1YHR=9.2NT[-KWG^M_T1UX7$)5Z^RM044^C:27IK>VGRV./^+7PVT7POXT73
MK<Q2I-)YA9,$?,?Z9]_6DU.RLM(T826\>1&@WX'7@<\>^/3KWJIK9U+4_$L%
M_J-V;IMZ@%F+8!(ZY/;CO^=>I:E;:+;^'VEN723?'ET)'''/'Y]/?U->SAJ;
MIVC5E[2"Y?AW;M'[O+S.*M[R@^MMFO/?_A]MSQ"RU73=7T](K]FCLTE'<@D@
M]^F1D8[5Z+?:=I6JZ-:6NE!8W1%$+@ ,2!@;CWYKR*ZL$O1(VFQG[*DA8JH(
M&,YSD<?_ %JZ'0]999(;,,8GA(4#.,X ]?\ 'CZ5I7A&I:C9.,[:]KVU;6S5
MUU[DQ@J<?K#;YHVLD_-6TZ:VZ?\ !U;2&_TZ<6-\"7!RCGI@9Q@GV/MZ?6WK
MT,,R1"\"LB 8)&>G'T]O\Y$7BSQ#I=K;H9[N-;U5XY&[IT!ZC_..XKA'\3G5
MM-G6+]XT:D*W7.W([<_YQGBL:,<)0G'#2FE?1ZJ[VZ]?GZ= UJISL[2L[):W
MT5GI;3MTZO2YG>)A9W$'D%=MLG.Z,8''/;^?J:Y/3]9LS;S:8"\C %(0<GG)
M_+MV'TK(MO&<$T\VCW48:X+%5##GG.,?R]?K77^$_#]O]L>]G@RH)905]>1Q
M_GT]:X<]H3=-+"3B^5*WO*VC6ZOY^FB/4R^O23M*$D[V;??2ZO;_ ('3UP;3
M2I-(?^TYBRR[]Z*#AOO97MGCV_3I7M/A?XM:IOM='N]CZ?<8C<N>BGY<G/MZ
M]/IQ6-_9\.LZB]N2/+1"%08&",]OK[5XOKEA<Z)K\MD+DIYTNV#G&S+8&.F/
MKGZ5QX&NZN%]E4:YX>[*6EKJRTT[Z?@+'894<5"K3YW&JU)K??EV_K:Y]!>)
M-(TVXUZ&72@A,X$CF,#8';!Z@'H2*J^)=)US2-/:_N1(\,*[D"Y(X&>G3@#_
M  SQ7,:+XD7P];06%^?/O)2C)<-EF .,<^H_4_K[\OB2PU'P\+2_B%RTT>$!
M4-D$8]/?MG^5<U.KB95OJVBIMW4FK;6T>FZ\V=%2E0I\E1QLVKVU>NFK6MO/
MUT/E'P_XUU*YOY9Y-T5M%N3:_!(&1_/IWXYKLM.\9%IKR*.-&CE!#L0"><YQ
MD9[\8_K796_P)U[Q(US>Z-I\L5K\\FQ%8#9USQ[?CCGFO)-0T8^$[Z\TZZ.V
MZ@++)&3@Y7J,'D=,<]>E>I0P=-UX5)8UQ<791OIO&\4KV>EK?(YZGO1]V/,N
M5=+V5UY?\#0Z2TU#4[.26XLI"+9MS-&IXQDMTR/T!SW]*H6]Y8>(M18:L9-D
M3'(.<#!YQDX]\^M8>B7[SRR"67RX02=A/;K]3Z=N?QJ_IFJ:3_:$\3HJA2^7
MX ;G'7Z>I]/Q]#&9/E^-@L12QDE5C9R5VG*22NN^MOZT9RT,96PKM5PD9QE\
M#W=M+>?K\CII_&>EZ#*FGZ1N\K 4D#IC('3C^56[;X@^(M/O[2\TNXG?#HQ5
MW8JN2I[GC'T[>U<1Y=E?ZXB0VP,);EPN0><=>@[^OK7=:SHZ:?IYEM!A\<;>
M2#R?Y]^#QWJ,'E=*K^[Q"=2Z2BW=MVMM;77[FO0FKF#I?O)0Y')J48Z_#[K?
M3MY:)(]:\!:]KGB3X@6>L:W/&L!"1_.PPI/'<CUZ^H/X?6^L^$[WPU,?%7FV
M]UI\X678I5B%(#'N><>G_P"K\JK/5O$=L6EMKN2&2-\QJI((*]"#D>PZX]N]
M>\>#?C#XL/V72O$^H2SZ<2J!)6+#:#@#D]P._P"9KR<9DSPTYN,)0@FTKI[:
M:^6G7\3NI9G[?DBW:-XI=M;77]7UZ]_O#PMK>F>/)WL+.RS<(A5QY>>1UP,=
MNW'?KD9'/P^'[;0O&!\K[5;WD,P;'S1QYW9Y'3 P#^?-)\%_BCX*T#Q=9H(8
M5^T-&)"=N/F&&Z_S_I7Z0>*_ ?PT\:^$;SQ-I5Q:VVKBV\U2K1A]_EYX^;/W
MO3^M<F'5>G2FN912E]O2Z5GI?^NGJL1.BZ\:"IM\Z3NE=)VCK?[NWKU?R+XM
M\7R)I<$-X5>X\M8T=3R 1CG!Z]:\MN++Q/I5B?$OAN42SJ/-,2ODD\L<@'FO
M;/AW\%];^(-SJ-A<*\UM#)*L-YAL +D AL$#'4$=\=B,^9?$/P5XU^"-_>K*
M9]0T3YB^0SI&F3D9.0,#/-;P<L5&-:7_ "Z5MM'YK1[)/S.1RC&;PD=4W??9
MNW6]TUU7?Y'?_#?QGX ^)^E-H/Q?:"TU%6$,33$*?,X .6'J0!_D5F_&S]BS
M7?$^CVUS\*KUI=("!HA9N6RIY /EG'3 _P .M?GCXOU\^+=76?PY>?99HYP\
MC1/L*2 DX^4C!!X_ 9.*_1_]DW]J75_AG_9WAKQI>F]L)F2(23D.J*?ESER0
M!@]?;-.C7M+WM8[23=O1+IOIWW^;KX1TH*M%WE!I/3F;VZ+6W7_,^2];B\;?
M ?PGJ&A>)=-D8FUEA:XDA/F9*LI)<C/Z_GSG^<#]HKQ-#)X_U749D5H;R>7=
MO'9V8_GZ=!^.:_MV_;);P'\0?AQ<ZWH]O;7TMS9R2L\0C.PNF1]WGO[$=\<U
M_&A^TY\&+S4M=OKC3XWVB:5O+0-\HW$]!P.!TQ].*MT%)2?67O*TM$GZ?D;8
M:O-/5/STMT6U^NWYZGYI^,M2M_[11M,E:-96!98VPN2?FZ8'K_AZ8EQHNJ:G
M:>9:^8W!+MR<Y&#D_CT]N_%>YZK\')-.TPZIJ.Z$Q-D^8K*!CKU_6NZ\ ^']
M'O['[-9R)<3L"NT8)ST[9/\ ]?\ 3FHX=<S7+TW>T4OS^6ATWC?F=V^EMV_N
M>MNY\Y>%/AK=:I&PB@D>^&>=A)SU'8]#7T9\)_#GB/PS<7T=RL\;QAB@(8 =
M<8_''X=LU]6^ /!.C>%;"35=6A2*0\KO0=.#QD?U_I796&B7GC*_$?@W0WU.
M6<["+>!G/)QCY%/KZCIVKJA0BZ+5U=-V;5O2VSOKNOTN2Y0LG*25E>UUY::_
M=YGZ"?L)?%-M!\.:G;ZY?C'V694MY)?F8A3@!"1SSZ?ABOLW]@_QAXT\4_M,
M:S-I6G7EOI"W[DSF)UB9/,ZAL8(('K[X[U\Q?L;_ /!._P"+7B_QGIWB+7([
MW1M!,L<D]C()8HWCR"X((P01GC'/Y5_4S\$_V<OAO\'-/@DT;1[>+6FAC^TW
M:1IO>0*-Y+@ GGJ3G)ZY[1AL/B')7DK:7;>K5]NW]6\CRL=B<,X*^NNBM>^R
MZ;+]+7/-?VM?AEJ7B'P5;ZYI4#3:I;P>8X5=S;D&3_3CG/\ +X!^'/[0D_PP
MMU\/>(K9[.]E=H4D*F/)SM!R<9YQG_(K]U6M[74+>>UOHEFMC$^8W 88(QC!
M_I]*_$+]LSP=HEWXWL[73]+%BGVD!KI$V*/W@!;( '')_,UICL-S).@E&2LN
MVUK-_CU?Y&>78JA%^QKTW.,]5Y?+^NUSO+?XLZCXGO9+/7IVB\+7$33F[9B%
M ()'SL<#@\?ADUY#X*^/5W%\5)/#7@%Y+_3;"ZP\BL9$($F#C!((/^/;%=OX
MX^$^LW/[/B6/@Y9+_5);55:^M\NT2LHR-Z988!]_4^M+^Q3^SWH7@/3F\3^-
M;Q(]:C=YKH7+_._)8YWX8\_F>*\M1Q'P\T='9M[]._SO^1W<V$]C-1@[-Z16
M^MM/+^M>_P!2^(KNV^)]QIUCK-NMG/%&KR2LH3YT 8G<1Z_T]*[?2_$5M>^%
MM=\ :!%'<ZAI]I(EM-@,5D1"H(;G&"*37K'0/'JRGPK/%9/;9B-U&RKNQE2<
MC'7&/KWKSS1[35?@]/>WDUJ]])J 8&_VM(/GSSNYZ#_/6NBTG'=;?$MK]=5?
M?\#C2<5#=:JWY[>EK-]?O.J_9UL_%?A*'7[CQM*T[B:=K6%VW$ %MH S^&/R
MZU>@MY_BMXPOH=6\JPTVP=VA9]L>0C_+@G'I[5UWPFM9/$<T^MZG>"2QFW.T
M+-@+G!*D?ICT&/:N:^+WA#5+>UUG4? 5V8YC#(=ENW.=I/\ !UY_.A.U!W5Y
M)W:>NBMLO7;RZ]RW[^Z3Y79)[*[:TUMY_P##GINGZUX6M7/@>6_M9!(#;@^8
MI'("\<UREE\!-!T+Q,VL6]PSPWLF]UR?*(D.>GW?XOQK\:++Q1\:]&^(LC7\
M=_+Y=\#YQ\[&T/D\XP.G<C'XU^G-I^T#X@/AS2;1M.EFO85B$\FPL?E50<G'
M3KU/7]>>&(I5[QE3=DUT:VL]WO9KYG5/#UL,E.,XV?9K1-)Z_E8]G\;^"_#\
M-_:V=E%'$9]HEE50O)&#D\>I_P .*ZO0?AEX?\(6\.I:9=QO>7I'V@!P2=X.
M00/\C^?F5E\1?#/C*UAL+Z_BT_7F11&CNJOOP,<9R"#Q^!Z<BNMT[1+FQEMW
MOM?WP[E9%:7A@3D8R>3CN*VYL/[:%E=V^/L[+LM'96L8I-X=KE>KL]6E?2[M
MZVMZ>I<^).A66I::FCR36B07+*\@E*!BQQZ\_I6#KGQ(T+X&?#.:WF$%RWV5
MC:1VV&;>4) POOCTSV->,_&+PMXQ\7>*;:#P[K<EO#%$9"D<C*'5%W9X/3C\
MOPKY.\/>/+>V\<:KX2^)U\-2L]$+XAN)-RL(ST <X/0Y_GS3]LG?EN[7BM[]
M-?/;H3"@OJZ>E^9-I;[].MUOKKYV9]A_ ;]I*X\>6>K07]E<VSM,[V[2QNBF
M/=Q]X8P0,CW_ !KI?B7^TS\.K>"+P;KUG/)/)^ZGEC1R &X[#US7,>&OB3\&
M]0\'7=SX2TZUL+NU<P^9"B*3@XSE>>V3^%>N:#\.?@WXC\)0^+?$^FVTMT%\
MV2ZD5> !GJ>GUSCCN:2E5]BDYK=76E[:?=IIOV]3?]W[9*%.5^35V=ME^N^O
M1ZN]EY#IUQK&F:8M_P#!U;MK.]Q)<*0V0CG+?D#_ )->@7=Q%HOAC^W[N\C;
MQN\9?[.9!YHGP2!M)W?>]L]J]Q\!Z]\*XM-NK;PE<6C10QO"8HRC;6QM (!/
MW3T^F?7/R-\1_@YXMA\;0^-QJ\CZ%-<>:+/>WEK&7W8V] -O'(Z#WJYWHTU-
M-M22>EY)7Y5;^OD<])JK-QDN25WI-6T7KY=3%LKFZ^(\<X^*44T,<4A-HY5@
MI13\G)XZ8_ETKT>T@\'Z3I<%OH[V4=MIOSB9BBO\@!Z]<_+ZG\*[W[?X&\6Z
M;8^#HA#'K<END6X;5D\PC')&#UXZ9SFO'/B'^RCXSE-K::+K<UM'>.!(%E8?
M(Y]<XZ8Z]!GK7-]6<O\ :'>][J^][K==;=MK?>^GV\E_LRTC:SULK::WV^7W
M)&EXZ_:6T?5/!5SX/\-HEWXG@5HH/^6B[E7"XZ]_RZ^M>?\ [/?QD^(FI:E_
MPB7B]5M4,S(?X$\MC@<9QT_'VKR/X@_![6O@#=V-Q'93:S?79C\R\ :4JSD;
MF.-W/4]>G6OI3P7\&=7\0:'HOCR.1K*\E>*29<[&YP[9 (/H.?<5$:N*^LK5
MVLDM+:::K^D]/)CKT,+]5=W>5[[W;EI?S:Z]OT][\>:-/:V:1:#>JUQ>8)C$
MG)W=>,Y[X[_C7F^J.G@32[)[Q"=7U-E3YAP&<]?;D@Y[UL:QX/\ %R^)]%U&
MUO99[.T$?GQ*S%3M^\< XY'KS[=:G^,D]OJT&D69M\W^844X&Y)!@;NF00<?
MIUKLM+K&7JUOM_F>9%1O9.ZY59+?2UK->>K6[9X]K.KZ5X,\1:?J_B.Z:5[U
M5DAAB?=C> 5&T9QCC'Z>WH?@JTD\<:]=:\L+OIELOF6Z7"\#:,J1N'Y?G[4[
M2?V<+S6]>T3Q!XHNC?6*)"Z6KON"J"I VG_ZQ]:]N\;ZAX8^$5O9QP"*QLK\
M1P%3M4 ,,$G/_P!>NBA145SRE:/=M6OI9;?\#OH*%9_"DW+975WIJG;=;_U=
MV^1?C!X[^-D-V\?@5-EE:.;<C. (S\AQ^%>@?LO^!=?T/Q)IWQ#\6D?VQJ%Y
M&UP/4N>?4Y!_2M7Q5IL7B22TA\*:LCMJ>R5UC93@NV['&?7C]*]<\':)K6ES
M>'-$U-F)2\@#2-W&1WZ'U';WYKF=#FQ'-!WN[K6\;Z-/NO\ @'5[?]PXM))O
M5=6M+]K+\CZGLM3M[IK^91PVJ:AV)Z7#C.>>OX?2BI-*TJW@AN8U*G_B87Y)
MSW-P^<^_K17I155)7;OU^&W3_+\7W.!RA?W;6TM^'_ _I:>F#H/H/Y4M(.@^
M@_E2UL8!1110 4444 ?E?\2?AOX?N/VB;GQ/K%H+A4E,A\R/<F-Y)Y(/N/U^
MG*>//'OA)?'>E:'IJ0V;[U1%.$4GIP#QC\Z[_P"*?[17@+3_ ([S?#?58H(]
M2>8P^>P4,V6QC)'?Z_SKS/XO_LVW/Q!\3Z1XJ\)7;6*QE)1-$Q4-_%P00#QC
MI_.N&<'SR<'=.6J5W;EZ:=^S/4IZ4Z;=U[JM?17=K^OEZGRG\8W\4Z'\3EO6
MFB72+F)=C(PQ@@=P<9Q6MX%\,:C?7S^(<R2:8I\R>4Y(51@MACGISWKQW]J'
MPM\3/#.HV4(GN-26V*"1U+MA(P <D$]L]_KBOIK]FOQ;!XG^'TWAJ[B$&H/;
M^5*67Y]^W!Y(SUS[US89\GMJ35E.3>SN]O3[N_X=<[5*4:C=U144K]-K^;7W
M_B>P>&/$-C+=F+2BDL*@1NY(+!^A.?T_'TZ_*?[:/C31M(^&?B33-2NVBN[V
MVG6 J^"&>-@.A]_I^/-?15A\/IO D=SJ?VTR+,[2+$6SU)(P,_K_ (5^)G_!
M2WXYP>'RNBW"F1[[,<;9R$W<9^OY5.9U_88%VD[J.JN^;96_K_@D97!XG,J3
M7O*\;Z::6M_GZ]C\<;?2S:^(M6O/-^TB>]GD5Y&W,%:0D<DGW_SBK(T:YU[5
MXM'MD8RZ@ZH"O.-YQV'H:Y;2KN6ZFEN&NL)<,SJ-V,;@2!UQT./\XK[A_9?^
M#/B/QM?MKFGZ7-J;6C^9%)'&7QLR01@>V?3FOSRC!8J;=F[RNK)O=I:^?;R5
MC]+QDUA*45)<JBERRMNU9Z:>EK?\ [OX*_L__$<R6_AJPLHY(+U4#RSH-JQR
M<$[F''7UZU[_ /$#]B?0_ &GG5;MX[O7+V/S)(;4B39(PSC:I(&"2/P_"O3H
M_$GCOP[>6_A[3].FT[6I"+-)O+(="<*#G@C!Y_\ KU]^?#3X(:SX>^'VI?$/
MXLZI_;?F6LMS;P7#"3RLQLRKM<G\> /PKWZ&!P]7#.FX.\;Q?=/LW^)\W5S#
M$4:U.JI^[-W5WK9M:.^]EKMU/Y>?B/!JGA3Q%)IKVKQHLK!=R%3MW<<?IZ#'
M6L>"WL=:A#:@VQ,#>,\^^/R_#'>O>_VI?'7AWQ%\6;Z'3M/C@M(;R: %4 'R
MR,.PQZ8]1^GB]SI(CMQ+ <Q.,X![$9_KT_\ KU\I6I*E5JPY9<E.;C=>5M//
M6UK6/KZ$Y5*-*HY+FG!2>FUTNO?>UCR_7X=)L7FBTW#J%?KS\V"._MS_ (UT
MO[/Z_;_%JQW<@AC$ORAF"KC?CG.!CICTZUQ>IQ(NHNCJ4C)/)SCGCC_]7/45
MSAU2[\,W1N])N#%*6!5D..K#TYZC^M:X:HJ6(AB%O22]W[NFGR\WNUH:RIJI
MAYX=M-3U=M+WM^B_/S/V%U!)]*ME^R".2$6^=T6&Z+]#^'U]>*\]\,_$?7;2
M]OM(>%A:73,C,ZD !LKGIV!_KFN+_9[\;7GBG1&M]:N?M5PD7"LVYC@#CDYY
M_/Z5ZC:V5AK.L7-L(18M"[8<KLW\G'/'7U]<U^F9?C?KV&5&+TGKZ?"M.BMU
MT^\_-<PP/]GU*DTKRY^9=7JXWL_N:MK^9W*^%_#=SH[W;R0_:I@7VY&=Y^;I
M]2>/PKRO6/!:1'SC-^[ZQH3\I (X R>#G'2M#7M)O]#E6Z&I%H$;(A#Y# 'I
MC(SG\N_>N;N=>U3Q5+;00*]O;VN!+-@@';@$D].<?_7Z5]#A(NE%1K6=."23
MNM;6MKY=7U:>_7R;\SYW&SEJ[KI:VB_J^OD7#;PZ=8AY-L9)VCR^#G''3W_S
MUJY9Z%>742WWG2A<;H@YQGTZ_3ZU9CTZW\R 7$XN(5(W+G(W*><CGG@]>WY5
MZ#>Z1<7NDAM)^[$F0JCT' X_I6%>-?$MSA;DI_ ^B2M9Z>O8VP_L+N\6VK;Z
M6>G?IZKYG/V^AW45G_:-W(IVCC)R?4=_\^XKC=>O;J[86,,LA2;Y<9) !XX'
M0<#I_6KCWVM&)M.U"5X(E?&7) QD=SWX]_PQ6I;Z=;XBE$@<ISOZ@^__ -;V
M[YK;!2Y)KG:NUJVU:]UW_J_J95;.4K/FL^FKCMIM?^ON:^@WN@^&HYK8*\DV
MTL&QG#CGZ]:Q+O21;6]GJ.TQW#C=+QM'0YQ]!G'&:ZZ[N7O/LMO]L#1)(H,>
M0?E&!C&1VY_"O<M3\ Z)XK\)VHL;V*&^@B&Y RAF(4=!D$YYYQ]<UZKI1B^2
MZM45W.6W31O_ (.YYL:M12<&M+I-=G=:)?=^2/BO4?#5MXDU(O<W3(!'\JEO
MEW #WY_3UKF--L-1\,ZL]K./,L)7VQ'&048_CC()]L9Q70^+X-0\):J;!]WF
M>;L5N0<= >.O'ZXKH+.%W-A<:B/,20KDD#Y03ZGI@<\].XKYM8!XK&RDG=4I
M<ONN_P#*O3775].I[<*SP5.$'%?O(\VJTM9/=K?U_P"&UO\ A$/AS!:'6[IT
MCU@QEU0X&7P&''KGH/H/2L#0;_+W[,52V3>(CD8*\X(S]!^'7M57X@6<-T88
M--/.!ED)Q[#/^>W%9FE:!JEWIYM-[P/M^\<J6R..>,Y/U[<>N&94/JU:%)N5
MJMK]4M5=:==7_3.O+;8J-2LVE[-V2VNTEWW_ !O>YU/AZ\CEU29H&WR;F!V_
MW1ZCIC'^)]*Y[QEHMMJ&J1W[R /;MO9<]2IR<@?S_.G>$M&\0^%M7DGO+":>
MS?=_I.UBF.1G=TYX]_Z]<OA-_$]U>:DMT(;>/<YBW8!&"2I&1Z?3UJ*-*A!K
M#I-.>J:^3O?_ (9=+#Q%2O-.LG?V3LE?M9>KV7H>?216.OW%K!:MBY@9$.>X
M!'OSQFOK;POI?A2T\-H=4F3^T+>/*(2,EU7@>N2<?7TKY5TK21'XAECL3S"6
M#..<E>#TXQQD_CBM&;7=9?Q+;Z;Y4C0"55E<!L!<C.>G;UQC'O737P=?V3K0
MLHTHZ6ZI+3Y_B<RQ#?*YVO)I/:RU5U_7JCZPT+X_OX82XTJRLE;>K0*Q4?<^
M[G..<CT_6OC;XTZQ#?:V^LV[!;J]<O,@Z L>?Z_YZ^X:E:V<LT%G:V.;AH0S
M7 7H< D9P>G/X=L5XCXB\#WOB#495.Z-;1LDG(W '\^V.O>O,G3Q$Z6'K*Z<
M:ROVM=7O]VZTZ7/2PE;#^UQ%*22O033Z7T>CZOYZF9X.M+35@(Y-R2E,L1G&
M<<Y]NN>N/UJQK7AJ S26VG2XNV!V[>I;\\_S.3^7:^'M.AT:TD2.UWW"1E?,
M"YYP><_SZ?6O-))]1M/$3ZC<.8HE<L%;. ,Y_'OQ_7@_9X58;D4-Y2BFWND[
M+73\_P $?,8J>(NZG-I2ER02W44[VM_PR)=+EU#0)&L+V,F^;)C8@$GJ1COS
M_GO73Z1K]Y]HFAUL-Y!^Z#SQGCIZ_P!*IR:A;:SJT=]&%N)8UQA1D\<>_P"O
M\JU+>R%[/-]J3:""$4C&/8?I^G->E@8+#2>)J>]&FO=M9NRM;;R3MU6QS3E/
M%1CS)WM%.+\K;7]>OKZZDN@27BC4K#:+;[Q'![YQCZ9]/RZT-2TR>XAC9/W3
MPJ"I4;22,YP?Z=\].U=;INCZC';;(IV%KR=FX_=Z^H[>W>LG5A+L/E,5-N27
M&3DXZ],9S^OMS7;3K87,J5563=[V:7E_7_#:82C6H5XN+]W39Z+5:K]5?\$1
M:%K=OH.V\NI)_ML)^0C<3D=.GT]1[]L>U:#^TKXFMD73(KV[%K+MC*%VVX.!
MS@],9]?\?G33?$VFSWWV:_TX.%.SS"O4CCJ1C.>G![=>M;4L$0NUN+>Q*6V<
MAPN ,X_BZ?3T(Y[U\/FN&I0ER5X2Y.:T>5;:JU^W_ /H,#[>3<G*+?5-Q;Y=
M-MM[6_1WN?OU^R3\=/#ND>&4'B![=!=(N^21E$F6')SUZ?\ U^PKWGX^>'=(
M^+_P_P!4M_ LEC>7FH6CI'L9)9E9XSCCD@Y[^O6OP#\%>+)L+IT6JF*W6/C$
MI7:V.!P0./IV_"O=/@Y^T#XV^%7C.(3:Q)JFERS#9;-*TJA"^,!<D# XZ?G7
M+-QH4HT:7PR2^#6U[==;;=7;\;95</S3EB*,K335T]+O2]K_ (?=L>-:I^SO
MXW^$#:U/XCMKHR2W$TT3&-P -Q8 'T_']#7R7XV^/5WX8NI;74;#44\DE8)H
MX9.-IXPP7GIGKWYK^JEK7P?^T9\.([V]LH(]7:V#E"D:NQVY(' /.?\ /2OE
MF?\ 8U^%7BJZ31==\%1/*KE3>/;(<Y.-V[;C\<_6LZN'4H1LG)M*[ZZVMYZ?
M?ZZHJACG"ZFT^6RE?Y*[OOIU[;G\\'@;_@H+XHDUU/ %_;:G/H=XPME>X20J
M!(=HY8>C#]*_1+X(?LHVOQUU9-9N]/?^S=1*NIEB.,2\Y^88_B//\Z_1*3_@
MDA\')]6L]7TW2+:)TDCGW+#$"I7G' 'I[ ?C7Z0?"_X+>&OA9H5EH>CV,4;V
M:(F\1)SL&!R![8_SBML/AVHZW^=[=--OZZ6,<7CU*T:"2V;ETV6EOP/Q%_:0
M_P""0GA#6/A9J*^'8(TUE;">8+%& =RHQ' 'J.G6OY=M&_9C\=_"'XGZ]X>N
M+.\G:PNYTBC\MF!V2$# P<]/?%?Z1>J:7<:C;SV^X 3P/!M(&,.".A&,<_A7
MY^WO_!.WPOK/Q$N?'&KPP3B]N#-)&T<9W!WWD$8YX]1QWIR34K):7\]KK;SW
M[JXJ&-DHV;U=U?KLKOM;_@(_F&_9X_8O^+GQ^\36-C?Z7>VOAYIHQ(S0.B^6
M67<0<#@J>U?T]_LL_P#!-#X5_!/3+&_O[&TOM42..61;B)7Q(5#$8;..?Y]N
M:^Z_ ?PB\$?#:QMX/#>DVMK+%&JLZ6\:DD+ZJO)XY]S^7JN6D"L^.G0#''8>
MW%;]-OD<->LY2<KNS:O9^:V_I_H<UI_A30M(@2UTK3+2R6-0J_9XE3T'\('X
MXK573?+^;)))Z$GISQ^ ( _0&N@MX$/.1GZ_3L/TJ"X(#D= /\_THU>W=?F8
M&?Y!53CJ1@\]!W]>O/3-?'O[3OP:MO$WA;5-7MX5-];V\DB.J_O P4L", G(
M./3VZU]HIM*YQD_GW^OIQ_.L/4M)_M6VN;"XP\%T"C*1G@J1TY&/3M^E.LM'
M;JD^O^?ETL%*I]7DI+6[5^MEIHOG_6A^ ?P3_:<\0>"?$MW\)M8MVN89;HVJ
M?:5SA2VSC(ST/^>:_076]-\(IX'U?6;JZ:VO9;-Y([>%RI+O&S8"C'.2!TKX
M7_::^"R_#;XVVGC&TLBMD]VDCRJA"9+Y.=N!Z>M?6OAC3QXP\/6&LS[I-/AC
MB:6WYQ*JH-RX.<G'X\=^WS\KW=_P_3].Q[E*>'<85-;-IRLNEUU]>GXGYG>$
M/BM\;+SXHW/@WP8+T:7)J@4&3>K-#YIY&<$_+R,?TK]V_"FDO?\ @73-*\?0
MQQ7Q@A\^6X 5AE!N.YN?Q_K7P[)\/K32_B#8?$;PMIXL8--DC^T6:1*#,4(R
M=H SN]P>O3BOKGQIKFL?$S0=/M]+C?2[RXCB@WJ/*8,!M)&-OL/K3H-^PDM4
MV[6?577==.WW>1C6L17IK#^[%)<RT2VC\K[ZV_R?SO\ &+5/&7PZOX;;P"TD
MV@S3H+B2W)=%0D!OF4X'!]A7U1\)_$.BP^ ?[:\0W4,UU/"6N(II%8C*?-N!
M)Z$\\<8KYI^))UCX8>#&T+5X7UC4[\8AE9#(ZEP=I!.3U((YJI\)OA#XW\8>
M#=1O+G4YK:"[AE\FU,CKY>]20-N>,9QTJJ+:Q%M_=:2Z7LEI?^OS,IIK#KK+
MFLY=[V^ZVOW7.V^+<O@G5?".H:]X0LK*764G*[HD0MNW8ZC)'Z\GIFM/X4>!
M;JY^'PUO6;:W:^N48QJRJ65L?+^?'M]*^4;JQU_X827_ (/U)I;D7=Z=L[DL
M%#,1NR>._OBON/P7+<:;X%TV1K\7";4;RE.=NY1VR>G\_K44;*<G9:R;MMKI
M=?F_1ZFM>/[JG&[?NK5-ZM<NNOY_H>6:9^S9>:KJMSXMENIK>ZMY'GBAC)"E
M%.X  'T&/_UU7U36)?$FJ1^%-!O)?[8TMA'.-YSNC.T]3W -?4D7C6ST;0I-
M5O;R.WA\IXBC$#.Y2!G/X?YZ_/GAGX:-%XLG^(FE7>8=:E9PRME1YA/3!P.*
MZ'1B]4[7Z:6Z)^O](Q]K)*VJ:22O\M]OU.8\:ZAXB^'FBRZ_=I)+=06SQY )
MYVD')]!_ACFOR6<7GQ+^+L=^TLL"ZQ?&*\ )7"/, V>G_P"HU^[7Q)T-M1\,
M2:)=VAU":^4KO"[]OF=^^,<^G3ZU^>'Q!_9^E^%MWH7BO3^9;J[262 <M$'D
MW]!TQU_#\^>M'V/:.L==U>Z73R]-3;#:MN_5OE\FEM\SZ>\(_L]>#?#2:'HU
MI=LR:G##-=-N)7S&"LV[ZD]"?K7U=XH^%^F6_@"Z\+Z==L//M&B@,;'.YHR!
MC!/)S[?@:\E^'NHP>)K+1;,\:G]FAQ)GYD(0<;N",$>WTZ5[%>W.KZ7<16MP
M'G%N5+R'G"]3GV SVKH5*@XJT6VTFVNETMM//UT9C[7$*5^9)*5M?+K\]SY2
M^"WP7U?X=WVI6NHWUU*U]<M+"LK.>';( R?H1^7/%?5'BK2-7N=,L+"0%K8"
M,.Q[+W]<8Z]/I4YU*QUS6+>6.XC6:W7+1@J&!3L0/ICG_&LO5?'5S?:P?#UO
M&7=<1AE&>>@.?8?AZ>_1%QI89I>^F_\ %RW:V[;[ZZ>6IAB)/$5XK5.R2TM;
M2/W_ -=#CO$GPN\/^#+>U^(5I>'^T+;:YB5N-RD8!YYY!Q6OJ7B?QYXG\-VF
MM:#EYF5509R<KC''7MVZDUN^)?!6KZSHO]DW%PVVX7S A;IW  ST'Z\4>%]*
MU7PIH[61EQ;::&D()R"$!)Z\=L=NOIQ2Z;Z*UK7MLKV7^5^X*ZLN9.2LE=Z]
M$KZ[M_UHS)\,:)KGBL?9?B%9)*ZPEXGN$!(=%R,%A_LU\C^+/C+X\\)_$>?P
M+81F#P[#,T5N>5BP&VC;G X'I6G\3_VY;3P[XO/AU+(!;;,+W04 94E3D@=\
M8_SBOD1/B3KW[17Q1ATOPWIDMM]FN@TFH1(P#@-D_.%Y'/K_ #->?B*T9<L:
M#M)-)VMK=QT_KS/2H8=+WL2FE:ZO\.R?Z/[S]2=/^(4G@OPRGB[Q1/ =,$>Y
M][J3C&3C)_ET[GH:Y^/QKX8^,^FWFJ^"&674HHW-FJX.)UZ8 P,[@.G7\L_)
MG[0_@CQGIW@FQT&XU>66V\N-)[;S&R<* PV@^OH,<#\/2?V.-#'A300+2)GN
MAEF0_,0W?KGO[?X5G[;$RQ$,/>[T];:/TNNOXCC0PM'#O$QO>_NW[II?T]MC
MMO!?Q]USX93:CIWQ?<P2P&1=-1V .Q<[,#([ '.._I7SMXE^*VH?M4?$.'PM
MX9N'33=/N@)2KYPBOR>N.P[_ )9KV_XS_ >_^*WB"37]1N6CC@$C"VSLW$*?
MEP,>W\J^7_@3\+_$7P?^,5Y>6MI+'8ZA.T23,"4&YR P/3T.?0YZ"NS$.2Y<
M/JT[7[6TN^O_  Z=]+F>'HQDOK*<5)ZZM;)):K]4M#[KTGX9ZKX)U+1CI=T]
MTUI%&+@,Y?:RJ,YSG'/_ -?TKV;P_P")-6U?Q'%'?1>7_9TD;[L8SLY/.1Z&
MO.?&OBVT\ +;WVK:U$)K\A@CR#*F3M@G(QT'X5[%\.+33/%VF0:O8W<>[461
M3*I X<$$_P#CQKHH:64;.WI[KT23\_E^!PXF-DIM6N[-M>EUMV-KPM\1#?6N
MIR!RPBU_6+?.[/\ JKHC^\.Y./0<45E>$_APNEVNK6PNQ)GQ%K4Q;=U,EV<]
M_:BNF+J65WKU]=/^!_5S%^ROI>W2UO+O\OP\C[-'0?0?RI:0=!]!_*EK<Y0H
MHHH **** /YL_P!JKP!JGC']M7'A@72ZE;W_ )DC1J^S ?)R1_CUK]=/AQ]K
MTSPKI^C:QO\ [0M;=(I2W#%U3:>O/;///TQ6/XPT+P=I7QEG\0S:?%#K,LC9
MOI(URQSG[Q!Y/USZ5WUV]NDZW28D\Y@P9<8;C.>..?PK"@O8>VFE=SDVTW?M
M>V]M]+'76K.M["'\D8QNEY*[V6W];,^<?BCX>TB&6\U+Q1! VGR1R!9)PO<-
M@@L,9],'UZ5\G?#^]\':1XNFAT1PL=U*X3RL!#EN,8X_SZU[S^UC/K?BKP['
MHNEB2V\OEY4W+E0.>1CMT]/>OG'X1>";2UM(KJ<^;?V2$O)DD[AU/KGC/_UJ
MBEKB8.S5TV]-+:;7TT_(WDK8:HOENM4K+OT[_P"=CZ-U"8:[J5WHT4Y=_LK&
M&/=N^8KE0%&<DDC/MVR37\M__!4C1]>TKQ^UOXBL[CR!=$6A\MN5+_+@D'/&
M!WP.U?T@_#R[U#_A:DM]=LPL(2<EB=FU#SG.1C"D_3@]..$_:Q_9J^$?[1NI
M#7-;U/3[0:/NDF,K0KS$-QSEA_%G_P#57)FV'IXBE6C3E&$_[SL]+=^^VW?7
M<[\DQ=' XBG.I&51/E?NIR:;MH[7_1W;VW/Y*/AM\&?%7C-89;)7AMF">5YH
M*9R,#KQ_0_@:_4'X(?%7Q;^R'X6U&'5+"VNKNZB86)=4;)*D)R1^@^E> ?M)
M>,=+^#WBL>#/A?=PW,5C)Y/G6N&'[HX'*9]!W'K]?G?Q'\6_$GC?3[>U\17#
MM<0J%CW9&/3/3UZYZ5\+2E+#2:I)*<9<LM$[O379WU71V^X_0,4OK<83K.U&
M:4X1OJD[)*S?X[_,_4G]G_\ :"UWXJ?%*VUSQCI<203ZDBQ1Q1@D*\HQP,XX
M-?>7_!0;XL>*OAM\,-,3PU(\>CZC9()8@2NU'B7@KD=FX^A^M?C1^Q)\2_#_
M ,+/&TOB3Q_-%?Z5:K]H@LY2& 9"&7 /T]NU=I^V;^V[!^TWJ-QX;\,0?V?H
MFEMY$,2C:K)'A<+P!T7M_P#6KVJ&(^KX*K4E93E[TKV6Z6RW\SYS$8)5<924
M+^SC912U7V6F[+OUTZ:GP!?ZE%XKUF?5;P8,EPTLDAZAF8D\_7//?KFMGQ!K
M-K865O%9,)!M )!SC@<?I_GJ>:MX8[2SEMMA#Y)+$=3CKGTS^%<E/=O;K/'.
MK2]0AY..W%?*2E&<Y3DW:3O;K>Z5WTW[K8^UIP]G2IPN[1@D[:NZ2T^7W;:C
M-8NK34D*CY9N.1P<X]:\MUFTN(RK;BP4\?@>YZY]L<5Z98BUN87$B^7.02"W
M'/)Y].PP3^M<3K4,L0F).]03MQ].WUSWQT^AK+$V:5K<SBEI;RMML]_P]!TG
M>]]KKOIZ[?UU/M']E2&-Y%G,@W?(&0G (XSQT[_Y[?;_ (@TO3SYES9,L=X!
MD^7QDCU(QW'//T[5^:_P+UK4M-@62QB=G9MFU ?H.G^0.E?=7A[4I[N,0ZK)
M]FGO %1I"1M+ =R./Q-?H'";P]2C&$HN,[*+YKZO2[7HM/EYGP7$\<11K\\7
MS7NTMWT7^:UZ'+7<.HW=U,NIS,+=0VS<W!)!Q_GC/IFJOA[58+(ZA8WT0CB8
MLD,H7!()(SG]>_;BO9=8^%M[<:*)K:^%Q)CSB48'Y>N."3G''OW%><P:3:S2
MQ:==Q>7/;D+(Y&"Q7J2>,_B>O.>U?=>QC&U&,ERRLW=WUT[O=]ONW/G(5:E6
M,:KTE"U[^5K:7_K\3#W*H2.SDD<RS#DDD@,>W?'.<$]O?%?1_AZ*[TNQT[(#
MQW"IYH/8%>F/UKYX\27-AX=FMQ8A;F=74F)?F;AAG@<_Y].G;CXAS36VF(4,
M  3?&?E*\ =/KG\JS>&=)_5[NTFG>/71-*_]+Y@JZ<>;:^[2U3T5OPMJO\SK
M/%.DV.L:T+5@L,>W<2G'S8YS@>V">E9%GH,6GM/#<,3:KD!CD\#OVYQ56Q\1
M1ZCXEA7.]7VJ2.F3D9ST'OV_G7K'B&VTRPMHVEF5EG7YA\I(W+SN_$X_,5IA
M\'0J-0EK*&[OHGH[/_A_OLT8NI[%N:B_>>[N^BV_X8\?U#1-,FA:;2;@FY&?
ME+?Q<]L_YQQUK'M[[QAHUQ#<)=OY$3#=$)#@@>V?3MZ=^U,\4PG2]U]I]P(K
M=N=VX!<XSSSW.!T[@UXMKVK>)O(EOH]0+VZ+N"!B=V,'C!_SCOTK;$X9PP]3
MVK;@DU&W2/1Z??Y_<@PTE*NY3T3=]=F[K\;_ #^1[CXAM+#QJT=[,T:ZA$,D
M$CE@._OFN9NH9Q82VZ@.;12 4^;[H[8ST^G%</X7&O\ B#29;NS,L5RH(."<
MY Z^_7G^E=CX$>ZT>6]?Q"3.!NWH_.X#D]<\<?J3BO"HX"51_P"P8J49OXHW
M:N]-.K\[[6/2KUZ,8?O_ 'X1MMJEM:V^GW;7,2+2]1;3#J:JS%9!PX.>"!QG
MGZ_XU+?:[>6R:?$(BD\I0+M!Y.<?Y[UUU_XML]4W65C;BUM(V.[Y=JG!^F/I
MW!X]:Y76-3BF>VELK%KQM/923&I;.P]?E![@^^*UQBI0A&-9N5:"]^3U;G97
MOY?-:E8&=-OW/=B]8IOENM+/L^O1M]#W"X\33V_@=;2]TP>;)"-MQY7S<K@$
MMCU&>O?O7@-EXCFL%NH6>18[@L!M)X#9'^ QSCGWK[9\(:[X(\>_#673M3AA
MT[6;>U94$H5'+*I]>>3Q[_7K\?Q:%;W/B:\TMEWP02NL<J_=;#G!'8\>YZ\5
MQX51FU52;Y&N7T35MK7L%64U4:2;6[M?K;9>=[G0>&++3[6TDU,-NEE^8ENN
M6//KP<D]?J>*Z?2M,MKAKB\2*)[A\^6P"[@><?0G/L._M6;IFC22:LVBA&BM
M67Y93PN<<#/UX_R*ZSP[X0UG1M3NTF+RVK,3#)U7D<=>.?UZY/%=57$2K6H.
M,N67Q-)J-M-+Z6?]:&7L4U\44WJTWOMM;7Y'8>&M NA97%W?1QEU1BA(7>!@
MX ].W^%>0WUV[:W=6HB*(SLI;:>?FYSVZ=.>^1QQ7L,*:K879$]UNM7X,>>-
MI)'0\=Q7G7CZZMM+E6XM[4&23YMRC^(X/\_ZFJA0;C]7T4+6=U;736^GGU_X
M'/[9T)2L]=EOL^GY?B9?]O\ AC1MUC<[3=2(1R!]X]/Z>M>,>*(H=8>[FBVQ
MP+N8,.,KCCD8'3I^E=/<:5;ZX5O)HC'<94ACP>WTQ^/UJGJ_AMYH8K2TN-ID
MPLB@]NG.<'K_ $KT<!3<:=2$5?E]U-:WVN^NGZ['/B'*52$[)7MKM=-K=?GH
M8OPY\*7=[(\VG S%&.[=SP,9]>3Z>E=SXDL+O3Y8PL>V=2/-"@_CTZ9Y^F*W
MO"-I>^"K4>7$Q$JC=)M..G))Q^.?\CJ)8X-4M+W4)75[C8Q5."2W/;_)^I-=
M-2O]7P\ENVTN5:R>JN]=?PW*JKEK1:7V;Z+36W7;33?<Q-(6[NM-V6V#,4VD
M'KT(]OS [&N8O-+N;6=OMO ?_6+]0>,<=O\ /I8T>]U'3VN+E@T$:N556X&T
M-C@?Y^HK2NX+C6,7(G\P9!9 >< 'CC\NGZUEA\2J-I4-)2LY-O3FTOITZ?)F
M/LM7*J[QTV[.WX6O_6IYMK.C2/L;2H 6WJS.%YZ@G)QZUTDVJ3+H*V!2,3B/
M$C=&'')'?M_*NN:YM;:Q-ND6VYQ@D@9& >_7_/:O,]1T:_O[@_9;DY?(9 V,
M<XQCMQ^GI2Q&*HXII5$G)Z.ZLKM+=V_JU_,UH..'?,F[2\V_=T_X!+H+V=E;
M2O)<RB5F))!/RYZ]ST]*]%\)?;-6OH[K2)1<O;,&82-EOD.<8SUX_P ?2N1A
MTI-,L'MKJU::=XS\^"2"5^GU[8Z]ZY'P3JFM>'_$%Q+;3M#;%SF,DXQN/&#Z
M_I7GO"1IM4L/KS6;>]EH]M7^5^^QK'%/$/EE%J$7>]NEEKV\_.W4^[= _:B^
M)'P^U&RL-/\ -CCBECCDC!(C:-3\PP#CM]?6OUV^!W[7/@;Q9I6F6/B5[*VU
MZX6-)7=XT?>0%SDG)^;_ #TK^?\ \5ZQ#>:4-6658[M1SR 2W )'N<$CKFO/
M="UW7C?6=WIVJ2VUR)%Q()F4###'0CTS^G<Y'1=3FIT_=:24M+*ZL]+Z?KN9
MUJ*E9PDI.UU;=WMOZ6?_  3^S72;Y+N"&?2KQ+BVF02!HI WR$ \8]L]A72P
M7D;'RV.9>0V3Z=>N?6OQQ_8P_:/U6RDL?#7BO4OMBO''&L\LFX $ 8RWY_H*
M_66QO+75YFO-/G62-E#@JP.<X/;I^!]*:344K/W=&_N6O]=3@::W37D]/7[C
MNQ$K /GOP/; Z>G2K04L$7S&XQQNR.W;M7+6U]<BX\AU;"G&<'U[]OP''2NE
MA5V;C/;U]17.!8VE< U956P..WM0H!8 XSS]>A_&K:H,#T(Z>F>?6@:U\A(-
MPY.<9]?I[U%=+N#'Z[??C\ZM=.@JG.KYW G&2?T_/\#Q0(CLA(@(DZ=CC'OQ
M^/7_ /74S,HDW G@Y/X#M]?\XJ&&0L=C9!Z<^Y/?K5U;;."2.<'O_C_GO3LY
M:;W_ !#SO_7]?/Y'RY^TE\-K#QGX9:ZGME=H&\UI0N7PG+=.>/3K[UX9\,_&
MOPSTO2['P8)U&H6\@BFB)&25^4@@8SSUX]:_1&_L;._L;BQNXEEAFADCVD9
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M8U9?#OB=9AX>M9B+263(!4'Y3DX'3^9KI_ /QBT/X9M=>']>EBM)1(T<1N"
M6P<#&[Z=*]-O?'Z>-A'/I++-#"0Z-"!AP.1ROTZ_C72W0>J6UG=:WM;[O/\
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M<?E7%2G0H3OR2C[S]VVRTOT-JKQ#A%MIRY5M9M[:-W_KR.@77-.&J10*54H
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MGJ2>N3GOVKZGN_'_ (;M/B3ID/AI4MXK::*!KA,!,;@N21UP/<8Z?7[.\5_
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M;KO;K\CRG5=6^*%O\2]+TZZM)?\ A$9O+\TR B%8SC=G/ ^7@_7->5?M@O\
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MXR?-%;*V_P#7F8UE*I&#MS7MTO[VCM^2OY&%::;IL?A*;2KN8"[W8#LP!!'
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M@]/2MJ]T*3Q1?K?6K?9HXR&\M3M#8X'3 Y /7USZUQ&D6&IO %-RHB)!(W8
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MP;X,O3KNFH%OGC9TV#&"1P3CW^AQW]/0/V0+.T/Q,>\\52LL;7/^A^8V!G>
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M+%.=9FBBB96!!WL <>O7C_ZYQCB*UDEHG;5]=U_EVV-Z%'V[<4VM+I[=NO\
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MIKOJF]]=^WH<6VLRZ[J<.G09C6-P6E&1T(W$GV_Q]#7O]MJT;:&-+^V&::%
M@RW3  XS]/>OG>71;S1+UI(3\TC[<^@)'?\ $]^].U&^O] FM+PR,RRE6E3<
M3UQV'TX[>U2\>L3%75GY:6VTL[6]"%A[1CHTXK5VO?;KUMY>IU-W=:IX;N)=
M1B5YRQ;Y>2 ISV_'].>#7-KXF_M8S2S?)(YR\9/3/4?IZ#\J[34)I=:T-;RS
M(#&/YE/7D#/7\?YXQ7B.N Z%I]U>LW[\*S;0<$GGI_\ JZURXJI1IX>==RF^
M7=*_EHK;=G^6AKA<-]8Q,(JRM9N.UTFK?TWU-#6=92UA6-5#"1]I0?PY_3OZ
M#^=:T'AZ*\M+<17/%X%W0@\#<#[^_P"(/O7E/A^RU3Q7:/?A_+5'R%;@\$8&
M#[>GZUW5A/>V%_90,[8C9 6).T 8SWX_#OQG%5ET')QJXB7-2G%3IIV?*KQT
MUNEUZ?\ !TQ:]^I32</9R:NM'I;JK;6TM]_4] T[X<BSW10H-Q7S,CU(R3Z?
M_6_&L@?:/[:CT.9B4DD\O>>B#.!GZ _R]:^@8;F :%'=PRQ-=O %ZJ2"0!UZ
M_GQZ>M?._B2__P"$>NY-0NQYMU,^82G52V,=.F#U^E>OBL'3C5I8F,4X6322
M3_EM>WGNN]SCH8GVE.I&2D^5\JN^S77\/GMJ9FNZ?<Z7XDCT@RG['+AC/R!@
MXR,^V?T]:NG2-)@O8&2Y5F4@M@CYN,_F2.O^2R[FE\2Z0+Q6\N_&"I)^?;UQ
MR=PZ_AFN&N]/U*V,#&=O,4KN^?T/7Z>GX=J\ZI2Q]3$QE3CRPE:4>565FU:W
M;]+FL:N'48IQU379WMR^6W9_,],/Q47P-KD"76F+/82[8UG* KD\ [B,'G\?
MZ?5_AWP=X/\ &O@G5/%^L3066^W>:V0E%Y*EEV@_E@=^G2OE)?#5GXUT&WL9
MFC%W;E)/,.-WR$'KU[?F>*ZV759YM/TWX<V&H;78I;OY<FWT3! /7 QG/>O-
MQF)Q&%E*G4;G.;WD[N.VBN[KR_X.O=AL/A\5+VT;QY-)**MMWMI?IMU^_P \
M\*Z)_P )3XKU#0[.9S917$B1RJ#M8!B%PPXI_B3PO?>!]7>"_C81EB+=F7 ?
MTP3QS_,_05^QOP"_9/\ !.D_#E]5N9[>3Q0]J;S)V&5FV[_KR>G/3GCK7P9^
MT5:V.I:U=Z0\:6][I;ND3L-I<QG@ @<]!U_Q-3*I*OA7A\1)1C-;W:TLNO?I
MOJ^YG*;6+56A[[I^ZXRU3V5FNVWZ'YY>,+K4CJR2N&CA+#:!G# ^W3IG/YUU
M>BQV=SI[+<H(KAUQ"QQEB<XQS_G\ZJ>)8)HV$=^H+(=L;8],X.?IW[$]NUO0
M],EO9+9Y) J(08\<9QCK^N?P]Z]+!X2G3RFFL$W4JJJU)RUOZ7MI_P '2QAB
M\1.5>+JI0BY*[C9)7MV\OT-JT\$:RUHTMO,YRV0H))VGVY]C72V7A35=.M_M
M2Q&>5%W2YRQ7:,Y^O_UZETW4-?@UE+:++6@3:.XZ8'Y8]/Z5UVEZQJMC-?VU
M\HV76Y8]PXY&!CZ_6B=6IAJ,_:74KV>KM?33_@;=E8CZNG)\NK?O)]7MU5K]
M;=/0\[O;'4O$:_9;.)ENHS@[0V0>F..G\N/RR)]&U?2U33YP_P!I8A<G.03^
M'''/N,U]%>%K[1?#:W%]?K$US+O=00.I!(XZ\9_QS7%W^H1>(-5NM2@0;86R
MB@>A./P(QG'2L8MQA'%.3:2YN6ZL[VLGTOW9,:LJ;4=7)N-[7O+5*_Z_<_5G
MA3P]:I8-%J;JUVZ%E5V&<G/0'V.<=/SYX35M+%OXCM[8W7V:SDEVR@-A2"V.
M?\_I3]8U#69YC<6'F)+&2NT9 .#CIU/0GIC^59LVGZIJ?DR7XDCD8@[R,8P<
MYSV_/M6=/%U,=1J*."7,MI1]VUNNFVGSOZG7/#T*=6$Y\UY1C*S;W=KZ/^KZ
MG2>)K:W\/7,$NEN+ZWDA#.0=PRP]L\G\^YJAX1\23Q7%PL<9!G)&S '7/;\3
MVST[U4N[I-+M?L<[>;A?]8QW <8QDYY[5Q&G:WY>JH+$J?WGS$<_Q$?_ %OP
M^M>/'$.EB8T[RC+9J[23T7E=_?\ F>C##JIAIR25FKK3=*S5DNK6WW:'V!X,
MUJ;4'ET5]2>T9U)\D,5R&Y(Q^GM^E>5>/[6==8DL;3-R0^)&QDG+9R>O^2 /
M?NOAO+HO]LPWFHDF[D58QCIENG'X^_2NX\=^!;G3+Y-=M86E@O=K+\FX -@]
M<=.G^->NHO=776]]-5TZ/^NQXEI:]&Y6;[+33IUUOH_O*/A>ZM]*\'?9Y;)?
M/* G*C.[GKQGZ>_/K7DWB2*;7AF/*K"<[ >P^G^'>O6=2M9QX;/EH5F=,*V,
M %A_CC%?/TEAXIT*\B-\[/!J#XAZD ,>/Y^_85V8"LE3J)*\M=6O):W=_7UZ
M=KK?#%;-QV5[=-?4UM+\)WVE*/$$1:-8^"XXZ >A&3_GKTH^(+N^OIH9R[RE
MB/F.2<XQ_G'L:]0%Y<0:,NCWRA1,@<,W'5?Z\$_CZUS\!TZ+3KT/'YKVZL58
M*"!M&1SS[?AR:N4Z3E'ZS)\NC^+3=:/^N^G;E_VAV2VZ.SN[VLF]-=>KU9YS
M?^%-3OECOE),2@,S>G)[_3_)KH="2UAN+.W@"M<*RB0CKVZ\YZC'US6/H?B?
M5]9FNM*L(RT"NRY SA<D'IGMS_\ 6JK=V.I:3?BYM]_F0N'F&#GCD^IX]2.]
M*M5PJ2^JJ\DDT^B24=;I-:V\_N0>QQ6SO:5M&]E9.^O2S7]:GO/B/2TCTZ.\
MMU$UVL08QCDG"YZ#_).*\?M[B;4X;V".P$5RH;> N,XR.G7\3[^U:MAKNMZ@
MZWJEEM441,KYVYZ=#V]?IVKI-.\)ZI/'>ZM:7,,;SJQ520,D\]..><?KWK'V
MV(E>M0UE&UT[[V2T\_OWV/0C0P\(1I5]YZ\RMY.U]$_*[V[G)?#3QDO@S7&>
M"U7^UQ, J 9;<"/3GZU]\^'OC7XGU".!+G3I+AI@B_,A/E=,'D<8/I^/M^>^
MD:2NA^(6U;6!ONXYBPR!M*@@]/3'!X!^O?Z(_P"%U:3:PV\.F6R)<J%61]HV
M\;1GD #GG]?0ULL3.IRO%7YM+OM?E[6U6^W=]$<.(PZA%J.D8VM;JM+7MO\
MUO<^B_'.KWTVE?:)5+SLN\1DYVCY3MQVQ_GM7D?A/Q[>Z?KVESQAK9K2='D*
MY&=K@YX_'_ZU<\GQ$O=:E+.IFA\IR OS*"1P/T_SD"LGX2Z?J?BCQOJ$=]9S
M+8+(2CE&"@9[$_R_PK#$8_#JK##MN2DEO=[6]=^GKY$PP&(GAY8A<JBO1-VM
MK;OMZVZ;G]*O[/'C9O&_@2RO2QD:WM(T8GGD(O/K_P#KKV=/-+N!D X .?7C
MOFOEC]E86>A^$#ID#@LR;<$\C([<_KQ7U9"S@X;H<=_0_7'2L9;Z;:?BD<-W
M;5)6O?\ +7]":WC>-L,2V>_7^7M_+-7<8)/KC\,5""1TH5F;=STSG/?'IZ4A
MC"5Z$_Y_E4%R2$^4=,XQ[@^E1/D2DGH,9^O'-,GE.!UQR,?ACUQ0!0B#/)M8
MX&?;T!Z\^OUQS5EHE#;4&3@#(]>GZ=OSJ MDY'%3P;LDGGIC\_;Z4 <;X_T4
MZAX7O$^V&RDA@DF63=M.47(&>.M?CGJ/A)_VF/B0/"7BF[DCLO!%XTMK<S94
M3_9Y,J%8XSG'K]":_9KQU;M/H,L<K%$==K')7Y3D'K[?6ODVZ^''AO2;ZQU?
MPVBI=RS!]5GB&"06!?>ZX/KU^M<.(H<SYG)M^MNRMI_7XL[:%9JT5&U]+I+?
M3U_3?UMR\/PZMM2ETWP]%"MQIVBQ);*I&5=80JY&>.WOU/7-===^+;3P%<6>
MG6RFWMK%U+QJ,*H3&0,<9Y/M7:W5A<:7K%CJ^B2I<:4D(^W>6=WS@#=NQW]?
MZ=*YS4KGP9K6HW7]JV<C/<J45MA(W,.><'J1VKFMR:)<JVTNKV\_ZZ'0Y)IN
M3E9[);W=KW[^?D?!/[3>IZ]\1O&FDZ]X.URY6:SEA9K&!GPY1@6!5#WQ^OM7
MU[\-?&WQ!_X0.SCU>SGB.D0(\A=&'G"-1G.?49SG@]^E0W/ASX<_#F=O%=Y8
MM+#OW()4W(&/3(.1_GM7T#X-U;2?%WAR\U"!+6WTJ]@9($VJO!! P,#/;';G
MC'>:5)O$WYO=M?EOI)Z:V;W=M;?=W=6M_L_+97YDKI:J]M;[WOO;T\CX#^+'
MQ=M=(W_%6;2TAGT*38PV;2[0GK@@9)VCK^76O>_V?/CS;?M.Z)'K6H1I!!HV
M'3>57/D=,# '&T<=<\GG%>&?M._!C5_$'@+6-)T.)WMKRXD8>2N<[R<?=&._
M_P!:OA_01\4/V1/"^CSR6M[)H^K2A;A(E<'RI6R00HYP#W'KGVPJ5,10QBKU
MHI06EE%)/:W2W1?\&QZ%.CA<1A(T*<[Y@TG'F>G+I??K9)7OY:GUM^W'K_Q$
M\7:"\7@/3)KNTTJZ6W=X4=AL1@C<H#QQGTKW?]D;PK;7_P &[*#Q7IJV>N7,
M82621 L@8C!R2 >IZ_3->17_ .T'977P;6]T31O.OKX1RW4,L.^8M( S8!!;
MKFOM+]G#5-&\6_"VSOM1B32=15=YBEQ"Q;D\!L'T [D?C6]%N>*\FKKM9V?3
MU\OQ."I&6%P\H27O<W*[]7I^&_F;:_#"Z\(^$]2FT:]:62X,C1QASD!@2.YX
MYSQ^E<#X5\,Z[9V&IS^*$+Q7B2+"SDG9G)!&>_(]/8YKJ/CSX]U+P/\ ";5=
M8T-C=WEOO6$1'<20"%/&3Z?XU\I? #XI_$_X@Z.9?&%I<1V%U*Z6VY7&WDA#
MSSTQ_G@.HU]8:UU5K/X5HE=+O_6AG%UOJ_-[MTUT5^72^F_]*W8]V^'_ ,-;
M;PSJ&I>*KC4#>6S22.MJS;E ))V 'ZXP/PZ5W-C;_;H/$NM:;X=CMYUM9OLM
MPL6UBX1L'<!W/3ZUK:+X;>PTZ1-0OXXX;AMR1R. <'D *2/4<?7M72^()M3\
M.^#+UM)19(GMG*.B@@G;Z@<Y_'KS2H+V#;=FW]IV?*GTU6N^_P#3NM/ZPH+5
M-*+=KKM=]-U;H^I\9> [#XB^+%\0V_B2.XBL5O94ADD#X$/F$#KQ@J!WYKV6
M\_9*\)^*])TS5[7R8-3T]DN)IU*AY"OS-N(P><&M'X93^*?$'@[7EE@6&X,L
M@1]FT_>/.?I]/2NI6T\:^'_"MQLO&\R1' R_J#Z'KR?PQZ5O+WKR^*3ZO5>>
MNW;R^YE*J^51T6J6B]$WTU:;)=%@\ Z3J6G:1J\=M-=Z=&D +!6+% $S['O7
M)?%;X,>&OC#K>FP:1K$>DM9S1L%241;MK XX*@@GBO/O!_A?4;_6[C4_$$DT
MLWG%T<%F &[/7H,?Y]:\V_:PG\;^&]+T_7_A9=W%K=:5LGU(+(R^;'&=SC@\
MY Q[G\:R]M%8:4<3%)IZ-KSNM='T(]A)XE?5Y2NTKV_'R2M]VGF?2FI7GBSP
M!J6B_#2P+7]F\<4+7@;<, !2=WT&>>/3UKI]:MO%C3Z?I*12R6J-$UU@%E*,
M=S9/3'7KGZ5^8/@;XE?'[XSW>G>*-",T"^'S%%J+3$_O#$0LA!/)SM.#SWK]
M=OA;K]W=>#GG\43VT>KFV"N\Q7.\+@X+8YSG]*6'Q*Q$5%-Q2VUZ*VJOO_6@
M5</[%N3LG?5OY?=O9?/SO\T?%+4?AUHGB?2H++3;9?$1C1952--[2XP6.!G.
M[VZ].*\3USXL:[\/_$UO>6\$TR7LBK+;!698HV(!.,'&!^''IG'T7??"K1K_
M ,37/Q!U*;[=]BG=XT0B1=JL<X )Q_G\5U6X^$VH6]_>ZM9Q+>^2T=NLD:[E
M=5VC' [X_P ]2M0]JU*.EM=/=32:=]-&_P"NR+H5\/2W;ES+E=[MW:BKK>VM
MGMUML4=8\7R?$?P:NCP1"*._M_,GE'!1V4\=CQZ')YKY^^#GAGQ?+X['A.]L
M9;O0H+P>7,Z,R2#><+GD'C\ASC-7M!DUS2[V]U:U<KX629BJ'@>5G@+[8XP.
M>:^V/@%X@TG7];TJ2QT]%5KJ)7G\L98Y^;+8]CSFNG"T'6G&3^SRZ]&XM/TZ
M/;7RT)Q%=8?#3PUTW4NUHDTI)6VZ[+T\CL?A_P"$+?2=&O;*/2EMUCU[6&\M
M8^,M<\MTZG S]**^G8;"T22^"PH,ZC?,<#'+7#DT5] Z]W?DAK9[+KR^?]:^
M=OEH822A%7>BMO+Y=3LYGB2VE>?'D)!(TV[IY2QDR9]M@.?:OY./^"LW[='A
MSP/\2;7X:?!'X-VGCGQK>W*VTVH6>G)=7$=R7"[MT:.XP^3UR#BOZO-4MI+W
M2-1LXR1+=Z;>6R$<$23VLD2D'L0S@U_%9^UAXMG_ ."?7[;EA\4/BOX-O?&'
MA2^UQ+TF6P:\MXX3<"4\M&ZA=I['&.]><>M!7EMS=;=]CR3X=_\ !3']O[]D
M?6]!UKQA\)M8L/ VMZC!:W<=UI4YM(;:1XF9666+R]J(ZG##' P*_LI_95_:
M'T3]I+X1^&?B!I\D,=_JNG0W&I6,> ;69T0L"H)V\OC'&,5_+'_P4)_X+:?L
MM_M,?!W2/A3\+/AOJ-]XKUS58DA>XTZWEFTYI8HH56V^SV4+1*78^83NW>5'
MC;L.[]K/^"._PJ\8>!/@#INN>)DNX(?$6GPSV5I=!E,"N8I H1@-N$XZ#_$"
M2MTL[O3TM_P3]A@,#%+1100?-?CC4)SXI:U5#M#'GMV(_#\J^?\ XZB[?P??
MBVG:.Y\EPBJ><[#V'//3^>._T9\1;5UU*XN+7:+D(Q7^]D+Q_+UKX]\41^(]
M4M]3>^#M#"LQ .<, K>W/0?AQ50;]A44GUTN[]E^FII37[VFM5=J^FK>FR>Z
M9_,;^VGKFKPK=V&H7<C2&XD58F=LXW, 0"<\_I7YNO%)_9 5/G\U?FQVSR>G
MKZU]O?M^:A>M\3;NR9'CA6YE&,';P6!XZ?Y/2OBJT=HK1 2"@'(_#/>OS+-%
M_M<Y3?,^?W+ZI)M+3JK/Y'ZUE*4<)&VBY5?ST6]M/T/L[]EO4]!TO3[B'5TC
M?]VW$F,J<9S\QX]?Y5[KK.L>%-8T+Q)!83PR2%)0D0=<ID-@ #G@X'3^5?G9
M\-==F;7+BQCF:&WE0QAB=J@D'^8/3Z5UU]X7\;Z')JFLZ5J)GT^1G=XEEW94
MY;H#^'/>KIUY)*"NDKK79Z:WV6OI;<Y:U!RKPG=VT:W6[B]]/N_,\@U*W.GZ
MW?-&A,AN9-H R,%SR./3C\.W..=UO4]0$;^7&XDZ ;3@\G'YX_R*];\/:YH4
ML_VG7K*5)C+L=Y$(5FW?-R1SGZ]_J*]EU'POX,U&P@U&W@6-6 8D@!3G]._7
MZ\5Q2I1Y^;E2O\+MJEOU_2_W'HQQ"C&SU:23:NT[6U=NOG\NZ/C/1HY[V!Q>
MJS3,-JQD-RQ],]#T_I7M7P@N+KP1JPO;R5K&U=]PR=H93@]" #GO7MW_  @G
M@NP\/MX@>2WW(ORQJ5R6 ],^HKYS\7:C_:D_V>(^5; XA*<?+S@YX_\ U>U<
M\XO#UJ<Z#?M-')IN]]-6E?;^EH=%*7U^A.G524$W%:=/=^7SZ:Z,^H/$'[0U
MG%J%K!:$7 ++&\@P<#/)R,^YZ\5ZCIGQ#T>Y73KB+54$TP1I(?,4$$]B,_E7
MYKP:>1.+>.1FFS]\Y)'_ -<#/3Z<BI;V36M'9;B"ZF\V(Y5?,(''/ SZ'_ZU
M?2X?BW'X2,(8B$7"*44Y*[:NO6^_R:^[Q\1PMAZ\>;#S?.[W5[).ZNUJ?KFO
MV77'22WF667:IV!@3VYP._7OT ]*Q=9TE7NX(M0PJ*P&UO0#CK]/_P!=?(WP
M)^+\EQ=II]_<;=0^6,-*^ >PSD^_;-?1WBC4-0NI%9[A6EFQY)1AP2!CIGU_
M.OIL)C</CE&=%I5:OOSCLE)I;+UVV_4^9Q.!Q6"E*GB/X<':,K:\J2WTUONW
MOI\S6FU V.H)86\FVT(48!^7YOIQW'^.*QO%'AL:HJS^86MN/-7.1CJ>GMSZ
M?KC,\.:?J%SJ)M]0?]XWW"Q^A&#UXX&?\*ZK4;AO#MK>#4\R6I!P!SQCCCKU
M_I7UF'PE"G@^?$KXE>2MS+I?=?+^M?GZN)JPQ,7A;7=M;]=.O=]=?U.2BTL:
M79%](<B(+\Z)TSWZ?Y[$=ZY2ZU=R6C8%9RQPQ'(/3/MSU/X#->N>%+_1M:TV
M064+ ,V&WKTR?Y8_GWKGO&7A"&":VEL\%I2"X7'!)SR/7 ]L^_?F6'P[H3>&
MG/>ZBV[>2\EZ>6AO4Q$G7IO%)13BKN/?1N]M-;==]/GL>$8=>FT\R":29-O
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M9U=4J=2WNZ+W7%M6ZVMI]R=SYKB*WL>EW%-[/>V]VM=O/1^9Z18Z'=32?VM
M3^ZR !GHO?\ SVYJ'6FM+X>5J;AD7B1&QT  P<]\9_K3_#_BAXF?3%()<E0.
M,[3TX_'T_'M5?6]"FNDF=MRM-N*[<_Q>WX\_3BOVNA6AB\#&=&"FZ4%&2E;H
MNJ>M_+35Z[GY16HRPM>,4]:SYDKZI/ET7_ ]6S4\+W.B*SZ9H<"/*000@!P>
MG/Z<X^O2KMUH.HF2>6XW%E)*H3G9^>?8UQ?A#3Y/!,\NJLLDTTF=H8$@$_Y'
M_P!>ND@\5ZG=RW=Q=1E1<$F($'CGC _G6N#P\9T9:04I-MZ+2^FEK:+;_ABW
M4<9.,M7=1=]7MHNMET?G]YD_;KG1V>YGMS*H^7E<CCT./IGI7%W^N1:IJL$:
MVX@$K8)"XZG'8#GG^O6NHNKZ[O2UK(%)+<CC[IZ9!YZ=J'TS2Y'AE7:LT&-^
M  <@Y/<?U_0UV8;"T*+YW-RM[S=[I/3[NNMKVW.:O54$W;5[*VGEZ_UYG+W5
MF+#685=?.@DP2#R.<$_S_P ]^WG\(6>L1)+ JXXR@& .,D?R_#TS6/=P[KV&
MZ9&>U!"Y STP>O3/.1U_+KZ=:1&+19+VPSN5,@$=2$]/RP16D,PPU:K*FI7:
M:B]=]K?\/;[]294I3I0DE:3U?2^VGE_PQ\[^*O!$C2?9T@\J%/F9\<$#KSW[
M_3Z5U7@:ZT>VT^XT#R%DD=&1WZXX*GG]3SV[5IZGXPBDLY+6[@(NGD:/(7YN
M<CK_ %]:MZ%X5M;:S;5+<D37 +<^IR>!^'^>*Y\=A<.XWOK)WNN_F^[MIK8V
MH/2.\6G9WNG=6]-&]OU,;5_!&GV&ERSVT:B21BY<#WSU_P#U=ZYG2)YXK66W
M$Q<X(V9SD?3VY/\ ^JO4DNXIX)K*[D /S*H<C/IQGC//;Z>]>$^(&N_#NN1-
M;[I;:1QD)EA@D^F!V_\ U]_G,VPBH2H8BF[)03?1/17NO-=3TL#B'4C4PTDG
MS/1O5K;2_P#E_E?I(82D;2.Y60L<1?\ UASWZ\=\UT5CI%Y<6S7:9Q&"2O/\
M( [GH<$?J>*S+:W%[-!J,BF*':K,K @9 'K_ /6ZXYQ7H-AJEN=/NK.U9%E=
M2L98CKC^>313FJ^&E["+<TO>T=KZ)].MG_6V<X_5ZZO)M1WNVVDFM%\];?D?
M._B#2=0U[4#''$T7EO@R<@\>X[9'X_ROKX:GL;55=S-,@X)!)4],CT_$C\>W
MKVCZ5.5G6Y$9F=B58;<XS[>WOT^M32^'9_WV2NX@A<GOCU/Y?SK##Y3"K/ZQ
M*<TXO5<S5I+ET2OM^3['5+,ZB]WV<.7X4^6[Z;_JWU?DB/P!H+3V-S<2,9;K
MRG\N/J<X.%'?M]?;-?(WBH_%#2OBC MEH5U!I3W0$ERL;A"ADQG.,8QUYQQ[
M9'U=X>FUO0=9&,R0EQA5Y7&3@8Z=_P#ZU>M>(O$4EWIVRYTRT%RZ8AE,2>8#
MM!!W8SGO_*N''X3$5:T5A6VTUJKINUNWS^[1FF K*%2\K.,FVKJZU2V3TMIM
M;\3B8? =KK%O9:I=0C[8;:-I93C<&*C(SG/!/?\ *N#U:TTKPEK,%XCK&Z2
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MR],\U[QX4O$M+'R+:7=Y:#S5!SQCO^OTKS;4?AS965C-K,$P_M) =B;ADXW
M8'7.<?\ ZS70? ^VN;[4+RRU%)"]R6CC+ X!.0#D@C]/;J>>^%"K1I2J4(*2
MF^:/,M$F];>3Z?@<U6M1K48P<I<\8J,NBNNG373;[S3U:_ADF,D3A6# L <'
M<&&?U_#N1VJKJ6O:M<BRB%U)]GA890,V" 1@8[<"NM\7^ ;C1]2VG<5E;> /
M<DC\O;\?;+:/2K"V\N\0B7 "%E[GCT/^>O)KMI\[A&KS.+C92ALF_=V2_P"&
MO:QYCC&]UHD[=M-[WW\K]78PM:N+.[AB>+ N4C 9>,LV/\_CT]!UWPD\9W.@
M>(;+;:Y@$RFX.#M*Y ;=D'C&?;\*R;.QT9HFO)9%W\E58CIC@8IECJ%M9:I!
M;6JQ![QU12< Y+#I^>!TZ=ZTJ2K2P[M9+=/K;1N[[Z::?>4U1<?>;=_7?3>_
M_ V1]^?%#XDZ(WA*._T6PCAO$M<O-&JJWF;>3E1G.<\^_&17YPM\2?$OC2^O
M=-O+J:Z3>XBB=F8#D@+@G'8#T/>OJB]T+5&T)+.<EH[F -@_W64$X_0>YZ=Z
M\-TKP59Z9K>^QDACOFER%D(7+$]LD$__ %^G%>;[+#TDL3)MRVDG_,[?/?2W
MIU-J,K/V*;=U=.^RTLK_ "ZVV=NQR_ABV33;^6VU,?99I%8H&&W)Y _'KQ73
M>#_ MUXHU[47U')TN-G*R2?=VY/<\8]^M=D_A>VEUV&3Q&RQR*H*;. P'TX.
M?\FK.N7&K2V>H:/X*VI*R% ZG#9^O_ZC].M=5?$X?!X55:T/=G;EM'5WY4M+
M?Y]M1QIXJKB8JC)MII.[]+V?_ ZI+<W+CP1<V.EO;^&K(W%MO\N62(94#.TY
M*\=R.<<<"I/^%56FD>&+W5Y8Q_:$L+.W3<C%2?J,'MQZ5Z=\%U\3^&_A_J5O
MXDDMY;^4.RO.REA_$<;NOM]>XZ^(^-_'VLYN[6%BUN-RW&P[H]O(./?K_DC/
M,Y*IA?K4-(JSBMKK1W=M.OGH.,&L5]7J)MVO+JT]+Z^7J?*CWFLZ'J]Q>)?R
MQ(ER=A#$;?F^4#GMGL>W:OT9_97@^)GCS7]%NA?W,NF6LT3$[W*LBL.,=.G_
M -;W^,=5TS0M:\.27<3IYX<-(%(W>9G@8SUR3^6:_1+]A;QXG@UK"QU2*-+6
M:14A:4 $Y( P3@=^*Y\)/ZS735UY)OE=FNGW]_GH7C(1IT'&UM;7^[1=[Z?U
M8_=O0HXX=&TV"XB)FAMHUD.!DL%4'.?<5UEN-R9'RIV';C\O_K5R^CZM8:M8
MVMQ;X*RQJPP01@@'^7OBNF,ZPQ ?PD#^1'Y_Y^G94NIM;V=O^&W_ *ZGB1M;
MKMI_P?\ @%L?=(#'DY_R,^U!)  Y;K_GO4-O(KJ=H(Y_3_\ 635BH&4I%)(R
MO;T]S55H"<GD^O'MZ8_K6L5!ZC^=4PP\PKC@GG^OZF@".!%4[R.![>_O].G%
M5M;07&E7L2'RR\3 2 8*_*><]N>]:ER@$.(^.Y_7V]ZY.]U6S-K/:-<PK(X9
M77> P['C/]":3V=]+Z?U<:;336Z:/REUCX)>&=8^.@U+4O$R#45N&EBB:7#!
MMS%5&6SUXP,?GT^IO"6AW\WBX:1]F:XM;%D6*YP6WA#Q@XQR.^?RHU7X'^%;
MKQ@?&O\ :,BW4<GF!5E(7=GIC..N?T.#7HVD_$'0?A]JUNNJI'*+V18[>3"E
MB<!0<^Y(_P#U5PTZ%"C)SYKROJO-M/Y_J>G4Q->O"G#ENDHQVV6FJ5^GS_!F
MEX\\?6%O'#X(E9;>]D01QKP&)Z#CK^'TQ7A-GHGBO0];M[BYU"4::9PZJ68(
M%)!QR?0_X5XG\?O%\VB?&W0_&.I"9?#<LT,@"9$95V4X/\(&#^G''3ZUU#4Q
M\1] TK5O"T)&GO'"&D"]MBY.X?B?;IZXPDO;NU[=?==M%^&NM]>_SK^"U)[V
M2MNM;)O7^OD==;:5J&O:O8W=G?L8A&BR -QD@>AZ8-?'?[9$WQ*^#TEAJOA<
M76K)JIC$WE;Y!;*Y'S';G&,Y]OQY^F=!\80^'M9M?#J+*]ZX56?D@-TSZ=17
MI=YI?_"7BZT_Q);07D,D>(5N$679D<;0V<$9'3'-4W*MAW3YK<CTCL^F^U[_
M )]B:-7V6(BY)2YM;[[I::Z_(^9OV<8KGQ'X1@UWQ#>F\U6:*.=K25BS1.?F
M*;&.1SQC%>]?$'QJ_A'PXFJ7&GY%@GFQQF/.W:N1CCWKQ71/A[XE\!_$:*>S
MF^S>%WG#21NVR$(6W$ '"X 'M7T9\5'\-^(]!.GB>TN?M,"P[8&C<AB@4Y S
MCDD=/ZYTBVL-R-M27X:)65]>]C.KKB5+EMJI/2VEXO73M_P#Y@\"?%GP)\==
M=;_A*8K=&L"8T@E51EE^4<,..GZ"J/Q5\[1KN2Q\'Q?9+5AMMY(!M&3D*1L'
MT_R:L^"_V?O#F@7=UJL,DD5U)ON46,%1QE^0OMV^IZ'F?P?X@TSQ/XUNO#UZ
MT21Z-*?,,Y W+&2"/FYZ=N?Z#GCRK#NERI2;34DM5;I??O:WY'1-T9UUB,/*
M348KFC)OE;T35G^%UUN<1X)^"NM^-XGE\37TDFH2 O;^:YR..,;B!V]?IWI;
MOR_@/XGTVUU?6/+2[N41$=^/F?  ZCN,=/;BO4?B[\0X/"%K%K?A7&RRD2"7
MR#\AP0K$E3C&.O\ ]>K<WPX\(?'SP=H7C7Q+<[-1A,4J*KY;<F&QCKU'YT-7
ML^J25UW5M4]4KVOI\B'B92O'$)PBE=1CIVTT5OEYGMWBCQ_;7'A/3IM+<7\U
MS!%*(U^8E"JL3QZK_CVKR'Q/\1]&U;P_#9VLZ+XAL1N.GC_6;TZKMX.<C'3^
M=;%SK?@GX9V=I+?*\]M9V_V6.-QNR-H52 ?3UX]J\XT#P?X9U[Q>OQ#TYV:V
MOI@_V,'*+N8'!CYP/P[9JN9MZMO57N].G_ )PRC?FMH^:SMUZ7^1T^G_ !+U
MKQ/X+N?#VLZ>]K(@*0H\90R <*1QDY_SUKQ#QIJ_B;P_IFGVVFVLEC"LN9[A
M0RC;GDG&.V3_ #KZ]\77WA#1C;ZG?VT5K!;P;CA B,5 ^]P.> >:^%?'7Q\T
MCQ-XK'A^VM =%,WDR3J@V*F=I.X9 P/?UZ"N>N]5[SLK/E3>BTNM_/??IH;8
M)7D[Q4F^9NZ_)^EEIY/8]:^'&KC4=>LKVYU7S;:.WS<R%LA7V_-DDXZ^O/?M
MSXCXQ\6:OI/Q<O1X0TM]4^VRF);F)#)L9F^]N4'V.<^E>\:3X0\.ZIIEK9>"
M;Z,SWJ)]IV2@NC-]X<$XZGOZ5Z+?Z)X3^ NBV>OZ[';:AJMQA\RJDD@+#CEA
MNR<GC^76M$DXK2Z:2\GHK^7X:$-\DM+]5#I9W6_K;OH>%^'_ !WXK\%^-M+;
MQ/;RSSWACDC$H8F+=SM&[TS_ )[]M^T5\:/%%V-%GTJTD6.W:!I=F1\J\\XY
M((]><8KQ7XD?$B'6/%%GX\NE@@T.T02B+"AL*,@ =!T SZU\D>,/C1\1_BGX
MR33? >GROH9D6$R>62NT$*2IQZ>G_P!:LZ&)?/\ 5</>3<E%[NUW%?E\M?4V
M5!ZXC$>ZG'35VLDK>5V_Q:LN_P!$^.OC/XK^)FHZ#X6T^VE8@6\<\:*V2WRJ
MV<#J/K[GUK]2/@3X7U#P]X.LH=1#1RF*-S$XYR0#T/.>?\\U\]?LP_!.QM;.
MT\2>*+.-M<$<<A$L8XDPIXW+QS^(_&OO@[2$5(UB50JA4&!QP.!QZ<>M>XL!
M[#$4VVG*2CZW<4_S_4\6>.]K1:CI%2:LK][6U]+O3Y.Y( &Y.?;Z>O\ DUJ:
M. -2M.!_K#_Z WY_Y-9V,8'L,?2M/1_^0E:_[Y_]!:MU%IMMIG.F_=7FGI;^
MGH=!'_K+O_K]N_\ T<U%$?\ K+O_ *_;O_T<U%9O?Y+\D:K9>B_(\%_:B_97
M^''[5?@F'P7\1=+MM2T^$RF-;B,2 "95##Y@<8*Y_&OS+M/^""W['UFR/%X/
MTP,A)7]RI49]ME?N9<3>1:S3XSY,$DN/7RXV?'Z5^,WQY_X+/_ ;]FCXC-X!
M^)VGZJDAN_LRW-K$X )?8"'\ITZ^JXQ^.$6N9[7_ ".5E_X(1?LB3ZA9W\OA
M#33-9S)-$RPJN&0[@0 /7_\ 77ZN? WX%>#_ (#>%+7PEX-LX[+3;6%($BB7
M"[4  _D/RKY]^!O_  45_9N^/4=J_A3Q1%9F[6,Q)J<T4!S( 54[MG///'X5
M]S6E[9W\"7-E=6]W;RH'CFMY4FC92,A@\;,#D$>XZ'F@3;ZW^9:SV[^E%- !
M.X9_SQ3J!'@_C<J=88'KNQV'?D_ES7C?CS6?[)TV2,Q>;&\;!EQZ@?7/WL_A
MWKV/QIY1UEPQ_>9/Y^WZ>HKQ3XBP@Z3,Y3>51B,<\[>.WM_.@#\P?VBOA_I?
MQ/\ #.LPW5HD4$%M/*N5 !8*Q[]\_H*_EY^(FAZOX?\ &NN:':;Q86=S*B(,
MA2JNR@ _E]!Q[U_6'XW\+^./$FFZG!HD++;>7,LNT8)CPV>GMG_ZU?SP_M6?
M##Q1X=\2W]_I5D\LD4LC7^U-S;@Y+9P,^ISSQ7R>>T'53K1^PG;R2Y;Z?\-Z
MOK]SP]B?9^SH-J\TE>]][7NG_7?N?)-MJ,$%FUG- $<J=Q('IWR.Y]?PQ2>$
MO&GB_P *ZL#X0U:73W>5/]4Q0\L"1P1T_P \57TETUIIX;J![:ZB4JX==GS
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MMG;KIU\Q<UIZ/_R$K7_?/_H)K,K3T?\ Y"5K_OG_ -!-4U9V&MUZK\SH(_\
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M\).4:O\ $E%JVJTL_=6C^7X>=C^7_P"/WPR\.Z*+S5/#L<=H[>9E8PJ<Y.>
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M&TL/B1XB\&>(?%MK)$ME)?W%F5N;]"H!,S),XWN,_*AW8 )4$L/ZCOAEX&\
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M_P#U9].M72I>PK277$)RNEJ[I+7T];[$5%.K1YU)\M"2CRWZW6J^[1#C\?\
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M5!SA+W'*-[-\NBEMOY?@?FMHUY-X2^*]H(+LRPS3H#:!^H+Y^[GT]!V]<5]
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MBNS#83#8>3D]V[I-7W>G]>6AY6(Q>(K*,4Y2Y=----.FU]M?._<HVEDT9$;
M").(@!C:HX  QZ=NW-;(0*,8S[X_S_GF@* <C/M^-.KO4?FNB>MNUOE^!QMW
MM=>OF& .@_3\OS[_ -:***:5O^&]/\B0HHHI@%:>C_\ (2M?]\_^@FLRM/1_
M^0E:_P"^?_033?DK?B-;KU7YG01_ZR[_ .OV[_\ 1S441_ZR[_Z_;O\ ]'-1
M7.]_DOR1LMEZ+\CH)8DG@D@E7=%-$\4BGHT<B%'4_5217\O/_!57_@E]\>/%
M?Q M/CG^RUK5QX?U33IQ?7D5@[Q2R2!S(=WDG=DD'Z^XK^@/]H3]J'X1_LP^
M'(/%/Q;U[^P=(G5C'<;%?<(^&X9TZ&OB.+_@M'^P+?6X8_%!)8)EY5[2"1'4
M]F1KC!'L1BINENT7'F3NE>V^GI_P#^5KQ?\ L]_\%)_CE=>'/"'QE^(NK:/X
M,T[5H!?SZE=W,=M,J-&DX_?$*=T:CVY[\U_9+^P+\%O!_P %/@7X8\.>'M2M
M-7U*/3K=-7O[:1)/.F6--Y)0G.Z3)SGT^E?AY_P5+_X*C_L=^/?@39^'/@]X
MOC/C*]UC-M<Z596^G7$:,J+@FS9FEWM@Y8@KCC.XX_1+_@C7X@UKQ)\ [+4]
M6U2^U0SV,+1S7KR.Y#-&0<N2>F/S%.]]@DV[-^:MZ6O^)^RM%%%!)X9XQR-9
M;///'UR?\#7*R;N,' /7_P#5T[UT'Q#:X34";8;G)/'<8S_3_/:N1M'N'C_?
MJ0P'<'Z=:QDVF[?JOZ_4=]M#+U\7$L$:69(EW#<5..GT[_4'_'Y/_:,^"&D^
M-?"<^NZI$LFH6$1DBD*\JR#<#DGID?AQ7V.T?SAB."W?'3G\:\Z^+*RS>#]1
MMHSF.2&0-MYQE2.W_P!;G\Z44I5Z:E'FNEOKVWOM?N;Q<DHJ$G%=D[=K?EN?
MG=\$?$>FQ:7?>$;J]A$MF9(PKL#A4R ,$YP,?E]*_+3]NKXG:;X3\6!K98F:
MUEP7 4C(;D^G?_ZW(Q];Z)X$\3V7Q UG4K2>=+$R3.3E@,9)_P ?\>@K\NOV
MP=+EUSQO<0:E+NM4G/G.QS@!N<G\#G_]9KP>(L7/+L-&I*FG'V]D^7:*MLT?
M4</X2.*QE2#G+^#MS/3;\=;_ .9\]>(?'<OQ.B++;&%8TXG";5. .A'&>3QZ
M^A%?/&O7VHZ/<O!)&X6,XC<CA^O0]/PY[5Z#J_BJQ\.K'H&DPJ;95&ZX0#)(
M'0D=\COZ?2N*US59->6-)+<*4QM8C[_'<\'\37QM2K*K-U5\-5^T27:5MEY'
MW-*"A3A#9TDH[?$EK>_7K;\V<HOB4Z@?LDD1WL"H./7@?7O^=65T9+:-[Z[.
MY1DJAX[9Q_D?SKI=&\/VLK&1H<3H,CY<Y(QCGOWQC\L],/5VNGNVMI RPH0.
MG&!@?3\__K5PU5:O#??>VVVWIII<[$KI-/2RNK:/75_/\=C,T?Q0='U:"XTV
M,QLTZ1G'?+#_ !/3IZ@9K],OAMK-F- MI]4M")KV)3YCCC+KURWK_+UZU^9$
M5K:6EW#=7"@1PL)%Z %A\P'XXKUR?X\ZS'86^F6MKLM[5 D4B#!*K\H.?H.*
M]' YABLOJN:<N5RNK.VEHV;WMWMO]YP9A@,/BZ?OJ[:2Z-KX;6\O);:=3[DU
MI?#ZM(T]]% ARX!<#Z#&0 <]*^'OCEJQAU.VN-%8W$-LZL6B/! ;OMSZ?_JK
MS3Q/\0]?UN$N;R>$C+85V''IUP?7_'&:W/A5,/%=V-,U5O/5R%9ICN;KQC=D
M^O;OTK3%YK7Q<U*2O+>+6ZO;YKR.;!950PMDK\MDVME=6W2V_P [-G80?M!:
MS:^%5TVRWB?RA$R#.\\;<XQGGOC'Y=<+PE^T)XF\)2S/<2OMNR?,5N3ACSP1
MVR.V*ZKQ]\*8_"/_ !-[2%'M)%W[<#'KT[<C/'I7SWJ%M:7\RR3JL:9/&.F,
M'V'Z^]<;G4=6G+FES-)O7:UOO\^OY'L1HX7V4^90O>ST3[7T[WV_J_V'X,^-
M^F_%#5H?#$\(%P\J_/@??)'//>OI?Q-\.[U]*M=+ED)L9D"G.2N&4'GG],_I
M7Y>?"1?L'Q(L)=+4L?M4>XH-V 6'7'M_B<U^H_QP^*^G^#O!.FO-*$OG@3.&
M =6*+^/IZ?6O0C6]I2G5DN;V?NZZW=DKZ_/^DCQ*E%4:\(4)<SJ.^MO=3MI]
MVWGJ?$WQ ^ FD>']3>YL]2@227+-%N4$N23Q@@YR??-<-X,^&WB"U\46FHVM
MM<310S;E= Q5L$<]^H_K]:\S\3^/M?\ %&LMJD6H7+6\<N]8P[D8!W#C)&#C
MK^@KU?PM^T)XC\/6L2P:4MRMDHW.R99BH[^_RGW[BO,HU<-3Q$92?QV;CNHN
MZM;_ (?2_P EZLZ>(JX6=.,=8V37EI?MKMHC[I\(7L$7B&V_X2O39(K01)&K
M2)M7=MQGD>I'/^1ZMJ-O"E\K:#.IM[AAY,2$9PV,  #TXQS7Y[R_M0S>-(X[
M2\L4L)8B%:1!M(P3G)_#K^GK]-_"+Q;!XBO]-.GW@N&M60R)))GE3DC!/08Q
MC].M?48'.Z^#KJC&4O9U+."3]WE?X;GRV-R>=7#RKM:P6L6KZJW^3Z:^I[3?
M6%Y%LCOD=79>K9&05Z]_?KW[]:XW4="GFN(DAGV^9@<'[O;DCZY(]NM>P_$E
M-8FM[6_BMU2,1JI,8] .<CU^O/\ /P^^O;JPBAN968,?FR2<@]>W<'C'/UK]
M*HYC0QV$PF&KS:<JFKV;VT=M;-O;3\SX6="OAZC?LTN:2M9;K371::_I='=V
MWALVUN4DO$,HB)5L@G=@GN?4'\ZYO0=1>V\0+;:G=JT:2#RR6(Q\PQCI^>?_
M *_"+XBU:ZOS(L\GV<#G).,=^Y]3QGIDXJ_X=L+;Q#K6Z6Y9)$?J6QSG'4\9
M)Z@_UKKQE?$0H5%\%"C:$+:)QLK-VW?;H.EAJ?-:K.U2I[R=W=7L[7]?2Q[[
MXK^(FIF*/0;6Z LFCVY_V<8]CG'^<\5X+>,8-1CN(IAM5PT^#C>#U'N#G//3
M\C7T%9?LZ_$/Q;(MYH\'G:6D>?/ZG 4@<_\ U^XZ]:\)\?\ @#Q#X'U<:?JN
M59VVD9]/7_(/6O C6P3Y7*K)3DDWNM=/GZZG91HXI3<8Q;C"UFWNKI:>7_#G
MHVDZ-HOB",7D07SDBYQCYFV\_J<XXQU^O"2^$AJ>K7-G<?+&I*HQZ#!)]\?G
M7,2>(]6\)QPQV.Z2:7;N1<G"MUR!VY^I'TKI[C7+VYT?[9;@I?SH3)@X96*\
MX[C_ #UQQZCI5)81N"7))64GU32U?F_RU.52:Q:;;34]5=I7]W7\'?TO8K-\
M0[SX8W#Z%8S>>9D,8V'(&X8P,9_R>O:HO OC6_M=?N-:U&)UENGW0N1P"3D$
M$X]?RKS'3]"U.[U:35=:#2Q1MYN7R3A2<CG.,#\ZZU/$VEZ].VGZ;$JM8_*Y
M"]TP#G'/)']<\5QX#*849-2J/FJOG3>O+?HK^;M_P#MS#'U:\5RP25-13MMI
M;>W?\+>9[S:>-].\1^+;"/Q;(&L/M$81I&^4?.,9S[8'Z8!Q7ZIZ!I&E7&@>
M'IO"\T,E@J0LZP[6 4*#SMS]#GTK\(M<MI=5^RP6SR02I.F94R"-I'0CZ>N!
M7[G_ +"?AQ=3\)VMAJU^)RL2*//EY'RG@9/!'3/Y]ZRQ5*<,2E.4HPB]&G9M
M=&VOG?3[S&C5IO#MRA>3:O=:Z6[?TSQ']I+XH>'HQ9>$+*QB_M560/,J -N!
M&02!GKS7F-W-<^,-!T/PS]D:-7\M)I@N!AN"2V!T!]>,=1BOH_\ :[^'OPM\
M*7S:P-1MG\0([NL/F(7W E@ ,YZC'2OBVV^.6DZ9:1V)A5;OA(9%49!&0I&!
MZ]^I)]Z=6A2Q&'?+4DG'[=]6W:SU^2];_/.E.K3Q$6X)QELFM+:=]K=7;\3:
MUGX8:G\--3@O-)NS/#/&'DC1B=I;D[L$\CH>_H*Q=4LHM8TG4[O4I%>[,3F)
M'.6C;;QUY&">/?%>F^$O$#ZZLM_K4WG0>2S()6SM3!/ .>@_^O7SKXIUS^T-
M?U.S\./)+"KL)D0$JF&(. ./Q'I[UYKIU\/03;;C%KWGJ[75E?\ 7U\ST5-5
M:RIQ2B_M66FRTMMM;O?L<5X(U:X\/7]RSMN87!5&]%W8'T S]>GO7H_Q"UUM
M;&D/% U[&6C^TB,%L#Y<@[1Z?YQ7'PV>DQ6$K/)MOR3O1CA@Q]C@]?S%>Y_"
M#_A$;;2]3E\0-%-.L<A@67#;3AMN V<<C''X"O:HU*.(HTXMI-)<^UE9+=:=
MOS^7F5:%JTU!RCRR:OMVOKU2_K<@FO/"[>$186EJMO=&T*E<8;S2GY]?;\*\
M+^%_B+4O!.OZK=7[.UEOE:)7)( R<8'\OTKI]0OX[[Q+-%9@K9?:65=O"[-V
M!TZ#'Z"K_CW3-(TO1UE1HQ/<1_-@C))7T_\ K8_$5=;VNE6A%RY%R[W2VU5_
M+\#:@J,5*C*5Y2U[KI^/6Q/I'BA[SQNGC:VG$20RYV A<X.X'CH/Y_6OM;PW
M8ZG\9;2XUJ.[:>;2(_-C@#ERYC&[ 4?3L.?2OR53Q%-I<<T*.P1@2H7./;'^
M/KUKV7]GW]ISQ!\-_%,5I(LDFF74P616W;"CM@YS\N,?_JKS\704\-[1JTI[
MOS;6WDGZ].PZ*BI\E[V=E+[OZMMKV/UY^$$?BB]O2EW826HLY!;?O(B R @$
MX(QC&/PKW;XO_LR^&?%.AQ>-6$%GJVF1+<F=56([T 8DD8ZD'TZYKRKX/?$K
MQ!X]\7Z;-8Z7;6_AVX6*2>= J@EMN22,<_\ UJ]F_:^\;W7@?X5^(4@O#")]
M/?[.T<A&7,1 Q@_U^E<M.E2]BFX0;TO)I7Z=?/\ K<J<ZBKP@N:,4DE%.R>S
MNU:]^GSMYEC]F[0XKB7^UIKJ/4)-+/D1NI#E0GR\G)Y'3GJ.:^]1(+D"8C&X
M <_IZ=N?PS7X_P#_  2]^(8\2:+KVG:W>M-?37<C0K*^YB#)QC<<D]*_8>>$
MV[^7C  7'Y5U1MRQLE:UK))==?+N_,\[%M^W3VL]EZ1?XV^8NU1V';MGKUY]
MJ<FU23MY..@]*K L'&!G\#[U8'051S]6^^K]2-F.\?-W'&>?\_TK7M]A0>9C
MIWY/;W'O6$827#\\=N.WXU8F25S$(L\XSCTXS_/_ #B@#= 4,-N,8SQ]#1(,
M9;]/P_\ K5'$FR)=Q.[&<>_ITS4VP8)Y)[?D?3Z4"NOR_'8I4&5,;6'; SW[
M<4I&,^QQ56;'# \@\^G^>*"NFVM]_P#@!Y:307: 8;[/+Y9]'(.W'X_2ORN\
M3?%KQU\'/C'+::Y+/J&@Z[>M#:PG<Z1+))M7CD<*>P_I7ZHSD06\\XEC&V)V
M/S@<*/K_ )]*^%]9\->&_BCXWG34&M6NM)N&DB,[H"#&3MVEO<=JQK?#V;\M
M]5Z'9AVG?R5OTM_PW<Y+QW\-O@M\4M>TA?$VFPW&LZDD5Y$,)O61P''!YX/'
M;GJ.X]L\.(/A-:VOAG3+62UT:((L2L" $( 'TX_SS7R%\3_!7Q*T'X@6'B;P
MO&]U:Z4%6*.([TVQYP %Z<?X5T7AOXT^-==N+^/XEZ3)IUK9QXMYS&REO+7
MP<#T_GFO,52$6[)7ZM*VEEK?KMKYHZY1J-<KG*4$K*+E=7T:5M_NZ;'T[J46
MJW^NVVKZ7-MA+*SXYQDC//XY].E9_P <O VB?$'P<^EZU,DNH7$'E0?,-RN5
M('?/!/\ G KSWPO\:?#%]I-WIVF7!?4UD,<(8G. <# )^G2KWB76;:72K6[>
M]8ZDI#>2'R 3TXS[CC]:?M:,FHN;O+3E?JK/5ZZ]^IFJ=6&L:79WLOEY?C\C
MDO@E^S'JG@_PGJ6G76I-#973/-;M)*1M4Y( 8GMQ].W)KZ&^'NG:CX?M;_2[
MJ[6XT^U1OWSD.JJH]26QT'M7(>'=3\9>)]!-D)&@MT3Y)?,VG;T'.1Z9^E>*
M^.OB/XB\ ./"]UYS1:R?LYNTRVT2?+G>/3.>OOUKHBE14O=3YEI?T7W]_P 5
M?<;>(K62C%2B[.22OTO=].VI[[J7C&RT^QU%],N(M5D1I ]O!MD(ZC&U<D
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M\@HJ1MI&X'GCC_/U[5'6A 4444 %%%% !6GH_P#R$K7_ 'S_ .@FLRM/1_\
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M5711G<0P'( Z_7]:_GY_:GO]<B\:7C7TQ6"^G?8&..&<D<G!& 1^%?NU\:/
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M6J6ENOGOV6AIA^(:5?$1CAKR;:TN[=+W^_K_ ,$_G>BT6"*X,DL#VLDC$,C
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MBA1M&U%7@'VIYA1,8/7G_/7_ #FHF&"16CNK:O:_IY?@<[W=OZ\QN!TQP?\
M/]*E1% !Q_D'\ZCJ9/NC\?YFJBDXV:35[V:[6&I26JDU\QU(5!Y(_G2T5=EV
M7W$W>_40*!R!_.FE%)SCG.?K_GVI]%%DMDON ****8!1110 44A('4_SI0<]
M* "M/1_^0E:_[Y_]!-9E:>C_ /(2M?\ ?/\ Z":!K=>J_,Z"/_67?_7[=_\
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MGOTJO%]E\&13Z:R^=,0R._7KU/U^OKSQ7<76AZIX<TI;Y;]TB:,?(KGH1P"
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MK9/_ (8Y<'0KSCAL;B*LZ.*<W^YC*RELM4OR_P SYNT3]FGP5'9I#K%E'+M
MX:-3R,#OGG'OWZUZ5HGPI\#^&5\O2K&!5!R 8EP#^/']?>O4F.\8)R/_ *_^
M(_SQ5!H#N8#) .>G_P!>O&@URIPVMI;L_P#A_P CU'^\G)U/>E=/EEKJDK^O
MG_2*MKIMA8C;;6L"#/18U'7W _0?TK; C"K_ */&.A^X.OY5##%G&<YR3VZ?
MKUZ5?)&  ,8K92J-74GHWUMV)G;ELEI=:6=N_P _GZ]"N2A'$4:GU"C/\JC9
M0W!&:LD9&* ,# J+5-&N^J;O?;=_UT,[>7X?UV7W$'3@58PFT?+SWX[?XT45
M4(N+<GO?3;1:=?P#^OZ^04A /4?Y^M+16FFMTG?35?,!-H]!^5.V[0/3_'FG
M%\C&/U_^M3*25M$ 4444P"BBB@ HHHH **<PP<#TI!R0/4T -*@]1_.E QP*
MN;1MSSTS^GTJLS9XQT- #*T]'_Y"5K_OG_T$UF5IZ/\ \A*U_P!\_P#H)H&M
MUZK\SH(_]9=_]?MW_P"CFHHC_P!9=_\ 7[=_^CFHK![_ "7Y(V6R]%^1T@Z#
MZ#^5+2#H/H/Y4M(84444 %%%% '\H7_!5^QM=$^.5]KFKM%/93M*JP\,W)/;
M!Z#CCU]*_%G5+&[FDEO?#>F7GV2Z);S(4DV("<Y) XXZ_P!>_P"[/_!4GX;W
MOBWXTW$BRO-"LLA%N<E,Y/'. /Y'TYKR#X"?#KPS8^"-4L/%>B6J_N9!%=21
MH63Y2 58@].O8U\Y5^M3Q%6,E*%-3DHM7UCI^/Y/T/J\//#PPM%QESU'!7B]
MD]-&M5;\>FQ^9'PI\3_$KPOJT5QH][?6PAD60AI9%7@_=QG';^8Z\U^]?[*'
M[1UYXN\.7.A_$'54@:.(Q@7,H5I2%* @L1NYQ_,\U^=WBWP;X0TJ0IH+Q'==
ML2R;>A;[O';M]/PQY]\2M.\0>';;2?$GAZ^FTZSLA&]WY#,HD"D,VX*0.0.<
M_G77A*OL:4^>3E9^ZGJXK2_]+=&>(H0KI<L(Q:LWRZ;V6_6_K^>O[L^ +6&T
M\=G4[2_1=&EN-R$R#:=S<$'..<_RKZK^+7@^W\9_#^_6PC2XOWMV-M,B!F&(
MSC# 9Z@'BOQ_^&'Q.L_%_P '+74M#UQY/$&G0J\L*2GS6DB0$Y7.>QR*^R_V
M4_VD?$/BV1O"GB"T=S9AH-\JG]YM!7/S#G/J3]>O/?&;E&,ELU?3TZ?CY_>>
M3B(<JO%65.R;VYK-=/)[^O8^)/&_PXU3Q1X;U[X?Z];--<VZ7+Q&1"SX4/M
MW#(QQQZ=*_G8^,?AN[\%>/=2\.W,+V\-K<R1QAP5!4.5&T$=,=.]?UW?&"1/
M#OC^ZU?[&%@O$82?* ,.S D\8[_X\5^+7[;'P)\-^,I;OQMHKI%>IOGF2-1D
ML,L>GO\ D.>.*^?SO NIAY8BE>I)-MZ;67;UO_PQ]+PWF3CB8X:JW"+2::>D
MKVLK?T]C\G],3P'I$<EWKD:2W,L+; <'YF&,XZ]^/?L:]X_9-_:'A^"OQ*M]
M7L76'1&ND=T! 789.1CZ?RX(YKY U_0I7N9H9I&:2WD,0C.>0O'/\_<^U<M)
M!<V&%BW!@>  >,8.?S(_+/45\-AZ]>CB(.-)0EHFXKTUOLNF^G4^[Q-"C*A6
MIU*CE"K)N*>NCMY[:_-:=3^T;X.?M</\6]8TR[TZ]1M)\F%'A5P3N(4'@'KD
MX[5^A]K<B]MXKE?NNJD \\,!]>#G^??K_$M^R7^TYKGPL\1Z9;74DALI;J&+
M87.T N!WXX'OV]J_K[^ /Q.TOXA>"-)U;[5");BWB;894!^:-3CDY_S^7W64
MYA[?GA/XH66K6]DWK_7H?FV?97'"RA.E%*+6ED[:M7VV_P""=YXZ\">'_&&D
M7)UR.$1Z?$]UO91_RS&_.21Z<_A7\UG_  4'_::U47MU\+_A[<+]ETUFM)5L
MWPY",8S_ *LY]\'_  Q^_O[6?Q5TCX6?"G6-6GU".VFNK"YB0K,H.7C8 >O_
M -;T-?Q;>.OB"_\ PLW7?&$LQU2'4+R>6-'8R;@\I( SNSU]#UP.*RSS'QI>
MSHQLIRBO>3U[NWK?3\#KX>P$ZU/V[DW&$K.+V5[?E;MH<CX?\+^(/$6L0_;)
MIFN7NEFFCF8M(<L"YPQR,^GIZ\5]Q^(1X6T;X;/I:11KJJVI5R5&_=Y9SUQW
M/MZU\D?"[Q7/K?Q-AUB_3[#ILLB1K#]Q#N.,X.!QWX/4U[)^T=;:MHK6=WHT
M;SVFH[3^[!9</_N\< _E^-?+T8Q>&Q$W=RYW:3>O3K]WS^X^O;<<30BI2Y>6
M*44[1Z:-?AM9>A\NVVLWUJ]W96^Y6>=PK*<$*3ZC_/UK[N_96_:OU[]GRTOC
M9W+&YNT?;O8Y!;.._K^5?G_'>R6-WFX@Q.P#,I7H2!GCUZ^]7--NX;ZYD,LG
MS$G"$XV]0 .WZ?6O(C+DDI0;@[MMQT;VLGZ?H>QB8QG",91C-<L?=:TW73IW
M_P"!<^KOVB_C]JOQQO'U#6YV:Z:5G3YLC#'(SZ>XYKY5OM3D2TAAGVF*(<8Z
MX&,9Z>N3S^%3/!))>B(\0DXW>V1SGV!R/KT[4SQ#8Z?;V147 :9UVA<YP<#'
MZ@#\CWHJ2J3M*I+VG5<VMD[6O?J]M%J*"5.*C"*I^ZKJ.BEMT^6O5K?0X;'V
MZ^+VYQ&.H]_U_P ]?;2\.SWEMXXT:*!WC_TB,$ D9_>#T/.?QZ=>U4-/M6LX
M_,+8);(&>J]>G/\ C7:>$[1=3\9:#<A=L=O/$TS#H0K D\?YS73@_=KPAM&7
M*W!72;;2N_RMVL1B[RPS;=Y)6CUMMLKZ=M.J^[](]1U?39O#VGV=] 3<_9HF
M$CCJVP$\_IT].M<4VHP-);*H&(2-AZ]#\O?VKK_$[6>J:=86VGQ*7CM(U,H'
M.X(,\@?0^HZ"N8\):5:7-R]MK,@M]A^1V.-W<<Y],_7VK]AR>A[/#J4K27*F
MET6BLOZ[]#\KS%_6,7[/91DE;M9I=-_3UZ'?6VAKJ]H+RY=<>7@<\\CI_GZX
MYXB\->$+S2I[O4['<+>(LSMSMQC/7I]#STQ6/?ZJUEJ7]BV$[20+_$IR"HXQ
MD'W/UQQ[^B^&?&%M!IE]HE^!']H1T\UNHRI&?7/(Y]>:QQE:M'#UJS<H8B+:
MHTXMKF2M;3>_X+[S;#TJ<:U.+BK-*_75V=^_]>1Y)\7?$D<_A.[=[B([$=",
MJ3D*<\_@<COVXK\NY;YFOKYY!F.5I-C <<EL<XX/I[GZU]B_'K1];LK"Z-C+
M++I<TCRF1=Q4 YZ\]NG]#7Q;#-$UM)&1F1=PW$8.0>??/X5^39C5K8G%OZW*
M4)2=]7UTT^Y>GJ?H^5QA3P_[A*[LVK>2O?MMY?>9%Q@9,:DDD\^Q/^>_Y<9P
M[HW,:[AG)SGD^V?S_#_#I()9#NA$6X$D!B,]^.?\]*I7]OF1(F&W>,?3IS]>
M>_'2O/J0C15_C3=^U[V=_->IZ=+FKRZ*<4M>FEOQV^X]_P#V<_$7A6+7(['Q
M L&^1E17F"D;FP <M_M5^P'P,^(]M\)?B#X?DLV1]-U6Y@\ORS\@#LF.G'3G
MTQGTK^>*:&ZTN_MY[.9H9(Y%DWHQ!^4YZ@C'\N!7UW\//C_J*?V6UUNNI]$,
M1C9B6(,;#G)Z'CC].E>WE6/^K3A*/NOW?A[::)_*_P">ESQ<YP+Q5.=-MW5U
MRZVDVNU]ULWZ[G]N_P 0?&5O??!Q/$=K;&[%QHA<1HN\[W@ST&>A/' ]Z_F'
M\76VL:_\2M?O=8@FMK.6ZF,$;AE"@R-MXX')_P X%?KW^QM^V[\)O%?PMAT7
MXF:G:V\RVJ6J6US(J_PJG20_I_3BOFS]MG3?AW:6K^+_ (9S6]S!< RN+8H0
M,_.3\OU_'@U^A4JN'KU:.*E4;M!<RWU5OO[]ON/S6%.M@Z=?#2INE&531Q5F
MUIZ7/!?#-A:Z?H$D5I:M/<F-L2!"W)''3W]Z\8UW3]1%[.U_(([=B2T;<!5/
M/([<'\![5T'P@^/6GKI=W87-JMQ=Q(R$NH)!4$=QVZ\>GY^+^./B&^O:UJ%M
M;,8S(S*(^0$Y(P.G(X^N>O:ML=F<8RPDJ-.-6]97E))OE3CO?5+IJ]#3"8.I
M9J4I0COII=:?.]_^&-K19H+#756QB9X2WS/&IVY)')(X_6NV\6R0X@O;S&Q-
MI (]/0?E^N:X7P9J4>F:>\=Q")KH@L)&QNSUX/MZUD>(?$>H>(;E;**'$$38
MD('  X_' _K7IU,3/VB=.E&2G%-T[>ZG:.RO_7HM.*:5.K/EOO;FOKTOKY]4
M=Q8Z%%XC9+^TF1 I"^5D9.1CI_DUIZYX-C\.61U&Y5O,D&Y&P0/KZ>OU]*\A
M&J:AX<N;.73YW93/&)(%)QPXSD?CW'XU]\0:+H/Q"^'MBUU<1QZJ;=-L1=0[
M/M].O7'^>:RE7W;Y8NUG%:+FLM5VW[V[7-?92GRR2?KU;NM=5MZ^9\47^EZ7
MJ&BM>W,Z?: _[N/</,/IQUST]/05-<ZCJ/AW0(+NTMI J(K(<'+8'&#WXY_^
MM7I>I_ NYLB]T;U_/CD,L=D"=LBJ<C !Z$#WS]>*VA$^HZ='I6IZ4(5T]0/F
MC \P(,?W<'./?/M6E#,Z?L9QG%3Y;I-KHK+\;?+[V76H22@_YDG=6NKVU?GU
MZO3Y'B>F^)O$WBO3$>_G-M:+*$\F5MK,,X  .,] .G^%?H+\+_@A#XV^#OB*
M[U#3W*PV$C0R^63N/EDY!P>O'3KSG-?*OA3X'>-/B?XMTVR\-Z?<0:5'>P&4
M11,$9 P+9V@#G_\ 7BOZ5O!_P9TGX>_LV3VES:1QZA:Z4INCL 9B(!NSD9/(
M/USU]>#V[K^_1I*-+F?/"*:4KOMWN^G8SKUJ5"$:=2I*<W%6D[WBM-F^]_+I
MYM_.G_!+OX3:7X8\!^(;A[,174-Y,L;O'A\*YQAL9XQ]./:OU/1)&?)S@< ]
ML#I_*OD;]C+4M*G\+:];:>JQ,EU.I1<+N.\CH/ZX_2OIB\\56&B7<=KJ<L4#
M3-MCWNJEBQP.I!).>PKJBDEI'E3LVEWM^9Y$FYMN5Y6V;U:U1U!!!QU/M5Q
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M5IMQI4TH-VV25G;5Z;Z?UTXWAJ<[2J3E*;M)W]ZSTV\EY?\ #HBNQ"[%51U
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M)'?KW_E]T_"3X@>%/#'BNVU&(P1_;Y581KM!&]AU _+TKY@TSPQXI\.ZC?\
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MDNI;J00B*4SNTA7Y"#D,3T';\>]<YXC\!-X"@D66 .<,C3<%D<Y&,XXY/O\
MSSQ7A343I1O)KF;;]J+>2Q)&W/I^)K]#P> G&C"_Q<JYEZI7TZ=CX"KB(5*L
MG)*I#F7*W;35?C\_EWT-#\(:3X<U26.%EDN+N;#*G(&]N<X],^W!K,^,W@RU
M\(?V;J>GQN;K4MK. IR"Y!Y_$GKV..M=3X/@A77'U6^N?/0,9$1VZ '<"/QX
M^I_"CXE^-;#6KE3=('@TPKY8(R $YX[<<?XU%7 3HK#XB#E.*JWE&3;LUR_.
MR\[$4L1[2KB(U4H0C2O%;=.B[ZO3_,\OTFUUD!)"'7?#N"D'."JGI^GZ9XS5
M'2=8N;+4[Z.ZB* EOF<8[GH3WKT+P]X@L-=07=K@)!A"@ Y"XR,8_P#K=<^^
M?XJ73;WF-$MR,&61<+G'7..YS@Y[?A7?7Q-:#5?#QYK6YHI.^G*G\]+_ ']3
MACA:$DFINT]Y-][?BM[^>IRIF9Y_MPC9K8/N)Y*CG(QZ\>WIT XZ2S\=^*!K
M&DIHCSBVBECWA&;9M! / .. ..O\Z]!^'WA.Q\4V3:6@5HMN#,/?CJ._'Y=.
M*]$\._![4+/5CI^EV#7@9\+(L9;&XCH0,\$\="?QYN.)H5XWKX>I"3WDKJ]]
M7_7ZF51^R?+0;J6?+)[I>?S_ *ZGTM8RV%]X/L_$%_)&=5C@0,A(^9@%ZCUZ
MC'Z8K>\#^ 9OB?JNF6]GI,R122JEU.L)".I< \[<$8]SV[9KO_A9^RGXY\6"
MRLKZ">VT]GBD8LKJNW<&([#&./PZ5^S7PP^#_A'X=^&=-TV#2X/[2MHXA)<A
M%WLX R<XSDGGGWK?#86G2HSE&-XRES1YM?=?2Z_'H<M;'OE2E\2M>W1Z+3HO
M^ 87P1^ WA#X;Z'8SP6%L=0-NCR-)$I;S-N3R1UR.OX^E>N?$:);OX=>)+7;
MA9;&5=BCC'EL/E XZ9K;+LNT(N$48 ]N1[9XI+RU75=/N--<C9<J8V!8="&&
M.>*N*4%:"Y5_=T1Y<Y>T:E+WMK<VMDO17V/BW]E335\(6'B2_N9?LMHDUS+F
M4[4/+MQG&>1@'U/-?#O[2'QT\=^./C5HN@^";J8:=I^H1)<O;R,(V5)E!SM)
MST].Y^M>Z_M/_$*7X7:3J/@_09OL]Q=B7<\+ $[NQQ^/]<U^<7P8\6ZE?^*K
MF1K9KO5//=DE*[G9]^>"1G(QG\1QFL83I/$*,Y[:\M]&_/\ X;MY(ZUAW-*K
M;W(Z66W3?^OU/Z4/A0)[OP3HMQ?R[[J+3(3.S$'#K$"Y8^N??-<_XN^+'AO2
M+74K4W4"W5M&_5@#N4'H?T_,U\H>'?CSJ/@OX=3)KRO:736S1PAN&P5P,=#Q
MT_#VK\_O%?Q"\1^,M9O;K3KJ9X+QW\PJS':&8^A]#V_#(Z5.O!3DHK1/2SV_
M73\D*C@ISD[WM+:^NBM_P?+5GTIXP\=>*?'FI7MAIEW*;&61XCY<AQM<X(X)
MYP?Y^M>4:1\%=>\&Z\FHZ'!/-=ZW)_I<FTL1YK#=DX[\GIZ?2O;_ -G/P->W
ML:M*&G,I#/(P)VDG/4YS^%?I!X<\!:3IL<<UY;1W$JA2F54E#CC&>G\N#^/5
MAERR>(JI22T3DM$M/^#ZG/B)RY7A82E32DKJ.CYDX_IN>>_!/X56_A?2(=3U
M&(/J5Q&LS"0 X8C<1R.N?Q%?0Y56P=H7V'3VX_PQ3H$4A8E&R-1A1@8 ]!P!
M_G%71$H &.GL/\*S;3DW':3NK7MKT7S_ !,_ALI[K2[5WI;KUZ>NXU8U*CC]
M!VX]*D"+T_R/R_\ K^U.J<=!]!_*JBYWTU?GMZF3?O77RMIT$VKZ5)\H4 =>
M,]?QI-W!7N>>O]/PI*U_K^OR)$(!.2/Y_P"-/.W QUXSU]/RIM%"]W9+[M_4
M;=^GW"@D=*"2>M)10(",\&@#' HHH"XH&3B@C!Q0,]LY]J')*%<8./UP10 E
M(6QUS4< (R'.,DXS^?\ AG_)J4@9QP??% !12(N.,]3U_"G'@XSGWH#O^']>
M@1E6R,<_C_3Z5:$:X''8>G^%5!QTX^G%!9LC&>3SUH M-$,' YZ^G;V%53QQ
MZ5<7)0D]2"3[<=*J'J?J?YT -!SR*6CIT%% #$7;GU)S3Z** &L-L9\O_6=O
MU[_2GQR2[ '/.,?I_GK244 !YSGO0!C@444 %:>C_P#(2M?]\_\ H)K,K3T?
M_D)6O^^?_030-;KU7YG01_ZR[_Z_;O\ ]'-11'_K+O\ Z_;O_P!'-16#W^2_
M)&RV7HOR.D'0?0?RI:0=!]!_*EI#"BBB@ HHHH \0\8<ZRV?7^I_P_R:XK4]
M&T_7;:2VU"".>%@5/FJ&ZKCC(..WXUV/C+(ULD'J3^I^O;%<X78CY>N.W?\
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MES=?:7BCY+94L0,=>,'UZ9[5O?"ZU.G31^*-(@V,3YH1E'.3N[@$\'^=?/\
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M->[MIZ&<I<SOK\R78OI_/_&G445O%62TZ(D3 SGO2T44P"BBC..O% !1110
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M_P"RIJDGAS38_$4+#3FCAD82H<<!6[X_R.*_4+PSX$\/>$=.M]/L+6!8[=0
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M.S7;=JZT_P ]]P&IG8N[[V.?R&/Z^_K6KH__ "$K7_?/_H)K,K3T?_D)6O\
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MTZ]Z]"#C5C&=)*-22YN9*SV7RZ:^G1[>"IUL/*49+W%+6_DUK=K^MNY\;_\
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MTVTZ?\,=6&KRI.T7RZI\RWW7GO\ UHC^:7XD?L>>'-#N[K6->@6,Q.\\2LF
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ME0G*F[P?*_*W]=#\OO$O_!*/]G+Q)?0WMQ8& P@!8HK6,(<8QG#CT]*GMO\
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MV?H?RH_L.S]#^5;-%%WY_P!?\,ON QO[$L_0T?V'9^A_*MFBE=_U_7D@,?\
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MK%K_ ,(WHUI]@0YMF9DV#LO7 [9)/<\=*VM,\&ZA\/K*YUN4M>2:@K22&+)
MW\\XSTW'/7C\Z]G.L5E?]GX98"#C6ITH^TY[<LI14;M=;-_HSS\OP^/6,JJO
M4CR2FTFF](O3K_P/T*LOB?4_#6BZI!%X?M;F!I)46=H%9MIW $9ST!&/Y<UR
M7P>\0+8^)9]0OD:""[D/F0*"(U#-TVGC_//3 ]!5[W5_#L]R8B82Q+1D<@$^
MG7..W7ZY%8FDWOAW27B^UV69"0&PN".>_N?P[_A\]5S;%9C@:%%QI1CAI6=D
ME)I6\NS?X'LT\MH8&NIJ<JLJTN>VKC%NUM%\WYZGJ?B3P!H7B?6(]?TV*%\@
M-(A"XYY)_GSU[5FR^'HM(CDTK0]4E@N-24QSQQ2$"'=P< '@CTZC'7O6;JGC
M!K&RCDT1&2*;$8P#W(  P.O\JC?1/$FF:<GC":WN"L@\X,P;!#9(QD8_^M]:
M\6E6Q-*I4E0Q52.NBO9/96=NMT^WR1[&*P]&K3IIT*<K13=]]H]+_@N_S.#\
M+?#\_"?Q\?$VJN=62Y?SF-QF3 )W'EL^WU]JZOQS=>&_B!XHL;RPTZVMT$D?
MVG;&HX!&XD@?S_K74Z)K-IX\M)QK"K:>1&4#2C9NP", GG\N...*\<NWU#PW
MJE[;Z;H]U=VK%PMW'$SHH/\ %N P.#VXKUJ&=XRK@L5ERR]5Y<O-*M&-Y-/K
M=*_737Y:,\QY'A(XFECGC9T:D=8TW*U-;:)-_P"76VY^D/P[B^'-QHB>&M0E
MA%K)9>45^7;YK*0!Z=>PZFOF3Q!\!-,\.>)]7\06D0_LDO)+;.B_+M)W+@A<
M=,X[5#\&KFTN)/,U69@X^<1EN588.T@GJ*^D+KXAZ ^EZEX;U&!)/M$+0VDI
M .PL"@^8_4>_IZU\W!)X>4*D94JO,^76SO?X7\]-3UXQC"M"KS*K%K?=7T]Y
M=$E\NNB/D2T\2QZ%>27D1$\$#,HA/S+\I)(QTY _I1_PG=QXVO3#IVE6RE#A
MLQJHX.,Y(YZ$?E7;W'P)U$:-J&O)=>;9R/)<*@;.V)B6V]^QQ[?K7R/XI\4S
M^'->M;#PU<I:W$4RK=#=@OAL-W[\_G^-:Y5@Y+%0GC*52E0C:SFK^TVLT^B^
M[_+/,ZT:E!PP=>-2H]XTWK"2MH[=?.WW;GJ&K^(O&/P^UR'6O[(5M/D812[8
MLKL;()Z=@3[>_:NPUKQ6OA[3[?QSX.A5=:U-5DN88E 97< L"!@_>)Z?7Z%Q
MXIO/$GA>UTZ[TU[Z5HXP[QQ%CDXR<@'N>I],GWRM3TZ;1;/2]EE((25,L;*3
ML!()R.G3@# _G7TD.2AFM*OA<5+!Q3C=T[*]VE?\=?GIN>/*4YX"='%858IQ
M5^6HFUII9:=-+'G?CGXL^,/'&A?8]?TI@^5'G-"2P]3GD_RX]*ZOX77]HFBC
M3;VU299$*D,@;:#G.<Y_H1CTKW[2;'P!K&CLFHM:17 M6?8WE@^9L.!CZ^WH
M#7A?P_DLM/\ $_B.*ZMR^F6YF-K)C* *6"E2..!CH<?K6G%6'Q3Y,:\R6+T2
MY7)<UFEV;UOK?Y>0<-8O"I3PM/+GA%S:M1:BWIS635M>UBIX@@L].F^R:/'%
M')-*&.W"XRV2/;T'^17MW@KX@^'?"FF6UMJZ1/>RA1EP"5+#U/OQUKXZ\;:K
MJ5]XADN=%=A''=;2 2<('Y_3KP.*[N_TH:OX=MKT;Y+^V0--L)R"HR>GOZ]3
M^GRD,#-X5XMU.:?:71NW_!VUZ^9]#5Q=&>)CA5&48Z7:5DVK=M=[:]KIGJ_C
M/P2=4UI?B()T;3%^<*6! !Y&%SCC_P"L,UY7K"Z;K5_#>2(CV\;# (!'!'U'
MH?\ ]=<G8>*?B'X@MG\+6%O=3:;'\A51(WR@8QP#^'\N]0-/J^AR#1=6TFYM
M&D)1)I8W4$MD9RP'ITZ_7BNW#4<RCAO;1P]:IA5:3FHMQZ+M9??TW[\.,JY?
M&O&BZU..)^&,6_>Z:?E^.R/0O$<GA>;2HXP(8I8D VJ "6QQT'<XZ^F37L/[
M/.K^9:WVB,F^RNU:(LPX (P< Y'\_P L5\S:?X>BU358=*N+U!).0PS)R >1
MP?K]>GH,_:/PU\&VV@:3=FVG07%K&S;L@DD+Z_X]S7)5Q$ZCTII<K2=ULTT[
M/LMTK:]%<[*6'C3I-2FWSJ+=F[.]M^SZVM_D?+GQ1^&]AX/\:SZHT<;Z9<R2
M22# VAF)/''OQ^5?,DOCNZ\->.(;*PTZ.XTG59UA+; 5C1WP2/3&3Z<_2OL;
MXE0ZKXQCO+++.\4K@,N2V 2#@CG&1UZ=*^>Q\+[B41SGF;3F\U@<%_ERW7OV
M_#.1T!]V685*.5RE6PT'!V^%--K3^NAX]+!X>>:Q]CBIJ<7KSM<L=MO*[LK:
MWT['?_$/X>G_ (1:#5M*56AN[<7,X09V%UW%<*.HS_\ JS7AG@KP[HNH6U]]
MHOI$O;17*1.6&74G@ XS_GGBOI+PWXEGNK(:1J!_T*$?9VB?T'RD8.0/_K]!
M5?6?AMI7V2[U+1H3:RS([!_NABRYSQ@<],?EWK@RG,<)AGB/:4W".(5H*#L[
MO17VZ[]F=V98+&3G&=.MSN$DFYKFT5MM-O\ ACYA\.V<=MXG?4=61'LK64A5
M8 AMI'8^H_I7:?$;Q5#XM:RLM TU+9;38/-BB*DE.^5]_P"GK5WPUX)N9]2D
MM]8FVVGF\R,0 1NZ#MTSGDX]:]JO-&\*Z+9BVM-/#2[0HNM@*N<#D-]3G/ZU
M%:+H^^Y*497=.,M=[6_X;_+3HP3C6DJ=1<LDE=Q34;JRU^=_33YV/"VE)+\-
M7FU^]8K'!A8G8D9"C VDGDFO*M'T'4=2N6ETRP1]/@=F\U4!^4'/8'G'T_PZ
M]#?ZW:S>&[9V*NI9(T)Z 9   _D*W?@[X@DT+6+_ ,,:W:&VBB+H))TP&YZ@
ML/3Z?G7=POEF"SS'RP>858T8\LG%RERQNEHE>V_].YQY_BL3E>%C7PT/:-.,
M'I=V35[;Z[^9F>&)=%\0^*H/"FM.MO <1OO(4>AZ@<#T.,8]*YWXX_#30_#F
MLV$/AR[2>,.C81P0.A.<>A_R>:Q/B3HE[%\18]3\.EUC>7=NAZ<L>?EX]3_]
M:LK7[;Q)!=17FIS23E]OEJY+%>W?T]?7IUKT,77P.4PKY%2HT9>])4ZZ5[Q3
MNO>WUT>^]NYPT*>*S"I1QKKUHT>2,JD);IVC=6[$?BW2_%#Z';6UO&9K00!G
M)&5 VC()_3'/:NM_9KU>R\.:A>-J<S64EN68[?E)P1^?.>#Z5W6A>'_&&O>%
MRL-C,\#)Q.(V**A 'WMN!@9]*71/A'%"CSSSB.YR6G7.TOR21SCGMG\NM?.9
M?F53!8MU'#X6TKK?7;\/*_GT]?&Y?1Q^"]E&7NO=7:;:MKIV>KZH\[^,&MM\
M3O%0T_34-RL4F!*RDD[3@8.#C_'\:\!\>>"M=F2UTJ[@)BLBI0!25.W&1]/I
MZ]Z^H;VVLM#U=8=)M&2\#8:;;G=UYS]>>_X5I1V#:S*9-2VAHQEV8 ''7C/;
MCK6=?/L;]9Q.(IRE'VVBI7:BVUK=>:VMW^1O0RW"TL)A:$X*3IV3FE[R322:
M>ZVU,7X8_$&X\)>!'T1=(C:4PF'>8><;2,YQU^O.17C6K^(39:U#K'E[7>8O
M-$%X"DG.1],]N_3I7M;^(=,LM1&D66CO?C'EM)#$6&0""3@$9]?7\:R=$\ 6
MGBS5M4FO5%FD*NZVTGR-QD@!2,G_ #Z5Z&$H9IB*5&M/ U8PK27*W'JVG>]E
MI?7]>W!BYY?1G5I1QE/FI+WDY.^R?*KO=?G8\&^+WCZS\4:98Z?IMH@E+PJ[
M*@#;LJ.<8[G&3S7[0?\ !/3Q#K?PM^$NI7^OVK_V9=V+,LDJ$!%:,G(W#C Z
M8(/3FOQTN_!VGV/C2,31^586MXA<N#L(1\]#QCC/IQQZ5^RGPO\ C!\-O$7P
MO;X7QZC8:=J-U9+9VQ+QQN\C1;  <@DYQQ[X^GT>64_:XNK1Q"@ITH/F<5;E
MM'3INKZ[?J>!FU>V6TI4)3_?5(J+;WU6ZOLUIH_Q.#USQ+I'Q'\0:ZOARU@U
M#4)+Z8A]JO)'N<\ X+9[=?QJBFM:_P##,!+BP>*>?[[>65VJ>,]/3OQGM6C^
MSO\ !36_AU\:#IFH2M<6>N7HGMIY"6C:.60D;<\<@Y_/UK].?CI^SDGBNRM$
MTG1Y);B*!&EN(HCM/R@G# >O7TK/*OKR_M.E1QE7V,9.ZDW9J]K))VV\NYEF
MCP3AE2Q.&I+$."::2NK13N_5Z^O8_.W2KO6M?LCJU[;W%WI1'F3!XV>)1R3G
M@C@=,GIZ8JU;?$&TT^>.'PW=);2PR9^SPR*I1USGY5/7/8<Y_"OVR^ /[+7@
MS5/@/X@\.ZE:Q1^(_P"S+HPET E$BPN%P3SG(X_PK^3+XTZ1\7/@O^U+K'AM
M+#4;C0!JMRB.JRF)8?M# =!MP%_"OH<CQ-/)L;3Q.,PE/&P;C\:=XMM*^O:]
M_5+5GDXRG0S3"2P\*KC447;WK))=-[7_ *ZGZ>V.K:?XO\36=[XLO09H IC>
M=^0PP1C=R,\#Z_ITFL^+K6/Q/865VBW&@6\L?[R3YHA&KCN?1?0<>F,U\C0^
M$/'?C[4=#3P]'=12S^0\SQ!UV;MNX$COU]/K7U5\4OA?XB\)> -%TR:RN)];
MOHHXVG".7WN%!._&<\G^N>#7UN9<29U7S*G@\D@Y822BY1@DI0BTG*+:6T5?
M7O>W0^;P>3Y33PLY9C*-&,9VO4;O)IJVV][)K]3]$E\-^&O'WPOBD^'NF6=Y
MJ:6P5_+1&(?:O' SG/KD\9]Z^*/'/P.^(^CQV.I^)+>>ST^*</-$%94,0;=R
M,8(P,YZ'CCK6Q\"/C-XC_9GT"#3/$.GW,TFIB)HGN$=@JOV^?TSCCO7WWKGQ
MQ\,_&7X;FTNX+:&\GM_+0[$5MS1\ <9ZGMC^6/%P_L,-7Q<L6N95%*4DG=J6
MCE=>7W]SOQ*E.GA%@)KDHVLW>TD^6UK]+'YSB'3YK[3G\,V-E)-:QHMQO$:D
MLH 8L/7/KWS[UY!\;O$EIHEE=7FJVEC97<$!=#;[ [,H.,;3DG(]?UZ?$O[5
MOCSXJ?"7XG2:#X)OIX8KZ9VB96; 0L<8P?<=/?L<U\>:!\7/B5XR^(4.@_$C
M59)[-K@)(LCG!0L.""<< _\ UL=?1R#/L/@9UO88*G5JXA^RPDZJO[/G]WF;
M:M=7Z:(YLPRK&8BC1D\5*$?XF+C!V]HHV=E:U]K>9^Q?P.\(^#?VA?AMX@M[
MF[V>)H8YOL,+_??"MLP#R<GV]>^*^,]>\">.?@/KNIQ1:?.[;YBDHA;H22NU
ML=QTY_G7Z?\ [.'PUTGPGX<L?&_A.!KDI%&\]M#EO,^4%OE7(/7N,FO4OVD/
M%7@F^\&V=]>>$S)KEY&D+@6N9 Y!4DC;NZ^O\N*X>).&(PJJI.<I8BJE4]Z[
MBG/EDDK[+F;];7L=>1\2U53=&$8>QA>GHE=)/E=O.VK[GYW? #X@ZK)9W.M:
MSK-W9ZFDG[JW,KH0<\8&<_A_3-?N)^Q;\5-)TO5K/Q+XDO7NVBG23%R2P(7Y
MA][\S_7M_.-XVUF_\%^)K"6+0;NWTF\GBD>3RW6*-&<%MW   '^'-?K;\*?B
MU\,(OAMIDNFZG:2ZT(H?/M8ID,RML^=64'(.<<<^]>SP[F=/$X.'#N9.BG@Y
MQE4F])SC>*2@_NZGG9QE<Z-7$YG@[RHUXZ/5\LG9M-][ZKL^Q_3I\+OCSH?C
M'P[=ZSI\,8M6\0:U;)M QF"Y ;I@=6HK\]OV+/%EGK7P2MM1MXW6.?Q7XFP&
MSG(NXLG\:*]W$8;+Z6(K4Z*_=4ZDHT]/LQ:2[]OZ29\M&6(:BY^TYFDY*VS]
MW3?IM\_O_H!'0?0?RI:0=!]!_*EKPC<**** "BBB@#^8O]M7_@HS!\,_VN-:
M^"/BC38SH<IN+2.[D0;3DL@.XCM]>/I7X&_MHZ_KMQXFN_%O@.VFN]&NYS<2
M?94:151FWG&T''';\Z^J?^"T-UX:T[]M+4[Z\@+7L,\\NZ,8;(8D9(_'GM7D
MG[,_[07P<UNPO/"WCRPM[F(JT*_:HT=AD;!RX('YX]J_/\=F<)8VK.<G2^JU
MW3M&]FHM>]*UKW^:_,_1\JRJM]2HU[1J2G0C.$;ZM-*UK[/]2[^R%^UWI>M:
M=;> /$-S<:9-$T<,A97C.[C/4?7_ #Q7Z-_%#Q7\*[?X7ZI?6E^NH>(H;:1K
M))#EG?RCMZCN<?IZ5\N^'O@O^SD?%">+O#XM(4\[[2]O#Y:$C.[&U<=LU]4^
M(OAY\(?B_P"&&T+PI<1Z)K4,#0I+-(L:O((]HZD9^;O_ (5SSQLIPJ2ISA4]
MHV[7;NM/NZ].]_+54(QG!U:<X-6<E'=:I/II9>77:Y^+UM\5-(U2]O!XITV!
MKR*\D5(I%4GRE<A3@@]1CV'>OIWX7P? [XDW]CHNJ3VEA),0CP9C09(QC''.
M3T_E7DGBG]AKQQX9\>WMU=7CZS92/(\;6K&1-A8D?<R,8[GKBK/@O]FW4M(\
M5Q:E$UU9O#(&VL[1X*G.,9Z9 _QJ,17PF)PT(O"TXU*:2FTE=R5KOYK;M\CK
MIPQ%"HY4LQDHU'>,9-WA%Z)/7U3ZZ]K'0?M1_L\^ OAWLO?"LEO<P7:#Y8RK
M [^YVD]O7UKY$TKX<ZKHNGR:MI4,@CN@6D"(> >3TSTY/^' K[3^+QUN2XL=
M(O[*ZO+>/9'YY5Y$^4]=W3''^>:^@_A7X"T36/#EM:75HBQRPXD,B#";L=<]
M,#^1^E>=DU# +&<V(QM7+I.=XS;]WET^'RT]3NS+%XNGA84ZO+C%):KMMKYW
MU>SO<_+CPM\/_!EG>S^*-8NB-5<,&@<'(;G/!YYZ>]>9>-M3T/1]5EFTVS6[
M\Y\X:,'';@%3GGTYK]A=9_9V^%B:S$MYJ]E"9Y@&A,L:\LP)!7/49]N/;BO$
M/VC?V1]-M[WP_<> ;-M2@N3$TS6B&08+9.2F??M[>N.G&9?4KXYSP>)CC*3G
M=U%\4]KR[7:_S[7SP>94/81C*E*%11Y4E;ECKM>Z:2?;4\V_8:\=^#/&?Q M
MO"?C+PM8K81O'MGN8(U4X*G.YUQ_+T/>OW;\3Z[H/A9].T3P'X-TR^L6$46^
M*"%P%(&>BGC!/T(^E?D+X#_90\6Z9<:==>'-&O;35G\K,L<3QN"0,DE0#Z_Y
MZ?K7\(_V<_B]IVD6=[JUW*\Q17 G)9EP!USDYQSGGWKV\/A)T9PA5PD)J44T
MFK]M7VT?X]-CP,9C,-5G.,*TJ=52M)IVU;6M^^W7?O9GKGAC]GCP=XX6WUWQ
MMH.FV=O($E\F1(5&6 )&WCG)].M>RZIX$_9]\*Z&WAU] TB%;J,Q17"0P@C<
MN.&"_B3G^M?+WCRR^-'ATVL4DUQ/IR2*ICA9L;00,87CH,_2O7M*\(R>-O!D
M>HZS'/!=V5OYA9RZL&1,]3SV/I]0*]"3P482I0RJ'MKVO*&CD^6[6FJW7EIZ
M'C_5L7!NI7S:?LI7E",*EY*+Y?/=??ZZGG/BS]F[X'+H=WJ%O:Z==.5>X1&$
M3<G+;<8P!Z=/SS7YL^*])\'#Q!-X?L] L(D64QQ.(HU!^;:O.!U'?].U;GQQ
M_;)T[X;>)Y_AQ9V<^J:AY[6@2#<[##;.0N3CT_#J17RK\2?&5_<Z.?%*W8T'
M595\ZV@NF$4I<@,!AL,3D@#'/UKP<75I^T5-X"$8QTJ<JM:5UY>7?\#Z' 8:
MM.FG#'5*DI1]R51^>E][_P# ^9^IME^Q'X7^,'P<FM)8M.L[M+1IT99(5<_)
MG&,Y[_IT-?CY\6/V;M<^&JZYX8TNQCFLK7SXGEC .Y02,\9Z@'WZ5WWP5_:*
M_:A2SE@T^XO[S2R3 DD+2M$8LD9^4G@^G3'KP:H?%WXH_$_PPK^(O%EA<36,
MO[R^5XV)96.Y\Y!]P<_RZ\V)=+V,9X?"U8.-KWCOL]-G:_GYGIX;#XC#U&JV
M+HXN51?PZDKJ.RY7KHU?MH^Q^6?A?X226OCZ6XMT>*Z@NS/+'L95RKACCC'!
MX_#V%>C?'#QT^L6MGX<C<R7.G*D4B9W<J N,?_7/''N?IWX:^*?"?QVUK4;;
MP5I8LM?6"59<1A7:4@YZ#.<GGC@]/;X*^.6@^(/A)XYU6+Q593I-/._DR3*P
M#9<[=N[CTP<_C66%B\QQ=!XB<Z-"FDI<TGNK/;^OD=-2E'#4*KA3C[:;NDK/
M>VBWVMNGJ=/\+/A]_;&H17VHWGD)&RR>3OPI"X/3/^<5]3>(;+PI/9P1B2-F
MTU1N4[?FV <]">2.WU]A\)>!O'.KV^H0W<DA6QD91@$@;&(ZXXZ9_.OH_6=3
ML;^*R:SGVR7FSS0' R6 R.OZ]^:>-CBZF)E1C"<:5.3C1J:KFIJUI>=_+R,<
M']7HT)U)RA[67O5(/=/LM/31^;>IY-XS\;7<FO1:?H[R6=OYJPGRLJ&&=O.W
M&<Y[]^O2N@\3^"/$;:;IEY;PR3O>A&:3:69MYS\V,GOZ"O7+3X-Z=JUK!J"2
M)]J#+,/NDENHS[G_ #[>\:3-;>'-"2+Q%9JXLHS]G,D8(;:!@@GKD#C].F*Q
MJ26%I.<?WF(22[V=D[]].GZLWY'B'!2DH4I).RLKI6>^B7];]?CQ/"NH^%]$
M&H7D&RY>(G!&&!QUQUZ\]<UO_"WX7Q_$+5EO-5(2!7#.&S@J.>AX[5A?$?XM
M+J&MR61MO)L49EC&TJI /'TX_P#K&NU^"WCS_2);*!3&)3MC;IG=N'!X]<\=
MZUG6KQPE'&.HE6J-0IJ]G#;5ZW6^O9Z]S&%&A*K.C2;Y+N][7>B^_3^K'5>.
MM1N/#.IP^"-/7;H6!&\B#Y.FT\@X_E4NBII.C6KPQQQW<=R")"P# ;AR>?Y]
M/QKL_'/PYU"YTH^(Y)PV<R!<Y?&?4\XZ#_Z_3SO1C9KI5U'.XCEC1L%SSD?7
MH17D8MXB@U*LU-U;3;@V[WL[O[U_2/5PT:-:FX8>+4J?N/GTLUO:R\_ZZ:.M
MZ9X T[1GU"V:&WU,DR%8]H8-GIQCN#^0_'@I/BU8/9#0XV^W-)F/Y_FV\[1U
MSQ['\NU6-,T*PU=[@W]Q^Y+,JL7.SGOZ<<GC'I4T/[.]N]CJGB?3]6AVVB/+
M''YJY)7<PP.O4<?XUZ^ RFOG,Z3I2Y:,8IS4W:_PMM;+;^NWEXC,,/E<*L<4
MW*M.3C"4/.R6_K^'4TYH]<\.^%4UE[0'2KMUSM ("OCCOZ_E5JZ\)65YHEAK
MFQ0+Y48CIC< >/I_^HUC^ -4\0>+;:?PEJL@DTJRF*@]01&V V>F./\ 'MCT
M66QN-8\0:'X T=C)'+-'"ACR?+R57G' _'\<=:\[.883"XN."R]N51>Y55_=
MYURW;?\ 7R/0RZ->>&^LXE^Y)7I2>_+HTM7H[=OQ/%?%6K6&AV"6D4;R/"1*
M-B%LE?F X';&".*^L_V<_&MO\;?!NK>']4TY;>'0X)%226,)O$2D<%@.F/RQ
M[UZ-\3O@U\/O@WX8L[KQBD6HZG=VZR^0 DD@W*,\=>2>GXC/;QSP+X\\)6ND
MZK9?#[3SI]]J$<D9C1!&[E@5P,8)YQC'/IU KSE[+#5%"LO?>ZBKZZ;];^7_
M  YWKFQ*YZ;Y8Q:3YKJZ5KO>UG\WV.'\=^%+.VTZ_@T>1;>6VN9,BW(!(1CQ
MA<>GIV_/JOA/\6/AS8:#/X4\6Z?;M>NC1&\N(U#@[2N[>ZYR#SUYK)\">"O&
M4WBB\N/$]K<C3)I7G*3*Q#H22V PZ$ _6MKQE\(/"GQ$FO;/PM8RZ=J%HK"6
MY13$-X&"Q/'&?\:]?(<TGE^*Q510IRA5BXPYTGO^=O\ +U?%G&%IXNA27M^6
M4>524&]+6L_+U?KZ?.OCWQ=HGAGQ,8/!MY]H6[N@PCB;<%1GSC"GC[V/P_&O
M6X=1MIM$L;S4CY5Y<*AS)\C;B!@C) YX/KZ>M>4:+^SP_AGQ/:W&M:JEPOVV
M-"\DN]57?CG)(Z#G/OZU]T?M!_LSS7GPM\/>+? >H1W;V5M!-=P6;@M\B!B&
M$>3G\?PKGQ>!KUHU,="*BG/GES*R>JOR>G]:FF QV&HNEA)MU/=C!:WVY4[O
M>]O3Y-' >"?B);^5+X6U.[S830LN]V& C+CN?Z?_ %_&-2^!OPY\2ZOKNNVF
MM1_;+'S9DB$HY8$MP,\G/'3ZXKYYO]<UFR:1;A)K.[LP8)5?*.Q4;6/..OIS
M[]*R_"?B/7#?72V!N9S=$K<;"S !OO9'0=3U_P#U:8'&SPD83Q\%B*523C2@
MU>UTDGMM_E?5)F&,P%.O5JK+YO#U(RO.SWUCKKO^'W[^_>%_'G_"*QW5K%IB
M7J6CO$CL@?Y8S@'D'VS[U=_X6!>^,+EK"#34\Z;"1)L "DG' _0$5C:=:65A
MIKW=XZ>9(0TD+;2_S=00>>.W'7M5*UUNUTC6-.U33K;8(Y%:5BIQ@$<G^?-9
MUL+&I"MB(U5!NHW&%]8K2R7W]NAM3Q4Z4Z.'G3E/W5&<VKJ377MYO7N=4OP+
M\=74ZW]Q/+:6TC"0+N9%V<<8R!TY.!7I-CX(T[3+>/29C%YMU\EQ/E2QSP>>
MOJ>N:Z9_&OBGXD1VNE^'IT@5851Y4.%! &03Z]<]/0>H\V\9>!/'?AYEOKS5
MO,%L1)(HER6 ^8@>Y&1^7I6<,BS#%X&IB%[65.,N:7,[N2C9W6MOOO\ /I%7
M-L)0Q4<+^ZC4J6MR*UFTEJ][WZ?KH<GXG\#>&?"^KF""X2;[2I8G<IP[ GWY
M'&?P^M4?"&CWRVGB.18Q+;B*7R%89'W3C:._I^-<?J>H77B"_CGD9U>#:K$D
M\E< GKC)[?0<^O4V]]J]I#%;:=<JRS8$L2G+,.XQGGC\?;GGS%4G-TL#!KVD
M_=4'\3E&VZ5^WEKIKH>C1]E"I.K43M3AS.M;W$W9JS>W3^F.^ /Q.T+PMXMG
MT_Q1IL(#7_E[Y8P!@R8^\PQCGC&?RK[-_:LB^%.L>!M-U[2(K"UOOL\4BM 8
MA(SE0>2HSU)X/-?G]X@T?2KZ\6RCMS::](?,5@"CF3.[CH2>^1UKA/$MWXR*
M1:%K,UU/:P_+#$SNVY5X P2<]AQQQ7UF$XKQV69;4R/&8.%/G?*G."51WLKJ
MZV:VZGA5N&L-F6/AG=+%RE*FW:E&7NWTZ7L^CVZ^9]A?"7X?_!74O"D_C+Q1
MXFCL]9M$S% 9PK';R,#(/;J,^F.]-U7X@>"K6"]M_".L?;-JLD@$N]B%!&<9
M.?I_6OCK1(;>*Y73]:-S8V<P"['D:-"6P,X)7KR<G^=(?#>G>!_%%E>V5]]M
MTS495WP"0O\ +(02,9/N.AKQYX'ZS3>(H3ARIIRA)V?,VG;2U_\ +\?3H8IT
ML2L+5A-IZ)J]DK+5_P!6MY,[S_A98@U*Y2-"79G#!N.?F]O7J>G2O7O@8/#O
MC#_A*)]=NHH)(89FBCDD5<D*2."03G%>(>/O#MO+JMGJ&A6$L<$MN'E*QD L
MP)[<8R1SU]"*^>WUGQ9X)URZ FFLK;4&*#<S(K!LCU /'Y^]<$JV,KRJ8!P7
M[N*?*].>-U\'GI>_7OT.VGA,!3<L4JK34M9J]E+32[Z]/RV/J6WT);CQ+J0M
MR%TV"ZE*.. 5#G'3KGOST_"I/$/C;RF.B1@I!%\@D4'D# !R/H1G\O;F?A[X
MICO+>32)KE/MUU&9?-+#)RN3S[Y_K[CS[7/'>GZ-XAN=*O-.EO'@8YF1"PX)
M Y _S]>O-2P+]M3I2IU(3E9WDKI6:O\ #?\ 3<Z,3BY0P[K^TI*FD[-OWN71
M:>?J3^++W6Q;QBR5TMFE0F= <_>YR1W/N>AYY-=YX@;Q==>"-(@TC3_M-RR(
M%G"[G=CCAFQGU/:N:3Q39:]9)#% (821B-D 8$XQ^OL*[*7XCWW@31H([BU^
MT1N%^Q H6VMP%(';'MV_"OH*-##5L5"CBY\M.%M.KLEKKL[Z+1:V]3QHU\0Z
M+JX%*4V]7+I9J_9;';? G19+'6H6\71^3K;(/*MG& P.,<'K_P#JKH/CKI4/
M]L6\F@V\=M?.Z^<80H8\\YVCGG/].E<%X!^($>NZW'J.M1_9-4;;]ED8; $(
M^4=N@Z]1]:V/BCJ>H6<O]KVTAO"@WN4.\#UYY_3_ .M7'F.#]C76(R_VL;/3
MET;M:VW3^MMNK!UWCHNECG34$_>U37,DO/OY&%:W-M8SV]M?A9-1,2\/@G<!
M[\]>F/\ $5S5Y]JUGQ!!#-&OV2"13-GHB!AD_3:#5?P_H&K^-6?Q4)6@6TC.
M\,V!P#U XSP*\WD\3ZI8>([[3HY/-:X9H=ZY)7^$'@_7^E>4J=3$U5*NYJO=
M.\^R<79Z-_U]WH.<,+_"Y'A_A:@[NSMMLO\ @'ZV:%\8/@EX.^#DVB2R63:^
MUHT>=T?FK*4QP!DYR?KVK\_[WQ=J&H3ZGK%C)*-/A:61-NX(R9+#V(P?_P!?
M2O)KCX1ZY<69U^XN[FX5I!<&U65C\N=Q&SL!S]./05[=I>M:!_PA?]@0Z:\=
M\T7E3$QG>#MPV3U^N?SKU*6&HXR-3GE&*HI*=M]&O/IY?\$\?$5J^%J<U!2=
M.3NHRUT=GHN^O^9X#%\4+_4]0EG2T4QV\S1M(PP>#MS_ )/TKW73]%U_Q+X?
M?4-+A<&:+!8 @#Y>>1]?;UKY0U/PCXC/B,:?H=O*;:XNU>544YP7!8<#\_S]
M#7Z#7?C31_A3\)[+3WD@.NW%JBF([3)'(4 (;OD$_P"2>.''TJ-H_5KS<>1W
MBDU=-6OUOI\_O._"5,7)KVK@HNSL[[-)VTWLOQ/ENQ\>7'PONKJWOM)CU#4W
M,BIYD8D96.?4'^7H2<UI_#KQS9:_XNEOO$DO]CQW,G^ISY2D'M@D C'M7:^$
M/@[??$'2K[XA:U>1B(;[B-6( 5?O8YXSR!]/?I\Y?$/2K:]\3Z3X>\.2[M0N
MKM8%:U;:=^X+_">>>O0XQ[U]U/'YO#*<O<H1IPBDE9+FM9;];V1\M+#Y?6S/
M&4O93E.7O73TOIYZ?(^N?%GPRTSQSJ<=MX8=762%I//C(*DXSRX_/\37COP<
M_9>^(?C/XUPVUKJ\UE9>%KY;J<I,R+(D,H)!(8#! _&OI#6+:\_9R^$4&H:Q
M/N\3:A8;K3S3F0&2/*]?FSST!YKY[_9S^(OQD;QA-K^ESR2?V_<-')&A);9*
M^T8QST/3G'O7+EM+$?[5C90E/VT9<EE>5W;67W]O\A8Z>&J0PF#C.%.-"2G/
MG=D[6=EW>Z[6VZG] G@?P0NH:GHFJSX\GPQ9)%<7QQ\TMK&!EI/<KG.?R'%<
M!J7[??C#P=\:K+X;R:+%=^&;V]CL(]0=0X*&019WX/3.?7C\:^M/ /PF\6S_
M +*6MZU^\@\17MC-<Y.5E+-'O.UL!@"?_P!=?A%KO@;XD:OX\L+J[>6.XT#5
M&GGE;(=EAF+GYC@G('Z^G3V:U*GEV58*IAXRJ8C%U$ZZ47=+3?SU?=;'B_N,
M?CL2\37C&G"#CA5S6:DDO/LDN_5=C^JF.:_T'P[I'C'1IECM]8T];B>&-P%_
M>Q E< ]RWIUX'-?CU^T_'X<3QW!KWB/P];N^LW6P7C6ZDAG<#=OQQU'<5>3]
MJWQCJ>@^'/ 5C/)YEDEK92G)S\H6,GKCMGGN1VYK[L^*'P2\/>.OV?M$\0:Q
M"D^O6]I'<!@H,BR! QR<$YR*Z*ZC5H4ZJC*+ERKV324KJW3U]/)W/,PE'ZJU
M*K*ZK2DHN^^NG3;O_P $^0_AYHVA>"[_ $?4+6S@FTZ\ACF\X*I\H$*< ]L=
M.,5'^T)\9[*TU/0X?[+2:TCEA,#M&-I;<,<[>#G Z]!7G%CXL;PO;/I>JHSV
MEDPAB)'*HA QDC(Z=/\ ]53_ !6\5>#O%G@JUFTK2FOM2TZ,2KY,>]]Z 'JH
M/?MQ^E>KE649WB\=06!G+"2K)1YM+*.G,FV]+QOVTVU,L9C<JP].4,9&.+AK
M[JZ3Z.RT=G;H_P#+[F\"?#/P!\?_  KIEQXGM;&RN8[1'@,GEJ>$!& <=<8Q
M_4<<+XD^%W@OP!#J]I#J*1IID$DEL(I!AV0,548X[>E?&W@;XI_$#2OA]>^)
M(K:]TRTTI#$@??$-B#OG X 'XG\O;/@?JDOQO\*^)M<UB[:YFMK6X;R_,+,Q
M1&.,9.3[>N>>*UXBRN6$Q-; X92Q.*HX7V^(G#WHVVFM+^]OJ^W<YLKQ5-PI
MUZK]E1J5$J49NS4;JWY=+^FA^%7[5/CAM>^)UR\-NUS=6-Q)!:'879P&PA'&
M>P]>37R;X>^#/Q7\5?$?3/$,^D75MI$EVC2S"!U41%EYW8  QG/I7ZZ_\*-\
M.Z[\1-:\4:Y$EM9Z7JCIY-PJC>$F(SAASG!K]9_A1^SGX$\7_#V]U73+S2HU
MBL\Q1A81(K(F1R!D'/.>/3O73D>4T98'+Z\HNG)U87G+W4IJ2]U]G=>EB,WS
M7$1QM7#T$I4X0]YQ_E<5HOD[Z^1Y[^R%JW@'P+HFC>'=6O8KNX>R1)[69U*B
M7RU'(;/.?7\.M>D^-?#%EXU\77/DZ/9OHUN6>)=J% !SD#I^ %?$^M^ )/AO
MJ.M>(DU+[2^GW4@A@BER?E8[<*"./\_7T#X,?$/QAXHFO]2EO?L6GPH^])VV
MY1-W3<<\@?\ UZ_0<?@J.;XBM2G5IT)8&E!S<_MI1CR\EK)WT/F:%=Y?AY5D
M[Q<VVK]9-;KO=OST. _:2@^&DNE2>%+K2[2#4V;[/',D2;XRWR@@[01@]/P/
MI7C_ ,)_V6O"'P\ATSQAJ'BYYH]8N4:/3I+DE4\ULA?++X&./0_SKZF\=_#S
MPIXHT#5OB7?RI=QZ,\K3!2"IDCW'D XZ].G7-?*6A>&_%GQ:O[.[TVZGTWPO
MI5V#!N=DBVPG@\D+T'_UJ_*.,\'A,#/#XK*JTHYKI'$03LI0TM))/M=K;4^_
MX8Q57%4?JN-IJ>6R7/[5KWN;>U]/1']&/[&GA+2M-^"5A;Z>RM:-XB\031,K
M<$2W$1)X!'445@?L0W36GP'TVS:_2Z-IXD\16QF#;PWE7,2]1D?YSWHKHP=>
MO4PN'G4JRE.=*G*;;U<G&#E?SO\ FCP<:J,<9B53C:"KU%'_  J>FW6WY'[\
M#H/H/Y4M(.@^@_E2UZYX84444 %%%% '\$/_  6L\A?VW=1BN$#"ZN98@&]6
M=@/\_AUKXS\-_LX'3O"FH>/;>5(&$;W$:JVW(P7XQC_Z]?:7_!;SPOK&H_MG
MW^I6,4K):W4TV4!(PK%AVZ<<_P"37YFW'[2?BMM"D^'MI;S@B,VS%5;G@H?K
MR..,?CQ7R^5XS),7F&=X#%8">)Q7+4C05))OVSO[TKKH_P!;6/OJN!SREEF2
MXRAB70PSJ4W6]J[0]A=.T6GM9/\ S.[^"?Q'U"U\5:B-?UF6"QLY)5CA:4A&
MV9 7:3@^GXUZYJOQL\8ZE=ZE=^%K^;38-.<^3+;N4,RITY!&<_TK\Z8]*\2:
M;J(O-0FDC6ZG,C1AB#ASG!_/W[\<XKT?5/&&L^'K&WM=.#2"\"APN2QW#VY)
MZ>N._I7P&(@LGQ*HXF%2E5JR?LZ4O.2LDDV]GM]W4^UIJEC=:5I0@E>MHJ=[
M1N^9]'\K'Z"^"_VS_'G@_29K_P 26TVKC:T0FN 9#QQG+ ^_IGGVKSS5OVWM
M;UO5WGM-/:V6=RRA(RHP3[ ?3K^%?,EUXHU&'PK:IK>G3+:SNF9&B(7#D#.=
MO^><^_7-9>#UT.QOH%B2XFB5E&%R&8=\\]?SYKAQ4\93KQ52E5H4JEI1=2+B
MII\MG'NNS];GIT:.52HRO"C5K05I.F^976E_O_R?8]?\7?MGZH-/M["3P^ES
M,Q53=-"&<>^?7G/OSUK[9_9D^+$7C?PS(UT%M':(Y).SRRR9//&.IQV].M?E
MA!\-KC5FDUJ>[A73HP7"L5 *KS@ CD\?@<>M>F?#?XJVGAR*^\*:,_DWLQ:&
M*53M&XY3(/ '..1U-+#8EQQ/-BL,\52C)*$9+[*Y;)6^?XIF5?!X?ZJU!Q=6
M:7+&=K*[6B]+'VAX]^%5]XJ\617VC>,)@ZW1?R%NCM&&Z8!QC@=N^.V*_1WX
M):;J/A7P]90:M;P:_-;QQ[7N&28KA?5L]?SS7X8>*S\5_ 6B3>,[?6Y)6D5[
MB*/SB2N02,#.>"0.GIZBO#?!/_!03XV:3JLNG7>IR)&'9$\R0X R1W^G7\^U
M?64,^A4JQPN$RV.$DTE&:6ZTLG=;_/RZ:?-3X<E]7GB?KSBX7E.,6M)75U'N
ME;YG]?UM\7/!_AK28+J?2M.AU=B$$*^2&!X'"@DYQ_G&*[^Y_:<\+:'I-K+J
MUW!9M=(H2,RH@&X#@ D<?YZU_'(/VO\ XO:AXXT_4-6U>:32Y+N(LBSGRPK.
M">,XQ@]>/R!KZ8_:3^+OCGQ/X*\/Z_X4NKNZ2TA@EN8[.1VQM 9@PC.!W'KU
MZU[&&S1QJ.GB9*-1.T9M:7LKJ]K+I_PQ\[B.'^>E'%0G*KSSY79^^Y.VKWTW
M_38_K5\)>,?!7CS13J&^UOE(WHK/&X.1N'<]3Q_];%*VH:7<6E[HNR*QM)ED
MC5T*J-K*1P1CKGV''UK^9C]E[]L#QA%X.L-.E:\AO(I(H9EE=PQVX# @XYZ_
M2OVC^'7B#Q!\4M'TG4+6Z:V$44378+8,C8&[N,_4=??%>A#-88I^QA2A&<7R
MNJ_AE:VJ>F^EF<&*RAX+E]K5;;2]Q.[6S<;.^VA\N7_[)7@^T_:%O_'NOVT.
MJZ69);I#<*KQ[L[Q@N"OIWKXJ_;._9\N/C!XAEF\$3MI-AI$H:*ULR4CD6)A
MQA,#H,'MZU^Y'Q?\+.GPZNK[2XWEU&VLW>0Q#,C%(SNY'/)SZ9Z'!K\?/"/Q
MWM$UO7_#&L:<]OJB230Q/=(078,R<;ASD\9_PYY,72C"M"C^[E5JVDK:I7L[
MM]]%U/2PE>I'#>UIMJ-)<C3^)62U\_Z2Z'HO['MO8>#/#MCX+UG1X;W6 \5K
MNEC5G)!52QW#//7/]1FOOGX\_LT^#O%OA33;76])M+9=9A0$,B* )$'J,C&?
MUS7Q7^SGX>\1^(_BM!=M83I;+>)<+/Y;"#R]X(.<;<?C[5^H'Q^O[W4[?0K"
MTE#G2Q DJ1'+?(O.0.>W^>WU6"P]&IA72Q&'BI1CRN5MTN7O_7H?,XW%5L/7
M5>AB9SE4;GR\SNMKII/2WXN_1Z?F#\!?V$?#'PE^+QU?1XHEL;B99G\L+M(8
MAB.F/;VY],5D_P#!3']C#PA\2/#DOB#2+2WBU>PA\Q/*1-\KHI;^$<G(_$X_
M#],]-O;:WTJ*Z";;]8U7<V=V0 .><^PQ7F7C&>'6W4Z^Z_8LGS/..4((P<@\
M?A@Y[XKS<=D>'J8*K*A'V<E*Z=K.VEO/?\/33LPF?XR>)I1JRO35HR7E[M^]
M][_YV/XK==\(Z]X5N1X8DLIH]16]^RQ*8F4L X12..OKU[]!7TU_PJ+6] \-
M:)K/B)FM#/'&\"L2N[*@C&[J.1^'MU_8C]I+]E_P7K]Y'XS\)VD$UU:2K<O]
MFB4C*-O).T>H/;MTK\P_VG?'&NW@\.>&K:PE\K1C'#<^2C# B*J=VT#@ 'KT
MYYZ5\1FF:8S#TZ-'V,/W$52DTO>=K+5VU?7U=S[_ "S!87%TYR<W>;YM[/IL
MKV^[7S*?@;7;2VU2UL]1OS%;I)& &?:"H(X.3@CUXQ_*O7?CCXLT2YTK2X-*
M$3(BQB5XR"9 % .=O7/7)-?GAX@N=9U+58#IDDL)@B5F"DJ0P'.<8Z8YSGIV
MR*Z[P'XAU'Q!<3:#JDKSS)F./<2Q&/E!'7O^'7CG%<5*E.%&&.QU.2H59>XD
MNKM\O^'TW.JK0H1G]5HU>><()M7].W77K^HGC/1]+UIU:%$1_E^91R6_7T Z
M_P ZUO VBZCHUU;3QP[8(F4^8?EW >_TQS_.M ^'6T_6_LM[,$C5A( YZKR<
M8/KT^GI7?:1H>O?$/5K7PQX4'D[62-YD& 0" 26Z?GV^E;U:.'K4JO[R*H\E
M\/S.W+.R^6G_  YQX12IUI1<96C*S;T>EKO\33U?XKZIJ-W#X<MQ++%A8F15
M++TYY&1^?!]JY[7_  )XXU26S.D6DRV,Y0W<B*PV(QR^<=,#)YX]<9%?95Y\
M)/ OP(\+1Z]XWEM[[798 XB)1Y!(1GD9)Z^@KQ2S_:"M+9Y[?3-.6YM-0W)!
M&D6YHU8D+CY3V/3I7D4^=8;EQ<)5'&\8SCJN71)W\M'OJ>JW2<X?5ZL8.Z<T
M[IMMQT=ENNWH<')X4TW3+&+19M0,5S(H\U]^&63&#SQTR>.U>@^&_AO>OX?O
M8++7)9A/&VR(2L0^X<#'((_#\LUX#XRGUO6-9$]O9W<+3R%U4JZXWGL., 9Y
M'L:[?P_X^U+X=7.ER:M.9K<LGFPLQ) R.",]AV.*UIU*^ PTZF&QE2#J/W8I
MVLFEINNEEZ_,YL4Z&)Q$(5<![3DWFU=2<4M?5WMW^XQ].TO7_!5Y>6,-K)]K
ME>0!MA&X-D[LX'Y_7OS7T]^S#X)OKF_UCQQK04W6D>9<1>8P#*8P7&-QSZ<5
MC?$CQUX7U_PW:^(?#L,)U>:)(Q%&H+^8X S@9QAC[]/SY;P_IOQ5\#>"]1\1
M7NI_9-.UJ!V%N[[&"2(3TR#T;T[UY^"P.-Q-3%8NGS5'0BZ]:M/6*5EHG=ZW
M75O>_4[L1C</"AA,-67L)8FHJ6'I;.]TM5V7Z[G%?M%_%W5_%WBB>[EGDOHM
M/FDM4LV)=,1DJ/E]/\,>U>9?#?QK;Z#JL7B/4K1+.*T<3>05"JX#;L$=/3KW
M[CK6#X,L_P#A+?%=Y!J%_$GF7+NTDSC:SLY.>3CZ<XY'--^-7AL^'472[:X6
M4W858F@88.X <%>#U]/SZUZ6'R:>)RZIFM6K&6CDE?WDDUT^3OV(Q&-H4\?0
MRUQJ*?+&,I1^!NT=7]_];'V%J/[5%MXBB%SIVE1PV]M#Y+/&@ ?:NWDCN??_
M /5YYX<_: D5==@%D+1KP2*ERB;3E@<'< .G;G_&O(/ W@Y]*\ ,;PF2ZF3S
M!&>9,<MC!YZ?A70:1I'AZ_\ #>I.)88M1M8G/E942%E4DC&0<GZ'I[<>?A,+
M#%U+^TY8Q=T[N[Y6O371_K:[.K&5Z>!@DL-3DVE'F=W>_*K^6Z?W?/G6UZ]U
MR>\MKC6)C(TKS12%SE#DL,$D8_SZU]2?LO\ QPUC3-0O?"?B>_GU/0(R\3"X
M9I(DCSM_C.WH/3K7Q%HI2[AN[>*&2*_29T25LC*Y89![]?4]?2OI/X9Z;I&D
M>']3.ID6]_/$X$TGRDL4ZASCN?7MWKLS+.(U**P=)N*I)4Y-^[S-65_.^_\
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MY_-GT9XCU22]-I9^$M+34+"!%$MQ'&' "@9^90>>OY?C7E/CKP%IGQ-T]K<
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M\T0V'@?4? WBS4=L6LN6D,LG!+DGG)]^O_ZZ\R_::GOO@W\*K+2OAE;R2F8
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M&68VO*55SH)\DOW=ULM.KW_+;7MUOPDU+2]-\9Q6OB:YV:5#(C+#(?W>%(Z
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MOAJ="CBEAYPIN+7/24;-1AI9/S];;_=^H6A_M3:%I?BZWEUHQWT$LB%VD*N
M&;KDY_SC&>M?5'CKQI^SO\8/#5O9W][IUI<7<2JR%HEP64$\?+T/'_UN3^!M
MJB[8Y-4N2)AA>6^;(^IS^/X\UVU_'86VC_;;?5;M;E%S!&EPP.>.  >2.A_I
M48>IB:.!JNG7=2D[KE<M6K+5)_A;[D*M0PE7'4HJ/)4NN67*FE&ZM[WEO]Q^
MMWPGTWX3_"?7Y$T+4[26)V\P)'*C @<]B?R_K7T]IW[2?@JZ\2VVD"UMYX9)
M52;[C C< >N1T_GU.:_G:\*^/=1L3/<75U??:%RJ&61^5 (&"6ST]3VKZA^
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MG/7../PK3T#18_$&M?9I0&:S<'!;&=O/U)_+WKYFMO$^I:/J5]+I[2"V,SJ
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MH/C*&SC<*$MS.8\L0-HQO.>2!CG.>GO)H?P\'B'3[VWU$31QV=J[Q(P;JB9
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MXEU;P7IEI#;0O=3Q*/,A'S=!R#G.,<XX]?:N_P!>^*VJ0:J+;5(%5!$0 P&
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M8&U18G!>(IOW@'G(/KZ?C[_D;X^_;V^)T7B,WEO/+'Y4NX!6(!YS@?,/P_\
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MO[-'PCLOV8=1\(P:C;>'O%+:K::I8V@GN6\BZ,J9>-6;/ ZFO?/@;:_M2_\
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M'PY>:##K&C/',RJLTF"&.[&3D#)SD=ZRM'U72WTQ[2X$22VRE<-@$[<CV/\
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MS&5IVB7'!/4Y '&<?6OE']H/XP^&/$FDVVEV4444TA5%$. ?FXPP4#U_E2?
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M7[/%[;> Y?%;7YMFDC^U ;RNY2-P[@GJ/U[FO'OA_HT'C.Y71FF"363E&E)
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M[VCV7YOU/J\=7HX+)Z4H2DU4M"'NZW:4=5OO:QV'[1WB.\^&,EIICWC:A;D
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MEU/5DB*EW\M%>7 [D=#ZCCUQ7VN>9[#!J=.*34&I>[=WJ*S5K=.;\?Q^9RW
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ME'[V,CC''<D?XUL>$OAY:^$)+6/5=-MX;:&-8A>&-1)P< AO?G/Y\]!\&_\
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MFI02327&+$%OE)9L#R\_YYP*_-?0/@OXS\(7HNM7T:\MY;!V:3SXY 3Y9/\
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MIHVJZI9>&]<DAO+J%$ABWLLCH1\H'//7/'Z=!7KGQX\1^(O#[60M(<Z1?;%
M13C8^!V]O7I7YPS:1X8^#GQ,M)1JIEU:]N8YDMBQ."S@[<9]?3IC%?II-XJT
MSXD>&='M;B!'N88XE^903PJC/.?8]A[FLUF>89CG-&JJ$J*CR_NU=0DURW;7
M][?7:[*E@<)EV&E-U7B>?:+3>KMU^?G^.G+> =!\%9@UG6]+,CRP>=+(8^A*
M;B<X/>O:O@)K'P@U'X@:I]BTI5U#3V9K>1ESB1"2I!/3YL=A[>^QX3T?PO\
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MPX?Q\)X.=6I)QA%OE4]'>*TLNFJW_I^9V?\ P2AT[P7\%'\<746=8U.T-]
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M^KW/VT7!\XHK;V 89*\9(SR*^2OC!X@\%:<9X(+!HYYT,=PY7;VPQ)_'G/\
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MWK\RK6;27U#R&*"X9BJD8P"6_K_GUK[8\?\ QOO--^'I^$][>EPJ>2)&/3C
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M@V'3+2U1WBEEMP@^0$YR5QVSD=0,=>O<N"LYQ'+[3-(8[#M*3]_F4.9)M/\
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M5YJDJF*:GR2G[S<9/M)NUNVFNAYN88G&YRW!5)1PU-Z2OJU%K9;ZI;'4>/\
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M-H9_[-/V:U$K2*K;-GR[L@C\?RK\VKX6A@<PQN+J35:=2O.<8:-1YK::Z?\
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MS5OC'<:[<7Y:P:1Y(?F.T9;*XYQP1QWX]Z\[N_%6IC4XM;GNWEMM.;=!EMP
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MMB6P23C!]:^7O"?A'X>7V@PW'C74[6+58MJ1I-)&')'& &;/7'Z<Y.:7Q?\
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M: Q%0=S1QD<CD=0?Q.:_&RP_:CT#Q5\?;3PAJ>G+I.EW.I"#SG0*@5I@N<D
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M9/E'L*=L5]4I)*VLK;NZOUM_2/DSXS_ GQU\.->M=*AC!^U0H%( Q\R^O/\
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MW]/:OS&\,_"?4_#VHWN@:E.MSK9D='+MO?S X![DYR3CITP/6OI^#]I/Q!X
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M47@#1-)-_JSQB(3&(O(#@#(X+9_#^M8&E_#7XB',OB1KBV2Y^812^8H0,"0
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MCV+QOY84L&*'TQR,C_/2OI?Q]H?AN;1++P[I5LAOG@CC/EJN\/MQDXYZD?\
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M82R[-<5RM8G 27*J=])3T2GRO735WMT/J,QRQ8K+GC:L_85XZ\LGJE9/E_\
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M%SD$9&.F.G\N:^D=#\>:E\3+.#1TU!]-4A4?9(4\O'L&&,8[\CTZ5SGQXO\
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M365S<W5Y,\@N%C8J"[$@A@.V?_K#->P?#/X Z[\-M4U'Q!XH:6*W9&DC$V0
M,9XW  =?IZ<5\[2H9?4PZHQ51UY.-X1;YN;W;KSUM\COK8CGUC2O&^KNM%[N
MJ733YLS_ !W\2O&NF>+(I;9+B2V:Y4EE#$;=XSR./T.!7T'XZ_:"N]+^%"&U
M0S:A+9@3Q9R^?*PP('OGM[=^4\)Z)X>\527FH77D3P0,^P!58@C.,=>^._ZY
MKP;XC^'KB#6S$89(]$DDV('!$6TY QGCIT^OM7T4<9#!U,OPM7!\KIN,I0EU
M2<7J^MU9V\SAAAXM8RK[5*G.-HMMV<FE=?+T:Z'@/@#4+/XD:S>K<Z1;6VKS
MS%HY&15D,A9B",@'KZ?I7Z9?LC_#'Q?X8UW4X_$$TW]@WZ,A5R?+$4@(QSE<
M8/3V&/6OR5U[PGX]T7XJ:)J'@=)ETQKB!YY(0PC"^8"^<#&,9YXX_ 5^V/@[
MXPVW@3P%:3^*;BWDO#:1>:H*^8"$&X'G.<CL.,?6O<S6M];H+$0;JT<>O98;
M"13;P\DHQNU:T;M:]?NL>/17L).,6KW3;NO)W^2].Y\._'K0/"?P>_:5LO%G
MASQ$UJIN_M-Q80R[4D<2%R"BD DGC\L5\\?MO?\ !8/6OAEHUQX>L=&\U;FS
M%JEQY9)<B,)NR!GD<GFO:/BU\';[]HCQS_PL+PS?/#IMD_GSQB1@"B'<W3C@
M _YZ_D)^WK\*M'\5VTN@Z3;MJ&OZ3&P=+=/,E9XAAAA06R2.X]?Q\.KD2HX"
MC+#XJ,<RPC53$X9-JI3BFGJO/?M\CU*&(]K52J4G4PVB=2_NWTLE\V_P]3D_
M@[\0[+]HV+4?%?C68:6MY*;B-6;9\SL67J1U)'\_>OISPM9^,/ 6KZ7<:?=W
M<OA*6XC\F<%_*6,L,$$$J,*<^_U%?EW\"#?^%-(?1?%4$^B+;7$4:+<AK?<J
M. 0 VTG('. :_HO^#%GX%^,7P0M?#.CW5DVLV%HNR16C:9Y0G8\L3G_]9K\_
MKU<;B\YE!UVW6E"*NW9J\8RUVT2=][]C[#GP6&PF'M0491BY-6U3M==5OI;R
MOY'LT?B>'Q%\/[+0K.^_M"^O+>,,K2;V4NO(()^7&?R]:PI?V<Q?>'K36GO3
MI5_I,@O3Y+[&EV9?!Q@Y..G3]*^;;+PQX\^#OV_Q!J1N7LM.E=81(6*E$/&W
M(&.G;UZU]._!+XSS_$R&>VU9&M+68&!&ERJMQMX)."3SD#]:_1<ZX8PV%R^%
M6@XXO2FY>R7,XR:BY*RN[IW[=7M8^.PN<UZV-;J)X>";5Y7U5]/DTM$EWZ79
M]N_LE>.KJ;X1I'(ID:S\4^(['S&R2XMKJ- Q.#R>O^<T5T'[-O@^TT[X>75O
M;N&B/BWQ),I4@ ^;=1MQ@8HKYU8>,4HIR2BDDI7O96WN[WT_'TMTU:ZE5G)-
M6<VUZ77]?>?M(.@^@_E2T@Z#Z#^5+2.(**** "BBB@#^!/\ X+3Z!JC_ +<N
MM7S))]C=[CRSM)7)+8'I_P#7Z=*^9_V:/&MOX7M=;T+Q+?\ D6FH"6.*&1PJ
MNK@@<,>XZX]QUK^H'_@H/_P2[\<?M._$V^\=^&)$C>;>T;84-N;<1SUZXZ\5
M^.NK?\$!?VM[[7EO8=;EAM(I=T2Q2[.-PQG##^H[U^?YOEF,Q6(Q%*EA:JI)
MNO"I%>[*H[:+K?;TZ79^G93F>74<%AWB,914Z=*$53;?-&UM+6]+]/O/R,^/
MOP\\.ZKJ=S=631);LTEPK+@ABQ+9R/7]?7O7@NA>#+.]\/:E;_:Q$\ 984W#
M+GMQGDD8']:_H=U?_@@K^U!JFE_9)M6=I1%L#&0$YQC^]ZD^Q]N<>)6O_!O%
M^V%:ZF7CUJ06;/DJ)0 1NS@@OZ=.#[^_E9#EF9X=U99A@*TXSFY1BTGU5GO\
M_P"F>CF.;977HP>'S*A";232;3B]+]+:=7^1^:_PN^%R^ O 4WC2]B6Y64MM
MC;GAL\X.>F.>/Q['B-0UP3:D-2TZW#K(V\QX^Y\V3Q^)^O?CI_0%X?\ ^"(?
M[4RZ(?#&M:D6TH1!0N]2-V/]['!_#Z'KYIJO_!O_ /M,0SW!T?4B(7)V NG0
MG_>&/RX_"L<3D68UJU6<,%5A3E4<HQLM%]_KVZ%4<]RR%&E&6/I<\8I2U>K7
M6_XZ[_<?G)\$/'OAY+Z\_P"$CTV"9#;,BK*JD!MIP1N'4<'\/K7,&VT?5_'V
MH:IIL*0VT<\C1QHH"@ L<#&,_ACU[U^I.B?\$#/VHK(K)-JS*[,-^V11E1CC
MAN_/:O6+/_@A=\?=,MU>SU _:W'[UBZYSWYSWR<?K6$\ISJG!T:>7XAPE?FL
ME9[?AYOOJ>C#.LCG'VT\SPRJ1LHQ>^ZU6F]]7^I^&GQ"\%W7B[7;222X:TM(
M)%)<$*&52!C)(]^,FNA\1^)=&\&Z3INCAD=(XT26<D9/ R23[9^AK]C=?_X(
M<?M1:A;K%;:IL8/DL)!G;G/KSC _#@5YOXO_ .#?[]I[Q';6T?\ :SAXPOF'
MS$R?7G?[?_K-/"Y7GF'@Z*RR3A-*[<5IJM[]5^&IQXC-LBK3A6>:1YXZM*3W
M=M%Y'YB:3XR\-ZA9)::?+$+B7"[@RYW'!'?KT'?VJU?_  _UB&U;Q#,IFLT'
MF$_>!4<\_P"?3I7W]IW_  ;T_M8:/>03V>M2[8Y%<CSAQ@C_ &^G;MG)KZUM
M/^",W[4K^$3X>O=1#.8?+W;U)^[M/.?3_/IU87AW&SIU57PDX3D[J-ERJ]MN
MSOMOTVT,,3Q#E\)4_88VG422OJV[JUKO=6\_\S\6/"&AZ/XY^TVTEI%^[1X]
MC*  >1GT)]>>@XKSMM-\0_##6M0@T'33+!+(P!C4E4!SW P,=CW/TK]V?#G_
M  1!_:*\-:7*;+42-2E<N6#C.6)/KZU:NO\ @BM^TQ=6DC2WR/=R Y9BC'/U
M)S[9!_''%<M#)<^P59XO"4*U.K2;C12T?*K?#9]3LJYWD.)PL:6(QE"?M$I3
M5V[-I73NK75W=>A^ 'B+PSJ7B"!=?U]"%A83B-SD[@=P !]QTQP?UKZ+XJ_X
M2'Q!HFG7$7V'3=)=%VJ,+*L>T 'L0<?CGKSQ^S.M?\$+OVQ]6=[5]5*V#.2$
M5U&%STQNST]ZL>&/^" O[2=G<I-J6ID!>X==W8]0>.XY^M>KAH\7?5<=B*E*
M7UK%J5*<9_'*%DE*_I=>>F]SBGC^&7/!T%7H>PPS52,M>53O%]NENWZ'XZ_$
MCXOQP>,;3PUI-BLMGY4<4A"@KR "3VZ'U/8GVX#QK:6GD)-'>"%KH#?;HPP"
MW)RHX'4=L5^RGC#_ (-[OVI;WQ*VLZ/JIVX(7=(IP>QZ]O\ ZX]2NE_\&^/[
M5-W97QUW5W>Z97^R_O5.&P<8&[CD=,#GU&*PRW*<;0PO/BLLJ5,5%NZY4U+5
M.Z[W2-\SS?+,3/#T\/FV'C2E43GJTH?"G>W331?>?E5H_A'P?;?#R:^F6W^V
MO"6#90ON*\'!.>OX]<^@^4X/%^J>"M;G>TUZ:&PDE8?9A*RQE2QXVYQT/<<5
M^\6C_P#!OQ^V7')<65_KDQTQG81IYV%"=AC</T_*O.?'?_!MG^UMKEVLNFZR
MZ(&!XE4'KD_Q?Y^M=F:0S+'T\OIX7*L3A)49152:BDE9K5O32W]6./+\1E.
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M0F0@LOS<#..WI7-_%_XF_%7P9\08=#MY;R*TM9UCVCS H"MCCMT'X?G7[R?
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M,2.I.&9@-QST/)X/'\^)_AC_ ,$ZOVA_ASX9M=!T^YB2.((C!=H&T8SZ=O\
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M#>)J15.KBG+#4\7:GBL/.]XQ:2<FMM'9Z^1^69I"C"LWAIQK):WAU>GKJ_\
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MK:=',8+L;78",$JP89^O\^.:^??#_BJ+QCK&LZ5XHU0VD$!G2V@EDV*=I(
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M+10 <]OY?_7%%%% !1110 4444 -R<X _'''3\/YTZBB@ IJECG(QZ<&G44
M'/?^7_US1SV_EG^HHHH 0D@=,GV_R:,\9QVSC^E+10 T$GJ,>V.?S_\ K4[G
M_(_^O110 4444 %%%% #<G=C''K@^E.-%% "*21R,<^AI:** "BBB@ HHHH
M0G Z9]J4=!110 4444 '/X?3^N?Z4444 '/?^7_US1110 4<]_Y8_J:** "B
MBB@ HHHH **** "BBB@ HHHH **** "CG_(_^O110 A)'(Y]L<_Y_"C)QG'/
M/%+10 BDD<C'/H:6BB@ Y[_R_P#KFBBB@!"2!P,F@9(R?RP?\:6B@ IK$C&!
MG\#3J* $Y[8_+_ZXI:** #GO_+_ZYHHHH **** #G_(_^O1SV_EG^HHHH **
M** #GO\ R_\ KFBBB@ HHHH 0Y /<_0_XT DCD<TM% #5_B_WC10O\7^\:*
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M*EIK1II^:L--/9I^@4444AA1110 4444 %%%% !1110 4444 %%%% !1110
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M9(\#_M':G^T?\4/B+\4]1TSQ!X,BUB]T;3Y]7>)WEM3-)&L4;3+DEE X'Y4
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MV?R>_:%]1_WRU'VA?4?]\M7]87_$.O\ %/\ Z!4__@'+_P#&Z/\ B'7^*?\
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MW<9Z]?T YM%;>VK^7^?ZG\X'[6LOPA^*G[>WP_NOV7K>#7(8--MS-JFD#,<
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M1:3^R/\ "?PMXDDT$?%.S$EO=:5.D1U)=0E\M8SEFW (Z,2"NX-P#SQ^Z/\
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MW][]!110 8;^]^@HPW][]!110 8;^]^@HPW][]!110 8;^]^@HPW][]!110
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# ?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>g0fyk5pshdve000009.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g0fyk5pshdve000009.jpg
M_]C_X  02D9)1@ ! 0$!+ $L  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" )8!!H# 2(  A$! Q$!_\0
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MU26D5JK6NWY?KV.:GT\2',DLQ.3SYCD_S[]<YZ4BV$:#.9&],L?3C&<\^]=
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M) QU(YXYZ=*J&$C@K^O_ ->JC/K?UO;;3OT]2=8+E<;W^U=::+IM^'<R/+.
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MWK]4_#'P]\+>$[6.VTS2[1?+"@2M!&7^48R,@\^_6NV550!54*HZ*H"@?0#
M%?F^:\9YKF#E"C/ZG1DK<E+XFO\ 'H_1]#Z##Y7AJ'*Y1562UO):7]/D?,'@
M?]E?X;>%X8GN]&MKRZC"G>R(?F'.2<'//Y\U]!:5X:T30U2/3+""U11A0D:X
M Z#!QQ6]17R4ZM6HW*K5J59-W;J2<G^)Z$(1IZ0BH^G^84445!0@(Z#'T%+2
M!<$GGFEH **** "DXSSC/;UI:0KD@\\4 +1110 4444 %%%% !1110 4444
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MSRC=83*Q3)4EX\?+C&<Y'?T]J\/^"/[6WQ0TOP+X>\$>"M#O8;2() ;Z&.4
MJI"%BZCD8.[J1@5^X7[>?_!*OXE?$+XB)X8^&D,[>"I[U99"D9V89\X( QQG
MZ>M7/#7_  2H^*'PG\"Z9:V&AVT\EK IED-JIESLY.0N<X!Y_G2K8>%;'X;&
MX*JJ53 MO#592<*D7-6DXK=W3>]_FKV]R688/,*6-P&*3IX/,:,*>*I5*<94
MZWLY*2BY.ZAK?WE_DC%_9Q\;W5UX<MIO&%X9M5G1)"LS9=9&P2#O)(.>GO\
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M0 4444 (>A^A_E0.@^@_E0>A^A_E0.@^@_E0 #H/H/Y4M(.@^@_E2T %%%%
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MC(_6DIIW6JL]WL]MANR5^9>GW?U\O4SQ'C^ 'T.1Q_C4?DG/(R/3']0:U2A
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M'O .U,@;B!TSGUQVSBOSV\2?&;QAK,C"*Y=(&.<!R/E_/TX'MUKF+_53K,,
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MU_!UKKHCN[[Q5=QVT5LI!D5I)A&ORYSR"#Z_K7SY^A)WU6J>J:ZGZ1T5Y/\
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M7*'TRVADN<#=.(\.6[G)QGO[^GO[PI)'(QSP/:JJ7]G(_EQW$3R?\\U=2_\
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MGGT-*.@HHH **** "BBB@!#T/T/\J!T'T'\J#T/T/\J!T'T'\J /S-_X*<V
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MX'887 '?@<^G':LZ1YVD:=P0['KG'N<?_K]>M?TMA\).%5X>>&P\,-AJ%..
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M/M@]*UMN_/3M[?RJO*F1D#H,<9[9/^36L7?5->G5>OZ&EG9*^DK;=]+KY/\
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M<X5*T)4HR4II>R<ZFM2#:U_<NR5OGOK<N/C79:?XBOEM+GSW8N+6$MG<V3M
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MO@OX61X[#7[>]N$W;L21=LC&T.W0CKFOYG?&'[0/Q4\8R3#6=:NGCDSN N'
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M@#!"C'./3H<_UIP&/J>O7DU\8?<BT444 %%%% !1110 4444 %%%% !1110
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MSV]_RR,UC6%CI#Z5Y[3*MV%/&>0><#J.> ,CZ?7HK4M=0R:=_ RL<'G/&?\
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MJ8X'#QYHQ@E3G;GA;235DM[]%K\NQ?MZKE&4I7Y=4W>\7I\K;GGOPX\!Z?\
M#+P5I/@C2E5[;288X5G4<N$0+G/7CM]?2NS6$$Y_#G_ZW^'X]JMJ"3QW]0,#
M]/\ Z]!7:<?C_3^E=5E2A&,+**T45?1+I_P^ASSYG+GDTY/73JM'O\]?,J^3
M]?S%*(B#G!_$BK%+@GH"?PJ5/R=_^&Z?U^+,W=IK756_3_+\" ACR1U]L^U-
M*9_A(^@_^M5GD>HH4X()[4_:+L_Z_K_ABXRY5&+3VZ+T_.Y3:'@9SC/?_/\
M/\J8T?S C)P/4>]7C@YXX)-(%]%_$ Y_/K34KO9]_P OZM_FPMSRT=MM_DK]
MC/\ )]C^8J,(Q[?Y_#-:NW'5?S'^-1NF<D =,=/K[5:;6S_KY@Z;ULU?I?\
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M(YM8N'2V@NVB4R,0N Q&.?I7L7[%VH7^HMXR;4;^2Z^RWLRIYLFX*HFQGD]
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M]/GU?X+J8\P#9!XZ?B<9_.LBX0DD'( Z>_<>V>M;,RDL<8ZY].F16?, 5.>
M!R<=.1_B?\YJ(V;MYVT[FUXVN[\NG:]]+?CL<_=@B*15SG:<?]\_AWK]E_\
M@D3H6K2:_>744<JVZ2%F;!"XW?WN.O3W_,U^3O@KP)X@^(OB.PT'0;&:\DGN
MDB<PHS *S!3G /8\Y_/%?U=_L*?LV+\$? EI=7L BU/4;5&D1T"R*S*"Q.0"
M""2/PK\_\0<SPE'*WEZJ0GC*\TG3CK[.,6GS37=Z[][,];+,/4=55K>XEO\
M<[:V_KH??HZ#Z"EIN[YMN/\ .,TZOPX^B"BBB@!#T/T/\J!T'T'\J#T/T/\
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MXB\+W.NKIMUJ$/G-_P L"RYSGIC/8<?EQQQU&O?8X[QH;- (P!@@<'KS^/\
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M>W=^9V3Z[Z6_/[]NK/?E!W:<M5T;OV73SZ]?4JQQ@ YYSCU[9SZ?UI^P>_\
MG\*F\LCT_4?CTJR(TQT!QW_7U-2ZC7;==/1_?9?CZ#]E?17V3Z>5_P"KE#R\
M],_EFGJA4=#]<&KNQ!V _'']:78OI_/_ !J%-)IIZKR?^12IR71>NE^C[^OX
M%+83_#^8Q_.H_*/O^5:6T#L/Y_SI-J],#\^?\:.=7NYZ[VL]+6\O^ /DGHVH
MZ6[;Z=_G;Y&>(C[^W&*-B_7_ #[8K0VJ >.W^?I54H<\8Q^-5&:M9/KK?3JE
MI?OL_P "73=TW=/R[Z;?UU*TB%@ . #[_P!<?IFJQ1EZC_/X\UI>6WX>O/\
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M'PV%BJ6&H4J,%;2$$NST:UUZW=CSIUW4:C*4M;;MN*CI?2^]GOM<P)(PC$;
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M(-5=S;*R2S*^[! PQ4@@#\3GJ*_4K]B/PK\,]6\*1SVVBV;ZO91*'E>*/<S
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M'\J  =!]!_*EI!T'T'\J6@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MOJ6O&_B>W6TC'AJ#[1=?9&C"Q#=NE*$ X'<GZ^M?B)\8?V;?VX_B7\2;G7O
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MI322.TX&Z4%V)P&ZX&1U/]:_5Z(-RQ)RN.WID_YZU.8X[C N$$@[ @$=/?\
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MV)"M$I?GD#[H)[UY+'#\4_B-)EC=Z/',1_STC&&//IT''X9KU\3Q=@J-18;
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M5FS+QG.<C]>N/J:Z/BU>N]Y+>^ET]-?EVU%35E+7S;>[>EUTVZ?D9$H95.>
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MX=^+_&%TMOI>DWRM*P5&:"3!R< @E>A^E?9'PT_8!^(GB&2"ZUZ%TLY2A(=
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M5BW,5!&,A3_7/2OZ0-%U*WU?2[+4;9Q)#=01R*XYW94=QUKH U**,]N_I10
M4444 %%%% "'H?H?Y4#H/H/Y4'H?H?Y4#H/H/Y4  Z#Z#^5+2#HOT'\J6@!#
MGMQ2C/>N=\3>*M"\(:9-K'B&_BT[3X$=Y+B9@J*J+N;J0.![_7%<'\,_CC\/
M/BY)J,?@?6X-7_LQBMRT$B.%*L%.=C-C#''6@#UZBBB@ I V>F:6C&.@Q^%
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M?5GAO]CGPQ_:8U+7(MSJ5=1LZ$<\#'^3[=?MZRL;73X$M[2&.&*-54*BA>%
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M-XHH]4F CM74!0)"2JDXP.N/_K5YEXD\/>(_!-Y+9>(;&:UBA8HDK1L ZAL
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MMC^M7HE!Z]<?I^'X?G[<5U&"!V!Q_GCO5F)6W=..W0#H>E8MI_DE;TU;Z_\
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M/-7W?EL==J=TFV[]--=ON,]D) SQZ?\ UZA,9/!'ZUIRQ,QP!^GI_P#K'TJ
M1LK ,#@D#.,CGU_R/TK3FNGNGVC>[V_-ZDSBD[*[BK6=K]OR>A0D$=K#)=SG
M;! "TA/0  GD]NW3MS7P+\4/%[_$;QS'X/MKU8M&AFS-)O 3Y6^8$YQST'_U
M^?I7]H+XBVW@'PG=VAD5;G4872+!^;<X(7 '/4]N.*_.+X;> O'GCW6+BYME
MN;>"[N3+_:(#@B-V[-CWY^GY?F_&6>3GB\%P]A*57$U*\XSQ=&BGS."?\*I)
M?#&=M>;IKZ?EG'N=U)8_!<.8"E5QE2K4IU,=1P_Q.F[-4:DDO=A4TN]DM&?5
MVM?&'1OA_HL'@CPG:&XU:%!$EQ;)N!DQMSN7C@GCZ>_')Z%\.OB5\3;A=0\7
MW%Q#I,S"0)N92(R<\\C) -?1?@'X#Z!X8BBO-=BCU74BJL;B;$CA\9)!;)Z^
MG%>S+$+:+[-:#R;=1@(  H''' _#MZ5[&#R#'9@H2SK$>RP=.,(8?*L,W"G3
MIQ22CB+:5.TO36^C/3PO#>8YDJ57/L1.A@Z<8QP^2X27)2ITX645B+64YV2O
MZ:L\7\+?!;P?X15);:,74ZA3F8"3YN_7//3_ #D5Z4J01 )':P1;1@>6@7&<
M^G^3Q5]UY.X<Y/.,?Y^E5)4(Y'/_ -8#]/\ ]=?98/!X/ TU2PF&HT8)6Y81
M5KZ.^JO?NT_/1GV&#P6#P--4<#AZ.%IQ=^6$%>RM:3DTVVO7H5')8G);'(P"
M?\_3^M5'&WD=?7D8'/8_YY]JN,IVC Y]O\1_GW]8G'!ROZ?X]J[X2;M%ZI=;
M/R7X):?YV9O)*3<^9MK=:I.]KNW]+IZYLPRN3U]?P/I5/Y=IW9_IZ?6M$J3G
MY3SGM_7%4G4J2"O<G/\ G_/&*W>JB[NUTW;K:SUM>W]=F827*][<U[V32U?]
M:?YE*4@KCMT'7T_/MQ^M4'4\CUQ_/_ZU:K*/7&?R_I5*4?>Q\V?3Z_C6L&[J
MUM;;Z?-7MW$XVU;O=;=+::]-=?N,EBP)&?R]^:K7$4$L;+/#'*K#:?,4,>1C
MW]__ -579E8'A<DG/3''^3BJLN=@'Z?4?Y_^MWZ8>]&W+%QD]5))V^6J?-K^
M9C**NT[.,E9K1JUE>Z=[W73=G@WC_P"$MAJD,NK:-N@U")6EC6'C+ Y' _#/
M/3@'I7G'@;Q_J^B:I_PC7BD2*4<102RY"[<[1R<#I_GT^NHR4^7;P^01QSG'
MY8]?Y5\T_&BPT%&,^Y+34U8,D@PKY'.>Q!]\\Y^E?$9_E/\ 8\WQ'D=2&!Q%
M"2>,PCER87&T[KF3C?E55I>Z]-;>A\+GV4T\KG_;V5XC^SZU+WJ^'IRY*&.A
MISPDF[1D^CZGM;-!+&L\<B&%U#!\C:=PSU'U_P <"J+LKY\ME< \E2#Z#MQ[
M^GOFOE.Q^*+#28]#-TWG1Y19"3DX&T#)/?\ ^M7NOP]N+B]TR26XD+[AE6))
M)'4$'/\ G]*];(^,,#GM>CA<)&]5T54K\LN:-"HHQYZ<FNM]$^O3S];*.)L%
MG,Z>'PJ:J2I>TK2O>%&:2;@U=W:OHUIZHZJ;&/?/O_\ JZ9_.L>8#KWP/YX_
ME6W(F,\YY(Z?7FLJ=3AMHR#T/H">/TS_ )XK[2.UKWM^"TMZ_P!=CZ*SM?IW
M??2]M?NML9$J[CQ]/TP3^!%9DN K ]?\C^E;+H ,YY/;TZ?_ %^*R)U()';G
MG'^>AKHC+IKHE?\ 5?U_P_,Z:C*ZTNM_-;V[)Z:=._4S7SZ<9X/^3]:H7 &W
M"\-@X].WK[?T]ZU64CW'3_(K+N98XC^\/ &,X^O_ .NNF#LHM7\K_ET[V)LF
MW=]-NVVWYE!"ZD[L?Y/M_GTK,FX8G^7/?./UJY]L@FD\N$N[L< !3SDX';_/
M.,=:I:E;ZC80FZFMY!#U#,AQZ#KQ_GI65?&X3"0G5Q.+P]"G%<TYU:L:<4E9
MR;YFEI?\UN5&G4E%2Y)/EZ17HE>6QF770DD*/?@_C^)/K6:,2*0@WGMMY.?;
MUKV;X:?"?7_BG<1PV-M)]G=\-(JG@<#.<>G/;WK2^*/P=U/X4^(--T&PA;4=
M6OBC):XW,=W( &"3GV_GT^?K<<Y!2IN5#&0QD;>ZZ#YXU'II&<;I]K_,[\/E
M>*KKVB@H1E]J4DTEILE\MOENSYZ>TU21U2WTN[E#$ %8G(],YQ[]1ZXKTSPA
M\ O'WCRY@2QL+J!92,&2-U&"?]W&?\]Z^P?V7M0@O/&1\(_$OP9#IQB \F:Z
MM@HD)'RDLRC(.,G&>*_6C2?#/AO2TBDTC2K*U4*#&\$>WCL1_P#JKY+'^(&(
MJQ<<!AU1NK<]3WI:]O,]>ADM"/\ ';G:VD?AZ?)KHOOUT/R^^&_[ H!MYO&*
MA@2KL#Z$C(P1^/2ON/P5^S=\./!"0_V?ID4DD8&6DB0@D#WY]\]>:^@*Y;Q+
MXT\-^$8#<^(=3ATZ$*6+S'"[0,GDX'2OB<9F>/Q\I2Q6*K55)WY'-J*VT23\
MNYZM.A1HV5.G&-M%I?\ /KYG+_$CP5H>M>#-7LGTZUC-M83-:LL* HZ1G9@A
M<]<<\G\:_+7X6?$KQ%X*7QMX;U6"2[L!/<PVD<JET$>YU& <C&,<8Q@@].GT
M/\0/VU?">M:K>^#/ %U%K%R5>"=H"KG'1N5+8]<>V.M8?PR\(Z?XH^WW]]9(
M;JZ9Y)XV495FSGJ/KU^E?0\/XFC#+,RP^-BJ^&<\/4A3<DITIPGS.=-OX6^M
MK-GRO$&'K2S#+ZV#E['$N%>G*I;W9PE%+EFOM6Z+6SZ'D'@'PKX>\7:U-J G
MEL+V:8OY".8T^=B<;1C\\=Z^F-!N_%'PYURS@M9)I=%E=!/(Q8J%)Y.3[ Y/
MU_'Q+QSX>D^&VKPZS8#[/;FX!=5X 7=DG (' ]/K7T5#XST+Q7\.&DLY4GU9
M80<<!U=4QCU_+%>OF]3ZQ1HU81>+P->*IVJ+FE2=E]JVCCT;:^>R\3*(PI5:
MU&<EAL=AVZJG3O%5HWO*ZZ\VOGY'V#I&JV^L64-Y:,&1XU+$8/)52?US[UK
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MZJ4Y<\-5?IL][H]",HSBG%\T7JFMMEL??2MN56'1@&'T(S2TU!M15_N@+^7
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M*JYVJJYZX &?KBG44 %%-+H#@LH/H6&?YT$;A^>/2@!U%(,]\?AFEH ****
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M-GMU*]5R2G*<DES1<G=2O;WD^JVM8OQ\\>_\^E7(P1@#MR?<9JI$.?Q'Z?\
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M*E6I@Z]6F\#2JPJ8N-.E2PKH)XET9MVJ2A.Z35MK'WO\:_VWK#PCHG@RXT>
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M1<^26D;(0>8Q*,"<X/7\Q7RY^T5_P5WN;CQ1X>\.>";*736GEBCND0N&C9G
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M8"^)?Q!^/'Q$U;Q+H0@T/5=4NI8+QK?#>6\SD,K%2?NX./\ "E;6UUZ]/O\
MS,Y0Y9<O-%[:IZ:V_P _P9]-?"C_ (*::EX7NVN?&MM+?Z)=2G;>2;S$J.W
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ME'5/K]S\]]?4XHI1C*+O#5)*6CLVM?O[ZV-9!AOJ?3Z\5RGB7PO]I7^T-/\
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M?5+. ?R2M*.W@BQY4$,>.FR)%QC_ '5%:U^/<]JJ485(48RWY8W:VV;U6O\
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MV]?-O2[M^+_X!9=F^7GBJ4S YP .G3'MZ=:<TI &>V!]?T'\ZJR-W'8#^?\
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MMYG +J,8"@\YP,#CKV Z>#?M*>+O!GQ.T?P[=:996T-R6MTN/*1!(,E0P?:
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MRO%PNX59TX2UM[E>R:>W1I?TS^;L10K8'%5\+625;#59T:B6JYX:.WE<W_\
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M6FW1UW3(VEB8DO;H,A1W^4?B<\5[1&Q)YZ#!X_$C]:O)(CQM'*BR)(I4JX!
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M!//IHA:YMP$9L1E=ZG@>F/K79>"/%WQT^,5QJ=]\,UD^PZ9*Y>- 2PCB.77
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MZC%/^#/[/WQ0_:9U^QU2^MKRP\$RR1R7D5PC1YA#*6!#*,_*3_\ 6K[KP_\
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M@X^GK]:R#<%<<?3\/\_6K2R IN.=PZ?0]._U]?Y5+35KZ7_KS_K8::=[._\
M5B[YGM_G\J 06W$X]OPQUJJ'; .>V>W_ -:E,@/RJ>?4?G4ZK:S]=^G];;[>
M0I)NRU+H8#D$?G2/(#SWQT%4A)@X8GG_ !I^]>QS]*2CK?E5W\_3=(3G9VU^
M1,90.HZ^_P#]:D,@(QQ^=59'^O0X^M0[F]?Y?X5=NF[V^?X:_J"DN_W_ -?U
MZ%MI!C  X[]/QS^M5G8;>O?^E0-/M.#SR0>GZ\9J!Y2>!P/\_G^/_P!>J4'Z
M7W]-/S)E):6?6^WY[!=W7V:!Y5^9U&43^\>W'^378_"[X9WWCJ__ +:U13'9
M1N#Y3#Y6 /'!X_3O7G&H;VB9T)W1#(''./3\OU]:^B_@M\7-"M+)/#NHA;:Z
M\Q )#A 3T^;(P<$Y[=^:\//:N)IT8T\/&7)*ZJU(WYHWZ*VNNFO_  #OP5.E
M+WY-7T<8Z6TMWZ+HM3Z5T?P;X=T..-;#3+:*2,+^]$8#EAWR !R1T.:Z?G&!
M@>G'^?\ /:JMO?V5VBO;74$RN 5V2HQ.>VT'.?;%6L\9Z_2OB/)MMK>[N_GU
MOZGJ_P!;!SC'?'6DY4'JQ_S]:4'(S2T (#D=,>U+110 4444 %%%% !1110
M4444 %%%% !1110 4BC:,=>:6C/;_/?_  H _E_^-2-_PV;XF/F$HMW<'!)P
M,2L>GTSZ?G7PO^T5X?U:#X^^&_&$=BTVDZ==0O/=[6*1JC@G) (QP>#V]<<?
MIO\ M=?#F_\ AY\>-2^(=\CQV.JW$IBD8$*3(Y. >G?'Z9S7D.L:;IWBBPC^
MWP1R6M\ XD9 7PZ]F]NV#[U_/OBCB:N59O2S%TI5<.\-/#UH*Z<J=>/+)Q[R
MBGHEY7Z'YMC*[PG%]=U%>-?#PA!_#=-)/E>FJN^O9V,;7OCM8^(O"5YI'A_2
M1X@NI-*^RM$L0D,3^3L.  <$8SGZ5T7["'Q/T_X.VWBZZ\6Q?V=>7[77D::\
M87F;("A'P>K=,?\ U^E^%7P[\%^#;E[K3(4FDN<^:)E#J-P!( 8D#OCI]:^@
M[3X.?#3Q)>+J=_$D-R7$CK"H1&8'=R!C.2/3O7'P/G628>E&C0HSA0J^S:E5
MMS*::NG#:-O*U]-3WZ=6C#FIQI/EE;5MMMZ/H]M7MON^I^<WC_X3_%?QM\8-
M=^+?@?2KJ#2;YIY)!!'(J3Q.2VTA!@A@<57^%$/CN/QZV@2>$9="-W)(E[JH
MMGC,CN2K.S[5SD\]>O/M7[E^&]1T#PIH*Z'IME9-:+$(\R0H7*@8SDC.2,]_
M\:\K\2+X=,TM];V-E%<G+&2.%%8'KD$*"#G'?\L&OU#/>(\O_LZ=.FJ;<J2@
MWII=*S?>U]+][=5;K>,?*X."Y8Q:A?Y;]_ZML?C#XT_9!\<7'QJE\2Q^)KJ#
M3RPN#()W"ODAF4G..^,9]>:^G=%TR;04ATV>8WDENA0SD[B^$QG.<\[>N?Z5
M[_XUUR-XY -H91M##&\X..OYG_)KQ*VE6>\9W;:I5\NYX&>G/3/\_K7\T<1Y
MUB,XSK 8:3INGAG"G%0A&]H->\Y)7?97NET['A9SBN; U74:48T[-;6;2^=K
M7_R[;_[)3FS_ &AFGLSLN'N0'*_>^\N>F#Z?A@&OZ3;!F>SMF?[QA0M]<#-?
MSL?L&>'+G5?VG=0FN8GETZ&5W2;!,9VG/7&.BXX.,\>U?T7HJQJ$4<*!^7^1
M7]9\*T9T<CP2G?FE34M>L7&/*_GK]QZ_"-*=+(Z"G?WYSJ0NM.26UMM/OV^8
M_..M%)PPZ<4M?1'TH4444 %(1D@^F?UI:0;NYS_GZ4 8NO>'=%\4:?+I>OZ=
M;:GI\V0]K<QAXVR,9(/>O@GXU?\ !/SP'\1)3+X3-MX19\F06BF(9/+8\M.0
M3T_6OT1I#GC'XUABL+AL;1EA\9AZ.*H233I5Z4*L%?=I33Y7YJQTX7&8O UH
MU\'B:^%K1::J4*DZ4G9W2;BUS+39W/PSU+_@D_K=B[7&G>.Y[H$Y*">4$9]%
M;!_S]!3++_@D_K>I[)=0\>7-F >5,\I)P.RKD_CCD=Z_="BOD/\ B'/!7M_K
M'^K^!]JG>_LURWT?P6MNK^I]='Q&XSC1]@L]Q?L[6MS7E;_%O?SW_%O\V_@S
M_P $[_!/P^O(KGQ5=0^+(X=K+#=*TJEU'?S4QUZGWXZ5^@7AWPGX?\)V8L/#
MFEVNE6@VCR+6,)'A>G ]O\]QT5%?783"87 48T,%AJ&$HQBH^SP]*%*+2VYE
M!+F?F^Q\EB\;C,?5E7QN)KXNK*3ESXBI.JXM[\O.WRKR5A!P/7_ZYS2T45T'
M*%%%% "'H?H?Y4#H/H/Y4'H?H?Y4#H/H/Y4  Z#Z#^5+2#H/H/Y4M !1110
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MQJ1>METYMEL_D<E6%2#OR25DHO1NVUWU_4UX&RIW<'.._;-:T! '..G]!_\
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MU)12C>UWUZ7M^G_#FD'"Y&<YXX_^L/>ID;UY/O\ @?\ /M6:'Z9_//\ @/\
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M!]!_*@]#]#_*@=!]!_*@ '0?0?RI:0=!]!_*EH **** "BBB@ HHHH ****
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MQ4R\+G///?C..!_7US6=',<8Y_(>W'^?RJ=6Y!)./Q]/2LM-U\:=O3JK_/\
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MNGOQS[\_U^E12S=!@#.!_G'Y_CU[5I:IX$\5^&D+7-I<7)7D[58YQU['M_\
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M]%9FCZI;ZSI]MJ-J=T%R@="#G@@'K^-:=?G9]!<**** "BBB@ HHHH ****
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M@ HIDDB1(TDKK'&@W,['"J!W)->&?$CX]^#? 5E-(=1M;R\C#?N(Y QRH/&
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MG7[3WQ$\ _M'?#'X/^&[RXL=$\6-I45])&SK&1<F$.6*@#HYSD^@H _4PP_
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M2S21V\L5\3\UN0X/T;//?MFOTP^ 7B$^(/!L,V[<(MD8[XP"!7Y>ZBS26,X
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MMKZON;$<;AP1.X]/;'X^W^'I6M#+.Q"^>X].3UZC_P"M[UC(_!.?3 S^>/\
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M !1110 AZ'Z'^5 Z#Z#^5!Z'Z'^5 Z#Z#^5  .@^@_E2T@Z#Z#^5+0 4444
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M&+U6WO.S\[=_(UDDW-Z8_P Y'4_Y]:T$<KWXQZ#UK%4\@@^E7XN#RW;."?\
M/K6<TK<ROJ_PMI_7](Y8+WK_ ":TMIKZW_,W8I5?GG(P>/J?7\.]:,;$8 Z_
M_7K"@<+C/KZ_7_&M*.3<.O;KGW_S^6:S_K^EN_D0UWO;[+UT5U^GZ>IT,,I
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M?;9Z?/OJ7S*V[@]./KVHM]2;2[^RNXF*G[5$"0<')9?7CU]N:SY)\8V_S/\
M];TK&U>9MEGLXQ=1YZ_WQ^7I77B:"K86O2=TZE*<?^!\[:?J9T9<E:G-)74E
MY+==?+IJ?N!\*K\ZEX'T2Y)W,ULFX]>=B]_6O1*\-_9]NC-\/-(1CDI!'U.2
M/E'%>Y5^"37+4JPLU[.I.GKO[KMJ?9Q;<8M[N*;^Y!12$D= 3_GZ4M2,****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M_KJ]?V6^&EBVE^"=$M7!#1VJ$C'.2JC^E=[56QM4LK2"VC&%AC5 /H *M5^
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MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHIIW9X Q_GWH
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ME%(#D ^U+7,:!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% "'H?H?Y4#H/H/Y4'H?H?Y4#H/H/Y4  Z#Z#^5+2#
MH/H/Y4M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M%(8U48&%&.@QZ5I445^,'TP4444 %%%% !1110 4444 %%%% !1110 4444
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M &6_*BB@ W?[+?E1N_V6_*BB@ W?[+?E1N_V6_*BB@ W?[+?E1N_V6_*BB@
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M]EORHHH -W^RWY4;O]EORHHH -W^RWY4;O\ 9;\J** #=_LM^5&[_9;\J**
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(!]!110!__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>g0fyk5pshdve000015.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g0fyk5pshdve000015.jpg
M_]C_X  02D9)1@ ! 0$!+ $L  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" *6!+ # 2(  A$! Q$!_\0
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M $P/0?E36 &W 'WAVI]-;^'_ 'A0 HZ#Z#^5+2#H/H/Y4M !11367<<YQ^%
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M''*]\'B5;?\ <5.MNT7W!8G#I:UZ7KSKR[O>Y].45\\_\-3?!+_H<;7\D_\
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M9>M]2\9^%_LFJ/YQ>*]M%6;)!W$B5=V!G/'-? EO\*I="_X*K2Z!H/A>\M]
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M/J*BOEW_ (;,_9R_Z*3HO_@1#_\ 'J/^&S/V<3T^).B_^!$'_P >H_L_'_\
M0'B?_!-3K:WV?-!]:PW_ $$4?_!D?\SZBHKY=_X;,_9R_P"BDZ+_ .!$/_QZ
MC_ALS]G+_HI.B_\ @1#_ /'J/[.Q_P#T!XG_ ,$5/+^[YH/K6&_Z"*/_ (,C
M_F?45%?+W_#9?[.7_12M%_\  B'_ ..TG_#9G[.7_12=%_\  B'_ ./4?V?C
MO^@/$_\ @FIY?W?-#^M8;_G_ $O_  9'_/S7WGU%17R[_P -F?LY?]%)T7_P
M(A_^/4?\-F?LY?\ 12=%_P# B'_X]1_9^/\ ^@/$_P#@FIY?W?-"^M8;_H(H
M_P#@R/\ F?45%?+O_#9G[.7_ $4G1?\ P(A_^/4?\-F?LY?]%)T7_P "(?\
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M34\O[OFOZ0OK6&_Z"*7_ (,C_GYGU%1FOEW_ (;+_9QZ_P#"R-%S_P!=X/\
MX]1_PV5^SCR?^%DZ(/\ MO#GG/\ TUH_L['Z?['B==OW-3R_N^:#ZUAO^@BE
M_P"#(^7GYGU%17RZO[9?[.).!\2=$_\  B#^DWM2G]LO]G(''_"R=%_\"(?_
M (]0LOQ[VP>)_P#!%3_Y$/K6&_Z"*7_@R/\ GYGU#17R\/VR_P!G(_\ -2=%
M'UN(?_CU(?VS/V<1U^)6B?\ @1!_\>H_L_'_ /0'B?\ P34\O[OFOZ0?6\+_
M -!%'O\ Q(_YZ'U%17R[_P -F?LY?]%)T7_P(A_^/4?\-F?LY?\ 12=%_P#
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MF^><)]H^S7+OMR,G.TGUY^M:-C!9^+_A<^FZK'Y.OE3'!J##;,21A6#$!O\
M)(.:^?+?0?B)\)]7L8HXY]>L=1D $DX9Q&CL.1N&!A>?TKVL/B*?-/#5<;7A
MC<$Y\U&;M#%0@DW.-;X5;^7Y+8XJN!CR?6%A:4Z5=Q4>5^]3E)Q6L=[-VUVT
MMJ=);Q^(]#\:6TVM7VH_\([+(H(>>79@XSU..G;_ !K]$O"/PN\%>,M!AO\
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MH4ZT\1-4J7/4M*"A.=E/G3]VVZMT,#_AK[X_-T\6:T<]QJ5QC_T,?D/H*/\
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M/B"9#IURGS>;;R, K@CK\I!SSQ1_:^:_]##$_P#@?I_E_6MSZEA?^@6E_P"
M>G]?\-<\-_X;(^.JG!\8ZSGWU*8_^U:E3]L'X]N,IXMUMAZKJ4Y_E+7Z #_@
MG;\*=&%GI'BWQ5#I_B:^2(164MPD;&60#"[6.?O-Z?K7RI^TQ^Q/X\^! @UO
M3[&2]\)W.)(]0C4RQF(\@F11@9!]?RS1_:V:_P#0PQ/_ ('Z?Y?CZW;P6%23
M^K4FM-HKR_R?EJ>5-^V#\?$Z^+-;&?[VI3_UD-.'[7_Q\'S'Q9K>/4ZC/M_]
M&UZ'^S;^Q#\8?VD=-U[7_"VBRW.C:#;S7%Q<*A*JD(W,20,= ?SKRCPG\ _&
MGCGXOWGP>\.Z?+=:]I]^;*ZA6-FV&.0QR9P#C !//UH_M?-=/^%#$Z?W_3_+
M^M;S]3PNG^S4O+W-]OZT[E__ (;&^.[-M'C#62WH-2G_ /CM*W[8'QZB&7\7
MZT!Z_P!HSJ/_ $:/2ON'Q+_P36_LCPSJ?V&[>7QMH5D;O5=-)PT)2/>X*]1M
MYKYZ^!7[&7B/XFZGJ4_B51IWA?2KEK6YO68($=&*D$D^W'/O[T?VMFO_ $,,
M3_X'Z?Y?CK<KZAAO^@:BMM.6_;Y^OKN]#R1/VP_CU)]SQ=K3C_9U*<GCCGYQ
MU^M./[7WQ] S_P )7KGXZE< ?GYM>_\ [2?["FO_  <T>'Q5X4234_#DJ!Q=
MJI9-N 3\P!!].HR:^+/A[X4N?'7B>'PU I-R95CG4=5R<'CKP<]/UK'$9]F&
M$H5L5B,SQ%.AAZ;JU:DJFD*<$N:3;Z*WX]=;BP.&<HQ6%I<TFHQ2CJVVK=]]
MM//L>G_\-B?'89_XK#6 W<?VG..ON9!3Q^V#\?&&1XMUL_34Y\?^C/Z5];V/
M[$WPVMK2T'B+Q''9ZE<!"T#3JIW, <%2<CJ.^?Z>.^/?V._$>@Z];?\ ".PR
M7WA>61 ;]0SQB-VQN#CCIWS_ (U\-@O&3(L?B'AZ?$./P\U&<H5<;3GA<-B%
M3MS+#UJEHU9NUHJ._2Z9V5,CY(\SP=!ZQC:"4I*]K<R6W;Y/J>4']L7X[@X/
MC#601U']IS<'_O[3Q^U_\?&^9/%>MM[C4I_YB0U]<:;^Q#\-_P"R]/N->\1Q
M6=_?*,0O,JD.P'&&/J0. *^??CI^R?XN^$MH/$VFVKWG@Q@7344!=#'G*G>H
M(^[[\\=C6F6>,&19OF%'*\-Q#C:.+Q%25+#?783PM'%5H24?8X:M4M&M5;7N
MQBVY;]0GD:IP<Y8.BXK62A:3BE;XDM8Z]6VM?D<7_P -??'[_H:]=_\ !C<?
M_':1OVO_ (]J,MXMUP?74;C_ ..?UKYY2XB=!-N_=DGGW_\ UU]3_ 3]DOXE
M_'J2^N?#VERS:18VSW4EPJ,1L1=Q.1D= ?\ Z]?4YQQ>\@P5?,\ZS_\ LW X
M:WML5BZ\:5.#YHQ4>:3LYMM)1W=_4Y:67T*TU3I8.G.4MHQA=]+_ "_SZG.K
M^V!\?FY_X2S6R.VW4+@?^U!FE/[7OQ^/_,U:V0.F=1N,_GYAKR?QOX;D\%^,
M]8\&WHV7NC3R6\ZG@[T=D((Z\$?Y'7 :(!!@,Y]%!)ZXZ D_I_\ 6[J.=YCB
M*%'$4LRQ-2CB*%+$4*D:EU.E5A&=*HK7NI1:DMMU\YE@L)"3C+#44T^6W+HF
MK;]DM?GIV/>!^U[\?N_BO7!_W$;C'Z24?\-??'WMXMUP\\_\3&XX_P#(GK7@
M<D4V S12A2,AO+8<'OW_  [TRWMY+AV$*2,5'/R-Z@?YYZ5K_:N;IQ_V[%<S
MVBY:O;9/>UKZ7_47U3!<DIJCAW%64I:<D=MY=-5U9[^?VOOC]_T->N8_["-P
M,?\ D3FD'[7OQ_R?^*LUP#WU"X/I_P!-*\#"."\;(ZL"00R$>W /6IX()7)V
M0R$J,MA'(_#\_P#]=$<VS:;]W&XMV:7*I-OIZ^NW=:]5]4P27,Z.&C#35V2:
MTU3VZZ>I[L/VOOC_ /\ 0U:Y_P"#&<G_ -#_ *T?\-??'_MXJUS\=1G_ /BS
MBO VY9E*LI!Y#*5(^F0/Y=*U]&T/4-=O+>QTV%II97"85=V.>IQZ<'WZ\54<
MRSF4HTX8[%U*DYQA"$)-R;?*N7EM=N^O7_.*F'P%&$ZU:EAJ5&G%SG5FE&FH
M))N;DW;;;7H>PG]L'X](>/%NM?\ @QG'_M3G^G\I!^U_\?6Y_P"$LUL#VU&X
MQ^C\5V^F?LY:6+.%->O5L]5N(@T,#2!69F'RC&0>OZ&O*O%OP;\0^%=5M;:Z
M@*Z9>2!+:8#.\'A>1P>.OUKWL5EO&6$H1Q-6IC'2E*,).G4=25.4N6RK12_=
MWT^)Z_>?+X#BW@S,,5+!87$X?ZQ",YT_;05.&(C3?O\ U:3=JS24G:*V1N?\
M-?\ Q^8Y'BS6RO0XU&8\X/I)[TW_ (;!^/;G8/%NM97(P-0G)XX_YZ#^M<=K
M/PRUNVUC3] TRVEGO=1$;(H1B-K[><CTSS['H:Z7QQ\(/^$ T6TN]4D$>ISJ
MK2P%AE2PS]?SYKDC2XH=/%U57QD:>!Y?K52<W&G3;2DH*;TE.UGRK5_GWRSC
MAF%3+:'M<-/$9KK@L/2C&=:I!:.I*FGS1I737.URI]>BT/\ AK[X_?\ 0UZ[
M_P"#&X_^.T?\-??'[_H:]=_\&-Q_\=KY]88/'3M25Y/]K9K_ -##$_\ @?I_
ME_6I[OU/"+?#4NGV5Y>7K]_D?0?_  U]\?O^AKUW_P &-Q_\=H_X:^^/W_0U
MZ[_X,;C_ ..U\^44?VMFO_0PQ/\ X'_7]>K%]4PG_0-2_P# 5Y>7K]_D?0?_
M  U]\?O^AKUW_P &-Q_\=H'[7WQ^_P"AKUW\=1N/_CM?/9('6EI?VMFO_0QQ
M'_@?]?UZL/JF$_Z!J7_@*\O+U^_R/TO_ &'OVI/C;X@^/_A'3M3\3ZQ/:RZ]
M9)(CWT[@J9T!!#/Z=?K7^JE\!KF:\^#7PWNKAB\\_AG3I)78Y9G8/DD]R:_R
M/?V!N?VB_!WMK]@?_)A*_P!;S]G_ (^"GPS]!X6T[]%>O1QV(K8G),NJ8BI*
MM5^LUU[2>LW'ET3EV71$8:G"ECL1&E"-.#H4I<L597>[9[(.@^@_E2T@Z#Z#
M^5+7SYZ84444 ?E/_P %0=4DT?P+HM_&AD>"02*BYR2LAP/KU_,$<U\-^!/$
MDOQ=^% TC4K22V2*U$8>12&($>W(/4<<CK[8/%??7_!2>&VE\+>&ENU#P-<J
MKHW((,ISZ^E?"_B[Q-IO@WX5Z:_A6R2&[>TB#+;H S$H <A,'D_7\>WW6$G3
M_LC)\-"DY8RMC*KP]:]O9-2C=OLEKKH>3",O[0S"K*2=&%"ES1MJ_=6G_#=O
M/6Y\,?A/8_#S1=8O?#\CC5IHI7BEW'Y9"&(Y[8X_#WQ7&>"KCQSJVO:EIGC+
MQ''- UR[PVQN,N(U8D *2#T&,<=.^,UZ?\&O%@OO!4EUXJ?['/?*T</F?(?G
M! /S8_#_ /77CE[\%/$R>.)/&FE:S<2V$LKNL*R,T>QB3T!(_B'/L,5V4ZLI
MXO,:68UZ*K**C3Q-6DJG-4II>[3GT6EK]^YOHJ=&6'BW&ZYH)VT=F[]V:_Q>
M.F>,+!O!6CZU#87EJFQAYRH[, .GS DDDC\:T/@?X2OO /AZ^LM=U SVEU%)
M'YTDFY29 1P22._KW^A'@_Q;_9V\?ZA?GQIX6U6:.] $LMLDI!<KR1M!&2<8
M(Z9Z5Z;X'_X26[^'DFC>,)I++4[<"-))6*,[( ,C=R<]<\YKIQ-*G_9>&I8/
M,*->C.O3>+I>S7MZ52^K5O><4[O3H1&K_M#]K1E"HDU3=_<DG:UUTTTMNSCK
M_P""FG>"O',GC78^JZ=K4[OY8_>HH=]WW>>GT'7I7HVL?$FTT)H]'\,-'I<\
ML +0C$3;B.A7W/M^5>Z?#S0YH_#L9UM5U"UM48PO,0V0%)&"V>PX/3//L/DK
MQ'X7\/>,?C/' E\;&02^4+9#L3D[0.,#V]/YF:&*>8UZM/'3E7A@J3O447*F
MXPLJ:E36THQ5G?\ ()QC0@I44E*K+9JS4G;[6^M]/N9\Y_$F#XJ?$+Q98V=K
M?-<:;YZB[6)BWR;QG</IU]J^N/ _AB'P?8VMI<P;@+9'F)7CS0N3V]<_KBO3
M1\*O#GPFDN]1U&_%S=Z@@:TC+AR&<?+_ )'/?-=QX;T*'7]&N9[^-8_D:1)"
M &\O!]<=B#D<_3BO)X@KK,88&> JO#TL#*,54IP=&%=2:<DH=7#;YZ'=ES^K
M.JJ]+VKKIMJ3YG%M+K]UCR[0/COH^EZZ- U2>*&'<T<,<A"YP2!M4XZ^WY9K
MY_\ &WQBU'7_ (KW/AF6?_BF88FG6-F_=LJ@G@'@\=/IC!J;X@?##PQXH\<V
MCZ+JKQZC87 WPQL1O=7Y!QUR?Z^M4O$WPEMO#NK?\)+XIF_L^V:T\J.X8[#+
M\A R??'/>OI<'ALII>SK34OK.(PCBZ3A[ZJOE494XWNY26JDM?O9YU:I7E+D
M@K4^=R3O[MNL97T27;3HC \-^*M5^(UYXBT+P%*-/U/2#(EK,#L!9,CC'N/U
MZGOA:AX>US4K(Z1\4?$T5YJ<4S$6WVD&7RP3\NW=GMCIQ5SX0^%M5T[QQ<W?
MA52=-U*5B;M"1YBR%OF+ X[YY^N*S?&WP \07GQ@?Q')XCN9HPOG36 F+1A<
MY;Y02.F>2./PKU(O"4,74HO$4L+!X>->E)T?:8F-2*2E1<OBASOY+SL<EJTZ
M<6X2E:;C*"E:G:ZM)?S6W_X!O:+?:YX;%MH_PKO'L\E8[@&0J7Y ;'.3G/;-
M?H7\,[ZXT[PY;OXUO8X]2N @:6X8 ,S8R 6/.2?\XKX)T.VTG2O$]O>"]6*T
MTV5?[0(< +M8;L_D<]C^=>@?M4>*=2\;^"_"D7P/NY;[4K:YMAJ M&+MA&4/
MN$9SV.1["OF\WPZQU;#86*5-5ZG/4QM2G9TI1BFHU9O1*5KJ^FOW]^&J*G"I
M5<F^6+2II[NZ^&/]:K4]3^+FH>*[#QSH[^&C(=(N'4S2PY\IQGJ"..>",XQG
M&:XK4O"/BGXOZ_=^&_%4LJ:!Y&R!BQ5-Q4CCD9)KZ1^']A+=_"[PU%XNM@GB
M"#3XA>22C$@F"#.[=EMV<_Y%9/B5-7MX+,>';8F3S4\R9%.XC=CD@9_STXS7
M@X7$0PE6-##T:,,12YZ4<797<HRNJU]K.VG>^GEW34ZM)2G*4H.S]F]6HZ>Z
MOZ70^<M.^$OBCX&Z%J]IX3^T.MQ*PC<LS+L))XSGU]_K7<6?BG4_#OPYO=5\
M2)$U_+;REOE D/RG.3C/.3_6N\\>?%:X\-:;8:7K=BKSSI&CNRY()]?T!]/2
MI+/P5IGQ*\*L?M4 2>-A]G\U!]\=-N>V< >]<V9YM5QN%K0Q7LG5J5U3KXBG
M[M2I:/+RIJW,VM#3#8>-&K2K1C+E]FI*$E[J7,G>^U_(\3_9R\1>'/$ESJ^J
M-:$WZ7$A21ESC!SP2.F>G^<^V_%2[T;4O"6MZ=JE]%9R7UG+#$)'",2T94;<
MG.03VZ_I7CH;PC^S[;WEK*42]N9"%4 <[CVP!]>^<YKR#XF?;_C0NAW7A_49
MK6"VN$>_$3,H$(<%]V&P!M'?']1GE66?4XT,73HU:&%G44HXB47/DE%J45Y\
M\M+]+Z&N,Q*Q-:2J/G:BE*',DK-6^7*M3POX2_ ?QK'K.OZ=IU[=-X;U2XG?
MYI79&5V8C;R1T...O'>OI_\ 9Z^"GBOX7^)_$]U)<SO;W*3&T#NQ4,P;;M!.
M.>HKU.#6]'^'WAO2CIDZ745O#%%?7",'82857W$=\@]>:^A/"=Y#KV@VNMP<
MPW 4[S_%D'@Y]OQ/XU]1F/$F88C#U/;TZ*CC8PI5J;@E/]VXN,W%ZIRC%7?6
MYY-+!485%[-U'[)\\)M^[K;W;OML]NNAP'@&T\9C5+]]=G:>U:61HH6)8E-Q
M*X!SVQT/7VKR'X[_ +14_P &[X-_95Q<P[L!(D8@#.#P.GT_2O;_ !O\4_"G
MPS9]2U6]5&"-B'<,%NPQGG)_//'6O@;XB?&[1_B/XAADNM!CO=&EE"F9X RA
M-^,Y((Z<\USY7ET\QQ5+%XK RJ8%0M*%-^R3LE=)VM*32UMJ77KQI4G3A44*
MU]Y:OIJKZJ[_ *>Q]C?"3XC:-\3_  Z?'FJ6RZ9;1Q>8S7BA$''(S)^?K^5<
M3\0OVE? WA"'4(U-MK%N0ZF"V*2C'3 1<CVY '>O#M4^(OASQ=HL7P=\$-_9
M$MY$(V>U'EE2R[2,IM_B/YBG_##]CZ30[]I?%EZ^KV[MO=;IMZD.<X._/J1U
M/XY%>C'*\LPT\1B,PJUL'34U/ Y;4;=2KAVTERSW79=]UYX2Q%>HZ4:$85&D
MHU:L;)*6F\=G?3TU/8_V>OC5X'^(^H7ECHFC'3+F;<KYB\O=NSDXVCKQV.<\
M=36A\1_@IIUS=ZJ;:8R27Y8W$:,2WSY)P <YY/;CISS76CX:>%/A1 ?$WAFR
MMX)_*(V0*N=Y&<X4=>,?7BL7P'JVN:QJ.H^(=8+BU1V>-)<A2H+8'S<=/IZ]
M^/E<]QOU>I/&93&M#"S2IM57SSA.-G:[[/5?IK;U<%1]HU2Q#C.<;227NQM>
M-OET_I%OX+?#UO UBUI9PS(KR;F\W<<YP3C/7^?MZX/[1VOR:):*ALI;O>/F
M\A2<;L@YQG&/S_.OH?P[XJ7Q!)(EM;1I'#N3<@'.T@9R,\<<],9^M&I:7H>K
MW4EIKEG#=%@P3S54\@'&,^__ .JN/),PE&M3QN+53$VDYSU<)MNW7RMMO;TT
MK'T;_NJ:C1]U)7UB]K-Z^?Y>B^$_@;X"\)^(]9&N:C%)IT[2!QY^8PS;L]&Q
MZY'ZYK[$\=2>"_ 6D?\ "0:C:P3"P :"41KN;:,@[@,GD>H]:_(S]M;XT_$+
MX/>*;/3/ NCR6NGK=KB2UC8*RANF4 '(QUXKT#PM^TJWQ ^&5CIOQ0$NGR7%
MO&F^5&4R,R@ G=U)//?OQ@5^D8_),RQU/+LY=>=7 8N2C]5HUN>M3I65U[NL
MKI:K3;[_  Z.(I4ISPJBE4IQNZCC[DY::+I>_<_1NP^,FG^,O!5QJ^B.(FCB
M=8U!YRH) !!SVX_.OFWPAX4U7QQXOE\5:Y;SDZ;*[P;@QW;"=N,^N,Y_#/>O
M*M:@\4>'/AWHFI_"RVFU73[FZ0W B1G_ ';.N2=N>"/\<=Z_0KX12-=^#M$N
M-1L(;+49K2-KV%PL;F0QC=N4@'KG_(KR:].GDV%KU\+"G46)K5*$.>5J]"$;
M*I&<'K'FUWM;OT-HOZS4C";G&<(J;M?D;>UGM^?EH>#>'H?$#?$O[7>W;VND
MJXC1)7*J55AC"D@=,"O>O'GB>^T9K3^S89)X#MW/&"5((Z\9'0^N3]*^>OVK
M]:;P+ID?B"U9[);<F8F$'Y@OS?P\'.,_YS7SE\*OVY=&\2&/2M7BCEBM(_*>
M64 '(&W)W<GISSUQFO$Q.:9=/%X!2E"KB70E%X."2]G&"O[2I):+2[NST,/E
MN-EAL1647]7A4A:M?XG)KW8KKO:VU_4^X;GXMZ!X>MX;V^M6^URE?,!7D,<9
MZ\]\?YS7C/C'P/I7QI\166O0(1:Q,DC[>/NG=^?;/U%?$7QC_:CTB_\ %]KH
M^A0>?'=3+&H2,E02V!R!@DD^_%?II^SCI5S=>#(=2NXA$;FU\]0PQC*>X_3\
M17'2SC)&ZDLOQ6(AF-&?O<DFZ:LTI0YMK+:W74ZJ^69AAX4YXO#QCA:L5RN>
MLFFE:7+O=VOW\][:-YX4T6#P+J'A/[&LK2V;0V[LFYU;R]H(;&0<G/!_PKX5
M^%GP4\>^"?'6KM)-++HMXUQ(MO(2RB,ECM5"?[I[?UKV#X\_M$W/PV\3V&C6
MEFUQ]HN1$[+$6V@OMZC^7'KDUZ_?^*-0_P"%<6_CW1[8SZI):>:;4C+'=&6P
M5QGKVXZU]#@:V:Y9@)8BO&E5PN=R4:;JM-*I=:N_P)[WVMON>56IX:O6C3IR
ME"IAH\SY;K2U[JV[VT_X+/S(N;/1K#X[:E(/#=VE_!<N4N4MW$9DW'+9"@'D
M>O/&/;[6\)_$2_NO%6FZ7>6<Q<!$B8JQ"KP!^1/7V_&JWPS\3VWC+5)=0\1^
M$K6UU260B28P*),YQDDKDGO[>M?4EEX1\+6#GQ$]M;1O;HTWF-L7:J+G@D=N
M0??ZURY[C,MKUL/1GA9N=*@J;C2Q*E'VZBES67V;ZVWM]QM@Z.(IPE*-3EYY
MM_O*;BYP5M+O9M/?]6CE?BS8:3J'@[4[G6+>)IH;4O;LZ+N1A&2"I(R,$>W\
MZ_*_P'KOC'6O%E]H F?_ (1ZVNG9"6;:%5B0 2<< #I7Z:W_ (R\(?&5->\)
M>'[^.2^L8Y(KB.)U8KL!5NA..GYYZFO@V[O/"WPMU[4-%O9_*O))9 9,8;)8
MC],'ZCH*^$QF5XBGBZV9.%:C6P5)5H1AS1G*"2;BX[\KOITTZGT^ QL'A?J4
ME"JL1-4O?7-R-VLUVUW>_8^HO GQZM/#.I0^%K]M\=LR1IDY!V\<>_3('Z]*
M^H+;XF7_ (LNK?3;&UDBLGV'SMF%(;!SGH>,<9K\P_ NCZ;\0/&,$VB2M<NL
MX,AQDXW\YS_D9[U^PO@?PI::?H%GILEC'%=K#'^_V@/P,]>O/:L</"ABXT\1
M"O4E3Q"=2=%IQE3J73DF^NM_N^[/&.6$FZ<Z,(5J*4(O2TX?9DH]_/\ ,V8-
M)N6M851R2JJ21GG(&?Y<5R'B+P'INL@MJEHLQ3)4O&&^88/<'\:[F^U&Z\/&
M(JGF6,.#<2GHJA>22>.!_GIGY<^*/[1=TFLVVC>![4ZE<F=8KA8T+A064-G:
M,CO_ )SGW,%&=&HITJD:496C[2514[-;0YK6C)K[+WZ'BR7MG*U-U.7WG!)R
M[7=M[:ZGDOQ'^&?CB_\ %NE)I%RUAX9MY%%RJ$Q1B(-\P., 97O].]8GQ'^!
M7@30)]-\5:9&-2UEQ#Y[0 2,)>-Q. 2,,3SR:^O-3U;3]9^'6=8N/[-\0W=N
M#Y8.V1'=,XQU!!)_IWK ^%?P\ECT"^O]3D_M5U\R2VCN#OP>2F Q/)XQ@?GG
M%?14.)J\84%"?)['FP\H45R?6XMJ_MJJ^))KJ]?,YI9?#EG*47:?O>\_>@TE
M;EB]=NW;N>:Z-\ O"WCW1]/NO$MF9(FC5C%*@;;@ @$$'_/TKRCXO?LE'Q!!
M8Z%H/F0>'H9D#10Y0; 0"<#@=.GU_#[7\ W6O>3KJZGIYM8+4RBQ39L#!=P7
M:#[#M^7KS/A+Q7XGN?&,UGXAMDM-!$S"">0A <, N"V.H_SBL_[<S*C5J5*%
M=+V#]K3I^U3A!M+^&MI25[)KT?<F.$HR@HR@[3M&4VG=VMHVO*WHON&?!_X(
M^'OA-X&BL=\,,7D 7%Q>8VJVWGYGZ$$G_(%58_">KG49;_3]0COM&9V,/V5P
MT8.XXQM) /MZ=*]'^.^D7?B?X8ZKHWAR^-O<W(;[/<PR8< GC:5.1QZ>_/->
M.? O2O%7@#P)#IFKW$^J79G8N\Q:0J"3W()XY_E7AXFM/'T,3BL7BF\3.LFZ
M#NYS3Y7SWOH_^#<[<.GAJD%2IZ)64]EI;W7Y/^MSWGPEI^KQC?=NRHH^7?GY
M5XZ9'Y^YZ]Z\5_:-U;7O#GAG4]5\+-+_ &G;VLDF8R?OJI/&.Y->WZQXXTGP
MYX=DUG6)?LMK'$3.W380.1[<]?P.:^4O$O[1?PFU"RNX+_4HIK/4 ]NK.RGE
MLKT/U]. >_%=^1X3$U:M&O#"U<10C4A&=-0<HR2<7*$FD[OEOY[>1S8NM%RE
MSU%"4K];6?1I6[V?DCX3^$7[:/C^\GUCPYXG@NKK4XYI8H>7<[=Q&..3P!^E
M>I0Z]X>^(5Y/Y_ARYM/$,.YOM[P,JJWS-N:0@8&1DDG\:S_">H_LV>%_B)'>
MW-Y:27FISB2.-MA#>8P8 ]<=?2OI?XC?$WX5>&M-DATW2[2W.OVXMX+^"--Z
M>:NT.&49!!;/7@_2OO\ %^PIXV-/+<FQ>&=>G&I"<>:E"Z251<OVH*S=MNO2
MYY%+VGLN:OBZ;C2;5K<[;YE;7=-IVON?+ND_%CQ/\/\ Q2EI<7D.KV,9V1P[
MA,L2@XVNO(&!D=.V:]FTKXXZE?>(+:Y>_M8;221-]I$RIL!/(9%P!CWY_2H/
MAU^SKX5CM;OQGJVLG48-5+SQ+/(6,(E^90H8G&-W'>M6']EGPWIAU;QTWB!Q
MI?EO/Y)EPL*A=WRC(Z8R*Y\3B<EKN<:\?95J<%2<E0<E6JNRY4KZ3N[\W6ZZ
M%1AB8\LJ>L'+GY'/X8Z:NZNUY>FYZ9?^-UU+Q+8SZ7>QS[HT#P(X8EBO.5!/
M0MT]3T[5N:GX/\8W%T->C=8+!</.BKM9D')!P 3D?E^&:^6O >H?#O1_$$NL
MZ=XE_M)K.[\AK8S;PK!MN-N2.H],5^BMMKVFZOX:M9I[E+:WU&)4B5F" A@0
M.&QCC\<5X^8J>7/#QH46Z;@J4_:T6IR5HNR@U=V6M]T=5%QK\W-*TE)RM&2:
M^=MD^JV]3S'PA\3+"[UN+PK;V3^;'A);@J=N\%0>1QR0?U'KGO/'/AWPEK[P
MMXI=%6R"LGF$;>!QGU!(^@_G'8^&/#'A."YUMTMC.T3S1W"LA=FP6'OU Z<5
M\%^/OBAXP\9>.3X7LQ)#IUQ<>1'<#<N4W[0<Y'."?P[5Q8;"+,L8YX'GPE.A
M2_>592<9.?VW%ORO[NZTVL:3J.C2C[:/M$Y:0BKVCHDFNNKM\EN?7.K:+X&@
MM(+RSN+9;&W=/NL@4!".3V [_G7S]^T7\2- L]-TC_A%-2TZXGM5021Q-&SJ
M0 ,''/7I7L+_  8>W^'PLK[5Y5N;VVW%BY+*TB<\]>,]>O\ *OE?2_V']6U/
M4+K5K/Q'-J:O(7%K-.2%R^[:JL<$?AQTKLRZ63O$WQV9J53#U)JG&<6_;0T3
M4I=/5[_@8U8XITDZ-"2C)1DW?2&S2C'7KT7>QY]XWO;#4O =IXIU_2+G4Y9"
MJQK:QL[!CCD[!G'?L><=3S['^S?\-]?UN[T;Q1IMO=6.EQ[)!:W6X +U *O_
M +/7C.>U?=?PC^#7AOP]X1CT3Q7I%MJ+1 #R9XT=01T(#@CZ<Y[#CBO9[/2-
M#TFW-KH5E%I\**=D,"JBC"\8"X'I_C7+B.(*>&H8O+\!3J*%2O5<:LJG-15*
M5DXTZ=_=TVZ;ZFBP[KNC6K6;C"*LDHR;37Q/6^G7JNAXE:? 30=5\6WOC*]A
M"W,-FV1& J[U0G^$8Y(/Z\U]G?L1Q);-XNMH?]3#,R)^$H _05\:6?QPTRQ\
M8:MX,FD(N/(G4+SC.UAGT_'BOLK]B.19V\6SJ<K)*Q'?K*I_ECVKR%6Q%;*,
M<ZWM.2/L(TO:1:5N=:QONM='\NA.(IJ&/P;CO)5+J^J7*MU;^E\C]!N?Y_\
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MM'=\8XW;CGK7;D%/-E7S/&99A?JV49E7<Z-&O%TZM&G&DXS<*,K2@YMW7?\
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MTOOIWM^@$ ]:6BBG9+2_,N[_ ."(^P?V!/\ DXSP=_V'['_TH2O];O\ 9_\
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M2P4!>N<_2OF_P]X2_:+\._$^$Z7JET?!XO%80K*_EF'>,#&<8VY'IBN]T?\
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MTN2*AK4;7O<L>]]$EZ*VQM&K-452J67*[ONM%^EM?^"<?\6M.T?4_ VHV>I
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M,6[I:\JOZI6U\WY-?F1:O\*_"MKKE_XUN+=CJ,D$C9 _B*DYX';Z\]Q7U_\
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M:5UH]==V[^?RF5^+G!><RG1P6/FZU*M.A[.I!Q<YPE:2C=ZZI]O(^</E!!"
M'J#T^AQBG.)F *-)%CO&Q1CC/)(Q_/\ "OH1?ASI11&=P",9!QUSSCU_2NQT
MKX8>&+N+$EPBM]1U'<_CG]:YJ>55IT85X5:4HN27)S+GOIHT]]_GL>GC>/\
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M+>#=8\.3-=WUV;G3KCF$[RZ#>21CG X'^!]=WXAZ./$U\-(O8GDTN1B'91E
MIZD]L >M>B>&]"_X1WPS:Z5/="3["@#32.-S;%Y/)YZ9SZY->(7_ ,7=/?QG
M)X.A59)I5>(2]2&.Y00W/7/'7H*X(U,3C,?6Q5&/M94O>E.$>54X1:_>66S2
ML_5&KA2I4H4Y/D4W;ENWJ[7C?S?X*YX!\2OA7IMC<66@^"M9CM$U!A'>VJSA
M6<.<,NW<.>?3]!6-K?[.T&B:'%8^"8Y+/QE.@GEOTRK,[#).\8/)]^F/:N_F
M^#NLW/Q&A\1WVK7$5M%<+-# 7;806W@8R!T[<XZ]<U];:Q#8:=IAU:X*1SV^
MG-&DA*AF8(=ISU_SZU]!B,]Q&$I82A1QDL2IP;J<L;.I4;BHPJM:5(I?9:V2
M\CECA:<IU)SI<O+)<MY644K:Q[7M]_8^6O@'_;?A:<:#X]UV"?4B3&5FE#2$
MC@#YB3Z=/P'6O&OVG_%WC^V\21:#86MY<^'W?</LX?RRI/;:,8(P?UYK-\*>
M'M7\:_%^\U>\U:>VMK:]9[>/S2$=5D..I Z #I^0K]'?^$>T#4HK6/6--M;N
M2&%%6>1$<MM&,ECD].?;-5B<3A\HS+#XRI1IXR53#J=6BHJG&E5DHV<.BY>M
MNO?6RHQEB:$Z2;HJ,VHS^*Z36C[/_+7<_/'P?H2>)_ -_IUUIL]M>20LJ32H
M5*L5S]XCL>_3'3%?)WQ^\%^)_"_PYM--M]95E>]RL7FY=5W'"D YX''2OU+^
M)PO]/OK;1O!^D0)9W#;+B6%5&P' )RN",9/M7@_BC]FQ_&<JS>(]6:'3[<"[
MD227:J8(9AAL#C/3&?7M79E&/P6#QT<RG3HX:&)J_6I04%6K.4;+EBMX[[=7
M\A8JEB*M)8=U*E54H>S6O)%1DT[Z[_Y?AUO[$>B:K:> -,GO0+MC:J26 =E+
M*>03TY/_ ->O._VR/V=_B+\4'LKOPM+-"(K@, A90OS9' &.V,_EUX\WUC]I
MZQ_9\U"V\'^"2^JV5HZ6]V\8:4(%(5N5!X&#7WY\*?CI#\2?!SZG';,;UK4O
M'&RD'S2@8 9&<[OY5R8]9SEF9?ZRTL/#V%>JYT7.-O=E?E4Z;MR-IW?>^H4/
MJM:BL$YMN,4IJ+]Y-+^;J_Z['G'[./ACQQ\._!UEX;\93O=W0MA'%DDLN$ _
M0?CQ65X\\*7GC'Q);Z;;WFZXM[@.]LC_ #@;@>0.:]R^&TWBC6=1U:[\161B
M2W,GV,.I'R#."-WMR*X[P;::'#\8=1U%[^22_+LK61)\M #U P1@8_ 5\G*O
MBJ^8YAB<3:%2M"51PPZ7LXN33]UK2+5]7JOO/4M"E3HPI:J+5I5-V]%M^'9O
M7J>P>$O"L6G66FP7T9,MK"J$GDY"CCGU/^<UY;\=]!\):K:?\5+/'%:1J=D;
ML!O"@X4 ]<]J^HKB2WN!))"4'/S8(R,@>G/;VKX[_:D^'M_XOTK3[FQNYK=;
M1Q+*(B0' (8@XZCC'Z5A@YTZ>)I5*E9T%!RE*:;O>U[OK=M)==]-BJW-5LDD
MW*UE:]KV3]>NG_#&7\(M.\-2:9>VGA:REA6*"78Q4XD*J<%2?4XYS@]A7R++
M\:_%UA\2?%?A/7]/O$TRT%PMI+(KB-@,A=N>/I_6OH*/QGJOP_\ AL+GPQIQ
MN-9L(!$RI$2\NU0I) &3GGJ?RIWPRTZW^-6GC5/%&@6^E:U*2+F9X5BD89(R
M2P!/0]3STKZ#+JGM*=;,ZU"$\-.:@YRJJ=:FX37[Q7UM)*]O-'-7A[*=/"PD
MXS47)^[:,U))63VT;\^K.;_9V\66&JZW?C5%^SA[AQ'+/PNTDXY;C'J.U?;U
MSX;\--+]LLXK>5Y0"98XT(;/JP[_ -3W-?/'B/X(?V9:BU\*[(9#(I:>$KD8
M()^9#P>_7I^GNG@SP]J.D>&[6UO+C[3=P*#(2V]C@>Y)]?RK+.L1A\34CCL%
M7E&-7EI2HW=TDE[TET5]%?N3A:<X1]C546X^\IOSZ>OG\NS'OI-L-T+0X@=2
M $&.63 Z?7MTYKX4^/6B:OX+\06.L3RHNA/,LDD<N/N%LG[W'3]/T^_-8\4Z
M/X<LUN]<988E(7<Q R1C'/0<_P N]>4_%/P+H/QMT&T;[7Y5C(%6*16X((_'
MKGKT[5S9-BG@\=2KUXRCAZK=.K4Y7+F3BDU%JWO)/IUMW+Q--5J?(FN=6Y8]
M'9KTVT5OSZ>7?#WXV> ?&-D?!MA;PG_B7LERR*HRWEX;IG.23W_"N3_9TUSX
M?^%_C)KVEZ?&EC=37,RRROA0Q9F)Y.!W/U'([YZ+P/\ LS:3\,]0FU.TN//>
M2)PKD@G)&,9_(>@X]J\7N?AG?:)XYU7Q+<N=/>>5WM9%RGF')(RW&>",CWQT
MKIQ^!R7%5,16PF*J4*4::DZE6HX^UJ2:34HOX[:Z:6^6AAZV-IQ5)P513]U0
MA'F:BDG[JZ>OD]3Z"^(,&C^)/C0=,OK+[9I_EM-]IV;X^<G@X(Z9Q\QKR>\^
M,/AWX5>/'TBPL6MX$G5<E2J.,\[0![]A3_'GQ-_X0CP>NK^7#=Z\<11S(1+.
M5P O3+'(_P ]:\%U$O\ $*TT[Q'XAL/L5Q-MD1S'M=SD$9XR:\G&XZCA?8X:
MO3G4PTJ$:,*E)N<>:*3=645IRO?MV/0P>!K8B%2JIQIN,FY1J>ZW>UX1;W:Z
MI]=.Q^J^E^-=+\=^&8]7LHE5DMUD8XY;Y03S_3N!TZ5\6?%?]J7PMX'UE=(U
M;1_-=9/++R0@AB2%X+#V]>_7BOH'X,6\-OX/CA1E5!&J?,=H(Q@<GC_)]:^"
M_P!L]/!NC>(]+N]<BMEMVEC,TT6UN-_))7/^?SKVN$L+@L5F$:->E6Q5&I!R
MH*C)QE)NVD;=?+773T\W,I5*-%\DXTW"?++G6N_F]ON]3US3].\#?'<6VH);
M16JED;8J!"0^#CMV/^'2OJ'2O"'@GPEX>3PP-0MK 74?E^5*ZHTN1C@'U]/_
M *U?)_P_N/!>D^ ]/\4^%;X?90D+N%8*. "0<?C_ )YK6UWPMKOQGUWP_KFA
M:O-:VFFF-KA(IB$81LI;<0<8P#G->MC:+JU'0EB<3A,NPE6=HUDW[*M"SA"5
M]VY+?R.6E+EA&I[.G5JS2MRM>\FE=WMLEY?F>Y>)/@GIYT(_\(A)Y&I.3*MS
M&0"S-E@=P(SR>.?<&O._#_[,#ZW<C5O&LC7>J6F3:2LVXAER4PWL>>#G]<>L
M^-[SQ9X;\.Z+I_AIOMMZJPPW#QMYC?+M4EL$^A)S]*Z3_A:FC^#-*TD^-+L6
ME_/!&TL;-A@Y4<$'WR,?D*\Z&.SB.'4<-4]O/$5)Q@X:XGD5KO3WE!K2UK>E
MK&_LL/)WG'EBDG/_ )]W=NO?KIOJSR'1/"OB/P'XDG;4[TKH<N8HT=SA4'R@
M<^WX?6OC_P#:1U_XFV/BZTL?AI'>36>H3J9YK7>457<9R4X _'TK[4^*'BS3
M/B5I!3P1=_:+J!-SK$X9A@>B\CZ<=^*^)=1_:!OOA=*VD:OHL6H:@DJPK)<1
M!I$);;E=PW9Z'CU ZUP1XHADN9J68Y9[6I'#OVL*T>6G*22]G))Z3DI:VWW.
M^CE$\=A'/#8A).JE"-/625TI<SZ*W5]-]%K[_P##_P#X6E9>'=*;6+AQ<'RF
MF\SA\$#()QGCZYKC_BIX2^)?B'Q9I&JZ)=&*UA,9N/?&-V#G^0^N*]MT?Q-J
M/C#X:+XLM+;R[OR/.2 +@Y,>X  ?Y)^@KRK1_&/CK5-#U:>:T,5S8^8858$,
MPC#8P&&3Z\>X'-89?C\8GC,YP^&PDZ,^9RI5E&Z6):7+"#=_<V5K=RL1AJ"E
M3P564_:)J//!^[S4[:]=W\K[GHU[X1CN/"!N_$,27FJV=L'@9T5SYJH3QG/\
M7^>:^3]-\5>)_#>M7/BG476*UTN5A;67"NT<;?*%7OD#_&N6T3]LQ8/&O_""
M>*XIHKG[2;=5>-@'(DV 9(QW_0?C]*:SX0\,^(IK?Q!JEP+2PN+4SQV@PJ3$
MJ2N5X!W<#I_6O2R_#8O*JL,/G>6Q6'S&/UO"SE2]JITI6E*G1=O<<E:[5[=3
M#%3IXF/-A:WO8>U&K'GY)<RLE*7=+>V[1J_#/]K:/Q9=W[ZM9O:6>GHV^292
MJ8CR,Y/'.W_]6<U[[9_&[PS\1_"^JP^#]1M)=3@BFC:.-E9RP4KMP#G/7CUZ
MC-?FSHNBZA>:QXTTV72AIGA(P7"0:C''Y9:/#88/@=1SG_&NB_9'\)>"_#_C
M#44T?Q-/J,\E^YEM))2Z9+G*;2<<_3IFO=S?A_)\1@<QKX>,L+.G0I/#TZ'[
MZ$>>*;52:TIU$WJMT_D>=AL9B:5;#1JN-2/M7S.2^)1:LDKZIVZ?YG3?#WPE
MXT\4?$35[2[L[JQ@DN)A<7CJZ1NA8Y8/C!!''7\>E?6OAGPSI'@;Q+!IVFW@
MN-2E9/-=9-Q$C8SG!]2<]\_ACZ0U"?P[;:>]A;Z;!8ZA=1!!=Q1HLC,R@!BZ
MC))SW_+M7R#H'@WQ/IWQ?::>6>ZL))#)'(^YE^\2H'Z?AUK\\R'"5J5'&T\7
MC9XCZO1G.%*I*\WJN2*;UM:RMV/<S+&1Q%2DZ.'5",I1BVHZ=/>]7UW?X,Z[
MX[^&K34[_1]1\0W9B^SM$REI"G0J1U(![^G&:^IOA=9:+J'@L3Z=+'/-!9;8
MY$*L=RQ\<YZ_X9Y!%?"7[46A?$36-(UK5GAGM=(T2$RI-&K#<L8SV]E[?XYW
M?V3OBHVG?!N^UR[N995LW:!O.+!BR94KM;GDCG_]5>A5PF-Q&#H3GB,/.A"I
M"&%PD+<ZG4M*SL_2^O=M;'-*I0H\T::G[=K][/E?)**Z^3TMZ7/H3PWJ/CEO
M%M[;7@N!IL<SJ@;<5*YP/89'USZUD_%CPCX-T:9/&LEE]JU=?G:-%!?=ZX&>
MO^37@/Q4_:H\2^%?#E]XBTK1'>VCC=UE2$EFPI(.0,_AC]!7Q'\/_P!K_P"*
M?Q)UF[U74="NIO#UO,X99;>0IL0G/!&,8';^5>[@.&\RQ_/CH4J.&PF'4:>(
MHJLJ;K/W4Z7-_-+6RO<XZF+I4ER\TIU9M2B^6_*K+WG_ (>M_P#A_P!4/!/C
M*T\9Z!>6E]ITMGI(1EG25"F5'!Z\=N.#G\:Z#PGX!^&.K.;32($51-F;(4KD
MGYR1R.N>V.N37S/\+OV@O#WCRZD\(0V<6F7$K^3( @BY/RMGUYS^/?I7T#>V
MEMX"T^[?2[GS;VXMGD78V[#,I/&#G@GZUYV/R]X7VV%C2KX*I6:G1PO/SP<=
M-9NUM79WZ?>:TJRJN$E*-91NIU+)2NVFXI;Z:JW7S/,OVA/&5[\'M0TZU\ V
M;7MF[1I>1V29ZD!MX3(]>N>WK7KW@K6T\6^#++7]55-'F94=A< 1,S<$YW8.
M?8\UP7P/:'Q-J6L7'C&SCU/,DC0K=@.%YP,;\]/\\'-==\;K;36T&VL;.4:)
M91./^/8^4I'I\N!W]>WK7D0P\ZV)P^7UJ:HUJ=EB*]-^UYU*SC>WQ6CI;TLD
MSJE.,*;JPE*49:TXOW&FK)W[/\UWV.R\0>+K;2O#DMY]L3[);0L6GW#9\BY)
MSG&./7]:_)WQ_P#M6V'B_P :'P!'#+KL,URUI$+,F4Q,7V;CLSC!]?3GK7T;
MXR^(_@JP\&-X-U;7,07L1@>Z68-(/,&W)(;/?D_TKPGX?_ /P7\'6N?C#HS1
M^)UNV>[MS=@2;'<F0!2^>G&#[$U^B9!EN7Y=0Q=3&TZM2LY*&6Q]E[*-:J[<
MK]J_@?EU/$Q=>I7E35&2@MZLD[V2M=<N[_X<]\\#?LT^)88['6M0FN8_#VI(
ML[V4KME$<;BI4GC"DC&/RKVKPY\&O!>@:PS:7>6X:[(26U9U+;FR&!3/7/ZF
MJWP0^..N?%-I]/OK7[+;0[HX(4&(T3#* ,#@ =QV%<_\2H],^%^JZCXQU/6[
MA)((WNK>S#L4\P9(4+TZ_3OZXKR<16S>KC:N#Q514<14C:%&A#F4DY+D4^7[
M2T;G^"-X+#QHJK%<T8M<\IZ62M??H];+IZMGE_QZ^$WP\\ ZW;>)-2TIF>25
M)C)''@%LALY4#J2/YUZGX>^.?@ZV\#V[7445MI=G$IA2089PBC YP3TQ_D5X
MIHGQRTW]I33KSP_J%J/M]K*8;+S$P753M5LGOQ_GO-\7_@D^D^!-/@+/:B)5
M>98L@,FT<';USGO7HUJ4W# 9=FCK?7:=91G^\;M3=G>FNEU9:W_ PO%^VJX=
MI4^6Z<8VYG9*S_/9:%]OC)X@^*VIKI/@:"XM]*BG".\88*RAL?PC!_K]*^MM
M0\=W/PN\$Z=87^G/J&H7:(N\1[V1G7&<X)SD]_Y9KX^^ EKKF@01)X;T9+FT
M3:+BZ\OG((#'.,YS]/:OORRC@URP@E\0:?#,T:J<2J"(\=@6R!C'Z?6N#.UA
M*%:E0AA::P="?/*G"JG6E.R_BR6MV^C6AIA(U9P<_:/G<;<THV2VV7H?#>I:
M)\3O'OBE+Q+AX-!N6\R2UDX A?JNT\CY3R.W>O2?#-Y\/_@WK,5MIVFK/KVH
ML$O+SRPR0.^-SL<$#:222?3MUKL?%'CWPWX5\3"!KB*VMBIB5(G4 ,=R@8'3
M\QQ^-><MI<6IQ^(]39([M=4AG&FW/#RQ,ZL$*$9(()'H/<TWB*^,HTXU*4L+
M@5",%1I+V<:R;2BIR5O:.%^9KJD$J<*4^95(U*W,]6N:UK.R71O7_@GF'[0O
MCSQ#XJUFT\%:+KD=Q%J;*LJ6LP_=QR_>1@AX(!P<GBOJ#]FG]G+PK\,] _X2
M&*WW^(KQ/-GGE 9C(X+$@GGDG_/?\@_AWX9^(VA?M&S1^()+RYT1K]IX)I@Y
M$<?F$JJEN,!2!CMCZU^XGPZ\>G4[LZ*@;R;=512>^T*,<]:[.)</6RS+L)@,
MOJP="I0AB,75HV@JG.U:-2V[6UGUUWU>>$Y*N(E4K)MJ5J49:N+5ON[7MKHK
M]N7\=^$+;XE7BZ!XDMI9(()Q)&XSM4*P8'Z# ]B,?2M.Y\!_"ZUL]+L-<U6U
M@N-"$8L;:29%D)CQM 4G)/R@=>?>OH+5HM/TK3I-2N8$1Y8V5)MHSN(PO/IZ
M?IWKXS\3?LXZCX]\3)X\O_$\FG:-8R?:&@2YV"1%._!0,,_*,?YS7QE+&+$P
MCA9XVI@Z5"G*5*,??YZS5FHQ7P\^SW:5^ESTW2</WJIJ?/-1FWHU'1.[>]M[
MGTU+\3O"F@:''!<3PQ0!!! 68#>H^5<$GG(Q7D'B+P6GC%X_%EBQDL8OW^%.
M8Y%^_P!/N\X_(UXYXYA\ >+[JS\*V'B(13::T:$B<!GDBP#QD<G'XCTQ5O4?
M&WCSPH-(\(>&;&6_T4(L%Q=!6<;,!22XSU'/7V]:TPF38FJJ*G"-&O*]6;K/
MDBZ4;2NF]Y26O?FWL.>(HTY-TFW!6BW%<S4VHWVV2]=>VAE2_%?2;#7Y_#^H
MZ>?LZ*\"E4PNY5QGCOVK]7?V!WAGT37;FV&VVE(:)?13(.,>O/?\^U?BK:V&
MJ>)_B7/ITVEE4$;2R2^5T;DMSCL2?RK]K/V"K7^S]&UZPXS!\I Z "0?Y'U-
M?19]AZ.'R.<:?NRG&A*4(RYHZRNY=E)Z_P!71XM.K.>8T^9>Z_:<K>C^%:6W
M?S7S/T4HHHK\S/>/\[S_ (.&6V_M(ZD9& 1+V<Y)_P"FA;_/2OQ/\,_$"VTO
M3K&$7"\1(I!8$ XYXR!QCGK7[._\'&CE?V@]8VDAA<7)!_X&QK^8@ZM?QV\(
M665B!A0N22<C' SR?\^E?L_#U#+:^*IRQU1TY4LMPDE!2Y923BKN+Z_+[^I^
M6\1\'X/BETHYAKAL/B,0W&RNY2>ZEJXVV\S[3\3:M-XFC=[(>;M4L?+Y'!ZG
M&?\ /'K7E?AW1+>]\2Q2ZTO_ !+[:16GC?I\C9;(/L/U.:]0_9[MYI;"^N=>
MB9;62$^6]PI0'Y3T+CG_ #TKRSXD:Y%HVLW\&G,%CDG?:8SQAB< 8]/R/YU]
MKQOD.45^&(8ZIF5:%.-)^PA.HY.4I)<L(WVUO_6I]CP9X<9?PY@J>:5Z=2OE
M\7..&A.I_"GIRR4'_-N[?\-]!_$;]IC3/#OA<^"O $$5H_V<03RQJJ,?E*-\
MRC.3SSG\J^!+JZN]0N[B_O)99I[F1I)&D<OAF8L<9)QG(]^Q-17EWY]PUQ(
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M?_7S^'&^,BL')0PU>7)9>T_>-PD[J^FUGJFK?JSW,)B:&,S&GAXXJ.(DTO\
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MPTBX(/<?7\^<<'I65<+:^=L&"<X)'_U_\^E7DT>6250LQ*?7IQT_3OR!1?\
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MNFZ$?/9UD8=N",YX[>N/IGG%;46KZM)"[Z1&4,(^7R\]O3'.3R./R[U\9B>
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M^&)'?POIW\I*_P ];X6>-/AYX;UWP-\/M!FMIM3CUC3XW*-&6W"6-2.,FO\
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M:#\[6L_FO+/V-FJTY3J4_<<8/?FLE?OOKZ)W2/3?$FG7%OHMSK\C@Q:=%Y@
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MBM=O2/SOLOA,QDJCHSKQD\3+W?87]R3;46Y+9:+2_3L?<&D_ W3-6^$L>A>
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M\MFP06)SD^_IZ 5[)H]Q?PV:7D7S+M! &<]/RZ\=/S-?/T=G]GNOG!X8$_\
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MC.3P,>_08XY]N:X#3M7M;2X01@,01UQ_];M[5TNO>-WCT\0VXVNR;<K[\?\
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MOH/RQV[<1H7QVT/Q*]O!:P@S715=JC+)D@?7CW&:MS^/_ 7C3P,NJ:O=V_\
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M)6"22##A2@(SGH?6O"-+\*_$'QM<6>N^,M.>"#22@CF*',BQ8&\G'.0,Y_\
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MQG^)5QX*\*RZE9Q?:Y9+9I(A&-Q)*G;@CG.>XX[>N/RT\)^,/CE\7_B=9ZA
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M2IT;25"E=)^T2^'3J<#XK\122R/9PR8C0[1M.!QP/8=O\XKS25]Q.223S_\
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M:,8V^O'MZYS^>:X^7P'8S6+7$2H)'&4X&>F1GTQW[]\D=>O\0WQEE$<J@;0
MI^AX]/09_/VJG:7$@MCYK%4&<?\ ZO3C_.*_.YT:?M)R="/O+X]FMK72W?\
M7HL!FF9X;+L/&GC*E!N2ER\W[N<;KW=+)^:WU7RXW2/#6I6TRHSDPJ^",9&.
MGOV S^76NJU.]M=%B0!?WF,,>W(_GUSZ]ZZ?3I8?+!'+/GKGOQGU_+I^.*X7
MQKIERY"PC>9.1CG&2/J?Y\=.#FG@:%7'2>'A.,.7W4G9/6RU_+^K'L4*]/,,
MRI2QE.+7*G.3C92:2;E?6_?S6AYYK-PVKLSHQSG( //_ .O.>_X9IOA[PY/=
MW:M.K+'GJ<@8R?Z$<9]^]4)[:ZTF2'SQC+#(Z< ]^_3^O/6OH?P9I5OK5E'P
MJ-Y1.X<'[I]\]?\ )K@S;*Y9'BH4Z\E5]LE.FH6?;9+=^:WN??YIG5;#Y-1>
M7J$*":HN<5\-VDWS?I]US@+NRM=(8"*92PX !'7T_P \G^?-:L+FX02C<1C[
MHR=P(Z\_7OVQ3_&%A=6/B9+82NT E)Y)QC=TZXZ\=.?7TU=4NK2Q:V>3&S8N
MY>W3W/7WQZ]:YJ&)E5A6J*"2C'6+5MDEHFM[MW[GCU<(L-6RODJ1Q.*S.*J\
M\7\*23<7;NO^!Y\Y%)<Z$;:^@PCLRD@]<\9X_$]>.!^'?7[VOBG3$GO=AF5
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M1I'MS #)$RDLS!?F'([XZ>W0\5A^$?CO8^$O'_\ PC'A7PI=V5O=S[);CR9
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M,L3CY7*\'*YQCKU_*N3_ &;)/&<OA6_D\4WDM[</([12.S.0O. ,D]OT_*O
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MI6OH[:):7[(^SS)PR;)(8/&T)8BC).<N1:QFDFM5_D]?(X/XA7DBZI'=R1%
M7SEE[9__ %'''7M7#ZUJ<%]#$<Y"J._I[]^/TKZ"^,&G:3=Z*DUL$$ZQ@_+C
MK^ SZ'H.>E?(5NMQ<SFU4DD,% /<''';_(KQ*E.>"Y54:FZD(W:ZR?*W>WGO
MW^1GPE6P/%&5PS)1G@IY36JTI*;:E&C%I<R\K:IZ>6Y[K\.;C1+JZ@M[J!6
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MP1^TWJ$_PY&DPQ6T%PT33")5&0P4G.,8XZY]?6N6\:> ] \.> 9=.,T:V5_
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MT5R0B[QY=->;^K?@O*?%WQ-\5?LD?#;3K[Q!:2>)9KYXEA$:M,4B<!5^Z"<
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MX;E+BTA \NX5@591CD$$CG/7/(/>N;L]?N]2"7.G.TD+R!6*'(VG [?GTKY
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MYHMQ]U)<UKVUE'7]5J>Q? ;P'\+M&TNY\8>%+-?#VLWP:YFLY,1.\C$L5VD
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M]I'NHWUTU?;UW.@D2ZU%XU4DC@<?7I]?Y?6O5_#WA6V%F+J\G11&NY@Q'S
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M<YP<@\?Y_&K7A8IH6O2V5^B!&?:X.!@#(_ ?A]:QOB.9[/6[>^T7<;5F5G"
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MN@>U?W$ZO]F;1]16\FC@M9-/NDGEE8(B0O;NLC,S$  (22:_ER^,_P#P2B^
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M<CLVTYR1GCITYZU^A/A;PS9^)](35_B!9:?%K]M#^X$_EK.7"<* WS<GH/\
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M[GT%=ZFVLEEMI ELJ +@X!P!W'J?P^E=#H?A6[GT:[O8T;,2.?,QQTP#GO\
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M@\_I7T#K'Q6CO##I:H H01Y4 8XQSQU!_P FJGB1['2;:/3[.! J )O"C/
M)S[?_KQ@8X?1/#$FM:S;^4 1YZM*>.$R#GCIP>.WT%;4Y0I*G0IJ4L1*5JCM
M[JC=77-Z=?O['Q.8U<LSR-?-\SA[*GEU*I+ QD[.4X:QDE;>3T7_  3<U*/5
MPT-S$SM#*0P89P@/KZ9%8?BC4$N-,6WE?S)0 #W(Z<=,]01[\5]2>-;'PQH?
M@V*"R:.345MP)1G+*Q3';..?T]L5\,W-U+/=R),6V>:< ]",GU_GT['@"N[$
M2A@YV@XMN,>3E?PRTO\ -=^_?4^>X0^N<3Q_M)T'@J&!KRA",U:M6C%NT[/H
MU\F/BNFMK4V\#8\P=<X[?AQ_DYK/T\SVUV'W'.[(/UQ_0_YXK2^Q><Z+;DL<
M 'H3VR!^?./3-;,.D,CJ9UVX&02/IW'?GL3G\*^HX9SVCELJBQ3<H54[RN[J
M35D[^5_\^Y]'F52GAYN+A3FZ\9*K&:49S5K)ZV;T^[[R+4HY-2"-,A<IWY/
M]"?Z?H364RM"H6,;"OZX&/\ ]73CMZ]4UP(76%5# =/UXX[X]AWYQ7*:C>;;
MQE "Y'88^OY^G..3BN#%4ZN,J5\QISG/"RQ&J:=HQNGM?7HNFR\R<MK.<*>7
M*BHQA#VE)-W6K3M;I_6]AUM?B2013+GD>O/'/XY/X^_2NFBAA+6Z1H.67/'N
M/;MG\.:Y[3--:\F5U'7T],\<@?KT'%>RZ!X4=]DDF"!@G=C(P1]3GW^OM6.+
MRV')1Q&'=.<*J5XW7-S+ENWI=/K_ ,-IYF<YS1P$U&=>5*K3BZ?L%>TGV27I
MI?Y:'*Z]IUK;6\+AER5!8=\$>HR>O'IGIDUQJK;.\:C"Y/)_3\NGT.<UZ5XS
MTNVC*Q1RG>!R <_7&.F/_P!8YKR6YLYE8K&QRK<$?Y_SG//?YUPJ4:]9N%E%
M^>E[?Y_<T>KDTJ>/R^A-XR<)SA)VJ>[9OK9ZVMU?_#>GV AT^V 296+#. 0>
M.??OWZC^5#7<$8,CD%I,\\9 _P XS^=>1W.IWUD=V]V"J1C.?J/T//O[YHT[
M5KW4;A(CN_>,% /;I_\ JYK[/)>':./HJOB\9"A"I91B[/5VM?M^5NQR5,DK
M0<ZD<1%TTW.I532NEJUUZ[>B1Z,1NN ]OEVW;@![=N.Y_P , 5Z1I-X;RRDL
M;F [G7:&(Z=L^_3_ #V7P=X3C013W7S!U#$-SZ=<].>Q/?KUKN]7LK"VAS;!
M!(/3 / .?H>/3'N:[LRRO 91#DI488IR]UU(STC+3WWI9?GWT=C\YQW$<:N9
M+!8=RF\/))5[]8M:MZ7O9IGB\_AJ+3IYFENE6*4E@A;'!S_7V_I69H>IV.A:
MHS+MDWL=IQD=1^G/X9XQFM;6M*N]4F(2=UP< !B,8YQ].N<_7ZXEIX4:TN$:
M];=@\'Z'/O\ EQ^%;8;A[ X7!O'8[,W'#5VI>PIU6FDTFX*/56[_ *'UM#-W
MBL+6CBL7&3G3]FJ4(KVK<4M=.CT2MMU/HG2KSPMKL*'6HX=I7'S*N.@]?3KZ
M?E77>'[3P1X:N6N]/AMR['*$(AQUQ_G]>./!O[/MIK?8MP8A&A;(;'0>V,=,
MCC..M<-<>+&TZ>2U@N6E\IF7);(./?\ KQD]Z>,Q?#>04Z6*R>%6KC:BYJ"J
M4^:G&32NY-_>FSPLIR7,\Q=:>69QCZ48M^VPDHS48J3LK.]GIUU73LCZ#^*O
MQ/@AT^10ZLP5E15P,<$#V_4]:^4M!U#5M:OY+F2:06^XE5+'@9/OC_/;BLCQ
M#K+ZS*!+(6PWW2Q(_GTX%:&GW,FG69>V3H.W7\AU'XD^A KFI9_A,3@M$WF6
M(JS]LZFL*:FDI<E]$K/IY[GU]/AJ62Y:Z5IXG%8R?-.M6?-9R=TE?X=7TMU/
M39;%9(U>-"TI&">Y/'/Z]N?I5VTT1WVBZC9D(R58<\CI@^WX?E7E.G^.-0BF
MV["Q#$89>O3CGV _R:]1TWQ5<W,:RR0E< =OH#C'^>>G.*\G'1>53I3PV(YH
MRM)U$K>^[7BK=N_73H>#B<NSK#4I\]&C=V5.3J>\DMN3L]O\]2KK/A*"VQ<6
MMOM8\@A<<GZ=_?C':ETK3[F$QM</A3C@]%';KGW]?S%=I'XBM+Z 12(/,Z8/
M;G_.??ISG#9+5)83C@_P_3.>QZG\Z\NI*KF%>]2JVW;=^2NWT?\ 7=''4S;&
MT,!]5Q4*GM.=+WTV^6Z^%O7\ONVBN;VSM(%WNG(ZY'\Q]>G(^M2Z5KFGM*EN
MLJ,\F,?4_AZ'//\ C5&\\*3ZC8G:[C&3GIV/T'^/'2L31?!KVEX)9)FS&PP"
M>>#]?8'C.<Y'/3U,%EV3<E6GC<<H323CRQ4KO2T=;)R?79KY@J6 ^HU,1*=:
ME4E!KE@Y.4ZEDDDEW>KT_$]A"K+&T<3'S"ORL#CG'7KU_/\ 4"M+PQIM_!<E
M[F]_=DG$9?MS^//^<]L![BWTZU,QE&Y5&<L .!_+_/8X\\F^(=O!=EC<, AQ
M@/WYQ^?%:8+-<VPM*MALMPOML-/FI*3I<S:TL]=G;>^UNQX2R;&9AA:M&-X4
MZK5TXWFKVM)2>SLM;??LSZD\VPEE$<@7"]6*CGW].V>WH:Z(LC:=(NGA0WEL
M-RJ.,@@$GK]?I]:^1[/X@R7\Y2 OACC//X\]./7)^M?0G@SQ!;Q:5+]L;+&%
MCECSTR!S_(D=?7-?+Y[4E0PKJXW"U(XF$XN#@K-3TM[OW7T,LDX:QF6YKA:<
MZS>$=6+J4>9MU(*W-S6TV:;OWW6IX7KGA;44U>[U.:0[5+N><9YSCO\ X<X]
MZS]0\5Z39Z)))=Q+))!GY6 8DJ.V>OITZ>F<CE_B%\4[B+Q%/IMLI-L9&1CU
M^7/.>,$#IWQ^%<_=>']0\26OVJS^:!H]\@'/49/'KSW[_3%?4X6EGZAE_$68
M8E8ZC@,/3MA6E5I8:,U&5-RI.\7*SU7?T/VN>&RS"UG]=C]6PU7DA0Q\Y>S]
MG%I)TK_94KV?^1ZW\.=>M?'MA>6%E*MA(B%4)^3'!Z8Q@<#W_ \\5I'A271O
M'4J:E=F[8RLR,6W< G'!XKF_AWIFJZ1JLEO:^9!\^)"H*CDG..G;C_#K7OT?
M@Z26\35VF+2XRV2,YP?J?K[BO3S//Z6?U\MQ"P;A7I34<17C3]A3DN9<L536
MFSW6NA^:\1T\)PWBN(:&!S"C]2S;!1]EA*:C4KJK.*O6C57O<KOS.W2QSOBV
M]U6]DDM--MG:&(8;8.#QSTXYP#_CBO([>SU2\U1;*-)8F\SYURP/)[]/R[_E
M7T=%J$FDW#6SVR3-<';D@'KQGG//U'_U[']A1V%S_;DT,<>\;]HQ@$X/;/.!
MCG\L'%?:\9T>%N'N#:^9Y%Q-/#9]5IQ4L-#$MU)2G&/M*4::MRZW5U8][@FG
M@,%@,%3P5&\\12C[6NGS.51J/.ZB>SYN[)- \,II^C/*\)EG6,ER1N(.#SZY
M'N!P,^]?-'Q$MXFN&F\G9*DA)^7D?,<_C^'\J^H8_B!I5DDL!92LNX,"1@9&
M./QZ]NW6O /'DEOJDTUQ;@"%BS9'0=>_;O7\KY#Q#G6#QV(JMSE_:,7&O7Q%
MZDJJE:ZO-];]O3NOU.AE6#Q\8U,73G&K@FG2=-\D6W;625D]'I?R]3P/6KU;
MFWBBC&6C7#8&.G7GKV.3_4BL.VR"1@YW8QWZ?Y-;L5@&NWB3YB21TX'.!^OT
M]B*+JS-A+EQR1G XZ\< ]/;/]:^ZPD8XC%8=2E&A"<DZE2UHQ3UT6S\E?];=
M#K4,.OJE*=ZRIRE"+E>4U)KKJVM>OX;'/W!)?@$=!R#@@X],G_\ 5FMB+3VM
M[9;H-G>!P?QSQGV_3VJG%:W-_.J0QDEB.WN/Y=<_RKL3I<UC:J+XC9P0,]L9
M_/M]:_8\I^J0I5<-@U'&8J5%/#8BK%0I4FK)RE)M:=>J^]'BXS%PIRAA)N'M
MJVD:3G>3;L]MDK]^S]2;PAX<?6=2@C?.V1E);L!D?T^OZ5]":SI&A^'K&&UF
MA265E4%MH)' R<GU]??Z5XEX6\0VFGW2)"W[PL-I&,C\<=/3\^>*]BN=0T^]
M@675).B@@DGCT[_G_2OL,AHYE[7V.(6$K0FE'VSE&5.+T<KWTCZ?=<_)^(\/
MGRSW ^WHU)Y93:E]7PS?-*5XI2DT]DDKJW30XG5/"ME=6S75J%3(+<?0?Y_K
MTKB=+O4TN^-K*I<;]H;)(P/PXX^N!^5>D:OX@TB"S>"SF!)! YR<8X_7''Z9
MYKR9A+J$V;5=TF]L,>O<GW]/?CVKU,_QN7Y5&-25.DG"G>:II3A4^%<L;65W
ML?;4IQ>&<,;3C1I3A9>WC:T6E:]_AMM\M>Q[5IL%C?LHDD5-_(8L!@]OIC]/
MPQ5/6/!5LTA>'4D3=_TUX[Y[^PSQ^E>??9]=MK,E"PD[%<\8X]??CIWR.M90
MN=7C0MJ%W*K'.T;B.IX^AQGGO7X5/B*O5S*M+)L#B*"G-1G&G"7-9N-V[)6O
MJUKUV/FZ?!M>C7>/P7$E&C&HW*CAJ%JT[2LU!=>W_#W/9-)E\.>%83)J"I=W
M 4E7(#_,.0<\GW[5YWXF\<W&OS2QI,4L(R=D2MMX7&.F.,9[=:J6^@ZQK&GR
M3I(9$"EE+'<2 /\ ]8_2O*[NWNM-O)()0RG<0<@CH<9]_;].E?L:PM/(\HH9
MOFE"HJ=>A[:I4Q*;]ZR<5%/:3>FFW:VWT60\(Y=2Q;QN*G+,<U>\\3)SC2Z_
MNZ<KJ#VU79KH=#->K)"YC)4#CDG\?K]/PZ]>=MX)+R[C5B2I?N21U_ _X ]*
MU+4P&+9*<*1Z]R#CCKG/Y>G%:MC90QS)-&PP".X[^WU]L?RK\UP6=8C%X_ZY
M2PT\-1JXGFG.G3YHSHZ)+166GSUN>Q7EA\MJ8BI)?O9M<O+%*,7=62=DOZ]#
MH)K6'3=.#!1OV#/3T'/K_P#K]:\\5A<W+ADX).1T]..WM_D\>J0LNHNL$H.,
M;>A(X_SWQ]:EE\%Q1[ITQSS[^OL>WTZ5^FYIEE+B#+YT\/6@W"DII)J,X*$4
MW)J_5IW?EJB(9EAZU)S^L4UB(P<N7F5TM+W7HN_9V.&DCBEM5LXL!B,<#GMZ
M=/Z8%,.@Q:=;>;.GS,,Y(ZG''7Z],=*WA8Q6-T6N2 J \D\$C&T?Y[5SOB+7
M3?G[/#Q''D CN%..>N1Q[^O2OD<'+$X#".6*J1K0I1=*FI+W5R645KH^G3UW
M/ P6*S'$YE2HX#VCP-23EB:\[M)Z7C%[:]OS/IC]@]H3^T7X/*#D>(;$=O\
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MTO)ZVN>=Z5KB27VVX(*EB,D] >GK_,\&K?B&S,SBXL@9.F0HSCIZ?7\^:X%
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M)9[:,M'\R[22RY&>2>I-> ?LY^#?$'C_ .*GB?Q5=WM^$EN)I5BE:01@LQ.
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M]S7BUKKOHULO5JU_(_/#XD>$/!?[0>NZYX0\)Z1'I,EO(\6HW@C5!,%8JY+
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M%.C==;WV[=._7T[0O#.GLGV:XVAV&.1GJ/U(/3V_#.#XD\,1^&;J.[LSRQR
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M*S;W]J[3O$?Q%N?#W@_1#;W\3"-[R*$CS'!VL=ZK\V3[\X&,5]Y_$OX+Z/\
M$V:WU74)F2^0#*@_T^G..<^U<EX,_9;^''@[4_\ A($MHI=69MY9D7<S @Y/
M!)R>#USBO<AG&4UJ'UG'4JE7,)8=8;V=**I47*-K3FHZ-/1:_P"9R2PV*4^6
MDXJAS\R<G[ROKI?5+7;N?&UK:?$GX@?%/3M+\5:?>7'A"9D:XCD$OE%2?F)!
MRHZ?A[5]?V?@O2O VN0VO@R-;*V41^9#'A>>"V0,=?7_ /57TJFFV4<.VWTJ
MV294\N&81*'!( &"!G^N,>G'QG\4K7XB^!/$UOJS02OIVH3#R\!B KMQD],
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MZNZ+']C=T$F3P5 R"3^?2OG?XJZKH%QXBT:XT[3!<S7,\9D9%S]Y@W)7CO\
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MW^RU&TDK;O=_\-;[\IJG.3CT_K3NGZ_KS17YN>Z?Y\?_  7LD1/VI+DLN?\
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MAEPLA&"1]/Y'O_2OI#X?>$+&S8+<A)-PP58 \G'U[^OI7G&C:W87ODQ1 %^
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MEO>#O!7B[18PKRS)$.VYL<=!U].>W3/U])>36;6W>&9G>-E*GJ>N,G..G?\
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MIP6T59)1;6K;TMYGJ=E%:RPJ;N+&5SN8=\ X[YX_SG%<=K^L"W\RVM'PF""
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M=6.K*UN]VT"/')C ,F2H#'O7>>!/VE? EEK>LZ9XMT2V:QTUY!;RWD"[R$)
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M6+IU,WA6IX.O.[=*+<H*5FI.*VUM\M=$COJ5X3PC6$:]O2T2>TI*UUKJ^O\
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M:+=#/<@>_P S?UQ_]>OY=K<,L2#^\HQ]/T]:][/]*^!2O_R+L-9?]N1_$\O
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M:KX9N[E!]FBZ#G:HZ<]/\YYKKOA_J0\+.;6]@S#)Q(67U..X//K^?8UYW#/
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M>GX_T]>:N+^[@N&^SR,I+$  XP??Z9_K7V#=0?#[3O$\OAJWCC^SI(8W8JO
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M\K;VNFUK>RUE]Y](>!_$/@SX;?#NTL_'WC"W;4'5<WMQ<+GYAUW,_.,>OO\
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MI*S4FW?V6KUMIN>'0I.K*O."E/#P?[B*<D^>ZOIM9]%;=>9\^^!O%%CXWO\
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MJ*712C;E3]7J<=X$\'I!(MQJ$6X9!&\9Z<]^I]._\J]CN_"D.HA988%\J,=
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M5J_BSX#:_?ZSI%YK+SW=K;7,DJJ#.S, B,>.2.E?-'N.VSZ].NFI]>?LQ?\
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M;M9VUT$UK4/%=KI4_P /[?2YKR('R+>[",P@7.T$-@[<<XP1^E9FI?$#Q7\
M?"%GY.F3:Q>W;9D55:0HKGH0 2,9P,^G6OJ.3QEHGA":W;5+"*:35$RDK1@E
M6D'!W$$CG\J\HOM%U[Q!XL.KZM;V[^#W?>@G16CC0MD$[@<8!]>W/3%+AVI#
M#X:G@<=A:=3"Q4JTI5)M>WDM%3BW=\W1)?<3F,G5JSQ%*;A*344H+6*T]YJU
MEKO^>AQ'@G]KS3-6O[/1/$4(TK4=41=L4JF-P\F !@@'@XQT/?.!7<RV&JVF
MNW>I7VNO!H^JH1;%Y,(OFK\N,G_:X/\ C7G7Q*^!GPVOO$>F_$"VU&S6#2"D
ML\%G*@V^4=Q#!#P..A[=:U]4\;^$OC;IT7@OP/<^5J&C1B)Y5?YE:(!=S$'H
M,$]?PXKWJN%R]RI5\KPM;#T:L&L?S4^:G@Y<RY9)R771NV_='GPG.;G"M43E
M!ITDGK5T7;I97[:OS/:O _PTO+*.]N8]?^VKJ2R&%A+N"B9>,8;I\Q[=CT[?
M&WBS_@G[XDM/&'B3XQ:SK4LUK D][9*T[$0L,R*5R>,8SV'I7V9\'-$U;1+*
M72]2U>*^NK.-PBQSB1U,:D@,,D@\8P>.WM67!\:-9\8>,-3^%&KVTZZ5(9+2
M68@["A)0G/3H1[<\8%?/2JYKA\;C<1A*].2H4H>VKQ@DYX92C>T79<SC==OO
M.^"H5*="$X6C)M1BV_CMO+_MYZ]CY*^"_@K4OB&-6O=?\3M]G\.R2BVNI921
M$MN3LC#.>.%VCD<<=17L_P ,/VJ?$=CX\'PL7PO)J&CV<XMH]?%NS12JC!-W
MF[=I!!SUZ=^U>UZA\!] \-Z%<^&_"E]Y;:T_GW+1OM?+G>R_+Z[B/_U&NR\"
M^!/#?A?P^^G1:;;3Z_:HS?;#"C3LX&<M(%+9R.F?UI8_.L%B:-2=2CS1;4<-
M0:]G:7*N:LVEWN[:+8*."G&HHIRZNI*'O/ENN5-/3MMT_'W74O%VCZ?8V9AE
MC34;M%;R!C>K. <8'IN/'_ZZFAT--3@MM5G8;B064X]F'7Z_F/05\?PVNOS>
M*S<ZC]H_<3@Q1_,4"*<# ^F/;TYYKM_&7[4OA'X4?8=(\1VEQ)/>>7%$$5B%
M9BJCU/7KW_2OG\.E6K4J6"G.OB*E[TH+6*25[;>ZD]'JSJJ4:E&#E5ARQ24E
M-O>[BM==M;?,\L_:P\*>*;JUAO=#MYM0LC(L4EC$&9<-P3L7V/IQCK3_ (<>
M ;SX4?"*_P#&UM;/8ZM<VK2F( J\#,F[H.1@G^?I7UGX)U^Q^(.E1:S;VD;V
M-P@F2.Y0,H5N1PPZCOVSWK<\06&GZSI=QX<N%A6RO$:)XDV[$5EQPHX&.G3M
M7M0S:I3PU'+*M&*HT<3&>)<=)SC%IN-2*T;7?KYG#/#*<Y5H74W'W+OW4]-;
M^=OZ2/S$7PSX1_:&\ Z[-XBUB.#Q;:O<&WNI'"S1NI.W!)#<')XQTZG-?EIX
M@^*_CK]E?Q3=692Y\8:;;7!$##S+A8D$A*D8W#@8[]CV%?NGXC_9M\.>#[:Z
MO-%NYD%ZSLR0,0NZ3V7@\G'08],Y(\KTC]E3PGX@>YD\46<5XM^28WNHQ(P!
M)/\ &"<\C/\ G/UF3<09;@JN-ECKXW+*TE[/"S@H3IQ:BG&G*.L>773U.'$8
M2M4A1C!>SKQC=U%)N-U9J_=NZW[:'4?L@_M%:S\</!-OJ-QI,E@H10RO&R <
M#@Y'8GTQ7UEKV@^&M5A^T:S9137,&#'(ZC*D<@Y/I@8]>.:X'X;^#_!WP5TM
M]#TBRBB@(W?NHU3'<#@#^1KSSXG?%+[;/_8N@!UOKEMD07.<G*_F2>GK]*^3
MQD:>,S>K7RNE4PF J3<Z:YFIQA>+?-*]]+:]&COHJ<:$5B.651+WF[.-[JW3
MR77;S)_B[X9F\>^$_P#A&=(F-I%&I7S(VV *,CJ"/Y_7BO.O@C\*-"^'J2R:
MQ>17]S$6/F.PD,9Y/WCG&#U_K6=\0S\3O#OP\\_34E.KW:'& =P5\X.>#QD<
M\53_ &=M!\3W>AZC+X]O]U[>I(T41E)=2XR  22"#V!'ZUZL)9C3RG$1PV.H
M1P<ZKC&"=Z]2H[*<K[I>?RON9..'GB*<JE-RJK:25H16FG:[T_K4^H]/\7Z#
M!J*C26BN+H.$94 ) &!C R<#'ZU^<O[??P-\1_%JZL=8T:.>#RGC:4Q[ESAM
MQ!((]3UZ=J^I]&\/2>#_ !.^I.TTELTI?#[BH7<3GG@ ?IR:]6^(FMZ=XD\#
MW::'/93ZIY9VPJZ&4/MZ;0<YS[#!_7R<CQU?+,THU4^;$*:INI.[CRSLM7KI
M%=?R.O&4*=7#R<?X;BO=C\2:M=176]MD^Q\2_!']G'Q3I'PKADT75);;6H(5
M+A)6\QR%Y'!!/]:]"T+QI\2/A=H6HWVO6%S?&U8Q;GC9MXY7=D@YX.?\YKT'
M]GR]\;^'QJ-YXLB<:39>9,T3 [6A3)P 1C!7ICTZUZ"G[2?P5^+&IW_P]&GV
MUE>QRO#*UQ&L8=TW#(+*,C([5[.=8C-,54Q=!4(XVE%QKU,30BFZ,6U:+:=Y
M1\CCPD:$/95)2=)6Y5&=TY-+^M=['E6A_"S1?CK86/CWQ%HJ7+F8/';21@F-
MLY! 8<<\< ?ER/=M=\#W.D^$_P"R]#MO)AMX"JVRD+B)4.1CZ=L=/:O#O%_[
M4GP_^ 6LZ=X*C$$D-Q<Q@>41Y8#M@' .W_ZP_+C_ (_^,OC[XWM-(\2? K_2
M-*O(HS<I#EP(I0-V=O PI/I6%#+\WJ/+98J=/#8.5Y8:OBYN&&;C9\O6TI6T
M=BI5\*GB/9\SJ)^\J:YIZVM:^K5M=SSF;1]'\23Z_P"$_!C+IOC2X2>WOS$<
M3%FW*Y8KSDDYYZYZUG?"?X8ZE\&M.U;3_%.F-JUWJERS&65/,(\ULE\L,\=>
MO KT?X9?#R\^#&E-\7?B!'-/XPU%?/O;4!F +@,XV\XY)XKT*P\;:A\7S<:O
MHVEO%9P*^X/%@Y P#R.Q!/![5[&+SNIA,)B)1P]7$Y5[2%/%UZ<4Y.M3:7NS
MOS2HWU@_RU.7#X)5JT8>UITZ\E>E&H[0496WCJE*]M'Z=ST'P9X"\+ZEI"36
M\433WH DM!@F+<,D%/X<9(QCMVKS+P_XOU/X>_&JU\"6L3)I-[(I90AV .W(
M/&/H?\:XKPU\49_@KXSFN_&BSR:;<RL+>([MJ@L2N >!@'I^/M6Y=_M+?!+Q
M'\3]-EALRNNS.GE2%1E2S CG!P<GOP/PKR<+B*F-^M3^J8G%9?5PM5P=2'+&
M%1I<C3O=>SMOUW>M[=E;#5,/.G3E4I1K1:YN6?,I1TN_GKIT?4^V/%ND7.O3
M2M8,8#;QJX8$C)VY/(^A/?O[5Y/I?Q4TW2=97PEKUVL-V'\N.60X).[ Y./3
MVZ].*[S7O',%I#IMQISILOUB#*",[650,X/H?\*^=/C+X5\+7 B\3M.T.JHO
MVD"([264;NQ'&?K[XS7B9=0C4C*AC%5JPE&2I*E!.=.::LN]EUNUT^?36DD^
M:DXIIQO*5U%JRV\_+Y'LOQ4^*@^'NE1:EY/]HV93?&X^=2"N>@XYX/;^M?%>
M@?MWZ/KGCA_#VHV":=:!MB7+Q[59QP!N( R?;@#UYK&MOB%J?Q&N8/",D,MW
MI]HZQ2-M+D(I"Y)Y'0>GZ5[#<_LB?"W7-+M-2$D-GJJ[)Y NR.8N-I(( #<D
M=>N:^EPN R/ X>,,WA4J5JJ_<U*7O3I+[/-!:*73M=G%*KC:M6^%<8TX.-XM
MV4]KI;7O_6]C4\1>/)O'6CZHB1%M+\MO)G4'9(I5N01P>.N,^]?._P +_#NA
MZ7XFO+^]O5:TDED$EJSY&TDAOE)XXQV/]:^]M'^&_A_3?AY=Z7!L1+&W*&XD
M !;:F 2Q'L3U],5\I^'OV=O$U_K=WXEM)I9O#_VAC(T)9HPFXYY7*]!^?J:\
M*N\-&.*J8:O/!X93C"I):U9PTLXQVYG9:[Z]F>A1G).$9QC.H[N":37/M9WZ
M:_EZGT)X'\;_  [\"-?2>'H[=&NMWVDIM&"?O9XYQ[^]<5XX_:'M_#RSZG /
MM>GL&,D0&Y2O)*D#@\<=P?QY\0^)WA :%>6^G>%&N7DNV1;SEC@MD./SKW_P
MM\#="U;P'''KVY[B:$-(9!E@7!W=1QUZ\X JLSP6"K952Q]+,*KQ5:4/85ZR
M4N>,%&\*]]5?:_GIL8X.I5I8YX>OAU.E[SJPCHTF[WA;JKK0^7]/_:<T;6=9
M.H>'?"ZQSQ2@SS1P!23G)+$*,]SGUS7WSX$^*%EXZT"&59474D1/,M21O7 R
M1MR2,<&OBK7O@8^@:LMCX"MHW6YR)CL7)/?! SQ^?\J^?]*U3XI_"OXNV]A,
MEU]BNKA8Y4 81!&89P/NC@G\*QRW"_VS.:6 ^I8W"T/:U)5:TITL52II*3I.
M5_BM=)6L=6.J4\-""I8GV]"K448Q4$JM*4MHS2[:ZOSN]S]@+O4(]1TNYLVA
M#A05D4+QTY'OG.?PKP3Q1\+CJ&BZC?:;='3##%+(S*VW:-I);/'0_E7T-X=M
M(KKPI::RA5Y[N!9;F,8+!F3<PQUZG_#O56ZTZVU/1[ZR+&**\A>&0#A@&4@G
M'7ITXZ^U94:M.->-6FW25*K%.*][6+2DN5[K1_UH<SC)PY9*_/&\5KM;>ZU7
MF? 'PM\0Z'H<FLV=[?)K^I6[2QJY/FO&X)"XSN(P?<?F*^?_ (NZ'XW^)U_?
MQ::MPUG LA%HF\!E&<* /\!CIDCFOO+P5^SKX4\*:OJ.I+.TTE_.\KK(<@%F
M+'K[DC_//N?AGP1X5LM2$EM';"5V F\U5"E<\YS^>/K7ULL_P& QE3&4(3Q%
M3DINE[>"4(U$HN5HKX-;I6L>>\'B:L(TY2=**D^=4]W!V23?_!T]=3X1_8T^
M%,'A^VO-8UCPX=-U*Q+[;B6+:TC1GAMS#/N.?Y''TEXB+_%77QIUQ'DZ2_\
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MSO;;JS@II99V9F)))X[]\\\?X\^E,3.,$98=/P/X>M#$Q2/">61BI..XP/\
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M1646\6]+F&*%I,%  ,&1>O)Y/0U]66]O%:PQV\"".&)0D4:C"H@& H'H*_C
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MNSTO5+N+2Q83R>9($V@'!Z 8_'BOQDUC]HWXI_!+PYX,M?$\=U>7FK+;K<R
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MKFDE=1:1Q;220?='.-I(XXYX_K7.^/=3^&?A+XB6VF>([*::_:8>4?++*&W
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MM1-)4I2U>VJC>WE\M-=#Z8TOP3\$KWQ/:PQSV+M(4>2VS& 9&*DY'KD]<?\
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M3(N\<X(...@Z_K7GD+LDPD;&U",_A_\ 7].X_&NG3Q-- K1V_&5Q@'@]?_U
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M'.<\SQ5"#Y')4$ZKVBM-^B26M_([GXD>.O"A\6'0+X1-+:RXYVDN00,>^?\
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MBJ*-XVYHWE.5OA2U?3OY=\W5;]I4DK26J>C^7KK^!^=/[2'Q%^,'P U.'3O
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MNW_ .CL+&RO;.)Y)%$JJ-V2,DX[Y]SC\NG2N@TS2YKJ416433LO6, G[H/\
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MC5""'B8@C&#D$<],<9_G7">'/VB_@[]OEU9/#"PZBQ8F5;4+(3G.=VW.>?\
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M\*6XC+WK?+&P7:"VX@*>.>O%>R:KKOA[XH:/)<_#3Q2FH?8HLM'#.OS%%Y&
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M:30B:(,25SMROMQP<\?K7[;_ +#G^H\48<RKYA(D/.X&13G//7/KZ>M?A/\
M#'X.ZC\3?%<GQN@+V,=S#]IDB?Y&RZA\'('3)!S]*_<[]@T&+2O$$#-N>,@,
M?7#J#_(5'$WU6.63IX>T:U*CAJ.+I*UJ=:$DIWDMWK;MYGG474^OT>?:4JTZ
M<W]N#22^=O3IU9^B5%%%?EY] ?Y^/_!=7P]-XN_:V;1K<$O>:J\.!_M3$>A]
M14OP _X)T1:I8^%DU&]^QR:C9Q3*68J<E XZXZ]O;N:](_X*XI&?VZ; S,B(
M=?Q\^,'-R.>?\_G7Z+V%[!HOA;P%JEI-'F'1X'_<MC!$"D9*XZ\\9]C6_%F
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MNOOZ\8KF;"SN(F#QG8XY&>.1GCCV/;TQQ4VH:Q-<NMG<R-(RD!!NR/;C)_\
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M</8?,,#3IN4*M)TY*M'W'&4?LWT4NBM;56]?4P^81P.6X'%YJG1I5U!R6O\
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ME?=_Q0_9GTC2?"MMKL/EVEX;5"]L"JL7*CJO7^O?-?/?[&'Q?GM=931=2@@
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M#2W@L-0T/2([.XBE5Y#'&%*@$'G SQSU[?K]7^'05CGEU*2,I.=T(D(R <D
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MRM-+FO;?IIWZ=#;\+?%CX<KIDVIZG!::+HY0M93'RXQ)QE=N<9)_GZU\[?M
M>!;#XF^"[WQ=X N%OKA?,"B!PS!2" X53GC.<]\5\+?M%:)\0M2\16?@GP^+
MZR\,:%,$D,9DC,T439QD8W?*,=_<UJ?!7XO^,?"/CF/P/&EQ)H#67D7"719E
M:0H$) ;U/0]\U]UA.&ZN$B\SP&*4JJ@L5+#SGS+V$>5VF[MJ=2+ORQZWNCRJ
MV-C)*A6IM23Y7**LN9VM;2UHVLWW=CT']ESP9<> [;7T\7>,I()]5$JO;37)
M!M/,+#A6<[=H/H.A(KW*;X#^);"RD\9>!/%D^N>9=&X813M)M5G)Q@,>Q_SD
MFOEO3OAIX[\>_&34I%^VVOANZNCYC)O2!8F8YV\[1CGICU],?J%\,_A[XA^'
M\D.F:3>KJ&@M #<1N_G;7VC<""3WSV_7FN?.\35PU26+^NX:>*Q5&E4JX7V<
M)47245^ZG)*\9K9=][7WK#1C42I^SJ1C!^Y5O)24M&_6UOUUZ9W@[QM9:-IF
MF6_CN]\C5@@ $QP[.J@=^>HZY/?BOD[]I;XSZ$VN6>G>%XD\2:\\R*NFJHE9
M5)4#"@'MT[>M?1GQ!\(Z-XF\?:8-4G$"I.@,2-M'WN00#CI_GFO,_B7^SAX<
M\&^+3\2/#-Y%>ZI'9^;'8.RRD2*N5/EDD\$9Z?3C%?(\.5LG_MO%XC%S;K5J
M;=/"TE:E"H_@I59*SA"2>]^G4]C,%B98+#TJ<&H0>M26O-'2\H.^K\CEK;X@
MZQI7AG2%U@OX9U"ZBCV6@)C*EE&!MXYZ?XFO0? &J:TEXNKZGXKE-J^':-IR
M1Y60W()Z8KP[X?\ @_Q+\;-0UR]\;SI8R:2TG]GQD^4J^5NV#;QCTX'OVK>\
M!_#'QK:^-+BTUN>>?PS([6T+1L601EMJX(XZ>^>:^OQ.&P-.CB*7M:-&M37M
M,1%1C.,HU$I1A0J25Y-1>KWNNNAXL*M2K*G*TI0;4:;5XOFBTO>2LE?]?F?<
M6L^+O FK>!-6L;+6([N26)TO,$'#,A!R<D_>_E7R5\$?@!X.\%^,9OB3/J$<
MEO?WC.D)8$!G<GA<\'G!XZ#FO4[GP9X-^&=R^DW\%Y<1>("&#D.4C$A/4\C
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M&N1PZ6L5]%ME6/&&P,<<8R/_ *_L:]-_9</A34OC-X7M_$<<,MA>ZQ;))'*
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M#XSSEATZGW^G'2O#[ [K^!IN(A)E\XQ@'T_//MTYKWSXOZR=0MM,V99$ACR
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M'_"D_AECD?\ "+:=_P"@O7^4+^QCI]U/^T1X-U.^D5I#K]B2JD<9GC_$^_\
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M4=:QK8+A.I).G2S>C%/X52B[_?\ U?U.E9AG2@XR6!F]U>HUKIZ?,_&_QO\
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M)O@_6[..260Q2HJD'RR"6 Z\C/;UZ=L5^RVH_LQ?L$WUR(;SQ'X?EF0X!-_
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ME37H]>^VUC\G?C!\</ ^K?#B:YF7^T[R6S9A9-&9"LK)D?*03UXZ'CI7YA>
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MC))7;ZK]=145CJV(I5,6\*U2Y^7V$FY7:2U7]>9Z735&,X.>E"L#Q^)]/?\
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M*=2K/DE'1^[9ZOLM/,^1-0^)7[0?A>QM=8U#Q3K!U&)Q)<P--<Y7!+$8+>W
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M 'IU*3! R?\ GJ?IZ^_6N"^(J?\ "*G4?"\6DZDEY.'CMYHTD4,QR 0P'/\
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M6W_,/2Z\O]WU_#Y']CY=I^Z=E_T\EY>>FWXON?#1_8V\<]?^%E:AQTS>3?\
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MJ7J!]_MLV<_7S?ZU6N_V-?&\1CQ\2K\YP/\ C]EQGC_;Y_.OO'>4XW/Z]?\
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M.!\2-0^OVR7_ .+)J,_L<^.<G_BY-]W'_'],/TW]?PK[E+N3DNWYGTQ1O?\
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MUV_D?<@_X*0?M3;L?\++UX#=_P _UUV(_P"FG/'OUKMK#_@H;^U7JMNBZ?\
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M7\%]%\,^&I]-MXH5U'R"+EF102^SYL9'))Y_+O7Y[XM8_,O#[B3&8'"XB-7
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M7ZCD>GXUY]XE^-OBGXT>%=<TK2];BTT-)(L"R3"-V1B0,?,#GTZC'>OH:/\
M9F*Q4,%*K3I57/DC6Y8NH]5S/UC>[6SOV/#J8?,:=*I7E"=2@FI.*G+D3:5K
MZ]]K/H_0]Q\'?M#W6B>.;VS\##[1:F9XW2$Y6,;N< 9' Z<''TKS'XI?M3^*
M/^%IZ=H,U[=Q174D?G+^\"*S')4]NI(_EQ7F_P !/A'K_AO5;&YEURW>YN[K
M==R32JV]7<;@"6).>V.<FOMKXG_!GX8XTO5[FVCG\1XA<SJJY,APQ(('0'D$
M'@5U_P!FRI9C[.CC'4P[_=2FHQ<H4].9QZ7>G9KN9O%X>=-.>&O5Y=Y/7FLN
M7Y>NMM^HNB_&'Q.-/DTQ&DAM-1A$9O3N78)% W[NW7VZ9KL/AOX^OO E_-;1
M^(I=5%XQG;=.7",2#LY; Y.,#GO7SU\>EN/#_@G0K;PC*DM]<"))HH"#,@X&
M"%^8$=^@S7S_ *7:>/M,6"Y=[KSI8U?#[N"1G')]1_DUCG4O[-IPJ4:DGAY/
MV322=:37*E)Q=W9K??KV'E]%XQSYXTXU8KG;=U&R:TTZ]NW71GZZZ%^UWXIM
M_$EMH=[IY.F2.(S<[21M)"@]^@Y]\GM7V%%\7]#F@MG6X7,T2R."X&&;:<=>
MV?Q]:_$?X37GB>]UA;SQ8_V?2[)P\LLPVC8N<DLW3IZUWGQ)^/VE)J=MI?@M
M9=06U98[F>T8R(NSAMQ0D#IW^E%++J%J+KUTHUJ4:KF]J?,KI3Y=+ZVT\_(Y
MZO+*3ITJ-JD)6]W7FVU7?K^&^Y^J.I?'_1=)U*"TN)56*9PH?.1@D#.<8XS_
M /7KV;1?%_AS7K>)[&\C>29 _P#K%SDC. ,]_P"O3%?D)X.^)/@CX@6]G8:E
M*+75[;:)3*^UU<  YR<@].O>N^\5:IXH\%V,6L>$[V6[M82)3Y+LP\M>3G:3
MV_\ KFG/+<)-)T:LO:1E92T<*BTM9JZ7EK\M-,8PFGRU%[)]5-6[?UOWMN?K
M!Y3D9&",9!!SGZ>M,(()!K\C8O\ @I+HOA&*QTGQ#:.;V(HET[]B/E;)/&<C
MO^E?<'PO_:E\"?$G0EUF"YMK5/+#NS.J@?+G!Y S_(=?;RL3A:N&<54MS3^"
M+?ORBM.9+32^FOD;*E5<>;V4G"#BG-:QZ=M]SZ2P?0_E25Q_AOXD>%O%\LMK
MHFHVMY+#E66"17.1QT4G!XQ^==F\,\9!>-U1AD$K@8Q[^_X5SRA.%E.+BWJK
MJUT2G_7EIOYC1U'U%2#.XDC''J#Z5"<\8[=?_K?Y%2 L#N).TGIQ[].:F.[5
MFV]%OH]'?[@?>]DM]-=?T[_(D^\#CICK]<BH&!Y4'/\ G\?Q]:FR$&.<'^GU
MJ$]>.GI^/^'O3NFEI:S3MT;TW=_)]UZ@KWNGTLFM[:?+O^A(H"J1N!R,?S_Q
MIF""0#D9R,9_/^G3CIFDJ50  <<GT]S[_A1SZO6U[/R6ROU] MMNWY;NUN_H
MK_\ !'H<D$C'U]A_G'I3F<$[1R1W_G_G-1L?X1G)Z?Y_"D] ,!L<_E^O)]?S
MJK+1IV=K[Z=NM_3\R&VK1?O+F[:_9_KT+/RD@Y!/IQ_*J5ZW,0SWZ9^G:IT#
M %L]#]?3U%4[P$O$3_>!_7V[\5*5I7C)VLN;31WM9*^SON#O:_*E9K]/^&W_
M "-/D>7U VG/_P!>H6@@&76(>9ZX'IUSU_S^-6L$K&/]G^@J)I(DX>5%.3P2
M.?U%)VTTUZI]_P ]RK/6]K/_ (&GI;3\2B3R <Y[ YIQ7 !]?T.*:VUFW#GI
M@C-*22.32O\ U:WX#NE9+?\ "RM^-K_@)1110,****!KMM<P/&1_XIO4?^O2
M7_T4*G_81Z>+_P#KLW_H^H/&.?\ A&]1_P"O27_T4,5/^PCT\7_]=F_]'U]#
M@O\ D3YEZX?_ -+B>+7_ -]PGK/_ -)1^C%%%%>,>B?Q2?\ !S.Q.CD>ADP.
M?4?U_G7\8W@#3+>:&">6]^RE K##;?F#9QP1Z?RYQ7]G/_!S+M_LD#!R6D'Z
MCW]:_B?TR9X+6#:67*\E6(SR>??GGV_"OI,UBI5,'=V2P.&=N_N1]=?EV.3+
MZOL?K,N7F:K2:7:SB_OOK]V_3]#?!G[0D.C>'+KP-JZB_L[ZV-I!)+\P4NH0
M$$[N<GK].G%?L3_P3>\8_#+P?X+\2^#=02R&O^)K>ZDLI',8D1IT;8 3\PZC
M'/X=J_EWEU"X:2"3>P\APR')R",8)/)[?T]*]O\ AM\;/%O@KQ3I7B>#4)HX
M]/D@RBRLJE(V7((![@'MZ=>WE8JM!97CLNH86A&>,IRC&O+XT[*]VMKOMN?=
M9!Q-##3A4Q6'C5]E)1BW%/D4N5.6O\JZ'V#^U)I7C7X1_M":UXIN[2<Z%)>3
M7$4RHS1R1-)O4;@-I&"!UP*O:Y\3_#GQ-\!/J(CBL[NU@(8@!&+!,=@#USTY
M].U?7VH_M+_!K]H;X;Q:+XHT.*]\42V:6RW$<(>03"/9DM@G[X]?2OS,\5?"
M_7_#^KWFEZ7:W<&B7TCO""K*BQN25'8?=('N,_CZF#X]Q.)X/HX/#X/#Y3C\
MBY,%BUK;&X96C*O!R^URJ]U=W[GP_'WT?^&N.,SPG%LJKGF$ZOML/B,,U&=.
M4I*7LZM-64H/3XEIL?+GBG4!/>21K)YJAV )/;/UQT_#CJ.E<BZ[A\@+,"#@
M9/X_Y//UKT/QG\.M>T*XDG%M/+#DG>JL5'<_GZ\>IQVP?#D%O&[37\9**#D$
M9P<=#D''7J/I[UXV%Q5+,G&O0G[12]Z3CJUM>_6UF_NWL>;B\JJ\(X)82O2G
M_LNE.$ERNLE:UDM-=UZGM?P:U'P];6-[-K2Q&6!"T:RXYXXP">N0?<5]5?L<
MZ]H'Q.^.T/A"[T^&2QGNX[9(V160[W"CC&.<^^>N>,U^;6NW_DS2G2]P5P0L
M<9(+=L #'4XSQ_.OMS]C72-6^#?B+3OCOXAMIX-'M;RWN-LRLH81N&ZMZX]_
MPKFS'"J<*E&@N;%UVHX3E=G[;3ETTOJGYKY'O\.8S%2GA,8X<M"+C5JT9Z\M
M.\;QE?IK_6EOT&_X*0?!6R_9<O/#WB:#2HX;#51;RILC7;MEP?X0!_%GIZ8K
M\V/%?[046M:79VFF1+%,8X]@7 (<@8Z8/7I_3-?L3_P4%^/'A3]L_P""6C:A
M9P1Z>-"L(?*D=0IE,$2XVD_>)V]ATK^9])WT_57C#DBQO/+!))4K$X /'L!T
M.!^/'V/!?'?%'"V65,KQ5.E]>PSE"3FKN,9V<=>MO-OHC],XDXCQ$L(L%*=.
M& Q"IU:$:-HN-E'JK-^C7;J?9/A_4?B?KVI:1J.K7%VVCVTL,B([R; BLI Y
M.,;>GZ>_]1OA3]HWX?3?L/Q^![CQ-#HVM'2EMV=+A(Y3((@I!YW9S^O'2OY?
M+#XG2:GX.@LM/\J&2U@"R$ *Q*CCGOZYXZ?GXUJGQ.\?ZE&^BP:G>K81R']W
M'/(J8![J&X'&/049CA.,?$V-.G+&7H8.M]8I4UI0I./O-N-TE=J][?<?'PQ>
M!RW&PQ5)2G4KPA[T+\_-[NC:]YO=>6]CZ/\ B_X-U&WU_4?$6G>*IK^)II95
ME^T%BPWELYW'J!W_ ! KGOAUXVGM[R-9G-Y-O"2,QW':.#D^G'?-?/5SX_U\
MV7]CRW+NS 1G>[,W((&23ZGTZ_3CJ? NG:Y9,;VWAEOI)F)$,0+MEAD84 GN
M?KVKN\.^)\PX6XJ5#/<P]OELI_49JI*].E;W937,VHI.UFO+Y_75.(/[02P*
MGBX148UYS5:HW"O!1E!Q7-IV:/J?XP> ?#_C_2(+ZU>&.^V*70%0P;CKQZ_3
MI5C]GGX?7?PT-]J\6H&VDN%9?ED"Y!!'8^_^<5\^>)]4^(>F0LZ:3J5J9>4$
ML<J@Y.1C<.P/Z\<5C:1\6/&5M9O8:D98'3/WMRGOC.<>W8=*_HK'UO#3$U*F
M-^K4\?.-"4JF9PB_J\7))^RG+EY7)IVO=^O?XR.8<2XWBNCF==1P\7.$(*LE
M%U</3Y82G9Z2<HK5]W]S_P!I"QO]0\2W6I32M="69I"Y);.6SU]\G/?Z]OF@
MN8UVJ2#G!Z]>,CMGH>OI7KWB'Q]_:KRP:B1(6)523GU7\\GM_AC#\/?#_5?%
M]P[:;:S&$98LJ$@ \]1Z>_I7\Z\5Y;D]7$PQV0UJ$</B*O*L(I7E";:Z=(MZ
M_/[OHL\R3"YGF:GD<U4J5I1C6HK1JK)+FD[*RCS7OK;TZ^>YY4DYXY]L_3Z_
M6KUE9'4+NWM!UGD$8[<LP'J#^G2NQ\0^ M3T#>7BDD$61(<$[2"0<X&.W//&
M17&12W%I)'=V_P DL+AD!/.X?USTKYJMAY97BZ%+,\-5I4YN$W+E:YZ=U?D>
MTM'WOJ?-XC)ZN3YBJ&;4I6IRC*=*E9N:]V3LT[+1VZZ[W9]8:9^R[/<^&/[>
M9T!,/G#YER>-W'//?U^E?/\ :>$+@>)O[$G?R81-Y;2$\!=V,YR,=/TZUOV7
M[1'Q!M-/_LAYC]C4>6%R?N]/\Y__ %<%<^,=0N[LWX;9<NQ8L#@[BV3@YYS7
M[9E>1^&V+PF&Q\H\[I3C6Q="4TN:FHQ<HRL[IWOMH8<1YOEF*E1I9#EKRR%&
MFHSJS5ZE:KI>33NNCM;<]B\4_!<Z?:Q3:+.+ZYDCWF-7#$' XP"?7TSC]/"[
M[P_J>FW'DZG 87#'(P>GU_ X'I74:?\ $_Q3I]RDK3M(B\8D;<,?3WZ\]#V[
MUW.@78^)NL06UUY<<LLBJS@  98 G/..H/Y"OSKQ#S'@VKCL-B.$<%5PU*C#
MEQE*2_<RY+7E'35NSTMH<65X:6*PZIXN<IYG.JN1:*%2G*UKM6UMOV^\\OTW
M0IM4NXK+3<O.Y "XQR>G^3U->D7G@OQ1X+LOM>JV+/#*F4.TMUZ8P#Z__KKZ
MR7]DK6=-L8_%.@:W;!XX?/\ +\Q,_*-^.N1^/UXKRAOB0]GK\?AWX@&"ZLK.
M3RY2 ""JG;^N/Z\"OR_%9Q2S.K&>#P]&G0A']Y32FJC:TLKI7>G2R/I8Y4\!
MIBD\/4G:,:MTX1NE:Z3;WUVW/ED7[RWS3/;,!GA60KC/X8XQ_CGO;BTZ;5+@
MM&FU<\C_ #^'?/\ *OJ+Q[KWPBO3')X<M(4;ROG"*H^;''0>WIS^(Q\XRZW#
M:WLWV/"QDG:#P>>/7Z<<_C6E/^T,5@JV(P^%JT*5+2#JJUVK:KR;U?3R.^&4
M4*&&IU<5F-&OAJE63=*E_$<DD]^BMI9:>1DZEH:VI #98=>YR/3MGCZG]:FT
M^PV0F0C.T'CN>IZ>OH!FJ&IZC--)YC-R3QZ#/T]__P!?>NS^'\*7VKVMKJ+A
M;>=]I+D ?,>/3ID\?XUC.>+]A&=5^TJ02<DNMK72\OPZ,^?Y\*\?)4X>SA[1
M1I*6EM4H\RTZ_+RL9Q\1VT=FUD8%#X9=Y4 ^F<D=3C_"O/;P)+*[H<ECT'3G
M\^?ZU]"_%CX72:,8M6TQ&DT]XP[21C*<CU''Y\D_A7SL()O,"Q1N[@C@ DY_
M+_/K7H4L34QM*-2;ERTXJ/PNT;?9NM+KJKW[K5EYWC,PQ-2CA\Q:DJ$(PP_+
M%07LM+<J7Q-KOJ]/4^N?V3/!FC>)_$EW;ZND4B(A(27;CH>?FXZ?YZ8[SXV?
M!K2TN-4O-%$2FRD=EBB((^7/&%_P[X[5\=^%/&_B;P%?R7NF+-;2R JS<KD$
M8ZCCIV^O%>M^&?BUKVLWSG59C/'=,/-1B6W;\9X)P3S_ )[?M7 T>'^),LEP
M]C:5..,G&7L:C23533EDI?%==NFGDE^D91Q;PC3X*_L+,<JY\3SS5:OR+GC&
MHDH5H24>=\C=VKV\M+'+>"O#9URZGL-3N6M1 S*$9MH..@PW'./\]1Z2/@+;
MZ_9W5Q93^9);;@@4YW8)QT/H >.N:S/&ULUB+?5-*A>V:\*C*@J"7(!/0=\]
M_IVKZ;^#7A_4_#V@#Q)KUVIL9(Q(T<C#D$9Z'ZU^3\69'C^%<TQ.75JBJQC+
MGC):IQ=G%>32_#\/@,PRBA@:U+DG*OA:M.-2E5>G[J;3IWVM*SL^GD?-W@C]
MG?6=7O+FTO87CBC+"-RO4C('4XKA/'?P@U#PIJ[VMW'Y=ON^5FXR!ZD].,'O
MTK]4_!OCOPK<23W$0MB""L:J%SOX S@9/)]>:^0?VE/#_B_7IY]<T^-AI43L
MP:-<*% [D<#@_P">_G</YC&&.MF%*E*C4BH1E6^%7Y?>?FO*^O8YZN&P#P-5
MTU.IB8.,H*.]M&W;RUU_R/BJPOY_"6KQWFD2M%=VD@DBEC)RK Y!!!X(/?@#
MO77^-/B_XR\=+;+XAU:ZOOLBA(1-*S[%4!< ,Q^H_3V\[16B:1[DEI 2ISSS
MSW//7/\ *J6]92PQ\V[].G]*UK4L(LQG*T:M"$W[.NGI3C.2NH^2VUU9XW\*
M"G=PE+=+2ZTT=K/^NG7676KL1E)96DC[*S$@?3/T[58L]0@N&\F<*J2.0QZ=
M_P#Z_7OQ6')I]VZCR$:7=T51D_IS^ S^'!ID>FWT<BI<PRVX<\,RE>I.",@?
M7T_/CZ:/">#Q%6A&EF%-3Q<J2H1M)R<ZEFKN*:LGWLB:OU^@E.IAZBIN//S<
MK<91T>Z5O7=VZ(^JO!'@[PHUD-1BN8IKI%W>664G."<8_G_3M;\3R)JNF2Z<
M$$,<>5! QD#([8!/^>V3X7I<][X7>UN%NF:WE9=Z[V(VG /&>_\ GM7J,(O?
M%]S;VNCYS($W[=Q.XD_GGKCWY]N[%\*YYEW$659%-4WB*E2E4PM:]HW3BU-O
MO'>U_P #VHYKB,[PM'"8'"QA'#4I>TI4H7E4MRIR>CE?JT]CRZ/PG;V4CR/)
M\P;*GOW[]C]#UK"U%KAI6@9S)"N0%)XP,GH?3Z<=?6OJ/Q)\+=2T#1DO=51X
MQLWY<8!^4$<GMS[9SUP:^:[M8Y+B41,/D9@?IR#Z>F/7U]_J_$O(<VRRC@UC
M\PP]=JDI.E3DGRS22NG?1WU?>YEA,EK2RVOC:E*6%]G5Y?955R2J6:YG!2LV
MKW^[3J8FDZ4-2ODM<^6"P& <8Y _KZ\>AKZ9MOACIVF>'SJ4ICD<PYY/.0/3
MGU^M?-FE330:S%Y60?,&<>H(^F#S]?TQ[?JVI^([S3UL[:5Q;^5R,GT!Z9&?
MQ_+&:^FX.R;+LP\.\=2PF"AB,ZQ490C5O%U)2M':[OWLKK4^&S;+\PQV*PWL
M*U3#X2C7A4KRBFN:$6KPOW=O7TU/)IEFTS5);R!S&L4F55#CA6'OUQQ[]:^T
MO@Y\7/#":7+;^(Q$LH@**\N 254XZ]^_^37PC=WMW#=2V]XC;@V-Q!P>3GG\
M<_F*EAEB/ D>,$'.UB.3]/KQ[?4U^997G'$?A[CYT8IQG6BXU:$I-14=$]M+
MIV^%:L_2\DXI_L&FZ=;"T\SRZ48\^ Q2;@ZB249I-7B_3UW/3?C#JFE:_P")
MKB;375[=I6V;3D8W''0GL/;O[5YS-"ENB!1@$KGZ>_8Y'/IU(ZTRQTXS3^;Y
MA<9'WCGN,?S_  KWJT^#&J:YX>76(6*0QIYC9XX SU[=/7]<U\;G.<8O-,UK
MYCBZE3VE>HI.'--POTTUNDM&_NT/-QF+EG>(Q6*H86EA*6(B_P!S25HTH.UH
M1NEMV[KL>0/;Z4MI'<RR+YPVGRR>OT'?KTZU]&> -;AUOP^=)TG3HY;PH$9@
M 3TQV'OUZ>E?+/BS2FM+D6<3-YEN2L@4G!*9R/Q_#CIZ5TGPL\7:IX/U&:YB
M?Y<' ?IQZ#IQV[Y_7[W!\,9=G&02S6&.I4<33@U4IPDO9QDK64E+7FTN_,^(
MYZN04L7*]3$W?/2C4WC=KW8VO=:Z?J=AXU^%6N6%Q+J=W:%(7<ER!G;SDGCT
MS^E>F>#/V>- \6>%KK7'U!$GMK<RB/> =X&[& 1GTZ>OI3=.^+K>+[B?1=9$
M3)<9"G _B! Z_P#UL#\J?H^MWWA.[U*T6Z*:7/&_EH7.W# \ 9]#T'X^M?/8
M2J\/2FL?.KF&"A"48T83DU3DM(MI.UMGMIM<^&XLS;.\WI83*^'<?_J]G,ZM
M&O.=6%UB:'-!U*<;[N4;I?=9'RQK&E'2=1U&P1RT5G,\:GL0K8XY]!_^NL*V
MN9X&;R)""V=V,@?Y)]Q^-=1XCO!<ZK?R1\K-,[%L9+9+'GVYKG(T1!D<$YZX
M^G'IVZ?XU\_@<QQ.78J>+P=2>&E*4O92I_%"+V3MT2TWZ/34_5H0D\+@:=?W
MZU/#THXJ;NE5K*$.>:[)R3?3=7V.BTJ.4AIU8R3D<=VSD_KV[]<]A4<K7HNQ
M+(C>9GY6P<C'((Q]>WYU-IE[%:Q,YP6P?IGGMC'^/([U9MM6@FE=[A1PWR#'
M/3_ZV/0URU<7BL7B*M?$SJ5IRE>56HVY-/5VNW\NFAWU51C3H\ON-15TK*S5
MK?*__#:%:_U*\.S[1,S@< ,S< 'W[X_(U[_\$M'TSQ1)+;7UO$5.0SN%X]?O
M<_B?K7S%K-P\TVZ($(#D#L!D?0?Y]JZ;PGXQUCPVK?V=(R%N"03GD<\COUR,
M\5^H<!9CE?"^8T<]S3_;\'*E*,J"2J.+Y=;QE=.^B>G73SX>:I7G+"_7)X15
MK)UI-RBM4D[O;M9?\ ^GKK1-/\.^-_[,T2YV.X8_NB.&R<8([@__ %C6<WAO
MQ-XO\6?V)JFM7'V6601QJ\K8"DX& 6P.HZ<'D^E<I\/-9COM?.MZO-NN%!?,
MC9).,XY/']#CTY]-T[47U;Q:=6L+J.--.D$CJ&4;O+;)QCUQCIT]J_7L^C@L
M5P;2SZG2C@,-F^:^UPWU:?+4AA9M)*:37)):N2CMOT,<VXRS'+*F R:KF&(J
MY3@JU%8EQ<E3KQ<X)\RBTI1FO=^?6QZKX>^&MQ\$/$%OKD%Z]R945RNXMG@]
M>3V[5[4/'-UXH\YT+1W4P.R,9!8XP.,>G'3\L5RL>KCX@I"@^9K- LG?(3@\
M\Y!QUZ'FK&@7FA67BW2K1I8XC:RH+D,P ^4C=N&3[^O>OD?&;A?A&GX<T\ZH
MM5,VP]"E]6Q%2M.K*M&22<;N[TUT7R/NLN698O.'6HY;'+LCDJ-;#U%"48.%
M117->UI-N[73?J<+XTL+:_MI-/U\"*ZDW;!)@;@< ?>ZYQ^5?#GQ0\)6WAJ8
M20X\J5N&'(QUZ]^#_GI7U[^U=XVT>U\6:>^DW$3)&L9D$+ #Y0H/W>,_EC(Z
M]*^3/'_C#3_&5GIUG;86>-560CKG"@_B>>/7WZ_SIP?BLQK95A<H^KJ.%Q=:
M+>(G&WL8RE'WN;737TM\CVLZS&E5IXC)DZ%:HJD50K2MSWNO=O?K?3SL<_\
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M4ZCJQG;WY)*4I:*VB2WV^9X1^U5\;/C--K-AX"^"/P_:YT$W"6-W<6=J2CP
MK&S,8U(Y ;K_ /6KZZ^"GPRN_"_PTMK[Q!HZZ)JVL6GF:MB/RW$LD>9-PP#D
M$G.>IZUK_"OQKH/A73[K4W.FZA<HK7++-'%-+PN=N6!.<X]/YXP+G]LSPKXW
MU^X\'W=C'9%&:$_((U;!*_+P!R?3/'3I7K9CQ-AL+2H95##0PU)V<Z]*4I5,
M6U;WYK:^CM?J<5#*\56=3$P4JJI:2C)**IW2M:]F_N>AYG=WVD_!#Q$_C'P5
M/_;^L7%P7GL5S*8R6RQVC.#_ %'K78W/[1E]X\U'3Y-1\-!-3E"Y#VY7RW;@
M8)7@_K7->%M8\$S_ !0>P?3Y)())-[S3*7@",1DC<"N/F_#CFO;/COXE^"_@
M/P'>ZOH)L3XGBA9H%B$6])-HQP.>&_KTXKES+-L)F.'IQC&I3JT>12Q=6,8U
M)TM+4N7;1;:W-</@ZV'KQO%U'4VA"[49.WO.VJU773?L>?Z[X-\13BYUZ34W
M6*YA8G3Q-E$5ESC82!Q^6*^1]?O'TZ:\\.7$033]0E9+ER!M_>-@D^W)ZG]:
MQ/A3\0OBG\1]4FNKC6E@TI9Y 87DX%ONP/E)QTSQC\*ZKXCZ'%J6I6L5IJ]L
M\B2)]J1)%W,P/S#CG)/_ .JOEZE.HX2EA:G[R-1U*?M+.ZA9ZI-_%T/<I\L*
MWLL5']THI3E%-1YG;9Z.\=WOJOD<YJ?[(6D:SX=.N>'IUD:2/SFC0_>+@L1@
M'GGL?7IW'A\O[+'B.VTZ\U2'6)-'%F6;R8IC&9-F?X<C.<=_K7WYX?\ BGIW
MPV\&36UY:FX,5ME"REM[!".,YSFOE&UO?B[\=/%UQ/X7MKJP\,"=A-$%9%>,
ML0>,8/!R,<?IFZ7U:AC<!F,E)5FI2<81O'VTDN:-GW=K_=U*C4Q=7"XK"<\(
MX=37+4JM)\GN\MK>5NGEU/B[Q9XP^(/AJ^TZP\-ZE?7-WIDZ[_*,K&0Q. 1\
MIYSCTY!K]-_@CXNU_P ?>$8=1\:Q/;WMG8E$^T90NZ(0&PW4YY'?Z<5V_P .
M_P!DBSM]575-?M/.F)5YO,CW GJQY&<')'TJG\>_#-[HL$>B>"633I 51M@$
M0([YQZ?RKV85L?F6*<J<*6#IRG=QJOEIIQM[REH_>ZK;H>?56"HT84G:M4@K
M.I33;:TO=>5W9Z7[GS0=1\5V7C_4;O4XI+[0X9I&MHY,O"BAL+M+97CZ=LXK
MU;PQXFO_ !=XF2 Z8B:; IW/L& !@XQC'7_]=6?#7@C5]6\,/8WM_!/JS1D.
MX96?=R,D_>_E[\UC^"_!GC7X=:O<ZE?%M0TH,TABC&]O+'S'@ XZ8XX[]J\7
M'RJ0S*+Q<*N-C5O3JJ#_ '-+E:4:D+/5+NNF_4]+"PHSP4U1G1PU6DDZ.K4Z
MR:3:E?JKVU]+E_QAXX\/PW>I>#]6NQH=C=H87O@?*V@@*2'^4\9[8KA=$U_X
M6?";2[FS\+7T?C+5-4=M\KXN&B,@[$YQ^GXUXG^TAJ%C\6/$=EI^AVTVB?9Y
M534)#NA+ $!R3A??GM7OGPA^ ?P\@TJWNK35X;S58[96FC>99&,@5<X!)Y)S
M[<]/7NQ>+>"PE.GA'*NW4@GAL2M)TWNTTK[/37Y'/A\/"K6OB%[)>RE)XBCK
MR5%\/-?HV];:Z_,E\.^"8M9E?Q)97C:?>7Y+O;H=AB+'/0$8QV_R#]D_#?QK
MX5T?2'\)>(-3COKR:/R0L\@)RPV\;SVR.?KZU\V-XETWPG?7&BC2IVN#E(I!
M$VPG&!MXP!Z?7IZ_/VM^ /B5J_CB'Q'I<>H067GB; +JGE]>G3VXST)'6MJ,
MLPPV <L#AX<JJ*K5A6;T;:=HR>O+'HD]EZF<U@\3B9PQE2HN6DU1J+E4IV22
M[[I+S[WL?9?C/]E#PM\0]7-W:V\"PWSEC*H7";SD'/;VZ9]*S?&'P+U?X6>$
M_P"P_"NHRK%+%M:2!VR@9>^TC!&<Y^G<5]!?!S7K_P#X1L6=[&_V^UC"N7R6
M+(H!Z\]??/K6)XS\9W]G,%U.PEN+6:;RE7RRX 9MH[?Y_EW2@L>J&-Q/+3E1
M@E6J0;LHOE;CRWLE?MK;\>&-:MA^;"0GS4[\T8RW;TY=?2S?]7\8^ /B+6?@
MU-+='6I]6UF])>.SFE9V+L<A0K$Y[].WO7Z#?![]JC5O&GBE?"WC&R_LUP0D
M1==N\'D'G Y^ISUZU^4W[1^AZKX3@TOXD:#?KI<5OY<S6LK^7N&=V-IP,\8P
M1W/;KZ7^SIXSO_BG;P>*E@=-0L-@DNH@54B/&3O P<XX/;ZFO3^J8;&TJU:-
M6E6]G348V:4J+LN63[]_*]CDKR:<'*G*,I:\]M&[1LNVFOGH?O-Y22N&MV5H
M9#F-RP (//!Z4CH8I#&Q! ]&##U[>]?F=X[_ &N[GPCX2NM$L(WN/$%LHAAV
M'=(6 V9XR<Y^A_K](_LR_$?5?'7P\DUKQ;*;34BK.JW!VL%(;'WR#T-?/RRZ
MNL.\4Y1=*%54VE?G;:34XK2\>[]$V+6%D])-7M>\5MOY]^Q]/2[1C!R #D]?
MY5%G_/->/O\ $_1]"CU&ZN;V&]6V+XA1P[87V!/0#OZUYC9?ME^![W4SHYLO
M)E60QY88Z'&<\<?YYHCEV*K*4Z5)U%"SG9JZ6FR=M;?B2JBC92T^_7K?\4?6
M ;"D8Z_UXZ8IM<9H7Q$\*:_#'-_:MG:I( ?GD1=N3[GK].?I7:H]E<!9+*\C
MNX6P1+$P=2#Z$$C_ #@5Q3IU(*4:D)15TM5O9)[^NUC6-I-:KF^:5OZMIWT!
M20<@9_ _6GD!OF;Y2<\=._O3P I"] >Y'7/&>1W_ $ZXIC(Q/4$#I_G%9JSM
MO;?3?RW^6X7^6ME?KMJAQ) ./RY_E5:[7_59)!)]<=#_ (5,']<G\JR=;:8^
M3Y)Q\WX_YX-:J;:Y4U':^FK>FBZ:;]#-KR;71=-D[W]?3;<Z,#"I@G.T=^1P
M/YYKGM2TF:\FCD29D"D9 .,]^>>GUS5NWED^S*K./-*C /7H/Q]:1=1$6V*0
M!I.G^?Z4HJ5.[5F^G5]-M/\ +<;<96O?Y;7?J211>4J1DYPHR??'K^%//!XY
M]Z"<\^M)6;;;N]^IHK)/Y6\OZ[A1110 4444 8'C+_D6]1_Z])?_ $2*G_81
MZ>+_ /KLW_H^H/&7_(MZC_UZ2_\ HD5/^PCT\7_]=F_]'U]%@?\ D3YG_P!R
M_P#Z<@>-7_WW">L__24?HQ1117BGHG\5_P#P<MQB73XD.!NDD'MUQWK^-JW\
M'JVC6UPG+^2#CKC'X^_'8Y^H']DO_!RXQCTV.0?P.YQ^()_/FOXV]+\7JNC6
M]K@>9Y2J/QR!S]?\!WK["O&A*KAUB'_S 8=Q_P# %IK_ $CXG,O[>IJG5R>T
ME'&5'BXM73I\R^>W;\M'QXTJXFNA:Q1EY-VT@#C@_E[?_JS5O4=$N[ I;R#[
MX!VG@<]?\?TP._LGPSBTO4+RY-YY8N),B(O@[6()[_6N>^(.DW>BZF\L\Z2H
M\A\H @X4YX_/_P#77S%6=6=>48TG[*D])26][6M;IYGV^#^JSP=.<\0_KU2,
M6Z$4TDK+F3\[NVFAH_"KXNK\+;Y99--2\9'!&Y0<$$$XR,=1]>?2OK$_M5:5
MXZC33[K3(;:<K\DNP*P..!G;].IS_7X"FTJXU*+[1!"W')8+VSD_I^A[UDQ,
M^FSHX+1RQNH/.. <>@SD#_(&*Y*^5X?%N?M(RI*M:-10;7,M+[-:]_,ZGQ+F
M66)4<+6:Y%[E.7P\R2LG?:]TNUO(_0W1_$-KXJ%]I%[IJRVS*ZQW+1A@-V0#
MGT]R>U?*7Q.T*V\,7%S#8[6BF=V.TCY03TQ^F.,=*^M/@-\2/AU;^%;_ $_Q
M D)UF>W9+65]NX2E3CD\Y!V_ECTS\6?%JZOT\17D;3>=:7-TQMP#NVQ,Y*C\
M!CVQ@XITLMCD=>G' 8E1H8BG94UJXI64N:ZT?])GBT.+,;QQ3QE'/,FJX:MD
M]:,*>)G&T,8I6:G!K5J/Y7-3]G'P'+\2_C%X0T"6W:>PO-2@BNLIN4(TRJV[
MC'0]_4=17]._[6W[+?PW\"_L\Z!H-B8;3&E0WT_EJJ@R+$K,"0.N1C!S].E?
MD5_P3]E^''P\U"'Q=XS:TCN+5EFMFN-@.X88$%L>GKQ7[#_M5?MP_LY^+/V=
M[[3Y)+2Y\21V$UI:[)$9Q^[*)CYLCUZ_XU\IF6/SB/$F6U\#0Q%3#8.JG6GR
MOV<KM7:>U[;>7S/T+)(X#"Y35CBXJ-2:7(E9>YI:+ZJ+TO\ J?SH_&CX]E?#
M]K\,O"Z_8K?2<VTTT&4\]4^0EB,9R!@YZU\8RHY<S2#)D;<[8R6)Z_0Y.3P>
M:U?$ES'J?B+4]<M05M+BXG:)3G[K2,5QWZ=O3WKWCX6_!E_B5I\LR7\5N\<;
M,$9AEB #@ G\,YK[C,\70Q%98B',G.,74YTN;F:3:=NVJ7R[,^;G]8QE2?.E
MHW'#THM\J@FN5QN[W:M^'4\5T77);3_1UD*1OD-@XR,\YS]>WO76KJ=E81O,
MA6261>>YR?\ #I6'XZ\$7O@?6;G3KD/MA=E64C ;!ZJ?RZ=N?:L;0-"U_P 7
MW+Z?X<TV[U2ZB4EXK1'E90,Y)5 3Q_/\*]?(LVSG+J.)EE-6I&A[&3Q:A&_)
M2=KS;>BLOF8T:ZPE=>UH*=>/\)25[/3:.STUUV?7J(EMJ^N:LJZ3 \]W/,BQ
MQ(I8[F<#'0^O\NN<5_1A^RC^P/XYT'X*6?QS\5^'C<Z?';1WS0SQ!AY00-]U
ME/& .W.?7BOR1_9<\#MI_C."3Q/ISPW.G7432VUS'\X,<@.&1AG@]> >/>OZ
MH?%?[>/A_P"'O[)\'@6[L;2'3'TM+3'E(IP(@N>.IX]?K7B9ODU7&3R>5/$1
M=#.*[4YR;C5I2<US3;T?+=O7SZGZED?"$UALISN6-H*CG%5QJTL0^5T(J2YJ
MCVM%-]=/P/R$^+/Q"^'7CK4#H.F^'K.SOM+)AFC2&-,M&2K=%'IU-?F5^T)8
M:%I3>98B*WO"3NBB*@]1V';)Z5Z]\3_C1X%BN-8\0>&E5=2U&265&4CAI&9L
M\<X'X?E7Q'$=<^*>KW,UW=-O#N54N<!1D].>F/UK^BJ.(P4>#J7ASDV$H8W.
M<=0]DL1!1=FW%^TE4?O<RL[6?_ \#Q+R3"Y+G6#S-<0T<92IX;W,%A)-4J"T
M7+)QU]YZ_P"8F@:%H&JZ<U[J5VD5Q&055F +'TY/?OP>OUK[3^#=W%I^@3P^
M'].2_N)8S&9/+!*\8S]WW_"OA#5/"UWH]W]DFN&$2RJI 8J,9[C_ .L,<U]R
M?#[QEH?PY\%V-U8O%<ZA=*H>/*L^6Z@KG\,?_7KYS)>#\#PY0S'!<78:C]<A
M@WB,-7=6SH>R<7JKWYVUM:[\[GI\#8W^TW3Q>7K"8*A@KRS*O7FU6K0DK+V=
MWJ[O2R[7-;4?#Q?1=:E\0V/ESSF9U#1\H6#''3L3V[5\':SI'DZG=+""+='?
M&1QC//X@9SQ[5^Y?A/P[X3\;_!?6/&OB6YM;2[2VEGCM92B2.1&7 "G!Y)QP
M*_%CXEZW8OK=];:)%B+[1-'E1D;0Q (/T_\ K5EQWQ;PQQ3PEE:P6'7]H86:
MH1JJ,8N<*=H*6B4FO=OK?77<PXLX*S#)*4\ZQF=T<9@<TK.O@L.ZCGBH<[T@
M[MVA9K2ZVT9YC)%#N,8 +;N>,\_3\N_%4I;14#,#MY/ _P#K_P#UZU=+BQ=#
MST+EN2!G/3)_^L.#^%&L-&LS(B;>P'3''I_^K'/X_BU.I6P\_90J58J27/%2
MDE)NVCU2:M\OQ1^<SA>/-.*:WO;;;3U_$Y\;I ?EZ'C //\ G_/:NAT#7[GP
MU)Y]H6CF;E77((.1C!'3H.?<$>]/28UFO(X/++[F4!?J<?7O^>*][TWX*7_B
M6*V^Q*T<EQM"K@9RV,<=<_ATZU[^6<.9IGGM7EN!JUZ5-?OZRB_9Q6B:<OAY
MN_S.K*L%C,PQ<*6!E_M.BIQ4K2;T45%[WU1F:)\?OB"N=)76+QX)AL$9E<J%
M/&,%L#@_RS[/TKX<>*/B5XDADCB><W<H\Z0@G&]@223WS_7(KFO'WPH\6_#&
M\@>ZLK@QOAQ*8VVA<_WL>@]\U]"?!?XM?\(QHES/]B#WT<1*.4R0P!QSC(YY
M_IUKGQ639E5JK+<'E]*CB,'3E?EI^].VLFVEJ^M[M:[OI[T,DSAXS%9;F5/%
M?7*474=.:DXM)7O%ZW32W3TZ,ZW7OV//$6E:5'/HL!O-0> .T"98@[<GCGG.
M0,C'O7C%A^S)\0FCU'4]<TR:SAL [R;T9  @)/7&>%]3]:^C?!/[<DGA[59)
M?$$4<^R8H$E 8"/=R/F]L^W\J](^*'[<?@WQ3X<EL-$L;2"2^BV7ACC12=ZC
M<<CUYY_3T\6&8YO@\/+ U4JD%)J<&DFGLTM-TWY=>FH4L7A:D*6%K14*.$;D
MJ,VX\U2*47[26CW3T1^9A\!>)?$.J2Z9X;LI+R:VF,;*B,QRI*G@ GU//ICU
MKK['P-X@\/7]K!XJAETB1&7#NIB.1ZD@$'IZ8^IKZ<_9,^,GP_\ #'Q4FO?$
M-M;-IM[-_P O"JR;W89/S9 &3^'0XKUO]MW6? ^O2C6O#3VC0W85X$L]BE,K
MD<)TQD].1TKY_$9C76,HY=]6J1]NK^VBF_Y7*-UZI:]C3#9?AJV'Q&;*I"3H
M2NL*O)JRBMVE;>S:/E_QC\0X7\,+X2MD%]MA"_:3AST ZD=<>IKYT\+0W/\
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M7"3KY1&I%5LPJ17L.5M;N2Y7=6NM=];.QTGQR^->G^+/#%GI=@JQW4<*)*$
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MYXV6VKLK-VZ'PK\0M8\2^-=<M_"M_820^(A-'$ZO&5D>0NJ'.1DY^H%?O/\
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MS54EI=MO^M#YTM/#7A;P3\+[B!Q!)JBP,HR5+JP3H/XNI-?GYJ6KK]OU#?&
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MIN/15R?H!FOPM_X*J_\ !3KPU^ROX$UC0;.ZN(?$DF4M_L\;ERP)4<H,^_\
MDU^Z6 R;3T9<'Z$8-?E%_P %$/V*_P!F/XE_#;Q+\1?BQI41NM&MWNUN9VC:
M.1E#2;-K#/;.<D=CU K\D/$/S1_9(_X+F?#NZ_9^N[OQQ?7A\4P0W3VPGBE:
M4N\6$QN!.0V&'3GW%;O[$W[>OQC_ &HOVA'70[/5)? 8U(!KF6&98A 9CDY8
M!<;>OXU^;O@GXZ_\$Y?A]HMWX5N/@S>>(9-.NIX'O[*Q:2"00L1P45EYV^N*
M_9O_ ()O?M5_LQ>)M8B\+?!;X32^$VN76-KF;3O)8%G"YWE <\YSG/\ *G?1
MZ;V$GYI_TM_ZZGV3_P %-=630?@_;ZTX!_L][B<J>XCVL/U]OZU_,MH_[7NN
M>.==32-"T!9WT]O(W+$&SARG.!S_ /7/'K_2M_P5*LCJ?P3_ +,7)DOEN84
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MPQAI87Z[3=?-<:^3,*U2]L/S[SN_><E>]M?\O1O ?[-=I,]K<ZJZQBX"MAL
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MW'KZ_D,_IY_P3<^">@>,_%+Z[KMJES!I<OFNSHK(NT@DMN'U_P ]?+R7'_\
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M_MUQ:64Q01W3.8_*0XZ.<8QR1^/<5^L'Q-^*>C?"CP/J"SW-BURENXEC*H6
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M"PT&Z?3#Y92V\QV5HAC R3@C''TP,>_R+XR\<IXMU1;KQQ<-K=]!,)PX<R#
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M<'SK4D!LY.1MX/\ ]?OWKB67?4<6\=1E3:]BJ;C[2ZA435U%/W;V6K[71O\
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M<'7'R@'Z]N3R>:Y\'EM:I2C2S'DJ4*=1RA&[4Y;>^K[2EV_S#%YKAU.,\O\
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M=4=*I*G&$J%5.$7B(MRYZ32ERRO[O,WNU_P HRYXRO/FIM2_=V2ES7MT7?\
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MY>!;3HDZ;G<9[<D<?7TK^1+P5X2FFT2WN$4RJ802%&X],\=1WQU]>M?UU_\
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M*P%3$RS["5LRPV4Z4<"Z4;8C1->U3@I<K5O>MY&W\7OA'X7TO0XM1\-NL[;
MR%!G)Q[#]/:O#_AAX5O=:U8VM]"RQM((Q\I/!)4=O;\*^UHI-(FTFTTFXC+M
M(@1-X!P2,#K[G.>?US6!X,O-)^'?C-9M:T=I]-GF7RY/*)0988.<8X)!]/Z_
M%>)_ F7Y3G.2T*]-NCBHT_:4,)#FQ$I1E'F=-)6Y5)?:3;6Y^@9)F_#'B/!<
M64<J_L.& Q'U7$X6G%*@YR^&I4M:T8JRO+:QC>+O@K#X?\+3ZG:Q@SF,R(0/
MF!"YZ8SG/;W) -0_L\^)O$R7CZ;JE@6T^&;:DTB8&U3Q@MCMT_GZ_8WC&_T7
MQ5H:MIWEI;7$89(.,@'G!'7@?YXKYVU>[A\':/-]DC6*5P^TA<'=C@Y&._\
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M8C& #P!G;M]O8?K7.6/B'54=(9I6:'<%)8Y^7TZG_)[\5K>(OL @M9K(J)Y
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M'E,L%KJLF7ES+O/4YSEO_K]>G;Z>R>'Y/#&G:'+;:@8OM'E?*3C.X9'N3_\
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MJ:?3+*1DFBB4.(W4'<">HZ=!FOZW_P#@HS/+;?#[1)X_O)=.PR,C*NIY_/\
M*OQKUW4O"/CJZT?1/$UK%)>&W1(Y0J@CY<#GKZU[%>.%A@<BQF*Q-:C[#$8R
M$(TK-5'-I*,D]+>?17MJ:Y57Q,<1F^%P^'I556I8>564K\\%%)IP_4^#_A]J
M&D^$_$>F^'?!SS:I##/$DT6UG1?F ;CH,?RK])QK&NZ7_9FJ6]@T&E&V3[9L
MC(5?D7?T&!C)]#UKP:,_"SX*^,X!_P (\;RXOYEVS&+> 6(P0<<=?7ZU]2Z[
M\9/"\6B0Z/\ V/F'4K0M'^Z&4WIQ@XXQQZ8'8U=5TLOQ</;RY\)4I>WHX><D
MYKG2E.25[*WV?2R+DZF+IIT:3C4C)4YU-;-Q:MJ]7?=WVWOV^#?V@IOAU=:G
M'XKN3;VU[:L)C(H42;UP3G@'J#^E>X?L_?M7V>H:'-H4!>XT^ULWA6<@D#8I
M48;UP*^"?C[H>I:_XG;2["PN9K+5Y3% L0<K%YS?*<@$#&?T-?</P'_9STKX
M:?"2\>_C:?6M2LGGB0\RKYD>X+QE@>?KQ[5\XL?+&?6:M&4XT:/M'1H8AWAS
M)JS@_BOUL[K8]NI@Z="CA:59QE6J\G/4H+WH)\M^=.Z6K['Y6?M@?&K4M1\>
M:MI OKM]+O)'1E0R,JJ[D$@#(QC/T!Z5^I__  3GUOP;X:^%4T0O<-J$(WM*
M=C*[C)^]W^;Z^@KXSTSX2^$_$7Q2GB\<Z25LFO&#//%QL\P\Y8>A]\=_2OH7
MQ%9^!O ^O:3X4\#ZG!I6F2O"LC+*L:!F*^F!U]?Y<UCE^(KRY'B\0W2IUHQH
M8:'*VO:R3G)WL_==M]/D=&.P^&5+V&%HRC5E3E*IB&G9J%N5/HF]^CL?H7X@
M\-W&GZ#K^M>'[][PZE#,R)O+!-Z,1CG_ #Z8Z_E=HEOXD\.?$.]U?7+!)();
MUUWRKG"ESSR..#USD9K](9/%>G^"/AHD5UK]M<S7MJ!;.TROO+1<8.2><U^6
M_P 1O&>O27]PIG!B-PTR3+T*YW#!'7@G]/>KSCVF-Q>$PL54BJU3VOM;6452
M:2E?X9-+IK=^AR9.E0P^)J24).$'!P;]Z<G:WGKK9_<T>X>,_"VIZIXO\.>)
M/#D8:Q::&2_2/)0)N5FSC@<#MSC]/T,N-&\/:IX$@DO=.MY8XM/59,QJP64(
M >V!SD5^<_PI\=:YK'A*_CMK223[!$?,N=A8+L!R=W; 'KZGBO?/ /[5G@73
MO"=SX0UJYMKW6KF1K1(-ZM,DKG8..2,$]./TKT,3"CA(4<%&K&G!Q?)4GRQJ
M5JDFN;F6CLY:Z:V,(2KXB4L1[.4W1E'GC#FDJ=/3KJE;K_P#X3^/0\.6_B23
M2#<"RAGD98EB.W8"Q& %QC]/KVKX-U_Q!;^"_&!L@TUY;7/$,DRLP)<8'S'J
M.1T]C7Z9?&OX)7]OJUK\5=2L[B_T21A=QV2J6_=DA\!?H1VQQWKX>^._C?X=
M:]#IT^G>&6TJ_M)HXF\R'8Q9!@L<@$Y('/K7QSR?.(5<37P>(A'#4:T*M:$G
M[RJ:23C??2U^A]71S3+G3H8?$T'.I5H3IPJ02:M*VDO/;T_/WGX*^--&\)Z5
M<:CX@T6**2[&^SO%A!D4,,J0VW. "#P1R,G&:^Q= ^*_A"\T.*:[N4F>9@J+
M,PWJ,G PW(P !TKYE^"GQ#^%DGA/3K#QGI<=X!;!5D* [/D^7)P<X_#C\:^.
M_C;\6+'PW\0'/A**2;0(Y2\5K;DE5VG(&U> ?7'UKU<34E0I3Q^,E"K.<8<D
MZ*O%P2BI*36TKZ:M?)6/*P^'CC:T,OH1G24)R?/-VM*]U:^K32O=77S/V+TW
M7HK/5;.;2[I4@N<, DH& ?;([=NM+KG_  @T_B2.?Q!>I+/<,HS,P*JS'&03
MP,'W-?CWX0_:,\8^*=:TW3K2VN=/19(D5I-Z_+D X)([$=!7Z1>)/"#^-_A[
MI<UO,]KX@CBBEDN@Y0R'"L<-QGDX]>:=>MBY4L+/#THX:-2G&<)UK^SG+W=-
M+)R:V^XB.&H8>M.->JZ]INE4=/6I#31ZMZ)_/3T/JRP\0>!_AU);W6EWT=Y/
M-'OB0.&VY7Y0 ">O Q@?X_$W[37CV;XN3W.DK/+9RQ(PBV[DW'!(YR.OZ=_;
MN_ 'PJ\1B&UUG6Y+F\CTT*HB+,_FJI'(!/.>YP:UOCK\,K#3]&T;Q?8VK6+M
M+']I1EV94$9R, ].O6NNKG&+HUL/F4.>F\$Z=7$0E#W:T(6BY0=M==KWTL[)
MG/3R_!MU,+*;JRQ5X4)1=Y4W+5<ZOIOT8?LA:EIOPL\"ZI/XCMXIKR)'\BXG
M \S 7 ()&3SSG-<-\:OVN/#GB%IM!B?R[]F:*U,?=\E%&5_+/OZUQ?B_QUH;
M:;I^BZ?J$$,C6ZK<1HZJQ;;ALA2#Z]02?RS\[Z-X3\+^(/%R*+5KZ_AFWHR9
M8(X<8)Z]^WJ,\UQYIQ)B,ZQF(Q5"M&@IN$HTJ:Y>:5HIN=DN:+V=M4^YZ.79
M'1R^G15>E4J\O/.4IM.,4ME&_5:6OTMNM3ZT^#6O>)]#M9O$'BTR_P!A2(SP
M"0DQLAR0<$$=,>IZU[C\$+W3/'WC;5]7M+YTTNS:1S!N/E85LG ) /IQ[?4[
M.E?"ZZ\0?"E],F8;T@Q#"HQ(J!?NX !SC@YYR/3BLWX4^";GP9$VBZ7IL\5S
M=LR7,NQLD-PQ)Q]?J17N9;EM#'T.>M"I3JT;5$J4W]6G>UYRYG=RZ_>>+CL<
MZ-6<H6;J7IWJ)>UBD]+6]U*UK/=?GZG\0K?PMK5M/.-,M[JVM2\4DC1*WS#Y
M2<XY.<'GGVYQ7S-_PA]G&EU?^'55YCN:&V P$;G 51V'&,?E7W_%X&T3PYX0
MN&UMES=QL[B0J3O;GOGU_'UKXT\:RV7A5;K5=%O(XX8]SI#O7#8SP!GOCT]N
M>W+B<%/!U*OU"KS4).+JTVFY5]8WC[OPKHW_ $WA<1#$Q@L6IQJ7Y:4[KEIV
MMJO/KHKW/S7\4>'?&'COXM6_A;6].E$:W:^6QC8KA7XYQCT/^'?].?A[\ +V
M\MM(M+F-K5-(6$Q%5*YV@$>@[<]N>_:I\%KWPGXSU4^(-7L(H=5M7R+R2-1G
M!Z[B,?7GOCZ?>?ASQ3X=N3);:?-;SRVXPYBVD_*.Y!Z]:C 83"X;$UL8[JO4
M^&&KAA^9)6A+MM;UN=68XS$8BC0PT()4Z5H2<5[]9*WO27=]];=^A\[^/="\
M%^&=-%SXPTVUFCB@,4=W/&I<,JX4[F'L"/;TK\B_VC=8N;3[6W@Z!7TJ\W>6
MT> $4GJN.G4_X5^SO[0'A=?'_A66T6)E6/<V]./F7/<#Z<?7/I7XU_&+P#XJ
ML;![6QAF6QL0WF2,I/RJ?7IZ]\FO1JXC#8=4ZV*_VRM34I4J;=U&/*N3HW=2
ML[KIW//PU"M7G*E0<Z-.5HU&WRQZ7O>VN]OZM\,^#K_Q]KFM3:&[W,=BK,Q<
M%\#&#@'./\,>U>O:;XBT/0-4_L?Q1>2&X#A8EDR0Q!P.OKCZ^G2D\):W:^'[
MSS)!'),91%,<#.<[6)(&0<@_A[&NQ\=Z)\.=4>RUV_F@2^.) H=5.XC/3USQ
MZ9_&L:6/PF:RIUZBCAU0A;$T5\4^6UN5+;7\?,*F"KX*I4IJ,JD:LDL//1+F
M?+=-O5_T]]O0;K]I#3OACHRMI\226[H"N.2 1U ['_//-=/\(?VOO^$MU9-+
MBE.Z_.T#=C;YGRX]N_ITKX)U?P/K?Q!\1?V;H]O<76E8\N+R@S+C.%P%X/\
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M[&:YM@!.Z=01U.0!W'<?3BO/?#O[.VNZ$MOJ.JW,UW'',LDEK,2R *P/W6)
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M/?\ 7/M7PUJ*>(]GV[4+F>XCGY!=F.<G(ZY^O)Z_G753VVOR6EO;O'.(/,0
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MMX-TWP3X;G\&?#^TM]1N=3B,%]<1A79"XV,=P'&,GKTKYC\-_LB^%/#WC/\
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M?^&O".J^#8IDMH ;AV"WC*HD!?."&QG(W?IWZ5[1H%XGPPT6XDANIKRUF1P
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M\W!U*_M72PU2=;$*\'4[Q23O>ST]-58^#_C#\7O'-UXC32/"^ARW5K H D2
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M.[^_?R_8>&^)*6-R7-\IQLUA:]/"P6!C&#E[6K3FKQC97OM=GF]_/$464-_
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MBG?M9VN_Z\DSX'!0H8'-L7@GA)4XM>U6(<?=DW:Z4K:6^=^PW21YCF(*-[<
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MW!5,1A$Z<(2YJ\;KEA)-:O[7S\C#LHM/\ JUO#<L]G'(J2#<?D&[&!V ]O\
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M2;5'08V\_P#Z^<V=-CUJ[T;3?%=M8I#>:F4DN80H4@2X8Y7U&?\ "CX4>!_
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MSUOIL8GP[\%:KIGB/4M5\0@+#O=H3+P2,L01G\O;Z5Z_>:YI4UP$M&!NH^,
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M(W)? W#)]>2",G'/_P!:K/<6]O;^3!"%7;C@8ZCCH.WY^WISL%E)>S8\SJ2
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MM*OE&#]E3RJCAO=K5I0Y>1XF%/7F3W;23LOET$GQX/BSPW;Z%J<NV%9 N&;
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MO2E5HY?AJ*R^5&CAI0CS2JIJ/O65[R3L[OK^/$:_XH?S_(M5WF5@#WP._P"
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M*_0S#M]*_P ME/'6G>(/B_\ #ZRMHT;_ (J;3@'51T^TQ@#(^@Y['BO]2?\
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MDC9QDEE;: ,Y[CCWQQ5JE&4)SE4?)3:4:,MV[W?*GJE;73;II8?/47+&-/\
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M,:]+#SD\/*,7-P4K7LK<SV_K0\&G4Q6-G*$,'6]GATW5Q%GR1:MNULVMKO\
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MABIYQP>/7'&/\@UI>%]:5]*7SH(X;SD,0H#Y'KWZYSGG]:Z*TU%7TA[>>03
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MW[5XO\2=6_MG7KO4%3#SRLS8'0EOQP,'Z\?2KUEJ']AQ,7E$B/GY>.,GD_\
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M)I->JO\ <=K%;0Q^)'U%PAL4EW(IQMP&)&.W3'Z"M_Q1XFO-5,-K:P*EC&5
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MG6K^%1'<0K'N@D91U9>002.X_6OA6'2_B9;:0(=+\5SO;7<H4Q+-)A().-I
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MK?HF>7L SL V5/.>>_7O7H7P^T?2+S5XEUGBUWC+8XQQW/IFO-(BYP #G/\
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M-AO#>L67B8:9=1R7<-E,$C."0P1\9''M_/ZCZG_X0O2;CPY'=WENMI(8@-S
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MQU" ;LP<YP>.?_KC_/2OHCX]>'[72]<(296D9SN .2#GIQ[]J\)CB()^7>,
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MOA.RO_&EM&D4Z13F*;;\LK ':=W3!S_C7T5I;:5H_AZSM-$DCM].CC46JJ0
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M:$4O)V:?F4E34FU3E%U7=;VUM;_@/_ACD/@GX[UGQ(NIR>*;1Q> 2JOVA#@
M XQNST]NOO7ZV_L*[?L?B4H %+DJ!P,&4'@#C\:^'W\$:6;2\N='LEM76-V9
MT0+GY2,G&/7D>GUX^VOV#D>'3_$<+Y+(V"?7$@_S^=5.LJ^79G6C%4U)X=>S
M7V4IQM=='U/,Q=HX[ Q2NU[3F;UUY5L_^#ZWN?HI1117RQWG\4?_  <UG_B2
MC_>D_48K^'2QD(@CQ_<'UYSW_P#K5_<9_P '-7.BC_>D_09K^'*T0K;Q]?N#
MMZ'']:]S.;\V"MTP5!^EHJS_ .&/,P=OW_\ V$U+^GN]].YTNE0-=SHJ8#;E
MQ]?R'OG%=/>V=U:S0B1MW (/7_'Z<>]<AITDT+;XB58 D'OGD?I6XE[>3Y:X
M8L5) /)QC@=_;C'?]/(C.?,I2DY)./,Y-NZ36EWK_7H>G27,U&S2?73R[):?
M\#Y=7'=HD/ERA3@<DXR,#K_C_AUR9-/O-2D\O3[>5R2>8U) Y]0IZ9/IBO5?
M@W\/4^)&N1:5>SBTMYI!$TSG:%!.-P)(_P ]:_0JZ^"_PS^#^@_9O[1M-9U6
MYMV92'BD:-RN1TST_7OQ7=C,73J*CR4URKW6UYI)W\_ZZ'HY7D51.MB9U/W4
MFY<LG;:VD5=-O3?6^I\=_LR^$/!FC>.M*U3XJO"FBP7<<MRDYX\L.I((;/8$
M<]<5^J_[6O[9W[/UA\)[;X<_!?3M+?=8?9KFX@2/S-Y3#'(!;O[?AS7XD?$>
MZO)-=OD@N&6TRX$2-C"Y)'1O?C&:\B\M%+;1(S,<'=(S=\\@YQGMGT]*53!Q
ME&AB'.<8M7Y8RM[RLE?71;:=%J95,1EN)=7"+"\_([/GC>TX-6>NE_Z\B>^N
M9+Z^N-08'S9I9'('^VV1G_/Z]:+R2 $M_+GGCUKM=!TJ.\DCBF 0RD8/'KQ^
MOT^E:/B3P#K6E-'>_8I&TIP,W04[,'D'=C'3M^/&*QJPE"?-.5OA5TV[)VM?
MUT_JQR4X^WH.=./N4YJG:WPVDHK[G\M-N]+PYXRO='L;BRMDRMRI#GOR,>W&
M#T'_ -:L6$/<7,K/G+N7.1QDDL?Y_IU-?27P2^ ,GQ*N$*R>7 226[ 8R1]<
MCL>.U8_QI^&UK\,O$*Z1!,LK_=8@@X. #TZ<]/7]1^C4LAS6EE.%S''5(O"T
M(<V&H5-9*G.TO=?FK6ZO?8^LS+(.(L)D-+B7%RC/!Y?!+!TJDHR45.TDDEK_
M %U/GZ]8Q2A<=,#/3ZY_+.>/UIZ7Y@"E&PZ$%<'&2.1T _'_ /74VH",C<6&
M\9R/SY]O3CZ=\5SS(SOOYQTXZ8[]O\_A7P^)JRIXBI*,FX-\VCUBWK9ORV_
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M^G:O%K*"DO=4>6*7I;_@),VR=UYT7[:I.M+GO&53XY7:2N_5[?\ !2C@8&3
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ME3K4]/:Q6D9I/797\O4_)^3&KQ"HQJP53+G",Y\\;TE&3C>.UKKKV\^OT/\
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M\%_$[X3^)_"WC^X@M/#M[93"^N9V1$C3RI%/S-@ E3GKVKW('@?0?RK\T?\
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MM#TY);A9(?E,;S.-S*2,<GO@?7/%=3%\'DU'6XI=+T\BXA(\MT3J 1M(P/\
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M4ERPMR\G)\*AUOJ[6\EU^PJ46Z-%SHQK4TE.5XPL[<ZE>^L]7'IKY:^ ^$?
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M-5J$7R)-7OU35[_=?8[Z.'JX##4ZCY*O+;ZQ./O3C%VNDTM4T^6SZGY\>#?
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M?Y''UU^PLXEL_$LHZ/(Q ^LBY_\ K5\(6FM^$=3ENK>/6(&E^SN4A61,YVY
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M[<CI_3W[UX)%IQ^T+;D9DW>G(/I]1T_.O4] T+4[VYM=,N2T-K/M7S"=H /
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M )['_/-8^N?L6^-_$?Q+N?%&NZE<G3Y)V92\C[$5CD')X&WTKZ3\*?"+P_\
M".SN+^^O8]9@4?O(F99!%D=P<XQCG_Z]>1[7&8[&8>5>BZJYI2=6+Y'&Z7*I
MQ>LKOMUN>LH83"8>I[*LO:646FN;GVYN5KX=-M+WV-W1_A[/XA\&PKX)F>TU
M7:&>%#Y;;R.<J,'.?TZ=*]=^&.B>/O"L'V3Q,TES*!A2Y+$#COSCVQ]>G%9?
M@6VU*ZBF\5^$=R6*@G[/$/E!YQQT_P ^N*]:\'>++QQJ%WXM7REA,FUI@%P1
MG'WL>Q_#'%>YAL74IQE@8X>5*52<IN<XN5I0LY/:^JVV/$Q%%U$Z\:R<()14
M%;G?,U:+=W=QUZ^74I^(/BAX0\&R6KZO:P?;IY%C+.J[LL>Y('3G_P"OTKW/
M1/%'A_6=%M+RWAMGM;J)7,:A2"&4'##D9_SZ5\5>.O!D/Q5UE9-,7S+6*4D2
MJ>$QCG(Z #D<\<YKW7X>^&+'P?IT.FW&KBZ>) IA,H8QX'3&3C;T_P#KUVX.
MK'%4)U*DW"O3DXJ33C!QC;ELO+RWT\SAQ%*--T84VY7CS3ANU)I72_X;R9TG
MQ%UOPUX0T.?6[;3[.UDB1I3)%&B.VU2W) !_7J*^-;&TC_:'>^UW3Y)+>;2"
M^UEXW&(Y!R.#G;]?YU[]\6AX7\:6)\-6VLQ"[VF.>W$@W <@Y&?K^OX^ P:G
M_P *(\.7>G>&+<7DM[E)Y(\-C?PV2.O7-<M)_6*^(IN#]K*"_P!I4TX+EMMK
M\3=M/^&/0:=&C1J0J.T)+]Q.+3;TNTWHXIIZ['RA\7?#9UN\_P"$6\1VTEQ:
MP/Y1F\O?\JG;DG![9[\#Z\?$OBCX')X>\=:5J'AEKR+21-$9XH0RJ1E2057M
MS7[I>!]%\$>+]!M]7UH03Z]J#[6MWV-(CN>1M))SVZ>O.:ZB\_9W\$Q7UJER
M+?S[MDEAM&V9P2"  1_/Z=*RJPK3PZPV J5$YM+$J$U\$6E)V^RYKOL;4L5"
M%253%0CHE*AS1>K=K)/LK]/OV/FSX8_";6-7\(6>H>'H'%VD,9CED0APXC!S
MGJ/F[_KUKS[XHZ]\=_AU:2/=&XNK=2846(LY"'C "GT]N.?7-?J!XF6S^$'P
MVU%M)MTBO(;!GMHE R76/Y< <YZ=NXKX8^%/C;5_B6-<O/B#I[-96UU*T"3Q
M<,B.Q& ^ 1COG]:X99?@\)5I5$ZLURN4J$YW4G9.4FK[I]MWML72QV)Q,*K]
ME1Y8R2C+EM*.UEKT\]K'Q1JG[*WC/XY^'IO'E_+>:7+Y;3NV9(LG!8[CD=^,
MY-;7[//PML/#^I2:)=W$=[J%O,(=Y<22<,!DX).?_K&OTIM?'UOXOTV]^&7A
M&Q73HKJ-K,7$,>T1ALH6W  \?A^/%?(T7P<N_P!FKXBKXD\1:Z=4L]3NA*5=
MRZH9&W;<$D #CC_ZU=^&R6CAO:8C"XN="K63E['62G"IJXN.MK]/N\R:^<5L
M2U1Q-*$E3Y(Q<%:W(TKW6CV3NM;]SW_QM<1_#KP?>G04N)M4FML>6 Q.XH0!
MC'J3_G%>&?"[5K?Q9IUW'X^MY;9_M)=6VE9-F[.03@_EQ7VWJUUX9\0>&+?Q
M.EG'=V]W"C*@4,.5'&.>O/'MZBJG@'X6Z!XK\W4S8I;VX;'DA @.?4=^<=0/
MUKGHX:M2QRK3FW*G&U%4VE%;752+O>[N5/%TOJDJ4(V]I).<Y)N?NV^&7;7R
M-+X>-\-;FTM]-TF9S<08"^8<9.._X@?EQUKZ6T#3K>!D!554J-K8[?7OQ_+I
MS7CVG_![2-#U9;S3"L3!@2BD=L=<?C_^JO;(XGMK=92V/)CX]PH_KQ^E>O74
M5[/EDM??J-:>\[/;;NO^ >+SR=[Z\ST;W6UEK==D_F:6HW\&A@R%/,1OO#J.
M02,_F<_AUKQ+QCHM_P"(VBU+1(O+<2!G"C&1D'G&,\?AVX[^EZ->CQ1-<VCQ
M^;Y)(&1V!_'T(_\ K5=6WU#3'>&"S*Q#(^Z3T_\ K?R'2IIU.5QK1Y9.+;;>
MSV^[?T5D3RWBU.+4UK9](Z?U9>GD>0>+/"EQ>>!I6,2QZK;PCYU7#;E /IZC
M&>>O4XI?@K8VB^'I8->2TEOUD(#2!&EQSZ\CT_'ZUWWBZYN$\*ZH\2DWOE/Y
M<..2=I(P!SR<#BOBOX5R?$2Y\87)U2"XM=--VP7=O5"A?KSQZ=.OKZ:4Z53$
MNI+W(N"<N9[R_N1ZI=U;\=33G48<B;<M+**]U/37UTT?KL?:U[I>FLTEHMRD
M<$W#*7 QDXPHSZ?IGTK$O/ASX9@TZ]GLX+:>]6%WAE*J6\W:Q&&QV/OS_/YK
M^,M_\0['Q9H]IX:MKF?3YI(1=31*Y5%9@&R5ST![]P37TGX3L];NM&CM[C?]
MIE@0$MD'>R\]?0]OR[BE["5*E%^U7[Y-N,=>6S5HRZJ]D_Z0W*4N66K<+7YG
MZ7M_77='&?">77[<ZU::Z50QR2BP13CY,G: !CMCCCI^??6[:I=3RVUXBR1L
M6"!_F(4YZ9Y'!]*XLZ5K'A;7P;QF<SR?NXRV<Y;^6/;^=>M16]E;POK-_?+;
MS+$&2V+;22%R!@GK_.G5A)OFE3C4Y^57IJ\6K17P]%Y_.QES0U<>=/I*^O,_
M\KV^?R7GFLZU:Z/YGAZ3S(Y;P[$91@+N./\ $50TSPI)X:*:I=3[K:Y.]FD;
M(VOS@DG'3'7UKA]7\4W/B?Q=':0:0SK%-B.[5&QC=P<X]LUZCX[TK6;[PB^F
M6<C&ZEM0D97.8V*  C!R"/Y^E91E1J8F$.5Q<9*,Y25XQ;25DNR6K[Z^ITSA
M4HX>+G-*,UI%+WF]-9>;Z/YW+5YXW\'V2C3["2TGU&XC8%861B&;GD#)!R?T
M]>GR5X^\,6O]M/KEW&L\H=I4@<!P,\]"".IK$^'?PM\5>#_%$^L^(;Z:_$DK
M&&.1W8("<J "?3 [# _"OIJ#X>WGB2]DU.]1DLBHVAL8 P>><#OV[\'CBLLZ
MR_"J=.CAZOMIM*V(C>-.$W9VZW:>^JZFF78F5/GK5?W:U]R6LI:+5;7OW^1\
MF>-?#]Q\3?!]UHDEO;V-LL+HI94C0C8V,YP,U\K? #X+-\+?&FI:I%Y-TEO/
M)*!;[7S\^[&%[_UZU]]?'OP#J-OX!OK3PA>-::@1(JM"2&Y&!C:0?\]*^:OV
M7?#?B'P#<W>H_$&[DU9YW=H[><ES)R2JA7.3T QC]:X<,U@JTI8JC#%IN$*D
MJJLZ;;5I4'9<K[V\_4]7G>)PSA0J>QY[R5-/62LK\_D_PZ6Z?7/A;P7K?CZ^
MC\6W5I+'I6G@%DDC(R$(/3 ]QSQV[U\Z?M3_ !;UOP]X@\-Z7X7L;HS6]Q"D
M2P(P!9'4<A1T/?\ +IT^L[']I=]/N%\+:9X8-K!=/Y(@6# D5^-W"CJ,GH/Y
M5[[IOP)\(>+[6S\<>)-%A$\6RY6.6-<HV ^ &&1V]#]*^SP-2ADN8T\PS/!2
MJTZM/GPT8RBWRSBE&-_Y=5>_9=[GR^(<J]/ZO2JN#IRM.U[.2:^3;_RLCRSX
M1-X]\;>$;'6/%L<EH4T^-H!("F?W8*GG!SG'X50M]+\33ZIJ/]JO+]CA9_L1
M#'! /R__ %L?K7O?Q"\3Z7I/A&.V\.%(&M=L MXE"D*I"]% /KQR/R&<7P$S
M^*+;3FG3>YVB8%<'WSQGZ?YSXV,K1KU*F*A2AAZ,JLFJ,&M%*UK_ ']M_5F^
M&4J,>65YZ)N4[ZM6>E]D]S@%UO4=*TUWN89 O**[@_=XYY]L=/;Z5YYK^O74
MMC.83(89PYD,>3@$'KCN,@\^E?>OCSX>:7J?A>.SL[55NC$,E54'<5P>G)Y[
M_A7R1JO@2]\)6SVUW:-<17&X!R.%#<#GMC^F/0URJK1A24XPBXQERU(?;FG:
MZ<O^!HO,Z*3C.33?O3=TND9*UG??3IY+IT_/+Q!\/;K4O$L&I6;I(&NU9U8J
M7^9O0\@8_"N@_:#\+:WX>\&:5K^G&XWV4,;NMN&R-JKGA?QQ]>>N:]?NOA]J
M&E^()/$)ORMB7,B6H.5+<D*%!QGM^/K7>:+<7WCFX7PEK6B-=:9>'RDF>$E=
MARN1D8Y'.?Z<UPO!UZ:KSP?-0A7UI4U)2]DG;WKK?=MKS^9ZBQM-U*'MHTZK
MHV]I)JTJEK736BNNC5K=3Y._9,DG\=7MYJVIS7ZRP*ZF.0OCY%QT)]?\XK^@
M#]A:)8+'Q)$F2J.0,YS_ *Q<YKY0\'?LW>'?A5I5[JNF6<:"XM'F:)54;2RD
M_= '()]^G:OK7]B%MX\5L!M4RMA1G"XE7C\.E>_A:E>ID6-C7FJLJ*PT.?1<
MUI+9;Z6]=CYC-)4:N<8>MAX6IR51I/[/NK^D?H-1117SYT'\5/\ P<PJ%T@'
M/&9<^V?P[Y/3].E?Q0V%L;RWMXXN7*+TZ\GT_KC^=?VM_P#!S*6;2-H!&6D
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M5O* QQG ''^/KSUXJ+3],M+N5X)IQ$1TR0/P[?Y]\5T!MK*PB:UA1;J5EX(
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M6M?\CTCPCXIL-,U2WO=:)W>;E?-S@<GUXX/^3UKN/C)\2].\1Z)!I5@ZM\F
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M'OV[-Q7GD8^O/KZ^_-?/LDN&7 YXS^7^ S_3FNOT#Q"^CW,,ZC*JP+#';O\
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MX<^DK=;[_/3Y]1.*ENA84\NWCA_@@0(F/88']*4L2 /2F8(4@L>N<_E[^U.
M 4<Y/T]>>M9MMZN[\_NO^EP22=N[^[;^M0IZNR]/7-,HJ6I.UGRK6[]+,II7
MTUMLSRCQ+\'_  ]XIU=-;O%4W<;;\D G@Y[@_3H:XKX@Z-\/-(T^/3M>MH_F
M4(KL@XX'?''IU]Z^C5R-[Y^ZI.WZ=A^7M7Q?^T+XLTV1);;48! 8<A)VXY&
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M_KQ\J_'KXPZC=:;JO]@Q/;6RERS1#9@ G.<8' _^OTK]O/$WPL\&^(YI[/\
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MAB\ ZM/&XBG*E5L_:8.I*7O2I/[*?7?U.H\+:OX/TKQSJ8U^R4(BOL#QC 8
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MU^I]._!\NG,K#>W;G'\\].?QYKGPV<XS,<+ED,74C)X;#1IP:O%II)2BT_\
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M)]>O/3W_ /U[6IW6K:K(\TY=X<DHIW$*!TQGCC'TSSWQ74>$TL8E=[W:V5.
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MNW:<I\BLY/;@=?T^O2OE59&0O@%W5V /?@XZ\C\OPXQ41^TW$Z+-N12W!)(
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M*4+27?NM?PT/$/!OP'TGQ!X T#2_'UE#-J%E869W2Q*SAEB7J6')R:]E\/>
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M4?H)136&[C//7_/YTX< #TKQCN/XO_\ @XTMFNO$7A>%<$OJL8Q]9D'.?:O
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M:EJ7AG7+;7]/F"16SH[KNQP#D\_Y]>M?:%]^T;X/2T_M3>!XB6':I5OF$JC
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MF/:3@<@D>GUQ]:]2US^R[^)&M B?+R%P.0 !TZ\]/U]O.+BQ*N2#D#/3^O\
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M<K[]OP][I^(7C!N#X6EV@8"_96X'3'3_ !_J,UPWG%K>RHK>Z]K'=M/\&O\
M,3SS+I:OVSM:-U!K:R7;77]>Y\(C]E+R]'L],BT\[;954YA]!@X&WVSU]/K7
MM?PN^%5WX$D5%M94C  (6,@<8/8?I^E?09^('BO((\)2C!&?]%;G'_ :C?QY
MXJ<Y_P"$2EZ?\^[CO[#Z?_JI3X:SAZNE2=[*RK0MTZ+^OD7'/LO@[J$[O1-T
MY=;?\'[O4A:*X+%OLTW/^R?\/<U$\4V&S;3;L'/R'T]?R_7UJROCOQ.N0?",
MG_@.W^'TIQ\=>)S_ ,RC+_X#-C\01^52N&LV7_+JC?\ Z^P=M5U^;Z>6]K:+
M/\!;>I=].27=?\%_+Y'K/PCL[IIF8V\JJ,\E&'?KT_KS7TRR/Q\K= .AKXWT
M?XP^+M&0B#PC*AQC*VSC/'KM^M:?_"_O'I_YE>?_ ,!Y/ZK71'A[,X02="FW
MIM6CKM]W;;\4<<\WPE2;;E-7V_=M+HM?E^1]:B*1NB,?;:?\*7R9.Z,/8@_X
M5\F)^T!X]0Y_X1>?_P !Y/?_ &/?UIQ_:"\>DY_X1:?G_IA)_P#$'^=5_J]F
MK2:H4K-=:T$^C=]=]_D].M\O[3PFEYU-[WY)>2MHMOEYGUF$=1@J?7I^'MSQ
MW]JC*N2?E;K_ '37R4_Q^\>D[CX7GX_Z=Y/;I\HI!\?_ !Z?^96G([?Z/)SU
MS_"/3L:K_5_-+).A3_\ !T5U7GV;_I,G^T\'&\N>H]OL/R\OZUL?6NQ_[K?]
M\G_"G"*0C.T_D?\ "ODK_A?WCWC_ (I><9[?9Y/?_9-.7]H#QZ./^$7G/_;O
M)_\ $4+A_,[?P*5]+)UH6Z7_ %[?@[5_:F#DE^\J*^OP23Z>7S_I'UF8W'53
M^1_EC-"QNQQM;\C_ (5\E'X_>/CU\,7'_@/)_P#$TY?C_P"/EZ>&)^G_ #PD
M/O\ W?IWX]*<<@S5:_5Z2Z7]M!J[MJETZ^GR#^T\))6=2IRJS^"2[+72[:_S
M/K9H7SPI_(G_ !IODR?W3^1_PKY-_P"&@?'W_0K3_P#?B3_XCUH_X:!\>_\
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M,=K8'^R??T%(4ESPK8]-O^(KY*_X:"\?C_F5Y\'KBWD'_LO^-'_#0'C[D_\
M"+S_ /?B3_XG^0_'UG_5_-=4J-.VE[UH;Z7?K^/43S7!72<JG-IK[.7EU2MK
MY^>Q]8^5+D (V21V/KS^E2&!QQM.<^AZ8],>O_ZZ^3&_:#\>DC_BEYA_V[R
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MUJ.)0&"R0W(!]AN ZG^GUK-^*'PQ_;(TK5UCT'P7K-U CX,B6ETV0#P<A?\
MZ_X<5Y.#X6S:O7^K5'1HTY6_>NK!J[M\6NWY=S[3!5,OGA'7CF$,/*I)\]%I
MN7+I[SUU_P"&/TM\,Z +I&*ZE:J&S@&1<^O3([>@Z_@:Z:W@TG3YVM=6U&S"
M')R\BX(_$Y_P]Q7Y2>&?#'[<GVBW63P=KD**ZEO]%NP,?]\XX'Z<BF?%GX=?
MMO:E!'-I'A37/."<[+6ZSD=>@S[=.G?/-?49KX=8[+,)0K8;'X+&2<4ZD(5J
M=_>2TM?I^A[%;!\/?V54QJSBA4K4+-T.6U23TTCKUMO;N?I?X]U717T74-.\
M/ZG9?;7A9(625/OE,#H>.>>,_P Z_._1/AAXYE\8WE[XIUFS;3))I&@S,AP"
M3C^+Z>G\Q7D'PT^"'[<>K+?_ -O>%]=MY55_(:2WNQD@#;C*X(Y^GXYKA/%W
MP5_;_@U">&S\,^(9X5E;RR+6[/R@@C&%]!U&/\?-J\$YQ3P%/%QK8.I[1>]2
M5:'/3>EERW_KI;0^7J_V=A\NPN;0Q2E'$5)0EAU_%I<K27-'>S5VGMTU/HW7
MO@WXZOO$;V\.KVTGA:];;+$LJD-&6R1MR<@J?3Z]ZWX?A)XR\'2VFE>"=0MK
M32+B2,WZ[PF=S#>2,]^<\>]?,W@/X7?M]C6].CU;PEK_ -A251,)+2[QL!4=
M2#COGK^AKTCXP_#']N$:E9/X7\):X(!$OFB*TN@-P'/1?7/3GFO'I\+YQ*RE
M&@K-Z^UANEIU_/L<5?.\LIX6=93J5*C:A[-0?/:5K^=OEKT/6/C7\*+BV7PH
MWA_4K1M>N6@^V.DBY#MC=GGUR>?K534OV?/B5J\FE)>W\%Q;QK!,P617PJ[3
MSU'U)_I7R@?A)^WQ>2PW-YX.U^2>%LQ,;2\.T@\8RO;'8CK^%?27PJT3]N*T
MN)+;Q!X+UR6(0F*-Y+.YP/EP.63ID_AT]:^@RS@S'XVJH5L1AL-!-)RE6@FW
M9?:OHMOQ[G;P<LBS_%.AF>.>44(W;JXB+DF]/=7;FTUV76VYZMXI^#9UF3PU
M9/>Z=&VDM$LZEHP24P#N&>N!SQUX]Z]\^'_PJ@TC7[;4%UFPCA6&-"D<T8!P
M .@/X_B.:_,'XE_"/]O:7Q1>:AHOA;7Q:S2EU5+6[V@$CT7''MZ>M5/#7PY_
MX*#V5TMS<^&/$+1H%(0VU[U7ZC_]6><5W8/P\Q6-QV(PF*S'!X:C2NU6=:%I
MI+1JS][_ ()[$5PY@LSKX6KF"J8>%3DA5I)J+@VK3NM&NK7_  Q^V_B#PW+9
M3K=0:E#)$Q!+"0,H&.YSC^0XSFFXTIK+9-JMF)0O&Z9>OXG.>OI[5^3QUG]O
M6.PN-*G^'.NS$J5CF^PW9(XP"#M]/_U<<>27O@K_ (*!7D_FIX+\0QH\A./L
MMZ,!B".-O09Q7=DG"6 RW$XF&/Q>'Q,&Y0IRT<;*RYEKN[W35OF=<LPX7P_M
MH4,Z]K)[?N)*W]U2V;Z7];;G[B>'--FFO5D22.YLU(+R189 H/4GL,8[_P Z
M]#U=]%F1+.*\M4( ! =<YQR.O7)/MZ^I_+#X7>*/VT? OA*ZT74OACK&HWMW
M"46X>PNG9&88!R8R>,]0<?SK&TWP]^VIK-[<WMSX+UJU&]Y8T-I=+C)+;1\O
MY=^U?,9YPW#$XZN\!&%*E3^"?/'EJW4;VCNGY+\3QL5F^54I\E'%^WC.*;FJ
M<HV;Z:_CZ'ZCQ>%-*N9&0WML]PR-LC5U)/'8#G)_K^%?B)_P4&\!QW/B&RM7
M<"-;D><#QE,C/Z$]:]2TR?\ ;IT3Q[:7;^ =<N--MGVE39W95UW#.?E(P1^?
M3BN._:9^#G[6OQANK?5K7X<ZK'*$7?&MC<\L.3T3)SBO.H9#GE%QJTH49*%F
MG*K"_+HKJ[VZV\EYGR^(XFP.#Q>%H2CB:KK8B/-5A3FX4J:<7>3MY>1^9WQB
M\">"-/\ ">G7&EB(7T=JGFE0 =X7U'.:^9OAIX:@\4:]!8WC!;8W!1V;IMWD
M>W;\*^]_%?[$W[8'B&SCM6^'&KA4CVM_H-SV'?*<\]^??M7.>#_^"?G[7&C3
MRS1_#K5H9,[U<6-R#DGL=GO[^V,U[63Y#F%;,:=7,X49T)2;K?OH:I+2-_PM
MU\M#ZFCQ)D.,XAP5;&0<<$DHXA1IR49\L4HM[;V^;W/G;XU_#[1_!EU8#0YH
MWAD13,$(.&P"<_7\?6O!)[6>5"\=M+*OJBD] >X_#^8K]#=>_8'_ &Q=?O4%
M_P" M8FC$B@;[*YX4?53Z#ICVKZ/\$_\$Z_CII6@J-1^'-[/=3( RO8S,5.!
MZIQS_GBM/]7,=C<=B84H8;#X53?L6ZT4N1.SW>I^<^(O&N79!B'F&49;C,QA
M7Q?LZ6$PM*<E&A=7F^5.UEKK:]O4_&C1=9N]!NUN[==DJ, 4?CC/(P1[?_KK
M[;^#\'AOXH-&GB!H%N(\ AMO.!^!Z_SZYKLOB7_P3;_:@_M9I]$^'.IF!W)V
MI8W& #SC 3UZ@55\#_L&_MC>%IC=VOP_UF%D).T65T,\=,;!U]L8]LYKZ/@Z
M%?(,^I/'X;#8W+6U&M"I4A*,7=/VD$]+[VU[=SMR/-N'LP>'SS$X-X?,,1A5
M2PU:OAY.M@9-)[66TK+R>MCSC]HGX=^%O#5H;K2'A\U/NA"H;CZ=?7_(KXGM
MGDF4!S_%@<]O\C(S_P#J_1_QI^Q/^VCXSFS<_#K6O(0[2K6-U@X_X#WY/OZ'
MBN 3_@F_^UROW/AMJXP<_P#'A<<?AL__ %UZ7B%5HYOC)0X=RZA@\'I*K7IU
M80=:?N[I?=JM#JJ9E359O%8F6+J07\;V4DJBNK.UM.B\[=C(^!TND>%K237+
MHQ--Y)P&VDYP>F?\XX]ZXGXA?$G^T-6U#[#*ZQW!8,@8A/3&,X[^F/;O7T;I
M?[!O[7]G9&T/PYUC:1M*_8+GO_P#/^/:N6U7_@GG^UO/*SI\,M6W.<DBPN>N
M >HC_GCV)Q7F\/8K,<DPF9X%X/#8M9GA_J[]M.G)PD[>\I/;?=;,^:RN,:O$
M&.SG$U:M"4(1H8:*Y^6=.+CT\U>Y\T^"HI$U"2^MY1'.<R%MP!SD-U]>?;VS
MBNRU7Q6=0EGL]6N-\Z'$!+[N1D ]??IQW[5[II'_  3O_:_MAE?A]K$9;&2+
M&YZ'K_RS]!ZD#O1K7_!.7]KGSX;F/X>ZO))D,S"RN?4G'"=?\^U&3\.\;9/E
M&.Q>"S_#X+"*?M:>54\;3<ZTF^:ZUV\ET/OL5Q#E4Z='#^Q=6:7OU)4VXP5D
MGT6O7?M\^3^'=[X1UQ5\/^)8HB)65$E*CHW'!^ASW_F1ZQXL_9IT7^RS?>&+
MRU*3IN5 R;L8SCJ/_P!?YC)LOV#?VNK'8T?PTU<7"A=LOV"YR". >$Y/'J/I
M7<:1^RC^W19W,22^"]=:T1E_=FSN\!>.Q7ICU[<]B3\-/*<]S7'/$YA&#JUJ
M\95ZSKP<G%V4GZ?KZFM'-<JJ5L-0J573HWITI3C2=H4VTFW;LG=I?>KGR]'X
MJ^)7P9EFM[;[9]@+,NY"PBV#//'RXQQVZ<"O'?&'Q!U+QSJB7E])+)-O#.H)
M8YSW[@YZ_4^U?MCXB_8S^/?BCX8"VO/AI?/K9M]K2&PE\W>1C.?+SU[]2?I7
MP[I'_!.']J+3M=:>3X;:I);NS?*;"XP,MQ_!C@?_ *Z^[S/@K'O!8>679AAL
M1@TDYT:F+IJ=*:2YG&+=[.RLE\D<G&W _ '#F.EQ%PUB*>:YKB\"ZF*="/)7
ME*4$Y0<Y-W>Z2Z.VA\-OK#QRV\+*P3<-X8'..G?MS^':OU&_9O\ V=?#WQX\
M&R:5I_D-XBN8=L"J TAD9, #&2><8QR.U>&>)_\ @GG^U;+K$DMG\,=5$1!V
M@6%QP>W2,=AU'Y\BOK7]C#X#_ME?L_?$;2]=N?AWK+:;;W$#O"UA<E-BON8$
M%,<CVZ#O7?PE4J9=A\TR_,Z&%;Q%)K!XN<Z<Y4YQ2M%/M/9]OO'X=9]E&1RP
MU6M"6&ABZ<OK%"M2<U&51)-5%:S:[GH/AW_@A_\ ';Q%.(4L;N".ZDQ!,\+*
MA5VRNTD <Y&/;C/.:\O^-W['OC#_ ()\S0W7C<3G4)?F@+JP3H"!G\?7'KFO
MZOI_VT?CB? NC0:=\+;JQU;2[>W9Y4TUU>1XD&X$B//S-GUY].WXG_\ !227
M]I_]M32UCF^%^I+=:>OEQR?V?.&DV\ Y$8/.WW'ISS7YA7P'%%'.(8W!NE3]
MGB5./LZJC!QC)2UN[-M;_>SMS;,\E>=NO"A3J0H5J>+PTG34Z*J4VITY*.MK
M->6Y^'?B[]J.U\0Z8_D/B\D4Q2X;C'"GOSC'YX]:\ML-(7Q'I-WX@T[#:F29
M"J\OTR?4\_TZ=CZ'IO\ P38_:PVS&7X;ZLK&1V&;&YY!)P.8^GM^G>O3/ 7[
M$W[7WA&[99?AKJ\ED5*F,V%RRMD8[ICO[8/2OH^,\3QYQ!3R3%4,='"ULHQ%
M/$4*=+$)1<J;3:DKZ\STWM^GTF6<8X#%8S$+/Z& H8'-:<J-6>%P_+/G:2C4
MJ):OE:OK9GR1<>'=*U:PGDNV2+6858RK(0&RHY R1CG/;\>:X/0O#LFMSSZ9
M#CST+!6(XX/'_P"OCVK[5\6?L$?M>ZMK<^JZ;\.M7MXIR=T2V-R%P<GH$[\_
MYQ4F@_L$_M<Z/-]L3X;ZL)L?,PL+G=G@D_ZOU]<_I7TO$>9T>*,!EM:OD-/
MY]0IPCC\72K4U'&3LE*I4BMY2M>[UZWU/S3&XG$935QT,EQ4,;"K.I'!QK0?
M+"ES+DNG]GE_+N?'UAJ>I_#BYNK&(+)+)N5\X/4'H<\?7Z4Y/[-UC?J>M;$9
MF+E>.I)/3Z'TR>G%?46N_L ?M?:QJ)O9OAMJ[;FR<V-R>P_V,<Y_7\*SK_\
MX)Y?M?3QJD7PYU=5QC:+&Y]QG&S_ #@_2OAZ.59I4Q,*'L*#PDKN*E5A9.Z:
MOM>_RMW/-Q&#PF/H/'+$O+L[J^QAC:N'A)<\(I*2C:Z_#LSYKN;719(B^D*K
ML@R0O.2.OZ_A^-<3>:MJ5KN$;308R-Z$KU/;!'Y_XFOM_P -?\$]_P!KC1V5
MYOAKJTB.1N!L+C&#SWC]S_\ K KT36?^"<W[2^L:29XOASJ45SMW;!8S@YQG
M'"?XUXF9X/.:6-A0EEU.5!S<8U:56#45HKM+97:U\CZ7(,IRNA@*M=YS.OC8
MW;IXF+YYQ7*]'+1WZ'YX^$?$5U'KUBVKZA<W%B95\Y)IF9-N<$89CVXXZ5[Q
M\5/%7A>?1H(-"2+_ %&'*A=V[&.V/SY]3VKU?1_^"9/[55RLTEQ\/]5C:#)0
M&RN!D@\?P<^H_/N*I7/_  3L_:W+- ?AMJ[HC[038W)R.F?N=\9!_P#KU]2^
M"<VPV74LRJ3PBC65X488JG*=W:W-33YE?5ZVL?-9IC,!CL;A^>DZWU6HFZKI
MR7(U9+E[K3ITZ'Q=HWAVYUV&:= <1\GJ1QT_7IW]:DAMI=&<M(1R2@R>G3^I
M/^37Z/\ @O\ X)^?M2:1I5TLOPZU,2.K!%^PW&3P?^F>?R^AQR*\NU__ ()]
M?M=WMQ(8_AKJ^P.2NVPN>F3Z(/I_G-9XO)<QGEV&INE2<U+F=-8BG;[.KUT?
M773[SSLMXDQ];.\PPSI5:66TW&-&O4ISN]$FH.VGXGQ]+H]S>+]JCE7#@,JY
M'3 Z?Y/MTJBWFVJ>3C=)G&1SWQ_7W/M7UU!_P3\_;*B"HOPZUG8,# L;G &/
M^N8Y^GT%;$/_  3Z_:X)5Y?AGJKMGD_V?<=![>7_ $_6LZ>19R\+4C0IX=1L
MG4YZ]--*RNE=_AVZ/KWX>O?%8FMBZGMJ<;SPT53DFYZ<M^^BW^X^)Y]+NWB,
MS<!LD#Z__6'^36'"I27$IQ@\@\' SGMUXZ8^O%?HK_P[^_:QG\M6^&VJJN,$
M?8+G&!COL]_\>M<?K'_!.3]K9KK?;_#;5]C,<XL+COD\?NSS^OY&O,I</9LI
M?O8T9*<O=7MH:+16>OS3U\M3Z2AFV$>"I8JI&=&I%OFI-.]EM=>?2RWTWU/C
M3RH[B+Y>B@9_^O\ _7_#-9IA+N85QG( QSD]/ZXQ_3)K[\T[_@G+^U6+!B_P
MZU59BIP/L-QG..G^K]^/\FJ5A_P3D_:Q6]263X<ZKM$@)'V"XP1QR?D_/MC\
M178N&\QC5A)NG))QDDJ\4HZQZ+YK<\G$<7TZU/$2I8>JJE&+<8NG/]ZXKW4O
M+3:_F?!S:;J%L0TRN(R.,@[=N?IZ5$ZI(/E8!_KU.!U/?\*_2/Q3^P)^U3<6
M,=K:_#+5/,VXWBPN,YXSTC![>O?DGK7D/_#N+]K]23_PK;6#D\?Z!<9]?[F:
M]'.<HQ%:>&>"H4[1I15:7MH)NHK7MK_6[L8Y!Q#5Q^#=?,J=3"UN=J-&4).\
M4]&M--$O1_(^0X))HXV/F$XZ<GZXZ\<?_JI$FD9V+?,"< #G']!7V?;_ /!.
MC]KL(?,^&^K#&>/L-QW_ . ?YZUIV/\ P3I_:TB<-)\-=6*G''V"?L,GJ@_Q
MKPUP_FE2NE*%*,4M9*M%]M'9]M/-_C[-#%9=4K.,ZLJ4:LO?FZ;T>FK273RV
M?>Y\CV=I:_8FF?"R 9P<9YZ?YQT)_&]X>TU=1FD\HJ"GKST/Y\]/7ZYKZTO?
M^">/[7/_ "P^'&K!>FU;&XQC'H$QR">E&F_L!?M@:69&A^&NK@N#TL+KN>3_
M *O'?/\ *O9P^6XJG"$70HJ5*3<9*I&\GTN_P7YH^2SB&/P];-*.!QSQ7UAQ
M6&J<C484]&TDUII_D>=6EYX=C\.2:0RQ-J[-L! &<G ],?RYZ#O67<O%X2TU
M+JT4-?-RI0?,&(R!D>A]^_(R:^C-#_X)[?M6@'5+OX>ZJ+C.0ILKGDDYX!C[
MGK77VG[!O[4M^[+J'PYU1XR<+NL9_EZXQF/'3I[>]>QPSP9'BKBC#+.JV%R[
M+</24ZDI5X4XUZBM[LG=)KOY/8]#A+%8;A+)\9"G6Q&+S3'8AUOWD925&4DE
M/V;:?+%:V_R/@"\\7ZWK.]-4\YD)PI8DX7MU].XK+2XT^RMIYWV^=ABF>N2/
MU.1WY/MGG[]U_P#8%_:>MXFM;/X8ZE(6X$BZ?<''8<B,X/! ^O;BO*+W_@G7
M^US.QQ\-]7VG/!L;GGZG9GO_ )[\W&W"4\KSWDX=Q%&KA:?P/#UX*-)JR:A*
M+ZI:Z_?L?4QQV4TJ-.NZSJ8G$Q]IB;TY.7M79^\WU7?K\CX9N=1:]>25\!PS
M;?IGC'3T/6KFB:+J^N7L5O96EQ+N?!E5&* '/4X([]/YU]C0?\$V/VMWO(@W
MPXU98S(H;_0+CH3S_P LQ_C].:_3OX"?\$]/BMX?\ ZG<:Y\/;H:X+=OLY>Q
MD\SS-AQ@F/.<^E?'X[+<ZA!RE0CB*E1JS=>,I?9]YR>OSO\ Y'-1Q^"K5.25
M9TU'WG^[?+;2R7>Z^[0_'[X7:)/H/Q<^'5G>$"<^)=-)!Z@_:8ACG/)S[=NG
M2O\ 6?\ V2QC]FOX+C_J2=*_G-7^9]I?[!G[5<OQS\):TOP]U3^SK3Q5:3,_
MV*X"I;K=(=Q.S   K_30_9@TG4="_9\^$>D:M UMJ6G^$--MKR!@5:*9#+N4
M@\@C(Z\UTXO"U\'D>74<5RQKO$5JDJ:FIN,917+=KU.7#UH5\SQDZ7-*E&E3
MIQG)-<UFM?.]K_TCWD;L#&W&/>E^?_9_6BBO!/5#Y_\ 9_6CY_\ 9_6BB@"C
M=6=OJ"/;WMI97D/(\J[MDN(^<9^24,O(]A7/CP+X4!)_X1GPWD_]0:V_KG],
M=O2BBKC5J034*DX)[J,I13];-$N,6[N,6^[BF_Q%_P"$&\*?]"SX;_#1[4?T
MH_X07PGG/_",>&\_]@:U_P#B:**OV]?_ )_5?_ Y?Y_U\V+DA:W)&W^%?U_F
M!\#>%3T\,^&Q_P!P:V_IB@>!O"@Z>&?#@^FCVP_I112]O7_Y_5?_  9/_,%2
MIK54X)^4(K] /@7PJ3SX:\.''_4(M_\ /Z4G_""^%!@KX9\. CTT>W_IBBBC
MV]?_ )_5?_!DO\P]G3;NZ<+]^2-_OL*/ _A<9QX;\.\]?^)1!_C2_P#"$>%_
M^A<\._\ @H@_QHHI_6,1_P _JO\ X,EY>?DON#DA_)#_ ,!7^0?\(1X7_P"A
M<\._^"B#_&C_ (0CPO\ ]"YX=_\ !1!_C111]8Q'_/ZK_P"#)>7GY+[@]G#^
M2'_@*_R#_A"/"_\ T+GAW_P40?XT?\(1X7_Z%SP[_P""B#_&BBDJ]=;5JO\
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M'A?_ *%SP[_X*(/\:**/K&(_Y_U?_!DO+S\OZU'R0_DC_P" K_(/^$(\+_\
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MY^7]:A[.GOR0[_"O\@_X0CPO_P!"YX=_\%$'^-'_  A'A?\ Z%SP[_X*(/\
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M=_\ !1!_C1_PA'A?_H7/#O\ X*(/\:**/K%?_G]5_P#!D_+S\E]P^2'\D?\
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M9ACN,.'7]*>? O@[^'PEX73W70M.7_T"W4_K112]O7_Y_5=/^GD_\Q>SI_\
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>    #@445,ISE\4I2MMS-NWWCC&,?ABH^B2_(__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>20
<FILENAME>g0fyk5pshdve000018.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g0fyk5pshdve000018.jpg
M_]C_X  02D9)1@ ! 0$!+ $L  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1"  " 7\# 2(  A$! Q$!_\0
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M .:NBB@ _P"&V?VS/^CM_P!IS_P_7Q4_^:NC_AMG]LS_ *.W_:<_\/U\5/\
MYJZ** #_ (;9_;,_Z.W_ &G/_#]?%3_YJZ/^&V?VS/\ H[?]IS_P_7Q4_P#F
MKHHH /\ AMG]LS_H[?\ :<_\/U\5/_FKH_X;9_;,_P"CM_VG/_#]?%3_ .:N
MBB@ _P"&V?VS/^CM_P!IS_P_7Q4_^:NC_AMG]LS_ *.W_:<_\/U\5/\ YJZ*
M* #_ (;9_;,_Z.W_ &G/_#]?%3_YJZ/^&V?VS/\ H[?]IS_P_7Q4_P#FKHHH
M /\ AMG]LS_H[?\ :<_\/U\5/_FKH_X;9_;,_P"CM_VG/_#]?%3_ .:NBB@
M_P"&V?VS/^CM_P!IS_P_7Q4_^:NC_AMG]LS_ *.W_:<_\/U\5/\ YJZ** #_
M (;9_;,_Z.W_ &G/_#]?%3_YJZ/^&V?VS/\ H[?]IS_P_7Q4_P#FKHHH /\
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M &G/_#]?%3_YJZ/^&V?VS/\ H[?]IS_P_7Q4_P#FKHHH /\ AMG]LS_H[?\
M:<_\/U\5/_FKH_X;9_;,_P"CM_VG/_#]?%3_ .:NBB@ _P"&V?VS/^CM_P!I
MS_P_7Q4_^:NC_AMG]LS_ *.W_:<_\/U\5/\ YJZ** #_ (;9_;,_Z.W_ &G/
A_#]?%3_YJZ/^&V?VS/\ H[?]IS_P_7Q4_P#FKHHH __9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>21
<FILENAME>g0fyk5pshdve000010.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g0fyk5pshdve000010.jpg
M_]C_X  02D9)1@ ! 0$!+ $L  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" /"!QT# 2(  A$! Q$!_\0
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M0?E1@>@_*EHH 3 ]!^5&!Z#\J6B@!,#T'Y48'H/RI:* $P/0?E1@>@_*EHH
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MZ9-HW%V)+<D]S0/2R:O_ $EM_78^],#T'Y48'H/RI:*!"8'H/RHP/0?E2T4
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MZ#\J,#T'Y4M% "8'H/RHP/0?E2T4 )@>@_*C ]!^5+10 F!Z#\J,#T'Y4M%
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M%J$CPQ>/?#D4B2&,+<:E;P;R,#*L[A3U'!(/IFO2],U?2M;M1=Z3J%GJ=H_
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MRI*RE'/!QA3P>.M?HQ;?#OP!XN^',OA'PI+#::-<HHDN+';F0$$'>4/S;O\
M&L>?X=_"?X.?"C7M"U8V&GZ)>Z=>V^K:A-Y4-W=)=1&.0AF.]MH&<CN3G[P%
M _Z_+_@GX-?!_3OVLOVW]4^(/C'PGXXN=(L/#7B"XTZR4W[PI\DTBQ 9=%S^
M[; ZX!]..SC^)?QQ_96\3P?#G]KBQF^(/@3Q?+_9T-Y)$;M+2WG;REE\XJ^
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M&"NWEC(!QNSC( //?\$V/B]\0_BQ\2?C=XP+ZE>^#[N?4I?"BWJR^6\7F.T
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MKP+\?/A;\1=0N-*\,>*+"[O[9F1[9KB!'9E."$'FDLW' QD]LGBO9<]^W7-
M!28&<XY_R*\5\<_M"?"GX>7R:;XE\4V%K>.P4PI/!(48D##_ +T;2">>.,&O
M1?"WB[P]XUTJ'6/#FI6^I6$X4K)!+&Y7(# .$9MI/;/7!QTH Z4@'J*6O.?B
M#\5? _POT\:AXPUNUTV$_=C>6+SR./F\MG5L'/!QSVJE\/?C-\//BA"TOA#Q
M!9Z@R]8!-")S_NQB1F;Z 9H ]3/0TB@@<G//O6-JWB'1]#,0U6^ALA-RC3NL
M:'&?XF88Z&O-/$/Q^^%7AFXAM=3\6::D\[K''''<P.2S=!_K0<GTQ0![+16=
MI.JV6MZ=:ZIITHGLKV(36\HQAXVZ$8)'Y$UH,P52S$*J@LS,0%50,DDG@ #D
MD\ <F@!:*\$\1?M+_!WPQK__  C>J^+;"/4_,$31QSV[HKDXP6\X=_:O9]'U
MK3->L8=2TB\@OK.X17CFMY$D4AAD E&8 X[9H U**\C^(_QQ^&_PJ2$^,/$-
MI8R3$!8%FA>9<G \R/S R$XZ$9QSZ5T7@7XD>#OB/ID>K>$]:M-3MGYV131&
M=>,Y:)79L8ZD<#OVH C\6?$[P1X(NK:R\3Z]9:5<W94017,J1M(7QMVAV7.<
MC%2ZS\2/!N@:-!X@U76[.TTBY :&]DE18G##*D,6"\CWK^=;_@M?KWBG2?B_
M\*X]#UZ]TJ"1]+,T5M*\:R F'.X*RYSS_4XKO?VY]:\26W_!/[X?7NGZW>6F
MH/:6?F7L4KK*Y,2=6#!LDYSR?7-!7+\-^K_#3_/\#]__  SXP\.^,+)=0\.Z
ME;ZG:, PFMW5UP>G*DUTU?D7_P $A]3UC4_@3!-K&IW&IW'V.',UP[.V?,CY
MRQ)K]=*"0HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "FC[S?A_*G4T?>;\/Y4 *.@^@_E2T@Z#Z#^5+0 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%?)?[7'[4OA7]F+P&=<UF7.LZPLMKX?MAM)FO2"D?RG
MD_O" !CK^@&KV1]:5\G_ +5_PIU[XI>$+:PT*XEMI[5V=I(G*$9;.3M(/3I^
M-?CG:_M$_P#!43QO'/XJ\*>#KO\ X1W4'^U^'2MHX66PD+&)P F#N3'/_P"N
MO1OAE_P5-\4?"6+7_#O[8FAZAI.MV]O-':^3:-&7F VA2=GS!F..QQR"#@T%
M<K?;IU[]/4_4C]G7PAKGPI^&E\->N9-2FL;?SSOD9VV6R.\@ZDYQSQ]?I^+$
MVJ?&7]N;]J#Q9\.M$\82Z=X(\,W5V=5TL7;1)]DMY&+HX+*H#*-@'<E0.H%?
M2?[(W[>NI?M$_$_6?"FAZ=J'_"$:I+/!;S74$BI]FN"\8;+#&-K9_E[^7_&;
M]GWXZ_L>_'W4/CI\ =/GU30?$DSR^*HX8FE1+6Y9C<AE"XP$)&&SZ8[4!\+M
MUT_1_=WMV/UC^!_['OPB^"%O8WGAW1 GB1((_MNJ&7<9KG:#(^-I/W\\[^?U
MKPGQM^QCX=\<_$^^^*OQWUB/4?#.@2-?:3!/=@0V20'?$7!+",*%Y^3/' /2
MODOX:?\ !4?Q/\2OVAO"/P:TS0KU!<"UA\07#V96.*X.T3C?MPN&SW_G7:?\
M%2_C7XZC'@GX.?"Z[N3/XMNX[+Q*]BS;[:WNIS"Q?RR2-L)#<^O04"2=TMF_
ME;MZ?\,4_BY_P5!TKP;XG3X0?!7P-=>++.P":+;Z_IB3SV]I%$OD1@M$'B7;
M@ G /?/6O-[GXQ?M/&RN_%%_I>I76A7,#/=:3)%+(7MY,2-'L*_W<+C%?HE^
MR'^QS\./@3\.M-\_2K#Q'XB\06.FZOJNJZO90WEQ'=75LES)'$\Z.1B24;B
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MFE6=S/<R+"N96DEB<\Y.,'D<FNM'PB^& D\T> O"WF9SG^Q[0\CI\ICVC\J
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M?SM_"7XH>(/VZ_VH?B3#\1?C?:>%/ 'AV^O/[/TF]U46\;0P3,J1I&TJCH,
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MV?+_ ,$^/AX!P/L=G_Z)0]Z\L_X++:=;^&/'/P3\+Z>I.G:0NCP6Y _A3R4
M].W;//>O4/V[GQ_P3W^'AP3_ *'9\8_Z8I_^N@-?<]>G;16_S/KG_@C^ /@/
M;XZFRA)_[^1U^OE?D%_P1];=\!K<X(_T* <^TD?^?RK]?:#,**** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ IH^\WX?RIU-'W
MF_#^5 "CH/H/Y4M(.@^@_E2T %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M^H"X)//-+0!_-;^T#_P0]\5W'Q U3QI^R[X__P"%8G4)Y9S%;7_]GJKROO\
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M'(S2T4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4T?>;\/Y4ZFC[S?A_*@!1T'T'\J6D'0?0?RI: "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HS12!<$GGF@!:\2_:*UQ-#^#/Q GW[)I_#>IVUN<X(EFMI
M%4CW!KVPG S7@O[2VAQZW\%_'A>3RVL?#VH7JDG"GR('<@GW[?\ UZ!K=>I^
M4/\ P2B73/A_X)^+OC[XCWUOI]J?$$\\.K:BQV06XN97;:[98$ <=L$^U?I]
M\.?VM?@S\4=4OM/\)>*++44M'>-;B*1661D)5@,$CJ.,?F>:_)+_ ()^:A\/
M?C/\#?C'X ^(FO66DZ%;ZU=V=Q,MTD,HC$\B2$,'#?=_6OO7]GO]AO\ 9Y^&
M%BFL?#7Q)-JUE.[W)NX[ZWN(LD[GWLEPQ3:<Y$JJVTABH!!(-M.[=[]/NV^_
M\#PW]I?]N;XGZ)\0X?A'\.O =Y?Q:G>Q6S>(;:"=PD+2 $^8@*@?Q'&,X]J^
MWK3QKHOAGX,:0_QB$9LM7LA'KB7JAE\FY1?,619#C"\YS@CU]/(/C+^U#^S)
M^S9J<2:]IECX@UE&"O=Z;;V>H75O(< J96CGVNK9^9<$=0QX-2Z/\7?@%^W-
MX&U'PM::J=%2>WEC@AOKBWM[S+KM A1C"#M/.T?-_=!/!!;6T:^_7;;^NI\+
M>/OV%/#/QB\0W'BS]CSXM0^#K2XD:\U73-+OQ;JT['>RLL+IC+%NHZ=:QG_8
MM_;$ELW\'CXI:NLS+Y*ZG]MN !U&_?YG0#G.?3FON']F?]B^\_9R\8WEYH.N
M:A?Z'=W1F FN9'B,18LNT%MNTKT[8/TKZF^//[0G@S]GS0%\2^,K>]EL71G+
M6: L%4E3EBC],=^G'K0/5M6UMMI;;_+^MS\WOV=_^"8.M^&_$L?B']H/QD?B
M:(95N8;2\N7NU25#O1/WC2+@, "1D =,UM_\%'?VDM2_9FT#X;?"7X<V:Z.O
MC9X]*L&LE,8L1-<M;IM*8("@Y&>>M?H7\ _V@_!/[1/A63Q=X'-Q_9L4JQ.+
MDKYBNVX@':J_W2#Q[5^*_P#P6(\4Z;-\8/V>M&M;)]4O[/7+$3_94\YH&>_\
MSY]H;;A6&<XZ=: 5W)>5OPML?I/\-M6\6?LU?L\P>+OB%JK^*;_4K?3M7/VB
M661H1>V;70B+;]P^65> V.,'FO0O@Q^TSX>^*/A;6O&XL$TVUTJ":6\EVE1Y
M<(W-N8_,>%ZDY_6K7Q5^'NK?%7]GKP]X9TB,K>W?AOP\XC*G*[='@0J5ZY!/
M/IT]Z\W_ &:_V:]6\"^ O$7@CQ@KI9ZY!/!,47:X6;Y6VYV\[2>XZ4"_S_K3
MR_R/G[]H;]G'X<_MR:-<?$'X,:[;:'\4M NR6URSE2&Y>6WR C2QE9"69=O)
M.6(&<GGZ+_8K@^*7A;PO+\/?B=)=:CJ/A^,P?VO=;W-V8\+NWN3NW >IZUX1
M\&/V7/B5\ _VD;B?PGXD#_"K4KU[NZTZ:Z_>$2MO9?*+ G[QR,=\?3]75AA1
MF=(HT=OO.L:JS?[S  G\30#?3==+K7^O^ ?F_P#M _\ !/3P;\9?B9;?$VVG
M@TO68IUGD9 8BQ!!8?( #G'<U])I\"%T?X,ZM\.O#5]_9NM:CI<EDFLH[*\<
M[A5$N_AOE"YSGJ37YT_M4_\ !4.R_9:_:-M_AMXDLKC4=$FN1"8+5#)(!N .
M54Y''T]N:]QN_P#@J;\!;7P4_C!K36"JVWG"RPOG&0H"$*>6'QD].I['O0'*
M^S_X<^./V1_BY\3/@=^V#JG[*'CO7;GQ+]IU&5X;V>=YPB2.Q4*S,PX![=N]
M?O[GG'T_7/\ A7\\_P"R3X2\3_M-?MH77[8&F:;=V/@W[:S(MY"\;[2_RD%E
MSCIW]:_H8H!VTMV5_4****!!1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4T?>;\/
MY4ZFC[S?A_*@!1T'T'\J6D'0?0?RI: "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M I"2.@S2T4 %?C?^W;^V5K1FO?V??@[IK>(O$WB=)=#UK[&IFFL8;DF";?Y>
M2BKNR>@.!GD5^R%?S@?!.YMO@_\ \%&OB3XF^)\?E>']>N]2AT6\UA5^R033
MR2"&6W:?Y%9&(92#U Z\T%Q2=V[:*]G_ %]YU_[/_P#P27\;>&/AIJP?X@W.
MB:C\0%.K:C9B>9&M);W,K(X0_*P+G@\XQD<YK[&^ O[)WQ,_9M^%?Q/TO5?'
M=UXA:?1-1;1)7NGF-L[0/M=,NQ0K\N>A]J_1]/'/@LV"ZDOBKPZ+ VXN%N/[
M7L%C\CR_,# &<,/D&0FW=QM"YXK\@?&?_!83X/:-\7_$'P1U#P]>ZM&6N=-C
MUJS1I-/D#[H&)D4-&R\[L]00"".A!:O3>W;MHOZZGPK^P9IGA?Q5\=_'G@+]
MH5QXVU34]=NUTJ+4LW!@6:9PBIYN_P"Z...F/S_1GXJ_\$TKNZ^)'AOQC\%_
M%;> M)TN^AN;W2+*X>U2>))%=HRJ&-&!48QS].U<'X(U7]E3X;>)I?CM/"LO
MB.XD.I6]I"5,@.3(JE ?O9[8Z_E6!XW_ ."WWP?TGQ[X;\ :3X5UR"[US48[
M(WU[&QB&Z41_(WEQJ =P.<$^_:@%S/:_;\N_R_X9'Z4_M%_%'QS\ /@C!XC\
M)>'9/&WB31K&ULGLDBDG>Y>UM8T>;:F2V]E))[_4U\.?#O\ ;=^"_P"T-X#N
M] _:JT&Q\$7MU'-;'3M4A: 0[FVL5$@S&_!*MM< C&SYLC]7O#WB'2/%O@S1
M_$\ZVKZ9J^D0:FPNEBE@$4L(D?<LH9"!\V01STQVK\-_C7\1?V!OCC\8]6^&
M_B729M-\0Z=<R6]U>Z7&+>U:1'*N_P"Y"*N6!/ Q^&*!+YJW5=KI?YGWY^RY
MX[_9-\&"Z^&_P6\;:=?W&IW1ECTZWE1B,[MBJ%;"GY^>.P]ZZS4_V0O WB#X
MA3_$CXAF#7C8RF]L8[M?,%GY3>8&4R*P3;@<C\CTKY__ &;_ -C[]CKX8^);
M'XB_#SQE;G5D5)DAU#7;2W$9!R%=+J=23@?PY_,8'Z.ZCXG\#ZI87>GS^+_#
M8AO('@D*:_I0<(XP2#]KZT ]-K_\$\8C_:M^ MEXJM_AIIWC'3YO$T'E6,&C
M0D;HQ$!%''RV?E"A>%[5]*6TWVB"*?&!*BN![,,C]#7YV:/^P_\ LQ:7\6?^
M%Q1^++6Y\5&Z^U+N\0:5]G\PL6 "B\?/)_N_A7V#\6)?$TWPO\2_\*SNHIO$
MR:4Z:%-;3),OVE8R(L21,RD\#D&@.NGD?D3^T#\7_&_A3]NO1_#FA>,;B6VN
M+J!6\*13.R%'(QF)6P."."./K7[0#Q5::3X-_P"$L\3S1Z59V>F?VAJDTY"+
M;1QC]X7W$<Y'0D9)].:_"[X,?!74/@EXSU[]K7]LG54?Q;97=Q<Z7;W\BC=%
M&[&,(LIVD[<8RI'3.:Y3XO?M+_&;_@H-XDC^&?[-5MJ^D?#>X=;/Q+J#;U2Z
MLUDVSR+,JJC J7.5P,= !0-WLK^E^GE_7?3='&Z/X \'?M@_\%'+SQ_<^'H_
M&GPNM+Z2![MXO.M(I%=E)W%608(QGM7ZWWW_  3_ /@;>^(FO6\-V*: [(QT
M58U\D!>3&$V;,<8''3K7<_LC?LL^%?V8_AW:>'-*A6XUJ\2*ZUC4)D5[AKMD
M#3*)6R_,A).".1UZU]:T WJK=-OU^_\ $XOP+\//!OPTT2+P[X(T&R\/Z1%M
M*V=C$(XRRC:&;'5L9YP.2>.:[,@GH2*6B@D0<#&<^]+110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %-'WF_#^5.IH^\WX?RH 4=!]!_*EI!T'T'\J6@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ IH^\WX?RIU-'WF_#^5 "CH/H/Y4M(.@^@_E2T
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ IH^\WX?RIU-'WF_#^5 "CH/H/Y4M
M(.@^@_E2T %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !110>
MAH ^1?VW/V=-)_:=_9^\:?#+4;.&YEU.PG:T:2-69)!;RKA<J2<DKQZC@5_D
ME?ME_ S4?V9OVA_&?PVO+*:TT[2-2OQ%)+&8HV7[1( 58@+C&.G3ZU_LV#(.
MUN<_CQCIR/:OX>/^#E7_ ()NS^)[O1/B)\+?#[77B/QE,PO9+*W)D61[ID;<
M8EW#.,_CGO0:TI\KL]G^?]?U<_!+_@B7^QIK/[3G[6/AN;6=)DOO MM?VMP\
M\D'F6R^7*K9WE2G4?R^E?ZHGP^\#Z-\./!^A^#/#\"6^E:%90V5K$BA%"1(J
M9"C &=HK^?W_ (-ZOV&E_9K_ &:+#6_&F@K!XUOH;,K<74&VXC#CS68,XWY!
M3;CI@_G_ $:T$U)7D^W3T"D.[L,_Y^M+36;;CCK00.HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "FC[S?A_*G4T?>;\/Y4 *.@^@_E2
MT@Z#Z#^5+0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ I
MH^\WX?RIU-'WF_#^5 "CH/H/Y4M(.@^@_E2T %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !112$D= 3_ )^E "U^;/\ P49_X*,_#?\ X)Y^
M!=-\<?$4H+'44>2/>0!A)7B(&2.<I7Z35_&#_P '@]W:/^SGX%LIL-(L3D*&
M(92;V=P<#TRI!/'L:"H+FDD^K/Z,_P#@GQ_P4 ^'O[??PXF^(?@ I_9\2QMA
M64Y#D#/RD^M?H77\@O\ P:?WME8?LR2Z3;A8O.M8SY>[))&&'!R>H_&OZ^J
MDN632Z,****"0HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "FC[S?A_*G4T?>;\/Y4 *.@^@_E2T@Z#Z#^5+0 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 444ASVQ^- "+NYW?AT_I3J** "BBB@!IW9&.G&>GK^=.HSGI10 449HS0
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MDC]:UB2!P.: %HI 21R.:123UX/ITH =1129.X#''K@^] "T4UB1C S^!IU
M!1110 4WYMW^S^'I^?6G44 (#G(]*6C\** "DW<XYS_];-+3=OS;OT_#% #J
M*** "D;=CY>N?\]:6C..M  ,X&>O>BBD8;ACIS0 M%-4GH1C&,<&G4 %%%%
M!1110 4444 %%%% %*^U'3],A-SJ5_9Z?;KG=/>W,%I",=<RSO&@Q_O"N;_X
M6)\/_P#H>?!W_A3:+_\ )M?R3_\ !R3_ ,%)_&/[/<%K\#_ GB"Z\/:WKT,5
MO;WME,\4HGND4* T9# [WQC/7BOY/_A[\'O^"UWQ5\.0>-_ /B;X@:OX9U1W
MN+&^AN=0:.2&4ET*D*W&UAT;I0:1IW2;:6NW6W??^NI_K,_\+#\ ?]#QX/\
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MO[OGY_EYG^K)_P +#\ ?]#QX/_\ "ET7_P"3:/\ A8?@#_H>/!__ (4NB_\
MR;7^4W_PR_\ \%W?^@K\1/\ P(U'_P")H_X9?_X+N_\ 05^(G_@1J/\ \30'
M)'^;MV_N^?G^7F?ZLG_"P_ '_0\>#_\ PI=%_P#DVC_A8?@#_H>/!_\ X4NB
M_P#R;7^4W_PR_P#\%W?^@K\1/_ C4?\ XFC_ (9?_P""[O\ T%?B)_X$:C_\
M30')'^;MV_N^?G^7F?ZLG_"P_ '_ $/'@_\ \*71?_DVC_A8?@#_ *'CP?\
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MH_X6'X _Z'CP?_X4NB__ ";7^4W_ ,,O_P#!=W_H*_$3_P "-1_^)H_X9?\
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M\>#_ /PI=%_^3:/^%A^ /^AX\'_^%+HO_P FU_E-_P##+_\ P7=_Z"OQ$_\
M C4?_B:/^&7_ /@N[_T%?B)_X$:C_P#$T!R1_F[=O[OGY_EYG^K)_P +#\ ?
M]#QX/_\ "ET7_P"3:/\ A8?@#_H>/!__ (4NB_\ R;7^4W_PR_\ \%W?^@K\
M1/\ P(U'_P")H_X9?_X+N_\ 05^(G_@1J/\ \30')'^;MV_N^?G^7F?ZLG_"
MP_ '_0\>#_\ PI=%_P#DVC_A8?@#_H>/!_\ X4NB_P#R;7^4W_PR_P#\%W?^
M@K\1/_ C4?\ XFC_ (9?_P""[O\ T%?B)_X$:C_\30')'^;MV_N^?G^7F?ZL
MG_"P_ '_ $/'@_\ \*71?_DVC_A8?@#_ *'CP?\ ^%+HO_R;7^4W_P ,O_\
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MFU_E-_\ #+__  7=_P"@K\1/_ C4?_B:/^&7_P#@N[_T%?B)_P"!&H__ !-
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M$:C_ /$T$\D?YNW;^[Y^?Y>9_JR?\+#\ ?\ 0\>#_P#PI=%_^3:/^%A^ /\
MH>/!_P#X4NB__)M?Y3?_  R__P %W?\ H*_$3_P(U'_XFC_AE_\ X+N_]!7X
MB?\ @1J/_P 30')'^;MV_N^?G^7F?ZLG_"P_ '_0\>#_ /PI=%_^3:/^%A^
M/^AX\'_^%+HO_P FU_E-_P##+_\ P7=_Z"OQ$_\  C4?_B:/^&7_ /@N[_T%
M?B)_X$:C_P#$T!R1_F[=O[OGY_EYG^K)_P +#\ ?]#QX/_\ "ET7_P"3:/\
MA8?@#_H>/!__ (4NB_\ R;7^4W_PR_\ \%W?^@K\1/\ P(U'_P")H_X9?_X+
MN_\ 05^(G_@1J/\ \30')'^;MV_N^?G^7F?ZLG_"P_ '_0\>#_\ PI=%_P#D
MVC_A8?@#_H>/!_\ X4NB_P#R;7^4W_PR_P#\%W?^@K\1/_ C4?\ XFC_ (9?
M_P""[O\ T%?B)_X$:C_\30')'^;MV_N^?G^7F?ZLG_"P_ '_ $/'@_\ \*71
M?_DVC_A8?@#_ *'CP?\ ^%+HO_R;7^4W_P ,O_\ !=W_ *"OQ$_\"-1_^)H_
MX9?_ ."[O_05^(G_ ($:C_\ $T!R1_F[=O[OGY_EYG^K)_PL/P!_T/'@_P#\
M*71?_DVC_A8?@#_H>/!__A2Z+_\ )M?Y3?\ PR__ ,%W?^@K\1/_  (U'_XF
MC_AE_P#X+N_]!7XB?^!&H_\ Q- <D?YNW;^[Y^?Y>9_JR?\ "P_ '_0\>#__
M  I=%_\ DVC_ (6'X _Z'CP?_P"%+HO_ ,FU_E-_\,O_ /!=W_H*_$3_ ,"-
M1_\ B:/^&7_^"[O_ $%?B)_X$:C_ /$T!R1_F[=O[OGY_EYG^K)_PL/P!_T/
M'@__ ,*71?\ Y-H_X6'X _Z'CP?_ .%+HO\ \FU_E-_\,O\ _!=W_H*_$3_P
M(U'_ .)H_P"&7_\ @N[_ -!7XB?^!&H__$T!R1_F[=O[OGY_EYG^K)_PL/P!
M_P!#QX/_ /"ET7_Y-H_X6'X _P"AX\'_ /A2Z+_\FU_E-_\ #+__  7=_P"@
MK\1/_ C4?_B:/^&7_P#@N[_T%?B)_P"!&H__ !- <D?YNW;^[Y^?Y>9_JR?\
M+#\ ?]#QX/\ _"ET7_Y-H_X6'X _Z'CP?_X4NB__ ";7^4W_ ,,O_P#!=W_H
M*_$3_P "-1_^)H_X9?\ ^"[O_05^(G_@1J/_ ,30')'^;MV_N^?G^7F?ZLG_
M  L/P!_T/'@__P *71?_ )-H_P"%A^ /^AX\'_\ A2Z+_P#)M?Y3?_#+_P#P
M7=_Z"OQ$_P# C4?_ (FC_AE__@N[_P!!7XB?^!&H_P#Q- <D?YNW;^[Y^?Y>
M9_JR?\+#\ ?]#QX/_P#"ET7_ .3:/^%A^ /^AX\'_P#A2Z+_ /)M?Y3?_#+_
M /P7=_Z"OQ$_\"-1_P#B:/\ AE__ (+N_P#05^(G_@1J/_Q- <D?YNW;^[Y^
M?Y>9_JR?\+#\ ?\ 0\>#_P#PI=%_^3:/^%A^ /\ H>/!_P#X4NB__)M?Y3?_
M  R__P %W?\ H*_$3_P(U'_XFC_AE_\ X+N_]!7XB?\ @1J/_P 30')'^;MV
M_N^?G^7F?ZLG_"P_ '_0\>#_ /PI=%_^3:/^%A^ /^AX\'_^%+HO_P FU_E-
M_P##+_\ P7=_Z"OQ$_\  C4?_B:/^&7_ /@N[_T%?B)_X$:C_P#$T!R1_F[=
MO[OGY_EYG^K)_P +#\ ?]#QX/_\ "ET7_P"3:/\ A8?@#_H>/!__ (4NB_\
MR;7^4W_PR_\ \%W?^@K\1/\ P(U'_P")H_X9?_X+N_\ 05^(G_@1J/\ \30'
M)'^;MV_N^?G^7F?ZLG_"P_ '_0\>#_\ PI=%_P#DVC_A8?@#_H>/!_\ X4NB
M_P#R;7^4W_PR_P#\%W?^@K\1/_ C4?\ XFC_ (9?_P""[O\ T%?B)_X$:C_\
M30')'^;MV_N^?G^7F?ZLG_"P_ '_ $/'@_\ \*71?_DVC_A8?@#_ *'CP?\
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MH_X6'X _Z'CP?_X4NB__ ";7^4W_ ,,O_P#!=W_H*_$3_P "-1_^)H_X9?\
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M\>#_ /PI=%_^3:/^%A^ /^AX\'_^%+HO_P FU_E-_P##+_\ P7=_Z"OQ$_\
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MJ<(N-.O;6^@.,36D\=Q&<]/GB9EY[<U_'Y\%;?\ :Z_X*36>K_&Y-8USPSH
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MXBDFF*\3QLZD%B!\CJ?I06XVFE&SVM?OUO?SU]-C^HS]CNZ^)&G_  1\*?\
M"[]>ANO&\ME +^>ZN44S2%?F8/*PSD@8&3_*OKA)8Y #&ZR*>0R,&4\9X920
M<CTK^;#XN?'WXPW'["'@7]HWPY/?1QZ1HMG?:HT'F?-LB1GW;2.H!)^HS7Z+
M_P#!+S]JN3]IW]E<?$R_N#-?Z1)<P:AYCY=#:6DLIW@\J/W$G7T-!#OO;K]Q
M^EMQJFFVDT=O=7]G;SRX\N&:XBCE?/39&S!VSGC YJ:[N[2R@>YO;B"UMH^7
MGN)4AB08/+2.RJ.,]37\R^I?M;?$K]HS]N_2O _@#4+W_A%_"6L^1K<=J[M
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MIO\ T#['_P !+?\ ^-T?V9IO_0.L?_ 2W_\ C=7J*#.[*/\ 9FF_] ZQ_P#
M2W_^-T?V9IO_ $#K'_P$M_\ XW5ZB@=WY_U_PR^XH_V9IO\ T#K'_P !+?\
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M_P#\;J]10%WY_P!?\,ON*/\ 9FF_] ZQ_P# 2W_^-T?V9IO_ $#K'_P$M_\
MXW5ZB@+OS_K_ (9?<4?[,TW_ *!UC_X"6_\ \;H_LS3?^@=8_P#@);__ !NK
MU% 7?G_7_#+[BC_9FF_] ZQ_\!+?_P"-T?V9IO\ T#K'_P !+?\ ^-U>HH"[
M\_Z_X9?<4?[,TW_H'6/_ ("6_P#\;H_LS3?^@=8_^ EO_P#&ZO44!=^?]?\
M#+[BC_9FF_\ 0.L?_ 2W_P#C=']F:;_T#K'_ ,!+?_XW5ZDR,X[^E 7?G_7_
M  R^XI?V9IO_ $#K'_P$M_\ XW1_9FF_] ZQ_P# 2W_^-U>HH"[\_P"O^&7W
M%'^S--_Z!UC_ . EO_\ &Z/[,TW_ *!UC_X"6_\ \;J]10%WY_U_PR^XH_V9
MIO\ T#K'_P !+?\ ^-T?V9IO_0.L?_ 2W_\ C=7J* N_/^O^&7W%'^S--_Z!
MUC_X"6__ ,;H_LS3?^@=8_\ @);_ /QNKU% 7?G_ %_PR^XH_P!F:;_T#K'_
M ,!+?_XW1_9FF_\ 0.L?_ 2W_P#C=7J* N_/^O\ AE]Q1_LS3?\ H'6/_@);
M_P#QNC^S--_Z!UC_ . EO_\ &ZO44!=^?]?\,ON*/]F:;_T#K'_P$M__ (W1
M_9FF_P#0.L?_  $M_P#XW5TD@<#F@$D<CF@+OS_K_AE]Q2_LS3?^@=8_^ EO
M_P#&Z/[,TW_H'6/_ ("6_P#\;J]SZ=Z* N_/^O\ AE]Q1_LS3?\ H'6/_@);
M_P#QNC^S--_Z!UC_ . EO_\ &ZO44!=^?]?\,ON*7]FZ=C']GV6/3[)!C_T7
M3DL+&+F.RM(SUREM"G_H*"K=% BH]A8RG,EE:2'U>VA<_FR$TS^S--_Z!UC_
M . EO_\ &ZO44!<H_P!F:;_T#K'_ ,!+?_XW1_9FF_\ 0.L?_ 2W_P#C=7J*
M!W?G_7_#+[BC_9FF_P#0.L?_  $M_P#XW1_9FF_] ZQ_\!+?_P"-U=R,X[^E
M+0%WY_U_PR^XH_V9IO\ T#K'_P !+?\ ^-T?V9IO_0.L?_ 2W_\ C=7J* N_
M/^O^&7W%'^S--_Z!UC_X"6__ ,;H_LS3?^@=8_\ @);_ /QNKU% 7?G_ %_P
MR^XH_P!F:;_T#K'_ ,!+?_XW1_9FF_\ 0.L?_ 2W_P#C=7J* N_/^O\ AE]Q
M1_LS3?\ H'6/_@);_P#QNC^S--_Z!UC_ . EO_\ &ZO44!=^?]?\,ON*/]F:
M;_T#K'_P$M__ (W1_9FF_P#0.L?_  $M_P#XW5ZB@+OS_K_AE]Q1_LS3?^@=
M8_\ @);_ /QNC^S--_Z!UC_X"6__ ,;J]10%WY_U_P ,ON*/]F:;_P! ZQ_\
M!+?_ .-T?V9IO_0.L?\ P$M__C=7J* N_/\ K_AE]Q1_LS3?^@=8_P#@);__
M !NC^S--_P"@=8_^ EO_ /&ZO44!=^?]?\,ON*/]F:;_ - ZQ_\  2W_ /C=
M']F:;_T#K'_P$M__ (W5ZB@+OS_K_AE]Q1_LS3?^@=8_^ EO_P#&Z/[,TW_H
M'6/_ ("6_P#\;J]10%WY_P!?\,ON*/\ 9FF_] ZQ_P# 2W_^-T?V9IO_ $#K
M'_P$M_\ XW5Z@G'6@+OS_K_AE]Q1_LS3?^@=8_\ @);_ /QNC^S--_Z!UC_X
M"6__ ,;J]10%WY_U_P ,ON*/]F:;_P! ZQ_\!+?_ .-T?V9IO_0.L?\ P$M_
M_C=7J* N_/\ K_AE]Q1_LS3?^@=8_P#@);__ !NC^S--_P"@=8_^ EO_ /&Z
MO44!=^?]?\,ON*/]F:;_ - ZQ_\  2W_ /C=']F:;_T#K'_P$M__ (W5ZB@+
MOS_K_AE]Q1_LS3?^@=8_^ EO_P#&Z/[,TW_H'6/_ ("6_P#\;J]10%WY_P!?
M\,ON*/\ 9FF_] ZQ_P# 2W_^-T?V9IO_ $#K'_P$M_\ XW5X]#2 DCD<T!=^
M?]?\,ON*7]F:;_T#K'_P$M__ (W1_9FF_P#0.L?_  $M_P#XW5ZB@+OS_K_A
ME]Q1_LS3?^@=8_\ @);_ /QNC^S--_Z!UC_X"6__ ,;JXQ(Q@9_ TH)(Y'-
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M5_EZE=I &.GM7\KO_!$K2-7B\>_ME^(A'-_PC&I7'B-]+N?F^QRQ-)<E##_
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M9&D8KUR,<^P[T%-KGC).Z:2^:BE_EN7?V1_AI:?&W_@DYH_PX>%;G^WO!MQ
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M SCO2T4  .0#ZT444 -4$9R<_F:=110 <]Q_7^@IH;)(QTS_ #I3NR,#CO\
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M.-^2*CTIV;:C9VM^I^I=( %S@4*P958=& 8?0C(H.[(P.._^<U\:?E(M%%%
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M/MZ_Z>>J_&[X0Z(7&K_$3PI8-"&9UN=6MT90O)^7<6)&.@!/H*_#W]L?_@X
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M6T=.I[1\SIR:O"7-+2VK/[7/B1\6/ OPIT:?6O&GB#3]'@BB:2..ZN(XI9\
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M\]Q_7^@HK^6_XA?MQ_\ !2KPA;7/Q+/A*^C^&4,PG$CV;*?L6[<QR4SQ'_\
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M  PC\2O!&AZE%YFA^(8[0W 4 N6N$4\#!/WF&,#^= ^65[6/VTHK^=WX'?\
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MDTNROLO0TQ&*Q&+G[3$UJE:>R=23E9=E?;Y!1117.<X4444 %%("#T/\Z6@
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M8Q^E 26B=M=/GIO_ %J?L.K;L\=*=1100%%%% !1110 4444 %%%% !1110
M4444 %%%4=2U&UTFPNM2O9%AM+.%I[B5CA4C7JQ)X &>M %ZC./;TKY1O?VT
MOV?]/OWTVZ\<:3'=1W'V5HS>VX;S@VS;@OUSCCWKZ.\-^)-(\7:3:ZYHEU'>
M:?=*)()XG5T=3@@AER#^% '09[=Z*:P/!'7IVZ<^M.&<#/7O0 4444 %%%%
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M"!@1P(%4"M2B@ KC?%_P^\&^/;5;/Q=X?T_7;=/N1WT(D"\D\'@]2?SKLJ*
M.4\)^!_"O@?3VTKPMHMGH]@^-UM:Q[8S@$ $'/&"1CH>]<3J'P"^$.J:Y_PD
ME]X&T2XUK?YGV]K<>=OSNW9!QG//2O8:* .6TWP5X4T>Z6^TS0K"SNT "W$$
M(20 <#YA4NJ^#_#6N7MOJ.K:/9WU[:[?L]S/$'DBV_=V'MBNDHH YCQ;H/\
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MVO+R[CL5UZ;2M.EU*=DECC\UH(I TQ(4J,,"01GJ#R*_HU_X*8_$GP;\6_\
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M#1TEC:7<_0%5?<3VQ@?C7N.E7<M[90W,T9BDD&60@C;T[5_)'_P1'\#?&/\
M;1\8WW[8?QVN=7CGMM16YT6TO'D,+Q-(6AVJY((P >!T^E?UV  #   ] ,#]
M*"/SZ^0M%%% !03CK13#AOEYX_IQ0!Q/Q \6OX,\/S:XMO\ :([8[IEP3MB
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M2- _9+N]9US5;/2[.RTZ.XEEO9HX(_+5!O(=RH.Q06P,DX &2>>7_P""N_\
MP7@T'P!'JOP#_9KU5=2^(=[OTR2XL;H22R7$LC0D1&+'R@@;1SC.<Y-!,E>;
MY4VO^ OZ_'0_I.L_VFOAWK/Q)/PTT'5K74M;BD\F:."19-L@X8#8QZ'CD?4>
MGT=NX![D X[].E?SV_\ !$7X#^-]=^%UO^T;\<'U.3XC>(+F.[@COS(S*DX:
M8O\ O#G;@ <=V].:_H2*Y.?3&/SH)=NGS%!R.F/:EHHH$%%%% 'D?Q>^*VF?
M";1+?7M7"BQ>;RYI&Z1J,;F)R,  YK=^'?Q-\&_%'0XM=\':U9ZM:LD9G6WE
M1Y+:1P<QRJK$J0RL ?3&<$XKGOCA\+=(^+7P^\0>&-5#YFTC4Q9.GWDO'LY1
M P^DH3D<^E?PPV7_  4,^/W_  26_:^USP/\5KK5)?A#KGB'R;87\LOD_89;
MXA/+#G&W9C&!T_&@I1YD[;KIY:?U]Q_=Y\6IIK?X8?$">W<QSP^$-?EAD!(*
M2)IMPR,".A# $5_CS?MD_M-?M(Z9^U'\7[#3?B+JEO86_CJ>&V@6]N%6.(:H
MRA0 XQ\N.@ K_5N^%7[7WP?_ &OOV:?&/C_X<>(M-EMKOP-K)N[(WL+W%K/<
M:'<R*OE[A(5:4-&ORL5^7<23FO\ (W_;60I^U?\ &50=V/'TP##H?^)H_3\*
M"Z:3;NM>CZI_HK7OY'^I_P#\$0/$GB'Q7_P3[^$NL^*+^74M8N;;_2+J9VD=
M\6MJ1EGRQY)/XU^LNK:MIVAZ?=:KJUY!8:?9QF6YNKAQ'%%&.K,S$"OQ;_X(
MR>-O"_PV_P""8GPU\6^+-:L=+TK1M'N-0OY+JXB@,<,%G9[0HD(+-*QV*$#$
M'DC -?A9_P %.O\ @N/XC^/GQ+/[*_[(U]<RRWVIV^E:A<Z?<,TLH,WD2.&B
MP&+!F)( '3H. $<K;T7G?ILO\S^P'X>_M%>#?B=XSU'PSX2O8=2M]/,J/>0L
M'5FB!#<J64<@G&37T/7Y:_\ !+3]G34_A/\ L]^$/$?CA[R;XAZ[;-=ZQ)>%
MFF4SQHY5B_S9S(X'7H:_4J@D,T4PX4YYR<T^@ HHHH \.^,7QO\ #WP:32;O
MQ)(D%AJ,H1[B0[5C&\H26) &,'D__6KTGPAXS\-^.]%MM?\ "^J6VJZ;<HC+
M/;2+($9T#^7)M)VN ?H<'!.#7SY^U_\  W3OC=\'/&.D2><FMVOA[4)-!EAX
M>._13+$01\V200,=S7\7/[+_ /P5F^,W_!-S]IC6/@3^TK<Z@_P^O?$PLM..
MJ32C%K]I,2;?,/"[.F.G'2@:3EHO7Y']J?[9U_?:9^R_\9[_ $V=K:^MO!6I
MRVTZ$JT<H0;6##D8]N:_R%_$'[3W[2T?[0_B2S7XD:J+-/B:T"PB^N-JP#4]
MNP#?C&WC&*_U<_BM^T'\,/VDOV&_BQX_^'GB+3[[2=5\ ZD\427D$MQ#*8HI
M%BD12&)9&)!"=B#7^1?XD0C]I#Q,N"?^+IL,@?\ 45'-!K3^&6FS_5'^OQ_P
M37U?5==_8O\ @CJFM73WNI77A>UDNKEV+M+(88B69CR3D\Y)K[,\3>*-!\'Z
M1<Z[XDU.VTG2K1=T]W=R+'&O!8*"Q +$*<#(Z=17YL_L5?%WP#\"_P#@G=\)
M/'7CO7[#3=&T3P3:75T9[J&&5F,",((T=BQ<HA;.TKCWP*_ER_;@_P""QWQ+
M_;U^/]E^S'^RS<WR^%D\1PV&H2Z;/)N>$SK!*Q,9&=R+G.!G).#F@S47)V7W
M]/Z\M_(_M8^%/QY\,_%W5]6M?"TT=YINGM((KV(AEE"'&=RDJ<]>*]ZKXA_8
M.^ 2_!'X$>![/5#/+XKO-$AFUV:YR9FN90"X=C\Q8$'.?6OMZ@D**** "@T4
M4 ?.WQ(_:0\"?"CQ/I7AWQGJ$.ER:Q(D=H\SK'NWL%!#,P'4_P!,U[WIFIV.
ML6-KJ6FW,5Y8WD2S6]Q"X>.2-QD$,I(SS@C/%?EU_P %4OV:;GXO? ;Q/XY\
M)R7L/Q"\$Z7)?Z#]B++)(]NI=%78=VX.J_F.O;^<?_@E]_P71\4_!GX@W'[.
MO[7MU=6DL&O/HNFR:E.R3)&LOV>&16ES@J,-D@CM@@D$*46TVNFZZ_\ !/W^
M_P""U/B;Q'X6_9'\::EX9U"73M1BTJZ:*>)V1E81.005(-?YJ?[*7[3'[1VH
M_M%Z#9:A\1-5FLI/'J1-"][<$&'[=@I@N>,?7TK_ $:?^"O_ (^\&_%+]@[Q
M)XP\&^(-.U:QU+0[B>)+2XCGE5)+8RKY@C)PPWE2"!T'TK_,Z_9%21OVEO#R
MG@'XA*-W8?\ $PZD^@]N*#6G\$M%NNG<_P!B;]FR[NK[X#?"F\OI6FN[CP;I
M4MQ*Q+-)(T;;F).22:[3Q_\ $KP7\,-&.O>-M=LM#T[+)%+=RK&9Y57=Y408
MC<YR .0,D5\5WO[5_P (_P!DS]D#X<^//B)XDTR&TT_P/IPAM1>PK/<3Q6AE
M9/+#-(H5F52"%+9RI[U_(EXF_P""C'QN_P""O?[7NF?!SX2W.J6GPK\.^)1%
M(]A+,(WM8[O+;MK %=A/MCIF@R46[]+;^1_<Y\*/BM9?%2UO=5TB,-I",38W
M:@[+F(L KAN0<CG@U[!7BWP!^&%M\(OA5X0\'("UWI>BV5OJ$S8,DMTL8\TL
MW4G<>23G(KV@'(S02+1110 5#<2-%!+*B[VCC9E7^\0,@5-10!\XO^TS\.-&
M\:0?#WQ;K5IH7BF^E1+"RN9%C:X\P@( '92-V1@C/T-?1JLKJK*0RL RLI#*
MRD9#*1D$$'((X(Y%?SO_ /!;[]G?QY9>"9/VJOA%<ZC#XS^'Z07(MM/=T\T6
MT9DRRQD=?)/;]37R)_P2'_X+X>'_ (L6^F?!?]H_4!I7C^&\.CPS7]P(Y5FA
M<0)N,QY4L/FSU'H<&@KE?+S+5=?+^OZ\NU_X.._B#X^\$_"ZXG\&:[<Z/.+$
M'?!,\1!\@'^!E[__ %Z_E&_X(Q_M"?'SQ-^T?X<L?$OCO4=2L9/$01X9;N=U
M,?VM0!AG/;CZ''2OZC?^#DG4-&UWX)0ZWH.K6>K65_I:RQO93).J@V^,ED)Q
MNX//3.#7\E/_  1&B\[]IOPNC.(D/B10TK\)&/MB\L3P/Q-!T0_A/1?-+LK_
M #W/]8?PC(\OA;P[)(2TCZ+ICNQY)9K.(L2?4FN&^*/QO^''P@@LV\<>(['2
M+G4\IIEG/*BSWDI.Q$1&93AGXSR?0'BOA[]LW_@H[\$/V'?@SI^M>*/$>F7F
MMGPQ;KIME!>Q,WVF'3U4%T4EMYE7*KGY>^2,5_+;^QC^T!\??^"SW[7TFNZQ
M=:S8?"WP-K4MYIH2686LMM:7)E4$9"E3&F/Q]*#G46U=Z+O;<_N3\!>+I/&>
MDC5Q;>1:W 66S?! FMY!F.0=B&7!X]O>N[K \*Z'!X:\.:'H-NH$>DZ796 (
M4 L;:W2-F..I9E)/N:WZ"0HHHH **** "BBB@ HHHH **** "FC[S?A_*G4T
M?>;\/Y4 *.@^@_E2T@Z#Z#^5+0 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M9+I'**H,4CQ-Q_%&=IY '(.0:#KA::4OM1WTW['WA^S5^WEXX_96^'^H^"_
MDEQI^HWMO)"FI6Y9'0.K 8=2",9X.?PSFL;X ^#?BU^WW^U9X*F\2WFH>+Q/
MXBM!JGGM/<!('NT+!\EU  )ZC@#GO7Q)?3B 0CRP[7$R6ZC&26E8(O8]S7]Q
MG_!LM_P3ZFT'[9\=O'&C^;8ZE#)=Z.UU;AE\UH]\1B9UXPY4Y'3.1R.0)I03
MDM'Z=>G]?<^C_K5_8[_9^\-_LX? WP7X"\.V$-@D.AZ7->Q1(J?Z2UHC,&V@
M9*ER._OR*^IAQ^9_4YIB*L:+&BA4C5450,!550% ]@, 4^@Y HHHH ,TG'4
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MWK^>^"6.:,218*-G!'3CZ4'5#WDI)*ZT?W+;SMZ'Z-?#;_@I?\5O@M^SO=?
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M006L?"6\,4$8 Z)%&J*/3A5%3_A28&<XY_R*!GG/X4'*+1110 4444 %%%%
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M\>T-\6PP88VA%],'I7^JY\!/A;I'P=^%/@SP)I-G#:+HFA:?:7/DQK'YEQ%
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MA6<20VVD:99:?%'$H1%6UMXXCM4<#<RECCN2:"ZTE>RUTU^^Z_K^GM4444&
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MM*23%F+D[-I(9L\'GFOT().1@9!QS@T<$E>?\X_&G4!=A112!L],T +1110
M4444 %%%% !7+>,_"&C^.O#FI>&->MDN],U.%H;B&10Z,&1DY5@0<!S74T4
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M>)M:\1^ =-L["XUO[2;G[- (B?M.[?N^49^]ZGZU]IT4 %%(#GD4M !1110
M4444 %%%% !1110 4444 %%%% !31]YOP_E3J:/O-^'\J %'0?0?RI:0=!]!
M_*EH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "D*[NN>*6B@#Y'_ &ROVL_!'[('PBUOXF^-+A(8+*TG
MDM5D=55Y(T8C[W4[@ ![_E_GR_M^_P#!PG\>OVE[O7? G@%M2T7P3)+=VMCJ
M-GO@5H@[QAD>/:"2,'(Z]>:_J4_X.4+5+K]C*]65G$:>8[HCLA=%<$KP>=V#
MQWZ?3_/ \0>)_">I?##PKIWASPN=.OM-D(OK[R<-<E&.\E\9;=COWSGKBCY=
M4;TXJRDUU>^R:6E_\M_4\;OO%WQ/U379-?N_'?B ZO+>&]%P]W/YRN3NP&+E
ML9QT((K]GOV$_P#@NE^TA^QUJ&D>&K^]U;Q)X326"'4)[R22Y5;<LJ/N,F\#
M"D]3@X_+\;[W5[26ZBG6V\H)$$==N"S[,9Z9ZCOCG\J]!\"7MC;:/KLNI^%W
MURSGC8F80EQ;<]2=IV[1S[=>.M!M*,914I*^RTTMM>W]>K/]7#_@GI_P4'\
M_MO?##2/$^ASJ-<DMX6O;=2O$CIE_E&""K<=,\X(XY_2*OX]_P#@VL&E2>%F
MFT:-[>W:0%H"Q(C^;[F.V.:_L(H.222>FS5UY?U_204444$A1110 4444 ?E
MO_P4@_X*2> /V&OAOJFM:C.LOB5+>9K.URA/FHOR (<DDM^?&..O^?+^W/\
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M4Z5X)\,ZWXLUN7R=)T&PFU&^ER!L@@7+')X'89YQGI725\V?MA1&;]F3XT1
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M1>5=5=3ZJP!!_(TISQ@?6JNGY%A9 ]1:6V?^_*5:)P0,=33.86BBB@ HHHH
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M6THM&\G>;0D'!S@[=OK7]OG_  ;#V]I'\,-5FTY7BM9[EI(X6=F\M"1\F.P
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M[W/Z-_\ @GS_ ,'%'QH^ %UX?\ _%0:CJW@>.2RL[O5+K?.J)O2/S&DDR%.
M><]"1WK_ $"?V5_VDO!G[5/PA\/_ !9\#7"W&D:S;PLQ1E<+,\2NRY4D#J>*
M_P AO0/%O@?PW\'?$FA^-O"XN];U2:-=+OWB^: N^$*N1E<9!'(YQ7^DS_P;
MQ6PM?^">O@D*7,<EVLD0=F<K&UN2JY;G@$<=,YI*]M;?(RJ02U5EY*]NG^?S
M/W9R <=Z6C'M^E%,Q"BBB@ HHHH *_#G_@J3_P %>_!'[#OA>_L-$;[?XWC@
MF,=N CLLP#*B["&QA@.W4\\=/W&K_/K_ ."^^J>%-"^->O2>*-/.J27,MPMI
M"Q+#?YC!0%.>YZ8H'&SDD[VOK;<_$W]M+_@K3^TO^VYKNIMK>NZYX>TJ6>0V
MT%M/-"KPEFV@HK+_  G/3\^M?G_X#^)WQ6^&?B6Q\2:#XZU^#4+*Y6Y)2\N%
M,S"0.0V''MU[]:MZI?):ZW'J4NC/I^FR8:WMVC*@QG.,*1@@C_(KG/$FHPZR
M[C2;?RKB10L2*F"6R,8 ^E+I:[]>N]_^ =D4K*R7+:S5NOGW_I]3^KO_ ()X
M_P#!Q_\ $7X<:MX6^&OQO@OKCP>LUCI_]L72M)'EBD)8SR @$CDG<*_O.^"G
MQ<\,_'+X:^&OB;X0G%QH7B6RCN[216#CYHXW90PX.WS!7^1[H/BWX2Z7^SI9
M^$?&7AN-?B+=:S8BPU)XA'<*3-'M*RD!\YQTS^=?Z;G_  1ZMGM/V ?@A"[,
MQ&E,5+L7;8;>SV@L>3@47_K[CGJ0MJE:[M9;;+5>O]:GZ=TF03CO2TQ@>-H/
M?.!].N*9D/HHHH **** "BBB@ HHHH **** "FC[S?A_*G4T?>;\/Y4 *.@^
M@_E2T@Z#Z#^5+0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%-9MN..M #J**,T %%%% !11GMW]** "BC..M&: "BC-%
M!1110 444A)! P3[_P"10 M%&<=:* "BBC- !11FD)P,T +12 Y&:6@ HHS1
M0 44T-R0>,9YS3LYZ4 %%%-W?-MQ^/X4 .HHHH **** "BBD8X&<=Z %HH!R
M ?6D)QCW.* %HK U'Q3X>TF]MM.U+5[*SOKL@6]M/*$EE+?=VJ?4],UO@YY'
M(/(([T %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!_/U_P</?#;
MQ9X]_8VU5O#%C<W\EGYAG@M8FED9$Q(WRJ"?N^W\J_SIK[Q7X6T;0/#7A'5-
M&FTK4]/N3'K'VV#[.QV28D)\Q5R20?SK_8S\9>"?"_Q T2Y\.^+]'M-;T>[5
MEGL;R,20N&7:V58$<CCI7\MG_!5'_@WO^$GQE\/^*_B?\(K>S\(W^CV-SJ\N
MGV@2W:78&DD $:(K[6*CCJ,DKUP&L)):2O:]TEW>FO\ P7Z'\&GB";X?77BN
MWEL7C_L8VX:8J1M$VPYY'&<_Y/%>O_"GXK^ O"_A3Q[X6ET@:O>:S!-!HH@A
M%Q,KR I'L"JS9!(/K_3Y[\>_"#5/A_\ %2;X27"2->+KPT%9#G);S_(WCOC/
M/XU_:U_P25_X-X/ -KX8\%_'?XP36^NVVO1V^J6^CW968M P27B-U;"[CM!;
M&3D \' :S<8I?$^UG^?KK?\ JWMG_!L]\*/'.A?#G4?%6MZ7?:;I5Y=-<VL=
M[ \+"&23<@4.%^7!';GI7]<YW9&.F>:\Z^&GPG\ ?"'0+?PS\/?#ECX<T>VA
MBA2VLHDC#+$H52Y15#,< L< $\@"O1J#F;;;;Z^7^04444""BBB@ HHHH _C
M'_X.;OA'X[U+PU9^+-)TK4-0TF*837*V,$DQ\C=O;<$4\ #O[\5_%M=Z_P""
M+N^\(65S9/IL=E#%'J\=VGDR>8N ^Y7 .0P/7UK_ &+OBK\%_AO\:= N?#7Q
M'\,Z?XCTNY@D@:&]A20HLBE2R;U8!ESD9!&:_C*_X*Z_\&\W@[2/"WC3]H#X
M174&D:;H:W&I3Z-:$0^7"!),H,2*HVG:1D#K@9R>0WA4C;EDFO-/T7]7N?R.
MV-]\,H/&U_/<-%_88MF%L21L\T+@8XQU]ZF_X2'P[XKT36/"&A:'<ZKJ][J$
M*:2UC;FX8!IPL>/+4D<G\!7D7P\^&=[\1?B=I_PM3?%<WFO?V 9 2&5A<>1O
M)Z]3G)[CFO\ 0M_X)8_\$ ?@Q\"_#'A/XD_%2SL?&.J:SIEGK,-G=*D[0F9!
M+"K>8CA<\-R<XP<= 0N4E'E;;;T=ON^[T_X9_:?_  0/\ >*O 7[$'A2R\4V
M5Q8W-PEN\4%S&T4JH(R>48 C@CM7[@USGA7PEX=\$Z-:^'_"^EVNCZ19J$MK
M&TC$<,2@  *HXX  KHZ#F;NVQHW9.>G..GK^=.HS10(**** &C=DYZ<XZ>OY
MTZBC.>E '\#7_!R/\*_'.C_%#0?'<VAZCJ7AJ'44N+DVMM),@@60,=Q5&P .
MIZ5_,/\ %SQU\/O''B#PP;*UCTVSL-/@BO;=E6)_.6,*V].#G<,'(R/SS_KP
M_';]FKX1_M%>&=0\-?$WPGINO07MG+;1SW4$<DMLSH0DB%U;[IQGC)&0"#@U
M_!K_ ,%EO^"#&F?LS^'_ !#^T3\/[Y(O"D-S<7+:?;/B.!5WS>4T8 VE5QP<
M<>Q%!M"47:,DU;JNOK^)_.C\-]1^'6B>)+_4-<:'[%"2]B)" &/)4<^^3[U=
M\<O;?&[Q/X9T;P#H&H7FJ0^(=/$!TZU>6+8MS'AB8T(]2?:JO[''[-VH_MC_
M !*T7X?Z9));)?ZHNG/*A*^7B?R22?\ /J.:_P!&W_@G+_P0J^ '[*/AS2=7
M\<:'I?C+Q2UG97J37,4<_D7+QQS?.[QDY0GD!LY&WCD@-)R4&MW9:+M:RUZ^
M=M#[F_X)1>$=>\$_L1?!_0_$=O+:ZG!HT)EAF0I(@^SVX 93R#D'K7Z-D,3C
M^'\/_P!?6L[1M%TSP]IMKI&C6<-AIUG&(K:U@4)%#&H "JHX   K4H.9N[;[
ML!QQZ449QUXHH$%%%% !5/4(VFL+Z%/ORV=S&G^])"ZK^I%7"< GTI%.1G'>
M@#_- _X+H?#+QI\/?VM/^$S\3>'M4O?#$NK&=I8K222 1&?.YG"E<8/<X_6O
MQY^('C3X8>,]=CEABAL[6*Q1/)PJ,)@@X*<'(/7@>^#7^L5^T[^Q3\"_VI_"
M>KZ!\1/!NE:A?WUK)':ZM+;QM<6TS*P5MS(QQD\XP00#GC%?Y[?_  63_P""
M+D?[#,VH_%CP[J(F\+WEQ<WEM;0OF)(6+.J@# &!\NW (88(!H-X24O=>C2T
MMMNM/\NVO>Q^+7PRU7P%X<\4SZGKAB:UMY'-I&Y 5@#\HP<=< 8Z\^M>B:#X
M8U/]H3]HOX;GX8^']4N&L/%&FO-):6DDEL$2[B.XLBE0,<Y)KL?^">/["^L?
MM]_$#1O"VFS/:V5S=PQ3SJS*J+YH#9/H0/Y\U_H[_P#!/_\ X(V_L\_L;^%-
M.34/#.D^)O&=ND#MJT\$4S13JB%W\TH69ED! VMC.3G& 5L]%TW_ $+G*,=+
MMR[;+I;Y=?\ ,_0_]DC1=1\._LV?!K1-6C:+4=-\$:7;7<;J59)4$A*L#T(R
M*^BJKVEK;V-M#:6D206UM&(H8D&$CC7HJ@< "K&:9RA113=W)!XQW_*@!U%%
M% !7#_$NRN-2^'OC73[8%KF\\-:S;P*!DF26RF5 !@Y))';/XUW%-=%D1XW4
M,CJR.I&0RL"&!'H0<4 ?Y'G[>WPZ\3_!?]L?QKJWC_P]JO\ 9-_XDN9XKE[.
M46IB:X8Y,C)LQ@^IXKYC^+'B#X:>)DBN- ,"7#(OFQH5R#@;LJ,<@YS_ $K_
M %-?VUO^"8?[/7[8/@W5]+UWPCI-AXIO(I!;ZZMO$)1)("-SOY9<,"0<AL$>
M_7_.G_X*K_\ !*[5?^"=7BC4M1>\>]T.:XN);5]Y>,Q.[-'M(^4C81C!P1GM
M4\NEM=7_ )?Y'3":E9-M222TTO\ U_5CXJ^$?B?X;>#+C[9K'DS3"$@1.026
M(X ![YZ<?AFOMC_@G1X \2_&C]LOPGXB^'_AS5(]*L_$-K+-.MG*+81K=(Q8
M/M"[<9.<]J3_ ()0_P#!+J[_ ."AOC/2[V6^:ST6.XMIIP7VQM&'#.&/W0"%
M.1[DYK_1N_8S_P"";'[/G[('@[2-*\,>$-)N/$UG%$+K7OL\9F>6-5&Y'\M6
M)+ MDDCGCGFJ)G)0;2;E)Z._3O\ ?T_-]/N;P#:3V'@CPG97((N+7P_I4$P(
MP1)'9Q*X/N"#774T(%0(@"*H"J%& JK@  >@ Q2C@8SGWH,!:*** "BD)P,T
MH.0#ZT %>!_M2:-?^(?V>_BSHNEHTFH:CX/U*WM40%F:5@A  '))P:]ZW?-M
MQ^/X5%<VT%Y;RVMS&LT$Z&.6)QE71NJL.X- T[-/S/\ (8^*&ES_ +.W[17C
MU_B+X9U".\OO$.H-'/>6<B6Y1[B0A@[IMZ'.?>OFCXB:OX&\1^-;?7-+,2VE
MW<*U['&051206X7CN<U_I[?\%!/^"/'[/O[9GA#4TM/#6E>'O&L\-PT>K0P1
MQ/-.48QGS%3<KL^ <MCG.1DU_FV_\%!OV*M5_8.^(^O>$=1GDN[2SO9H89F8
ML'7SV12,]L8/3I4VU>FZW^[3];G53FIWOH[6MT:W_#5?\.<EX0\8_#'PGXGG
MF>*&\T^6Q=!"H5W,[1D !.N2>, 'KTQBOW!_X(#?##QOXV_:@NO&>A:!JECX
M6CU43Q2W%I)% 8A.&RC,JKTSWP?H<URW_!&;_@B5:_MMVFF_&KQ1J*IX5M9[
M6\GLYW_=.A*G9M.0V[I@ EB<8K_0,_9L_8[^"'[+_A72?#_PV\':7I-U8VL<
M5UJ4%O&D]S,$4.Y*HORY7C.6ZG(SM#6RZZ+4RFXQO&-_/MI;]-/ZU^HK1&CM
M;:-OO1V\*-]5C53^HJQ2$$]#BE%,Q"BBB@ H//'K132V"!CKC^= "@8&*_-;
M_@K7X/U_QQ^PY\7]!\-V\MUJ=QI,IBAA0O(X%K<@A5&23STQ7Z59QUK*UK1-
M+\1:9=:/K-G#J&FWL9BN;2=0\4T; @JRG@@@G\Z!IV:?F?XVVE3Z;\(I-7\+
M>,M O=/U\^(+W[7)?VK0J4:XD#$&1!D8.00>G-87CR^^'>J:_I-SHSQFQ=4;
M4/+((#]6R1P.??\ QK_19_X*6_\ !"/X$?M3>&=>\1^ -'T[P;XHM]/OM2D:
MUCC@,\]O"\[A'1%SN"LP!.[^'GO_ )Q?[3'P-OOV9/B=K_PTO7>Y?2=7;2EF
M8EMY,YA##GG/7\S[4'3!QG?5WW:[[:_?V[_?W7PH\<_#_P $:]XJ%W9IJ=GJ
M%A-%80HJS2"9HR%V(-QW;NF!GM7]0'_!ME\*O'6K?$G7?'(T74].\.2ZDUQ:
M_:[:6&,0F7>I7>@&-IXQBN,_X([_ /! '1?COX4\,?M&?$N^CF\-ZA-;7<&E
M73;EN%8+,\:QL#OPI&>, $9(R!7]R_P._9N^$7[/7ARQ\-_#'PEIOA^VM+6*
MW>6T@CCEN&10K22%$098Y[<# ))R2&4JB=TNJ2^5E_EY'O%%%&<]*#(****
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MGCR6,2D=!UZCOUQ7^K%_P2R\):WX(_8A^#/AWQ%;R6NJ66BI]HAE0I(F;>U
MW*0".5;L*^!O^";?_!"WX"_LE^&])UCQQHFF>,?%DEG9WJSW444YM[B2-9<,
M[1L04W D*V[=\IP0<?OGI&CZ;H.G6VE:3:166GVB".WM85"Q1(!@*JC@  4]
M3&<[I13;2[^=GIK]]S3HHHH,PHHHH **** "BBB@ HHHH **** "FC[S?A_*
MG4T?>;\/Y4 *.@^@_E2T@Z#Z#^5+0 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M?:@,#P,TZF,,#Y1SGL/\*!#BV"!SS2T@' R.<#J.:6@ HHHH **** "BBB@
MHHHH *:-V3GISCIZ_G3J* "L[5M5L]$TR^U>_D$-EIUO+=7,K$ )%""78D\
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MUOP38ZN^EZG=6IN9;>';.89-S)N0;1D\^E!HHP4M^5J2<;_)KU>_2W3T[/\
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M'4_L&M064D\ZV[22^7+O6(L!MRV<BOT6^,/_  ;W?M ?";X#P_&7PS;:C?\
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M4?#^E3731N'*736D8F5\=S(K'\>>:]5H, HHHH **** "BBB@ HHHH ****
M"FC[S?A_*G4T?>;\/Y4 *.@^@_E2T@Z#Z#^5+0 4444 %%%% !1110 4444
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MD14=TX$@,>0/O8 [#'[E_L"?MI?'?]J'Q5K(^(?P\G\(^&K1;G[!<O8/:1W
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MOY-:[]#]2=9T>PUC1]0T>[LK6YL[ZQN;-[:>".2!DG@>(J8V4J!AN, 8ZC!
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M,U]O?$+X!?##XFSI=>)_#=A<7:?>N8[:!)I#S\TC"/+-TRQY;&3D\U[,
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M[65MRD848]^>PKZ'T[1M+T@.NF6-O9)(<NEM$L2GG/W5 '6M+!SDG/&,8_\
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M"\$8('?!->QVMG:V,0AL[>*VB&,1PH$08Z85< 8S5FB@+L**0$Y.1T/'!I:
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M\][</"H0O)))YC;BO)Y)]S7Z6T4 82^&]!&H0:J=*L!JMO&L:7RVT2W055
M\T*'/3J3G'4UNT8[XY]<44 %%%% !1110!2OM-L=3B$-_:PW<0.?+GC61,]_
ME8$<UX9^T/\  CP[\=/@SXF^$-]:P6NC>(8%@EAMXTAC"C>#A5"CD2'/Z]*]
M_P G<1CCUP?:EH!.VI\=_L9_LA>!_P!D'X;)X%\'VL4:O<27$TRJN\F1B2"P
MZYSS7V&&STS2T8QT&/PH YWQ=X?M/%GAC7?#-_&LMGKNEWFEW*,-RM%=PO$V
M0>N <_4"O@G]D'_@GK\-_P!DSQ7XP\4>$((XI_%M_/?7D:*!&SSNSMN0'!Y8
M]1]0*_1BB@#&M_#NAVE^^J6NE65M?R B2Y@MXXI7!Z[F15R36P#GD4M'3H*
M"BBB@ HHHH RM1T/2-7:%M3T^UOC;G="+F%)0ASG*AP<'/-?)?[8_P"Q_P""
M?VN?AQ#\/?%=O$NF0W"2K"D:)%A#N V *O'3ITZ=J^QMQR=W YQP:?0!X;^S
ME\$M _9Y^$?A?X4^&88X=)\-V[0P+&H4'=M&3MXSA![5[E129.X#''K@^] 7
M/(?CI\'_  Y\=/AGXF^&_B>VCGTWQ!I\]F_F(&V&1"N1GID'%>!?L1?L:>#O
MV-? .M^!?"4:C3]7U1]0EC(5D)<R$KMY&TA\%2,$<5]N44#N[-=&9%AH&BZ7
M/+<Z=IEG93SY\V2V@2$R9.3NV 9R>M:](!@D^II:! 3CFD!SR*0$G((X[<=>
MM.Z=!0 44@&"3ZFEH Q;[P[H6IWEO?ZCI5C>WEJ1]FGNK>.:2$CH8S(K;2.V
M*^)/VSOV%O '[8=EH%GXTA26+0;N"YMHF ,8:!PZ84X Y'.!CVK[T(S@^E+0
M%SS_ .%?@'3/A;\//"?P_P!&B2'3?"VDP:7:I& %$<);' X_B_2O0*** /FC
M]JC]FGP9^U%\+=9^'/B^TBFM]1BVQRNBLR'G@$].N<Y[>M9'[)/[,7AC]F#X
M/6GPCT:"*?1K:XEE\F9$EB974+M*-N4@?3KSUP:^KJ*!W=K=#/L-*TW2U9-.
MLK>S1OO);Q+$IYST4 =>:T*0D@<#F@$D<CF@0M%%% !1323D #CC/!]:=0!C
MR>']#EU!=6ETFPDU) 52]>VB:X4'@XD*EA]>M?GM\:O^"=/PQ^-WQ0TKXE>*
MK>.[U+2;V.]M1,JN(Y(Y%D7;NSCD=J_1_+;2<<YZ8/M0K9^O<<T!=K8R]!TF
MWT#1-*T2U4+;:586MA JC $5M$L2 #V"BM:BB@#X@_:U_8D^'/[5-C:CQ39Q
M/?V<L4L,[(N\-$05(8^F![U[K\'O@WX?^&/PP\/?#<V5MJ&G:#$(X$NX8YP-
MH0(5WAL%=O!!&,GU->U4A('7B@+D4%O!:Q+#;0QP1( J1Q($10.  J@  5-1
M10 4444 %%%% !1110 4444 %%%% !31]YOP_E3J:/O-^'\J %'0?0?RI:0=
M!]!_*EH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M$_M2>*]/\*^$=4L[B\U"18HEB>$G)8+T4Y]?Z=J_:V-Q(D;CI(JL/HR[A^E
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MGA7X1:U:ZQ\0M1\/1Z='%;SQ226\PL$MHXX]CEA@J26X8YP1ZA55.4TDM?\
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MLL9/SIG!+# 8':> :^^O C:G+X;T^[U5F:ZO8(KLAB<H)D#A3GD$ BOXK_\
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M00><@C!!K_)/_P""Y>E0S?M7?$UVN;Q2=8O.([AU _TM^P8 5_9S_P $D_\
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M?]GW]G7PU\3]2T9+'Q=XEL<3M- %N-KP#+;B W208/-?T69STYKD_!'@[1O
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M7[2VM:6TFF:+/:S;;J#Y&*NH7&]"/3OWYK_0QBBC@C2*&-(HHU"I'&H1%4<
M*J@  >PH.:K*[LKV7W;(DI, '..32T4&04444 %%%% !1110 4444 %%%% !
M31]YOP_E3J:/O-^'\J %'0?0?RI:0=!]!_*EH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
M@G )]*** $4Y&<=Z_FX_X.%/V"8?VE_@+)XW\/Z4G]K^#[&XOK^6"$;W2$S2
M!V90">-@.2>?KBOZ2*X?XE>#+#XA^!/%/@O4H(Y[/Q%H]WIDJ2J&7%PF <,#
M@@@=.>W>@:;3N?XF&J0S:-K]_P"%;J,Q75GJKZ(JL"#YJN8 ,8Z[@/\ /-?W
MI?\ !LQ_P3ZD^'OAR_\ C/X]T,7']L6[7>ASW< (#2J&C,;2 XV[P?EQ_6OQ
MU_:2_P""1OB+_AYO9_";1-!O#X>U+Q>FJRW,5H_V3:]XLARZILQ@U_H?_LP?
M!K3_ (#?!/P-\-+"S@M3X=TBWM;CR8U0O.L:([.0H).$7@^F>I-!M4J<T4NZ
MN]?1['ORJ%"JHVJ@"A1T"@8 ^@ XIU%%!@%%%% !1110 4444 -=5D1HW 9)
M%9&4]&5@593ZY!(Q7\2G_!SA_P $_I_%-OIWQN\!:']FM--B2\UR>U@VH)%3
M?+O:,=RK-D\].M?VUL"0,=0<_P"<U\P_MA? K3_VB?@#X\^&=[9074^MZ1<1
M6C2Q*[QS>3*H*'!()W=!_P#7H*C)Q::Z?CY?,_QH/#]K<>*?$>D^$K"-I[C5
M-4712J@LPE:00'@#.0WX_@37^G3_ ,$!?V#[?]EG]G6U\1ZYI<8USQ?9VE];
M330CS8XI1'*71FR03@KU]:_ED_8=_P""2GB!O^"DNL?#/Q1H-XN@>'/%=QJM
MO<W%I(+4I#=M*-KLFS& <8^O:O\ 2'\#^%K'P3X1\/>%--AC@L]!TNTTZ".-
M0JA;>,+D >IR?QH-*L^:R7J_G9_U_D=511108A1110 4444 %%%% %'4]/MM
M6TZ]TN\C66TO[6:TN(V 97BGC:-U(/!!#=#7^;S_ ,'&_P"P9>?![XY'XD^"
M]#>V\+ZI<'4+ZZMX"D!\TF9RS(-F?F/6O])2ORF_X*[?LF:=^U%^RIXUT2TT
MJ&[\56UC,=,G$*R7/_'M/PAVLV5*KTXZ=Z"H2Y9)_?Z7/\ICX'^ ]4^,WQ=\
M$> ](L9=0M->U:VL+LQ(751)<1QONV@XQD]:_P!9S_@E[^R#HO[(/[-7A3PE
M86T5O>ZQI6G:E?;45)$,T D\MR.>2RO@^Q]*_D-_X-_/^"7>MZ)^TOXLD^,?
MAZ=+?P;JM_?:;)?VC $6MP\J"(RH!DA<+R.>^*_T#+6TBLK*VL;9 D%I;P6L
M"  !8K>-(HU Z<(@%!=6?,]+V7]?TRU12#H/H*6@R"BBB@ HHHH **0[LC'3
M/-+0!S_BGP[IWB_P[K'AK58DN-.UFQFL;N)U5U>*48(*G(Z@5_F$?\%\?V&=
M2_9S_:>UCQ9X>T=['P5?WMS=&XBA*6[&21W)#*-ASD'KTYSR:_U%@NWIGFOP
MW_X+F_L4V_[5/[+6OIX?T>.X\8V$%Y)#<0P![IT6WW1[6"ESA\YQZC'L&E.?
M*^R_X;_(_P T+]D?X.ZG^T9^T#X&^'5CITM_I6N:E90W$B1M(@5KB-6)(&T#
M'J:_UN_V$OV:-'_96_9Y\'?#72H(H6M]-LKJZ6- A$KVD9V,1R2NXYST/:OY
M'O\ @V^_X)JW?A;QWXJ\4?%W0)HM4\#W<S:=)?VA61GBN"L7EF1!_%M[_6O[
MJD18T2-!A(U5% [*H"J/P  H'5GS.R>G]?U^8N>GOCCZTM(5R0>>*6@R"BBB
M@ HHHH ***0-DD<\4 >,?M!?!_2/CM\*/%7PSUN**6Q\16,MNRRJK+O,4J(?
MFX!R_6O\F'_@IU^R_JO[*G[57C7PC'I,MAX7@U+4)+>X\ID@96G<J0VT+T-?
M[ U?R2?\')7_  3X/QF^&&G>-OAAH)F\:W[W"WTMG:[[EWWL0Q:-6<JRLO7N
M",=Z#2G-Q=KV3_'8_D+_ ."2G[)VI?M4_M8>$-&N])DO_"0U&QFN;CRC) H6
M5&)+8V\8Y_R:_P!8'X.?#+1O@]\.O#7P\T"*.'3/#UC%:0)$@1/DC1&.%XR=
M@YK^:C_@W#_8!;X#_!:7Q?\ $?0S!XX3[*+:6ZMMERC-\S-N=0P  (X.>0.G
M3^J6@=67-+;;]=0S1FD(R,4 8&*#(6BBB@ HHHH **** /@G_@HU^RQI?[67
M[-?C+X?7EK%/>+IUY=V1>-6<LD#,44GGJN0!WR:_R4?VE_A=J7[/GQN\;_#?
M4[*2SLO#NI7EO$\D;(I$=PZKC< #D8XK_:@EC2:*2&10T<L;Q2*>C)(I5U/L
M5)%?P0_\'$O_  3(O-6^,?A;Q!\*-!GFNOB%J<,FH26%HS%/M%R-_FF)#@@[
MB<GJ*#:E+E=GL_.VMT?!_P#P;S_L(:C\<_VC=/\ B5XFT9[_ ,$65U;W:S30
MF2W78X?.7!08P,GM7^E]HNCV'A_2=/T72X$MM/TRUBM+2"-0J1Q1+A0 .!W)
MQW-?D#_P16_8WA_9._92\,Z1JVE16_B?4K.QFN;AX%2Y"-;AI%9BH899A^OU
MK]DJ")RYI7"BBB@@**** "BB@G'- !2 $=230#D9I: /PG_X+I_L/VO[5?[,
M.L2Z%I,<GB;0H+V^>XAA!F>&"+SLEE&[C#=\8%?Y<'C32;KX=>+-=\#ZC&T=
MWX>U!]+E5U(;S$G:'H?<?Y&#7^VWXET6V\1^']:T*]@CN+?5M,OK!XI5#(RW
M5M)#R"#T+Y'T]*_S@/\ @IE_P2<UO1?^"@^@^%/#N@WDNB_$?Q+:ZC//:VCO
M;1I=WHFPS+'L  ?DF@WI3MH]M7_7G?\ ,^Z?^#9;_@GU/::]-^T'XST?[9H^
MH)]JTM[F#=%YIC,L84N, 9QR.<$8SUK^ZZ**."*.&%!'%$BQQHHPJHHPJ@>@
M KX]_84_9TT[]F']G/P+\,;2SAMKG3--M7NW2-4DDD>U@P'(4'Y3NX]SFOL:
M@RE)R=PHHHH)"BBB@ HHHH 0@GH2*7/;O128Y![C_/\ 6@#^7S_@XQ_8#7]H
M3X(+X^\&Z,JZUX9LYK[5;BVA&]HX&=M[L@W<J%SNR.3FO\WF^$^DZU<>%)5;
M[78ZHNB2(0=WF[_*(V]<[N.*_P!LCXK>!K#XD_#SQ=X)U&VAN;?Q%HEYII2:
M-7 ,Z84C<#@A@.1SVK_-X^+?_!(SQ!8?\%/K?X20:#>/X=UKQBNJO<I:.;15
M:]\P N(]F,$<GMZ4&]*=DXOU7RT2_$_<[_@VD_8 /PF\#WGQF\8:,LS^)[+[
M3H\MU!NPTRAE=&<9!429!'?%?U]* HVJ,!<* .@  P!]!Q7AW[.'PBT[X&_!
MOP1\-=.M8;:/PUH]O92"*-4WRQQHCLV "3\@'/I^->Y4&+=W</PHHHH$%%%%
M !^%%%% !^%,=4E1XI &2161T/(9'4AE([@J2"/2GTTX!W'/^1B@#^%K_@YO
M_P""?<DMU8?&SX=: ;>T.+[7+FU@(4,#OFWM&!G!SG./UK^*GP[97OBKQ/H/
MA32X'NY]2U:#2)TC4LP=Y! X(4$@YSU%?[(W[;?P$TS]HO\ 9W\?_#V[T^WO
M+W4=%NETUI8E>2.=HF7"$@D$Y&,=QQU-?P)_\$YO^"3'B:U_X*-:SX"\?Z!=
M_P#".:-XINM2M)[NT;[-LCN_,7:SIM "]_?/K0=%.I:+[QU6G33?S_,_JX_X
M(/\ ["UC^RG^S?I?B.\T^.'6?&NF6EZKR1*)4298Y6921N&>5SG//)S7[UUS
MGA#PSI_@SPQH?A;2HDAT_0M.MM.M8T7:HCMXPN0!ZG)_&NCH,&[NX8QT&/PH
MHHH$%%%% !1110 5EZWI5MKNCZGHUXBR6NJ6-S8W".H96BN8FB<$'@\-6I10
M!_F<?\'$/["%Q^SW\?6\:>"M$>+P[X@NO[3OKNWA*0C[3B9BS(NW^(]>GY5^
M"GP!^'.K_&KXS> _!&C6,NI6>LZS:V-^(HV<*DDZ(^[;V&3U_2O]3+_@LA^R
M#HW[2_[+'C86NDQ7GC*RLBNE2B!9;C_CWE $9VLXVF-1QTRM?S%_\&\__!+O
MQ!X5^/OBO5_C5X>F6+P]J.HWVDR:A:$'_1YGDA$1E08)V@+@CG&#0=,*B4-M
MM/Z^_P#K<_KI_P"":W[)FA?LE?LX^$?"&DVL5M<:KHVEZE?HD81UFFMA*4?
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M!!Z$&@ I,CU%+42O"6*HZ%USE0X+#URH)(_$4 2TW=\VW'^<9IU,8H@,CLJ
M=69@JCMR20!0 ^BD5E8!E(93R&4@@_0C@TM !2$D=!FFK(C,RJZ,R\,JL"R_
M[P!R/QI] #>&';I]<9I0,#%  '04M !1110 4444 %%%% !1110 4444 %%%
M% !1110 444<]O7GZ?XT %-SDX*].G'_ -:G5Y'\4/C9X ^$NAW6M^*-<L(5
MMD+FU6[@^T,%!S\NYB",8P1N]JTITJE:<:=*$JDY-*,81<FV_))FE.G4JS5.
MG"52<FE&,4VVV]+)'KG/IQ_GMC^M&:_#;7?^"S'PLL?B$NEVJ*V@170M';S
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M)IM76JO9M7LU_6YT .1TQ[4BKMSSG/M3J:=V1CIWZ?C[U@<([-%- PQ/8_\
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M(!@8KQ;XJ_';P-\)]+EU#7-3M9)$4M]GBN(RXP.-VUCU]./SXKXB\,_\%)O
M.J>+6TZ['EZ9+/Y$;;@-N6VAE))&?\G(SEV;V3^X^/SGCWA/(,;A\NS3.L'A
ML9B)QA&BZB<H<VBE5Y;\D;Z:ZI[I'ZCX]OTHKBO!WQ \+^.-,M]3T+5+2XCN
M$5Q"+B(RKN (^7(+=>P_^OVF><8/]*1]50Q%#%4H5\-5IUZ-2*G3J4Y*<)1D
MKIIKNF+1110;!1110 4444 %%%,>1(E+R.D:#J[L$4?5F( _$T KO1*[>B2Z
MCZ*^;OC+^TW\/?@_92RZGJ5K=W2*?W,-Q&X5@#P=K$D@X[XY[BOE3X;_ /!1
M[P!XH\1OI6I$0V]Q,8K>0N%V'>0O+' &..>QZ<5Y>(SG+,+7CAZ^+I0JS=N5
MR6C_ +SZ;GZ#D_A9Q[GV3U\^ROAO,<3EE"/.\1&DXJI%:R=*,K2GRK5V6VUS
M]/*:R[L<XQ[5SWAWQ9H/BFPM]0T;4K2[BN8UD5(YXVD7<,A60-NS[@8/Z5T=
M>E&<9Q4H24HR5U*+NFGLTT?!UZ%?#59T,12J4*U.3A4I582A.$HNS4HR2::8
MT,>ZD#U/_P"J@DC&!G/I_DTK#((H'  ]!5&0M%%% !1110 4444 %%%% !11
M10 4T?>;\/Y4ZFC[S?A_*@#^,>_T+7?^"AW_  5-M/!7CJ]FO/A7H"?:5TBY
M:22R*Q2>9(/))*'(0\!>3ZU_39J'AG]D7]F;P_H_AO6M \(^%[*WL8;:W$VG
MH9)XU&W?(1M4ER">!TP#D]?YJOV)O'6F_!O_ (*OWO@'QU-#H,ES;R16U[J3
M"!96D9T4*[[<\D#C)P>G:OZ,_P!K?]D6S_:?.D70U$QP6MHJQR6]VD<<@PQ1
MT<2!74@@AE)!!XH+>T=TFNG>RUM]WW?,D\ K^Q!XX\4)J'P^TSP*WBYY@4OM
M+M5M]0:8GY26+L#EN3\H/J:P/VYOVU]!_9"\ ;-*6VU/QY<P)%H&A2;&:X9D
MQ$%B;)?<2,#;["OYI_AQX9^(7[,?_!2"R^&*ZWJ(TF/Q#%$UK<7,NW8+A5QL
M9L>M7O\ @X(USX@7W[5O[.FB>#KRXM[K5)-&RPD86[.Q@ \Q/NMDXR3Z_D D
MFU9MVU=UVMH?6=K^VO\ \%#_ !-X8D^,T/PTO8-.M_M&H_9%BE5!IUJIN&?9
MT"+",CC&*_5;_@FM_P % A^VCX9UVVUZRATCQGX586^IZ>JK'(9(6\N<L@P2
M5.221V)/K7YG>'_A/_P4?OOA GACP[)'<:'K'AC[#;R0V@*&&_LE@DP5C(R(
MWZ]:]#_X(^_\$[?V@_V3?B'XU\=?%*]N=GBI[Z6XMI2ZQF2[+$!4*J/E9B>F
M1@T!96>U[]]MK]7MK^9X3\;O^"WOQC^'W[<GC']ECP7X,D\0?V?>7-G9,MJU
MQM=&:-&4;&QD@$%>:X+QU_P5/_;B_9^\<V7C'XG?#74M/^&NH7L(N;^YLYUM
MXX9W4L"SKL ",#@\?6O(/V8_"?ASQG_P7D^)QUZQ@O%L=5O&B2>))%\V.1B/
MO@CEAU]*_:/_ (+PZ-I+?\$^OB#+_9]DD]E=67V*9+:));8>7,"L#*H,:G:F
M0I ^44 U\,;:NWWNR[_\#L?>?P<_:I\+?$_]F>#]HGSH(-%.AW>J3X95C22V
MM4F$78?,[A<=\'%?AUJO_!2_]JG]I?QOXBT/]G_P,^H>#O#6H2VD^J6<9V,T
M3M&I+Q@ EBHR22>?2N(^ 7B/Q)I7_!$ZQATB6Y9KO3)X+B=';='$\.')<8P!
M@9S["OBC_@E3X$_;'D\,_$"X^!=\E[I-WJ,UQ>D1BXDCD$S.%9MK$'<<?4\T
M!RZ.[ZV]-=_\O+7T_5/]F#_@J3\9O#WQA_X4Q^TWX6'ABUDNA8Z5J5XGEO-(
MSD*J22 -R3]T,0<BOB#_ (.#/CC^T(?">EVGA7P_>'X?:G<6T]OJT4<WDM$P
M1H\2)A2"A4]>AS[BU\3/^":7[>O[0/QO^'OCSQK=W6G6?A_7;6_U![>)[;SH
MH9XY) [*J[@0.]??'_!;FTC\,?L/>"O"NH6]K)J.BPZ3975U-$C3&6"SM+9B
M'(SS)"['DY9B>IH#3W=M=&M=-E?Y_P!=S\S?V%OVR_V__"?[,'A#P_X,^%VJ
M:UH,40&G:BEG<R"551/,"N%.<_+GGD]:]G_91_X*B_$;QA^W-X;^ 'QL^$<>
MA^*]4O+:%=7NK$Q7,1ED"%@\B!QM.3U]_2OVX_X).P6\O[#'P<=K&UCSI]QM
M*V\8\U<0$2L=OS,<E-W<(!VK\#/C.8)O^"Z/@R2*SM;0I=PLJ6L*0J&$S%>$
M4<YZ?6@-VURV>W7NE^&[[_??]P_^"EW_  42M/V)O#FCV>BVD6L^./$R>7I6
ME[!--YL[>7;@1X8[GX8''<8K\AM,_P""@O\ P4EMX+'XDCX0:Q<Z?JEW:RQ6
MAL+ED?3[XJZ.4*$,K0G)XQCVS7(_\%/)8?&7[>OPTTOQY,8M.T_5](_LR"Z;
M]Q*(Y(-@"/\ *V[Z<Y]Z_K"\&Z-HC^ O"-H^EZ:^GIX7T$)!)9VS6XC72[;8
MP1XR@RIW!L9!8G.230'NI+12OO\ *SM^-G8^&O$/[4'QNM/V9-!^)VD^ GN?
MB)JNG12S^'A9DM#<O"K%?(V94ASC[H[8K\A_&7[87_!2"+2K_P"(\OPOU"T3
M2YWN&L1;S(OV.$[RWE\<",'H,?K7[3?MG?ME?"S]C/P9:ZGXGL].FN-3@D_L
M33RD)B>?<8HT2+&#\P!"KP<C@C(K\BM5^._[87[4?P\\7^-/ .A1Z'X(FTB_
MGBWZ>L4+V1MW*LI\O;_JSG/OW% E9[K=[ZV7_#778^^/^":/_!1"?]L_2M9\
M-^)["+2?'/A>":'6[(*%E26'<DAD P20>I//K7XK:''Y/_!>;3HO^>>N*G_?
M-R!3_P#@W;37(/VFOVBX/$\[2ZZL^L"[ /[H.)I2VU1P.<]A3]-W?\/\+7GC
M_A(?_;L9[?6@+6YEY;_-?\,=7_P7_ACN/VPOV.(I3A&U?2,GZ:H#7W]^T]_P
M46\=_LF>*/@OX=O=$D7P)J_A[0+1]4:(K V^W@A4M)C8<* !D]%'0#!_/3_@
MX.=T_:Y_8[9#@C6-'Y_[B@K]"O\ @L)^SY=?&']A_P"'NH^&=/+^*/#>D^&+
MZ*ZMHLW"VRZ+87#Y=5W!1)O8Y/\ %04G;E<E=;6?:T=?SL?J_-\>-+3]FV3X
M]K)$=,3P?_PDVX,OE^6)A">>G7M7YL?L-_\ !0OQW^UM\8M8TJPT>0^!M+U&
MXLSJ21OY.(9?+^^!M_7\QBOS#LOV\=,D_8$C_92DUJ'_ (6-)X:_X1=K7SU^
MW;"V\IMW;]WGCICKVK]1_P#@B3^SQ<?!3]FFXN?$&GE/$6OZP;\W5Q%B=K6<
M2R@AV4,0Q*G.>WTH%I:6BO?3TNK-?HS]I7=8T9W(544LS'@!5&22?8"OP2_;
M1_X*@^/_  I\8Y/V=_V>/#\?BKQH\QM)A;J)9U+-Y9Y3++SGH1U]!7[7?%34
M+[2_A]XJOM-5VO8-)NF@" EB_ED#;CG/TK^$OP)I/Q\\6_\ !23Q!K_PNU(G
MQQ'K-P$L[DF:0?OV*@1-N/TXH""N[O9?=?M_7S/U:G_X*'?MM?LW^)_#-]\5
MOA].G@O798'UJ]NHF:*RBED =CY@95V<\GICBOV@\??MC:4?V7X_C]X&ECU"
MV32UO[I82'6&40B22+*YZ,#Q^&.]?AY^U9^QU_P4C_:.\%:CX#UPRQ1W*I&E
MS#:E7C3=N)5Q'D8+'H<]^E?5^A_LY>-?V4?^"9>H_"7XEWDNH>(I-.G%Q+<.
M975C VY,OD@@,.,#&>G2@';3;3MUV_2_7]3XS\/_ /!93]J_]H#5]>\)?!'X
M;WFNV^FR30WNHVUE)(T"I(8^9$3(Y [^]>I_L5_\%;?CO-^TDO[.O[1OA"?P
M[')?+:PWU] \3;Y'"X5Y0"/F]#GM7JG_  06\$^&M"T7XKW=C86K7=U*S23R
M6\;RKNU&'<$=E)4,#AL$9&1T.#\T?\%%M*TRS_;E\,ZUI]G;V%^WB>W#R6<2
M0,X%VN=S1JI)))SGKGZ4#]UOEM;HGY_UM]W5G[6_M[?MTZ;^RK\/(M2\.Q0Z
MSXPUJ '0=.*K(;EIE_<E(SDDDD8P#UX]:_#GQC_P46_X* Z5\.;GXW+\--42
MS(ENA;?9;@1K:@&16 VXP4QC^? KN_\ @KU<6FB>'O@/XVN+OSM0TZPTJX33
MV?<USY4<+X\HGYRP&,8)(KAM:_X*TZ7\4OV==+_9R\._""['B[5=-M_#IOUT
MIS;ABAA\]$$902.7PT@&2JH,CG($8Z)V3OW[77];K?J?:G_!,;_@HS\;/VP_
M#GB+4O&?A.XM(]"@N3J,<L3X!B5MRD,/[RXQ^'M71?L>_MS:-\7/VX_'?P4L
MO!%KI%SH+W:R:O';HDLS0LX?+A0V3CGD\&O4_P#@EQ^R[XM_9M^!?C37_&=H
MEK<^.-*O-5AMI(DBFACN(FD13&0&5#NQR,'H.]?E=_P345/^'J_Q@=% )O-4
M)..?F>3(_6CHOZ?S"*3YM.BMY-Z]#ZE_X**?\%A?B#^R;^T3:?!3P+X;;Q%K
M.H7RV5I9" W'FM(_EI^["L">>.#^-?+'Q8_X*@_\% /A5=^&_B5KOPIU2U\+
MZM+:RZ@K6-RL-O93B.0L1MV*!$XXP !QC%<7^VQX7T;7_P#@LG\-VU:WBN47
MQ+9'RID$D3$749^96!!S^/O7]"__  4>T#09OV7O%UG-I.G&*VTB\2S!M(<V
MJ6]JJQ) =G[M5&T #@;5QTH)=M-/7>_3\'_21VO['?[77AS]ICX,V7Q)DFM[
M*>VL(9M<C!55M)1%NG#@8"["#G..<YK\D/CI_P %0/CQ\1/C?K_P-_9Q\'_V
M[;:-<7$5SJ=G'N8QP.X8M(@!("ID9;&?QKP__@F3K.KZ-^Q+^T1<:7)<2W5L
M-7CMD1VW1+MG'[L#[N !C&*_.']@+PQ^U+X@^//C37_@WJ N-<N]1U-+R"51
M/.B2RRH^5PS+A6/7% [*\ERZ;)O9/_@]/^"?JYX%_P""FW[4/P*^,_AKX9?'
MGP.^G^%-=GM%FUB\B)6W%V5Y$D@.P[6!R&'XXK]KOVA?VQ/A_P#!3X)-\5SJ
M5K<G4],2Y\/6[NA2\NIX!+%$,G#G<0F #GFOYVOVBO\ @G__ ,%"_P!I;Q)I
M=SXOEGM4T_4+)OM,-NT3B&WD5<;U0$?(HKBO^"Y/ACX@_ C]CS]F[X7)J-U)
MXI2]TJQGNTG8AY8)!;N96#89=\9R#Q_*@=E)Q2MMK;Y?BW\]3Z'T?]NG]O\
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M5-HUM?0!G38;JXLQ.8<$X.R4[,?@:_GU\"_\%0_VZ?CMXVU#QK\-_A=J-_\
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M-BOHKQ7\)_%/[-W_  2!\7^$-7@^Q^(+'P--/J!@007""X@8?O-@#JP*J1N
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M/&#_ /JK\)K#3-<\<:A$8T;S482AE''RG/;CL,C_  S7W'^S#XXUB?XO^ O
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MQU_PU<VWPQU34[V:QU9H'6*1))&*D2GY3D=:_57_ (+(_!_X@_'#]B'Q_P"
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MKBL7B<56CRU<16J5ZD;-)2JR<Y))ZVN]#Z:*48QBMHQ27HE9!1117,4%%%%
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MBDKNZ::T]4)[.^ST?S/X4_V]?V./C=\(OB]XB^)5EX<N[OPY<ZC/>&YCMY)
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MERG/4GK_ /J_;/[,X>BZ67X[#4''#X6%>E7@K3A1BD_:S:TLW%I7W:U/U_\
ML_(8\F!Q>'HR5##PK4ZR^.G25FJDVNDI*VNO1=$?&'Q&^)=EXF^,,7C.))WB
M.KB_:0(QC!$WF??QC''/Y"OUSN?^"O7B/P/\.O#?@KP7I_VZ]M=.ATY94C\R
M2%=O\+*,H 2V,$#D\=:^O?#7_!('PA;?!\:%J'D2>,)]-5Q>L5\Q+AX-VPL3
MN#!SM(/S \  U^3>C?L?1?!GX\0?#GQRK/)K&HFVTR:XR5!DE*QE2_'<=">G
M>A9EPMG\?8U(/$K*8RE1H3O:K"*LZD5HVDEKV2V)^O\ #>>1]G.G]8_LV,I4
M:$KOVE.,5>I&WV4E?OT/7O /[:OQFLO'FE?$7QC>7D&D:C?P@VSR2! LLBC!
M5FP!EO3Z>W]2?PI\90^/_A_X9\6P.LB:QIL-R2IW?,RC()]1D9K^13]JSX3^
M*/AM\2M%^'LFZ31#'%J4$B!@JQA?-'/88P<;NO-?MU_P2^^/T?CWPM>_#VXN
MU,GA&W^SV\3O\W[LJC 9]AFOE>+LLPN(RK"YK@*-*$:<5SJA&T5AI-1IWZ\R
M=[W^>I\[Q1E^'KY9ALSP=*G",$G)4E9+#SM&G=)?$I?%>VV^I^NE%%%?F!^<
MA35).<C'X&G44 (Q(' SSZ&N9\7ZVOA_P]J&JN0/L\#,,\<[2>_TKIZ^3OVA
M_&OV$VOAV&3='?*JSA2<#>"N&Y]__K5T86E[:M"'2_-+SC%IR7W?Y'=EV%EC
M,91HI7CS*53_ *]Q:<OO6GS/ ;WXL^+SJ,_B"P>62VCF?]V&8KA<],''8'GC
M\.G12_M+7>O>&[_2=5A\F>: P$E=K-QU/K^9]?2N1^'WA>]UW5K[2@=FG11O
M<,6^Z<#=C/\ ,<YSTZ5CV'PK/C;QC<Z9I0*PV5QLG=,A3M;!SCN<>O7K7TJI
M8%RE&K"$?8QC5A-*SC#3EYO[S:6F_D?H<\/D_-.->E1BL'2IUHUXKWH1T<%/
MIS2>B/(=$U9+#Q&NI$.%6Z:8,00.7W<DC';KG%?4.I?M/:R+2TT;2+<NPBCA
M,JC+84 #YP.P]>X&/2O3_$'[,FG3>&#;6!C34H;<L91@,S(N3@]SQ^/2O /
M7PW@CUBZ\/WP U&-V6%W&22"<8)]QD8]>!14KX#&1=7EE.6'O[DMK:6ETT[_
M )$2QN2YK!XBK2]O/"*RIST?+I^]=OLW5VE^1V/@/XH^(-/\20W>N32B"]E
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M*V?M9:[\.] TGP=\,]1?_A)))MEXMK*1*AD;!#*AW#;C'..WK7[1>.O&&F^
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M6X9VRBL<?+G/(7TK[(_X* ?%IM.NM(\'V,WG6=X!#?B-LJI?A@V#V)[U\<?
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M[$:C_P $ZOV3-2.AF?X96*MX?N8;G3FCD56CDA*E"Q\HY(*@Y&._'/'XU_\
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M1M9K^2S:6)+E3<B5PQC*[L[MI'/0#I7Z2_L)?M#_ +%GQJO?"]U+X3TKX?\
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M/-9UG2]*\+ZM8#4$MI)H8[Q$NU=]P3"ONRV0/UK^JG3OV$/V9M&U^V\3Z/\
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MJ.="-XX>FUM[:_*^CTOT.''8=UX024FU*UD]+-J\GITMZ]CXX\=Z-:?LL_\
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M$?VK*!.C$ =-OY<YK^M']A30/B-X4^ 'A/PY\2XY4U_3;.)7,V=[*\:==W/
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MJ^:?BW^R%^SS\<K_ /M/XG?#?1/$U_SFZNH@)23G)+ <GF@$UL]M?QZGYJ>
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M8+RW,< N+2W2%]NY PRRG/S'G)X'%?K@RAU9#T92I^C C_&OE_X2?L9?LW_
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MF;2CJ)E,BQNK-",2<C@KQC^0K]UJP/#/AC0O!VC6?A[PWIUOI6CV"".TLK9
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M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%( 02<DY[>E
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M\0Y/[1G_ $,VL?\ ?VY_^+H#DC_.OZ^7K_2U_K/_ .'U'[&'_0X0?^#&T_\
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M8?\ 0X0?^#&T_P#B*/\ A]1^QA_T.$'_ (,;3_XBOY,/^(<G]HS_ *&;6/\
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M#A!_X,;3_P"(K^3#_B')_:,_Z&;6/^_MS_\ %T?\0Y/[1G_0S:Q_W]N?_BZ
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M1_Q#D_M&?]#-K'_?VY_^+H#DC_.OZ^7K_2U_K/\ ^'U'[&'_ $.$'_@QM/\
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MC/\ H9M8_P"_MS_\71_Q#D_M&?\ 0S:Q_P!_;G_XN@.2/\Z_KY>O]+7^L_\
MX?4?L8?]#A!_X,;3_P"(H_X?4?L8?]#A!_X,;3_XBOY,/^(<G]HS_H9M8_[^
MW/\ \71_Q#D_M&?]#-K'_?VY_P#BZ Y(_P Z_KY>O]+7^L__ (?4?L8?]#A!
M_P"#&T_^(H_X?4?L8?\ 0X0?^#&T_P#B*_DP_P"(<G]HS_H9M8_[^W/_ ,71
M_P 0Y/[1G_0S:Q_W]N?_ (N@.2/\Z_KY>O\ 2U_K/_X?4?L8?]#A!_X,;3_X
MBC_A]1^QA_T.$'_@QM/_ (BOY,/^(<G]HS_H9M8_[^W/_P 71_Q#D_M&?]#-
MK'_?VY_^+H#DC_.OZ^7K_2U_K/\ ^'U'[&'_ $.$'_@QM/\ XBC_ (?4?L8?
M]#A!_P"#&T_^(K^3#_B')_:,_P"AFUC_ +^W/_Q='_$.3^T9_P!#-K'_ ']N
M?_BZ Y(_SK^OEZ_TM?ZS_P#A]1^QA_T.$'_@QM/_ (BC_A]1^QA_T.$'_@QM
M/_B*_DP_XAR?VC/^AFUC_O[<_P#Q='_$.3^T9_T,VL?]_;G_ .+H#DC_ #K^
MOEZ_TM?ZS_\ A]1^QA_T.$'_ (,;3_XBC_A]1^QA_P!#A!_X,;3_ .(K^3#_
M (AR?VC/^AFUC_O[<_\ Q='_ !#D_M&?]#-K'_?VY_\ BZ Y(_SK^OEZ_P!+
M7^L__A]1^QA_T.$'_@QM/_B*/^'U'[&'_0X0?^#&T_\ B*_DP_XAR?VC/^AF
MUC_O[<__ !='_$.3^T9_T,VL?]_;G_XN@.2/\Z_KY>O]+7^L_P#X?4?L8?\
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M_BZ Y(_SK^OEZ_TM?ZS_ /A]1^QA_P!#A!_X,;3_ .(H_P"'U'[&'_0X0?\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M 'R/\*-B_P!U?^^1_A3J* &[%_NK_P!\C_"C8O\ =7_OD?X4ZB@!NQ?[J_\
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MJ_\ ?(_PIU% #=B_W5_[Y'^%&Q?[J_\ ?(_PIU% #=B_W5_[Y'^%&Q?[J_\
M?(_PIU% #=B_W5_[Y'^%&Q?[J_\ ?(_PIU% #=B_W5_[Y'^%&Q?[J_\ ?(_P
MIU% #=B_W5_[Y'^%&Q?[J_\ ?(_PIU% #=B_W5_[Y'^%&Q?[J_\ ?(_PIU%
M#=B_W5_[Y'^%&Q?[J_\ ?(_PIU% #=B_W5_[Y'^%&Q?[J_\ ?(_PIU% #=B_
MW5_[Y'^%&Q?[J_\ ?(_PIU% #=B_W5_[Y'^%&Q?[J_\ ?(_PIU% #=B_W5_[
MY'^%&Q?[J_\ ?(_PIU% #=B_W5_[Y'^%&Q?[J_\ ?(_PIU% #=B_W5_[Y'^%
M&Q?[J_\ ?(_PIU% #=B_W5_[Y'^%&Q?[J_\ ?(_PIU% #=B_W5_[Y'^%&Q?[
MJ_\ ?(_PIU% #=B_W5_[Y'^%&Q?[J_\ ?(_PIU% #=B_W5_[Y'^%&Q?[J_\
M?(_PIU% #=B_W5_[Y'^%&Q?[J_\ ?(_PIU% #=B_W5_[Y'^%&Q?[J_\ ?(_P
MIU% #=B_W5_[Y'^%&Q?[J_\ ?(_PIU% #=B_W5_[Y'^%&Q?[J_\ ?(_PIU%
M#=J_W5_[Y%.I"2!P.:0EL# Z]>#0 ZBBB@ HHHH **** "BBB@ IH^\WX?RI
MU-'WF_#^5 "CH/H/Y4M(.@^@_E2T %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %?RE_\ !RC^P/)\<?@A_P +*\ Z"/[>\/V4
MMWJL]I;YD<0LYRS1J7)**&.3U)]J_JR.21_=[].HY^OI7'?$#P)X?^)/A+6O
M!GB>RAOM'URSELKN&:)91Y<JE20K<9 )_.@:;33[.Y_"I_P;/_\ !/%]4\73
M?'OQ=I1CD\*W:VS?:8"-T\#%0,2)URC8Y!]Z_O;$:HB)&!&B*%55&%"J %
MQ@ # %?/7[.W[-'PY_9G\.:GX9^'>GQV-AJM^VH7(2%(LRDN<80D8RY/U%?0
MX8$D=Q0.4N9MZ@>1C./>E%%%!(4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !31]YOP_E3J:/O-^'\J %'0?0?RI:0=!]!_*EH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M\/Y4ZFC[S?A_*@!1T'T'\J6D'0?0?RI: "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M8I6\/I+K4TR@S@M;)(OG]!E\YZ=*^2_^"LG[.OQE\5>/+W]IW1-0U;Q_X/\
M&\G]H:?I&ERRWR6BW1\Y1Y<9D"[0P'W105&"4E=VCT?\U]K6_KRZ'SO^PK_P
M4M^*_P"P[\=Y_'VB:Q?GP+K?B1;E_#L+S/;06<MR'9?)#; JJW0C''M7^G)_
MP3__ ."A'PD_;F^%NB>*_"&NV)\3264+ZOHHDB2>*<Q!I-L(?<"&# KM'3@<
MXK^!K_@D'_P14^(G[8VKMX]^)>AWVD>!%MLBTU&W:/:[*>TH #9(_$=J^\?B
MQ^R!^U?_ ,$>?VCO"_BSX$'Q#J_PN\0ZE:R76GZ?)/+;16TER%D7RXRR#"AA
MC@@@B@N:@W:-K]7Z67];:G^@!17S-^R5\9=0^./P8\+^,]6TZYTW5KC3K(:C
M!=(R2_:)(-SE@P!SN#9_#BOID9[T'.%%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !31]YOP_E3J:/O-^'\J %'0?0?RI:0=!]!_*EH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH 0KD@\\4M(3@9I P/ S0 ZN!^)7
MQ)\*_"KPIJGB_P 7:C!I^F:9;37#M+(B-)Y2%MB!B,DX .,]>AJ#XG_%#PE\
M)?"NH^+?%^J6NFZ?80/*/M$R1-.R*2$C#'))P>0#SQUK^<7QYXW^.W_!4#XO
M7'@OX=+JGA_X.>';^1-:U.-I8K"^T^&;;-ME^2-@Z\#DYW #)- UYZ&-\8/B
M]\8/^"E'Q='PY\"37^A_ G3M46#5O$D:RV]J;>*8)+NN!MCVL@).3@]3BOWJ
M_99^ /P:^ WP^L? 7P^30M2N[*V:+7-5MFM[F\U*9P%E:X=2Q9& Z')R6W$C
M&/PM^.G[9_[.?[+?AW4/V%_@C=Z1H'Q-U'3!9ZAXI8PQ3KJD=J8KEOM)PP<W
M.6!WD]Z_$_\ 8X_X*X_%?]B?]K*]^'7Q\\;MXP\+ZYJ[P17TE\;FVBM[JXVC
MYRS* J/ZCIUZ4%M.2NEHME]VO]>A^ZW_  6<_P""+G@O]J;PKJ_Q=^%.B6FE
M?$K25?4$M]/@$<EQ<Q1&3SD$2@MND5B0"2N1DGC/\M'[%'[7'BO]D3XV6?[.
MO[8_AZ;Q!X/M=4.F,/$5LS6MG;I<^0I1KM=@"H 1CM^O^C]\+/VA/A=\7/AO
MI?Q)T'Q1HS^'M3TZ.[GEEO(?)MUEA\R2.0LQ#*%)!&"2,@@]_P",3_@MS\&/
MA3^W!XSU'2OV8?" E^('A^XG_MC7O#UKL$\T,SLSB:V4'DXYS^5 X-OW7:ST
MU6VJ]-C^PW]DK5?@)K_PHT77?V?H=%@\)ZG9V=S+'I!A_=3S0+*8YA"S ;69
MPO S@Y&>![AXM^'W@GQY%;P>,?#.D^(HK4[K>/5+87"PG.[* D8^;GZU_G5_
M\$MO^"@G[4/_  3L^-&B_L^_%W1_$6J>$;F_L].^PWINI6 #K#G;)D@ -GC\
M^!7^B/\ ##QW;_$OP+X>\;6EI+8V^OV,=[%:S9\R)9 "%;(!R,]Q01*/*^ZZ
M'2:%X<T+PQ8IIOA_2[/2+"/&RTLHA%"NT8&%'H"0*VJ**"0HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH *:/O-^'\J=31]YOP_E0 HZ#Z#^5+
M2#H/H/Y4M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MTHH **,]N]% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %-'WF_#^5.IH^\WX?RH 4=!]!_*EI!T'T'\J6@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH 3'(/<?Y_K2T44 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4T?>;\/Y4ZFC[S?A_*@!1T'T'\J6D'0?0?RI: "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BD)((&"??_(I: "BC
M-% !112 DDC!'O\ Y% "T4F>< 9'J.E+0 44A.!TS[4HH **,T4 %%%% !11
M10 44A)'09I10 449[=_2B@ HHHH **** "BBC- !1110 4444 %%%% !111
M0 44@))(P1[_ .103CW/IWH 6BD!R/?N/2C/. ,CU'2@!:*** "BBB@ HHHS
MCK0 4444 %%%% !1110 4444 %%%(21T&: %HH%% !11FC- !1110 4444 %
M%&:,T %%%&<=>* "BB@T %%("3U&*6@ HHHH **3)SC!QZ_A]*6@ HHHH **
M*,T %%%% !132Q!^Z3[_ .13J "BBB@ HHHH **** "BBD!)ZC% "T444 %%
M%% !1110 4444 %%%% !1110 4444 %%%&>W?TH **0$GJ"/\_2EH **** "
MBBC/;O0 4444 %%%% !1110 4449H **,T9H ***0DCH"?\ /TH 6BBC- !1
M110 444&@ HI 2>HQ2F@ HI 2>HQ2T %-'WF_#^5.IH^\WX?RH 4=!]!_*EI
M!T'T'\J6@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M^SL5/(:[N8+<$#T,SJ"/I7PA9?%#3OV/_P!B[1/%OQ"U=;K4_"_@^.ZFDO)
MTU[?8&$;S#N;*@'N3D#Z?SVZ9^V+^V=_P40\:ZK=_#30M7T/X:6FIS6%IJ]E
M!<0P-&)'6,JT8";2BY&,#% *+=_SZ/\ X?\ K<_L LM4TS41NT_4;&^ Y)M+
MJ"YQ[GR7?%7Z_E@^'7C']O\ _9J^+_A?PP/#VM^+O"&I75O'J>H30W5PD,4D
M@$C,[9  4GD\5_3QX0U>]UCPSI6K:K"+.\N;**>\B8",0R&-6DW9P%"G.2>
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M2=Q)R*_I#^#-]*WPM\*WVJW0,C:3:RSW,[A0<V\1+.[GN<]3GMUH'9VOT?\
M7]>AZS1^!_S^->,_%+XQ^'OA]X$USQBMY;W,>D0N^ Z%69%9CWYQM_6O@3]D
M7_@IAX7_ &D/B5KO@.=;+3CILUQ!!,#''YCPE@HSQNW,%% C]8, G..12U"M
MQ \/VA98S!M+^;N C"CJQ8G  [DG%>>-\7?AXFLC07\3:<NIM)Y0@,T?+YQC
M=NQUXH ]))QR> .23VK.@UC2;FX:SMM3T^XNTR'M8;RWEN$QUW0I(TBX[Y48
MJ:Z)EL;DPL&,EK,8G0[@2T+;&4J<$$D$$'GL:_%W]E3P9\;M/_;2\?:OXJUN
M[NO!4D^IO8V,MS(\4:8E,86-F(&/E[>W'2@.Y^Q-YXO\*Z;J46C7VOZ59ZK,
M1Y6GW%Y%%=R%NFR%V#MG(Q@5-K7BCP]X<CBFUW6+#2HIL"*2]G6%),G VLW!
MS7\I/_!0CXD_$_1O^"M?PG\-Z#XNU'3O"\L^D->Z3#<3)!*A$'F;HU8(0>2<
MCH:^C?\ @LQ\7O&NM+\"_A_\%]>U"/6]1OM.M]<.GF4,B23#=YAB.>%/)/7L
M*"G&W+K\6OHKVN?T*W/Q"\#VEHM_<^*=%ALWP%N9+V(1-G&,-G!ZBNCT[4K'
M5[2+4-,NX+ZQG7,-S;N)(I #]Y''##_.*_CQ_:*NOC#'/\*OV=O#_C36?^$W
M\06ND3W7E2W._P R183(KLK9ZDY'^-?U&?LF^#/$WP_^ G@/PIXQNYKOQ#IN
MFB+4+BX9FE>4JF=Y;YL@@]3WZT":M;6]U?8^D2,\&BD4;1CKS7->)_&/ASP=
M9B^\1ZI:Z9;L<*T\B(6]2JLP)';/3/% CIJ:\B1(TDCK'&@+.[L$15'4LS$*
MH'<D@5SOAOQ?X<\76GVWP]JMKJ4'<P2HS*/4H&) /KT]:^7OV\OC#%\%/V7/
MBWXSBOELM6T_PK?/I9\P1R_:=N49.0V1L/3O0"UT[GO=]\8_A;INJKHE]X]\
M,6^JLVP63ZK;&;?_ '2%<C<>F,_7%>A6MU;7L$=U:3QW-O,H>*:%@\<BGHR,
M."#ZBOXK/^"8'[*7Q _X*$6'B']H7Q7\=]6TB_TOQC(8=%.IW(W6R7$I">0K
MLVS:B@G 49'3(K^R/X;^$Y/ W@KP_P"%)+]]3?1;"*S:^D9F>X,8_P!8S-R2
MW7GGF@J2Y=+Z]5;8[&:X@MQON+B&!"<*9I(XE/\ P)RN3GL#4J.DBAXV5T;E
M71@RD>H920?P-?B)_P %MOVK/&/[*_P9\(>)?!\T\-WJ6MP6TK0%E.QK@)SM
M(.,<5^AW[%WQ(O?B1^RS\)OB+XAGVW>O^%K74;Z>=L89S@L[-[\<_K0*SY>;
M2U[>=_Z=SZNP,YQS_D4M8-_XGT#3-+?6KS5;.+3$&3=^?&8_3 8-@L.XSD?E
M2>'_ !1H/BFU-[H.IVNI6ZG:SV\J2%3_ +05B1['I0(WZ:&!R>>*Y"Y^('@^
MTUL>'KG7M/AU<G;]D>XC5PW]PY;A@>"#T/6NM,D2Q^9N3RR V\$%2IZ$$<$$
M'@C(Q0 \'(S2UF'5](42N=0LE$"L\I-Q$I10#DD%@> /3K[FL?0?&_A;Q-<7
M-IHFLV=_<VC%9X(9HVD4J<-A0Q+ 'J0/?H,T =733C[Q'3'\ZY?Q!XV\+^%I
M((M>UFRTZ2Y8+%'/,BNQ8X&5+ @$],CGKTKH[:ZM[VWBNK6:*YMYT62*:)UD
MCD1@""K*2#Q^(/!YH F!R,TM98UK2?M1L1?VWVH'!@\U/,!_W<YJY<W=M9P-
M<W4T<$"8+2R,%0 ],L>/>@"Q15"TU33[Z![FSNX;BW3EI8G#H!C/W@<4Q=9T
MIK>6[&H6AMX QFE\^/;%LSNW_-\IXX!Z]LT :6:0YQQUKD-"\>>$?$E[<6&B
MZW8WU[;DB6"*>-I 1P0JAB21SG SCFNPH 09QSUH&>_-<?XH\?\ A'P:J-XB
MUNRTXR'"I--&'^K(6!7\<5KZ#XBT;Q-81ZEH=_;ZA9R=)8)%< ]0&"D[21TS
MP>V<&@#5EGA@7?/+%"O]Z618U_[Z<@?K6;_;VA&38-9THR9QL&H6I;)[;1-G
M/MBOR(_X+ ?M/^+_ -G#X6Z#>>#GFCU'7#)"K0E@V3,\8Y4@\8_6OQZ^%GB#
M]N+XA^ &^*?AM]=U%_*6]@M4^U.'^4S(FT$YW 'C^>#04HW5[V5[?E_F?V(J
M58!T(97 8,IW*P/((()!!SP1Q7-S^,O"=IJ\?A^X\0Z3;ZU*0L>E2WD*7SD\
M +;LPD)/TK\!/^"77_!5+QM\=?BGKO[.GQPT=O#WBOPO]JL[>:ZB,<\\UHLB
MI'N?#L'D0+@DXW9'I7Q-^U+\1_BM9_\ !=7X:>$]'\97]IX'NKG39)]$%U)'
M92HSJ9,Q[Q%]<CF@.76S=M+W[_TC^OJBN+G^(?@VVUH>'I]?T^/5FVXMFN(@
M<OC SOQGFNS!! ((((!!'((/(((X((Z&@D6BN3\4^./"_@RW2Y\1ZO:Z;'(?
ME\Z1 YQWV%@V.>#CGMTJYX=\4Z!XLL5U'0-2MM2M6_C@E1RO3[RJQ90<\$\&
M@#H*0@'K2,ZHK.[*B*"S,Q"JJCDEF.  !R23@5YU-\6_A[!J3:3+XFTY+Y'*
M-$9XQA@<$;MW4&@#T>BL'2_$^@ZTY32]3M;UAU$$JR8_[Y)J37O$.C^&;"34
M]<OX-/LHOO33R*@)[A0Q!8CJ<=!UZB@#:I"<<FN4\+>./"_C2WDN?#>KVNIQ
MQ'$GDR(77J,E Q;&1@G& < ]:ZSKU% #0V[./UH!YVGK^GK_ "IV,=!C\*Y3
MQ-XU\+^#XDG\1:M:::LGW!-(BR'H,[2P;'/!Z4 =716+H7B'1O$MBFI:'J%O
MJ%G)TEMY%<#/0,%)*D]L]><=#AR^(-':_DTS^T+9;Z,D-;O*BN2.H )&3_/M
M0!L45!<7,%K!)<W,T<$$2[Y)9&"(J^I8D#GMZ]JS;?Q!HUU#]H@U"WD@SCSE
MD4QYY_CSCMZT ;-%8.J^)M T:Q?4]2U6QM[2( M,UQ"1CJ,#?S_2CP_XGT'Q
M1:"]T'4[74;?)!:WE1RI']Y58D?7I0!O$9X--(.,+Q_G\:JSZA96L@BN;J&!
MVQ@2R*F<],;B*YW4?'?A+2IX[6]UW3XKB5@J1"XB9V8G   ;J: .NHJN+NV-
MJ+SSHUM3$)O/9@L8B(W;RQ. ,=\UPUA\4O >IZNVAV?B/3Y=25S&8//C&7!Q
MM#%L'GCTH ]!HH!SR.0>01Z?UKC/$GQ!\(>$I88-?UNRL)IR!'%+,@?)..5W
M KSZ\T =B <8;G_/X4X#' K/TS5=/UBUCO=,NX;RVE4,DL+JZD,,C.TG!-87
MB?QUX5\')&_B+6+33O.($:S2H'.>AVE@0#V)ZT =:3@$G@#DD\  =2369%K&
MCW,[6L&J:?<7*$AK>&\MY9T(ZAHHY&D4^Q4&J-GK>F^)=%N;W0[V&]@GM9UA
MFA<, [POLR5)P<D$<]J_&W]E/P7\<M._:]^(.J>+-:O+OP?)J%XUA9RW#R1Q
M1F9\!4+84!<'@#I0-)6>MFNEMS]LZ*H_VGI_VLV!O+<7BC=]F:5%F(/=48@M
MU[ _E7+WWQ%\%Z=K$>@WFOZ?#JDK!%MFN(@VXX^4Y?KS@C'7B@1VU%,4@[2A
M#(XW!E.X$$ @A@2"",$'OGBN=\2^,/#GA"V2[\0ZI:Z;#(<(9Y%5G]U4D$C/
M&>F>!SF@#I:0MCKFN$L/B;X%U*%9K/Q)ILJ,0% N8@Q)X "[\YKM;>>&[ACN
M('66&1=R.N"K ]P>1^5 $](,\Y_"J]U>6MD@DNYXX(R=H>5@BY^IK(U?Q3X>
MT&R.H:KJUE:V@Y$KW$6&'JN'Y'N* -_YL]>/3\/IZTM8VA>(=&\2V*ZCH>H6
M^HV;,5\ZWD60!AV;:3M/IGK@XZ'&&?B)X,&M?\(^?$&G#5M_E_93<1!M^=NW
M._'7CTH [6D(!QGMTI&=54NS (JEF8G@*!DDGT YK.L=:TK4Y)8K"^MKN2 D
M3)!*LC1D'!#!2<'/% &D3CDU0U/5=-T:TDO]6OK73K*$9ENKR9(((Q_M2.0H
M_.B_U33M,19-1N[>T1VVJT\BH&/H-Q&3]*_+;_@L=XH\1>'/V%_B1KW@W6)M
M)U2.UWVFI6<K(Z PR$,DD9!P<=CSVH&M;>;L?J)H^N:/X@M!?Z)J5GJMDS%5
MNK&=+B L.H$D9*Y_&M6OPX_X(A_$?Q-=?\$\8O'GQ"UZ?6M1TJ?7-0N-0OIF
MD=H;&S:>-&DE).'<!!DXR17=_LM_\%4O#'QY^+/BSX=ZA#9:=%X>U*>QCN08
MHC)Y4ACW%LC/0'\?PH&XM7\OZ_4_8&ZOK.Q7S+Z\MK.,G"O<SQ0)GC^.5E&?
M;-/M[NUNT\RTN8+F/^_;RQS)_P!]1LP_6OSC_;QUK5_&'PZTG3OA=XDCBUQK
MYG9K.[".86\O:/D<'KNYKUO]CS2O&'AGX76C?$#4'GO/LL.^YN92PW#;DEV8
M]O?I0+M^*['V0<]N*6L:\U_1-/L'U6ZU*SBL40NURT\?EE>IP=V">#QVQSBJ
M7ASQCX;\6PRS>']6M-22%MDH@F1W0^I16)Q[C@< XR*!%[5_$&B:#&DVM:I9
M:7%(=J27LZ0(Q]%9R 35NPU*PU2!;G3KRWO;=P"LUM*LL; \@AD)'-?AO_P7
M&\8>,_"/PD\#W7@[7KK0KJ752LTUK*\3.OGJ,$HRG':OK+_@F-K_ (A\0?L^
MZ!>>(]2GU2^?3K)GN9W:1V8HN22Q)R>_)H&UHGWO^!^D=%<AXH\>>%/!JQMX
MBUFTT[S3A%EE0/VQE2P(SGC(YK8T37=)\16$6I:-?07]G*,K-!(KCZ-M)VG'
M.#U'2@1KU&\T4:&261(D'5Y&5%'U9B /SJ2OS4_X*O\ [0&O?LU?L?>-OB9X
M:9X]6L)H;>W:(E7!EBF/!4@]56@#]%#X@T$/Y9UK20^<;#J-H&S]/.S6I'+'
M,@DAD26-N5>-E=&^C*2I_ U_&M^RUXN_;3_:1^!L'QMT*[URXDO#/+8VRM=$
M2,"710 2.1Q^O6OK/]@W_@JI\5$_:,L_V0_CQHLVG^)Y[Z*RLY+R)EF.Z18M
MRF3+ L.N#VH+<=+IW\ONO_F?T\TA.!FEH/3GIWSTH( '/-(<XXZUYWJ/Q8^'
M^DZPN@WWB33X-39Q&(#/&0&) VE@^!R<5W\4T-U"DUO+'-!*H>.6)U>-U/(*
MLI*D?CQWH F&>]%4!JFG;VC^VVJNG#(\\:L,>S,.E<V/B%X..M#P_P#V_I_]
MJDX%L;F($M_=#%\9]J .SHI 00"""#R".01Z@C@USWB#Q9X>\+0I/KVJVFG)
M(ZI&)YD1W9NF$+!B/?&/UH M:GX@T/1FC35M7T_36EQY2WMU#;F3)P-@E=<\
M\<5H6MW:WL2SVEQ#<PN,K+!(LL; ]"&0D'-?SG?\%H/B9XOTK7OA//\ #KQC
M)IUK=RV1N?[/O"HE#7 SN6)QG*[1S7ZY_L,ZKJ^L? 7PS>:U>RW]\]I9F2XF
M9G=F-LI8DL2>6YZT#MHGW9]?SW5M:KON;B"W0=6GE2)?S=E%9R:_H$C'9K6D
MNR]0NHVA([<@3?TKY3_:_P!%^(>L^![B#X?/<IJ;0.J&W+A]^#@@IR.HK^6?
M]LSXJ?MF?L@>!K?Q[J][K?V34M4:SC+O= !F=<*,L.@8$#_]= XQYNMGV_IG
M]HI\0:"K;6UO20W]TZC: _EYU:4,\-P@D@EBGC/22)UD0_1D)!_.OX]_V:M2
M_;5^/?@WPW\0[.[UPZ?K$=O<Y5KK;L<ACT8C'S?Y[?U$?LR:=XNTOX6:/:>-
M6F;7(T07!GW;\^6,YW<]: <4ENK]E_7KZZ'T+2'/;BD*Y(.>F.WH<UQ6N_$;
MP9X;U"+2]9UZQL[Z9@J6\DT>\,QP%8;LJ>>01D=Z"=7LCMQGO28&<]ZAMKF"
M[@CN;6:.>"9 \4L3AT=6&05920>#]1T/-87B7Q?X=\(6@OO$.J6VG0$X4SR(
MK-ZE59@2!Z]/UH Z2L+6_$_A[PU'%+K^LZ=H\<[B.%]0NHK997)P%0R,H9B>
M !WJ/P[XIT'Q;8C4?#^I6VHVA(S)!(K[3G(W*I)7.#C/O7\YW_!Q?X]^(/@7
MX8_!"X\!>)K[PW<7GC*WBO);*>6!IX?ML0*,8V7(()&#[4#2<FEW/Z/+C7=&
MM-,76;G4[*#2619%U&2=%M"CYVN)R=A5L'!SV-+I.N:/KMN+O1M3LM3MCP)K
M*XCN(_\ OJ-C7XK?M'^+O&-E_P $>= \46&N75MXK?P#X?F?64E<7+SO_:>^
M0R A\MM7OG@51_X(:^,O&?C#]G"&^\9:]=Z]?_:9Q]INY7E?&6(&YV)XQ_*@
M+.U_.Q^YE%%4-3U33]'LYK_4[N&SM(%+R33NL:@ 9."Q&3[#F@1?I, '..37
M%>&_B)X-\6SRVV@ZY8W]Q"2K11S1^9D=0J[B6/L.>M=A/<06R&2>5(D )+N0
MJ@#KDF@"0$,/:G 8X%85_P")M TO3I=5O-4LH;"$$R7'GQ%!C@CANH[@X('6
MH?#GB[P[XLMFNO#^JVFI0H<.;>5'9.WS*K$@9XSTS]10!KW>HZ?8*'OKZTLD
M/ :ZN8;=3G_:E=!SVYJ:"X@NHEFMIHKB%QE)89%EC<>JNA96'T)K\R_^"C/A
MGXI^(?!=I%\-M3N=-O%N[<N]O*\1*"12PRK#J#^O->F>$OB/J?[//[%H\?\
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M1(D4J-(,=2$#$D#N1TKK6*J"S%55026; "@<DDG@ =SVH =31]YOP_E7"?\
M"S_ QUQ?#@\0V!U=I!$ML)XR3(3@*&W8SGBN['WF_#^5 "CH/H/Y4M(.@^@_
ME2T %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M_A=\7/$-]JGPTU^^T]<S7#R6XMKF2,C!)*D&-ASGH>..O[1_\$1O&_A/Q/\
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M[^XU _ZI@X4&6(H,G)^]7[F?L[_!71O@)\-]*^'VAW?VVRTN.*))\[MWE1A
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M?L ?"[QAX#TS6[7Q-HWBMIEUB>=_-1GN3B9Y#(%.XAF&6'RDY(S7YZ?M5?\
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MCX!_%Z&YGU;PC9WUM::C<JTK2BQAFC 6=MQQ(54D X)'(]/A_P#X):Q+:?\
M!8#]HJ <YOO$+?\ ?8NC[^I]J!6MS+1Z=-5NNIL?\%<?VKOVGOA[^W9X1^%_
MP.UF[LH]6DL[:2&"9T&)TC4G:I]3G_(J+XY?LL_\%#='^$6I?M(2^-M12\\.
M:!_PE-W:_;7#^1$4+9B\S=U8<XQS1^WXMO-_P5^^',=S&LR?:]-^1AD# CYY
MR.G/3UK^C7]JXJO[$_Q>VKM0?"F]0* ,!/+MTVXZ8V\?2@MZ>ST6J73TUOW_
M *W6GYZ_\$>_VX/&/[0W[*_C'Q1\1YY;_P 4> ?M$%P[NSR,FGPW*R9SDY,J
MQGZ?6OS(^%WCO]K+_@H/^U!\6?".A^+;FQ\(^";V_%M:"\,2QPV]P\:!MSHJ
M\%0,XSD=Z](_X(0ZKI>A?LY_M#3WT:BSFNO$,;H%)7YFN1R/;_/:OS,_9]_:
M:^,/[+W[87QH\0_ W27\0V^N:EJ7VG3Q$+B%DDN)"4DA(96 .#AE(R!0%O>F
MDEI:UUZ?U;N=EX]?]M3X/?M]>'?V>%\=7EQI4VJVGFVBW[L7A9U<X4.004(Y
MZ$?7G^WCX1Z=K&D_#CPG8:\[2:O!I%LMZ[DEFG* L6)SSFOYNOV+?V9/'W[6
M/[5\'[87QHNAI'B.QN!=IHLTH23"D$1QP'YC@#:J 8 XX )K^HD#RD1$'RHH
M4#'0* !TQVH,V[]%ZVU??\3\XO\ @J+\2?%?PL_9HUCQ1X-N7M=:MY9Q!)&Y
M1LK"C* 1WW=*_G,_96MO^"A'[>.@ZRVF^+=1T[1M)$A+/=O&C*)A$OS,P7G>
M!U]!@]_W\_X*_L!^RO?[L[3?S CU'DQ]:\._X(H):0?";4TLX%A$MKOF*@#>
MPN82&;WS_,T#3LKVU;=GVM;]3^?_ %#]IC]OG]F+]JM?V/XO$NI7E_>W_P!A
M>87,DGWF\LG(+<')/7W%?6'[5/P#_;_^!/@B3]J:Y\::@=.T.&TU?5;/[:^4
MCE!G(DCWY4,$.,CG/<5+\?8;.\_X+<PO?6Z7$B:PNPNH)7$H"X!Z8P /8>@Q
M7[L_\%7Y O\ P3T^,/&%;PQ9IMQV%K*0N/0;1^0H+;^';75Z=[?\%?AN<=_P
M3S_:O\2?M._L)>(?BMJMP\OB/1_#7B"W><N2WVO3M#NID;=UR)(,YZ]Z_/G_
M ((6?M/_ !@^.WQM_:?T3XD:I/?Z?X8UK4(='265I!%%'J(C55!SC"]/:NW_
M ."$<9N/^"9'Q)A@&7D@\:(@ ZNV@:KM4#GDY  [^E?(G_!N]K%C9_M*_M<:
M'>R+:ZI/X@U8V]O<$0R3;=3+L(D?:9#L4D!020#Q0G=)]Q=)+3?M;;;7SZ+J
M?;W_  7P_:)^*GP!^'?PMU#X9ZE-I]UJOB6SM[QH96C+0O=B-E.#SE2:[#]N
MKQ%JGC+_ ((RV/BS7Y&FUK6/ ?AV]OY6.YGN+F#4_-);N2(ES]*^+O\ @Y)^
M+'@)_#WP?^'D>J13>+5\5Z>SVD4BOL#WJ,%<*3AE!PWH>,<'/UQ^V6'A_P""
M(_A]'&"OPZ\+!O;_ $;5C].E!*O[O^+MZ'D'_!-/PEXV\?\ _!(C7/#_ ,/+
MQM/UB\M->C,J/Y;;+2SDNIU!R#ED0*!D$YK\"_V'?V6_VE_&_P"T5\0M$\%>
M(KNUUJUURYANY4F=2TJW4F6)##DM_6OZ9O\ @AVY'_!,F^=,@BU\:LNWKN&A
M3D$8[Y Q^%? 7_!)O5"G[9OQ9BEOH[&9_%%\%-U,EON)O).07*Y]NN>F*"VW
M[Z75+]+_ ('FG[;'P<_;U_95\+^%O'UUXTN;RP.I1VMPC79EC(B:(L#\Q!;;
M(,CKC&>U?KI\-_CQ\1=6_P"";6L_$+4[LKXNLM!DE2Y1BK"=+7.0PP?O#-2?
M\%R+J:+]GKPU"LCK&VN3.44\%O\ 1E)(]P ,^U>._#)7F_X)8^)A'DG^PY6/
MT%N"WZ4"LFH.W6S\_P"K?B?EO^R5XT_;^_;9N]=\):#XJU&ST33[^_0S-=R(
MGV:!I3C>6  **1UQ^M;GBWQ7^VW_ ,$[?VI_A]I_C;Q1?:E\.-<NM,DU;?=/
M+;E+N2)I 3N*$89E//!!!K[?_P""#OQ,^'>H2^*?!^FWEM'XI@NM36Z@:2..
M21D\\E%!(+L2,*HR6;  )P*R_P#@N=XS\,3_ !(^'OP^\R.X\5ZBVD"P@A(E
MGB,C1E043+HQ9N1UYSB@-5)I)=MK:/TO^/X'KO\ P6-\;:;\4?V8_A;XWT=E
M:SU.XM;L%3E?]),3X!'8,3QVKV#X!_'?3/V7O^"=K_&#464#3M!41 G!$RVP
MV-T[-_G(KXP_;QT35/"?[ /P3TK7%9;T+I<FV0$.$81,@P><@-69^TEI6M:G
M_P $;M3_ +(BEN&?1T1H85:1E5K=0S;4R<@<YQP*!6^%/K)KTU2W/*_@!<?M
M ?MZWGB#XOZI\;M,T/P1J%Q=#0=*N-9B@> ^8PC'EM*I&T%>,=1VJ/X1?M?_
M !D_8Z_;?\)?LS>.OB39^,_#/BJ]L5MS;:BMTL<-U(@12%=API_3L17G'_!(
MG_@FB/CK^REI7B#3?CKK'A;7!?2&]T*VU"Y5[7<SL=]I 6D1%8!2Y3:"5!^]
M7Z)^"?\ @@CX'\._'_P[\<_&7Q;N?%OBG1)[>>P&H7%VT_\ H\@9 BW$:NW*
M$ KGH1VH'=)V;T2MM?\ SVTZ>I_1397<5]:6UY P:&Z@BN(R#D%)HUD7GZ,*
M_&C_ (+T6OVG_@GS\1&R +6]L[D@_P 0CBG8J!W) K]C-%TU='TJPTQ',J6-
MM#;*YSEEB0(#S[+7XV?\%[I6B_X)]>/2"0'U33T?'=&CG# ^Q%!$=UZH_%[_
M ()J_P#!;;P%^SE^QEX:\!7WP=\1:WJ7A47VV\TNTN%AO) B(GGM% 3*H:+Y
M,.K ,X!^;(XW]B;Q3HW[>/\ P4IT[]J:_B@\ -I>L1SPZ!>*MC,X6<.JB%A&
MQ)X&-O6OV)_X(L?LX? 'QA^P?\/]5\0_"_P;KVHZEYO]H7.H6%M>7$F(T*^8
M1B2/<6?EC\^.,;37Y&_M_P#@KP9^S=_P4.\&+^S_ 'X\-7-WJNG/<^&/#K;;
M/=+,C/&T5K\G!++AAGC!H*]W5;=+ZN^JZ=W_ %Y?VP!@X5HV5E8;@P(*L.,$
M$9!_"OEC]L7PA\9_&_P;U?0?@5JS:+XZNI MK>K+Y12%D96&[([D'@]J])^
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M?M.^"O"_QB\1WVI>!/B!K-K96'GW#R0F.\N%C^0EBI7Y^,'^E?>/_!NI\0?
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M!KEC/9F9PS(@F0H2VP,X SGY48^U 7UN?Q*_\$S?V*/VHOB9X)^*GQ _9?\
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M  3#_P""L7A&*?P=X0^.<MIX#^T26D%G_;2C9I#YA,(!GX_<.R@<?E7["_\
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F5%% !@>@_*C ]!^5%% !@>@_*C ]!^5%% !@>@_*EZ=!110!_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>22
<FILENAME>g0fyk5pshdve000008.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g0fyk5pshdve000008.jpg
M_]C_X  02D9)1@ ! 0$!+ $L  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" !8 %@# 2(  A$! Q$!_\0
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M>:2WZ-K[M/+_ #T/U_\ ^"(GPXN_%?QK\(^/K>W>:+2[S5899T4LJ FT)#,
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M$/%?BN,5%O+9[>]/!S<GI!;^W7=GRSX'R.4F^7%QUVC726R?_/OS/H+X;?\
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)R,=****@9__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>23
<FILENAME>g0fyk5pshdve000006.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g0fyk5pshdve000006.jpg
M_]C_X  02D9)1@ ! 0$!+ $L  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" !8 %@# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#^_8 8' Z#
MM5/4=1T_2;.;4-3N[:PLK=#)/=74B0PQHH+$L[D#H"<=3C@&C4-1L])T^ZU+
M4)X[:RL;:2YN9Y6")'#"A=V+,0. #CGD\5_)+_P5Q_X*X7TVH:G\$_@GJ<GV
M%9)+'4]4T^8>:)>8I"7B(/7=QN.WD#I7TG#'#&8\4YC# X&#44U+$XAI^SP]
M*ZO*3VYFOACU9Y.<YSA<EPDL3B97;NJ5)/WZL^R7975WT1^DW[9__!:7X,?L
MZR:MX5\*)9^)/%,*S6\%RTZSVB3#<H=8HMH)##H[NHZXZ8_F9^-__!7_ /:H
M^,>KWUO#:Z</#MU++Y$4,; B!RP0<'T([U^=>E^&/%'Q&U235_%%Y<ZM)<S-
M+)<7I:23YW+_ 'G8]SZ\?K7T7H'P^T71(H\0QRE0,!@#C'7&?\_6OZPX6\,\
M@R2E%_5*>-Q5E[3%XJ*J>\DM:47\'^%:?K^(9QQ?F>95)WQ$\/13:AAZ#Y?=
M?\[37,_6WWZ'F>M_$#XG?$"5[G6(GBDN"2WEO,F"W4\./TS@>W3FTT3Q;;.)
MU>Y+*=P_?W!YZC'[P _KZ"OJ,V]C$O[NUB4CH  "?\]L>_UJ+Y20!I5V5S@R
MBW<PX]=^W'ZU^AT\KP]."A"%-15KJ-."5M+))KIM?H?*RQ=63UG-MN_QR?5;
M_):7_P"&\F\+_M#?&GX63177AZW#2VVUHC*96&Z,@KG+=\?UK]-_V8?^"Z7Q
MZ^%VKZ?9?%+3=*OO#4,D4<L$D3%S'D*W.X,.#U!R.H(."?B.?3].N(RDMG$Q
M8<DJ 03P<_3W_P :\K\5_"C2M7BDGABC,OS,J8XR/0#G.>G?/KU'B9KPCD^:
MT9TL9E^%Q*FG'G=.*JQ323<)))Q>]G_2]+ 9YCL#5A/#8JM1:DFX^T;A*S7Q
MQOJO7IYV/[S?V0O^"B_P._:VTN&3PYJ5GHNMM"C/IMW>Q 2S$ ND DVN,$D*
M&9R<8W5^@PVL R[2" 01@@@\@@C@@CD$=:_RY/ OQ%^*'[-_C+3_ !5X3UG4
M=/\ [)N8YQ9VDDL<4^R0/M958 @@8]",=>E?W ?\$MO^"E_AS]K'P9IOA#Q=
M?P67Q%TZUA@-O-*BRW7EH$PP8ABQP,=<8QWS7\Q<?^&5?AR-3,\J]IB<K4K5
MJ;3=;"7LDY=9P[R^S==#]BX8XQI9JXX/&N-+&V]R>BAB'U4>BGY=3]FF ^7@
M?>';ZT4K?P_[PHK\@/NS\/?^"TO[:#_L[?!B/PMX4U98O%?B*UNOM$-O,1.E
MI,I@5&"$-GY';C(PPSZ#^(;PQI>J?$;Q/>>*-6>:XDU:Y-[<R2L[_/))O8Y?
M.."<#^M?HS_P6"^-^J?&/]J>V@@OI+GP]_9L<$< E+0*P)'"9(Y_,?C7SC\.
M]!BT/185V*&EBR/EY"X)X^O^//-?VIX9<+TLCR'"7C'ZUC*<,7BZB5IR]IRR
MA2>FU/9?B?SUQ?G,\RS3$/FO0PTG1H4TW;W='-><NME\SL-,TZTTBS2TMHU4
MJJAF"CDXYR<?YP*L@,[+#$"T\IVPQ@<NY/  [DD_G2DXYJUH\T5IX@T/4YQN
MMM/OX;F=#T:..0,P([\#H:_5-HOE7PP;C%+=QC=1^=CXQ:R2;MS22;?1-I-_
M)79^A'[)?_!/7X@_'F]L]=\76<_AOPD)8I3J-QF&%X<@GYGP"".O;ZBOW&^+
M'[!_P$^''[,?B.[TO2K'5M;T?29&35T2%V>6.!SN$B@G@KGKR<=S7XV?$_\
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M>#DY7O'6ZKK7Y'RDN!,BE)NV,CKM'$)+9/\ Y]GT)\-?^"(7QB\27UM;^/\
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$@H__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>24
<FILENAME>g0fyk5pshdve000014.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g0fyk5pshdve000014.jpg
M_]C_X  02D9)1@ ! 0$!+ $L  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" .$!T8# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#^\_6-9&FQ
MV(-G'<F>'?\ O, )A4Z#:Q).>3GL.O48P\5KC_D$V_/NN/RV?X4WQ3PND#_I
MU/Z*E<G0!UO_  E2_P#0)MO_ !W_ .)H'BA,C&D6V?;9G\/DKDJY/XB^*H/A
M]X+U+QA=G$&GPR2MG@?(,XY^A_G[54(N4E%)MR:BDNK;LO\ +\2924(RG)VC
M"+E)]HK=GK__  D,I&1H<>#R#M'\]@IG_"3'=M_L>#=Z8&?_ $"OPRN/^"J'
MBF[UZ\LO#OA[[;HVF3S"^O$0%8K>%B'=F&<!5!S]*^@+#_@HSX USX3ZU\0M
M%O8;K4/#L;C5+9'1C!<1 [D(#<'>".>F/R]&>49A"*E*A?F<8KEDGRN5E%2M
MM=Z*ZUNNIY%+B#*:LIQAB4E",I^\N7FA#XW#^;EUO;_A_P!4?^$AD'+:)$!C
M.2H'_M,U ?%2[MO]DVX]<X_^-C_'\:_"#P;_ ,%8_$.O/9:OK'A^2T\(7=[]
MF_M(P$1>4)-I8R;<#CD\]CTQ7Z\_#'XE>$OB[X:L/$7@^_BU!9[9)KGRI%D\
MIF0,0=N=O)[_ /UJQQ678S!I2Q%/EB]+QU49*UU)[)W>WWG1@<WR[,7*.#K^
MTG&*ER27)-IV]Z,7K);^\M-CVE?$^XG&D6YQW&.#_P!^S_C33XJ7H=)M^">I
M4_S08]^M?"W[1_[6.A?L\:CX?T_5G17U^[BM(P[ ?-,X3N>N3[=^:^J?#>HI
MXA\)Z)XJC;-MK-C'J"MV\MT#D\>@]/\ Z]83P]6G2I5IP:IUFU3E_,UND=4,
M50JUJV'IS4JV'476AUAS;-^NYZ$OB8O]S2+=L=0H!Q]?DIA\4@<-I%L".WR_
M_$"OS+_:6_X*._!?X"^+?#?@*SUV&[\5:U?Q6,UD73=')(ZQL,9Z#/M_C]Z>
M&]1_X2'PGX>\4ICRM=T^"^3'3$T8?\>O7\ZJMA,3AZ5&M6I3I4Z]_8RFG[]M
M[;?G;S(H8W!XFM7P]#$4ZU;#<OUB--\RI\]N5-K[7==#OQXK4DC^RK;CW7_X
M@?SI?^$J7_H$VW_CO_Q-<ECV_2BN<ZCK?^$J7_H$VW_CO_Q-'_"5+_T";;_Q
MW_XFN2HH ZW_ (2I?^@3;?\ CO\ \31_PE2_] FV_P#'?_B:Y*B@#K?^$J7_
M *!-M_X[_P#$T#Q4N<?V3;8_X#_\1C^?TKDJ0C(Q0!UI\5*#QI-MR?\ 9_I'
M_/%3+XCD<9318F'J%!_]DK@-3U"RT32KO6M4D$.G:?&TMS,> B("2<D\< ?X
MXK\G_BU_P4KUS0?&4GAWX4:,/$>G6EPT5[<( _E(CD.W /W0#ZUU87!XG&2<
M</#FY?C;=HK;1R;LF^B>[L<>-S'!Y?",\54<>9^["*<JDEIJH+5I7=VOR/V<
M;Q/L.UM(MU/H0H/_ *!3?^$I4==)MO\ QW_XFO@#X3?MM?#_ ,=^"-3\1>(K
M^'3=5T&W:76+9W5/L[(A+C!(^Z01D?\ Z_<OA#\</ GQE\/WOB?PSJD%SIMA
M+)'-*LR%5\OALMNQQBE5PF)H\_M:4H^S:C)V?+S/:SZWW3[#H8_!XGV7L<13
MFZT.>G'FCS.*TDVDVU9[]K.^Q]&GQ4O_ $";;_QW_P"(I1XJ!7/]DP8SUR-O
MZQBO,].\9^$-6%R;+5+9UL@WVH_:(_EVY+<9YP/\^OAFD_M5?"S7OB5+\,M*
MUJWGUB!S'+$LT98$'!R 3T/7\_:HA0K3Y^6E.7)'FE:+]V.]WIMZFT\10I^S
MYZU./M9J%.\TN>3Z1ON?7O\ PE2Y_P"03;?^._\ Q&/UIW_"4IWTJV_-?_C9
M_E7$G4])8RF&[B=(/]<RRJ0G'.2"<?B?T',;ZOH\5H^H27MN+*,$O-YR!1M'
M(W;MN:RL]?=>EE91;UZ+YFC:3^)6\W^/HM=3N3XJ7G_B4VW_ ([_ /$?T_"@
M>*E_Z!-M_P"._P!4'\J\WTCQ7X;\2/*FA7\-TT)Q(%E5L$=>A/H?\FMNAJ4=
M))IV3LU8$U)7BU)=T[K[T=;_ ,)6!P-*M\'W']$(_,TG_"5#)_XE-MC\/Y[,
M5R2+@-D\]OU]:6D5W_KJCK?^$J7_ *!-M_X[_P#$T?\ "5+_ - FV_\ '?\
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M5% '6_\ "5+_ - FV_\ '?\ XFC_ (2I?^@3;?\ CO\ \37)44 =;_PE2_\
M0)MO_'?_ (FC_A*E_P"@3;?^._\ Q-<E10!UO_"5+_T";;_QW_XFC_A*E_Z!
M-M_X[_\ $UR5% '6_P#"5+_T";;_ ,=_^)H_X2I?^@3;?^.__$UR5% '6_\
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MR/7/^$J7_H$VW7_9_P#B#_GO1_PE*_\ 0*MO_'?_ (BN2HKY,^\.M_X2I?\
MH$VW_CO_ ,31_P )4O\ T";;_P =_P#B:Y*B@#K?^$J7_H$VW_CO_P 31_PE
M2_\ 0)MO_'?_ (FN2HH ZW_A*E_Z!-M_X[_\31_PE2_] FV_\=_^)KDJ* .M
M_P"$J7_H$VW_ ([_ /$T?\)4O_0)MO\ QW_XFN2HH ZW_A*E_P"@3;?^._\
MQ-'_  E2_P#0)MO_ !W_ .)KDJ* .M_X2I?^@3;?^.__ !-'_"5+_P! FV_\
M=_\ B:Y*B@#K?^$J7_H$VW_CO_Q-'_"5+_T";;_QW_XFN2HH ZW_ (2I?^@3
M;?\ CO\ \31_PE2_] FV_P#'?_B:Y*B@#K?^$J7_ *!-M_X[_P#$T?\ "5+_
M - FV_\ '?\ XFN2HH ZW_A*E_Z!-M_X[_\ $T?\)4O_ $";;_QW_P")KDJ*
M .M_X2I?^@3;?^.__$T?\)4O_0)MO_'?_B:Y*B@#K?\ A*E_Z!-M_P"._P#Q
M-'_"5+_T";;_ ,=_^)KDJ* .M_X2I?\ H$VW_CO_ ,31_P )4O\ T";;_P =
M_P#B:Y*B@#K?^$J7_H$VW_CO_P 31_PE2_\ 0)MO_'?_ (FN2HH ZW_A*E_Z
M!-M_X[_\31_PE2_] FV_\=_^)KDJ* .M_P"$J7_H$VW_ ([_ /$T?\)4O_0)
MMO\ QW_XFN2HH ZW_A*E_P"@3;?^._\ Q-'_  E2_P#0)MO_ !W_ .)KDJ*
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M._\ Q-'_  E2_P#0)MO_ !W_ .)KDJ* .M_X2I?^@3;?^.__ !-'_"5+_P!
MFV_\=_\ B:Y*B@#K?^$J7_H$VW_CO_Q-'_"5+_T";;_QW_XFN2HH ZW_ (2I
M?^@3;?\ CO\ \31_PE2_] FV_P#'?_B:Y*B@#K?^$J7_ *!-M_X[_P#$T?\
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M_P"._P#Q-'_"5+_T";;_ ,=_^)KDJ* .M_X2I?\ H$VW_CO_ ,31_P )4O\
MT";;_P =_P#B:Y*B@#K?^$J7_H$VW_CO_P 31_PE2_\ 0)MO_'?_ (FN2HH
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MQU->34R_&4:+KU*$HTU>[?36R;[)]SW*.:9?7KK#4\3"59M)137O-I/E3O\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MSC\6O$?C"Y\3WFI6^M7\ERUO)-*ZJ)',F,,2.^.W'4<U^O<CAEA '*Q*K?4
M9S7B8^CA:56*P=9UZ3IQES---2LN9??YGT65U\=B<,YYCAUA<0JDX^S3O>,9
M6BVUWCJT_F0T445PGI!1110 4444 2P."Q[<=^/3^?U[5_-7_P %\K*\GC^&
MUU-X8U'Q)HMKJ5I)J<6GP23,+=9E+\1AL?+G'3G\J_I/''3CZ<5S7B/X>_#O
MQY$(/'OA73_$T$?,:7\$4ZIW&!(K>G;'6O2RK'1R[&T<7.$JJIMITXOE;4E:
MZET:_0\C/<K>=97B,NC66'=?D_>RCSQ3A.,E>/5-JW71N^A_&UXS\1_ /7/
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M\XG@\KE@Z'NUY5?:>TZ)*STOM_3[GL9APW2S+.H9ABK5,+&C[-T>[MU[KO\
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MVI7NI-*ZN^ST/J,CP>(P&6T<)B5!5*,I17LU:,H:<LO5VU&4445YIZP4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% "'H?H?Y5V?A'^+_
M 'C_ $KC#T/T/\J[/PC_ !?[Q_I0!WG\?_ ?ZT4?Q_\  ?ZT4 >>^*>FD?\
M7J?_ $&.N3KYG^+'_!0_]DSX:ZW8^&_&?C6VM]6$!86S/'&T2D*-N?,)?IU(
M7H>.>/,?^'I'[$8X/CJU)/3]_&/Y-79'+\?*TH8'$S3M9^QDXM.SNFUYJWGH
M<#S7*HMQGF>"A.+2<'B*:DG?5-7=O3L?="G# GL:^7?VL/A!XF^,/PUU72/
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MVF_.^^A\W'*>$W&LI9M"M.I[)>TK8^$JD/9->S]G)OW;76RV/Q\^('_!+_\
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M_P""9?Y>:^\/[7RG_H:8'_PHAY>?FC[DI02,^]?#7_#TC]B/_H>;7_P(C_\
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M_ B/_P"*H_LW,/\ H!Q?_@F7^7FOO#^V,I?_ #-,#T_YB(>7GYH^Y**^&_\
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M#3 _^%$/+S\T?<E;GA__ (_F_P"O>?\ ]%FOS_\ ^'I'[$?_ $/-K_X$1_\
MQ5:6E_\ !4S]B2.X9AX_M+<^5)^\,D4HQCE=IE0?-TSGCG@FAY;F%G_L.*V_
MY\S_ ,O-#CG&4II_VG@79IV^LTU?X7U:75=3^8C]MO\ Y29:>.__  D,>/\
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MA_VOE/\ T-,#_P"%$/+S\T?<E%?#?_#TC]B/_H>;7_P(C_\ BJ/^'I'[$?\
MT/-K_P"!$?\ \51_9N8?] .+_P#!,O\ +S7WA_:^4_\ 0TP/_A1#R\_-'W)1
M7PW_ ,/2/V(_^AYM?_ B/_XJC_AZ1^Q'_P!#S:_^!$?_ ,51_9N8?] .+_\
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M3 _^%$/+S\T?<E%?#?\ P](_8C_Z'FU_\"(__BJ/^'I'[$?_ $/-K_X$1_\
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MC]B/_H>;7_P(C_\ BJ/^'I'[$?\ T/-K_P"!$?\ \51_9N8?] .+_P#!,O\
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M !5']FYA_P! .+_\$R_R\U]X?VOE/_0TP/\ X40\O/S1]R45\-_\/2/V(_\
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M)17PW_P](_8C_P"AYM?_  (C_P#BJ/\ AZ1^Q'_T/-K_ .!$?_Q5']FYA_T
MXO\ \$R_R\U]X?VOE/\ T-,#_P"%$/+S\T?<E%?#?_#TC]B/_H>;7_P(C_\
MBJ/^'I'[$?\ T/-K_P"!$?\ \51_9N8?] .+_P#!,O\ +S7WA_:^4_\ 0TP/
M_A1#R\_-'W)17PW_ ,/2/V(_^AYM?_ B/_XJC_AZ1^Q'_P!#S:_^!$?_ ,51
M_9N8?] .+_\ !,O\O-?>']KY3_T-,#_X40\O/S1]R45\-_\ #TC]B/\ Z'FU
M_P# B/\ ^*H_X>D?L1_]#S:_^!$?_P 51_9N8?\ 0#B__!,O\O-?>']KY3_T
M-,#_ .%$/+S\T?<E%?#?_#TC]B/_ *'FU_\  B/_ .*H_P"'I'[$?_0\VO\
MX$1__%4?V;F'_0#B_P#P3+_+S7WA_:^4_P#0TP/_ (40\O/S1]R45\-_\/2/
MV(_^AYM?_ B/_P"*H_X>D?L1_P#0\VO_ ($1_P#Q5']FYA_T XO_ ,$R_P O
M-?>']KY3_P!#3 _^%$/+S\T?<E%?#?\ P](_8C_Z'FU_\"(__BJ/^'I'[$?_
M $/-K_X$1_\ Q5']FYA_T XO_P $R_R\U]X?VOE/_0TP/_A1#R\_-'W)17PW
M_P /2/V(_P#H>;7_ ,"(_P#XJC_AZ1^Q'_T/-K_X$1__ !5']FYA_P! .+_\
M$R_R\U]X?VOE/_0TP/\ X40\O/S1]R45\-_\/2/V(_\ H>;7_P "(_\ XJC_
M (>D?L1_]#S:_P#@1'_\51_9N8?] .+_ /!,O\O-?>']KY3_ -#3 _\ A1#R
M\_-'W)17PW_P](_8C_Z'FU_\"(__ (JC_AZ1^Q'_ -#S:_\ @1'_ /%4?V;F
M'_0#B_\ P3+_ "\U]X?VOE/_ $-,#_X40\O/S1]R45\-_P##TC]B/_H>;7_P
M(C_^*H_X>D?L1_\ 0\VO_@1'_P#%4?V;F'_0#B__  3+_+S7WA_:^4_]#3 _
M^%$/+S\T?<E%?#?_  ](_8C_ .AYM?\ P(C_ /BJ/^'H_P"Q%_T/-K_X$1__
M !=+^SLP_P"@'%_^"9?Y>:^\/[8RA6;S/ VT_P"8B']W3?S1]R4P$MTXQUS_
M )-?#I_X*D_L1#_F>;7Z?:(\_7[_ /2E_P"'I'[$?_0\6O\ X$1__%T++LQ:
M3^H8K6UOW,O+R^[OIW!YQE#?_(SP"OLEB:?EV?G_ %L?<VTXW=O_ *^*;7PW
M_P /2/V)/^AZM<>GVA/_ (O'7VH_X>D?L1_]#S:_^!$?_P 53_LW,/\ H!Q?
M_@F7^7FOO#^U\H_Z&F!Z?\Q$.MO/S/N2BOAO_AZ1^Q'_ -#S:_\ @1'_ /%4
M?\/2/V(_^AYM?_ B/_XJC^S<P_Z <7_X)E_EYK[P_M?*?^AI@?\ PHAY>?FC
M[DHKX;_X>D?L1_\ 0\VO_@1'_P#%4?\ #TC]B/\ Z'FU_P# B/\ ^*H_LW,/
M^@'%_P#@F7^7FOO#^U\I_P"AI@?_  HAY>?FC[DHKX;_ .'I'[$?_0\VO_@1
M'_\ %4?\/2/V(_\ H>;7_P "(_\ XJC^S<P_Z <7_P""9?Y>:^\/[7RG_H:8
M'_PHAY>?FC[DHKX;_P"'I'[$?_0\VO\ X$1__%4?\/2/V(_^AYM?_ B/_P"*
MH_LW,/\ H!Q?_@F7^7FOO#^U\I_Z&F!_\*(>7GYH^Y**^&_^'I'[$?\ T/-K
M_P"!$?\ \51_P](_8C_Z'FU_\"(__BJ/[-S#_H!Q?_@F7^7FOO#^U\I_Z&F!
M_P#"B'EY^:/N2BOAO_AZ1^Q'_P!#S:_^!$?_ ,51_P /2/V(_P#H>;7_ ,"(
M_P#XJC^S<P_Z <7_ ."9?Y>:^\/[7RG_ *&F!_\ "B'EY^:/N2BOAO\ X>D?
ML1_]#S:_^!$?_P 51_P](_8C_P"AYM?_  (C_P#BJ/[-S#_H!Q?_ ()E_EYK
M[P_M?*?^AI@?_"B'EY^:/N2BOAO_ (>D?L1_]#S:_P#@1'_\51_P](_8C_Z'
MFU_\"(__ (JC^S<P_P"@'%_^"9?Y>:^\/[7RG_H:8'_PHAY>?FC[DHKX;_X>
MD?L1_P#0\VO_ ($1_P#Q5'_#TC]B/_H>;7_P(C_^*H_LW,/^@'%_^"9?Y>:^
M\/[7RG_H:8'_ ,*(>7GYH^Y**^&_^'I'[$?_ $/-K_X$1_\ Q5'_  ](_8C_
M .AYM?\ P(C_ /BJ/[-S#_H!Q?\ X)E_EYK[P_M?*?\ H:8'_P *(>7GYH^Y
M**^&_P#AZ1^Q'_T/-K_X$1__ !5'_#TC]B/_ *'FU_\  B/_ .*H_LW,/^@'
M%_\ @F7^7FOO#^U\I_Z&F!_\*(>7GYH^Y**^&_\ AZ1^Q'_T/-K_ .!$?_Q5
M'_#TC]B/_H>;7_P(C_\ BJ/[-S#_ * <7_X)E_EYK[P_M?*?^AI@?_"B'EY^
M:/N2BOAO_AZ1^Q'_ -#S:_\ @1'_ /%4?\/2/V(_^AYM?_ B/_XJC^S<P_Z
M<7_X)E_EYK[P_M?*?^AI@?\ PHAY>?FC[DHKX;_X>D?L1_\ 0\VO_@1'_P#%
M4?\ #TC]B/\ Z'FU_P# B/\ ^*H_LW,/^@'%_P#@F7^7FOO#^U\I_P"AI@?_
M  HAY>?FC[DHKX;_ .'I'[$?_0\VO_@1'_\ %4?\/2/V(_\ H>;7_P "(_\
MXJC^S<P_Z <7_P""9?Y>:^\/[7RG_H:8'_PHAY>?FC[DHKX;_P"'I'[$?_0\
MVO\ X$1__%4?\/2/V(_^AYM?_ B/_P"*H_LW,/\ H!Q?_@F7^7FOO#^U\I_Z
M&F!_\*(>7GYH^Y**^&_^'I'[$?\ T/-K_P"!$?\ \51_P](_8C_Z'FU_\"(_
M_BJ/[-S#_H!Q?_@F7^7FOO#^U\I_Z&F!_P#"B'EY^:/N2BOAO_AZ1^Q'_P!#
MS:_^!$?_ ,51_P /2/V(_P#H>;7_ ,"(_P#XJC^S<P_Z <7_ ."9?Y>:^\/[
M7RG_ *&F!_\ "B'EY^:/N2BOAO\ X>D?L1_]#S:_^!$?_P 51_P](_8C_P"A
MYM?_  (C_P#BJ/[-S#_H!Q?_ ()E_EYK[P_M?*?^AI@?_"B'EY^:/N2BOAO_
M (>D?L1_]#S:_P#@1'_\51_P](_8C_Z'FU_\"(__ (JC^S<P_P"@'%_^"9?Y
M>:^\/[7RG_H:8'_PHAY>?FC[DHKX;_X>D?L1_P#0\VO_ ($1_P#Q5'_#TC]B
M/_H>;7_P(C_^*H_LW,/^@'%_^"9?Y>:^\/[7RG_H:8'_ ,*(>7GYH^Y**^&_
M^'I'[$?_ $/-K_X$1_\ Q5'_  ](_8C_ .AYM?\ P(C_ /BJ/[-S#_H!Q?\
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M<)B*<(VYISI.,5?NWH:T<RRW$5(T:&/PE:K+6,*=>$I-63TBG=VW9];?Q_\
M ?ZT4?Q_\!_K17*=A_,M^U__ ,$6+OXX_$G3O'-OK%]$'L]KI%=R!0^0W(1@
M <-[$>PKYB'_  0#U'C.N:AG _Y?)O\ XNOZPO%EU<0_V4L4KH'M2S;3C<<)
MR??BN0^WWG_/S+_WU7W&$SW,UAJ"5:*2@DER[1C*R7W+[S\^Q7!^05,36J2P
MLG*I-SD^;[4DF^W6Y_+8W_! 740,_P!N:CU_Y_9__BZ4?\$!-1(!_MW4>?\
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M@1_^!OR_X/X'\M1_X("Z@O\ S'-1R?\ I\G'Z[N:D'_! 34 >=<U''_7Y/\
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MS[,[/]^F_P##;:W=>7SOV'_J;P\M?JKNFM.9MO:^W]>A_+=_PX#U#MKFH_\
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M_P _U_X#Z?Y?UT?^IO#UO]S:?67.]5IT_K9'\I6I_P#!!O4;34[>S&M:EB3
M/^ES=ST/S \GIP?;TKHV_P"" >HC;_Q/-2&5!_X_)QG_ ,>_GS7]*>OW]X?$
M5EFXEY*?Q>XKOVO[SY?])E^Z/XC717SO,8T\,XU5'FIWE:*U=TF_N.>CPAD$
MZE=/"R:51<OO;:1;_/0_EK_X<":C_P!!W4?_  ,G_P#BZ/\ AP)J/_0=U'_P
M,G_^+K^I+[?>?\_,O_?5'V^\_P"?F7_OJN;^WLT_Y_K_ ,!]/^#]YO\ ZF</
M_P#0(_\ P+T_KY+Y?RV_\.!-1_Z#NH_^!D__ ,71_P .!-1_Z#NH_P#@9/\
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MWWG_ #\R_P#?5)9]FG_/]=-.77[._GO]X?ZF</\ _0(__ GY?U\E\OY;?^'
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M]K]O,^K7!G#_ /T"/Y2?E_E^"^7\MO\ PX$U'_H.ZC_X&3__ !='_#@34?\
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MX]_\_P!J7_?Z7_XJC_43C+_H+H?^2^7EZ_<'_$5O"S_H6XW[I>7^3^Y'WO\
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MEY>OW!_Q%;PL_P"A;C?NEY?Y/[D?>_\ PX2M_P#H;[O_ ,#Y/_BZ/^'"5O\
M]#?=_P#@?)_\77P1_P /@?CW_P _VI?]_I?_ (JC_A\#\>_^?[4O^_TO_P 5
M1_J)QE_T%T/_ "7R\O7[@_XBMX6?]"W&_=+R_P G]R/O?_APE;_]#?=_^!\G
M_P 71_PX2M_^AON__ ^3_P"+KX(_X? _'O\ Y_M2_P"_TO\ \51_P^!^/?\
MS_:E_P!_I?\ XJC_ %$XR_Z"Z'_DOEY>OW!_Q%;PL_Z%N-^Z7E_D_N1][_\
M#A*W_P"AON__  /D_P#BZ/\ APE;_P#0WW?_ ('R?_%U\$?\/@?CW_S_ &I?
M]_I?_BJ/^'P/Q[[WVI?]_I?_ (H4+@3C)Z?6\/\ ^2^7_!^Y"_XBMX6?]"W&
M].DO+_)_<C[W_P"'"5O_ -#?=_\ @?)_\71_PX2M_P#H;[O_ ,#Y/_BZ^"/^
M'P/Q[_Y_M2_[_2__ !5'_#X'X]_\_P!J7_?Z7_XJC_4/C+_H+P_RY?[O^;_
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M&_=+R_R?W(^]_P#APE;_ /0WW?\ X'R?_%T?\.$K?_H;[O\ \#Y/_BZ^"/\
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M /0WW?\ X'R?_%T?\.$K?_H;[O\ \#Y/_BZ^"/\ A\#\>_\ G^U+_O\ 2_\
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M#Y/_ (NO@@?\%@OCV>?MVI<_]-I?_BJ</^"P/QY[WVJ9]II/_BJ/]1.,M/\
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MI?\ ?Z7_ .*H_P"'P/Q[_P"?[4O^_P!+_P#%4?ZB<9?]!=#_ ,E\O+U^X/\
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M_P#PX2M_^AON_P#P/D_^+H_X<)6__0WW?_@?)_\ %U\$_P##X'X^?\_NI_\
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MJG'_ (+ ?'L8_P!.U/\ [^RCI]2:7^HG&3_YBZ'HG%/IM][^X7_$5_"Q-?\
M"=C;[Z*?3E_KMLF?>W_#@])CM@\57DK]D6^D)S] X]?\]G_\.!-1_P"@YJ/_
M (&3_P#Q=<G_ ,$_/^"EWQA^-7QNM_".OW=^;&2XC0^9*Y7#.%/!/&<]_K@=
M_P"KJSU"\DT^VE:XEW/'&Q^8]649KXSB&GG_  WBX8/&XBFZDZ4:B<$FK.VF
MFFGZ^C/T[@NIP9QSEU7,<KP5:%&C6=&4:LI*7-&UW9]-K?+U/Y<?^' FH_\
M0=U'_P #)_\ XNC_ (<":C_T'=1_\#)__BZ_J2^WWG_/S+_WU1]OO/\ GYE_
M[ZKY]9[FEOX\=+7]WT_X/WH^Q_U,X?\ ^@1_^!>G]?)?+^6W_AP)J/\ T'=1
M_P# R?\ ^+H_X<":C_T'=1_\#)__ (NOZE%OKLGFYEZ?W\4W[?>?\_,O_?5'
M]O9I_P _UT^SZ7_7[_N2X-X>?_,(]';XNUOZ^2^7\MO_  X$U'_H.ZC_ .!D
M_P#\71_PX$U'_H.ZC_X&3_\ Q=?U)?;[S_GXE_[Z-'V^\_Y^9?\ OJC^W<T2
M3]O'7^[VM?\ 7[QK@SA]V?U1]/M>G]?)?+^6W_AP)J/_ $'=1_\  R?_ .+H
M_P"' FH_]!W4?_ R?_XNOZDOM]Y_S\R_]]4?;[S_ )^9?^^J/[>S3_G^O_ ?
M3_@_>'^IG#__ $"/_P "]/Z^2^7\MO\ PX$U'_H.ZC_X&3__ !='_#@34?\
MH.ZC_P"!D_\ \77]27V^\_Y^9?\ OJC[?>?\_,O_ 'U1_;V:?\_U_P" ^G_!
M^\/]3.'_ /H$?_@7I_7R7R_EM_X<":C_ -!W4?\ P,G_ /BZ/^' FH_]!W4?
M_ R?_P"+K^I+[?>?\_,O_?5'V^\_Y^9?^^J/[>S3_G^O_ ?3_@_>'^IG#_\
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M\/\ 4SA__H$?_@7I_7R7R_EM_P"' FH_]!W4?_ R?_XNC_AP)J/_ $'=1_\
M R?_ .+K^I+[?>?\_,O_ 'U1]OO/^?F7_OJC^WLT_P"?Z_\  ?3_ (/WA_J9
MP_\ ] C_ / O3^ODOE_+;_PX$U'_ *#NH_\ @9/_ /%T?\.!-1_Z#NH_^!D_
M_P 77]27V^\_Y^9?^^J/M]Y_S\R_]]4?V]FG_/\ 7_@/I_P?O#_4SA__ *!'
M_P"!>G]?)?+^6W_AP)J/_0=U'_P,G_\ BZ/^' FH_P#0=U'_ ,#)_P#XNOZD
MOM]Y_P _,O\ WU1]OO/^?F7_ +ZH_M[-/^?Z_P# ?3_@_>'^IG#_ /T"/_P+
MT_KY+Y?RV_\ #@34?^@[J/\ X&3_ /Q='_#@34?^@[J/_@9/_P#%U_4E]OO/
M^?F7_OJC[?>?\_,O_?5']O9I_P _U_X#Z?\ !^\/]3.'_P#H$?\ X%Z?U\E\
MOY;?^' FH_\ 0=U'_P #)_\ XNC_ (<":C_T'=1_\#)__BZ_J2^WWG_/S+_W
MU1]OO/\ GYE_[ZH_M[-/^?Z_\!]/^#]X?ZF</_\ 0(__  +T_KY+Y?RV_P##
M@34?^@[J/_@9/_\ %T?\.!-1_P"@[J/_ (&3_P#Q=?U)?;[S_GYE_P"^J/M]
MY_S\R_\ ?5']O9I_S_7_ (#Z?\'[P_U,X?\ ^@1_^!>G]?)?+^6W_AP)J/\
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M3_\ Q=?U)?;[S_GYE_[ZH^WWG_/S+_WU1_;V:?\ /]?^ ^G_  ?O#_4SA_\
MZ!'_ .!>G]?)?+^6W_AP)J/_ $'=1_\  R?_ .+I3_P0%U+C_B>:B>W_ !]S
M''_CU?U(_;[S_GYE_P"^J/M]Y_S\R_\ ?5/^WLT2TQ"3V?N^FWW,/]3.'_\
MH$?_ (&_+\OT7R_EIG_X( ZC)%(G]N:C\Z,O%Y,.H(_O>]?K5_P2]_X)W7/[
M%IU=IK^YN_[0,G^OG>7&\<_>SSGCK7Z5F_O "?M$O _O&NX\'7,\_F"61GP2
M!DYZ G^E<&9YOC\3@*U*M54H3<5)66K37_!^\]'*>&,GR_,*&*PN'=.M34^2
M7,W:ZBGI]W_ .\_C_P" _P!:*/X_^ _UHKXT^X/,_&/WM(_Z\S_):XVNR\8_
M>TC_ *\S_):XVOH<+_NU'_ __2Y'B5_XL_7]$%%%%;F04444 %%%% !1110
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M)K5/5-:II[?Y_,P?,FT[J2;33WC+9I^?<3 ]!^0_PHP/0?E0"2.1S2T!^/\
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M,****!A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M_27>SMVYK:7\K_U8]1O3OV]7^GS/!?%O[0GA[P9>M8W8C,B-M)./7'KT'O\
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MQ\*?W%_.C_AK'PI_<7\ZA_X9#\'_ //VO^?PH_X9#\'_ //VO^?PK#_C?O\
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MI\[?)C\+3M&.*M\<Y7DWO?4\2E)0C6C%>U;H*U:F^5)7_P"7D5M)>>OI<V/
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MH?\ @CIXO\?_  G^-/B3]GGQ[;W]IINB7$\=M'+%(EL&1ROREP%[=NO!^O\
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M<LQN*R_&4Y4\3@ZT\/5C-6ES4VX\UNTK77EL+11170<H4444 %%%% !1110
M4UFVXXZTZB@!5/0D<>GX5/INF77B'6].T&RB:234YTMUVC."[!?X<G\N]59"
M$&&X+<+[D\#I[U^H7_!-7]F"Y^*7CV#7_$,$2Z=IMPL]N]P  =C;EY88[=1D
M"O(SW.,-D.58O-<7)1IX:E*44W9SJ;0C%=7S6_JY]!PKP[C.*L^RW(L%!SJX
MW$0A4:6D*2E%U)2>T4X72?\ P#]@OV#_ -E/0?!GP7DL/&.FQ33ZUI3RP^?"
MK,&EB++@LN<_-QW_ #K\'_V\_P!G[4OA)\5=7UV.U>VT&^N9FM<*5CVO(2NW
MC;W ]_TK^P"RTFWT?3K'2+26UBATZ)+=0DB %$4*,8/I]*^$OV_OV:[+XW_#
M.^OK1+/[;HUH\Y>-D,C-'&6ZC)[9^O%?RYP9X@8C"<9U\QS"M)X/.Z_LL2FV
MXTU*5J4HP^RW=)VL[^A_<OB3X28+'^'.&RC)\-%9APQA8UL$X)>TKSA!2KPG
M/>27O-;IG\@\;B1%<<A@"*4 @DD\<X'/K6CK^A7?A?7M5T&^4HVGW4ELO!&0
MCD#CMT]ZSP,#%?UQ&49QC*+O"<8SBT]XR2DG=>31_GW*,Z<Y4ZD7"I3G*G.,
ME9J<'RR7WH6BBBJ$%13/Y<;/Z"I:AG0R1,H[U4+<\.;2//'F_P /,K_A<4OA
MEZ:>OG_7^1]Z?LQ>'K;P9HUW\4+B-7\NW?:74,-P&1U';K]/PKYG^,?CK5OB
M/XTU._OKF4V1ED^SQQR,JJH;"@ <<9'0=A]:^H/V9-<M?&OAR\^&#RHD[6SE
M1(P4$[2._?U]>*^5?BQX.U3P%XWU72KJTN&MXY9!%)%"S(1O./F QZ=_PYX_
ME[PUC@*GC]XE3XF]B^/J&#HOA[ZTH^TAPA[2/U6> Y](S<OC<'=K38_UF^B1
M')UX44I91[%XB685/[5<.7V_UCE]Z-1KWN1=+Z7T..\-:OJWA#6].U70KN>&
MX2[B\PF5\,@8$@C=@@@8(]/K7Z$_&,0_&;X5Z3JHCC_M/2K1'NYE4!G:.($E
MF !_$XZ_6OSQT33=4\1:SING:797332W<*LQA<!49U#$G&.GKBOT.^+:Q_!K
MX3:/8O+&;W6+2-9XE8%E:6(*=RYR/0\>O/%:^/<<"N/O!VMEOLO^(C//:\<G
ME0Y?K=3+N6+QL<<Z>LL*J'-[&-3W5+56/L/I%+*9>#_%*SI4?8QITGA/:\OM
M/K'/[GU?[7,Y6YN7IUZ'YL<I+- >3!(T1^J':?Z'_/*JV3C'^?RI ?,FGG_Y
M[RM+_P!]G/XGH.*?7]--OW;[\D.;RER1YO\ R:Y_C3%Z>7Z7T_ _1;_@D_\
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MA:Z1 V^"QC6&-_[RHJJ"/^^?\\5^6<6++%F'_"?;VFOUM0_A*KI?D:_$_/\
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MGY+I\A0ITJ:M3IQIW;<N1)*3>[:75V6H4445)84444 >6_&G_D0]9_Z]9?\
MT!J_@]_;M_Y+1J?_ %_3?^C37]X?QI!/@360/^?67_T6U?P=_MW$#XT:GR.+
MZ<'D<8E-?M?A*_\ :JZZ\C_)'\Q?2._Y%> _Z_Q_./\ D_N/D2BF[U_O+^8_
MQHWK_>7\Q_C7[J?R(.HIN]?[R_F/\:-Z_P!Y?S'^- #J*;O7^\OYC_&C>O\
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M[V_#YGT?^T3\=F^.^J0ZM=Q@3Q$$M@ D@]SWZYYZ=J^=5^Z*AC6->1M7&.A
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M]XC\':'8:)HSR6T%I D++&=@.Q0O('!QVR#VK\P]Z?WE_,5&T5KG@1G\0/\
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M_,?XTQ#J*;O7^\OYC_&C>O\ >7\Q_C0 ZCKU%-WK_>7\Q_C1O7^\OYC_ !H
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M'2W_ +L?\CXKA6\<PX@NK)XN4EOM>.OSZ>G<]$HK(^W2^A_[Y'^%'VZ7T/\
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M_P#?$G^-?W(?9M"_Z!.G?]\Q_P#Q-'V;0O\ H$Z=_P!\Q_\ Q-'_ !%7/O\
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M #X7_P#WQ)_C1_PZH^,W_/A?_P#?$G^-?W(?9M"_Z!.G?]\Q_P#Q-'V;0O\
MH$Z=_P!\Q_\ Q-'_ !%7/O\ H'I?AY?\'[_(/^)=>$?^@O%??Z?U\_6_\-__
M  ZH^,W_ #X7_P#WQ)_C1_PZH^,W_/A?_P#?$G^-?W(?9M"_Z!.G?]\Q_P#Q
M-'V;0O\ H$Z=_P!\Q_\ Q-'_ !%7/O\ H'I?AY?\'[_(/^)=>$?^@O%??Z?U
M\_6_\-__  ZH^,W_ #X7_P#WQ)_C1_PZH^,W_/A?_P#?$G^-?W(?9M"_Z!.G
M?]\Q_P#Q-'V;0O\ H$Z=_P!\Q_\ Q-'_ !%7/O\ H'I?AY?\'[_(/^)=>$?^
M@O%??Z?U\_6_\-__  ZH^,__ #X7_P#WQ)_C1_PZH^,W_/A?_P#?$G^-?W(?
M9M"_Z!.G?]\Q_P#Q-'V;0O\ H$Z=_P!\Q_\ Q-'_ !%7/O\ H'I?AY?\'[_(
M/^)=>$?^@O%??Z?U\_6_\-__  ZH^,W_ #X7_P#WQ)_C1_PZH^,W_/A?_P#?
M$G^-?W(?9M"_Z!.G?]\Q_P#Q-'V;0O\ H$Z=_P!\Q_\ Q-'_ !%7/O\ H'I?
MAY?\'[_(/^)=>$?^@O%??Z?U\_6_\-__  ZH^,W_ #X7_P#WQ)_C1_PZH^,W
M_/A?_P#?$G^-?W(?9M"_Z!.G?]\Q_P#Q-'V;0O\ H$Z=_P!\Q_\ Q-'_ !%7
M/O\ H'I?AY?\'[_(/^)=>$?^@O%??Z?U\_6_\-__  ZH^,W_ #X7_P#WQ)_C
M1_PZH^,W_/A?_P#?$G^-?W(?9M"_Z!.G?]\Q_P#Q-'V;0O\ H$Z=_P!\Q_\
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M_P#B:/\ B*N??] ]+\/+_@_?Y!_Q+KPC_P!!>*^_T_KY^M_X;_\ AU1\9O\
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M_P#B:/\ B*N??] ]+\/+_@_?Y!_Q+KPC_P!!>*^_T_KY^M_X;_\ AU1\9O\
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MMT3_ * EG_WY7_XFC_B*F??] ]'I_P"V^7K^/8/^)=^$/^@O%=/_ &W^OO\
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M^XB\B/\ N_Y_*CR(_P"[_G\JE!R,TM+FEW?]?U_5V"Z:+[O3_+\"'R(_[O\
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MV2V_YX1_]\T?ZC\,?]"Z/_@3\O\ @_AYA_Q%GC[_ *'<_P#P!?U_7FS]]/\
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M'W&N?\\9O^^#_A1_P^WUT?\ +&7\%S^F*_ O[+;?\\(_^^11]GMCQY$>1_L
M>W4"FN!^%^N7+RM+T_X/X!_Q%GCW_H=S_P#!:\OZ^_OK^^G_  ^XUP=89OQ0
M_P"%'_#[C7/^>,W_ 'P?\*_ HVEL1CR8_P#OD4HM+8<>1'Q_LBC_ %'X8_Z%
MT?\ P)^5_P!;?\.'_$6>/O\ H=S_ / %_7]>9^^G_#[C7?\ GC-_WP?\*/\
MA]QKO_/&;_O@_P"%?@7]DMO^>$?_ 'S1]DMO^>$?_?-+_4?AC_H71_\  GY?
M\'\/,/\ B+/'W_0[G_X OZ_KS9^^G_#[C7?^>,W_ 'P?\*/^'W&N_P#/&;_O
M@_X5^!?V2V_YX1_]\T?9+;_GA'_WS1_J/PQ_T+H_^!/R_P"#^'F'_$6>/O\
MH=S_ / %_7]>;/WT_P"'W&N_\\9O^^#_ (4?\/N-=_YXS?\ ?!_PK\"_LEM_
MSPC_ .^:/LEM_P \(_\ OFC_ %'X8_Z%T?\ P)^7_!_#S#_B+/'W_0[G_P"
M+^OZ\V?OI_P^XUW_ )XS?]\'_"C_ (?<:[_SQF_[X/\ A7X%_9+;_GA'_P!\
MT?9+;_GA'_WS1_J/PQ_T+H_^!/R_X/X>8?\ $6>/O^AW/_P!?U_7FS]]/^'W
M&N_\\9O^^#_A1_P^XUW_ )XS?]\'_"OP+^R6W_/"/_OFC[+;?\\(_P#OFC_4
M?AC_ *%T?_ GY?\ !_#S#_B+/'W_ $.Y_P#@"_K^O-G[Z?\ #[G7!UAF'_ #
M_A1_P^XUS_GC-_WP?\*_ H6ML>1#'_WR*7[);?\ /&/_ +Y%'^H_#'_0NC_X
M$_+_ (/X>8?\18X^W_MN6O\ <72V_P#7YZ_OI_P^XUW_ )XS?]\'_"C_ (?<
M:[_SQF_[X/\ A7X%_9+;_GA'_P!\T?9+;_GA'_WS1_J/PQ_T+H_^!/R_X/X>
M8?\ $6>/O^AU/_P6OZZ?GW9^^G_#[C7?^>,W_?!_PH_X?<:[_P \9O\ O@_X
M5^!?V2V_YX1_]\T?9+;_ )X1_P#?-'^H_#'_ $+H_P#@3\O^#^'F'_$6>/O^
MAW/_ , 7]?UYL_?3_A]QKO\ SQF_[X/^%'_#[C7?^>,W_?!_PK\"_LEM_P \
M(_\ OFC[);?\\(_^^:/]1^&/^A='_P "?E_P?P\P_P"(L\??]#N?_@"_K^O-
MG[Z?\/N-=_YXS?\ ?!_PH_X?<:[_ ,\9O^^#_A7X%_9+;_GA'_WS1]DMO^>$
M?_?-'^H_#'_0NC_X$_+_ (/X>8?\19X^_P"AW/\ \ 7]?UYL_?3_ (?<:[_S
MQF_[X/\ A1_P^XUW_GC-_P!\'_"OP+^R6W_/"/\ [YH^R6W_ #PC_P"^:/\
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M+>7X?UV7W$/D1_W?\_E1Y$?]W_/Y5-11S2[O^OZ_K4+>7X?UV7W$/D1_W?\
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MR56#M9Q>R:O=DU%%%>N?.A1110 4444 %%%% !3'=47<YPO _/C%/KT+X/\
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MJL(XE5@S$N.!C'/I7]@O[#GQ]^#WP#^%&@>"O$7C#3HM2MK:WCFBEN(@Z.J
M,#ELC!'/?Z\5_/YXJ\56'[,?PYM/"VGV<+:OKED&6<JOG*TJ#E6QN&,Y'H>G
M!-?G-JGB7Q?K6I2ZQ)XDU.VEDE:18H[F0*H+[@% ?  ^N,U_(6)H>*/TC:>-
MS/AOBVGX8>'>"QU;#\-9E0R^CF^,XLIT9.E4QU:A6TPT/:P=/W--/F?Z=_1_
M^CIEG#.3X3BOB'$U<1GN=8*%1X*+<*>!H3M.$+Q7OO5.[UUZ61_H[^"_BAX'
M^(]HNH>%=:M=2C=0P,$J..03CY2?_P!?2NZY'%?Q+?\ !.']M/Q_\/?B?I/@
MO5]6O;S0KBXMX&:YF9^&=5/WF/\ /\>U?VF^$]<M_%/AK3=?M&#17=M!)D'/
MWXU;WZ9^M?E>7UN+>%>-<S\+>/E0Q6?9=EE/.LHX@PFF'S[(ZE14J6*Q-./N
M87'.7Q8>*:4=5H?IO%G"_P#8,Z>)P\W4P6(FX0YOBIU-'R=+QMUL;E([+&C2
M.=L:<NQZ #DTM9GB5VC\+:O(A(=;>7:PZCY37V\5>26MVTE;S:1\:H\TXJ_Q
M222VW:OMO]QS6H?%[X1Z'.;/7/&.GV%ZIPUO+<1HP(/((+=NG8]ZICXY?! M
M@>/-+ZC_ )>X>,_\"_K7\T_[2VE:QKWQ;OI'\1ZG:(+R3;%%<R(F"YXVAL>O
MI].*\R/@?403CQ5JO;K=3<<?[W%?H=+@K!3H4*U7,ZT95J<:KC&BG&+ERW2?
M:_W^CT^SI\+86=*E4ECZR=2$9./LTTKVT3^_7MJNQ_5:WQP^!PL=3#>/-++-
M8SJH-U%DGRVQCYN6SC@XXSS7\YOQ7^,/B?PK\>=7\9?#OQ')=:+8:A)-/;6T
M[&.YC2;<P"JVTY4=AWKP,^"-28$'Q7JN"""/M4W(/8Y:M70/"EKX>>23[0]^
M\^?-:X8N7SG.[=UZY]_UKVLHX=P>42Q-2.+GC/K%&--T:U)*%M+OM=INW5/5
MGJ9=DV$RU5YK$2Q+KTU3=.I37+:Z;;??=+L?T-_LL_M7>%OCUX7LX+R]@L/$
MUK;QV\NG.RI/+*J@%MK%6)+ G.._Y_7KQO&<,".!UZG(X]?>OY--)U?Q3\+O
M$]KXZ\"WES#=PW"37-C Q$/ECESL4@= 1T]:_?+]E#]KSPU\<?#]II-[<1CQ
M7:1I'J$;.-_FH K#;GKG/7]:^1X@X;E@U/'X"+G@I2O.FM9X:3>L9+K"_P ,
MCYO.,CEAE+&8-.>%<OWE-*\L/)M7O_<WL_/9'VM13B,<]CR/I3:^./G%+=6^
M=M-^C"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH 0]#]#_*N\\$]9?J?Y&N#
M/0_0_P J[SP3UE^I_D:Y\9_ND_\ $OT-\+_O$/27Z'H?\?\ P'^M%'\?_ ?Z
MT5\^>R>9^,?O:1_UYG^2UQM=EXQ^]I'_ %YG^2UQM?0X7_=J/^!_^ER/$K_Q
M9^OZ(****W,@JS:QK([ASM C<CZA21_*JU*"1TXH _ ?_@J?^VE^TA^SM'/!
M\(O VK>)8I Z.UC:SS87!&?W2-V/KST/6OXKOBS^T_\ &WQQ^U#X9^+_ (E\
M'ZI8?$"PN[>ZM-'FBG2YDFCE#JJQE0Q);C@$]O6O]2_5_"'@OQ#I]['XA\+Z
M/K4KQ,$.H6D,YR5(R#(C'.<?YYK^1W]J3_@FW\4_%W_!1WP-\4O"_A"S@^'&
MGZQ9S7MG;V*+8M"ET'=60($*E,YZC\Z\[&4*DN62E.2E-+ELFEM[R]//Y:'I
MX+$4HWC*G&+C!^_S6<[VNGZVM^%K'K7_  3#_P""AW[7'QP^(%GX0^)GPVUS
M0/#ULL%K#>WEG<Q1M#&H1&#2(HP5 (.2*_JA@^>QM9FP))44NO<':,_K7%^#
M/AWX \,^']'&E>"] TG4H--LHYKBRL((93-' JR,65 Q.X')SZUV8(^Z.B\
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MCTK]!_$%OIW_  D-D!IMH%#(2!$@'7)Z+CD'TKOVM=*^7_B5V?W1_P L(_\
MXFMJG@SF\*=!OQ)SZ?/"Z7+\&VFL_/\ JQA2RNM*=9?VA53C42NH_'I%WZ]'
MU_X#_+C_ (3;XV_\^-__ -\2?X4?\)M\;?\ GQO_ /OB3_"OU%^RZ5_T"[/_
M +\1_P#Q-'V72O\ H%V?_?B/_P")K'_B#N;?]'&S[_P%>7]_T^[R-_[(K_\
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MU?ME\4_^"DUE\4? NI>#]5BCECOHI$+ORPWJ1WSCTXX^G?\ &37/LKZM<RV
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 AZ'Z'^5=YX)ZR_4_R-<&>A^A_E7>>">LO
MU/\ (USXS_=)_P")?H;X7_>(>DOT/0_X_P#@/]:*/X_^ _UHKY\]D\S\8_>T
MC_KS/\EKC:[+QC][2/\ KS/\EKC:^APO^[4?\#_]+D>)7_BS]?T04445N9!1
M110 5"UCI\CK-);Q-.O(<Q(6SZ[L9]._OUJ:BG?;R=P%SC@<# &!QV /\J3\
M***0DK;>H4444#"BBB@"IJ/_ "#KG_<;^0KF_!O_ ![7?^^?YM72:C_R#KG_
M '&_D*YOP;_Q[7?^^?YM73#_ ':M_CA^:.2I_O5#_!/\T=?1117,=84444 %
M%%% "C/4=O;I5E+J:,<'C&!D#^9!JL"1D>M&XXQVIJ36S:O]P)NZZ+JUONAT
MDCRN&9AQZ*/7_/:I1=3*,!AC_=']:KT4^>?\S^\=WYDDDKR_?.?P%,SQC'/K
M244-WU;;E]^@O\[^?W[C@N03GIGMZ#-&WY=V?PQ[XI"2>O-)4@_)O?MNOO"A
MU/0'&._X444#^0!=WRY_'Z?GUI!\KJG7GK^)_P *6E'4?4?SIIM".!\0<^(;
M( 8^X*[]OX?]T5P&O?\ (Q67U3^E=^W\/^Z*ZL1_"PO_ %Z?YHY,.[U<0^]1
M^GPQZ#:***Y#K"BBB@ IQ7 !SUQV]1FFT4 '/I12@D CUI*;>R2]=7OW *!\
MIRO!]<?C_.BBB+L[]MM;"U[]=K>FG]=RPMU.!C>#_P !6H3,ZMO!^8YYX_EC
MWIM%/GG_ #/[RKO35Z;>19^US=-P_P"^5_PJN[%LLW)Y)_PI**<I-VO)OUVN
M#;>[&J<@\8Y_H*=114""BBB@ HHHH **** "MK0?^/[_ +8S?^BVK%K:T'_C
M^_[8S?\ HMJ3V?H_R*A\<?\ %'\T?Q5_MK?\I+[+_L8%_P#2L5_87\*O^21>
M"/\ L&6O_I.E?QY?MKY_X>867I_PD*=,_P#/T.N.V?\ Z_%?V&_"K_DD7@C_
M +!EK_Z3I7TF=?[EE/\ V#+_ -)@?"\*/_A2XB5G_OC=^FKCIZZ'7T445\X?
M<7"BBB@":">2W??$0K YY /Z&M0:_J0 'FQ\# _=)_A6+10U%I72;UW2=O0:
ME);-KT;1:N;R>Z.9F#'.>% _E58GT&*2BC]-%Z(+_P!/7\PHHHH$%%%% 'EO
MQI_Y$/6?^O67_P! :OX/?V[?^2T:G_U_3?\ HTU_>-\8H)+KP;J=G#S-<6TB
MHHY8ED8#'XG]/8U_&#^V;^R/\8O%?Q8U#5-(TC4);66\ED5T@=@0SDCG:>V/
M3\,\_LGA7B</A\36>(KTZ*<)6=27*G9+8_FSZ0N"QF,RS QPF&K8F4:T7*-&
M#FXKW=9)+1:'Y=T5]0_\,3?'+_H!ZG_WXF_^)H_X8F^.7_0#U/\ [\3?_$U^
MV_VKE?\ T,,+_P"#5Y?Y_AZV_D_^PL[_ .A3C_\ P1+R_P W]Q\O45]0_P##
M$WQR_P"@'J?_ 'XF_P#B:/\ AB;XY?\ 0#U/_OQ-_P#$T?VKE?\ T,,+_P"#
M5Y?Y_AZV/["SO_H4X_\ \$2\O\W]Q\O45]0_\,3?'+_H!ZG_ -^)O_B:/^&)
MOCE_T ]3_P"_$W_Q-']JY7_T,,+_ .#5Y?Y_AZV/["SO_H4X_P#\$2\O\W]Q
M\O45]0_\,3?'+_H!ZG_WXF_^)H_X8F^.7_0#U/\ [\3?_$T?VKE?_0PPO_@U
M>7^?X>MC^PL[_P"A3C__  1+R_S?W'R]17U#_P ,3?'+_H!ZG_WXF_\ B:/^
M&)OCE_T ]3_[\3?_ !-']JY7_P!##"_^#5Y?Y_AZV/["SO\ Z%./_P#!$O+_
M #?W'R]17U#_ ,,3?'+_ * >I_\ ?B;_ .)H_P"&)OCE_P! /4_^_$W_ ,31
M_:N5_P#0PPO_ (-7E_G^'K8_L+._^A3C_P#P1+R_S?W'R]1U&*^H?^&)OCE_
MT ]3_P"_$W_Q-+_PQ/\ '+_H!ZE_X#R__$T?VKE?_0PPM_\ KZO+^OEY.Q_8
M>>6M_9..W6]"7EY>=OD_0^4FLX&))!R3W;WSQT- LX0,8;_OH_\ UZ^JC^Q+
M\<B<_P!B:G_X#2_H=O%+_P ,3?'/_H":EC_KWF_P_I0LWRVUGF.&?G[5=;>?
M1/\ !^9/^K^<O7^Q\9_X3RZV\OZ^^WRLEI G(4Y[$L<CI_A5@ *,#@?Y%?4?
M_#$WQR_Z >I_^ \O_P 32']B;XY$8_L/4_\ P'E_^(I_VME;WS'"^7[U/MWM
M;?\ #[A9#G>RRC'1VVP\O+3;S?IKVN?+I; )'Z'_ #ZT Y&:^H1^Q+\<O^@'
MJ?\ X#R_T04O_#$OQR_Z >I_]^)O_B:7]JY7_P!##"_^#(^7^?X>MJ619W9+
M^R<=Z^PE_=Z6TM=_<?+U%?4/_#$WQR_Z >I_]^)O_B:/^&)OCE_T ]3_ ._$
MW_Q-']JY7_T,,+_X-7E_G^'K8_L+._\ H4X__P $2\O\W]Q\O45]0_\ #$WQ
MR_Z >I_]^)O_ (FC_AB;XY?] /4_^_$W_P 31_:N5_\ 0PPO_@U>7^?X>MC^
MPL[_ .A3C_\ P1+R_P W]Q\O45]0_P##$WQR_P"@'J?_ 'XF_P#B:/\ AB;X
MY?\ 0#U/_OQ-_P#$T?VKE?\ T,,+_P"#5Y?Y_AZV/["SO_H4X_\ \$2\O\W]
MQ\O>^.:*^H?^&)OCE_T ]3_[\3?_ !-'_#$WQR_Z >I_]^)O_B:/[5RO_H88
M7_P9'R_S_#UL+(\\_P"A3CM;?\N)?W?\W]WW?+$ENDG+!N/0XZU%]B@YX//H
M2#^=?5O_  Q/\<\8_L34\'_IWE_^)H_X8G^.7_0#U+_P'E_^(I_VME=O^1CA
MKV5E[56Z>?9_U9D/A_.FT_[(QM[ZWP[N]NMO/7_@'RG]C@]&_P"^JE2*.+[O
M'7J?SKZF_P"&)OCE_P! 35/IY$O_ ,3FD/[$OQR/_,$U/_P'E/\ -:7]KY:]
M\RPTKOK57EY].^^GW-9!G5[K)\:GW^KRZV\O-_=]WR_17U#_ ,,3?'+_ * >
MI_\ ?B;_ .)H_P"&)OCE_P! /4_^_$W_ ,31_:N5_P#0PPO_ (-7E_G^'K:O
M["SO_H4X_P#\$2\O\W]Q\O45]0_\,3?'+_H!ZG_WXF_^)H_X8F^.7_0#U/\
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M#"_^#5Y=?ZV];']A9VTE_9..M_UXEUM?IY_AZV^4_L=OUP?KNH^QVY[$_P#
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MZ'J1\N]MW.;>3@*X).2!^7M7]EG_  35\#:]X#^!6@:/X@@D@O(+2!'65"C
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MPO\ X)I^7_ ^_P!+<_\ \*N^&'_0LVG_ (#Q?_$T?\*N^&'_ $+-I_X#Q?\
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M/*Q]5PW_ $"87_P33\O^!]_I;G_^%7?##_H6;3_P'B_^)H_X5=\,/^A9M/\
MP'B_^)KH-EQ_S\I_WU_]:C9<?\_*?]]?_6H]IB/^@FKT_P"7DO[OG_6GE8^J
MX;_H$PO_ ()I^7_ ^_TMS_\ PJ[X8?\ 0LVG_@/%_P#$T?\ "KOAA_T+-I_X
M#Q?_ !-=!LN/^?E/^^O_ *U&RX_Y^4_[Z_\ K4>TQ'_035Z?\O)?W?/^M/*Q
M]5PW_0)A?_!-/R_X'W^EN?\ ^%7?##_H6;3_ ,!XO_B:/^%7?##_ *%FT_\
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M\_ZT\K'U7#?] F%_\$T_+_@??Z6Y_P#X5=\,/^A9M/\ P'B_^)H_X5=\,/\
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M_H6;3_P'B_\ B:V?]/\ ]JC_ $__ &J/:8C3_::O3_E[+^[Y^G_ Z'U7#_\
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M_P"!T/JN'_Z \-_X(AY>7I_2TQO^%7?##_H6;3_P'B_^)H_X5=\,/^A9M/\
MP'B_^)K9_P!/_P!JC_3_ /:H]IB-/]IJ]/\ E[+^[Y^G_ Z'U7#_ /0'AO\
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M#PW_ ((AY>7I_2TQO^%7?##_ *%FT_\  >+_ .)H_P"%7?##_H6;3_P'B_\
MB:V?]/\ ]JC_ $__ &J/:8C3_::O3_E[+^[Y^G_ Z'U7#_\ 0'AO_!$/+R]/
MZ6F-_P *N^&'_0LVG_@/%_\ $T?\*N^&'_0LVG_@/%_\36S_ *?_ +5'^G_[
M5'M,1I_M-7I_R]E_=\_3_@=#ZKA_^@/#?^"(>7EZ?TM,;_A5WPP_Z%FT_P#
M>+_XFC_A5WPP_P"A9M/_  'B_P#B:V?]/_VJ/]/_ -JCVF(T_P!IJ]/^7LO[
MOGZ?\#H?5</_ - >&_\ !$/+R]/Z6F-_PJ[X8?\ 0LVG_@/%_P#$T?\ "KOA
MA_T+-I_X#Q?_ !-;/^G_ .U1_I_^U1[3$:?[35Z?\O9?W?/T_P"!T/JN'_Z
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M_P"M;%Y]OZ^_S_JS-:BLG_3_ /:H_P!/_P!JCD_O+[_3S\_ZUL7GV_K[_/\
MJS-:BLG_ $__ &J/]/\ ]JCD_O+[_3S\_P"M;%Y]OZ^_S_JS-:BLG_3_ /:H
M_P!/_P!JCD_O+[_3S\_ZUL7GV_K[_/\ JS-:BLG_ $__ &J/]/\ ]JCD_O+[
M_3S\_P"M;%Y]OZ^_S_JS-:BLG_3_ /:H_P!/_P!JCD_O+[_3S\_ZUL7GV_K[
M_/\ JS-:BLG_ $__ &J/]/\ ]JCD_O+[_3S\_P"M;%Y]OZ^_S_JS-:BLG_3_
M /:H_P!/_P!JCD_O+[_3S\_ZUL7GV_K[_/\ JS-:BLG_ $__ &J/]/\ ]JCD
M_O+[_3S\_P"M;%Y]OZ^_S_JS-:BLG_3_ /:H_P!/_P!JCD_O+[_3S\_ZUL7G
MV_K[_/\ JS-:BLG_ $__ &J/]/\ ]JCD_O+[_3S\_P"M;%Y]OZ^_S_JS-:BL
MG_3_ /:H_P!/_P!JCD_O+[_3S\_ZUL7GV_K[_/\ JS-:BLG_ $__ &J/]/\
M]JCD_O+[_3S\_P"M;%Y]OZ^_S_JS-:BLG_3_ /:H_P!/_P!JCD_O+[_3S\_Z
MUL7GV_K[_/\ JS-:BLG_ $__ &J/]/\ ]JCD_O+[_3S\_P"M;%Y]OZ^_S_JS
M-:BLG_3_ /:H_P!/_P!JCD_O+[_3S\_ZUL7GV_K[_/\ JS-:BLG_ $__ &J/
M]/\ ]JCD_O+[_3S\_P"M;%Y]OZ^_S_JS-:BLG_3_ /:H_P!/_P!JCD_O+[_3
MS\_ZUL7GV_K[_/\ JS-:BLG_ $__ &J/]/\ ]JCD_O+[_3S\_P"M;%Y]OZ^_
MS_JS-:BLG_3_ /:H_P!/_P!JCD_O+[_3S\_ZUL7GV_K[_/\ JS-:BLG_ $__
M &J/]/\ ]JCD_O+[_3S\_P"M;%Y]OZ^_S_JS-:BLG_3_ /:H_P!/_P!JCD_O
M+[_3S\_ZUL7GV_K[_/\ JS-:BLG_ $__ &J/]/\ ]JCD_O+[_3S\_P"M;%Y]
MOZ^_S_JS-:BLG_3_ /:H_P!/_P!JCD_O+[_3S\_ZUL7GV_K[_/\ JS-:BLG_
M $__ &J/]/\ ]JCD_O+[_3S\_P"M;%Y]OZ^_S_JS-:BLG_3_ /:H_P!/_P!J
MCD_O+[_3S\_ZUL7GV_K[_/\ JS-:BLG_ $__ &J/]/\ ]JCD_O+[_3S\_P"M
M;%Y]OZ^_S_JS-:BLG_3_ /:H_P!/_P!JCD_O+[_3S\_ZUL7GV_K[_/\ JS-:
MBLG_ $__ &J/]/\ ]JCD_O+[_3S\_P"M;%Y]OZ^_S_JS-:BLG_3_ /:H_P!/
M_P!JCD_O+[_3S\_ZUL7GV_K[_/\ JS-:BLG_ $__ &J/]/\ ]JCD_O+[_3S\
M_P"M;%Y]OZ^_S_JS-4]#]#7>^"<CS,]R2/R/_P!:O+F^W;,_-GG^O:O1? 2W
M!\PR\X)//OG\^E<N-36%J6DK777TTW_0Z,*Y?6*=UNG^GK^AZ=_'_P !_K11
M_'_P'^M%?.GMGF?C#[VD?]>9_DM<;79>,?O:1_UYG^2UQM?0X7_=J/\ @?\
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MY^7]7T_<S_A^%X]_Y\I_RD_QH_X?A>/?^?*?\I/\:_#/R(?^>2?]\BCR(?\
MGDG_ 'R*/]2>%_\ H5T^G5_W?\OR\K/_ (BEQ]:_]OU[72^%?W?/R_J^G[F?
M\/PO'O\ SY3_ )2?XTG_  _"\>Y ^Q7&?H^/QYS^O_U_PT\B'_GDG_?(H$40
M/$2#WVK_ )_2E_J3PO?_ )%5/9=7;I^.G_ 6EE_Q%/CU?\S^N]K>ZM-M=_+_
M (&K1^YG_#\+Q[_SY3_E)_C1_P /PO'O_/E/^4G^-?ADT*$@^6F._P H]?\
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M (BGQZK?\+]9>7*O[OGY?U?3]R?^'X7CW_GRG_*3_&C_ (?A>/?^?*?\I/\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MPWB1L8%\PA0Q8+COGG^0K[M\)^*]*\<:)9>(=%ECEM+^!+A41@3&KKN"MSU
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M;2'CMU)X ^I/%<;KGQ,^'GA:\33O$&NVMI>R$*D1N(P2[' &-W<\5\Y?MO\
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MX*_92AO;&.[^(-^- ,JAHUFE\HDD<8#$?E[UT7[+W@_3?"5I=_$OQ##'-9K
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MM)L^0O'W[+>I>-M5FU-/$,MJDKLZH)B-HSGIGT./I^5<)_PQ7J1Z^*I^F/\
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M6_Y27V7_ &,"_P#I6*_L+^%7_)(O!'_8,M?_ $G2OX]/VUO^4E]E_P!C O\
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MA+_O-?\ P/\ )'\Q?2-_Y%> _P"O\?S@?(=%%%?NI_(@4444 %%%% !1110
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M/="TX0Z*TCS3R1*-A)R6)*@#ZG@8YYS7X[0S+.F\<_,RGO\ =.*_7/X^?\%
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M3Y'HKZX_X83^-W_0"U;_ ,!I/\*/^&$_C=_T M6_\!I/\*/[7RG_ *&&'_\
M UUMY_WD'^K7$/\ T)\;_P""I_\ R/K_ $]/D>BOKC_AA/XW?] +5O\ P&D_
MPH_X83^-W_0"U;_P&D_PH_M?*?\ H88?_P #76WG_>0?ZM<0_P#0GQO_ (*G
M_P#(^O\ 3T^1Z0C(P1P:^N?^&$_C=_T M6_\!I/\*/\ AA/XW?\ 0"U;_P !
MI/\ "C^V,I_Z&&'Z?;7EY_WD+_5KB%Z/)\;_ ."I_P#R/K_3T^/&L[;!;RP3
M[D^M(ME;$ ^4/U]:^Q/^&$_C=_T M6_\!I/\*/\ AA/XW?\ 0"U;_P !I/\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M1;!]Z_W0\O\ @_UL7Q?\M+[WY?\ !_I*\_\ PD6D?\]A^?\ ]>C_ (2+2/\
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M )_XWI]J77E_S_#S#V,O^@;+^G_+JG_=_N^GX7ZWRO['^$?_ $+EC_WX@_\
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MH_L?X1_]"Y8_]^(/_B:U?^$?\)?]!.#_ +[6C_A'_"7_ $$X/^^UHYZ'_/\
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MKR__ "7X![&6G^S8#I_RZI_W?[OI_2=\K^Q_A'_T+EC_ -^(/_B:4Z/\(_\
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M_P (II/HW_?0_P *+8/O7^Z'E_P?ZV+XO^6E][\O^#_25Y_^$BTC_GL/S_\
MKT?\)%I'_/8?G_\ 7J#_ (132?1O^^A_A1_PBFD^C?\ ?0_PHM@^]?[H>7_!
M_K8OB_Y:7WOR_P"#_25Y_P#A(M(_Y[#\_P#Z]'_"1:1_SV'Y_P#UZ@_X132?
M1O\ OH?X4?\ "*:3Z-_WT/\ "BV#[U_NAY?\'^MB^+_EI?>_+_@_TE>?_A(M
M(_Y[#\__ *]'_"1:1_SV'Y__ %Z@_P"$4TGT;_OH?X4?\(II/HW_ 'T/\*+8
M/O7^Z'E_P?ZV+XO^6E][\O\ @_TE>?\ X2+2/^>P_/\ ^O1_PD6D?\]A^?\
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M4TGT;_OH?X4?\(II/HW_ 'T/\*+8/O7^Z'E_P?ZV+XO^6E][\O\ @_TE>?\
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MB_Y:7WOR_P"#_25Y_P#A(M(_Y[#\_P#Z]'_"1:1_SV'Y_P#UZ@_X132?1O\
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M[H>7_!_K8OB_Y:7WOR_X/])7G_X2+2/^>P_/_P"O1_PD6D?\]A^?_P!>H/\
MA%-)]&_[Z'^%'_"*:3Z-_P!]#_"BV#[U_NAY?\'^MB^+_EI?>_+_ (/])7G_
M .$BTC_GL/S_ /KT?\)%I'_/8?G_ /7J#_A%-)]&_P"^A_A1_P (II/HW_?0
M_P *+8/O7^Z'E_P?ZV+XO^6E][\O^#_25Y_^$BTC_GL/S_\ KT?\)%I'_/8?
MG_\ 7J#_ (132?1O^^A_A1_PBFD^C?\ ?0_PHM@^]?[H>7_!_K8OB_Y:7WOR
M_P"#_25Y_P#A(M(_Y[#\_P#Z]'_"1:1_SV'Y_P#UZ@_X132?1O\ OH?X4?\
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M5Y_^$BTC_GL/S_\ KT?\)%I'_/8?G_\ 7J#_ (132?1O^^A_A1_PBFD^C?\
M?0_PHM@^]?[H>7_!_K8OB_Y:7WOR_P"#_25Y_P#A(M(_Y[#\_P#Z]'_"1:1_
MSV'Y_P#UZ@_X132?1O\ OH?X4?\ "*:3Z-_WT/\ "BV#[U_NAY?\'^MB^+_E
MI?>_+_@_TE>?_A(M(_Y[#\__ *]'_"1:1_SV'Y__ %Z@_P"$4TGT;_OH?X4?
M\(II/HW_ 'T/\*+8/O7^Z'E_P?ZV+XO^6E][\O\ @_TE>?\ X2+2/^>P_/\
M^O1_PD6D?\]A^?\ ]>H/^$4TGT;_ +Z'^%'_  BFD^C?]]#_  HM@^]?[H>7
M_!_K8OB_Y:7WOR_X/])7G_X2+2/^>P_/_P"O1_PD6D?\]A^?_P!>H/\ A%-)
M]&_[Z'^%'_"*:3Z-_P!]#_"BV#[U_NAY?\'^MB^+_EI?>_+_ (/])7G_ .$B
MTC_GL/S_ /KT?\)%I'_/8?G_ /7J#_A%-)]&_P"^A_A1_P (II/HW_?0_P *
M+8/O7^Z'E_P?ZV+XO^6E][\O^#_25Y_^$BTC_GL/S_\ KT?\)%I'_/8?G_\
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M -\_S:NF'^[5O\</S1R5/]ZH?X)_FCKZ***YCK"BBB@ HHHH ***!STY^E
M>AI!NQDC'./\]ZD\M_[IIO/3],?Y-&OR#\P((Q[TE2;)#@%3@>W2F$8.*?2_
MX=0_K\A****&[O:WD 4444@"E'4?4?SI*4=1]1_.@#@=>_Y&*R^J?TKOV_A_
MW17 :]_R,5E]4_I7?M_#_NBNO$?PL+_UZ?YHX\-_$K_]?'_Z3$;1117(=@44
M44 %%%% "*-HQUYI:#TX^]Z_A_C[4@SCGK0 M%%')Z GZ"GI9]^@"CD\\"@]
M3]:-C$9*L![\?ES0 20!G^=(+M_=_2#9_'DY]/TI*E9)%&,';@'IZG\^M,&.
M=P/^?RH ;1113;O;2VGW@%%%%( HHHH **** "MK0?\ C^_[8S?^BVK%K:T'
M_C^_[8S?^BVI/9^C_(J'QQ_Q1_-'\5?[:W_*2^R_[&!?_2L5_87\*O\ DD7@
MC_L&6O\ Z3I7\>G[:W_*2^R_[&!?_2L5_87\*O\ DD7@C_L&6O\ Z3I7TF=?
M[EE'_8,O_28'PW"G_(QXB_[#9?G Z^BBBOG#[<**** "BCD]!3]CCG:::O=6
MWOH!'D4M1_=8D]#GI^=24.]]=P6NMG]VP4444@"BBDSR!W- [NUNAYE\7[Q]
M(\(:EK4/^NL())8P.I*HS#]1^=?QG_MH?\%EOC/\(/BQ?>$M%6Z^R6MY+ FT
MN!M1RHY#<\#'J>>.*_LG^.8)^''B#I_QYS_^BG]J_P V/_@I,H/[0&KKM7=_
M:D_.!_SU<'T-?:\,X:AB&E7I1JJ*ERJ6J7PMZ;?(_,>/L?C,OC2G@\1.A*;B
MI.#LY*RWOVO;9Z;=#[-_X?Q?'G_GG??^1*/^'\7QY_YYWW_D2OQ+"+@?*O\
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M[Y'^%&Q?[J_]\C_"C^R<M_Z!*?W>G^3^\/\ 63/?^AEB/O\ ^#Y?U=G[:?\
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MD&XSC)6<6MTT]F$XSA*4)IQG!\KC)---:6:MT$HHHJ"0HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M?QK[4^'?Q:\!?%[1X=;\":E#?VLZAP(Y4=UR,_,H;(]\X^E? O[.O["7[/\
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M_EM.Z36S5_O"BBBI&%%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !7O_['O_)QWA'_ +"-G_Z-2O *^@/V//\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MT_Y)QX@_Z\Y__135_FR_\%)O^2^ZO_V%)_\ T8U?>\(_&O27Z'Y/XD_PZ/\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MG\O\:+L!M%.V-Z?R_P :-C>G\O\ &@!M.8 '@Y_S[4;&]/Y?XTH4@C*_R_\
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MX>==Q<')03;6V_D?SX;U_O+^8HWK_>7\Q_C7ZM_\.;_VA/\ H$ZG_P" \_\
M\31_PYO_ &A/^@3J?_@//_\ $U]G_:F7_P#072Z?:77E\_[WX'Y=_8.<?]"^
MO_X!+K;R\_ZUM^4F]?[R_F/\:-Z_WE_,?XU^K?\ PYO_ &A/^@3J?_@//_\
M$T?\.;_VA/\ H$ZG_P" \_\ \31_:F7_ /072Z?:77E\_P"]^ ?V#G'_ $ 8
MC_P!^7EY_P!:V_*3>O\ >7\Q_C1O7^\OYC_&OU;_ .'-_P"T)_T"=3_\!Y__
M (FC_AS?^T)_T"=3_P# >?\ ^)H_M3+_ /H+I=/M+KR^?][\ _L'./\ H Q'
M_@#\O+S_ *UM^4F]?[R_F/\ &C>O]Y?S'^-?JW_PYO\ VA/^@3J?_@//_P#$
MT?\ #F_]H3_H$ZG_ . \_P#\31_:F7_]!=+I]I=>7S_O?@']@YQ_T 8C_P
M?EY>?]:V_*3>O]Y?S'^-&]?[R_F/\:_5O_AS?^T)_P! G4__  'G_P#B:/\
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M:-Z_WE_,?XU^K?\ PYO_ &A/^@3J?_@//_\ $T?\.;_VA/\ H$ZG_P" \_\
M\31_:F7_ /072Z?:77E\_P"]^ ?V#G'_ $ 8C_P!^7EY_P!:V_*3>O\ >7\Q
M_C1O7^\OYC_&OU;_ .'-_P"T)_T"=3_\!Y__ (FC_AS?^T)_T"=3_P# >?\
M^)H_M3+_ /H+I=/M+KR^?][\ _L'./\ H Q'_@#\O+S_ *UM^4F]?[R_F/\
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M13MC>G\O\:-C>G\O\: &T4[8WI_+_&C8WI_+_&@!M%.V-Z?R_P :-C>G\O\
M&@!M%.V-Z?R_QHV-Z?R_QH ;13MC>G\O\:-C>G\O\: &T4[8WI_+_&C8WI_+
M_&@!M%.V-Z?R_P :-C>G\O\ &@!M%.V-Z?R_QHV-Z?R_QH ;13MC>G\O\:-C
M>G\O\: &T4[8WI_+_&C8WI_+_&@!M%.V-Z?R_P :-C>G\O\ &@!M%.V-Z?R_
MQHV-Z?R_QH ;13MC>G\O\:-C>G\O\: &T4[8WI_+_&C8WI_+_&@!M%.V-Z?R
M_P :-C>G\O\ &@!M%.V-Z?R_QHV-Z?R_QH ;13MC>G\O\:-C>G\O\: &T4[8
MWI_+_&C8WI_+_&@!M%.V-Z?R_P :-C>G\O\ &@!M%.V-Z?R_QHV-Z?R_QH ;
M13MC>G\O\:-C>G\O\: &T4[8WI_+_&C8WI_+_&@!M%.V-Z?R_P :-C>G\O\
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MX^7^7]65LOJ\_P#H(J_AY?Y?U96X#^TO$W_/ _Y_"C^TO$W_ #P/^?PKO\G
M;C)XZ?US[4F\^W^?QIJO%[8>E^/E_E_5E8^KS_Z"*OX>7^7]65N!_M+Q-_SP
M/^?PH_M+Q-_SP/\ G\*[[>?;_/XT;S[?Y_&E]8A_T#TOQ\O\OZLK'U>?_015
M_#R_R_JRMP/]I>)O^>!_S^%']I>)O^>!_P _A7?;S[?Y_&C>?;_/XT?6(?\
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M/+_+^K*W _VEXF_YX'_/X4?VEXF_YX'_ #^%=]O/M_G\:-Y]O\_C1]8A_P!
M]+\?+_+^K*Q]7G_T$5?P\O\ +^K*W _VEXF_YX'_ #^%']I>)O\ G@?\_A7?
M;S[?Y_&C>?;_ #^-'UB'_0/2_'R_R_JRL?5Y_P#015_#R_R_JRMP/]I>)O\
MG@?\_A1_:7B;_G@?\_A7?;S[?Y_&C>?;_/XT?6(?] ]+\?+_ "_JRL?5Y_\
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M2\3?\\#_ )_"C^TO$W_/ _Y_"N_W%>P&>>G^>:8TI7' .::KQ>BP]+\>EO\
M+^M+'U>?_015_#R_R_JRMP?]I>)O^>!_S^%']I>)O^>!_P _A7?;S[?Y_&D\
MWW7_ #^-+ZQ#_H'I?CY?Y?U96/J\_P#H(J_AY?Y?U96X+^TO$W_/ _Y_"C^T
MO$W_ #P/^?PKOMY]O\_C1YA]O\_C1]8A_P! ]+\?+_+^K*Q]7G_T$5?P\O\
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MOMY]O\_C1O/M_G\:/K$/^@>E^/E_E_5E8^KS_P"@BK^'E_E_5E;@?[2\3?\
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MN/\ QH^HYC_T+5]\O+^[_7WV/[<R/3_A8CT^S#^[_7R]+?K1]E7_ *%2T_\
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M$>GV8?W?Z^7I;]:/LJ_]"I:?^ Z__$T?95_Z%2T_\!U_^)K\E_\ A^I\"?\
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MW,CT_P"%B/3[,/[O]?+TM^M'V5?^A4M/_ =?_B:/LJ_]"I:?^ Z__$U^2_\
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ME_\ A^I\"?\ GIIG_?<?^-'_  _4^!/_ #TTS_ON/_&CZCF/_0M7WR\O[O\
M7WV/[<R/3_A8CT^S#^[_ %\O2WZT?95_Z%2T_P# =?\ XFC[*O\ T*EI_P"
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M_K[[']N9'I_PL1Z?9A_=_KY>EOUH^RK_ -"I:?\ @.O_ ,31]E7_ *%2T_\
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MOMY]O\_C1O/M_G\:/K$/^@>E^/E_E_5E8^KS_P"@BK^'E_E_5E;@?[2\3?\
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M?Y?U96/J\_\ H(J_AY?Y?U96X'^TO$W_ #P/^?PH_M+Q-_SP/^?PKOMY]O\
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MG\:/K$/^@>E^/E_E_5E8^KS_ .@BK^'E_E_5E;@?[2\3?\\#_G\*/[2\3?\
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M !]Z**FDMY8T$DB%4;H3TYII-W\@;LTM=2$%2I.><_X>U((U.23CZ_\ ZQ0
M!TJ>&WFN#B%"Y'I_G%#>VEAD0!/ INW!)YSSG\ZT/[-OP3BW;<!G&1_]?M47
MV*Z+[/*;?U(^M&EO._RL'XE6BM%=+OMP!MV]<<'^M4Y8I879)8RA!Z'\?\^E
M("*BBB@ HHHH **** "BBB@ K:T'_C^_[8S?^BVK%K:T'_C^_P"V,W_HMJ3V
M?H_R*A\<?\4?S1_%7^VM_P I+[+_ +&!?_2L5_87\*O^21>"/^P9:_\ I.E?
MQZ?MK?\ *2^R_P"Q@7_TK%?V%_"K_DD7@C_L&6O_ *3I7TF=?[EE'_8,O_28
M'PW"G_(QXB_[#9?G Z^BBBOG#[<**** "BI88VD?:JEF/  &236A_8NIX#?9
M9"#TZ4FTMVEZC5^BO\KF21G!]*?N.,<8X_2IKFRNK8?OHFB.>_'\JK#H._%/
M\17U>@M%%%  #CFE))Y-(3@$^E-#9&>G- _6_EZGE7QS)'PW\08X)LY^>X_=
M/TK_ #9/^"D]QJR_M :OY&IW$4?]J3G:KN ,R'C@C _PK_29^.A!^''B#!_Y
M<Y^G_7)J_P VC_@I."/C]JX'.=3G[?\ 35O\*^\X1;Y^5_#RR=W:W3O_ %Y'
MY-XE7]G0U=^:&S:_E[>7](^%/M6N?]!BY_[Z;_XJC[5KG_08N?\ OIO_ (JG
MT5]Y\E]R\O+R7W'Y!=^?]?\ #+[AGVK7/^@Q<_\ ?3?_ !5'VK7/^@Q<_P#?
M3?\ Q5/HH^2^Y>7EY+[@N_/^O^&7W#/M6N?]!BY_[Z;_ .*H^U:Y_P!!BY_[
MZ;_XJGT4?)?<O+R\E]P7?G_7_#+[AGVK7/\ H,7/_?3?_%4?:M<_Z#%S_P!]
M-_\ %4^BCY+[EY>7DON"[\_Z_P"&7W#/M6N?]!BY_P"^F_\ BJ0W&MG@ZQ<_
M]]-_C4E%'R7W+R\O)?<%WY_U_P ,ON(C<Z[P!K%UCH?G;I^)_E2BYUP#']L7
M/_?3?XU)36SCKC')/MWH^2^Y>7EY+[AIK3XK=?PV^Y?AU#[3KG_08N<]OG;_
M !H^TZX#SJ]R?^!O_P#%59T_3=6UNX2ST*SEU&\; 6&%&=B>G09/7]?PKLV^
M#'QL1#</X!U<0;=YD^S3;=F,[N4/8'\.?6N'%YKE& G&CF&;Y1EU::3A1Q^8
M83!U91NES1IUZD)M;6=OF7##XFNI.AAL57@MY4:-6JEMNZ<6EHEY'!_:];&3
M_;%UQG^-A^'7/ZT@NM<<DC6+K\7;V[[JL7]AJ.CSFSUNUDL+I3M:&571PPX(
M((7N/3K^D0XZ<?2NR$J=2$*M*5.K3J14J=6FXU*<XZ-2IU(MQG%Z:Q=O4S=H
MJ[<XM-*4974D]/LO5-:;V&?:=<_Z#%S_ -]-_P#%4?:M<_Z#%S_WTW_Q5/HJ
MODON7EY>2^X5WW?]6_R0S[5KG_08N?\ OIO_ (JC[5KG_08N?^^F_P#BJ?11
M\E]R\O+R7W#N_/\ K_AE]PS[5KG_ $&+G_OIO_BJ/M6N?]!BY_[Z;_XJGT4?
M)?<O+R\E]P7?G_7_  R^X9]JUS_H,7/_ 'TW_P 51]JUS_H,7/\ WTW_ ,53
MZ*/DON7EY>2^X+OS_K_AE]PS[5KG_08N?^^F_P#BJ/M6N?\ 08N?^^F_^*I]
M%'R7W+R\O)?<%WY_U_PR^X9]JUS_ *#%S_WTW_Q5'VK7/^@Q<_\ ?3?_ !5/
MHH^2^Y>7EY+[@N_/^O\ AE]PS[5KG_08N?\ OIO_ (JC[5KG_08N?^^F_P#B
MJ?11\E]R\O+R7W!=^?\ 7_#+[AGVK7/^@Q<_]]-_\51]JUS_ *#%S_WTW_Q5
M/HH^2^Y>7EY+[@N_/^O^&7W#/M6N?]!BY_[Z;_XJC[5KG_08N?\ OIO_ (JG
MT4?)?<O+R\E]P7?G_7_#+[AGVK7/^@Q<_P#?3?\ Q5'VK7/^@Q<_]]-_\53Z
M*/DON7EY>2^X+OS_ *_X9?<,^U:Y_P!!BY_[Z;_XJC[5KG_08N?^^F_^*I]%
M'R7W+R\O)?<%WY_U_P ,ON&?:M<_Z#%S_P!]-_\ %4?:M<_Z#%S_ -]-_P#%
M4^BCY+[EY>7DON"[\_Z_X9?<,^U:Y_T&+G_OIO\ XJC[5KG_ $&+G_OIO_BJ
M?11\E]R\O+R7W!=^?]?\,ON&?:M<_P"@Q<_]]-_\51]JUS_H,7/_ 'TW_P 5
M3Z*/DON7EY>2^X+OS_K_ (9?<,^U:Y_T&+G_ +Z;_P"*H^U:Y_T&+G_OIO\
MXJGT4?)?<O+R\E]P7?G_ %_PR^X9]JUS_H,7/_?3?_%4?:M<_P"@Q<_]]-_\
M53Z*/DON7EY>2^X+OS_K_AE]PS[5KG_08N?^^F_^*H^U:Y_T&+G_ +Z;_P"*
MI]%'R7W+R\O)?<%WY_U_PR^X9]JUS_H,7/\ WTW_ ,51]JUS_H,7/_?3?_%4
M^BCY+[EY>7DON"[\_P"O^&7W#/M6N?\ 08N?^^F_^*H^U:Y_T&+G_OIO_BJ?
M11\E]R\O+R7W!=^?]?\ #+[AGVK7/^@Q<_\ ?3?_ !5'VK7/^@Q<_P#?3?\
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MOIV_N?Y_U=W/JV%_Z"%T^S_A\O-?<OE_7=_PT_\ !+_H;= _\&-K_P#'*/\
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MV)RBC3PJS?!RQ&*PU.T8QKJ=N>$;Z)Z]+&'1117[<?@ 4444 %%%% !1110
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MX)_0W"U*C6S*K&O2A6@L+5E&$U=*2Y;2]5K_ %JLQ_VS/CXK8"W!X!SN;O\
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M_$4?VIPO_P! F:_^#J7E_7_#L/J&;_\ /_!_^"Y>7EY?CZW^5_\ AX+\!O\
MGE>_]^G_ /B:/^'@OP&_YY7O_?I__B:^J/\ AC;]G?\ Z)]IWZ?_ !%'_#&_
M[.XZ_#_3OT_^(H_M3A?_ *!,U_\ !U+R_K_AV'U#-_\ G_@__!<O+R\OQ];_
M "R?^"@?P'&/W5]S_P!,G_S_ "I#_P %!/@,#CRKW_OT_P#@:^I_^&-_V>.I
M^'^G?7(_^(H_X8W_ &=SS_PK_3C[\?\ Q%']J<+_ /0)FO\ X.I>7]?\.P^H
M9O\ \_\ !_\ @N7EY>7X^M_E?_AX+\!O^>5[_P!^G_\ B:/^'@OP&_YY7O\
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M ,%!?@,,?NKWG_ID_P#A7U3_ ,,;?L[_ /1/M._3_P"(I#^QI^SN<?\ %O\
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M/1>EK?=OKOMJ?G[KO_!.[X:W/@2R\':->'2&L6,RWMEF*>1\DY+IM/7U/?\
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M1:;>A-WJK[O7S?F5=1RVGW9Q_P LVS_WSQ7->#L?9KO']\_^A/\ TKI-2/\
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MO\_-?>:-%9W]L:5_S]I^8H_MC2O^?M/S%'LJG_/N?_@+_KK_ %9A[2'\\?\
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MYBC^V-*_Y^T_,4>RJ?\ /N?_ ("_ZZ_U9A[2'\\?_ E_GYK[S1HK._MC2O\
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MV0O^A2TG_P !8?\ XFOH/];L-_T!8G[GY?W?ZU\CXC_B&V9?]!^%Z?\ MO\
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M %NPW_0%B?N?E_=_K7R#_B&V9?\ 0?A>G_MO^;^[R/\ -2\[6?\ H6]9_P#
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M  ZW_9"_Z%+2?_ 6'_XFC_6[#?\ 0%B?N?E_=_K7R#_B&V9?]!^%Z?\ MO\
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M %NPW_0%B?N?E_=_K7R#_B&V9?\ 0?A>G_MO^;^[R/\ -2\[6?\ H6]9_P#
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MY^:^\T:*SO[8TK_G[3\Q1_;&E?\ /VGYBCV53_GW/_P%_P!=?ZLP]I#^>/\
MX$O\_-?>:-%9W]L:5_S]I^8H_MC2O^?M/S%'LJG_ #[G_P" O^NO]68>TA_/
M'_P)?Y^:^\T:*SO[8TK_ )^T_,4?VQI7_/VGYBCV53_GW/\ \!?]=?ZLP]I#
M^>/_ ($O\_-?>:-%9W]L:5_S]I^8H_MC2O\ G[3\Q1[*I_S[G_X"_P"NO]68
M>TA_/'_P)?Y^:^\T:*SO[8TK_G[3\Q1_;&E?\_:?F*/95/\ GW/_ ,!?]=?Z
MLP]I#^>/_@2_S\U]YHT5G?VQI7_/VGYBC^V-*_Y^T_,4>RJ?\^Y_^ O^NO\
M5F'M(?SQ_P# E_GYK[S1HK._MC2O^?M/S%']L:5_S]I^8H]E4_Y]S_\  7_7
M7^K,/:0_GC_X$O\ /S7WFC16=_;&E?\ /VGYBC^V-*_Y^T_,4>RJ?\^Y_P#@
M+_KK_5F'M(?SQ_\  E_GYK[S1HK._MC2O^?M/S%']L:5_P _:?F*/95/^?<_
M_ 7_ %U_JS#VD/YX_P#@2_S\U]YHT5G?VQI7_/VGYBC^V-*_Y^T_,4>RJ?\
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M?!OX!>+/"OBX3^*I+"PGMX=/NU>[EEV(X\]8W+EMW!!'7\*^?? O_!3#XZ?
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MGX]_\%1O%+?$;P1\&?"K7T7AS4[*V6[U#>ZQB5XUP3+P/O'U_'M7Z1_\$_\
MXT?'#Q+?>.=,\73/>>"])L)[G1KCS/,WD1,R8;)YQZ<_K5?XC_\ !'?X?^+]
M!TI=,O+;3_%.F011Q:N.)-\0 #!Q@]L]<_RKZ^_9 _9"U3]G/0[[1M;\0CQ
ME[$\+L6\SY&! !)SG />@&U96[?CUN?C3XZ#>.OVAO$GB;5+F6*_TV[OHK-7
M8B0!&81[>0<=.!7XY?$#X6?M ^(_VP+?Q9I.OW,/@_2-76?48?M!5VM8Y@S
M -S\JGC'IUK^BCXI?LU^-8/VT+&WT/2+A_!>N2[KN]2-S AN22Q9@-GR[N<D
M?@,9U-;_ ."2GBR]^,C^/M/^(:VOAZYN5DN]&$K 2Q;PS(5Z8(R#QSF@<9)7
M3TZK^K'X_P"B_$1_CA^W!\-OA!J>JZQ8_#N!=.LM>N[N26/3S(&2.<L[D1D
M9Y)KUW_@L?\ ";0?V:XOA3)\"==O+FXU.XC.M1Z+<QRR)&;R2,--]CFE4*T
M1AN;)!R1C&?VH^+G_!,+X>>)?!]NGP\^S^%?B#%;JK^)H@L,SW(3_6B9=K@[
M^>O;/ICRCX(?\$K-7TN/4!\??&H^)$C[_P"S6O)GO/L@P?*V^:S[=G'3'3-
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M87][/^$^VFJ.3#X>@ZF(_=1UJ:;Z647W.0_X0O3_ /GL_P"G^-'_  A>G_\
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M_P!!FW_[_C_XJC_A"]'_ .@S;_\ ?\?_ !5?QR?\/D?B5_SUN?\ OM_\*/\
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M]TO+^OO[:?V-_P#"%Z/_ -!FW_[_ (_^*H_X0O1_^@S;_P#?\?\ Q5?QR?\
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MH_\ T&;?_O\ C_XJC_A"]'_Z#-O_ -_Q_P#%5_')_P /D?B5_P ];G_OM_\
M"C_A\C\2O^>MS_WV_P#A0_#;B[^>#M9[Q\OZ^?W'_$>^ ?\ GW5^Z7E_7S?R
M_L:;P7I0'[O58Y3_ '8Y=S?D&-0_\(=8_P#/Q+_WT?\ &OYQ_P#@G3_P4E\;
M_M#?'RW\":T]P;6211AV9A@L!G#'U!_#M7].%]"()V13GY4./]Y0?_K=/\*^
M0S[*\TX=QD<#CJW[Z5&-;W;649>:T>NY^D\(<3Y)QKED\VRFF_JU/$RPLO:7
M3]I%*75[-?+\3A_^$.L?^?F7_OK_ .RH_P"$.L?^?F7_ +Z_^RKJ<'=D\?[/
M/ICV_E3J\3ZWB/\ G[+\/\CZKZM1O;V<?O?3Y^7]7.4_X0ZQ_P"?F7_OK_[*
MC_A#K'_GYE_[Z_\ LJZNBG]9Q-K^UE9^G^0?5Z'_ #[7X_Y^7]79RG_"'6/_
M #\R_P#?7_V5'_"'6/\ S\R_]]?_ &5=403T.*123U!&,=>]"Q6)>U67?[/^
M0?5Z'_/M?C_GY?U=G+?\(=8_\_,O_?7_ -E1_P (=8_\_,O_ 'U_]E75T4OK
M6)>U23^[_(7U>C_S[7X^7GY?GW9RG_"'6/\ S\R_]]?_ &5'_"'6/_/S+_WU
M_P#95U=%'UK$?\_9?A_D/ZO0_P"?:_'_ #\OZNSE/^$.L?\ GYE_[Z_^RH_X
M0ZQ_Y^9?^^O_ +*NKHH^MXC_ )^R_#_(/J]#_GVOQ_S\OZNSE/\ A#K'_GYE
M_P"^O_LJ/^$.L?\ GYE_[Z_^RKJZ*/K>(_Y^R_#_ "#ZO0_Y]K\?\_+^KLY3
M_A#K'_GYE_[Z_P#LJ/\ A#K'_GYE_P"^O_LJZNBCZWB/^?LOP_R#ZO0_Y]K\
M?\_+^KLY3_A#K'_GYE_[Z_\ LJ/^$.L?^?F7_OK_ .RKJZ*/K>(_Y^R_#_(/
MJ]#_ )]K\?\ /R_J[.4_X0ZQ_P"?F7_OK_[*C_A#K'_GYE_[Z_\ LJZNBCZW
MB/\ G[+\/\@^KT/^?:_'_/R_J[.4_P"$.L?^?F7_ +Z_^RI#X.LL<7,N?][_
M .O7644?6\1_S]E^'^0?5Z'_ #[7X_Y^7]79R@\'67>YES_O?_7II\%Z>>L\
MGY_US76T4?6\1_S]E^'^0OJU!Z>SC^/^?E_5V<E_PA>G?\]G_,?XT?\ "%Z?
M_P ]G_3_ !KK:*/K>(_Y^R_#_(/JU#_GU'\?+S\D<E_PA>G_ //9_P!/\:/^
M$+T__GL_Z?XUUM%'UO$?\_9?A_D'U:A_SZC^/EY^2.2_X0O3_P#GL_Z?XT?\
M(7I__/9_T_QKK:*/K>(_Y^R_#_(/JU#_ )]1_'R\_)')?\(7I_\ SV?]/\:/
M^$+T_P#Y[/\ I_C76T4?6\1_S]E^'^0?5J'_ #ZC^/EY^2.2_P"$+T__ )[/
M^G^-'_"%Z?\ \]G_ $_QKK:*/K>(_P"?LOP_R#ZM0_Y]1_'R\_)')?\ "%Z?
M_P ]G_3_ !H_X0O3_P#GL_Z?XUUM%'UO$?\ /V7X?Y!]6H?\^H_CY>?DCDO^
M$+T__GL_Z?XT?\(7I_\ SV?]/\:ZVBCZWB/^?LOP_P @^K4/^?4?Q\O/R1R7
M_"%Z?_SV?]/\:/\ A"]/_P">S_I_C76T4?6\1_S]E^'^0?5J'_/J/X^7GY(Y
M+_A"]/\ ^>S_ *?XT?\ "%Z?_P ]G_3_ !KK:*/K>(_Y^R_#_(/JU#_GU'\?
M+S\D<E_PA>G_ //9_P!/\:/^$+T__GL_Z?XUUM%'UO$?\_9?A_D'U:A_SZC^
M/EY^2.2_X0O3_P#GL_Z?XT?\(7I__/9_T_QKK:*/K>(_Y^R_#_(/JU#_ )]1
M_'R\_)')?\(7I_\ SV?]/\:/^$+T_P#Y[/\ I_C76T4?6\1_S]E^'^0?5J'_
M #ZC^/EY^2.2_P"$+T__ )[/^G^-'_"%Z?\ \]G_ $_QKK:*/K>(_P"?LOP_
MR#ZM0_Y]1_'R\_)')?\ "%Z?_P ]G_3_ !H_X0O3_P#GL_Z?XUUM%'UO$?\
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MK:*/K>(_Y^R_#_(/JU#_ )]1_'R\_)')?\(7I_\ SV?]/\:/^$+T_P#Y[/\
MI_C76T4?6\1_S]E^'^0?5J'_ #ZC^/EY^2.2_P"$+T__ )[/^G^-'_"%Z?\
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MC(PRI_$?YQ3J8KK5=>OEVM^-PHHHH **** *FH_\@ZY_W&_D*YOP;_Q[7?\
MOG^;5TFH_P#(.N?]QOY"N;\&_P#'M=_[Y_FU=,/]VK?XX?FCDJ?[U0_P3_-'
M7T445S'6%%%% !1110 X[L#/3M3:"V!N8_*O4GH .O7CI7(ZG\1_ >C3_9=4
MUJ"UN,[#&77[WKC(KGQ.,P>"IJKC<9A<'3ORJIBJT*$&W;12J-*[Z*^I,IP@
MKU)Q@MKSERKTNSKJ*R-/\1Z#K-N;S2KZ.XM5&YI%8$ 8R3Z<#U_4<UA7?Q.^
M'NGRFWO-?@AG4E60R+D,.HZ]?;G_  BKF664:5.O5S+ 4J%5)TJU3%4H4JNV
MM.<I*,U=[Q;1/M*:2;K4^5[2<DD]MG?6VIVE%8^D^)- \0IYFAWT=ZH&6*.K
M<?A6R#@\C/L:Z*56C7IQJT*U+$4:BO"M1G&K3DK[QG%V?R=BXR4E>+4EWBTU
M]ZT&+NYW?AT_I3J7DGIU-+L;T_E_C6B3>R\M/E_G_5AC:*=L;T_E_C1L;T_E
M_C3Y9=G_ %_P_P#5F VE'4?4?SI=C>G\O\:<J,648[CN*7++L_Z_X?\ JS \
M^U[_ )&*R^J?TKOV_A_W17!Z^C#Q%9<=T_GBN_>-AL..JCN*Z\0I>RPNC_A/
MIYHY,,G[3$>51W^Z*(J*=L;T_E_C1L;T_E_C7+RR[/\ K_A_ZLSK&T4[8WI_
M+_&C8WI_+_&CEEV?]?\ #_U9@-H'/'K3MC>G\O\ &J]Q=VMDR"[E6$N<('8+
MD_YQ_G%)VBN:;C"*M>4VHQ5[6NWIUZ[[";LKW2VU>VX]EVD+G@DY_(8[4X%4
M&#GOM_S^(J0QDJLG#(PW*VX'(XP<Y].?PIF,]1G\*;NG=QLM&NS6FJ\F.S2O
MW?\ 5O+^KC=S*">X/'TZ4\D%<C[QR?SS^'I1MRI/H>F/I4%U/;64)N;N80P1
M@EW)V[5QD_D/I4MQC&3FU",5=RD^6,4M>:3>BBEUV7XH;LKO1+=O1$J[L?-U
MS_GI2UPZ_%3X;M<FS'B&W-R&V&/S%SOSC'7'7CIWKIIM<T>VM1J%Q>1QV##>
MLQ8 %2,@Y/'OV_PXZ.999B55EALRP&(C0_C2HXJE4C1MHW4<)-02?65MC.-2
ME)R<:L)65Y<LXM1];/3S-+\#_G\:48P<]>,=?QKA5^*OPV:86X\16_G;MFSS
M$^]G&,YKM+6ZM-0A6YLIEEMWP4D4A@0>G(/T_.JPV88#&.:P688+&2I_''"X
MFE6E!;>\J<I-*_5V73<I58335.=*;6_*U)K;>S=G^OR):***ZB@HHHH ****
M "BBB@ K:T'_ (_O^V,W_HMJQ:VM!_X_O^V,W_HMJ3V?H_R*A\<?\4?S1_%7
M^VM_RDOLO^Q@7_TK%?V%_"K_ ))%X(_[!EK_ .DZ5_'I^VM_RDOLO^Q@7_TK
M%?V%_"K_ ))%X(_[!EK_ .DZ5])G7^Y91_V#+_TF!\-PI_R,>(O^PV7YP.OH
MHHKYP^W"BBB@ IP8@$>M5;W4+#1[6;4M5F6VT^U0R7,[D!8XQR6)[8 /6OG3
M5_VX_P!C[0+V;3=5^*NDV]];/Y5Q";R%FCD!VE3ASW!^F#[U<*=6=_9T:E7H
M^2#G:_5VV,JN(P]%+V^(HT$_A]M4C3YN]N9JY])TX*2"?2O.? WQF^%/Q7C\
M[X;>);?Q!#C.Z"19!@C.?E)_6O1VR"5(VD<$#U[U+C*+M*+C);J2::?FGL7"
MI"I%2ISC4A+52A)2C+T:T8RBBBD4 ..:4DDY-)10O/8#ROXU[O\ A ]9Q_SZ
MS9_[]MZ_Y]:_@X_;MB4_&C4LHIS?SEN%YS)W_6O[R?C2^[P'K"XY%I(?_(;?
MYZ5_![^W;_R6C4_^OZ;_ -&FOVOPE_WJOO\  ^O=+^OZU_F+Z1T;99@+K_E]
M&RT[Q_/2_D?'WD0_\\D_[Y%'D0_\\D_[Y%2T5^[7?G_7_#+[C^1+>7X?UV7W
M$7D0_P#/)/\ OD4>1#_SR3_OD5+11=^?]?\ #+[@MY?A_79?<1>1#_SR3_OD
M4>1#_P \D_[Y%2T47?G_ %_PR^X+>7X?UV7W$7D0_P#/)/\ OD4>1#_SR3_O
MD5+11=^?]?\ #+[@MY?A_79?<1>1#_SR3_OD4>1#_P \D_[Y%2T47?G_ %_P
MR^X+>7X?UV7W$7D0_P#/)/\ OD4>1#_SR3_OD5+11=^?]?\ #+[@MY?A_79?
M<1B"'(S$F,_W12M#"3Q&F.PV\?E3ZM6&GWVJW,5GIL#7-Q*_EK&BECN)
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MBS(10?.3D*!UY]/\]J_N?U7B\)_V(_SV@_UK^&'_ ((Q*3^US9G<1^_3\!N
MK^YW5OENWYS\J8'_  !< =>O:OYO\6M.)J?_ &+Z/^%:K;ST_'S/[;^CBO\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 <A\3]W_  J_Q?C_ *!\W_H!]?;-?*/_  3V
MW>?XFQWU"8]N?G(KZO\ B<?^+8>+_P#L'S?^BVKY1_X)[ F;Q-VQJ$PS_P!M
M":])7_U>S6UE^_H:OII YH7_ +7P.G_+NM]UXZGZN5_)!_P7'^.?Q"^&_P 7
M[*Q\+ZK?65LR*2EO-)&O0_W2.>GMCZU_6]GG&.V<_P!*_C(_X. ;F&'XSV0=
MSG8HP%)[>O;Z>M>AX4T:=?B[#4ZU*-6#P]=N,X\T=.6VC3_0_//'[%5\)X?8
MNMAZ]3#5%C<(E5I3Y)J[DK<VFG==3\<(_P!L'XV% ?\ A(M8)R>EW-C'XM]:
MKG]L/XW?VQX>C'B+5PLNKVB.#=R_,K2H"/O^G7CI[U\V6^H6ICY=EY/&QO\
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MQ)NO"G@:XCL[?0[EH]129PAD6)P'V@D9SM..OX=_2$_:L\"67CF#X;:B9O\
MA)@JQRA6 5I -K, 5.<L#_%SUKY/^)_P]\)^"_B%=>-O 7C!+#75G>>]T6"7
M#WDA;+1E%;)W,2.GUKQ?X5K#XQ_:%N?'/C?2#I)TZ!GBFF0I]I:)25<%@,ES
MR#SUKS+7MIHDW;:[TZ_JCW&VO)N7JK>7]7_3];KKXN^%K+5K/1[F22*YO2HC
M9B @W=-V1_6O!-=_:8MO#7QBC\&7TRSZ3.0$:)PP0. 03@GD9[C QZ9KXO\
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M)V\BWC2&,$DX2,!5QSZ =J4DGK03DYIJC:,=>:8NOY^N@M%%% !112D8Z'-
M%/4?^0=<_P"XW\A7-^#?^/:[_P!\_P VKI-1_P"0=<_[C?R%<WX+YM;K/&7_
M "Y:NF'^[5O\</S1R5/]ZH?X)_FCKZ***YCK"BBB@ HHHH <"N"'4.I_A(!4
M_4&N USX9>%_$%R+R[@CBEW9(C0#/?G &<^_^!KO:*YL7@,!F%+V.882AC*2
MDI*G7@II-6U3Z/\ RV(G3A5NJE.,E=:-)K1(P=*\,:1HEFUA96\0A9=K-L'(
M(QS_ /7_ "X%<W=?"GPI?3FXDA02LQ=L*.N>AXZ?B?K7H5%85<HRFO1I8>ME
MN$JT*"2HTITHN%)+6T%;37^MB71IRBHRIPLMDTFE;[NR,;1O#FE>'XS#I]O$
MOJX10W3'4 ?_ %ZV:*4G))KMI4:.'I1HX>G"A2IJT*5.*C&*\K67_#&D(QBE
M%))*RLE96_KY@.HSTSS0<9XZ4E%7<84Y5 .]NAX[_P!![>M-HR>G:FGYM=M_
M+3\/P 7.#D<>E'5@3G.1ZCN/3%&#Z'\J5!EADXY'\Q2UT[?/\ Z_/3RT7IU.
M U[_ )&&R^J?TKOV_A_W17 >(#CQ%9_5<>^,5W[?P_[HKKQ#;I875Z4WWTU1
MR8>_M,1??VCO_P" Q&T445RW?G_7_#+[CK"BBBB[\_Z_X9?< 4H('503V)[4
ME-9=V.<8]J+O^OZ\D YV8CKSQ@=OUIIW8&.O&>GI^5.HI7!?EL, ;()[?_7]
M*CNK:WO+>6VN8DEBD!#!U#8!&#C(-3T4-*2<914HR34HR2:E%[IIW33#2W+9
M6[6]/\CS)?A#X/-[_: A3S"^\Q[/DW>F.G^<UVEUX>TN\LETV6",6JKL "C[
MH&/\]OTK7V\@CC';'UJ16VYXZUY^'RC*<)&M'#9;A*$<3?ZPJ=)+VU]^?O?K
M8RC1I134:<4I?$DM_4\VB^$GA&&?STA3=OW[=GR[LYZ8]?>N_MK2WL[>.VMH
MDBCB  V*%SC&#QQV]ZL45IA,NR[+W-X# X;"2J*TY4:<8REMNTN^OS'"E3IZ
MTX1@_P"ZK!11178:7"BBB@ HHHH **** "MK0?\ C^_[8S?^BVK%K:T'_C^_
M[8S?^BVI/9^C_(J'QQ_Q1_-'\5?[:W_*2^R_[&!?_2L5_87\*O\ DD7@C_L&
M6O\ Z3I7\>G[:W_*2^R_[&!?_2L5_87\*O\ DD7@C_L&6O\ Z3I7TF=?[EE'
M_8,O_28'PW"G_(QXB_[#9?G Z^BBBOG#[<**** ,_6-)L_$&FW>CZDBR6-]$
MT%PC %6C<88$8Y&/6N-^'?PF\'?"-+^+P9:0V2ZI(\MV($6,.TA+$D+C/)/4
M>U>A4H.#FJYFH\J;2;O*/1M;.W=$.G!SC4<4YPNH3:]Z*>]GTN&X Y?)S]>M
M(J_+D=.O/T%*QW')']:,GWJ?S_X;_@E.^EOG_7F)1110,**** /+?C3_ ,B'
MK/\ UZR_^@-7\'O[=O\ R6C4_P#K^F_]&FO[P_C5@> ]8Y_Y=9<^WR-7\'G[
M=IS\:-3Q_P _TW_HTU^U^$O^\U_\#_)'\Q_2.5LKP'_7^/YP/D.BBBOW4_D,
M**** "BBB@ HHHH *4 G@4E&2.E  >./2D;)4@=2*<3G'L/SI*!-:*SUO=K]
M/U/=/@)\1]-^%7BBT\57$:/>V4BR0[AW4A@>?I_*OU"D_P""L&OND$:ML6")
M845) !M0 +W]/RK\1GC23[XS4/V2W_YYBOF<WX0R+/<3'%YGA5B:T(\D'+51
MCHVHK2W73S^[[7A[Q!XIX6P<\#D>.>"P]2:J58P5I5)I))S:6K25OZT_;Y/^
M"L/B)&W+*0>1_K/48]:^*?VI/VG+/X^V2S2PQC4SDO*!ESNQGYNO(./3C\OA
M8V<!(.W'M3X[>.)BR#&1C'Y?X5SY;P-PWE&,IX_ 8)8?%4M8SAI?REW7EWU\
MCLS?Q/XRS[+ZV5YMF3Q>"KKWZ51<R3LES1TTEIOY+:[%@0QQ(AY(%3445]<?
MGZTT6RT"BBB@ HHHH **** "K.FZC?:'J=GK.F2R17EA*LT(0X#.AR 0.N3]
M:K45%2G3K4JM"O3A6H5Z52C7HU(J5.M1JQ<*M*I%Z2A4@W&2ZIE1G.G*-2G*
M5.I3E&=.<7:4)Q?-&<7TE%I-/NC] O"'[1O@3Q_I%OI_QJM896LXEAB<A2VU
M0 #D]3CK[]?6M?5OC5\"?AW8SS_">S@&INC&-BB[ED*GD'C'/H*_-^6VAFYD
M0-]?>F)96T9!2(#%?SYB/HR>'U3'U*V&S3BW+L@JUWB*W N S:=#A"M*4XSG
M3GEM[>RG/F<H\UI7EW/V_"?2-\6<%D4>'Z7$$IX6-#ZO'%U$Y8^-+EY%%5]]
M(Z+LDCMO'?CW7_B5K<VM>(9':59"8%+$JJY)&![ X_#Z5R=%%?O679=@,GP&
M$RK*L'0R_+<!1CA\%@<+!4\/AJ,$DH4H+X5U?=ML_%<3B<1C,16Q>+K5,1BL
M34E5KUZLG.I5J2=Y3G)ZML****[# **** /U%_X(Q?\ )V]G_P!=U_F:_N>U
M;_C[/^Y'_P"@+7\,/_!&+_D[>S_Z[J?U_P#KU_<WJR?Z86S_  QG'_ %-?SA
MXM_\E-2_[ *7Z']M?1Q_Y(/%?]CK$?\ I"*#_O+>YM6_U5W$T$H[&-P0V?P/
M^>:^)/%?_!.KX ^-]>O?$VK1;=2U&1I;@A0,NY+-SCU)]N:^VJ7)'3(K\YPF
M-Q>"<Y83$U<+*HDIRI2<7))[.WE<_H6ABL5A6Y87$5,/*5E)TY<KDDT]>^Q\
M!G_@F%^SD#@H?^^14T?_  2^_9QE#J4/$<A!( Y521Z?7K7WKFG!F"L%X+!A
MGV88/^?TKK_M_/-5_:V,M;2TUO96Z>7_  YU?VOFW_0QQ/\ X';M_EM\C^2K
MX\^#_P#A6W[1D_PD^'5E=W%A-=O9Q-"K,%)?8IP ?;V]>E?L=^QI^Q'9>&HK
M3X@_$N 3:K*J7-A!<Q[MA*AU#!QQR0#P/Q[_ $[I_P"R1X&C^+<OQ<U>RM]0
MU"25IHUD1'9)"V[(W9Y!_P ?I]7RRJRK#"OEVL0"P0@ *B#@  <<#H.U?09S
MQ74Q>"PN"P<IPE]5IPQ^*;M5K5$ES)-6M?9N^NYZ^9\0RQ.%H8;"N2;H0CBZ
M[?OU)I)-+M_>_F0DDB%8XH8DMX($$4<40"IL4 #@ "H:*<S;L<=*^*5OM7:_
M'U/E[N^UEY?Y;C:***0;=][A1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110!R/Q-;;\,/%Y_P"H=-_Z P_K7RG_ ,$]0?.\
M3GUU&8_^1"/ZU]6?$[_DE_B_C_F'S?\ HMJ^4O\ @GJ3YWB?_L(R_P#H9KTX
M_P#)/YK_ -?\/;[HW_-?<<T/^1O@?^O5;_VT_5NOYV?^"JG_  5:\1?L4?$B
MV\)Z7(R0S("0KE>N#ZCGU_#KFOZ)<<Y]L?KFOX*?^#F.TMYOCY8/(@9O*3OC
MV['KW_SFO)X4P6'Q^;4\/BH>TI2IS;CW:M;TMO<Y>/,RQF59#4Q>!J.E75:E
M!36C49-WL>C1?\''_C5U+"XD[_\ +8_SW=..P-0_\1(GC4ZCI%IY[[;_ %&V
MM&S,3Q-(J$]2._\ D5_)7:Z=9"'/DC)8C&3VS]?7L!]:J-I]HOB#PIMA W:]
M8 \MT^T1GU]J_5UPED2VPB\D_E^JO]VQ^$KCKB:ZOF-3>-FM[W2\MWY]?D?Z
M[/[(GQAN/CQ\#O"'Q'O"6FUVRAN&).>9(8W/(Z_>]37TS-*L,4LS_<BC>1O]
MU%+-^@-?G3_P2L14_8R^%:J, :/:8'_;I!7Z#ZV2NC:JPX*Z=>L/JMO(1^9%
M?AV/IPI8W%4Z:Y80K3C%=HIV1_3F6U9ULOP56I+FJ5<+0J3EWE.G&3?WL^:H
MOVM?AW+XUE\$*MR=1BN/L\DVX>2C;]F6.SC'7K7TQ#JNFSP17$=]:&*9%=&-
MQ$ 0XR!RXY]NN:_G\^'VJ^+O$_[07C'0=-\)R7,+ZA<1MJ_D.?LP$S*) X7
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MK_@G[*-<0*"S30JJ\,S2( OU).!^-.CEBF7?%)'*O]Z-U=?S4D?K7XH?$O\
M:.^)-IXY'@K3A=BR\53[](O%$@5HI6_=E'Z 88=/Y&OK']E[Q=\6XO$MWX/\
M;:?<_P!EI'YT.H3*Y# C<OSL<'.1W[\=:3C:UWO^'XZO7;U[ I-]':Z7]+T/
M>?BM^TGX)^$FI6^E:['<3W=PZ(D=NPSECCIL8UU^@?&3PCXAT*'6[.Y \U _
MV)G4W*9&0&0#/_CHKXO^*.C>']>_:,TFR\0VT=[8K(1MFP4X+8/S9&,C\^E?
M.]MXE?PE^U'J^B6-V[^&$&(M,3<T$8 '10=OY#M3DDDFM]WZ::]]_P"NQ=W7
M9Z?/S_3U\C]C]%\4:7K5JUU#,D"JVTK/(D9^OS%>_&*W6N+=$$KSPK$W21I4
M5#]'+!3^!K\D?B5\0?'+>+K2/2A/I/@KS4>^U&/<D42J06RPP.WK^@JA\4_C
M]XH\0^&(O"OPVOKC4)]/B&R^@:0M/*H&5WJ>23QWI*-TK:]7_=VM?UZ=;ASW
MMH]=/NM_GW_X'Z^?:K;9YOVB#R_^>GFQ[/\ OO=M_6B.ZMIE+Q7$$JCJT<L;
MJ/JRL0/SK\N?@KX[\?Z]\+=;T?XCW5SH>MQ6\WV*:9GC>3:K;2K-@\X]<_T\
MA^ /QZ^(&I^+_&OP[M[FZU:2R6ZCM9V,DG(+!2IR>?I^E-0;\M==-D^M_P!$
M'-HM-^G7I_G<_:-+FUE8^7<02,O!"31N1]0K''7N*5+JVD<QQW$#R#K&DL;.
M/JH8L/RK\F9/C'K'P?\  _BGQ!XQUJ=?$WVN:+3]+D=RYW-M0(A)/?L.<?EQ
MOPR^)_QWO-2\/^/K2RO=1T;Q'>QK-"1(R0PRR@;L<@?+GL/6CDZWTO:_G9/O
MV8[_ 'Z77:Y^MOC?QII/@#0I_$&LL4L8&"O@X.X@]"0?05X]XH_:?\!>%_#=
MAXGN?/GL+_'E^4X+#/3)V$>O;/TKBOVGM2EU?X=Z7I-TAB;4XH;B[!XV2,BE
ME/(Z$'C%?G#\==8O_!/PHTZWTW2FUY(8PRH$:78?48S@#TQVI+E:6[?-9]O0
M+ZV7;^OZT/U^T/XZ>"]<\%R^-X;CR=+BC,C)+(HEX&['W1SCCA37+^#?VF/!
MGC346L=.M;V*-7*F[E_U&U3@ONV ;1ZYQT^E?EEX8UG4]?\ V5;_ ,13M)H]
MW ^5TSYHS(0>$V<'!Z=,<^M?1'P/\17VH?LY:YJ4_@]=+O++1+Q8-9$.R60@
M*?/WE021QT.3GTJ^1)7M=<R6^U[?UMU)YGZ/K>[[=MMSZ\\;?M1^!/!FM0Z+
M+%=:E+*RJ9K)@\2,W9L(V,=^:]%T[XO>%+_1EUOS_(MBGF,)G560;2QW9 Q@
M#GBOB/\ 8GT#PMXZ\">)]9\:6UMK>IP:M+"MU?\ S200?OPS1ESN#H0@5CD#
M.,&L/Q?IS:OJOB#P;HMV]I9WC36]J8R0L8.57!! &,@9SQ2LM='I;7H]K^F]
M_P!4--V3NK/7Y:?KN?6MG^U!X&U+6Y=%TV"\O6AR'N8")( 0<$;EC('(/?\
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M>^">DISW/'YC^1S^%<^,_P!TJ?XHF^&_WBGYJ7XV^[YGH7\?_ ?ZT4?Q_P#
M?ZT5\^>R>9^,1DZ1P2/L?;_@&*XX*5Z C\#_ %IWQ"US5;6?1$M[-I%;3P[-
M@GYF"Y!XXQW_ ,:\]_X2/7"5_P!"?G'13C\1_G/2OJ\)A*WU:C).%G'3WXIV
MYGO_ %^1\WB,325:I&7/\2^P^BBK7Z_Y>1Z"0QZ@_E28/H?RK@?^$CUP=;(_
M]\&C_A(];_Y\S_WQ6_U2MM>GI_T\C_F9?6J7]_\ \ 9WV#Z'\J,'T/Y5P/\
MPD>M_P#/F?\ OBC_ (2/6_\ GS/_ 'Q1]3J]Z?\ X,C_ )A]:I?W_P#P!G?8
M/H?RHP?0_E7 _P#"1ZW_ ,^9_P"^*/\ A(];_P"?,_\ ?%'U.KWI_P#@R/\
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M )A]:I?W_P#P!G?8/H?RHP?0_E7 _P#"1ZW_ ,^9_P"^*/\ A(];_P"?,_\
M?%'U.KWI_P#@R/\ F'UJE_?_ / &=]@^A_*C!]#^5<#_ ,)'K?\ SYG_ +XH
M_P"$CUO_ )\S_P!\4?4ZO>G_ .#(_P"8?6J7]_\ \ 9WV#Z'\J,'T/Y5P/\
MPD>M_P#/F?\ OBE'B+7#_P N1/\ P''\Z/J=7O3_ /!D?\P^M4O[_P#X SOP
M'/ !YSV]OI1M8,!@]1V/^%>?GQ)K@SBR;(_V3G]*0>)-=)4_86SN'&TYQ5+"
M5K6O3LWO[2._:][?UV#ZU2_O_P#@#':^N?$-EE3G*]CT(Q7?L#\O!^Z.U>&:
MUK^KOK=HS6;*ZD8&PY//;''0#K_*NU/B37"%S8D?*/X3717PM5TL,DZ>E-I^
M_'>Z.6AB*4:N)O[2_M$O@?\ +'^NM^AWF#Z'\J,'T/Y5P/\ PD>M_P#/F?\
MOBC_ (2/6_\ GS/_ 'Q7+]3J]Z?_ (,C_F=7UJE_?_\  &=]@^A_*C!]#^5<
M#_PD>M_\^9_[XH_X2/6_^?,_]\4?4ZO>G_X,C_F'UJE_?_\  &=]@^A_*C!]
M#^5<#_PD>M_\^9_[XH_X2/6_^?,_]\4?4ZO>G_X,C_F'UJE_?_\  &=]@^A_
M*C!]#^5<#_PD>M_\^9_[XH_X2/6_^?,_]\4?4ZO>G_X,C_F'UJE_?_\  &=]
M@^A_*C!]#^5<#_PD>M_\^9_[XH_X2/6_^?,_]\4?4ZO>G_X,C_F'UJE_?_\
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MH#_H'7W_ 'YE_P#B:/\ AV=^T!_T#K[_ +\R_P#Q-?W);=-_Z%>W_P"_*?\
MQ%&W3?\ H5[?_ORG_P 10O%+/=/]DPG3[4/[G^7X/Y'_ !+WPK_T,<=_Y-Y>
M7I^/F?PV_P##L[]H#_H'7W_?F7_XFC_AV=^T!_T#K[_OS+_\37]R6W3?^A7M
M_P#ORG_Q%&W3?^A7M_\ ORG_ ,10O%+/=/\ 9,)T^U#^Y_E^#^1_Q+WPK_T,
M<=_Y-Y>7I^/F?PV_\.SOV@/^@=??]^9?_B:/^'9W[0'_ $#K[_OS+_\ $U_<
MEMTW_H5[?_ORG_Q%&W3?^A7M_P#ORG_Q%"\4L]T_V3"=/M0_N?Y?@_D?\2]\
M*_\ 0QQW_DWEY>GX^9_#;_P[._: _P"@=??]^9?_ (FC_AV=^T!_T#K[_OS+
M_P#$U_<EMTW_ *%>W_[\I_\ $4;=-_Z%>W_[\I_\10O%+/=/]DPG3[4/[G^7
MX/Y'_$O?"O\ T,<=_P"3>7EZ?CYG\-O_  [._: _Z!U]_P!^9?\ XFC_ (=G
M?M ?] Z^_P"_,O\ \37]R6W3?^A7M_\ ORG_ ,11MTW_ *%>W_[\I_\ $4+Q
M2SW3_9,)T^U#^Y_E^#^1_P 2]\*_]#''?^3>7EZ?CYG\-O\ P[._: _Z!U]_
MWYE_^)H_X=G?M ?] Z^_[\R__$U_<EMTW_H5[?\ [\I_\11MTW_H5[?_ +\I
M_P#$4+Q2SW3_ &3"=/M0_N?Y?@_D?\2]\*_]#''?^3>7EZ?CYG\-O_#L[]H#
M_H'7W_?F7_XFC_AV=^T!_P! Z^_[\R__ !-?W);=-_Z%>W_[\I_\11MTW_H5
M[?\ [\I_\10O%+/=/]DPG3[4/[G^7X/Y'_$O?"O_ $,<=_Y-Y>7I^/F?PV_\
M.SOV@/\ H'7W_?F7_P")H_X=G?M ?] Z^_[\R_\ Q-?W);=-_P"A7M_^_*?_
M !%&W3?^A7M_^_*?_$4+Q2SW3_9,)T^U#^Y_E^#^1_Q+WPK_ -#''?\ DWEY
M>GX^9_#;_P .SOV@/^@=??\ ?F7_ .)H_P"'9W[0'_0.OO\ OS+_ /$U_<EM
MTW_H5[?_ +\I_P#$4;=-_P"A7M_^_*?_ !%"\4L]T_V3"=/M0_N?Y?@_D?\
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M$CUO_GS/_?%'U.KWI_\ @R/^8?6J7]__ , 9WV#Z'\J,'T/Y5P/_  D>M_\
M/F?^^*/^$CUO_GS/_?%'U.KWI_\ @R/^8?6J7]__ , 9WV#Z'\J,'T/Y5P/_
M  D>M_\ /F?^^*/^$CUO_GS/_?%'U.KWI_\ @R/^8?6J7]__ , 9WV#Z'\J,
M'T/Y5P/_  D>M_\ /F?^^*/^$CUO_GS/_?%'U.KWI_\ @R/^8?6J7]__ , 9
MWV#Z'\J,'T/Y5P/_  D>M_\ /F?^^*/^$CUO_GS/_?%'U.KWI_\ @R/^8?6J
M7]__ , 9WV#Z'\J,'T/Y5P/_  D>M_\ /F?^^*/^$CUO_GS/_?%'U.KWI_\
M@R/^8?6J7]__ , 9WV#Z'\J,'T/Y5P/_  D>M_\ /F?^^*/^$CUO_GS/_?%'
MU.KWI_\ @R/^8?6J7]__ , 9WV#Z'\J,'T/Y5P/_  D>M_\ /F?^^*/^$CUO
M_GS/_?%'U.KWI_\ @R/^8?6J7]__ , 9WV#Z'\J,'T/Y5P/_  D>M_\ /F?^
M^*/^$CUO_GS/_?%'U.KWI_\ @R/^8?6J7]__ , 9WV#Z'\J,'T/Y5P/_  D>
MM_\ /F?^^*/^$CUO_GS/_?%'U.KWI_\ @R/^8?6J7]__ , 9WV#Z'\J,'T/Y
M5P/_  D>M_\ /F?^^*/^$CUO_GS/_?%'U.KWI_\ @R/^8?6J7]__ , 9WV#Z
M'\J,'T/Y5P/_  D>M_\ /F?^^*/^$CUO_GS/_?%'U.KWI_\ @R/^8?6J7]__
M , 9WV#Z'\J,'T/Y5P/_  D>M_\ /F?^^*/^$CUO_GS/_?%'U.KWI_\ @R/^
M8?6J7]__ , 9WV#Z'\J,'T/Y5P/_  D>M_\ /F?^^*/^$CUO_GS/_?%'U.KW
MI_\ @R/^8?6J7]__ , 9WV#Z'\J,'T/Y5P/_  D>M_\ /F?^^*/^$CUO_GS/
M_?%'U.KWI_\ @R/^8?6J7]__ , 9WV#Z'\J,'T/Y5P/_  D>M_\ /F?^^*/^
M$CUO_GS/_?%'U.KWI_\ @R/^8?6J7]__ , 9WV#Z'\J,'T/Y5P/_  D>M_\
M/F?^^*/^$CUO_GS/_?%'U.KWI_\ @R/^8?6J7]__ , 9WV#Z'\J,'T/Y5P/_
M  D>M_\ /F?^^*/^$CUO_GS/_?%'U.KWI_\ @R/^8?6J7]__ , 9WV#Z'\J,
M'T/Y5P/_  D>M_\ /F?^^*/^$CUO_GS/_?%'U.KWI_\ @R/^8?6J7]__ , 9
MWV#Z'\J,'T/Y5P/_  D>M_\ /F?^^*/^$CUO_GS/_?%'U.KWI_\ @R/^8?6J
M7]__ , 9WV#Z'\J,'T/Y5P/_  D>M_\ /F?^^*/^$CUO_GS/_?%'U.KWI_\
M@R/^8?6J7]__ , 9WV#Z'\J,'T/Y5P/_  D>M_\ /F?^^*/^$CUO_GS/_?%'
MU.KWI_\ @R/^8?6J7]__ , 9WV#Z'\J,'T/Y5P/_  D>M_\ /F?^^*/^$CUO
M_GS/_?%'U.KWI_\ @R/^8?6J7]__ , 9WV#Z'\J,'T/Y5P/_  D>M_\ /F?^
M^*/^$CUO_GS/_?%'U.KWI_\ @R/^8?6J7]__ , 9WV#Z'\J,'T/Y5P/_  D>
MM_\ /F?^^*/^$CUO_GS/_?%'U.KWI_\ @R/^8?6J7]__ , 9WV#Z'\J,'T/Y
M5P/_  D>M_\ /F?^^*/^$CUO_GS/_?%'U.KWI_\ @R/^8?6J7]__ , 9WV#Z
M'\J,'T/Y5P/_  D>M_\ /F?^^*/^$CUO_GS/_?%'U.KWI_\ @R/^8?6J7]__
M , 9WV#Z'\J,'T/Y5P/_  D>M_\ /F?^^*/^$CUO_GS/_?%'U.KWI_\ @R/^
M8?6J7]__ , 9WV#Z'\J,'T/Y5P/_  D>M_\ /F?^^*/^$CUO_GS/_?%'U.KW
MI_\ @R/^8?6J7]__ , 9WV#Z'\J,'T/Y5P/_  D>M_\ /F?^^*/^$CUO_GS/
M_?%'U.KWI_\ @R/^8?6J7]__ , 9H_$T'_A6'B_@_P#(/G[?],G]?\^G-?*'
M_!/7_7^)_P#L(R_^AFO<OB7XDUO_ (5EXN!LC@Z=/D[3_P \VSP/\_T^<O\
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M'FH#_P $Y_VCAKGAN3_A%=:V0ZU92.3:3G:BS1EB#MXQ@\GO[5_J#"R_9VX
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M\[KTUB<I=^;EKU;\OO.W+%WLM?+U?<_7&;/G2\'_ %C#IZ$TW:[#H?E'I_\
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MN<1&.7TV8.><>G^>G6AEV]8@/7*_UQ_C7YAV?QN^-/A%EEU/0[QXE/S$Q2'
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M&!?_ $K%?V%_"K_DD7@C_L&6O_I.E?1YTO\ 8LI_[!T^N_+%W_%_>?#<*?\
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MQ/3[<O[O^7Y>8?\ $QO&'_0)@?\ P3#^NB^X_NE_X>S?LZ_WM/\ _'/\:/\
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M(O\ H)Q/3[<O[O\ E^7F'_$QO&'_ $"8'_P3#^NB^X_NE_X>S?LZ_P![3_\
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M/ZKJWC&]FBFOK:4L9I7(+LK[>N> R^WXYJ>3SUUZ=K?Y]_\ @M2;6B2UZO\
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MCMCCGG)]:;@M7>RM?\5_7K]PE-Z:79^[2:WI$D4DR:E9M%%_K)//C")_O,2
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M(ZA_Z-DK]NM8_P"03JG_ &#KW_TFEK\1?V'_ /DY+XP?]A'4/_1LE?8\-?\
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M06+S.I3?*Y*K%<SINSL^NX\D#)[4Q<GDDX_S_+%/IK$C&!G\#7]A/;L[[_\
M _X)_!(ZBBB@ HHHH **** "E!/;O^M&3@#L*;VP3VQG^M"?;?R&K;6MK=NZ
M2UWT[K\?RCN@YLKMH2/.\F3RNGW]I Y]<U>_933PG)\30GQ41);HW:G3)KD
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M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 <C\3?^27^+_\
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M9*UW:[LK;L+NR5VU&_*FVU&^KLME?R)Z9(BRQO&XRDB,C#U5P58?B":7)^7
MZ]>#[4N3N QQZX/O0!P?A7X:^$O!NI:GJVA:;%;7^KL7O+C:A=RS;CA@H89/
MN>..YKGO&7P0\!>.M2;5O$&F_:;QP09"5(P1@C!!Z_6O7J*:;3NFTP/GSP]^
MS)\*/#&H?VGI.A)!=[@QD CR6'.>$!'))ZUWOCOX7>$_B+H5MX>\2V7VK3;5
MD:&+CY2F-O4=L5Z*2!C/?I2_YZ'^E',[[L+>7X'AVH?L\_#35-"M?#UYI'FZ
M;91B*WC)0E%"[1R4/0"N?T_]E3X0:;$\-MH*B.3(8$1DG(P>=E?2'4?4?SH
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MCEM1N8.<KP4Z<^@ZUXA8_ GXI^*IU75]3O[6%R X\R4?+T(/KP<__6XKZ/\
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M7;\O\P]I#^;\_P#+S_JS->BLC^UT_P"?2]_\!I?_ (FC^UT_Y]+W_P !I?\
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M)#-TSM'KSVJW@Y&.%&..G?T%97]KI_SZ7O\ X#2__$T?VNG_ #Z7O_@-+_\
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MVNG_ #Z7O_@-+_\ $T<DNWY?YA[2'\WY_P"7G_5F:]( !TK)_M=/^?2]_P#
M:7_XFC^UT_Y]+W_P&E_^)HY9+IL_(7M(?SKOMTTT_P"'_0U@-O0?SJO<6-O<
M@-+&C$-D$J"<X]_\_P!:/]KI_P ^E[_X#2__ !-*NK(3C['??A;R?U']*3IM
MWYHJ2>ZE9I^J>_S*5:,?AG*,K_%%RBTM-+K;^D)J:B.T2-0 JR08 _ZZ 5_>
M'_P1^Y_8\TK'_/O%G\$0_P J_@GU;5T, Q:7V/-AY-O(.D@/4J.>WUK^]/\
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M* .1^)O_ "2_Q?\ ]@^;_P!%M7RE_P $]/\ 7^)_^PC+_P"AFOJWXF_\DO\
M%^?^@=.?RB>OE'_@GH09O$V/^@C+_P"AFO37_)/YIYUZ'_MB_0YH?\C? _\
M7JO_ .VGZN4R218HWD<A5168D\#"@G^E/KR7XM^+X_#?ARZ\IV^UNK!54$D
MKZ#DYW?A7PC=E<^J6K2\SY8^-GCV35-=%I;2,/[/D^4JV/N/[?Y]/;Z2^"GB
M]=?\.PVUQ,&NH54!2WS;0",=2?3_ !K\]+[4VU.ZEOKA)#),[%LHV>N>X/M_
M2O4?A#XS?PYXD@69I4M7=$VX8+\S?@/\BLHR]Z[Z_P!?@:./NJW3II?7STV_
MR\C]*.V!Z8%0W*RO;3)$<3-"ZQMZ.5(4Y^M1:?>1W]I!>1<QSQJR_3G_ !JY
M6ID?E-\;_&GQQ^'/Q&TS0XM9F:S\372IIRK*V$623 Q@]!D#'8@BON?X9^)[
MS3K"Q\.>+-22Y\1R6R7;*9 9/+9-QR"<X''^3FOF;]J_0M3U/XK_  LNK2!Y
MK>TNH&E8*65,3@X/IS@URWBO4-6\"?'R+Q5XDN+F'PN^A"*(@/Y8D,!  YVY
MR*UT:5^JNVEKI;^OR)V;]4M;[:?CKN?<=Y\6O"EI)J$)O(FFTXL)XQ(NX%#R
M".H->:?\-1^!GN&M87$MPCE7B60%EP<$D9_STK\X?  \4^./BGXSO89KQ_#F
MI7,[63.'\LQL6VXZCIBMKX<_!G5E^+^O)>M-)IIM+B2(.K% Y!Q@-\N<\^M/
MD6O5I)I7_K?^EHR>9MV5EKO_ %_6O0_4_0_BWX3U[0[S6;2_A/V*-WFMO,7S
M 5!.,9SVYSBN4\%?M >%/&.K7NF1$6?V(N'GF<",A,Y.3VX_*OS"\">%?B%H
M?C/QYYLU[_PBL-S<!QB4QI"KOD 'C[N?3CFNTLVT_P 1Z;K6G_#J6;^WS;3Q
MSM$K+()-K!N5YZ^E1RINT>NM^B7I_3&Y-)/Y-/\ K3_@GZ*VGQU\*ZIXL/A3
M1I%U*X20QRSV[ATC(."3M.!@^M>._'CXQ:Q::G:^#= N&T2\ED!;4IF,4;;C
MM 5R5''3&>IS]/#?V!_AGKGAW5?&FH^,6FO=5%Q*8Y+M69HRTH7Y"_/1CC%>
M^?M/^'?AMXCT>>#Q#J']A:Q8QR26=[!^[EDF17>./>.3E\#Z4WRQG:.NRN^[
MMK8'S.-[^?;3M_7Y'+7G[1$WP5\.VDGC&5O$<MTD96:"0R98XP0R$GN1_P#7
MKV#3?VBM'O\ P/:>-AI=PME<[2T8#?NU;'S,3GIGG/2OS-^&>G:_X@TG6Y/&
MMK-JGA70WD73KZ\C:3S88V/EL"X.> #D=:]+U'XOIHWPYU32[#1=^@M:RP6C
MK 2$EV%5*C'!SZ?UJN7FLE:Z>O2^BT[+_@_?,9.Z3?W^FG]=;GV#X]^/^GMX
M.;Q'X8NTD\B,/-'&X+QG&6#X.>,&G_ S]H[2OBCHMW;7#K9ZA9QW,;7,K;49
MPC!#SW#YY^E?F/\  C3_ !)J?@#Q_?:X+M]-NY+B2U259,1Q9<@(&Z?+Z5VW
MPUMX[_PGJVE> C-'KL7G^?Y2,K[ANS]WGJ./7GWJ>6,5[UTT^7376ZMWZ>0<
MTKK;76WKT_K_ (;ZJ@^,_B>P^(MUH3:J+^R:=DC\N3>%7)QT/'&/_P!9KT>Q
M^,&I^'_$.H7&JSG4=/B@:1[:)]S0C:#D@'Y2.O\ C7Y^_ CPOXVB^(5Z_B)+
MJ>1)907G20X8$\@MZ8']171:UXGUWX?_ !/\0'6;>XN]$U>"2VP\;ND*2#;N
M7((&!Z?C5-:JZ2O'5);[?\!]Q*6C;YG9];V7;3=OIV9^EOAGX\^'?%>@:EKN
MD0O<II>_[3!$Q=T*9W XY&,=ZS-(_:-\)ZSI.MW]JI^TZ)!--<V1;,O[D,3E
M?O <5\8^ /$&F?##X>^+_$/AN-]5CU=;J>6W9&?RC(K/M"G.,9QT_2OG3]D;
M4]?\=>-/BEJ^HVUQ%97=KJ"Q6<D;+%R'VA58 'OTJ>6+YDMTM/72ZW]=64IM
MJ-EOU>ST_K;\3[\\)_M8V'Q=\/>(_P#A&[*32[K1KIK:6Z<NJ QN03N8D#H<
M\\UZFOQMT?PCX-TR^U.\36[V0XNOLT@=HMVT?.5)P%.2<^_M7PI\.].TW0OA
M1\5=+M+'[!X@O+Z^%H8XBDC,Q?81@ G)(_PKRG]G*+7O"&E>,9/C-+=RZ=?P
MW:Z)]L5V"L^\1;!)G&,C&!3Y5JK/=;]5Y>E]?S'S7:M:]M>RNU^.FW<_7[3O
MC#X3U#PE+XM2\B2QAB,DRF1<QD#)5CZ]NOUQ7.?#C]H#PG\1]3NM.TQEB\@L
MJ3/(/+E9>RGISV^M?G+X9\*^*-7^#_C2WT^>Z%C>WTSV)'F#%NSML"\=,8Z?
M_JZ+X6> M;\':)X8DM/.2[>\C^US*KJ\@+_,&/!QQSGZ<5+C;6^E[/JUI\D/
MFU2MVOY7=OF?KD"" 0<@\@CH12UG:07.EZ>9,ES9V^\GJ6\I<Y_&M&H*"BBB
M@ HHHH **** ,[6/^03JG_8.O?\ TFEK\1?V'_\ DY+XP?\ 81U#_P!&R5^W
M6L?\@G5/^P=>_P#I-+7XB_L/_P#)R7Q@_P"PCJ'_ *-DK['AK_D6\0?]@V'_
M /3R/GLY_P![RG_K_4_*)^J$_P#KI/\ ?;^=14^8MY\HQQYC<X/J:0 $')Z=
M/>N8=_7[F,/0_0_RKO/!/67ZG^1K@ST/T/\ *NZ\%9S)QW-<^-?^R3_Q1_%I
M&^$UKP>MK/IKK;T_,]%_C_X#_6BC^/\ X#_6BOGSV3S#QC+ ITC?,BM]C/!(
MZ$)@^^>1Q7&?:+7_ )^(_P Q_C5WXA:1-//H<B3.H&G(A Z%ALR<9'M^M>?_
M -A7.<^>_P#3_P!"KZO"4:3PU&]:WN_R_P!Y^?F_N/G*]2O[:=J*MS?S+IRK
M\5=]ODCL_M%MT^T1Y^H_QH\^V_Y^(_S_ /KUQ9T&X/6=_IV_]"IW]AW/_/9O
M\_\  JZ/84O^?W_DOI_P?N\S'VF(T_<+I]M>5^OF_P"DSLO/MO\ GXC_ #_^
MO1Y]M_S\1_G_ /7KC?[#N?\ GLW^?^!4?V'<_P#/9O\ /_ J/84O^?W_ )+Z
M>?K]WF'M,1_SX73[2_N^?F_N\CLO/MO^?B/\_P#Z]'GVW_/Q'^?_ ->N-_L.
MY_Y[-_G_ (%1_8=S_P ]F_S_ ,"H]A2_Y_?^2^GGZ_=YA[3$?\^%T^TO[OGY
MO[O([+S[;_GXC_/_ .O1Y]M_S\1_G_\ 7KC?[#N?^>S?Y_X%1_8=S_SV;_/_
M  *CV%+_ )_?^2^GGZ_=YA[3$?\ /A=/M+^[Y^;^[R.R\^V_Y^(_S_\ KT>?
M;?\ /Q'^?_UZXW^P[G_GLW^?^!4?V'<_\]F_S_P*CV%+_G]_Y+Z>?K]WF'M,
M1_SX73[2_N^?F_N\CLOM%J.MQ&/Q'^-'GVW_ #\1_G_]>N+;0KHXQ.P_/^C5
M*-"N0"WG/D'_  ]SZT>PH_\ /[M]GO;S\W]P*IB'_P N4MOM+^[Y^;^XZ349
M[;^S[K]^GW&[^WU_S[5S?@Z>W%M=@S(/G;J1V)_S_2JE_HES]BN6\YS\A_0?
M7'^/ZUS_ (5T2X>"XVRN ';H3_(8]/UKHA1I?5JW[W[<.GH82G6^M4+T8WY)
M_:3[;?U^1ZUY]M_S\1_G_P#7H\^V_P"?B/\ /_Z]<;_8=S_SV;_/_ J/[#N?
M^>S?Y_X%7/["E_S^_P#)?3S]?N\S?VF(_P"?"Z?:7]WS\W]WD=EY]M_S\1_G
M_P#7H\^V_P"?B/\ /_Z]<;_8=S_SV;_/_ J/[#N?^>S?Y_X%1["E_P _O_)?
M3S]?N\P]IB/^?"Z?:7]WS\W]WD=EY]M_S\1_G_\ 7H\^V_Y^(_S_ /KUQO\
M8=S_ ,]F_P _\"H_L.Y_Y[-_G_@5'L*7_/[_ ,E]//U^[S#VF(_Y\+I]I?W?
M/S?W>1V7GVW_ #\1_G_]>CS[;_GXC_/_ .O7&_V'<_\ /9O\_P# J/[#N?\
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M[Y^;^X[+S[;_ )^(_P __KT>?;?\_$?Y_P#UZXW^P[G_ )[-_G_@5']AW/\
MSV;_ #_P*CV%+_G]_P"2^GGZ_=YA[3$?\^%T^TO[OGYO[O([+S[;_GXC_/\
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M_+V7]W^[Y?U97/\ 4GAC3_C%,KZ?\N*7]WS\OZTO^>W_  ZM_91_Z%^R_P#
M>+_"C_AU;^RC_P!"_9?^ \7^%?H3_P (K>_]!&'_ +_'_P"*H_X16]_Z",/_
M '^/_P 51_K!G'_0]QW3_E[+^[_=\OZLKG^I/#&G_&*97T_Y<4O[OGY?UI?\
M]O\ AU;^RC_T+]E_X#Q?X4?\.K?V4?\ H7[+_P !XO\ "OT)_P"$5O?^@C#_
M -_C_P#%4?\ "*WO_01A_P"_Q_\ BJ/]8,X_Z'N.Z?\ +V7]W^[Y?U97/]2>
M&-/^,4ROI_RXI?W?/R_K2_Y[?\.K?V4?^A?LO_ >+_"C_AU;^RC_ -"_9?\
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M_P!#W'=/^7LO[O\ =\OZLKG^I/#&G_&*97T_Y<4O[OGY?UI?\]O^'5O[*/\
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M]WR_JRN?ZD\,:?\ &*97T_Y<4O[OGY?UI?\ /;_AU;^RC_T+]E_X#Q?X4?\
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M*/\ T+]E_P" \7^%??/]C7G_ #\2?FW_ ,71_8UY_P _$GYM_P#%T?V[G/\
MT/,=T_Y?/^[Y>7]65Q<&<+:?\8KE73_EQ2_N>?E^?8^!O^'5O[*/_0OV7_@/
M%_A1_P .K?V4?^A?LO\ P'B_PK[Y_L:\_P"?B3\V_P#BZ/[&O/\ GXD_-O\
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M;_XNC^QKS_GXD_-O_BZ/[=SG_H>8[I_R^?\ =\O+^K*XN#.%M/\ C%<JZ?\
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M_P#)?3S]?N\SV?:8C_GPNGVE_=\_-_=Y'9>?;?\ /Q'^?_UZ//MO^?B/\_\
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M )[-_G_@5'L*7_/[_P E]//U^[S#VF(_Y\+I]I?W?/S?W>1V7GVW_/Q'^?\
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M^>S?Y_X%1["E_P _O_)?3S]?N\P]IB/^?"Z?:7]WS\W]WD=EY]M_S\1_G_\
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M1?\ 8;+\X'7T445\X?;A1110 4A.!FEHII7_ #U'Y>>X@.1FEI0">E&"1G'
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M_C?X5^'OV:W_ .>2?E1]FM_^>2?E1_J7PW_T+J7_ (#'R\O+^M+'_$3N./\
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M+_A\Q\1_^?V?_OXW^%'_  ^8^(__ #^S_P#?QO\ "OP]^S6__/)/RH^S6_\
MSR3\J/\ 4OAO_H74O_ 8^7EY?UI8_P"(G<<?]#O$?^!/R\O)'[A?\/F/B/\
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M!/R\O)'[A?\ #YCXC_\ /[/_ -_&_P */^'S'Q'_ .?V?_OXW^%?A[]FM_\
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MFO7MD,DODHS[57DY"CL!S_+/3EWAN;MDM;%6ENI98T2-!ECE@.!U_*OZ4?\
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M<]1ZY[_CGBNU_P"$H\-X(_M6#!_VQ_A[5^R-I_P29^#-E&T,.L,(V=I-HD(
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M?QG_ (ETQ_\ '&_QKY3_ .">G^O\3_\ 81E_]#-?5OQ-_P"27^+_ /L'S?\
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MY?Q3JCRQ74N^0R2+(S C/7G/?\17Z9>"OV??#'@OP_=^&[6YGN=/N@0\<PR
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MK'_()U3_ +!U[_Z32U^(O[#_ /R<E\8/^PCJ'_HV2OL>&O\ D6\0?]@V'_\
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M_P!^'_\ B:/^'<O[3G_0!O?^_#__ !-']MY+_P!#7!?^#H^7^;^X/]5N)O\
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M  F?EY^OW>9\945]F_\ #N7]IS_H WO_ 'X?_P")H_X=R_M.?] &]_[\/_\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M &S:?WU_S^-']LVG]]?\_C4/_"-VO_/3]/\ [*C_ (1NU_YZ?I_]E71_LO\
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MRF_MFT_OK_G\:/[9M/[Z_P"?QJ'_ (1NT_YZ?Y_[ZH_X1NT_YZ?Y_P"^J/\
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MU_'RM-_;-I_?7_/XT?VS:?WU_P _C4/_  C=K_ST_3_[*C_A&[7_ )Z?I_\
M94?[+_-/_P !]/+_ (?YL7-B/Y(=/M/^[Y>;_'RM-_;-I_?7_/XT?VS:?WU_
MS^-0_P#"-VG_ #T_S_WU1_PC=I_ST_S_ -]4?[+_ #3_ / ?3R_KYL.;$?R0
MZ=7_ '?+S?X_*;^V;3^^O^?QH_MFT_OK_G\:A_X1NT_YZ?Y_[ZH_X1NT_P">
MG^?^^J/]E_FG_P" ^GE_7S8<V(_DATZO^[Y>;_'Y3?VS:?WU_P _C1_;-I_?
M7_/XU#_PC=I_ST_S_P!]4?\ "-VG_/3_ #_WU1_LO\T__ ?3R_KYL.;$?R0Z
M=7_=\O-_C\IO[9M/[Z_Y_&C^V;3^^O\ G\:A_P"$;M/^>G^?^^J/^$;M/^>G
M^?\ OJC_ &7^:?\ X#Z>7]?-AS8C^2'3J_[OEYO\?E-_;-I_?7_/XUM:%K=H
MMZ277_43?^@'ZUS_ /PC=I_ST_S_ -]5LZ'X:M#>$&0\P3=/^N;>Y_E2E]5Y
M7>4[6=]/)7Z>3_ILJ$L1S1]R%[JWO/?W;=.[?X_+^.']LK0KN^_X*/V6J11L
M;<:^C%QG'_'T&SZ?XU_6_P###5[:'X3^"X'=0T>FVVX=P1 @[<_YZ5_)9^V1
MXIO--_X*+V6A0Q@VYUY%W8YP+D#/KTZ_XU_6;\,?#]K<_"GP9</(0\NFVS,.
MH!,"GH?KCZ=*^AS=X?ZIE?.Y).@N5J-]++39[:7O_P  ^*X8=19AG_LXQ;^M
MOG4G9*5X]=WT^74['^VK3^^/U'\Z<=;M3UD4U7'AJT'_ "U/T[?D#2_\(W:?
M\]/\_P#?5?/_ .R_S3_\!]/+^OFS[-2Q&GN0Z7U?]WR\W]S^4W]LVG]]?\_C
M1_;-I_?7_/XU#_PC=I_ST_S_ -]4?\(W:?\ /3_/_?5'^R_S3_\  ?3R_KYL
M.;$?R0Z=7_=\O-_C\IO[9M/[Z_Y_&C^V;3^^O^?QJ'_A&[3_ )Z?Y_[ZH_X1
MRT/_ "T_0C^9H_V7^:?_ (#Z>7_#_-AS8C3W8?>_[M^GF_Q\K3?VS:?WU_S^
M-']LVG]]?\_C47_"-VO_ #T/Y?\ V5)_PC=I_P ]/\_]]4?[+_-/_P !]/Z_
MX=A?$?RPZ?:?]WR\W^/E:;^V;3^^O^?QH_MFT_OK_G\:A_X1NT_YZ?Y_[ZH_
MX1NT_P">G^?^^J/]E_FG_P" ^GE_7S8<V(_DATZO^[Y>;_'Y3?VS:?WU_P _
MC3O[;M-I&]>3Z_3_  JO_P (W:?\]/\ /_?5+_PC=H3_ *P_3O\ GG^E%L+_
M #3T\O3[_P"GU#FQ&_)#[W_=\O-_C\N1\7:K;2S62[E*;AN''][OGVK=6'PI
M<P0-<6-M)*(TRS01$DX&3DC)/X\5S?C31;+3S;74KX@A(:1LX 0<GGVQVZ"O
M+M9_:2^!/A.6/3-:\1:;;WD:A'CDNHU8,.,$9SG((KLY*,Z&'5/VS?O:0B]G
M:][;6_(X'4<*]=XA8>*?LVG5DK/TO?4]T^P^#O\ H'VG_@/%_A1]A\'?] ^T
M_P# >+_"OG7_ (:V_9V_Z&?2O_ V+_XJC_AK;]G;_H9]*_\  V+_ .*K-49:
M>[BNGV9?W//S_!=BOK>&TUP'3[4?[OGYO[_0^BOL/@[_ *!]I_X#Q?X4?8?!
MW_0/M/\ P'B_PKYU_P"&MOV=O^AGTK_P-B_^*H_X:V_9V_Z&?2O_  -B_P#B
MJ%1EI[N*Z?9E_<\_/\%V#ZWAM-<!T^U'^[Y^;^_T/HK[#X._Z!]I_P" \7^%
M'V'P=_T#[3_P'B_PKYU_X:V_9V_Z&?2O_ V+_P"*H_X:V_9V_P"AGTK_ ,#8
MO_BJ%1EI[N*Z?9E_<\_/\%V#ZWAM-<!T^U'^[Y^;^_T/HK[#X._Z!]I_X#Q?
MX4?8?!W_ $#[3_P'B_PKYU_X:V_9V_Z&?2O_  -B_P#BJ/\ AK;]G;_H9]*_
M\#8O_BJ%1EI[N*Z?9E_<\_/\%V#ZWAM-<!T^U'^[Y^;^_P!#Z*^P^#O^@?:?
M^ \7^%'V'P=_T#[3_P !XO\ "OG7_AK;]G;_ *&?2O\ P-B_^*H_X:V_9V_Z
M&?2O_ V+_P"*H5&6GNXKI]F7]SS\_P %V#ZWAM-<!T^U'^[Y^;^_T/HK[#X.
M_P"@?:?^ \7^%'V'P=_T#[3_ ,!XO\*^=?\ AK;]G;_H9]*_\#8O_BJ/^&MO
MV=O^AGTK_P #8O\ XJA49:>[BNGV9?W//S_!=@^MX;37 =/M1_N^?F_O]#Z*
M^P^#O^@?:?\ @/%_A1]A\'?] ^T_\!XO\*^=?^&MOV=?^AGTK_P-B_\ BJ!^
MUM^SJ>1XGTK_ ,#8O_BJ%1EI[N*Z?9E_<\_/\%V#ZWAM-<!T^U'^[Y^;^_T/
MHK[#X._Z!]I_X#Q?X4?8?!W_ $#[3_P'B_PKYU_X:V_9U_Z&?2O_  -B_P#B
MJ/\ AK;]G7_H9]*_\#8O_BJ%1EI[N*Z?9E_<\_/\%V#ZUAM'? 6T7Q1_NWZ^
M;_JQ]%?8?!W_ $#[3_P'B_PH^P^#O^@?:?\ @/%_A7SK_P -;?L[?]#/I7_@
M;%_\51_PUM^SM_T,^E?^!L7_ ,50J,M/=Q73[,O[GGY_@NP?6\-IK@.GVH_W
M?/S?W^A]%?8?!W_0/M/_  'B_P */L/@[_H'VG_@/%_A7SK_ ,-;?L[?]#/I
M7_@;%_\ %4?\-;?L[?\ 0SZ5_P"!L7_Q5"HRT]W%=/LR_N>?G^"[!];PVFN
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M!U S7SD/VMOV=20!XGTK)Z?Z;%_\57M7@CQ%X,^)MDVI>$K^&]M$&2\$BR*
M1G^%O3^GK4RIQIKFG]9A%]9*27V=/Q?S70N%:E5ERT8X.I):V@XM_9[>K^?E
M8[2/5[&- D12.,<!5&T#'3@8_P _H_\ MFT_OK_G\:KMX=M1T<YS_=/^-/\
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MG_X#Z>7]?-AS8C^2'3J_[OEYO\?ER_Q-UJU_X5AXO&]>=.G_ /1;?XU\Q_\
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MS_7I7U3JOB_0=*O;;3[JXCDN[APB1Q[9&4L0 "!D@\CBNG78RK*%'*A@=HW
M$9ZXR.*\#F=M>UOP7^1Y]OSO]W_#'YB>+O@Q9?#3QWK.NZQX>?Q7IGBF9I)(
M5B,ZQB;)9<88#:6(QTX]:;K7@GQ)X:\/7FI^#])N+3PQJEN\?_"/HAVH9E()
M\H#MNP>*_2*XU/0+CS1=/93BV)$GVA(91&1G/^L#8Z>U6K.32M3M0UI':W-H
M#M55BA:($=@N"G'L*I3VNK[7UWM^3)Y5]VR[:W^9^4OP*_9Z\2>$?"GCGQ8]
MI+#=:T+B:&Q=6W ONDPJGGJ>PYKTB#X:^(O'_P *AH6H6$MM=07;D(R%25#-
M@@$#(XY[<GJ.GZ1+! D?E+#$L1&#$L:"/'H4 V_I2);V\2[8X(8U_NQQ(H_)
M5%+G>NF[OZ;?Y!RJUO*SMI?S/S9OOV<M6E\"?V)Y3>:L0C7Y3GI[<^W^<5QG
MB']EO4M*^&EJEY;2Z@UK+Y\EH,L756W;2O/!&>"/;FOU<\M,8\M2/3:/Y$4U
MX8I4\N6*-XS_ ,LW177_ +Y((_SBA3DGJ].J[@X1[/\ JWE_5_F?GEX6^&_A
MWQQ\&M3\)67A%M"U**V\G>83$TKQ[@6!V@G<"#4?B#]GG6-1^ -C\.XE=;B.
M;G:"'VY(Y(Y[^O)S7Z'0V=I;@K!:V\ /4101Q@_4(HS^-3;$QC8N/3:,?EBC
MGUVZW7K:W8=M+>5K_P!=S\[O@!X2\4? "^T[PE-I\E]::DL<<UQY;,(MS <N
M.F"<]0?Y5Z/^UE\.=8\5:9H^MZ)')-<:5<).T,>26\EED&0.N:^Q7MK:1Q(]
MO \B_==XHV=?HQ4D?@:DDCCE7;+&DBGJLB*ZG\&!%)RN[V5[W?GM_E_3U"VE
MMT?F%)X&\9>,HM"^(]U83P7O@NV2)+/8RM.8% ^Y@;B<9Z?GFM/X<_#GQ3\1
MO$'B;Q)KMG/81WUI+:Q0NK1_PLBX4@>E?I,MK;)&T26T"1-]Z-88UC;_ 'D"
MA3^(I8;:WMQBWMX8 >HAB2(?DBK3YM'IZ>5[>G:]^X-7^^_J_P#AC\VO!/[-
MVJ>'M(\7Z>8FV:G<7#QY!R0Y."">>IZ>_P!:@\.?L^ZQX8\)>,GV2*TMC=E%
MP06RC$ >O)Z#]*_2_8G/R)SU^4<_7BJMY;V<UM-:7(B2&Z1HG4[4#AQ@CG -
M)2?5[M7?7\ <8M;:]_Z_4_#G]FZW\;:WIOC[X03Z/<QV.KWMW$+]HG"KYCNH
M(D('J/XJ]H^%_P"Q/K7@R[UZ&XFD>WV33*"S?O"X9PN<\^F._P#/]._#7@;P
MWX5\]])TVUAFN9#++<"&,2L2<\/@D<\Y!!-=?@<G YX)QR1Z'N?QJN?5VO9K
M7IKWZ]D2HO3F=Y+K_7Y[GYG_  ,\$^'O#OCG4]*U7P,_VYGD2'5WM^,[_O\
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MZ9:-A@J3C@CUJ6;P_I4]ZE_+9PO/&!L+1J0".AQC\:V555 55"J.@4  ?0#
MI-W=[#2MYBT444AA1G'7BBD*[NN>* ,_6/\ D$ZI_P!@Z]_])I:_#G]BB]AM
M?VDOC!YA /\ :.H=?>:3WS7[C:Q_R"=4_P"P=>_^DTM?AO\ L5:;!??M)?&
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MGI^%?0X7_=J/^%_^E/\ ']+'B5OXM3_$O_24&<GKS^M /H?RI" IR<C/'/\
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M YXW#!]J&[='\@7W#,T5(T;#&$;&/[IIG(/N* #!]#^5)3BY(QQ3: "BBB@
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M_%GIO_#0OQV_Z''4?_ R;_XNC_AH7X[?]#CJ/_@9-_\ %UYE11[.E_SYI?\
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MT$5O_!DO+S\OQ9Z</VA?CL""?&&H_P#@7-[_ .W[TK?M"_'7J/&.H_3[9/\
MI\U>9<;3_>SQU]OP]:;^'^?QI.G2_P"?5/39<D;=--M@6)KK>O6L^JJ2TM;5
M^NF_F>GO^T-\=B>/&.H]/^?R;_XNF_\ #0OQV_Z''4?_  ,F_P#BZ\R]??\
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M]#CJ/_@9-_\ %UYE11[.E_SYI?\ @M?UT_J[#ZQB/^@BM_X,EY>?E^+/3?\
MAH7X[?\ 0XZC_P"!DW_Q='_#0OQV_P"AQU'_ ,#)O_BZ\RHH]G2_Y\TO_!:_
MKI_5V'UC$?\ 016_\&2\O/R_%GIO_#0OQV_Z''4?_ R;_P"+H_X:%^.W_0XZ
MC_X&3?\ Q=>944>SI?\ /FE_X+7]=/ZNP^L8C_H(K?\ @R7EY^7XL]-_X:%^
M.W_0XZC_ .!DW_Q='_#0OQV_Z''4?_ R;_XNO,J*/94O^?-+_P %K^NG]78?
M6,1_T$5O_!DO+S\OQ9Z7_P -"_'47%L!XQU#)9<C[9,?XAQ]_']:_O*_X($^
M*O$OB[X ZA>^*;^74;L09$DTC2-DQKW8G\?KCJ*_SX5(^VVV#U;/XEA_A7^@
M+_P;W?\ )O6H?]>__LBU\MQ9"$<KFXTX1]^%G&*3_*_X_P# ^Z\.ZM6?$,%4
MK59KV%6T93E)/1;IZ770_=T]3]3_ #IP!()!/?CUXIIZGZG^= )!XZU^9+TO
MY'[P)14HC9N>>>?NFD,38XSG_=_QJVI<R35]%LM&M.JV_3T#77\!BL 2, GC
M_(X_E24>44PQS_G\/ZTHQGGI4VU[==6#\OO\[?H)SUQQ13G;(P.@Z?E[TQ=V
M/FZY_P ]*+O7;6WX6M_7X"2:WWZBT444AA1110 4444 %%%% !1110 4444
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M^@1DV];_ ':?/K^/4^B?CW^TO_PI_7M+\.V.AMKFHZFL92&,.S OCC"$>O\
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MP5*36\LEI=1F*Z@)6:)AAD8$@J1U&.GX4ZNP^+$,=K\8O'EK JI!#J]TL:(
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M1110 4444 %%%% %? ^VVO ZCM_M"O\ 0%_X-[3C]GG4>,YM_P OD6O\_O\
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MS]CO]E!->M(H_A?I"H2FY!90\Y/^YV'K]*[EOV,OV2OEQ\+=''RC/^@P\_\
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MPHHHH **** "MK0?^/[_ +8S?^BVK%K:T'_C^_[8S?\ HMJ3V?H_R*A\<?\
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M)(J2RNJC"@G!)R/7_"OPJK9\->*->\&:G%J^AZA=6\\,@D"12M&A((."%/?
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MZ_XCL6@U"TBD5Y(7FB97#*IR""QZ^F/I\ 3_ /!0OXVW&E#1FM85A$)@\]5
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MS+\&L!AH8>,W4Y9.7,U9W?EV706BGL !C^+C/7TIE?0>?]:G:%%%% !1110
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MENDW?\SMX@PM;%Y=.C0@YS<X-12UT/XYX;N'8/F/4_PM_A4#WD/]L>'\N?\
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M>>">LOU/\C7!GH?H?Y5WG@GK+]3_ "-<^,_W2?\ B7Z&^%_WB'I+]#T/^/\
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MJ_Y^5/\ P'T_S_K2Y_J#Q#_SZI?^!>GGYH_BG_MBP_YZ-_WPU']L6'_/1O\
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M_P"M1_K1E7_/RI_X#Z?Y_P!:7/\ 4'B'_GU2_P# O3S\T?Q3_P!L6'_/1O\
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M_P"M1_K1E7_/RI_X#Z?Y_P!:7/\ 4'B'_GU2_P# O3S\T?Q3_P!L6'_/1O\
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M:/\ AWS\)/\ H+ZE_P!_I?\ &C^R.'/^AAF/_A/#^O\ AO2[_M+-/^@7#_\
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M_P#10='_ ._A_P *^)_^'?/PD_Z"^I?]_I?\:/\ AWS\)/\ H+ZE_P!_I?\
M&C^R.'/^AAF/_A/#^O\ AO2Y_:6:?] N'_\ !DO+_@_?Y'VQ_P -2_ G_HH.
MC_\ ?P_X4G_#4GP(_P"B@:-_WV?\*^*/^'?/PD_Z"^I?]_I?\:/^'?/PD_Z"
M^I?]_I?\:/[(X<_Z&&8_^$\/Z_X;TN?VEFG_ $"X?_P9+R_X/W^1]L?\-2_
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M/^%?$_\ P[Y^$G_07U+_ +_2_P"-'_#OGX2?]!?4O^_TO^-']D<.?]##,?\
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M=^\_^#_P+Z?-XBC5=:H_K$TN965EHERV^[;[O4\__P"$JUG_ *!Y_P"_9_\
MB:/^$JUG_H'G_O@__$UZ!B/_ )Y)_P!\C_XFC$?_ #R3_OD?_$UO[>C_ - T
M.G67E_P?Z>F7L:W_ $$3^Y?UW_IZ>?\ _"5:S_T#S_WP?_B:/^$JUG_H'G_O
M@_\ Q->@8C_YY)_WR/\ XFC$?_/)/^^1_P#$T>VH_P#0-#[WY?\ !_K8]C6_
MZ")_<OZ[_P!/3S__ (2K6?\ H'G_ +X/_P 31_PE6L_] \_]\'_XFO0,1_\
M/)/^^1_\31B/_GDG_?(_^)H]M1_Z!H?>_+_@_P!;'L:W_01/[E_7?^GIY_\
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MZ")_<OZ[_P!/3S__ (2K6?\ H'G_ +X/_P 31_PE6L_] \_]\'_XFO0,1_\
M/)/^^1_\31B/_GDG_?(_^)H]M1_Z!H?>_+_@_P!;'L:W_01/[E_7?^GIY_\
M\)5K/_0//_?!_P#B:/\ A*M9_P"@>?\ O@__ !->@8C_ .>2?]\C_P")HQ'_
M ,\D_P"^1_\ $T>WH_\ 0-#[WY?\'^MCV-;_ *")_<OZ[_T]//\ _A*M9_Z!
MY_[X/_Q-'_"5:S_T#S_WP?\ XFO0,1_\\D_[Y'_Q-. AQS''G_=_P%'MZ/\
MT#0_\"?E_P '^GH>QK?]!$_N7]=_Z>GGO_"5:S_T#S_WP?\ XFC_ (2K6?\
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MS_\ $5VN(_\ GDG_ 'R/_B:,1_\ /)/^^1_\31[:A_T#0^]^7^7]:6/95O\
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M:WI]QP0\4:U@?\2\D_[O_P!:D_X2K6?^@>?^^#_\37H(*#D1)_WR/\*3$?\
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M2?\ ?(_^)HQ'_P \D_[Y'_Q-'MJ/_0-#[WY?\'^MCV-;_H(G]R_KO_3T\_\
M^$JUG_H'G_O@_P#Q-'_"5:S_ - \_P#?!_\ B:] Q'_SR3_OD?\ Q-&(_P#G
MDG_?(_\ B:/;4?\ H&A][\O^#_6Q[&M_T$3^Y?UW_IZ>?_\ "5:S_P! \_\
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MB/\ YY)_WR/_ (FCVU'_ *!H?>_+_@_UL>QK?]!$_N7]=_Z>GG__  E6L_\
M0//_ 'P?_B:/^$JUG_H'G_O@_P#Q->@8C_YY)_WR/_B:,1_\\D_[Y'_Q-'MJ
M/_0-#[WY?\'^MCV-;_H(G]R_KO\ T]//_P#A*M9_Z!Y_[X/_ ,31_P )5K/_
M $#S_P!\'_XFO0,1_P#/)/\ OD?_ !-&(_\ GDG_ 'R/_B:/;4?^@:'WOR_X
M/];'L:W_ $$3^Y?UW_IZ>?\ _"5:S_T#S_WP?_B:/^$JUG_H'G_O@_\ Q->@
M8C_YY)_WR/\ XFC$?_/)/^^1_P#$T>VH_P#0-#[WY?\ !_K8]C6_Z")_<OZ[
M_P!/3S__ (2K6?\ H'G_ +X/_P 31_PE6L_] \_]\'_XFO0,1_\ /)/^^1_\
M31B/_GDG_?(_^)H]M1_Z!H?>_+_@_P!;'L:W_01/[E_7?^GIY_\ \)5K/_0/
M/_?!_P#B:/\ A*M9_P"@>?\ O@__ !->@8C_ .>2?]\C_P")HQ'_ ,\D_P"^
M1_\ $T>VH_\ 0-#[WY?\'^MCV-;_ *")_<OZ[_T]//\ _A*M9_Z!Y_[X/_Q-
M'_"5:S_T#S_WP?\ XFO0,1_\\D_[Y'_Q-&(_^>2?]\C_ .)H]M1_Z!H?>_+_
M (/];'L:W_01/[E_7?\ IZ>?_P#"5:S_ - \_P#?!_\ B:/^$JUG_H'G_O@_
M_$UZ!B/_ )Y)_P!\C_XFC$?_ #R3_OD?_$T>VH_] T/O?E_P?ZV/8UO^@B?W
M+^N_]/3S_P#X2K6?^@>?^^#_ /$T?\)5K/\ T#S_ -\'_P")KT#$?_/)/^^1
M_P#$T8C_ .>2?]\C_P")H]M1_P"@:'WOR_X/];'L:W_01/[E_7?^GIY__P )
M5K/_ $#S_P!\'_XFC_A*M9_Z!Y_[X/\ \37H&(_^>2?]\C_XFC$?_/)/^^1_
M\31[:C_T#0^]^7_!_K8]C6_Z")_<OZ[_ -/3S_\ X2K6?^@>?^^#_P#$T?\
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M?\)9K?\ SX-_WRW_ ,37?XC_ .>2?]\C_P")HQ'_ ,\D_P"^1_\ $T>VH_\
M0-#[WY?\'^MCV-;_ *")_<OZ[_T]. _X2S6_^?!O^^6_^)H_X2S6_P#GP;_O
MEO\ XFN_Q'_SR3_OD?\ Q-&(_P#GDG_?(_\ B:/;4?\ H&A][\O^#_6Q[&M_
MT$3^Y?UW_IZ<!_PEFM_\^#?]\M_\31_PEFM_\^#?]\M_\37?XC_YY)_WR/\
MXFC$?_/)/^^1_P#$T>VH_P#0-#[WY?\ !_K8]C6_Z")_<OZ[_P!/3@/^$LUO
M_GP;_OEO_B:/^$LUO_GP;_OEO_B:[_$?_/)/^^1_\31B/_GDG_?(_P#B:/;4
M?^@:'WOR_P"#_6Q[&M_T$3^Y?UW_ *>G ?\ "6:W_P ^#?\ ?+?_ !-'_"6:
MW_SX-_WRW_Q-=_B/_GDG_?(_^)HQ'_SR3_OD?_$T>VH_] T/O?E_P?ZV/8UO
M^@B?W+^N_P#3TX#_ (2S6_\ GP;_ +Y;_P")H_X2S6_^?!O^^6_^)KO\1_\
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M_I<CQ*_\6?K^B&T4]U8-RK+GH",'CBCRI,9V-CKG%;F0RBBGK'(REU1BHZL
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ME)&X@ C'!!]>:2OL&K.QZ2"BBBD 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MK*]N8H9QA6YV.RL>G3'<5^?GQ^U@W-YXTU_PA<IJ"6-_,'OK%PZ(OFG),L?
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M2;GXC:C<>"_$.JF^N--:ZE:V"-,9"NPL5'7 & /;G%?TFYJ;SFQC:"?[W?\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M )$.:'\\/_ X?Y^:^\Z&BN>_X3SX;?\ 0\:)_P"!L'_Q='_">?#;_H>-$_\
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M=_Z=^OW>I^+?\2W<1_\ 0\R?I_R]?]W^_P"OZ_:/X(_[)US_ *!U]_X"R?\
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M>I_=_P"G?K]WJ'_$MW$?_0\R?I_R]?\ =_O^OZ_:/X(_[)US_H'7W_@+)_\
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MSX;G'_%;Z+P,?\?D'_Q5'LJO_/JK_P""Y_\ R(^:'\\/_ X?Y^:^\WZ*Y_\
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M1[*K_P ^JO\ X*J?_(BYX?ST_P#P.'6WGYHZ&BN?_P"$[^&__0[Z+_X&0?\
MQ5'_  G?PW_Z'?1?_ R#_P"*H]E5_P"?57_P7/\ ^1'S0_GA_P"!P_S\U]YT
M%%<__P )W\-_^AWT7_P,@_\ BJ/^$[^&_P#T.^B_^!D'_P 51[*K_P ^JO\
MX+G_ /(AS0_GA_X'#_/S7WG045S_ /PG?PW_ .AWT7_P,@_^*H_X3OX;_P#0
M[Z+_ .!D'_Q5'LJO_/JK_P""Y_\ R(<T/YX?^!P_S\U]YT%%<_\ \)W\-_\
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M\%S_ /D0YH?SP_\  X?Y^:^\Z"BN?_X3OX;_ /0[Z+_X&0?_ !5'_"=_#?\
MZ'?1?_ R#_XJCV57_GU5_P#!<_\ Y$.:'\\/_ X?Y^:^\Z"BN?\ ^$[^&_\
MT.^B_P#@9!_\51_PG?PW_P"AWT7_ ,#(/_BJ/95?^?57_P %S_\ D0YH?SP_
M\#A_GYK[SH**Y_\ X3OX;_\ 0[Z+_P"!D'_Q5'_"=_#?_H=]%_\  R#_ .*H
M]E5_Y]5?_!<__D0YH?SP_P# X?Y^:^\Z"D).1@=3SP:P/^$[^&__ $.^B_\
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M .*H]E5_Y]5?_!<__D0YH?SP_P# X?Y^:^\Z"BN?_P"$[^&__0[Z+_X&0?\
MQ5'_  G?PW_Z'?1?_ R#_P"*H]E5_P"?57_P7/\ ^1#FA_/#_P #A_GYK[SH
M**Y__A._AO\ ]#OHO_@9!_\ %4?\)W\-_P#H=]%_\#(/_BJ/95?^?57_ ,%S
M_P#D0YH?SP_\#A_GYK[SH*3<588&1WZ]^.M8'_"=_#?_ *'?1?\ P,@_^*I1
MXZ^&Y!(\<:*<9_Y?(?3UW$4.E57_ "ZJ]/\ EU/K_P!NBYX?SPW2^./EY^9T
M!.3G%)7/#QW\.23_ ,5KHN/47D'_ ,4?Z4O_  G?PW_Z'?1?_ R#_P"*H]E5
M_P"?57_P74_^1_X8.:%W[\-;?;CY6^UYK[SH**Y__A._AO\ ]#OHO_@9!_\
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MZJ_^"Y__ "(<T/YX?^!P_P _-?>=!2,2!P,\^AK _P"$[^&__0[Z+_X&0?\
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MJ>7][R1^27_#KNT_Z*GK/_?Z\H_X==VG_14]9_[_ %Y7ZVT4?ZV9]_T'2_\
M!=+R_N>7]:6/[$RS_H%C_P"!5/+^]Y(_)+_AUW:?]%3UG_O]>4?\.N[3_HJ>
ML_\ ?Z\K];:*/];,^_Z#I?\ @NEY?W/+^M+']B99_P! L?\ P*IY?WO)'Y)?
M\.N[3_HJ>L_]_KRC_AUW:?\ 14]9_P"_UY7ZVT4?ZV9]_P!!TO\ P72\O[GE
M_6EC^Q,L_P"@6/\ X%4\O[WDC\DO^'7=I_T5/6?^_P!>4?\ #KNT_P"BIZS_
M -_KROUMHH_ULS[_ *#I?^"Z7E_<\OZTL?V)EG_0+'_P*IY?WO)'Y)?\.N[3
M_HJ>L_\ ?Z\H_P"'7=I_T5/6?^_UY7ZVT4?ZV9]_T'2_\%TO+^YY?UI8_L3+
M/^@6/_@53R_O>2/R2_X==VG_ $5/6?\ O]>4?\.N[3_HJ>L_]_KROUMHH_UL
MS[_H.E_X+I>7]SR_K2Q_8F6?] L?_ JGE_>\D?DE_P .N[3_ **GK/\ W^O*
M/^'7=I_T5/6?^_UY7ZVT4?ZV9]_T'2_\%TO+^YY?UI8_L3+/^@6/_@53R_O>
M2/R2_P"'7=I_T5/6?^_UY1_PZ[M/^BIZS_W^O*_6VBC_ %LS[_H.E_X+I>7]
MSR_K2Q_8F6?] L?_  *IY?WO)'Y)?\.N[3_HJ>L_]_KRC_AUW:?]%3UG_O\
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M[OGY/\.VGY[?\.R+3_HJ6I?^!DO_ ,71_P .R+3_ **EJ7_@9+_\77Z$X/\
M??\ [ZHP?[[_ /?5'^M>?_\ 0>__  32_P#D0_L3*_\ H&73[4O[OGY/\.VG
MY[?\.R+3_HJ6I?\ @9+_ /%T?\.R+3_HJ6I?^!DO_P 77Z$X/]]_^^J,'^^_
M_?5'^M>?_P#0>_\ P32_^1#^Q,K_ .@9=/M2_N^?D_P[:?GN/^"8]GW^*>I#
M_M\E/_L])_P[(M/^BIZE_P"!DO\ \77Z%J2#DN_3^]2')).]^3_>H_UKS_\
MZ#W_ .":7_R(?V+E?_0,NGVI?W;]?)_AV/S2\4_\$ZM+\+Z<=0N_BMJ21KDD
MM>R+@ 9)^9^?3/N:Q_ _[ .B^-HKB2Q^+&HR"#.[;>2-TP.@<G_#KTS7VO\
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M?_0,NGVI?W?/R?X=M/SV_P"'9%I_T5+4O_ R7_XNC_AV1:?]%2U+_P #)?\
MXNOT)P?[[_\ ?5&#_??_ +ZH_P!:\_\ ^@]_^":7_P B']B97_T#+I]J7]WS
M\G^';3\]O^'9%I_T5+4O_ R7_P"+H_X=D6G_ $5+4O\ P,E_^+K]"<'^^_\
MWU1@_P!]_P#OJC_6O/\ _H/?_@FE_P#(A_8F5_\ 0,NGVI?W?/R?X=M/SV_X
M=D6G_14M2_\  R7_ .+H_P"'9%I_T5+4O_ R7_XNOT)P?[[_ /?5*,@@[WX/
M]ZC_ %KS_P#Z#W_X)I?_ "(+),KT_P!F73[4O[OGY/\ #MI^9OBW_@G?I7A.
MP:_O/BMJ,<2J6):]E7@#GJ_3/L/\*?@;_@GWHOCFPFOM.^*^HR1PMM8K>ROR
M/4(QQWY/XX[_ %[^TID^#+L>9(/]'?D,0>%([$=QG\!7)_L<@CP?J@\R5OGD
M^\Y/.2,@Y]J[5Q)GWU%UO[2]]34;*C1V;77EZ>EM]-C@_LS+UF4<-]5BX2I.
M3?/-;6MIS;?/MV/(Q_P3'M._Q3U(>G^F2_\ Q=-'_!,BU[_%+4O_  -E_P#B
MA7Z%'(YWOQ_M4@)/(=_^^JXO]:^(/^A@_P#P31U\_A._^Q,K_P"@9=/M2_N[
M>]Y/\#\]_P#AV1:?]%2U+_P,E_\ BZ/^'9%I_P!%2U+_ ,#)?_BZ_0G!_OO_
M -]48/\ ??\ [ZH_UKS_ /Z#W_X)I?\ R(?V)E?_ $#+I]J7]WS\G^';3\]O
M^'9%I_T5+4O_  ,E_P#BZ/\ AV1:?]%2U+_P,E_^+K]"<'^^_P#WU1@_WW_[
MZH_UKS__ *#W_P"":7_R(?V)E?\ T#+I]J7]WS\G^';3\]O^'9%I_P!%2U+_
M ,#)?_BZ/^'9%I_T5+4O_ R7_P"+K]"<'^^__?5&#_??_OJC_6O/_P#H/?\
MX)I?_(A_8F5_] RZ?:E_=\_)_AVT_/;_ (=D6G_14M2_\#)?_BZ/^'9%I_T5
M+4O_  ,E_P#BZ_0G!_OO_P!]48/]]_\ OJC_ %KS_P#Z#W_X)I?_ "(?V)E?
M_0,NGVI?W?/R?X=M/SV'_!,>T_Z*GJ7_ (&2_P#Q=(W_  3'M0>/BEJ6/>\E
M'Z;L\_X].M?H4-PYWOQ_M&E+-E27?&X<;C^E'^M?$&WU_P#\HT;]/[OK]X+)
M,L_Z!HW2ZRG_ '5;27E_PQ^8WC/_ ()Z:/X/TN74K_XKZC'!&N6)O9!T^KCV
MH\#?\$\]'\::(-8T[XKZC+ 6*[EO96&?<JQ ]B>/RP?I[]J@,W@#41YDBYC8
MY#$'I[?6I_V059?A2P\R1L3MRSDGJ!U.>:ZGQ+GRPD:RS!N7/R6]A1MKRN_P
M[V_R.%97EW]HK#O"QY'1YT^>>CTTM?\ X;Y6/"?^'9%I_P!%2U+_ ,#93_[/
M1_P[(M/^BI:E_P"!DO\ \77Z$X/]]_\ OJC!_OO_ -]5R_ZUY_\ ]![_ /!-
M'_Y$[O[%RO\ Z!ET^U+^[Y^3_#MI^>W_  [(M/\ HJ6I?^!DO_Q='_#LBT_Z
M*EJ7_@9+_P#%U^A.#_??_OJC!_OO_P!]4?ZUY_\ ]![_ /!-+_Y$/[$RO_H&
M73[4O[OGY/\ #MI^>W_#LBT_Z*EJ7_@9+_\ %T?\.R+3_HJ6I?\ @9+_ /%U
M^A.#_??_ +ZHP?[[_P#?5'^M>?\ _0>__!-+_P"1#^Q,K_Z!ET^U+^[Y^3_#
MMI^>W_#LBT_Z*EJ7_@9+_P#%T?\ #LBT_P"BI:E_X&2__%U^A.#_ 'W_ .^J
M,'^^_P#WU1_K7G__ $'O_P $TO\ Y$/[$RO_ *!ET^U+^[Y^3_#MI^>W_#LB
MT_Z*EJ7_ (&2_P#Q='_#LBT_Z*EJ7_@9+_\ %U^A.#_??_OJC!_OO_WU1_K7
MG_\ T'O_ ,$TO_D0_L3*_P#H&73[4O[OGY/\.VGY[G_@F/9]OBGJ1_[?)1_[
M/1_P['L\?\E4U+/I]KE_^+K]",'^^_\ WU2@-D?._4?Q&C_6O/\ _H/?_@FE
M_P#(A_8F5Z?[,NGVI=.7^]Y/\/E^7/C_ /X)_:-X"T9];U/XL:C%;(P3+7TB
MCKR,EQTXR?UK6\&?\$Z]*\8^'K7Q#8?%;4Y;6Z'R,MY,R_BX;:",\9QGMFO=
M?VU0Q^$EQNDD7]^.48@_>'?K7H7[*JLOP)T "1SA5Y9V)ST///X5VSXDSV.
MA768OGE7Y&G0HZ*RV]W[_P!-#AAEV7RS*IA?JD5"&'56_/4UE>-U\75>=UZ;
M_-H_X)D6O?XI:E_X&R__ !0H'_!,BUR0?BEJ./\ K\F_GOQ7Z%C<#G>__?1I
M5)7.7D_[ZKB7%7$%E_M[OI_RYI;_ /@)WK)<K5_]E6RM[TUKIY^I^>G_  [(
MM/\ HJ6I?^!DO_Q='_#LBT_Z*EJ7_@9+_P#%U^A.#_??_OJC!_OO_P!]4?ZU
MY_\ ]![_ /!-+_Y$7]B97_T#+I]J7]WS\G^';3\]O^'9%I_T5+4O_ R7_P"+
MH_X=D6G_ $5+4O\ P,E_^+K]"<'^^_\ WU1@_P!]_P#OJC_6O/\ _H/?_@FE
M_P#(A_8F5_\ 0,NGVI?W?/R?X=M/SV_X=D6G_14M2_\  R7_ .+H_P"'9%I_
MT5+4O_ R7_XNOT)P?[[_ /?5&#_??_OJC_6O/_\ H/?_ ()I?_(A_8F5_P#0
M,NGVI?W?/R?X=M/SV_X=D6G_ $5+4O\ P,E_^+H_X=D6G_14M2_\#)?_ (NO
MT)P?[[_]]48/]]_^^J/]:\__ .@]_P#@FE_\B']B97_T#+I]J7]WS\G^';3\
M]O\ AV1:?]%2U+_P,E_^+H_X=D6G_14M2_\  V7_ .+K]"<'^^__ 'U0=W]Y
M_P#OHT?ZUY__ -![_P#!-+_Y$/[$RO\ Z!ET^U+^[Y^3_#MI^67Q/_8*\/\
MPST:VU?5OBQJ4,-S,L*L][+'\Q(&!O8;ADC!&1GN<5UGAO\ X)OZ;XC\/Z?K
MMK\5-3:WU&%9HG%W,RE7&0=X;9N[XSGIQWKO_P#@H6IE^&/AS][*F-0M\%79
M3_K%ZX/UKZ8^!&X?!'P0N^0_\2^#DL<GY%ZGO^-=M3B3/(8&A7_M"3G.M.#O
M1H[)+^[K^!PTLLR^>8XC#/#1]G2P].HK3G>\FKZ<UDNV^M^A\?#_ ()CVHZ_
M%/4C_P!OLG_Q6?UIW_#LBT_Z*EJ7_@9+_P#%U^A>6QMW/C_>/KFFX/\ ??\
M[ZKB_P!:^(.N8/\ \$TMNWPG<LERO_H%2UU]Z6OPNZO+U_#M<_/;_AV1:?\
M14M2_P# R7_XNC_AV1:?]%2U+_P,E_\ BZ_0G!_OO_WU1@_WW_[ZH_UKS_\
MZ#W_ .":7_R(?V)E?_0,NGVI?W?/R?X=M/SV_P"'9%I_T5+4O_ R7_XNC_AV
M1:?]%2U+_P #)?\ XNOT)P?[[_\ ?5&#_??_ +ZH_P!:\_\ ^@]_^":7_P B
M']B97_T#+I]J7]WS\G^';3\]O^'9%I_T5+4O_ R7_P"+H_X=D6G_ $5+4O\
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MKR:LX:&69?/,,;AY8:/)0C1<?>GKS)7=N;OYNQ\(_P##LBT_Z*EJ7_@9+_\
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M4GZ5TPZ#Z#^5><_%KP=>>/? /B#PK83?9[K5;1X(9BX0(S*P!+$@#KZB@$?
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MA[&'3Y95\QK;R\K&Q .=HZA?U[U]'>+/COI'AFRU*\N)H$2P:16$C(&^3.<
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M5[%"[")F5SM49(!YXXKZ>\/?MX>*_%UU-I/AS2DN]0B)$:^2)&=4'WB "26
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MM!=O3/-+110(**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH *X?Q2ZL54') ''X5W%<AXEB01A\?-C^0X_*@#@-C>G\O
M\:4QL.W^?QQ2;F]?Y?X4I=CW_P _CF@!-C>G\O\ &C8WI_+_ !I07)P,D^@
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MY?XT;F]?Y?X4;F]?Y?X4@#8WI_+_ !HV-Z?R_P :-S>O\O\ "C<WK_+_  H
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MS>O\O\*4%CP#_+_"@!-C>G\O\:,%2,\<_P">E&YO7^7^%-&XMR<C/ ^I'TH
M^;/VK/!OB#QO\-IM(\.V[7-ZTRL$52YQNY^4<FNU_9T\/:KX5^$.C:#K<+0:
ME;J/-B8%2#QP0><]?RZ5[<L=T@\P6Y>/;U=,KU]^*B6&\E=I4@;9Z1KA1SZ
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MU ->QP3K^[@E9R$Y!Z,3^G0U]PVW[->M3_LTO\+[WS&N9G7>""24X!'Y$_\
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MZ7\F?'YWFV883.<%A:5"M#+?8UZF(Q--<SF^1-15D_>IOWEWVL[L_5?]FO\
M;R^*?Q"^-VH_"CXE:0^GBVOI;>%O+*AD5RJ$9 [?EP.*_7^555MT?*'!4GW
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M0]WV:44WKZZ_/=6/Z5O^&N?@%_T-6D?^#"W_ /CE'_#7/P!_Z&K2/_!A;_\
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MY^OW^0?ZQ\7Z?\8I6Z?\O:?]WS]?N\C^E;_AKGX _P#0U:1_X,+?_P".4?\
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M_ 9^7GZ_?Y"_UCXOT_XQ2MT_Y>T_[OGZ_=Y']*W_  US\ ?^AJTC_P &%O\
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M[=WWOJ^O3R/Z3K;]JO\ 9PTU#!I.NZ#I]MT$-M>VJ(!QT"N!4_\ PUS\ ?\
MH:M(_P#!A;__ !ROYJO^(>[]MO\ Z+X/_"E0?RN*3_B'N_;;_P"B^#_PI4_^
M2:'DW#M[_P!OP?K&=^GGZKYE+B+BY62X3JI::*I35OA\_7[O(_I6_P"&N?@#
M_P!#5I'_ (,+?_XY1_PUS\ ?^AJTC_P86_\ \<K^:G_B'N_;;_Z+X/\ PI4_
M^2:/^(>[]MO_ *+X/_"E3_Y)I?V-P[_T/Z?_ (#/R\_7[_(?^L?%^G_&*5NG
M_+VG_=\_7[O(_I6_X:Y^ /\ T-6D?^#"W_\ CE'_  US\ ?^AJTC_P &%O\
M_'*_FI_XA[OVV_\ HO@_\*5/_DFC_B'N_;;_ .B^#_PI4_\ DFC^QN'?^A_3
M_P# 9^7GZ_?Y!_K'Q?I_QBE;I_R]I_W?/U^[R/Z5O^&N?@#_ -#5I'_@PM__
M (Y1_P -<_ '_H:M(_\ !A;_ /QROYJ?^(>[]MO_ *+X/_"E3_Y)H_XA[OVV
M_P#HO@_\*5/_ ))H_L;AW_H?T_\ P&?EY^OW^0?ZQ\7Z?\8I6Z?\O:?]WS]?
MN\C^E;_AKGX _P#0U:1_X,+?_P".4?\ #7/P!_Z&K2/_  86_P#\<K^:G_B'
MN_;;_P"B^#_PI4_^2:/^(>[]MO\ Z+X/_"E3_P"2:/[&X=_Z']/_ ,!GY>?K
M]_D'^L?%^G_&*5NG_+VG_=\_7[O(_I6_X:Y^ /\ T-6D?^#"W_\ CE"_M>?
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MI_XA[OVV_P#HO@_\*5/_ ))H_P"(>[]MO_HO@_\ "E3_ .2:/[&X=_Z']/\
M\!GY>?K]_D'^L?%^G_&*5NG_ "]I_P!WS]?N\C^E;_AKGX _]#5I'_@PM_\
MXY1_PUS\ ?\ H:M(_P#!A;__ !ROYJ?^(>[]MO\ Z+X/_"E3_P"2:/\ B'N_
M;;_Z+X/_  I4_P#DFC^QN'?^A_3_ / 9^7GZ_?Y!_K'Q?I_QBE;I_P O:?\
M=\_7[O(_I6_X:Y^ /_0U:1_X,+?_ ..4G_#77P!!Q_PE>D9/_40@_P#CE?S5
M?\0]W[;?_1?!_P"%*G_R32?\0]G[;1.?^%^#(_ZF9?\ Y)H_L;AW_H?T_P#P
M&?EY^OW^0O\ 6/B_3_C%*W3_ )>T_P"[Y^OW>1_2O_PUU\ NG_"5:1C_ +",
M'_QRHI_VKOV=+^,V^I^(-#O[,C#6T]];/&1[JTF#^(K^:[_B'N_;;_Z+X/\
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M08$G'3_"E/[77P"/)\5:1_X,(/\ XY7\U/\ Q#W?MM_]%\'_ (4J#^5Q2?\
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MN?@#_P!#5I'_ (,+?_XY1_PUS\ ?^AJTC_P86_\ \<K^:G_B'N_;;_Z+X/\
MPI4_^2:/^(>[]MO_ *+X/_"E3_Y)H_L;AW_H?T__  &?EY^OW^0?ZQ\7Z?\
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M?TK)^UG^SO;QB.R\1Z+:PIQ'!%?VR(BC'RJ%D P/IVIW_#7/P QQXJTC/?\
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M3_\  9^7GZ_?Y!_K'Q?I_P 8I6Z?\O:?]WS]?N\C^E;_ (:Y^ /_ $-6D?\
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MS4_\0]W[;?\ T7P?^%*G_P DT?\ $/=^VW_T7P?^%*G_ ,DT?V-P[_T/Z?\
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6J-O^TWY__6HHH 4#'<GZG-%%% '_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>25
<FILENAME>g0fyk5pshdve000013.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g0fyk5pshdve000013.jpg
M_]C_X  02D9)1@ ! 0$!+ $L  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" &M!QT# 2(  A$! Q$!_\0
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M(?VA=_\ /8_D/\*/[0N_^>Q_(?X4?ZS9K_S^C_X+C_7?^EJ?ZG9#_P ^*_\
MX/J?_)^2^X_EO_X<2W?_ $$-1_\  V^_^/4?\.);O_H(:C_X&WW_ ,>K^I#^
MT+O_ )['\A_A1_:%W_SV/Y#_  H_UFS7_G]'_P %Q_KO_2U/]3LA_P"?%?\
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M #XK_P#@^I_\GY+[C^6__AQ+=_\ 00U'_P #;[_X]1_PXEN_^@AJ/_@;??\
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M_00U'_P-OO\ X]7]20U"[(.9VXZ?=_J*;_:%W_SV/Y#_  I?ZS9K_P _H_\
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MOY%77M#\/>,M#N_#7B?2K"_TV]AEBE-U;QS-^\7:3EU;H#D=>:_EW_X*7_\
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M"=N<<\\8-?&'Z,+12*21R,<^AI: "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHIJK\Q(.2<\#MSFGO=Z+T
M^2"U[+SZ=?)^1@^.O OA_P"*W@K6/ ?BFTM[O2M0L+M&%Q&L@W/$ZKPP(ZL
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH *:/O-^'\J=31]YOP_E0!_&C_P $*;:.?6;_ %%QF47]Z,G[V/M<@ _S
MG\,U_4IJ(!O9VQR7)K^77_@A'_Q\:@<?\Q*__P#2R2OZB]0.;R8_[7]*^OXE
M_P"1M6?]V"O_ -N1LC\]X+5L@HK>U>M_Z7+U*5%%%> ?5:ZZ?\$**** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%!. 3Z4 %%(IR,X[TN: "BBD)(QQG/Z4 +31]YOP_E3J:/O-^'\J /X
MV_\ @A'_ *_4/^PE?_\ I9)7]15__P ?<W^]7\NO_!"/_7ZA_P!A*_\ _2R2
MOZBK_P#X^YO]ZOK^)?\ D:U_2'_I$3\^X,_Y$-'_ *_UO_2Y%.BBBO /J0HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MWFOO/?J*\!_X:A^!/_11-!_\"D_^*H_X:A^!/_11-!_\"D_^*H]A7_Y\U?\
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M1E%]I)I_B;PG":O"49KO%J2^]-BT445)04444 %%%%  <X..O:D7=CYNN?\
M/2N8\1>-/"_A2/S/$&M6.F+C.+F=$;'J5)R!CGG''/2O+Y_VFO@=;2&*?XA:
M$C@X*FZ3.?SK2-*K4^"G.?7W8-_DC*=>A3=JE:E!]ISC%_BT>\45X#_PU#\"
M?^BB:#_X%)_\51_PU#\"?^BB:#_X%)_\55>PK_\ /FK_ . 2_P O/^K,S^N8
M3_H*P_\ X.I^7][S7WGOU%> _P##4/P)_P"BB:#_ .!2?_%4?\-0_ G_ **)
MH/\ X%)_\51["O\ \^:O_@$O\O/^K,/KF$_Z"L/_ .#J?E_>\U]Y[]17@/\
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MH/\ X%)_\51["O\ \^:O_@$O\O/^K,/KF$_Z"L/_ .#J?E_>\U]Y[]17@/\
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M6L-_T$4?_!L/_DOZ^\]9IK$#@]Z\H_X7E\*_^AQTK_O\*0_''X5GKXOTL_\
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M_P %&_\ E*%\/?\ L,V/_I6M?VS_  *_Y)5X/_[!-K_Z)CKZ+B;_ )%^0_\
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MI_RX7E_D_P"GHO\ 4')E_P Q6::6T^M2Z<O^7X>:/XM_^'5/_!2?_H;M=_\
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M_,5+^[_E^'FC^+?_ (=4?\%)_P#H;M=_\"[G_P"*H_X=4?\ !2?_ *&[7?\
MP+N?_BJ_M(_X2#5O^?M_R'^%)_PD&K<XO&SZ87_"C_6[,?\ H'P'3_EPO+_)
M_P!/0_U!R;3_ &K-.G_,5+^[_E^'FC^+C_AU1_P4G_Z&[7?_  +N?_BJ</\
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M_7A(.5_TNXZC&._]/ZU_:1_PD&K?\_;_ )#_  I1XAU<=+Q_R7_"E_K=F/\
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MA<.W"M*D[./M)K[36KZ_,_G:A_8X_;H\8!=0OM=U:/S_ -X5\^;^/GINX_\
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M_0_FE_X8(_;1_P"ABU/_ ,")?_BJ/^&"/VT?^ABU/_P(E_\ BJ_I:_MC4/\
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MI2FWS*K=I)I;KSZ'9T49[=Z*\H]L**** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "KEI][_ ($/Y53JY:?>_P"!#^5 UNO5?F?QL?\
M!1O_ )2A?#W_ +#-C_Z5K7]L_P "O^25>#_^P3:_^B8Z_B8_X*-_\I0OA[_V
M&;'_ -*UK^V?X%?\DJ\'_P#8)M?_ $3'7T7$W_(OR'_L#7_I,3X_@S_D=\4_
M]AJ_*)ZY1117QI^CA1110 4444 %%%% !1110 4444 %%%% !1110 5^2_\
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M@G!'IZ&OP^_X*L_!W3[KPIX:^(=I:J^KVFI6UR9U7YUV3*V<@9SQ_GBOI?\
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ME^38:JLHS?"87AK,JN.P.8NK"KE\U*:P_M%\=]J;4GULU9>1Y=^Q%';^-O\
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M_CTQ8^.Z^-/^"F?[#/B37+KPQ+I?B:RMKJZL+5K=DDE5$D*%5*ACGCI_^O\
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MP5(TW5IOVO\ X>W-I:2RQ1W^FN76-B %>(GD @=\G\R*_6W]LK]D_3_VB_V
M= UV.P2Z\7:)X;C?3U\L&=98K-&0( -_WAV_IBBGF,<%ALEI5'S87%TY8?$0
MZ)3CRQ<NB:;W[7"ME,\QQW$E>A&4<;EU>GB\+.UI7IN,YQ3W:G:S79]F?S\_
M'OXT:1^T)^TUX \>Z1<Q3(;S2TE$;ACYFZ/<&P3SGKG^5?VA?!C_ )(E\/\
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M_P"/O7]+MKN?O\\L:L>>O?\ K7YC_P#!<&YS\ O@HDP+QR-H<A54W9=TM,G
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MT^"?BE\ /"/P\\(Z%L\4RP:6$GL;:-7A*P0(?+>- XW,"[[G8;B2NT9!S/\
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M\@/5O^P?=?\ HEJ_@M^.FT_\%:_#8(Y_X2&WQU_Y^Z_O2\0?\@/5O^P?=?\
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MVE11]U^\G+FCUYOOU/C[_@GG\!8?V??A!:1PVX@'B.RCNS"4VM'YRB3:1C/
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M&_=4I;M+HWU[FBI4U5G75.*K5(QA.JE[\XPMR1D]VHVT[!11169?G;4****
M"BBB@ KX&_X*I?\ )H/B'_KVN?\ T&6OOFO@;_@JE_R:#XA_Z]KG_P!!EKNR
MS_D88/\ ["*?_I2//S?_ )%.9?\ 8'5_]M/YQO\ @FW_ ,F__M#GUTC6#_XY
M/7T-_P $'<?\);\1_P"]_P )3?8Z_P#/R_X>M?//_!-O_D@'[1'_ &"=8_\
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MS_T,EA_Z5)_C7]>&F_\ '[!_O?T-?R'_ /!?O_D?O!O'_,R6'_I2M?2<*_\
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MW>>GV1OSVG_/YU\#_P#!,?\ Y)Q\3,=/^%AWO_H=[7WU^VSS\'KO(_Y=&_\
M037P-_P3'_Y)S\3/^RB7O_H=[7Z3E^OAEFK[9YE]OOK(^9J/_C,L+_V*\3^=
M#_(_./\ X(1_Z_4/^PE?_P#I9)7]15__ ,?<W^]7\NO_  0C_P!?J'_82O\
M_P!+)*_J*O\ _C[F_P!ZOAN)?^1K7](?^D1(X,_Y$-'_ *_UO_2Y%.BBBO /
MJ0HHHH **** "BBG*I<A1U/X4 -HJ:6"2$ N  >F"#4- !1110 4444  YX]
M:=@ D-S]/\BFTADC3YI6"KZE@/U--:Z=PVU>B[BGVZ44W[3;@%_,3R3@%]ZE
M1[DYX]OSH62&8%[=Q(G]Y2&&?J/IWHLUTO;=K9/33\^O_!2=]FMKVZO5+3TZ
MCP2.E(1D[N__ .O_ !HY]**6NG^6_P#7X=!]OO"BBB@ I02.G%)1D#D\ =3V
M ^M 72U>W7^M0IR[>=WX=?Z4WS8)/]1(DF/O;6#8/O@G'^?:BCY?UU!:I/=/
M9]PHHHH!;(**** "BBB@ HHHH *0YQQU_P ^M+10 J\K@CYN/_K^WK0,9YZ4
MT20@A6E57Z;2Z@^G3K3E!?[HW<9XYX]:?]?UT_K4$W=WVOTWZ?CY6' J&/IC
MCK[4RL*?Q=X6M;K^S;C4H4U'.S[/Y@W[\XQLSGK6VC+(BR(=T;C*-Z@\@_Y_
M"FXRCJTTFE:ZMTU:]?Z[(YE+X7%VWY=6O\7F.HHHJ0"BBB@ HI0">E!!'6@!
M**** "BBE )Z4 )12D$=:2@ HHIVTXSVH ;15B&VEG!,8! ]6 _G43HT;%6Z
MCKCF@=G:]G;T&4444""BBB@ JY:?>_X$/Y53JY:$!N?7^A% X[KU/XU_^"CF
M?^'H?P]]/[9L<_\ @6M?VS_ S/\ PJGP?CK_ &3:_P#HF.OXF?\ @HZ-W_!4
M'X>X[ZQ8]._^DKGZ]<U_;-\"OE^%/@_=P!I%KDGC&(8^3GI7T7$M_P"S\ATM
M_L:MUOI%'Q_!G_([XI_[#5^43UQ=V/FZY_STI:@^U6V<?:(,CJ/-CR/PW4?:
MK;_GX@_[^Q__ !5?'6?9_<?HW,NZ^\GHJ#[5;?\ /Q!_W]C_ /BJ/M5M_P _
M$'_?V/\ ^*HL^S^[^NZ^\.9=U]Y/14'VJV_Y^(/^_L?_ ,51]JMO^?B#_O['
M_P#%46?9_=_7=?>',NZ^\GH.<''7M4'VJV_Y^(/^_L?_ ,51]JMO^?B#_O['
M_P#%46?9_=_7=?>%UW1\C_MO?\D&\5?]>%[_ .B*_P X[XNVXN/BOXOP[1.-
M1N&2:/B12L[LI#=1R*_T;_VVY[;_ (4-XJW3Q!OL%V4'FH"V8<<#/.>*_P Y
MCXJD'XL>,".1]ON3G_ML]?TKX%N2P>;.VBG#?9OFCT]/O/XK^E+KF/#ZNM83
MV>NJ2_X-TS]0?^";'_!3#QK^S'XOTOP?XRU.ZNO ]U=0VJ?:KAV5(RP7G<Q
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M88/_ $JK^]/Q!_R ]6_[!]U_Z):OX+/CI_REM\-?]C#!_P"E5?8<(_QLP_[
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M(U5WTU(**/4>AP:* "BBB@ HHHH **** "BBB@ KX&_X*I?\F@^(?^O:Y_\
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M[1;_ //>'_OZG_Q5'VBW_P">\/\ W]3_ .*HL^S^X":OXI?^"HH#?M%>(U8
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MD5U>VFYF\5AU-4G7I>T;LH<ZYKO[*5]_)'LA;! YYIX']X''T-<QXL\8^%_
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MLV'RWA8>0P_O!\A2,'@_7UIAFL)6(LK^WO0.\$BR<]_ND].:_+KQA^TTK_\
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M3RS,RC!P.AXK^C7X._L[?#+X*0K<?#S7(M5L)8UDCGCG$T.U@"OSABOZ_P"
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M$G\N(1K)SC:!C;P?PQ7]*_P(\)_#+Q]^S!X>\+?$:SM;XZE9PQ62W@C.TRQ
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M  ]%_:>_Z"%W_P!_W_QH_P"'HO[3W_00N_\ O^_^-? U%'^J?"W_ $3^6?\
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MYT3\X_\ @A'_ *_4/^PE?_\ I9)7]15__P ?<W^]7\NO_!"/_7ZA_P!A*_\
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M?EY:/86R&C79C&,MD-Q7[C6'P]\$:?HDOA2/1;?_ (1F6,Q-I@B3R2A&W;M
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M>(4?S4!QQSD'N/R_6K3_ -F'X(^%-'U2ZT/P7I]MKD-E(UG=I;Q"03*A*%6
MSD, 1SUS7P;\-/V6]=\9?'&?X@^-[5S'X?OS)HQG4X2.*0F,(7!'&!C'\JZJ
M..P4Y*M&DX4<'AY1A&K)2E.I*-H-:_9>O2WW'!6RS,J5.IAZE6.(KYGBJ=6K
M.E!QA3I0DG4@UTYE==NGF?HAX>^'=A\)OV:?%?A32XECBD\'/<""-=N^26S+
M'"#&22?2OR3_ ."2$=_;_%#XRM=Z7<V0.H:J8Y;B)H]^7F&8V( (/&/Y5^Y5
M\5U&R&G7"^9:O9I931D?*\(785(]-O'>N"\'_##P5\/[J]O?"NCV^F76HL[W
MDD$21F9I,[RQ0#)YYZYKR*6-Y,-C:,XRG/&2A+G3LH.+3=^KOJO0^BQ&6\^-
MRK$TIQIT\LC4C[*UW-3BDE%_W;:GX@Z-'J#?\%!]5EDTBX>'^U9-MX\+&/!G
M/(<C'&.N0/PYKT/]OW^T7^.G@,PZ==7D9DM4,L<;R+&691U P,8]??VK]<HO
MA/X$A\12>+TT6V&O2MYCWWEIYA?/=]NX\^]6M?\ AGX+\67UOJFOZ1!?7UH5
M,$TD2,T93H02,CI]?SY['FD'B*%54I/V6%6':OO[JC=?=VOV//\ ["K+"XN@
MJ\6\3CEBHM1=HQYXOEDN]M%YKH?SO?\ !0/X+7$?A3X<^+M=L+^\T626RDO(
M[:-W>*$^66R%!QA<^A_2O0_"VB_L.ZYX"\(6VM6&LW<\5K9"[LK@RR1BY"QY
MS$WRCYP>HX-?O/XB^''@3QIH@\/>*]#MM6TR)/+MK>:)'2(  +@,"!C Q@<8
MKPS3/V.O@OINJB_3PM8_95<.EL(H]JX;*G&,<'& !T]*UIYQ%X:E1F\13E1E
M.471FHJ2DX^Z]W>W7RN<M7ARHL96Q5#ZE5AB:=*$X8JDZCIRIZ.2>W++M;9I
M'RW^TKX4T>#]E_2[WX8:?-#X.T73DGBL88RK^7'%N \L>W;&>M>"_L>?MC6>
MI_"'Q3X%\*:-J-GXOLK:ZMBTD4BEG1'4D9'4XXP >HK]H9_!_A:X\.R^$&TJ
M'_A')(?(_L\HIB\LKMVA2 !P<=.E>2^$/V8_@_X"U6YU?PWX6L=/GO&9[AHH
M(U,AD.6SM7OG!_I7)#'8>6'J4*]*<W[95:4G);WNU47VGW?7YG?6RO&+&4,1
MA<12HP^K^PKTU!_RJ*="U^1+HM.N[/YV- \9_#_QOXQ^)UE\=;;Q"-8LQ>M;
MH#<"*1@7VA5Z'D#IV_"O5?\ @GOJ_A[PW\3=<U+PYHFHQ^&8;F<'[9"_[RV5
MVS@N!G*CWR#CBOW U[]DSX)Z]K4NO3>$-/\ M=WS?/Y$0,X/S,&.T9SWZ]1F
MNY\.? GX1^#E,?AKPK9:<DD?ES"&&)/,R/F)VKR3SU[_ *]M?-\-4H5*4:=9
M>UA"/L^=*E3Y4D^5+OTUZ(\O#\-XVEBJ->I7PLGAZM2HJT:3]M54Y7BIR>CY
M;^\NO0_$?]M35_V6/%T7C;Q3X;TC4],^*VCP2S:<VFI)"TU[&"1S&%+9D'OZ
M]*A^#VN?%OXO?L$ZU+XRM=4:]T2XF;3X;L2FY:Q@Y3A_F.4'!_#Z_K[K'[)/
MP:UO76UVY\+6+23OON@T2'S<G<=PQSGWS].U>V:9\/O >A:$_A;2-!M;30)8
M#!/81PHL3@C:V55=O(]C[>^;S6A##4J-.G5JSIU:56,J\N9TE3MS4X/M+7O8
MZ8\/XFIBL1B,17H485\-5H2IX:#IPK2JM.%6HKVE.&U]?N/QC_9)_;!TS0_@
M]K7P_P!)T74(/&^E6T]O;EXY 3,BLG''7(SC^N*^/])^(7A+QMX]\8+^T/;^
M(8]2>/4#8K&;A8RI$GEC&0#P1T]!]:_H)T']F+X/^&=>N=?TOPM96\]W(TDV
MR) 6+$[N@'4G/-0>)_V5_@MXIU4:S=^$K!KK'SR&"/+#G/.T')YZ_K54\SP%
M.M7J0P]:'MTI.I":52,[IM1;V1E4R+,ZU#"TZN*P]3ZG>$*4J;="I#11<XI^
M]..EG^A^&'_!+FS\.P?M'^+E\%Z5J5IHWVV[^SW-Y'*H>,R$@AW'MUS_ "S4
M/B3XK)\!_P#@JFGBSQ3HNI3Z+>WH1+Q(9?)#/(1GS ,8R>Y]>F*_H!\$_ KX
M6?#2;[;X*\,V>C7[DF6XMX8XW<G&22J@Y/>LGQ]^SA\(OB1J5OX@U[PM8W?B
M*WD$JZC)#&90P8'[Y7=G.><C^E-YQ0J8S$5JE*HZ6(PGU5IR7M%>RY^;;I<5
M/AW%TLOPN'IXFA'$8/,%CZ<E"U%^\FZ?)T5M%>[V['YI?\%"?'D'Q(\8^"_%
M'AW3+R?3[S[&Z%8V8A2J<L0,9QUQW[#I7R/^T;X8\0_"CP?X,^+DVDWFH:=]
MHLYI;6.%Y&C0;"<J 2, =<#^=?T#2?!SX?W=A8:??Z';7"Z:B);;XT;RPF-N
M-PXP,=,GU/%:FN?##X?^+?#Q\*>)] M=3T1(S'!:2PQND?!"X#*0,<8X'05A
MA\TI4(X>FJ4G2HMQG&^LZ;Z)]&OZN=6*R*MC98RI4Q$(5L0H3HS2O&E6BHZM
M6U5T]/D]DC\_O@Y_P4^^%.K^$? 7@)?#^H+K=U96D# Q2;8I&C1#N'08/K[]
MJ_2?0M0&M:7;ZK"OE1W4:S*A&"%D (!]^??\Z^=O"W['OP+\)ZQ_;5IX.T];
MJ%RUFPACS!ALKMPIQCC&,8_ 5]*0P0VD,=M9H(+>)51(UX"HN0 ![#&*X<9/
M!2DGA*56G=N4_:24KR;NN6VR2;7Y^7JY?3S.G"V8UZ%9Q4:=/V,.1<L8J-Y+
MK)[W7ENK$M%%%<1Z 5<M/O?\"'\JIU<M/O?\"'\J!K=>J_,_C9_X*-?\I0_A
MY_V&K#_TK6OZU/BK_P F1:W_ -B.O_I+7\E?_!1K_E*'\//^PU8?^E:U_6I\
M5?\ DR+6_P#L1U_]):^QS'X^$?7"?^G*1^>9/OQ]_AQ/_J-(_P ZCQ=_R4?Q
MY_V';S_T<]9E:?B[_DH_CS_L.WG_ *.>LRO[,I?PJ/\ UXH?^FH'^;=3^/B?
M^PK$_P#IZ844459(4444 %%%% !2CJ/J*2E!P<T #9R<]:8N[G=^'3^E2N^[
M'\SU[TRE)O=);ZK_ " 4 GIU_P ^XJ&5%?Y#\K9R& Y!Z#!['_/IB0 ABP)Y
M[4I'<CGU(JK_ )B>STOY'W9^Q#^W+\1?V4/'FEW-GJM]+X>DNXA>P2W$GDK;
M[U#@+NP/ES[],U_=S^RA^UI\._VH_ .F^)?"NJVK:D+*V.I6/VB(RBX9-LC1
MQYW'+8)7!.6/  P/\U6:))497';KW'TK[U_X)]_M1?&7X+?&'0M*\!W&HZGI
MT][:QS:-!Y\D<BM* ?D7*D?48]:_*O$/P]P?$6%J9EA/9X3-,/3E4=1VC3Q%
M..KC5>REO:3VZG[IX/\ B[F7!F84,ES%U\PR+&U84HT;NI6P=2HXQ4\.MW%7
M]Z"OS6]#_1/\09_L+5L]?[/N_P#T4]?P6_'3_E+;X:_[&&#_ -*J_N$^'7B_
M6O'GP?M/$_B+3FTG5M2T.>6ZLGC,;1O]C5^4/(W,Q_SS7\/?QT_Y2V^&O^QA
M@_\ 2JOYWX6I3HXK-*4[<U/"8B$K/FCS133M):->:W/["X[KT\3@,AQ%+F]G
M6S'!U8<T7&7).=.4>:+UB[/5/5']G&C_ /(!TK_KPL__ $2E6ZJ:/_R =*_Z
M\+/_ -$I5NOG'N_5_F?9KX8?X5^;"BBBD 444#GIS].: "BBB@ HHHH AO($
MO+.:T?($D<B@_P"TRD#!SZXK\<?CW\)?VVM+\>WNJ_ S4;R/1[IY!M65U4*2
M=N"">WU_P_90\<G@>]7X-4O;==L,Q5?8 ]./\_C75A<5/"S<HTZ55/1PK1YX
M-76Z.''8"EF$(0J5:^'<)*4:N&FZ=165K7[6W7]+\@/V7OV*/&^J^/+;XO?M
M*;KSQKIP:6SEN,NZS#YEPS@D?-Z'W%>B^%OV1/$&C?M;:A\<I=W]F2N! <<"
M-#A,''8 >G]:_36XO+BZ.9W+GU(']*C:YF\H1;B4_NC_ /56]3,\55G4ES1C
M[6G[#V<%:$*;M[L%HDG^>IS4LDP-*E1IQC.]#$+%*K*5ZM6NDDIU9?:?^6Q\
M=?MP_LM>'OVI_A+JOAJ6TA;Q'(#]CNC&K3IQA=KD%@>GIT^N/F+]CC]A_P 0
M_L[_  NU;PO=33'5I$G-C*Q.\.P.P ^W'3IQZU^K\<CQ.'0[6'0U-+<2RD2/
M)N;CTXX_S_*HAF&)AA7@U/\ <.HJG*];25MO+38UK91@:V/692@UBHTG1<X.
MRE!VNVM/?71M;:'X)^+_ (2?\%%;;Q!K6C>$M3OAX-U*\= HED_X\Y7PV "/
MX#^=?=/[&O['6E_ V>;XC^)8(Y?B/JY\W5970&1Y91NEW,PR<L6R>_;CK^A:
M:KJ*1^6EPP7IPHX QQ_DU2EEDF;=(VYO7I^E:U\TQ%:C[%4Z-&$O=JRHPY)U
M4DM*G27H8X;(\)AJZQ'M<1B:D&Y45BI^UCAVVFW23^%_9+9EL'DN93IMFDD\
M<H\Q84#[F!P=P&<Y/YBOR3_:'^&?[7^F>,K[Q)\!+^[A6XD=T2*1U4;F&,8/
M&.WJ..>_ZNU=@U"[MAB&4IT[#^O^?2N;#8F6%FYQA3JJ4>64*T>>+MT:?;R.
MW&X.&.I1I5*M:ARRYHU</+V=2+TU4EY=C\,_@Q^Q!\;/B1\6M/\ BQ^T[--=
MZO8S12J+C=(,QLK?QYZX]><U]2?MN?L3V7QGTK0=2^'T?V3Q'X4CAETEK=0A
M-S;JK)G9UPZCZ^G2OTHGU"[N1MFE+@^H%003R6[!HCM(.>GX]_\ /I70\UQ3
MQ%+$)PINBN6E3A%JE"#5G!1[-77<XX9'E\<)7P<X3K1Q,E.M6JRYJ\IK52<]
M[Q>JVU/P*T/]DO\ ; ^-=[I/@7]H:[NKCX;Z'+;Q6D4I9D^S6Y4)P>/NJ/ZY
MQBOU;U[P'XP^%7P;T_P!\#1Y%SHEFL6GF,;2)%AV@\=RWZU]33:O>S+MEEW)
MCH0/Y@9ZU2CF>)_,C.ULY!Z^_>IQ&95L0Z2E3HPI4FIQHTXVHN;^*4H7UD]F
M]GJ]R\'D^&P:JJG5Q%2M7@J<L55J<V(5-+2G&;VC%VLE:UE;4_F>UW]AG]M_
MQ!\9Q\=;NXG/BJ&^\V%R6+>2'R,-[J/QZ=A7[H?LXV?Q?LO#L,7Q?D>34UB5
M6+Y^\ !_%^)_KS7U#_;6HX"_:#@#&-JX_E5&:XDN&!D;)]>/SZ"KQF:5\;3I
MTZU+#Q]G&,:<J4.64()*T4]+)?J1E^28?+:M2M1K8J4ZK<ZL*M3FC.<K-SDN
MK??]!BN8WWIQALCMP#D=,>E?./Q7_9G\$?&'QOH'CSQ&@?5O#<\4]DQ&2'B<
M.I!]<@< ^_N/HS;SUX_O8X_SGCK29(R >.GUK@IU:E)J=*3A+5<T7:5I637H
MUTZZH].M1I5X>SK4U4AS1DHR5US1DI)OTMI<=YTGV:RL\DPV-M':Q9.<1Q(J
MKU/^S_G%-))Q[49Z^_\ C302>H(_S]*A]^^^FSZK4UNVOP[Z)))_=]WH+112
MCDXSCWI"$HI3P<9S[TT$GJ"/\_2@!:*<1@ YSGMZ4W- !11FB@ KX&_X*I?\
MF@^(?^O:Y_\ 09:^^:^!O^"J7_)H/B'_ *]KG_T&6N[+/^1A@_\ L(I_^E(\
M_-_^13F7_8'5_P#;3^<;_@FW_P D _:(_P"P3K'_ *+GKZ$_X(/?\C?\1_\
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M3K_Y,X^"/_8J6O\ (5]GWW_'E>?]>MQ_Z*>OF,9_R,,3_P!A=7_TZS[K+/\
MD5X#_L!PW_IB!_%5_P %,?\ DL>M_P#7_+_Z.-?G(GW%_P!U?Y"OT;_X*8_\
MECUO_K_E_P#1QK\Y$^XO^ZO\A7][<'?\DQD__8)3_P#28G\VY]_R.,?_ -?G
M^;'4445]*>2%%%% !1110 4444 %%%% !1UX/0^O2DQ\P;T[?G_C2,2.@)SG
M\*/UV_#=[+3N'57OIV=CJ? ?CSQ3\+?$]CXK\)7]W;7EK<QS/'#*T:%(V#$$
M*1UQ_@:_K%_X)]?\%$_#?QHT'3O!_C+4H;7Q+;0PVX>YE"LTBC:1\S<@GK^A
MP#7\B2C:",]<Y^A[5L>$/&OB3X;>);#7_"%Y/9ZC!/'*L-N[[IF#KQA#SDYX
MQW]\5\5QKP1EW&> E1KQC2S"E%_5,8DE*,M+0F].:'?Y^9]#P[Q%B^'\4JE.
M3GA)M*MA[MJ2;2;BGM+M^A_HNQ2QS1I+"ZRQR ,DD;!D92,@AAD$$?SJ&^YL
MKK_KWE_1":_.'_@G+\<_B%\7OA3ILWC?2[FWEMX84CN[B-U,JB-0#EQSN'\L
M^M?H]>_\>=U_U[S?^@-7\19QE.(R3-,3EF(E3G6PM=TI3I24H2Y6K24DVM=.
MNA_16 QM/,<'1QE%2C"O34XJ2M)75[?*^_7<_E-^(V?^'A2_]A9O_1I_^O7]
M(?A[/_"-Z9G_ )X0_P#HM:_F[^(P/_#PM#GC^UCQ_P!M&K^D3P]_R+>F?]<(
M?_1:U^L>(G^Y<(_]B+"[>D=]KOSU]3X;A?\ CYYY9A5_]*B:-%%%?F)]<%%%
M% !113B,=#F@!M%%&: "GKL*3(_\<3JO^\5('\Z0K@ YZX[>HS3:'J!^;'Q3
M^''[3FE>,]0USX4WMREI=2,559'"J&.>!GC\N>E:?P2_9=\47OC0_%3XR9N/
M&,<3>5)*"S+(5(/+9/4]CGITZ5^C\5]<PKMCDP/H#4<US-.<R-N_"OHI<49A
M]4>$I4,'AW*DJ$\90I<F+J459.G*HK7C)*S[Z]SRUD^&=;VTZM>LHS]K&A5G
M>A"I=/GC#I)/57^1\4>%?V?]7T3XN:IXZ?BVNYB\>!_#OW8!^AY_"NV_:I_9
M_P!*^/7P]7P^L$8U9%.VX5 9@<8'SXW<?7_"OJ#SY"H0G*C''TH61D/F(VUO
M3KSGK]?PKC>=YC]=P681J*&)P$:<:$H72M32C'FM\6FC5K/R.A8#"^PK89P<
MJ->_M8MZMR:<FM[/L?"_[.G[-FI_!CX<ZKX7#/\ ;KBWDCMY"?GW%65#GKD9
M'_U\5X%J?P[_ &R=(U'4=(\-7]U_PC6IW,T<H\QP/LDS%6&,]-C=,CFOUD>>
M61@S-EAT.!5E=1NU7:)..F,"NZGQ3F,<1B<7B,-@<95QE15:JQ=+VD%..TX+
M[+6ZU]-CGEE&&=&C0I5<1AZ="/+3="?)+E=KJ3ZIK1KJCXV_9>_9MLO@U)?>
M*M3B23Q3KN9=49U!+2R99\G&3\S'_P"OUK[$D:SDBN%%E;1O*C@,D:ALMD=0
M!S_G-0-,\SG>23GK]3_7K0PVG'6O&QV.Q.98JIC,74<Z]3E5UHHQCI&$5TC%
M))+HDO4[L-AZ.#HQH4(J-.-]+:W>\F^KD]6^_P"/P1\9O!O[15EK4FH_"*[G
MC21R65'=5PQ.>!QTXZ]?<XKS3X8_LQ?%'QEXWM_%OQRD>YDMIDG19BSKN5@W
M&0?3CMZ9K]2HKRX@XC?'X TDUY<3C$C[AZ8%>O0XGS##X5X2AAL#2G.DZ+QL
M*-L7R.R<?:]W]S5^IQ3RG#U*_MJE7$5(J2FL/.=Z"GW4-.I\6_M)_LP6'Q(M
MM*UGPPHB\0^%TC_L9HP!M:%5,6,<C#+[>GI7R]8_L]?M&?%6^TS0?C)=W$GA
M71KF(689B1Y$# (,9P?E'?M7ZW1RO$VY#M-6FO;N92CRDJ>^T<_EC_(IX/BC
M,\%AH8:"P]9TE-8;$XBGSXG"<_Q_5Y_8YG=OU%7R?"8BLZLI58*HH^WIPERT
MJSA;E56/VK62OY'AVO\ AC7_  ?\+K?PQ\- (M6T^S%M:O&-K-^Z\L$XYZCO
MG^>?RMN_V8/VJ-2\7OXSO)Y3JAN7E!R<X+%EY/;^7%?MRK-$P=#\X[CG&/ZY
M)JXVJ7; *)0, =AGM_G\:SRSB;'90J_L,/@Z]3%RDZU;$TO:5I*;]^+E_+)M
MMZ=?D/&97A\>J*JU,13A0M[.G2GR0CRV2=N]E^-SP+X"V/Q%TSPXEC\2G:2]
M@B"1%L]0N!UQC\*]PBG,4P>/.Z-MP[=#Q_DTZ2:24@R-N([XJ+&.<=>^.M>-
MB*TL57JUY4Z=)U9<SIT5RTHWW45T1Z%*'LH0IQG.:@DE*H^:3MW?^9XIXL^!
M7A7QC\0]-^)6IH&UO2W1X'(!*E""N#SW _PZ5[E/.\Y0N2=D:1CZ(,#]*@SG
MI13K8BO75&%>HZD<-3]EAXO54J3L^2/97U>K_$(4Z4.>=*,8NM+FJM*W/))+
MF?=Z;]N@44[ VDYYST_+\:;C/'KQ^=8+1)+;\#1OM_3ZA11M*\$Y[^O^%%']
M?U;0044447 **** "BBB@#Y6_;9_Y(]=_P#7HW_H)KX&_P""9'_).?B9_P!E
M$O?_ $.]K[Y_;9_Y(]=_]>C?^@FO@;_@F1_R3GXF?]E$O?\ T.]K](R__DV6
M:_\ 8\R__P!*K'S-3_DLL+_V*\3^=$_./_@A'_K]0_["5_\ ^EDE?U%7_P#Q
M]S?[U?RZ_P#!"/\ U^H?]A*__P#2R2OZBK__ (^YO]ZOAN)?^1K7](?^D1(X
M,_Y$-'_K_6_]+D4Z***\ ^I"BBB@ HHHH **** %R1T)I*** %R>F3BDHHH
M7)'3(I*** #)HHHH *.#C< RY^9",JX_NL.XHJ4PN$$F/E/?(_E0&K]$G?\
M 8@L5XM-.L[%L#S'M84B:3 )RY49)[_YY BER03T_P /:FCCH,?3BI(XW<G9
MU'7G!Q1=]1[Z=?+_ "2W\R.ER3U)H(()!ZBDH$%*V54$G([#\O\ &DIK MCG
MI^/^>E =_P /Z]!X&5W=OU[?XTX;F&..,4B1.Y&WH.,=!W]_Z=J.4./0\X[T
M[^7]:?U]X6?G_2_IC:7)Z<X]*5CDYQ3:0>@4'GCUHIRJ7. .::\]/,:W& 8X
M%!+9&/7G_/Y]*D=&0X8<TRD$E9V\E?U[!FER1TR*2B@6O;J&:,XR>?PHHH
MV1D\@]0>^.QZT\F(#$5O%"3R6C4*S?[Q &?\_BRBFNOG;7YA?ROM^?<4$CD4
ME%%(+_U_P>H4444 %+D^II** "ER?>DHH 7)'0FDHHH <H8]#C'N:;2$$X&<
M?Y]>U2;"3A<'W].OUH_03N[65W?;;YW%RNWOG'OUQ^5)C"9!/Y^^,_E32""0
M>HHR>G./2C7IWU]/\QB49(Z444 %%%% "Y)ZDTE%% !1110 5<M/O?\  A_*
MJ=7+3[W_  (?RH&MUZK\S^-G_@HU_P I0_AY_P!AJP_]*UK^M3XJ_P#)D6M_
M]B.O_I+7\E?_  4:_P"4H?P\_P"PU8?^E:U_6I\5?^3(M;_[$=?_ $EK[',?
MCX1]<)_Z<I'YYD^_'W^'$_\ J-(_SJ/%W_)1_'G_ &';S_T<]9E:?B[_ )*/
MX\_[#MY_Z.>LRO[,I?PJ/_7BA_Z:@?YMU/X^)_["L3_Z>F%%%%62%%%% !11
M10 4444 %%%% !3W8<<^O7C^=1D@ D] ,FNQ^''PY\6_%WQ38>$O!^FW&HW=
MY<PQ8AB=P [@'E5/'Z>]14J4Z-.=6K.-.E3BYSJ3?+&,4KMMO8NE3JUZM.A0
MI3K5ZTXPI4J:<ISE)I)**3;U?0I^!_ WB;XG>)-/\*^%=-N[Z\U&X2V5K6-Y
M0C2,%!.T<!<]SZU_95_P2Z_X)4:#\&]"TGXE_%32H;SQ9<P6U[8175NKLA;Y
ME9A(. I!R<$]!T/'3?\ !,'_ ():^%O@5X?TGXB_$+2;>^\47L"7$5C>1!GM
MI2B,'*LI*A7)R/E)P0#W'[P111P11PPHL<42+'%&@PJ1HH5$4#H%4  >@K^9
MO$CQ-EF4JN2Y%5E3P46X8K%1=GB)+24(-/2'1ZV?3:Y_;/@SX)4LFAA^*.*:
M$:N:5(QJX' 5(IPP<6E*-6K%JSK:IQ3^%[F-K4,-OX>U.&WBCAACTVY2.*)%
M1$58& 554     8%?P8_'3_E+;X:_P"QA@_]*J_O3\0?\@/5O^P?=?\ HEJ_
M@L^.G_*6WPU_V,,'_I57YWPBVZV8?]@-9_\ DK/U_P 0M,/DVG_,UPR_\J0/
M[.-'_P"0#I7_ %X6?_HE*MU4T?\ Y .E?]>%G_Z)2K=> ]WZO\SZU?##_"OS
M84444@ \\>M"?)T_7_(]*4'J,9S_ /7Z>_- 8_,N.G.?R_S_ %I]M[>FVU[?
MG8%=NW](<><%023UP#UXI-K]=K8_W3_A7S7\8/VJ?AE\$+VWT[QCK=MIUW=D
M+!%+*BLY)PN 3D\G&!WKQ31O^"@WPVN?%5MH^LZC!8Z)?21QVNH2$)'(93A,
M.V <D^O?Z5U4\!BZM-5849N#3DI<KM)+^737Y'%4S++Z-3V53%4XU.90<6U[
MLGMSZ^ZF[K7U\C[]IVQ\9V-CUP:XW6_B-X*T#P=_PG=[J]O'X?E@-Q:W;3($
ME0KN4@D@'CT_"OBR']O_ ,''7UAN)88_"TEW]ECU4D>6S%MHP_ _7OBII83$
M5^9TJ4I*+LVHV]Y;K2ZYO(TKXW!X9PCB*T(^T5XJZ=XNUI/M%WO=Z;'Z!-N8
MA<<8P?P_KQZ5(D9Z%6X'H?K_ (UYGK'Q<\%Z7\/G^)2ZI!)X>B@-S)=^:IC5
M F\DD'&,<GTKXXOO^"C?PIEMDOO#FK6VI0"Y^SW+Q,LBQ!2%<D@D#'/Z]J*>
M$Q-;F<*4Y<LG&3L_=DK:/3?7\R*^88'#<JKXFG!SBIPC=7E%V]Z*NKK7IIYG
MZ(D'=M"L3GL/>FRAH8Y)Y,K%"A=\@C@#)S]/\^M?$FO_ +>WP8L_#5MJF@^(
MK34M;DC5IK"*1))(W(!*E%)(()(P0/RKT3X0?M0> _CEX7UVRTG5(#XFBLYE
M;3E=1*AV''[O=N'Y#\ZN6#Q-.G[25":I\UG)P::5UJ^JCY[>80S# U9QI4\5
M2G4E%SC&$T^;W;J-T_B[QU9WD/QU\%3^)%\)1W$)U5Y/)$8<%]V[;]W.2<\8
MQ7L+0R)MW(P#JK@D8&& /]:_G \3?&C2_A;^U$\OB#6/(NH=3)BL6D/S[9C\
MH4GG)XX'-?K'\,?V[_AU\0_%=MX4UC4+?3)Y(X;:U\UEA,KX55 +D9+<8 R<
MFNK%995I*G.E3G4IRH^UE+5]MK:M:]/NZGFX'/,/B:E>CB:L*-:&(]C3C>S=
MK)<VNDGMKO?OO]L@M@@#@^QI"K 9*D#U((%?._Q9_:>^&WP8U"UM_%NLVUC9
MWZ>9:SRRH/,5AE=N2,@\=,UQ?PB_:]\)_%_Q!JMKI-Q')X:TD-)-J@XC$2 D
MMYG"]!GK]*XU@\2Z+KJE+V25^>VC\EW?DCU/K^#C4^KRK06(<N7V:DG-:*6J
MOHK=>S['UZJ.WW58_0'^=17,@M+>:ZF&V.W7=)GC"J!GK_D\U\'?$C]OCP%X
M:UR72/ ]Y%K\=E<&#4)+<B<0;#MD+&/.-O))SCCGTKV7X?\ [2'PY^-_@3Q!
M#X8UNWN?$UM93?;-.CE3S+=PA+90'=\I!'(&,8HEA,3",)SIRC3DT]8O2[2O
M+LFM$0LPP4ZTZ%/$4Y55%M)25IM*_+%W][7=)Z6.WTOXX>#-:\12>%;.>%]3
MC9E= X+?+U. ?K^5=;I?COP[K>L7'A_3[VVFU*S)$T$<BM(ISSE0<K_ATS7X
MI? [4-6/[5VLVMQ<2/ 'ND92S$1C<XSC..!GWP*^I?@#I6DZ?^T=\1];LO&7
M]L7,#SR3:,+GS/LN"[%?*WG;C!'08S],]E; 4J:J.,Y7AAX54FF[RDTFF_LK
M7^GOYV$S:K7]CS4XVJ8RIAI:\MH4XI\R7VWY+Y]#]-#&Q&-K?D?\* I! (/;
MJ#G'_P"JOAKX@_MQ>&?AYJLUGK?EVUO#<O"TL@"@$.5ZGCKG%>G>$OVH_ OB
M_P (WGC"RU&%[&SA,TL@==H51N)W9QQ]?\:XG@\0H*HZ<N2324K:-MV27F>D
MLQP$JCI+$1YXZR@VDU%;OI9+775?D?2S A\ ?+C^GY]:4@CJ",^H(KS;X5_$
M_1/BYX;U;Q1X?N$N;#1TGDN)8V#*JP EB2.F ISTQS[UP/P^_:5\%?$K6?%.
MA:'?PW%WX1:=-01'5C&;<D/NP<Y!4]1CK4O#UKS3IM>R4?::?!?;G[-W7_!>
MAO\ 6,/>C>K']_?V&JO4LO>Y->G7RW/HD;R-H4G\#GK3&5P0-K#GD$<_KSZ]
M*^*?&/[=_P )?#376DV&MVUWXDLW=)M/617D4QEMV5!R,$<_3I53P/\ M_\
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M]?0G_!![_D;_ (C_ /8T7W_I2]?/?_!-O_D@'[1'_8)UC_T7/7T)_P $'O\
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M&-*K-0E&FW&<N2+2TE+:R[R[]3>5>A3G*G*K",X056HFTN6#2]YZZ+STV/:
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M)]Q?]U?Y"OT;_P""F/\ R6/6_P#K_E_]'&OSD3[B_P"ZO\A7][<'?\DQD_\
MV"4__28G\VY]_P CC'_]?G^;'4445]*>2%%%% !1110 4444 %%%% !3"2O7
MG/3'^13ZKOYLLT=I:H\U[<,J6\"*6+LQ"@  $\FGT_-O9+35]K=7V!NR^=K=
M?*W=L?)(^8X+>%[FYGD$4<,0W2;FX4;1SR2.E?L7_P $\_\ @G/XA^+&M:=X
MY\?:?-%H$3Q7$<5W"0K1;M_1L#&,#/Y5T?\ P3M_X)O:U\2-8T[XB_$737M]
M(BDANXK:ZC94=5*N#M< '(_//?-?U2>#?!F@>!-"LM \.V$%C8V<$<*I"BIO
M\M<;FV@#KG''UR>:_ O$_P 4Z>60JY#P]5C4QLTXXO&P:DL-=6E3IR7V_B5T
M]/R_3N#N"YXJ5+,\TIN.'C:5##S34JKT?--.WNW7S*/@'P!X;^&_AZQ\->&[
M""SLK.**,"*)$+%$" G ]B0,]ZZ^^_X\[K_KWF_]%M5C;\V[^G]?UJO??\>=
MU_U[S?\ HMJ_EB=6I7K2JUIRJ5:D^:=2;<I2DWK*3W;/V>,(4Z:ITXJ$(1Y8
MQ6R26R[(_E-^)!'_  \,4#OJQQ_W\;\:_I#\/'/AO3#_ -,(?_1:U_-W\1>/
M^"A2 G)_M8\GK_K6_&OZ1/#W_(N:;_UPA_\ 18K]I\1/]RX1_P"Q'A?R7]?J
M?GG"_P#'SS_L85?SB:-%%%?F)]<%%%% !2X)Z _E2HI=E0=6.!]3TKQ#XE?'
MWP5\*=:MM$\4:E#8W%U@1+*ZJQ+=, G.2?\ />ML/AL1BZOL,+1G7K.,IJG3
M3<G&.[22;=C.K5IT8>TJSC3AS*/-)I*[:26K7<]Q*X4'!YQZ_P">M, 4\G[W
M;C\NWK7R1:_M?>"?[?@TS4[V*UTV\D6.RNG*JLI8@)AC@'D^M?26L>,O#>A>
M&H_%VH:A%#HLL7G17+.H5EVAEP2>X]SU[8KHQ&6X_"2HQQ&%JTY8C2C[DFJC
M?V(NVLU>SBM4_N(I8JA54Y4ZL)*EK4U7NI6NW=_#YG4!9&&,' YY!QZ>GO48
M##AN3[>GX5\BQ_M;Z ^L1P[D_L*:8Q17^1Y;#. =^=OIW_,FO?M>^)GA;1_!
MZ^-X]0BETH1B2:<2*408!.6R1T[55?*<QPTJ$:V%J1>(:C123=YNUH/32=W\
M._EW4,7AJJJ.%6+5-<T]DHQ5O>6NL5O?L=]M8]%8_@:%4EL8/OP?2OD:^_;"
M\!M:6U]H=_%?Q,VV[*$.L*AL,25R!@#H:U[S]K7X:2Z*+S0=9M]0U5%!GM(G
M61HS_$"JDD$8/!'0=JU>1YO[O_"?B5SRY%^[E[LEH_::>XF]4V[-$+'X)WMB
M:6BO\2U5D_=U]ZWE^I]13%8D:1AA4R6SGL,_R]*\[@^*OABZ\1#PG%+&=4+;
M @(W9.,<9]_3WKD?AM\=/"7Q;TO4++2+Z*36;=)%N+17'F1D(<Y7.X8QSZ_R
M_-/4OB=IW@/]J'SM4U'RS%=$"V9SR5)XV$\\UZ.5</5L94S'#8FC6IXK!X:5
M>%))\TI12<7:VL)='MYG+C,SI8>&%JTY1E2KUH0E.ZLD[)Z]U>UMU8_:"2)X
MFVLI' /((X-,P3T!_*OFKP?^U1X+\7^)?[#U&^BLIYRL=FCLJ><YX7;G&<D]
MAZ&NQ\>?'+P9\-[A8?$NHPV,<T9DMV=U7S!C*XR>0<^_Y9KR9Y3F5.O3PT\'
M56(J052--0DW..FL%;WK7UML=L<7A94W5C6I^S3:<N9+E?\ >VLWY[GL[+A0
M<$$X['T_+KBF ,<X4G'H":^?/AU^T+H'Q!NKR6&5%T.T+G[?P$**<[M^<= >
M]<GXV_:P\*^']5.G>'IX]4CB<BX>(B01A20Y8KD# &<G']:N&3YG.M+"K!U'
M7C%3FK-*"[2>T9>3_P"&EXW"JE&LZT?9R?+%WUD_[JZI=SZO((4L1@+DD'KQ
MR>*\ZL_BQX6U#Q--X.@GB.K6^[S$#*679D'(!XZ'M63\-/C5X,^*NG3KH>IQ
M3:G!#+]IMD==\3A3D$9SD8Z$=J_.?X>WFH-^V-XFMI;AOLNVY!!9MJ ;OFQG
M' /\CVS7=EN1SQ#S:&-C4PU;+L%+%1IRBXMN,HI)IV;3O>^S^XYL9F$:*P+H
MN-6.*Q*H\T7S))I-[;/>_;S/U4M_$^CW=Y+I]O<PO<PMLD164L&]#@DYXQC_
M !-=#M?:!M..H.#W^E?$_@JVL-.^(/B;4(O$7VUH[N5FM?.W^658_+MSQC/^
M<"NO\4?M3Z'X5O18:B5B2/"&1\+D+QG)Z]#R.WY5A5R;$3KPH8"-3%2=&%22
M<)1DG*,9-)-)[R?3S1JL=3A3=3$N-%*;@FFFFDTK[Z>9]3X/3!S]*;MP<\Y/
MK_GVKQ;2?CGX7U?P9>^-X;R,Z=8*7GEW#8N ">20.??_  KM/!'CW2?'G@ZZ
M\;:3.D^F6@D:25""@$0).2/3!]S7GU<%BZ$9SK8>=.%.M'#SE).RK22<:;T^
M)WT6[['3#$T)\BA4A-SA[6-FFY4U:\N[CK\NNYV^".H/Y4OS$ 8)]./\/:O)
MO"'QA\.^-9=2ATVYCE?2F=9PK@E3'G.<'C&/?Z\5YOXF_:O^'V@ZA=:+#JD$
MNK6F[S;8,K.&7.5VCGJ/\\UM3RK,JM65"G@ZLZL5%SBHN\(RLU*5D^5.^[TM
MU(EC,+""J2KTU3F[1DY*TFK72UU=^E_U/I\(5XPW//(Y_E2E6'52/J"*^7/#
M?[7'PTUC3+R?4M9@M-3@#>5:/(BNY&<#:3N/2G^!?VJ?!OB[Q"V@W=]%:[Y#
M%;.[!/-.2%P6Z[NV/_UZO(\WBJSE@*\507-4;A+X='S1T]Y6>MOO)CCL'+V2
M6(I-U?@7,KW[2_E;Z+KT/J 8/&"6[8]/I^=.".6 VL,GKM/]?S_"O,/'WQ2T
M#P+9"XEN4>[F3?;0]3(I^Z1ZC_Z_:O*/ W[5?AK6=>@TCQ--'I+W,_E6@E81
M^:2=J!=Q!.>V/;VK&EE>8U\/+$T<-4G1@G+1.[LM7&*UFH]6M%OYNY8O"TZJ
MHU*RC.26]E&+[.3=K[:/OIY>W>)?B/H'A*Y2UU:6-)9&"#<0#DD@>F><^_3'
M:NJTV^BU>PBU.T!:VG 96 .,'GT__5WK\V?VR]=AT;7M-UFXO_LNE2R1SQ3;
M\*Z$[@0<X].<X_2NZ^&W[7GA;2?#.@Z1<W*FRE$41NS@#!"@G?T[?YZ5[,^&
M\15RK X_ T:M>KB.;VT5%M1Y5JE_>5G[J_4\^.:TH8VOA\3.%.%-1Y&W[S<F
MDKV=^6VSVTZ7/O>BLGP]XDT7Q5IT&JZ!=)>VTL2N[QL&"E@#U!('-:Y.23ZF
MOF)1<9.$XN,X-J4)*THM;IQ>J:9ZZLTI)J49*\))W36FOW"4444@"BBB@#Y6
M_;9_Y(]=_P#7HW_H)KX&_P""9'_).?B9_P!E$O?_ $.]K[Y_;9_Y(]=_]>C?
M^@FO@;_@F1_R3GXF?]E$O?\ T.]K](R__DV6:_\ 8\R__P!*K'S-3_DLL+_V
M*\3^=$_./_@A'_K]0_["5_\ ^EDE?U%7_P#Q]S?[U?RZ_P#!"/\ U^H?]A*_
M_P#2R2OZBK__ (^YO]ZOAN)?^1K7](?^D1(X,_Y$-'_K_6_]+D4Z**I:WJUE
MX=T:]UR_D6.ULH)YWD8@ >4A?&3TZ=*\%7;22O=VLNMSZENR;;LEJWT26]_Z
MT--8)6&[8X'^Z?\ /X=:88W7.X%<>H(SCTXK^6S]JC_@X0D^"OQRD^%VB:%]
MNTJQOS;W%\B JJ+,(\D@>F>>V.?6OW7_ &*/VKM'_;#^&EEXVT?:)!:)-=1K
MCY&\L,V<>A)^O>O4Q>2YA@L-2Q>(H\E"JDX24D_B5X\R6U[II/4\7+^(LIS/
M&5LOPF(<\51YN:#A)*7(^63@VK2BI*2;75-;H^N:*4\$CT-)7E'M!6'XH\1V
M'@[1;GQ!JI"V5I#)-)G@;(UW-R?:MRO!OVI/,'P<UHH3@V<X8#(^4QL#R/;G
M\/RUHP52K3A+:<XQ=NS=C.M-TZ-:HE=TZ<II/9N/?R/C3Q!_P6+_ &>/#OB#
M4/#']@WFH7FE2/'=26T;R &-BK9*Y'49_3M7U_\  /\ :H^&W[2VB7>N>#I8
MK$V4#W$MA,ZI<;$4LPV,0W &>1UK\4_V'_"_[)U]XM^(EU\8M+TN6ZWWYDN;
MP1,4.7R<OD@YYXJA^SQ<&S_;5\267P.N9)/A&MOJ F2SW?8D0"0=5_=# ^GL
M>HKZ/$99@7'$TZ%/$T:F&I1JNO6E>C/2+<(^;N['QV%SW-.?!5<36P6)HXW$
M2P\<-AX6KT7?W:D]WRQ7Q>I^E/Q*_P""JWP%^%/B[4? FI:9-JNMZ5(\5U':
M*TKAD;!R%!(YSU'],ZOPI_X*>? WXO\ B.'PO9Z=-X?N9W6..YU%3;Q%F.!\
MTI49_'.<?6OR]_91^&/PV^(_[>'Q=A^('AZW\0VD6I7 CBN4655Q(X. X(XX
M_P C%?7W_!2S]CWX?^'/A)8^,O@EHUOX+\06%TETUU8*+>0K&^X@F+8V/EQ^
M?TI5,'E-/$4<%.&)C6K4J36(=1.DIU8*5W#>R>EM_P RJ&9\0UL+B\RA5P53
M#X2O6C+"*DU6J4J,^5VJ-Z2>CN]]3]@X)[>]MHKVRGCNK2=0\4\+!XG5@""K
M#@]>U2 $^P[D] /4FOSW_P""<_QCU'QS\'-$\)>);LW>L:!;+#=7DSY>5H0$
M)9W.23M)[\CBOT&:ZL[B"]L[>>-IKB*2!"KJQC9QMW#!/*D\8]*\#$T'AJ]2
MC)WY)6YK/5=)>CW1]7@L53QN&H8J&D:L(R<7O&5ES0?I+2^G7:Q\O?M!?ME_
M"C]F&!+KQI-#?(Q7>L+A_*W?W]IXQCOTQ7I?P.^-OA/]HWP4GQ"\#!?[%< @
M*<@!L\$CT_PK\K_V]_V1%@^$?Q%\>>+=3;6_-CN+BP@FD9Q;9WNH56)VXX Q
M^0KVO_@CE&D'[*M];0C9'#=R1H.N%5VQC//3\J]&KA,&LJ^M4I3GB(5X4JDK
MVIOGL]([IJ]M>QX^'S',GG_]G8J%*GA:F%J5Z4(J]5>SDH^]-.SYM7;HOP_4
MFPM3=S^4.NQV_P"^5+?T-?G7X3_;"@\0_M::E^STA)FLI7C8 YVX;;R,G&#Z
MX]J_2/P]Q?@>D,W_ **:OY*/BE\5_%7P3_X*?^(-?\#:!+XBUB]NIHOL\$33
M,A>5AG:N3U_SZ+)\''&RQM-I.<,)*I2NU%*?-NV]+)#X@S&IEE/+:T9.-.KF
M,*-?EBY2E2<4^6,5K)M]#^LRZLO*NI8(SO\ */S;1G;QGDC(Z>E?"W[5/[3T
M'P$N- AD.UM7O8;7[Q'^L=4[$?D>Y_"O@73_ /@I5\9? _QJT/PA\1/!5YIN
MD>++F%9;NXMI42V6<J/O.H P&]1Q^%/_ ."G%]IOC!?A9K&ER+=6U_J&FS[U
M;<%>62-B.."06(_F.E;83*IT\=AJ>+C&5&M&4XR@U*+Y5W5[6?S,L7GU&OE^
M+KX"4X5\-4A3G3J0<)Q<IQ5U&6MFGOLNO4_;/P1J9\4^!O#GBI02NM6,%T&Q
MD?O$W$D_3M70! Q*HX=QU1>6'U'45^8WQ@_;4MOV:?@E\+/!FAVPU/QAJNA6
M46G:8@\R:5Y($" (,L221QCDU\?:E_P4&_:0^%\VA^*/%7P[U*'3-=NHQ.);
M28+!:S.N)3N3  1@P)^IQTKFAE.)K\TZ2A&$ZE2-",Y*,JBB]X)VNK=5V.FO
MQ!EV$<:5:=6=2-*E+$NG2E.-%SC%^\XWL[MW3U2OI8_?<!B_EA6+^@&3^76I
MXX-TBQ%@'8@;,'=S[=?T_6OCGQ%^V%X3T;]G>/XWV=Q#<:E]@^T76GJZEHIF
MB#^64S\I5SC! R1TK\Y_!7[?W[17Q#U/3_%OAKX>ZC>>&KR_\M9X[29HO+$N
M <A-O*]<>WXYT<KQ=95)\L*<*<G3DZDE']XMXZOM]YK7SS+L-*C"52=6=>$:
MM.-&G*K^[DTE.7)MO9IGZ._M'_M%0_!2[M[6;*--*D:Y)&=QQSS_ /7KZ!^%
M'B@_$#P'I_BQ<[+M$?=U^\,]>_7'7_&OQ<_;'\9:M\0=-T76_%NFOH]VAMYI
MXI5,>W:0SY!QCIW]*[3P_P#MV3>"/ 7PZ^'7PAT\^+-2O;FTL]9BLU^T-9*Q
M2.1F"9*;!DY.,?0UV2RZ53"T%2@G6<Y1J3O[B44M7/;IWUV/.I9U"CF&+6)J
MOZM[.#H0Y7[24I.,?=IKWKZZI+3?H?M4$)R3PH."V#MX]Z7RPW^J82XZ[ 3C
M^=?GM\7/V@OC?X<T?0K+PKX)N]1GU>PBGNI4@<M;S2QJS(V%R""3GIC@>U?(
M.C_\%!OBQ\)/B/X=\'?%?PK<:5!XLOH[6TEN8W0'SW"*074=2W8?AQ7)1RO$
MUXMTW2E)1E)052/-*,=VE^7<]#$9Y@<-4C"LJT(RE"#J.E)0A*?+RQE)Z:WL
MGYZZV/W&1&<X /7G@\5XK\>/B;%\)?"5[X@=M_V6%I6"YR  3SC./\^E?-_[
M77[9T?P$\#:'?>%+8:UXN\0VD-Q;:5&/,E)N4#KA%!;N ,#/H>]?CY^T-^VC
M^T)XE^'"S>*_AYJ%MI_B2+9*\MI,%MXY<?-EDXX(R3[5M@,JKXF5*HU!4IU.
M2TIJ,I<K]YQ3W2UU6]M&<F:\0X/!0Q&'A.I+%4Z7/S4Z<IQI<R]WFDDUU3MT
MOY'[]?LQ_&"+X[^#;SQ-;99;:5D.#DC''/7OCZ_I7T*(UZ-(%?LAX8GT [GL
M,5^0?[&/QET3]GS]D+4?B+K+I"E]&\R1R,%_TB1=PBY/=N,<?K7D-_\ M[_'
M;6-+U+XGZ7X,NW\&::'N;6Z6)S#<PQMN!!"X;*CG@YYS14RJM4Q.)AAXQC1I
MUO90E.22<E;W(M[MMO\ S"AGN&H8' RQ<IU,36PL:]2%.#DU"^LW;X8V[];]
MC]UV1E.UE*GW!'X\U@ZWXDTSPW']HU65(+<8+32,%C4>I+8  SSS7S+^QQ^U
M-9_M1_#Y_$][$NFZS9.;>6Q(VOYB8!^4X.?J,U[9\7?AC=?%KP;J?@ZRO#IN
MH:A"\4%ZK&-H7=2%8,#D8)!_"N"=%T<0Z&)7LW"7)4?\MMY76CLG?3='L4\5
M'$X2.*P7[]5*:G17P\[:T3;^%\VEGJ=QHGB+PQXEM?M6B:_I=^<[3;VUS%)*
M&]"B,3D9P?>M>2&2+!=&4'H2I /YCK7\_/CWX4?';_@G,UY\1M1\7WWBW0FN
M);XV37<ERB0@EPACWOQCVXQUS7W)^PO_ ,%!;+]LFTN;<69LKS3<QSH8RA#1
M#!Z@=Q].V*[<1E52-)XO"U(XG!)I2KQT<&_LRB];INWJ>;A<\I5,1'+\;1G@
M<QDFX8:3YO:)6]Z,]MKNWWGZ/*,D9.U?XG/W4'=F/8"OG;XO?M7_  H^!U_;
MZ;XDU2QO+JY=8]D,\;M&[L%PX#'&#C]/7GZ*O;=KG2]2TR-_+GU&TDMH9AD&
M&20%5<'L5X.>.^,5_.5^W+^QWXI^'TVN>/\ Q#XLN-;6^O?M5E;RW#O]F5IM
MZJH+D* ,# _P%9Y;AL-BJZAB*WLT[*$%?FJ-NVCV25[NYKG>-QV P?M\%AU5
MDES5:DI>Y1BK/WH_:YE]UM=+'] _@3QOH_Q*\+IXRT!E.DR1B4,I!7:5W DC
MCH1_^H5\E_'#_@H?\)?V>]0_LOQ)I%UJUP'\MC:1M*%.=N25!QC.3Z"M/_@G
MS)-??LMVUI(Q+SPK;+(3DK\NS.>OO]?3MWME^Q]\(/$-]K.K_%#1++7UGMKR
M=);Q8W$3B-F!S)G!!''TI*&#P^*KPQ4:M2E2FXQA3ERSFM+:_??;]2_:9CB\
M#@ZV E1I5\31A4J5*\>>G!R2;7+N[_T][0_ /]K[X6_M+0;_  7/#:78P6L)
M7 N4SSAHR=V1R/Q^E?3#H8W9&ZJ2#7\OW[)^FZAX/_X*8^.?"7P_GDA\$6NH
MW:0Z9;LQMHD$S@+A3L&T8' Q7]2 MFF6Y+C$UO!-.X/=HD9B/J=OMFM,TP='
M!XBG&E*3I5J%.O%2^*'M%?EEWMWZ]#+(LQKYIAJT\1",:^'Q-7"U)P_AU)4G
MRN<%I9/>WD43'(JAV1U0]&*D*?Q(Q2B*1EWB-R@_B"G;Z]>E?GA\$_V[7^*G
M[3GBC]GG6=,&EV7AVYFMTU&1?+$@A9E!\Q@ >!ZUPGQH_P""F.C?"/\ :W\/
M?LQ16L=U9:Y>PVKZF &1/-E\LGS1E0.G?TK*.5XV59T%2O56'^MVOI]7MS<]
M[:OE^S_F:RSK+88>.)EB5&D\6L%S.+3^L\RBX<KL]7HGMMZGZDHCR9V*S8Z[
M03CZXI4BDD.%1B?93_A7Q#^V-^V/:_LN:C\.[/1;5=:C\=SV$#-'B7ROMS(,
MDKG&-Y[?7J*X#X\_MZW/PNL?"VG^#])&N^-O$^FP7T&C1@/,7N(@ZIY8RW5@
M,8SVJ*>7XJK&A*%.\<1S^S;=O@=IN7\JCU;T-*V:X"@\1&I7M+"^S]LHQ<FG
M52=.,+?'*71*[\C]'7AF3[T4@]]I _7%-5'<X568^@!-?CMX#_X*7?%*+QCH
MOA;XX> 9_!*Z_=1V^GR7<#0>=YKA$*F15SD,,'ZX!Z'[&_:1_:ZTOX)>$],O
M?"D<>N^+]8M4N;/1D99)9?-4,@6,;FY)&,#^574RS%TJM.C.$7.LOW;A-3@]
MKOG7NV77MY:&=+.<NJT:]=5I1IT.7VD:D)4ZL7*W+'V<K2<I7]VRUOHC[(%M
M.?\ EE(/JI_PKYE_:4_:&T/]GGPU::_K9Q%=7,=NN3CYF(&/QS^GL:_.K0O^
M"GOQST_Q%X<L_B#\,+G0=%UVXCBEO9K:1$BAD<#>Q90 -IS6G_P5%UW0OB!\
M"/"7B#2;A+JTN+NRN[LH^1!O97<,0<#;D]?2NBAE=6GC,)2Q<4J=>=KTYJ:T
MZ.2T3OT>]NCT.+%YYAZF6XZOE]67UC#4U/EK4Y4Y*_+:2C-7:UWMHK]C]8OA
M7XLA^)?P[T/QYIR,UGK,*31%02,.H/49'?/Y?CVPCD8[0C$CL%.:_(+P1^W!
MIWP8^ OP<\"_#NU3Q3JNI6UG;WEO; 7+V[.L2N&$88C'/IW%>O?&[]O+4?@_
MX!T_7H]#:X\8ZC!%+'HGEGS2\J@A?+P3G)QC;_/%95,MQ+K<E.DDJE:I&BFT
MI.,963DFM%MJ_P CII9S@/JL:M;$>_1P]"KB737-!3G"+<8M74G=M<J;?Y'Z
M0-#*O+1N/JIJ.OS6_9P_;(^.?QDFTZ;Q9\-[K0])U$@I=R6S(/+8C:V2H'0@
M]?QK]*]H\J!\Y:2,.P_NDX./UQ^%<E?#5<-)PJ<O,F](R4MKWU6G3;<[L)C*
M&-I*MA_:>S=K.I3E3D]-^66MGT?80@C!]:2C)HK#T_K3_.YU:Z_@%%%%( HH
MHH *N6GWO^!#^54ZN6GWO^!#^5 UNO5?F?QL_P#!1K_E*'\//^PU8?\ I6M?
MUJ?%597_ &(M<6&)YI/^$&7;'&"78BTZ  $DU_)5_P %&S_QM"^'H[_VS8\=
M_P#C[6O[4?A3HFG^)O@IX<T35H$NM/U#0K>WN89 &5XV@C!!!X.>>#V.*^KS
MJM'#TN&,0TW&A3HU6ENXTY4YV7FTK'PG#F'EC,7QMA(2Y98FI5H1F]5&52BX
M)OT<K_(_S*O%UCXI;XC>.BGA366!UV]P19SXP+AP#G9@[NHP>F*S/[/\6?\
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M44@%R1G'<$?YZ4Z'.V3=_=/^>/>F5/",^9[(3^5 17O-WUL_166CMY'\W_\
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M.VB:0,VTD!0$&<XS@>F /J?XA_$W]FN^^(GBO0/"UG-KFL+->QWTMLAN4AG
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M#7](WA[CPWI@]((?_1:U_-Y\1O\ E(4O_86/_HUJ_I#\/?\ (N:;_P!<(?\
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M<5.I.G*_NJ3<DY+S_K:Q\2_$_P"!GAS1?VN=!\'6-_<PZ)>7T2SP)(5C96D
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M^782C7NJU.G::;;:;=TFWK=)I?(****\4[PHHHH ^5OVV?\ DCUW_P!>C?\
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M 8'!SGW]Q\/S_P#!+3XVZ;?WR^#OC#J&B>')G9M/TJ"]ECBM$+$JJHL@  !
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MI^TC^U%XDO+;XH^,]$;X8SW;PM%=7\#;+1W*D%7DXPAP>_'!S7ZB_LW?L>_
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M.,C#9^M=-_P3[_X)W> ?V4_ ^DW-[I5I>^,)K6":>[EB1Y89&0,Q9BI.X$G
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MXVWME;7Z?W;J-91VSPP(YIK0Z)&,VOA_2K23/^LM[6*-P2#D@JH.?Q_.FC@
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MAA56^_X\[K_KWF_]%M5JJM]_QYW7_7O-_P"BVIK=>J_,3V?H_P C^4WXC?\
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MPC^\=H^;_>XYZ\YI-FEL/WND6$K?WG@C8_F5Z_6H\D^II*7+W;WTLY+MUO\
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M_3\;_P!;$WG3K\OG2<?[9^M,:21_O.S?5B?YTKQ.@RP].^32'+<@=,TAW?\
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M&>3R><^M+YC9R>1Z'./US^->7^.OCM\'/A(\<?Q,\56GAYY^+=;B>.(R$]
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M5QU<X'?UH(C&2K"6,XVR)RI]>>*_+K_@I?\ M'^+_@%X!FOO!<,UQJBMO6*
M,6*+@DX7GH".G_UZ7_!+S]N2W_:K\*0^%]>E$7C*PE:.\MI6VS+MZA@YW9!'
MYUZ/]FXGZ@\PBE*@I<L[?%%:/F:Z1\]ON:/*6<X'^U5D\Y2CBI4_:1;TA/\
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M$Z_^3./@C_V*EK_(5]LU\MC_ /?L7_V$UO\ TY(^[RK_ )%F7_\ 8%A?_3,
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M;?\ 8\R]_C5V_.Q\S4_Y++"_]BO$_G1/SC_X(1_Z_4/^PE?_ /I9)7]15_\
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MP5),, 2,CIW[U^-/[;GP#^$'A?X9>$M<\/>%K2PUG3K:S>VNXHD1T=44[@P
M.01[&ONC]@O5]0UCX&6T]_.]Q+ J11,Y+%8U7"@9)/ 'Y5XF.P^$EA(8O"PJ
M4KU)4ZD9R3YF[6E$^JRK$YA#,*N7X^M1Q"C1A7HSI1<7&/*KQEWU:9\)?\%;
M/'/C7P[J?A_0;"/4?^$"U!H8M=FL=X6.&1E64EDQT4D\_4FF_LK_ + _[*'Q
M5\&^'_'&@>/O+UZ"XMK^;3IM2'VK[8"DCH8C(7)WY& !R0,5^KGQ8^%G@#XQ
M>';OPAXOLK6ZO]0B>&UEG$>Y&==J%"_0@G.17\\?[5'[*OQA_P""</B3P_\
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M0MALY$1'"'($F!OZ<=>:_/C]JO\ :(U/XW?#2[^&>B:&VHWNMA$,T=N2T)?
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M%+5M*LM?T?4M(U !H+NRGA0$9P\D;*./J1_DU_/Q?_LB?MC_  <^._BCQ?\
M Z6XC\,>([RX>;RMR@0S2,3C'&=I'Y]Z_H3K2CU:^AC$4<VU , ;1P/\_P#U
MZUPF/K8)553C3J1K1Y9TZL>:#2=T[=]_P,,RRNAF3P\JE2O0J8:?/2JT)*%5
M-I)QYND6E9KJ?@C\ /V&OCGI/[3B_''XCO-+Y\+-<-*"3Y\GS-RPQ][TQQQZ
M5]2:#^REXVTW]HO5/B;,&_L>\NS/'P?N[]V,XP>#R<X^O6OU%EU"ZF3RY),I
MZ8 J(W4S1B(OE!QCCCMS6U7-<35DY25-7H1H-0C9*DK-*U]+/].R.>AD&7X>
M$8P=:5L2\6Y2E>4JS23<GI?;Y=#\Z?VL_P!FKQ=\8=0T"ZT ,5TZ>WDFP,_+
M&RL1QUZ$<X_6O)_VJOV&]=^+'PX\!7WAI3%\0O 4%L^FF,8;[5;(C)DXS]]/
M\:_6V*>:+(C8C.<X&:$N)XI/-CD*R9SG&>?I6=',L11]BZ;BGAVY0TWYM)1E
MM=--W1MB,GP6)>)]JIM8N,(U=4N7D:<90WM.+5T^_FS\/?@EX2_X*,7>MVOA
MKXL7%W_P@]F(]/3<SX.G18CVG/'^K'^>!6K^U!^Q/\6-+UO1/'7[.;26_BF)
MX[C43;@H9)<AWW;,9RWKGKZ5^W4^L7]Q'Y<DV1_N@?R'7GUJM;WUS:',,FPG
M(Z YR,=_\^N:W><5U75>G0PU+1J5*G3M2J72UG'2[=KWMUT.;^P,*\++#5,3
MC,0^:+AB*U12Q%)IJW)/[-E\[6/P%T']EW]L3]HOQ-H&D?M1R7,W@O0+NUFM
MTFW,@%NZMT;CHHP<5]8_M+_L=>(/&NL?"^P\"IM\/^!5L(?D7CR[78#T''W:
M_4^?5KVY7RY9MP/; !JK%=2P K&^T-U''.>*B>:XB56G4C&E15*,E"E2CRTH
MN:M.7+?XI+=E4^'\#3HUJ4ZF)Q$L1*FZN(KSYJ\E2:<(\]_ABT[(^1/C!\&=
M>\;?!G3/ VF;O[2M;"*WDP,_,D:KR.W(/Z5X5X4_99\8Z/\ LZ^,OAG.&_MG
M7(I8[?CG+@@=1[YSUSVYK]+DFDC<R*V&]<9_2GFZF,BREOG4Y!P*YX8VM""@
ME&RJQKJZ^W%\R\[?YZ'74RS"U:GMIJ?/["6%5I:*E*/+?_%RK1[WW/A/]D3]
MG_Q/\%_@AXH\">( ?[3UB&]2#((.Z='V>G<BO'_V:/V3/&_PL\:^.-=UH-]F
MU^YO);7((XG+E?;^+U_D,_J7-<2SN'D;<PQ@XQTQV'TITEU/,JJ[9"\#@5?]
MH5Y/$MN*^MN,JSL^C7PVV^:]25E.#2P4??ME\7'#J^K4DE+G[^O=GY<?LZ?L
MH^-_AA^U;XC^,&L!O[!U2>:6'(.,2.6')QZCG\NM>L_MH? +Q/\ '.=)?#8)
MQ<K-P,_*&W?_ *N?Q%?>$UU-)"L,CAD7&%P 1Q^?8<U%#/)!Q&=H^E$LPKRQ
M-/$R4/:4J<:4;)V<(VM==QPRG"0P=;!1YU0JUIUYZ^_[2HTY6=]KJ_EZ'Q9)
M\#O$4G[-+?"TAO[;^P&W'KO\LITY[XP,=*Y_]C;]GWQ/\$OA[XT\->(PWVK7
M$O5M\C!S.KA,<#/4?UXK[R\V0R>:#E^N<?TI99Y9V#2-N(Z5#QM:5.I2O'DJ
MU/:STU4TU;Y:=-5K\[CEV&C7H8BTW4P]'ZO3U5E3:2;?]ZVWR\C\J_V;OV-_
M%?@3XM_$_7/%ZD^%_'8OH2KKP8;O?^'(./\ ]0Q\Z^+_ -D;]I/X#?$/6KW]
MF;38)?#6N:A/>7>8%8,TSE\GY>>6ZX^HYK]X9;N>9%CD;<B_=&.G2IX-3O;9
M/+AEVIZ8!]/QKJ6;XE595)1I5(U(4Z=2E.-Z<U3246UW21Q/(,!*C"E">(I.
ME5J5:=>G+EKPE5E>I&,FG[K?3Y;GYL_LMZ)^U->:CJ&G_M :=;P:#>AHL+$$
M!C*X.< <8)X/?T[_ "'^TC^QS^T9X1^-\7Q)_9F>:WMY;D2W*0;E7!8,>$&#
M^/K^7[OW.H75V L\F\#H,#C_ #_GMAUMJ-Y:J4@D*@]1@'-13S6M2Q$Z\*-"
M*J0Y)T%#]RUL_==]?/TV-*V28;$86CAJV(Q<W2G[2GB>>V)A+313TLNENW0_
MG,\4?L.?M5?&WXK?#_XB_%.6YFG\/7UG=7HDW,%\B1';[V1_">O?TS7]$NDX
ML?#?AO2F_P!9I6DVME-QT:&-5;]0?6M!M5OF#*TN0WWAM'/Z5G*,N6)Z\G/?
MI_.L\;F%7&QHPJ1IPA04HTX4XV24FFUZ=MS7+LJP^63Q$Z$ZU2>+<9UZE>;G
M*4H))-O1WZW[K3H?E%^V1^QYXW^-_P <OAS\0/#Z;]+\,ZA:7-Z"FX;8I(V;
ML<<*?Q'0U^LFG2+:Z)X:T^.-89-+TNSLYPGRY>"-%;ICH5/^> ^.[G@5XXG"
MHV<C .0357N3W)R3ZUE6Q52O1H49J*AAHRA24=':33=[MMZKHC?#8*AA,1B\
M314O:8V4)UN9WCS0CRKD716W_P M%^>/_!0']G/QS\>-'M[CP#N;6[%0UN1R
M?, !7W^\./\ ]5?G=X&^$O\ P4Q\,^'9/ 'G7:>&+L&QN"I<?Z$V4;H.FP\#
M\Z_HG@NIK<[H7VD<] ?IU_/_ .M6@VN:BR[3-^.U?7/3'_UZZ\/FE;#45A_8
M8:M3BU*/MH*;@[)WCKU>MSS\7D6'Q>*>,^M8S#5IKEJ_5JGLX5([6DEJ[K[O
M/I^<'[&G[%>C_ D7GC'Q&OVSQIKI:XU.2Z =TN)?WDFTMG!$A:OT)9B<#LO"
M^P[4Z6629BSG)-1UPXC$5<35E5K2<YR[[)+1179):)=CT\)A,/@:,</AJ:IT
MH]%O*3UE*6KO*3U;[ZA1116!T!1110 5<M/O?\"'\JIU<M/O?\"'\J!K=>J_
M,_C8_P""C?\ RE"^'O\ V&;'_P!*UK^V?X%?\DJ\'_\ 8)M?_1,=?Q,?\%&_
M^4H7P]_[#-C_ .E:U_;/\"O^25>#_P#L$VO_ *)CKZ+B;_D7Y#_V!K_TF)\?
MP9_R.^*?^PU?E$]<HHHKXT_1PHHHH **** "BBB@ HHHH **** "BBB@ HHH
MH *_F:_X.!_V/=0^(_PR_P"%Z^';&2?5_!SVT[-:Q;KC;:QF0$%5+#_5')!S
M]>M?TRUP/Q.^'F@_%3P3KO@?Q+:Q7FDZY9S6T\,R!TR\3QJQ# CY=YYQD5Z.
M58^>6X_#XR'_ "ZJ+G7\U-M*<7ZH\C/<JIYSE>+R^I:]:G+V4G]BJDW3G\I6
M/YO/^"('[:>D_&+X/6'P6UK4(K/Q)X8)LYK:^E"W+/:DQ[=CD/D[>F/:OWAN
M83 [I@\,P5\8# $@$=L=,8K^(C]KC]GKXT?\$LOVK;KXT?#&QU"V^'=_K$U]
M<I:1SBU\EKGS'!$8$6 I(_\ UU_3;^PK_P %$_A!^US\/=$,WB"SM?&MM801
M7>FR31QSO=>6H<-&[!RQ?.<C/<XKZ?/<L4K9OEZ]M@<7:I+DNY4*L[<\9I7T
MN_1+Y'P_"N=3A!\/YR_J^;9>_8T_:>['%4(65.=.3M?W;:*Y^@(R1@]3G-"K
MC@9/?_/;M6E)IMTJ>>$!A?YD<.I!5N5Y!(Y!JAM(;!..O/YU\PM6NJ[?-?\
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M^V7P=_9/\%_"N]LTAEFT 1:NAC"EY+B!4(D& 25P<YYY.:_CI_X**>!/$'[
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MHH"[VZ!2@X.:2BB[VZ !.>:*** "BBB@! NWIGFEHHH **** "BBB@ HHHH
M*N6GWO\ @0_E5.KEI][_ ($/Y4#6Z]5^9_&Q_P %&_\ E*%\/?\ L,V/_I6M
M?VS_  *_Y)5X/_[!-K_Z)CK^)C_@HW_RE"^'O_89L?\ TK6O[9_@5_R2KP?_
M -@FU_\ 1,=?1<3?\B_(?^P-?^DQ/C^#/^1WQ3_V&K\HGKE%%%?&GZ.%%%%
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M;Q&_Z!,LZ=(_W?/^O*WN][_P_<_9 _Y]S^?_ -E2?\/V_P!C_P#Y]S_WU_\
M9UP?_$.M\'?^@I:?G+_\31_Q#K?!W_H*6GYR_P#Q-+_C#O\ G]C>GVG_ '?Z
M_P"&=SF\1M/]ERSITC_=\_Z\OL]V/^"[7['X_P"7<_\ ?7^#"E_X?M_L@?\
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M9TZ1_N^?]>5O=[S_ (?M_L?_ //N?^^O_LZ/^'[?['__ #[G_OK_ .SK@_\
MB'6^#O\ T%+3\Y?_ (FC_B'6^#O_ $%+3\Y?_B:/^,._Y_8[_P "?E_7Y[.Y
MS>(W_0)EG3I'^[Y_UY6]WO/^'[?['_\ S[G_ +Z_^SH_X?M_L?\ _/N?^^O_
M +.N#_XAUO@[_P!!2T_.7_XFC_B'6^#O_04M/SE_^)H_XP[_ )_8[_P)^7]?
MGL[G-XC?] F6=.D?[OG_ %Y6]WO/^'[?['__ #[G_OK_ .SH_P"'[?['_P#S
M[G_OK_[.N#_XAUO@[_T%+3\Y?_B:/^(=;X._]!2T_.7_ .)H_P",._Y_8[_P
M)^7]?GL[G-XC?] F6=.D?[OG_7E;W>\_X?M_L?\ _/N?^^O_ +.C_A^W^Q__
M ,^Y_P"^O_LZX/\ XAUO@[_T%+3\Y?\ XFC_ (AUO@[_ -!2T_.7_P")H_XP
M[_G]CO\ P)^7]?GL[G-XC?\ 0)EG3I'^[Y_UY6]WO/\ A^W^Q_\ \^Y_[Z_^
MSH_X?O?L?A6?[.3A2>#UQ[;OZ5P?_$.M\'?^@I:?G+_\34D/_!NQ\&DD#/J=
MJRY&Y<R<C\5_&E;@[3]]C?\ P)_W?G_3OLP4O$;_ *!<LZ=%_=\_Z_\ 2?/O
MBG_P<!?L]VNG7:>!]$OKK4 C>2L",Y9P#@#:#G+$<5^0_P 3O^"BO[<G[;NN
M2_#OX*:!XFTS0-5N#:_:1;W$2^1<'R\A@H'"GMR..N*_HO\ AG_P0=_9F\&Z
MC;7NL:/IVKK#()'22+>'QC(PT?.>1S^/M^J'PN_9$_9[^#L5L/ OPWT'2KBU
M";+Q+2,W!9 ,-E54#D9Q@X]3UIK..',NO+ X"KC*RUA4Q,E*$9::\KMM^>P2
MX=XPSFT<US:E@,-*WM:&"BXU)QTO'GCHMK?Y'\X__!-[_@AA=V'B*P^,_P"U
M2UWK?B02KJEM::FOV@F9V$P79-D8WD9Z8 /?K_5IX?T#2?"^CZ?H6AV-OI^F
M:9:PVEI:VT211I%"@1?E0 9(&2?4^E;"@  * %    P !P !Q@ < 8Z4M?+Y
MEFN,S6M[;%3NE_#I1TITEVA'H?;Y)D.79#AOJ^!I6<M:U:?O5J\OYJD]V_+H
M%(5!W C(88((R",8((/8C@YZTM%>:>T?CQ_P4A_X)1?"G]L[PGJNJ6.EVVE?
M$"*"233[VSMXXIGN0K%&61!OW[R,C\LXX_E/N_#'_!1/_@E;XEN[&VB\3:]X
M*L[UEMU47,ZBPB8A0!R,; /KZ=Z_T-Z\[\>_"?X=_$ZT-EX[\*:3XCM_+:+;
MJ%NLI",,8#'GCMG./H*^FRKB6O@:/U+%TH8[ -W]A6LY0[^SDTVOZ]#XK/>#
M,+F==YA@*]3*\T2TQ.'?+&H[W_?0C;F/Y*O@'_P7_P##<%I;6_QH\,ZQ;:FH
M6.[^TV\L>'4 .3N48YSU]NP%?=%A_P %Y?V0+F!':T>-F4%@W!#$=.H/0?\
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MX?M_L?\ _/N?^^O_ +.C_A^W^Q__ ,^Y_P"^O_LZX/\ XAUO@[_T%+3\Y?\
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MB-_T"99TZ1_N^?\ 7E;W>\_X?M_L?]?LYS_O?_9T?\/V_P!C_P#Y]S_WU_\
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M2T_.7_XFC_C#O^?V-_\  G_=_K\]G<YO$73_ &3+/NC_ '?/^O+IWG_#]O\
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M^SK@_P#B'6^#O_04M/SE_P#B:/\ B'6^#O\ T%+3\Y?_ (FC_C#O^?V._P#
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M^-O^@; =.B_N_P"7X>ENT_X>J_LZ_P#/(?\ ?5'_  ]5_9U_YY#_ +ZKB_\
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M^I/_ (BC_ASS\./^?Z#_ +ZD_P#B*:I^$B_YC,X_\#EIMMIY6]-.N@GQNO\
MF'P"VOHO[O\ ET[>:.T_X>J_L[?\\A^?_P!>D_X>J_L[?\\A^!']<UQG_#GG
MX<?\_P!!_P!]2?\ Q%'_  YY^''_ #_0?]]2?_$4<GA)_P!!F<;W^.7EY?U\
M]#_C-MOJ^ MII9?W?\OP\SM/^'JO[.O_ #R'_?0H_P"'JO[.O_/(?]]5Q?\
MPYY^''_/]!_WU)_\11_PYY^''_/]!_WU)_\ $4O9^$G_ $&9Q_X'+R\O+\%\
MB_&W_0-@.G1?W?\ +\/2W:?\/5?V=?\ GD/^^J/^'JO[.O\ SR'_ 'U7%_\
M#GGX<?\ /]!_WU)_\11_PYY^''_/]!_WU)_\11[/PD_Z#,X_\#EY>7E^"^1?
MC;_H&P'3HO[O^7X>ENT_X>J_LZ_\\A_WU1_P]5_9U_YY#_OJN+_X<\_#C_G^
M@_[ZD_\ B*/^'//PX_Y_H/\ OJ3_ .(H]GX2?]!F<?\ @<O+R\OP7R+\;?\
M0-@.G1?W?\OP]+=I_P /5?V=?^>0_P"^J/\ AZK^SK_SR'_?5<7_ ,.>?AQ_
MS_0?]]2?_$4?\.>?AQ_S_0?]]2?_ !%'L_"3_H,SC_P.7EY>7X+Y%^-O^@;
M=.B_N_Y?AZ6[3_AZK^SK_P \A_WU1_P]5_9U_P">0_[ZKB_^'//PX_Y_H/\
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MV>_A'\.8X%\+>#=*L)8 NVX6W4S%E'#$J /IP<>M>OWEREE:RW#X6.&,L>P
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MZ5HKYJ_X:_\ V<O^BI>'/_ @_P#Q-'_#7_[.7_14O#G_ ($'_P")H_LK,_\
MH7XW_P ):W_R ?V[DO\ T-\M_P#"W#>7_3SS1]*T5\U?\-?_ +.7_14O#G_@
M0?\ XFC_ (:__9R_Z*EX<_\  @__ !-']E9G_P!"_&_^$M;_ .0#^W<E_P"A
MOEO_ (6X;R_Z>>:/I6BOFK_AK_\ 9R_Z*EX<_P# @_\ Q-'_  U_^SE_T5+P
MY_X$'_XFC^RLS_Z%^-_\):W_ ,@']NY+_P!#?+?_  MPWE_T\\T?2M%?-7_#
M7_[.7_14O#G_ ($'_P")H_X:_P#V<O\ HJ7AS_P(/_Q-']E9G_T+\;_X2UO_
M ) /[=R7_H;Y;_X6X;R_Z>>:/I6BOFK_ (:__9R_Z*EX<_\  @__ !-'_#7_
M .SE_P!%2\.?^!!_^)H_LK,_^A?C?_"6M_\ (!_;N2_]#?+?_"W#>7_3SS1]
M*T5\U?\ #7_[.7_14O#G_@0?_B:/^&O_ -G+_HJ7AS_P(/\ \31_969_]"_&
M_P#A+6_^0#^W<E_Z&^6_^%N&\O\ IYYH^E:*^:O^&O\ ]G+_ **EX<_\"#_\
M31_PU_\ LY?]%2\.?^!!_P#B:/[*S/\ Z%^-_P#"6M_\@']NY+_T-\M_\+<-
MY?\ 3SS1]*T5\U?\-?\ [.7_ $5+PY_X$'_XFC_AK_\ 9R_Z*EX<_P# @_\
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MY?\ 3SS1]*T5\U?\-?\ [.7_ $5+PY_X$'_XFC_AK_\ 9R_Z*EX<_P# @_\
MQ-']E9G_ -"_&_\ A+6_^0#^W<E_Z&^6_P#A;AO+_IYYH^E:*^:O^&O_ -G+
M_HJ7AS_P(/\ \31_PU_^SE_T5+PY_P"!!_\ B:/[*S/_ *%^-_\ "6M_\@']
MNY+_ -#?+?\ PMPWE_T\\T?2M%?-7_#7_P"SE_T5+PY_X$'_ .)H_P"&O_V<
MO^BI>'/_  (/_P 31_969_\ 0OQO_A+6_P#D _MW)?\ H;Y;_P"%N&\O^GGF
MCZ5HKYJ_X:__ &<O^BI>'/\ P(/_ ,31_P -?_LY?]%2\.?^!!_^)H_LK,_^
MA?C?_"6M_P#(!_;N2_\ 0WRW_P +<-Y?]//-'TK17S5_PU_^SE_T5+PY_P"!
M!_\ B:/^&O\ ]G+_ **EX<_\"#_\31_969_]"_&_^$M;_P"0#^W<E_Z&^6_^
M%N&\O^GGFCZ5HKYJ_P"&O_V<O^BI>'/_  (/_P 31_PU_P#LY?\ 14O#G_@0
M?_B:/[*S/_H7XW_PEK?_ " ?V[DO_0WRW_PMPWE_T\\T?2M%?-7_  U_^SE_
MT5+PY_X$'_XFC_AK_P#9R_Z*EX<_\"#_ /$T?V5F?_0OQO\ X2UO_D _MW)?
M^AOEO_A;AO+_ *>>:/I6BOFK_AK_ /9R_P"BI>'/_ @__$T?\-?_ +.7_14O
M#G_@0?\ XFC^RLS_ .A?C?\ PEK?_(!_;N2_]#?+?_"W#>7_ $\\T?2M%?-7
M_#7_ .SE_P!%2\.?^!!_^)H_X:__ &<O^BI>'/\ P(/_ ,31_969_P#0OQO_
M (2UO_D _MW)?^AOEO\ X6X;R_Z>>:/I6BOFK_AK_P#9R_Z*EX<_\"#_ /$T
M?\-?_LY?]%2\.?\ @0?_ (FC^RLS_P"A?C?_  EK?_(!_;N2_P#0WRW_ ,+<
M-Y?]//-'TK17S5_PU_\ LY?]%2\.?^!!_P#B:/\ AK_]G+_HJ7AS_P "#_\
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M=CO_  EK_P#R'FOO#^U,M_Z&&#_\*:/_ ,GYK[SV.BO'/^%_?"+_ *';2/\
MO^O^-'_"_OA%_P!#MI'_ '_7_&C^RLS_ .A=CO\ PEK_ /R'FOO#^U,M_P"A
MA@__  IH_P#R?FOO/8Z*\<_X7]\(O^AVTC_O^O\ C1_PO[X1?]#MI'_?]?\
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MT9ZO17CG_"_OA%_T.VD?]_U_QH_X7]\(O^AVTC_O^O\ C5_V5F;_ .9=C?\
MPEK_ /R!']J9;_T,,'_X4T?_ )/S7WGL=%>.?\+^^$7_ $.VD?\ ?]?\:/\
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MUG_P*F_^*H_X<[^&?^AIUG_P*F_^*K]TZ*Z?]>>)_P#H9U/_  &'EY>2//\
M^(6<$?\ 0FI?^!S\O[WE^78_"S_ASOX9_P"AIUG_ ,"IO_BJ/^'._AG_ *&G
M6?\ P*F_^*K]TZ*/]>>)_P#H9U/_  &'EY>2#_B%G!'_ $)J7_@<_+^]Y?EV
M/PL_X<[^&?\ H:=9_P# J;_XJC_ASOX9_P"AIUG_ ,"IO_BJ_=.BC_7GB?\
MZ&=3_P !AY>7D@_XA9P1_P!":E_X'/R_O>7Y=C\+/^'._AG_ *&G6?\ P*F_
M^*H_X<[^&?\ H:=9_P# J;_XJOW3HH_UYXG_ .AG4_\  8>7EY(/^(6<$?\
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M$?\ 0FI?^!S\O[WE^78_"S_ASOX9_P"AIUG_ ,"IO_BJ/^'._AG_ *&G6?\
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MTZ*/]>>)_P#H9U/_  &'EY>2#_B%G!'_ $)J7_@<_+^]Y?EV/PL_X<[^&?\
MH:=9_P# J;_XJC_ASOX9_P"AIUG_ ,"IO_BJ_=.BC_7GB?\ Z&=3_P !AY>7
MD@_XA9P1_P!":E_X'/R_O>7Y=C\+/^'._AG_ *&G6?\ P*F_^*H_X<[^&?\
MH:=9_P# J;_XJOW3HH_UYXG_ .AG4_\  8>7EY(/^(6<$?\ 0FI?^!S\O[WE
M^78_"S_ASOX9_P"AIUG_ ,"IO_BJ/^'._AG_ *&G6?\ P*F_^*K]TZ*/]>>)
M_P#H9U/_  &'EY>2#_B%G!'_ $)J7_@<_+^]Y?EV/PL_X<[^&?\ H:=9_P#
MJ;_XJC_ASOX9_P"AIUG_ ,"IO_BJ_=.BC_7GB?\ Z&=3_P !AY>7D@_XA9P1
M_P!":E_X'/R_O>7Y=C\+/^'._AG_ *&G6?\ P*F_^*H_X<[^&?\ H:=9_P#
MJ;_XJOW3HH_UYXG_ .AG4_\  8>7EY(/^(6<$?\ 0FI?^!S\O[WE^78_"S_A
MSOX9_P"AIUG_ ,"IO_BJ/^'._AG_ *&G6?\ P*F_^*K]TZ*/]>>)_P#H9U/_
M  &'EY>2#_B%G!'_ $)J7_@<_+^]Y?EV/PL_X<[^&?\ H:=9_P# J;_XJC_A
MSOX9_P"AIUG_ ,"IO_BJ_=.BC_7GB?\ Z&=3_P !AY>7D@_XA9P1_P!":E_X
M'/R_O>7Y=C\+/^'._AG_ *&G6?\ P*F_^*H_X<[^&?\ H:=9_P# J;_XJOW3
MHH_UYXG_ .AG4_\  8>7EY(/^(6<$?\ 0FI?^!S\O[WE^78_"S_ASOX9_P"A
MIUG_ ,"IO_BJ/^'._AG_ *&G6?\ P*F_^*K]TZ*/]>>)_P#H9U/_  &'EY>2
M#_B%G!'_ $)J7_@<_+^]Y?EV/PL_X<[^&?\ H:=9_P# J;_XJC_ASOX9_P"A
MIUG_ ,"IO_BJ_=.BC_7GB?\ Z&=3_P !AY>7D@_XA9P1_P!":E_X'/R_O>7Y
M=C\+/^'._AG_ *&G6?\ P*F_^*H_X<[^&?\ H:=9_P# J;_XJOW3HH_UYXG_
M .AG4_\  8>7EY(/^(6<$?\ 0FI?^!S\O[WE^78_"S_ASOX9_P"AIUG_ ,"I
MO_BJ/^'._AG_ *&G6?\ P*F_^*K]TZ*/]>>)_P#H9U/_  &'EY>2#_B%G!'_
M $)J7_@<_+^]Y?EV/PL_X<[^&?\ H:=9_P# J;_XJC_ASOX9_P"AIUG_ ,"I
MO_BJ_=.BC_7GB?\ Z&=3_P !AY>7D@_XA9P1_P!":E_X'/R_O>7Y=C\+/^'.
M_AG_ *&G6?\ P*F_^*H_X<[^&?\ H:=9_P# J;_XJOW3HH_UYXG_ .AG4_\
M 8>7EY(/^(6<$?\ 0FI?^!S\O[WE^78_#/2_^"-?@.37;"_UC7]2N[6UE1WA
MGGD>-PA!P58G(.#D8.?RK]?_ (3_  J\,?![PG9^$/"EN+?3;2.)<! F]HDV
M;B!GKD]3WKTPDCH"?\_2ES7FYGQ%G&<4Z=',,;5KTJ3O"F](*7\S2W:Z'NY%
MP?P]PY4JULHRVCA:U5<LZT4W4<++W%*3;47;5=1H)&XGIVZ=.?\ /-*#GD4A
M^;&#TZ@=_K3NG05XA],%%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %?(?QY_9+\(?&F\MM3O&:TO;=MV^'*,6Z@[AUY]:^NR">AQ2 G'(/
M _/]*[LNS+'95B8XS+\1/#8B":C4@];/=-/1I^9Q9AEV"S3#2PF/P\,1AYM.
M5.:=KQ=TTU9IKR9^90_X)]Z0-J?VU?[5&T?OI.@X'?'3'^>*7_AWYH^?^0U?
M_P#?Y_\ $C]:_34'(Z8]J6OHO]?.)[6_M*I;_##_ "_K3L>#_J3PU_T+:?\
MX%/I;S\C\RO^'?>C_P#0:O\ _O\ -_\ %4?\.^]'_P"@U?\ _?YO_BJ_36BE
M_KUQ/_T,JG_@,/+^[Z_?Y!_J3PW_ -"ZG]\O+^]Y?UK?\RO^'?>C_P#0:O\
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MQ/\ ]#*I_P" P\O[OK]_D'^I/#?_ $+J?WR\O[WE_6M_S*_X=]Z/_P!!J_\
M^_S?_%4?\.^]'_Z#5_\ ]_F_^*K]-:*/]>N)_P#H95/_  &'E_=]?O\ (/\
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MC2BFGIJK+1W5_P#AA?ZD<--6>6TFNS<K6LDTU?5.VQY7\(OA1H/P@\*P>%M
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M!BEHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M#VG>*_#^J>']5MX[FQU73[FRFCE4,NVY@>'=@@\KOR/I7\%7_!0[]G?XD?\
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M*I):RY4K*^P@&,GUI:*3(]16!U"T444 %%%% !11FB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***,XZT %%&:,YZ
M4 >;^-_A=X:\?3VD^N1&1[,J8L*&^Z<CJ1C]?I77Z'H=GX>T^+3=/7;;Q !
M1C&!CM[5LT5T3Q6(J4:>'G6G*A2O[.DW[D+ZOE72YA'"X>%:IB8481KU4E4J
MJ-IS2T2D^M@HHHKG-PHHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M+>9;'6&B19A*T9V;IMI8,' P<@9ZD$'/\9GC+X:?MD?\$@/C'+K'AF#7=?\
MA5;ZBIECC%W/:1V:S_/D#=&%$8] ,5]]">#XJHJ2G#"9Y2@DXR:C3QBBEJNG
M,WWUO]S_ "B4,QX#Q,HRA5QW#%>I=2@G.M@')K=+7V<=M-/1:']Q+QRQN0ZL
M .A*X!Z<BD((X-?DW^Q7_P %=/@7^TUH^GV?C/Q!8^%_$8BAMYK&XDCMY3<J
MH5@5D*G._P!N/SQ^LVDW.G>*+3^T/#-U%J>GR#=#<Q2QR!DP"""K'MSU_J:^
M6Q6#Q.#J2I8FC.E.+M[T6D];>Z[6?R/NL#C\%F5"&(P.)I8BG-72A).:3M\4
M-XN[ZD9.!DTY2#@GI_\ 6]J?+;R0';*O()!SS_GV_P#KU$IR.F*Y5ZK^NG74
MZTGKIJM7I;3IN./4XZ9XI*** M9]=;?ET"BBB@ HHHH **** "BBB@ HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M4 %%%% !1110 4444 %-'WF_#^5.IH^\WX?RH 4=!]!_*E//'K2#H/H/Y4M
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M0_FH^ __  7\^#%S96MO\5=#U*QU%PD<WVN*2,K)QNSO [@CKGWQ7Z!^%O\
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MY?\ !_K8_M7CK_HFX=/^7U/^[?K_ (OZL?MI_P /"OV;_P#H:=#_ / VW_\
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M_AX5^S?_ -#3H?\ X&V__P <K\2_^(:;XL_]%WN/_!M-_P#%4?\ $--\6?\
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M6?\ HN]Q_P"#:;_XJC_B&F^+/_1=[C_P;3?_ !5'U/A;_H<R_P#!-3R_X/\
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M.4?\/"OV;_\ H:=#_P# VW_^.5^)?_$--\6?^B[W'_@VF_\ BJ/^(:;XL_\
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M_P"VA\*?C7X*UKQWH%R]KHVAQ22W3W4B@E8E+-M)"CH/IGCBOG?6_P#@J?\
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M!U(1D8((_+_Z])AO[WZ"C#?WOT% "@8XY^O^?\*6FX;^]^@HPW]_/_ 1_3%
M#J*;AO[WZ"C#?WOT% #J*;AO[WZ"C#?WOT% #J*;AO[WZ"C#?WOT% #J*;AO
M[WZ"C#?WOT% #J*;AO[WZ"C#?WOT% #J*;AO[WZ"C#?WOT% #J*;AO[WZ"C#
M?WOT% #J*;AO[WZ"C#?WOT% #J*;AO[WZ"C#?WOT% #J*;AO[WZ"C#?WOT%
M#J*;AO[WZ"C#?WOT% #J*;AO[WZ"C#?WOT% #J*;AO[WZ"C#?WOT% #J*;AO
M[WZ"C#?WOT% #J*;AO[WZ"C#?WOT% #J*;AO[WZ"C#?WOT% #J*;AO[WZ"C#
M?WOT% #J*;AO[WZ"C#?WOT% #J*;AO[WZ"C#?WOT% #J*;AO[WZ"C#?WOT%
M#J*;AO[WZ"C#?WOT% #J*;AO[WZ"C#?WOT% #J*;AO[WZ"C#?WOT% #J*;AO
M[WZ"C#?WOT% #J*;AO[WZ"C#?WOT% #J*;AO[W_CHHPW][_QT4 .HIFUO[Y_
M[Y7_  I<-_>_04 .HIN&_O?H*,-_>_04 .HIN&_O?H*,-_>_04 .HIN&_O?H
M*,-_>_04 .HIN&_O?H*,-_>_04 .HIN&_O?H*,-_>_04 .HIN&_O?H*,-_>_
M04 .HIN&_O?H*,-_>_04 .HIN&_O?H*,-_>_04 .HIN&_O?H*,-_>_04 .HI
MN&_O?H*,-_>_04 .HIN&_O?H*,-_>_04 .HIN&_O?H*,-_>_04 .HIN&_O?H
M*,-_>_04 .HIN&_O?H*,-_>_04 .HIN&_O?H*,-_>_04 .HIN&_O?H*,-_>_
M04 .HIN&_O?H*,-_>_04 .HIN&_O?H*,-_>_04 .HIN&_O?H*,-_>_04 .HI
MN&_O?H*,-_>_04 .HIN&_O?H*,-_>_04 .HIN&_O?H*,-_>_04 .HIN&_O?H
M*,-_>_04 .HIN&_O?H*,-_>_04 172-+;7,2</)!-&AZ89XV5>>W)%?S/_M4
M_#__ (*L_#CXK:]XH_9H&M7?AS4KJ<PQPK<R0^7*[\#8"OW6Z9_I7],FUO[Y
M'_ 5_J#2X;^]^@KT,OS"6 J2G]7H8F,XJ,J6(ASP:O?;H_,\K-LJCFM&G2>*
MQ>#E2DYPK8.K[*JFTD];.ZT/Y(/V5O\ @F-^UM\;_P!I;3?V@/VRM-GMIK:^
MAO&-U;.A+QR)(Q!D09(QVY[>P^C/^"Q?_!-/XV?'0_#CQC^S1:7$OB#X?"SE
MM$MXFDD5[-U()6,,5^X#U[@U_2GAO[WZ"C#?WOT%>B^),=]>H8V,*$%AX.E2
MPRA_L\:<DHRCR7U32/&7!F5K*\5ELIXF;QE55J^,E47UN=:,E*,^>VZ:NOS[
M_P R_B7]CW]N3]J3]CK2/A3\:QJ=EXG\/64,&GJ4F225K2!8XUVN%+ [ , '
M.1[5\0Z/^Q#_ ,%-=/\ @YXA_9RT_P $K+X1N8WL8M3ETMC<FW;,9;S6AWYV
MD\Y^E?VC8;^]^@HPW][]!6E+B;$THRA'"8-TG7>(ITG3]RC5;3<H)/NC.OP9
M@\1.G5GC\Q5>.&6$J5HUE[2O02Y5"HW%K;JEV['\E>E?LH>.?V'?V+=5TGXO
MVFH&ZOTN5400R#;>/&&*MM7C#..#T&#VY_-W]G+X-?M5?V#XV^-GPP&D?V%8
MRW%]:V=^D?GR0Q%I@"CC<6*@#G)^O2O[=/VE_A3H/QB^%^K>#O$LLB:9=!G8
MQ06\KK((V5)%$RD H"V-I7.>3P,?@M'_ ,$^(O#<FI:1X8_:!^*7A_0;R:03
MZ'IZ:?'I[1DY,7EF7[A!VGVKUL#Q#2EAL1+%-1Q.(Q*E4<J#K494[Q;C&*E%
MQ=K*]W\SP<RX0Q$<7@Z> C*6#P6$E3I6Q:P]=56DE*4W"2E%-[61R'[ ?[3O
MQ._;VTKQY^S)\;?#4MG-IFF7^GV\\=HZ69>"&1"ZMM$87"$YSCKSWKYZ\._L
M5?\ !1O]B?Q]XVM/V>/!L>M^#/$FJS3VDTNFFX"V[W)==K^4Z_= '!^N.*_H
M8_8;_93\"? ;0[K5] O+S5=<OT,5[K&H6MG%>7(D!\PRO$K.2_.<..N"2*_0
M?#?WOT%<&(SZEAL5B88#"TIX"NJ<JF&KP?LW5C9N:C>\;]$[[L]/"<*UL;@<
M#4S3'8F&9X2=3V6-PM2*K1H3Y>6E.?+:=E=727H?D7_P3XTW]M0Z[?:K^TQX
M7@T.RGAD-LR67V5BY5MHYC0GYOJ<' K]8M:^W_V5?_V8,W_V:7[+V/G;&\O'
M(YW8K2PW][]!1AO[WZ"OG<7B?K5=UO8TJ-[+V=&+C!)=DV]SZ_ 8+ZCA8X98
MBOB.7F?MJ\E*JW+O));;KL?Q[_\ !2']CG_@K%^UQ\1;_0-+L]2?X86%Q-_8
MI$,S1>5YCM'@A2O3'?\ 2O;?^"6/[,G_  4^_9C^(>D>$/BA::C'\(@;>._,
MD,RPB)'7?DLH3D#VSBOZF\-_>_048;^]^@KVI\2XB> _L[ZG@%A^3E5J'OQ=
MK.HI<W\1[N33U/FZ?!>#IYK_ &NLQS9XMU.>3>*O"44[JDX\FM+IRWVT*][:
M1WUG<V<PS%<PR0R#U5U*G^=?Q@_M$>$M9_9N_P""P?@KQ=_9]Y%H.HZQ8SFZ
M6%TM666Y$@/F;0I!4Y!! .0<U_:-AO[WZ"OS._;5_92\&_&WQ-H7BO6]7U'2
M]:TA[7[%>6%I9/+&+;:8U\R0+(0,?Q,3[GOAD.84\#B,1&NFZ&*PM7#U+*[7
M.E:276W7NM#JXIRJMF>$PDL,XK$X+'X;%TN=\J:I3O*/-TNO(Y3_ (*,?L.^
M&_\ @H'\%='O=/C4^)+#35N_#EPJ?O2[EIX_+?@G;*Q Y[8[8K\"O WP#_X+
M2_LTZ;J7PI^&L'B"Z\'3^9IME+Y-TZIIS!HHRI"G'[O!&,^PK^O[X*Z//X?^
M&GA?1)=4N=5&EV*V<5[=Q1)<20Q\H)!%A25W'DDG!QG  'J>&_O?H*O"9]7P
M-&6"='#XW!QJ2G2IXJFYJ'O74H[<K>^VYEC^%L+FF(IYG]8QF6YA4H4X5ZV!
MK>S=1<JO&=E:26R?;H?S$?\ !/#_ ()+_%2T^+9_:!_:ZBNKOQI'/)J-K%J"
M%I4NF;S(]BR@$8D(/&.!GMBO6_\ @HO_ ,$]?CG^T)\=_!GC'X>6TQ\->';V
MR/[J-BJ6UN\9Q\HP,*O^<<?T.8;^]^@HPW][]!4RXBS">-6.;I\\:3HTZ7+^
MZI4VK<L(WTT]32/"&4PRO^RTJWLI5HXBK7Y_]HK5HRYN>I4M=W:V/Q<_;;_8
MO^+GQM_9&\)_"3PC'*_BC2M)M;6Z55+.)(H51@5&6'S#I@?4=*_&O]L7X/>(
M_P!E_P#X)SZ9\"_B-9:BGCJ]U"..T(AE6/S7<;"WR@;06SZ8ZY%?V;X;^]^@
MKX0_;R_9K\'?M'?#BWT#Q=>WEE'9R.]I=V-O:RSP2$[@Z&8!@P;D8< 'D '.
M>C*L\G1JX:CB8KZI3QGUR7LX_O%5Z6UU5VKQ_(Y,]X8AB:.+Q6#D_K\\O_L^
MFJTOW#HOE7O)+25DWS:Z].I_)?X#\!?MM?LT_LL>&_CSX;BT+4/#^A:7;:C:
MVACADOV@8,RJ5P9-VV(C&,Y[<5^JGPFN_%7_  6*_8;N])^(&@7&F^,=",WV
M3?:O&@OXT6)-A*  ;E&WH,G YX,MC^P+,VD6W@B[_:)^*U]X*C\NW'A>Y&GO
MI?V=&.V$Q^9G: S#KT-?N1^R9\"_"/P$^%6G^$O!N_["[K-/++;VT,DTRQ@>
M8X@1<L=[$[F;KQ@Y)]#,L[P=2BZ]"*EF$,8JV'Q-.A*@Z5.[DX2O*7,VMVK7
M?WGD9-PQF-'$+#8NI)936R[V&+P=3$K%*K67*E4I_NX>S2Z+6VF^I_*+H_[*
M7_!8+X,^&]:_9\\ VVN2?#*]+6-C(D-RT:V,I*?*0I&/*(P1Q[5^R/\ P3@_
MX)M:Y^SI\+_'/B'XB0.?B]XST?48YI)4_?K>7EC<A@Y8;P3<.B@=3T]2/W'P
MW][]!1AO[WZ"O)Q?$6+Q5"5!4<-AU5E">(G0I\L\1.#3O4?6[5VNI[V6\'X#
M+L5#%/$XW&.A"=+"T\75]I3PL):6HJRY7%-J+Z+H?S!_L<?\$R_VC?A+\;/C
M/XX\86MRFE^,]3U6ZTMI(G4,EU)(T>TLHSG<,8/Z<UW/[!O_  3C^/WP(_;Z
M\>?'GQG;3Q^"==-]]CD>)T1A,)=F'("G._UY_'%?TAX;^]^@HPW][]!4UN(<
M=6^M<T:*^MX>&%JVA;]W!12Y==)>ZKO\"Z'".68=X"4)8AO+L9/&T'*I>]:H
MVY<^GO1UT6EC^;O]M'_@G'^T!\9O^"B7@3]H3PE;SR> ]#NK::^D$;&()&ZE
MAN V@@#N>F>,U^5W[?ND:]\1OVQ8/AC\-H9H/&EFUMI]U)J*,MJL\92-R/,&
MS ;/;IS]/[E<-_>_05^'O[9?["'@KXD?%J[^*%IXV\3>"_&-W.T\FK>'K:PC
MN1*[@EA(?*)(//(/->EE'$')4I1QGNPPN"EAL,Z=/FM=K6K&ZY_O7W;>1G_"
M;JTL0\N;E4S',H8S&QK5N39*+5"?*_9O_MV1^)D'[0/[9_\ P3]^)'@3PKXB
MTC3-;T/6)=/CEN-*MUFGCCE9 W,2EA@'VQ7WG_P6,^/UQXX_96^#-Y#9W?\
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M[H?@AI%U?4;*XMHVB)#J9(RJD8YSD]1SUKVK#?WOT%&&_O?H*^(K9G.KF?\
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IO?H* '44W#?WOT%&&_O?H* '4T?>;\/Y48;^]^@I0,9.<D^WI0!__]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
